Naloxone	B-Chemical	D009270
reverses	O	O
the	O	O
antihypertensive	O	O
effect	O	O
of	O	O
clonidine	B-Chemical	D003000
.	O	O

In	O	O
unanesthetized	O	O
,	O	O
spontaneously	O	O
hypertensive	B-Disease	D006973
rats	O	O
the	O	O
decrease	O	O
in	O	O
blood	O	O
pressure	O	O
and	O	O
heart	O	O
rate	O	O
produced	O	O
by	O	O
intravenous	O	O
clonidine	B-Chemical	D003000
,	O	O
5	O	O
to	O	O
20	O	O
micrograms	O	O
/	O	O
kg	O	O
,	O	O
was	O	O
inhibited	O	O
or	O	O
reversed	O	O
by	O	O
nalozone	B-Chemical	-1
,	O	O
0	O	O
.	O	O

2	O	O
to	O	O
2	O	O
mg	O	O
/	O	O
kg	O	O
.	O	O

The	O	O
hypotensive	B-Disease	D007022
effect	O	O
of	O	O
100	O	O
mg	O	O
/	O	O
kg	O	O
alpha	B-Chemical	D008750
-	I-Chemical	D008750
methyldopa	I-Chemical	D008750
was	O	O
also	O	O
partially	O	O
reversed	O	O
by	O	O
naloxone	B-Chemical	D009270
.	O	O

Naloxone	B-Chemical	D009270
alone	O	O
did	O	O
not	O	O
affect	O	O
either	O	O
blood	O	O
pressure	O	O
or	O	O
heart	O	O
rate	O	O
.	O	O

In	O	O
brain	O	O
membranes	O	O
from	O	O
spontaneously	O	O
hypertensive	B-Disease	D006973
rats	O	O
clonidine	B-Chemical	D003000
,	O	O
10	O	O
(	O	O
-	O	O
8	O	O
)	O	O
to	O	O
10	O	O
(	O	O
-	O	O
5	O	O
)	O	O
M	O	O
,	O	O
did	O	O
not	O	O
influence	O	O
stereoselective	O	O
binding	O	O
of	O	O
[	B-Chemical	-1
3H	I-Chemical	-1
]	I-Chemical	-1
-	I-Chemical	-1
naloxone	I-Chemical	-1
(	O	O
8	O	O
nM	O	O
)	O	O
,	O	O
and	O	O
naloxone	B-Chemical	D009270
,	O	O
10	O	O
(	O	O
-	O	O
8	O	O
)	O	O
to	O	O
10	O	O
(	O	O
-	O	O
4	O	O
)	O	O
M	O	O
,	O	O
did	O	O
not	O	O
influence	O	O
clonidine	B-Chemical	D003000
-	O	O
suppressible	O	O
binding	O	O
of	O	O
[	B-Chemical	-1
3H	I-Chemical	-1
]	I-Chemical	-1
-	I-Chemical	-1
dihydroergocryptine	I-Chemical	-1
(	O	O
1	O	O
nM	O	O
)	O	O
.	O	O

These	O	O
findings	O	O
indicate	O	O
that	O	O
in	O	O
spontaneously	O	O
hypertensive	B-Disease	D006973
rats	O	O
the	O	O
effects	O	O
of	O	O
central	O	O
alpha	O	O
-	O	O
adrenoceptor	O	O
stimulation	O	O
involve	O	O
activation	O	O
of	O	O
opiate	O	O
receptors	O	O
.	O	O

As	O	O
naloxone	B-Chemical	D009270
and	O	O
clonidine	B-Chemical	D003000
do	O	O
not	O	O
appear	O	O
to	O	O
interact	O	O
with	O	O
the	O	O
same	O	O
receptor	O	O
site	O	O
,	O	O
the	O	O
observed	O	O
functional	O	O
antagonism	O	O
suggests	O	O
the	O	O
release	O	O
of	O	O
an	O	O
endogenous	O	O
opiate	O	O
by	O	O
clonidine	B-Chemical	D003000
or	O	O
alpha	B-Chemical	D008750
-	I-Chemical	D008750
methyldopa	I-Chemical	D008750
and	O	O
the	O	O
possible	O	O
role	O	O
of	O	O
the	O	O
opiate	O	O
in	O	O
the	O	O
central	O	O
control	O	O
of	O	O
sympathetic	O	O
tone	O	O
.	O	O

Lidocaine	B-Chemical	D008012
-	O	O
induced	O	O
cardiac	B-Disease	D006323
asystole	I-Disease	D006323
.	O	O

Intravenous	O	O
administration	O	O
of	O	O
a	O	O
single	O	O
50	O	O
-	O	O
mg	O	O
bolus	O	O
of	O	O
lidocaine	B-Chemical	D008012
in	O	O
a	O	O
67	O	O
-	O	O
year	O	O
-	O	O
old	O	O
man	O	O
resulted	O	O
in	O	O
profound	O	O
depression	B-Disease	D003866
of	O	O
the	O	O
activity	O	O
of	O	O
the	O	O
sinoatrial	O	O
and	O	O
atrioventricular	O	O
nodal	O	O
pacemakers	O	O
.	O	O

The	O	O
patient	O	O
had	O	O
no	O	O
apparent	O	O
associated	O	O
conditions	O	O
which	O	O
might	O	O
have	O	O
predisposed	O	O
him	O	O
to	O	O
the	O	O
development	O	O
of	O	O
bradyarrhythmias	B-Disease	D001919
;	O	O
and	O	O
,	O	O
thus	O	O
,	O	O
this	O	O
probably	O	O
represented	O	O
a	O	O
true	O	O
idiosyncrasy	O	O
to	O	O
lidocaine	B-Chemical	D008012
.	O	O

Suxamethonium	B-Chemical	D013390
infusion	O	O
rate	O	O
and	O	O
observed	O	O
fasciculations	B-Disease	D005207
.	O	O

A	O	O
dose	O	O
-	O	O
response	O	O
study	O	O
.	O	O

Suxamethonium	B-Chemical	D013390
chloride	O	O
(	O	O
Sch	B-Chemical	D013390
)	O	O
was	O	O
administered	O	O
i	O	O
.	O	O

v	O	O
.	O	O

to	O	O
36	O	O
adult	O	O
males	O	O
at	O	O
six	O	O
rates	O	O
:	O	O
0	O	O
.	O	O

25	O	O
mg	O	O
s	O	O
-	O	O
1	O	O
to	O	O
20	O	O
mg	O	O
s	O	O
-	O	O
1	O	O
.	O	O

The	O	O
infusion	O	O
was	O	O
discontinued	O	O
either	O	O
when	O	O
there	O	O
was	O	O
no	O	O
muscular	O	O
response	O	O
to	O	O
tetanic	B-Disease	D013746
stimulation	O	O
of	O	O
the	O	O
ulnar	O	O
nerve	O	O
or	O	O
when	O	O
Sch	B-Chemical	D013390
120	O	O
mg	O	O
was	O	O
exceeded	O	O
.	O	O

Six	O	O
additional	O	O
patients	O	O
received	O	O
a	O	O
30	O	O
-	O	O
mg	O	O
i	O	O
.	O	O

v	O	O
.	O	O

bolus	O	O
dose	O	O
.	O	O

Fasciculations	B-Disease	D005207
in	O	O
six	O	O
areas	O	O
of	O	O
the	O	O
body	O	O
were	O	O
scored	O	O
from	O	O
0	O	O
to	O	O
3	O	O
and	O	O
summated	O	O
as	O	O
a	O	O
total	O	O
fasciculation	B-Disease	D005207
score	O	O
.	O	O

The	O	O
times	O	O
to	O	O
first	O	O
fasciculation	B-Disease	D005207
,	O	O
twitch	B-Disease	D013746
suppression	O	O
and	O	O
tetanus	B-Disease	D013746
suppression	O	O
were	O	O
inversely	O	O
related	O	O
to	O	O
the	O	O
infusion	O	O
rates	O	O
.	O	O

Fasciculations	B-Disease	D005207
in	O	O
the	O	O
six	O	O
areas	O	O
and	O	O
the	O	O
total	O	O
fasciculation	B-Disease	D005207
score	O	O
were	O	O
related	O	O
directly	O	O
to	O	O
the	O	O
rate	O	O
of	O	O
infusion	O	O
.	O	O

Total	O	O
fasciculation	B-Disease	D005207
scores	O	O
in	O	O
the	O	O
30	O	O
-	O	O
mg	O	O
bolus	O	O
group	O	O
and	O	O
the	O	O
5	O	O
-	O	O
mg	O	O
s	O	O
-	O	O
1	O	O
and	O	O
20	O	O
-	O	O
mg	O	O
s	O	O
-	O	O
1	O	O
infusion	O	O
groups	O	O
were	O	O
not	O	O
significantly	O	O
different	O	O
.	O	O

Galanthamine	B-Chemical	D005702
hydrobromide	I-Chemical	D005702
,	O	O
a	O	O
longer	O	O
acting	O	O
anticholinesterase	O	O
drug	O	O
,	O	O
in	O	O
the	O	O
treatment	O	O
of	O	O
the	O	O
central	O	O
effects	O	O
of	O	O
scopolamine	B-Chemical	D012601
(	O	O
Hyoscine	B-Chemical	D012601
)	O	O
.	O	O

Galanthamine	B-Chemical	D005702
hydrobromide	I-Chemical	D005702
,	O	O
an	O	O
anticholinesterase	O	O
drug	O	O
capable	O	O
of	O	O
penetrating	O	O
the	O	O
blood	O	O
-	O	O
brain	O	O
barrier	O	O
,	O	O
was	O	O
used	O	O
in	O	O
a	O	O
patient	O	O
demonstrating	O	O
central	O	O
effects	O	O
of	O	O
scopolamine	B-Chemical	D012601
(	O	O
hyoscine	B-Chemical	D012601
)	O	O
overdosage	B-Disease	D062787
.	O	O

It	O	O
is	O	O
longer	O	O
acting	O	O
than	O	O
physostigmine	B-Chemical	D010830
and	O	O
is	O	O
used	O	O
in	O	O
anaesthesia	O	O
to	O	O
reverse	O	O
the	O	O
non	O	O
-	O	O
depolarizing	O	O
neuromuscular	O	O
block	O	O
.	O	O

However	O	O
,	O	O
studies	O	O
into	O	O
the	O	O
dose	O	O
necessary	O	O
to	O	O
combating	O	O
scopolamine	B-Chemical	D012601
intoxication	O	O
are	O	O
indicated	O	O
.	O	O

Effects	O	O
of	O	O
uninephrectomy	O	O
and	O	O
high	O	O
protein	O	O
feeding	O	O
on	O	O
lithium	B-Chemical	D008094
-	O	O
induced	O	O
chronic	B-Disease	D007676
renal	I-Disease	D007676
failure	I-Disease	D007676
in	O	O
rats	O	O
.	O	O

Rats	O	O
with	O	O
lithium	B-Chemical	D008094
-	O	O
induced	O	O
nephropathy	B-Disease	D007674
were	O	O
subjected	O	O
to	O	O
high	O	O
protein	O	O
(	O	O
HP	O	O
)	O	O
feeding	O	O
,	O	O
uninephrectomy	O	O
(	O	O
NX	O	O
)	O	O
or	O	O
a	O	O
combination	O	O
of	O	O
these	O	O
,	O	O
in	O	O
an	O	O
attempt	O	O
to	O	O
induce	O	O
glomerular	O	O
hyperfiltration	O	O
and	O	O
further	O	O
progression	O	O
of	O	O
renal	B-Disease	D051437
failure	I-Disease	D051437
.	O	O

Newborn	O	O
female	O	O
Wistar	O	O
rats	O	O
were	O	O
fed	O	O
a	O	O
lithium	B-Chemical	D008094
-	O	O
containing	O	O
diet	O	O
(	O	O
50	O	O
mmol	O	O
/	O	O
kg	O	O
)	O	O
for	O	O
8	O	O
weeks	O	O
and	O	O
then	O	O
randomized	O	O
to	O	O
normal	O	O
diet	O	O
,	O	O
HP	O	O
diet	O	O
(	O	O
40	O	O
vs	O	O
.	O	O

19%	O	O
)	O	O
,	O	O
NX	O	O
or	O	O
HP+NX	O	O
for	O	O
another	O	O
8	O	O
weeks	O	O
.	O	O

Corresponding	O	O
non	O	O
-	O	O
lithium	B-Chemical	D008094
pretreated	O	O
groups	O	O
were	O	O
generated	O	O
.	O	O

When	O	O
comparing	O	O
all	O	O
lithium	B-Chemical	D008094
treated	O	O
versus	O	O
non	O	O
-	O	O
lithium	B-Chemical	D008094
-	O	O
treated	O	O
groups	O	O
,	O	O
lithium	B-Chemical	D008094
caused	O	O
a	O	O
reduction	O	O
in	O	O
glomerular	O	O
filtration	O	O
rate	O	O
(	O	O
GFR	O	O
)	O	O
without	O	O
significant	O	O
changes	O	O
in	O	O
effective	O	O
renal	O	O
plasma	O	O
flow	O	O
(	O	O
as	O	O
determined	O	O
by	O	O
a	O	O
marker	O	O
secreted	O	O
into	O	O
the	O	O
proximal	O	O
tubules	O	O
)	O	O
or	O	O
lithium	B-Chemical	D008094
clearance	O	O
.	O	O

Consequently	O	O
,	O	O
lithium	B-Chemical	D008094
pretreatment	O	O
caused	O	O
a	O	O
fall	O	O
in	O	O
filtration	O	O
fraction	O	O
and	O	O
an	O	O
increase	O	O
in	O	O
fractional	O	O
Li	B-Chemical	D008094
excretion	O	O
.	O	O

Lithium	B-Chemical	D008094
also	O	O
caused	O	O
proteinuria	B-Disease	D011507
and	O	O
systolic	O	O
hypertension	B-Disease	D006973
in	O	O
absence	O	O
of	O	O
glomerulosclerosis	B-Disease	D005921
.	O	O

HP	O	O
failed	O	O
to	O	O
accentuante	O	O
progression	O	O
of	O	O
renal	B-Disease	D051437
failure	I-Disease	D051437
and	O	O
in	O	O
fact	O	O
tended	O	O
to	O	O
increase	O	O
GFR	O	O
and	O	O
decrease	O	O
plasma	O	O
creatinine	B-Chemical	D003404
levels	O	O
in	O	O
lithium	B-Chemical	D008094
pretreated	O	O
rats	O	O
.	O	O

NX	O	O
caused	O	O
an	O	O
additive	O	O
deterioration	O	O
in	O	O
GFR	O	O
which	O	O
,	O	O
however	O	O
,	O	O
was	O	O
ameliorated	O	O
by	O	O
HP	O	O
.	O	O

NX+HP	O	O
caused	O	O
a	O	O
further	O	O
rise	O	O
in	O	O
blood	O	O
pressure	O	O
in	O	O
Li	B-Chemical	D008094
-	O	O
pretreated	O	O
rats	O	O
.	O	O

The	O	O
results	O	O
indicate	O	O
that	O	O
Li	B-Chemical	D008094
-	O	O
induced	O	O
nephropathy	B-Disease	D007674
,	O	O
even	O	O
when	O	O
the	O	O
GFR	O	O
is	O	O
only	O	O
modestly	O	O
reduced	O	O
,	O	O
is	O	O
associated	O	O
with	O	O
proteinuria	B-Disease	D011507
and	O	O
arterial	O	O
systolic	O	O
hypertension	B-Disease	D006973
.	O	O

In	O	O
this	O	O
model	O	O
of	O	O
chronic	B-Disease	D007676
renal	I-Disease	D007676
failure	I-Disease	D007676
the	O	O
decline	O	O
in	O	O
GFR	O	O
is	O	O
not	O	O
accompanied	O	O
by	O	O
a	O	O
corresponding	O	O
fall	O	O
in	O	O
effective	O	O
renal	O	O
plasma	O	O
flow	O	O
,	O	O
which	O	O
may	O	O
be	O	O
the	O	O
functional	O	O
expression	O	O
of	O	O
the	O	O
formation	O	O
of	O	O
nonfiltrating	O	O
atubular	O	O
glomeruli	O	O
.	O	O

The	O	O
fractional	O	O
reabsorption	O	O
of	O	O
tubular	O	O
fluid	O	O
by	O	O
the	O	O
proximal	O	O
tubules	O	O
is	O	O
reduced	O	O
,	O	O
leaving	O	O
the	O	O
distal	O	O
delivery	O	O
unchanged	O	O
.	O	O

(	O	O
ABSTRACT	O	O
TRUNCATED	O	O
AT	O	O
250	O	O
WORDS	O	O
)	O	O
Treatment	O	O
of	O	O
Crohn's	B-Disease	D003424
disease	I-Disease	D003424
with	O	O
fusidic	B-Chemical	D005672
acid	I-Chemical	D005672
:	O	O
an	O	O
antibiotic	O	O
with	O	O
immunosuppressive	O	O
properties	O	O
similar	O	O
to	O	O
cyclosporin	B-Chemical	D016572
.	O	O

Fusidic	B-Chemical	D005672
acid	I-Chemical	D005672
is	O	O
an	O	O
antibiotic	O	O
with	O	O
T	O	O
-	O	O
cell	O	O
specific	O	O
immunosuppressive	O	O
effects	O	O
similar	O	O
to	O	O
those	O	O
of	O	O
cyclosporin	B-Chemical	D016572
.	O	O

Because	O	O
of	O	O
the	O	O
need	O	O
for	O	O
the	O	O
development	O	O
of	O	O
new	O	O
treatments	O	O
for	O	O
Crohn's	B-Disease	D003424
disease	I-Disease	D003424
,	O	O
a	O	O
pilot	O	O
study	O	O
was	O	O
undertaken	O	O
to	O	O
estimate	O	O
the	O	O
pharmacodynamics	O	O
and	O	O
tolerability	O	O
of	O	O
fusidic	B-Chemical	D005672
acid	I-Chemical	D005672
treatment	O	O
in	O	O
chronic	O	O
active	O	O
,	O	O
therapy	O	O
-	O	O
resistant	O	O
patients	O	O
.	O	O

Eight	O	O
Crohn's	B-Disease	D003424
disease	I-Disease	D003424
patients	O	O
were	O	O
included	O	O
.	O	O

Fusidic	B-Chemical	D005672
acid	I-Chemical	D005672
was	O	O
administered	O	O
orally	O	O
in	O	O
a	O	O
dose	O	O
of	O	O
500	O	O
mg	O	O
t	O	O
.	O	O

d	O	O
.	O	O

s	O	O
.	O	O

and	O	O
the	O	O
treatment	O	O
was	O	O
planned	O	O
to	O	O
last	O	O
8	O	O
weeks	O	O
.	O	O

The	O	O
disease	O	O
activity	O	O
was	O	O
primarily	O	O
measured	O	O
by	O	O
a	O	O
modified	O	O
individual	O	O
grading	O	O
score	O	O
.	O	O

Five	O	O
of	O	O
8	O	O
patients	O	O
(	O	O
63%	O	O
)	O	O
improved	O	O
during	O	O
fusidic	B-Chemical	D005672
acid	I-Chemical	D005672
treatment	O	O
:	O	O
3	O	O
at	O	O
two	O	O
weeks	O	O
and	O	O
2	O	O
after	O	O
four	O	O
weeks	O	O
.	O	O

There	O	O
were	O	O
no	O	O
serious	O	O
clinical	O	O
side	O	O
effects	O	O
,	O	O
but	O	O
dose	O	O
reduction	O	O
was	O	O
required	O	O
in	O	O
two	O	O
patients	O	O
because	O	O
of	O	O
nausea	B-Disease	D009325
.	O	O

Biochemically	O	O
,	O	O
an	O	O
increase	O	O
in	O	O
alkaline	O	O
phosphatases	O	O
was	O	O
noted	O	O
in	O	O
5	O	O
of	O	O
8	O	O
cases	O	O
(	O	O
63%	O	O
)	O	O
,	O	O
and	O	O
the	O	O
greatest	O	O
increases	O	O
were	O	O
seen	O	O
in	O	O
those	O	O
who	O	O
had	O	O
elevated	O	O
levels	O	O
prior	O	O
to	O	O
treatment	O	O
.	O	O

All	O	O
reversed	O	O
to	O	O
pre	O	O
-	O	O
treatment	O	O
levels	O	O
after	O	O
cessation	O	O
of	O	O
treatment	O	O
.	O	O

The	O	O
results	O	O
of	O	O
this	O	O
pilot	O	O
study	O	O
suggest	O	O
that	O	O
fusidic	B-Chemical	D005672
acid	I-Chemical	D005672
may	O	O
be	O	O
of	O	O
benefit	O	O
in	O	O
selected	O	O
chronic	O	O
active	O	O
Crohn's	B-Disease	D003424
disease	I-Disease	D003424
patients	O	O
in	O	O
whom	O	O
conventional	O	O
treatment	O	O
is	O	O
ineffective	O	O
.	O	O

Because	O	O
there	O	O
seems	O	O
to	O	O
exist	O	O
a	O	O
scientific	O	O
rationale	O	O
for	O	O
the	O	O
use	O	O
of	O	O
fusidic	B-Chemical	D005672
acid	I-Chemical	D005672
at	O	O
the	O	O
cytokine	O	O
level	O	O
in	O	O
inflammatory	B-Disease	D015212
bowel	I-Disease	D015212
disease	I-Disease	D015212
,	O	O
we	O	O
suggest	O	O
that	O	O
the	O	O
role	O	O
of	O	O
this	O	O
treatment	O	O
should	O	O
be	O	O
further	O	O
investigated	O	O
.	O	O

Electrocardiographic	O	O
evidence	O	O
of	O	O
myocardial	B-Disease	D009202
injury	I-Disease	D009202
in	O	O
psychiatrically	O	O
hospitalized	O	O
cocaine	B-Chemical	D003042
abusers	O	O
.	O	O

The	O	O
electrocardiograms	O	O
(	O	O
ECG	O	O
)	O	O
of	O	O
99	O	O
cocaine	B-Chemical	D003042
-	O	O
abusing	O	O
patients	O	O
were	O	O
compared	O	O
with	O	O
the	O	O
ECGs	O	O
of	O	O
50	O	O
schizophrenic	B-Disease	D012559
controls	O	O
.	O	O

Eleven	O	O
of	O	O
the	O	O
cocaine	B-Chemical	D003042
abusers	O	O
and	O	O
none	O	O
of	O	O
the	O	O
controls	O	O
had	O	O
ECG	O	O
evidence	O	O
of	O	O
significant	O	O
myocardial	B-Disease	D009202
injury	I-Disease	D009202
defined	O	O
as	O	O
myocardial	B-Disease	D009203
infarction	I-Disease	D009203
,	O	O
ischemia	B-Disease	D007511
,	O	O
and	O	O
bundle	B-Disease	D002037
branch	I-Disease	D002037
block	I-Disease	D002037
.	O	O

Sulpiride	B-Chemical	D013469
-	O	O
induced	O	O
tardive	B-Disease	D004421
dystonia	I-Disease	D004421
.	O	O

Sulpiride	B-Chemical	D013469
is	O	O
a	O	O
selective	O	O
D2	O	O
-	O	O
receptor	O	O
antagonist	O	O
with	O	O
antipsychotic	O	O
and	O	O
antidepressant	B-Chemical	D000928
properties	O	O
.	O	O

Although	O	O
initially	O	O
thought	O	O
to	O	O
be	O	O
free	O	O
of	O	O
extrapyramidal	O	O
side	O	O
effects	O	O
,	O	O
sulpiride	B-Chemical	D013469
-	O	O
induced	O	O
tardive	B-Disease	D004409
dyskinesia	I-Disease	D004409
and	O	O
parkinsonism	B-Disease	D010302
have	O	O
been	O	O
reported	O	O
occasionally	O	O
.	O	O

We	O	O
studied	O	O
a	O	O
37	O	O
-	O	O
year	O	O
-	O	O
old	O	O
man	O	O
who	O	O
developed	O	O
persistent	O	O
segmental	O	O
dystonia	B-Disease	D004421
within	O	O
2	O	O
months	O	O
after	O	O
starting	O	O
sulpiride	B-Chemical	D013469
therapy	O	O
.	O	O

We	O	O
could	O	O
not	O	O
find	O	O
any	O	O
previous	O	O
reports	O	O
of	O	O
sulpiride	B-Chemical	D013469
-	O	O
induced	O	O
tardive	B-Disease	D004421
dystonia	I-Disease	D004421
.	O	O

Ocular	O	O
and	O	O
auditory	O	O
toxicity	B-Disease	D064420
in	O	O
hemodialyzed	O	O
patients	O	O
receiving	O	O
desferrioxamine	B-Chemical	D003676
.	O	O

During	O	O
an	O	O
18	O	O
-	O	O
month	O	O
period	O	O
of	O	O
study	O	O
41	O	O
hemodialyzed	O	O
patients	O	O
receiving	O	O
desferrioxamine	B-Chemical	D003676
(	O	O
10	O	O
-	O	O
40	O	O
mg	O	O
/	O	O
kg	O	O
BW	O	O
/	O	O
3	O	O
times	O	O
weekly	O	O
)	O	O
for	O	O
the	O	O
first	O	O
time	O	O
were	O	O
monitored	O	O
for	O	O
detection	O	O
of	O	O
audiovisual	B-Disease	D014786
toxicity	I-Disease	D014786
.	O	O

6	O	O
patients	O	O
presented	O	O
clinical	O	O
symptoms	O	O
of	O	O
visual	O	O
or	O	O
auditory	O	O
toxicity	B-Disease	D064420
.	O	O

Moreover	O	O
,	O	O
detailed	O	O
ophthalmologic	O	O
and	O	O
audiologic	O	O
studies	O	O
disclosed	O	O
abnormalities	O	O
in	O	O
7	O	O
more	O	O
asymptomatic	O	O
patients	O	O
.	O	O

Visual	B-Disease	D014786
toxicity	I-Disease	D014786
was	O	O
of	O	O
retinal	O	O
origin	O	O
and	O	O
was	O	O
characterized	O	O
by	O	O
a	O	O
tritan	O	O
-	O	O
type	O	O
dyschromatopsy	B-Disease	-1
,	O	O
sometimes	O	O
associated	O	O
with	O	O
a	B-Disease	D014786
loss	I-Disease	D014786
of	I-Disease	D014786
visual	I-Disease	D014786
acuity	I-Disease	D014786
and	O	O
pigmentary	B-Disease	D012164
retinal	I-Disease	D012164
deposits	I-Disease	D012164
.	O	O

Auditory	B-Disease	D006311
toxicity	I-Disease	D006311
was	O	O
characterized	O	O
by	O	O
a	O	O
mid	O	O
-	O	O
to	O	O
high	O	O
-	O	O
frequency	O	O
neurosensorial	B-Disease	D006319
hearing	I-Disease	D006319
loss	I-Disease	D006319
and	O	O
the	O	O
lesion	O	O
was	O	O
of	O	O
the	O	O
cochlear	O	O
type	O	O
.	O	O

Desferrioxamine	B-Chemical	D003676
withdrawal	O	O
resulted	O	O
in	O	O
a	O	O
complete	O	O
recovery	O	O
of	O	O
visual	O	O
function	O	O
in	O	O
1	O	O
patient	O	O
and	O	O
partial	O	O
recovery	O	O
in	O	O
3	O	O
,	O	O
and	O	O
a	O	O
complete	O	O
reversal	O	O
of	O	O
hearing	B-Disease	D034381
loss	I-Disease	D034381
in	O	O
3	O	O
patients	O	O
and	O	O
partial	O	O
recovery	O	O
in	O	O
3	O	O
.	O	O

This	O	O
toxicity	B-Disease	D064420
appeared	O	O
in	O	O
patients	O	O
receiving	O	O
the	O	O
higher	O	O
doses	O	O
of	O	O
desferrioxamine	B-Chemical	D003676
or	O	O
coincided	O	O
with	O	O
the	O	O
normalization	O	O
of	O	O
ferritin	O	O
or	O	O
aluminium	B-Chemical	-1
serum	O	O
levels	O	O
.	O	O

The	O	O
data	O	O
indicate	O	O
that	O	O
audiovisual	B-Disease	D014786
toxicity	I-Disease	D014786
is	O	O
not	O	O
an	O	O
infrequent	O	O
complication	O	O
in	O	O
hemodialyzed	O	O
patients	O	O
receiving	O	O
desferrioxamine	B-Chemical	D003676
.	O	O

Periodical	O	O
audiovisual	O	O
monitoring	O	O
should	O	O
be	O	O
performed	O	O
on	O	O
hemodialyzed	O	O
patients	O	O
receiving	O	O
the	O	O
drug	O	O
in	O	O
order	O	O
to	O	O
detect	O	O
adverse	O	O
effects	O	O
as	O	O
early	O	O
as	O	O
possible	O	O
.	O	O

Myasthenia	B-Disease	D009157
gravis	I-Disease	D009157
presenting	O	O
as	O	O
weakness	O	O
after	O	O
magnesium	B-Chemical	D008274
administration	O	O
.	O	O

We	O	O
studied	O	O
a	O	O
patient	O	O
with	O	O
no	O	O
prior	O	O
history	O	O
of	O	O
neuromuscular	B-Disease	D009468
disease	I-Disease	D009468
who	O	O
became	O	O
virtually	O	O
quadriplegic	B-Disease	D011782
after	O	O
parenteral	O	O
magnesium	B-Chemical	D008274
administration	O	O
for	O	O
preeclampsia	B-Disease	D011225
.	O	O

The	O	O
serum	O	O
magnesium	B-Chemical	D008274
concentration	O	O
was	O	O
3	O	O
.	O	O

0	O	O
mEq	O	O
/	O	O
L	O	O
,	O	O
which	O	O
is	O	O
usually	O	O
well	O	O
tolerated	O	O
.	O	O

The	O	O
magnesium	B-Chemical	D008274
was	O	O
stopped	O	O
and	O	O
she	O	O
recovered	O	O
over	O	O
a	O	O
few	O	O
days	O	O
.	O	O

While	O	O
she	O	O
was	O	O
weak	O	O
,	O	O
2	O	O
-	O	O
Hz	O	O
repetitive	O	O
stimulation	O	O
revealed	O	O
a	O	O
decrement	O	O
without	O	O
significant	O	O
facilitation	O	O
at	O	O
rapid	O	O
rates	O	O
or	O	O
after	O	O
exercise	O	O
,	O	O
suggesting	O	O
postsynaptic	B-Disease	D009468
neuromuscular	I-Disease	D009468
blockade	I-Disease	D009468
.	O	O

After	O	O
her	O	O
strength	O	O
returned	O	O
,	O	O
repetitive	O	O
stimulation	O	O
was	O	O
normal	O	O
,	O	O
but	O	O
single	O	O
fiber	O	O
EMG	O	O
revealed	O	O
increased	O	O
jitter	O	O
and	O	O
blocking	O	O
.	O	O

Her	O	O
acetylcholine	B-Chemical	D000109
receptor	O	O
antibody	O	O
level	O	O
was	O	O
markedly	O	O
elevated	O	O
.	O	O

Although	O	O
paralysis	B-Disease	D010243
after	O	O
magnesium	B-Chemical	D008274
administration	O	O
has	O	O
been	O	O
described	O	O
in	O	O
patients	O	O
with	O	O
known	O	O
myasthenia	B-Disease	D009157
gravis	I-Disease	D009157
,	O	O
it	O	O
has	O	O
not	O	O
previously	O	O
been	O	O
reported	O	O
to	O	O
be	O	O
the	O	O
initial	O	O
or	O	O
only	O	O
manifestation	O	O
of	O	O
the	O	O
disease	O	O
.	O	O

Patients	O	O
who	O	O
are	O	O
unusually	O	O
sensitive	O	O
to	O	O
the	O	O
neuromuscular	O	O
effects	O	O
of	O	O
magnesium	B-Chemical	D008274
should	O	O
be	O	O
suspected	O	O
of	O	O
having	O	O
an	O	O
underlying	O	O
disorder	B-Disease	D020511
of	I-Disease	D020511
neuromuscular	I-Disease	D020511
transmission	I-Disease	D020511
.	O	O

Chloroacetaldehyde	B-Chemical	C004656
and	O	O
its	O	O
contribution	O	O
to	O	O
urotoxicity	O	O
during	O	O
treatment	O	O
with	O	O
cyclophosphamide	B-Chemical	D003520
or	O	O
ifosfamide	B-Chemical	D007069
.	O	O

An	O	O
experimental	O	O
study	O	O
/	O	O
short	O	O
communication	O	O
.	O	O

Based	O	O
on	O	O
clinical	O	O
data	O	O
,	O	O
indicating	O	O
that	O	O
chloroacetaldehyde	B-Chemical	C004656
(	O	O
CAA	B-Chemical	C004656
)	O	O
is	O	O
an	O	O
important	O	O
metabolite	O	O
of	O	O
oxazaphosphorine	O	O
cytostatics	O	O
,	O	O
an	O	O
experimental	O	O
study	O	O
was	O	O
carried	O	O
out	O	O
in	O	O
order	O	O
to	O	O
elucidate	O	O
the	O	O
role	O	O
of	O	O
CAA	B-Chemical	C004656
in	O	O
the	O	O
development	O	O
of	O	O
hemorrhagic	O	O
cystitis	O	O
.	O	O

The	O	O
data	O	O
demonstrate	O	O
that	O	O
CAA	B-Chemical	C004656
after	O	O
i	O	O
.	O	O

v	O	O
.	O	O

administration	O	O
does	O	O
not	O	O
contribute	O	O
to	O	O
bladder	B-Disease	D001745
damage	I-Disease	D001745
.	O	O

When	O	O
instilled	O	O
directly	O	O
into	O	O
the	O	O
bladder	O	O
,	O	O
CAA	B-Chemical	C004656
exerts	O	O
urotoxic	O	O
effects	O	O
,	O	O
it	O	O
is	O	O
,	O	O
however	O	O
,	O	O
susceptible	O	O
to	O	O
detoxification	O	O
with	O	O
mesna	B-Chemical	D015080
.	O	O

Source	O	O
of	O	O
pain	B-Disease	D010146
and	O	O
primitive	O	O
dysfunction	O	O
in	O	O
migraine	B-Disease	D008881
:	O	O
an	O	O
identical	O	O
site?	O	O
Twenty	O	O
common	O	O
migraine	B-Disease	D008881
patients	O	O
received	O	O
a	O	O
one	O	O
sided	O	O
frontotemporal	O	O
application	O	O
of	O	O
nitroglycerin	B-Chemical	D005996
(	O	O
10	O	O
patients	O	O
)	O	O
or	O	O
placebo	O	O
ointment	O	O
(	O	O
10	O	O
patients	O	O
)	O	O
in	O	O
a	O	O
double	O	O
blind	O	O
study	O	O
.	O	O

Early	O	O
onset	O	O
migraine	B-Disease	D008881
attacks	O	O
were	O	O
induced	O	O
by	O	O
nitroglycerin	B-Chemical	D005996
in	O	O
seven	O	O
out	O	O
of	O	O
10	O	O
patients	O	O
versus	O	O
no	O	O
patient	O	O
in	O	O
the	O	O
placebo	O	O
group	O	O
.	O	O

Subsequently	O	O
20	O	O
migraine	B-Disease	D008881
patients	O	O
,	O	O
who	O	O
developed	O	O
an	O	O
early	O	O
onset	O	O
attack	O	O
with	O	O
frontotemporal	O	O
nitroglycerin	B-Chemical	D005996
,	O	O
received	O	O
the	O	O
drug	O	O
in	O	O
a	O	O
second	O	O
induction	O	O
test	O	O
at	O	O
other	O	O
body	O	O
areas	O	O
.	O	O

No	O	O
early	O	O
onset	O	O
migraine	B-Disease	D008881
was	O	O
observed	O	O
.	O	O

Thus	O	O
the	O	O
migraine	B-Disease	D008881
-	O	O
inducing	O	O
effect	O	O
of	O	O
nitroglycerin	B-Chemical	D005996
seems	O	O
to	O	O
depend	O	O
on	O	O
direct	O	O
stimulation	O	O
of	O	O
the	O	O
habitual	O	O
site	O	O
of	O	O
pain	B-Disease	D010146
,	O	O
suggesting	O	O
that	O	O
the	O	O
frontotemporal	O	O
region	O	O
is	O	O
of	O	O
crucial	O	O
importance	O	O
in	O	O
the	O	O
development	O	O
of	O	O
a	O	O
migraine	B-Disease	D008881
crisis	O	O
.	O	O

This	O	O
is	O	O
not	O	O
consistent	O	O
with	O	O
a	O	O
CNS	O	O
origin	O	O
of	O	O
migraine	B-Disease	D008881
attack	O	O
.	O	O

Clotiazepam	B-Chemical	C084599
-	O	O
induced	O	O
acute	O	O
hepatitis	B-Disease	D056486
.	O	O

We	O	O
report	O	O
the	O	O
case	O	O
of	O	O
a	O	O
patient	O	O
who	O	O
developed	O	O
acute	O	O
hepatitis	B-Disease	D056486
with	O	O
extensive	B-Disease	D047508
hepatocellular	I-Disease	D047508
necrosis	I-Disease	D047508
,	O	O
7	O	O
months	O	O
after	O	O
the	O	O
onset	O	O
of	O	O
administration	O	O
of	O	O
clotiazepam	B-Chemical	C084599
,	O	O
a	O	O
thienodiazepine	B-Chemical	C013295
derivative	O	O
.	O	O

Clotiazepam	B-Chemical	C084599
withdrawal	O	O
was	O	O
followed	O	O
by	O	O
prompt	O	O
recovery	O	O
.	O	O

The	O	O
administration	O	O
of	O	O
several	O	O
benzodiazepines	B-Chemical	D001569
,	O	O
chemically	O	O
related	O	O
to	O	O
clotiazepam	B-Chemical	C084599
,	O	O
did	O	O
not	O	O
interfere	O	O
with	O	O
recovery	O	O
and	O	O
did	O	O
not	O	O
induce	O	O
any	O	O
relapse	O	O
of	O	O
hepatitis	B-Disease	D056486
.	O	O

This	O	O
observation	O	O
shows	O	O
that	O	O
clotiazepam	B-Chemical	C084599
can	O	O
induce	O	O
acute	O	O
hepatitis	B-Disease	D056486
and	O	O
suggests	O	O
that	O	O
there	O	O
is	O	O
no	O	O
cross	O	O
hepatotoxicity	B-Disease	D056486
between	O	O
clotiazepam	B-Chemical	C084599
and	O	O
several	O	O
benzodiazepines	B-Chemical	D001569
.	O	O

Arterial	O	O
hypertension	B-Disease	D006973
as	O	O
a	O	O
complication	O	O
of	O	O
prolonged	O	O
ketoconazole	B-Chemical	D007654
treatment	O	O
.	O	O

Two	O	O
of	O	O
14	O	O
patients	O	O
with	O	O
Cushing's	B-Disease	D003480
syndrome	I-Disease	D003480
treated	O	O
on	O	O
a	O	O
long	O	O
-	O	O
term	O	O
basis	O	O
with	O	O
ketoconazole	B-Chemical	D007654
developed	O	O
sustained	O	O
hypertension	B-Disease	D006973
.	O	O

In	O	O
both	O	O
cases	O	O
normal	O	O
plasma	O	O
and	O	O
urinary	O	O
free	O	O
cortisol	B-Chemical	D006854
levels	O	O
had	O	O
been	O	O
achieved	O	O
following	O	O
ketoconazole	B-Chemical	D007654
therapy	O	O
,	O	O
yet	O	O
continuous	O	O
blood	O	O
pressure	O	O
monitoring	O	O
demonstrated	O	O
hypertension	B-Disease	D006973
31	O	O
(	O	O
patient	O	O
1	O	O
)	O	O
and	O	O
52	O	O
weeks	O	O
(	O	O
patient	O	O
2	O	O
)	O	O
after	O	O
treatment	O	O
.	O	O

In	O	O
patient	O	O
1	O	O
,	O	O
plasma	O	O
levels	O	O
of	O	O
deoxycorticosterone	B-Chemical	D003900
and	O	O
11	B-Chemical	D003350
-	I-Chemical	D003350
deoxycortisol	I-Chemical	D003350
were	O	O
elevated	O	O
.	O	O

In	O	O
patient	O	O
2	O	O
,	O	O
in	O	O
addition	O	O
to	O	O
an	O	O
increase	O	O
in	O	O
both	O	O
deoxycorticosterone	B-Chemical	D003900
and	O	O
11	B-Chemical	D003350
-	I-Chemical	D003350
deoxycortisol	I-Chemical	D003350
levels	O	O
,	O	O
plasma	O	O
aldosterone	B-Chemical	D000450
values	O	O
were	O	O
raised	O	O
,	O	O
with	O	O
a	O	O
concomitant	O	O
suppression	O	O
of	O	O
renin	O	O
levels	O	O
.	O	O

Our	O	O
findings	O	O
show	O	O
that	O	O
long	O	O
-	O	O
term	O	O
treatment	O	O
with	O	O
high	O	O
doses	O	O
of	O	O
ketoconazole	B-Chemical	D007654
may	O	O
induce	O	O
enzyme	O	O
blockade	O	O
leading	O	O
to	O	O
mineralocorticoid	O	O
-	O	O
related	O	O
hypertension	B-Disease	D006973
.	O	O

Effects	O	O
of	O	O
an	O	O
inhibitor	O	O
of	O	O
angiotensin	B-Chemical	D000809
converting	O	O
enzyme	O	O
(	O	O
Captopril	B-Chemical	D002216
)	O	O
on	O	O
pulmonary	O	O
and	O	O
renal	O	O
insufficiency	O	O
due	O	O
to	O	O
intravascular	B-Disease	D004211
coagulation	I-Disease	D004211
in	O	O
the	O	O
rat	O	O
.	O	O

Induction	O	O
of	O	O
intravascular	B-Disease	D004211
coagulation	I-Disease	D004211
and	O	O
inhibition	O	O
of	O	O
fibrinolysis	O	O
by	O	O
injection	O	O
of	O	O
thrombin	O	O
and	O	O
tranexamic	B-Chemical	D014148
acid	I-Chemical	D014148
(	O	O
AMCA	B-Chemical	D014148
)	O	O
in	O	O
the	O	O
rat	O	O
gives	O	O
rise	O	O
to	O	O
pulmonary	O	O
and	O	O
renal	O	O
insufficiency	O	O
resembling	O	O
that	O	O
occurring	O	O
after	O	O
trauma	B-Disease	D014947
or	O	O
sepsis	B-Disease	D018805
in	O	O
man	O	O
.	O	O

Injection	O	O
of	O	O
Captopril	B-Chemical	D002216
(	O	O
1	O	O
mg	O	O
/	O	O
kg	O	O
)	O	O
,	O	O
an	O	O
inhibitor	O	O
of	O	O
angiotensin	B-Chemical	D000809
converting	O	O
enzyme	O	O
(	O	O
ACE	O	O
)	O	O
,	O	O
reduced	O	O
both	O	O
pulmonary	O	O
and	O	O
renal	O	O
insufficiency	O	O
in	O	O
this	O	O
rat	O	O
model	O	O
.	O	O

The	O	O
lung	O	O
weights	O	O
were	O	O
lower	O	O
and	O	O
PaO2	O	O
was	O	O
improved	O	O
in	O	O
rats	O	O
given	O	O
this	O	O
enzyme	O	O
-	O	O
blocking	O	O
agent	O	O
.	O	O

The	O	O
contents	O	O
of	O	O
albumin	O	O
in	O	O
the	O	O
lungs	O	O
were	O	O
not	O	O
changed	O	O
,	O	O
indicating	O	O
that	O	O
Captopril	B-Chemical	D002216
did	O	O
not	O	O
influence	O	O
the	O	O
extravasation	O	O
of	O	O
protein	O	O
.	O	O

Renal	B-Disease	D007674
damage	I-Disease	D007674
as	O	O
reflected	O	O
by	O	O
an	O	O
increase	O	O
in	O	O
serum	O	O
urea	B-Chemical	D014508
and	O	O
in	O	O
kidney	O	O
weight	O	O
was	O	O
prevented	O	O
by	O	O
Captopril	B-Chemical	D002216
.	O	O

The	O	O
amount	O	O
of	O	O
fibrin	O	O
in	O	O
the	O	O
kidneys	O	O
was	O	O
also	O	O
considerably	O	O
lower	O	O
than	O	O
in	O	O
animals	O	O
which	O	O
received	O	O
thrombin	O	O
and	O	O
AMCA	B-Chemical	D014148
alone	O	O
.	O	O

It	O	O
is	O	O
suggested	O	O
that	O	O
the	O	O
effects	O	O
of	O	O
Captopril	B-Chemical	D002216
on	O	O
the	O	O
lungs	O	O
may	O	O
be	O	O
attributable	O	O
to	O	O
a	O	O
vasodilatory	O	O
effect	O	O
due	O	O
to	O	O
a	O	O
reduction	O	O
in	O	O
the	O	O
circulating	O	O
level	O	O
of	O	O
Angiotension	B-Chemical	D000804
II	I-Chemical	D000804
and	O	O
an	O	O
increase	O	O
in	O	O
prostacyclin	B-Chemical	D011464
(	O	O
secondary	O	O
to	O	O
an	O	O
increase	O	O
in	O	O
bradykinin	B-Chemical	D001920
)	O	O
.	O	O

Captopril	B-Chemical	D002216
may	O	O
,	O	O
by	O	O
the	O	O
same	O	O
mechanism	O	O
,	O	O
reduce	O	O
the	O	O
increase	O	O
in	O	O
glomerular	O	O
filtration	O	O
that	O	O
is	O	O
known	O	O
to	O	O
occur	O	O
after	O	O
an	O	O
injection	O	O
of	O	O
thrombin	O	O
,	O	O
thereby	O	O
diminishing	O	O
the	O	O
aggregation	O	O
of	O	O
fibrin	O	O
monomers	O	O
in	O	O
the	O	O
glomeruli	O	O
,	O	O
with	O	O
the	O	O
result	O	O
that	O	O
less	O	O
fibrin	O	O
will	O	O
be	O	O
deposited	O	O
and	O	O
thus	O	O
less	O	O
kidney	B-Disease	D007674
damage	I-Disease	D007674
will	O	O
be	O	O
produced	O	O
.	O	O

A	O	O
randomized	O	O
comparison	O	O
of	O	O
labetalol	B-Chemical	D007741
and	O	O
nitroprusside	B-Chemical	D009599
for	O	O
induced	O	O
hypotension	B-Disease	D007022
.	O	O

In	O	O
a	O	O
randomized	O	O
study	O	O
,	O	O
labetalol	B-Chemical	D007741
-	O	O
induced	O	O
hypotension	B-Disease	D007022
and	O	O
nitroprusside	B-Chemical	D009599
-	O	O
induced	O	O
hypotension	B-Disease	D007022
were	O	O
compared	O	O
in	O	O
20	O	O
patients	O	O
(	O	O
10	O	O
in	O	O
each	O	O
group	O	O
)	O	O
scheduled	O	O
for	O	O
major	O	O
orthopedic	O	O
procedures	O	O
.	O	O

Each	O	O
patient	O	O
was	O	O
subjected	O	O
to	O	O
an	O	O
identical	O	O
anesthetic	O	O
protocol	O	O
and	O	O
similar	O	O
drug	O	O
-	O	O
induced	O	O
reductions	B-Disease	D007022
in	I-Disease	D007022
mean	I-Disease	D007022
arterial	I-Disease	D007022
blood	I-Disease	D007022
pressure	I-Disease	D007022
(	O	O
BP	O	O
)	O	O
(	O	O
50	O	O
to	O	O
55	O	O
mmHg	O	O
)	O	O
.	O	O

Nitroprusside	O	O
infusion	O	O
was	O	O
associated	O	O
with	O	O
a	O	O
significant	O	O
(	O	O
p	O	O
less	O	O
than	O	O
0	O	O
.	O	O

05	O	O
)	O	O
increase	B-Disease	D016534
in	I-Disease	D016534
heart	I-Disease	D016534
rate	I-Disease	D016534
and	I-Disease	D016534
cardiac	I-Disease	D016534
output	I-Disease	D016534
;	O	O
rebound	O	O
hypertension	B-Disease	D006973
was	O	O
observed	O	O
in	O	O
three	O	O
patients	O	O
after	O	O
discontinuation	O	O
of	O	O
nitroprusside	B-Chemical	D009599
.	O	O

Labetalol	B-Chemical	D007741
administration	O	O
was	O	O
not	O	O
associated	O	O
with	O	O
any	O	O
of	O	O
these	O	O
findings	O	O
.	O	O

Arterial	O	O
PO2	B-Chemical	C093415
decreased	O	O
in	O	O
both	O	O
groups	O	O
.	O	O

It	O	O
was	O	O
concluded	O	O
that	O	O
labetalol	B-Chemical	D007741
offers	O	O
advantages	O	O
over	O	O
nitroprusside	B-Chemical	D009599
.	O	O

Chronic	O	O
carbamazepine	B-Chemical	D002220
treatment	O	O
in	O	O
the	O	O
rat	O	O
:	O	O
efficacy	O	O
,	O	O
toxicity	B-Disease	D064420
,	O	O
and	O	O
effect	O	O
on	O	O
plasma	O	O
and	O	O
tissue	O	O
folate	B-Chemical	D005492
concentrations	O	O
.	O	O

Folate	B-Chemical	D005492
depletion	O	O
has	O	O
often	O	O
been	O	O
a	O	O
problem	O	O
in	O	O
chronic	O	O
antiepileptic	O	O
drug	O	O
(	O	O
AED	O	O
)	O	O
therapy	O	O
.	O	O

Carbamazepine	B-Chemical	D002220
(	O	O
CBZ	B-Chemical	D002220
)	O	O
,	O	O
a	O	O
commonly	O	O
used	O	O
AED	O	O
,	O	O
has	O	O
been	O	O
implicated	O	O
in	O	O
some	O	O
clinical	O	O
studies	O	O
.	O	O

A	O	O
rat	O	O
model	O	O
was	O	O
developed	O	O
to	O	O
examine	O	O
the	O	O
effects	O	O
of	O	O
chronic	O	O
CBZ	B-Chemical	D002220
treatment	O	O
on	O	O
folate	B-Chemical	D005492
concentrations	O	O
in	O	O
the	O	O
rat	O	O
.	O	O

In	O	O
the	O	O
course	O	O
of	O	O
developing	O	O
this	O	O
model	O	O
,	O	O
a	O	O
common	O	O
vehicle	O	O
,	O	O
propylene	B-Chemical	D019946
glycol	I-Chemical	D019946
,	O	O
by	O	O
itself	O	O
in	O	O
high	O	O
doses	O	O
,	O	O
was	O	O
found	O	O
to	O	O
exhibit	O	O
protective	O	O
properties	O	O
against	O	O
induced	O	O
seizures	B-Disease	D012640
and	O	O
inhibited	O	O
weight	B-Disease	D015430
gain	I-Disease	D015430
.	O	O

Seizures	B-Disease	D012640
induced	O	O
by	O	O
hexafluorodiethyl	B-Chemical	D005481
ether	I-Chemical	D005481
(	O	O
HFDE	B-Chemical	D005481
)	O	O
were	O	O
also	O	O
found	O	O
to	O	O
be	O	O
a	O	O
more	O	O
sensitive	O	O
measure	O	O
of	O	O
protection	O	O
by	O	O
CBZ	B-Chemical	D002220
than	O	O
seizures	B-Disease	D012640
induced	O	O
by	O	O
maximal	O	O
electroshock	O	O
(	O	O
MES	O	O
)	O	O
.	O	O

Oral	O	O
administration	O	O
of	O	O
CBZ	B-Chemical	D002220
as	O	O
an	O	O
aqueous	O	O
suspension	O	O
every	O	O
8	O	O
h	O	O
at	O	O
a	O	O
dose	O	O
of	O	O
250	O	O
mg	O	O
/	O	O
kg	O	O
was	O	O
continuously	O	O
protective	O	O
against	O	O
HFDE	B-Chemical	D005481
-	O	O
induced	O	O
seizures	B-Disease	D012640
and	O	O
was	O	O
minimally	O	O
toxic	O	O
as	O	O
measured	O	O
by	O	O
weight	B-Disease	D015430
gain	I-Disease	D015430
over	O	O
8	O	O
weeks	O	O
of	O	O
treatment	O	O
.	O	O

The	O	O
CBZ	B-Chemical	D002220
levels	O	O
measured	O	O
in	O	O
plasma	O	O
and	O	O
brain	O	O
of	O	O
these	O	O
animals	O	O
,	O	O
however	O	O
,	O	O
were	O	O
below	O	O
those	O	O
normally	O	O
considered	O	O
protective	O	O
.	O	O

This	O	O
treatment	O	O
with	O	O
CBZ	B-Chemical	D002220
had	O	O
no	O	O
apparent	O	O
adverse	O	O
effect	O	O
on	O	O
folate	B-Chemical	D005492
concentrations	O	O
in	O	O
the	O	O
rat	O	O
,	O	O
and	O	O
,	O	O
indeed	O	O
,	O	O
the	O	O
folate	B-Chemical	D005492
concentration	O	O
increased	O	O
in	O	O
liver	O	O
after	O	O
6	O	O
weeks	O	O
of	O	O
treatment	O	O
and	O	O
in	O	O
plasma	O	O
at	O	O
8	O	O
weeks	O	O
of	O	O
treatment	O	O
.	O	O

Inhibition	O	O
of	O	O
sympathoadrenal	O	O
activity	O	O
by	O	O
atrial	O	O
natriuretic	O	O
factor	O	O
in	O	O
dogs	O	O
.	O	O

In	O	O
six	O	O
conscious	O	O
,	O	O
trained	O	O
dogs	O	O
,	O	O
maintained	O	O
on	O	O
a	O	O
normal	O	O
sodium	B-Chemical	D012964
intake	O	O
of	O	O
2	O	O
to	O	O
4	O	O
mEq	O	O
/	O	O
kg	O	O
/	O	O
day	O	O
,	O	O
sympathetic	O	O
activity	O	O
was	O	O
assessed	O	O
as	O	O
the	O	O
release	O	O
rate	O	O
of	O	O
norepinephrine	B-Chemical	D009638
and	O	O
epinephrine	B-Chemical	D004837
during	O	O
15	O	O
-	O	O
minute	O	O
i	O	O
.	O	O

v	O	O
.	O	O

infusions	O	O
of	O	O
human	O	O
alpha	O	O
-	O	O
atrial	O	O
natriuretic	O	O
factor	O	O
.	O	O

Mean	O	O
arterial	O	O
pressure	O	O
(	O	O
as	O	O
a	O	O
percentage	O	O
of	O	O
control	O	O
+	O	O
/	O	O
-	O	O
SEM	O	O
)	O	O
during	O	O
randomized	O	O
infusions	O	O
of	O	O
0	O	O
.	O	O

03	O	O
,	O	O
0	O	O
.	O	O

1	O	O
,	O	O
0	O	O
.	O	O

3	O	O
,	O	O
or	O	O
1	O	O
.	O	O

0	O	O
microgram	O	O
/	O	O
kg	O	O
/	O	O
min	O	O
was	O	O
99	O	O
+	O	O
/	O	O
-	O	O
1	O	O
,	O	O
95	O	O
+	O	O
/	O	O
-	O	O
1	O	O
(	O	O
p	O	O
less	O	O
than	O	O
0	O	O
.	O	O

05	O	O
)	O	O
,	O	O
93	O	O
+	O	O
/	O	O
-	O	O
1	O	O
(	O	O
p	O	O
less	O	O
than	O	O
0	O	O
.	O	O

01	O	O
)	O	O
,	O	O
or	O	O
79	O	O
+	O	O
/	O	O
-	O	O
6%	O	O
(	O	O
p	O	O
less	O	O
than	O	O
0	O	O
.	O	O

001	O	O
)	O	O
,	O	O
respectively	O	O
,	O	O
but	O	O
no	O	O
tachycardia	B-Disease	D013610
and	O	O
no	O	O
augmentation	O	O
of	O	O
the	O	O
norepinephrine	B-Chemical	D009638
release	O	O
rate	O	O
(	O	O
up	O	O
to	O	O
0	O	O
.	O	O

3	O	O
microgram	O	O
/	O	O
kg	O	O
/	O	O
min	O	O
)	O	O
were	O	O
observed	O	O
,	O	O
which	O	O
is	O	O
in	O	O
contrast	O	O
to	O	O
comparable	O	O
hypotension	B-Disease	D007022
induced	O	O
by	O	O
hydralazine	B-Chemical	D006830
or	O	O
nitroglycerin	B-Chemical	D005996
.	O	O

The	O	O
release	O	O
rate	O	O
of	O	O
epinephrine	B-Chemical	D004837
(	O	O
control	O	O
,	O	O
6	O	O
.	O	O

7	O	O
+	O	O
/	O	O
-	O	O
0	O	O
.	O	O

6	O	O
ng	O	O
/	O	O
kg	O	O
/	O	O
min	O	O
)	O	O
declined	O	O
immediately	O	O
during	O	O
infusions	O	O
of	O	O
atrial	O	O
natriuretic	O	O
factor	O	O
to	O	O
a	O	O
minimum	O	O
of	O	O
49	O	O
+	O	O
/	O	O
-	O	O
5%	O	O
of	O	O
control	O	O
(	O	O
p	O	O
less	O	O
than	O	O
0	O	O
.	O	O

001	O	O
)	O	O
during	O	O
0	O	O
.	O	O

1	O	O
microgram	O	O
/	O	O
kg	O	O
/	O	O
min	O	O
and	O	O
to	O	O
63	O	O
+	O	O
/	O	O
-	O	O
5%	O	O
(	O	O
0	O	O
.	O	O

1	O	O
greater	O	O
than	O	O
p	O	O
greater	O	O
than	O	O
0	O	O
.	O	O

05	O	O
)	O	O
or	O	O
95	O	O
+	O	O
/	O	O
-	O	O
13%	O	O
(	O	O
not	O	O
significant	O	O
)	O	O
during	O	O
0	O	O
.	O	O

3	O	O
or	O	O
1	O	O
.	O	O

0	O	O
microgram	O	O
/	O	O
kg	O	O
/	O	O
min	O	O
.	O	O

Steady	O	O
state	O	O
arterial	O	O
plasma	O	O
concentrations	O	O
of	O	O
atrial	O	O
natriuretic	O	O
factor	O	O
were	O	O
39	O	O
+	O	O
/	O	O
-	O	O
10	O	O
pg	O	O
/	O	O
ml	O	O
(	O	O
n	O	O
=	O	O
6	O	O
)	O	O
during	O	O
infusions	O	O
of	O	O
saline	O	O
and	O	O
284	O	O
+	O	O
/	O	O
-	O	O
24	O	O
pg	O	O
/	O	O
ml	O	O
(	O	O
n	O	O
=	O	O
6	O	O
)	O	O
and	O	O
1520	O	O
+	O	O
/	O	O
-	O	O
300	O	O
pg	O	O
/	O	O
ml	O	O
(	O	O
n	O	O
=	O	O
9	O	O
)	O	O
during	O	O
0	O	O
.	O	O

03	O	O
and	O	O
0	O	O
.	O	O

1	O	O
microgram	O	O
/	O	O
kg	O	O
/	O	O
min	O	O
infusions	O	O
of	O	O
the	O	O
factor	O	O
.	O	O

(	O	O
ABSTRACT	O	O
TRUNCATED	O	O
AT	O	O
250	O	O
WORDS	O	O
)	O	O
Death	B-Disease	D003643
from	O	O
chemotherapy	O	O
in	O	O
gestational	B-Disease	D031901
trophoblastic	I-Disease	D031901
disease	I-Disease	D031901
.	O	O

Multiple	O	O
cytotoxic	O	O
drug	O	O
administration	O	O
is	O	O
the	O	O
generally	O	O
accepted	O	O
treatment	O	O
of	O	O
patients	O	O
with	O	O
a	O	O
high	O	O
-	O	O
risk	O	O
stage	O	O
of	O	O
choriocarcinoma	B-Disease	D002822
.	O	O

Based	O	O
on	O	O
this	O	O
principle	O	O
a	O	O
27	O	O
-	O	O
year	O	O
old	O	O
woman	O	O
,	O	O
classified	O	O
as	O	O
being	O	O
in	O	O
the	O	O
high	O	O
-	O	O
risk	O	O
group	O	O
(	O	O
Goldstein	O	O
and	O	O
Berkowitz	O	O
score	O	O
:	O	O
11	O	O
)	O	O
,	O	O
was	O	O
treated	O	O
with	O	O
multiple	O	O
cytotoxic	O	O
drugs	O	O
.	O	O

The	O	O
multiple	O	O
drug	O	O
schema	O	O
consisted	O	O
of	O	O
:	O	O
Etoposide	B-Chemical	D005047
16	O	O
.	O	O

213	O	O
,	O	O
Methotrexate	B-Chemical	D008727
,	O	O
Cyclophosphamide	B-Chemical	D003520
,	O	O
Actomycin	B-Chemical	D003609
-	I-Chemical	D003609
D	I-Chemical	D003609
,	O	O
and	O	O
Cisplatin	B-Chemical	D002945
.	O	O

On	O	O
the	O	O
first	O	O
day	O	O
of	O	O
the	O	O
schedule	O	O
,	O	O
moderate	O	O
high	O	O
doses	O	O
of	O	O
Methotrexate	B-Chemical	D008727
,	O	O
Etoposide	B-Chemical	D005047
and	O	O
Cyclophosphamide	B-Chemical	D003520
were	O	O
administered	O	O
.	O	O

Within	O	O
8	O	O
hours	O	O
after	O	O
initiation	O	O
of	O	O
therapy	O	O
the	O	O
patient	O	O
died	O	O
with	O	O
a	O	O
clinical	O	O
picture	O	O
resembling	O	O
massive	O	O
pulmonary	B-Disease	D011655
obstruction	I-Disease	D011655
due	O	O
to	O	O
choriocarcinomic	O	O
tissue	O	O
plugs	O	O
,	O	O
probably	O	O
originating	O	O
from	O	O
the	O	O
uterus	O	O
.	O	O

Formation	O	O
of	O	O
these	O	O
plugs	O	O
was	O	O
probably	O	O
due	O	O
to	O	O
extensive	O	O
tumor	B-Disease	D009369
necrosis	B-Disease	D009336
at	O	O
the	O	O
level	O	O
of	O	O
the	O	O
walls	O	O
of	O	O
the	O	O
major	O	O
uterine	O	O
veins	O	O
,	O	O
which	O	O
resulted	O	O
in	O	O
an	O	O
open	O	O
exchange	O	O
of	O	O
tumor	B-Disease	D009369
plugs	O	O
to	O	O
the	O	O
vascular	O	O
spaces	O	O
;	O	O
decrease	O	O
in	O	O
tumor	B-Disease	D009369
tissue	O	O
coherence	O	O
secondary	O	O
to	O	O
chemotherapy	O	O
may	O	O
have	O	O
further	O	O
contributed	O	O
to	O	O
the	O	O
formation	O	O
of	O	O
tumor	B-Disease	D009369
emboli	O	O
.	O	O

In	O	O
view	O	O
of	O	O
the	O	O
close	O	O
time	O	O
association	O	O
between	O	O
the	O	O
start	O	O
of	O	O
chemotherapy	O	O
and	O	O
the	O	O
acute	O	O
onset	O	O
of	O	O
massive	O	O
embolism	B-Disease	D004617
other	O	O
explanations	O	O
,	O	O
such	O	O
as	O	O
spontaneous	O	O
necrosis	B-Disease	D009336
,	O	O
must	O	O
be	O	O
considered	O	O
less	O	O
likely	O	O
.	O	O

Patients	O	O
with	O	O
large	O	O
pelvic	B-Disease	D010386
tumor	I-Disease	D010386
loads	O	O
are	O	O
,	O	O
according	O	O
to	O	O
existing	O	O
classifications	O	O
,	O	O
at	O	O
high	O	O
risk	O	O
to	O	O
die	O	O
and	O	O
to	O	O
develop	O	O
drug	O	O
resistance	O	O
.	O	O

Notwithstanding	O	O
these	O	O
facts	O	O
our	O	O
findings	O	O
suggest	O	O
that	O	O
these	O	O
patients	O	O
might	O	O
benefit	O	O
from	O	O
relatively	O	O
mild	O	O
initial	O	O
treatment	O	O
,	O	O
especially	O	O
true	O	O
for	O	O
patients	O	O
not	O	O
previously	O	O
exposed	O	O
to	O	O
this	O	O
drug	O	O
.	O	O

Close	O	O
observation	O	O
of	O	O
the	O	O
response	O	O
status	O	O
both	O	O
clinically	O	O
and	O	O
with	O	O
beta	O	O
-	O	O
hCG	O	O
values	O	O
may	O	O
indicate	O	O
whether	O	O
and	O	O
when	O	O
more	O	O
agressive	O	O
combination	O	O
chemotherapy	O	O
should	O	O
be	O	O
started	O	O
.	O	O

(	O	O
ABSTRACT	O	O
TRUNCATED	O	O
AT	O	O
250	O	O
WORDS	O	O
)	O	O
Sexual	B-Disease	D012735
dysfunction	I-Disease	D012735
among	O	O
patients	O	O
with	O	O
arthritis	B-Disease	D001168
.	O	O

The	O	O
relationship	O	O
of	O	O
arthritis	B-Disease	D001168
and	O	O
sexual	B-Disease	D012735
dysfunction	I-Disease	D012735
was	O	O
investigated	O	O
among	O	O
169	O	O
patients	O	O
with	O	O
rheumatoid	B-Disease	D001172
arthritis	I-Disease	D001172
,	O	O
osteoarthritis	B-Disease	D010003
and	O	O
spondyloarthropathy	B-Disease	D025242
,	O	O
130	O	O
of	O	O
whom	O	O
were	O	O
pair	O	O
-	O	O
matched	O	O
to	O	O
controls	O	O
.	O	O

Assessments	O	O
of	O	O
marital	O	O
happiness	O	O
and	O	O
depressed	B-Disease	D003866
mood	I-Disease	D003866
were	O	O
also	O	O
made	O	O
using	O	O
the	O	O
CES	O	O
-	O	O
D	O	O
and	O	O
the	O	O
Azrin	O	O
Marital	O	O
Happiness	O	O
Scale	O	O
(	O	O
AMHS	O	O
)	O	O
.	O	O

Sexual	B-Disease	D012735
dysfunctions	I-Disease	D012735
were	O	O
found	O	O
to	O	O
be	O	O
common	O	O
among	O	O
patients	O	O
and	O	O
controls	O	O
,	O	O
the	O	O
majority	O	O
in	O	O
both	O	O
groups	O	O
reporting	O	O
one	O	O
or	O	O
more	O	O
dysfunctions	O	O
.	O	O

Impotence	B-Disease	D007172
was	O	O
more	O	O
common	O	O
among	O	O
male	O	O
patients	O	O
than	O	O
controls	O	O
and	O	O
was	O	O
found	O	O
to	O	O
be	O	O
associated	O	O
with	O	O
co	O	O
-	O	O
morbidity	O	O
and	O	O
the	O	O
taking	O	O
of	O	O
methotrexate	B-Chemical	D008727
.	O	O

Depressed	B-Disease	D003866
mood	I-Disease	D003866
was	O	O
more	O	O
common	O	O
among	O	O
patients	O	O
and	O	O
was	O	O
associated	O	O
with	O	O
certain	O	O
sexual	O	O
difficulties	O	O
,	O	O
but	O	O
not	O	O
with	O	O
impotence	B-Disease	D007172
.	O	O

Marital	O	O
unhappiness	O	O
,	O	O
as	O	O
indicated	O	O
by	O	O
AMHS	O	O
scores	O	O
,	O	O
was	O	O
not	O	O
associated	O	O
with	O	O
arthritis	B-Disease	D001168
but	O	O
was	O	O
associated	O	O
with	O	O
sexual	B-Disease	D012735
dysfunction	I-Disease	D012735
,	O	O
sexual	O	O
dissatisfaction	O	O
and	O	O
being	O	O
female	O	O
.	O	O

Does	O	O
paracetamol	B-Chemical	D000082
cause	O	O
urothelial	B-Disease	D014523
cancer	I-Disease	D014523
or	O	O
renal	O	O
papillary	O	O
necrosis?	O	O
The	O	O
risk	O	O
of	O	O
developing	O	O
renal	B-Disease	D007681
papillary	I-Disease	D007681
necrosis	I-Disease	D007681
or	O	O
cancer	O	O
of	O	O
the	O	O
renal	O	O
pelvis	O	O
,	O	O
ureter	O	O
or	O	O
bladder	O	O
associated	O	O
with	O	O
consumption	O	O
of	O	O
either	O	O
phenacetin	B-Chemical	D010615
or	O	O
paracetamol	B-Chemical	D000082
was	O	O
calculated	O	O
from	O	O
data	O	O
acquired	O	O
by	O	O
questionnaire	O	O
from	O	O
381	O	O
cases	O	O
and	O	O
808	O	O
controls	O	O
.	O	O

The	O	O
risk	O	O
of	O	O
renal	B-Disease	D007681
papillary	I-Disease	D007681
necrosis	I-Disease	D007681
was	O	O
increased	O	O
nearly	O	O
20	O	O
-	O	O
fold	O	O
by	O	O
consumption	O	O
of	O	O
phenacetin	B-Chemical	D010615
,	O	O
which	O	O
also	O	O
increased	O	O
the	O	O
risk	O	O
for	O	O
cancer	O	O
of	O	O
the	O	O
renal	O	O
pelvis	O	O
and	O	O
bladder	O	O
but	O	O
not	O	O
for	O	O
ureteric	B-Disease	D014516
cancer	I-Disease	D014516
.	O	O

By	O	O
contrast	O	O
,	O	O
we	O	O
were	O	O
unable	O	O
to	O	O
substantiate	O	O
an	O	O
increased	O	O
risk	O	O
from	O	O
paracetamol	B-Chemical	D000082
consumption	O	O
for	O	O
renal	B-Disease	D007681
papillary	I-Disease	D007681
necrosis	I-Disease	D007681
or	O	O
any	O	O
of	O	O
these	O	O
cancers	B-Disease	D009369
although	O	O
there	O	O
was	O	O
a	O	O
suggestion	O	O
of	O	O
an	O	O
association	O	O
with	O	O
cancer	B-Disease	D014516
of	I-Disease	D014516
the	I-Disease	D014516
ureter	I-Disease	D014516
.	O	O

Dapsone	B-Chemical	D003622
-	O	O
associated	O	O
Heinz	O	O
body	O	O
hemolytic	B-Disease	D000743
anemia	I-Disease	D000743
in	O	O
a	O	O
Cambodian	O	O
woman	O	O
with	O	O
hemoglobin	O	O
E	O	O
trait	O	O
.	O	O

A	O	O
Cambodian	O	O
woman	O	O
with	O	O
hemoglobin	O	O
E	O	O
trait	O	O
(	O	O
AE	O	O
)	O	O
and	O	O
leprosy	B-Disease	D007918
developed	O	O
a	O	O
Heinz	O	O
body	O	O
hemolytic	B-Disease	D000743
anemia	I-Disease	D000743
while	O	O
taking	O	O
a	O	O
dose	O	O
of	O	O
dapsone	B-Chemical	D003622
(	O	O
50	O	O
mg	O	O
/	O	O
day	O	O
)	O	O
not	O	O
usually	O	O
associated	O	O
with	O	O
clinical	O	O
hemolysis	B-Disease	D006461
.	O	O

Her	O	O
red	O	O
blood	O	O
cells	O	O
(	O	O
RBCs	O	O
)	O	O
had	O	O
increased	O	O
incubated	O	O
Heinz	O	O
body	O	O
formation	O	O
,	O	O
decreased	O	O
reduced	O	O
glutathione	B-Chemical	D005978
(	O	O
GSH	B-Chemical	D005978
)	O	O
,	O	O
and	O	O
decreased	O	O
GSH	B-Chemical	D005978
stability	O	O
.	O	O

The	O	O
pentose	B-Chemical	D010428
phosphate	I-Chemical	D010428
shunt	O	O
activity	O	O
of	O	O
the	O	O
dapsone	B-Chemical	D003622
-	O	O
exposed	O	O
AE	O	O
RBCs	O	O
was	O	O
increased	O	O
compared	O	O
to	O	O
normal	O	O
RBCs	O	O
.	O	O

Although	O	O
the	O	O
AE	O	O
RBCs	O	O
from	O	O
an	O	O
individual	O	O
not	O	O
taking	O	O
dapsone	B-Chemical	D003622
had	O	O
increased	O	O
incubated	O	O
Heinz	O	O
body	O	O
formation	O	O
,	O	O
the	O	O
GSH	B-Chemical	D005978
content	O	O
and	O	O
GSH	B-Chemical	D005978
stability	O	O
were	O	O
normal	O	O
.	O	O

The	O	O
pentose	B-Chemical	D010428
phosphate	I-Chemical	D010428
shunt	O	O
activity	O	O
of	O	O
the	O	O
non	O	O
-	O	O
dapsone	B-Chemical	D003622
-	O	O
exposed	O	O
AE	O	O
RBCs	O	O
was	O	O
decreased	O	O
compared	O	O
to	O	O
normal	O	O
RBCs	O	O
.	O	O

Thus	O	O
,	O	O
AE	O	O
RBCs	O	O
appear	O	O
to	O	O
have	O	O
an	O	O
increased	O	O
sensitivity	O	O
to	O	O
oxidant	O	O
stress	O	O
both	O	O
in	O	O
vitro	O	O
and	O	O
in	O	O
vivo	O	O
,	O	O
since	O	O
dapsone	B-Chemical	D003622
does	O	O
not	O	O
cause	O	O
hemolytic	B-Disease	D000743
anemia	I-Disease	D000743
at	O	O
this	O	O
dose	O	O
in	O	O
hematologically	O	O
normal	O	O
individuals	O	O
.	O	O

Given	O	O
the	O	O
influx	O	O
of	O	O
Southeast	O	O
Asians	O	O
into	O	O
the	O	O
United	O	O
States	O	O
,	O	O
oxidant	O	O
medications	O	O
should	O	O
be	O	O
used	O	O
with	O	O
caution	O	O
,	O	O
especially	O	O
if	O	O
an	O	O
infection	B-Disease	D007239
is	O	O
present	O	O
,	O	O
in	O	O
individuals	O	O
of	O	O
ethnic	O	O
backgrounds	O	O
that	O	O
have	O	O
an	O	O
increased	O	O
prevalence	O	O
of	O	O
hemoglobin	O	O
E	O	O
.	O	O

Severe	O	O
complications	O	O
of	O	O
antianginal	O	O
drug	O	O
therapy	O	O
in	O	O
a	O	O
patient	O	O
identified	O	O
as	O	O
a	O	O
poor	O	O
metabolizer	O	O
of	O	O
metoprolol	B-Chemical	D008790
,	O	O
propafenone	B-Chemical	D011405
,	O	O
diltiazem	B-Chemical	D004110
,	O	O
and	O	O
sparteine	B-Chemical	D013034
.	O	O

A	O	O
47	O	O
-	O	O
year	O	O
-	O	O
old	O	O
patient	O	O
suffering	O	O
from	O	O
coronary	B-Disease	D003324
artery	I-Disease	D003324
disease	I-Disease	D003324
was	O	O
admitted	O	O
to	O	O
the	O	O
CCU	O	O
in	O	O
shock	B-Disease	D012769
with	O	O
III	O	O
.	O	O

AV	B-Disease	D054537
block	I-Disease	D054537
,	O	O
severe	O	O
hypotension	B-Disease	D007022
,	O	O
and	O	O
impairment	B-Disease	D018754
of	I-Disease	D018754
ventricular	I-Disease	D018754
function	I-Disease	D018754
.	O	O

One	O	O
week	O	O
prior	O	O
to	O	O
admission	O	O
a	O	O
therapy	O	O
with	O	O
standard	O	O
doses	O	O
of	O	O
metoprolol	B-Chemical	D008790
(	O	O
100	O	O
mg	O	O
t	O	O
.	O	O

i	O	O
.	O	O

d	O	O
.	O	O

and	O	O
then	O	O
100	O	O
mg	O	O
b	O	O
.	O	O

i	O	O
.	O	O

d	O	O
.	O	O

)	O	O
had	O	O
been	O	O
initiated	O	O
.	O	O

Two	O	O
days	O	O
before	O	O
admission	O	O
diltiazem	B-Chemical	D004110
(	O	O
60	O	O
mg	O	O
b	O	O
.	O	O

i	O	O
.	O	O

d	O	O
.	O	O

)	O	O
was	O	O
prescribed	O	O
in	O	O
addition	O	O
.	O	O

Analyses	O	O
of	O	O
a	O	O
blood	O	O
sample	O	O
revealed	O	O
unusually	O	O
high	O	O
plasma	O	O
concentrations	O	O
of	O	O
metoprolol	B-Chemical	D008790
(	O	O
greater	O	O
than	O	O
3000	O	O
ng	O	O
/	O	O
ml	O	O
)	O	O
and	O	O
diltiazem	B-Chemical	D004110
(	O	O
526	O	O
ng	O	O
/	O	O
ml	O	O
)	O	O
.	O	O

The	O	O
patient	O	O
recovered	O	O
within	O	O
1	O	O
week	O	O
following	O	O
discontinuation	O	O
of	O	O
antianginal	O	O
therapy	O	O
.	O	O

Three	O	O
months	O	O
later	O	O
the	O	O
patient	O	O
was	O	O
exposed	O	O
to	O	O
a	O	O
single	O	O
dose	O	O
of	O	O
metoprolol	B-Chemical	D008790
,	O	O
diltiazem	B-Chemical	D004110
,	O	O
propafenone	B-Chemical	D011405
(	O	O
since	O	O
he	O	O
had	O	O
received	O	O
this	O	O
drug	O	O
in	O	O
the	O	O
past	O	O
)	O	O
,	O	O
and	O	O
sparteine	B-Chemical	D013034
(	O	O
as	O	O
a	O	O
probe	O	O
for	O	O
the	O	O
debrisoquine	B-Chemical	D003647
/	O	O
sparteine	B-Chemical	D013034
type	O	O
polymorphism	O	O
of	O	O
oxidative	O	O
drug	O	O
metabolism	O	O
)	O	O
.	O	O

It	O	O
was	O	O
found	O	O
that	O	O
he	O	O
was	O	O
a	O	O
poor	O	O
metabolizer	O	O
of	O	O
all	O	O
four	O	O
drugs	O	O
,	O	O
indicating	O	O
that	O	O
their	O	O
metabolism	O	O
is	O	O
under	O	O
the	O	O
same	O	O
genetic	O	O
control	O	O
.	O	O

Therefore	O	O
,	O	O
patients	O	O
belonging	O	O
to	O	O
the	O	O
poor	O	O
-	O	O
metabolizer	O	O
phenotype	O	O
of	O	O
sparteine	B-Chemical	D013034
/	O	O
debrisoquine	B-Chemical	D003647
polymorphism	O	O
in	O	O
drug	O	O
metabolism	O	O
,	O	O
which	O	O
constitutes	O	O
6	O	O
.	O	O

4%	O	O
of	O	O
the	O	O
German	O	O
population	O	O
,	O	O
may	O	O
experience	O	O
adverse	B-Disease	D064420
drug	I-Disease	D064420
reactions	I-Disease	D064420
when	O	O
treated	O	O
with	O	O
standard	O	O
doses	O	O
of	O	O
one	O	O
of	O	O
these	O	O
drugs	O	O
alone	O	O
.	O	O

Moreover	O	O
,	O	O
the	O	O
coadministration	O	O
of	O	O
these	O	O
frequently	O	O
used	O	O
drugs	O	O
is	O	O
expected	O	O
to	O	O
be	O	O
especially	O	O
harmful	O	O
in	O	O
this	O	O
subgroup	O	O
of	O	O
patients	O	O
.	O	O

Triazolam	B-Chemical	D014229
-	O	O
induced	O	O
brief	O	O
episodes	O	O
of	O	O
secondary	O	O
mania	B-Disease	D001714
in	O	O
a	O	O
depressed	B-Disease	D003866
patient	O	O
.	O	O

Large	O	O
doses	O	O
of	O	O
triazolam	B-Chemical	D014229
repeatedly	O	O
induced	O	O
brief	O	O
episodes	O	O
of	O	O
mania	B-Disease	D001714
in	O	O
a	O	O
depressed	B-Disease	D003866
elderly	O	O
woman	O	O
.	O	O

Features	O	O
of	O	O
organic	B-Disease	D019965
mental	I-Disease	D019965
disorder	I-Disease	D019965
(	O	O
delirium	B-Disease	D003693
)	O	O
were	O	O
not	O	O
present	O	O
.	O	O

Manic	B-Disease	D001714
excitement	O	O
was	O	O
coincident	O	O
with	O	O
the	O	O
duration	O	O
of	O	O
action	O	O
of	O	O
triazolam	B-Chemical	D014229
.	O	O

The	O	O
possible	O	O
contribution	O	O
of	O	O
the	O	O
triazolo	B-Chemical	D014229
group	O	O
to	O	O
changes	O	O
in	O	O
affective	O	O
status	O	O
is	O	O
discussed	O	O
.	O	O

On	O	O
the	O	O
mechanisms	O	O
of	O	O
the	O	O
development	O	O
of	O	O
tolerance	O	O
to	O	O
the	O	O
muscular	B-Disease	D009127
rigidity	I-Disease	D009127
produced	O	O
by	O	O
morphine	B-Chemical	D009020
in	O	O
rats	O	O
.	O	O

The	O	O
development	O	O
of	O	O
tolerance	O	O
to	O	O
the	O	O
muscular	B-Disease	D009127
rigidity	I-Disease	D009127
produced	O	O
by	O	O
morphine	B-Chemical	D009020
was	O	O
studied	O	O
in	O	O
rats	O	O
.	O	O

Saline	O	O
-	O	O
pretreated	O	O
controls	O	O
given	O	O
a	O	O
test	O	O
dose	O	O
of	O	O
morphine	B-Chemical	D009020
(	O	O
20	O	O
mg	O	O
/	O	O
kg	O	O
i	O	O
.	O	O

p	O	O
.	O	O

)	O	O
showed	O	O
a	O	O
pronounced	O	O
rigidity	B-Disease	D009127
recorded	O	O
as	O	O
tonic	O	O
activity	O	O
in	O	O
the	O	O
electromyogram	O	O
.	O	O

Rats	O	O
treated	O	O
for	O	O
11	O	O
days	O	O
with	O	O
morphine	B-Chemical	D009020
and	O	O
withdrawn	O	O
for	O	O
36	O	O
-	O	O
40	O	O
h	O	O
showed	O	O
differences	O	O
in	O	O
the	O	O
development	O	O
of	O	O
tolerance	O	O
:	O	O
about	O	O
half	O	O
of	O	O
the	O	O
animals	O	O
showed	O	O
a	O	O
rigidity	B-Disease	D009127
after	O	O
the	O	O
test	O	O
dose	O	O
of	O	O
morphine	B-Chemical	D009020
that	O	O
was	O	O
not	O	O
significantly	O	O
less	O	O
than	O	O
in	O	O
the	O	O
controls	O	O
and	O	O
were	O	O
akinetic	B-Disease	D018476
(	O	O
A	O	O
group	O	O
)	O	O
.	O	O

The	O	O
other	O	O
rats	O	O
showed	O	O
a	O	O
strong	O	O
decrease	O	O
in	O	O
the	O	O
rigidity	B-Disease	D009127
and	O	O
the	O	O
occurrence	O	O
of	O	O
stereotyped	O	O
(	O	O
S	O	O
)	O	O
licking	O	O
and	O	O
/	O	O
or	O	O
gnawing	O	O
in	O	O
presence	O	O
of	O	O
akinetic	B-Disease	D018476
or	O	O
hyperkinetic	B-Disease	D006948
(	O	O
K	O	O
)	O	O
behaviour	O	O
(	O	O
AS	O	O
/	O	O
KS	O	O
group	O	O
)	O	O
,	O	O
suggesting	O	O
signs	O	O
of	O	O
dopaminergic	O	O
activation	O	O
.	O	O

The	O	O
rigidity	B-Disease	D009127
was	O	O
considerably	O	O
decreased	O	O
in	O	O
both	O	O
groups	O	O
after	O	O
20	O	O
days'	O	O
treatment	O	O
.	O	O

In	O	O
a	O	O
further	O	O
series	O	O
of	O	O
experiments	O	O
,	O	O
haloperidol	B-Chemical	D006220
(	O	O
0	O	O
.	O	O

2	O	O
mg	O	O
/	O	O
kg	O	O
i	O	O
.	O	O

p	O	O
.	O	O

)	O	O
was	O	O
used	O	O
in	O	O
order	O	O
to	O	O
block	O	O
the	O	O
dopaminergic	O	O
activation	O	O
and	O	O
to	O	O
estimate	O	O
the	O	O
real	O	O
degree	O	O
of	O	O
the	O	O
tolerance	O	O
to	O	O
the	O	O
rigidity	B-Disease	D009127
without	O	O
any	O	O
dopaminergic	O	O
interference	O	O
.	O	O

Haloperidol	B-Chemical	D006220
enhanced	O	O
the	O	O
rigidity	B-Disease	D009127
in	O	O
the	O	O
A	O	O
group	O	O
.	O	O

However	O	O
,	O	O
the	O	O
level	O	O
in	O	O
the	O	O
AS	O	O
/	O	O
KS	O	O
group	O	O
remained	O	O
considerably	O	O
lower	O	O
than	O	O
in	O	O
the	O	O
A	O	O
group	O	O
.	O	O

The	O	O
results	O	O
suggest	O	O
that	O	O
rigidity	B-Disease	D009127
,	O	O
which	O	O
is	O	O
assumed	O	O
to	O	O
be	O	O
due	O	O
to	O	O
an	O	O
action	O	O
of	O	O
morphine	B-Chemical	D009020
in	O	O
the	O	O
striatum	O	O
,	O	O
can	O	O
be	O	O
antagonized	O	O
by	O	O
another	O	O
process	O	O
leading	O	O
to	O	O
dopaminergic	O	O
activation	O	O
in	O	O
the	O	O
striatum	O	O
.	O	O

Nevertheless	O	O
,	O	O
there	O	O
occurs	O	O
some	O	O
real	O	O
tolerance	O	O
to	O	O
this	O	O
effect	O	O
.	O	O

The	O	O
rapid	O	O
alternations	O	O
of	O	O
rigidity	B-Disease	D009127
and	O	O
the	O	O
signs	O	O
of	O	O
dopaminergic	O	O
activation	O	O
observed	O	O
in	O	O
the	O	O
animals	O	O
of	O	O
the	O	O
AS	O	O
/	O	O
KS	O	O
group	O	O
might	O	O
be	O	O
due	O	O
to	O	O
rapid	O	O
shifts	O	O
in	O	O
the	O	O
predominance	O	O
of	O	O
various	O	O
DA	O	O
-	O	O
innervated	O	O
structures	O	O
.	O	O

Compression	O	O
neuropathy	O	O
of	O	O
the	O	O
radial	O	O
nerve	O	O
due	O	O
to	O	O
pentazocine	B-Chemical	D010423
-	O	O
induced	O	O
fibrous	B-Disease	D005355
myopathy	I-Disease	D005355
.	O	O

Fibrous	B-Disease	D005355
myopathy	I-Disease	D005355
is	O	O
a	O	O
common	O	O
,	O	O
well	O	O
-	O	O
known	O	O
side	O	O
effect	O	O
of	O	O
repeated	O	O
pentazocine	B-Chemical	D010423
injection	O	O
.	O	O

However	O	O
,	O	O
compression	B-Disease	D009408
neuropathy	I-Disease	D009408
due	O	O
to	O	O
fibrotic	O	O
muscle	O	O
affected	O	O
by	O	O
pentazocine	B-Chemical	D010423
-	O	O
induced	O	O
myopathy	B-Disease	D009135
has	O	O
not	O	O
previously	O	O
been	O	O
reported	O	O
.	O	O

In	O	O
a	O	O
37	O	O
-	O	O
year	O	O
-	O	O
old	O	O
woman	O	O
with	O	O
documented	O	O
pentazocine	B-Chemical	D010423
-	O	O
induced	O	O
fibrous	B-Disease	D005355
myopathy	I-Disease	D005355
of	O	O
triceps	O	O
and	O	O
deltoid	O	O
muscles	O	O
bilaterally	O	O
and	O	O
a	O	O
three	O	O
-	O	O
week	O	O
history	O	O
of	O	O
right	O	O
wrist	O	O
drop	O	O
,	O	O
electrodiagnostic	O	O
examination	O	O
showed	O	O
a	O	O
severe	O	O
but	O	O
partial	O	O
lesion	O	O
of	O	O
the	O	O
right	O	O
radial	O	O
nerve	O	O
distal	O	O
to	O	O
the	O	O
branches	O	O
to	O	O
the	O	O
triceps	O	O
,	O	O
in	O	O
addition	O	O
to	O	O
the	O	O
fibrous	B-Disease	D005355
myopathy	I-Disease	D005355
.	O	O

Surgery	O	O
revealed	O	O
the	O	O
right	O	O
radial	O	O
nerve	O	O
to	O	O
be	O	O
severely	O	O
compressed	O	O
by	O	O
the	O	O
densely	O	O
fibrotic	O	O
lateral	O	O
head	O	O
of	O	O
the	O	O
triceps	O	O
.	O	O

Decompression	O	O
and	O	O
neurolysis	O	O
were	O	O
performed	O	O
with	O	O
good	O	O
subsequent	O	O
recovery	O	O
of	O	O
function	O	O
.	O	O

Recurrent	O	O
reversible	O	O
acute	B-Disease	D058186
renal	I-Disease	D058186
failure	I-Disease	D058186
from	O	O
amphotericin	B-Chemical	D000666
.	O	O

A	O	O
patient	O	O
with	O	O
cryptogenic	O	O
cirrhosis	B-Disease	D005355
and	O	O
disseminated	O	O
sporotrichosis	B-Disease	D013174
developed	O	O
acute	B-Disease	D058186
renal	I-Disease	D058186
failure	I-Disease	D058186
immediately	O	O
following	O	O
the	O	O
administration	O	O
of	O	O
amphotericin	B-Chemical	D000666
B	O	O
on	O	O
four	O	O
separate	O	O
occasions	O	O
.	O	O

The	O	O
abruptness	O	O
of	O	O
the	O	O
renal	B-Disease	D051437
failure	I-Disease	D051437
and	O	O
its	O	O
reversibility	O	O
within	O	O
days	O	O
suggests	O	O
that	O	O
there	O	O
was	O	O
a	O	O
functional	O	O
component	O	O
to	O	O
the	O	O
renal	B-Disease	D007674
dysfunction	I-Disease	D007674
.	O	O

We	O	O
propose	O	O
that	O	O
amphotericin	B-Chemical	D000666
,	O	O
in	O	O
the	O	O
setting	O	O
of	O	O
reduced	O	O
effective	O	O
arterial	O	O
volume	O	O
,	O	O
may	O	O
activate	O	O
tubuloglomerular	O	O
feedback	O	O
,	O	O
thereby	O	O
contributing	O	O
to	O	O
acute	B-Disease	D058186
renal	I-Disease	D058186
failure	I-Disease	D058186
.	O	O

Pneumonitis	O	O
with	O	O
pleural	O	O
and	O	O
pericardial	O	O
effusion	O	O
and	O	O
neuropathy	B-Disease	D009422
during	O	O
amiodarone	B-Chemical	D000638
therapy	O	O
.	O	O

A	O	O
patient	O	O
with	O	O
sinuatrial	B-Disease	D002318
disease	I-Disease	D002318
and	O	O
implanted	O	O
pacemaker	O	O
was	O	O
treated	O	O
with	O	O
amiodarone	B-Chemical	D000638
(	O	O
maximum	O	O
dose	O	O
1000	O	O
mg	O	O
,	O	O
maintenance	O	O
dose	O	O
800	O	O
mg	O	O
daily	O	O
)	O	O
for	O	O
10	O	O
months	O	O
,	O	O
for	O	O
control	O	O
of	O	O
supraventricular	B-Disease	D013617
tachyarrhythmias	I-Disease	D013617
.	O	O

He	O	O
developed	O	O
pneumonitis	B-Disease	D011014
,	O	O
pleural	O	O
and	O	O
pericardial	O	O
effusions	O	O
,	O	O
and	O	O
a	O	O
predominantly	O	O
proximal	B-Disease	D009468
motor	I-Disease	D009468
neuropathy	I-Disease	D009468
.	O	O

Immediate	O	O
but	O	O
gradual	O	O
improvement	O	O
followed	O	O
withdrawal	O	O
of	O	O
amiodarone	B-Chemical	D000638
and	O	O
treatment	O	O
with	O	O
prednisolone	B-Chemical	D011239
.	O	O

Review	O	O
of	O	O
this	O	O
and	O	O
previously	O	O
reported	O	O
cases	O	O
indicates	O	O
the	O	O
need	O	O
for	O	O
early	O	O
diagnosis	O	O
of	O	O
amiodarone	B-Chemical	D000638
pneumonitis	B-Disease	D011014
,	O	O
immediate	O	O
withdrawal	O	O
of	O	O
amiodarone	B-Chemical	D000638
,	O	O
and	O	O
prompt	O	O
but	O	O
continued	O	O
steroid	B-Chemical	D013256
therapy	O	O
to	O	O
ensure	O	O
full	O	O
recovery	O	O
.	O	O

Indomethacin	B-Chemical	D007213
-	O	O
induced	O	O
renal	B-Disease	D051437
insufficiency	I-Disease	D051437
:	O	O
recurrence	O	O
on	O	O
rechallenge	O	O
.	O	O

We	O	O
have	O	O
reported	O	O
a	O	O
case	O	O
of	O	O
acute	O	O
oliguric	O	O
renal	B-Disease	D051437
failure	I-Disease	D051437
with	O	O
hyperkalemia	B-Disease	D006947
in	O	O
a	O	O
patient	O	O
with	O	O
cirrhosis	B-Disease	D005355
,	O	O
ascites	B-Disease	D001201
,	O	O
and	O	O
cor	B-Disease	D011660
pulmonale	I-Disease	D011660
after	O	O
indomethacin	B-Chemical	D007213
therapy	O	O
.	O	O

Prompt	O	O
restoration	O	O
of	O	O
renal	O	O
function	O	O
followed	O	O
drug	O	O
withdrawal	O	O
,	O	O
while	O	O
re	O	O
-	O	O
exposure	O	O
to	O	O
a	O	O
single	O	O
dose	O	O
of	O	O
indomethacin	B-Chemical	D007213
caused	O	O
recurrence	O	O
of	O	O
acute	O	O
reversible	O	O
oliguria	B-Disease	D009846
.	O	O

Our	O	O
case	O	O
supports	O	O
the	O	O
hypothesis	O	O
that	O	O
endogenous	O	O
renal	O	O
prostaglandins	B-Chemical	D011453
play	O	O
a	O	O
role	O	O
in	O	O
the	O	O
maintenance	O	O
of	O	O
renal	O	O
blood	O	O
flow	O	O
when	O	O
circulating	O	O
plasma	O	O
volume	O	O
is	O	O
diminished	O	O
.	O	O

Since	O	O
nonsteroidal	O	O
anti	O	O
-	O	O
inflammatory	O	O
agents	O	O
interfere	O	O
with	O	O
this	O	O
compensatory	O	O
mechanism	O	O
and	O	O
may	O	O
cause	O	O
acute	B-Disease	D058186
renal	I-Disease	D058186
failure	I-Disease	D058186
,	O	O
they	O	O
should	O	O
be	O	O
used	O	O
with	O	O
caution	O	O
in	O	O
such	O	O
patients	O	O
.	O	O

Comparison	O	O
of	O	O
the	O	O
subjective	O	O
effects	O	O
and	O	O
plasma	O	O
concentrations	O	O
following	O	O
oral	O	O
and	O	O
i	O	O
.	O	O

m	O	O
.	O	O

administration	O	O
of	O	O
flunitrazepam	B-Chemical	D005445
in	O	O
volunteers	O	O
.	O	O

Flunitrazepam	B-Chemical	D005445
0	O	O
.	O	O

5	O	O
,	O	O
1	O	O
.	O	O

0	O	O
or	O	O
2	O	O
.	O	O

0	O	O
mg	O	O
was	O	O
given	O	O
by	O	O
the	O	O
oral	O	O
or	O	O
i	O	O
.	O	O

m	O	O
.	O	O

routes	O	O
to	O	O
groups	O	O
of	O	O
volunteers	O	O
and	O	O
its	O	O
effects	O	O
compared	O	O
.	O	O

Plasma	O	O
concentrations	O	O
of	O	O
the	O	O
drug	O	O
were	O	O
estimated	O	O
by	O	O
gas	O	O
-	O	O
liquid	O	O
chromatography	O	O
,	O	O
in	O	O
a	O	O
smaller	O	O
number	O	O
of	O	O
the	O	O
subjects	O	O
.	O	O

The	O	O
most	O	O
striking	O	O
effect	O	O
was	O	O
sedation	O	O
which	O	O
increased	O	O
with	O	O
the	O	O
dose	O	O
,	O	O
2	O	O
mg	O	O
producing	O	O
deep	O	O
sleep	O	O
although	O	O
the	O	O
subjects	O	O
could	O	O
still	O	O
be	O	O
aroused	O	O
.	O	O

The	O	O
effects	O	O
of	O	O
i	O	O
.	O	O

m	O	O
.	O	O

administration	O	O
were	O	O
apparent	O	O
earlier	O	O
and	O	O
sometimes	O	O
lasted	O	O
longer	O	O
than	O	O
those	O	O
following	O	O
oral	O	O
administration	O	O
.	O	O

Dizziness	B-Disease	D004244
was	O	O
less	O	O
marked	O	O
than	O	O
sedation	O	O
,	O	O
but	O	O
increased	O	O
with	O	O
the	O	O
dose	O	O
.	O	O

There	O	O
was	O	O
pain	B-Disease	D010146
on	O	O
i	O	O
.	O	O

m	O	O
.	O	O

injection	O	O
of	O	O
flunitrazepam	B-Chemical	D005445
significantly	O	O
more	O	O
often	O	O
than	O	O
with	O	O
isotonic	O	O
saline	O	O
.	O	O

Plasma	O	O
concentrations	O	O
varied	O	O
with	O	O
dose	O	O
and	O	O
route	O	O
and	O	O
corresponded	O	O
qualitatively	O	O
with	O	O
the	O	O
subjective	O	O
effects	O	O
.	O	O

The	O	O
drug	O	O
was	O	O
still	O	O
present	O	O
in	O	O
measurable	O	O
quantities	O	O
after	O	O
24	O	O
h	O	O
even	O	O
with	O	O
the	O	O
smallest	O	O
dose	O	O
.	O	O

Changes	O	O
in	O	O
heart	O	O
size	O	O
during	O	O
long	O	O
-	O	O
term	O	O
timolol	B-Chemical	D013999
treatment	O	O
after	O	O
myocardial	B-Disease	D009203
infarction	I-Disease	D009203
.	O	O

The	O	O
effect	O	O
of	O	O
long	O	O
-	O	O
term	O	O
timolol	B-Chemical	D013999
treatment	O	O
on	O	O
heart	O	O
size	O	O
after	O	O
myocardial	B-Disease	D009203
infarction	I-Disease	D009203
was	O	O
evaluated	O	O
by	O	O
X	O	O
-	O	O
ray	O	O
in	O	O
a	O	O
double	O	O
-	O	O
blind	O	O
study	O	O
including	O	O
241	O	O
patients	O	O
(	O	O
placebo	O	O
126	O	O
,	O	O
timolol	B-Chemical	D013999
115	O	O
)	O	O
.	O	O

The	O	O
follow	O	O
-	O	O
up	O	O
period	O	O
was	O	O
12	O	O
months	O	O
.	O	O

The	O	O
timolol	B-Chemical	D013999
-	O	O
treated	O	O
patients	O	O
showed	O	O
a	O	O
small	O	O
but	O	O
significant	O	O
increase	O	O
in	O	O
heart	O	O
size	O	O
from	O	O
baseline	O	O
in	O	O
contrast	O	O
to	O	O
a	O	O
decrease	O	O
in	O	O
the	O	O
placebo	O	O
group	O	O
.	O	O

These	O	O
differences	O	O
may	O	O
be	O	O
caused	O	O
by	O	O
timolol	B-Chemical	D013999
-	O	O
induced	O	O
bradycardia	B-Disease	D001919
and	O	O
a	O	O
compensatory	O	O
increase	O	O
in	O	O
end	O	O
-	O	O
diastolic	O	O
volume	O	O
.	O	O

The	O	O
timolol	B-Chemical	D013999
-	O	O
related	O	O
increase	O	O
in	O	O
heart	O	O
size	O	O
was	O	O
observed	O	O
only	O	O
in	O	O
patients	O	O
with	O	O
normal	O	O
and	O	O
borderline	O	O
heart	O	O
size	O	O
.	O	O

In	O	O
patients	O	O
with	O	O
cardiomegaly	B-Disease	D006332
,	O	O
the	O	O
increase	O	O
in	O	O
heart	O	O
size	O	O
was	O	O
similar	O	O
in	O	O
both	O	O
groups	O	O
.	O	O

After	O	O
re	O	O
-	O	O
infarction	B-Disease	D007238
,	O	O
heart	O	O
size	O	O
increased	O	O
in	O	O
the	O	O
placebo	O	O
group	O	O
and	O	O
remained	O	O
unchanged	O	O
in	O	O
the	O	O
timolol	B-Chemical	D013999
group	O	O
.	O	O

Vitamin	B-Chemical	D002762
D3	I-Chemical	D002762
toxicity	B-Disease	D064420
in	O	O
dairy	O	O
cows	O	O
.	O	O

Large	O	O
parenteral	O	O
doses	O	O
of	O	O
vitamin	B-Chemical	D002762
D3	I-Chemical	D002762
(	O	O
15	O	O
to	O	O
17	O	O
.	O	O

5	O	O
x	O	O
10	O	O
(	O	O
6	O	O
)	O	O
IU	O	O
vitamin	B-Chemical	D002762
D3	I-Chemical	D002762
)	O	O
were	O	O
associated	O	O
with	O	O
prolonged	O	O
hypercalcemia	B-Disease	D006934
,	O	O
hyperphosphatemia	B-Disease	D054559
,	O	O
and	O	O
large	O	O
increases	O	O
of	O	O
vitamin	B-Chemical	D002762
D3	I-Chemical	D002762
and	O	O
its	O	O
metabolites	O	O
in	O	O
the	O	O
blood	O	O
plasma	O	O
of	O	O
nonlactating	O	O
nonpregnant	O	O
and	O	O
pregnant	O	O
Jersey	O	O
cows	O	O
.	O	O

Calcium	B-Chemical	D002118
concentrations	O	O
1	O	O
day	O	O
postpartum	O	O
were	O	O
higher	O	O
in	O	O
cows	O	O
treated	O	O
with	O	O
vitamin	B-Chemical	D002762
D3	I-Chemical	D002762
about	O	O
32	O	O
days	O	O
prepartum	O	O
(	O	O
8	O	O
.	O	O

8	O	O
mg	O	O
/	O	O
100	O	O
ml	O	O
)	O	O
than	O	O
in	O	O
control	O	O
cows	O	O
(	O	O
5	O	O
.	O	O

5	O	O
mg	O	O
/	O	O
100	O	O
ml	O	O
)	O	O
.	O	O

None	O	O
of	O	O
the	O	O
cows	O	O
treated	O	O
with	O	O
vitamin	B-Chemical	D002762
D3	I-Chemical	D002762
showed	O	O
signs	O	O
of	O	O
milk	B-Disease	D010319
fever	I-Disease	D010319
during	O	O
the	O	O
peripartal	O	O
period	O	O
;	O	O
however	O	O
,	O	O
22%	O	O
of	O	O
the	O	O
control	O	O
cows	O	O
developed	O	O
clinical	O	O
signs	O	O
of	O	O
milk	B-Disease	D010319
fever	I-Disease	D010319
during	O	O
this	O	O
period	O	O
.	O	O

Signs	O	O
of	O	O
vitamin	B-Chemical	D002762
D3	I-Chemical	D002762
toxicity	B-Disease	D064420
were	O	O
not	O	O
observed	O	O
in	O	O
nonlactating	O	O
nonpregnant	O	O
cows	O	O
;	O	O
however	O	O
,	O	O
pregnant	O	O
cows	O	O
commonly	O	O
developed	O	O
severe	O	O
signs	O	O
of	O	O
vitamin	B-Chemical	D002762
D3	I-Chemical	D002762
toxicity	B-Disease	D064420
and	O	O
10	O	O
of	O	O
17	O	O
cows	O	O
died	O	O
.	O	O

There	O	O
was	O	O
widespread	O	O
metastatic	O	O
calcification	O	O
in	O	O
the	O	O
cows	O	O
that	O	O
died	O	O
.	O	O

Because	O	O
of	O	O
the	O	O
extreme	O	O
toxicity	B-Disease	D064420
of	O	O
vitamin	B-Chemical	D002762
D3	I-Chemical	D002762
in	O	O
pregnant	O	O
Jersey	O	O
cows	O	O
and	O	O
the	O	O
low	O	O
margin	O	O
of	O	O
safety	O	O
between	O	O
doses	O	O
of	O	O
vitamin	B-Chemical	D002762
D3	I-Chemical	D002762
that	O	O
prevent	O	O
milk	B-Disease	D010319
fever	I-Disease	D010319
and	O	O
doses	O	O
that	O	O
induce	O	O
milk	B-Disease	D010319
fever	I-Disease	D010319
,	O	O
we	O	O
concluded	O	O
that	O	O
vitamin	B-Chemical	D002762
D3	I-Chemical	D002762
cannot	O	O
be	O	O
used	O	O
practically	O	O
to	O	O
prevent	O	O
milk	B-Disease	D010319
fever	I-Disease	D010319
when	O	O
injected	O	O
several	O	O
weeks	O	O
prepartum	O	O
.	O	O

Diseases	B-Disease	D010523
of	I-Disease	D010523
peripheral	I-Disease	D010523
nerves	I-Disease	D010523
as	O	O
seen	O	O
in	O	O
the	O	O
Nigerian	O	O
African	O	O
.	O	O

The	O	O
anatomical	O	O
and	O	O
aetiological	O	O
diagnoses	O	O
of	O	O
peripheral	B-Disease	D010523
nerve	I-Disease	D010523
disease	I-Disease	D010523
excluding	O	O
its	O	O
primary	O	O
benign	O	O
and	O	O
malignant	O	O
disorders	O	O
,	O	O
as	O	O
seen	O	O
in	O	O
358	O	O
Nigerians	O	O
are	O	O
presented	O	O
.	O	O

There	O	O
is	O	O
a	O	O
male	O	O
preponderance	O	O
and	O	O
the	O	O
peak	O	O
incidence	O	O
is	O	O
in	O	O
the	O	O
fourth	O	O
decade	O	O
.	O	O

Sensori	B-Disease	D010523
-	I-Disease	D010523
motor	I-Disease	D010523
neuropathy	I-Disease	D010523
was	O	O
the	O	O
commonest	O	O
presentation	O	O
(	O	O
50%	O	O
)	O	O
.	O	O

Guillain	B-Disease	D020275
-	I-Disease	D020275
Barr	I-Disease	D020275
syndrome	I-Disease	D020275
was	O	O
the	O	O
commonest	O	O
identifiable	O	O
cause	O	O
(	O	O
15	O	O
.	O	O

6%	O	O
)	O	O
,	O	O
accounting	O	O
for	O	O
half	O	O
of	O	O
the	O	O
cases	O	O
with	O	O
motor	B-Disease	D010523
neuropathy	I-Disease	D010523
.	O	O

Peripheral	B-Disease	D010523
neuropathy	I-Disease	D010523
due	O	O
to	O	O
nutritional	B-Disease	D044342
deficiency	I-Disease	D044342
of	O	O
thiamine	B-Chemical	D013831
and	O	O
riboflavin	B-Chemical	D012256
was	O	O
common	O	O
(	O	O
10	O	O
.	O	O

1%	O	O
)	O	O
and	O	O
presented	O	O
mainly	O	O
as	O	O
sensory	O	O
and	O	O
sensori	B-Disease	D010523
-	I-Disease	D010523
motor	I-Disease	D010523
neuropathy	I-Disease	D010523
.	O	O

Diabetes	B-Disease	D003920
mellitus	I-Disease	D003920
was	O	O
the	O	O
major	O	O
cause	O	O
of	O	O
autonomic	B-Disease	D009422
neuropathy	I-Disease	D009422
.	O	O

Isoniazid	B-Chemical	D007538
was	O	O
the	O	O
most	O	O
frequent	O	O
agent	O	O
in	O	O
drug	O	O
-	O	O
induced	O	O
neuropathy	B-Disease	D009422
.	O	O

Migraine	B-Disease	D008881
(	O	O
20%	O	O
)	O	O
was	O	O
not	O	O
an	O	O
uncommon	O	O
cause	O	O
of	O	O
cranial	B-Disease	D003389
neuropathy	I-Disease	D003389
although	O	O
malignancies	B-Disease	D009369
arising	O	O
from	O	O
the	O	O
reticuloendothelial	O	O
system	O	O
or	O	O
related	O	O
structures	O	O
of	O	O
the	O	O
head	O	O
and	O	O
neck	O	O
were	O	O
more	O	O
frequent	O	O
(	O	O
26%	O	O
)	O	O
.	O	O

In	O	O
26	O	O
.	O	O

5%	O	O
of	O	O
all	O	O
the	O	O
cases	O	O
,	O	O
the	O	O
aetiology	O	O
of	O	O
the	O	O
neuropathy	B-Disease	D009422
was	O	O
undetermined	O	O
.	O	O

Heredofamilial	O	O
and	O	O
connective	B-Disease	D003240
tissue	I-Disease	D003240
disorders	I-Disease	D003240
were	O	O
rare	O	O
.	O	O

Some	O	O
of	O	O
the	O	O
factors	O	O
related	O	O
to	O	O
the	O	O
clinical	O	O
presentation	O	O
and	O	O
pathogenesis	O	O
of	O	O
the	O	O
neuropathies	B-Disease	D009422
are	O	O
briefly	O	O
discussed	O	O
.	O	O

A	O	O
double	O	O
-	O	O
blind	O	O
study	O	O
of	O	O
the	O	O
efficacy	O	O
and	O	O
safety	O	O
of	O	O
dothiepin	B-Chemical	D004308
hydrochloride	I-Chemical	D004308
in	O	O
the	O	O
treatment	O	O
of	O	O
major	O	O
depressive	B-Disease	D003866
disorder	I-Disease	D003866
.	O	O

In	O	O
a	O	O
6	O	O
-	O	O
week	O	O
double	O	O
-	O	O
blind	O	O
parallel	O	O
treatment	O	O
study	O	O
,	O	O
dothiepin	B-Chemical	D004308
and	O	O
amitriptyline	B-Chemical	D000639
were	O	O
compared	O	O
to	O	O
placebo	O	O
in	O	O
the	O	O
treatment	O	O
of	O	O
33	O	O
depressed	B-Disease	D003866
outpatients	O	O
.	O	O

Dothiepin	B-Chemical	D004308
and	O	O
amitriptyline	B-Chemical	D000639
were	O	O
equally	O	O
effective	O	O
in	O	O
alleviating	O	O
the	O	O
symptoms	O	O
of	O	O
depressive	B-Disease	D003866
illness	I-Disease	D003866
,	O	O
and	O	O
both	O	O
were	O	O
significantly	O	O
superior	O	O
to	O	O
placebo	O	O
.	O	O

The	O	O
overall	O	O
incidence	O	O
of	O	O
side	O	O
effects	O	O
and	O	O
the	O	O
frequency	O	O
and	O	O
severity	O	O
of	O	O
blurred	B-Disease	D014786
vision	I-Disease	D014786
,	O	O
dry	B-Disease	D014987
mouth	I-Disease	D014987
,	O	O
and	O	O
drowsiness	O	O
were	O	O
significantly	O	O
less	O	O
with	O	O
dothiepin	B-Chemical	D004308
than	O	O
with	O	O
amitriptyline	B-Chemical	D000639
.	O	O

Dothiepin	B-Chemical	D004308
also	O	O
produced	O	O
fewer	O	O
CNS	O	O
and	O	O
cardiovascular	O	O
effects	O	O
.	O	O

There	O	O
were	O	O
no	O	O
clinically	O	O
important	O	O
changes	O	O
in	O	O
laboratory	O	O
parameters	O	O
.	O	O

Dothiepin	B-Chemical	D004308
thus	O	O
was	O	O
found	O	O
to	O	O
be	O	O
an	O	O
effective	O	O
antidepressant	B-Chemical	D000928
drug	O	O
associated	O	O
with	O	O
fewer	O	O
side	O	O
effects	O	O
than	O	O
amitriptyline	B-Chemical	D000639
in	O	O
the	O	O
treatment	O	O
of	O	O
depressed	B-Disease	D003866
outpatients	O	O
.	O	O

Behavioral	O	O
effects	O	O
of	O	O
diazepam	B-Chemical	D003975
and	O	O
propranolol	B-Chemical	D011433
in	O	O
patients	O	O
with	O	O
panic	B-Disease	D016584
disorder	I-Disease	D016584
and	O	O
agoraphobia	B-Disease	D000379
.	O	O

The	O	O
effects	O	O
of	O	O
oral	O	O
doses	O	O
of	O	O
diazepam	B-Chemical	D003975
(	O	O
single	O	O
dose	O	O
of	O	O
10	O	O
mg	O	O
and	O	O
a	O	O
median	O	O
dose	O	O
of	O	O
30	O	O
mg	O	O
/	O	O
day	O	O
for	O	O
2	O	O
weeks	O	O
)	O	O
and	O	O
propranolol	B-Chemical	D011433
(	O	O
single	O	O
dose	O	O
of	O	O
80	O	O
mg	O	O
and	O	O
a	O	O
median	O	O
dose	O	O
of	O	O
240	O	O
mg	O	O
/	O	O
day	O	O
for	O	O
2	O	O
weeks	O	O
)	O	O
on	O	O
psychological	O	O
performance	O	O
of	O	O
patients	O	O
with	O	O
panic	B-Disease	D016584
disorders	I-Disease	D016584
and	O	O
agoraphobia	B-Disease	D000379
were	O	O
investigated	O	O
in	O	O
a	O	O
double	O	O
-	O	O
blind	O	O
,	O	O
randomized	O	O
and	O	O
crossover	O	O
design	O	O
.	O	O

Both	O	O
drugs	O	O
impaired	B-Disease	D008569
immediate	I-Disease	D008569
free	I-Disease	D008569
recall	I-Disease	D008569
but	O	O
the	O	O
decrease	O	O
was	O	O
greater	O	O
for	O	O
diazepam	B-Chemical	D003975
than	O	O
propranolol	B-Chemical	D011433
.	O	O

Delayed	B-Disease	D008569
free	I-Disease	D008569
recall	I-Disease	D008569
was	I-Disease	D008569
also	I-Disease	D008569
impaired	I-Disease	D008569
but	O	O
the	O	O
two	O	O
drugs	O	O
did	O	O
not	O	O
differ	O	O
.	O	O

Patients	O	O
tapped	O	O
faster	O	O
after	O	O
propranolol	B-Chemical	D011433
than	O	O
diazepam	B-Chemical	D003975
and	O	O
they	O	O
were	O	O
more	O	O
sedated	O	O
after	O	O
diazepam	B-Chemical	D003975
than	O	O
propranolol	B-Chemical	D011433
.	O	O

After	O	O
2	O	O
weeks	O	O
of	O	O
treatment	O	O
,	O	O
patients	O	O
tested	O	O
5	O	O
-	O	O
8	O	O
h	O	O
after	O	O
the	O	O
last	O	O
dose	O	O
of	O	O
medication	O	O
did	O	O
not	O	O
show	O	O
any	O	O
decrement	O	O
of	O	O
performance	O	O
.	O	O

These	O	O
results	O	O
are	O	O
similar	O	O
to	O	O
those	O	O
previously	O	O
found	O	O
in	O	O
healthy	O	O
subjects	O	O
.	O	O

Accumulation	O	O
of	O	O
drugs	O	O
was	O	O
not	O	O
reflected	O	O
in	O	O
prolonged	O	O
behavioral	B-Disease	D001523
impairment	I-Disease	D001523
.	O	O

Effect	O	O
of	O	O
aspirin	B-Chemical	D001241
on	O	O
N	B-Chemical	D005200
-	I-Chemical	D005200
[	I-Chemical	D005200
4	I-Chemical	D005200
-	I-Chemical	D005200
(	I-Chemical	D005200
5	I-Chemical	D005200
-	I-Chemical	D005200
nitro	I-Chemical	D005200
-	I-Chemical	D005200
2	I-Chemical	D005200
-	I-Chemical	D005200
furyl	I-Chemical	D005200
)	I-Chemical	D005200
-	I-Chemical	D005200
2	I-Chemical	D005200
-	I-Chemical	D005200
thiazolyl	I-Chemical	D005200
]	I-Chemical	D005200
-	I-Chemical	D005200
formamide	I-Chemical	D005200
-	O	O
induced	O	O
epithelial	O	O
proliferation	O	O
in	O	O
the	O	O
urinary	O	O
bladder	O	O
and	O	O
forestomach	O	O
of	O	O
the	O	O
rat	O	O
.	O	O

The	O	O
co	O	O
-	O	O
administration	O	O
of	O	O
aspirin	B-Chemical	D001241
with	O	O
N	B-Chemical	D005200
-	I-Chemical	D005200
[	I-Chemical	D005200
4	I-Chemical	D005200
-	I-Chemical	D005200
(	I-Chemical	D005200
5	I-Chemical	D005200
-	I-Chemical	D005200
nitro	I-Chemical	D005200
-	I-Chemical	D005200
2	I-Chemical	D005200
-	I-Chemical	D005200
furyl	I-Chemical	D005200
)	I-Chemical	D005200
-	I-Chemical	D005200
2	I-Chemical	D005200
-	I-Chemical	D005200
thiazolyl	I-Chemical	D005200
]	I-Chemical	D005200
-	I-Chemical	D005200
formamide	I-Chemical	D005200
(	O	O
FANFT	B-Chemical	D005200
)	O	O
to	O	O
rats	O	O
resulted	O	O
in	O	O
a	O	O
reduced	O	O
incidence	O	O
of	O	O
FANFT	B-Chemical	D005200
-	O	O
induced	O	O
bladder	B-Disease	D001749
carcinomas	I-Disease	D001749
but	O	O
a	O	O
concomitant	O	O
induction	O	O
of	O	O
forestomach	B-Disease	D013274
tumors	I-Disease	D013274
.	O	O

An	O	O
autoradiographic	O	O
study	O	O
was	O	O
performed	O	O
on	O	O
male	O	O
F	O	O
-	O	O
344	O	O
rats	O	O
fed	O	O
diet	O	O
containing	O	O
FANFT	B-Chemical	D005200
at	O	O
a	O	O
level	O	O
of	O	O
0	O	O
.	O	O

2%	O	O
and	O	O
/	O	O
or	O	O
aspirin	B-Chemical	D001241
at	O	O
a	O	O
level	O	O
of	O	O
0	O	O
.	O	O

5%	O	O
to	O	O
evaluate	O	O
the	O	O
effect	O	O
of	O	O
aspirin	B-Chemical	D001241
on	O	O
the	O	O
increased	O	O
cell	O	O
proliferation	O	O
induced	O	O
by	O	O
FANFT	B-Chemical	D005200
in	O	O
the	O	O
forestomach	O	O
and	O	O
bladder	O	O
.	O	O

FANFT	B-Chemical	D005200
-	O	O
induced	O	O
cell	O	O
proliferation	O	O
in	O	O
the	O	O
bladder	O	O
was	O	O
significantly	O	O
suppressed	O	O
by	O	O
aspirin	B-Chemical	D001241
co	O	O
-	O	O
administration	O	O
after	O	O
4	O	O
weeks	O	O
but	O	O
not	O	O
after	O	O
12	O	O
weeks	O	O
.	O	O

In	O	O
the	O	O
forestomach	O	O
,	O	O
and	O	O
also	O	O
in	O	O
the	O	O
liver	O	O
,	O	O
aspirin	B-Chemical	D001241
did	O	O
not	O	O
affect	O	O
the	O	O
FANFT	B-Chemical	D005200
-	O	O
induced	O	O
increase	O	O
in	O	O
labeling	O	O
index	O	O
.	O	O

The	O	O
present	O	O
results	O	O
are	O	O
consistent	O	O
with	O	O
the	O	O
carcinogenicity	O	O
experiment	O	O
suggesting	O	O
that	O	O
different	O	O
mechanisms	O	O
are	O	O
involved	O	O
in	O	O
FANFT	B-Chemical	D005200
carcinogenesis	B-Disease	D063646
in	O	O
the	O	O
bladder	O	O
and	O	O
forestomach	O	O
,	O	O
and	O	O
that	O	O
aspirin's	O	O
effect	O	O
on	O	O
FANFT	B-Chemical	D005200
in	O	O
the	O	O
forestomach	O	O
is	O	O
not	O	O
due	O	O
to	O	O
an	O	O
irritant	O	O
effect	O	O
associated	O	O
with	O	O
increased	O	O
cell	O	O
proliferation	O	O
.	O	O

Also	O	O
,	O	O
there	O	O
appears	O	O
to	O	O
be	O	O
an	O	O
adaptation	O	O
by	O	O
the	O	O
rats	O	O
to	O	O
the	O	O
chronic	O	O
ingestion	O	O
of	O	O
aspirin	B-Chemical	D001241
.	O	O

Provocation	O	O
of	O	O
postural	O	O
hypotension	B-Disease	D007022
by	O	O
nitroglycerin	B-Chemical	D005996
in	O	O
diabetic	B-Disease	D003920
autonomic	O	O
neuropathy?	O	O
The	O	O
effect	O	O
of	O	O
nitroglycerin	B-Chemical	D005996
on	O	O
heart	O	O
rate	O	O
and	O	O
systolic	O	O
blood	O	O
pressure	O	O
was	O	O
compared	O	O
in	O	O
5	O	O
normal	O	O
subjects	O	O
,	O	O
12	O	O
diabetic	B-Disease	D003920
subjects	O	O
without	O	O
autonomic	B-Disease	D009422
neuropathy	I-Disease	D009422
,	O	O
and	O	O
5	O	O
diabetic	B-Disease	D003920
subjects	O	O
with	O	O
autonomic	B-Disease	D009422
neuropathy	I-Disease	D009422
.	O	O

The	O	O
magnitude	O	O
and	O	O
time	O	O
course	O	O
of	O	O
the	O	O
increase	O	O
in	O	O
heart	O	O
rate	O	O
and	O	O
the	O	O
decrease	O	O
in	O	O
systolic	O	O
blood	O	O
pressure	O	O
after	O	O
nitroglycerin	B-Chemical	D005996
were	O	O
similar	O	O
in	O	O
the	O	O
normal	O	O
and	O	O
diabetic	B-Disease	D003920
subjects	O	O
without	O	O
autonomic	B-Disease	D009422
neuropathy	I-Disease	D009422
,	O	O
whereas	O	O
a	O	O
lesser	O	O
increase	O	O
in	O	O
heart	O	O
rate	O	O
and	O	O
a	O	O
greater	O	O
decrease	O	O
in	O	O
systolic	O	O
blood	O	O
pressure	O	O
occurred	O	O
in	O	O
the	O	O
diabetic	B-Disease	D003920
subjects	O	O
with	O	O
autonomic	B-Disease	D009422
neuropathy	I-Disease	D009422
.	O	O

It	O	O
is	O	O
therefore	O	O
suggested	O	O
that	O	O
caution	O	O
should	O	O
be	O	O
exercised	O	O
when	O	O
prescribing	O	O
vasodilator	O	O
drugs	O	O
in	O	O
diabetic	B-Disease	D003920
patients	O	O
,	O	O
particularly	O	O
those	O	O
with	O	O
autonomic	B-Disease	D009422
neuropathy	I-Disease	D009422
.	O	O

Characterization	O	O
of	O	O
estrogen	B-Chemical	D004967
-	O	O
induced	O	O
adenohypophyseal	B-Disease	D010911
tumors	I-Disease	D010911
in	O	O
the	O	O
Fischer	O	O
344	O	O
rat	O	O
.	O	O

Pituitary	B-Disease	D010911
tumors	I-Disease	D010911
were	O	O
induced	O	O
in	O	O
F344	O	O
female	O	O
rats	O	O
by	O	O
chronic	O	O
treatment	O	O
with	O	O
diethylstilbestrol	B-Chemical	D004054
(	O	O
DES	B-Chemical	D004054
,	O	O
8	O	O
-	O	O
10	O	O
mg	O	O
)	O	O
implanted	O	O
subcutaneously	O	O
in	O	O
silastic	O	O
capsules	O	O
.	O	O

Over	O	O
a	O	O
range	O	O
of	O	O
1	O	O
-	O	O
150	O	O
days	O	O
of	O	O
DES	B-Chemical	D004054
treatment	O	O
,	O	O
pairs	O	O
of	O	O
control	O	O
and	O	O
DES	B-Chemical	D004054
-	O	O
treated	O	O
rats	O	O
were	O	O
sacrificed	O	O
,	O	O
and	O	O
their	O	O
pituitaries	O	O
dissociated	O	O
enzymatically	O	O
into	O	O
single	O	O
-	O	O
cell	O	O
preparations	O	O
.	O	O

The	O	O
cell	O	O
populations	O	O
were	O	O
examined	O	O
regarding	O	O
total	O	O
cell	O	O
recovery	O	O
correlated	O	O
with	O	O
gland	O	O
weight	O	O
,	O	O
intracellular	O	O
prolactin	O	O
(	O	O
PRL	O	O
)	O	O
content	O	O
and	O	O
subsequent	O	O
release	O	O
in	O	O
primary	O	O
culture	O	O
,	O	O
immunocytochemical	O	O
PRL	O	O
staining	O	O
,	O	O
density	O	O
and	O	O
/	O	O
or	O	O
size	O	O
alterations	O	O
via	O	O
separation	O	O
on	O	O
Ficoll	O	O
-	O	O
Hypaque	O	O
and	O	O
by	O	O
unit	O	O
gravity	O	O
sedimentation	O	O
,	O	O
and	O	O
cell	O	O
cycle	O	O
analysis	O	O
,	O	O
after	O	O
acriflavine	B-Chemical	D000167
DNA	O	O
staining	O	O
,	O	O
by	O	O
laser	O	O
flow	O	O
cytometry	O	O
.	O	O

Total	O	O
cell	O	O
yields	O	O
from	O	O
DES	B-Chemical	D004054
-	O	O
treated	O	O
pituitaries	O	O
increased	O	O
from	O	O
1	O	O
.	O	O

3	O	O
times	O	O
control	O	O
yields	O	O
at	O	O
8	O	O
days	O	O
of	O	O
treatment	O	O
to	O	O
58	O	O
.	O	O

9	O	O
times	O	O
control	O	O
values	O	O
by	O	O
day	O	O
150	O	O
.	O	O

Intracellular	O	O
PRL	O	O
content	O	O
ranged	O	O
from	O	O
1	O	O
.	O	O

9	O	O
to	O	O
9	O	O
.	O	O

4	O	O
times	O	O
control	O	O
levels	O	O
,	O	O
and	O	O
PRL	O	O
release	O	O
in	O	O
vitro	O	O
was	O	O
significantly	O	O
and	O	O
consistently	O	O
higher	O	O
than	O	O
controls	O	O
,	O	O
after	O	O
at	O	O
least	O	O
8	O	O
days	O	O
of	O	O
DES	B-Chemical	D004054
exposure	O	O
.	O	O

Beyond	O	O
8	O	O
days	O	O
of	O	O
DES	B-Chemical	D004054
exposure	O	O
,	O	O
the	O	O
immunochemically	O	O
PRL	O	O
-	O	O
positive	O	O
proportion	O	O
of	O	O
cells	O	O
increased	O	O
to	O	O
over	O	O
50%	O	O
of	O	O
the	O	O
total	O	O
population	O	O
.	O	O

Increased	O	O
density	O	O
and	O	O
/	O	O
or	O	O
size	O	O
and	O	O
PRL	O	O
content	O	O
were	O	O
indicated	O	O
for	O	O
the	O	O
majority	O	O
of	O	O
the	O	O
PRL	O	O
cell	O	O
population	O	O
in	O	O
both	O	O
types	O	O
of	O	O
separation	O	O
protocols	O	O
.	O	O

All	O	O
these	O	O
effects	O	O
of	O	O
DES	B-Chemical	D004054
were	O	O
more	O	O
pronounced	O	O
among	O	O
previously	O	O
ovariectomized	O	O
animals	O	O
.	O	O

The	O	O
data	O	O
extend	O	O
the	O	O
findings	O	O
of	O	O
other	O	O
investigators	O	O
,	O	O
further	O	O
establishing	O	O
the	O	O
DES	B-Chemical	D004054
-	O	O
induced	O	O
tumor	B-Disease	D009369
as	O	O
a	O	O
model	O	O
for	O	O
study	O	O
of	O	O
PRL	O	O
cellular	O	O
control	O	O
mechanisms	O	O
.	O	O

Triamterene	B-Chemical	D014223
nephrolithiasis	B-Disease	D053040
complicating	O	O
dyazide	B-Chemical	C020743
therapy	O	O
.	O	O

A	O	O
case	O	O
of	O	O
triamterene	B-Chemical	D014223
nephrolithiasis	B-Disease	D053040
is	O	O
reported	O	O
in	O	O
a	O	O
man	O	O
after	O	O
4	O	O
years	O	O
of	O	O
hydrochlorothiazide	B-Chemical	C020743
-	I-Chemical	C020743
triamterene	I-Chemical	C020743
therapy	O	O
for	O	O
hypertension	B-Disease	D006973
.	O	O

The	O	O
stone	O	O
passed	O	O
spontaneously	O	O
and	O	O
was	O	O
found	O	O
to	O	O
contain	O	O
a	O	O
triamterene	B-Chemical	D014223
metabolite	O	O
admixed	O	O
with	O	O
uric	B-Chemical	D014527
acid	I-Chemical	D014527
salts	I-Chemical	D014527
.	O	O

Factors	O	O
affecting	O	O
triamterene	B-Chemical	D014223
nephrolithiasis	B-Disease	D053040
are	O	O
discussed	O	O
and	O	O
2	O	O
previously	O	O
reported	O	O
cases	O	O
are	O	O
reviewed	O	O
.	O	O

Metabolic	O	O
involvement	O	O
in	O	O
adriamycin	B-Chemical	D004317
cardiotoxicity	B-Disease	D066126
.	O	O

The	O	O
cardiotoxic	B-Disease	D066126
effects	O	O
of	O	O
adriamycin	B-Chemical	D004317
were	O	O
studied	O	O
in	O	O
mammalian	O	O
myocardial	O	O
cells	O	O
in	O	O
culture	O	O
as	O	O
a	O	O
model	O	O
system	O	O
.	O	O

Adriamycin	B-Chemical	D004317
inhibited	O	O
cell	O	O
growth	O	O
and	O	O
the	O	O
rhythmic	O	O
contractions	O	O
characteristic	O	O
of	O	O
myocardial	O	O
cells	O	O
in	O	O
culture	O	O
.	O	O

A	O	O
possible	O	O
involvement	O	O
of	O	O
energy	O	O
metabolism	O	O
was	O	O
suggested	O	O
previously	O	O
,	O	O
and	O	O
in	O	O
this	O	O
study	O	O
the	O	O
adenylate	O	O
energy	O	O
charge	O	O
and	O	O
phosphorylcreatine	B-Chemical	D010725
mole	O	O
fraction	O	O
were	O	O
determined	O	O
in	O	O
the	O	O
adriamycin	B-Chemical	D004317
-	O	O
treated	O	O
cells	O	O
.	O	O

The	O	O
adenylate	O	O
energy	O	O
charge	O	O
was	O	O
found	O	O
to	O	O
be	O	O
significantly	O	O
decreased	O	O
,	O	O
while	O	O
the	O	O
phophorylcreatine	B-Chemical	D010725
mole	O	O
fraction	O	O
was	O	O
unchanged	O	O
.	O	O

Such	O	O
disparity	O	O
suggests	O	O
an	O	O
inhibition	O	O
of	O	O
creatine	B-Chemical	D003401
phosphokinase	O	O
.	O	O

The	O	O
addition	O	O
of	O	O
1	O	O
mM	O	O
adenosine	B-Chemical	D000241
to	O	O
the	O	O
myocardial	O	O
cell	O	O
cultures	O	O
markedly	O	O
increases	O	O
the	O	O
ATP	B-Chemical	D000255
concentration	O	O
through	O	O
a	O	O
pathway	O	O
reportedly	O	O
leading	O	O
to	O	O
a	O	O
compartmentalized	O	O
ATP	B-Chemical	D000255
pool	O	O
.	O	O

In	O	O
the	O	O
adriamycin	B-Chemical	D004317
-	O	O
treated	O	O
cells	O	O
,	O	O
the	O	O
addition	O	O
of	O	O
adenosine	B-Chemical	D000241
increased	O	O
the	O	O
adenylate	O	O
charge	O	O
and	O	O
,	O	O
concomitant	O	O
with	O	O
this	O	O
inrcease	O	O
,	O	O
the	O	O
cells'	O	O
functional	O	O
integrity	O	O
,	O	O
in	O	O
terms	O	O
of	O	O
percentage	O	O
of	O	O
beating	O	O
cells	O	O
and	O	O
rate	O	O
of	O	O
contractions	O	O
,	O	O
was	O	O
maintained	O	O
.	O	O

Age	O	O
-	O	O
dependent	O	O
sensitivity	O	O
of	O	O
the	O	O
rat	O	O
to	O	O
neurotoxic	B-Disease	D020258
effects	O	O
of	O	O
streptomycin	B-Chemical	D013307
.	O	O

Streptomycin	B-Chemical	D013307
sulfate	O	O
(	O	O
300	O	O
mg	O	O
/	O	O
kg	O	O
s	O	O
.	O	O

c	O	O
.	O	O

)	O	O
was	O	O
injected	O	O
for	O	O
various	O	O
periods	O	O
into	O	O
preweanling	O	O
rats	O	O
and	O	O
for	O	O
3	O	O
weeks	O	O
into	O	O
weanling	O	O
rats	O	O
.	O	O

Beginning	O	O
at	O	O
8	O	O
days	O	O
of	O	O
age	O	O
,	O	O
body	O	O
movement	O	O
and	O	O
hearing	O	O
were	O	O
examined	O	O
for	O	O
6	O	O
and	O	O
up	O	O
to	O	O
17	O	O
weeks	O	O
,	O	O
respectively	O	O
.	O	O

Abnormal	B-Disease	D004409
movements	I-Disease	D004409
and	O	O
deafness	B-Disease	D003638
occurred	O	O
only	O	O
in	O	O
rats	O	O
treated	O	O
during	O	O
the	O	O
preweaning	O	O
period	O	O
;	O	O
within	O	O
this	O	O
period	O	O
the	O	O
greatest	O	O
sensitivities	O	O
for	O	O
these	O	O
abnormalities	O	O
occurred	O	O
from	O	O
2	O	O
to	O	O
11	O	O
-	O	O
17	O	O
and	O	O
5	O	O
to	O	O
11	O	O
days	O	O
of	O	O
age	O	O
,	O	O
respectively	O	O
,	O	O
indicating	O	O
that	O	O
the	O	O
cochlea	O	O
is	O	O
more	O	O
sensitive	O	O
to	O	O
streptomycin	B-Chemical	D013307
than	O	O
the	O	O
site	O	O
(	O	O
vestibular	O	O
or	O	O
central	O	O
)	O	O
responsible	O	O
for	O	O
the	O	O
dyskinesias	B-Disease	D004409
.	O	O

Crescentic	O	O
fibrillary	O	O
glomerulonephritis	B-Disease	D005921
associated	O	O
with	O	O
intermittent	O	O
rifampin	B-Chemical	D012293
therapy	O	O
for	O	O
pulmonary	B-Disease	D014397
tuberculosis	I-Disease	D014397
.	O	O

This	O	O
case	O	O
study	O	O
reveals	O	O
an	O	O
unusual	O	O
finding	O	O
of	O	O
rapidly	O	O
proliferative	O	O
crescentic	O	O
glomerulonephritis	B-Disease	D005921
in	O	O
a	O	O
patient	O	O
treated	O	O
with	O	O
rifampin	B-Chemical	D012293
who	O	O
had	O	O
no	O	O
other	O	O
identifiable	O	O
causes	O	O
for	O	O
developing	O	O
this	O	O
disease	O	O
.	O	O

This	O	O
patient	O	O
underwent	O	O
a	O	O
10	O	O
-	O	O
month	O	O
regimen	O	O
of	O	O
rifampin	B-Chemical	D012293
and	O	O
isoniazid	B-Chemical	D007538
for	O	O
pulmonary	B-Disease	D014397
tuberculosis	I-Disease	D014397
and	O	O
was	O	O
discovered	O	O
to	O	O
have	O	O
developed	O	O
signs	O	O
of	O	O
severe	O	O
renal	B-Disease	D051437
failure	I-Disease	D051437
five	O	O
weeks	O	O
after	O	O
completion	O	O
of	O	O
therapy	O	O
.	O	O

Renal	O	O
biopsy	O	O
revealed	O	O
severe	O	O
glomerulonephritis	B-Disease	D005921
with	O	O
crescents	O	O
,	O	O
electron	O	O
dense	O	O
fibrillar	O	O
deposits	O	O
and	O	O
moderate	O	O
lymphocytic	O	O
interstitial	O	O
infiltrate	O	O
.	O	O

Other	O	O
possible	O	O
causes	O	O
of	O	O
rapidly	O	O
progressive	O	O
glomerulonephritis	B-Disease	D005921
were	O	O
investigated	O	O
and	O	O
ruled	O	O
out	O	O
.	O	O

This	O	O
report	O	O
documents	O	O
the	O	O
unusual	O	O
occurrence	O	O
of	O	O
rapidly	O	O
progressive	O	O
glomerulonephritis	B-Disease	D005921
with	O	O
crescents	O	O
and	O	O
fibrillar	O	O
glomerulonephritis	B-Disease	D005921
in	O	O
a	O	O
patient	O	O
treated	O	O
with	O	O
rifampin	B-Chemical	D012293
.	O	O

Time	O	O
course	O	O
of	O	O
lipid	O	O
peroxidation	O	O
in	O	O
puromycin	B-Chemical	D011692
aminonucleoside	I-Chemical	D011692
-	O	O
induced	O	O
nephropathy	B-Disease	D007674
.	O	O

Reactive	O	O
oxygen	B-Chemical	D010100
species	O	O
have	O	O
been	O	O
implicated	O	O
in	O	O
the	O	O
pathogenesis	O	O
of	O	O
acute	O	O
puromycin	B-Chemical	D011692
aminonucleoside	I-Chemical	D011692
(	O	O
PAN	B-Chemical	D011692
)	O	O
-	O	O
induced	O	O
nephropathy	B-Disease	D007674
,	O	O
with	O	O
antioxidants	O	O
significantly	O	O
reducing	O	O
the	O	O
proteinuria	B-Disease	D011507
.	O	O

The	O	O
temporal	O	O
relationship	O	O
between	O	O
lipid	O	O
peroxidation	O	O
in	O	O
the	O	O
kidney	O	O
and	O	O
proteinuria	B-Disease	D011507
was	O	O
examined	O	O
in	O	O
this	O	O
study	O	O
.	O	O

Rats	O	O
were	O	O
treated	O	O
with	O	O
a	O	O
single	O	O
IV	O	O
injection	O	O
of	O	O
puromycin	B-Chemical	D011692
aminonucleoside	I-Chemical	D011692
,	O	O
(	O	O
PAN	B-Chemical	D011692
,	O	O
7	O	O
.	O	O

5	O	O
mg	O	O
/	O	O
kg	O	O
)	O	O
and	O	O
24	O	O
hour	O	O
urine	O	O
samples	O	O
were	O	O
obtained	O	O
prior	O	O
to	O	O
sacrifice	O	O
on	O	O
days	O	O
3	O	O
,	O	O
5	O	O
,	O	O
7	O	O
,	O	O
10	O	O
,	O	O
17	O	O
,	O	O
27	O	O
,	O	O
41	O	O
(	O	O
N	O	O
=	O	O
5	O	O
-	O	O
10	O	O
per	O	O
group	O	O
)	O	O
.	O	O

The	O	O
kidneys	O	O
were	O	O
removed	O	O
,	O	O
flushed	O	O
with	O	O
ice	O	O
cold	O	O
TRIS	O	O
buffer	O	O
.	O	O

Kidney	O	O
cortices	O	O
from	O	O
each	O	O
animal	O	O
were	O	O
used	O	O
to	O	O
prepare	O	O
homogenates	O	O
.	O	O

Tissue	O	O
lipid	O	O
peroxidation	O	O
was	O	O
measured	O	O
in	O	O
whole	O	O
homogenates	O	O
as	O	O
well	O	O
as	O	O
in	O	O
lipid	O	O
extracts	O	O
from	O	O
homogenates	O	O
as	O	O
thiobarbituric	B-Chemical	C029684
acid	I-Chemical	C029684
reactive	O	O
substances	O	O
.	O	O

Proteinuria	B-Disease	D011507
was	O	O
evident	O	O
at	O	O
day	O	O
5	O	O
,	O	O
peaked	O	O
at	O	O
day	O	O
7	O	O
and	O	O
persisted	O	O
to	O	O
day	O	O
27	O	O
.	O	O

Lipid	O	O
peroxidation	O	O
in	O	O
homogenates	O	O
was	O	O
maximal	O	O
at	O	O
day	O	O
3	O	O
and	O	O
declined	O	O
rapidly	O	O
to	O	O
control	O	O
levels	O	O
by	O	O
day	O	O
17	O	O
.	O	O

This	O	O
study	O	O
supports	O	O
the	O	O
role	O	O
of	O	O
lipid	O	O
peroxidation	O	O
in	O	O
mediating	O	O
the	O	O
proteinuric	B-Disease	D011507
injury	I-Disease	D011507
in	O	O
PAN	B-Chemical	D011692
nephropathy	B-Disease	D007674
.	O	O

Clomipramine	B-Chemical	D002997
-	O	O
induced	O	O
sleep	B-Disease	D012893
disturbance	I-Disease	D012893
does	O	O
not	O	O
impair	O	O
its	O	O
prolactin	O	O
-	O	O
releasing	O	O
action	O	O
.	O	O

The	O	O
present	O	O
study	O	O
was	O	O
undertaken	O	O
to	O	O
examine	O	O
the	O	O
role	O	O
of	O	O
sleep	B-Disease	D012893
disturbance	I-Disease	D012893
,	O	O
induced	O	O
by	O	O
clomipramine	B-Chemical	D002997
administration	O	O
,	O	O
on	O	O
the	O	O
secretory	O	O
rate	O	O
of	O	O
prolactin	O	O
(	O	O
PRL	O	O
)	O	O
in	O	O
addition	O	O
to	O	O
the	O	O
direct	O	O
drug	O	O
effect	O	O
.	O	O

Two	O	O
groups	O	O
of	O	O
supine	O	O
subjects	O	O
were	O	O
studied	O	O
under	O	O
placebo	O	O
-	O	O
controlled	O	O
conditions	O	O
,	O	O
one	O	O
during	O	O
the	O	O
night	O	O
,	O	O
when	O	O
sleeping	O	O
(	O	O
n	O	O
=	O	O
7	O	O
)	O	O
and	O	O
the	O	O
other	O	O
at	O	O
daytime	O	O
,	O	O
when	O	O
awake	O	O
(	O	O
n	O	O
=	O	O
6	O	O
)	O	O
.	O	O

Each	O	O
subject	O	O
received	O	O
a	O	O
single	O	O
50	O	O
mg	O	O
dose	O	O
of	O	O
clomipramine	B-Chemical	D002997
given	O	O
orally	O	O
2	O	O
hours	O	O
before	O	O
blood	O	O
collection	O	O
.	O	O

Plasma	O	O
PRL	O	O
concentrations	O	O
were	O	O
analysed	O	O
at	O	O
10	O	O
min	O	O
intervals	O	O
and	O	O
underlying	O	O
secretory	O	O
rates	O	O
calculated	O	O
by	O	O
a	O	O
deconvolution	O	O
procedure	O	O
.	O	O

For	O	O
both	O	O
experiments	O	O
the	O	O
drug	O	O
intake	O	O
led	O	O
to	O	O
significant	O	O
increases	O	O
in	O	O
PRL	O	O
secretion	O	O
,	O	O
acting	O	O
preferentially	O	O
on	O	O
tonic	O	O
secretion	O	O
as	O	O
pulse	O	O
amplitude	O	O
and	O	O
frequency	O	O
did	O	O
not	O	O
differ	O	O
significantly	O	O
from	O	O
corresponding	O	O
control	O	O
values	O	O
.	O	O

During	O	O
the	O	O
night	O	O
clomipramine	B-Chemical	D002997
ingestion	O	O
altered	O	O
the	O	O
complete	O	O
sleep	O	O
architecture	O	O
in	O	O
that	O	O
it	O	O
suppressed	O	O
REM	O	O
sleep	O	O
and	O	O
the	O	O
sleep	O	O
cycles	O	O
and	O	O
induced	O	O
increased	O	O
wakefulness	O	O
.	O	O

As	O	O
the	O	O
relative	O	O
increase	O	O
in	O	O
PRL	O	O
secretion	O	O
expressed	O	O
as	O	O
a	O	O
percentage	O	O
of	O	O
the	O	O
mean	O	O
did	O	O
not	O	O
significantly	O	O
differ	O	O
between	O	O
the	O	O
night	O	O
and	O	O
day	O	O
time	O	O
studies	O	O
(	O	O
46	O	O
+	O	O
/	O	O
-	O	O
19%	O	O
vs	O	O
34	O	O
+	O	O
/	O	O
-	O	O
10%	O	O
)	O	O
,	O	O
it	O	O
can	O	O
be	O	O
concluded	O	O
that	O	O
the	O	O
observed	O	O
sleep	B-Disease	D012893
disturbance	I-Disease	D012893
did	O	O
not	O	O
interfere	O	O
with	O	O
the	O	O
drug	O	O
action	O	O
per	O	O
se	O	O
.	O	O

The	O	O
presence	O	O
of	O	O
REM	O	O
sleep	O	O
was	O	O
shown	O	O
not	O	O
to	O	O
be	O	O
a	O	O
determining	O	O
factor	O	O
either	O	O
for	O	O
secretory	O	O
pulse	O	O
amplitude	O	O
and	O	O
frequency	O	O
,	O	O
as	O	O
,	O	O
for	O	O
both	O	O
,	O	O
mean	O	O
nocturnal	O	O
values	O	O
were	O	O
similar	O	O
with	O	O
and	O	O
without	O	O
prior	O	O
clomipramine	B-Chemical	D002997
ingestion	O	O
.	O	O

Angioedema	B-Disease	D000799
following	O	O
the	O	O
intravenous	O	O
administration	O	O
of	O	O
metoprolol	B-Chemical	D008790
.	O	O

A	O	O
72	O	O
-	O	O
year	O	O
-	O	O
old	O	O
woman	O	O
was	O	O
admitted	O	O
to	O	O
the	O	O
hospital	O	O
with	O	O
"flash"	O	O
pulmonary	B-Disease	D011654
edema	I-Disease	D011654
,	O	O
preceded	O	O
by	O	O
chest	B-Disease	D002637
pain	I-Disease	D002637
,	O	O
requiring	O	O
intubation	O	O
.	O	O

Her	O	O
medical	O	O
history	O	O
included	O	O
coronary	B-Disease	D003324
artery	I-Disease	D003324
disease	I-Disease	D003324
with	O	O
previous	O	O
myocardial	B-Disease	D009203
infarctions	I-Disease	D009203
,	O	O
hypertension	B-Disease	D006973
,	O	O
and	O	O
diabetes	B-Disease	D003920
mellitus	I-Disease	D003920
.	O	O

A	O	O
history	O	O
of	O	O
angioedema	B-Disease	D000799
secondary	O	O
to	O	O
lisinopril	B-Chemical	D017706
therapy	O	O
was	O	O
elicited	O	O
.	O	O

Current	O	O
medications	O	O
did	O	O
not	O	O
include	O	O
angiotensin	B-Chemical	D000809
-	O	O
converting	O	O
enzyme	O	O
inhibitors	O	O
or	O	O
beta	O	O
-	O	O
blockers	O	O
.	O	O

She	O	O
had	O	O
no	O	O
previous	O	O
beta	O	O
-	O	O
blocking	O	O
drug	O	O
exposure	O	O
.	O	O

During	O	O
the	O	O
first	O	O
day	O	O
of	O	O
hospitalization	O	O
(	O	O
while	O	O
intubated	O	O
)	O	O
,	O	O
intravenous	O	O
metoprolol	B-Chemical	D008790
was	O	O
given	O	O
,	O	O
resulting	O	O
in	O	O
severe	O	O
angioedema	B-Disease	D000799
.	O	O

The	O	O
angioedema	B-Disease	D000799
resolved	O	O
after	O	O
therapy	O	O
with	O	O
intravenous	O	O
steroids	B-Chemical	D013256
and	O	O
diphenhydramine	B-Chemical	D004155
hydrochloride	O	O
.	O	O

Effect	O	O
of	O	O
coniine	B-Chemical	C007112
on	O	O
the	O	O
developing	O	O
chick	O	O
embryo	O	O
.	O	O

Coniine	B-Chemical	C007112
,	O	O
an	O	O
alkaloid	O	O
from	O	O
Conium	O	O
maculatum	O	O
(	O	O
poison	O	O
hemlock	O	O
)	O	O
,	O	O
has	O	O
been	O	O
shown	O	O
to	O	O
be	O	O
teratogenic	O	O
in	O	O
livestock	O	O
.	O	O

The	O	O
major	O	O
teratogenic	O	O
outcome	O	O
is	O	O
arthrogryposis	B-Disease	D001176
,	O	O
presumably	O	O
due	O	O
to	O	O
nicotinic	O	O
receptor	O	O
blockade	O	O
.	O	O

However	O	O
,	O	O
coniine	B-Chemical	C007112
has	O	O
failed	O	O
to	O	O
produce	O	O
arthrogryposis	B-Disease	D001176
in	O	O
rats	O	O
or	O	O
mice	O	O
and	O	O
is	O	O
only	O	O
weakly	O	O
teratogenic	O	O
in	O	O
rabbits	O	O
.	O	O

The	O	O
purpose	O	O
of	O	O
this	O	O
study	O	O
was	O	O
to	O	O
evaluate	O	O
and	O	O
compare	O	O
the	O	O
effects	O	O
of	O	O
coniine	B-Chemical	C007112
and	O	O
nicotine	B-Chemical	D009538
in	O	O
the	O	O
developing	O	O
chick	O	O
.	O	O

Concentrations	O	O
of	O	O
coniine	B-Chemical	C007112
and	O	O
nicotine	B-Chemical	D009538
sulfate	O	O
were	O	O
0	O	O
.	O	O

015%	O	O
,	O	O
0	O	O
.	O	O

03%	O	O
,	O	O
0	O	O
.	O	O

075%	O	O
,	O	O
0	O	O
.	O	O

15%	O	O
,	O	O
0	O	O
.	O	O

75%	O	O
,	O	O
1	O	O
.	O	O

5%	O	O
,	O	O
3%	O	O
,	O	O
and	O	O
6%	O	O
and	O	O
1%	O	O
,	O	O
5%	O	O
,	O	O
and	O	O
10%	O	O
,	O	O
respectively	O	O
.	O	O

Both	O	O
compounds	O	O
caused	O	O
deformations	B-Disease	D009140
and	O	O
lethality	O	O
in	O	O
a	O	O
dose	O	O
-	O	O
dependent	O	O
manner	O	O
.	O	O

All	O	O
concentrations	O	O
of	O	O
nicotine	B-Chemical	D009538
sulfate	O	O
caused	O	O
some	O	O
lethality	O	O
but	O	O
a	O	O
no	O	O
effect	O	O
level	O	O
for	O	O
coniine	B-Chemical	C007112
lethality	O	O
was	O	O
0	O	O
.	O	O

75%	O	O
.	O	O

The	O	O
deformations	B-Disease	D009140
caused	O	O
by	O	O
both	O	O
coniine	B-Chemical	C007112
and	O	O
nicotine	B-Chemical	D009538
sulfate	O	O
were	O	O
excessive	B-Disease	D009140
flexion	I-Disease	D009140
or	I-Disease	D009140
extension	I-Disease	D009140
of	I-Disease	D009140
one	I-Disease	D009140
or	I-Disease	D009140
more	I-Disease	D009140
toes	I-Disease	D009140
.	O	O

No	O	O
histopathological	O	O
alterations	O	O
or	O	O
differences	O	O
in	O	O
bone	O	O
formation	O	O
were	O	O
seen	O	O
in	O	O
the	O	O
limbs	O	O
or	O	O
toes	O	O
of	O	O
any	O	O
chicks	O	O
from	O	O
any	O	O
group	O	O
;	O	O
however	O	O
,	O	O
extensive	O	O
cranial	B-Disease	D002543
hemorrhage	I-Disease	D002543
occurred	O	O
in	O	O
all	O	O
nicotine	B-Chemical	D009538
sulfate	O	O
-	O	O
treated	O	O
chicks	O	O
.	O	O

There	O	O
was	O	O
a	O	O
statistically	O	O
significant	O	O
(	O	O
P	O	O
<	O	O
or	O	O
=	O	O
0	O	O
.	O	O

01	O	O
)	O	O
decrease	O	O
in	O	O
movement	O	O
in	O	O
coniine	B-Chemical	C007112
and	O	O
nicotine	B-Chemical	D009538
sulfate	O	O
treated	O	O
chicks	O	O
as	O	O
determined	O	O
by	O	O
ultrasound	O	O
.	O	O

Control	O	O
chicks	O	O
were	O	O
in	O	O
motion	O	O
an	O	O
average	O	O
of	O	O
33	O	O
.	O	O

67%	O	O
of	O	O
the	O	O
time	O	O
,	O	O
while	O	O
coniine	B-Chemical	C007112
-	O	O
treated	O	O
chicks	O	O
were	O	O
only	O	O
moving	O	O
8	O	O
.	O	O

95%	O	O
of	O	O
a	O	O
5	O	O
-	O	O
min	O	O
interval	O	O
,	O	O
and	O	O
no	O	O
movement	O	O
was	O	O
observed	O	O
for	O	O
nicotine	B-Chemical	D009538
sulfate	O	O
treated	O	O
chicks	O	O
.	O	O

In	O	O
summary	O	O
,	O	O
the	O	O
chick	O	O
embryo	O	O
provides	O	O
a	O	O
reliable	O	O
and	O	O
simple	O	O
experimental	O	O
animal	O	O
model	O	O
of	O	O
coniine	B-Chemical	C007112
-	O	O
induced	O	O
arthrogryposis	B-Disease	D001176
.	O	O

Data	O	O
from	O	O
this	O	O
model	O	O
support	O	O
a	O	O
mechanism	O	O
involving	O	O
nicotinic	O	O
receptor	O	O
blockade	O	O
with	O	O
subsequent	O	O
decreased	O	O
fetal	O	O
movement	O	O
.	O	O

Epidural	O	O
blood	O	O
flow	O	O
during	O	O
prostaglandin	B-Chemical	D000527
E1	I-Chemical	D000527
or	O	O
trimethaphan	B-Chemical	D014294
induced	O	O
hypotension	B-Disease	D007022
.	O	O

To	O	O
evaluate	O	O
the	O	O
effect	O	O
of	O	O
prostaglandin	B-Chemical	D000527
E1	I-Chemical	D000527
(	O	O
PGE1	B-Chemical	D000527
)	O	O
or	O	O
trimethaphan	B-Chemical	D014294
(	O	O
TMP	B-Chemical	D014294
)	O	O
induced	O	O
hypotension	B-Disease	D007022
on	O	O
epidural	O	O
blood	O	O
flow	O	O
(	O	O
EBF	O	O
)	O	O
during	O	O
spinal	O	O
surgery	O	O
,	O	O
EBF	O	O
was	O	O
measured	O	O
using	O	O
the	O	O
heat	O	O
clearance	O	O
method	O	O
in	O	O
30	O	O
patients	O	O
who	O	O
underwent	O	O
postero	O	O
-	O	O
lateral	O	O
interbody	O	O
fusion	O	O
under	O	O
isoflurane	B-Chemical	D007530
anaesthesia	O	O
.	O	O

An	O	O
initial	O	O
dose	O	O
of	O	O
0	O	O
.	O	O

1	O	O
microgram	O	O
.	O	O

kg	O	O
-	O	O
1	O	O
.	O	O

min	O	O
-	O	O
1	O	O
of	O	O
PGE1	B-Chemical	D000527
(	O	O
15	O	O
patients	O	O
)	O	O
,	O	O
or	O	O
10	O	O
micrograms	O	O
.	O	O

kg	O	O
-	O	O
1	O	O
.	O	O

min	O	O
-	O	O
1	O	O
of	O	O
TMP	B-Chemical	D014294
(	O	O
15	O	O
patients	O	O
)	O	O
was	O	O
administered	O	O
intravenously	O	O
after	O	O
the	O	O
dural	O	O
opening	O	O
and	O	O
the	O	O
dose	O	O
was	O	O
adjusted	O	O
to	O	O
maintain	O	O
the	O	O
mean	O	O
arterial	O	O
blood	O	O
pressure	O	O
(	O	O
MAP	O	O
)	O	O
at	O	O
about	O	O
60	O	O
mmHg	O	O
.	O	O

The	O	O
hypotensive	B-Disease	D007022
drug	O	O
was	O	O
discontinued	O	O
at	O	O
the	O	O
completion	O	O
of	O	O
the	O	O
operative	O	O
procedure	O	O
.	O	O

After	O	O
starting	O	O
PGE1	B-Chemical	D000527
or	O	O
TMP	B-Chemical	D014294
,	O	O
MAP	O	O
and	O	O
rate	O	O
pressure	O	O
product	O	O
(	O	O
RPP	O	O
)	O	O
decreased	O	O
significantly	O	O
compared	O	O
with	O	O
preinfusion	O	O
values	O	O
(	O	O
P	O	O
<	O	O
0	O	O
.	O	O

01	O	O
)	O	O
,	O	O
and	O	O
the	O	O
degree	O	O
of	O	O
hypotension	B-Disease	D007022
due	O	O
to	O	O
PGE1	B-Chemical	D000527
remained	O	O
constant	O	O
until	O	O
60	O	O
min	O	O
after	O	O
its	O	O
discontinuation	O	O
.	O	O

Heart	O	O
rate	O	O
(	O	O
HR	O	O
)	O	O
did	O	O
not	O	O
change	O	O
in	O	O
either	O	O
group	O	O
.	O	O

EBFF	O	O
did	O	O
not	O	O
change	O	O
during	O	O
PGE1	B-Chemical	D000527
infusion	O	O
whereas	O	O
in	O	O
the	O	O
TMP	B-Chemical	D014294
group	O	O
,	O	O
EBF	O	O
decreased	O	O
significantly	O	O
at	O	O
30	O	O
and	O	O
60	O	O
min	O	O
after	O	O
the	O	O
start	O	O
of	O	O
TMP	B-Chemical	D014294
(	O	O
preinfusion	O	O
:	O	O
45	O	O
.	O	O

9	O	O
+	O	O
/	O	O
-	O	O
13	O	O
.	O	O

9	O	O
ml	O	O
/	O	O
100g	O	O
/	O	O
min	O	O
.	O	O

30	O	O
min	O	O
:	O	O
32	O	O
.	O	O

3	O	O
+	O	O
/	O	O
-	O	O
9	O	O
.	O	O

9	O	O
ml	O	O
/	O	O
100	O	O
g	O	O
/	O	O
min	O	O
(	O	O
P	O	O
<	O	O
0	O	O
.	O	O

05	O	O
)	O	O
.	O	O

60	O	O
min	O	O
:	O	O
30	O	O
+	O	O
/	O	O
-	O	O
7	O	O
.	O	O

5	O	O
ml	O	O
/	O	O
100	O	O
g	O	O
/	O	O
min	O	O
(	O	O
P	O	O
<	O	O
0	O	O
.	O	O

05	O	O
)	O	O
)	O	O
.	O	O

These	O	O
results	O	O
suggest	O	O
that	O	O
PGE1	B-Chemical	D000527
may	O	O
be	O	O
preferable	O	O
to	O	O
TMP	B-Chemical	D014294
for	O	O
hypotensive	B-Disease	D007022
anaesthesia	O	O
in	O	O
spinal	O	O
surgery	O	O
because	O	O
TMP	B-Chemical	D014294
decreased	O	O
EBF	O	O
.	O	O

Immunohistochemical	O	O
studies	O	O
with	O	O
antibodies	O	O
to	O	O
neurofilament	O	O
proteins	O	O
on	O	O
axonal	B-Disease	D001480
damage	I-Disease	D001480
in	O	O
experimental	O	O
focal	O	O
lesions	O	O
in	O	O
rat	O	O
.	O	O

Immunohistochemistry	O	O
with	O	O
monoclonal	O	O
antibodies	O	O
against	O	O
neurofilament	O	O
(	O	O
NF	O	O
)	O	O
proteins	O	O
of	O	O
middle	O	O
and	O	O
high	O	O
molecular	O	O
weight	O	O
class	O	O
,	O	O
NF	O	O
-	O	O
M	O	O
and	O	O
NF	O	O
-	O	O
H	O	O
,	O	O
was	O	O
used	O	O
to	O	O
study	O	O
axonal	B-Disease	D001480
injury	I-Disease	D001480
in	O	O
the	O	O
borderzone	O	O
of	O	O
focal	O	O
lesions	O	O
in	O	O
rats	O	O
.	O	O

Focal	O	O
injury	B-Disease	D001480
in	I-Disease	D001480
the	I-Disease	D001480
cortex	I-Disease	D001480
was	O	O
produced	O	O
by	O	O
infusion	O	O
of	O	O
lactate	B-Chemical	D019344
at	O	O
acid	O	O
pH	O	O
or	O	O
by	O	O
stab	O	O
caused	O	O
by	O	O
needle	O	O
insertion	O	O
.	O	O

Infarcts	B-Disease	D002544
in	I-Disease	D002544
substantia	I-Disease	D002544
nigra	I-Disease	D002544
pars	I-Disease	D002544
reticulata	I-Disease	D002544
were	O	O
evoked	O	O
by	O	O
prolonged	O	O
pilocarpine	B-Chemical	D010862
-	O	O
induced	O	O
status	B-Disease	D013226
epilepticus	I-Disease	D013226
.	O	O

Immunohistochemical	O	O
staining	O	O
for	O	O
NFs	O	O
showed	O	O
characteristic	O	O
terminal	O	O
clubs	O	O
of	O	O
axons	O	O
in	O	O
the	O	O
borderzone	O	O
of	O	O
lesions	O	O
.	O	O

Differences	O	O
in	O	O
the	O	O
labelling	O	O
pattern	O	O
occurred	O	O
with	O	O
different	O	O
antibodies	O	O
which	O	O
apparently	O	O
depended	O	O
on	O	O
molecular	O	O
weight	O	O
class	O	O
of	O	O
NFs	O	O
and	O	O
phosphorylation	O	O
state	O	O
.	O	O

These	O	O
immunohistochemical	O	O
changes	O	O
of	O	O
NFs	O	O
can	O	O
serve	O	O
as	O	O
a	O	O
marker	O	O
for	O	O
axonal	B-Disease	D001480
damage	I-Disease	D001480
in	O	O
various	O	O
experimental	O	O
traumatic	B-Disease	D014947
or	O	O
ischemic	O	O
lesions	O	O
.	O	O

Increase	O	O
of	O	O
Parkinson	B-Disease	D009069
disability	I-Disease	D009069
after	O	O
fluoxetine	B-Chemical	D005473
medication	O	O
.	O	O

Depression	B-Disease	D003866
is	O	O
a	O	O
major	O	O
clinical	O	O
feature	O	O
of	O	O
Parkinson's	B-Disease	D010300
disease	I-Disease	D010300
.	O	O

We	O	O
report	O	O
the	O	O
increased	O	O
amount	O	O
of	O	O
motor	B-Disease	D009069
disability	I-Disease	D009069
in	O	O
four	O	O
patients	O	O
with	O	O
idiopathic	B-Disease	D010300
Parkinson's	I-Disease	D010300
disease	I-Disease	D010300
after	O	O
exposure	O	O
to	O	O
the	O	O
antidepressant	B-Chemical	D000928
fluoxetine	B-Chemical	D005473
.	O	O

The	O	O
possibility	O	O
of	O	O
a	O	O
clinically	O	O
relevant	O	O
dopamine	B-Chemical	D004298
-	O	O
antagonistic	O	O
capacity	O	O
of	O	O
fluoxetine	B-Chemical	D005473
in	O	O
Parkinson's	B-Disease	D010300
disease	I-Disease	D010300
patients	O	O
must	O	O
be	O	O
considered	O	O
.	O	O

Acetaminophen	B-Chemical	D000082
-	O	O
induced	O	O
hypotension	B-Disease	D007022
.	O	O

Through	O	O
30	O	O
years	O	O
of	O	O
widespread	O	O
use	O	O
,	O	O
acetaminophen	B-Chemical	D000082
has	O	O
been	O	O
shown	O	O
to	O	O
be	O	O
a	O	O
remarkably	O	O
safe	O	O
medication	O	O
in	O	O
therapeutic	O	O
dosages	O	O
.	O	O

The	O	O
potential	O	O
for	O	O
acetaminophen	B-Chemical	D000082
to	O	O
produce	O	O
cardiovascular	B-Disease	D002318
toxicities	I-Disease	D002318
is	O	O
very	O	O
low	O	O
.	O	O

However	O	O
,	O	O
acetaminophen	B-Chemical	D000082
has	O	O
been	O	O
demonstrated	O	O
to	O	O
produce	O	O
symptoms	O	O
of	O	O
anaphylaxis	B-Disease	D000707
,	O	O
including	O	O
hypotension	B-Disease	D007022
,	O	O
in	O	O
sensitive	O	O
individuals	O	O
.	O	O

This	O	O
article	O	O
describes	O	O
two	O	O
critically	B-Disease	D016638
ill	I-Disease	D016638
patients	O	O
in	O	O
whom	O	O
transient	O	O
episodes	O	O
of	O	O
hypotension	B-Disease	D007022
reproducibly	O	O
developed	O	O
after	O	O
administration	O	O
of	O	O
acetaminophen	B-Chemical	D000082
.	O	O

Other	O	O
symptoms	O	O
of	O	O
allergic	B-Disease	D004342
reactions	I-Disease	D004342
were	O	O
not	O	O
clinically	O	O
detectable	O	O
.	O	O

The	O	O
hypotensive	B-Disease	D007022
episodes	O	O
were	O	O
severe	O	O
enough	O	O
to	O	O
require	O	O
vasopressor	O	O
administration	O	O
.	O	O

The	O	O
reports	O	O
illustrate	O	O
the	O	O
need	O	O
for	O	O
clinicians	O	O
to	O	O
consider	O	O
acetaminophen	B-Chemical	D000082
in	O	O
patients	O	O
with	O	O
hypotension	B-Disease	D007022
of	O	O
unknown	O	O
origin	O	O
.	O	O

Acute	O	O
hepatitis	B-Disease	D056486
,	O	O
autoimmune	B-Disease	D000744
hemolytic	I-Disease	D000744
anemia	I-Disease	D000744
,	O	O
and	O	O
erythroblastocytopenia	B-Disease	-1
induced	O	O
by	O	O
ceftriaxone	B-Chemical	D002443
.	O	O

An	O	O
80	O	O
-	O	O
yr	O	O
-	O	O
old	O	O
man	O	O
developed	O	O
acute	O	O
hepatitis	B-Disease	D056486
shortly	O	O
after	O	O
ingesting	O	O
oral	O	O
ceftriaxone	B-Chemical	D002443
.	O	O

Although	O	O
the	O	O
transaminases	O	O
gradually	O	O
returned	O	O
to	O	O
baseline	O	O
after	O	O
withholding	O	O
the	O	O
beta	B-Chemical	D047090
lactam	I-Chemical	D047090
antibiotic	O	O
,	O	O
there	O	O
was	O	O
a	O	O
gradual	O	O
increase	O	O
in	O	O
serum	O	O
bilirubin	B-Chemical	D001663
and	O	O
a	O	O
decrease	O	O
in	O	O
hemoglobin	O	O
concentration	O	O
caused	O	O
by	O	O
an	O	O
autoimmune	B-Disease	D000744
hemolytic	I-Disease	D000744
anemia	I-Disease	D000744
and	O	O
erythroblastocytopenia	B-Disease	-1
.	O	O

These	O	O
responded	O	O
to	O	O
systemic	O	O
steroids	B-Chemical	D013256
and	O	O
immunoglobulins	O	O
.	O	O

Despite	O	O
the	O	O
widespread	O	O
use	O	O
of	O	O
these	O	O
agents	O	O
this	O	O
triad	O	O
of	O	O
side	O	O
effects	O	O
has	O	O
not	O	O
previously	O	O
been	O	O
reported	O	O
in	O	O
connection	O	O
with	O	O
beta	B-Chemical	D047090
lactam	I-Chemical	D047090
antibiotics	O	O
.	O	O

Adverse	O	O
effects	O	O
of	O	O
the	O	O
atypical	O	O
antipsychotics	O	O
.	O	O

Collaborative	O	O
Working	O	O
Group	O	O
on	O	O
Clinical	O	O
Trial	O	O
Evaluations	O	O
.	O	O

Adverse	O	O
effects	O	O
of	O	O
antipsychotics	O	O
often	O	O
lead	O	O
to	O	O
noncompliance	O	O
.	O	O

Thus	O	O
,	O	O
clinicians	O	O
should	O	O
address	O	O
patients'	O	O
concerns	O	O
about	O	O
adverse	O	O
effects	O	O
and	O	O
attempt	O	O
to	O	O
choose	O	O
medications	O	O
that	O	O
will	O	O
improve	O	O
their	O	O
patients'	O	O
quality	O	O
of	O	O
life	O	O
as	O	O
well	O	O
as	O	O
overall	O	O
health	O	O
.	O	O

The	O	O
side	O	O
effect	O	O
profiles	O	O
of	O	O
the	O	O
atypical	O	O
antipsychotics	O	O
are	O	O
more	O	O
advantageous	O	O
than	O	O
those	O	O
of	O	O
the	O	O
conventional	O	O
neuroleptics	O	O
.	O	O

Conventional	O	O
agents	O	O
are	O	O
associated	O	O
with	O	O
unwanted	O	O
central	O	O
nervous	O	O
system	O	O
effects	O	O
,	O	O
including	O	O
extrapyramidal	B-Disease	D001480
symptoms	I-Disease	D001480
(	O	O
EPS	B-Disease	D001480
)	O	O
,	O	O
tardive	B-Disease	D004409
dyskinesia	I-Disease	D004409
,	O	O
sedation	O	O
,	O	O
and	O	O
possible	O	O
impairment	O	O
of	O	O
some	O	O
cognitive	O	O
measures	O	O
,	O	O
as	O	O
well	O	O
as	O	O
cardiac	O	O
effects	O	O
,	O	O
orthostatic	B-Disease	D007024
hypotension	I-Disease	D007024
,	O	O
hepatic	O	O
changes	O	O
,	O	O
anticholinergic	O	O
side	O	O
effects	O	O
,	O	O
sexual	B-Disease	D012735
dysfunction	I-Disease	D012735
,	O	O
and	O	O
weight	B-Disease	D015430
gain	I-Disease	D015430
.	O	O

The	O	O
newer	O	O
atypical	O	O
agents	O	O
have	O	O
a	O	O
lower	O	O
risk	O	O
of	O	O
EPS	B-Disease	D001480
,	O	O
but	O	O
are	O	O
associated	O	O
in	O	O
varying	O	O
degrees	O	O
with	O	O
sedation	O	O
,	O	O
cardiovascular	O	O
effects	O	O
,	O	O
anticholinergic	O	O
effects	O	O
,	O	O
weight	B-Disease	D015430
gain	I-Disease	D015430
,	O	O
sexual	B-Disease	D012735
dysfunction	I-Disease	D012735
,	O	O
hepatic	O	O
effects	O	O
,	O	O
lowered	O	O
seizure	B-Disease	D012640
threshold	O	O
(	O	O
primarily	O	O
clozapine	B-Chemical	D003024
)	O	O
,	O	O
and	O	O
agranulocytosis	B-Disease	D000380
(	O	O
clozapine	B-Chemical	D003024
only	O	O
)	O	O
.	O	O

Since	O	O
the	O	O
incidence	O	O
and	O	O
severity	O	O
of	O	O
specific	O	O
adverse	O	O
effects	O	O
differ	O	O
among	O	O
the	O	O
various	O	O
atypicals	O	O
,	O	O
the	O	O
clinician	O	O
should	O	O
carefully	O	O
consider	O	O
which	O	O
side	O	O
effects	O	O
are	O	O
most	O	O
likely	O	O
to	O	O
lead	O	O
to	O	O
the	O	O
individual's	O	O
dissatisfaction	O	O
and	O	O
noncompliance	O	O
before	O	O
choosing	O	O
an	O	O
antipsychotic	O	O
for	O	O
a	O	O
particular	O	O
patient	O	O
.	O	O

Effects	O	O
of	O	O
tetrandrine	B-Chemical	C009438
and	O	O
fangchinoline	B-Chemical	C060802
on	O	O
experimental	O	O
thrombosis	B-Disease	D013927
in	O	O
mice	O	O
and	O	O
human	O	O
platelet	B-Disease	D001791
aggregation	I-Disease	D001791
.	O	O

Tetrandrine	B-Chemical	C009438
(	O	O
TET	B-Chemical	C009438
)	O	O
and	O	O
fangchinoline	B-Chemical	C060802
(	O	O
FAN	B-Chemical	C060802
)	O	O
are	O	O
two	O	O
naturally	O	O
occurring	O	O
analogues	O	O
with	O	O
a	O	O
bisbenzylisoquinoline	B-Chemical	D044182
structure	O	O
.	O	O

The	O	O
present	O	O
study	O	O
was	O	O
undertaken	O	O
to	O	O
investigate	O	O
the	O	O
effects	O	O
of	O	O
TET	B-Chemical	C009438
and	O	O
FAN	B-Chemical	C060802
on	O	O
the	O	O
experimental	O	O
thrombosis	B-Disease	D013927
induced	O	O
by	O	O
collagen	O	O
plus	O	O
epinephrine	B-Chemical	D004837
(	O	O
EP	B-Chemical	D004837
)	O	O
in	O	O
mice	O	O
,	O	O
and	O	O
platelet	B-Disease	D001791
aggregation	I-Disease	D001791
and	O	O
blood	B-Disease	D001778
coagulation	I-Disease	D001778
in	O	O
vitro	O	O
.	O	O

In	O	O
the	O	O
in	O	O
vivo	O	O
study	O	O
,	O	O
the	O	O
administration	O	O
(	O	O
50	O	O
mg	O	O
/	O	O
kg	O	O
,	O	O
i	O	O
.	O	O

p	O	O
.	O	O

)	O	O
of	O	O
TET	B-Chemical	C009438
and	O	O
FAN	B-Chemical	C060802
in	O	O
mice	O	O
showed	O	O
the	O	O
inhibition	O	O
of	O	O
thrombosis	B-Disease	D013927
by	O	O
55%	O	O
and	O	O
35%	O	O
,	O	O
respectively	O	O
,	O	O
while	O	O
acetylsalicylic	B-Chemical	D001241
acid	I-Chemical	D001241
(	O	O
ASA	B-Chemical	D001241
,	O	O
50	O	O
mg	O	O
/	O	O
kg	O	O
,	O	O
i	O	O
.	O	O

p	O	O
.	O	O

)	O	O
,	O	O
a	O	O
positive	O	O
control	O	O
,	O	O
showed	O	O
only	O	O
30%	O	O
inhibition	O	O
.	O	O

In	O	O
the	O	O
vitro	O	O
human	O	O
platelet	B-Disease	D001791
aggregations	I-Disease	D001791
induced	O	O
by	O	O
the	O	O
agonists	O	O
used	O	O
in	O	O
tests	O	O
,	O	O
TET	B-Chemical	C009438
and	O	O
FAN	B-Chemical	C060802
showed	O	O
the	O	O
inhibitions	O	O
dose	O	O
dependently	O	O
.	O	O

In	O	O
addition	O	O
,	O	O
neither	O	O
TET	B-Chemical	C009438
nor	O	O
FAN	B-Chemical	C060802
showed	O	O
any	O	O
anticoagulation	O	O
activities	O	O
in	O	O
the	O	O
measurement	O	O
of	O	O
the	O	O
activated	O	O
partial	O	O
thromboplastin	O	O
time	O	O
(	O	O
APTT	O	O
)	O	O
,	O	O
prothrombin	O	O
time	O	O
(	O	O
PT	O	O
)	O	O
and	O	O
thrombin	O	O
time	O	O
(	O	O
TT	O	O
)	O	O
using	O	O
human	O	O
-	O	O
citrated	O	O
plasma	O	O
.	O	O

These	O	O
results	O	O
suggest	O	O
that	O	O
antithrombosis	O	O
of	O	O
TET	B-Chemical	C009438
and	O	O
FAN	B-Chemical	C060802
in	O	O
mice	O	O
may	O	O
be	O	O
mainly	O	O
related	O	O
to	O	O
the	O	O
antiplatelet	O	O
aggregation	O	O
activities	O	O
.	O	O

Gemcitabine	B-Chemical	C056507
plus	O	O
vinorelbine	B-Chemical	C030852
in	O	O
nonsmall	B-Disease	D002289
cell	I-Disease	D002289
lung	I-Disease	D002289
carcinoma	I-Disease	D002289
patients	O	O
age	O	O
70	O	O
years	O	O
or	O	O
older	O	O
or	O	O
patients	O	O
who	O	O
cannot	O	O
receive	O	O
cisplatin	B-Chemical	D002945
.	O	O

Oncopaz	O	O
Cooperative	O	O
Group	O	O
.	O	O

BACKGROUND	O	O
:	O	O
Although	O	O
the	O	O
prevalence	O	O
of	O	O
nonsmall	B-Disease	D002289
cell	I-Disease	D002289
lung	I-Disease	D002289
carcinoma	I-Disease	D002289
(	O	O
NSCLC	B-Disease	D002289
)	O	O
is	O	O
high	O	O
among	O	O
elderly	O	O
patients	O	O
,	O	O
few	O	O
data	O	O
are	O	O
available	O	O
regarding	O	O
the	O	O
efficacy	O	O
and	O	O
toxicity	B-Disease	D064420
of	O	O
chemotherapy	O	O
in	O	O
this	O	O
group	O	O
of	O	O
patients	O	O
.	O	O

Recent	O	O
reports	O	O
indicate	O	O
that	O	O
single	O	O
agent	O	O
therapy	O	O
with	O	O
vinorelbine	B-Chemical	C030852
(	O	O
VNB	B-Chemical	C030852
)	O	O
or	O	O
gemcitabine	B-Chemical	C056507
(	O	O
GEM	B-Chemical	C056507
)	O	O
may	O	O
obtain	O	O
a	O	O
response	O	O
rate	O	O
of	O	O
20	O	O
-	O	O
30%	O	O
in	O	O
elderly	O	O
patients	O	O
,	O	O
with	O	O
acceptable	O	O
toxicity	B-Disease	D064420
and	O	O
improvement	O	O
in	O	O
symptoms	O	O
and	O	O
quality	O	O
of	O	O
life	O	O
.	O	O

In	O	O
the	O	O
current	O	O
study	O	O
the	O	O
efficacy	O	O
and	O	O
toxicity	B-Disease	D064420
of	O	O
the	O	O
combination	O	O
of	O	O
GEM	B-Chemical	C056507
and	O	O
VNB	B-Chemical	C030852
in	O	O
elderly	O	O
patients	O	O
with	O	O
advanced	O	O
NSCLC	B-Disease	D002289
or	O	O
those	O	O
with	O	O
some	O	O
contraindication	O	O
to	O	O
receiving	O	O
cisplatin	B-Chemical	D002945
were	O	O
assessed	O	O
.	O	O

METHODS	O	O
:	O	O
Forty	O	O
-	O	O
nine	O	O
patients	O	O
with	O	O
advanced	O	O
NSCLC	B-Disease	D002289
were	O	O
included	O	O
,	O	O
38	O	O
of	O	O
whom	O	O
were	O	O
age	O	O
>	O	O
/	O	O
=	O	O
70	O	O
years	O	O
and	O	O
11	O	O
were	O	O
age	O	O
<	O	O
70	O	O
years	O	O
but	O	O
who	O	O
had	O	O
some	O	O
contraindication	O	O
to	O	O
receiving	O	O
cisplatin	B-Chemical	D002945
.	O	O

All	O	O
patients	O	O
were	O	O
evaluable	O	O
for	O	O
response	O	O
and	O	O
toxicity	B-Disease	D064420
.	O	O

Treatment	O	O
was	O	O
comprised	O	O
of	O	O
VNB	B-Chemical	C030852
,	O	O
25	O	O
mg	O	O
/	O	O
m	O	O
(	O	O
2	O	O
)	O	O
,	O	O
plus	O	O
GEM	B-Chemical	C056507
,	O	O
1000	O	O
mg	O	O
/	O	O
m	O	O
(	O	O
2	O	O
)	O	O
,	O	O
both	O	O
on	O	O
Days	O	O
1	O	O
,	O	O
8	O	O
,	O	O
and	O	O
15	O	O
every	O	O
28	O	O
days	O	O
.	O	O

Patients	O	O
received	O	O
a	O	O
minimum	O	O
of	O	O
three	O	O
courses	O	O
unless	O	O
progressive	O	O
disease	O	O
was	O	O
detected	O	O
.	O	O

RESULTS	O	O
:	O	O
One	O	O
hundred	O	O
sixty	O	O
-	O	O
five	O	O
courses	O	O
were	O	O
administered	O	O
,	O	O
with	O	O
a	O	O
median	O	O
of	O	O
3	O	O
.	O	O

6	O	O
courses	O	O
per	O	O
patient	O	O
.	O	O

The	O	O
overall	O	O
response	O	O
rate	O	O
was	O	O
26%	O	O
(	O	O
95%	O	O
confidence	O	O
interval	O	O
,	O	O
15	O	O
-	O	O
41%	O	O
)	O	O
.	O	O

Two	O	O
patients	O	O
attained	O	O
a	O	O
complete	O	O
response	O	O
(	O	O
4%	O	O
)	O	O
and	O	O
11	O	O
patients	O	O
(	O	O
22%	O	O
)	O	O
achieved	O	O
a	O	O
partial	O	O
response	O	O
.	O	O

Eastern	O	O
Cooperative	O	O
Oncology	O	O
Group	O	O
performance	O	O
status	O	O
improved	O	O
in	O	O
35%	O	O
of	O	O
those	O	O
patients	O	O
with	O	O
an	O	O
initial	O	O
value	O	O
>	O	O
0	O	O
,	O	O
whereas	O	O
relief	O	O
of	O	O
at	O	O
least	O	O
1	O	O
symptom	O	O
without	O	O
worsening	O	O
of	O	O
other	O	O
symptoms	O	O
was	O	O
noted	O	O
in	O	O
27	O	O
patients	O	O
(	O	O
55%	O	O
)	O	O
.	O	O

The	O	O
median	O	O
time	O	O
to	O	O
progression	O	O
was	O	O
16	O	O
weeks	O	O
and	O	O
the	O	O
1	O	O
-	O	O
year	O	O
survival	O	O
rate	O	O
was	O	O
33%	O	O
.	O	O

Toxicity	B-Disease	D064420
was	O	O
mild	O	O
.	O	O

Six	O	O
patients	O	O
(	O	O
12%	O	O
)	O	O
had	O	O
World	O	O
Health	O	O
Organization	O	O
Grade	O	O
3	O	O
-	O	O
4	O	O
neutropenia	B-Disease	D009503
,	O	O
2	O	O
patients	O	O
(	O	O
4%	O	O
)	O	O
had	O	O
Grade	O	O
3	O	O
-	O	O
4	O	O
thrombocytopenia	B-Disease	D013921
,	O	O
and	O	O
2	O	O
patients	O	O
(	O	O
4%	O	O
)	O	O
had	O	O
Grade	O	O
3	O	O
neurotoxicity	B-Disease	D020258
.	O	O

Three	O	O
patients	O	O
with	O	O
severe	O	O
neutropenia	B-Disease	D009503
(	O	O
6%	O	O
)	O	O
died	O	O
of	O	O
sepsis	B-Disease	D018805
.	O	O

The	O	O
median	O	O
age	O	O
of	O	O
those	O	O
patients	O	O
developing	O	O
Grade	O	O
3	O	O
-	O	O
4	O	O
neutropenia	B-Disease	D009503
was	O	O
significantly	O	O
higher	O	O
than	O	O
that	O	O
of	O	O
the	O	O
remaining	O	O
patients	O	O
(	O	O
75	O	O
years	O	O
vs	O	O
.	O	O

72	O	O
years	O	O
;	O	O
P	O	O
=	O	O
0	O	O
.	O	O

047	O	O
)	O	O
.	O	O

CONCLUSIONS	O	O
:	O	O
The	O	O
combination	O	O
of	O	O
GEM	B-Chemical	C056507
and	O	O
VNB	B-Chemical	C030852
is	O	O
moderately	O	O
active	O	O
and	O	O
well	O	O
tolerated	O	O
except	O	O
in	O	O
patients	O	O
age	O	O
>	O	O
/	O	O
=	O	O
75	O	O
years	O	O
.	O	O

This	O	O
age	O	O
group	O	O
had	O	O
an	O	O
increased	O	O
risk	O	O
of	O	O
myelosuppression	B-Disease	D001855
.	O	O

Therefore	O	O
the	O	O
prophylactic	O	O
use	O	O
of	O	O
granulocyte	O	O
-	O	O
colony	O	O
stimulating	O	O
factor	O	O
should	O	O
be	O	O
considered	O	O
with	O	O
this	O	O
treatment	O	O
.	O	O

New	O	O
chemotherapy	O	O
combinations	O	O
with	O	O
higher	O	O
activity	O	O
and	O	O
lower	O	O
toxicity	B-Disease	D064420
are	O	O
needed	O	O
for	O	O
elderly	O	O
patients	O	O
with	O	O
advanced	O	O
NSCLC	B-Disease	D002289
.	O	O

Warfarin	B-Chemical	D014859
-	O	O
induced	O	O
artery	B-Disease	D061205
calcification	I-Disease	D061205
is	O	O
accelerated	O	O
by	O	O
growth	O	O
and	O	O
vitamin	B-Chemical	D014807
D	I-Chemical	D014807
.	O	O

The	O	O
present	O	O
studies	O	O
demonstrate	O	O
that	O	O
growth	O	O
and	O	O
vitamin	B-Chemical	D014807
D	I-Chemical	D014807
treatment	O	O
enhance	O	O
the	O	O
extent	O	O
of	O	O
artery	B-Disease	D061205
calcification	I-Disease	D061205
in	O	O
rats	O	O
given	O	O
sufficient	O	O
doses	O	O
of	O	O
Warfarin	B-Chemical	D014859
to	O	O
inhibit	O	O
gamma	O	O
-	O	O
carboxylation	O	O
of	O	O
matrix	O	O
Gla	O	O
protein	O	O
,	O	O
a	O	O
calcification	B-Disease	D002114
inhibitor	O	O
known	O	O
to	O	O
be	O	O
expressed	O	O
by	O	O
smooth	O	O
muscle	O	O
cells	O	O
and	O	O
macrophages	O	O
in	O	O
the	O	O
artery	O	O
wall	O	O
.	O	O

The	O	O
first	O	O
series	O	O
of	O	O
experiments	O	O
examined	O	O
the	O	O
influence	O	O
of	O	O
age	O	O
and	O	O
growth	O	O
status	O	O
on	O	O
artery	B-Disease	D061205
calcification	I-Disease	D061205
in	O	O
Warfarin	B-Chemical	D014859
-	O	O
treated	O	O
rats	O	O
.	O	O

Treatment	O	O
for	O	O
2	O	O
weeks	O	O
with	O	O
Warfarin	B-Chemical	D014859
caused	O	O
massive	O	O
focal	O	O
calcification	B-Disease	D002114
of	O	O
the	O	O
artery	O	O
media	O	O
in	O	O
20	O	O
-	O	O
day	O	O
-	O	O
old	O	O
rats	O	O
and	O	O
less	O	O
extensive	O	O
focal	O	O
calcification	B-Disease	D002114
in	O	O
42	O	O
-	O	O
day	O	O
-	O	O
old	O	O
rats	O	O
.	O	O

In	O	O
contrast	O	O
,	O	O
no	O	O
artery	B-Disease	D061205
calcification	I-Disease	D061205
could	O	O
be	O	O
detected	O	O
in	O	O
10	O	O
-	O	O
month	O	O
-	O	O
old	O	O
adult	O	O
rats	O	O
even	O	O
after	O	O
4	O	O
weeks	O	O
of	O	O
Warfarin	B-Chemical	D014859
treatment	O	O
.	O	O

To	O	O
directly	O	O
examine	O	O
the	O	O
importance	O	O
of	O	O
growth	O	O
to	O	O
Warfarin	B-Chemical	D014859
-	O	O
induced	O	O
artery	B-Disease	D061205
calcification	I-Disease	D061205
in	O	O
animals	O	O
of	O	O
the	O	O
same	O	O
age	O	O
,	O	O
20	O	O
-	O	O
day	O	O
-	O	O
old	O	O
rats	O	O
were	O	O
fed	O	O
for	O	O
2	O	O
weeks	O	O
either	O	O
an	O	O
ad	O	O
libitum	O	O
diet	O	O
or	O	O
a	O	O
6	O	O
-	O	O
g	O	O
/	O	O
d	O	O
restricted	O	O
diet	O	O
that	O	O
maintains	O	O
weight	O	O
but	O	O
prevents	O	O
growth	O	O
.	O	O

Concurrent	O	O
treatment	O	O
of	O	O
both	O	O
dietary	O	O
groups	O	O
with	O	O
Warfarin	B-Chemical	D014859
produced	O	O
massive	O	O
focal	O	O
calcification	B-Disease	D002114
of	O	O
the	O	O
artery	O	O
media	O	O
in	O	O
the	O	O
ad	O	O
libitum	O	O
-	O	O
fed	O	O
rats	O	O
but	O	O
no	O	O
detectable	O	O
artery	B-Disease	D061205
calcification	I-Disease	D061205
in	O	O
the	O	O
restricted	O	O
-	O	O
diet	O	O
,	O	O
growth	O	O
-	O	O
inhibited	O	O
group	O	O
.	O	O

Although	O	O
the	O	O
explanation	O	O
for	O	O
the	O	O
association	O	O
between	O	O
artery	B-Disease	D061205
calcification	I-Disease	D061205
and	O	O
growth	O	O
status	O	O
cannot	O	O
be	O	O
determined	O	O
from	O	O
the	O	O
present	O	O
study	O	O
,	O	O
there	O	O
was	O	O
a	O	O
relationship	O	O
between	O	O
higher	O	O
serum	O	O
phosphate	B-Chemical	D010710
and	O	O
susceptibility	O	O
to	O	O
artery	B-Disease	D061205
calcification	I-Disease	D061205
,	O	O
with	O	O
30%	O	O
higher	O	O
levels	O	O
of	O	O
serum	O	O
phosphate	B-Chemical	D010710
in	O	O
young	O	O
,	O	O
ad	O	O
libitum	O	O
-	O	O
fed	O	O
rats	O	O
compared	O	O
with	O	O
either	O	O
of	O	O
the	O	O
groups	O	O
that	O	O
was	O	O
resistant	O	O
to	O	O
Warfarin	B-Chemical	D014859
-	O	O
induced	O	O
artery	B-Disease	D061205
calcification	I-Disease	D061205
,	O	O
ie	O	O
,	O	O
the	O	O
10	O	O
-	O	O
month	O	O
-	O	O
old	O	O
rats	O	O
and	O	O
the	O	O
restricted	O	O
-	O	O
diet	O	O
,	O	O
growth	O	O
-	O	O
inhibited	O	O
young	O	O
rats	O	O
.	O	O

This	O	O
observation	O	O
suggests	O	O
that	O	O
increased	O	O
susceptibility	O	O
to	O	O
Warfarin	B-Chemical	D014859
-	O	O
induced	O	O
artery	B-Disease	D061205
calcification	I-Disease	D061205
could	O	O
be	O	O
related	O	O
to	O	O
higher	O	O
serum	O	O
phosphate	B-Chemical	D010710
levels	O	O
.	O	O

The	O	O
second	O	O
set	O	O
of	O	O
experiments	O	O
examined	O	O
the	O	O
possible	O	O
synergy	O	O
between	O	O
vitamin	B-Chemical	D014807
D	I-Chemical	D014807
and	O	O
Warfarin	B-Chemical	D014859
in	O	O
artery	B-Disease	D061205
calcification	I-Disease	D061205
.	O	O

High	O	O
doses	O	O
of	O	O
vitamin	B-Chemical	D014807
D	I-Chemical	D014807
are	O	O
known	O	O
to	O	O
cause	O	O
calcification	B-Disease	D002114
of	O	O
the	O	O
artery	O	O
media	O	O
in	O	O
as	O	O
little	O	O
as	O	O
3	O	O
to	O	O
4	O	O
days	O	O
.	O	O

High	O	O
doses	O	O
of	O	O
the	O	O
vitamin	B-Chemical	D014812
K	I-Chemical	D014812
antagonist	O	O
Warfarin	B-Chemical	D014859
are	O	O
also	O	O
known	O	O
to	O	O
cause	O	O
calcification	B-Disease	D002114
of	O	O
the	O	O
artery	O	O
media	O	O
,	O	O
but	O	O
at	O	O
treatment	O	O
times	O	O
of	O	O
2	O	O
weeks	O	O
or	O	O
longer	O	O
yet	O	O
not	O	O
at	O	O
1	O	O
week	O	O
.	O	O

In	O	O
the	O	O
current	O	O
study	O	O
,	O	O
we	O	O
investigated	O	O
the	O	O
synergy	O	O
between	O	O
these	O	O
2	O	O
treatments	O	O
and	O	O
found	O	O
that	O	O
concurrent	O	O
Warfarin	B-Chemical	D014859
administration	O	O
dramatically	O	O
increased	O	O
the	O	O
extent	O	O
of	O	O
calcification	B-Disease	D002114
in	O	O
the	O	O
media	O	O
of	O	O
vitamin	B-Chemical	D014807
D	I-Chemical	D014807
-	O	O
treated	O	O
rats	O	O
at	O	O
3	O	O
and	O	O
4	O	O
days	O	O
.	O	O

There	O	O
was	O	O
a	O	O
close	O	O
parallel	O	O
between	O	O
the	O	O
effect	O	O
of	O	O
vitamin	B-Chemical	D014807
D	I-Chemical	D014807
dose	O	O
on	O	O
artery	B-Disease	D061205
calcification	I-Disease	D061205
and	O	O
the	O	O
effect	O	O
of	O	O
vitamin	B-Chemical	D014807
D	I-Chemical	D014807
dose	O	O
on	O	O
the	O	O
elevation	O	O
of	O	O
serum	O	O
calcium	B-Chemical	D002118
,	O	O
which	O	O
suggests	O	O
that	O	O
vitamin	B-Chemical	D014807
D	I-Chemical	D014807
may	O	O
induce	O	O
artery	B-Disease	D061205
calcification	I-Disease	D061205
through	O	O
its	O	O
effect	O	O
on	O	O
serum	O	O
calcium	B-Chemical	D002118
.	O	O

Because	O	O
Warfarin	B-Chemical	D014859
treatment	O	O
had	O	O
no	O	O
effect	O	O
on	O	O
the	O	O
elevation	O	O
in	O	O
serum	O	O
calcium	B-Chemical	D002118
produced	O	O
by	O	O
vitamin	B-Chemical	D014807
D	I-Chemical	D014807
,	O	O
the	O	O
synergy	O	O
between	O	O
Warfarin	B-Chemical	D014859
and	O	O
vitamin	B-Chemical	D014807
D	I-Chemical	D014807
is	O	O
probably	O	O
best	O	O
explained	O	O
by	O	O
the	O	O
hypothesis	O	O
that	O	O
Warfarin	B-Chemical	D014859
inhibits	O	O
the	O	O
activity	O	O
of	O	O
matrix	O	O
Gla	O	O
protein	O	O
as	O	O
a	O	O
calcification	B-Disease	D002114
inhibitor	O	O
.	O	O

High	O	O
levels	O	O
of	O	O
matrix	O	O
Gla	O	O
protein	O	O
are	O	O
found	O	O
at	O	O
sites	O	O
of	O	O
artery	B-Disease	D061205
calcification	I-Disease	D061205
in	O	O
rats	O	O
treated	O	O
with	O	O
vitamin	B-Chemical	D014807
D	I-Chemical	D014807
plus	O	O
Warfarin	B-Chemical	D014859
,	O	O
and	O	O
chemical	O	O
analysis	O	O
showed	O	O
that	O	O
the	O	O
protein	O	O
that	O	O
accumulated	O	O
was	O	O
indeed	O	O
not	O	O
gamma	B-Chemical	D015055
-	I-Chemical	D015055
carboxylated	I-Chemical	D015055
.	O	O

These	O	O
observations	O	O
indicate	O	O
that	O	O
although	O	O
the	O	O
gamma	B-Chemical	D015055
-	I-Chemical	D015055
carboxyglutamate	I-Chemical	D015055
residues	O	O
of	O	O
matrix	O	O
Gla	O	O
protein	O	O
are	O	O
apparently	O	O
required	O	O
for	O	O
its	O	O
function	O	O
as	O	O
a	O	O
calcification	B-Disease	D002114
inhibitor	O	O
,	O	O
they	O	O
are	O	O
not	O	O
required	O	O
for	O	O
its	O	O
accumulation	O	O
at	O	O
calcification	B-Disease	D002114
sites	O	O
.	O	O

Antidepressant	B-Chemical	D000928
-	O	O
induced	O	O
mania	B-Disease	D001714
in	O	O
bipolar	B-Disease	D001714
patients	O	O
:	O	O
identification	O	O
of	O	O
risk	O	O
factors	O	O
.	O	O

BACKGROUND	O	O
:	O	O
Concerns	O	O
about	O	O
possible	O	O
risks	O	O
of	O	O
switching	O	O
to	O	O
mania	B-Disease	D001714
associated	O	O
with	O	O
antidepressants	B-Chemical	D000928
continue	O	O
to	O	O
interfere	O	O
with	O	O
the	O	O
establishment	O	O
of	O	O
an	O	O
optimal	O	O
treatment	O	O
paradigm	O	O
for	O	O
bipolar	B-Disease	D001714
depression	O	O
.	O	O

METHOD	O	O
:	O	O
The	O	O
response	O	O
of	O	O
44	O	O
patients	O	O
meeting	O	O
DSM	O	O
-	O	O
IV	O	O
criteria	O	O
for	O	O
bipolar	B-Disease	D001714
disorder	O	O
to	O	O
naturalistic	O	O
treatment	O	O
was	O	O
assessed	O	O
for	O	O
at	O	O
least	O	O
6	O	O
weeks	O	O
using	O	O
the	O	O
Montgomery	O	O
-	O	O
Asberg	O	O
Depression	O	O
Rating	O	O
Scale	O	O
and	O	O
the	O	O
Bech	O	O
-	O	O
Rafaelson	O	O
Mania	O	O
Rating	O	O
Scale	O	O
.	O	O

Patients	O	O
who	O	O
experienced	O	O
a	O	O
manic	B-Disease	D001714
or	O	O
hypomanic	B-Disease	D001714
switch	O	O
were	O	O
compared	O	O
with	O	O
those	O	O
who	O	O
did	O	O
not	O	O
on	O	O
several	O	O
variables	O	O
including	O	O
age	O	O
,	O	O
sex	O	O
,	O	O
diagnosis	O	O
(	O	O
DSM	B-Disease	D001714
-	I-Disease	D001714
IV	I-Disease	D001714
bipolar	I-Disease	D001714
I	I-Disease	D001714
vs	O	O
.	O	O

bipolar	B-Disease	D001714
II	O	O
)	O	O
,	O	O
number	O	O
of	O	O
previous	O	O
manic	B-Disease	D001714
episodes	O	O
,	O	O
type	O	O
of	O	O
antidepressant	B-Chemical	D000928
therapy	O	O
used	O	O
(	O	O
electroconvulsive	O	O
therapy	O	O
vs	O	O
.	O	O

antidepressant	B-Chemical	D000928
drugs	O	O
and	O	O
,	O	O
more	O	O
particularly	O	O
,	O	O
selective	O	O
serotonin	B-Chemical	D017367
reuptake	I-Chemical	D017367
inhibitors	I-Chemical	D017367
[	O	O
SSRIs	B-Chemical	D017367
]	O	O
)	O	O
,	O	O
use	O	O
and	O	O
type	O	O
of	O	O
mood	O	O
stabilizers	O	O
(	O	O
lithium	B-Chemical	D008094
vs	O	O
.	O	O

anticonvulsants	O	O
)	O	O
,	O	O
and	O	O
temperament	O	O
of	O	O
the	O	O
patient	O	O
,	O	O
assessed	O	O
during	O	O
a	O	O
normothymic	O	O
period	O	O
using	O	O
the	O	O
hyperthymia	O	O
component	O	O
of	O	O
the	O	O
Semi	O	O
-	O	O
structured	O	O
Affective	O	O
Temperament	O	O
Interview	O	O
.	O	O

RESULTS	O	O
:	O	O
Switches	O	O
to	O	O
hypomania	B-Disease	D001714
or	O	O
mania	B-Disease	D001714
occurred	O	O
in	O	O
27%	O	O
of	O	O
all	O	O
patients	O	O
(	O	O
N	O	O
=	O	O
12	O	O
)	O	O
(	O	O
and	O	O
in	O	O
24%	O	O
of	O	O
the	O	O
subgroup	O	O
of	O	O
patients	O	O
treated	O	O
with	O	O
SSRIs	B-Chemical	D017367
[	O	O
8	O	O
/	O	O
33	O	O
]	O	O
)	O	O
;	O	O
16%	O	O
(	O	O
N	O	O
=	O	O
7	O	O
)	O	O
experienced	O	O
manic	B-Disease	D001714
episodes	O	O
,	O	O
and	O	O
11%	O	O
(	O	O
N	O	O
=	O	O
5	O	O
)	O	O
experienced	O	O
hypomanic	B-Disease	D001714
episodes	O	O
.	O	O

Sex	O	O
,	O	O
age	O	O
,	O	O
diagnosis	O	O
(	O	O
bipolar	B-Disease	D001714
I	O	O
vs	O	O
.	O	O

bipolar	B-Disease	D001714
II	O	O
)	O	O
,	O	O
and	O	O
additional	O	O
treatment	O	O
did	O	O
not	O	O
affect	O	O
the	O	O
risk	O	O
of	O	O
switching	O	O
.	O	O

The	O	O
incidence	O	O
of	O	O
mood	O	O
switches	O	O
seemed	O	O
not	O	O
to	O	O
differ	O	O
between	O	O
patients	O	O
receiving	O	O
an	O	O
anticonvulsant	O	O
and	O	O
those	O	O
receiving	O	O
no	O	O
mood	O	O
stabilizer	O	O
.	O	O

In	O	O
contrast	O	O
,	O	O
mood	O	O
switches	O	O
were	O	O
less	O	O
frequent	O	O
in	O	O
patients	O	O
receiving	O	O
lithium	B-Chemical	D008094
(	O	O
15%	O	O
,	O	O
4	O	O
/	O	O
26	O	O
)	O	O
than	O	O
in	O	O
patients	O	O
not	O	O
treated	O	O
with	O	O
lithium	B-Chemical	D008094
(	O	O
44%	O	O
,	O	O
8	O	O
/	O	O
18	O	O
;	O	O
p	O	O
=	O	O
.	O	O

04	O	O
)	O	O
.	O	O

The	O	O
number	O	O
of	O	O
previous	O	O
manic	B-Disease	D001714
episodes	O	O
did	O	O
not	O	O
affect	O	O
the	O	O
probability	O	O
of	O	O
switching	O	O
,	O	O
whereas	O	O
a	O	O
high	O	O
score	O	O
on	O	O
the	O	O
hyperthymia	O	O
component	O	O
of	O	O
the	O	O
Semistructured	O	O
Affective	O	O
Temperament	O	O
Interview	O	O
was	O	O
associated	O	O
with	O	O
a	O	O
greater	O	O
risk	O	O
of	O	O
switching	O	O
(	O	O
p	O	O
=	O	O
.	O	O

008	O	O
)	O	O
.	O	O

CONCLUSION	O	O
:	O	O
The	O	O
frequency	O	O
of	O	O
mood	O	O
switching	O	O
associated	O	O
with	O	O
acute	O	O
antidepressant	B-Chemical	D000928
therapy	O	O
may	O	O
be	O	O
reduced	O	O
by	O	O
lithium	B-Chemical	D008094
treatment	O	O
.	O	O

Particular	O	O
attention	O	O
should	O	O
be	O	O
paid	O	O
to	O	O
patients	O	O
with	O	O
a	O	O
hyperthymic	O	O
temperament	O	O
,	O	O
who	O	O
have	O	O
a	O	O
greater	O	O
risk	O	O
of	O	O
mood	O	O
switches	O	O
.	O	O

Caffeine	B-Chemical	D002110
-	O	O
induced	O	O
cardiac	B-Disease	D001145
arrhythmia	I-Disease	D001145
:	O	O
an	O	O
unrecognised	O	O
danger	O	O
of	O	O
healthfood	O	O
products	O	O
.	O	O

We	O	O
describe	O	O
a	O	O
25	O	O
-	O	O
year	O	O
-	O	O
old	O	O
woman	O	O
with	O	O
pre	O	O
-	O	O
existing	O	O
mitral	B-Disease	D008945
valve	I-Disease	D008945
prolapse	I-Disease	D008945
who	O	O
developed	O	O
intractable	O	O
ventricular	B-Disease	D014693
fibrillation	I-Disease	D014693
after	O	O
consuming	O	O
a	O	O
"natural	O	O
energy"	O	O
guarana	O	O
health	O	O
drink	O	O
containing	O	O
a	O	O
high	O	O
concentration	O	O
of	O	O
caffeine	B-Chemical	D002110
.	O	O

This	O	O
case	O	O
highlights	O	O
the	O	O
need	O	O
for	O	O
adequate	O	O
labelling	O	O
and	O	O
regulation	O	O
of	O	O
such	O	O
products	O	O
.	O	O

Bladder	O	O
retention	B-Disease	D016055
of	I-Disease	D016055
urine	I-Disease	D016055
as	O	O
a	O	O
result	O	O
of	O	O
continuous	O	O
intravenous	O	O
infusion	O	O
of	O	O
fentanyl	B-Chemical	D005283
:	O	O
2	O	O
case	O	O
reports	O	O
.	O	O

Sedation	O	O
has	O	O
been	O	O
commonly	O	O
used	O	O
in	O	O
the	O	O
neonate	O	O
to	O	O
decrease	O	O
the	O	O
stress	O	O
and	O	O
pain	B-Disease	D010146
from	O	O
the	O	O
noxious	O	O
stimuli	O	O
and	O	O
invasive	O	O
procedures	O	O
in	O	O
the	O	O
neonatal	O	O
intensive	O	O
care	O	O
unit	O	O
,	O	O
as	O	O
well	O	O
as	O	O
to	O	O
facilitate	O	O
synchrony	O	O
between	O	O
ventilator	O	O
and	O	O
spontaneous	O	O
breaths	O	O
.	O	O

Fentanyl	B-Chemical	D005283
,	O	O
an	O	O
opioid	O	O
analgesic	O	O
,	O	O
is	O	O
frequently	O	O
used	O	O
in	O	O
the	O	O
neonatal	O	O
intensive	O	O
care	O	O
unit	O	O
setting	O	O
for	O	O
these	O	O
very	O	O
purposes	O	O
.	O	O

Various	O	O
reported	O	O
side	O	O
effects	O	O
of	O	O
fentanyl	B-Chemical	D005283
administration	O	O
include	O	O
chest	B-Disease	D009127
wall	I-Disease	D009127
rigidity	I-Disease	D009127
,	O	O
hypotension	B-Disease	D007022
,	O	O
respiratory	B-Disease	D012131
depression	I-Disease	D012131
,	O	O
and	O	O
bradycardia	B-Disease	D001919
.	O	O

Here	O	O
,	O	O
2	O	O
cases	O	O
of	O	O
urinary	B-Disease	D001745
bladder	I-Disease	D001745
retention	I-Disease	D001745
leading	O	O
to	O	O
renal	O	O
pelvocalyceal	O	O
dilatation	O	O
mimicking	O	O
hydronephrosis	B-Disease	D006869
as	O	O
a	O	O
result	O	O
of	O	O
continuous	O	O
infusion	O	O
of	O	O
fentanyl	B-Chemical	D005283
are	O	O
reported	O	O
.	O	O

Combined	O	O
antiretroviral	O	O
therapy	O	O
causes	O	O
cardiomyopathy	B-Disease	D009202
and	O	O
elevates	O	O
plasma	O	O
lactate	B-Chemical	D019344
in	O	O
transgenic	O	O
AIDS	B-Disease	D000163
mice	O	O
.	O	O

Highly	O	O
active	O	O
antiretroviral	O	O
therapy	O	O
(	O	O
HAART	O	O
)	O	O
is	O	O
implicated	O	O
in	O	O
cardiomyopathy	B-Disease	D009202
(	O	O
CM	B-Disease	D009202
)	O	O
and	O	O
in	O	O
elevated	O	O
plasma	O	O
lactate	B-Chemical	D019344
(	O	O
LA	B-Chemical	D019344
)	O	O
in	O	O
AIDS	B-Disease	D000163
through	O	O
mechanisms	O	O
of	O	O
mitochondrial	B-Disease	D028361
dysfunction	I-Disease	D028361
.	O	O

To	O	O
determine	O	O
mitochondrial	O	O
events	O	O
from	O	O
HAART	O	O
in	O	O
vivo	O	O
,	O	O
8	O	O
-	O	O
week	O	O
-	O	O
old	O	O
hemizygous	O	O
transgenic	O	O
AIDS	B-Disease	D000163
mice	O	O
(	O	O
NL4	O	O
-	O	O
3Delta	O	O
gag	O	O
/	O	O
pol	O	O
;	O	O
TG	O	O
)	O	O
and	O	O
wild	O	O
-	O	O
type	O	O
FVB	O	O
/	O	O
n	O	O
littermates	O	O
were	O	O
treated	O	O
with	O	O
the	O	O
HAART	O	O
combination	O	O
of	O	O
zidovudine	B-Chemical	D015215
,	O	O
lamivudine	B-Chemical	D019259
,	O	O
and	O	O
indinavir	B-Chemical	D019469
or	O	O
vehicle	O	O
control	O	O
for	O	O
10	O	O
days	O	O
or	O	O
35	O	O
days	O	O
.	O	O

At	O	O
termination	O	O
of	O	O
the	O	O
experiments	O	O
,	O	O
mice	O	O
underwent	O	O
echocardiography	O	O
,	O	O
quantitation	O	O
of	O	O
abundance	O	O
of	O	O
molecular	O	O
markers	O	O
of	O	O
CM	B-Disease	D009202
(	O	O
ventricular	O	O
mRNA	O	O
encoding	O	O
atrial	O	O
natriuretic	O	O
factor	O	O
[	O	O
ANF	O	O
]	O	O
and	O	O
sarcoplasmic	O	O
calcium	B-Chemical	D002118
ATPase	O	O
[	O	O
SERCA2	O	O
]	O	O
)	O	O
,	O	O
and	O	O
determination	O	O
of	O	O
plasma	O	O
LA	B-Chemical	D019344
.	O	O

Myocardial	O	O
histologic	O	O
features	O	O
were	O	O
analyzed	O	O
semiquantitatively	O	O
and	O	O
results	O	O
were	O	O
confirmed	O	O
by	O	O
transmission	O	O
electron	O	O
microscopy	O	O
.	O	O

After	O	O
35	O	O
days	O	O
in	O	O
the	O	O
TG	O	O
+	O	O
HAART	O	O
cohort	O	O
,	O	O
left	O	O
ventricular	O	O
mass	O	O
increased	O	O
160%	O	O
by	O	O
echocardiography	O	O
.	O	O

Molecularly	O	O
,	O	O
ANF	O	O
mRNA	O	O
increased	O	O
250%	O	O
and	O	O
SERCA2	O	O
mRNA	O	O
decreased	O	O
57%	O	O
.	O	O

Biochemically	O	O
,	O	O
LA	B-Chemical	D019344
was	O	O
elevated	O	O
(	O	O
8	O	O
.	O	O

5	O	O
+	O	O
/	O	O
-	O	O
2	O	O
.	O	O

0	O	O
mM	O	O
)	O	O
.	O	O

Pathologically	O	O
,	O	O
granular	O	O
cytoplasmic	O	O
changes	O	O
were	O	O
found	O	O
in	O	O
cardiac	O	O
myocytes	O	O
,	O	O
indicating	O	O
enlarged	O	O
,	O	O
damaged	O	O
mitochondria	O	O
.	O	O

Findings	O	O
were	O	O
confirmed	O	O
ultrastructurally	O	O
.	O	O

No	O	O
changes	O	O
were	O	O
found	O	O
in	O	O
other	O	O
cohorts	O	O
.	O	O

After	O	O
10	O	O
days	O	O
,	O	O
only	O	O
ANF	O	O
was	O	O
elevated	O	O
,	O	O
and	O	O
only	O	O
in	O	O
the	O	O
TG	O	O
+	O	O
HAART	O	O
cohort	O	O
.	O	O

Results	O	O
show	O	O
that	O	O
cumulative	O	O
HAART	O	O
caused	O	O
mitochondrial	O	O
CM	B-Disease	D009202
with	O	O
elevated	O	O
LA	B-Chemical	D019344
in	O	O
AIDS	B-Disease	D000163
transgenic	O	O
mice	O	O
.	O	O

Oral	B-Chemical	D003276
contraceptives	I-Chemical	D003276
and	O	O
the	O	O
risk	O	O
of	O	O
myocardial	B-Disease	D009203
infarction	I-Disease	D009203
.	O	O

BACKGROUND	O	O
:	O	O
An	O	O
association	O	O
between	O	O
the	O	O
use	O	O
of	O	O
oral	B-Chemical	D003276
contraceptives	I-Chemical	D003276
and	O	O
the	O	O
risk	O	O
of	O	O
myocardial	B-Disease	D009203
infarction	I-Disease	D009203
has	O	O
been	O	O
found	O	O
in	O	O
some	O	O
,	O	O
but	O	O
not	O	O
all	O	O
,	O	O
studies	O	O
.	O	O

We	O	O
investigated	O	O
this	O	O
association	O	O
,	O	O
according	O	O
to	O	O
the	O	O
type	O	O
of	O	O
progestagen	B-Chemical	D011372
included	O	O
in	O	O
third	O	O
-	O	O
generation	O	O
(	O	O
i	O	O
.	O	O

e	O	O
.	O	O

,	O	O
desogestrel	B-Chemical	D017135
or	O	O
gestodene	B-Chemical	C033273
)	O	O
and	O	O
second	O	O
-	O	O
generation	O	O
(	O	O
i	O	O
.	O	O

e	O	O
.	O	O

,	O	O
levonorgestrel	B-Chemical	D016912
)	O	O
oral	B-Chemical	D003276
contraceptives	I-Chemical	D003276
,	O	O
the	O	O
dose	O	O
of	O	O
estrogen	B-Chemical	D004967
,	O	O
and	O	O
the	O	O
presence	O	O
or	O	O
absence	O	O
of	O	O
prothrombotic	O	O
mutations	O	O
METHODS	O	O
:	O	O
In	O	O
a	O	O
nationwide	O	O
,	O	O
population	O	O
-	O	O
based	O	O
,	O	O
case	O	O
-	O	O
control	O	O
study	O	O
,	O	O
we	O	O
identified	O	O
and	O	O
enrolled	O	O
248	O	O
women	O	O
18	O	O
through	O	O
49	O	O
years	O	O
of	O	O
age	O	O
who	O	O
had	O	O
had	O	O
a	O	O
first	O	O
myocardial	B-Disease	D009203
infarction	I-Disease	D009203
between	O	O
1990	O	O
and	O	O
1995	O	O
and	O	O
925	O	O
control	O	O
women	O	O
who	O	O
had	O	O
not	O	O
had	O	O
a	O	O
myocardial	B-Disease	D009203
infarction	I-Disease	D009203
and	O	O
who	O	O
were	O	O
matched	O	O
for	O	O
age	O	O
,	O	O
calendar	O	O
year	O	O
of	O	O
the	O	O
index	O	O
event	O	O
,	O	O
and	O	O
area	O	O
of	O	O
residence	O	O
.	O	O

Subjects	O	O
supplied	O	O
information	O	O
on	O	O
oral	B-Chemical	D003276
-	I-Chemical	D003276
contraceptive	I-Chemical	D003276
use	O	O
and	O	O
major	O	O
cardiovascular	O	O
risk	O	O
factors	O	O
.	O	O

An	O	O
analysis	O	O
for	O	O
factor	O	O
V	O	O
Leiden	O	O
and	O	O
the	O	O
G20210A	O	O
mutation	O	O
in	O	O
the	O	O
prothrombin	O	O
gene	O	O
was	O	O
conducted	O	O
in	O	O
217	O	O
patients	O	O
and	O	O
763	O	O
controls	O	O
RESULTS	O	O
:	O	O
The	O	O
odds	O	O
ratio	O	O
for	O	O
myocardial	B-Disease	D009203
infarction	I-Disease	D009203
among	O	O
women	O	O
who	O	O
used	O	O
any	O	O
type	O	O
of	O	O
combined	O	O
oral	B-Chemical	D003276
contraceptive	I-Chemical	D003276
,	O	O
as	O	O
compared	O	O
with	O	O
nonusers	O	O
,	O	O
was	O	O
2	O	O
.	O	O

0	O	O
(	O	O
95	O	O
percent	O	O
confidence	O	O
interval	O	O
,	O	O
1	O	O
.	O	O

5	O	O
to	O	O
2	O	O
.	O	O

8	O	O
)	O	O
.	O	O

The	O	O
adjusted	O	O
odds	O	O
ratio	O	O
was	O	O
2	O	O
.	O	O

5	O	O
(	O	O
95	O	O
percent	O	O
confidence	O	O
interval	O	O
,	O	O
1	O	O
.	O	O

5	O	O
to	O	O
4	O	O
.	O	O

1	O	O
)	O	O
among	O	O
women	O	O
who	O	O
used	O	O
second	O	O
-	O	O
generation	O	O
oral	B-Chemical	D003276
contraceptives	I-Chemical	D003276
and	O	O
1	O	O
.	O	O

3	O	O
(	O	O
95	O	O
percent	O	O
confidence	O	O
interval	O	O
,	O	O
0	O	O
.	O	O

7	O	O
to	O	O
2	O	O
.	O	O

5	O	O
)	O	O
among	O	O
those	O	O
who	O	O
used	O	O
third	O	O
-	O	O
generation	O	O
oral	B-Chemical	D003276
contraceptives	I-Chemical	D003276
.	O	O

Among	O	O
women	O	O
who	O	O
used	O	O
oral	B-Chemical	D003276
contraceptives	I-Chemical	D003276
,	O	O
the	O	O
odds	O	O
ratio	O	O
was	O	O
2	O	O
.	O	O

1	O	O
(	O	O
95	O	O
percent	O	O
confidence	O	O
interval	O	O
,	O	O
1	O	O
.	O	O

5	O	O
to	O	O
3	O	O
.	O	O

0	O	O
)	O	O
for	O	O
those	O	O
without	O	O
a	O	O
prothrombotic	O	O
mutation	O	O
and	O	O
1	O	O
.	O	O

9	O	O
(	O	O
95	O	O
percent	O	O
confidence	O	O
interval	O	O
,	O	O
0	O	O
.	O	O

6	O	O
to	O	O
5	O	O
.	O	O

5	O	O
)	O	O
for	O	O
those	O	O
with	O	O
a	O	O
mutation	O	O
CONCLUSIONS	O	O
:	O	O
The	O	O
risk	O	O
of	O	O
myocardial	B-Disease	D009203
infarction	I-Disease	D009203
was	O	O
increased	O	O
among	O	O
women	O	O
who	O	O
used	O	O
second	O	O
-	O	O
generation	O	O
oral	B-Chemical	D003276
contraceptives	I-Chemical	D003276
.	O	O

The	O	O
results	O	O
with	O	O
respect	O	O
to	O	O
the	O	O
use	O	O
of	O	O
third	O	O
-	O	O
generation	O	O
oral	B-Chemical	D003276
contraceptives	I-Chemical	D003276
were	O	O
inconclusive	O	O
but	O	O
suggested	O	O
that	O	O
the	O	O
risk	O	O
was	O	O
lower	O	O
than	O	O
the	O	O
risk	O	O
associated	O	O
with	O	O
second	O	O
-	O	O
generation	O	O
oral	B-Chemical	D003276
contraceptives	I-Chemical	D003276
.	O	O

The	O	O
risk	O	O
of	O	O
myocardial	B-Disease	D009203
infarction	I-Disease	D009203
was	O	O
similar	O	O
among	O	O
women	O	O
who	O	O
used	O	O
oral	B-Chemical	D003276
contraceptives	I-Chemical	D003276
whether	O	O
or	O	O
not	O	O
they	O	O
had	O	O
a	O	O
prothrombotic	O	O
mutation	O	O
.	O	O

Effects	O	O
of	O	O
5	O	O
-	O	O
HT1B	O	O
receptor	O	O
ligands	O	O
microinjected	O	O
into	O	O
the	O	O
accumbal	O	O
shell	O	O
or	O	O
core	O	O
on	O	O
the	O	O
cocaine	B-Chemical	D003042
-	O	O
induced	O	O
locomotor	B-Disease	D009069
hyperactivity	I-Disease	D009069
in	O	O
rats	O	O
.	O	O

The	O	O
present	O	O
study	O	O
was	O	O
designed	O	O
to	O	O
examine	O	O
the	O	O
effect	O	O
of	O	O
5	O	O
-	O	O
HT1B	O	O
receptor	O	O
ligands	O	O
microinjected	O	O
into	O	O
the	O	O
subregions	O	O
of	O	O
the	O	O
nucleus	O	O
accumbens	O	O
(	O	O
the	O	O
shell	O	O
and	O	O
the	O	O
core	O	O
)	O	O
on	O	O
the	O	O
locomotor	B-Disease	D009069
hyperactivity	I-Disease	D009069
induced	O	O
by	O	O
cocaine	B-Chemical	D003042
in	O	O
rats	O	O
.	O	O

Male	O	O
Wistar	O	O
rats	O	O
were	O	O
implanted	O	O
bilaterally	O	O
with	O	O
cannulae	O	O
into	O	O
the	O	O
accumbens	O	O
shell	O	O
or	O	O
core	O	O
,	O	O
and	O	O
then	O	O
were	O	O
locally	O	O
injected	O	O
with	O	O
GR	B-Chemical	C103477
55562	I-Chemical	C103477
(	O	O
an	O	O
antagonist	O	O
of	O	O
5	O	O
-	O	O
HT1B	O	O
receptors	O	O
)	O	O
or	O	O
CP	B-Chemical	C065046
93129	I-Chemical	C065046
(	O	O
an	O	O
agonist	O	O
of	O	O
5	O	O
-	O	O
HT1B	O	O
receptors	O	O
)	O	O
.	O	O

Given	O	O
alone	O	O
to	O	O
any	O	O
accumbal	O	O
subregion	O	O
,	O	O
GR	B-Chemical	C103477
55562	I-Chemical	C103477
(	O	O
0	O	O
.	O	O

1	O	O
-	O	O
10	O	O
microg	O	O
/	O	O
side	O	O
)	O	O
or	O	O
CP	B-Chemical	C065046
93129	I-Chemical	C065046
(	O	O
0	O	O
.	O	O

1	O	O
-	O	O
10	O	O
microg	O	O
/	O	O
side	O	O
)	O	O
did	O	O
not	O	O
change	O	O
basal	O	O
locomotor	O	O
activity	O	O
.	O	O

Systemic	O	O
cocaine	B-Chemical	D003042
(	O	O
10	O	O
mg	O	O
/	O	O
kg	O	O
)	O	O
significantly	O	O
increased	O	O
the	O	O
locomotor	O	O
activity	O	O
of	O	O
rats	O	O
.	O	O

GR	B-Chemical	C103477
55562	I-Chemical	C103477
(	O	O
0	O	O
.	O	O

1	O	O
-	O	O
10	O	O
microg	O	O
/	O	O
side	O	O
)	O	O
,	O	O
administered	O	O
intra	O	O
-	O	O
accumbens	O	O
shell	O	O
prior	O	O
to	O	O
cocaine	B-Chemical	D003042
,	O	O
dose	O	O
-	O	O
dependently	O	O
attenuated	O	O
the	O	O
psychostimulant	O	O
-	O	O
induced	O	O
locomotor	B-Disease	D009069
hyperactivity	I-Disease	D009069
.	O	O

Such	O	O
attenuation	O	O
was	O	O
not	O	O
found	O	O
in	O	O
animals	O	O
which	O	O
had	O	O
been	O	O
injected	O	O
with	O	O
GR	B-Chemical	C103477
55562	I-Chemical	C103477
into	O	O
the	O	O
accumbens	O	O
core	O	O
.	O	O

When	O	O
injected	O	O
into	O	O
the	O	O
accumbens	O	O
shell	O	O
(	O	O
but	O	O
not	O	O
the	O	O
core	O	O
)	O	O
before	O	O
cocaine	B-Chemical	D003042
,	O	O
CP	B-Chemical	C065046
93129	I-Chemical	C065046
(	O	O
0	O	O
.	O	O

1	O	O
-	O	O
10	O	O
microg	O	O
/	O	O
side	O	O
)	O	O
enhanced	O	O
the	O	O
locomotor	O	O
response	O	O
to	O	O
cocaine	B-Chemical	D003042
;	O	O
the	O	O
maximum	O	O
effect	O	O
being	O	O
observed	O	O
after	O	O
10	O	O
microg	O	O
/	O	O
side	O	O
of	O	O
the	O	O
agonist	O	O
.	O	O

The	O	O
later	O	O
enhancement	O	O
was	O	O
attenuated	O	O
after	O	O
intra	O	O
-	O	O
accumbens	O	O
shell	O	O
treatment	O	O
with	O	O
GR	B-Chemical	C103477
55562	I-Chemical	C103477
(	O	O
1	O	O
microg	O	O
/	O	O
side	O	O
)	O	O
.	O	O

Our	O	O
findings	O	O
indicate	O	O
that	O	O
cocaine	B-Chemical	D003042
induced	O	O
hyperlocomotion	B-Disease	D009069
is	O	O
modified	O	O
by	O	O
5	O	O
-	O	O
HT1B	O	O
receptor	O	O
ligands	O	O
microinjected	O	O
into	O	O
the	O	O
accumbens	O	O
shell	O	O
,	O	O
but	O	O
not	O	O
core	O	O
,	O	O
this	O	O
modification	O	O
consisting	O	O
in	O	O
inhibitory	O	O
and	O	O
facilitatory	O	O
effects	O	O
of	O	O
the	O	O
5	O	O
-	O	O
HT1B	O	O
receptor	O	O
antagonist	O	O
(	O	O
GR	B-Chemical	C103477
55562	I-Chemical	C103477
)	O	O
and	O	O
agonist	O	O
(	O	O
CP	B-Chemical	C065046
93129	I-Chemical	C065046
)	O	O
,	O	O
respectively	O	O
.	O	O

In	O	O
other	O	O
words	O	O
,	O	O
the	O	O
present	O	O
results	O	O
suggest	O	O
that	O	O
the	O	O
accumbal	O	O
shell	O	O
5	O	O
-	O	O
HT1B	O	O
receptors	O	O
play	O	O
a	O	O
permissive	O	O
role	O	O
in	O	O
the	O	O
behavioural	O	O
response	O	O
to	O	O
the	O	O
psychostimulant	O	O
.	O	O

Ticlopidine	B-Chemical	D013988
-	O	O
induced	O	O
cholestatic	O	O
hepatitis	O	O
.	O	O

OBJECTIVE	O	O
:	O	O
To	O	O
report	O	O
2	O	O
cases	O	O
of	O	O
ticlopidine	B-Chemical	D013988
-	O	O
induced	O	O
cholestatic	O	O
hepatitis	O	O
,	O	O
investigate	O	O
its	O	O
mechanism	O	O
,	O	O
and	O	O
compare	O	O
the	O	O
observed	O	O
main	O	O
characteristics	O	O
with	O	O
those	O	O
of	O	O
the	O	O
published	O	O
cases	O	O
.	O	O

CASE	O	O
SUMMARIES	O	O
:	O	O
Two	O	O
patients	O	O
developed	O	O
prolonged	O	O
cholestatic	O	O
hepatitis	O	O
after	O	O
receiving	O	O
ticlopidine	B-Chemical	D013988
following	O	O
percutaneous	O	O
coronary	O	O
angioplasty	O	O
,	O	O
with	O	O
complete	O	O
remission	O	O
during	O	O
the	O	O
follow	O	O
-	O	O
up	O	O
period	O	O
.	O	O

T	O	O
-	O	O
cell	O	O
stimulation	O	O
by	O	O
therapeutic	O	O
concentration	O	O
of	O	O
ticlopidine	B-Chemical	D013988
was	O	O
demonstrated	O	O
in	O	O
vitro	O	O
in	O	O
the	O	O
patients	O	O
,	O	O
but	O	O
not	O	O
in	O	O
healthy	O	O
controls	O	O
.	O	O

DISCUSSION	O	O
:	O	O
Cholestatic	O	O
hepatitis	O	O
is	O	O
a	O	O
rare	O	O
complication	O	O
of	O	O
the	O	O
antiplatelet	O	O
agent	O	O
ticlopidine	B-Chemical	D013988
;	O	O
several	O	O
cases	O	O
have	O	O
been	O	O
reported	O	O
but	O	O
few	O	O
in	O	O
the	O	O
English	O	O
literature	O	O
.	O	O

Our	O	O
patients	O	O
developed	O	O
jaundice	B-Disease	D007565
following	O	O
treatment	O	O
with	O	O
ticlopidine	B-Chemical	D013988
and	O	O
showed	O	O
the	O	O
clinical	O	O
and	O	O
laboratory	O	O
characteristics	O	O
of	O	O
cholestatic	O	O
hepatitis	O	O
,	O	O
which	O	O
resolved	O	O
after	O	O
discontinuation	O	O
of	O	O
the	O	O
drug	O	O
.	O	O

Hepatitis	B-Disease	D056486
may	O	O
develop	O	O
weeks	O	O
after	O	O
discontinuation	O	O
of	O	O
the	O	O
drug	O	O
and	O	O
may	O	O
run	O	O
a	O	O
prolonged	O	O
course	O	O
,	O	O
but	O	O
complete	O	O
remission	O	O
was	O	O
observed	O	O
in	O	O
all	O	O
reported	O	O
cases	O	O
.	O	O

An	O	O
objective	O	O
causality	O	O
assessment	O	O
revealed	O	O
that	O	O
the	O	O
adverse	O	O
drug	O	O
event	O	O
was	O	O
probably	O	O
related	O	O
to	O	O
the	O	O
use	O	O
of	O	O
ticlopidine	B-Chemical	D013988
.	O	O

The	O	O
mechanisms	O	O
of	O	O
this	O	O
ticlopidine	B-Chemical	D013988
-	O	O
induced	O	O
cholestasis	B-Disease	D002779
are	O	O
unclear	O	O
.	O	O

Immune	O	O
mechanisms	O	O
may	O	O
be	O	O
involved	O	O
in	O	O
the	O	O
drug's	O	O
hepatotoxicity	B-Disease	D056486
,	O	O
as	O	O
suggested	O	O
by	O	O
the	O	O
T	O	O
-	O	O
cell	O	O
stimulation	O	O
study	O	O
reported	O	O
here	O	O
.	O	O

CONCLUSIONS	O	O
:	O	O
Cholestatic	O	O
hepatitis	O	O
is	O	O
a	O	O
rare	O	O
adverse	O	O
effect	O	O
of	O	O
ticlopidine	B-Chemical	D013988
that	O	O
may	O	O
be	O	O
immune	O	O
mediated	O	O
.	O	O

Patients	O	O
receiving	O	O
the	O	O
drug	O	O
should	O	O
be	O	O
monitored	O	O
with	O	O
liver	O	O
function	O	O
tests	O	O
along	O	O
with	O	O
complete	O	O
blood	O	O
cell	O	O
counts	O	O
.	O	O

This	O	O
complication	O	O
will	O	O
be	O	O
observed	O	O
even	O	O
less	O	O
often	O	O
in	O	O
the	O	O
future	O	O
as	O	O
ticlopidine	B-Chemical	D013988
is	O	O
being	O	O
replaced	O	O
by	O	O
the	O	O
newer	O	O
antiplatelet	O	O
agent	O	O
clopidogrel	B-Chemical	C055162
.	O	O

Epithelial	O	O
sodium	B-Chemical	D012964
channel	O	O
(	O	O
ENaC	O	O
)	O	O
subunit	O	O
mRNA	O	O
and	O	O
protein	O	O
expression	O	O
in	O	O
rats	O	O
with	O	O
puromycin	B-Chemical	D011692
aminonucleoside	I-Chemical	D011692
-	O	O
induced	O	O
nephrotic	B-Disease	D009404
syndrome	I-Disease	D009404
.	O	O

In	O	O
experimental	O	O
nephrotic	B-Disease	D009404
syndrome	I-Disease	D009404
,	O	O
urinary	O	O
sodium	B-Chemical	D012964
excretion	O	O
is	O	O
decreased	O	O
during	O	O
the	O	O
early	O	O
phase	O	O
of	O	O
the	O	O
disease	O	O
.	O	O

The	O	O
molecular	O	O
mechanism	O	O
(	O	O
s	O	O
)	O	O
leading	O	O
to	O	O
salt	O	O
retention	O	O
has	O	O
not	O	O
been	O	O
completely	O	O
elucidated	O	O
.	O	O

The	O	O
rate	O	O
-	O	O
limiting	O	O
constituent	O	O
of	O	O
collecting	O	O
duct	O	O
sodium	B-Chemical	D012964
transport	O	O
is	O	O
the	O	O
epithelial	O	O
sodium	B-Chemical	D012964
channel	O	O
(	O	O
ENaC	O	O
)	O	O
.	O	O

We	O	O
examined	O	O
the	O	O
abundance	O	O
of	O	O
ENaC	O	O
subunit	O	O
mRNAs	O	O
and	O	O
proteins	O	O
in	O	O
puromycin	B-Chemical	D011692
aminonucleoside	I-Chemical	D011692
(	O	O
PAN	B-Chemical	D011692
)	O	O
-	O	O
induced	O	O
nephrotic	B-Disease	D009404
syndrome	I-Disease	D009404
.	O	O

The	O	O
time	O	O
courses	O	O
of	O	O
urinary	O	O
sodium	B-Chemical	D012964
excretion	O	O
,	O	O
plasma	O	O
aldosterone	B-Chemical	D000450
concentration	O	O
and	O	O
proteinuria	B-Disease	D011507
were	O	O
studied	O	O
in	O	O
male	O	O
Sprague	O	O
-	O	O
Dawley	O	O
rats	O	O
treated	O	O
with	O	O
a	O	O
single	O	O
dose	O	O
of	O	O
either	O	O
PAN	B-Chemical	D011692
or	O	O
vehicle	O	O
.	O	O

The	O	O
relative	O	O
amounts	O	O
of	O	O
alphaENaC	O	O
,	O	O
betaENaC	O	O
and	O	O
gammaENaC	O	O
mRNAs	O	O
were	O	O
determined	O	O
in	O	O
kidneys	O	O
from	O	O
these	O	O
rats	O	O
by	O	O
real	O	O
-	O	O
time	O	O
quantitative	O	O
TaqMan	O	O
PCR	O	O
,	O	O
and	O	O
the	O	O
amounts	O	O
of	O	O
proteins	O	O
by	O	O
Western	O	O
blot	O	O
.	O	O

The	O	O
kinetics	O	O
of	O	O
urinary	O	O
sodium	B-Chemical	D012964
excretion	O	O
and	O	O
the	O	O
appearance	O	O
of	O	O
proteinuria	B-Disease	D011507
were	O	O
comparable	O	O
with	O	O
those	O	O
reported	O	O
previously	O	O
.	O	O

Sodium	B-Chemical	D012964
retention	O	O
occurred	O	O
on	O	O
days	O	O
2	O	O
,	O	O
3	O	O
and	O	O
6	O	O
after	O	O
PAN	B-Chemical	D011692
injection	O	O
.	O	O

A	O	O
significant	O	O
up	O	O
-	O	O
regulation	O	O
of	O	O
alphaENaC	O	O
and	O	O
betaENaC	O	O
mRNA	O	O
abundance	O	O
on	O	O
days	O	O
1	O	O
and	O	O
2	O	O
preceded	O	O
sodium	B-Chemical	D012964
retention	O	O
on	O	O
days	O	O
2	O	O
and	O	O
3	O	O
.	O	O

Conversely	O	O
,	O	O
down	O	O
-	O	O
regulation	O	O
of	O	O
alphaENaC	O	O
,	O	O
betaENaC	O	O
and	O	O
gammaENaC	O	O
mRNA	O	O
expression	O	O
on	O	O
day	O	O
3	O	O
occurred	O	O
in	O	O
the	O	O
presence	O	O
of	O	O
high	O	O
aldosterone	B-Chemical	D000450
concentrations	O	O
,	O	O
and	O	O
was	O	O
followed	O	O
by	O	O
a	O	O
return	O	O
of	O	O
sodium	B-Chemical	D012964
excretion	O	O
to	O	O
control	O	O
values	O	O
.	O	O

The	O	O
amounts	O	O
of	O	O
alphaENaC	O	O
,	O	O
betaENaC	O	O
and	O	O
gammaENaC	O	O
proteins	O	O
were	O	O
not	O	O
increased	O	O
during	O	O
PAN	B-Chemical	D011692
-	O	O
induced	O	O
sodium	B-Chemical	D012964
retention	O	O
.	O	O

In	O	O
conclusion	O	O
,	O	O
ENaC	O	O
mRNA	O	O
expression	O	O
,	O	O
especially	O	O
alphaENaC	O	O
,	O	O
is	O	O
increased	O	O
in	O	O
the	O	O
very	O	O
early	O	O
phase	O	O
of	O	O
the	O	O
experimental	O	O
model	O	O
of	O	O
PAN	B-Chemical	D011692
-	O	O
induced	O	O
nephrotic	B-Disease	D009404
syndrome	I-Disease	D009404
in	O	O
rats	O	O
,	O	O
but	O	O
appears	O	O
to	O	O
escape	O	O
from	O	O
the	O	O
regulation	O	O
by	O	O
aldosterone	B-Chemical	D000450
after	O	O
day	O	O
3	O	O
.	O	O

NO	B-Chemical	D009569
-	O	O
induced	O	O
migraine	B-Disease	D008881
attack	O	O
:	O	O
strong	O	O
increase	O	O
in	O	O
plasma	O	O
calcitonin	B-Chemical	D015740
gene	I-Chemical	D015740
-	I-Chemical	D015740
related	I-Chemical	D015740
peptide	I-Chemical	D015740
(	O	O
CGRP	B-Chemical	D015740
)	O	O
concentration	O	O
and	O	O
negative	O	O
correlation	O	O
with	O	O
platelet	O	O
serotonin	B-Chemical	D012701
release	O	O
.	O	O

The	O	O
aim	O	O
of	O	O
the	O	O
present	O	O
study	O	O
was	O	O
to	O	O
investigate	O	O
changes	O	O
in	O	O
the	O	O
plasma	O	O
calcitonin	B-Chemical	D015740
gene	I-Chemical	D015740
-	I-Chemical	D015740
related	I-Chemical	D015740
peptide	I-Chemical	D015740
(	O	O
CGRP	B-Chemical	D015740
)	O	O
concentration	O	O
and	O	O
platelet	O	O
serotonin	B-Chemical	D012701
(	O	O
5	B-Chemical	D012701
-	I-Chemical	D012701
hydroxytriptamine	I-Chemical	D012701
,	O	O
5	B-Chemical	D012701
-	I-Chemical	D012701
HT	I-Chemical	D012701
)	O	O
content	O	O
during	O	O
the	O	O
immediate	O	O
headache	B-Disease	D006261
and	O	O
the	O	O
delayed	O	O
genuine	O	O
migraine	B-Disease	D008881
attack	O	O
provoked	O	O
by	O	O
nitroglycerin	B-Chemical	D005996
.	O	O

Fifteen	O	O
female	O	O
migraineurs	B-Disease	D020326
(	I-Disease	D020326
without	I-Disease	D020326
aura	I-Disease	D020326
)	I-Disease	D020326
and	O	O
eight	O	O
controls	O	O
participated	O	O
in	O	O
the	O	O
study	O	O
.	O	O

Sublingual	O	O
nitroglycerin	B-Chemical	D005996
(	O	O
0	O	O
.	O	O

5	O	O
mg	O	O
)	O	O
was	O	O
administered	O	O
.	O	O

Blood	O	O
was	O	O
collected	O	O
from	O	O
the	O	O
antecubital	O	O
vein	O	O
four	O	O
times	O	O
:	O	O
60	O	O
min	O	O
before	O	O
and	O	O
after	O	O
the	O	O
nitroglycerin	B-Chemical	D005996
application	O	O
,	O	O
and	O	O
60	O	O
and	O	O
120	O	O
min	O	O
after	O	O
the	O	O
beginning	O	O
of	O	O
the	O	O
migraine	B-Disease	D008881
attack	O	O
(	O	O
mean	O	O
344	O	O
and	O	O
404	O	O
min	O	O
;	O	O
12	O	O
subjects	O	O
)	O	O
.	O	O

In	O	O
those	O	O
subjects	O	O
who	O	O
had	O	O
no	O	O
migraine	B-Disease	D008881
attack	O	O
(	O	O
11	O	O
subjects	O	O
)	O	O
a	O	O
similar	O	O
time	O	O
schedule	O	O
was	O	O
used	O	O
.	O	O

Plasma	O	O
CGRP	B-Chemical	D015740
concentration	O	O
increased	O	O
significantly	O	O
(	O	O
P<0	O	O
.	O	O

01	O	O
)	O	O
during	O	O
the	O	O
migraine	B-Disease	D008881
attack	O	O
and	O	O
returned	O	O
to	O	O
baseline	O	O
after	O	O
the	O	O
cessation	O	O
of	O	O
the	O	O
migraine	B-Disease	D008881
.	O	O

In	O	O
addition	O	O
,	O	O
both	O	O
change	O	O
and	O	O
peak	O	O
,	O	O
showed	O	O
significant	O	O
positive	O	O
correlations	O	O
with	O	O
migraine	B-Disease	D008881
headache	B-Disease	D006261
intensity	O	O
(	O	O
P<0	O	O
.	O	O

001	O	O
)	O	O
.	O	O

However	O	O
,	O	O
plasma	O	O
CGRP	B-Chemical	D015740
concentrations	O	O
failed	O	O
to	O	O
change	O	O
during	O	O
immediate	O	O
headache	B-Disease	D006261
and	O	O
in	O	O
the	O	O
subjects	O	O
with	O	O
no	O	O
migraine	B-Disease	D008881
attack	O	O
.	O	O

Basal	O	O
CGRP	B-Chemical	D015740
concentration	O	O
was	O	O
significantly	O	O
higher	O	O
and	O	O
platelet	O	O
5	B-Chemical	D012701
-	I-Chemical	D012701
HT	I-Chemical	D012701
content	O	O
tended	O	O
to	O	O
be	O	O
lower	O	O
in	O	O
subjects	O	O
who	O	O
experienced	O	O
a	O	O
migraine	B-Disease	D008881
attack	O	O
.	O	O

Platelet	O	O
serotonin	B-Chemical	D012701
content	O	O
decreased	O	O
significantly	O	O
(	O	O
P<0	O	O
.	O	O

01	O	O
)	O	O
after	O	O
nitroglycerin	B-Chemical	D005996
in	O	O
subjects	O	O
with	O	O
no	O	O
migraine	B-Disease	D008881
attack	O	O
but	O	O
no	O	O
consistent	O	O
change	O	O
was	O	O
observed	O	O
in	O	O
patients	O	O
with	O	O
migraine	B-Disease	D008881
attack	O	O
.	O	O

In	O	O
conclusion	O	O
,	O	O
the	O	O
fact	O	O
that	O	O
plasma	O	O
CGRP	B-Chemical	D015740
concentration	O	O
correlates	O	O
with	O	O
the	O	O
timing	O	O
and	O	O
severity	O	O
of	O	O
a	O	O
migraine	B-Disease	D008881
headache	B-Disease	D006261
suggests	O	O
a	O	O
direct	O	O
relationship	O	O
between	O	O
CGRP	B-Chemical	D015740
and	O	O
migraine	B-Disease	D008881
.	O	O

In	O	O
contrast	O	O
,	O	O
serotonin	B-Chemical	D012701
release	O	O
from	O	O
platelets	O	O
does	O	O
not	O	O
provoke	O	O
migraine	B-Disease	D008881
,	O	O
it	O	O
may	O	O
even	O	O
counteract	O	O
the	O	O
headache	B-Disease	D006261
and	O	O
the	O	O
concomitant	O	O
CGRP	B-Chemical	D015740
release	O	O
in	O	O
this	O	O
model	O	O
.	O	O

Coronary	B-Disease	D003323
aneurysm	I-Disease	D003323
after	O	O
implantation	O	O
of	O	O
a	O	O
paclitaxel	B-Chemical	D017239
-	O	O
eluting	O	O
stent	O	O
.	O	O

Formation	O	O
of	O	O
coronary	B-Disease	D003323
aneurysm	I-Disease	D003323
is	O	O
a	O	O
rare	O	O
complication	O	O
of	O	O
stenting	O	O
with	O	O
bare	O	O
metal	O	O
stents	O	O
,	O	O
but	O	O
based	O	O
on	O	O
experimental	O	O
studies	O	O
drug	O	O
-	O	O
eluting	O	O
stents	O	O
may	O	O
induce	O	O
toxic	O	O
effects	O	O
on	O	O
the	O	O
vessel	O	O
wall	O	O
with	O	O
incomplete	O	O
stent	O	O
apposition	O	O
,	O	O
aneurysm	B-Disease	D000783
formation	O	O
and	O	O
with	O	O
the	O	O
potential	O	O
of	O	O
stent	O	O
thrombosis	B-Disease	D013927
or	O	O
vessel	B-Disease	-1
rupture	I-Disease	-1
.	O	O

We	O	O
present	O	O
a	O	O
43	O	O
-	O	O
year	O	O
-	O	O
old	O	O
man	O	O
who	O	O
developed	O	O
a	O	O
coronary	B-Disease	D003323
aneurysm	I-Disease	D003323
in	O	O
the	O	O
right	O	O
coronary	O	O
artery	O	O
6	O	O
months	O	O
after	O	O
receiving	O	O
a	O	O
paclitaxel	B-Chemical	D017239
-	O	O
eluting	O	O
stent	O	O
.	O	O

The	O	O
patient	O	O
was	O	O
asymptomatic	O	O
and	O	O
the	O	O
aneurysm	B-Disease	D000783
was	O	O
detected	O	O
in	O	O
a	O	O
routine	O	O
control	O	O
.	O	O

Angiography	O	O
and	O	O
intracoronary	O	O
ultrasound	O	O
demonstrated	O	O
lack	O	O
of	O	O
contact	O	O
between	O	O
stent	O	O
and	O	O
vessel	O	O
wall	O	O
in	O	O
a	O	O
15	O	O
-	O	O
mm	O	O
long	O	O
segment	O	O
with	O	O
maximal	O	O
aneurysm	B-Disease	D000783
diameter	O	O
of	O	O
6	O	O
.	O	O

0	O	O
mm	O	O
.	O	O

The	O	O
patient	O	O
was	O	O
successfully	O	O
treated	O	O
with	O	O
a	O	O
graft	O	O
stent	O	O
.	O	O

Behavioral	O	O
effects	O	O
of	O	O
urotensin	B-Chemical	D014579
-	I-Chemical	D014579
II	I-Chemical	D014579
centrally	O	O
administered	O	O
in	O	O
mice	O	O
.	O	O

Urotensin	B-Chemical	D014579
-	I-Chemical	D014579
II	I-Chemical	D014579
(	O	O
U	B-Chemical	D014579
-	I-Chemical	D014579
II	I-Chemical	D014579
)	O	O
receptors	O	O
are	O	O
widely	O	O
distributed	O	O
in	O	O
the	O	O
central	O	O
nervous	O	O
system	O	O
.	O	O

Intracerebroventricular	O	O
(	O	O
i	O	O
.	O	O

c	O	O
.	O	O

v	O	O
.	O	O

)	O	O
injection	O	O
of	O	O
U	B-Chemical	D014579
-	I-Chemical	D014579
II	I-Chemical	D014579
causes	O	O
hypertension	B-Disease	D006973
and	O	O
bradycardia	B-Disease	D001919
and	O	O
stimulates	O	O
prolactin	O	O
and	O	O
thyrotropin	O	O
secretion	O	O
.	O	O

However	O	O
,	O	O
the	O	O
behavioral	O	O
effects	O	O
of	O	O
centrally	O	O
administered	O	O
U	B-Chemical	D014579
-	I-Chemical	D014579
II	I-Chemical	D014579
have	O	O
received	O	O
little	O	O
attention	O	O
.	O	O

In	O	O
the	O	O
present	O	O
study	O	O
,	O	O
we	O	O
tested	O	O
the	O	O
effects	O	O
of	O	O
i	O	O
.	O	O

c	O	O
.	O	O

v	O	O
.	O	O

injections	O	O
of	O	O
U	B-Chemical	D014579
-	I-Chemical	D014579
II	I-Chemical	D014579
on	O	O
behavioral	O	O
,	O	O
metabolic	O	O
,	O	O
and	O	O
endocrine	O	O
responses	O	O
in	O	O
mice	O	O
.	O	O

Administration	O	O
of	O	O
graded	O	O
doses	O	O
of	O	O
U	B-Chemical	D014579
-	I-Chemical	D014579
II	I-Chemical	D014579
(	O	O
1	O	O
-	O	O
10	O	O
,	O	O
000	O	O
ng	O	O
/	O	O
mouse	O	O
)	O	O
provoked	O	O
:	O	O
(	O	O
1	O	O
)	O	O
a	O	O
dose	O	O
-	O	O
dependent	O	O
reduction	O	O
in	O	O
the	O	O
number	O	O
of	O	O
head	O	O
dips	O	O
in	O	O
the	O	O
hole	O	O
-	O	O
board	O	O
test	O	O
;	O	O
(	O	O
2	O	O
)	O	O
a	O	O
dose	O	O
-	O	O
dependent	O	O
reduction	O	O
in	O	O
the	O	O
number	O	O
of	O	O
entries	O	O
in	O	O
the	O	O
white	O	O
chamber	O	O
in	O	O
the	O	O
black	O	O
-	O	O
and	O	O
-	O	O
white	O	O
compartment	O	O
test	O	O
,	O	O
and	O	O
in	O	O
the	O	O
number	O	O
of	O	O
entries	O	O
in	O	O
the	O	O
central	O	O
platform	O	O
and	O	O
open	O	O
arms	O	O
in	O	O
the	O	O
plus	O	O
-	O	O
maze	O	O
test	O	O
;	O	O
and	O	O
(	O	O
3	O	O
)	O	O
a	O	O
dose	O	O
-	O	O
dependent	O	O
increase	O	O
in	O	O
the	O	O
duration	O	O
of	O	O
immobility	O	O
in	O	O
the	O	O
forced	O	O
-	O	O
swimming	O	O
test	O	O
and	O	O
tail	O	O
suspension	O	O
test	O	O
.	O	O

Intracerebroventricular	O	O
injection	O	O
of	O	O
U	B-Chemical	D014579
-	I-Chemical	D014579
II	I-Chemical	D014579
also	O	O
caused	O	O
an	O	O
increase	O	O
in	O	O
:	O	O
food	O	O
intake	O	O
at	O	O
doses	O	O
of	O	O
100	O	O
and	O	O
1	O	O
,	O	O
000	O	O
ng	O	O
/	O	O
mouse	O	O
,	O	O
water	O	O
intake	O	O
at	O	O
doses	O	O
of	O	O
100	O	O
-	O	O
10	O	O
,	O	O
000	O	O
ng	O	O
/	O	O
mouse	O	O
,	O	O
and	O	O
horizontal	O	O
locomotion	O	O
activity	O	O
at	O	O
a	O	O
dose	O	O
of	O	O
10	O	O
,	O	O
000	O	O
ng	O	O
/	O	O
mouse	O	O
.	O	O

Whatever	O	O
was	O	O
the	O	O
dose	O	O
,	O	O
the	O	O
central	O	O
administration	O	O
of	O	O
U	B-Chemical	D014579
-	I-Chemical	D014579
II	I-Chemical	D014579
had	O	O
no	O	O
effect	O	O
on	O	O
body	O	O
temperature	O	O
,	O	O
nociception	O	O
,	O	O
apomorphine	B-Chemical	D001058
-	O	O
induced	O	O
penile	B-Disease	D010409
erection	I-Disease	D010409
and	O	O
climbing	O	O
behavior	O	O
,	O	O
and	O	O
stress	O	O
-	O	O
induced	O	O
plasma	O	O
corticosterone	B-Chemical	D003345
level	O	O
.	O	O

Taken	O	O
together	O	O
,	O	O
the	O	O
present	O	O
study	O	O
demonstrates	O	O
that	O	O
the	O	O
central	O	O
injection	O	O
of	O	O
U	B-Chemical	D014579
-	I-Chemical	D014579
II	I-Chemical	D014579
at	O	O
doses	O	O
of	O	O
1	O	O
-	O	O
10	O	O
,	O	O
000	O	O
ng	O	O
/	O	O
mouse	O	O
induces	O	O
anxiogenic	O	O
-	O	O
and	O	O
depressant	O	O
-	O	O
like	O	O
effects	O	O
in	O	O
mouse	O	O
.	O	O

These	O	O
data	O	O
suggest	O	O
that	O	O
U	B-Chemical	D014579
-	I-Chemical	D014579
II	I-Chemical	D014579
may	O	O
be	O	O
involved	O	O
in	O	O
some	O	O
aspects	O	O
of	O	O
psychiatric	B-Disease	D001523
disorders	I-Disease	D001523
.	O	O

Recurrent	O	O
dysphonia	B-Disease	D055154
and	O	O
acitretin	B-Chemical	D017255
.	O	O

We	O	O
report	O	O
the	O	O
case	O	O
of	O	O
a	O	O
woman	O	O
complaining	O	O
of	O	O
dysphonia	B-Disease	D055154
while	O	O
she	O	O
was	O	O
treated	O	O
by	O	O
acitretin	B-Chemical	D017255
.	O	O

Her	O	O
symptoms	O	O
totally	O	O
regressed	O	O
after	O	O
drug	O	O
withdrawal	O	O
and	O	O
reappeared	O	O
when	O	O
acitretin	B-Chemical	D017255
was	O	O
reintroduced	O	O
.	O	O

To	O	O
our	O	O
knowledge	O	O
,	O	O
this	O	O
is	O	O
the	O	O
first	O	O
case	O	O
of	O	O
acitretin	B-Chemical	D017255
-	O	O
induced	O	O
dysphonia	B-Disease	D055154
.	O	O

This	O	O
effect	O	O
may	O	O
be	O	O
related	O	O
to	O	O
the	O	O
pharmacological	O	O
effect	O	O
of	O	O
this	O	O
drug	O	O
on	O	O
mucous	O	O
membranes	O	O
.	O	O

Pharmacological	O	O
modulation	O	O
of	O	O
pain	B-Disease	D010146
-	O	O
related	O	O
brain	O	O
activity	O	O
during	O	O
normal	O	O
and	O	O
central	O	O
sensitization	O	O
states	O	O
in	O	O
humans	O	O
.	O	O

Abnormal	O	O
processing	O	O
of	O	O
somatosensory	O	O
inputs	O	O
in	O	O
the	O	O
central	O	O
nervous	O	O
system	O	O
(	O	O
central	O	O
sensitization	O	O
)	O	O
is	O	O
the	O	O
mechanism	O	O
accounting	O	O
for	O	O
the	O	O
enhanced	O	O
pain	B-Disease	D010146
sensitivity	O	O
in	O	O
the	O	O
skin	O	O
surrounding	O	O
tissue	B-Disease	D017695
injury	I-Disease	D017695
(	O	O
secondary	B-Disease	D006930
hyperalgesia	I-Disease	D006930
)	O	O
.	O	O

Secondary	B-Disease	D006930
hyperalgesia	I-Disease	D006930
shares	O	O
clinical	O	O
characteristics	O	O
with	O	O
neurogenic	B-Disease	D006930
hyperalgesia	I-Disease	D006930
in	O	O
patients	O	O
with	O	O
neuropathic	B-Disease	D009437
pain	I-Disease	D009437
.	O	O

Abnormal	O	O
brain	O	O
responses	O	O
to	O	O
somatosensory	O	O
stimuli	O	O
have	O	O
been	O	O
found	O	O
in	O	O
patients	O	O
with	O	O
hyperalgesia	B-Disease	D006930
as	O	O
well	O	O
as	O	O
in	O	O
normal	O	O
subjects	O	O
during	O	O
experimental	O	O
central	O	O
sensitization	O	O
.	O	O

The	O	O
aim	O	O
of	O	O
this	O	O
study	O	O
was	O	O
to	O	O
assess	O	O
the	O	O
effects	O	O
of	O	O
gabapentin	B-Chemical	C040029
,	O	O
a	O	O
drug	O	O
effective	O	O
in	O	O
neuropathic	B-Disease	D009437
pain	I-Disease	D009437
patients	O	O
,	O	O
on	O	O
brain	O	O
processing	O	O
of	O	O
nociceptive	O	O
information	O	O
in	O	O
normal	O	O
and	O	O
central	O	O
sensitization	O	O
states	O	O
.	O	O

Using	O	O
functional	O	O
magnetic	O	O
resonance	O	O
imaging	O	O
(	O	O
fMRI	O	O
)	O	O
in	O	O
normal	O	O
volunteers	O	O
,	O	O
we	O	O
studied	O	O
the	O	O
gabapentin	B-Chemical	C040029
-	O	O
induced	O	O
modulation	O	O
of	O	O
brain	O	O
activity	O	O
in	O	O
response	O	O
to	O	O
nociceptive	O	O
mechanical	O	O
stimulation	O	O
of	O	O
normal	O	O
skin	O	O
and	O	O
capsaicin	B-Chemical	D002211
-	O	O
induced	O	O
secondary	B-Disease	D006930
hyperalgesia	I-Disease	D006930
.	O	O

The	O	O
dose	O	O
of	O	O
gabapentin	B-Chemical	C040029
was	O	O
1	O	O
,	O	O
800	O	O
mg	O	O
per	O	O
os	O	O
,	O	O
in	O	O
a	O	O
single	O	O
administration	O	O
.	O	O

We	O	O
found	O	O
that	O	O
(	O	O
i	O	O
)	O	O
gabapentin	B-Chemical	C040029
reduced	O	O
the	O	O
activations	O	O
in	O	O
the	O	O
bilateral	O	O
operculoinsular	O	O
cortex	O	O
,	O	O
independently	O	O
of	O	O
the	O	O
presence	O	O
of	O	O
central	O	O
sensitization	O	O
;	O	O
(	O	O
ii	O	O
)	O	O
gabapentin	B-Chemical	C040029
reduced	O	O
the	O	O
activation	O	O
in	O	O
the	O	O
brainstem	O	O
,	O	O
only	O	O
during	O	O
central	O	O
sensitization	O	O
;	O	O
(	O	O
iii	O	O
)	O	O
gabapentin	B-Chemical	C040029
suppressed	O	O
stimulus	O	O
-	O	O
induced	O	O
deactivations	O	O
,	O	O
only	O	O
during	O	O
central	O	O
sensitization	O	O
;	O	O
this	O	O
effect	O	O
was	O	O
more	O	O
robust	O	O
than	O	O
the	O	O
effect	O	O
on	O	O
brain	O	O
activation	O	O
.	O	O

The	O	O
observed	O	O
drug	O	O
-	O	O
induced	O	O
effects	O	O
were	O	O
not	O	O
due	O	O
to	O	O
changes	O	O
in	O	O
the	O	O
baseline	O	O
fMRI	O	O
signal	O	O
.	O	O

These	O	O
findings	O	O
indicate	O	O
that	O	O
gabapentin	B-Chemical	C040029
has	O	O
a	O	O
measurable	O	O
antinociceptive	O	O
effect	O	O
and	O	O
a	O	O
stronger	O	O
antihyperalgesic	O	O
effect	O	O
most	O	O
evident	O	O
in	O	O
the	O	O
brain	O	O
areas	O	O
undergoing	O	O
deactivation	O	O
,	O	O
thus	O	O
supporting	O	O
the	O	O
concept	O	O
that	O	O
gabapentin	B-Chemical	C040029
is	O	O
more	O	O
effective	O	O
in	O	O
modulating	O	O
nociceptive	O	O
transmission	O	O
when	O	O
central	O	O
sensitization	O	O
is	O	O
present	O	O
.	O	O

MDMA	B-Chemical	D018817
polydrug	O	O
users	O	O
show	O	O
process	O	O
-	O	O
specific	O	O
central	O	O
executive	O	O
impairments	O	O
coupled	O	O
with	O	O
impaired	B-Disease	D003072
social	I-Disease	D003072
and	I-Disease	D003072
emotional	I-Disease	D003072
judgement	I-Disease	D003072
processes	I-Disease	D003072
.	O	O

In	O	O
recent	O	O
years	O	O
working	O	O
memory	B-Disease	D008569
deficits	I-Disease	D008569
have	O	O
been	O	O
reported	O	O
in	O	O
users	O	O
of	O	O
MDMA	B-Chemical	D018817
(	O	O
3	B-Chemical	D018817
,	I-Chemical	D018817
4	I-Chemical	D018817
-	I-Chemical	D018817
methylenedioxymethamphetamine	I-Chemical	D018817
,	O	O
ecstasy	B-Chemical	D018817
)	O	O
.	O	O

The	O	O
current	O	O
study	O	O
aimed	O	O
to	O	O
assess	O	O
the	O	O
impact	O	O
of	O	O
MDMA	B-Chemical	D018817
use	O	O
on	O	O
three	O	O
separate	O	O
central	O	O
executive	O	O
processes	O	O
(	O	O
set	O	O
shifting	O	O
,	O	O
inhibition	O	O
and	O	O
memory	O	O
updating	O	O
)	O	O
and	O	O
also	O	O
on	O	O
"prefrontal"	O	O
mediated	O	O
social	O	O
and	O	O
emotional	O	O
judgement	O	O
processes	O	O
.	O	O

Fifteen	O	O
polydrug	O	O
ecstasy	B-Chemical	D018817
users	O	O
and	O	O
15	O	O
polydrug	O	O
non	O	O
-	O	O
ecstasy	B-Chemical	D018817
user	O	O
controls	O	O
completed	O	O
a	O	O
general	O	O
drug	O	O
use	O	O
questionnaire	O	O
,	O	O
the	O	O
Brixton	O	O
Spatial	O	O
Anticipation	O	O
task	O	O
(	O	O
set	O	O
shifting	O	O
)	O	O
,	O	O
Backward	O	O
Digit	O	O
Span	O	O
procedure	O	O
(	O	O
memory	O	O
updating	O	O
)	O	O
,	O	O
Inhibition	O	O
of	O	O
Return	O	O
(	O	O
inhibition	O	O
)	O	O
,	O	O
an	O	O
emotional	O	O
intelligence	O	O
scale	O	O
,	O	O
the	O	O
Tromso	O	O
Social	O	O
Intelligence	O	O
Scale	O	O
and	O	O
the	O	O
Dysexecutive	O	O
Questionnaire	O	O
(	O	O
DEX	O	O
)	O	O
.	O	O

Compared	O	O
with	O	O
MDMA	B-Chemical	D018817
-	O	O
free	O	O
polydrug	O	O
controls	O	O
,	O	O
MDMA	B-Chemical	D018817
polydrug	O	O
users	O	O
showed	O	O
impairments	O	O
in	O	O
set	O	O
shifting	O	O
and	O	O
memory	O	O
updating	O	O
,	O	O
and	O	O
also	O	O
in	O	O
social	O	O
and	O	O
emotional	O	O
judgement	O	O
processes	O	O
.	O	O

The	O	O
latter	O	O
two	O	O
deficits	O	O
remained	O	O
significant	O	O
after	O	O
controlling	O	O
for	O	O
other	O	O
drug	O	O
use	O	O
.	O	O

These	O	O
data	O	O
lend	O	O
further	O	O
support	O	O
to	O	O
the	O	O
proposal	O	O
that	O	O
cognitive	O	O
processes	O	O
mediated	O	O
by	O	O
the	O	O
prefrontal	O	O
cortex	O	O
may	O	O
be	O	O
impaired	O	O
by	O	O
recreational	O	O
ecstasy	B-Chemical	D018817
use	O	O
.	O	O

Severe	O	O
citrate	B-Chemical	C102006
toxicity	B-Disease	D064420
complicating	O	O
volunteer	O	O
apheresis	O	O
platelet	O	O
donation	O	O
.	O	O

We	O	O
report	O	O
a	O	O
case	O	O
of	O	O
severe	O	O
citrate	B-Chemical	C102006
toxicity	B-Disease	D064420
during	O	O
volunteer	O	O
donor	O	O
apheresis	O	O
platelet	O	O
collection	O	O
.	O	O

The	O	O
donor	O	O
was	O	O
a	O	O
40	O	O
-	O	O
year	O	O
-	O	O
old	O	O
female	O	O
,	O	O
first	O	O
-	O	O
time	O	O
apheresis	O	O
platelet	O	O
donor	O	O
.	O	O

Past	O	O
medical	O	O
history	O	O
was	O	O
remarkable	O	O
for	O	O
hypertension	B-Disease	D006973
,	O	O
hyperlipidemia	B-Disease	D006949
,	O	O
and	O	O
depression	B-Disease	D003866
.	O	O

Reported	O	O
medications	O	O
included	O	O
bumetanide	B-Chemical	D002034
,	O	O
pravastatin	B-Chemical	D017035
,	O	O
and	O	O
paroxetine	B-Chemical	D017374
.	O	O

Thirty	O	O
minutes	O	O
from	O	O
the	O	O
start	O	O
of	O	O
the	O	O
procedure	O	O
,	O	O
the	O	O
donor	O	O
noted	O	O
tingling	O	O
around	O	O
the	O	O
mouth	O	O
,	O	O
hands	O	O
,	O	O
and	O	O
feet	O	O
.	O	O

She	O	O
then	O	O
very	O	O
rapidly	O	O
developed	O	O
acute	O	O
onset	O	O
of	O	O
severe	O	O
facial	O	O
and	O	O
extremity	O	O
tetany	B-Disease	D013746
.	O	O

Empirical	O	O
treatment	O	O
with	O	O
intravenous	O	O
calcium	B-Chemical	D002125
gluconate	I-Chemical	D002125
was	O	O
initiated	O	O
,	O	O
and	O	O
muscle	B-Disease	C536214
contractions	I-Disease	C536214
slowly	O	O
subsided	O	O
over	O	O
approximately	O	O
10	O	O
to	O	O
15	O	O
minutes	O	O
.	O	O

The	O	O
events	O	O
are	O	O
consistent	O	O
with	O	O
a	O	O
severe	O	O
reaction	O	O
to	O	O
calcium	B-Chemical	D002118
chelation	O	O
by	O	O
sodium	B-Chemical	C102006
citrate	I-Chemical	C102006
anticoagulant	O	O
resulting	O	O
in	O	O
symptomatic	O	O
systemic	O	O
hypocalcemia	B-Disease	D006996
.	O	O

Upon	O	O
additional	O	O
retrospective	O	O
analysis	O	O
,	O	O
it	O	O
was	O	O
noted	O	O
that	O	O
bumetanide	B-Chemical	D002034
is	O	O
a	O	O
loop	B-Chemical	D049994
diuretic	I-Chemical	D049994
that	O	O
may	O	O
cause	O	O
significant	O	O
hypocalcemia	B-Disease	D006996
.	O	O

We	O	O
conclude	O	O
that	O	O
careful	O	O
screening	O	O
for	O	O
medications	O	O
and	O	O
underlying	O	O
conditions	O	O
predisposing	O	O
to	O	O
hypocalcemia	B-Disease	D006996
is	O	O
recommended	O	O
to	O	O
help	O	O
prevent	O	O
severe	O	O
reactions	O	O
due	O	O
to	O	O
citrate	B-Chemical	C102006
toxicity	B-Disease	D064420
.	O	O

Laboratory	O	O
measurement	O	O
of	O	O
pre	O	O
-	O	O
procedure	O	O
serum	O	O
calcium	B-Chemical	D002118
levels	O	O
in	O	O
selected	O	O
donors	O	O
may	O	O
identify	O	O
cases	O	O
requiring	O	O
heightened	O	O
vigilance	O	O
.	O	O

The	O	O
case	O	O
also	O	O
illustrates	O	O
the	O	O
importance	O	O
of	O	O
maintaining	O	O
preparedness	O	O
for	O	O
managing	O	O
rare	O	O
but	O	O
serious	O	O
reactions	O	O
in	O	O
volunteer	O	O
apheresis	O	O
blood	O	O
donors	O	O
.	O	O

Proteinuria	B-Disease	D011507
after	O	O
conversion	O	O
to	O	O
sirolimus	B-Chemical	D020123
in	O	O
renal	O	O
transplant	O	O
recipients	O	O
.	O	O

Sirolimus	B-Chemical	D020123
(	O	O
SRL	B-Chemical	D020123
)	O	O
is	O	O
a	O	O
new	O	O
,	O	O
potent	O	O
immunosuppressive	O	O
agent	O	O
.	O	O

More	O	O
recently	O	O
,	O	O
proteinuria	B-Disease	D011507
has	O	O
been	O	O
reported	O	O
as	O	O
a	O	O
consequence	O	O
of	O	O
sirolimus	B-Chemical	D020123
therapy	O	O
,	O	O
although	O	O
the	O	O
mechanism	O	O
has	O	O
remained	O	O
unclear	O	O
.	O	O

We	O	O
retrospectively	O	O
examined	O	O
the	O	O
records	O	O
of	O	O
25	O	O
renal	O	O
transplant	O	O
patients	O	O
,	O	O
who	O	O
developed	O	O
or	O	O
displayed	O	O
increased	O	O
proteinuria	B-Disease	D011507
after	O	O
SRL	B-Chemical	D020123
conversion	O	O
.	O	O

The	O	O
patient	O	O
cohort	O	O
(	O	O
14	O	O
men	O	O
,	O	O
11	O	O
women	O	O
)	O	O
was	O	O
treated	O	O
with	O	O
SRL	B-Chemical	D020123
as	O	O
conversion	O	O
therapy	O	O
,	O	O
due	O	O
to	O	O
chronic	B-Disease	D051436
allograft	I-Disease	D051436
nephropathy	I-Disease	D051436
(	O	O
CAN	B-Disease	D007674
)	O	O
(	O	O
n	O	O
=	O	O
15	O	O
)	O	O
neoplasia	B-Disease	D009369
(	O	O
n	O	O
=	O	O
8	O	O
)	O	O
;	O	O
Kaposi's	B-Disease	D012514
sarcoma	I-Disease	D012514
,	O	O
Four	O	O
skin	B-Disease	D012878
cancers	I-Disease	D012878
,	O	O
One	O	O
intestinal	B-Disease	D007414
tumors	I-Disease	D007414
,	O	O
One	O	O
renal	B-Disease	D002292
cell	I-Disease	D002292
carsinom	I-Disease	D002292
)	O	O
or	O	O
BK	O	O
virus	O	O
nephropathy	B-Disease	D007674
(	O	O
n	O	O
=	O	O
2	O	O
)	O	O
.	O	O

SRL	B-Chemical	D020123
was	O	O
started	O	O
at	O	O
a	O	O
mean	O	O
of	O	O
78	O	O
+	O	O
/	O	O
-	O	O
42	O	O
(	O	O
15	O	O
to	O	O
163	O	O
)	O	O
months	O	O
after	O	O
transplantation	O	O
.	O	O

Mean	O	O
follow	O	O
-	O	O
up	O	O
on	O	O
SRL	B-Chemical	D020123
therapy	O	O
was	O	O
20	O	O
+	O	O
/	O	O
-	O	O
12	O	O
(	O	O
6	O	O
to	O	O
43	O	O
)	O	O
months	O	O
.	O	O

Proteinuria	B-Disease	D011507
increased	O	O
from	O	O
0	O	O
.	O	O

445	O	O
(	O	O
0	O	O
to	O	O
1	O	O
.	O	O

5	O	O
)	O	O
g	O	O
/	O	O
d	O	O
before	O	O
conversion	O	O
to	O	O
3	O	O
.	O	O

2	O	O
g	O	O
/	O	O
dL	O	O
(	O	O
0	O	O
.	O	O

2	O	O
to	O	O
12	O	O
)	O	O
after	O	O
conversion	O	O
(	O	O
P	O	O
=	O	O
0	O	O
.	O	O

001	O	O
)	O	O
.	O	O

Before	O	O
conversion	O	O
8	O	O
(	O	O
32%	O	O
)	O	O
patients	O	O
had	O	O
no	O	O
proteinuria	B-Disease	D011507
,	O	O
whereas	O	O
afterwards	O	O
all	O	O
patients	O	O
had	O	O
proteinuria	B-Disease	D011507
.	O	O

In	O	O
28%	O	O
of	O	O
patients	O	O
proteinuria	B-Disease	D011507
remained	O	O
unchanged	O	O
,	O	O
whereas	O	O
it	O	O
increased	O	O
in	O	O
68%	O	O
of	O	O
patients	O	O
.	O	O

In	O	O
40%	O	O
it	O	O
increased	O	O
by	O	O
more	O	O
than	O	O
100%	O	O
.	O	O

Twenty	O	O
-	O	O
eight	O	O
percent	O	O
of	O	O
patients	O	O
showed	O	O
increased	O	O
proteinuria	B-Disease	D011507
to	O	O
the	O	O
nephrotic	B-Disease	D009404
range	O	O
.	O	O

Biopsies	O	O
performed	O	O
in	O	O
five	O	O
patients	O	O
revealed	O	O
new	O	O
pathological	O	O
changes	O	O
:	O	O
One	O	O
membranoproliferative	B-Disease	D015433
glomerulopathy	I-Disease	D015433
and	O	O
interstitial	B-Disease	D009395
nephritis	I-Disease	D009395
.	O	O

These	O	O
patients	O	O
showed	O	O
persistently	O	O
good	O	O
graft	O	O
function	O	O
.	O	O

Serum	O	O
creatinine	B-Chemical	D003404
values	O	O
did	O	O
not	O	O
change	O	O
significantly	O	O
:	O	O
1	O	O
.	O	O

98	O	O
+	O	O
/	O	O
-	O	O
0	O	O
.	O	O

8	O	O
mg	O	O
/	O	O
dL	O	O
before	O	O
SRL	B-Chemical	D020123
therapy	O	O
and	O	O
2	O	O
.	O	O

53	O	O
+	O	O
/	O	O
-	O	O
1	O	O
.	O	O

9	O	O
mg	O	O
/	O	O
dL	O	O
at	O	O
last	O	O
follow	O	O
-	O	O
up	O	O
(	O	O
P	O	O
=	O	O
.	O	O

14	O	O
)	O	O
.	O	O

Five	O	O
grafts	O	O
were	O	O
lost	O	O
and	O	O
the	O	O
patients	O	O
returned	O	O
to	O	O
dialysis	O	O
.	O	O

Five	O	O
patients	O	O
displayed	O	O
CAN	B-Disease	D007674
and	O	O
Kaposi's	B-Disease	D012514
sarcoma	I-Disease	D012514
.	O	O

Mean	O	O
urinary	O	O
protein	O	O
of	O	O
patients	O	O
who	O	O
returned	O	O
to	O	O
dialysis	O	O
was	O	O
1	O	O
.	O	O

26	O	O
(	O	O
0	O	O
.	O	O

5	O	O
to	O	O
3	O	O
.	O	O

5	O	O
)	O	O
g	O	O
/	O	O
d	O	O
before	O	O
and	O	O
4	O	O
.	O	O

7	O	O
(	O	O
3	O	O
to	O	O
12	O	O
)	O	O
g	O	O
/	O	O
d	O	O
after	O	O
conversion	O	O
(	O	O
P	O	O
=	O	O
.	O	O

01	O	O
)	O	O
.	O	O

Mean	O	O
serum	O	O
creatinine	B-Chemical	D003404
level	O	O
before	O	O
conversion	O	O
was	O	O
2	O	O
.	O	O

21	O	O
mg	O	O
/	O	O
dL	O	O
and	O	O
thereafter	O	O
,	O	O
4	O	O
.	O	O

93	O	O
mg	O	O
/	O	O
dL	O	O
(	O	O
P	O	O
=	O	O
.	O	O

02	O	O
)	O	O
.	O	O

Heavy	O	O
proteinuria	B-Disease	D011507
was	O	O
common	O	O
after	O	O
the	O	O
use	O	O
of	O	O
SRL	B-Chemical	D020123
as	O	O
rescue	O	O
therapy	O	O
for	O	O
renal	O	O
transplantation	O	O
.	O	O

Therefore	O	O
,	O	O
conversion	O	O
should	O	O
be	O	O
considered	O	O
for	O	O
patients	O	O
who	O	O
have	O	O
not	O	O
developed	O	O
advanced	O	O
CAN	B-Disease	D007674
and	O	O
proteinuria	B-Disease	D011507
.	O	O

The	O	O
possibility	O	O
of	O	O
de	O	O
novo	O	O
glomerular	O	O
pathology	O	O
under	O	O
SRL	B-Chemical	D020123
treatment	O	O
requires	O	O
further	O	O
investigation	O	O
by	O	O
renal	O	O
biopsy	O	O
.	O	O

In	O	O
vitro	O	O
characterization	O	O
of	O	O
parasympathetic	O	O
and	O	O
sympathetic	O	O
responses	O	O
in	O	O
cyclophosphamide	B-Chemical	D003520
-	O	O
induced	O	O
cystitis	B-Disease	D003556
in	O	O
the	O	O
rat	O	O
.	O	O

In	O	O
cyclophosphamide	B-Chemical	D003520
-	O	O
induced	O	O
cystitis	B-Disease	D003556
in	O	O
the	O	O
rat	O	O
,	O	O
detrusor	O	O
function	O	O
is	O	O
impaired	O	O
and	O	O
the	O	O
expression	O	O
and	O	O
effects	O	O
of	O	O
muscarinic	O	O
receptors	O	O
altered	O	O
.	O	O

Whether	O	O
or	O	O
not	O	O
the	O	O
neuronal	O	O
transmission	O	O
may	O	O
be	O	O
affected	O	O
by	O	O
cystitis	B-Disease	D003556
was	O	O
presently	O	O
investigated	O	O
.	O	O

Responses	O	O
of	O	O
urinary	O	O
strip	O	O
preparations	O	O
from	O	O
control	O	O
and	O	O
cyclophosphamide	B-Chemical	D003520
-	O	O
pretreated	O	O
rats	O	O
to	O	O
electrical	O	O
field	O	O
stimulation	O	O
and	O	O
to	O	O
agonists	O	O
were	O	O
assessed	O	O
in	O	O
the	O	O
absence	O	O
and	O	O
presence	O	O
of	O	O
muscarinic	O	O
,	O	O
adrenergic	O	O
and	O	O
purinergic	O	O
receptor	O	O
antagonists	O	O
.	O	O

Generally	O	O
,	O	O
atropine	B-Chemical	D001285
reduced	O	O
contractions	O	O
,	O	O
but	O	O
in	O	O
contrast	O	O
to	O	O
controls	O	O
,	O	O
it	O	O
also	O	O
reduced	O	O
responses	O	O
to	O	O
low	O	O
electrical	O	O
field	O	O
stimulation	O	O
intensity	O	O
(	O	O
1	O	O
-	O	O
5	O	O
Hz	O	O
)	O	O
in	O	O
inflamed	O	O
preparations	O	O
.	O	O

In	O	O
both	O	O
types	O	O
,	O	O
purinoceptor	O	O
desensitization	O	O
with	O	O
alpha	B-Chemical	C002630
,	I-Chemical	C002630
beta	I-Chemical	C002630
-	I-Chemical	C002630
methylene	I-Chemical	C002630
adenosine	I-Chemical	C002630
-	I-Chemical	C002630
5'	I-Chemical	C002630
-	I-Chemical	C002630
triphosphate	I-Chemical	C002630
(	O	O
alpha	B-Chemical	C002630
,	I-Chemical	C002630
beta	I-Chemical	C002630
-	I-Chemical	C002630
meATP	I-Chemical	C002630
)	O	O
caused	O	O
further	O	O
reductions	O	O
at	O	O
low	O	O
frequencies	O	O
(	O	O
<10	O	O
Hz	O	O
)	O	O
.	O	O

The	O	O
muscarinic	O	O
receptor	O	O
antagonists	O	O
atropine	B-Chemical	D001285
,	O	O
4	B-Chemical	C042375
-	I-Chemical	C042375
diphenylacetoxy	I-Chemical	C042375
-	I-Chemical	C042375
N	I-Chemical	C042375
-	I-Chemical	C042375
methylpiperidine	I-Chemical	C042375
(	O	O
4	B-Chemical	C042375
-	I-Chemical	C042375
DAMP	I-Chemical	C042375
)	O	O
(	O	O
'M	O	O
(	O	O
1	O	O
)	O	O
/	O	O
M	O	O
(	O	O
3	O	O
)	O	O
/	O	O
M	O	O
(	O	O
5	O	O
)	O	O
-	O	O
selective'	O	O
)	O	O
,	O	O
methoctramine	B-Chemical	C054938
(	O	O
'M	O	O
(	O	O
2	O	O
)	O	O
-	O	O
selective'	O	O
)	O	O
and	O	O
pirenzepine	B-Chemical	D010890
(	O	O
'M	O	O
(	O	O
1	O	O
)	O	O
-	O	O
selective'	O	O
)	O	O
antagonized	O	O
the	O	O
tonic	O	O
component	O	O
of	O	O
the	O	O
electrical	O	O
field	O	O
stimulation	O	O
-	O	O
evoked	O	O
contractile	O	O
response	O	O
more	O	O
potently	O	O
than	O	O
the	O	O
phasic	O	O
component	O	O
.	O	O

4	B-Chemical	C042375
-	I-Chemical	C042375
DAMP	I-Chemical	C042375
inhibited	O	O
the	O	O
tonic	O	O
contractions	O	O
in	O	O
controls	O	O
more	O	O
potently	O	O
than	O	O
methoctramine	B-Chemical	C054938
and	O	O
pirenzepine	B-Chemical	D010890
.	O	O

In	O	O
inflamed	O	O
preparations	O	O
,	O	O
the	O	O
muscarinic	O	O
receptor	O	O
antagonism	O	O
on	O	O
the	O	O
phasic	O	O
component	O	O
of	O	O
the	O	O
electrical	O	O
field	O	O
stimulation	O	O
-	O	O
evoked	O	O
contraction	O	O
was	O	O
decreased	O	O
and	O	O
the	O	O
pirenzepine	B-Chemical	D010890
and	O	O
4	B-Chemical	C042375
-	I-Chemical	C042375
DAMP	I-Chemical	C042375
antagonism	O	O
on	O	O
the	O	O
tonic	O	O
component	O	O
was	O	O
much	O	O
less	O	O
efficient	O	O
than	O	O
in	O	O
controls	O	O
.	O	O

In	O	O
contrast	O	O
to	O	O
controls	O	O
,	O	O
methoctramine	B-Chemical	C054938
increased	O	O
-	O	O
-	O	O
instead	O	O
of	O	O
decreased	O	O
-	O	O
-	O	O
the	O	O
tonic	O	O
responses	O	O
at	O	O
high	O	O
frequencies	O	O
.	O	O

While	O	O
contractions	O	O
to	O	O
carbachol	B-Chemical	D002217
and	O	O
ATP	B-Chemical	D000255
were	O	O
the	O	O
same	O	O
in	O	O
inflamed	O	O
and	O	O
in	O	O
control	O	O
strips	O	O
when	O	O
related	O	O
to	O	O
a	O	O
reference	O	O
potassium	B-Chemical	D011188
response	O	O
,	O	O
isoprenaline	B-Chemical	D007545
-	O	O
induced	O	O
relaxations	O	O
were	O	O
smaller	O	O
in	O	O
inflamed	O	O
strips	O	O
.	O	O

Thus	O	O
,	O	O
in	O	O
cystitis	B-Disease	D003556
substantial	O	O
changes	O	O
of	O	O
the	O	O
efferent	O	O
functional	O	O
responses	O	O
occur	O	O
.	O	O

While	O	O
postjunctional	O	O
beta	O	O
-	O	O
adrenoceptor	O	O
-	O	O
mediated	O	O
relaxations	O	O
are	O	O
reduced	O	O
,	O	O
effects	O	O
by	O	O
prejunctional	O	O
inhibitory	O	O
muscarinic	O	O
receptors	O	O
may	O	O
be	O	O
increased	O	O
.	O	O

Associations	O	O
between	O	O
use	O	O
of	O	O
benzodiazepines	B-Chemical	D001569
or	O	O
related	O	O
drugs	O	O
and	O	O
health	O	O
,	O	O
physical	O	O
abilities	O	O
and	O	O
cognitive	O	O
function	O	O
:	O	O
a	O	O
non	O	O
-	O	O
randomised	O	O
clinical	O	O
study	O	O
in	O	O
the	O	O
elderly	O	O
.	O	O

OBJECTIVE	O	O
:	O	O
To	O	O
describe	O	O
associations	O	O
between	O	O
the	O	O
use	O	O
of	O	O
benzodiazepines	B-Chemical	D001569
or	O	O
related	O	O
drugs	O	O
(	O	O
BZDs	B-Chemical	D001569
/	O	O
RDs	O	O
)	O	O
and	O	O
health	O	O
,	O	O
functional	O	O
abilities	O	O
and	O	O
cognitive	O	O
function	O	O
in	O	O
the	O	O
elderly	O	O
.	O	O

METHODS	O	O
:	O	O
A	O	O
non	O	O
-	O	O
randomised	O	O
clinical	O	O
study	O	O
of	O	O
patients	O	O
aged	O	O
>	O	O
or	O	O
=65	O	O
years	O	O
admitted	O	O
to	O	O
acute	O	O
hospital	O	O
wards	O	O
during	O	O
1	O	O
month	O	O
.	O	O

164	O	O
patients	O	O
(	O	O
mean	O	O
age	O	O
+	O	O
/	O	O
-	O	O
standard	O	O
deviation	O	O
[	O	O
SD	O	O
]	O	O
81	O	O
.	O	O

6	O	O
+	O	O
/	O	O
-	O	O
6	O	O
.	O	O

8	O	O
years	O	O
)	O	O
were	O	O
admitted	O	O
.	O	O

Of	O	O
these	O	O
,	O	O
nearly	O	O
half	O	O
(	O	O
n	O	O
=	O	O
78	O	O
)	O	O
had	O	O
used	O	O
BZDs	B-Chemical	D001569
/	O	O
RDs	O	O
before	O	O
admission	O	O
,	O	O
and	O	O
the	O	O
remainder	O	O
(	O	O
n	O	O
=	O	O
86	O	O
)	O	O
were	O	O
non	O	O
-	O	O
users	O	O
.	O	O

Cognitive	O	O
ability	O	O
was	O	O
assessed	O	O
by	O	O
the	O	O
Mini	O	O
-	O	O
Mental	O	O
State	O	O
Examination	O	O
(	O	O
MMSE	O	O
)	O	O
.	O	O

Patients	O	O
scoring	O	O
>	O	O
or	O	O
=20	O	O
MMSE	O	O
sum	O	O
points	O	O
were	O	O
interviewed	O	O
(	O	O
n	O	O
=	O	O
79	O	O
)	O	O
and	O	O
questioned	O	O
regarding	O	O
symptoms	O	O
and	O	O
functional	O	O
abilities	O	O
during	O	O
the	O	O
week	O	O
prior	O	O
to	O	O
admission	O	O
.	O	O

Data	O	O
on	O	O
use	O	O
of	O	O
BZDs	B-Chemical	D001569
/	O	O
RDs	O	O
before	O	O
admission	O	O
,	O	O
current	O	O
medications	O	O
and	O	O
discharge	O	O
diagnoses	O	O
were	O	O
collected	O	O
from	O	O
medical	O	O
records	O	O
.	O	O

Health	O	O
,	O	O
physical	O	O
abilities	O	O
and	O	O
cognitive	O	O
function	O	O
were	O	O
compared	O	O
between	O	O
BZD	O	O
/	O	O
RD	O	O
users	O	O
and	O	O
non	O	O
-	O	O
users	O	O
,	O	O
and	O	O
adjustments	O	O
were	O	O
made	O	O
for	O	O
confounding	O	O
variables	O	O
.	O	O

The	O	O
residual	O	O
serum	O	O
concentrations	O	O
of	O	O
oxazepam	B-Chemical	D010076
,	O	O
temazepam	B-Chemical	D013693
and	O	O
zopiclone	B-Chemical	C515050
were	O	O
analysed	O	O
.	O	O

RESULTS	O	O
:	O	O
The	O	O
mean	O	O
+	O	O
/	O	O
-	O	O
SD	O	O
duration	O	O
of	O	O
BZD	O	O
/	O	O
RD	O	O
use	O	O
was	O	O
7	O	O
+	O	O
/	O	O
-	O	O
7	O	O
years	O	O
(	O	O
range	O	O
1	O	O
-	O	O
31	O	O
)	O	O
.	O	O

Two	O	O
or	O	O
three	O	O
BZDs	B-Chemical	D001569
/	O	O
RDs	O	O
were	O	O
concomitantly	O	O
taken	O	O
by	O	O
26%	O	O
of	O	O
users	O	O
(	O	O
n	O	O
=	O	O
20	O	O
)	O	O
.	O	O

Long	O	O
-	O	O
term	O	O
use	O	O
of	O	O
these	O	O
drugs	O	O
was	O	O
associated	O	O
with	O	O
female	O	O
sex	O	O
and	O	O
use	O	O
of	O	O
a	O	O
higher	O	O
number	O	O
of	O	O
drugs	O	O
with	O	O
effects	O	O
on	O	O
the	O	O
CNS	O	O
,	O	O
which	O	O
tended	O	O
to	O	O
be	O	O
related	O	O
to	O	O
diagnosed	O	O
dementia	B-Disease	D003704
.	O	O

After	O	O
adjustment	O	O
for	O	O
these	O	O
variables	O	O
as	O	O
confounders	O	O
,	O	O
use	O	O
of	O	O
BZDs	B-Chemical	D001569
/	O	O
RDs	O	O
was	O	O
not	O	O
associated	O	O
with	O	O
cognitive	O	O
function	O	O
as	O	O
measured	O	O
by	O	O
the	O	O
MMSE	O	O
.	O	O

However	O	O
,	O	O
use	O	O
of	O	O
BZDs	B-Chemical	D001569
/	O	O
RDs	O	O
was	O	O
associated	O	O
with	O	O
dizziness	B-Disease	D004244
,	O	O
inability	B-Disease	D007319
to	I-Disease	D007319
sleep	I-Disease	D007319
after	O	O
awaking	O	O
at	O	O
night	O	O
and	O	O
tiredness	B-Disease	D005221
in	O	O
the	O	O
mornings	O	O
during	O	O
the	O	O
week	O	O
prior	O	O
to	O	O
admission	O	O
and	O	O
with	O	O
stronger	O	O
depressive	B-Disease	D003866
symptoms	I-Disease	D003866
measured	O	O
at	O	O
the	O	O
beginning	O	O
of	O	O
the	O	O
hospital	O	O
stay	O	O
.	O	O

Use	O	O
of	O	O
BZDs	B-Chemical	D001569
/	O	O
RDs	O	O
tended	O	O
to	O	O
be	O	O
associated	O	O
with	O	O
a	O	O
reduced	O	O
ability	O	O
to	O	O
walk	O	O
and	O	O
shorter	O	O
night	O	O
-	O	O
time	O	O
sleep	O	O
during	O	O
the	O	O
week	O	O
prior	O	O
to	O	O
admission	O	O
.	O	O

A	O	O
higher	O	O
residual	O	O
serum	O	O
concentration	O	O
of	O	O
temazepam	B-Chemical	D013693
correlated	O	O
with	O	O
a	O	O
lower	O	O
MMSE	O	O
sum	O	O
score	O	O
after	O	O
adjustment	O	O
for	O	O
confounding	O	O
variables	O	O
.	O	O

CONCLUSIONS	O	O
:	O	O
Long	O	O
-	O	O
term	O	O
use	O	O
and	O	O
concomitant	O	O
use	O	O
of	O	O
more	O	O
than	O	O
one	O	O
BZD	O	O
/	O	O
RD	O	O
were	O	O
common	O	O
in	O	O
elderly	O	O
patients	O	O
hospitalised	O	O
because	O	O
of	O	O
acute	O	O
illnesses	O	O
.	O	O

Long	O	O
-	O	O
term	O	O
use	O	O
was	O	O
associated	O	O
with	O	O
daytime	O	O
and	O	O
night	O	O
-	O	O
time	O	O
symptoms	O	O
indicative	O	O
of	O	O
poorer	O	O
health	O	O
and	O	O
potentially	O	O
caused	O	O
by	O	O
the	O	O
adverse	O	O
effects	O	O
of	O	O
these	O	O
drugs	O	O
.	O	O

Acute	O	O
vocal	B-Disease	D014826
fold	I-Disease	D014826
palsy	I-Disease	D014826
after	O	O
acute	O	O
disulfiram	B-Chemical	D004221
intoxication	O	O
.	O	O

Acute	O	O
peripheral	B-Disease	D010523
neuropathy	I-Disease	D010523
caused	O	O
by	O	O
a	O	O
disulfiram	B-Chemical	D004221
overdose	B-Disease	D062787
is	O	O
very	O	O
rare	O	O
and	O	O
there	O	O
is	O	O
no	O	O
report	O	O
of	O	O
it	O	O
leading	O	O
to	O	O
vocal	B-Disease	D014826
fold	I-Disease	D014826
palsy	I-Disease	D014826
.	O	O

A	O	O
49	O	O
-	O	O
year	O	O
-	O	O
old	O	O
woman	O	O
was	O	O
transferred	O	O
to	O	O
our	O	O
department	O	O
because	O	O
of	O	O
quadriparesis	B-Disease	D011782
,	O	O
lancinating	O	O
pain	B-Disease	D010146
,	O	O
sensory	B-Disease	C580162
loss	I-Disease	C580162
,	O	O
and	O	O
paresthesia	B-Disease	D010292
of	O	O
the	O	O
distal	O	O
limbs	O	O
.	O	O

One	O	O
month	O	O
previously	O	O
,	O	O
she	O	O
had	O	O
taken	O	O
a	O	O
single	O	O
high	O	O
dose	O	O
of	O	O
disulfiram	B-Chemical	D004221
(	O	O
130	O	O
tablets	O	O
of	O	O
ALCOHOL	B-Chemical	D000431
STOP	O	O
TAB	O	O
,	O	O
Shin	O	O
-	O	O
Poong	O	O
Pharm	O	O
.	O	O

Co	O	O
.	O	O

,	O	O
Ansan	O	O
,	O	O
Korea	O	O
)	O	O
in	O	O
a	O	O
suicide	O	O
attempt	O	O
.	O	O

She	O	O
was	O	O
not	O	O
an	O	O
alcoholic	O	O
.	O	O

For	O	O
the	O	O
first	O	O
few	O	O
days	O	O
after	O	O
ingestion	O	O
,	O	O
she	O	O
was	O	O
in	O	O
a	O	O
confused	O	O
state	O	O
and	O	O
had	O	O
mild	O	O
to	O	O
moderate	O	O
ataxia	B-Disease	D001259
and	O	O
giddiness	B-Disease	D004244
.	O	O

She	O	O
noticed	O	O
hoarseness	B-Disease	D006685
and	O	O
distally	O	O
accentuated	O	O
motor	O	O
and	O	O
sensory	O	O
dysfunction	O	O
after	O	O
she	O	O
had	O	O
recovered	O	O
from	O	O
this	O	O
state	O	O
.	O	O

A	O	O
nerve	O	O
conduction	O	O
study	O	O
was	O	O
consistent	O	O
with	O	O
severe	O	O
sensorimotor	O	O
axonal	O	O
polyneuropathy	B-Disease	D011115
.	O	O

Laryngeal	O	O
electromyography	O	O
(	O	O
thyroarytenoid	O	O
muscle	O	O
)	O	O
showed	O	O
ample	O	O
denervation	O	O
potentials	O	O
.	O	O

Laryngoscopy	O	O
revealed	O	O
asymmetric	O	O
vocal	O	O
fold	O	O
movements	O	O
during	O	O
phonation	O	O
.	O	O

Her	O	O
vocal	O	O
change	O	O
and	O	O
weakness	O	O
began	O	O
to	O	O
improve	O	O
spontaneously	O	O
about	O	O
3	O	O
weeks	O	O
after	O	O
transfer	O	O
.	O	O

This	O	O
was	O	O
a	O	O
case	O	O
of	O	O
acute	O	O
palsy	B-Disease	D010243
of	O	O
the	O	O
recurrent	O	O
laryngeal	O	O
nerve	O	O
and	O	O
superimposed	O	O
severe	O	O
acute	O	O
sensorimotor	O	O
axonal	O	O
polyneuropathy	B-Disease	D011115
caused	O	O
by	O	O
high	O	O
-	O	O
dose	O	O
disulfiram	B-Chemical	D004221
intoxication	O	O
.	O	O

Higher	O	O
optical	O	O
density	O	O
of	O	O
an	O	O
antigen	O	O
assay	O	O
predicts	O	O
thrombosis	B-Disease	D013927
in	O	O
patients	O	O
with	O	O
heparin	B-Chemical	D006493
-	O	O
induced	O	O
thrombocytopenia	B-Disease	D013921
.	O	O

OBJECTIVES	O	O
:	O	O
To	O	O
correlate	O	O
optical	O	O
density	O	O
and	O	O
percent	O	O
inhibition	O	O
of	O	O
a	O	O
two	O	O
-	O	O
step	O	O
heparin	B-Chemical	D006493
-	O	O
induced	O	O
thrombocytopenia	B-Disease	D013921
(	O	O
HIT	B-Disease	D013921
)	O	O
antigen	O	O
assay	O	O
with	O	O
thrombosis	B-Disease	D013927
;	O	O
the	O	O
assay	O	O
utilizes	O	O
reaction	O	O
inhibition	O	O
characteristics	O	O
of	O	O
a	O	O
high	O	O
heparin	B-Chemical	D006493
concentration	O	O
.	O	O

PATIENTS	O	O
AND	O	O
METHODS	O	O
:	O	O
Patients	O	O
with	O	O
more	O	O
than	O	O
50%	O	O
decrease	O	O
in	O	O
platelet	O	O
count	O	O
or	O	O
thrombocytopenia	B-Disease	D013921
(	O	O
<150	O	O
x	O	O
10	O	O
(	O	O
9	O	O
)	O	O
/	O	O
L	O	O
)	O	O
after	O	O
exposure	O	O
to	O	O
heparin	B-Chemical	D006493
,	O	O
who	O	O
had	O	O
a	O	O
positive	O	O
two	O	O
-	O	O
step	O	O
antigen	O	O
assay	O	O
[	O	O
optical	O	O
density	O	O
(	O	O
OD	O	O
)	O	O
>0	O	O
.	O	O

4	O	O
and	O	O
>50	O	O
inhibition	O	O
with	O	O
high	O	O
concentration	O	O
of	O	O
heparin	B-Chemical	D006493
]	O	O
were	O	O
included	O	O
in	O	O
the	O	O
study	O	O
.	O	O

RESULTS	O	O
:	O	O
Forty	O	O
of	O	O
94	O	O
HIT	B-Disease	D013921
patients	O	O
had	O	O
thrombosis	B-Disease	D013927
at	O	O
diagnosis	O	O
;	O	O
54	O	O
/	O	O
94	O	O
had	O	O
isolated	O	O
-	O	O
HIT	B-Disease	D013921
without	O	O
thrombosis	B-Disease	D013927
.	O	O

Eight	O	O
of	O	O
the	O	O
isolated	O	O
-	O	O
HIT	B-Disease	D013921
patients	O	O
developed	O	O
thrombosis	B-Disease	D013927
within	O	O
the	O	O
next	O	O
30	O	O
d	O	O
;	O	O
thus	O	O
,	O	O
a	O	O
total	O	O
of	O	O
48	O	O
patients	O	O
had	O	O
thrombosis	B-Disease	D013927
at	O	O
day	O	O
30	O	O
.	O	O

At	O	O
diagnosis	O	O
there	O	O
was	O	O
no	O	O
significant	O	O
difference	O	O
in	O	O
OD	O	O
between	O	O
HIT	B-Disease	D013921
patients	O	O
with	O	O
thrombosis	B-Disease	D013927
and	O	O
those	O	O
with	O	O
isolated	O	O
-	O	O
HIT	B-Disease	D013921
.	O	O

However	O	O
,	O	O
OD	O	O
was	O	O
significantly	O	O
higher	O	O
in	O	O
all	O	O
patients	O	O
with	O	O
thrombosis	B-Disease	D013927
(	O	O
n	O	O
=	O	O
48	O	O
,	O	O
1	O	O
.	O	O

34	O	O
+	O	O
/	O	O
-	O	O
0	O	O
.	O	O

89	O	O
)	O	O
,	O	O
including	O	O
isolated	O	O
-	O	O
HIT	B-Disease	D013921
patients	O	O
who	O	O
later	O	O
developed	O	O
thrombosis	B-Disease	D013927
within	O	O
30	O	O
d	O	O
(	O	O
n	O	O
=	O	O
8	O	O
,	O	O
1	O	O
.	O	O

84	O	O
+	O	O
/	O	O
-	O	O
0	O	O
.	O	O

64	O	O
)	O	O
as	O	O
compared	O	O
to	O	O
isolated	O	O
-	O	O
HIT	B-Disease	D013921
patients	O	O
who	O	O
did	O	O
not	O	O
develop	O	O
thrombosis	B-Disease	D013927
(	O	O
0	O	O
.	O	O

96	O	O
+	O	O
/	O	O
-	O	O
0	O	O
.	O	O

75	O	O
;	O	O
P	O	O
=	O	O
0	O	O
.	O	O

011	O	O
and	O	O
P	O	O
=	O	O
0	O	O
.	O	O

008	O	O
)	O	O
.	O	O

The	O	O
Receiver	O	O
Operative	O	O
Characteristic	O	O
Curve	O	O
showed	O	O
that	O	O
OD	O	O
>1	O	O
.	O	O

27	O	O
in	O	O
the	O	O
isolated	O	O
-	O	O
HIT	B-Disease	D013921
group	O	O
had	O	O
a	O	O
significantly	O	O
higher	O	O
chance	O	O
of	O	O
developing	O	O
thrombosis	B-Disease	D013927
by	O	O
day	O	O
30	O	O
.	O	O

None	O	O
of	O	O
these	O	O
groups	O	O
showed	O	O
significant	O	O
difference	O	O
in	O	O
percent	O	O
inhibition	O	O
.	O	O

Multivariate	O	O
analysis	O	O
showed	O	O
a	O	O
2	O	O
.	O	O

8	O	O
-	O	O
fold	O	O
increased	O	O
risk	O	O
of	O	O
thrombosis	B-Disease	D013927
in	O	O
females	O	O
.	O	O

Similarly	O	O
,	O	O
thrombotic	B-Disease	D013927
risk	O	O
increased	O	O
with	O	O
age	O	O
and	O	O
OD	O	O
values	O	O
.	O	O

CONCLUSION	O	O
:	O	O
Higher	O	O
OD	O	O
is	O	O
associated	O	O
with	O	O
significant	O	O
risk	O	O
of	O	O
subsequent	O	O
thrombosis	B-Disease	D013927
in	O	O
patients	O	O
with	O	O
isolated	O	O
-	O	O
HIT	B-Disease	D013921
;	O	O
percent	O	O
inhibition	O	O
,	O	O
however	O	O
,	O	O
was	O	O
not	O	O
predictive	O	O
.	O	O

Central	O	O
retinal	B-Disease	D012170
vein	I-Disease	D012170
occlusion	I-Disease	D012170
associated	O	O
with	O	O
clomiphene	B-Chemical	D002996
-	O	O
induced	O	O
ovulation	O	O
.	O	O

OBJECTIVE	O	O
:	O	O
To	O	O
report	O	O
a	O	O
case	O	O
of	O	O
central	O	O
retinal	B-Disease	D012170
vein	I-Disease	D012170
occlusion	I-Disease	D012170
associated	O	O
with	O	O
clomiphene	B-Chemical	D002996
citrate	O	O
(	O	O
CC	B-Chemical	D002996
)	O	O
.	O	O

DESIGN	O	O
:	O	O
Case	O	O
study	O	O
.	O	O

SETTING	O	O
:	O	O
Ophthalmology	O	O
clinic	O	O
of	O	O
an	O	O
academic	O	O
hospital	O	O
.	O	O

PATIENT	O	O
(	O	O
S	O	O
)	O	O
:	O	O
A	O	O
36	O	O
-	O	O
year	O	O
-	O	O
old	O	O
woman	O	O
referred	O	O
from	O	O
the	O	O
infertility	B-Disease	D007247
clinic	O	O
for	O	O
blurred	B-Disease	D014786
vision	I-Disease	D014786
.	O	O

INTERVENTION	O	O
(	O	O
S	O	O
)	O	O
:	O	O
Ophthalmic	O	O
examination	O	O
after	O	O
CC	B-Chemical	D002996
therapy	O	O
.	O	O

MAIN	O	O
OUTCOME	O	O
MEASURE	O	O
(	O	O
S	O	O
)	O	O
:	O	O
Central	O	O
retinal	B-Disease	D012170
vein	I-Disease	D012170
occlusion	I-Disease	D012170
after	O	O
ovulation	O	O
induction	O	O
with	O	O
CC	B-Chemical	D002996
.	O	O

RESULT	O	O
(	O	O
S	O	O
)	O	O
:	O	O
A	O	O
36	O	O
-	O	O
year	O	O
-	O	O
old	O	O
Chinese	O	O
woman	O	O
developed	O	O
central	O	O
retinal	B-Disease	D012170
vein	I-Disease	D012170
occlusion	I-Disease	D012170
after	O	O
eight	O	O
courses	O	O
of	O	O
CC	B-Chemical	D002996
.	O	O

A	O	O
search	O	O
of	O	O
the	O	O
literature	O	O
on	O	O
the	O	O
thromboembolic	B-Disease	D013923
complications	O	O
of	O	O
CC	B-Chemical	D002996
does	O	O
not	O	O
include	O	O
this	O	O
severe	O	O
ophthalmic	O	O
complication	O	O
,	O	O
although	O	O
mild	O	O
visual	B-Disease	D014786
disturbance	I-Disease	D014786
after	O	O
CC	B-Chemical	D002996
intake	O	O
is	O	O
not	O	O
uncommon	O	O
.	O	O

CONCLUSION	O	O
(	O	O
S	O	O
)	O	O
:	O	O
This	O	O
is	O	O
the	O	O
first	O	O
reported	O	O
case	O	O
of	O	O
central	O	O
retinal	B-Disease	D012170
vein	I-Disease	D012170
occlusion	I-Disease	D012170
after	O	O
treatment	O	O
with	O	O
CC	B-Chemical	D002996
.	O	O

Extra	O	O
caution	O	O
is	O	O
warranted	O	O
in	O	O
treating	O	O
infertility	B-Disease	D007247
patients	O	O
with	O	O
CC	B-Chemical	D002996
,	O	O
and	O	O
patients	O	O
should	O	O
be	O	O
well	O	O
informed	O	O
of	O	O
this	O	O
side	O	O
effect	O	O
before	O	O
commencement	O	O
of	O	O
therapy	O	O
.	O	O

Nicotine	B-Chemical	D009538
-	O	O
induced	O	O
nystagmus	B-Disease	D009759
correlates	O	O
with	O	O
midpontine	O	O
activation	O	O
.	O	O

The	O	O
pathomechanism	O	O
of	O	O
nicotine	B-Chemical	D009538
-	O	O
induced	O	O
nystagmus	B-Disease	D009759
(	O	O
NIN	B-Disease	D009759
)	O	O
is	O	O
unknown	O	O
.	O	O

The	O	O
aim	O	O
of	O	O
this	O	O
study	O	O
was	O	O
to	O	O
delineate	O	O
brain	O	O
structures	O	O
that	O	O
are	O	O
involved	O	O
in	O	O
NIN	B-Disease	D009759
generation	O	O
.	O	O

Eight	O	O
healthy	O	O
volunteers	O	O
inhaled	O	O
nicotine	B-Chemical	D009538
in	O	O
darkness	O	O
during	O	O
a	O	O
functional	O	O
magnetic	O	O
resonance	O	O
imaging	O	O
(	O	O
fMRI	O	O
)	O	O
experiment	O	O
;	O	O
eye	O	O
movements	O	O
were	O	O
registered	O	O
using	O	O
video	O	O
-	O	O
oculography	O	O
.	O	O

NIN	B-Disease	D009759
correlated	O	O
with	O	O
blood	O	O
oxygen	B-Chemical	D010100
level	O	O
-	O	O
dependent	O	O
(	O	O
BOLD	O	O
)	O	O
activity	O	O
levels	O	O
in	O	O
a	O	O
midpontine	O	O
site	O	O
in	O	O
the	O	O
posterior	O	O
basis	O	O
pontis	O	O
.	O	O

NIN	B-Disease	D009759
-	O	O
induced	O	O
midpontine	O	O
activation	O	O
may	O	O
correspond	O	O
to	O	O
activation	O	O
of	O	O
the	O	O
dorsomedial	O	O
pontine	O	O
nuclei	O	O
and	O	O
the	O	O
nucleus	O	O
reticularis	O	O
tegmenti	O	O
pontis	O	O
,	O	O
structures	O	O
known	O	O
to	O	O
participate	O	O
in	O	O
the	O	O
generation	O	O
of	O	O
multidirectional	O	O
saccades	O	O
and	O	O
smooth	O	O
pursuit	O	O
eye	O	O
movements	O	O
.	O	O

Protective	O	O
effect	O	O
of	O	O
verapamil	B-Chemical	D014700
on	O	O
gastric	B-Disease	D006471
hemorrhagic	I-Disease	D006471
ulcers	B-Disease	D014456
in	O	O
severe	O	O
atherosclerotic	B-Disease	D050197
rats	O	O
.	O	O

Studies	O	O
concerning	O	O
with	O	O
pathogenesis	O	O
of	O	O
gastric	B-Disease	D006471
hemorrhage	I-Disease	D006471
and	O	O
mucosal	O	O
ulceration	O	O
produced	O	O
in	O	O
atherosclerotic	B-Disease	D050197
rats	O	O
are	O	O
lacking	O	O
.	O	O

The	O	O
aim	O	O
of	O	O
this	O	O
study	O	O
is	O	O
to	O	O
examine	O	O
the	O	O
role	O	O
of	O	O
gastric	O	O
acid	O	O
back	O	O
-	O	O
diffusion	O	O
,	O	O
mast	O	O
cell	O	O
histamine	B-Chemical	D006632
release	O	O
,	O	O
lipid	O	O
peroxide	O	O
(	O	O
LPO	O	O
)	O	O
generation	O	O
and	O	O
mucosal	O	O
microvascular	O	O
permeability	O	O
in	O	O
modulating	O	O
gastric	B-Disease	D006471
hemorrhage	I-Disease	D006471
and	O	O
ulcer	B-Disease	D014456
in	O	O
rats	O	O
with	O	O
atherosclerosis	B-Disease	D050197
induced	O	O
by	O	O
coadministration	O	O
of	O	O
vitamin	B-Chemical	D004872
D2	I-Chemical	D004872
and	O	O
cholesterol	B-Chemical	D002784
.	O	O

Additionally	O	O
,	O	O
the	O	O
protective	O	O
effect	O	O
of	O	O
verapamil	B-Chemical	D014700
on	O	O
this	O	O
ulcer	B-Disease	D014456
model	O	O
was	O	O
evaluated	O	O
.	O	O

Male	O	O
Wistar	O	O
rats	O	O
were	O	O
challenged	O	O
intragastrically	O	O
once	O	O
daily	O	O
for	O	O
9	O	O
days	O	O
with	O	O
1	O	O
.	O	O

0	O	O
ml	O	O
/	O	O
kg	O	O
of	O	O
corn	O	O
oil	O	O
containing	O	O
vitamin	B-Chemical	D004872
D2	I-Chemical	D004872
and	O	O
cholesterol	B-Chemical	D002784
to	O	O
induce	O	O
atherosclerosis	B-Disease	D050197
.	O	O

Control	O	O
rats	O	O
received	O	O
corn	O	O
oil	O	O
only	O	O
.	O	O

After	O	O
gastric	O	O
surgery	O	O
,	O	O
rat	O	O
stomachs	O	O
were	O	O
irrigated	O	O
for	O	O
3	O	O
h	O	O
with	O	O
either	O	O
simulated	O	O
gastric	O	O
juice	O	O
or	O	O
normal	O	O
saline	O	O
.	O	O

Gastric	O	O
acid	O	O
back	O	O
-	O	O
diffusion	O	O
,	O	O
mucosal	O	O
LPO	O	O
generation	O	O
,	O	O
histamine	B-Chemical	D006632
concentration	O	O
,	O	O
microvascular	O	O
permeability	O	O
,	O	O
luminal	B-Chemical	D010634
hemoglobin	O	O
content	O	O
and	O	O
ulcer	B-Disease	D014456
areas	O	O
were	O	O
determined	O	O
.	O	O

Elevated	O	O
atherosclerotic	B-Disease	D050197
parameters	O	O
,	O	O
such	O	O
as	O	O
serum	O	O
calcium	B-Chemical	D002118
,	O	O
total	O	O
cholesterol	B-Chemical	D002784
and	O	O
low	O	O
-	O	O
density	O	O
lipoprotein	O	O
concentration	O	O
were	O	O
obtained	O	O
in	O	O
atherosclerotic	B-Disease	D050197
rats	O	O
.	O	O

Severe	O	O
gastric	O	O
ulcers	B-Disease	D014456
accompanied	O	O
with	O	O
increased	O	O
ulcerogenic	O	O
factors	O	O
,	O	O
including	O	O
gastric	O	O
acid	O	O
back	O	O
-	O	O
diffusion	O	O
,	O	O
histamine	B-Chemical	D006632
release	O	O
,	O	O
LPO	O	O
generation	O	O
and	O	O
luminal	B-Chemical	D010634
hemoglobin	O	O
content	O	O
were	O	O
also	O	O
observed	O	O
in	O	O
these	O	O
rats	O	O
.	O	O

Moreover	O	O
,	O	O
a	O	O
positive	O	O
correlation	O	O
of	O	O
histamine	B-Chemical	D006632
to	O	O
gastric	B-Disease	D006471
hemorrhage	I-Disease	D006471
and	O	O
to	O	O
ulcer	B-Disease	D014456
was	O	O
found	O	O
in	O	O
those	O	O
atherosclerotic	B-Disease	D050197
rats	O	O
.	O	O

This	O	O
hemorrhagic	B-Disease	D006471
ulcer	B-Disease	D014456
and	O	O
various	O	O
ulcerogenic	O	O
parameters	O	O
were	O	O
dose	O	O
-	O	O
dependently	O	O
ameliorated	O	O
by	O	O
daily	O	O
intragastric	O	O
verapamil	B-Chemical	D014700
.	O	O

Atherosclerosis	B-Disease	D050197
could	O	O
produce	O	O
gastric	B-Disease	D006471
hemorrhagic	I-Disease	D006471
ulcer	B-Disease	D014456
via	O	O
aggravation	O	O
of	O	O
gastric	O	O
acid	O	O
back	O	O
-	O	O
diffusion	O	O
,	O	O
LPO	O	O
generation	O	O
,	O	O
histamine	B-Chemical	D006632
release	O	O
and	O	O
microvascular	O	O
permeability	O	O
that	O	O
could	O	O
be	O	O
ameliorated	O	O
by	O	O
verapamil	B-Chemical	D014700
in	O	O
rats	O	O
.	O	O

Adriamycin	B-Chemical	D004317
-	O	O
induced	O	O
autophagic	O	O
cardiomyocyte	O	O
death	B-Disease	D003643
plays	O	O
a	O	O
pathogenic	O	O
role	O	O
in	O	O
a	O	O
rat	O	O
model	O	O
of	O	O
heart	B-Disease	D006333
failure	I-Disease	D006333
.	O	O

BACKGROUND	O	O
:	O	O
The	O	O
mechanisms	O	O
underlying	O	O
heart	B-Disease	D006333
failure	I-Disease	D006333
induced	O	O
by	O	O
adriamycin	B-Chemical	D004317
are	O	O
very	O	O
complicated	O	O
and	O	O
still	O	O
unclear	O	O
.	O	O

The	O	O
aim	O	O
of	O	O
this	O	O
study	O	O
was	O	O
to	O	O
investigate	O	O
whether	O	O
autophagy	O	O
was	O	O
involved	O	O
in	O	O
the	O	O
progression	O	O
of	O	O
heart	B-Disease	D006333
failure	I-Disease	D006333
induced	O	O
by	O	O
adriamycin	B-Chemical	D004317
,	O	O
so	O	O
that	O	O
we	O	O
can	O	O
develop	O	O
a	O	O
novel	O	O
treatment	O	O
strategy	O	O
for	O	O
heart	B-Disease	D006333
failure	I-Disease	D006333
.	O	O

METHODS	O	O
:	O	O
3	B-Chemical	C025946
-	I-Chemical	C025946
methyladenine	I-Chemical	C025946
(	O	O
3MA	B-Chemical	C025946
)	O	O
,	O	O
a	O	O
specific	O	O
inhibitor	O	O
on	O	O
autophagy	O	O
was	O	O
used	O	O
in	O	O
a	O	O
heart	B-Disease	D006333
failure	I-Disease	D006333
model	O	O
of	O	O
rats	O	O
induced	O	O
by	O	O
adriamycin	B-Chemical	D004317
.	O	O

Neonatal	O	O
cardiomyocytes	O	O
were	O	O
isolated	O	O
from	O	O
Sprague	O	O
-	O	O
Dawley	O	O
rat	O	O
hearts	O	O
and	O	O
randomly	O	O
divided	O	O
into	O	O
controls	O	O
,	O	O
an	O	O
adriamycin	B-Chemical	D004317
-	O	O
treated	O	O
group	O	O
,	O	O
and	O	O
a	O	O
3MA	B-Chemical	C025946
plus	O	O
adriamycin	B-Chemical	D004317
-	O	O
treated	O	O
group	O	O
.	O	O

We	O	O
then	O	O
examined	O	O
the	O	O
morphology	O	O
,	O	O
expression	O	O
of	O	O
beclin	O	O
1	O	O
gene	O	O
,	O	O
mitochondrial	O	O
permeability	O	O
transition	O	O
(	O	O
MPT	O	O
)	O	O
,	O	O
and	O	O
Na+	O	O
-	O	O
K+	O	O
ATPase	O	O
activity	O	O
in	O	O
vivo	O	O
.	O	O

We	O	O
also	O	O
assessed	O	O
cell	O	O
viability	O	O
,	O	O
mitochondrial	O	O
membrane	O	O
potential	O	O
changes	O	O
and	O	O
counted	O	O
autophagic	O	O
vacuoles	O	O
in	O	O
cultured	O	O
cardiomyocytes	O	O
.	O	O

In	O	O
addition	O	O
,	O	O
we	O	O
analyzed	O	O
the	O	O
expression	O	O
of	O	O
autophagy	O	O
associated	O	O
gene	O	O
,	O	O
beclin	O	O
1	O	O
using	O	O
RT	O	O
-	O	O
PCR	O	O
and	O	O
Western	O	O
blotting	O	O
in	O	O
an	O	O
animal	O	O
model	O	O
.	O	O

RESULTS	O	O
:	O	O
3MA	B-Chemical	C025946
significantly	O	O
improved	O	O
cardiac	O	O
function	O	O
and	O	O
reduced	O	O
mitochondrial	O	O
injury	O	O
.	O	O

Furthermore	O	O
,	O	O
adriamycin	B-Chemical	D004317
induced	O	O
the	O	O
formation	O	O
of	O	O
autophagic	O	O
vacuoles	O	O
,	O	O
and	O	O
3MA	B-Chemical	C025946
strongly	O	O
downregulated	O	O
the	O	O
expression	O	O
of	O	O
beclin	O	O
1	O	O
in	O	O
adriamycin	B-Chemical	D004317
-	O	O
induced	O	O
failing	O	O
heart	O	O
and	O	O
inhibited	O	O
the	O	O
formation	O	O
of	O	O
autophagic	O	O
vacuoles	O	O
.	O	O

CONCLUSION	O	O
:	O	O
Autophagic	O	O
cardiomyocyte	O	O
death	B-Disease	D003643
plays	O	O
an	O	O
important	O	O
role	O	O
in	O	O
the	O	O
pathogenesis	O	O
of	O	O
heart	B-Disease	D006333
failure	I-Disease	D006333
in	O	O
rats	O	O
induced	O	O
by	O	O
adriamycin	B-Chemical	D004317
.	O	O

Mitochondrial	O	O
injury	O	O
may	O	O
be	O	O
involved	O	O
in	O	O
the	O	O
progression	O	O
of	O	O
heart	B-Disease	D006333
failure	I-Disease	D006333
caused	O	O
by	O	O
adriamycin	B-Chemical	D004317
via	O	O
the	O	O
autophagy	O	O
pathway	O	O
.	O	O

Confusion	B-Disease	D003221
,	O	O
a	O	O
rather	O	O
serious	O	O
adverse	O	O
drug	O	O
reaction	O	O
with	O	O
valproic	B-Chemical	D014635
acid	I-Chemical	D014635
:	O	O
a	O	O
review	O	O
of	O	O
the	O	O
French	O	O
Pharmacovigilance	O	O
database	O	O
.	O	O

INTRODUCTION	O	O
:	O	O
Confusion	B-Disease	D003221
is	O	O
an	O	O
adverse	O	O
drug	O	O
reaction	O	O
frequently	O	O
observed	O	O
with	O	O
valproic	B-Chemical	D014635
acid	I-Chemical	D014635
.	O	O

Some	O	O
case	O	O
reports	O	O
are	O	O
published	O	O
in	O	O
the	O	O
literature	O	O
but	O	O
no	O	O
systematic	O	O
study	O	O
from	O	O
a	O	O
sample	O	O
of	O	O
patients	O	O
has	O	O
been	O	O
published	O	O
.	O	O

We	O	O
performed	O	O
this	O	O
study	O	O
in	O	O
order	O	O
to	O	O
describe	O	O
the	O	O
main	O	O
characteristics	O	O
of	O	O
this	O	O
adverse	O	O
drug	O	O
reaction	O	O
.	O	O

METHODS	O	O
:	O	O
Using	O	O
the	O	O
French	O	O
Pharmacovigilance	O	O
database	O	O
,	O	O
we	O	O
selected	O	O
the	O	O
cases	O	O
of	O	O
confusion	B-Disease	D003221
reported	O	O
since	O	O
1985	O	O
with	O	O
valproic	B-Chemical	D014635
acid	I-Chemical	D014635
.	O	O

RESULTS	O	O
:	O	O
272	O	O
cases	O	O
of	O	O
confusion	B-Disease	D003221
were	O	O
reported	O	O
with	O	O
valproic	B-Chemical	D014635
acid	I-Chemical	D014635
:	O	O
153	O	O
women	O	O
and	O	O
119	O	O
men	O	O
.	O	O

Confusion	B-Disease	D003221
mostly	O	O
occurred	O	O
during	O	O
the	O	O
two	O	O
first	O	O
weeks	O	O
following	O	O
valproic	B-Chemical	D014635
acid	I-Chemical	D014635
exposure	O	O
(	O	O
39	O	O
.	O	O

7%	O	O
)	O	O
.	O	O

It	O	O
was	O	O
"serious"	O	O
for	O	O
almost	O	O
2	O	O
/	O	O
3	O	O
of	O	O
the	O	O
patients	O	O
(	O	O
62	O	O
.	O	O

5%	O	O
)	O	O
and	O	O
its	O	O
outcome	O	O
favourable	O	O
in	O	O
most	O	O
of	O	O
the	O	O
cases	O	O
(	O	O
82%	O	O
)	O	O
.	O	O

The	O	O
occurrence	O	O
of	O	O
this	O	O
ADR	O	O
was	O	O
more	O	O
frequent	O	O
in	O	O
patients	O	O
aged	O	O
between	O	O
61	O	O
and	O	O
80	O	O
years	O	O
.	O	O

CONCLUSION	O	O
:	O	O
This	O	O
work	O	O
shows	O	O
that	O	O
confusion	B-Disease	D003221
with	O	O
valproic	B-Chemical	D014635
acid	I-Chemical	D014635
is	O	O
a	O	O
serious	O	O
,	O	O
rather	O	O
frequent	O	O
but	O	O
reversible	O	O
adverse	O	O
drug	O	O
reaction	O	O
.	O	O

It	O	O
occurs	O	O
especially	O	O
in	O	O
older	O	O
patients	O	O
and	O	O
during	O	O
the	O	O
first	O	O
two	O	O
weeks	O	O
of	O	O
treatment	O	O
.	O	O

Learning	O	O
and	O	O
memory	O	O
deficits	O	O
in	O	O
ecstasy	B-Chemical	D018817
users	O	O
and	O	O
their	O	O
neural	O	O
correlates	O	O
during	O	O
a	O	O
face	O	O
-	O	O
learning	O	O
task	O	O
.	O	O

It	O	O
has	O	O
been	O	O
consistently	O	O
shown	O	O
that	O	O
ecstasy	B-Chemical	D018817
users	O	O
display	O	O
impairments	O	O
in	O	O
learning	O	O
and	O	O
memory	O	O
performance	O	O
.	O	O

In	O	O
addition	O	O
,	O	O
working	O	O
memory	O	O
processing	O	O
in	O	O
ecstasy	B-Chemical	D018817
users	O	O
has	O	O
been	O	O
shown	O	O
to	O	O
be	O	O
associated	O	O
with	O	O
neural	O	O
alterations	O	O
in	O	O
hippocampal	O	O
and	O	O
/	O	O
or	O	O
cortical	O	O
regions	O	O
as	O	O
measured	O	O
by	O	O
functional	O	O
magnetic	O	O
resonance	O	O
imaging	O	O
(	O	O
fMRI	O	O
)	O	O
.	O	O

Using	O	O
functional	O	O
imaging	O	O
and	O	O
a	O	O
face	O	O
-	O	O
learning	O	O
task	O	O
,	O	O
we	O	O
investigated	O	O
neural	O	O
correlates	O	O
of	O	O
encoding	O	O
and	O	O
recalling	O	O
face	O	O
-	O	O
name	O	O
associations	O	O
in	O	O
20	O	O
recreational	O	O
drug	O	O
users	O	O
whose	O	O
predominant	O	O
drug	O	O
use	O	O
was	O	O
ecstasy	B-Chemical	D018817
and	O	O
20	O	O
controls	O	O
.	O	O

To	O	O
address	O	O
the	O	O
potential	O	O
confounding	O	O
effects	O	O
of	O	O
the	O	O
cannabis	B-Chemical	D002188
use	O	O
of	O	O
the	O	O
ecstasy	B-Chemical	D018817
using	O	O
group	O	O
,	O	O
a	O	O
second	O	O
analysis	O	O
included	O	O
14	O	O
previously	O	O
tested	O	O
cannabis	B-Chemical	D002188
users	O	O
(	O	O
Nestor	O	O
,	O	O
L	O	O
.	O	O

,	O	O
Roberts	O	O
,	O	O
G	O	O
.	O	O

,	O	O
Garavan	O	O
,	O	O
H	O	O
.	O	O

,	O	O
Hester	O	O
,	O	O
R	O	O
.	O	O

,	O	O
2008	O	O
.	O	O

Deficits	O	O
in	O	O
learning	O	O
and	O	O
memory	O	O
:	O	O
parahippocampal	O	O
hyperactivity	B-Disease	D006948
and	O	O
frontocortical	O	O
hypoactivity	O	O
in	O	O
cannabis	B-Chemical	D002188
users	O	O
.	O	O

Neuroimage	O	O
40	O	O
,	O	O
1328	O	O
-	O	O
1339	O	O
)	O	O
.	O	O

Ecstasy	B-Chemical	D018817
users	O	O
performed	O	O
significantly	O	O
worse	O	O
in	O	O
learning	O	O
and	O	O
memory	O	O
compared	O	O
to	O	O
controls	O	O
and	O	O
cannabis	B-Chemical	D002188
users	O	O
.	O	O

A	O	O
conjunction	O	O
analysis	O	O
of	O	O
the	O	O
encode	O	O
and	O	O
recall	O	O
phases	O	O
of	O	O
the	O	O
task	O	O
revealed	O	O
ecstasy	B-Chemical	D018817
-	O	O
specific	O	O
hyperactivity	B-Disease	D006948
in	O	O
bilateral	O	O
frontal	O	O
regions	O	O
,	O	O
left	O	O
temporal	O	O
,	O	O
right	O	O
parietal	O	O
,	O	O
bilateral	O	O
temporal	O	O
,	O	O
and	O	O
bilateral	O	O
occipital	O	O
brain	O	O
regions	O	O
.	O	O

Ecstasy	B-Chemical	D018817
-	O	O
specific	O	O
hypoactivity	O	O
was	O	O
evident	O	O
in	O	O
the	O	O
right	O	O
dorsal	O	O
anterior	O	O
cingulated	O	O
cortex	O	O
(	O	O
ACC	O	O
)	O	O
and	O	O
left	O	O
posterior	O	O
cingulated	O	O
cortex	O	O
.	O	O

In	O	O
both	O	O
ecstasy	B-Chemical	D018817
and	O	O
cannabis	B-Chemical	D002188
groups	O	O
brain	O	O
activation	O	O
was	O	O
decreased	O	O
in	O	O
the	O	O
right	O	O
medial	O	O
frontal	O	O
gyrus	O	O
,	O	O
left	O	O
parahippocampal	O	O
gyrus	O	O
,	O	O
left	O	O
dorsal	O	O
cingulate	O	O
gyrus	O	O
,	O	O
and	O	O
left	O	O
caudate	O	O
.	O	O

These	O	O
results	O	O
elucidated	O	O
ecstasy	B-Chemical	D018817
-	O	O
related	O	O
deficits	O	O
,	O	O
only	O	O
some	O	O
of	O	O
which	O	O
might	O	O
be	O	O
attributed	O	O
to	O	O
cannabis	B-Chemical	D002188
use	O	O
.	O	O

These	O	O
ecstasy	B-Chemical	D018817
-	O	O
specific	O	O
effects	O	O
may	O	O
be	O	O
related	O	O
to	O	O
the	O	O
vulnerability	O	O
of	O	O
isocortical	O	O
and	O	O
allocortical	O	O
regions	O	O
to	O	O
the	O	O
neurotoxic	B-Disease	D020258
effects	O	O
of	O	O
ecstasy	B-Chemical	D018817
.	O	O

Prolonged	O	O
elevation	O	O
of	O	O
plasma	O	O
argatroban	B-Chemical	C031942
in	O	O
a	O	O
cardiac	O	O
transplant	O	O
patient	O	O
with	O	O
a	O	O
suspected	O	O
history	O	O
of	O	O
heparin	B-Chemical	D006493
-	O	O
induced	O	O
thrombocytopenia	B-Disease	D013921
with	O	O
thrombosis	B-Disease	D013927
.	O	O

BACKGROUND	O	O
:	O	O
Direct	O	O
thrombin	O	O
inhibitors	O	O
(	O	O
DTIs	O	O
)	O	O
provide	O	O
an	O	O
alternative	O	O
method	O	O
of	O	O
anticoagulation	O	O
for	O	O
patients	O	O
with	O	O
a	O	O
history	O	O
of	O	O
heparin	B-Chemical	D006493
-	O	O
induced	O	O
thrombocytopenia	B-Disease	D013921
(	O	O
HIT	B-Disease	D013921
)	O	O
or	O	O
HIT	B-Disease	D013921
with	O	O
thrombosis	B-Disease	D013927
(	O	O
HITT	B-Disease	D013921
)	O	O
undergoing	O	O
cardiopulmonary	O	O
bypass	O	O
(	O	O
CPB	O	O
)	O	O
.	O	O

In	O	O
the	O	O
following	O	O
report	O	O
,	O	O
a	O	O
65	O	O
-	O	O
year	O	O
-	O	O
old	O	O
critically	B-Disease	D016638
ill	I-Disease	D016638
patient	O	O
with	O	O
a	O	O
suspected	O	O
history	O	O
of	O	O
HITT	B-Disease	D013921
was	O	O
administered	O	O
argatroban	B-Chemical	C031942
for	O	O
anticoagulation	O	O
on	O	O
bypass	O	O
during	O	O
heart	O	O
transplantation	O	O
.	O	O

The	O	O
patient	O	O
required	O	O
massive	O	O
transfusion	O	O
support	O	O
(	O	O
55	O	O
units	O	O
of	O	O
red	O	O
blood	O	O
cells	O	O
,	O	O
42	O	O
units	O	O
of	O	O
fresh	O	O
-	O	O
frozen	O	O
plasma	O	O
,	O	O
40	O	O
units	O	O
of	O	O
cryoprecipitate	O	O
,	O	O
40	O	O
units	O	O
of	O	O
platelets	O	O
,	O	O
and	O	O
three	O	O
doses	O	O
of	O	O
recombinant	O	O
Factor	O	O
VIIa	O	O
)	O	O
for	O	O
severe	O	O
intraoperative	O	O
and	O	O
postoperative	O	O
bleeding	O	O
.	O	O

STUDY	O	O
DESIGN	O	O
AND	O	O
METHODS	O	O
:	O	O
Plasma	O	O
samples	O	O
from	O	O
before	O	O
and	O	O
after	O	O
CPB	O	O
were	O	O
analyzed	O	O
postoperatively	O	O
for	O	O
argatroban	B-Chemical	C031942
concentration	O	O
using	O	O
a	O	O
modified	O	O
ecarin	O	O
clotting	O	O
time	O	O
(	O	O
ECT	O	O
)	O	O
assay	O	O
.	O	O

RESULTS	O	O
:	O	O
Unexpectedly	O	O
high	O	O
concentrations	O	O
of	O	O
argatroban	B-Chemical	C031942
were	O	O
measured	O	O
in	O	O
these	O	O
samples	O	O
(	O	O
range	O	O
,	O	O
0	O	O
-	O	O
32	O	O
microg	O	O
/	O	O
mL	O	O
)	O	O
,	O	O
and	O	O
a	O	O
prolonged	O	O
plasma	O	O
argatroban	B-Chemical	C031942
half	O	O
life	O	O
(	O	O
t	O	O
(	O	O
1	O	O
/	O	O
2	O	O
)	O	O
)	O	O
of	O	O
514	O	O
minutes	O	O
was	O	O
observed	O	O
(	O	O
published	O	O
elimination	O	O
t	O	O
(	O	O
1	O	O
/	O	O
2	O	O
)	O	O
is	O	O
39	O	O
-	O	O
51	O	O
minutes	O	O
[	O	O
<	O	O
or	O	O
=	O	O
181	O	O
minutes	O	O
with	O	O
hepatic	B-Disease	D008107
impairment	I-Disease	D008107
]	O	O
)	O	O
.	O	O

CONCLUSIONS	O	O
:	O	O
Correlation	O	O
of	O	O
plasma	O	O
argatroban	B-Chemical	C031942
concentration	O	O
versus	O	O
the	O	O
patient's	O	O
coagulation	O	O
variables	O	O
and	O	O
clinical	O	O
course	O	O
suggest	O	O
that	O	O
prolonged	O	O
elevated	O	O
levels	O	O
of	O	O
plasma	O	O
argatroban	B-Chemical	C031942
may	O	O
have	O	O
contributed	O	O
to	O	O
the	O	O
patient's	O	O
extended	O	O
coagulopathy	B-Disease	D001778
.	O	O

Because	O	O
DTIs	O	O
do	O	O
not	O	O
have	O	O
reversal	O	O
agents	O	O
,	O	O
surgical	O	O
teams	O	O
and	O	O
transfusion	O	O
services	O	O
should	O	O
remain	O	O
aware	O	O
of	O	O
the	O	O
possibility	O	O
of	O	O
massive	O	O
transfusion	O	O
events	O	O
during	O	O
anticoagulation	O	O
with	O	O
these	O	O
agents	O	O
.	O	O

This	O	O
is	O	O
the	O	O
first	O	O
report	O	O
to	O	O
measure	O	O
plasma	O	O
argatroban	B-Chemical	C031942
concentration	O	O
in	O	O
the	O	O
context	O	O
of	O	O
CPB	O	O
and	O	O
extended	O	O
coagulopathy	B-Disease	D001778
.	O	O

Antituberculosis	B-Chemical	D000995
therapy	O	O
-	O	O
induced	O	O
acute	B-Disease	D017114
liver	I-Disease	D017114
failure	I-Disease	D017114
:	O	O
magnitude	O	O
,	O	O
profile	O	O
,	O	O
prognosis	O	O
,	O	O
and	O	O
predictors	O	O
of	O	O
outcome	O	O
.	O	O

Antituberculosis	B-Chemical	D000995
therapy	O	O
(	O	O
ATT	O	O
)	O	O
-	O	O
associated	O	O
acute	B-Disease	D017114
liver	I-Disease	D017114
failure	I-Disease	D017114
(	O	O
ATT	O	O
-	O	O
ALF	B-Disease	D017114
)	O	O
is	O	O
the	O	O
commonest	O	O
drug	O	O
-	O	O
induced	O	O
ALF	B-Disease	D017114
in	O	O
South	O	O
Asia	O	O
.	O	O

Prospective	O	O
studies	O	O
on	O	O
ATT	O	O
-	O	O
ALF	B-Disease	D017114
are	O	O
lacking	O	O
.	O	O

The	O	O
current	O	O
study	O	O
prospectively	O	O
evaluated	O	O
the	O	O
magnitude	O	O
,	O	O
clinical	O	O
course	O	O
,	O	O
outcome	O	O
,	O	O
and	O	O
prognostic	O	O
factors	O	O
in	O	O
ATT	O	O
-	O	O
ALF	B-Disease	D017114
.	O	O

From	O	O
January	O	O
1986	O	O
to	O	O
January	O	O
2009	O	O
,	O	O
1223	O	O
consecutive	O	O
ALF	B-Disease	D017114
patients	O	O
were	O	O
evaluated	O	O
:	O	O
ATT	O	O
alone	O	O
was	O	O
the	O	O
cause	O	O
in	O	O
70	O	O
(	O	O
5	O	O
.	O	O

7%	O	O
)	O	O
patients	O	O
.	O	O

Another	O	O
15	O	O
(	O	O
1	O	O
.	O	O

2%	O	O
)	O	O
had	O	O
ATT	O	O
and	O	O
simultaneous	O	O
hepatitis	B-Disease	D006525
virus	I-Disease	D006525
infection	I-Disease	D006525
.	O	O

In	O	O
44	O	O
(	O	O
62	O	O
.	O	O

8%	O	O
)	O	O
patients	O	O
,	O	O
ATT	O	O
was	O	O
prescribed	O	O
empirically	O	O
without	O	O
definitive	O	O
evidence	O	O
of	O	O
tuberculosis	B-Disease	D014376
.	O	O

ATT	O	O
-	O	O
ALF	B-Disease	D017114
patients	O	O
were	O	O
younger	O	O
(	O	O
32	O	O
.	O	O

87	O	O
[	O	O
+	O	O
/	O	O
-	O	O
15	O	O
.	O	O

8	O	O
]	O	O
years	O	O
)	O	O
,	O	O
and	O	O
49	O	O
(	O	O
70%	O	O
)	O	O
of	O	O
them	O	O
were	O	O
women	O	O
.	O	O

Most	O	O
had	O	O
hyperacute	O	O
presentation	O	O
;	O	O
the	O	O
median	O	O
icterus	B-Disease	D007565
encephalopathy	B-Disease	D001927
interval	O	O
was	O	O
4	O	O
.	O	O

5	O	O
(	O	O
0	O	O
-	O	O
30	O	O
)	O	O
days	O	O
.	O	O

The	O	O
median	O	O
duration	O	O
of	O	O
ATT	O	O
before	O	O
ALF	B-Disease	D017114
was	O	O
30	O	O
(	O	O
7	O	O
-	O	O
350	O	O
)	O	O
days	O	O
.	O	O

At	O	O
presentation	O	O
,	O	O
advanced	O	O
encephalopathy	B-Disease	D001927
and	O	O
cerebral	B-Disease	D001929
edema	I-Disease	D001929
were	O	O
present	O	O
in	O	O
51	O	O
(	O	O
76%	O	O
)	O	O
and	O	O
29	O	O
(	O	O
41	O	O
.	O	O

4%	O	O
)	O	O
patients	O	O
,	O	O
respectively	O	O
.	O	O

Gastrointestinal	B-Disease	D006471
bleed	I-Disease	D006471
,	O	O
seizures	B-Disease	D012640
,	O	O
infection	B-Disease	D007239
,	O	O
and	O	O
acute	B-Disease	D058186
renal	I-Disease	D058186
failure	I-Disease	D058186
were	O	O
documented	O	O
in	O	O
seven	O	O
(	O	O
10%	O	O
)	O	O
,	O	O
five	O	O
(	O	O
7	O	O
.	O	O

1%	O	O
)	O	O
,	O	O
26	O	O
(	O	O
37	O	O
.	O	O

1%	O	O
)	O	O
,	O	O
and	O	O
seven	O	O
(	O	O
10%	O	O
)	O	O
patients	O	O
,	O	O
respectively	O	O
.	O	O

Compared	O	O
with	O	O
hepatitis	B-Disease	D016751
E	I-Disease	D016751
virus	O	O
(	O	O
HEV	O	O
)	O	O
and	O	O
non	O	O
-	O	O
A	O	O
non	O	O
-	O	O
E	O	O
-	O	O
induced	O	O
ALF	B-Disease	D017114
,	O	O
ATT	O	O
-	O	O
ALF	B-Disease	D017114
patients	O	O
had	O	O
nearly	O	O
similar	O	O
presentations	O	O
except	O	O
for	O	O
older	O	O
age	O	O
and	O	O
less	O	O
elevation	O	O
of	O	O
liver	O	O
enzymes	O	O
.	O	O

The	O	O
mortality	O	O
rate	O	O
among	O	O
patients	O	O
with	O	O
ATT	O	O
-	O	O
ALF	B-Disease	D017114
was	O	O
high	O	O
(	O	O
67	O	O
.	O	O

1%	O	O
,	O	O
n	O	O
=	O	O
47	O	O
)	O	O
,	O	O
and	O	O
only	O	O
23	O	O
(	O	O
32	O	O
.	O	O

9%	O	O
)	O	O
patients	O	O
recovered	O	O
with	O	O
medical	O	O
treatment	O	O
.	O	O

In	O	O
multivariate	O	O
analysis	O	O
,	O	O
three	O	O
factors	O	O
independently	O	O
predicted	O	O
mortality	O	O
:	O	O
serum	O	O
bilirubin	B-Chemical	D001663
(	O	O
>or=10	O	O
.	O	O

8	O	O
mg	O	O
/	O	O
dL	O	O
)	O	O
,	O	O
prothrombin	O	O
time	O	O
(	O	O
PT	O	O
)	O	O
prolongation	O	O
(	O	O
>or=26	O	O
seconds	O	O
)	O	O
,	O	O
and	O	O
grade	O	O
III	O	O
/	O	O
IV	O	O
encephalopathy	B-Disease	D001927
at	O	O
presentation	O	O
.	O	O

CONCLUSION	O	O
:	O	O
ATT	O	O
-	O	O
ALF	B-Disease	D017114
constituted	O	O
5	O	O
.	O	O

7%	O	O
of	O	O
ALF	B-Disease	D017114
at	O	O
our	O	O
center	O	O
and	O	O
had	O	O
a	O	O
high	O	O
mortality	O	O
rate	O	O
.	O	O

Because	O	O
the	O	O
mortality	O	O
rate	O	O
is	O	O
so	O	O
high	O	O
,	O	O
determining	O	O
which	O	O
factors	O	O
are	O	O
predictors	O	O
is	O	O
less	O	O
important	O	O
.	O	O

A	O	O
high	O	O
proportion	O	O
of	O	O
patients	O	O
had	O	O
consumed	O	O
ATT	O	O
empirically	O	O
,	O	O
which	O	O
could	O	O
have	O	O
been	O	O
prevented	O	O
.	O	O

Central	B-Disease	D002493
nervous	I-Disease	D002493
system	I-Disease	D002493
complications	I-Disease	D002493
during	O	O
treatment	O	O
of	O	O
acute	B-Disease	D054198
lymphoblastic	I-Disease	D054198
leukemia	I-Disease	D054198
in	O	O
a	O	O
single	O	O
pediatric	O	O
institution	O	O
.	O	O

Central	B-Disease	D002493
nervous	I-Disease	D002493
system	I-Disease	D002493
(	I-Disease	D002493
CNS	I-Disease	D002493
)	I-Disease	D002493
complications	I-Disease	D002493
during	O	O
treatment	O	O
of	O	O
childhood	O	O
acute	B-Disease	D054198
lymphoblastic	I-Disease	D054198
leukemia	I-Disease	D054198
(	O	O
ALL	B-Disease	D054198
)	O	O
remain	O	O
a	O	O
challenging	O	O
clinical	O	O
problem	O	O
.	O	O

Outcome	O	O
improvement	O	O
with	O	O
more	O	O
intensive	O	O
chemotherapy	O	O
has	O	O
significantly	O	O
increased	O	O
the	O	O
incidence	O	O
and	O	O
severity	O	O
of	O	O
adverse	O	O
events	O	O
.	O	O

This	O	O
study	O	O
analyzed	O	O
the	O	O
incidence	O	O
of	O	O
neurological	B-Disease	D002493
complications	I-Disease	D002493
during	O	O
ALL	B-Disease	D054198
treatment	O	O
in	O	O
a	O	O
single	O	O
pediatric	O	O
institution	O	O
,	O	O
focusing	O	O
on	O	O
clinical	O	O
,	O	O
radiological	O	O
,	O	O
and	O	O
electrophysiological	O	O
findings	O	O
.	O	O

Exclusion	O	O
criteria	O	O
included	O	O
CNS	O	O
leukemic	B-Disease	D017254
infiltration	I-Disease	D017254
at	O	O
diagnosis	O	O
,	O	O
therapy	O	O
-	O	O
related	O	O
peripheral	B-Disease	D010523
neuropathy	I-Disease	D010523
,	O	O
late	O	O
-	O	O
onset	O	O
encephalopathy	B-Disease	D001927
,	O	O
or	O	O
long	O	O
-	O	O
term	O	O
neurocognitive	B-Disease	D002493
defects	I-Disease	D002493
.	O	O

During	O	O
a	O	O
9	O	O
-	O	O
year	O	O
period	O	O
,	O	O
we	O	O
retrospectively	O	O
collected	O	O
27	O	O
neurological	O	O
events	O	O
(	O	O
11%	O	O
)	O	O
in	O	O
as	O	O
many	O	O
patients	O	O
,	O	O
from	O	O
253	O	O
children	O	O
enrolled	O	O
in	O	O
the	O	O
ALL	B-Disease	D054198
front	O	O
-	O	O
line	O	O
protocol	O	O
.	O	O

CNS	O	O
complications	O	O
included	O	O
posterior	O	O
reversible	O	O
leukoencephalopathy	B-Disease	D056784
syndrome	O	O
(	O	O
n	O	O
=	O	O
10	O	O
)	O	O
,	O	O
stroke	B-Disease	D020521
(	O	O
n	O	O
=	O	O
5	O	O
)	O	O
,	O	O
temporal	B-Disease	D004833
lobe	I-Disease	D004833
epilepsy	I-Disease	D004833
(	O	O
n	O	O
=	O	O
2	O	O
)	O	O
,	O	O
high	O	O
-	O	O
dose	O	O
methotrexate	B-Chemical	D008727
toxicity	B-Disease	D064420
(	O	O
n	O	O
=	O	O
2	O	O
)	O	O
,	O	O
syndrome	O	O
of	O	O
inappropriate	B-Disease	D007177
antidiuretic	I-Disease	D007177
hormone	I-Disease	D007177
secretion	I-Disease	D007177
(	O	O
n	O	O
=	O	O
1	O	O
)	O	O
,	O	O
and	O	O
other	O	O
unclassified	O	O
events	O	O
(	O	O
n	O	O
=	O	O
7	O	O
)	O	O
.	O	O

In	O	O
conclusion	O	O
,	O	O
CNS	O	O
complications	O	O
are	O	O
frequent	O	O
events	O	O
during	O	O
ALL	B-Disease	D054198
therapy	O	O
,	O	O
and	O	O
require	O	O
rapid	O	O
detection	O	O
and	O	O
prompt	O	O
treatment	O	O
to	O	O
limit	O	O
permanent	O	O
damage	O	O
.	O	O

Safety	O	O
of	O	O
capecitabine	B-Chemical	C110904
:	O	O
a	O	O
review	O	O
.	O	O

IMPORTANCE	O	O
OF	O	O
THE	O	O
FIELD	O	O
:	O	O
Fluoropyrimidines	B-Chemical	-1
,	O	O
in	O	O
particular	O	O
5	B-Chemical	D005472
-	I-Chemical	D005472
fluorouracil	I-Chemical	D005472
(	O	O
5	B-Chemical	D005472
-	I-Chemical	D005472
FU	I-Chemical	D005472
)	O	O
,	O	O
have	O	O
been	O	O
the	O	O
mainstay	O	O
of	O	O
treatment	O	O
for	O	O
several	O	O
solid	O	O
tumors	B-Disease	D009369
,	O	O
including	O	O
colorectal	O	O
,	O	O
breast	O	O
and	O	O
head	O	O
and	O	O
neck	O	O
cancers	O	O
,	O	O
for	O	O
>	O	O
40	O	O
years	O	O
.	O	O

AREAS	O	O
COVERED	O	O
IN	O	O
THIS	O	O
REVIEW	O	O
:	O	O
This	O	O
article	O	O
reviews	O	O
the	O	O
pharmacology	O	O
and	O	O
efficacy	O	O
of	O	O
capecitabine	B-Chemical	C110904
with	O	O
a	O	O
special	O	O
emphasis	O	O
on	O	O
its	O	O
safety	O	O
.	O	O

WHAT	O	O
THE	O	O
READER	O	O
WILL	O	O
GAIN	O	O
:	O	O
The	O	O
reader	O	O
will	O	O
gain	O	O
better	O	O
insight	O	O
into	O	O
the	O	O
safety	O	O
of	O	O
capecitabine	B-Chemical	C110904
in	O	O
special	O	O
populations	O	O
such	O	O
as	O	O
patients	O	O
with	O	O
advanced	O	O
age	O	O
,	O	O
renal	B-Disease	D007674
and	I-Disease	D007674
kidney	I-Disease	D007674
disease	I-Disease	D007674
.	O	O

We	O	O
also	O	O
explore	O	O
different	O	O
dosing	O	O
and	O	O
schedules	O	O
of	O	O
capecitabine	B-Chemical	C110904
administration	O	O
.	O	O

TAKE	O	O
HOME	O	O
MESSAGE	O	O
:	O	O
Capecitabine	B-Chemical	C110904
is	O	O
an	O	O
oral	O	O
prodrug	O	O
of	O	O
5	B-Chemical	D005472
-	I-Chemical	D005472
FU	I-Chemical	D005472
and	O	O
was	O	O
developed	O	O
to	O	O
fulfill	O	O
the	O	O
need	O	O
for	O	O
a	O	O
more	O	O
convenient	O	O
therapy	O	O
and	O	O
provide	O	O
an	O	O
improved	O	O
safety	O	O
/	O	O
efficacy	O	O
profile	O	O
.	O	O

It	O	O
has	O	O
shown	O	O
promising	O	O
results	O	O
alone	O	O
or	O	O
in	O	O
combination	O	O
with	O	O
other	O	O
chemotherapeutic	O	O
agents	O	O
in	O	O
colorectal	O	O
,	O	O
breast	O	O
,	O	O
pancreaticobiliary	O	O
,	O	O
gastric	O	O
,	O	O
renal	O	O
cell	O	O
and	O	O
head	O	O
and	O	O
neck	O	O
cancers	O	O
.	O	O

The	O	O
most	O	O
commonly	O	O
reported	O	O
toxic	O	O
effects	O	O
of	O	O
capecitabine	B-Chemical	C110904
are	O	O
diarrhea	B-Disease	D003967
,	O	O
nausea	B-Disease	D009325
,	O	O
vomiting	B-Disease	D014839
,	O	O
stomatitis	B-Disease	D013280
and	O	O
hand	B-Disease	D060831
-	I-Disease	D060831
foot	I-Disease	D060831
syndrome	I-Disease	D060831
.	O	O

Capecitabine	B-Chemical	C110904
has	O	O
a	O	O
well	O	O
-	O	O
established	O	O
safety	O	O
profile	O	O
and	O	O
can	O	O
be	O	O
given	O	O
safely	O	O
to	O	O
patients	O	O
with	O	O
advanced	O	O
age	O	O
,	O	O
hepatic	O	O
and	O	O
renal	O	O
dysfunctions	O	O
.	O	O

Effects	O	O
of	O	O
pallidal	O	O
neurotensin	B-Chemical	D009496
on	O	O
haloperidol	B-Chemical	D006220
-	O	O
induced	O	O
parkinsonian	B-Disease	D002375
catalepsy	I-Disease	D002375
:	O	O
behavioral	O	O
and	O	O
electrophysiological	O	O
studies	O	O
.	O	O

OBJECTIVE	O	O
:	O	O
The	O	O
globus	O	O
pallidus	O	O
plays	O	O
a	O	O
critical	O	O
role	O	O
in	O	O
movement	O	O
regulation	O	O
.	O	O

Previous	O	O
studies	O	O
have	O	O
indicated	O	O
that	O	O
the	O	O
globus	O	O
pallidus	O	O
receives	O	O
neurotensinergic	O	O
innervation	O	O
from	O	O
the	O	O
striatum	O	O
,	O	O
and	O	O
systemic	O	O
administration	O	O
of	O	O
a	O	O
neurotensin	B-Chemical	D009496
analog	O	O
could	O	O
produce	O	O
antiparkinsonian	O	O
effects	O	O
.	O	O

The	O	O
present	O	O
study	O	O
aimed	O	O
to	O	O
investigate	O	O
the	O	O
effects	O	O
of	O	O
pallidal	O	O
neurotensin	B-Chemical	D009496
on	O	O
haloperidol	B-Chemical	D006220
-	O	O
induced	O	O
parkinsonian	B-Disease	D010302
symptoms	I-Disease	D010302
.	O	O

METHODS	O	O
:	O	O
Behavioral	O	O
experiments	O	O
and	O	O
electrophysiological	O	O
recordings	O	O
were	O	O
performed	O	O
in	O	O
the	O	O
present	O	O
study	O	O
.	O	O

RESULTS	O	O
:	O	O
Bilateral	O	O
infusions	O	O
of	O	O
neurotensin	B-Chemical	D009496
into	O	O
the	O	O
globus	O	O
pallidus	O	O
reversed	O	O
haloperidol	B-Chemical	D006220
-	O	O
induced	O	O
parkinsonian	B-Disease	D002375
catalepsy	I-Disease	D002375
in	O	O
rats	O	O
.	O	O

Electrophysiological	O	O
recordings	O	O
showed	O	O
that	O	O
microinjection	O	O
of	O	O
neurotensin	B-Chemical	D009496
induced	O	O
excitation	O	O
of	O	O
pallidal	O	O
neurons	O	O
in	O	O
the	O	O
presence	O	O
of	O	O
systemic	O	O
haloperidol	B-Chemical	D006220
administration	O	O
.	O	O

The	O	O
neurotensin	B-Chemical	D009496
type	O	O
-	O	O
1	O	O
receptor	O	O
antagonist	O	O
SR48692	B-Chemical	C079087
blocked	O	O
both	O	O
the	O	O
behavioral	O	O
and	O	O
the	O	O
electrophysiological	O	O
effects	O	O
induced	O	O
by	O	O
neurotensin	B-Chemical	D009496
.	O	O

CONCLUSION	O	O
:	O	O
Activation	O	O
of	O	O
pallidal	O	O
neurotensin	B-Chemical	D009496
receptors	O	O
may	O	O
be	O	O
involved	O	O
in	O	O
neurotensin	B-Chemical	D009496
-	O	O
induced	O	O
antiparkinsonian	O	O
effects	O	O
.	O	O

Antihypertensive	O	O
drugs	O	O
and	O	O
depression	B-Disease	D003866
:	O	O
a	O	O
reappraisal	O	O
.	O	O

Eighty	O	O
-	O	O
nine	O	O
new	O	O
referral	O	O
hypertensive	B-Disease	D006973
out	O	O
-	O	O
patients	O	O
and	O	O
46	O	O
new	O	O
referral	O	O
non	O	O
-	O	O
hypertensive	B-Disease	D006973
chronically	O	O
physically	O	O
ill	O	O
out	O	O
-	O	O
patients	O	O
completed	O	O
a	O	O
mood	O	O
rating	O	O
scale	O	O
at	O	O
regular	O	O
intervals	O	O
for	O	O
one	O	O
year	O	O
.	O	O

The	O	O
results	O	O
showed	O	O
a	O	O
high	O	O
prevalence	O	O
of	O	O
depression	B-Disease	D003866
in	O	O
both	O	O
groups	O	O
of	O	O
patients	O	O
,	O	O
with	O	O
no	O	O
preponderance	O	O
in	O	O
the	O	O
hypertensive	B-Disease	D006973
group	O	O
.	O	O

Hypertensive	B-Disease	D006973
patients	O	O
with	O	O
psychiatric	B-Disease	D001523
histories	O	O
had	O	O
a	O	O
higher	O	O
prevalence	O	O
of	O	O
depression	B-Disease	D003866
than	O	O
the	O	O
comparison	O	O
patients	O	O
.	O	O

This	O	O
was	O	O
accounted	O	O
for	O	O
by	O	O
a	O	O
significant	O	O
number	O	O
of	O	O
depressions	B-Disease	D003866
occurring	O	O
in	O	O
methyl	B-Chemical	D008750
dopa	I-Chemical	D008750
treated	O	O
patients	O	O
with	O	O
psychiatric	B-Disease	D001523
histories	O	O
.	O	O

Pulmonary	O	O
shunt	O	O
and	O	O
cardiovascular	O	O
responses	O	O
to	O	O
CPAP	O	O
during	O	O
nitroprusside	B-Chemical	D009599
-	O	O
induced	O	O
hypotension	B-Disease	D007022
.	O	O

The	O	O
effects	O	O
of	O	O
continuous	O	O
positive	O	O
airway	O	O
pressure	O	O
(	O	O
CPAP	O	O
)	O	O
on	O	O
cardiovascular	O	O
dynamics	O	O
and	O	O
pulmonary	O	O
shunt	O	O
(	O	O
QS	O	O
/	O	O
QT	O	O
)	O	O
were	O	O
investigated	O	O
in	O	O
12	O	O
dogs	O	O
before	O	O
and	O	O
during	O	O
sodium	B-Chemical	D009599
nitroprusside	I-Chemical	D009599
infusion	O	O
that	O	O
decreased	O	O
mean	O	O
arterial	O	O
blood	O	O
pressure	O	O
40	O	O
-	O	O
50	O	O
per	O	O
cent	O	O
.	O	O

Before	O	O
nitroprusside	B-Chemical	D009599
infusion	O	O
,	O	O
5	O	O
cm	O	O
H2O	B-Chemical	D014867
CPAP	O	O
significantly	O	O
,	O	O
P	O	O
less	O	O
than	O	O
.	O	O

05	O	O
,	O	O
decreased	O	O
arterial	O	O
blood	O	O
pressure	O	O
,	O	O
but	O	O
did	O	O
not	O	O
significantly	O	O
alter	O	O
heart	O	O
rate	O	O
,	O	O
cardiac	O	O
output	O	O
,	O	O
systemic	O	O
vascular	O	O
resistance	O	O
,	O	O
or	O	O
QS	O	O
/	O	O
QT	O	O
.	O	O

Ten	O	O
cm	O	O
H2O	B-Chemical	D014867
CPAP	O	O
before	O	O
nitroprusside	B-Chemical	D009599
infusion	O	O
produced	O	O
a	O	O
further	O	O
decrease	B-Disease	D007022
in	I-Disease	D007022
arterial	I-Disease	D007022
blood	I-Disease	D007022
pressure	I-Disease	D007022
and	O	O
significantly	O	O
increased	O	O
heart	O	O
rate	O	O
and	O	O
decreased	B-Disease	D002303
cardiac	I-Disease	D002303
output	I-Disease	D002303
and	O	O
QS	O	O
/	O	O
QT	O	O
.	O	O

Nitroprusside	B-Chemical	D009599
caused	O	O
significant	O	O
decreases	B-Disease	D007022
in	I-Disease	D007022
arterial	I-Disease	D007022
blood	I-Disease	D007022
pressure	I-Disease	D007022
and	O	O
systemic	O	O
vascular	O	O
resistance	O	O
and	O	O
increases	O	O
in	O	O
heart	O	O
rate	O	O
,	O	O
but	O	O
did	O	O
not	O	O
change	O	O
cardiac	O	O
output	O	O
or	O	O
QS	O	O
/	O	O
QT	O	O
.	O	O

Five	O	O
cm	O	O
H2O	B-Chemical	D014867
CPAP	O	O
during	O	O
nitroprusside	B-Chemical	D009599
did	O	O
not	O	O
further	O	O
alter	O	O
any	O	O
of	O	O
the	O	O
above	O	O
-	O	O
mentioned	O	O
variables	O	O
.	O	O

However	O	O
,	O	O
10	O	O
cm	O	O
H2O	B-Chemical	D014867
CPAP	O	O
decreased	O	O
arterial	O	O
blood	O	O
pressure	O	O
,	O	O
cardiac	O	O
output	O	O
,	O	O
and	O	O
QS	O	O
/	O	O
QT	O	O
.	O	O

These	O	O
data	O	O
indicate	O	O
that	O	O
nitroprusside	B-Chemical	D009599
infusion	O	O
rates	O	O
that	O	O
decrease	O	O
mean	O	O
arterial	O	O
blood	O	O
pressure	O	O
by	O	O
40	O	O
-	O	O
50	O	O
per	O	O
cent	O	O
do	O	O
not	O	O
change	O	O
cardiac	O	O
output	O	O
or	O	O
QS	O	O
/	O	O
QT	O	O
.	O	O

During	O	O
nitroprusside	B-Chemical	D009599
infusion	O	O
low	O	O
levels	O	O
of	O	O
CPAP	O	O
do	O	O
not	O	O
markedly	O	O
alter	O	O
cardiovascular	O	O
dynamics	O	O
,	O	O
but	O	O
high	O	O
levels	O	O
of	O	O
CPAP	O	O
(	O	O
10	O	O
cm	O	O
H2O	B-Chemical	D014867
)	O	O
,	O	O
while	O	O
decreasing	O	O
QS	O	O
/	O	O
QT	O	O
,	O	O
produce	O	O
marked	O	O
decreases	B-Disease	D007022
in	I-Disease	D007022
arterial	I-Disease	D007022
blood	I-Disease	D007022
pressure	I-Disease	D007022
and	O	O
cardiac	O	O
output	O	O
.	O	O

Mediation	O	O
of	O	O
enhanced	O	O
reflex	O	O
vagal	O	O
bradycardia	B-Disease	D001919
by	O	O
L	B-Chemical	D007980
-	I-Chemical	D007980
dopa	I-Chemical	D007980
via	O	O
central	O	O
dopamine	B-Chemical	D004298
formation	O	O
in	O	O
dogs	O	O
.	O	O

L	B-Chemical	D007980
-	I-Chemical	D007980
Dopa	I-Chemical	D007980
(	O	O
5	O	O
mg	O	O
/	O	O
kg	O	O
i	O	O
.	O	O

v	O	O
.	O	O

)	O	O
decreased	O	O
blood	O	O
pressure	O	O
and	O	O
heart	O	O
rate	O	O
after	O	O
extracerebral	O	O
decarboxylase	O	O
inhibition	O	O
with	O	O
MK	B-Chemical	D002230
-	I-Chemical	D002230
486	I-Chemical	D002230
(	O	O
25	O	O
mg	O	O
/	O	O
kg	O	O
i	O	O
.	O	O

v	O	O
.	O	O

)	O	O
in	O	O
anesthetize	O	O
MAO	B-Chemical	D008995
-	O	O
inhibited	O	O
dogs	O	O
.	O	O

In	O	O
addition	O	O
,	O	O
reflex	O	O
bradycardia	B-Disease	D001919
caused	O	O
by	O	O
injected	O	O
norepinephrine	B-Chemical	D009638
was	O	O
significantly	O	O
enhanced	O	O
by	O	O
L	B-Chemical	D007980
-	I-Chemical	D007980
dopa	I-Chemical	D007980
,	O	O
DL	B-Chemical	D015103
-	I-Chemical	D015103
Threo	I-Chemical	D015103
-	I-Chemical	D015103
dihydroxyphenylserine	I-Chemical	D015103
had	O	O
no	O	O
effect	O	O
on	O	O
blood	O	O
pressure	O	O
,	O	O
heart	O	O
rate	O	O
or	O	O
reflex	O	O
responses	O	O
to	O	O
norepinephrine	B-Chemical	D009638
.	O	O

FLA	B-Chemical	D005406
-	I-Chemical	D005406
63	I-Chemical	D005406
,	O	O
a	O	O
dopamine	B-Chemical	D004298
-	O	O
beta	O	O
-	O	O
oxidase	O	O
inhibitor	O	O
,	O	O
did	O	O
not	O	O
have	O	O
any	O	O
effect	O	O
on	O	O
the	O	O
hypotension	B-Disease	D007022
,	O	O
bradycardia	B-Disease	D001919
or	O	O
reflex	O	O
-	O	O
enhancing	O	O
effect	O	O
of	O	O
L	B-Chemical	D007980
-	I-Chemical	D007980
dopa	I-Chemical	D007980
.	O	O

Pimozide	B-Chemical	D010868
did	O	O
not	O	O
affect	O	O
the	O	O
actions	O	O
of	O	O
L	B-Chemical	D007980
-	I-Chemical	D007980
dopa	I-Chemical	D007980
on	O	O
blood	O	O
pressure	O	O
and	O	O
heart	O	O
rate	O	O
but	O	O
completely	O	O
blocked	O	O
the	O	O
enhancement	O	O
of	O	O
reflexes	O	O
.	O	O

Removal	O	O
of	O	O
the	O	O
carotid	O	O
sinuses	O	O
caused	O	O
an	O	O
elevation	O	O
blood	O	O
pressure	O	O
and	O	O
heart	O	O
rate	O	O
and	O	O
abolished	O	O
the	O	O
negative	O	O
chronotropic	O	O
effect	O	O
of	O	O
norepinephrine	B-Chemical	D009638
.	O	O

However	O	O
,	O	O
L	B-Chemical	D007980
-	I-Chemical	D007980
dopa	I-Chemical	D007980
restored	O	O
the	O	O
bradycardia	B-Disease	D001919
caused	O	O
by	O	O
norepinephrine	B-Chemical	D009638
in	O	O
addition	O	O
to	O	O
decreasing	O	O
blood	O	O
pressure	O	O
and	O	O
heart	O	O
rate	O	O
.	O	O

5	B-Chemical	D006916
-	I-Chemical	D006916
HTP	I-Chemical	D006916
(	O	O
5	O	O
mg	O	O
/	O	O
kg	O	O
i	O	O
.	O	O

v	O	O
.	O	O

)	O	O
decreased	O	O
blood	O	O
pressure	O	O
and	O	O
heart	O	O
rate	O	O
and	O	O
decreased	O	O
the	O	O
reflex	O	O
bradycardia	B-Disease	D001919
to	O	O
norepinephrine	B-Chemical	D009638
.	O	O

It	O	O
is	O	O
concluded	O	O
that	O	O
L	B-Chemical	D007980
-	I-Chemical	D007980
dopa	I-Chemical	D007980
enhances	O	O
reflex	O	O
bradycardia	B-Disease	D001919
through	O	O
central	O	O
alpha	O	O
-	O	O
receptor	O	O
stimulation	O	O
.	O	O

Furthermore	O	O
,	O	O
the	O	O
effects	O	O
are	O	O
mediated	O	O
through	O	O
dopamine	B-Chemical	D004298
rather	O	O
than	O	O
norepinephrine	B-Chemical	D009638
and	O	O
do	O	O
not	O	O
require	O	O
the	O	O
carotid	O	O
sinus	O	O
baroreceptors	O	O
.	O	O

Cocaine	B-Chemical	D003042
-	O	O
induced	O	O
myocardial	B-Disease	D009203
infarction	I-Disease	D009203
:	O	O
clinical	O	O
observations	O	O
and	O	O
pathogenetic	O	O
considerations	O	O
.	O	O

Clinical	O	O
and	O	O
experimental	O	O
data	O	O
published	O	O
to	O	O
date	O	O
suggest	O	O
several	O	O
possible	O	O
mechanisms	O	O
by	O	O
which	O	O
cocaine	B-Chemical	D003042
may	O	O
result	O	O
in	O	O
acute	B-Disease	D009203
myocardial	I-Disease	D009203
infarction	I-Disease	D009203
.	O	O

In	O	O
individuals	O	O
with	O	O
preexisting	O	O
,	O	O
high	O	O
-	O	O
grade	O	O
coronary	O	O
arterial	O	O
narrowing	O	O
,	O	O
acute	B-Disease	D009203
myocardial	I-Disease	D009203
infarction	I-Disease	D009203
may	O	O
result	O	O
from	O	O
an	O	O
increase	O	O
in	O	O
myocardial	O	O
oxygen	B-Chemical	D010100
demand	O	O
associated	O	O
with	O	O
cocaine	B-Chemical	D003042
-	O	O
induced	O	O
increase	O	O
in	O	O
rate	O	O
-	O	O
pressure	O	O
product	O	O
.	O	O

In	O	O
other	O	O
individuals	O	O
with	O	O
no	O	O
underlying	O	O
atherosclerotic	B-Disease	D050197
obstruction	I-Disease	D050197
,	O	O
coronary	B-Disease	D054059
occlusion	I-Disease	D054059
may	O	O
be	O	O
due	O	O
to	O	O
spasm	B-Disease	D013035
,	O	O
thrombus	B-Disease	D013927
,	O	O
or	O	O
both	O	O
.	O	O

With	O	O
regard	O	O
to	O	O
spasm	B-Disease	D013035
,	O	O
the	O	O
clinical	O	O
findings	O	O
are	O	O
largely	O	O
circumstantial	O	O
,	O	O
and	O	O
the	O	O
locus	O	O
of	O	O
cocaine	B-Chemical	D003042
-	O	O
induced	O	O
vasoconstriction	O	O
remains	O	O
speculative	O	O
.	O	O

Although	O	O
certain	O	O
clinical	O	O
and	O	O
experimental	O	O
findings	O	O
support	O	O
the	O	O
hypothesis	O	O
that	O	O
spasm	B-Disease	D013035
involves	O	O
the	O	O
epicardial	O	O
,	O	O
medium	O	O
-	O	O
size	O	O
vessels	O	O
,	O	O
other	O	O
data	O	O
suggest	O	O
intramural	O	O
vasoconstriction	O	O
.	O	O

Diffuse	O	O
intramural	O	O
vasoconstriction	O	O
is	O	O
not	O	O
consistent	O	O
with	O	O
reports	O	O
of	O	O
segmental	O	O
,	O	O
discrete	O	O
infarction	B-Disease	D007238
.	O	O

Whereas	O	O
certain	O	O
in	O	O
vivo	O	O
data	O	O
suggest	O	O
that	O	O
these	O	O
effects	O	O
are	O	O
alpha	O	O
-	O	O
mediated	O	O
,	O	O
other	O	O
in	O	O
vitro	O	O
data	O	O
suggest	O	O
the	O	O
opposite	O	O
.	O	O

The	O	O
finding	O	O
of	O	O
cocaine	B-Chemical	D003042
-	O	O
induced	O	O
vasoconstriction	O	O
in	O	O
segments	O	O
of	O	O
(	O	O
noninnervated	O	O
)	O	O
human	O	O
umbilical	O	O
artery	O	O
suggests	O	O
that	O	O
the	O	O
presence	O	O
or	O	O
absence	O	O
of	O	O
intact	O	O
innervation	O	O
is	O	O
not	O	O
sufficient	O	O
to	O	O
explain	O	O
the	O	O
discrepant	O	O
data	O	O
involving	O	O
the	O	O
possibility	O	O
of	O	O
alpha	O	O
-	O	O
mediated	O	O
effects	O	O
.	O	O

Finally	O	O
,	O	O
the	O	O
contribution	O	O
of	O	O
a	O	O
primary	O	O
,	O	O
thrombotic	B-Disease	D013927
effect	O	O
of	O	O
cocaine	B-Chemical	D003042
has	O	O
not	O	O
been	O	O
excluded	O	O
.	O	O

Rabbit	B-Disease	D001480
syndrome	I-Disease	D001480
,	O	O
antidepressant	B-Chemical	D000928
use	O	O
,	O	O
and	O	O
cerebral	O	O
perfusion	O	O
SPECT	O	O
scan	O	O
findings	O	O
.	O	O

The	O	O
rabbit	B-Disease	D001480
syndrome	I-Disease	D001480
is	O	O
an	O	O
extrapyramidal	O	O
side	O	O
effect	O	O
associated	O	O
with	O	O
chronic	O	O
neuroleptic	O	O
therapy	O	O
.	O	O

Its	O	O
occurrence	O	O
in	O	O
a	O	O
patient	O	O
being	O	O
treated	O	O
with	O	O
imipramine	B-Chemical	D007099
is	O	O
described	O	O
,	O	O
representing	O	O
the	O	O
first	O	O
reported	O	O
case	O	O
of	O	O
this	O	O
syndrome	O	O
in	O	O
conjunction	O	O
with	O	O
antidepressants	B-Chemical	D000928
.	O	O

Repeated	O	O
cerebral	O	O
perfusion	O	O
SPECT	O	O
scans	O	O
revealed	O	O
decreased	B-Disease	D001480
basal	I-Disease	D001480
ganglia	I-Disease	D001480
perfusion	I-Disease	D001480
while	O	O
the	O	O
movement	B-Disease	D009069
disorder	I-Disease	D009069
was	O	O
present	O	O
,	O	O
and	O	O
a	O	O
return	O	O
to	O	O
normal	O	O
perfusion	O	O
when	O	O
the	O	O
rabbit	B-Disease	D001480
syndrome	I-Disease	D001480
resolved	O	O
.	O	O

Acute	O	O
bronchodilating	O	O
effects	O	O
of	O	O
ipratropium	B-Chemical	D009241
bromide	I-Chemical	D009241
and	O	O
theophylline	B-Chemical	D013806
in	O	O
chronic	B-Disease	D029424
obstructive	I-Disease	D029424
pulmonary	I-Disease	D029424
disease	I-Disease	D029424
.	O	O

The	O	O
bronchodilator	O	O
effects	O	O
of	O	O
a	O	O
single	O	O
dose	O	O
of	O	O
ipratropium	B-Chemical	D009241
bromide	I-Chemical	D009241
aerosol	O	O
(	O	O
36	O	O
micrograms	O	O
)	O	O
and	O	O
short	O	O
-	O	O
acting	O	O
theophylline	B-Chemical	D013806
tablets	O	O
(	O	O
dose	O	O
titrated	O	O
to	O	O
produce	O	O
serum	O	O
levels	O	O
of	O	O
10	O	O
-	O	O
20	O	O
micrograms	O	O
/	O	O
mL	O	O
)	O	O
were	O	O
compared	O	O
in	O	O
a	O	O
double	O	O
-	O	O
blind	O	O
,	O	O
placebo	O	O
-	O	O
controlled	O	O
crossover	O	O
study	O	O
in	O	O
21	O	O
patients	O	O
with	O	O
stable	O	O
,	O	O
chronic	B-Disease	D029424
obstructive	I-Disease	D029424
pulmonary	I-Disease	D029424
disease	I-Disease	D029424
.	O	O

Mean	O	O
peak	O	O
forced	O	O
expiratory	O	O
volume	O	O
in	O	O
1	O	O
second	O	O
(	O	O
FEV1	O	O
)	O	O
increases	O	O
over	O	O
baseline	O	O
and	O	O
the	O	O
proportion	O	O
of	O	O
patients	O	O
attaining	O	O
at	O	O
least	O	O
a	O	O
15%	O	O
increase	O	O
in	O	O
the	O	O
FEV1	O	O
(	O	O
responders	O	O
)	O	O
were	O	O
31%	O	O
and	O	O
90%	O	O
,	O	O
respectively	O	O
,	O	O
for	O	O
ipratropium	B-Chemical	D009241
and	O	O
17%	O	O
and	O	O
50%	O	O
,	O	O
respectively	O	O
,	O	O
for	O	O
theophylline	B-Chemical	D013806
.	O	O

The	O	O
average	O	O
FEV1	O	O
increases	O	O
during	O	O
the	O	O
6	O	O
-	O	O
hour	O	O
observation	O	O
period	O	O
were	O	O
18%	O	O
for	O	O
ipratropium	B-Chemical	D009241
and	O	O
8%	O	O
for	O	O
theophylline	B-Chemical	D013806
.	O	O

The	O	O
mean	O	O
duration	O	O
of	O	O
action	O	O
was	O	O
3	O	O
.	O	O

8	O	O
hours	O	O
with	O	O
ipratropium	B-Chemical	D009241
and	O	O
2	O	O
.	O	O

4	O	O
hours	O	O
with	O	O
theophylline	B-Chemical	D013806
.	O	O

While	O	O
side	O	O
effects	O	O
were	O	O
rare	O	O
,	O	O
those	O	O
experienced	O	O
after	O	O
theophylline	B-Chemical	D013806
use	O	O
did	O	O
involve	O	O
the	O	O
cardiovascular	O	O
and	O	O
gastrointestinal	O	O
systems	O	O
.	O	O

These	O	O
results	O	O
show	O	O
that	O	O
ipratropium	B-Chemical	D009241
is	O	O
a	O	O
more	O	O
potent	O	O
bronchodilator	O	O
than	O	O
oral	O	O
theophylline	B-Chemical	D013806
in	O	O
patients	O	O
with	O	O
chronic	B-Disease	D029424
airflow	I-Disease	D029424
obstruction	I-Disease	D029424
.	O	O

Irreversible	O	O
damage	O	O
to	O	O
the	O	O
medullary	O	O
interstitium	O	O
in	O	O
experimental	O	O
analgesic	O	O
nephropathy	B-Disease	D007674
in	O	O
F344	O	O
rats	O	O
.	O	O

Renal	B-Disease	D007681
papillary	I-Disease	D007681
necrosis	I-Disease	D007681
(	O	O
RPN	B-Disease	D007681
)	O	O
and	O	O
a	O	O
decreased	O	O
urinary	O	O
concentrating	O	O
ability	O	O
developed	O	O
during	O	O
continuous	O	O
long	O	O
-	O	O
term	O	O
treatment	O	O
with	O	O
aspirin	B-Chemical	D001241
and	O	O
paracetamol	B-Chemical	D000082
in	O	O
female	O	O
Fischer	O	O
344	O	O
rats	O	O
.	O	O

Renal	O	O
structure	O	O
and	O	O
concentrating	O	O
ability	O	O
were	O	O
examined	O	O
after	O	O
a	O	O
recovery	O	O
period	O	O
of	O	O
up	O	O
to	O	O
18	O	O
weeks	O	O
,	O	O
when	O	O
no	O	O
analgesics	O	O
were	O	O
given	O	O
,	O	O
to	O	O
investigate	O	O
whether	O	O
the	O	O
analgesic	O	O
-	O	O
induced	O	O
changes	O	O
were	O	O
reversible	O	O
.	O	O

There	O	O
was	O	O
no	O	O
evidence	O	O
of	O	O
repair	O	O
to	O	O
the	O	O
damaged	O	O
medullary	O	O
interstitial	O	O
matrix	O	O
,	O	O
or	O	O
proliferation	O	O
of	O	O
remaining	O	O
undamaged	O	O
type	O	O
1	O	O
medullary	O	O
interstitial	O	O
cells	O	O
after	O	O
the	O	O
recovery	O	O
period	O	O
following	O	O
analgesic	O	O
treatment	O	O
.	O	O

The	O	O
recovery	O	O
of	O	O
urinary	O	O
concentrating	O	O
ability	O	O
was	O	O
related	O	O
to	O	O
the	O	O
length	O	O
of	O	O
analgesic	O	O
treatment	O	O
and	O	O
the	O	O
extent	O	O
of	O	O
the	O	O
resulting	O	O
inner	O	O
medullary	O	O
structural	O	O
damage	O	O
.	O	O

During	O	O
the	O	O
early	O	O
stages	O	O
of	O	O
analgesic	O	O
treatment	O	O
,	O	O
the	O	O
changes	O	O
in	O	O
urinary	O	O
concentrating	O	O
ability	O	O
were	O	O
reversible	O	O
,	O	O
but	O	O
after	O	O
prolonged	O	O
analgesic	O	O
treatment	O	O
,	O	O
maximum	O	O
urinary	O	O
concentrating	O	O
ability	O	O
failed	O	O
to	O	O
recover	O	O
.	O	O

This	O	O
study	O	O
shows	O	O
that	O	O
prolonged	O	O
analgesic	O	O
treatment	O	O
in	O	O
Fischer	O	O
344	O	O
rats	O	O
causes	O	O
progressive	O	O
and	O	O
irreversible	O	O
damage	O	O
to	O	O
the	O	O
interstitial	O	O
matrix	O	O
and	O	O
type	O	O
1	O	O
interstitial	O	O
cells	O	O
leading	O	O
to	O	O
RPN	B-Disease	D007681
.	O	O

The	O	O
associated	O	O
urinary	O	O
concentrating	O	O
defect	O	O
is	O	O
reversible	O	O
only	O	O
during	O	O
the	O	O
early	O	O
stages	O	O
of	O	O
structural	O	O
damage	O	O
to	O	O
the	O	O
inner	O	O
medulla	O	O
.	O	O

Less	O	O
frequent	O	O
lithium	B-Chemical	D008094
administration	O	O
and	O	O
lower	O	O
urine	O	O
volume	O	O
.	O	O

OBJECTIVE	O	O
:	O	O
This	O	O
study	O	O
was	O	O
designed	O	O
to	O	O
determine	O	O
whether	O	O
patients	O	O
maintained	O	O
on	O	O
a	O	O
regimen	O	O
of	O	O
lithium	B-Chemical	D008094
on	O	O
a	O	O
once	O	O
-	O	O
per	O	O
-	O	O
day	O	O
schedule	O	O
have	O	O
lower	O	O
urine	O	O
volumes	O	O
than	O	O
do	O	O
patients	O	O
receiving	O	O
multiple	O	O
doses	O	O
per	O	O
day	O	O
.	O	O

METHOD	O	O
:	O	O
This	O	O
was	O	O
a	O	O
cross	O	O
-	O	O
sectional	O	O
study	O	O
of	O	O
85	O	O
patients	O	O
from	O	O
a	O	O
lithium	B-Chemical	D008094
clinic	O	O
who	O	O
received	O	O
different	O	O
dose	O	O
schedules	O	O
.	O	O

Patients	O	O
were	O	O
admitted	O	O
to	O	O
the	O	O
hospital	O	O
for	O	O
measurement	O	O
of	O	O
lithium	B-Chemical	D008094
level	O	O
,	O	O
creatinine	B-Chemical	D003404
clearance	O	O
,	O	O
urine	O	O
volume	O	O
,	O	O
and	O	O
maximum	O	O
osmolality	O	O
.	O	O

RESULTS	O	O
:	O	O
Multiple	O	O
daily	O	O
doses	O	O
of	O	O
lithium	B-Chemical	D008094
were	O	O
associated	O	O
with	O	O
higher	O	O
urine	O	O
volumes	O	O
.	O	O

The	O	O
dosing	O	O
schedule	O	O
,	O	O
duration	O	O
of	O	O
lithium	B-Chemical	D008094
treatment	O	O
,	O	O
and	O	O
daily	O	O
dose	O	O
of	O	O
lithium	B-Chemical	D008094
did	O	O
not	O	O
affect	O	O
maximum	O	O
osmolality	O	O
or	O	O
creatinine	B-Chemical	D003404
clearance	O	O
.	O	O

CONCLUSIONS	O	O
:	O	O
Urine	O	O
volume	O	O
can	O	O
be	O	O
reduced	O	O
by	O	O
giving	O	O
lithium	B-Chemical	D008094
once	O	O
daily	O	O
and	O	O
/	O	O
or	O	O
by	O	O
lowering	O	O
the	O	O
total	O	O
daily	O	O
dose	O	O
.	O	O

Lithium	B-Chemical	D008094
-	O	O
induced	O	O
polyuria	B-Disease	D011141
seems	O	O
to	O	O
be	O	O
related	O	O
to	O	O
extrarenal	O	O
as	O	O
well	O	O
as	O	O
to	O	O
renal	O	O
effects	O	O
.	O	O

Effect	O	O
of	O	O
adriamycin	B-Chemical	D004317
combined	O	O
with	O	O
whole	O	O
body	O	O
hyperthermia	B-Disease	D005334
on	O	O
tumor	B-Disease	D009369
and	O	O
normal	O	O
tissues	O	O
.	O	O

Thermal	O	O
enhancement	O	O
of	O	O
Adriamycin	B-Chemical	D004317
-	O	O
mediated	O	O
antitumor	O	O
activity	O	O
and	O	O
normal	O	O
tissue	O	O
toxicities	B-Disease	D064420
by	O	O
whole	O	O
body	O	O
hyperthermia	B-Disease	D005334
were	O	O
compared	O	O
using	O	O
a	O	O
F344	O	O
rat	O	O
model	O	O
.	O	O

Antitumor	O	O
activity	O	O
was	O	O
studied	O	O
using	O	O
a	O	O
tumor	B-Disease	D009369
growth	O	O
delay	O	O
assay	O	O
.	O	O

Acute	O	O
normal	O	O
tissue	O	O
toxicities	B-Disease	D064420
(	O	O
i	O	O
.	O	O

e	O	O
.	O	O

,	O	O
leukopenia	B-Disease	D007970
and	O	O
thrombocytopenia	B-Disease	D013921
)	O	O
and	O	O
late	O	O
normal	O	O
tissue	O	O
toxicities	B-Disease	D064420
(	O	O
i	O	O
.	O	O

e	O	O
.	O	O

,	O	O
myocardial	O	O
and	O	O
kidney	O	O
injury	O	O
)	O	O
were	O	O
evaluated	O	O
by	O	O
functional	O	O
/	O	O
physiological	O	O
assays	O	O
and	O	O
by	O	O
morphological	O	O
techniques	O	O
.	O	O

Whole	O	O
body	O	O
hyperthermia	B-Disease	D005334
(	O	O
120	O	O
min	O	O
at	O	O
41	O	O
.	O	O

5	O	O
degrees	O	O
C	O	O
)	O	O
enhanced	O	O
both	O	O
Adriamycin	B-Chemical	D004317
-	O	O
mediated	O	O
antitumor	O	O
activity	O	O
and	O	O
toxic	O	O
side	O	O
effects	O	O
.	O	O

The	O	O
thermal	O	O
enhancement	O	O
ratio	O	O
calculated	O	O
for	O	O
antitumor	O	O
activity	O	O
was	O	O
1	O	O
.	O	O

6	O	O
.	O	O

Thermal	O	O
enhancement	O	O
ratios	O	O
estimated	O	O
for	O	O
"acute"	O	O
hematological	O	O
changes	O	O
were	O	O
1	O	O
.	O	O

3	O	O
,	O	O
whereas	O	O
those	O	O
estimated	O	O
for	O	O
"late"	O	O
damage	O	O
(	O	O
based	O	O
on	O	O
morphological	O	O
cardiac	O	O
and	O	O
renal	O	O
lesions	O	O
)	O	O
varied	O	O
between	O	O
2	O	O
.	O	O

4	O	O
and	O	O
4	O	O
.	O	O

3	O	O
.	O	O

Thus	O	O
,	O	O
while	O	O
whole	O	O
body	O	O
hyperthermia	B-Disease	D005334
enhances	O	O
Adriamycin	B-Chemical	D004317
-	O	O
mediated	O	O
antitumor	O	O
effect	O	O
,	O	O
normal	O	O
tissue	O	O
toxicity	B-Disease	D064420
is	O	O
also	O	O
increased	O	O
,	O	O
and	O	O
the	O	O
potential	O	O
therapeutic	O	O
gain	O	O
of	O	O
the	O	O
combined	O	O
modality	O	O
treatment	O	O
is	O	O
eroded	O	O
.	O	O

Prazosin	B-Chemical	D011224
-	O	O
induced	O	O
stress	B-Disease	D014550
incontinence	I-Disease	D014550
.	O	O

A	O	O
case	O	O
of	O	O
genuine	O	O
stress	B-Disease	D014550
incontinence	I-Disease	D014550
due	O	O
to	O	O
prazosin	B-Chemical	D011224
,	O	O
a	O	O
common	O	O
antihypertensive	O	O
drug	O	O
,	O	O
is	O	O
presented	O	O
.	O	O

Prazosin	B-Chemical	D011224
exerts	O	O
its	O	O
antihypertensive	O	O
effects	O	O
through	O	O
vasodilatation	O	O
caused	O	O
by	O	O
selective	O	O
blockade	O	O
of	O	O
postsynaptic	O	O
alpha	O	O
-	O	O
1	O	O
adrenergic	O	O
receptors	O	O
.	O	O

As	O	O
an	O	O
alpha	O	O
-	O	O
blocker	O	O
,	O	O
it	O	O
also	O	O
exerts	O	O
a	O	O
significant	O	O
relaxant	O	O
effect	O	O
on	O	O
the	O	O
bladder	O	O
neck	O	O
and	O	O
urethra	O	O
.	O	O

The	O	O
patient's	O	O
clinical	O	O
course	O	O
is	O	O
described	O	O
and	O	O
correlated	O	O
with	O	O
initial	O	O
urodynamic	O	O
studies	O	O
while	O	O
on	O	O
prazosin	B-Chemical	D011224
and	O	O
subsequent	O	O
studies	O	O
while	O	O
taking	O	O
verapamil	B-Chemical	D014700
.	O	O

Her	O	O
incontinence	B-Disease	D014549
resolved	O	O
with	O	O
the	O	O
change	O	O
of	O	O
medication	O	O
.	O	O

The	O	O
restoration	O	O
of	O	O
continence	O	O
was	O	O
accompanied	O	O
by	O	O
a	O	O
substantial	O	O
rise	O	O
in	O	O
maximum	O	O
urethral	O	O
pressure	O	O
,	O	O
maximum	O	O
urethral	O	O
closure	O	O
pressure	O	O
,	O	O
and	O	O
functional	O	O
urethral	O	O
length	O	O
.	O	O

Patients	O	O
who	O	O
present	O	O
with	O	O
stress	B-Disease	D014550
incontinence	I-Disease	D014550
while	O	O
taking	O	O
prazosin	B-Chemical	D011224
should	O	O
change	O	O
their	O	O
antihypertensive	O	O
medication	O	O
before	O	O
considering	O	O
surgery	O	O
,	O	O
because	O	O
their	O	O
incontinence	B-Disease	D014549
may	O	O
resolve	O	O
spontaneously	O	O
with	O	O
a	O	O
change	O	O
in	O	O
drug	O	O
therapy	O	O
.	O	O

Myocardial	B-Disease	D009203
infarction	I-Disease	D009203
following	O	O
sublingual	O	O
administration	O	O
of	O	O
isosorbide	B-Chemical	D007548
dinitrate	I-Chemical	D007548
.	O	O

A	O	O
78	O	O
-	O	O
year	O	O
-	O	O
old	O	O
with	O	O
healed	O	O
septal	O	O
necrosis	B-Disease	D009336
suffered	O	O
a	O	O
recurrent	O	O
myocardial	B-Disease	D009203
infarction	I-Disease	D009203
of	O	O
the	O	O
anterior	O	O
wall	O	O
following	O	O
the	O	O
administration	O	O
of	O	O
isosorbide	B-Chemical	D007548
dinitrate	I-Chemical	D007548
5	O	O
mg	O	O
sublingually	O	O
.	O	O

After	O	O
detailing	O	O
the	O	O
course	O	O
of	O	O
events	O	O
,	O	O
we	O	O
discuss	O	O
the	O	O
role	O	O
of	O	O
paradoxical	O	O
coronary	O	O
spasm	B-Disease	D013035
and	O	O
hypotension	B-Disease	D007022
-	O	O
mediated	O	O
myocardial	B-Disease	D017202
ischemia	I-Disease	D017202
occurring	O	O
downstream	O	O
to	O	O
significant	O	O
coronary	B-Disease	D023921
arterial	I-Disease	D023921
stenosis	I-Disease	D023921
in	O	O
the	O	O
pathophysiology	O	O
of	O	O
acute	B-Disease	D054058
coronary	I-Disease	D054058
insufficiency	I-Disease	D054058
.	O	O

Fluoxetine	B-Chemical	D005473
-	O	O
induced	O	O
akathisia	B-Disease	D017109
:	O	O
clinical	O	O
and	O	O
theoretical	O	O
implications	O	O
.	O	O

Five	O	O
patients	O	O
receiving	O	O
fluoxetine	B-Chemical	D005473
for	O	O
the	O	O
treatment	O	O
of	O	O
obsessive	B-Disease	D009771
compulsive	I-Disease	D009771
disorder	I-Disease	D009771
or	O	O
major	B-Disease	D003865
depression	I-Disease	D003865
developed	O	O
akathisia	B-Disease	D017109
.	O	O

The	O	O
typical	O	O
fluoxetine	B-Chemical	D005473
-	O	O
induced	O	O
symptoms	O	O
of	O	O
restlessness	O	O
,	O	O
constant	O	O
pacing	O	O
,	O	O
purposeless	O	O
movements	O	O
of	O	O
the	O	O
feet	O	O
and	O	O
legs	O	O
,	O	O
and	O	O
marked	O	O
anxiety	B-Disease	D001008
were	O	O
indistinguishable	O	O
from	O	O
those	O	O
of	O	O
neuroleptic	O	O
-	O	O
induced	O	O
akathisia	B-Disease	D017109
.	O	O

Three	O	O
patients	O	O
who	O	O
had	O	O
experienced	O	O
neuroleptic	O	O
-	O	O
induced	O	O
akathisia	B-Disease	D017109
in	O	O
the	O	O
past	O	O
reported	O	O
that	O	O
the	O	O
symptoms	O	O
of	O	O
fluoxetine	B-Chemical	D005473
-	O	O
induced	O	O
akathisia	B-Disease	D017109
were	O	O
identical	O	O
,	O	O
although	O	O
somewhat	O	O
milder	O	O
.	O	O

Akathisia	B-Disease	D017109
appeared	O	O
to	O	O
be	O	O
a	O	O
common	O	O
side	O	O
effect	O	O
of	O	O
fluoxetine	B-Chemical	D005473
and	O	O
generally	O	O
responded	O	O
well	O	O
to	O	O
treatment	O	O
with	O	O
the	O	O
beta	O	O
-	O	O
adrenergic	O	O
antagonist	O	O
propranolol	B-Chemical	D011433
,	O	O
dose	O	O
reduction	O	O
,	O	O
or	O	O
both	O	O
.	O	O

The	O	O
authors	O	O
suggest	O	O
that	O	O
fluoxetine	B-Chemical	D005473
-	O	O
induced	O	O
akathisia	B-Disease	D017109
may	O	O
be	O	O
caused	O	O
by	O	O
serotonergically	O	O
mediated	O	O
inhibition	O	O
of	O	O
dopaminergic	O	O
neurotransmission	O	O
and	O	O
that	O	O
the	O	O
pathophysiology	O	O
of	O	O
fluoxetine	B-Chemical	D005473
-	O	O
induced	O	O
akathisia	B-Disease	D017109
and	O	O
tricyclic	O	O
antidepressant	B-Chemical	D000928
-	O	O
induced	O	O
"jitteriness"	O	O
may	O	O
be	O	O
identical	O	O
.	O	O

Chronic	B-Disease	D006521
active	I-Disease	D006521
hepatitis	I-Disease	D006521
associated	O	O
with	O	O
diclofenac	B-Chemical	D004008
sodium	I-Chemical	D004008
therapy	O	O
.	O	O

Diclofenac	B-Chemical	D004008
sodium	I-Chemical	D004008
(	O	O
Voltarol	B-Chemical	D004008
,	O	O
Geigy	O	O
Pharmaceuticals	O	O
)	O	O
is	O	O
a	O	O
non	O	O
-	O	O
steroidal	O	O
anti	O	O
-	O	O
inflammatory	O	O
derivative	O	O
of	O	O
phenylacetic	B-Chemical	C025136
acid	I-Chemical	C025136
.	O	O

Although	O	O
generally	O	O
well	O	O
-	O	O
tolerated	O	O
,	O	O
asymptomatic	O	O
abnormalities	B-Disease	D056486
of	I-Disease	D056486
liver	I-Disease	D056486
function	I-Disease	D056486
have	O	O
been	O	O
recorded	O	O
and	O	O
,	O	O
less	O	O
commonly	O	O
,	O	O
severe	O	O
hepatitis	B-Disease	D056486
induced	O	O
by	O	O
diclofenac	B-Chemical	D004008
.	O	O

The	O	O
patient	O	O
described	O	O
developed	O	O
chronic	B-Disease	D006521
active	I-Disease	D006521
hepatitis	I-Disease	D006521
after	O	O
six	O	O
months	O	O
therapy	O	O
with	O	O
diclofenac	B-Chemical	D004008
sodium	I-Chemical	D004008
which	O	O
progressed	O	O
despite	O	O
the	O	O
withdrawal	O	O
of	O	O
the	O	O
drug	O	O
,	O	O
a	O	O
finding	O	O
not	O	O
previously	O	O
reported	O	O
.	O	O

Stroke	B-Disease	D020521
associated	O	O
with	O	O
cocaine	B-Chemical	D003042
use	O	O
.	O	O

We	O	O
describe	O	O
eight	O	O
patients	O	O
in	O	O
whom	O	O
cocaine	B-Chemical	D003042
use	O	O
was	O	O
related	O	O
to	O	O
stroke	B-Disease	D020521
and	O	O
review	O	O
39	O	O
cases	O	O
from	O	O
the	O	O
literature	O	O
.	O	O

Among	O	O
these	O	O
47	O	O
patients	O	O
the	O	O
mean	O	O
(	O	O
+	O	O
/	O	O
-	O	O
SD	O	O
)	O	O
age	O	O
was	O	O
32	O	O
.	O	O

5	O	O
+	O	O
/	O	O
-	O	O
12	O	O
.	O	O

1	O	O
years	O	O
;	O	O
76%	O	O
(	O	O
34	O	O
/	O	O
45	O	O
)	O	O
were	O	O
men	O	O
.	O	O

Stroke	B-Disease	D020521
followed	O	O
cocaine	B-Chemical	D003042
use	O	O
by	O	O
inhalation	O	O
,	O	O
intranasal	O	O
,	O	O
intravenous	O	O
,	O	O
and	O	O
intramuscular	O	O
routes	O	O
.	O	O

Intracranial	B-Disease	D002532
aneurysms	I-Disease	D002532
or	O	O
arteriovenous	B-Disease	D001165
malformations	I-Disease	D001165
were	O	O
present	O	O
in	O	O
17	O	O
of	O	O
32	O	O
patients	O	O
studied	O	O
angiographically	O	O
or	O	O
at	O	O
autopsy	O	O
;	O	O
cerebral	B-Disease	D020293
vasculitis	I-Disease	D020293
was	O	O
present	O	O
in	O	O
two	O	O
patients	O	O
.	O	O

Cerebral	B-Disease	D002544
infarction	I-Disease	D002544
occurred	O	O
in	O	O
10	O	O
patients	O	O
(	O	O
22%	O	O
)	O	O
,	O	O
intracerebral	B-Disease	D002543
hemorrhage	I-Disease	D002543
in	O	O
22	O	O
(	O	O
49%	O	O
)	O	O
,	O	O
and	O	O
subarachnoid	B-Disease	D013345
hemorrhage	I-Disease	D013345
in	O	O
13	O	O
(	O	O
29%	O	O
)	O	O
.	O	O

These	O	O
data	O	O
indicate	O	O
that	O	O
(	O	O
1	O	O
)	O	O
the	O	O
apparent	O	O
incidence	O	O
of	O	O
stroke	B-Disease	D020521
related	O	O
to	O	O
cocaine	B-Chemical	D003042
use	O	O
is	O	O
increasing	O	O
;	O	O
(	O	O
2	O	O
)	O	O
cocaine	B-Chemical	D003042
-	O	O
associated	O	O
stroke	B-Disease	D020521
occurs	O	O
primarily	O	O
in	O	O
young	O	O
adults	O	O
;	O	O
(	O	O
3	O	O
)	O	O
stroke	B-Disease	D020521
may	O	O
follow	O	O
any	O	O
route	O	O
of	O	O
cocaine	B-Chemical	D003042
administration	O	O
;	O	O
(	O	O
4	O	O
)	O	O
stroke	B-Disease	D020521
after	O	O
cocaine	B-Chemical	D003042
use	O	O
is	O	O
frequently	O	O
associated	O	O
with	O	O
intracranial	B-Disease	D002532
aneurysms	I-Disease	D002532
and	O	O
arteriovenous	B-Disease	D001165
malformations	I-Disease	D001165
;	O	O
and	O	O
(	O	O
5	O	O
)	O	O
in	O	O
cocaine	B-Chemical	D003042
-	O	O
associated	O	O
stroke	B-Disease	D020521
,	O	O
the	O	O
frequency	O	O
of	O	O
intracranial	B-Disease	D020300
hemorrhage	I-Disease	D020300
exceeds	O	O
that	O	O
of	O	O
cerebral	B-Disease	D002544
infarction	I-Disease	D002544
.	O	O

Glyburide	B-Chemical	D005905
-	O	O
induced	O	O
hepatitis	B-Disease	D056486
.	O	O

Drug	O	O
-	O	O
induced	O	O
hepatotoxicity	B-Disease	D056486
,	O	O
although	O	O
common	O	O
,	O	O
has	O	O
been	O	O
reported	O	O
only	O	O
infrequently	O	O
with	O	O
sulfonylureas	B-Chemical	D013453
.	O	O

For	O	O
glyburide	B-Chemical	D005905
,	O	O
a	O	O
second	O	O
-	O	O
generation	O	O
sulfonylurea	B-Chemical	D013453
,	O	O
only	O	O
two	O	O
brief	O	O
reports	O	O
of	O	O
hepatotoxicity	B-Disease	D056486
exist	O	O
.	O	O

Two	O	O
patients	O	O
with	O	O
type	B-Disease	D003924
II	I-Disease	D003924
diabetes	I-Disease	D003924
mellitus	I-Disease	D003924
developed	O	O
an	O	O
acute	B-Disease	D056486
hepatitis	I-Disease	D056486
-	I-Disease	D056486
like	I-Disease	D056486
syndrome	I-Disease	D056486
soon	O	O
after	O	O
initiation	O	O
of	O	O
glyburide	B-Chemical	D005905
therapy	O	O
.	O	O

There	O	O
was	O	O
no	O	O
serologic	O	O
evidence	O	O
of	O	O
viral	B-Disease	D014777
infection	I-Disease	D014777
,	O	O
and	O	O
a	O	O
liver	O	O
biopsy	O	O
sample	O	O
showed	O	O
a	O	O
histologic	O	O
pattern	O	O
consistent	O	O
with	O	O
drug	B-Disease	D056486
-	I-Disease	D056486
induced	I-Disease	D056486
hepatitis	I-Disease	D056486
.	O	O

Both	O	O
patients	O	O
recovered	O	O
quickly	O	O
after	O	O
stopping	O	O
glyburide	B-Chemical	D005905
therapy	O	O
and	O	O
have	O	O
remained	O	O
well	O	O
for	O	O
a	O	O
follow	O	O
-	O	O
up	O	O
period	O	O
of	O	O
1	O	O
year	O	O
.	O	O

Glyburide	B-Chemical	D005905
can	O	O
produce	O	O
an	O	O
acute	B-Disease	D056486
hepatitis	I-Disease	D056486
-	I-Disease	D056486
like	I-Disease	D056486
illness	I-Disease	D056486
in	O	O
some	O	O
persons	O	O
.	O	O

Systolic	O	O
pressure	O	O
variation	O	O
is	O	O
greater	O	O
during	O	O
hemorrhage	B-Disease	D006470
than	O	O
during	O	O
sodium	B-Chemical	D009599
nitroprusside	I-Chemical	D009599
-	O	O
induced	O	O
hypotension	B-Disease	D007022
in	O	O
ventilated	O	O
dogs	O	O
.	O	O

The	O	O
systolic	O	O
pressure	O	O
variation	O	O
(	O	O
SPV	O	O
)	O	O
,	O	O
which	O	O
is	O	O
the	O	O
difference	O	O
between	O	O
the	O	O
maximal	O	O
and	O	O
minimal	O	O
values	O	O
of	O	O
the	O	O
systolic	O	O
blood	O	O
pressure	O	O
(	O	O
SBP	O	O
)	O	O
after	O	O
one	O	O
positive	O	O
-	O	O
pressure	O	O
breath	O	O
,	O	O
was	O	O
studied	O	O
in	O	O
ventilated	O	O
dogs	O	O
subjected	O	O
to	O	O
hypotension	B-Disease	D007022
.	O	O

Mean	O	O
arterial	O	O
pressure	O	O
was	O	O
decreased	O	O
to	O	O
50	O	O
mm	O	O
Hg	O	O
for	O	O
30	O	O
minutes	O	O
either	O	O
by	O	O
hemorrhage	B-Disease	D006470
(	O	O
HEM	B-Disease	D006470
,	O	O
n	O	O
=	O	O
7	O	O
)	O	O
or	O	O
by	O	O
continuous	O	O
infusion	O	O
of	O	O
sodium	B-Chemical	D009599
nitroprusside	I-Chemical	D009599
(	O	O
SNP	B-Chemical	D009599
,	O	O
n	O	O
=	O	O
7	O	O
)	O	O
.	O	O

During	O	O
HEM	B-Disease	D006470
-	O	O
induced	O	O
hypotension	B-Disease	D007022
the	O	O
cardiac	O	O
output	O	O
was	O	O
significantly	O	O
lower	O	O
and	O	O
systemic	O	O
vascular	O	O
resistance	O	O
higher	O	O
compared	O	O
with	O	O
that	O	O
in	O	O
the	O	O
SNP	B-Chemical	D009599
group	O	O
.	O	O

The	O	O
systemic	O	O
,	O	O
central	O	O
venous	O	O
,	O	O
pulmonary	O	O
capillary	O	O
wedge	O	O
pressures	O	O
,	O	O
and	O	O
heart	O	O
rates	O	O
,	O	O
were	O	O
similar	O	O
in	O	O
the	O	O
two	O	O
groups	O	O
.	O	O

Analysis	O	O
of	O	O
the	O	O
respiratory	O	O
changes	O	O
in	O	O
the	O	O
arterial	O	O
pressure	O	O
waveform	O	O
enabled	O	O
differentiation	O	O
between	O	O
the	O	O
two	O	O
groups	O	O
.	O	O

The	O	O
SPV	O	O
during	O	O
hypotension	B-Disease	D007022
was	O	O
15	O	O
.	O	O

7	O	O
+	O	O
/	O	O
-	O	O
6	O	O
.	O	O

7	O	O
mm	O	O
Hg	O	O
in	O	O
the	O	O
HEM	B-Disease	D006470
group	O	O
,	O	O
compared	O	O
with	O	O
9	O	O
.	O	O

1	O	O
+	O	O
/	O	O
-	O	O
2	O	O
.	O	O

0	O	O
mm	O	O
Hg	O	O
in	O	O
the	O	O
SNP	B-Chemical	D009599
group	O	O
(	O	O
P	O	O
less	O	O
than	O	O
0	O	O
.	O	O

02	O	O
)	O	O
.	O	O

The	O	O
delta	O	O
down	O	O
,	O	O
which	O	O
is	O	O
the	O	O
measure	O	O
of	O	O
decrease	O	O
of	O	O
SBP	O	O
after	O	O
a	O	O
mechanical	O	O
breath	O	O
,	O	O
was	O	O
20	O	O
.	O	O

3	O	O
+	O	O
/	O	O
-	O	O
8	O	O
.	O	O

4	O	O
and	O	O
10	O	O
.	O	O

1	O	O
+	O	O
/	O	O
-	O	O
3	O	O
.	O	O

8	O	O
mm	O	O
Hg	O	O
in	O	O
the	O	O
HEM	B-Disease	D006470
and	O	O
SNP	B-Chemical	D009599
groups	O	O
,	O	O
respectively	O	O
,	O	O
during	O	O
hypotension	B-Disease	D007022
(	O	O
P	O	O
less	O	O
than	O	O
0	O	O
.	O	O

02	O	O
)	O	O
.	O	O

It	O	O
is	O	O
concluded	O	O
that	O	O
increases	O	O
in	O	O
the	O	O
SPV	O	O
and	O	O
the	O	O
delta	O	O
down	O	O
are	O	O
characteristic	O	O
of	O	O
a	O	O
hypotensive	B-Disease	D007022
state	O	O
due	O	O
to	O	O
a	O	O
predominant	O	O
decrease	O	O
in	O	O
preload	O	O
.	O	O

They	O	O
are	O	O
thus	O	O
more	O	O
important	O	O
during	O	O
absolute	O	O
hypovolemia	B-Disease	D020896
than	O	O
during	O	O
deliberate	O	O
hypotension	B-Disease	D007022
.	O	O

Drug	O	O
-	O	O
induced	O	O
arterial	O	O
spasm	B-Disease	D013035
relieved	O	O
by	O	O
lidocaine	B-Chemical	D008012
.	O	O

Case	O	O
report	O	O
.	O	O

Following	O	O
major	O	O
intracranial	O	O
surgery	O	O
in	O	O
a	O	O
35	O	O
-	O	O
year	O	O
-	O	O
old	O	O
man	O	O
,	O	O
sodium	B-Chemical	D013874
pentothal	I-Chemical	D013874
was	O	O
intravenously	O	O
infused	O	O
to	O	O
minimize	O	O
cerebral	B-Disease	D002545
ischaemia	I-Disease	D002545
.	O	O

Intense	O	O
vasospasm	B-Disease	D020301
with	O	O
threatened	O	O
gangrene	B-Disease	D005734
arose	O	O
in	O	O
the	O	O
arm	O	O
used	O	O
for	O	O
the	O	O
infusion	O	O
.	O	O

Since	O	O
the	O	O
cranial	O	O
condition	O	O
precluded	O	O
use	O	O
of	O	O
more	O	O
usual	O	O
methods	O	O
,	O	O
lidocaine	B-Chemical	D008012
was	O	O
given	O	O
intra	O	O
-	O	O
arterially	O	O
,	O	O
with	O	O
careful	O	O
cardiovascular	O	O
monitoring	O	O
,	O	O
to	O	O
counteract	O	O
the	O	O
vasospasm	B-Disease	D020301
.	O	O

The	O	O
treatment	O	O
was	O	O
rapidly	O	O
successful	O	O
.	O	O

Cerebral	O	O
blood	O	O
flow	O	O
and	O	O
metabolism	O	O
during	O	O
isoflurane	B-Chemical	D007530
-	O	O
induced	O	O
hypotension	B-Disease	D007022
in	O	O
patients	O	O
subjected	O	O
to	O	O
surgery	O	O
for	O	O
cerebral	B-Disease	D002532
aneurysms	I-Disease	D002532
.	O	O

Cerebral	O	O
blood	O	O
flow	O	O
and	O	O
cerebral	O	O
metabolic	O	O
rate	O	O
for	O	O
oxygen	B-Chemical	D010100
were	O	O
measured	O	O
during	O	O
isoflurane	B-Chemical	D007530
-	O	O
induced	O	O
hypotension	B-Disease	D007022
in	O	O
10	O	O
patients	O	O
subjected	O	O
to	O	O
craniotomy	O	O
for	O	O
clipping	O	O
of	O	O
a	O	O
cerebral	B-Disease	D002532
aneurysm	I-Disease	D002532
.	O	O

Flow	O	O
and	O	O
metabolism	O	O
were	O	O
measured	O	O
5	O	O
-	O	O
13	O	O
days	O	O
after	O	O
the	O	O
subarachnoid	B-Disease	D013345
haemorrhage	I-Disease	D013345
by	O	O
a	O	O
modification	O	O
of	O	O
the	O	O
classical	O	O
Kety	O	O
-	O	O
Schmidt	O	O
technique	O	O
using	O	O
xenon	B-Chemical	D014978
-	O	O
133	O	O
i	O	O
.	O	O

v	O	O
.	O	O

Anaesthesia	O	O
was	O	O
maintained	O	O
with	O	O
an	O	O
inspired	O	O
isoflurane	B-Chemical	D007530
concentration	O	O
of	O	O
0	O	O
.	O	O

75%	O	O
(	O	O
plus	O	O
67%	O	O
nitrous	B-Chemical	D009609
oxide	I-Chemical	D009609
in	O	O
oxygen	B-Chemical	D010100
)	O	O
,	O	O
during	O	O
which	O	O
CBF	O	O
and	O	O
CMRO2	O	O
were	O	O
34	O	O
.	O	O

3	O	O
+	O	O
/	O	O
-	O	O
2	O	O
.	O	O

1	O	O
ml	O	O
/	O	O
100	O	O
g	O	O
min	O	O
-	O	O
1	O	O
and	O	O
2	O	O
.	O	O

32	O	O
+	O	O
/	O	O
-	O	O
0	O	O
.	O	O

16	O	O
ml	O	O
/	O	O
100	O	O
g	O	O
min	O	O
-	O	O
1	O	O
at	O	O
PaCO2	O	O
4	O	O
.	O	O

1	O	O
+	O	O
/	O	O
-	O	O
0	O	O
.	O	O

1	O	O
kPa	O	O
(	O	O
mean	O	O
+	O	O
/	O	O
-	O	O
SEM	O	O
)	O	O
.	O	O

Controlled	O	O
hypotension	B-Disease	D007022
to	O	O
an	O	O
average	O	O
MAP	O	O
of	O	O
50	O	O
-	O	O
55	O	O
mm	O	O
Hg	B-Chemical	D008628
was	O	O
induced	O	O
by	O	O
increasing	O	O
the	O	O
dose	O	O
of	O	O
isoflurane	B-Chemical	D007530
,	O	O
and	O	O
maintained	O	O
at	O	O
an	O	O
inspired	O	O
concentration	O	O
of	O	O
2	O	O
.	O	O

2	O	O
+	O	O
/	O	O
-	O	O
0	O	O
.	O	O

2%	O	O
.	O	O

This	O	O
resulted	O	O
in	O	O
a	O	O
significant	O	O
decrease	O	O
in	O	O
CMRO2	O	O
(	O	O
to	O	O
1	O	O
.	O	O

73	O	O
+	O	O
/	O	O
-	O	O
0	O	O
.	O	O

16	O	O
ml	O	O
/	O	O
100	O	O
g	O	O
min	O	O
-	O	O
1	O	O
)	O	O
,	O	O
while	O	O
CBF	O	O
was	O	O
unchanged	O	O
.	O	O

After	O	O
the	O	O
clipping	O	O
of	O	O
the	O	O
aneurysm	B-Disease	D000783
the	O	O
isoflurane	B-Chemical	D007530
concentration	O	O
was	O	O
reduced	O	O
to	O	O
0	O	O
.	O	O

75%	O	O
.	O	O

There	O	O
was	O	O
a	O	O
significant	O	O
increase	O	O
in	O	O
CBF	O	O
,	O	O
although	O	O
CMRO2	O	O
was	O	O
unchanged	O	O
,	O	O
compared	O	O
with	O	O
pre	O	O
-	O	O
hypotensive	B-Disease	D007022
values	O	O
.	O	O

These	O	O
changes	O	O
might	O	O
offer	O	O
protection	O	O
to	O	O
brain	O	O
tissue	O	O
during	O	O
periods	O	O
of	O	O
induced	O	O
hypotension	B-Disease	D007022
.	O	O

Allergic	B-Disease	D004342
reaction	I-Disease	D004342
to	O	O
5	B-Chemical	D005472
-	I-Chemical	D005472
fluorouracil	I-Chemical	D005472
infusion	O	O
.	O	O

An	O	O
allergic	B-Disease	D004342
reaction	I-Disease	D004342
consisting	O	O
of	O	O
angioneurotic	B-Disease	D000799
edema	I-Disease	D000799
secondary	O	O
to	O	O
continuous	O	O
infusion	O	O
5	B-Chemical	D005472
-	I-Chemical	D005472
fluorouracil	I-Chemical	D005472
occurred	O	O
in	O	O
a	O	O
patient	O	O
with	O	O
recurrent	O	O
carcinoma	B-Disease	D009062
of	I-Disease	D009062
the	I-Disease	D009062
oral	I-Disease	D009062
cavity	I-Disease	D009062
,	O	O
cirrhosis	B-Disease	D005355
,	O	O
and	O	O
cisplatin	B-Chemical	D002945
-	O	O
induced	O	O
impaired	B-Disease	D007674
renal	I-Disease	D007674
function	I-Disease	D007674
.	O	O

This	O	O
reaction	O	O
occurred	O	O
during	O	O
the	O	O
sixth	O	O
and	O	O
seventh	O	O
courses	O	O
of	O	O
infusional	O	O
chemotherapy	O	O
.	O	O

Oral	O	O
diphenhydramine	B-Chemical	D004155
and	O	O
prednisone	B-Chemical	D011241
were	O	O
ineffective	O	O
in	O	O
preventing	O	O
the	O	O
recurrence	O	O
of	O	O
the	O	O
allergic	B-Disease	D004342
reaction	I-Disease	D004342
.	O	O

Discontinuance	O	O
of	O	O
effective	O	O
chemotherapy	O	O
in	O	O
this	O	O
patient	O	O
during	O	O
partial	O	O
remission	O	O
resulted	O	O
in	O	O
fatal	O	O
disease	O	O
progression	O	O
.	O	O

Amiodarone	B-Chemical	D000638
-	O	O
induced	O	O
sinoatrial	B-Disease	D012848
block	I-Disease	D012848
.	O	O

We	O	O
observed	O	O
sinoatrial	B-Disease	D012848
block	I-Disease	D012848
due	O	O
to	O	O
chronic	O	O
amiodarone	B-Chemical	D000638
administration	O	O
in	O	O
a	O	O
5	O	O
-	O	O
year	O	O
-	O	O
old	O	O
boy	O	O
with	O	O
primary	B-Disease	D009202
cardiomyopathy	I-Disease	D009202
,	O	O
Wolff	B-Disease	D014927
-	I-Disease	D014927
Parkinson	I-Disease	D014927
-	I-Disease	D014927
White	I-Disease	D014927
syndrome	I-Disease	D014927
and	O	O
supraventricular	B-Disease	D013617
tachycardia	I-Disease	D013617
.	O	O

Reduction	O	O
in	O	O
the	O	O
dosage	O	O
of	O	O
amiodarone	B-Chemical	D000638
resulted	O	O
in	O	O
the	O	O
disappearance	O	O
of	O	O
the	O	O
sinoatrial	B-Disease	D012848
block	I-Disease	D012848
and	O	O
the	O	O
persistence	O	O
of	O	O
asymptomatic	O	O
sinus	B-Disease	D012804
bradycardia	I-Disease	D012804
.	O	O

Possible	O	O
teratogenicity	O	O
of	O	O
sulphasalazine	B-Chemical	D012460
.	O	O

Three	O	O
infants	O	O
,	O	O
born	O	O
of	O	O
two	O	O
mothers	O	O
with	O	O
inflammatory	B-Disease	D015212
bowel	I-Disease	D015212
disease	I-Disease	D015212
who	O	O
received	O	O
treatment	O	O
with	O	O
sulphasalazine	B-Chemical	D012460
throughout	O	O
pregnancy	O	O
,	O	O
were	O	O
found	O	O
to	O	O
have	O	O
major	O	O
congenital	B-Disease	D000013
anomalies	I-Disease	D000013
.	O	O

In	O	O
the	O	O
singleton	O	O
pregnancy	O	O
,	O	O
the	O	O
mother	O	O
had	O	O
ulcerative	B-Disease	D003093
colitis	I-Disease	D003093
,	O	O
and	O	O
the	O	O
infant	O	O
,	O	O
a	O	O
male	O	O
,	O	O
had	O	O
coarctation	B-Disease	D001017
of	I-Disease	D001017
the	I-Disease	D001017
aorta	I-Disease	D001017
and	O	O
a	O	O
ventricular	B-Disease	D006345
septal	I-Disease	D006345
defect	I-Disease	D006345
.	O	O

In	O	O
the	O	O
twin	O	O
pregnancy	O	O
,	O	O
the	O	O
mother	O	O
had	O	O
Crohn's	B-Disease	D003424
disease	I-Disease	D003424
.	O	O

The	O	O
first	O	O
twin	O	O
,	O	O
a	O	O
female	O	O
,	O	O
had	O	O
a	O	O
left	O	O
Potter	B-Disease	D007690
-	I-Disease	D007690
type	I-Disease	D007690
IIa	I-Disease	D007690
polycystic	I-Disease	D007690
kidney	I-Disease	D007690
and	O	O
a	O	O
rudimentary	B-Disease	-1
left	I-Disease	-1
uterine	I-Disease	-1
cornu	I-Disease	-1
.	O	O

The	O	O
second	O	O
twin	O	O
,	O	O
a	O	O
male	O	O
,	O	O
had	O	O
some	O	O
features	O	O
of	O	O
Potter's	B-Disease	-1
facies	I-Disease	-1
,	O	O
hypoplastic	B-Disease	-1
lungs	I-Disease	-1
,	O	O
absent	B-Disease	-1
kidneys	I-Disease	-1
and	I-Disease	-1
ureters	I-Disease	-1
,	O	O
and	O	O
talipes	B-Disease	D003025
equinovarus	I-Disease	D003025
.	O	O

Despite	O	O
reports	O	O
to	O	O
the	O	O
contrary	O	O
,	O	O
it	O	O
is	O	O
suggested	O	O
that	O	O
sulphasalazine	B-Chemical	D012460
may	O	O
be	O	O
teratogenic	O	O
.	O	O

Veno	B-Disease	D006504
-	I-Disease	D006504
occlusive	I-Disease	D006504
liver	I-Disease	D006504
disease	I-Disease	D006504
after	O	O
dacarbazine	B-Chemical	D003606
therapy	O	O
(	O	O
DTIC	B-Chemical	D003606
)	O	O
for	O	O
melanoma	B-Disease	D008545
.	O	O

A	O	O
case	O	O
of	O	O
veno	B-Disease	D006504
-	I-Disease	D006504
occlusive	I-Disease	D006504
disease	I-Disease	D006504
of	I-Disease	D006504
the	I-Disease	D006504
liver	I-Disease	D006504
with	O	O
fatal	O	O
outcome	O	O
after	O	O
dacarbazine	B-Chemical	D003606
(	O	O
DTIC	B-Chemical	D003606
)	O	O
therapy	O	O
for	O	O
melanoma	B-Disease	D008545
is	O	O
reported	O	O
.	O	O

There	O	O
was	O	O
a	O	O
fulminant	O	O
clinical	O	O
course	O	O
from	O	O
start	O	O
of	O	O
symptoms	O	O
until	O	O
death	B-Disease	D003643
.	O	O

At	O	O
autopsy	O	O
the	O	O
liver	O	O
was	O	O
enlarged	O	O
and	O	O
firm	O	O
with	O	O
signs	O	O
of	O	O
venous	B-Disease	D006940
congestion	I-Disease	D006940
.	O	O

Small	O	O
-	O	O
and	O	O
medium	O	O
-	O	O
sized	O	O
hepatic	O	O
veins	O	O
were	O	O
blocked	O	O
by	O	O
thrombosis	B-Disease	D013927
.	O	O

Eosinophilic	O	O
infiltrations	O	O
were	O	O
found	O	O
around	O	O
the	O	O
vessels	O	O
.	O	O

Published	O	O
cases	O	O
from	O	O
the	O	O
literature	O	O
are	O	O
reviewed	O	O
and	O	O
pertinent	O	O
features	O	O
discussed	O	O
.	O	O

A	O	O
case	O	O
of	O	O
tardive	B-Disease	D004409
dyskinesia	I-Disease	D004409
caused	O	O
by	O	O
metoclopramide	B-Chemical	D008787
.	O	O

Abnormal	B-Disease	D004409
involuntary	I-Disease	D004409
movements	I-Disease	D004409
appeared	O	O
in	O	O
the	O	O
mouth	O	O
,	O	O
tongue	O	O
,	O	O
neck	O	O
and	O	O
abdomen	O	O
of	O	O
a	O	O
64	O	O
-	O	O
year	O	O
-	O	O
old	O	O
male	O	O
patient	O	O
after	O	O
he	O	O
took	O	O
metoclopramide	B-Chemical	D008787
for	O	O
gastrointestinal	B-Disease	D005767
disorder	I-Disease	D005767
in	O	O
a	O	O
regimen	O	O
of	O	O
30	O	O
mg	O	O
per	O	O
day	O	O
for	O	O
a	O	O
total	O	O
of	O	O
about	O	O
260	O	O
days	O	O
.	O	O

The	O	O
symptoms	O	O
exacerbated	O	O
to	O	O
a	O	O
maximum	O	O
in	O	O
a	O	O
month	O	O
.	O	O

When	O	O
the	O	O
metoclopramide	B-Chemical	D008787
administration	O	O
was	O	O
discontinued	O	O
,	O	O
the	O	O
abnormal	B-Disease	D004409
movements	I-Disease	D004409
gradually	O	O
improved	O	O
to	O	O
a	O	O
considerable	O	O
extent	O	O
.	O	O

Attention	O	O
to	O	O
the	O	O
possible	O	O
induction	O	O
of	O	O
specific	O	O
tardive	B-Disease	D004409
dyskinesia	I-Disease	D004409
is	O	O
called	O	O
for	O	O
in	O	O
the	O	O
use	O	O
of	O	O
this	O	O
drug	O	O
.	O	O

Further	O	O
observations	O	O
on	O	O
the	O	O
electrophysiologic	O	O
effects	O	O
of	O	O
oral	O	O
amiodarone	B-Chemical	D000638
therapy	O	O
.	O	O

A	O	O
case	O	O
is	O	O
presented	O	O
of	O	O
a	O	O
reversible	O	O
intra	B-Disease	D006327
-	I-Disease	D006327
Hisian	I-Disease	D006327
block	I-Disease	D006327
occurring	O	O
under	O	O
amiodarone	B-Chemical	D000638
treatment	O	O
for	O	O
atrial	B-Disease	D013617
tachycardia	I-Disease	D013617
in	O	O
a	O	O
patient	O	O
without	O	O
clear	O	O
intraventricular	B-Disease	D006345
conduction	I-Disease	D006345
abnormalities	I-Disease	D006345
.	O	O

His	O	O
bundle	O	O
recordings	O	O
showed	O	O
an	O	O
atrial	B-Disease	D013617
tachycardia	I-Disease	D013617
with	O	O
intermittent	O	O
exit	O	O
block	O	O
and	O	O
greatly	O	O
prolonged	O	O
BH	O	O
and	O	O
HV	O	O
intervals	O	O
(	O	O
40	O	O
and	O	O
100	O	O
msec	O	O
,	O	O
respectively	O	O
)	O	O
.	O	O

Thirty	O	O
days	O	O
after	O	O
amiodarone	B-Chemical	D000638
discontinuation	O	O
,	O	O
His	O	O
bundle	O	O
electrograms	O	O
showed	O	O
atrial	B-Disease	D001282
flutter	I-Disease	D001282
without	O	O
intra	O	O
-	O	O
Hisian	O	O
or	O	O
infra	O	O
-	O	O
Hisian	O	O
delay	O	O
.	O	O

Amiodarone	B-Chemical	D000638
should	O	O
be	O	O
used	O	O
with	O	O
caution	O	O
during	O	O
long	O	O
-	O	O
term	O	O
oral	O	O
therapy	O	O
in	O	O
patients	O	O
with	O	O
or	O	O
without	O	O
clear	O	O
intraventricular	O	O
conduction	O	O
defects	O	O
.	O	O

Busulfan	B-Chemical	D002066
-	O	O
induced	O	O
hemorrhagic	O	O
cystitis	B-Disease	D003556
.	O	O

A	O	O
case	O	O
of	O	O
a	O	O
busulfan	B-Chemical	D002066
-	O	O
induced	O	O
hemorrhage	O	O
cystitis	B-Disease	D003556
is	O	O
reported	O	O
.	O	O

Spontaneous	O	O
resolution	O	O
occurred	O	O
following	O	O
cessation	O	O
of	O	O
the	O	O
drug	O	O
.	O	O

The	O	O
similarity	O	O
between	O	O
the	O	O
histologic	O	O
appearances	O	O
of	O	O
busulfan	B-Chemical	D002066
cystitis	B-Disease	D003556
and	O	O
both	O	O
radiation	O	O
and	O	O
cyclophosphamide	B-Chemical	D003520
-	O	O
induced	O	O
cystitis	B-Disease	D003556
is	O	O
discussed	O	O
and	O	O
the	O	O
world	O	O
literature	O	O
reviewed	O	O
.	O	O

In	O	O
view	O	O
of	O	O
the	O	O
known	O	O
tendency	O	O
of	O	O
busulfan	B-Chemical	D002066
to	O	O
induce	O	O
cellular	O	O
atypia	O	O
and	O	O
carcinoma	B-Disease	D002277
in	O	O
other	O	O
sites	O	O
,	O	O
periodic	O	O
urinary	O	O
cytology	O	O
is	O	O
suggested	O	O
in	O	O
patients	O	O
on	O	O
long	O	O
-	O	O
term	O	O
therapy	O	O
.	O	O

Rebound	O	O
hypertensive	B-Disease	D006973
after	O	O
sodium	B-Chemical	D009599
nitroprusside	I-Chemical	D009599
prevented	O	O
by	O	O
saralasin	B-Chemical	D012504
in	O	O
rats	O	O
.	O	O

The	O	O
role	O	O
of	O	O
the	O	O
renin	O	O
-	O	O
-	O	O
angiotensin	B-Chemical	D000809
system	O	O
in	O	O
the	O	O
maintenance	O	O
of	O	O
blood	O	O
pressure	O	O
during	O	O
halothane	B-Chemical	D006221
anesthesia	O	O
and	O	O
sodium	B-Chemical	D009599
nitroprusside	I-Chemical	D009599
(	O	O
SNP	B-Chemical	D009599
)	O	O
-	O	O
induced	O	O
hypotension	B-Disease	D007022
was	O	O
evaluated	O	O
.	O	O

Control	O	O
rats	O	O
received	O	O
halothane	B-Chemical	D006221
anesthesia	O	O
(	O	O
1	O	O
MAC	O	O
)	O	O
for	O	O
one	O	O
hour	O	O
,	O	O
followed	O	O
by	O	O
SNP	B-Chemical	D009599
infusion	O	O
,	O	O
40	O	O
microgram	O	O
/	O	O
kg	O	O
/	O	O
min	O	O
,	O	O
for	O	O
30	O	O
min	O	O
,	O	O
followed	O	O
by	O	O
a	O	O
30	O	O
-	O	O
min	O	O
recovery	O	O
period	O	O
.	O	O

A	O	O
second	O	O
group	O	O
of	O	O
rats	O	O
was	O	O
treated	O	O
identically	O	O
and	O	O
,	O	O
in	O	O
addition	O	O
,	O	O
received	O	O
an	O	O
infusion	O	O
of	O	O
saralasin	B-Chemical	D012504
(	O	O
a	O	O
competitive	O	O
inhibitor	O	O
of	O	O
angiotensin	B-Chemical	D000809
II	O	O
)	O	O
throughout	O	O
the	O	O
experimental	O	O
period	O	O
.	O	O

In	O	O
each	O	O
group	O	O
,	O	O
SNP	B-Chemical	D009599
infusion	O	O
resulted	O	O
in	O	O
an	O	O
initial	O	O
decrease	O	O
in	O	O
blood	O	O
pressure	O	O
from	O	O
86	O	O
torr	O	O
and	O	O
83	O	O
torr	O	O
,	O	O
respectively	O	O
,	O	O
to	O	O
48	O	O
torr	O	O
.	O	O

During	O	O
the	O	O
SNP	B-Chemical	D009599
infusion	O	O
the	O	O
control	O	O
animals	O	O
demonstrated	O	O
a	O	O
progressive	O	O
increase	B-Disease	D006973
in	I-Disease	D006973
blood	I-Disease	D006973
pressure	I-Disease	D006973
to	O	O
61	O	O
torr	O	O
,	O	O
whereas	O	O
the	O	O
saralasin	B-Chemical	D012504
-	O	O
treated	O	O
animals	O	O
showed	O	O
no	O	O
change	O	O
.	O	O

Following	O	O
discontinuation	O	O
of	O	O
SNP	B-Chemical	D009599
,	O	O
blood	O	O
pressure	O	O
in	O	O
the	O	O
control	O	O
animals	O	O
rebounded	O	O
to	O	O
94	O	O
torr	O	O
,	O	O
as	O	O
compared	O	O
with	O	O
78	O	O
torr	O	O
in	O	O
the	O	O
saralasin	B-Chemical	D012504
-	O	O
treated	O	O
rats	O	O
.	O	O

This	O	O
study	O	O
indicates	O	O
that	O	O
with	O	O
stable	O	O
halothane	B-Chemical	D006221
anesthesia	O	O
,	O	O
the	O	O
partial	O	O
recovery	O	O
of	O	O
blood	O	O
pressure	O	O
during	O	O
SNP	B-Chemical	D009599
infusion	O	O
and	O	O
the	O	O
post	O	O
-	O	O
SNP	B-Chemical	D009599
rebound	O	O
of	O	O
blood	O	O
pressure	O	O
can	O	O
be	O	O
completely	O	O
blocked	O	O
by	O	O
saralasin	B-Chemical	D012504
.	O	O

This	O	O
demonstrates	O	O
the	O	O
participation	O	O
of	O	O
the	O	O
renin	O	O
-	O	O
-	O	O
angiotensin	B-Chemical	D000809
system	O	O
in	O	O
antagonizing	O	O
the	O	O
combined	O	O
hypotensive	B-Disease	D007022
effects	O	O
of	O	O
halothane	B-Chemical	D006221
and	O	O
SNP	B-Chemical	D009599
.	O	O

Toxic	B-Disease	D056486
hepatitis	I-Disease	D056486
induced	O	O
by	O	O
antithyroid	O	O
drugs	O	O
:	O	O
four	O	O
cases	O	O
including	O	O
one	O	O
with	O	O
cross	O	O
-	O	O
reactivity	O	O
between	O	O
carbimazole	B-Chemical	D002231
and	O	O
benzylthiouracil	B-Chemical	C019269
.	O	O

OBJECTIVE	O	O
:	O	O
This	O	O
study	O	O
was	O	O
conducted	O	O
to	O	O
assess	O	O
the	O	O
occurrence	O	O
of	O	O
hepatic	B-Disease	D056486
adverse	I-Disease	D056486
effects	I-Disease	D056486
encountered	O	O
with	O	O
antithyroid	O	O
drugs	O	O
.	O	O

METHODS	O	O
:	O	O
Retrospective	O	O
review	O	O
of	O	O
medical	O	O
records	O	O
of	O	O
236	O	O
patients	O	O
with	O	O
hyperthyroidism	B-Disease	D006980
admitted	O	O
in	O	O
our	O	O
department	O	O
(	O	O
in	O	O
-	O	O
or	O	O
out	O	O
-	O	O
patients	O	O
)	O	O
from	O	O
1986	O	O
to	O	O
1992	O	O
.	O	O

RESULTS	O	O
:	O	O
Four	O	O
patients	O	O
(	O	O
1	O	O
.	O	O

7%	O	O
)	O	O
were	O	O
identified	O	O
with	O	O
toxic	B-Disease	D056486
hepatitis	I-Disease	D056486
which	O	O
could	O	O
reasonably	O	O
be	O	O
attributed	O	O
to	O	O
the	O	O
use	O	O
of	O	O
antithyroid	O	O
agent	O	O
.	O	O

Two	O	O
patients	O	O
had	O	O
a	O	O
cholestatic	B-Disease	D002779
hepatitis	B-Disease	D056486
induced	O	O
by	O	O
carbimazole	B-Chemical	D002231
(	O	O
N	B-Chemical	D002231
omercazole	I-Chemical	D002231
)	O	O
.	O	O

Two	O	O
others	O	O
had	O	O
a	O	O
mixed	O	O
(	O	O
cholestatic	B-Disease	D002779
and	O	O
cytolytic	O	O
)	O	O
hepatitis	B-Disease	D056486
following	O	O
carbimazole	B-Chemical	D002231
.	O	O

One	O	O
of	O	O
the	O	O
latter	O	O
two	O	O
patients	O	O
further	O	O
experienced	O	O
a	O	O
cytolytic	O	O
hepatitis	B-Disease	D056486
which	O	O
appeared	O	O
after	O	O
Benzylthiouracil	B-Chemical	C019269
(	O	O
Basd	B-Chemical	C019269
ne	I-Chemical	C019269
)	O	O
had	O	O
replaced	O	O
carbimazole	B-Chemical	D002231
.	O	O

Biological	O	O
features	O	O
of	O	O
hepatitis	B-Disease	D056486
disappeared	O	O
in	O	O
all	O	O
cases	O	O
after	O	O
cessation	O	O
of	O	O
the	O	O
incriminated	O	O
drug	O	O
,	O	O
while	O	O
biliary	O	O
,	O	O
viral	O	O
and	O	O
immunological	O	O
searches	O	O
were	O	O
negative	O	O
.	O	O

Only	O	O
2	O	O
patients	O	O
of	O	O
our	O	O
retrospective	O	O
study	O	O
experienced	O	O
a	O	O
mild	O	O
or	O	O
severe	O	O
neutropenia	B-Disease	D009503
.	O	O

CONCLUSION	O	O
:	O	O
Toxic	B-Disease	D056486
hepatitis	I-Disease	D056486
is	O	O
a	O	O
potential	O	O
adverse	O	O
effect	O	O
of	O	O
antithyroid	O	O
drugs	O	O
which	O	O
warrants	O	O
,	O	O
as	O	O
for	O	O
haematological	O	O
disturbances	O	O
,	O	O
a	O	O
pre	O	O
-	O	O
therapeutic	O	O
determination	O	O
and	O	O
a	O	O
careful	O	O
follow	O	O
-	O	O
up	O	O
of	O	O
relevant	O	O
biological	O	O
markers	O	O
.	O	O

Moreover	O	O
,	O	O
hepatotoxicity	B-Disease	D056486
may	O	O
not	O	O
be	O	O
restricted	O	O
to	O	O
one	O	O
class	O	O
of	O	O
antithyroid	O	O
agents	O	O
.	O	O

Study	O	O
of	O	O
the	O	O
role	O	O
of	O	O
vitamin	B-Chemical	D014805
B12	I-Chemical	D014805
and	O	O
folinic	B-Chemical	D002955
acid	I-Chemical	D002955
supplementation	O	O
in	O	O
preventing	O	O
hematologic	O	O
toxicity	B-Disease	D064420
of	O	O
zidovudine	B-Chemical	D015215
.	O	O

A	O	O
prospective	O	O
,	O	O
randomized	O	O
study	O	O
was	O	O
conducted	O	O
to	O	O
evaluate	O	O
the	O	O
role	O	O
of	O	O
vitamin	B-Chemical	D014805
B12	I-Chemical	D014805
and	O	O
folinic	B-Chemical	D002955
acid	I-Chemical	D002955
supplementation	O	O
in	O	O
preventing	O	O
zidovudine	B-Chemical	D015215
(	O	O
ZDV	B-Chemical	D015215
)	O	O
-	O	O
induced	O	O
bone	B-Disease	D001855
marrow	I-Disease	D001855
suppression	I-Disease	D001855
.	O	O

Seventy	O	O
-	O	O
five	O	O
human	B-Disease	D015658
immunodeficiency	I-Disease	D015658
virus	I-Disease	D015658
(	I-Disease	D015658
HIV	I-Disease	D015658
)	I-Disease	D015658
-	I-Disease	D015658
infected	I-Disease	D015658
patients	O	O
with	O	O
CD4+	O	O
cell	O	O
counts	O	O
<	O	O
500	O	O
/	O	O
mm3	O	O
were	O	O
randomized	O	O
to	O	O
receive	O	O
either	O	O
ZDV	B-Chemical	D015215
(	O	O
500	O	O
mg	O	O
daily	O	O
)	O	O
alone	O	O
(	O	O
group	O	O
I	O	O
,	O	O
n	O	O
=	O	O
38	O	O
)	O	O
or	O	O
in	O	O
combination	O	O
with	O	O
folinic	B-Chemical	D002955
acid	I-Chemical	D002955
(	O	O
15	O	O
mg	O	O
daily	O	O
)	O	O
and	O	O
intramascular	O	O
vitamin	B-Chemical	D014805
B12	I-Chemical	D014805
(	O	O
1000	O	O
micrograms	O	O
monthly	O	O
)	O	O
(	O	O
group	O	O
II	O	O
,	O	O
n	O	O
=	O	O
37	O	O
)	O	O
.	O	O

Finally	O	O
,	O	O
15	O	O
patients	O	O
were	O	O
excluded	O	O
from	O	O
the	O	O
study	O	O
(	O	O
noncompliance	O	O
14	O	O
,	O	O
death	B-Disease	D003643
1	O	O
)	O	O
;	O	O
thus	O	O
,	O	O
60	O	O
patients	O	O
(	O	O
31	O	O
in	O	O
group	O	O
I	O	O
and	O	O
29	O	O
in	O	O
group	O	O
II	O	O
)	O	O
were	O	O
eligible	O	O
for	O	O
analysis	O	O
.	O	O

No	O	O
significant	O	O
differences	O	O
between	O	O
groups	O	O
were	O	O
found	O	O
at	O	O
enrollment	O	O
.	O	O

During	O	O
the	O	O
study	O	O
,	O	O
vitamin	B-Chemical	D014805
B12	I-Chemical	D014805
and	O	O
folate	B-Chemical	D005492
levels	O	O
were	O	O
significantly	O	O
higher	O	O
in	O	O
group	O	O
II	O	O
patients	O	O
;	O	O
however	O	O
,	O	O
no	O	O
differences	O	O
in	O	O
hemoglobin	O	O
,	O	O
hematocrit	O	O
,	O	O
mean	O	O
corpuscular	O	O
volume	O	O
,	O	O
and	O	O
white	O	O
-	O	O
cell	O	O
,	O	O
neutrophil	O	O
and	O	O
platelet	O	O
counts	O	O
were	O	O
observed	O	O
between	O	O
groups	O	O
at	O	O
3	O	O
,	O	O
6	O	O
,	O	O
9	O	O
and	O	O
12	O	O
months	O	O
.	O	O

Severe	O	O
hematologic	O	O
toxicity	B-Disease	D064420
(	O	O
neutrophil	O	O
count	O	O
<	O	O
1000	O	O
/	O	O
mm3	O	O
and	O	O
/	O	O
or	O	O
hemoglobin	O	O
<	O	O
8	O	O
g	O	O
/	O	O
dl	O	O
)	O	O
occurred	O	O
in	O	O
4	O	O
patients	O	O
assigned	O	O
to	O	O
group	O	O
I	O	O
and	O	O
7	O	O
assigned	O	O
to	O	O
group	O	O
II	O	O
.	O	O

There	O	O
was	O	O
no	O	O
correlation	O	O
between	O	O
vitamin	B-Chemical	D014805
B12	I-Chemical	D014805
or	O	O
folate	B-Chemical	D005492
levels	O	O
and	O	O
development	O	O
of	O	O
myelosuppression	B-Disease	D001855
.	O	O

Vitamin	B-Chemical	D014805
B12	I-Chemical	D014805
and	O	O
folinic	B-Chemical	D002955
acid	I-Chemical	D002955
supplementation	O	O
of	O	O
ZDV	B-Chemical	D015215
therapy	O	O
does	O	O
not	O	O
seem	O	O
useful	O	O
in	O	O
preventing	O	O
or	O	O
reducing	O	O
ZDV	B-Chemical	D015215
-	O	O
induced	O	O
myelotoxicity	B-Disease	D001855
in	O	O
the	O	O
overall	O	O
treated	O	O
population	O	O
,	O	O
although	O	O
a	O	O
beneficial	O	O
effect	O	O
in	O	O
certain	O	O
subgroups	O	O
of	O	O
patients	O	O
cannot	O	O
be	O	O
excluded	O	O
.	O	O

Acute	O	O
confusion	B-Disease	D003221
induced	O	O
by	O	O
a	O	O
high	O	O
-	O	O
dose	O	O
infusion	O	O
of	O	O
5	B-Chemical	D005472
-	I-Chemical	D005472
fluorouracil	I-Chemical	D005472
and	O	O
folinic	B-Chemical	D002955
acid	I-Chemical	D002955
.	O	O

A	O	O
61	O	O
-	O	O
year	O	O
-	O	O
old	O	O
man	O	O
was	O	O
treated	O	O
with	O	O
combination	O	O
chemotherapy	O	O
incorporating	O	O
cisplatinum	B-Chemical	D002945
,	O	O
etoposide	B-Chemical	D005047
,	O	O
high	O	O
-	O	O
dose	O	O
5	B-Chemical	D005472
-	I-Chemical	D005472
fluorouracil	I-Chemical	D005472
(	O	O
2	O	O
,	O	O
250	O	O
mg	O	O
/	O	O
m2	O	O
/	O	O
24	O	O
hours	O	O
)	O	O
and	O	O
folinic	B-Chemical	D002955
acid	I-Chemical	D002955
for	O	O
an	O	O
inoperable	O	O
gastric	B-Disease	D013274
adenocarcinoma	I-Disease	D013274
.	O	O

He	O	O
developed	O	O
acute	O	O
neurologic	O	O
symptoms	O	O
of	O	O
mental	O	O
confusion	B-Disease	D003221
,	O	O
disorientation	B-Disease	D003221
and	O	O
irritability	B-Disease	D001523
,	O	O
and	O	O
then	O	O
lapsed	O	O
into	O	O
a	O	O
deep	O	O
coma	B-Disease	D003128
,	O	O
lasting	O	O
for	O	O
approximately	O	O
40	O	O
hours	O	O
during	O	O
the	O	O
first	O	O
dose	O	O
(	O	O
day	O	O
2	O	O
)	O	O
of	O	O
5	B-Chemical	D005472
-	I-Chemical	D005472
fluorouracil	I-Chemical	D005472
and	O	O
folinic	B-Chemical	D002955
acid	I-Chemical	D002955
infusion	O	O
.	O	O

This	O	O
complication	O	O
reappeared	O	O
on	O	O
day	O	O
25	O	O
during	O	O
the	O	O
second	O	O
dose	O	O
of	O	O
5	B-Chemical	D005472
-	I-Chemical	D005472
fluorouracil	I-Chemical	D005472
and	O	O
folinic	B-Chemical	D002955
acid	I-Chemical	D002955
,	O	O
which	O	O
were	O	O
then	O	O
the	O	O
only	O	O
drugs	O	O
given	O	O
.	O	O

Because	O	O
folinic	B-Chemical	D002955
acid	I-Chemical	D002955
was	O	O
unlikely	O	O
to	O	O
be	O	O
associated	O	O
with	O	O
this	O	O
condition	O	O
,	O	O
neurotoxicity	B-Disease	D020258
due	O	O
to	O	O
high	O	O
-	O	O
dose	O	O
5	B-Chemical	D005472
-	I-Chemical	D005472
fluorouracil	I-Chemical	D005472
was	O	O
highly	O	O
suspected	O	O
.	O	O

The	O	O
pathogenesis	O	O
of	O	O
5	B-Chemical	D005472
-	I-Chemical	D005472
fluorouracil	I-Chemical	D005472
neurotoxicity	B-Disease	D020258
may	O	O
be	O	O
due	O	O
to	O	O
a	O	O
Krebs	O	O
cycle	O	O
blockade	O	O
by	O	O
fluoroacetate	B-Chemical	D005463
and	O	O
fluorocitrate	B-Chemical	C007744
,	O	O
thiamine	B-Chemical	D013831
deficiency	O	O
,	O	O
or	O	O
dihydrouracil	B-Chemical	C007419
dehydrogenase	O	O
deficiency	O	O
.	O	O

High	O	O
-	O	O
dose	O	O
5	B-Chemical	D005472
-	I-Chemical	D005472
fluorouracil	I-Chemical	D005472
/	O	O
folinic	B-Chemical	D002955
acid	I-Chemical	D002955
infusion	O	O
therapy	O	O
has	O	O
recently	O	O
become	O	O
a	O	O
popular	O	O
regimen	O	O
for	O	O
various	O	O
cancers	B-Disease	D009369
.	O	O

It	O	O
is	O	O
necessary	O	O
that	O	O
both	O	O
oncologists	O	O
and	O	O
neurologists	O	O
be	O	O
fully	O	O
aware	O	O
of	O	O
this	O	O
unusual	O	O
complication	O	O
.	O	O

Effect	O	O
of	O	O
switching	O	O
carbamazepine	B-Chemical	D002220
to	O	O
oxcarbazepine	B-Chemical	C036006
on	O	O
the	O	O
plasma	O	O
levels	O	O
of	O	O
neuroleptics	O	O
.	O	O

A	O	O
case	O	O
report	O	O
.	O	O

Carbamazepine	B-Chemical	D002220
was	O	O
switched	O	O
to	O	O
its	O	O
10	O	O
-	O	O
keto	O	O
analogue	O	O
oxcarbazepine	B-Chemical	C036006
among	O	O
six	O	O
difficult	O	O
-	O	O
to	O	O
-	O	O
treat	O	O
schizophrenic	B-Disease	D012559
or	O	O
organic	B-Disease	D019965
psychotic	I-Disease	D019965
patients	O	O
using	O	O
concomitantly	O	O
haloperidol	B-Chemical	D006220
,	O	O
chlorpromazine	B-Chemical	D002746
or	O	O
clozapine	B-Chemical	D003024
.	O	O

This	O	O
change	O	O
resulted	O	O
within	O	O
2	O	O
-	O	O
4	O	O
weeks	O	O
in	O	O
the	O	O
50	O	O
-	O	O
200%	O	O
increase	O	O
in	O	O
the	O	O
plasma	O	O
levels	O	O
of	O	O
these	O	O
neuroleptics	O	O
and	O	O
the	O	O
appearance	O	O
of	O	O
extrapyramidal	B-Disease	D001480
symptoms	I-Disease	D001480
.	O	O

None	O	O
of	O	O
the	O	O
patients	O	O
showed	O	O
any	O	O
clinical	O	O
deteriotation	O	O
during	O	O
the	O	O
following	O	O
3	O	O
-	O	O
6	O	O
months	O	O
.	O	O

The	O	O
results	O	O
of	O	O
this	O	O
case	O	O
report	O	O
support	O	O
the	O	O
idea	O	O
that	O	O
in	O	O
contrast	O	O
with	O	O
carbamazepine	B-Chemical	D002220
oxcarbazepine	B-Chemical	C036006
does	O	O
not	O	O
induce	O	O
the	O	O
hepatic	O	O
microsomal	O	O
enzyme	O	O
systems	O	O
regulating	O	O
the	O	O
inactivation	O	O
of	O	O
antipsychotic	O	O
drugs	O	O
.	O	O

Erythema	B-Disease	D004892
multiforme	I-Disease	D004892
and	O	O
hypersensitivity	B-Disease	D009205
myocarditis	I-Disease	D009205
caused	O	O
by	O	O
ampicillin	B-Chemical	D000667
.	O	O

OBJECTIVE	O	O
:	O	O
To	O	O
report	O	O
a	O	O
case	O	O
of	O	O
erythema	B-Disease	D004892
multiforme	I-Disease	D004892
and	O	O
hypersensitivity	B-Disease	D009205
myocarditis	I-Disease	D009205
caused	O	O
by	O	O
ampicillin	B-Chemical	D000667
.	O	O

CASE	O	O
SUMMARY	O	O
:	O	O
A	O	O
13	O	O
-	O	O
year	O	O
-	O	O
old	O	O
boy	O	O
was	O	O
treated	O	O
with	O	O
ampicillin	B-Chemical	D000667
and	O	O
gentamicin	B-Chemical	D005839
because	O	O
of	O	O
suspected	O	O
septicemia	B-Disease	D018805
.	O	O

Medications	O	O
were	O	O
discontinued	O	O
when	O	O
erythema	B-Disease	D004892
multiforme	I-Disease	D004892
and	O	O
congestive	B-Disease	D006333
heart	I-Disease	D006333
failure	I-Disease	D006333
caused	O	O
by	O	O
myocarditis	B-Disease	D009205
occurred	O	O
.	O	O

The	O	O
patient	O	O
was	O	O
treated	O	O
with	O	O
methylprednisolone	B-Chemical	D008775
and	O	O
gradually	O	O
improved	O	O
.	O	O

Macrophage	O	O
-	O	O
migration	O	O
inhibition	O	O
(	O	O
MIF	O	O
)	O	O
test	O	O
with	O	O
ampicillin	B-Chemical	D000667
was	O	O
positive	O	O
.	O	O

DISCUSSION	O	O
:	O	O
After	O	O
most	O	O
infections	B-Disease	D007239
causing	O	O
erythema	B-Disease	D004892
multiforme	I-Disease	D004892
and	O	O
myocarditis	B-Disease	D009205
were	O	O
ruled	O	O
out	O	O
,	O	O
a	O	O
drug	B-Disease	D004342
-	I-Disease	D004342
induced	I-Disease	D004342
allergic	I-Disease	D004342
reaction	I-Disease	D004342
was	O	O
suspected	O	O
.	O	O

Positive	O	O
MIF	O	O
test	O	O
for	O	O
ampicillin	B-Chemical	D000667
showed	O	O
sensitization	O	O
of	O	O
the	O	O
patient's	O	O
lymphocytes	O	O
to	O	O
ampicillin	B-Chemical	D000667
.	O	O

CONCLUSIONS	O	O
:	O	O
Hypersensitivity	B-Disease	D009205
myocarditis	I-Disease	D009205
is	O	O
a	O	O
rare	O	O
and	O	O
dangerous	O	O
manifestation	O	O
of	O	O
allergy	B-Disease	D004342
to	O	O
penicillins	B-Chemical	D010406
.	O	O

Immediate	O	O
allergic	B-Disease	D004342
reactions	I-Disease	D004342
to	O	O
amoxicillin	B-Chemical	D000658
.	O	O

A	O	O
large	O	O
group	O	O
of	O	O
patients	O	O
with	O	O
suspected	O	O
allergic	B-Disease	D004342
reactions	I-Disease	D004342
to	O	O
beta	B-Chemical	D047090
-	I-Chemical	D047090
lactam	I-Chemical	D047090
antibiotics	O	O
was	O	O
evaluated	O	O
.	O	O

A	O	O
detailed	O	O
clinical	O	O
history	O	O
,	O	O
together	O	O
with	O	O
skin	O	O
tests	O	O
,	O	O
RAST	O	O
(	O	O
radioallergosorbent	O	O
test	O	O
)	O	O
,	O	O
and	O	O
controlled	O	O
challenge	O	O
tests	O	O
,	O	O
was	O	O
used	O	O
to	O	O
establish	O	O
whether	O	O
patients	O	O
allergic	B-Disease	D004342
to	O	O
beta	B-Chemical	D047090
-	I-Chemical	D047090
lactam	I-Chemical	D047090
antibiotics	O	O
had	O	O
selective	O	O
immediate	O	O
allergic	B-Disease	D004342
responses	O	O
to	O	O
amoxicillin	B-Chemical	D000658
(	O	O
AX	B-Chemical	D000658
)	O	O
or	O	O
were	O	O
cross	O	O
-	O	O
reacting	O	O
with	O	O
other	O	O
penicillin	B-Chemical	D010406
derivatives	O	O
.	O	O

Skin	O	O
tests	O	O
were	O	O
performed	O	O
with	O	O
benzylpenicilloyl	B-Chemical	-1
-	I-Chemical	-1
poly	I-Chemical	-1
-	I-Chemical	-1
L	I-Chemical	-1
-	I-Chemical	-1
lysine	I-Chemical	-1
(	O	O
BPO	B-Chemical	-1
-	I-Chemical	-1
PLL	I-Chemical	-1
)	O	O
,	O	O
benzylpenicilloate	B-Chemical	-1
,	O	O
benzylpenicillin	B-Chemical	D010400
(	O	O
PG	B-Chemical	D010400
)	O	O
,	O	O
ampicillin	B-Chemical	D000667
(	O	O
AMP	B-Chemical	D000667
)	O	O
,	O	O
and	O	O
AX	B-Chemical	D000658
.	O	O

RAST	O	O
for	O	O
BPO	B-Chemical	-1
-	I-Chemical	-1
PLL	I-Chemical	-1
and	O	O
AX	B-Chemical	D000658
-	O	O
PLL	O	O
was	O	O
done	O	O
.	O	O

When	O	O
both	O	O
skin	O	O
test	O	O
and	O	O
RAST	O	O
for	O	O
BPO	B-Chemical	-1
were	O	O
negative	O	O
,	O	O
single	O	O
-	O	O
blind	O	O
,	O	O
placebo	O	O
-	O	O
controlled	O	O
challenge	O	O
tests	O	O
were	O	O
done	O	O
to	O	O
ensure	O	O
tolerance	O	O
of	O	O
PG	B-Chemical	D010400
or	O	O
sensitivity	O	O
to	O	O
AX	B-Chemical	D000658
.	O	O

A	O	O
total	O	O
of	O	O
177	O	O
patients	O	O
were	O	O
diagnosed	O	O
as	O	O
allergic	B-Disease	D004342
to	O	O
beta	B-Chemical	D047090
-	I-Chemical	D047090
lactam	I-Chemical	D047090
antibiotics	O	O
.	O	O

We	O	O
selected	O	O
the	O	O
54	O	O
(	O	O
30	O	O
.	O	O

5%	O	O
)	O	O
cases	O	O
of	O	O
immediate	O	O
AX	B-Chemical	D000658
allergy	B-Disease	D004342
with	O	O
good	O	O
tolerance	O	O
of	O	O
PG	B-Chemical	D010400
.	O	O

Anaphylaxis	B-Disease	D000707
was	O	O
seen	O	O
in	O	O
37	O	O
patients	O	O
(	O	O
69%	O	O
)	O	O
,	O	O
the	O	O
other	O	O
17	O	O
(	O	O
31%	O	O
)	O	O
having	O	O
urticaria	B-Disease	D014581
and	O	O
/	O	O
or	O	O
angioedema	B-Disease	D000799
.	O	O

All	O	O
the	O	O
patients	O	O
were	O	O
skin	O	O
test	O	O
negative	O	O
to	O	O
BPO	B-Chemical	-1
;	O	O
49	O	O
of	O	O
51	O	O
(	O	O
96%	O	O
)	O	O
were	O	O
also	O	O
negative	O	O
to	O	O
MDM	B-Disease	D007645
,	O	O
and	O	O
44	O	O
of	O	O
46	O	O
(	O	O
96%	O	O
)	O	O
to	O	O
PG	B-Chemical	D010400
.	O	O

Skin	O	O
tests	O	O
with	O	O
AX	B-Chemical	D000658
were	O	O
positive	O	O
in	O	O
34	O	O
(	O	O
63%	O	O
)	O	O
patients	O	O
.	O	O

RAST	O	O
was	O	O
positive	O	O
for	O	O
AX	B-Chemical	D000658
in	O	O
22	O	O
patients	O	O
(	O	O
41%	O	O
)	O	O
and	O	O
to	O	O
BPO	B-Chemical	-1
in	O	O
just	O	O
5	O	O
(	O	O
9%	O	O
)	O	O
.	O	O

None	O	O
of	O	O
the	O	O
sera	O	O
with	O	O
negative	O	O
RAST	O	O
for	O	O
AX	B-Chemical	D000658
were	O	O
positive	O	O
to	O	O
BPO	B-Chemical	-1
.	O	O

Challenge	O	O
tests	O	O
with	O	O
AX	B-Chemical	D000658
were	O	O
performed	O	O
in	O	O
23	O	O
subjects	O	O
(	O	O
43%	O	O
)	O	O
to	O	O
establish	O	O
the	O	O
diagnosis	O	O
of	O	O
immediate	O	O
allergic	B-Disease	D004342
reaction	O	O
to	O	O
AX	B-Chemical	D000658
,	O	O
and	O	O
in	O	O
15	O	O
cases	O	O
(	O	O
28%	O	O
)	O	O
both	O	O
skin	O	O
test	O	O
and	O	O
RAST	O	O
for	O	O
AX	B-Chemical	D000658
were	O	O
negative	O	O
.	O	O

PG	B-Chemical	D010400
was	O	O
well	O	O
tolerated	O	O
by	O	O
all	O	O
54	O	O
patients	O	O
.	O	O

We	O	O
describe	O	O
the	O	O
largest	O	O
group	O	O
of	O	O
AX	B-Chemical	D000658
-	O	O
allergic	B-Disease	D004342
patients	O	O
who	O	O
have	O	O
tolerated	O	O
PG	B-Chemical	D010400
reported	O	O
so	O	O
far	O	O
.	O	O

Diagnosis	O	O
of	O	O
these	O	O
patients	O	O
can	O	O
be	O	O
achieved	O	O
only	O	O
if	O	O
specific	O	O
AX	B-Chemical	D000658
-	O	O
related	O	O
reagents	O	O
are	O	O
employed	O	O
.	O	O

Further	O	O
studies	O	O
are	O	O
necessary	O	O
to	O	O
determine	O	O
the	O	O
exact	O	O
extent	O	O
of	O	O
this	O	O
problem	O	O
and	O	O
to	O	O
improve	O	O
the	O	O
efficacy	O	O
of	O	O
diagnostic	O	O
methods	O	O
.	O	O

Persistent	O	O
paralysis	B-Disease	D010243
after	O	O
prolonged	O	O
use	O	O
of	O	O
atracurium	B-Chemical	D001279
in	O	O
the	O	O
absence	O	O
of	O	O
corticosteroids	O	O
.	O	O

Neuromuscular	O	O
blocking	O	O
agents	O	O
(	O	O
NMBAs	O	O
)	O	O
are	O	O
often	O	O
used	O	O
for	O	O
patients	O	O
requiring	O	O
prolonged	O	O
mechanical	O	O
ventilation	O	O
.	O	O

Reports	O	O
of	O	O
persistent	O	O
paralysis	B-Disease	D010243
after	O	O
the	O	O
discontinuance	O	O
of	O	O
these	O	O
drugs	O	O
have	O	O
most	O	O
often	O	O
involved	O	O
aminosteroid	O	O
-	O	O
based	O	O
NMBAs	O	O
such	O	O
as	O	O
vecuronium	B-Chemical	D014673
bromide	I-Chemical	D014673
,	O	O
especially	O	O
when	O	O
used	O	O
in	O	O
conjunction	O	O
with	O	O
corticosteroids	O	O
.	O	O

Atracurium	B-Chemical	D001279
besylate	I-Chemical	D001279
,	O	O
a	O	O
short	O	O
-	O	O
acting	O	O
benzylisoquinolinium	B-Chemical	-1
NMBA	O	O
that	O	O
is	O	O
eliminated	O	O
independently	O	O
of	O	O
renal	O	O
or	O	O
hepatic	O	O
function	O	O
,	O	O
has	O	O
also	O	O
been	O	O
associated	O	O
with	O	O
persistent	O	O
paralysis	B-Disease	D010243
,	O	O
but	O	O
only	O	O
when	O	O
used	O	O
with	O	O
corticosteroids	O	O
.	O	O

We	O	O
report	O	O
a	O	O
case	O	O
of	O	O
atracurium	B-Chemical	D001279
-	O	O
related	O	O
paralysis	B-Disease	D010243
persisting	O	O
for	O	O
approximately	O	O
50	O	O
hours	O	O
in	O	O
a	O	O
patient	O	O
who	O	O
was	O	O
not	O	O
treated	O	O
with	O	O
corticosteroids	O	O
.	O	O

Habitual	O	O
use	O	O
of	O	O
acetaminophen	B-Chemical	D000082
as	O	O
a	O	O
risk	O	O
factor	O	O
for	O	O
chronic	B-Disease	D007676
renal	I-Disease	D007676
failure	I-Disease	D007676
:	O	O
a	O	O
comparison	O	O
with	O	O
phenacetin	B-Chemical	D010615
.	O	O

Six	O	O
epidemiologic	O	O
studies	O	O
in	O	O
the	O	O
United	O	O
States	O	O
and	O	O
Europe	O	O
indicate	O	O
that	O	O
habitual	O	O
use	O	O
of	O	O
phenacetin	B-Chemical	D010615
is	O	O
associated	O	O
with	O	O
the	O	O
development	O	O
of	O	O
chronic	B-Disease	D007676
renal	I-Disease	D007676
failure	I-Disease	D007676
and	O	O
end	B-Disease	D007676
-	I-Disease	D007676
stage	I-Disease	D007676
renal	I-Disease	D007676
disease	I-Disease	D007676
(	O	O
ESRD	B-Disease	D007676
)	O	O
,	O	O
with	O	O
a	O	O
relative	O	O
risk	O	O
in	O	O
the	O	O
range	O	O
of	O	O
4	O	O
to	O	O
19	O	O
.	O	O

As	O	O
a	O	O
result	O	O
of	O	O
these	O	O
and	O	O
other	O	O
studies	O	O
,	O	O
phenacetin	B-Chemical	D010615
has	O	O
now	O	O
been	O	O
withdrawn	O	O
from	O	O
the	O	O
market	O	O
in	O	O
most	O	O
countries	O	O
.	O	O

However	O	O
,	O	O
three	O	O
case	O	O
control	O	O
studies	O	O
,	O	O
one	O	O
each	O	O
in	O	O
North	O	O
Carolina	O	O
,	O	O
northern	O	O
Maryland	O	O
,	O	O
and	O	O
West	O	O
Berlin	O	O
,	O	O
Germany	O	O
,	O	O
showed	O	O
that	O	O
habitual	O	O
use	O	O
of	O	O
acetaminophen	B-Chemical	D000082
is	O	O
also	O	O
associated	O	O
with	O	O
chronic	B-Disease	D007676
renal	I-Disease	D007676
failure	I-Disease	D007676
and	O	O
ESRD	B-Disease	D007676
,	O	O
with	O	O
a	O	O
relative	O	O
risk	O	O
in	O	O
the	O	O
range	O	O
of	O	O
2	O	O
to	O	O
4	O	O
.	O	O

These	O	O
studies	O	O
suggest	O	O
that	O	O
both	O	O
phenacetin	B-Chemical	D010615
and	O	O
acetaminophen	B-Chemical	D000082
may	O	O
contribute	O	O
to	O	O
the	O	O
burden	O	O
of	O	O
ESRD	B-Disease	D007676
,	O	O
with	O	O
the	O	O
risk	O	O
of	O	O
the	O	O
latter	O	O
being	O	O
somewhat	O	O
less	O	O
than	O	O
that	O	O
of	O	O
the	O	O
former	O	O
.	O	O

This	O	O
apparent	O	O
difference	O	O
in	O	O
risk	O	O
may	O	O
not	O	O
be	O	O
due	O	O
to	O	O
differences	O	O
in	O	O
nephrotoxic	B-Disease	D007674
potential	O	O
of	O	O
the	O	O
drugs	O	O
themselves	O	O
.	O	O

A	O	O
lower	O	O
relative	O	O
risk	O	O
would	O	O
be	O	O
expected	O	O
for	O	O
acetaminophen	B-Chemical	D000082
if	O	O
the	O	O
risk	O	O
of	O	O
both	O	O
drugs	O	O
in	O	O
combination	O	O
with	O	O
other	O	O
analgesics	O	O
was	O	O
higher	O	O
than	O	O
the	O	O
risk	O	O
of	O	O
either	O	O
agent	O	O
alone	O	O
.	O	O

Thus	O	O
,	O	O
acetaminophen	B-Chemical	D000082
has	O	O
been	O	O
used	O	O
both	O	O
as	O	O
a	O	O
single	O	O
agent	O	O
and	O	O
in	O	O
combination	O	O
with	O	O
other	O	O
analgesics	O	O
,	O	O
whereas	O	O
phenacetin	B-Chemical	D010615
was	O	O
available	O	O
only	O	O
in	O	O
combinations	O	O
.	O	O

The	O	O
possibility	O	O
that	O	O
habitual	O	O
use	O	O
of	O	O
acetaminophen	B-Chemical	D000082
alone	O	O
increases	O	O
the	O	O
risk	O	O
of	O	O
ESRD	B-Disease	D007676
has	O	O
not	O	O
been	O	O
clearly	O	O
demonstrated	O	O
,	O	O
but	O	O
cannot	O	O
be	O	O
dismissed	O	O
.	O	O

Reduction	O	O
of	O	O
heparan	B-Chemical	D006497
sulphate	I-Chemical	D006497
-	O	O
associated	O	O
anionic	O	O
sites	O	O
in	O	O
the	O	O
glomerular	O	O
basement	O	O
membrane	O	O
of	O	O
rats	O	O
with	O	O
streptozotocin	B-Chemical	D013311
-	O	O
induced	O	O
diabetic	B-Disease	D003928
nephropathy	I-Disease	D003928
.	O	O

Heparan	B-Chemical	D006497
sulphate	I-Chemical	D006497
-	O	O
associated	O	O
anionic	O	O
sites	O	O
in	O	O
the	O	O
glomerular	O	O
basement	O	O
membrane	O	O
were	O	O
studied	O	O
in	O	O
rats	O	O
8	O	O
months	O	O
after	O	O
induction	O	O
of	O	O
diabetes	B-Disease	D003920
by	O	O
streptozotocin	B-Chemical	D013311
and	O	O
in	O	O
age	O	O
-	O	O
adn	O	O
sex	O	O
-	O	O
matched	O	O
control	O	O
rats	O	O
,	O	O
employing	O	O
the	O	O
cationic	O	O
dye	O	O
cuprolinic	B-Chemical	C015445
blue	I-Chemical	C015445
.	O	O

Morphometric	O	O
analysis	O	O
at	O	O
the	O	O
ultrastructural	O	O
level	O	O
was	O	O
performed	O	O
using	O	O
a	O	O
computerized	O	O
image	O	O
processor	O	O
.	O	O

The	O	O
heparan	B-Chemical	D006497
sulphate	I-Chemical	D006497
specificity	O	O
of	O	O
the	O	O
cuprolinic	B-Chemical	C015445
blue	I-Chemical	C015445
staining	O	O
was	O	O
demonstrated	O	O
by	O	O
glycosaminoglycan	B-Chemical	D006025
-	O	O
degrading	O	O
enzymes	O	O
,	O	O
showing	O	O
that	O	O
pretreatment	O	O
of	O	O
the	O	O
sections	O	O
with	O	O
heparitinase	O	O
abolished	O	O
all	O	O
staining	O	O
,	O	O
whereas	O	O
chondroitinase	O	O
ABC	O	O
had	O	O
no	O	O
effect	O	O
.	O	O

The	O	O
majority	O	O
of	O	O
anionic	O	O
sites	O	O
(	O	O
74%	O	O
in	O	O
diabetic	B-Disease	D003920
and	O	O
81%	O	O
in	O	O
control	O	O
rats	O	O
)	O	O
were	O	O
found	O	O
within	O	O
the	O	O
lamina	O	O
rara	O	O
externa	O	O
of	O	O
the	O	O
glomerular	O	O
basement	O	O
membrane	O	O
.	O	O

A	O	O
minority	O	O
of	O	O
anionic	O	O
sites	O	O
were	O	O
scattered	O	O
throughout	O	O
the	O	O
lamina	O	O
densa	O	O
and	O	O
lamina	O	O
rara	O	O
interna	O	O
,	O	O
and	O	O
were	O	O
significantly	O	O
smaller	O	O
than	O	O
those	O	O
in	O	O
the	O	O
lamina	O	O
rara	O	O
externa	O	O
of	O	O
the	O	O
glomerular	O	O
basement	O	O
membrane	O	O
(	O	O
p<0	O	O
.	O	O

001	O	O
and	O	O
p<0	O	O
.	O	O

01	O	O
for	O	O
diabetic	B-Disease	D003920
and	O	O
control	O	O
rats	O	O
,	O	O
respectively	O	O
)	O	O
.	O	O

Diabetic	B-Disease	D003920
rats	O	O
progressively	O	O
developed	O	O
albuminuria	B-Disease	D000419
reaching	O	O
40	O	O
.	O	O

3	O	O
(	O	O
32	O	O
.	O	O

2	O	O
-	O	O
62	O	O
.	O	O

0	O	O
)	O	O
mg	O	O
/	O	O
24	O	O
h	O	O
after	O	O
8	O	O
months	O	O
in	O	O
contrast	O	O
to	O	O
the	O	O
control	O	O
animals	O	O
(	O	O
0	O	O
.	O	O

8	O	O
(	O	O
0	O	O
.	O	O

2	O	O
-	O	O
0	O	O
.	O	O

9	O	O
)	O	O
mg	O	O
/	O	O
24	O	O
h	O	O
,	O	O
p<0	O	O
.	O	O

002	O	O
)	O	O
.	O	O

At	O	O
the	O	O
same	O	O
time	O	O
,	O	O
the	O	O
number	O	O
of	O	O
heparan	B-Chemical	D006497
sulphate	I-Chemical	D006497
anionic	O	O
sites	O	O
and	O	O
the	O	O
total	O	O
anionic	O	O
site	O	O
surface	O	O
(	O	O
number	O	O
of	O	O
anionic	O	O
sites	O	O
x	O	O
mean	O	O
anionic	O	O
site	O	O
surface	O	O
)	O	O
in	O	O
the	O	O
lamina	O	O
rara	O	O
externa	O	O
of	O	O
the	O	O
glomerular	O	O
basement	O	O
membrane	O	O
was	O	O
reduced	O	O
by	O	O
19%	O	O
(	O	O
p<0	O	O
.	O	O

021	O	O
)	O	O
and	O	O
by	O	O
26%	O	O
(	O	O
p<0	O	O
.	O	O

02	O	O
)	O	O
,	O	O
respectively	O	O
.	O	O

Number	O	O
and	O	O
total	O	O
anionic	O	O
site	O	O
surface	O	O
in	O	O
the	O	O
remaining	O	O
part	O	O
of	O	O
the	O	O
glomerular	O	O
basement	O	O
membrane	O	O
(	O	O
lamina	O	O
densa	O	O
and	O	O
lamina	O	O
rara	O	O
interna	O	O
)	O	O
were	O	O
not	O	O
significantly	O	O
changed	O	O
.	O	O

We	O	O
conclude	O	O
that	O	O
in	O	O
streptozotocin	B-Chemical	D013311
-	O	O
diabetic	B-Disease	D003920
rats	O	O
with	O	O
an	O	O
increased	O	O
urinary	O	O
albumin	O	O
excretion	O	O
,	O	O
a	O	O
reduced	O	O
heparan	B-Chemical	D006497
sulphate	I-Chemical	D006497
charge	O	O
barrier	O	O
/	O	O
density	O	O
is	O	O
found	O	O
at	O	O
the	O	O
lamina	O	O
rara	O	O
externa	O	O
of	O	O
the	O	O
glomerular	O	O
basement	O	O
membrane	O	O
.	O	O

Effect	O	O
of	O	O
some	O	O
anticancer	O	O
drugs	O	O
and	O	O
combined	O	O
chemotherapy	O	O
on	O	O
renal	B-Disease	D007674
toxicity	I-Disease	D007674
.	O	O

The	O	O
nephrotoxic	B-Disease	D007674
action	O	O
of	O	O
anticancer	O	O
drugs	O	O
such	O	O
as	O	O
nitrogranulogen	B-Chemical	D008466
(	O	O
NG	B-Chemical	D008466
)	O	O
,	O	O
methotrexate	B-Chemical	D008727
(	O	O
MTX	B-Chemical	D008727
)	O	O
,	O	O
5	B-Chemical	D005472
-	I-Chemical	D005472
fluorouracil	I-Chemical	D005472
(	O	O
5	B-Chemical	D005472
-	I-Chemical	D005472
FU	I-Chemical	D005472
)	O	O
and	O	O
cyclophosphamide	B-Chemical	D003520
(	O	O
CY	B-Chemical	D003520
)	O	O
administered	O	O
alone	O	O
or	O	O
in	O	O
combination	O	O
[	O	O
MTX	B-Chemical	D008727
+	O	O
5	B-Chemical	D005472
-	I-Chemical	D005472
FU	I-Chemical	D005472
+	O	O
CY	B-Chemical	D003520
(	O	O
CMF	O	O
)	O	O
]	O	O
was	O	O
evaluated	O	O
in	O	O
experiments	O	O
on	O	O
Wistar	O	O
rats	O	O
.	O	O

After	O	O
drug	O	O
administration	O	O
,	O	O
creatinine	B-Chemical	D003404
concentrations	O	O
in	O	O
the	O	O
plasma	O	O
and	O	O
in	O	O
the	O	O
urine	O	O
of	O	O
the	O	O
rats	O	O
were	O	O
determined	O	O
,	O	O
as	O	O
well	O	O
as	O	O
creatinine	B-Chemical	D003404
clearance	O	O
.	O	O

Histopathologic	O	O
evaluation	O	O
of	O	O
the	O	O
kidneys	O	O
was	O	O
also	O	O
performed	O	O
.	O	O

After	O	O
MTX	B-Chemical	D008727
administration	O	O
a	O	O
significant	O	O
increase	O	O
(	O	O
p	O	O
=	O	O
0	O	O
.	O	O

0228	O	O
)	O	O
in	O	O
the	O	O
plasma	O	O
creatinine	B-Chemical	D003404
concentration	O	O
and	O	O
a	O	O
significant	O	O
(	O	O
p	O	O
=	O	O
0	O	O
.	O	O

0001	O	O
)	O	O
decrease	O	O
in	O	O
creatinine	B-Chemical	D003404
clearance	O	O
was	O	O
noted	O	O
compared	O	O
to	O	O
controls	O	O
.	O	O

After	O	O
the	O	O
administration	O	O
of	O	O
NG	B-Chemical	D008466
,	O	O
5	B-Chemical	D005472
-	I-Chemical	D005472
FU	I-Chemical	D005472
and	O	O
CY	B-Chemical	D003520
neither	O	O
a	O	O
statistically	O	O
significant	O	O
increase	O	O
in	O	O
creatinine	B-Chemical	D003404
concentration	O	O
nor	O	O
an	O	O
increase	O	O
in	O	O
creatinine	B-Chemical	D003404
clearance	O	O
was	O	O
observed	O	O
compared	O	O
to	O	O
the	O	O
group	O	O
receiving	O	O
no	O	O
cytostatics	O	O
.	O	O

Following	O	O
polytherapy	O	O
according	O	O
to	O	O
the	O	O
CMF	O	O
regimen	O	O
,	O	O
a	O	O
statistically	O	O
significant	O	O
decrease	O	O
(	O	O
p	O	O
=	O	O
0	O	O
.	O	O

0343	O	O
)	O	O
in	O	O
creatinine	B-Chemical	D003404
clearance	O	O
was	O	O
found	O	O
,	O	O
but	O	O
creatinine	B-Chemical	D003404
concentration	O	O
did	O	O
not	O	O
increase	O	O
significantly	O	O
compared	O	O
to	O	O
controls	O	O
.	O	O

CY	B-Chemical	D003520
caused	O	O
hemorrhagic	O	O
cystitis	O	O
in	O	O
40%	O	O
of	O	O
rats	O	O
,	O	O
but	O	O
it	O	O
did	O	O
not	O	O
cause	O	O
this	O	O
complication	O	O
when	O	O
combined	O	O
with	O	O
5	B-Chemical	D005472
-	I-Chemical	D005472
FU	I-Chemical	D005472
and	O	O
MTX	B-Chemical	D008727
.	O	O

Histologic	O	O
changes	O	O
were	O	O
found	O	O
in	O	O
rat	O	O
kidneys	O	O
after	O	O
administration	O	O
of	O	O
MTX	B-Chemical	D008727
,	O	O
CY	B-Chemical	D003520
and	O	O
NG	B-Chemical	D008466
,	O	O
while	O	O
no	O	O
such	O	O
change	O	O
was	O	O
observed	O	O
after	O	O
5	B-Chemical	D005472
-	I-Chemical	D005472
FU	I-Chemical	D005472
and	O	O
joint	O	O
administration	O	O
of	O	O
MTX	B-Chemical	D008727
+	O	O
5	B-Chemical	D005472
-	I-Chemical	D005472
FU	I-Chemical	D005472
+	O	O
CY	B-Chemical	D003520
compared	O	O
to	O	O
controls	O	O
.	O	O

Our	O	O
studies	O	O
indicate	O	O
that	O	O
nephrotoxicity	B-Disease	D007674
of	O	O
MTX	B-Chemical	D008727
+	O	O
5	B-Chemical	D005472
-	I-Chemical	D005472
FU	I-Chemical	D005472
+	O	O
CY	B-Chemical	D003520
administered	O	O
jointly	O	O
is	O	O
lower	O	O
than	O	O
in	O	O
monotherapy	O	O
.	O	O

Lithium	B-Chemical	D008094
-	O	O
associated	O	O
cognitive	B-Disease	D003072
and	I-Disease	D003072
functional	I-Disease	D003072
deficits	I-Disease	D003072
reduced	O	O
by	O	O
a	O	O
switch	O	O
to	O	O
divalproex	B-Chemical	D014635
sodium	I-Chemical	D014635
:	O	O
a	O	O
case	O	O
series	O	O
.	O	O

BACKGROUND	O	O
:	O	O
Lithium	B-Chemical	D008094
remains	O	O
a	O	O
first	O	O
-	O	O
line	O	O
treatment	O	O
for	O	O
the	O	O
acute	O	O
and	O	O
maintenance	O	O
treatment	O	O
of	O	O
bipolar	B-Disease	D001714
disorder	I-Disease	D001714
.	O	O

Although	O	O
much	O	O
has	O	O
been	O	O
written	O	O
about	O	O
the	O	O
management	O	O
of	O	O
the	O	O
more	O	O
common	O	O
adverse	O	O
effects	O	O
of	O	O
lithium	B-Chemical	D008094
,	O	O
such	O	O
as	O	O
polyuria	B-Disease	D011141
and	O	O
tremor	B-Disease	D014202
,	O	O
more	O	O
subtle	O	O
lithium	B-Chemical	D008094
side	O	O
effects	O	O
such	O	O
as	O	O
cognitive	B-Disease	D003072
deficits	I-Disease	D003072
,	O	O
loss	B-Disease	D003072
of	I-Disease	D003072
creativity	I-Disease	D003072
,	O	O
and	O	O
functional	B-Disease	D003072
impairments	I-Disease	D003072
remain	O	O
understudied	O	O
.	O	O

This	O	O
report	O	O
summarizes	O	O
our	O	O
experience	O	O
in	O	O
switching	O	O
bipolar	B-Disease	D001714
patients	O	O
from	O	O
lithium	B-Chemical	D008094
to	O	O
divalproex	B-Chemical	D014635
sodium	I-Chemical	D014635
to	O	O
alleviate	O	O
such	O	O
cognitive	B-Disease	D003072
and	I-Disease	D003072
functional	I-Disease	D003072
impairments	I-Disease	D003072
.	O	O

METHOD	O	O
:	O	O
Open	O	O
,	O	O
case	O	O
series	O	O
design	O	O
.	O	O

RESULTS	O	O
:	O	O
We	O	O
report	O	O
seven	O	O
cases	O	O
where	O	O
substitution	O	O
of	O	O
lithium	B-Chemical	D008094
,	O	O
either	O	O
fully	O	O
or	O	O
partially	O	O
,	O	O
with	O	O
divalproex	B-Chemical	D014635
sodium	I-Chemical	D014635
was	O	O
extremely	O	O
helpful	O	O
in	O	O
reducing	O	O
the	O	O
cognitive	B-Disease	D003072
,	I-Disease	D003072
motivational	I-Disease	D003072
,	I-Disease	D003072
or	I-Disease	D003072
creative	I-Disease	D003072
deficits	I-Disease	D003072
attributed	O	O
to	O	O
lithium	B-Chemical	D008094
in	O	O
our	O	O
bipolar	B-Disease	D001714
patients	O	O
.	O	O

CONCLUSION	O	O
:	O	O
In	O	O
this	O	O
preliminary	O	O
report	O	O
,	O	O
divalproex	B-Chemical	D014635
sodium	I-Chemical	D014635
was	O	O
a	O	O
superior	O	O
alternative	O	O
to	O	O
lithium	B-Chemical	D008094
in	O	O
bipolar	B-Disease	D001714
patients	O	O
experiencing	O	O
cognitive	B-Disease	D003072
deficits	I-Disease	D003072
,	O	O
loss	B-Disease	D003072
of	I-Disease	D003072
creativity	I-Disease	D003072
,	O	O
and	O	O
functional	B-Disease	D003072
impairments	I-Disease	D003072
.	O	O

Treatment	O	O
of	O	O
previously	O	O
treated	O	O
metastatic	O	O
breast	B-Disease	D001943
cancer	I-Disease	D001943
by	O	O
mitoxantrone	B-Chemical	D008942
and	O	O
48	O	O
-	O	O
hour	O	O
continuous	O	O
infusion	O	O
of	O	O
high	O	O
-	O	O
dose	O	O
5	B-Chemical	D005472
-	I-Chemical	D005472
FU	I-Chemical	D005472
and	O	O
leucovorin	B-Chemical	D002955
(	O	O
MFL	B-Chemical	C085788
)	O	O
:	O	O
low	O	O
palliative	O	O
benefit	O	O
and	O	O
high	O	O
treatment	O	O
-	O	O
related	O	O
toxicity	B-Disease	D064420
.	O	O

For	O	O
previously	O	O
treated	O	O
advanced	O	O
breast	B-Disease	D001943
cancer	I-Disease	D001943
,	O	O
there	O	O
is	O	O
no	O	O
standard	O	O
second	O	O
-	O	O
line	O	O
therapy	O	O
.	O	O

Combination	O	O
chemotherapy	O	O
with	O	O
mitoxantrone	B-Chemical	D008942
,	O	O
high	O	O
-	O	O
dose	O	O
5	B-Chemical	D005472
-	I-Chemical	D005472
fluorouracil	I-Chemical	D005472
(	O	O
5	B-Chemical	D005472
-	I-Chemical	D005472
FU	I-Chemical	D005472
)	O	O
and	O	O
leucovorin	B-Chemical	D002955
(	O	O
MFL	B-Chemical	C085788
regimen	O	O
)	O	O
had	O	O
been	O	O
reported	O	O
as	O	O
an	O	O
effective	O	O
and	O	O
well	O	O
tolerated	O	O
regimen	O	O
.	O	O

From	O	O
October	O	O
1993	O	O
to	O	O
November	O	O
1995	O	O
,	O	O
we	O	O
treated	O	O
13	O	O
patients	O	O
with	O	O
previously	O	O
chemotherapy	O	O
-	O	O
treated	O	O
metastatic	O	O
breast	B-Disease	D001943
cancer	I-Disease	D001943
by	O	O
mitoxantrone	B-Chemical	D008942
,	O	O
12	O	O
mg	O	O
/	O	O
m2	O	O
,	O	O
on	O	O
day	O	O
1	O	O
and	O	O
continuous	O	O
infusion	O	O
of	O	O
5	B-Chemical	D005472
-	I-Chemical	D005472
FU	I-Chemical	D005472
,	O	O
3000	O	O
mg	O	O
/	O	O
m2	O	O
,	O	O
together	O	O
with	O	O
leucovorin	B-Chemical	D002955
,	O	O
300	O	O
mg	O	O
/	O	O
m2	O	O
,	O	O
for	O	O
48	O	O
h	O	O
from	O	O
day	O	O
1	O	O
to	O	O
2	O	O
.	O	O

Each	O	O
course	O	O
of	O	O
chemotherapy	O	O
was	O	O
given	O	O
every	O	O
4	O	O
weeks	O	O
.	O	O

Most	O	O
of	O	O
these	O	O
patients	O	O
had	O	O
more	O	O
than	O	O
two	O	O
metastatic	O	O
sites	O	O
,	O	O
with	O	O
lung	O	O
metastasis	O	O
predominant	O	O
.	O	O

Seven	O	O
patients	O	O
had	O	O
been	O	O
treated	O	O
with	O	O
anthracycline	B-Chemical	D018943
.	O	O

Seven	O	O
patients	O	O
had	O	O
previously	O	O
received	O	O
radiotherapy	O	O
and	O	O
seven	O	O
had	O	O
received	O	O
hormone	O	O
therapy	O	O
.	O	O

Median	O	O
number	O	O
of	O	O
courses	O	O
of	O	O
MFL	B-Chemical	C085788
regimen	O	O
given	O	O
was	O	O
six	O	O
and	O	O
the	O	O
median	O	O
cumulative	O	O
dose	O	O
of	O	O
mitoxantrone	B-Chemical	D008942
was	O	O
68	O	O
.	O	O

35	O	O
mg	O	O
/	O	O
m2	O	O
.	O	O

One	O	O
patient	O	O
had	O	O
complete	O	O
response	O	O
,	O	O
seven	O	O
had	O	O
stable	O	O
disease	O	O
,	O	O
none	O	O
had	O	O
partial	O	O
response	O	O
and	O	O
five	O	O
had	O	O
progressive	O	O
disease	O	O
.	O	O

The	O	O
overall	O	O
objective	O	O
response	O	O
rate	O	O
was	O	O
7	O	O
.	O	O

6%	O	O
.	O	O

The	O	O
median	O	O
follow	O	O
-	O	O
up	O	O
period	O	O
was	O	O
14	O	O
months	O	O
.	O	O

Median	O	O
survival	O	O
was	O	O
16	O	O
months	O	O
.	O	O

Median	O	O
progression	O	O
-	O	O
free	O	O
survival	O	O
was	O	O
5	O	O
months	O	O
.	O	O

A	O	O
complete	O	O
responder	O	O
had	O	O
relapse	O	O
-	O	O
free	O	O
survival	O	O
up	O	O
to	O	O
17	O	O
months	O	O
.	O	O

Major	O	O
toxicities	B-Disease	D064420
were	O	O
cardiotoxicity	B-Disease	D066126
and	O	O
leukopenia	B-Disease	D007970
.	O	O

Eight	O	O
patients	O	O
were	O	O
dead	O	O
in	O	O
the	O	O
last	O	O
follow	O	O
-	O	O
up	O	O
;	O	O
two	O	O
of	O	O
them	O	O
died	O	O
of	O	O
treatment	O	O
-	O	O
related	O	O
toxicity	B-Disease	D064420
.	O	O

The	O	O
MFL	B-Chemical	C085788
regimen	O	O
achieves	O	O
little	O	O
palliative	O	O
benefit	O	O
and	O	O
induces	O	O
severe	O	O
toxicity	B-Disease	D064420
at	O	O
a	O	O
fairly	O	O
high	O	O
rate	O	O
.	O	O

Administration	O	O
of	O	O
this	O	O
regimen	O	O
to	O	O
breast	B-Disease	D001943
cancer	I-Disease	D001943
patients	O	O
who	O	O
have	O	O
been	O	O
treated	O	O
by	O	O
chemotherapy	O	O
and	O	O
those	O	O
with	O	O
impaired	B-Disease	D006331
heart	I-Disease	D006331
function	I-Disease	D006331
requires	O	O
careful	O	O
attention	O	O
.	O	O

Upregulation	O	O
of	O	O
the	O	O
expression	O	O
of	O	O
vasopressin	B-Chemical	D014667
gene	O	O
in	O	O
the	O	O
paraventricular	O	O
and	O	O
supraoptic	O	O
nuclei	O	O
of	O	O
the	O	O
lithium	B-Chemical	D008094
-	O	O
induced	O	O
diabetes	B-Disease	D003919
insipidus	I-Disease	D003919
rat	O	O
.	O	O

The	O	O
expression	O	O
of	O	O
arginine	B-Chemical	D001127
vasopressin	I-Chemical	D001127
(	O	O
AVP	B-Chemical	D001127
)	O	O
gene	O	O
in	O	O
the	O	O
paraventricular	O	O
(	O	O
PVN	O	O
)	O	O
and	O	O
supraoptic	O	O
nuclei	O	O
(	O	O
SON	O	O
)	O	O
was	O	O
investigated	O	O
in	O	O
rats	O	O
with	O	O
lithium	B-Chemical	D008094
(	O	O
Li	B-Chemical	D008094
)	O	O
-	O	O
induced	O	O
polyuria	B-Disease	D011141
,	O	O
using	O	O
in	O	O
situ	O	O
hybridization	O	O
histochemistry	O	O
and	O	O
radioimmunoassay	O	O
.	O	O

The	O	O
male	O	O
Wistar	O	O
rats	O	O
consuming	O	O
a	O	O
diet	O	O
that	O	O
contained	O	O
LiCl	B-Chemical	D018021
(	O	O
60	O	O
mmol	O	O
/	O	O
kg	O	O
)	O	O
for	O	O
4	O	O
weeks	O	O
developed	O	O
marked	O	O
polyuria	B-Disease	D011141
.	O	O

The	O	O
Li	B-Chemical	D008094
-	O	O
treated	O	O
rats	O	O
produced	O	O
a	O	O
large	O	O
volume	O	O
of	O	O
hypotonic	O	O
urine	O	O
with	O	O
low	O	O
ionic	O	O
concentrations	O	O
.	O	O

Plasma	O	O
sodium	B-Chemical	D012964
concentrations	O	O
were	O	O
found	O	O
to	O	O
be	O	O
slightly	O	O
increased	O	O
in	O	O
the	O	O
Li	B-Chemical	D008094
-	O	O
treated	O	O
rats	O	O
compared	O	O
with	O	O
those	O	O
in	O	O
controls	O	O
.	O	O

Plasma	O	O
concentration	O	O
of	O	O
AVP	B-Chemical	D001127
and	O	O
transcripts	O	O
of	O	O
AVP	B-Chemical	D001127
gene	O	O
in	O	O
the	O	O
PVN	O	O
and	O	O
SON	O	O
were	O	O
significantly	O	O
increased	O	O
in	O	O
the	O	O
Li	B-Chemical	D008094
-	O	O
treated	O	O
rats	O	O
compared	O	O
with	O	O
controls	O	O
.	O	O

These	O	O
results	O	O
suggest	O	O
that	O	O
dehydration	B-Disease	D003681
and	O	O
/	O	O
or	O	O
the	O	O
activation	O	O
of	O	O
visceral	O	O
afferent	O	O
inputs	O	O
may	O	O
contribute	O	O
to	O	O
the	O	O
elevation	O	O
of	O	O
plasma	O	O
AVP	B-Chemical	D001127
and	O	O
the	O	O
upregulation	O	O
of	O	O
AVP	B-Chemical	D001127
gene	O	O
expression	O	O
in	O	O
the	O	O
PVN	O	O
and	O	O
the	O	O
SON	O	O
of	O	O
the	O	O
Li	B-Chemical	D008094
-	O	O
induced	O	O
diabetes	B-Disease	D003919
insipidus	I-Disease	D003919
rat	O	O
.	O	O

Suxamethonium	B-Chemical	D013390
-	O	O
induced	O	O
cardiac	B-Disease	D006323
arrest	I-Disease	D006323
and	O	O
death	B-Disease	D003643
following	O	O
5	O	O
days	O	O
of	O	O
immobilization	O	O
.	O	O

The	O	O
present	O	O
report	O	O
describes	O	O
a	O	O
case	O	O
of	O	O
cardiac	B-Disease	D006323
arrest	I-Disease	D006323
and	O	O
subsequent	O	O
death	B-Disease	D003643
as	O	O
a	O	O
result	O	O
of	O	O
hyperkalaemia	B-Disease	D006947
following	O	O
the	O	O
use	O	O
of	O	O
suxamethonium	B-Chemical	D013390
in	O	O
a	O	O
23	O	O
-	O	O
year	O	O
-	O	O
old	O	O
Malawian	O	O
woman	O	O
.	O	O

Five	O	O
days	O	O
after	O	O
the	O	O
onset	O	O
of	O	O
the	O	O
symptoms	O	O
of	O	O
meningitis	B-Disease	D008581
,	O	O
the	O	O
patient	O	O
aspirated	O	O
stomach	O	O
contents	O	O
and	O	O
needed	O	O
endotracheal	O	O
intubation	O	O
.	O	O

Forty	O	O
seconds	O	O
after	O	O
injection	O	O
of	O	O
suxamethonium	B-Chemical	D013390
,	O	O
bradycardia	B-Disease	D001919
and	O	O
cardiac	B-Disease	D006323
arrest	I-Disease	D006323
occurred	O	O
.	O	O

Attempts	O	O
to	O	O
resuscitate	O	O
the	O	O
patient	O	O
were	O	O
not	O	O
successful	O	O
.	O	O

The	O	O
serum	O	O
level	O	O
of	O	O
potassium	B-Chemical	D011188
was	O	O
observed	O	O
to	O	O
be	O	O
8	O	O
.	O	O

4	O	O
mequiv	O	O
L	O	O
-	O	O
1	O	O
.	O	O

Apart	O	O
from	O	O
the	O	O
reduction	O	O
in	O	O
the	O	O
patient's	O	O
level	O	O
of	O	O
consciousness	O	O
,	O	O
there	O	O
were	O	O
no	O	O
signs	O	O
of	O	O
motor	O	O
neurone	O	O
damage	O	O
or	O	O
of	O	O
any	O	O
of	O	O
the	O	O
other	O	O
known	O	O
predisposing	O	O
conditions	O	O
for	O	O
hyperkalaemia	B-Disease	D006947
following	O	O
the	O	O
administration	O	O
of	O	O
suxamethonium	B-Chemical	D013390
.	O	O

It	O	O
is	O	O
postulated	O	O
that	O	O
her	O	O
death	B-Disease	D003643
was	O	O
caused	O	O
by	O	O
hypersensitivity	B-Disease	D004342
to	O	O
suxamethonium	B-Chemical	D013390
,	O	O
associated	O	O
with	O	O
her	O	O
5	O	O
-	O	O
day	O	O
immobilization	O	O
.	O	O

An	O	O
unusual	O	O
toxic	O	O
reaction	O	O
to	O	O
axillary	O	O
block	O	O
by	O	O
mepivacaine	B-Chemical	D008619
with	O	O
adrenaline	B-Chemical	D004837
.	O	O

An	O	O
increase	B-Disease	D006973
in	I-Disease	D006973
blood	I-Disease	D006973
pressure	I-Disease	D006973
,	O	O
accompanied	O	O
by	O	O
atrial	B-Disease	D001281
fibrillation	I-Disease	D001281
,	O	O
agitation	B-Disease	D011595
,	O	O
incomprehensible	B-Disease	D019954
shouts	I-Disease	D019954
and	O	O
loss	B-Disease	D014474
of	I-Disease	D014474
consciousness	I-Disease	D014474
,	O	O
was	O	O
observed	O	O
in	O	O
an	O	O
elderly	O	O
,	O	O
ASA	O	O
classification	O	O
group	O	O
II	O	O
,	O	O
cardiovascularly	O	O
medicated	O	O
male	O	O
,	O	O
12	O	O
min	O	O
after	O	O
performance	O	O
of	O	O
axillary	O	O
block	O	O
with	O	O
mepivacaine	B-Chemical	D008619
850	O	O
mg	O	O
containing	O	O
adrenaline	B-Chemical	D004837
0	O	O
.	O	O

225	O	O
mg	O	O
,	O	O
for	O	O
correction	O	O
of	O	O
Dupuytren's	B-Disease	D004387
contracture	I-Disease	D004387
.	O	O

After	O	O
intravenous	O	O
administration	O	O
of	O	O
labetalol	B-Chemical	D007741
,	O	O
metoprolol	B-Chemical	D008790
and	O	O
midazolam	B-Chemical	D008874
the	O	O
patient's	O	O
condition	O	O
improved	O	O
,	O	O
and	O	O
15	O	O
min	O	O
later	O	O
he	O	O
woke	O	O
up	O	O
.	O	O

The	O	O
block	O	O
was	O	O
successful	O	O
and	O	O
surgery	O	O
was	O	O
conducted	O	O
as	O	O
scheduled	O	O
despite	O	O
persisting	O	O
atrial	B-Disease	D001281
fibrillation	I-Disease	D001281
.	O	O

Postoperatively	O	O
,	O	O
the	O	O
patient	O	O
refused	O	O
DC	O	O
cardioversion	O	O
and	O	O
was	O	O
treated	O	O
medically	O	O
.	O	O

Both	O	O
the	O	O
temporal	O	O
relationship	O	O
of	O	O
events	O	O
and	O	O
the	O	O
response	O	O
to	O	O
treatment	O	O
suggest	O	O
that	O	O
a	O	O
rapid	O	O
systemic	O	O
absorption	O	O
of	O	O
mepivacaine	B-Chemical	D008619
with	O	O
adrenaline	B-Chemical	D004837
and	O	O
/	O	O
or	O	O
interaction	O	O
of	O	O
these	O	O
drugs	O	O
with	O	O
the	O	O
patient's	O	O
cardiovascular	O	O
medications	O	O
were	O	O
responsible	O	O
for	O	O
the	O	O
perioperative	O	O
complications	O	O
.	O	O

Clinical	O	O
and	O	O
histopathologic	O	O
examination	O	O
of	O	O
renal	O	O
allografts	O	O
treated	O	O
with	O	O
tacrolimus	B-Chemical	D016559
(	O	O
FK506	B-Chemical	D016559
)	O	O
for	O	O
at	O	O
least	O	O
one	O	O
year	O	O
.	O	O

BACKGROUND	O	O
:	O	O
We	O	O
clinically	O	O
and	O	O
pathologically	O	O
analyzed	O	O
renal	O	O
allografts	O	O
from	O	O
1	O	O
9	O	O
renal	O	O
transplant	O	O
patients	O	O
treated	O	O
with	O	O
tacrolimus	B-Chemical	D016559
(	O	O
FK506	B-Chemical	D016559
)	O	O
for	O	O
more	O	O
than	O	O
1	O	O
year	O	O
.	O	O

METHODS	O	O
:	O	O
Twenty	O	O
-	O	O
six	O	O
renal	O	O
allograft	O	O
biopsy	O	O
specimens	O	O
from	O	O
1	O	O
9	O	O
renal	O	O
transplant	O	O
patients	O	O
who	O	O
underwent	O	O
transplantations	O	O
between	O	O
1991	O	O
and	O	O
1993	O	O
were	O	O
evaluated	O	O
.	O	O

Thirteen	O	O
biopsies	O	O
were	O	O
performed	O	O
from	O	O
stable	O	O
functioning	O	O
renal	O	O
allografts	O	O
with	O	O
informed	O	O
consent	O	O
(	O	O
nonepisode	O	O
biopsy	O	O
)	O	O
and	O	O
the	O	O
other	O	O
13	O	O
were	O	O
from	O	O
dysfunctional	O	O
renal	O	O
allografts	O	O
with	O	O
a	O	O
clinical	O	O
indication	O	O
for	O	O
biopsy	O	O
(	O	O
episode	O	O
biopsy	O	O
)	O	O
.	O	O

RESULTS	O	O
:	O	O
The	O	O
main	O	O
pathologic	O	O
diagnoses	O	O
(	O	O
some	O	O
overlap	O	O
)	O	O
were	O	O
acute	O	O
rejection	O	O
(	O	O
AR	O	O
;	O	O
n	O	O
=	O	O
4	O	O
)	O	O
,	O	O
chronic	O	O
rejection	O	O
(	O	O
CR	O	O
;	O	O
n=5	O	O
)	O	O
,	O	O
AR+CR	O	O
(	O	O
n	O	O
=4	O	O
)	O	O
,	O	O
recurrent	O	O
IgA	B-Disease	D005922
nephropathy	I-Disease	D005922
(	O	O
n	O	O
=5	O	O
)	O	O
,	O	O
normal	O	O
findings	O	O
(	O	O
n	O	O
=2	O	O
)	O	O
,	O	O
minimal	O	O
-	O	O
type	O	O
chronic	O	O
FK506	B-Chemical	D016559
nephropathy	B-Disease	D007674
(	O	O
n	O	O
=	O	O
9	O	O
)	O	O
,	O	O
and	O	O
mild	O	O
-	O	O
type	O	O
FK506	B-Chemical	D016559
nephropathy	B-Disease	D007674
(	O	O
n	O	O
=	O	O
11	O	O
)	O	O
.	O	O

Of	O	O
the	O	O
nonepisode	O	O
biopsies	O	O
,	O	O
7	O	O
and	O	O
4	O	O
biopsies	O	O
showed	O	O
minimal	O	O
-	O	O
type	O	O
and	O	O
mild	O	O
-	O	O
type	O	O
chronic	O	O
FK506	B-Chemical	D016559
nephropathy	B-Disease	D007674
,	O	O
respectively	O	O
.	O	O

Chronic	O	O
FK506	B-Chemical	D016559
nephropathy	B-Disease	D007674
consisted	O	O
of	O	O
rough	O	O
and	O	O
foamy	O	O
tubular	O	O
vacuolization	O	O
(	O	O
5	O	O
biopsies	O	O
)	O	O
,	O	O
arteriolopathy	O	O
(	O	O
angiodegeneration	O	O
of	O	O
the	O	O
arteriolar	O	O
wall	O	O
;	O	O
20	O	O
biopsies	O	O
)	O	O
,	O	O
focal	B-Disease	D005923
segmental	I-Disease	D005923
glomerulosclerosis	I-Disease	D005923
(	O	O
4	O	O
biopsies	O	O
)	O	O
and	O	O
the	O	O
striped	O	O
form	O	O
of	O	O
interstitial	B-Disease	D005355
fibrosis	I-Disease	D005355
(	O	O
11	O	O
biopsies	O	O
)	O	O
.	O	O

The	O	O
serum	O	O
creatinine	B-Chemical	D003404
levels	O	O
of	O	O
patients	O	O
in	O	O
the	O	O
mild	O	O
-	O	O
type	O	O
chronic	O	O
FK506	B-Chemical	D016559
nephropathy	B-Disease	D007674
group	O	O
,	O	O
which	O	O
included	O	O
7	O	O
episode	O	O
biopsies	O	O
,	O	O
were	O	O
statistically	O	O
higher	O	O
than	O	O
those	O	O
in	O	O
the	O	O
minimum	O	O
-	O	O
type	O	O
chronic	O	O
FK506	B-Chemical	D016559
-	O	O
nephropathy	B-Disease	D007674
group	O	O
(	O	O
P<	O	O
0	O	O
.	O	O

001	O	O
)	O	O
.	O	O

CONCLUSIONS	O	O
:	O	O
This	O	O
study	O	O
demonstrates	O	O
that	O	O
chronic	O	O
FK506	B-Chemical	D016559
nephropathy	B-Disease	D007674
consists	O	O
primarily	O	O
of	O	O
arteriolopathy	O	O
manifesting	O	O
as	O	O
insudative	O	O
hyalinosis	O	O
of	O	O
the	O	O
arteriolar	O	O
wall	O	O
,	O	O
and	O	O
suggests	O	O
that	O	O
mild	O	O
-	O	O
type	O	O
chronic	O	O
FK506	B-Chemical	D016559
nephropathy	B-Disease	D007674
is	O	O
a	O	O
condition	O	O
which	O	O
may	O	O
lead	O	O
to	O	O
deterioration	O	O
of	O	O
renal	O	O
allograft	O	O
function	O	O
.	O	O

Memory	O	O
facilitation	O	O
and	O	O
stimulation	O	O
of	O	O
endogenous	O	O
nerve	O	O
growth	O	O
factor	O	O
synthesis	O	O
by	O	O
the	O	O
acetylcholine	B-Chemical	D000109
releaser	O	O
PG	B-Chemical	C087567
-	I-Chemical	C087567
9	I-Chemical	C087567
.	O	O

The	O	O
effects	O	O
of	O	O
PG	B-Chemical	C087567
-	I-Chemical	C087567
9	I-Chemical	C087567
(	O	O
3alpha	B-Chemical	C087567
-	I-Chemical	C087567
tropyl	I-Chemical	C087567
2	I-Chemical	C087567
-	I-Chemical	C087567
(	I-Chemical	C087567
p	I-Chemical	C087567
-	I-Chemical	C087567
bromophenyl	I-Chemical	C087567
)	I-Chemical	C087567
propionate	I-Chemical	C087567
)	O	O
,	O	O
the	O	O
acetylcholine	B-Chemical	D000109
releaser	O	O
,	O	O
on	O	O
memory	O	O
processes	O	O
and	O	O
nerve	O	O
growth	O	O
factor	O	O
(	O	O
NGF	O	O
)	O	O
synthesis	O	O
were	O	O
evaluated	O	O
.	O	O

In	O	O
the	O	O
mouse	O	O
passive	O	O
-	O	O
avoidance	O	O
test	O	O
,	O	O
PG	B-Chemical	C087567
-	I-Chemical	C087567
9	I-Chemical	C087567
(	O	O
10	O	O
-	O	O
30	O	O
mg	O	O
/	O	O
kg	O	O
,	O	O
i	O	O
.	O	O

p	O	O
.	O	O

)	O	O
,	O	O
administered	O	O
20	O	O
min	O	O
before	O	O
the	O	O
training	O	O
session	O	O
,	O	O
prevented	O	O
amnesia	B-Disease	D000647
induced	O	O
by	O	O
both	O	O
the	O	O
non	O	O
selective	O	O
antimuscarinic	O	O
drug	O	O
scopolamine	B-Chemical	D012601
and	O	O
the	O	O
M1	O	O
-	O	O
selective	O	O
antagonist	O	O
S	B-Chemical	C098725
-	I-Chemical	C098725
(	I-Chemical	C098725
-	I-Chemical	C098725
)	I-Chemical	C098725
-	I-Chemical	C098725
ET	I-Chemical	C098725
-	I-Chemical	C098725
126	I-Chemical	C098725
.	O	O

In	O	O
the	O	O
same	O	O
experimental	O	O
conditions	O	O
,	O	O
PG	B-Chemical	C087567
-	I-Chemical	C087567
9	I-Chemical	C087567
(	O	O
5	O	O
-	O	O
20	O	O
microg	O	O
per	O	O
mouse	O	O
,	O	O
i	O	O
.	O	O

c	O	O
.	O	O

v	O	O
.	O	O

)	O	O
was	O	O
also	O	O
able	O	O
to	O	O
prevent	O	O
antimuscarine	O	O
-	O	O
induced	O	O
amnesia	B-Disease	D000647
,	O	O
demonstrating	O	O
a	O	O
central	O	O
localization	O	O
of	O	O
the	O	O
activity	O	O
.	O	O

At	O	O
the	O	O
highest	O	O
effective	O	O
doses	O	O
,	O	O
PG	B-Chemical	C087567
-	I-Chemical	C087567
9	I-Chemical	C087567
did	O	O
not	O	O
produce	O	O
any	O	O
collateral	O	O
symptoms	O	O
as	O	O
revealed	O	O
by	O	O
the	O	O
Irwin	O	O
test	O	O
,	O	O
and	O	O
it	O	O
did	O	O
not	O	O
modify	O	O
spontaneous	O	O
motility	O	O
and	O	O
inspection	O	O
activity	O	O
,	O	O
as	O	O
revealed	O	O
by	O	O
the	O	O
hole	O	O
-	O	O
board	O	O
test	O	O
.	O	O

PG	B-Chemical	C087567
-	I-Chemical	C087567
9	I-Chemical	C087567
was	O	O
also	O	O
able	O	O
to	O	O
increase	O	O
the	O	O
amount	O	O
of	O	O
NGF	O	O
secreted	O	O
in	O	O
vitro	O	O
by	O	O
astrocytes	O	O
in	O	O
a	O	O
dose	O	O
-	O	O
dependent	O	O
manner	O	O
.	O	O

The	O	O
maximal	O	O
NGF	O	O
contents	O	O
obtained	O	O
by	O	O
PG	B-Chemical	C087567
-	I-Chemical	C087567
9	I-Chemical	C087567
were	O	O
17	O	O
.	O	O

6	O	O
-	O	O
fold	O	O
of	O	O
the	O	O
control	O	O
value	O	O
.	O	O

During	O	O
culture	O	O
,	O	O
no	O	O
morphological	O	O
changes	O	O
were	O	O
found	O	O
at	O	O
effective	O	O
concentrations	O	O
of	O	O
PG	B-Chemical	C087567
-	I-Chemical	C087567
9	I-Chemical	C087567
.	O	O

The	O	O
current	O	O
work	O	O
indicates	O	O
the	O	O
ability	O	O
of	O	O
PG	B-Chemical	C087567
-	I-Chemical	C087567
9	I-Chemical	C087567
to	O	O
induce	O	O
beneficial	O	O
effects	O	O
on	O	O
cognitive	O	O
processes	O	O
and	O	O
stimulate	O	O
activity	O	O
of	O	O
NGF	O	O
synthesis	O	O
in	O	O
astroglial	O	O
cells	O	O
.	O	O

Therefore	O	O
,	O	O
PG	B-Chemical	C087567
-	I-Chemical	C087567
9	I-Chemical	C087567
could	O	O
represent	O	O
a	O	O
potential	O	O
useful	O	O
drug	O	O
able	O	O
to	O	O
improve	O	O
the	O	O
function	O	O
of	O	O
impaired	O	O
cognitive	O	O
processes	O	O
.	O	O

Angioedema	B-Disease	D000799
due	O	O
to	O	O
ACE	B-Chemical	D000806
inhibitors	I-Chemical	D000806
:	O	O
common	O	O
and	O	O
inadequately	O	O
diagnosed	O	O
.	O	O

The	O	O
estimated	O	O
incidence	O	O
of	O	O
angioedema	B-Disease	D000799
during	O	O
angiotensin	B-Chemical	D000806
-	I-Chemical	D000806
converting	I-Chemical	D000806
enzyme	I-Chemical	D000806
(	I-Chemical	D000806
ACE	I-Chemical	D000806
)	I-Chemical	D000806
inhibitor	I-Chemical	D000806
treatment	O	O
is	O	O
between	O	O
1	O	O
and	O	O
7	O	O
per	O	O
thousand	O	O
patients	O	O
.	O	O

This	O	O
potentially	O	O
serious	O	O
adverse	O	O
effect	O	O
is	O	O
often	O	O
preceded	O	O
by	O	O
minor	O	O
manifestations	O	O
that	O	O
may	O	O
serve	O	O
as	O	O
a	O	O
warning	O	O
.	O	O

Recurarization	O	O
in	O	O
the	O	O
recovery	O	O
room	O	O
.	O	O

A	O	O
case	O	O
of	O	O
recurarization	O	O
in	O	O
the	O	O
recovery	O	O
room	O	O
is	O	O
reported	O	O
.	O	O

Accumulation	O	O
of	O	O
atracurium	B-Chemical	D001279
in	O	O
the	O	O
intravenous	O	O
line	O	O
led	O	O
to	O	O
recurarization	O	O
after	O	O
flushing	O	O
the	O	O
line	O	O
in	O	O
the	O	O
recovery	O	O
room	O	O
.	O	O

A	O	O
respiratory	B-Disease	D012131
arrest	I-Disease	D012131
with	O	O
severe	O	O
desaturation	B-Disease	D001049
and	O	O
bradycardia	B-Disease	D001919
occurred	O	O
.	O	O

Circumstances	O	O
leading	O	O
to	O	O
this	O	O
event	O	O
and	O	O
the	O	O
mechanisms	O	O
enabling	O	O
a	O	O
neuromuscular	B-Disease	D020879
blockade	I-Disease	D020879
to	O	O
occur	O	O
,	O	O
following	O	O
the	O	O
administration	O	O
of	O	O
a	O	O
small	O	O
dose	O	O
of	O	O
relaxant	O	O
,	O	O
are	O	O
discussed	O	O
.	O	O

Recurrent	O	O
use	O	O
of	O	O
newer	O	O
oral	B-Chemical	D003276
contraceptives	I-Chemical	D003276
and	O	O
the	O	O
risk	O	O
of	O	O
venous	B-Disease	D054556
thromboembolism	I-Disease	D054556
.	O	O

The	O	O
epidemiological	O	O
studies	O	O
that	O	O
assessed	O	O
the	O	O
risk	O	O
of	O	O
venous	B-Disease	D054556
thromboembolism	I-Disease	D054556
(	O	O
VTE	B-Disease	D054556
)	O	O
associated	O	O
with	O	O
newer	O	O
oral	B-Chemical	D003276
contraceptives	I-Chemical	D003276
(	O	O
OC	B-Chemical	D003276
)	O	O
did	O	O
not	O	O
distinguish	O	O
between	O	O
patterns	O	O
of	O	O
OC	B-Chemical	D003276
use	O	O
,	O	O
namely	O	O
first	O	O
-	O	O
time	O	O
users	O	O
,	O	O
repeaters	O	O
and	O	O
switchers	O	O
.	O	O

Data	O	O
from	O	O
a	O	O
Transnational	O	O
case	O	O
-	O	O
control	O	O
study	O	O
were	O	O
used	O	O
to	O	O
assess	O	O
the	O	O
risk	O	O
of	O	O
VTE	B-Disease	D054556
for	O	O
the	O	O
latter	O	O
patterns	O	O
of	O	O
use	O	O
,	O	O
while	O	O
accounting	O	O
for	O	O
duration	O	O
of	O	O
use	O	O
.	O	O

Over	O	O
the	O	O
period	O	O
1993	O	O
-	O	O
1996	O	O
,	O	O
551	O	O
cases	O	O
of	O	O
VTE	B-Disease	D054556
were	O	O
identified	O	O
in	O	O
Germany	O	O
and	O	O
the	O	O
UK	O	O
along	O	O
with	O	O
2066	O	O
controls	O	O
.	O	O

Totals	O	O
of	O	O
128	O	O
cases	O	O
and	O	O
650	O	O
controls	O	O
were	O	O
analysed	O	O
for	O	O
repeat	O	O
use	O	O
and	O	O
135	O	O
cases	O	O
and	O	O
622	O	O
controls	O	O
for	O	O
switching	O	O
patterns	O	O
.	O	O

The	O	O
adjusted	O	O
rate	O	O
ratio	O	O
of	O	O
VTE	B-Disease	D054556
for	O	O
repeat	O	O
users	O	O
of	O	O
third	O	O
generation	O	O
OC	B-Chemical	D003276
was	O	O
0	O	O
.	O	O

6	O	O
(	O	O
95%	O	O
CI	O	O
:	O	O
0	O	O
.	O	O

3	O	O
-	O	O
1	O	O
.	O	O

2	O	O
)	O	O
relative	O	O
to	O	O
repeat	O	O
users	O	O
of	O	O
second	O	O
generation	O	O
pills	O	O
,	O	O
whereas	O	O
it	O	O
was	O	O
1	O	O
.	O	O

3	O	O
(	O	O
95%	O	O
CI	O	O
:	O	O
0	O	O
.	O	O

7	O	O
-	O	O
2	O	O
.	O	O

4	O	O
)	O	O
for	O	O
switchers	O	O
from	O	O
second	O	O
to	O	O
third	O	O
generation	O	O
pills	O	O
relative	O	O
to	O	O
switchers	O	O
from	O	O
third	O	O
to	O	O
second	O	O
generation	O	O
pills	O	O
.	O	O

We	O	O
conclude	O	O
that	O	O
second	O	O
and	O	O
third	O	O
generation	O	O
agents	O	O
are	O	O
associated	O	O
with	O	O
equivalent	O	O
risks	O	O
of	O	O
VTE	B-Disease	D054556
when	O	O
the	O	O
same	O	O
agent	O	O
is	O	O
used	O	O
repeatedly	O	O
after	O	O
interruption	O	O
periods	O	O
or	O	O
when	O	O
users	O	O
are	O	O
switched	O	O
between	O	O
the	O	O
two	O	O
generations	O	O
of	O	O
pills	O	O
.	O	O

These	O	O
analyses	O	O
suggest	O	O
that	O	O
the	O	O
higher	O	O
risk	O	O
observed	O	O
for	O	O
the	O	O
newer	O	O
OC	B-Chemical	D003276
in	O	O
other	O	O
studies	O	O
may	O	O
be	O	O
the	O	O
result	O	O
of	O	O
inadequate	O	O
comparisons	O	O
of	O	O
pill	O	O
users	O	O
with	O	O
different	O	O
patterns	O	O
of	O	O
pill	O	O
use	O	O
.	O	O

Development	O	O
of	O	O
apomorphine	B-Chemical	D001058
-	O	O
induced	O	O
aggressive	B-Disease	D010554
behavior	I-Disease	D010554
:	O	O
comparison	O	O
of	O	O
adult	O	O
male	O	O
and	O	O
female	O	O
Wistar	O	O
rats	O	O
.	O	O

The	O	O
development	O	O
of	O	O
apomorphine	B-Chemical	D001058
-	O	O
induced	O	O
(	O	O
1	O	O
.	O	O

0	O	O
mg	O	O
/	O	O
kg	O	O
s	O	O
.	O	O

c	O	O
.	O	O

once	O	O
daily	O	O
)	O	O
aggressive	B-Disease	D010554
behavior	I-Disease	D010554
of	O	O
adult	O	O
male	O	O
and	O	O
female	O	O
Wistar	O	O
rats	O	O
obtained	O	O
from	O	O
the	O	O
same	O	O
breeder	O	O
was	O	O
studied	O	O
in	O	O
two	O	O
consecutive	O	O
sets	O	O
.	O	O

In	O	O
male	O	O
animals	O	O
,	O	O
repeated	O	O
apomorphine	B-Chemical	D001058
treatment	O	O
induced	O	O
a	O	O
gradual	O	O
development	O	O
of	O	O
aggressive	B-Disease	D010554
behavior	I-Disease	D010554
as	O	O
evidenced	O	O
by	O	O
the	O	O
increased	O	O
intensity	O	O
of	O	O
aggressiveness	B-Disease	D010554
and	O	O
shortened	O	O
latency	O	O
before	O	O
the	O	O
first	O	O
attack	O	O
toward	O	O
the	O	O
opponent	O	O
.	O	O

In	O	O
female	O	O
rats	O	O
,	O	O
only	O	O
a	O	O
weak	O	O
tendency	O	O
toward	O	O
aggressiveness	B-Disease	D010554
was	O	O
found	O	O
.	O	O

In	O	O
conclusion	O	O
,	O	O
the	O	O
present	O	O
study	O	O
demonstrates	O	O
gender	O	O
differences	O	O
in	O	O
the	O	O
development	O	O
of	O	O
the	O	O
apomorphine	B-Chemical	D001058
-	O	O
induced	O	O
aggressive	B-Disease	D010554
behavior	I-Disease	D010554
and	O	O
indicates	O	O
that	O	O
the	O	O
female	O	O
rats	O	O
do	O	O
not	O	O
fill	O	O
the	O	O
validation	O	O
criteria	O	O
for	O	O
use	O	O
in	O	O
this	O	O
method	O	O
.	O	O

Serotonergic	B-Chemical	D018490
antidepressants	I-Chemical	D018490
and	O	O
urinary	B-Disease	D014549
incontinence	I-Disease	D014549
.	O	O

Many	O	O
new	O	O
serotonergic	B-Chemical	D018490
antidepressants	I-Chemical	D018490
have	O	O
been	O	O
introduced	O	O
over	O	O
the	O	O
past	O	O
decade	O	O
.	O	O

Although	O	O
urinary	B-Disease	D014549
incontinence	I-Disease	D014549
is	O	O
listed	O	O
as	O	O
one	O	O
side	O	O
effect	O	O
of	O	O
these	O	O
drugs	O	O
in	O	O
their	O	O
package	O	O
inserts	O	O
there	O	O
is	O	O
only	O	O
one	O	O
report	O	O
in	O	O
the	O	O
literature	O	O
.	O	O

This	O	O
concerns	O	O
2	O	O
male	O	O
patients	O	O
who	O	O
experienced	O	O
incontinence	B-Disease	D014549
while	O	O
taking	O	O
venlafaxine	B-Chemical	C047426
.	O	O

In	O	O
the	O	O
present	O	O
paper	O	O
the	O	O
authors	O	O
describe	O	O
2	O	O
female	O	O
patients	O	O
who	O	O
developed	O	O
incontinence	B-Disease	D014549
secondary	O	O
to	O	O
the	O	O
selective	O	O
serotonin	B-Chemical	D012701
reuptake	O	O
inhibitors	O	O
paroxetine	B-Chemical	D017374
and	O	O
sertraline	B-Chemical	D020280
,	O	O
as	O	O
well	O	O
as	O	O
a	O	O
third	O	O
who	O	O
developed	O	O
this	O	O
side	O	O
effect	O	O
on	O	O
venlafaxine	B-Chemical	C047426
.	O	O

In	O	O
2	O	O
of	O	O
the	O	O
3	O	O
cases	O	O
the	O	O
patients	O	O
were	O	O
also	O	O
taking	O	O
lithium	B-Chemical	D016651
carbonate	I-Chemical	D016651
and	O	O
beta	O	O
-	O	O
blockers	O	O
,	O	O
both	O	O
of	O	O
which	O	O
could	O	O
have	O	O
contributed	O	O
to	O	O
the	O	O
incontinence	B-Disease	D014549
.	O	O

Animal	O	O
studies	O	O
suggest	O	O
that	O	O
incontinence	B-Disease	D014549
secondary	O	O
to	O	O
serotonergic	B-Chemical	D018490
antidepressants	I-Chemical	D018490
could	O	O
be	O	O
mediated	O	O
by	O	O
the	O	O
5HT4	O	O
receptors	O	O
found	O	O
on	O	O
the	O	O
bladder	O	O
.	O	O

Further	O	O
research	O	O
is	O	O
needed	O	O
to	O	O
delineate	O	O
the	O	O
frequency	O	O
of	O	O
this	O	O
troubling	O	O
side	O	O
effect	O	O
and	O	O
how	O	O
best	O	O
to	O	O
treat	O	O
it	O	O
.	O	O

Hypotension	B-Disease	D007022
following	O	O
the	O	O
initiation	O	O
of	O	O
tizanidine	B-Chemical	C023754
in	O	O
a	O	O
patient	O	O
treated	O	O
with	O	O
an	O	O
angiotensin	B-Chemical	D000809
converting	O	O
enzyme	O	O
inhibitor	O	O
for	O	O
chronic	O	O
hypertension	B-Disease	D006973
.	O	O

Centrally	O	O
acting	O	O
alpha	O	O
-	O	O
2	O	O
adrenergic	O	O
agonists	O	O
are	O	O
one	O	O
of	O	O
several	O	O
pharmacologic	O	O
agents	O	O
used	O	O
in	O	O
the	O	O
treatment	O	O
of	O	O
spasticity	B-Disease	D009128
related	O	O
to	O	O
disorders	B-Disease	D002493
of	I-Disease	D002493
the	I-Disease	D002493
central	I-Disease	D002493
nervous	I-Disease	D002493
system	I-Disease	D002493
.	O	O

In	O	O
addition	O	O
to	O	O
their	O	O
effects	O	O
on	O	O
spasticity	B-Disease	D009128
,	O	O
certain	O	O
adverse	O	O
cardiorespiratory	O	O
effects	O	O
have	O	O
been	O	O
reported	O	O
.	O	O

Adults	O	O
chronically	O	O
treated	O	O
with	O	O
angiotensin	B-Chemical	D000809
converting	O	O
enzyme	O	O
inhibitors	O	O
may	O	O
have	O	O
a	O	O
limited	O	O
ability	O	O
to	O	O
respond	O	O
to	O	O
hypotension	B-Disease	D007022
when	O	O
the	O	O
sympathetic	O	O
response	O	O
is	O	O
simultaneously	O	O
blocked	O	O
.	O	O

The	O	O
authors	O	O
present	O	O
a	O	O
10	O	O
-	O	O
year	O	O
-	O	O
old	O	O
boy	O	O
chronically	O	O
treated	O	O
with	O	O
lisinopril	B-Chemical	D017706
,	O	O
an	O	O
angiotensin	B-Chemical	D000809
converting	O	O
enzyme	O	O
inhibitor	O	O
,	O	O
to	O	O
control	O	O
hypertension	B-Disease	D006973
who	O	O
developed	O	O
hypotension	B-Disease	D007022
following	O	O
the	O	O
addition	O	O
of	O	O
tizanidine	B-Chemical	C023754
,	O	O
an	O	O
alpha	O	O
-	O	O
2	O	O
agonist	O	O
,	O	O
for	O	O
the	O	O
treatment	O	O
of	O	O
spasticity	B-Disease	D009128
.	O	O

The	O	O
possible	O	O
interaction	O	O
of	O	O
tizanidine	B-Chemical	C023754
and	O	O
other	O	O
antihypertensive	O	O
agents	O	O
should	O	O
be	O	O
kept	O	O
in	O	O
mind	O	O
when	O	O
prescribing	O	O
therapy	O	O
to	O	O
treat	O	O
either	O	O
hypertension	B-Disease	D006973
or	O	O
spasticity	B-Disease	D009128
in	O	O
such	O	O
patients	O	O
.	O	O

Peritubular	O	O
capillary	O	O
basement	O	O
membrane	O	O
reduplication	O	O
in	O	O
allografts	O	O
and	O	O
native	O	O
kidney	B-Disease	D007674
disease	I-Disease	D007674
:	O	O
a	O	O
clinicopathologic	O	O
study	O	O
of	O	O
278	O	O
consecutive	O	O
renal	O	O
specimens	O	O
.	O	O

BACKGROUND	O	O
:	O	O
An	O	O
association	O	O
has	O	O
been	O	O
found	O	O
between	O	O
transplant	B-Disease	D007674
glomerulopathy	I-Disease	D007674
(	O	O
TG	B-Disease	D007674
)	O	O
and	O	O
reduplication	O	O
of	O	O
peritubular	O	O
capillary	O	O
basement	O	O
membranes	O	O
(	O	O
PTCR	O	O
)	O	O
.	O	O

Although	O	O
such	O	O
an	O	O
association	O	O
is	O	O
of	O	O
practical	O	O
and	O	O
theoretical	O	O
importance	O	O
,	O	O
only	O	O
one	O	O
prospective	O	O
study	O	O
has	O	O
tried	O	O
to	O	O
confirm	O	O
it	O	O
.	O	O

METHODS	O	O
:	O	O
We	O	O
examined	O	O
278	O	O
consecutive	O	O
renal	O	O
specimens	O	O
(	O	O
from	O	O
135	O	O
transplants	O	O
and	O	O
143	O	O
native	O	O
kidneys	O	O
)	O	O
for	O	O
ultrastructural	O	O
evidence	O	O
of	O	O
PTCR	O	O
.	O	O

In	O	O
addition	O	O
to	O	O
renal	O	O
allografts	O	O
with	O	O
TG	B-Disease	D007674
,	O	O
we	O	O
also	O	O
examined	O	O
grafts	O	O
with	O	O
acute	O	O
rejection	O	O
,	O	O
recurrent	O	O
glomerulonephritis	B-Disease	D005921
,	O	O
chronic	B-Disease	D051436
allograft	I-Disease	D051436
nephropathy	I-Disease	D051436
and	O	O
stable	O	O
grafts	O	O
(	O	O
"protocol	O	O
biopsies"	O	O
)	O	O
.	O	O

Native	O	O
kidney	O	O
specimens	O	O
included	O	O
a	O	O
wide	O	O
range	O	O
of	O	O
glomerulopathies	B-Disease	D007674
as	O	O
well	O	O
as	O	O
cases	O	O
of	O	O
thrombotic	B-Disease	D057049
microangiopathy	I-Disease	D057049
,	O	O
malignant	B-Disease	D006974
hypertension	I-Disease	D006974
,	O	O
acute	O	O
interstitial	B-Disease	D009395
nephritis	I-Disease	D009395
,	O	O
and	O	O
acute	B-Disease	D007683
tubular	I-Disease	D007683
necrosis	I-Disease	D007683
.	O	O

RESULTS	O	O
:	O	O
We	O	O
found	O	O
PTCR	O	O
in	O	O
14	O	O
of	O	O
15	O	O
cases	O	O
of	O	O
TG	B-Disease	D007674
,	O	O
in	O	O
7	O	O
transplant	O	O
biopsy	O	O
specimens	O	O
without	O	O
TG	B-Disease	D007674
,	O	O
and	O	O
in	O	O
13	O	O
of	O	O
143	O	O
native	O	O
kidney	O	O
biopsy	O	O
specimens	O	O
.	O	O

These	O	O
13	O	O
included	O	O
cases	O	O
of	O	O
malignant	B-Disease	D006974
hypertension	I-Disease	D006974
,	O	O
thrombotic	B-Disease	D057049
microangiopathy	I-Disease	D057049
,	O	O
lupus	B-Disease	D008181
nephritis	I-Disease	D008181
,	O	O
Henoch	B-Disease	D011695
-	I-Disease	D011695
Schonlein	I-Disease	D011695
nephritis	I-Disease	D011695
,	O	O
crescentic	O	O
glomerulonephritis	B-Disease	D005921
,	O	O
and	O	O
cocaine	B-Chemical	D003042
-	O	O
related	O	O
acute	B-Disease	D058186
renal	I-Disease	D058186
failure	I-Disease	D058186
.	O	O

Mild	O	O
PTCR	O	O
in	O	O
allografts	O	O
without	O	O
TG	B-Disease	D007674
did	O	O
not	O	O
predict	O	O
renal	B-Disease	D051437
failure	I-Disease	D051437
or	O	O
significant	O	O
proteinuria	B-Disease	D011507
after	O	O
follow	O	O
-	O	O
up	O	O
periods	O	O
of	O	O
between	O	O
3	O	O
months	O	O
and	O	O
1	O	O
year	O	O
.	O	O

CONCLUSIONS	O	O
:	O	O
We	O	O
conclude	O	O
that	O	O
in	O	O
transplants	O	O
,	O	O
there	O	O
is	O	O
a	O	O
strong	O	O
association	O	O
between	O	O
well	O	O
-	O	O
developed	O	O
PTCR	O	O
and	O	O
TG	B-Disease	D007674
,	O	O
while	O	O
the	O	O
significance	O	O
of	O	O
mild	O	O
PTCR	O	O
and	O	O
its	O	O
predictive	O	O
value	O	O
in	O	O
the	O	O
absence	O	O
of	O	O
TG	B-Disease	D007674
is	O	O
unclear	O	O
.	O	O

PTCR	O	O
also	O	O
occurs	O	O
in	O	O
certain	O	O
native	O	O
kidney	B-Disease	D007674
diseases	I-Disease	D007674
,	O	O
though	O	O
the	O	O
association	O	O
is	O	O
not	O	O
as	O	O
strong	O	O
as	O	O
that	O	O
for	O	O
TG	B-Disease	D007674
.	O	O

We	O	O
suggest	O	O
that	O	O
repeated	O	O
endothelial	B-Disease	D014947
injury	I-Disease	D014947
,	O	O
including	O	O
immunologic	B-Disease	D007154
injury	I-Disease	D007154
,	O	O
may	O	O
be	O	O
the	O	O
cause	O	O
of	O	O
this	O	O
lesion	O	O
both	O	O
in	O	O
allografts	O	O
and	O	O
native	O	O
kidneys	O	O
.	O	O

Conformationally	O	O
restricted	O	O
analogs	O	O
of	O	O
BD1008	B-Chemical	C085527
and	O	O
an	O	O
antisense	O	O
oligodeoxynucleotide	B-Chemical	D009838
targeting	O	O
sigma1	O	O
receptors	O	O
produce	O	O
anti	O	O
-	O	O
cocaine	B-Chemical	D003042
effects	O	O
in	O	O
mice	O	O
.	O	O

Cocaine's	O	O
ability	O	O
to	O	O
interact	O	O
with	O	O
sigma	O	O
receptors	O	O
suggests	O	O
that	O	O
these	O	O
proteins	O	O
mediate	O	O
some	O	O
of	O	O
its	O	O
behavioral	O	O
effects	O	O
.	O	O

Therefore	O	O
,	O	O
three	O	O
novel	O	O
sigma	O	O
receptor	O	O
ligands	O	O
with	O	O
antagonist	O	O
activity	O	O
were	O	O
evaluated	O	O
in	O	O
Swiss	O	O
Webster	O	O
mice	O	O
:	O	O
BD1018	B-Chemical	-1
(	O	O
3S	B-Chemical	-1
-	I-Chemical	-1
1	I-Chemical	-1
-	I-Chemical	-1
[	I-Chemical	-1
2	I-Chemical	-1
-	I-Chemical	-1
(	I-Chemical	-1
3	I-Chemical	-1
,	I-Chemical	-1
4	I-Chemical	-1
-	I-Chemical	-1
dichlorophenyl	I-Chemical	-1
)	I-Chemical	-1
ethyl	I-Chemical	-1
]	I-Chemical	-1
-	I-Chemical	-1
1	I-Chemical	-1
,	I-Chemical	-1
4	I-Chemical	-1
-	I-Chemical	-1
diazabicyclo	I-Chemical	-1
[	I-Chemical	-1
4	I-Chemical	-1
.	I-Chemical	-1

3	I-Chemical	-1
.	I-Chemical	-1

0	I-Chemical	-1
]	I-Chemical	-1
nonane	I-Chemical	-1
)	O	O
,	O	O
BD1063	B-Chemical	C093337
(	O	O
1	B-Chemical	C093337
-	I-Chemical	C093337
[	I-Chemical	C093337
2	I-Chemical	C093337
-	I-Chemical	C093337
(	I-Chemical	C093337
3	I-Chemical	C093337
,	I-Chemical	C093337
4	I-Chemical	C093337
-	I-Chemical	C093337
dichlorophenyl	I-Chemical	C093337
)	I-Chemical	C093337
ethyl	I-Chemical	C093337
]	I-Chemical	C093337
-	I-Chemical	C093337
4	I-Chemical	C093337
-	I-Chemical	C093337
methylpiperazine	I-Chemical	C093337
)	O	O
,	O	O
and	O	O
LR132	B-Chemical	-1
(	O	O
1R	O	O
,	O	O
2S	O	O
-	O	O
(	O	O
+	O	O
)	O	O
-	O	O
cis	O	O
-	O	O
N	O	O
-	O	O
[	O	O
2	O	O
-	O	O
(	O	O
3	O	O
,	O	O
4	O	O
-	O	O
dichlorophenyl	O	O
)	O	O
ethyl	O	O
]	O	O
-	O	O
2	O	O
-	O	O
(	O	O
1	O	O
-	O	O
pyrrolidinyl	O	O
)	O	O
cyclohexylamine	O	O
)	O	O
.	O	O

Competition	O	O
binding	O	O
assays	O	O
demonstrated	O	O
that	O	O
all	O	O
three	O	O
compounds	O	O
have	O	O
high	O	O
affinities	O	O
for	O	O
sigma1	O	O
receptors	O	O
.	O	O

The	O	O
three	O	O
compounds	O	O
vary	O	O
in	O	O
their	O	O
affinities	O	O
for	O	O
sigma2	O	O
receptors	O	O
and	O	O
exhibit	O	O
negligible	O	O
affinities	O	O
for	O	O
dopamine	B-Chemical	D004298
,	O	O
opioid	O	O
,	O	O
GABA	B-Chemical	D005680
(	O	O
A	O	O
)	O	O
and	O	O
NMDA	B-Chemical	D016202
receptors	O	O
.	O	O

In	O	O
behavioral	O	O
studies	O	O
,	O	O
pre	O	O
-	O	O
treatment	O	O
of	O	O
mice	O	O
with	O	O
BD1018	B-Chemical	-1
,	O	O
BD1063	B-Chemical	C093337
,	O	O
or	O	O
LR132	B-Chemical	-1
significantly	O	O
attenuated	O	O
cocaine	B-Chemical	D003042
-	O	O
induced	O	O
convulsions	B-Disease	D012640
and	O	O
lethality	O	O
.	O	O

Moreover	O	O
,	O	O
post	O	O
-	O	O
treatment	O	O
with	O	O
LR132	B-Chemical	-1
prevented	O	O
cocaine	B-Chemical	D003042
-	O	O
induced	O	O
lethality	O	O
in	O	O
a	O	O
significant	O	O
proportion	O	O
of	O	O
animals	O	O
.	O	O

In	O	O
contrast	O	O
to	O	O
the	O	O
protection	O	O
provided	O	O
by	O	O
the	O	O
putative	O	O
antagonists	O	O
,	O	O
the	O	O
well	O	O
-	O	O
characterized	O	O
sigma	O	O
receptor	O	O
agonist	O	O
di	B-Chemical	C050232
-	I-Chemical	C050232
o	I-Chemical	C050232
-	I-Chemical	C050232
tolylguanidine	I-Chemical	C050232
(	O	O
DTG	B-Chemical	C050232
)	O	O
and	O	O
the	O	O
novel	O	O
sigma	O	O
receptor	O	O
agonist	O	O
BD1031	B-Chemical	-1
(	O	O
3R	B-Chemical	-1
-	I-Chemical	-1
1	I-Chemical	-1
-	I-Chemical	-1
[	I-Chemical	-1
2	I-Chemical	-1
-	I-Chemical	-1
(	I-Chemical	-1
3	I-Chemical	-1
,	I-Chemical	-1
4	I-Chemical	-1
-	I-Chemical	-1
dichlorophenyl	I-Chemical	-1
)	I-Chemical	-1
ethyl	I-Chemical	-1
]	I-Chemical	-1
-	I-Chemical	-1
1	I-Chemical	-1
,	I-Chemical	-1
4	I-Chemical	-1
-	I-Chemical	-1
diazabicyclo	I-Chemical	-1
[	I-Chemical	-1
4	I-Chemical	-1
.	I-Chemical	-1

3	I-Chemical	-1
.	I-Chemical	-1

0	I-Chemical	-1
]	I-Chemical	-1
nonane	I-Chemical	-1
)	O	O
each	O	O
worsened	O	O
the	O	O
behavioral	O	O
toxicity	B-Disease	D064420
of	O	O
cocaine	B-Chemical	D003042
.	O	O

At	O	O
doses	O	O
where	O	O
alone	O	O
,	O	O
they	O	O
produced	O	O
no	O	O
significant	O	O
effects	O	O
on	O	O
locomotion	O	O
,	O	O
BD1018	B-Chemical	-1
,	O	O
BD1063	B-Chemical	C093337
and	O	O
LR132	B-Chemical	-1
significantly	O	O
attenuated	O	O
the	O	O
locomotor	O	O
stimulatory	O	O
effects	O	O
of	O	O
cocaine	B-Chemical	D003042
.	O	O

To	O	O
further	O	O
validate	O	O
the	O	O
hypothesis	O	O
that	O	O
the	O	O
anti	O	O
-	O	O
cocaine	B-Chemical	D003042
effects	O	O
of	O	O
the	O	O
novel	O	O
ligands	O	O
involved	O	O
antagonism	O	O
of	O	O
sigma	O	O
receptors	O	O
,	O	O
an	O	O
antisense	O	O
oligodeoxynucleotide	B-Chemical	D009838
against	O	O
sigma1	O	O
receptors	O	O
was	O	O
also	O	O
shown	O	O
to	O	O
significantly	O	O
attenuate	O	O
the	O	O
convulsive	B-Disease	D012640
and	O	O
locomotor	O	O
stimulatory	O	O
effects	O	O
of	O	O
cocaine	B-Chemical	D003042
.	O	O

Together	O	O
,	O	O
the	O	O
data	O	O
suggests	O	O
that	O	O
functional	O	O
antagonism	O	O
of	O	O
sigma	O	O
receptors	O	O
is	O	O
capable	O	O
of	O	O
attenuating	O	O
a	O	O
number	O	O
of	O	O
cocaine	B-Chemical	D003042
-	O	O
induced	O	O
behaviors	O	O
.	O	O

Pharmacokinetic	O	O
/	O	O
pharmacodynamic	O	O
assessment	O	O
of	O	O
the	O	O
effects	O	O
of	O	O
E4031	B-Chemical	C063968
,	O	O
cisapride	B-Chemical	D020117
,	O	O
terfenadine	B-Chemical	D016593
and	O	O
terodiline	B-Chemical	C010637
on	O	O
monophasic	O	O
action	O	O
potential	O	O
duration	O	O
in	O	O
dog	O	O
.	O	O

1	O	O
.	O	O

Torsades	B-Disease	D016171
de	I-Disease	D016171
pointes	I-Disease	D016171
(	O	O
TDP	B-Disease	D016171
)	O	O
is	O	O
a	O	O
potentially	O	O
fatal	O	O
ventricular	B-Disease	D017180
tachycardia	I-Disease	D017180
associated	O	O
with	O	O
increases	O	O
in	O	O
QT	O	O
interval	O	O
and	O	O
monophasic	O	O
action	O	O
potential	O	O
duration	O	O
(	O	O
MAPD	O	O
)	O	O
.	O	O

TDP	B-Disease	D016171
is	O	O
a	O	O
side	O	O
-	O	O
effect	O	O
that	O	O
has	O	O
led	O	O
to	O	O
withdrawal	O	O
of	O	O
several	O	O
drugs	O	O
from	O	O
the	O	O
market	O	O
(	O	O
e	O	O
.	O	O

g	O	O
.	O	O

terfenadine	B-Chemical	D016593
and	O	O
terodiline	B-Chemical	C010637
)	O	O
.	O	O

2	O	O
.	O	O

The	O	O
potential	O	O
of	O	O
compounds	O	O
to	O	O
cause	O	O
TDP	B-Disease	D016171
was	O	O
evaluated	O	O
by	O	O
monitoring	O	O
their	O	O
effects	O	O
on	O	O
MAPD	O	O
in	O	O
dog	O	O
.	O	O

Four	O	O
compounds	O	O
known	O	O
to	O	O
increase	O	O
QT	O	O
interval	O	O
and	O	O
cause	O	O
TDP	B-Disease	D016171
were	O	O
investigated	O	O
:	O	O
terfenadine	B-Chemical	D016593
,	O	O
terodiline	B-Chemical	C010637
,	O	O
cisapride	B-Chemical	D020117
and	O	O
E4031	B-Chemical	C063968
.	O	O

On	O	O
the	O	O
basis	O	O
that	O	O
only	O	O
free	O	O
drug	O	O
in	O	O
the	O	O
systemic	O	O
circulation	O	O
will	O	O
elicit	O	O
a	O	O
pharmacological	O	O
response	O	O
target	O	O
,	O	O
free	O	O
concentrations	O	O
in	O	O
plasma	O	O
were	O	O
selected	O	O
to	O	O
mimic	O	O
the	O	O
free	O	O
drug	O	O
exposures	O	O
in	O	O
man	O	O
.	O	O

Infusion	O	O
regimens	O	O
were	O	O
designed	O	O
that	O	O
rapidly	O	O
achieved	O	O
and	O	O
maintained	O	O
target	O	O
-	O	O
free	O	O
concentrations	O	O
of	O	O
these	O	O
drugs	O	O
in	O	O
plasma	O	O
and	O	O
data	O	O
on	O	O
the	O	O
relationship	O	O
between	O	O
free	O	O
concentration	O	O
and	O	O
changes	O	O
in	O	O
MAPD	O	O
were	O	O
obtained	O	O
for	O	O
these	O	O
compounds	O	O
.	O	O

3	O	O
.	O	O

These	O	O
data	O	O
indicate	O	O
that	O	O
the	O	O
free	O	O
ED50	O	O
in	O	O
plasma	O	O
for	O	O
terfenadine	B-Chemical	D016593
(	O	O
1	O	O
.	O	O

9	O	O
nM	O	O
)	O	O
,	O	O
terodiline	B-Chemical	C010637
(	O	O
76	O	O
nM	O	O
)	O	O
,	O	O
cisapride	B-Chemical	D020117
(	O	O
11	O	O
nM	O	O
)	O	O
and	O	O
E4031	B-Chemical	C063968
(	O	O
1	O	O
.	O	O

9	O	O
nM	O	O
)	O	O
closely	O	O
correlate	O	O
with	O	O
the	O	O
free	O	O
concentration	O	O
in	O	O
man	O	O
causing	O	O
QT	O	O
effects	O	O
.	O	O

For	O	O
compounds	O	O
that	O	O
have	O	O
shown	O	O
TDP	B-Disease	D016171
in	O	O
the	O	O
clinic	O	O
(	O	O
terfenadine	B-Chemical	D016593
,	O	O
terodiline	B-Chemical	C010637
,	O	O
cisapride	B-Chemical	D020117
)	O	O
there	O	O
is	O	O
little	O	O
differentiation	O	O
between	O	O
the	O	O
dog	O	O
ED50	O	O
and	O	O
the	O	O
efficacious	O	O
free	O	O
plasma	O	O
concentrations	O	O
in	O	O
man	O	O
(	O	O
<	O	O
10	O	O
-	O	O
fold	O	O
)	O	O
reflecting	O	O
their	O	O
limited	O	O
safety	O	O
margins	O	O
.	O	O

These	O	O
data	O	O
underline	O	O
the	O	O
need	O	O
to	O	O
maximize	O	O
the	O	O
therapeutic	O	O
ratio	O	O
with	O	O
respect	O	O
to	O	O
TDP	B-Disease	D016171
in	O	O
potential	O	O
development	O	O
candidates	O	O
and	O	O
the	O	O
importance	O	O
of	O	O
using	O	O
free	O	O
drug	O	O
concentrations	O	O
in	O	O
pharmacokinetic	O	O
/	O	O
pharmacodynamic	O	O
studies	O	O
.	O	O

Fatal	O	O
myeloencephalopathy	B-Disease	D001927
due	O	O
to	O	O
accidental	O	O
intrathecal	O	O
vincristin	B-Chemical	D014750
administration	O	O
:	O	O
a	O	O
report	O	O
of	O	O
two	O	O
cases	O	O
.	O	O

We	O	O
report	O	O
on	O	O
two	O	O
fatal	O	O
cases	O	O
of	O	O
accidental	O	O
intrathecal	O	O
vincristine	B-Chemical	D014750
instillation	O	O
in	O	O
a	O	O
5	O	O
-	O	O
year	O	O
old	O	O
girl	O	O
with	O	O
recurrent	O	O
acute	B-Disease	D054198
lymphoblastic	I-Disease	D054198
leucemia	I-Disease	D054198
and	O	O
a	O	O
57	O	O
-	O	O
year	O	O
old	O	O
man	O	O
with	O	O
lymphoblastic	B-Disease	D054198
lymphoma	I-Disease	D054198
.	O	O

The	O	O
girl	O	O
died	O	O
seven	O	O
days	O	O
,	O	O
the	O	O
man	O	O
four	O	O
weeks	O	O
after	O	O
intrathecal	O	O
injection	O	O
of	O	O
vincristine	B-Chemical	D014750
.	O	O

Clinically	O	O
,	O	O
the	O	O
onset	O	O
was	O	O
characterized	O	O
by	O	O
the	O	O
signs	O	O
of	O	O
opistothonus	O	O
,	O	O
sensory	O	O
and	O	O
motor	O	O
dysfunction	O	O
and	O	O
ascending	O	O
paralysis	B-Disease	D010243
.	O	O

Histological	O	O
and	O	O
immunohistochemical	O	O
investigations	O	O
(	O	O
HE	O	O
-	O	O
LFB	O	O
,	O	O
CD	O	O
-	O	O
68	O	O
,	O	O
Neurofilament	O	O
)	O	O
revealed	O	O
degeneration	O	O
of	O	O
myelin	O	O
and	O	O
axons	O	O
as	O	O
well	O	O
as	O	O
pseudocystic	B-Disease	-1
transformation	I-Disease	-1
in	O	O
areas	O	O
exposed	O	O
to	O	O
vincristine	B-Chemical	D014750
,	O	O
accompanied	O	O
by	O	O
secondary	O	O
changes	O	O
with	O	O
numerous	O	O
prominent	O	O
macrophages	O	O
.	O	O

The	O	O
clinical	O	O
course	O	O
and	O	O
histopathological	O	O
results	O	O
of	O	O
the	O	O
two	O	O
cases	O	O
are	O	O
presented	O	O
.	O	O

A	O	O
review	O	O
of	O	O
all	O	O
reported	O	O
cases	O	O
in	O	O
the	O	O
literature	O	O
is	O	O
given	O	O
.	O	O

A	O	O
better	O	O
controlled	O	O
regimen	O	O
for	O	O
administering	O	O
vincristine	B-Chemical	D014750
and	O	O
intrathecal	O	O
chemotherapy	O	O
is	O	O
recommended	O	O
.	O	O

Intravenous	O	O
administration	O	O
of	O	O
prochlorperazine	B-Chemical	D011346
by	O	O
15	O	O
-	O	O
minute	O	O
infusion	O	O
versus	O	O
2	O	O
-	O	O
minute	O	O
bolus	O	O
does	O	O
not	O	O
affect	O	O
the	O	O
incidence	O	O
of	O	O
akathisia	B-Disease	D017109
:	O	O
a	O	O
prospective	O	O
,	O	O
randomized	O	O
,	O	O
controlled	O	O
trial	O	O
.	O	O

STUDY	O	O
OBJECTIVE	O	O
:	O	O
We	O	O
sought	O	O
to	O	O
compare	O	O
the	O	O
rate	O	O
of	O	O
akathisia	B-Disease	D017109
after	O	O
administration	O	O
of	O	O
intravenous	O	O
prochlorperazine	B-Chemical	D011346
as	O	O
a	O	O
2	O	O
-	O	O
minute	O	O
bolus	O	O
or	O	O
15	O	O
-	O	O
minute	O	O
infusion	O	O
.	O	O

METHODS	O	O
:	O	O
We	O	O
conducted	O	O
a	O	O
prospective	O	O
,	O	O
randomized	O	O
,	O	O
double	O	O
-	O	O
blind	O	O
study	O	O
in	O	O
the	O	O
emergency	O	O
department	O	O
of	O	O
a	O	O
central	O	O
-	O	O
city	O	O
teaching	O	O
hospital	O	O
.	O	O

Patients	O	O
aged	O	O
18	O	O
years	O	O
or	O	O
older	O	O
treated	O	O
with	O	O
prochlorperazine	B-Chemical	D011346
for	O	O
headache	B-Disease	D006261
,	O	O
nausea	B-Disease	D009325
,	O	O
or	O	O
vomiting	B-Disease	D014839
were	O	O
eligible	O	O
for	O	O
inclusion	O	O
.	O	O

Study	O	O
participants	O	O
were	O	O
randomized	O	O
to	O	O
receive	O	O
10	O	O
mg	O	O
of	O	O
prochlorperazine	B-Chemical	D011346
administered	O	O
intravenously	O	O
by	O	O
means	O	O
of	O	O
2	O	O
-	O	O
minute	O	O
push	O	O
(	O	O
bolus	O	O
group	O	O
)	O	O
or	O	O
10	O	O
mg	O	O
diluted	O	O
in	O	O
50	O	O
mL	O	O
of	O	O
normal	O	O
saline	O	O
solution	O	O
administered	O	O
by	O	O
means	O	O
of	O	O
intravenous	O	O
infusion	O	O
during	O	O
a	O	O
15	O	O
-	O	O
minute	O	O
period	O	O
(	O	O
infusion	O	O
group	O	O
)	O	O
.	O	O

The	O	O
main	O	O
outcome	O	O
was	O	O
the	O	O
number	O	O
of	O	O
study	O	O
participants	O	O
experiencing	O	O
akathisia	B-Disease	D017109
within	O	O
60	O	O
minutes	O	O
of	O	O
administration	O	O
.	O	O

Akathisia	O	O
was	O	O
defined	O	O
as	O	O
either	O	O
a	O	O
spontaneous	O	O
report	O	O
of	O	O
restlessness	O	O
or	O	O
agitation	B-Disease	D011595
or	O	O
a	O	O
change	O	O
of	O	O
2	O	O
or	O	O
more	O	O
in	O	O
the	O	O
patient	O	O
-	O	O
reported	O	O
akathisia	B-Disease	D017109
rating	O	O
scale	O	O
and	O	O
a	O	O
change	O	O
of	O	O
at	O	O
least	O	O
1	O	O
in	O	O
the	O	O
investigator	O	O
-	O	O
observed	O	O
akathisia	B-Disease	D017109
rating	O	O
scale	O	O
.	O	O

The	O	O
intensity	O	O
of	O	O
headache	B-Disease	D006261
and	O	O
nausea	B-Disease	D009325
was	O	O
measured	O	O
with	O	O
a	O	O
100	O	O
-	O	O
mm	O	O
visual	O	O
analog	O	O
scale	O	O
.	O	O

RESULTS	O	O
:	O	O
One	O	O
hundred	O	O
patients	O	O
were	O	O
enrolled	O	O
.	O	O

One	O	O
study	O	O
participant	O	O
was	O	O
excluded	O	O
after	O	O
protocol	O	O
violation	O	O
.	O	O

Seventy	O	O
-	O	O
three	O	O
percent	O	O
(	O	O
73	O	O
/	O	O
99	O	O
)	O	O
of	O	O
the	O	O
study	O	O
participants	O	O
were	O	O
treated	O	O
for	O	O
headache	B-Disease	D006261
and	O	O
70%	O	O
(	O	O
70	O	O
/	O	O
99	O	O
)	O	O
for	O	O
nausea	B-Disease	D009325
.	O	O

In	O	O
the	O	O
bolus	O	O
group	O	O
,	O	O
26	O	O
.	O	O

0%	O	O
(	O	O
13	O	O
/	O	O
50	O	O
)	O	O
had	O	O
akathisia	B-Disease	D017109
compared	O	O
with	O	O
32	O	O
.	O	O

7%	O	O
(	O	O
16	O	O
/	O	O
49	O	O
)	O	O
in	O	O
the	O	O
infusion	O	O
group	O	O
(	O	O
Delta=	O	O
-	O	O
6	O	O
.	O	O

7%	O	O
;	O	O
95%	O	O
confidence	O	O
interval	O	O
[	O	O
CI	O	O
]	O	O
-	O	O
24	O	O
.	O	O

6%	O	O
to	O	O
11	O	O
.	O	O

2%	O	O
)	O	O
.	O	O

The	O	O
difference	O	O
between	O	O
the	O	O
bolus	O	O
and	O	O
infusion	O	O
groups	O	O
in	O	O
the	O	O
percentage	O	O
of	O	O
participants	O	O
who	O	O
saw	O	O
a	O	O
50%	O	O
reduction	O	O
in	O	O
their	O	O
headache	B-Disease	D006261
intensity	O	O
within	O	O
30	O	O
minutes	O	O
was	O	O
11	O	O
.	O	O

8%	O	O
(	O	O
95%	O	O
CI	O	O
-	O	O
9	O	O
.	O	O

6%	O	O
to	O	O
33	O	O
.	O	O

3%	O	O
)	O	O
.	O	O

The	O	O
difference	O	O
in	O	O
the	O	O
percentage	O	O
of	O	O
patients	O	O
with	O	O
a	O	O
50%	O	O
reduction	O	O
in	O	O
their	O	O
nausea	B-Disease	D009325
was	O	O
12	O	O
.	O	O

6%	O	O
(	O	O
95%	O	O
CI	O	O
-	O	O
4	O	O
.	O	O

6%	O	O
to	O	O
29	O	O
.	O	O

8%	O	O
)	O	O
.	O	O

CONCLUSION	O	O
:	O	O
A	O	O
50%	O	O
reduction	O	O
in	O	O
the	O	O
incidence	O	O
of	O	O
akathisia	B-Disease	D017109
when	O	O
prochlorperazine	B-Chemical	D011346
was	O	O
administered	O	O
by	O	O
means	O	O
of	O	O
15	O	O
-	O	O
minute	O	O
intravenous	O	O
infusion	O	O
versus	O	O
a	O	O
2	O	O
-	O	O
minute	O	O
intravenous	O	O
push	O	O
was	O	O
not	O	O
detected	O	O
.	O	O

The	O	O
efficacy	O	O
of	O	O
prochlorperazine	B-Chemical	D011346
in	O	O
the	O	O
treatment	O	O
of	O	O
headache	B-Disease	D006261
and	O	O
nausea	B-Disease	D009325
likewise	O	O
did	O	O
not	O	O
appear	O	O
to	O	O
be	O	O
affected	O	O
by	O	O
the	O	O
rate	O	O
of	O	O
administration	O	O
,	O	O
although	O	O
no	O	O
formal	O	O
statistical	O	O
comparisons	O	O
were	O	O
made	O	O
.	O	O

Antithymocyte	B-Chemical	D000961
globulin	I-Chemical	D000961
in	O	O
the	O	O
treatment	O	O
of	O	O
D	B-Chemical	D010396
-	I-Chemical	D010396
penicillamine	I-Chemical	D010396
-	O	O
induced	O	O
aplastic	B-Disease	D000741
anemia	I-Disease	D000741
.	O	O

A	O	O
patient	O	O
who	O	O
received	O	O
antithymocyte	B-Chemical	D000961
globulin	I-Chemical	D000961
therapy	O	O
for	O	O
aplastic	B-Disease	D000741
anemia	I-Disease	D000741
due	O	O
to	O	O
D	B-Chemical	D010396
-	I-Chemical	D010396
penicillamine	I-Chemical	D010396
therapy	O	O
is	O	O
described	O	O
.	O	O

Bone	O	O
marrow	O	O
recovery	O	O
and	O	O
peripheral	O	O
blood	O	O
recovery	O	O
were	O	O
complete	O	O
1	O	O
month	O	O
and	O	O
3	O	O
months	O	O
,	O	O
respectively	O	O
,	O	O
after	O	O
treatment	O	O
,	O	O
and	O	O
blood	O	O
transfusion	O	O
or	O	O
other	O	O
therapies	O	O
were	O	O
not	O	O
necessary	O	O
in	O	O
a	O	O
follow	O	O
-	O	O
up	O	O
period	O	O
of	O	O
more	O	O
than	O	O
2	O	O
years	O	O
.	O	O

Use	O	O
of	O	O
antithymocyte	B-Chemical	D000961
globulin	I-Chemical	D000961
may	O	O
be	O	O
the	O	O
optimal	O	O
treatment	O	O
of	O	O
D	B-Chemical	D010396
-	I-Chemical	D010396
penicillamine	I-Chemical	D010396
-	O	O
induced	O	O
aplastic	B-Disease	D000741
anemia	I-Disease	D000741
.	O	O

The	O	O
relationship	O	O
between	O	O
hippocampal	O	O
acetylcholine	B-Chemical	D000109
release	O	O
and	O	O
cholinergic	O	O
convulsant	O	O
sensitivity	O	O
in	O	O
withdrawal	O	O
seizure	B-Disease	D012640
-	O	O
prone	O	O
and	O	O
withdrawal	O	O
seizure	B-Disease	D012640
-	O	O
resistant	O	O
selected	O	O
mouse	O	O
lines	O	O
.	O	O

BACKGROUND	O	O
:	O	O
The	O	O
septo	O	O
-	O	O
hippocampal	O	O
cholinergic	O	O
pathway	O	O
has	O	O
been	O	O
implicated	O	O
in	O	O
epileptogenesis	O	O
,	O	O
and	O	O
genetic	O	O
factors	O	O
influence	O	O
the	O	O
response	O	O
to	O	O
cholinergic	O	O
agents	O	O
,	O	O
but	O	O
limited	O	O
data	O	O
are	O	O
available	O	O
on	O	O
cholinergic	O	O
involvement	O	O
in	O	O
alcohol	B-Chemical	D000431
withdrawal	O	O
severity	O	O
.	O	O

Thus	O	O
,	O	O
the	O	O
relationship	O	O
between	O	O
cholinergic	O	O
activity	O	O
and	O	O
responsiveness	O	O
and	O	O
alcohol	B-Chemical	D000431
withdrawal	O	O
was	O	O
investigated	O	O
in	O	O
a	O	O
genetic	O	O
animal	O	O
model	O	O
of	O	O
ethanol	B-Chemical	D000431
withdrawal	O	O
severity	O	O
.	O	O

METHODS	O	O
:	O	O
Cholinergic	O	O
convulsant	O	O
sensitivity	O	O
was	O	O
examined	O	O
in	O	O
alcohol	B-Chemical	D000431
-	O	O
na	O	O
ve	O	O
Withdrawal	O	O
Seizure	B-Disease	D012640
-	O	O
Prone	O	O
(	O	O
WSP	O	O
)	O	O
and	O	O
-	O	O
Resistant	O	O
(	O	O
WSR	O	O
)	O	O
mice	O	O
.	O	O

Animals	O	O
were	O	O
administered	O	O
nicotine	B-Chemical	D009538
,	O	O
carbachol	B-Chemical	D002217
,	O	O
or	O	O
neostigmine	B-Chemical	D009388
via	O	O
timed	O	O
tail	O	O
vein	O	O
infusion	O	O
,	O	O
and	O	O
the	O	O
latencies	O	O
to	O	O
onset	O	O
of	O	O
tremor	B-Disease	D014202
and	O	O
clonus	O	O
were	O	O
recorded	O	O
and	O	O
converted	O	O
to	O	O
threshold	O	O
dose	O	O
.	O	O

We	O	O
also	O	O
used	O	O
microdialysis	O	O
to	O	O
measure	O	O
basal	O	O
and	O	O
potassium	B-Chemical	D011188
-	O	O
stimulated	O	O
acetylcholine	B-Chemical	D000109
(	O	O
ACh	B-Chemical	D000109
)	O	O
release	O	O
in	O	O
the	O	O
CA1	O	O
region	O	O
of	O	O
the	O	O
hippocampus	O	O
.	O	O

Potassium	B-Chemical	D011188
was	O	O
applied	O	O
by	O	O
reverse	O	O
dialysis	O	O
twice	O	O
,	O	O
separated	O	O
by	O	O
75	O	O
min	O	O
.	O	O

Hippocampal	O	O
ACh	B-Chemical	D000109
also	O	O
was	O	O
measured	O	O
during	O	O
testing	O	O
for	O	O
handling	O	O
-	O	O
induced	O	O
convulsions	B-Disease	D012640
.	O	O

RESULTS	O	O
:	O	O
Sensitivity	O	O
to	O	O
several	O	O
convulsion	B-Disease	D012640
endpoints	O	O
induced	O	O
by	O	O
nicotine	B-Chemical	D009538
,	O	O
carbachol	B-Chemical	D002217
,	O	O
and	O	O
neostigmine	B-Chemical	D009388
were	O	O
significantly	O	O
greater	O	O
in	O	O
WSR	O	O
versus	O	O
WSP	O	O
mice	O	O
.	O	O

In	O	O
microdialysis	O	O
experiments	O	O
,	O	O
the	O	O
lines	O	O
did	O	O
not	O	O
differ	O	O
in	O	O
basal	O	O
release	O	O
of	O	O
ACh	B-Chemical	D000109
,	O	O
and	O	O
50	O	O
mM	O	O
KCl	B-Chemical	C522374
increased	O	O
ACh	B-Chemical	D000109
output	O	O
in	O	O
both	O	O
lines	O	O
of	O	O
mice	O	O
.	O	O

However	O	O
,	O	O
the	O	O
increase	O	O
in	O	O
release	O	O
of	O	O
ACh	B-Chemical	D000109
produced	O	O
by	O	O
the	O	O
first	O	O
application	O	O
of	O	O
KCl	B-Chemical	C522374
was	O	O
2	O	O
-	O	O
fold	O	O
higher	O	O
in	O	O
WSP	O	O
versus	O	O
WSR	O	O
mice	O	O
.	O	O

When	O	O
hippocampal	O	O
ACh	B-Chemical	D000109
was	O	O
measured	O	O
during	O	O
testing	O	O
for	O	O
handling	O	O
-	O	O
induced	O	O
convulsions	B-Disease	D012640
,	O	O
extracellular	O	O
ACh	B-Chemical	D000109
was	O	O
significantly	O	O
elevated	O	O
(	O	O
192%	O	O
)	O	O
in	O	O
WSP	O	O
mice	O	O
,	O	O
but	O	O
was	O	O
nonsignificantly	O	O
elevated	O	O
(	O	O
59%	O	O
)	O	O
in	O	O
WSR	O	O
mice	O	O
.	O	O

CONCLUSIONS	O	O
:	O	O
These	O	O
results	O	O
suggest	O	O
that	O	O
differences	O	O
in	O	O
cholinergic	O	O
activity	O	O
and	O	O
postsynaptic	O	O
sensitivity	O	O
to	O	O
cholinergic	O	O
convulsants	B-Disease	D012640
may	O	O
be	O	O
associated	O	O
with	O	O
ethanol	B-Chemical	D000431
withdrawal	O	O
severity	O	O
and	O	O
implicate	O	O
cholinergic	O	O
mechanisms	O	O
in	O	O
alcohol	B-Chemical	D000431
withdrawal	O	O
.	O	O

Specifically	O	O
,	O	O
WSP	O	O
mice	O	O
may	O	O
have	O	O
lower	O	O
sensitivity	O	O
to	O	O
cholinergic	O	O
convulsants	B-Disease	D012640
compared	O	O
with	O	O
WSR	O	O
because	O	O
of	O	O
postsynaptic	O	O
receptor	O	O
desensitization	O	O
brought	O	O
on	O	O
by	O	O
higher	O	O
activity	O	O
of	O	O
cholinergic	O	O
neurons	O	O
.	O	O

Prenatal	O	O
dexamethasone	B-Chemical	D003907
programs	O	O
hypertension	B-Disease	D006973
and	O	O
renal	B-Disease	D007674
injury	I-Disease	D007674
in	O	O
the	O	O
rat	O	O
.	O	O

Dexamethasone	O	O
is	O	O
frequently	O	O
administered	O	O
to	O	O
the	O	O
developing	O	O
fetus	O	O
to	O	O
accelerate	O	O
pulmonary	O	O
development	O	O
.	O	O

The	O	O
purpose	O	O
of	O	O
the	O	O
present	O	O
study	O	O
was	O	O
to	O	O
determine	O	O
if	O	O
prenatal	O	O
dexamethasone	B-Chemical	D003907
programmed	O	O
a	O	O
progressive	O	O
increase	B-Disease	D006973
in	I-Disease	D006973
blood	I-Disease	D006973
pressure	I-Disease	D006973
and	O	O
renal	B-Disease	D007674
injury	I-Disease	D007674
in	O	O
rats	O	O
.	O	O

Pregnant	O	O
rats	O	O
were	O	O
given	O	O
either	O	O
vehicle	O	O
or	O	O
2	O	O
daily	O	O
intraperitoneal	O	O
injections	O	O
of	O	O
dexamethasone	B-Chemical	D003907
(	O	O
0	O	O
.	O	O

2	O	O
mg	O	O
/	O	O
kg	O	O
body	O	O
weight	O	O
)	O	O
on	O	O
gestational	O	O
days	O	O
11	O	O
and	O	O
12	O	O
,	O	O
13	O	O
and	O	O
14	O	O
,	O	O
15	O	O
and	O	O
16	O	O
,	O	O
17	O	O
and	O	O
18	O	O
,	O	O
or	O	O
19	O	O
and	O	O
20	O	O
.	O	O

Offspring	O	O
of	O	O
rats	O	O
administered	O	O
dexamethasone	B-Chemical	D003907
on	O	O
days	O	O
15	O	O
and	O	O
16	O	O
gestation	O	O
had	O	O
a	O	O
20%	O	O
reduction	B-Disease	D007674
in	I-Disease	D007674
glomerular	I-Disease	D007674
number	I-Disease	D007674
compared	O	O
with	O	O
control	O	O
at	O	O
6	O	O
to	O	O
9	O	O
months	O	O
of	O	O
age	O	O
(	O	O
22	O	O
527+	O	O
/	O	O
-	O	O
509	O	O
versus	O	O
28	O	O
050+	O	O
/	O	O
-	O	O
561	O	O
,	O	O
P<0	O	O
.	O	O

05	O	O
)	O	O
,	O	O
which	O	O
was	O	O
comparable	O	O
to	O	O
the	O	O
percent	O	O
reduction	O	O
in	O	O
glomeruli	O	O
measured	O	O
at	O	O
3	O	O
weeks	O	O
of	O	O
age	O	O
.	O	O

Six	O	O
-	O	O
to	O	O
9	O	O
-	O	O
month	O	O
old	O	O
rats	O	O
receiving	O	O
prenatal	O	O
dexamethasone	B-Chemical	D003907
on	O	O
days	O	O
17	O	O
and	O	O
18	O	O
of	O	O
gestation	O	O
had	O	O
a	O	O
17%	O	O
reduction	O	O
in	O	O
glomeruli	O	O
(	O	O
23	O	O
380+	O	O
/	O	O
-	O	O
587	O	O
)	O	O
compared	O	O
with	O	O
control	O	O
rats	O	O
(	O	O
P<0	O	O
.	O	O

05	O	O
)	O	O
.	O	O

Male	O	O
rats	O	O
that	O	O
received	O	O
prenatal	O	O
dexamethasone	B-Chemical	D003907
on	O	O
days	O	O
15	O	O
and	O	O
16	O	O
,	O	O
17	O	O
and	O	O
18	O	O
,	O	O
and	O	O
13	O	O
and	O	O
14	O	O
of	O	O
gestation	O	O
had	O	O
elevated	B-Disease	D006973
blood	I-Disease	D006973
pressures	I-Disease	D006973
at	O	O
6	O	O
months	O	O
of	O	O
age	O	O
;	O	O
the	O	O
latter	O	O
group	O	O
did	O	O
not	O	O
have	O	O
a	O	O
reduction	B-Disease	D007674
in	I-Disease	D007674
glomerular	I-Disease	D007674
number	I-Disease	D007674
.	O	O

Adult	O	O
rats	O	O
given	O	O
dexamethasone	B-Chemical	D003907
on	O	O
days	O	O
15	O	O
and	O	O
16	O	O
of	O	O
gestation	O	O
had	O	O
more	O	O
glomeruli	O	O
with	O	O
glomerulosclerosis	B-Disease	D005921
than	O	O
control	O	O
rats	O	O
.	O	O

This	O	O
study	O	O
shows	O	O
that	O	O
prenatal	O	O
dexamethasone	B-Chemical	D003907
in	O	O
rats	O	O
results	O	O
in	O	O
a	O	O
reduction	B-Disease	D007674
in	I-Disease	D007674
glomerular	I-Disease	D007674
number	I-Disease	D007674
,	O	O
glomerulosclerosis	B-Disease	D005921
,	O	O
and	O	O
hypertension	B-Disease	D006973
when	O	O
administered	O	O
at	O	O
specific	O	O
points	O	O
during	O	O
gestation	O	O
.	O	O

Hypertension	B-Disease	D006973
was	O	O
observed	O	O
in	O	O
animals	O	O
that	O	O
had	O	O
a	O	O
reduction	O	O
in	O	O
glomeruli	O	O
as	O	O
well	O	O
as	O	O
in	O	O
a	O	O
group	O	O
that	O	O
did	O	O
not	O	O
have	O	O
a	O	O
reduction	B-Disease	D007674
in	I-Disease	D007674
glomerular	I-Disease	D007674
number	I-Disease	D007674
,	O	O
suggesting	O	O
that	O	O
a	O	O
reduction	B-Disease	D007674
in	I-Disease	D007674
glomerular	I-Disease	D007674
number	I-Disease	D007674
is	O	O
not	O	O
the	O	O
sole	O	O
cause	O	O
for	O	O
the	O	O
development	O	O
of	O	O
hypertension	B-Disease	D006973
.	O	O

The	O	O
risk	O	O
of	O	O
venous	B-Disease	D054556
thromboembolism	I-Disease	D054556
in	O	O
women	O	O
prescribed	O	O
cyproterone	B-Chemical	D017373
acetate	I-Chemical	D017373
in	O	O
combination	O	O
with	O	O
ethinyl	B-Chemical	D004997
estradiol	I-Chemical	D004997
:	O	O
a	O	O
nested	O	O
cohort	O	O
analysis	O	O
and	O	O
case	O	O
-	O	O
control	O	O
study	O	O
.	O	O

BACKGROUND	O	O
:	O	O
Cyproterone	B-Chemical	D017373
acetate	I-Chemical	D017373
combined	O	O
with	O	O
ethinyl	B-Chemical	D004997
estradiol	I-Chemical	D004997
(	O	O
CPA	B-Chemical	D017373
/	O	O
EE	B-Chemical	D004997
)	O	O
is	O	O
licensed	O	O
in	O	O
the	O	O
UK	O	O
for	O	O
the	O	O
treatment	O	O
of	O	O
women	O	O
with	O	O
acne	B-Disease	D000152
and	O	O
hirsutism	B-Disease	D006628
and	O	O
is	O	O
also	O	O
a	O	O
treatment	O	O
option	O	O
for	O	O
polycystic	B-Disease	D011085
ovary	I-Disease	D011085
syndrome	I-Disease	D011085
(	O	O
PCOS	B-Disease	D011085
)	O	O
.	O	O

Previous	O	O
studies	O	O
have	O	O
demonstrated	O	O
an	O	O
increased	O	O
risk	O	O
of	O	O
venous	B-Disease	D054556
thromboembolism	I-Disease	D054556
(	O	O
VTE	B-Disease	D054556
)	O	O
associated	O	O
with	O	O
CPA	B-Chemical	D017373
/	O	O
EE	B-Chemical	D004997
compared	O	O
with	O	O
conventional	O	O
combined	O	O
oral	B-Chemical	D003276
contraceptives	I-Chemical	D003276
(	O	O
COCs	O	O
)	O	O
.	O	O

We	O	O
believe	O	O
the	O	O
results	O	O
of	O	O
those	O	O
studies	O	O
may	O	O
have	O	O
been	O	O
affected	O	O
by	O	O
residual	O	O
confounding	O	O
.	O	O

METHODS	O	O
:	O	O
Using	O	O
the	O	O
General	O	O
Practice	O	O
Research	O	O
Database	O	O
we	O	O
conducted	O	O
a	O	O
cohort	O	O
analysis	O	O
and	O	O
case	O	O
-	O	O
control	O	O
study	O	O
nested	O	O
within	O	O
a	O	O
population	O	O
of	O	O
women	O	O
aged	O	O
between	O	O
15	O	O
and	O	O
39	O	O
years	O	O
with	O	O
acne	B-Disease	D000152
,	O	O
hirsutism	B-Disease	D006628
or	O	O
PCOS	B-Disease	D011085
to	O	O
estimate	O	O
the	O	O
risk	O	O
of	O	O
VTE	B-Disease	D054556
associated	O	O
with	O	O
CPA	B-Chemical	D017373
/	O	O
EE	B-Chemical	D004997
.	O	O

RESULTS	O	O
:	O	O
The	O	O
age	O	O
-	O	O
adjusted	O	O
incidence	O	O
rate	O	O
ratio	O	O
for	O	O
CPA	B-Chemical	D017373
/	O	O
EE	B-Chemical	D004997
versus	O	O
conventional	O	O
COCs	O	O
was	O	O
2	O	O
.	O	O

20	O	O
[	O	O
95%	O	O
confidence	O	O
interval	O	O
(	O	O
CI	O	O
)	O	O
1	O	O
.	O	O

35	O	O
-	O	O
3	O	O
.	O	O

58	O	O
]	O	O
.	O	O

Using	O	O
as	O	O
the	O	O
reference	O	O
group	O	O
women	O	O
who	O	O
were	O	O
not	O	O
using	O	O
oral	O	O
contraception	O	O
,	O	O
had	O	O
no	O	O
recent	O	O
pregnancy	O	O
or	O	O
menopausal	O	O
symptoms	O	O
,	O	O
the	O	O
case	O	O
-	O	O
control	O	O
analysis	O	O
gave	O	O
an	O	O
adjusted	O	O
odds	O	O
ratio	O	O
(	O	O
OR	O	O
(	O	O
adj	O	O
)	O	O
)	O	O
of	O	O
7	O	O
.	O	O

44	O	O
(	O	O
95%	O	O
CI	O	O
3	O	O
.	O	O

67	O	O
-	O	O
15	O	O
.	O	O

08	O	O
)	O	O
for	O	O
CPA	B-Chemical	D017373
/	O	O
EE	B-Chemical	D004997
use	O	O
compared	O	O
with	O	O
an	O	O
OR	O	O
(	O	O
adj	O	O
)	O	O
of	O	O
2	O	O
.	O	O

58	O	O
(	O	O
95%	O	O
CI	O	O
1	O	O
.	O	O

60	O	O
-	O	O
4	O	O
.	O	O

18	O	O
)	O	O
for	O	O
use	O	O
of	O	O
conventional	O	O
COCs	O	O
.	O	O

CONCLUSIONS	O	O
:	O	O
We	O	O
have	O	O
demonstrated	O	O
an	O	O
increased	O	O
risk	O	O
of	O	O
VTE	B-Disease	D054556
associated	O	O
with	O	O
the	O	O
use	O	O
of	O	O
CPA	B-Chemical	D017373
/	O	O
EE	B-Chemical	D004997
in	O	O
women	O	O
with	O	O
acne	B-Disease	D000152
,	O	O
hirsutism	B-Disease	D006628
or	O	O
PCOS	B-Disease	D011085
although	O	O
residual	O	O
confounding	O	O
by	O	O
indication	O	O
cannot	O	O
be	O	O
excluded	O	O
.	O	O

Pseudoacromegaly	B-Disease	D004194
induced	O	O
by	O	O
the	O	O
long	O	O
-	O	O
term	O	O
use	O	O
of	O	O
minoxidil	B-Chemical	D008914
.	O	O

Acromegaly	B-Disease	D000172
is	O	O
an	O	O
endocrine	B-Disease	D004700
disorder	I-Disease	D004700
caused	O	O
by	O	O
chronic	O	O
excessive	O	O
growth	O	O
hormone	O	O
secretion	O	O
from	O	O
the	O	O
anterior	O	O
pituitary	O	O
gland	O	O
.	O	O

Significant	O	O
disfiguring	O	O
changes	O	O
occur	O	O
as	O	O
a	O	O
result	O	O
of	O	O
bone	O	O
,	O	O
cartilage	O	O
,	O	O
and	O	O
soft	O	O
tissue	O	O
hypertrophy	B-Disease	D006984
,	O	O
including	O	O
the	O	O
thickening	O	O
of	O	O
the	O	O
skin	O	O
,	O	O
coarsening	O	O
of	O	O
facial	O	O
features	O	O
,	O	O
and	O	O
cutis	B-Disease	C535610
verticis	I-Disease	C535610
gyrata	I-Disease	C535610
.	O	O

Pseudoacromegaly	B-Disease	D004194
,	O	O
on	O	O
the	O	O
other	O	O
hand	O	O
,	O	O
is	O	O
the	O	O
presence	O	O
of	O	O
similar	O	O
acromegaloid	O	O
features	O	O
in	O	O
the	O	O
absence	O	O
of	O	O
elevated	O	O
growth	O	O
hormone	O	O
or	O	O
insulin	O	O
-	O	O
like	O	O
growth	O	O
factor	O	O
levels	O	O
.	O	O

We	O	O
present	O	O
a	O	O
patient	O	O
with	O	O
pseudoacromegaly	B-Disease	D004194
that	O	O
resulted	O	O
from	O	O
the	O	O
long	O	O
-	O	O
term	O	O
use	O	O
of	O	O
minoxidil	B-Chemical	D008914
at	O	O
an	O	O
unusually	O	O
high	O	O
dose	O	O
.	O	O

This	O	O
is	O	O
the	O	O
first	O	O
case	O	O
report	O	O
of	O	O
pseudoacromegaly	B-Disease	D004194
as	O	O
a	O	O
side	O	O
effect	O	O
of	O	O
minoxidil	B-Chemical	D008914
use	O	O
.	O	O

Combined	O	O
androgen	O	O
blockade	O	O
-	O	O
induced	O	O
anemia	B-Disease	D000740
in	O	O
prostate	B-Disease	D011471
cancer	I-Disease	D011471
patients	O	O
without	O	O
bone	O	O
involvement	O	O
.	O	O

BACKGROUND	O	O
:	O	O
To	O	O
determine	O	O
the	O	O
onset	O	O
and	O	O
extent	O	O
of	O	O
combined	O	O
androgen	O	O
blockade	O	O
(	O	O
CAB	O	O
)	O	O
-	O	O
induced	O	O
anemia	B-Disease	D000740
in	O	O
prostate	B-Disease	D011471
cancer	I-Disease	D011471
patients	O	O
without	O	O
bone	O	O
involvement	O	O
.	O	O

PATIENTS	O	O
AND	O	O
METHODS	O	O
:	O	O
Forty	O	O
-	O	O
two	O	O
patients	O	O
with	O	O
biopsy	O	O
-	O	O
proven	O	O
prostatic	B-Disease	D000230
adenocarcinoma	I-Disease	D000230
[	O	O
26	O	O
with	O	O
stage	O	O
C	O	O
(	O	O
T3N0M0	O	O
)	O	O
and	O	O
16	O	O
with	O	O
stage	O	O
D1	O	O
(	O	O
T3N1M0	O	O
)	O	O
]	O	O
were	O	O
included	O	O
in	O	O
this	O	O
study	O	O
.	O	O

All	O	O
patients	O	O
received	O	O
CAB	O	O
[	O	O
leuprolide	B-Chemical	D016729
acetate	I-Chemical	D016729
(	O	O
LHRH	B-Chemical	D016729
-	I-Chemical	D016729
A	I-Chemical	D016729
)	O	O
3	O	O
.	O	O

75	O	O
mg	O	O
,	O	O
intramuscularly	O	O
,	O	O
every	O	O
28	O	O
days	O	O
plus	O	O
250	O	O
mg	O	O
flutamide	B-Chemical	D005485
,	O	O
tid	O	O
,	O	O
per	O	O
Os	O	O
]	O	O
and	O	O
were	O	O
evaluated	O	O
for	O	O
anemia	B-Disease	D000740
by	O	O
physical	O	O
examination	O	O
and	O	O
laboratory	O	O
tests	O	O
at	O	O
baseline	O	O
and	O	O
4	O	O
subsequent	O	O
intervals	O	O
(	O	O
1	O	O
,	O	O
2	O	O
,	O	O
3	O	O
and	O	O
6	O	O
months	O	O
post	O	O
-	O	O
CAB	O	O
)	O	O
.	O	O

Hb	O	O
,	O	O
PSA	O	O
and	O	O
Testosterone	B-Chemical	D013739
measurements	O	O
were	O	O
recorded	O	O
.	O	O

Patients	O	O
with	O	O
stage	O	O
D2	O	O
-	O	O
3	O	O
disease	O	O
,	O	O
abnormal	O	O
hemoglobin	O	O
level	O	O
or	O	O
renal	O	O
and	O	O
liver	O	O
function	O	O
tests	O	O
that	O	O
were	O	O
higher	O	O
than	O	O
the	O	O
upper	O	O
limits	O	O
were	O	O
excluded	O	O
from	O	O
the	O	O
study	O	O
.	O	O

The	O	O
duration	O	O
of	O	O
the	O	O
study	O	O
was	O	O
six	O	O
months	O	O
.	O	O

RESULTS	O	O
:	O	O
The	O	O
mean	O	O
hemoglobin	O	O
(	O	O
Hb	O	O
)	O	O
levels	O	O
were	O	O
significantly	O	O
declined	O	O
in	O	O
all	O	O
patients	O	O
from	O	O
baseline	O	O
of	O	O
14	O	O
.	O	O

2	O	O
g	O	O
/	O	O
dl	O	O
to	O	O
14	O	O
.	O	O

0	O	O
g	O	O
/	O	O
dl	O	O
,	O	O
13	O	O
.	O	O

5	O	O
g	O	O
/	O	O
dl	O	O
,	O	O
13	O	O
.	O	O

2	O	O
g	O	O
/	O	O
dl	O	O
and	O	O
12	O	O
.	O	O

7	O	O
g	O	O
/	O	O
dl	O	O
at	O	O
1	O	O
,	O	O
2	O	O
,	O	O
3	O	O
and	O	O
6	O	O
months	O	O
post	O	O
-	O	O
CAB	O	O
,	O	O
respectively	O	O
.	O	O

Severe	O	O
and	O	O
clinically	O	O
evident	O	O
anemia	B-Disease	D000740
of	O	O
Hb	O	O
<	O	O
11	O	O
g	O	O
/	O	O
dl	O	O
with	O	O
clinical	O	O
symptoms	O	O
was	O	O
detected	O	O
in	O	O
6	O	O
patients	O	O
(	O	O
14	O	O
.	O	O

3%	O	O
)	O	O
.	O	O

This	O	O
CAB	O	O
-	O	O
induced	O	O
anemia	B-Disease	D000740
was	O	O
normochromic	O	O
and	O	O
normocytic	O	O
.	O	O

At	O	O
six	O	O
months	O	O
post	O	O
-	O	O
CAB	O	O
,	O	O
patients	O	O
with	O	O
severe	O	O
anemia	B-Disease	D000740
had	O	O
a	O	O
Hb	O	O
mean	O	O
value	O	O
of	O	O
10	O	O
.	O	O

2	O	O
+	O	O
/	O	O
-	O	O
0	O	O
.	O	O

1	O	O
g	O	O
/	O	O
dl	O	O
(	O	O
X	O	O
+	O	O
/	O	O
-	O	O
SE	O	O
)	O	O
,	O	O
whereas	O	O
the	O	O
other	O	O
patients	O	O
had	O	O
mild	O	O
anemia	B-Disease	D000740
with	O	O
Hb	O	O
mean	O	O
value	O	O
of	O	O
13	O	O
.	O	O

2	O	O
+	O	O
/	O	O
-	O	O
0	O	O
.	O	O

17	O	O
(	O	O
X	O	O
+	O	O
/	O	O
-	O	O
SE	O	O
)	O	O
.	O	O

The	O	O
development	O	O
of	O	O
severe	O	O
anemia	B-Disease	D000740
at	O	O
6	O	O
months	O	O
post	O	O
-	O	O
CAB	O	O
was	O	O
predictable	O	O
by	O	O
the	O	O
reduction	O	O
of	O	O
Hb	O	O
baseline	O	O
value	O	O
of	O	O
more	O	O
than	O	O
2	O	O
.	O	O

5	O	O
g	O	O
/	O	O
dl	O	O
after	O	O
3	O	O
months	O	O
of	O	O
CAB	O	O
(	O	O
p	O	O
=	O	O
0	O	O
.	O	O

01	O	O
)	O	O
.	O	O

The	O	O
development	O	O
of	O	O
severe	O	O
CAB	O	O
-	O	O
induced	O	O
anemia	B-Disease	D000740
in	O	O
prostate	B-Disease	D011471
cancer	I-Disease	D011471
patients	O	O
did	O	O
not	O	O
correlate	O	O
with	O	O
T	O	O
baseline	O	O
values	O	O
(	O	O
T	O	O
<	O	O
3	O	O
ng	O	O
/	O	O
ml	O	O
versus	O	O
T	O	O
>	O	O
or	O	O
=	O	O
3	O	O
ng	O	O
/	O	O
ml	O	O
)	O	O
,	O	O
with	O	O
age	O	O
(	O	O
<	O	O
76	O	O
yrs	O	O
versus	O	O
>	O	O
or	O	O
=	O	O
76	O	O
yrs	O	O
)	O	O
,	O	O
and	O	O
clinical	O	O
stage	O	O
(	O	O
stage	O	O
C	O	O
versus	O	O
stage	O	O
D1	O	O
)	O	O
.	O	O

Severe	O	O
and	O	O
clinically	O	O
evident	O	O
anemia	B-Disease	D000740
was	O	O
easily	O	O
corrected	O	O
by	O	O
subcutaneous	O	O
injections	O	O
(	O	O
3	O	O
times	O	O
/	O	O
week	O	O
for	O	O
1	O	O
month	O	O
)	O	O
of	O	O
recombinant	O	O
erythropoietin	O	O
(	O	O
rHuEPO	O	O
-	O	O
beta	O	O
)	O	O
.	O	O

CONCLUSION	O	O
:	O	O
Our	O	O
data	O	O
suggest	O	O
that	O	O
rHuEPO	O	O
-	O	O
beta	O	O
correctable	O	O
CAB	O	O
-	O	O
induced	O	O
anemia	B-Disease	D000740
occurs	O	O
in	O	O
14	O	O
.	O	O

3%	O	O
of	O	O
prostate	B-Disease	D011471
cancer	I-Disease	D011471
patients	O	O
after	O	O
6	O	O
months	O	O
of	O	O
therapy	O	O
.	O	O

Reversible	O	O
dilated	B-Disease	D002311
cardiomyopathy	I-Disease	D002311
related	O	O
to	O	O
amphotericin	B-Chemical	D000666
B	I-Chemical	D000666
therapy	O	O
.	O	O

We	O	O
describe	O	O
a	O	O
patient	O	O
who	O	O
developed	O	O
dilated	B-Disease	D002311
cardiomyopathy	I-Disease	D002311
and	O	O
clinical	O	O
congestive	O	O
heart	B-Disease	D006333
failure	I-Disease	D006333
after	O	O
2	O	O
months	O	O
of	O	O
therapy	O	O
with	O	O
amphotericin	B-Chemical	D000666
B	I-Chemical	D000666
(	O	O
AmB	B-Chemical	D000666
)	O	O
for	O	O
disseminated	O	O
coccidioidomycosis	B-Disease	D003047
.	O	O

His	O	O
echocardiographic	O	O
abnormalities	O	O
and	O	O
heart	B-Disease	D006333
failure	I-Disease	D006333
resolved	O	O
after	O	O
posaconazole	B-Chemical	C101425
was	O	O
substituted	O	O
for	O	O
AmB	B-Chemical	D000666
.	O	O

It	O	O
is	O	O
important	O	O
to	O	O
recognize	O	O
the	O	O
rare	O	O
and	O	O
potentially	O	O
reversible	O	O
toxicity	B-Disease	D064420
of	O	O
AmB	B-Chemical	D000666
.	O	O

Risks	O	O
of	O	O
the	O	O
consumption	O	O
of	O	O
beverages	O	O
containing	O	O
quinine	B-Chemical	D011803
.	O	O

Although	O	O
the	O	O
United	O	O
States	O	O
Food	O	O
and	O	O
Drug	O	O
Administration	O	O
banned	O	O
its	O	O
use	O	O
for	O	O
nocturnal	B-Disease	D020922
leg	I-Disease	D020922
cramps	I-Disease	D020922
due	O	O
to	O	O
lack	O	O
of	O	O
safety	O	O
and	O	O
efficacy	O	O
,	O	O
quinine	B-Chemical	D011803
is	O	O
widely	O	O
available	O	O
in	O	O
beverages	O	O
including	O	O
tonic	O	O
water	O	O
and	O	O
bitter	O	O
lemon	O	O
.	O	O

Numerous	O	O
anecdotal	O	O
reports	O	O
suggest	O	O
that	O	O
products	O	O
containing	O	O
quinine	B-Chemical	D011803
may	O	O
produce	O	O
neurological	B-Disease	D002493
complications	I-Disease	D002493
,	O	O
including	O	O
confusion	B-Disease	D003221
,	O	O
altered	O	O
mental	O	O
status	O	O
,	O	O
seizures	B-Disease	D012640
,	O	O
and	O	O
coma	B-Disease	D003128
,	O	O
particularly	O	O
in	O	O
older	O	O
women	O	O
.	O	O

Psychologists	O	O
need	O	O
to	O	O
inquire	O	O
about	O	O
consumption	O	O
of	O	O
quinine	B-Chemical	D011803
-	O	O
containing	O	O
beverages	O	O
as	O	O
part	O	O
of	O	O
an	O	O
evaluation	O	O
process	O	O
.	O	O

Organophosphate	B-Chemical	D010755
-	O	O
induced	O	O
convulsions	B-Disease	D012640
and	O	O
prevention	O	O
of	O	O
neuropathological	B-Disease	D004194
damages	I-Disease	D004194
.	O	O

Such	O	O
organophosphorus	B-Chemical	D010755
(	O	O
OP	B-Chemical	D010755
)	O	O
compounds	O	O
as	O	O
diisopropylfluorophosphate	B-Chemical	D007531
(	O	O
DFP	B-Chemical	D007531
)	O	O
,	O	O
sarin	B-Chemical	D012524
and	O	O
soman	B-Chemical	D012999
are	O	O
potent	O	O
inhibitors	O	O
of	O	O
acetylcholinesterases	O	O
(	O	O
AChEs	O	O
)	O	O
and	O	O
butyrylcholinesterases	O	O
(	O	O
BChEs	O	O
)	O	O
.	O	O

The	O	O
acute	O	O
toxicity	B-Disease	D064420
of	O	O
OPs	B-Chemical	D010755
is	O	O
the	O	O
result	O	O
of	O	O
their	O	O
irreversible	O	O
binding	O	O
with	O	O
AChEs	O	O
in	O	O
the	O	O
central	O	O
nervous	O	O
system	O	O
(	O	O
CNS	O	O
)	O	O
,	O	O
which	O	O
elevates	O	O
acetylcholine	B-Chemical	D000109
(	O	O
ACh	B-Chemical	D000109
)	O	O
levels	O	O
.	O	O

The	O	O
protective	O	O
action	O	O
of	O	O
subcutaneously	O	O
(	O	O
SC	O	O
)	O	O
administered	O	O
antidotes	O	O
or	O	O
their	O	O
combinations	O	O
in	O	O
DFP	B-Chemical	D007531
(	O	O
2	O	O
.	O	O

0	O	O
mg	O	O
/	O	O
kg	O	O
BW	O	O
)	O	O
intoxication	O	O
was	O	O
studied	O	O
in	O	O
9	O	O
-	O	O
10	O	O
-	O	O
weeks	O	O
-	O	O
old	O	O
Han	O	O
-	O	O
Wistar	O	O
male	O	O
rats	O	O
.	O	O

The	O	O
rats	O	O
received	O	O
AChE	O	O
reactivator	O	O
pralidoxime	B-Chemical	D011220
-	I-Chemical	D011220
2	I-Chemical	D011220
-	I-Chemical	D011220
chloride	I-Chemical	D011220
(	O	O
2PAM	B-Chemical	D011220
)	O	O
(	O	O
30	O	O
.	O	O

0	O	O
mg	O	O
/	O	O
kg	O	O
BW	O	O
)	O	O
,	O	O
anticonvulsant	O	O
diazepam	B-Chemical	D003975
(	O	O
2	O	O
.	O	O

0	O	O
mg	O	O
/	O	O
kg	O	O
BW	O	O
)	O	O
,	O	O
A	O	O
(	O	O
1	O	O
)	O	O
-	O	O
adenosine	B-Chemical	D000241
receptor	O	O
agonist	O	O
N	B-Chemical	C048599
(	I-Chemical	C048599
6	I-Chemical	C048599
)	I-Chemical	C048599
-	I-Chemical	C048599
cyclopentyl	I-Chemical	C048599
adenosine	I-Chemical	C048599
(	O	O
CPA	B-Chemical	C048599
)	O	O
(	O	O
2	O	O
.	O	O

0	O	O
mg	O	O
/	O	O
kg	O	O
BW	O	O
)	O	O
,	O	O
NMDA	B-Chemical	D016202
-	O	O
receptor	O	O
antagonist	O	O
dizocilpine	B-Chemical	D016291
maleate	I-Chemical	D016291
(	O	O
+	O	O
-	O	O
MK801	B-Chemical	D016291
hydrogen	O	O
maleate	O	O
)	O	O
(	O	O
2	O	O
.	O	O

0	O	O
mg	O	O
/	O	O
kg	O	O
BW	O	O
)	O	O
or	O	O
their	O	O
combinations	O	O
with	O	O
cholinolytic	O	O
drug	O	O
atropine	B-Chemical	D001285
sulfate	I-Chemical	D001285
(	O	O
50	O	O
.	O	O

0	O	O
mg	O	O
/	O	O
kg	O	O
BW	O	O
)	O	O
immediately	O	O
or	O	O
30	O	O
min	O	O
after	O	O
the	O	O
single	O	O
SC	O	O
injection	O	O
of	O	O
DFP	B-Chemical	D007531
.	O	O

The	O	O
control	O	O
rats	O	O
received	O	O
atropine	B-Chemical	D001285
sulfate	I-Chemical	D001285
,	O	O
but	O	O
also	O	O
saline	O	O
and	O	O
olive	O	O
oil	O	O
instead	O	O
of	O	O
other	O	O
antidotes	O	O
and	O	O
DFP	B-Chemical	D007531
,	O	O
respectively	O	O
.	O	O

All	O	O
rats	O	O
were	O	O
terminated	O	O
either	O	O
24	O	O
h	O	O
or	O	O
3	O	O
weeks	O	O
after	O	O
the	O	O
DFP	B-Chemical	D007531
injection	O	O
.	O	O

The	O	O
rats	O	O
treated	O	O
with	O	O
DFP	B-Chemical	D007531
-	O	O
atropine	B-Chemical	D001285
showed	O	O
severe	O	O
typical	O	O
OP	B-Chemical	D010755
-	O	O
induced	O	O
toxicity	B-Disease	D064420
signs	O	O
.	O	O

When	O	O
CPA	B-Chemical	C048599
,	O	O
diazepam	B-Chemical	D003975
or	O	O
2PAM	B-Chemical	D011220
was	O	O
given	O	O
immediately	O	O
after	O	O
DFP	B-Chemical	D007531
-	O	O
atropine	B-Chemical	D001285
,	O	O
these	O	O
treatments	O	O
prevented	O	O
,	O	O
delayed	O	O
or	O	O
shortened	O	O
the	O	O
occurrence	O	O
of	O	O
serious	O	O
signs	O	O
of	O	O
poisoning	B-Disease	D011041
.	O	O

Atropine	B-Chemical	D001285
-	O	O
MK801	B-Chemical	D016291
did	O	O
not	O	O
offer	O	O
any	O	O
additional	O	O
protection	O	O
against	O	O
DFP	B-Chemical	D007531
toxicity	B-Disease	D064420
.	O	O

In	O	O
conclusion	O	O
,	O	O
CPA	B-Chemical	C048599
,	O	O
diazepam	B-Chemical	D003975
and	O	O
2PAM	B-Chemical	D011220
in	O	O
combination	O	O
with	O	O
atropine	B-Chemical	D001285
prevented	O	O
the	O	O
occurrence	O	O
of	O	O
serious	O	O
signs	O	O
of	O	O
poisoning	B-Disease	D011041
and	O	O
thus	O	O
reduced	O	O
the	O	O
toxicity	B-Disease	D064420
of	O	O
DFP	B-Chemical	D007531
in	O	O
rat	O	O
.	O	O

Differential	O	O
modulation	O	O
by	O	O
estrogen	B-Chemical	D004967
of	O	O
alpha2	O	O
-	O	O
adrenergic	O	O
and	O	O
I1	O	O
-	O	O
imidazoline	B-Chemical	D048288
receptor	O	O
-	O	O
mediated	O	O
hypotension	B-Disease	D007022
in	O	O
female	O	O
rats	O	O
.	O	O

We	O	O
have	O	O
recently	O	O
shown	O	O
that	O	O
estrogen	B-Chemical	D004967
negatively	O	O
modulates	O	O
the	O	O
hypotensive	B-Disease	D007022
effect	O	O
of	O	O
clonidine	B-Chemical	D003000
(	O	O
mixed	O	O
alpha2	O	O
-	O	O
/	O	O
I1	O	O
-	O	O
receptor	O	O
agonist	O	O
)	O	O
in	O	O
female	O	O
rats	O	O
and	O	O
implicates	O	O
the	O	O
cardiovascular	O	O
autonomic	O	O
control	O	O
in	O	O
this	O	O
interaction	O	O
.	O	O

The	O	O
present	O	O
study	O	O
investigated	O	O
whether	O	O
this	O	O
effect	O	O
of	O	O
estrogen	B-Chemical	D004967
involves	O	O
interaction	O	O
with	O	O
alpha2	O	O
-	O	O
and	O	O
/	O	O
or	O	O
I1	O	O
-	O	O
receptors	O	O
.	O	O

Changes	O	O
evoked	O	O
by	O	O
a	O	O
single	O	O
intraperitoneal	O	O
injection	O	O
of	O	O
rilmenidine	B-Chemical	C032302
(	O	O
600	O	O
microg	O	O
/	O	O
kg	O	O
)	O	O
or	O	O
alpha	B-Chemical	D008750
-	I-Chemical	D008750
methyldopa	I-Chemical	D008750
(	O	O
100	O	O
mg	O	O
/	O	O
kg	O	O
)	O	O
,	O	O
selective	O	O
I1	O	O
-	O	O
and	O	O
alpha2	O	O
-	O	O
receptor	O	O
agonists	O	O
,	O	O
respectively	O	O
,	O	O
in	O	O
blood	O	O
pressure	O	O
,	O	O
hemodynamic	O	O
variability	O	O
,	O	O
and	O	O
locomotor	O	O
activity	O	O
were	O	O
assessed	O	O
in	O	O
radiotelemetered	O	O
sham	O	O
-	O	O
operated	O	O
and	O	O
ovariectomized	O	O
(	O	O
Ovx	O	O
)	O	O
Sprague	O	O
-	O	O
Dawley	O	O
female	O	O
rats	O	O
with	O	O
or	O	O
without	O	O
12	O	O
-	O	O
wk	O	O
estrogen	B-Chemical	D004967
replacement	O	O
.	O	O

Three	O	O
time	O	O
domain	O	O
indexes	O	O
of	O	O
hemodynamic	O	O
variability	O	O
were	O	O
employed	O	O
:	O	O
the	O	O
standard	O	O
deviation	O	O
of	O	O
mean	O	O
arterial	O	O
pressure	O	O
as	O	O
a	O	O
measure	O	O
of	O	O
blood	O	O
pressure	O	O
variability	O	O
and	O	O
the	O	O
standard	O	O
deviation	O	O
of	O	O
beat	O	O
-	O	O
to	O	O
-	O	O
beat	O	O
intervals	O	O
(	O	O
SDRR	O	O
)	O	O
and	O	O
the	O	O
root	O	O
mean	O	O
square	O	O
of	O	O
successive	O	O
differences	O	O
in	O	O
R	O	O
-	O	O
wave	O	O
-	O	O
to	O	O
-	O	O
R	O	O
-	O	O
wave	O	O
intervals	O	O
as	O	O
measures	O	O
of	O	O
heart	O	O
rate	O	O
variability	O	O
.	O	O

In	O	O
sham	O	O
-	O	O
operated	O	O
rats	O	O
,	O	O
rilmenidine	B-Chemical	C032302
or	O	O
alpha	B-Chemical	D008750
-	I-Chemical	D008750
methyldopa	I-Chemical	D008750
elicited	O	O
similar	O	O
hypotension	B-Disease	D007022
that	O	O
lasted	O	O
at	O	O
least	O	O
5	O	O
h	O	O
and	O	O
was	O	O
associated	O	O
with	O	O
reductions	O	O
in	O	O
standard	O	O
deviation	O	O
of	O	O
mean	O	O
arterial	O	O
pressure	O	O
.	O	O

SDRR	O	O
was	O	O
reduced	O	O
only	O	O
by	O	O
alpha	B-Chemical	D008750
-	I-Chemical	D008750
methyldopa	I-Chemical	D008750
.	O	O

Ovx	O	O
significantly	O	O
enhanced	O	O
the	O	O
hypotensive	B-Disease	D007022
response	O	O
to	O	O
alpha	B-Chemical	D008750
-	I-Chemical	D008750
methyldopa	I-Chemical	D008750
,	O	O
in	O	O
contrast	O	O
to	O	O
no	O	O
effect	O	O
on	O	O
rilmenidine	B-Chemical	C032302
hypotension	B-Disease	D007022
.	O	O

The	O	O
enhanced	O	O
alpha	B-Chemical	D008750
-	I-Chemical	D008750
methyldopa	I-Chemical	D008750
hypotension	B-Disease	D007022
in	O	O
Ovx	O	O
rats	O	O
was	O	O
paralleled	O	O
with	O	O
further	O	O
reduction	O	O
in	O	O
SDRR	O	O
and	O	O
a	B-Disease	D001523
reduced	I-Disease	D001523
locomotor	I-Disease	D001523
activity	I-Disease	D001523
.	O	O

Estrogen	O	O
replacement	O	O
(	O	O
17beta	B-Chemical	D004958
-	I-Chemical	D004958
estradiol	I-Chemical	D004958
subcutaneous	O	O
pellet	O	O
,	O	O
14	O	O
.	O	O

2	O	O
microg	O	O
/	O	O
day	O	O
,	O	O
12	O	O
wk	O	O
)	O	O
of	O	O
Ovx	O	O
rats	O	O
restored	O	O
the	O	O
hemodynamic	O	O
and	O	O
locomotor	O	O
effects	O	O
of	O	O
alpha	B-Chemical	D008750
-	I-Chemical	D008750
methyldopa	I-Chemical	D008750
to	O	O
sham	O	O
-	O	O
operated	O	O
levels	O	O
.	O	O

These	O	O
findings	O	O
suggest	O	O
that	O	O
estrogen	B-Chemical	D004967
downregulates	O	O
alpha2	O	O
-	O	O
but	O	O
not	O	O
I1	O	O
-	O	O
receptor	O	O
-	O	O
mediated	O	O
hypotension	B-Disease	D007022
and	O	O
highlight	O	O
a	O	O
role	O	O
for	O	O
the	O	O
cardiac	O	O
autonomic	O	O
control	O	O
in	O	O
alpha	B-Chemical	D008750
-	I-Chemical	D008750
methyldopa	I-Chemical	D008750
-	O	O
estrogen	B-Chemical	D004967
interaction	O	O
.	O	O

Cardioprotective	O	O
effect	O	O
of	O	O
tincture	B-Chemical	C007145
of	I-Chemical	C007145
Crataegus	I-Chemical	C007145
on	O	O
isoproterenol	B-Chemical	D007545
-	O	O
induced	O	O
myocardial	B-Disease	D009203
infarction	I-Disease	D009203
in	O	O
rats	O	O
.	O	O

Tincture	B-Chemical	C007145
of	I-Chemical	C007145
Crataegus	I-Chemical	C007145
(	O	O
TCR	B-Chemical	C007145
)	O	O
,	O	O
an	O	O
alcoholic	B-Chemical	C007145
extract	I-Chemical	C007145
of	I-Chemical	C007145
the	I-Chemical	C007145
berries	I-Chemical	C007145
of	I-Chemical	C007145
hawthorn	I-Chemical	C007145
(	O	O
Crataegus	B-Chemical	C007145
oxycantha	I-Chemical	C007145
)	O	O
,	O	O
is	O	O
used	O	O
in	O	O
herbal	O	O
and	O	O
homeopathic	O	O
medicine	O	O
.	O	O

The	O	O
present	O	O
study	O	O
was	O	O
done	O	O
to	O	O
investigate	O	O
the	O	O
protective	O	O
effect	O	O
of	O	O
TCR	B-Chemical	C007145
on	O	O
experimentally	O	O
induced	O	O
myocardial	B-Disease	D009203
infarction	I-Disease	D009203
in	O	O
rats	O	O
.	O	O

Pretreatment	O	O
of	O	O
TCR	B-Chemical	C007145
,	O	O
at	O	O
a	O	O
dose	O	O
of	O	O
0	O	O
.	O	O

5	O	O
mL	O	O
/	O	O
100	O	O
g	O	O
bodyweight	O	O
per	O	O
day	O	O
,	O	O
orally	O	O
for	O	O
30	O	O
days	O	O
,	O	O
prevented	O	O
the	O	O
increase	O	O
in	O	O
lipid	O	O
peroxidation	O	O
and	O	O
activity	O	O
of	O	O
marker	O	O
enzymes	O	O
observed	O	O
in	O	O
isoproterenol	B-Chemical	D007545
-	O	O
induced	O	O
rats	O	O
(	O	O
85	O	O
mg	O	O
kg	O	O
(	O	O
-	O	O
1	O	O
)	O	O
s	O	O
.	O	O

c	O	O
.	O	O

for	O	O
2	O	O
days	O	O
at	O	O
an	O	O
interval	O	O
of	O	O
24	O	O
h	O	O
)	O	O
.	O	O

TCR	B-Chemical	C007145
prevented	O	O
the	O	O
isoproterenol	B-Chemical	D007545
-	O	O
induced	O	O
decrease	O	O
in	O	O
antioxidant	O	O
enzymes	O	O
in	O	O
the	O	O
heart	O	O
and	O	O
increased	O	O
the	O	O
rate	O	O
of	O	O
ADP	B-Chemical	D000244
-	O	O
stimulated	O	O
oxygen	B-Chemical	D010100
uptake	O	O
and	O	O
respiratory	O	O
coupling	O	O
ratio	O	O
.	O	O

TCR	B-Chemical	C007145
protected	O	O
against	O	O
pathological	O	O
changes	O	O
induced	O	O
by	O	O
isoproterenol	B-Chemical	D007545
in	O	O
rat	O	O
heart	O	O
.	O	O

The	O	O
results	O	O
show	O	O
that	O	O
pretreatment	O	O
with	O	O
TCR	B-Chemical	C007145
may	O	O
be	O	O
useful	O	O
in	O	O
preventing	O	O
the	O	O
damage	O	O
induced	O	O
by	O	O
isoproterenol	B-Chemical	D007545
in	O	O
rat	O	O
heart	O	O
.	O	O

Safety	O	O
and	O	O
adverse	O	O
effects	O	O
associated	O	O
with	O	O
raloxifene	B-Chemical	D020849
:	O	O
multiple	O	O
outcomes	O	O
of	O	O
raloxifene	B-Chemical	D020849
evaluation	O	O
.	O	O

OBJECTIVE	O	O
:	O	O
To	O	O
examine	O	O
the	O	O
effect	O	O
of	O	O
raloxifene	B-Chemical	D020849
on	O	O
major	O	O
adverse	O	O
events	O	O
that	O	O
occur	O	O
with	O	O
postmenopausal	O	O
estrogen	B-Chemical	D004967
therapy	O	O
or	O	O
tamoxifen	B-Chemical	D013629
.	O	O

METHODS	O	O
:	O	O
The	O	O
Multiple	O	O
Outcomes	O	O
of	O	O
Raloxifene	B-Chemical	D020849
Evaluation	O	O
,	O	O
a	O	O
multicenter	O	O
,	O	O
randomized	O	O
,	O	O
double	O	O
-	O	O
blind	O	O
trial	O	O
,	O	O
enrolled	O	O
7	O	O
,	O	O
705	O	O
postmenopausal	O	O
women	O	O
with	O	O
osteoporosis	B-Disease	D010024
.	O	O

Women	O	O
were	O	O
randomly	O	O
assigned	O	O
to	O	O
raloxifene	B-Chemical	D020849
60	O	O
mg	O	O
/	O	O
d	O	O
or	O	O
120	O	O
mg	O	O
/	O	O
d	O	O
or	O	O
placebo	O	O
.	O	O

Outcomes	O	O
included	O	O
venous	B-Disease	D054556
thromboembolism	I-Disease	D054556
,	O	O
cataracts	B-Disease	D002386
,	O	O
gallbladder	B-Disease	D005705
disease	I-Disease	D005705
,	O	O
and	O	O
endometrial	B-Disease	D004714
hyperplasia	I-Disease	D004714
or	O	O
cancer	O	O
.	O	O

RESULTS	O	O
:	O	O
During	O	O
a	O	O
mean	O	O
follow	O	O
-	O	O
up	O	O
of	O	O
3	O	O
.	O	O

3	O	O
years	O	O
,	O	O
raloxifene	B-Chemical	D020849
was	O	O
associated	O	O
with	O	O
an	O	O
increased	O	O
risk	O	O
for	O	O
venous	B-Disease	D054556
thromboembolism	I-Disease	D054556
(	O	O
relative	O	O
risk	O	O
[	O	O
RR	O	O
]	O	O
2	O	O
.	O	O

1	O	O
;	O	O
95%	O	O
confidence	O	O
interval	O	O
[	O	O
CI	O	O
]	O	O
1	O	O
.	O	O

2	O	O
-	O	O
3	O	O
.	O	O

8	O	O
)	O	O
.	O	O

The	O	O
excess	O	O
event	O	O
rate	O	O
was	O	O
1	O	O
.	O	O

8	O	O
per	O	O
1	O	O
,	O	O
000	O	O
woman	O	O
-	O	O
years	O	O
(	O	O
95%	O	O
CI	O	O
-	O	O
0	O	O
.	O	O

5	O	O
-	O	O
4	O	O
.	O	O

1	O	O
)	O	O
,	O	O
and	O	O
the	O	O
number	O	O
needed	O	O
to	O	O
treat	O	O
to	O	O
cause	O	O
1	O	O
event	O	O
was	O	O
170	O	O
(	O	O
95%	O	O
CI	O	O
100	O	O
-	O	O
582	O	O
)	O	O
over	O	O
3	O	O
.	O	O

3	O	O
years	O	O
.	O	O

Risk	O	O
in	O	O
the	O	O
raloxifene	B-Chemical	D020849
group	O	O
was	O	O
higher	O	O
than	O	O
in	O	O
the	O	O
placebo	O	O
group	O	O
for	O	O
the	O	O
first	O	O
2	O	O
years	O	O
,	O	O
but	O	O
decreased	O	O
to	O	O
about	O	O
the	O	O
same	O	O
rate	O	O
as	O	O
in	O	O
the	O	O
placebo	O	O
group	O	O
thereafter	O	O
.	O	O

Raloxifene	B-Chemical	D020849
did	O	O
not	O	O
increase	O	O
risk	O	O
for	O	O
cataracts	B-Disease	D002386
(	O	O
RR	O	O
0	O	O
.	O	O

9	O	O
;	O	O
95%	O	O
CI	O	O
0	O	O
.	O	O

8	O	O
-	O	O
1	O	O
.	O	O

1	O	O
)	O	O
,	O	O
gallbladder	B-Disease	D005705
disease	I-Disease	D005705
(	O	O
RR	O	O
1	O	O
.	O	O

0	O	O
;	O	O
95%	O	O
CI	O	O
0	O	O
.	O	O

7	O	O
-	O	O
1	O	O
.	O	O

3	O	O
)	O	O
,	O	O
endometrial	B-Disease	D004714
hyperplasia	I-Disease	D004714
(	O	O
RR	O	O
1	O	O
.	O	O

3	O	O
;	O	O
95%	O	O
CI	O	O
0	O	O
.	O	O

4	O	O
-	O	O
5	O	O
.	O	O

1	O	O
)	O	O
,	O	O
or	O	O
endometrial	B-Disease	D016889
cancer	I-Disease	D016889
(	O	O
RR	O	O
0	O	O
.	O	O

9	O	O
;	O	O
95%	O	O
CI	O	O
0	O	O
.	O	O

3	O	O
-	O	O
2	O	O
.	O	O

7	O	O
)	O	O
.	O	O

CONCLUSION	O	O
:	O	O
Raloxifene	B-Chemical	D020849
was	O	O
associated	O	O
with	O	O
an	O	O
increased	O	O
risk	O	O
for	O	O
venous	B-Disease	D054556
thromboembolism	I-Disease	D054556
,	O	O
but	O	O
there	O	O
was	O	O
no	O	O
increased	O	O
risk	O	O
for	O	O
cataracts	B-Disease	D002386
,	O	O
gallbladder	B-Disease	D005705
disease	I-Disease	D005705
,	O	O
endometrial	B-Disease	D004714
hyperplasia	I-Disease	D004714
,	O	O
or	O	O
endometrial	B-Disease	D016889
cancer	I-Disease	D016889
.	O	O

LEVEL	O	O
OF	O	O
EVIDENCE	O	O
:	O	O
I	O	O
Ceftriaxone	B-Chemical	D002443
-	O	O
associated	O	O
biliary	B-Disease	D001660
pseudolithiasis	I-Disease	D001660
in	O	O
paediatric	O	O
surgical	O	O
patients	O	O
.	O	O

It	O	O
is	O	O
well	O	O
known	O	O
that	O	O
ceftriaxone	B-Chemical	D002443
leads	O	O
to	O	O
pseudolithiasis	B-Disease	D001660
in	O	O
some	O	O
patients	O	O
.	O	O

Clinical	O	O
and	O	O
experimental	O	O
studies	O	O
also	O	O
suggest	O	O
that	O	O
situations	O	O
causing	O	O
gallbladder	B-Disease	D005705
dysfunction	I-Disease	D005705
,	O	O
such	O	O
as	O	O
fasting	O	O
,	O	O
may	O	O
have	O	O
a	O	O
role	O	O
for	O	O
the	O	O
development	O	O
of	O	O
pseudolithiasis	B-Disease	D001660
.	O	O

In	O	O
this	O	O
study	O	O
,	O	O
we	O	O
prospectively	O	O
evaluated	O	O
the	O	O
incidence	O	O
and	O	O
clinical	O	O
importance	O	O
of	O	O
pseudolithiasis	B-Disease	D001660
in	O	O
paediatric	O	O
surgical	O	O
patients	O	O
receiving	O	O
ceftriaxone	B-Chemical	D002443
treatment	O	O
,	O	O
who	O	O
often	O	O
had	O	O
to	O	O
fast	O	O
in	O	O
the	O	O
post	O	O
-	O	O
operative	O	O
period	O	O
.	O	O

Fifty	O	O
children	O	O
who	O	O
were	O	O
given	O	O
ceftriaxone	B-Chemical	D002443
were	O	O
evaluated	O	O
by	O	O
serial	O	O
abdominal	O	O
sonograms	O	O
.	O	O

Of	O	O
those	O	O
,	O	O
13	O	O
(	O	O
26%	O	O
)	O	O
developed	O	O
biliary	O	O
pathology	O	O
.	O	O

Comparison	O	O
of	O	O
the	O	O
patients	O	O
with	O	O
or	O	O
without	O	O
pseudolithiasis	B-Disease	D001660
revealed	O	O
no	O	O
significant	O	O
difference	O	O
with	O	O
respect	O	O
to	O	O
age	O	O
,	O	O
sex	O	O
,	O	O
duration	O	O
of	O	O
the	O	O
treatment	O	O
and	O	O
starvation	O	O
variables	O	O
.	O	O

After	O	O
cessation	O	O
of	O	O
the	O	O
treatment	O	O
,	O	O
pseudolithiasis	B-Disease	D001660
resolved	O	O
spontaneously	O	O
within	O	O
a	O	O
short	O	O
period	O	O
.	O	O

The	O	O
incidence	O	O
of	O	O
pseudolithiasis	B-Disease	D001660
is	O	O
not	O	O
affected	O	O
by	O	O
fasting	O	O
.	O	O

Evaluation	O	O
of	O	O
the	O	O
anticocaine	O	O
monoclonal	O	O
antibody	O	O
GNC92H2	B-Chemical	-1
as	O	O
an	O	O
immunotherapy	O	O
for	O	O
cocaine	B-Disease	D062787
overdose	I-Disease	D062787
.	O	O

The	O	O
illicit	O	O
use	O	O
of	O	O
cocaine	B-Chemical	D003042
continues	O	O
in	O	O
epidemic	O	O
proportions	O	O
and	O	O
treatment	O	O
for	O	O
cocaine	B-Disease	D062787
overdose	I-Disease	D062787
remains	O	O
elusive	O	O
.	O	O

Current	O	O
protein	O	O
-	O	O
based	O	O
technology	O	O
offers	O	O
a	O	O
new	O	O
therapeutic	O	O
venue	O	O
by	O	O
which	O	O
antibodies	O	O
bind	O	O
the	O	O
drug	O	O
in	O	O
the	O	O
blood	O	O
stream	O	O
,	O	O
inactivating	O	O
its	O	O
toxic	O	O
effects	O	O
.	O	O

The	O	O
therapeutic	O	O
potential	O	O
of	O	O
the	O	O
anticocaine	O	O
antibody	O	O
GNC92H2	B-Chemical	-1
was	O	O
examined	O	O
using	O	O
a	O	O
model	O	O
of	O	O
cocaine	B-Disease	D062787
overdose	I-Disease	D062787
.	O	O

Swiss	O	O
albino	O	O
mice	O	O
prepared	O	O
with	O	O
intrajugular	O	O
catheters	O	O
were	O	O
tested	O	O
in	O	O
photocell	O	O
cages	O	O
after	O	O
administration	O	O
of	O	O
93	O	O
mg	O	O
/	O	O
kg	O	O
(	O	O
LD50	O	O
)	O	O
of	O	O
cocaine	B-Chemical	D003042
and	O	O
GNC92H2	B-Chemical	-1
infusions	O	O
ranging	O	O
from	O	O
30	O	O
to	O	O
190	O	O
mg	O	O
/	O	O
kg	O	O
.	O	O

GNC92H2	B-Chemical	-1
was	O	O
delivered	O	O
30	O	O
min	O	O
before	O	O
,	O	O
concomitantly	O	O
or	O	O
3	O	O
min	O	O
after	O	O
cocaine	B-Chemical	D003042
treatment	O	O
.	O	O

Significant	O	O
blockade	O	O
of	O	O
cocaine	B-Chemical	D003042
toxicity	B-Disease	D064420
was	O	O
observed	O	O
with	O	O
the	O	O
higher	O	O
dose	O	O
of	O	O
GNC92H2	B-Chemical	-1
(	O	O
190	O	O
mg	O	O
/	O	O
kg	O	O
)	O	O
,	O	O
where	O	O
premorbid	O	O
behaviors	O	O
were	O	O
reduced	O	O
up	O	O
to	O	O
40%	O	O
,	O	O
seizures	B-Disease	D012640
up	O	O
to	O	O
77%	O	O
and	O	O
death	B-Disease	D003643
by	O	O
72%	O	O
.	O	O

Importantly	O	O
,	O	O
GNC92H2	B-Chemical	-1
prevented	O	O
death	B-Disease	D003643
even	O	O
post	O	O
-	O	O
cocaine	B-Chemical	D003042
injection	O	O
.	O	O

The	O	O
results	O	O
support	O	O
the	O	O
important	O	O
potential	O	O
of	O	O
GNC92H2	B-Chemical	-1
as	O	O
a	O	O
therapeutic	O	O
tool	O	O
against	O	O
cocaine	B-Disease	D062787
overdose	I-Disease	D062787
.	O	O

The	O	O
effects	O	O
of	O	O
short	O	O
-	O	O
term	O	O
raloxifene	B-Chemical	D020849
therapy	O	O
on	O	O
fibrinolysis	O	O
markers	O	O
:	O	O
TAFI	O	O
,	O	O
tPA	O	O
,	O	O
and	O	O
PAI	O	O
-	O	O
1	O	O
.	O	O

BACKGROUND	O	O
:	O	O
Markers	O	O
of	O	O
fibrinolysis	O	O
,	O	O
thrombin	O	O
-	O	O
activatable	O	O
fibrinolysis	O	O
inhibitor	O	O
(	O	O
TAFI	O	O
)	O	O
,	O	O
tissue	O	O
-	O	O
type	O	O
plasminogen	O	O
activator	O	O
(	O	O
tPA	O	O
)	O	O
,	O	O
and	O	O
plasminogen	O	O
activator	O	O
inhibitor	O	O
-	O	O
1	O	O
(	O	O
PAI	O	O
-	O	O
1	O	O
)	O	O
levels	O	O
were	O	O
studied	O	O
for	O	O
the	O	O
evaluation	O	O
of	O	O
short	O	O
-	O	O
term	O	O
effects	O	O
of	O	O
raloxifene	B-Chemical	D020849
administration	O	O
in	O	O
postmenopausal	O	O
women	O	O
.	O	O

METHODS	O	O
:	O	O
Thirty	O	O
-	O	O
nine	O	O
postmenopausal	O	O
women	O	O
with	O	O
osteopenia	B-Disease	D001851
or	O	O
osteoporosis	B-Disease	D010024
were	O	O
included	O	O
in	O	O
this	O	O
prospective	O	O
,	O	O
controlled	O	O
clinical	O	O
study	O	O
.	O	O

Twenty	O	O
-	O	O
five	O	O
women	O	O
were	O	O
given	O	O
raloxifene	B-Chemical	D020849
hydrochloride	O	O
(	O	O
60	O	O
mg	O	O
/	O	O
day	O	O
)	O	O
plus	O	O
calcium	B-Chemical	D002118
(	O	O
500	O	O
mg	O	O
/	O	O
day	O	O
)	O	O
.	O	O

Age	O	O
-	O	O
matched	O	O
controls	O	O
(	O	O
n	O	O
=	O	O
14	O	O
)	O	O
were	O	O
given	O	O
only	O	O
calcium	B-Chemical	D002118
.	O	O

Plasma	O	O
TAFI	O	O
,	O	O
tPA	O	O
,	O	O
and	O	O
PAI	O	O
-	O	O
1	O	O
antigen	O	O
levels	O	O
were	O	O
measured	O	O
at	O	O
baseline	O	O
and	O	O
after	O	O
3	O	O
months	O	O
of	O	O
treatment	O	O
by	O	O
commercially	O	O
available	O	O
ELISA	O	O
kits	O	O
.	O	O

Variations	O	O
of	O	O
individuals	O	O
were	O	O
assessed	O	O
by	O	O
Wilcoxon's	O	O
test	O	O
.	O	O

Relationship	O	O
between	O	O
those	O	O
markers	O	O
and	O	O
demographic	O	O
characteristics	O	O
were	O	O
investigated	O	O
.	O	O

RESULTS	O	O
:	O	O
Three	O	O
months	O	O
of	O	O
raloxifene	B-Chemical	D020849
treatment	O	O
was	O	O
associated	O	O
with	O	O
a	O	O
significant	O	O
decrease	O	O
in	O	O
the	O	O
plasma	O	O
TAFI	O	O
antigen	O	O
concentrations	O	O
(	O	O
16%	O	O
change	O	O
,	O	O
P	O	O
<	O	O
0	O	O
.	O	O

01	O	O
)	O	O
,	O	O
and	O	O
a	O	O
significant	O	O
increase	O	O
in	O	O
tPA	O	O
antigen	O	O
concentrations	O	O
(	O	O
25%	O	O
change	O	O
,	O	O
P	O	O
<	O	O
0	O	O
.	O	O

05	O	O
)	O	O
.	O	O

A	O	O
significant	O	O
correlation	O	O
was	O	O
found	O	O
between	O	O
baseline	O	O
TAFI	O	O
antigen	O	O
concentrations	O	O
and	O	O
the	O	O
duration	O	O
of	O	O
amenorrhea	B-Disease	D000568
(	O	O
P	O	O
<	O	O
0	O	O
.	O	O

05	O	O
;	O	O
r	O	O
=	O	O
0	O	O
.	O	O

33	O	O
)	O	O
.	O	O

CONCLUSION	O	O
:	O	O
We	O	O
suggest	O	O
that	O	O
the	O	O
increased	O	O
risk	O	O
of	O	O
venous	B-Disease	D054556
thromboembolism	I-Disease	D054556
due	O	O
to	O	O
raloxifene	B-Chemical	D020849
treatment	O	O
may	O	O
be	O	O
related	O	O
to	O	O
increased	O	O
tPA	O	O
levels	O	O
,	O	O
but	O	O
not	O	O
TAFI	O	O
levels	O	O
.	O	O

Ketoconazole	B-Chemical	D007654
induced	O	O
torsades	B-Disease	D016171
de	I-Disease	D016171
pointes	I-Disease	D016171
without	O	O
concomitant	O	O
use	O	O
of	O	O
QT	O	O
interval	O	O
-	O	O
prolonging	O	O
drug	O	O
.	O	O

Ketoconazole	B-Chemical	D007654
is	O	O
not	O	O
known	O	O
to	O	O
be	O	O
proarrhythmic	O	O
without	O	O
concomitant	O	O
use	O	O
of	O	O
QT	O	O
interval	O	O
-	O	O
prolonging	O	O
drugs	O	O
.	O	O

We	O	O
report	O	O
a	O	O
woman	O	O
with	O	O
coronary	B-Disease	D003324
artery	I-Disease	D003324
disease	I-Disease	D003324
who	O	O
developed	O	O
a	O	O
markedly	O	O
prolonged	B-Disease	D008133
QT	I-Disease	D008133
interval	I-Disease	D008133
and	O	O
torsades	B-Disease	D016171
de	I-Disease	D016171
pointes	I-Disease	D016171
(	O	O
TdP	B-Disease	D016171
)	O	O
after	O	O
taking	O	O
ketoconazole	B-Chemical	D007654
for	O	O
treatment	O	O
of	O	O
fungal	B-Disease	D009181
infection	I-Disease	D009181
.	O	O

Her	O	O
QT	O	O
interval	O	O
returned	O	O
to	O	O
normal	O	O
upon	O	O
withdrawal	O	O
of	O	O
ketoconazole	B-Chemical	D007654
.	O	O

Genetic	O	O
study	O	O
did	O	O
not	O	O
find	O	O
any	O	O
mutation	O	O
in	O	O
her	O	O
genes	O	O
that	O	O
encode	O	O
cardiac	O	O
IKr	O	O
channel	O	O
proteins	O	O
.	O	O

We	O	O
postulate	O	O
that	O	O
by	O	O
virtue	O	O
of	O	O
its	O	O
direct	O	O
blocking	O	O
action	O	O
on	O	O
IKr	O	O
,	O	O
ketoconazole	B-Chemical	D007654
alone	O	O
may	O	O
prolong	O	O
QT	O	O
interval	O	O
and	O	O
induce	O	O
TdP	B-Disease	D016171
.	O	O

This	O	O
calls	O	O
for	O	O
attention	O	O
when	O	O
ketoconazole	B-Chemical	D007654
is	O	O
administered	O	O
to	O	O
patients	O	O
with	O	O
risk	O	O
factors	O	O
for	O	O
acquired	O	O
long	B-Disease	D008133
QT	I-Disease	D008133
syndrome	I-Disease	D008133
.	O	O

Pharmacological	O	O
evidence	O	O
for	O	O
the	O	O
potential	O	O
of	O	O
Daucus	O	O
carota	O	O
in	O	O
the	O	O
management	O	O
of	O	O
cognitive	B-Disease	D003072
dysfunctions	I-Disease	D003072
.	O	O

The	O	O
present	O	O
study	O	O
was	O	O
aimed	O	O
at	O	O
investigating	O	O
the	O	O
effects	O	O
of	O	O
Daucus	O	O
carota	O	O
seeds	O	O
on	O	O
cognitive	O	O
functions	O	O
,	O	O
total	O	O
serum	O	O
cholesterol	B-Chemical	D002784
levels	O	O
and	O	O
brain	O	O
cholinesterase	O	O
activity	O	O
in	O	O
mice	O	O
.	O	O

The	O	O
ethanolic	O	O
extract	B-Chemical	D010936
of	I-Chemical	D010936
Daucus	I-Chemical	D010936
carota	I-Chemical	D010936
seeds	I-Chemical	D010936
(	O	O
DCE	B-Chemical	D010936
)	O	O
was	O	O
administered	O	O
orally	O	O
in	O	O
three	O	O
doses	O	O
(	O	O
100	O	O
,	O	O
200	O	O
,	O	O
400	O	O
mg	O	O
/	O	O
kg	O	O
)	O	O
for	O	O
seven	O	O
successive	O	O
days	O	O
to	O	O
different	O	O
groups	O	O
of	O	O
young	O	O
and	O	O
aged	O	O
mice	O	O
.	O	O

Elevated	O	O
plus	O	O
maze	O	O
and	O	O
passive	O	O
avoidance	O	O
apparatus	O	O
served	O	O
as	O	O
the	O	O
exteroceptive	O	O
behavioral	O	O
models	O	O
for	O	O
testing	O	O
memory	O	O
.	O	O

Diazepam	B-Chemical	D003975
-	O	O
,	O	O
scopolamine	B-Chemical	D012601
-	O	O
and	O	O
ageing	O	O
-	O	O
induced	O	O
amnesia	B-Disease	D000647
served	O	O
as	O	O
the	O	O
interoceptive	O	O
behavioral	O	O
models	O	O
.	O	O

DCE	B-Chemical	D010936
(	O	O
200	O	O
,	O	O
400	O	O
mg	O	O
/	O	O
kg	O	O
,	O	O
p	O	O
.	O	O

o	O	O
.	O	O

)	O	O
showed	O	O
significant	O	O
improvement	O	O
in	O	O
memory	O	O
scores	O	O
of	O	O
young	O	O
and	O	O
aged	O	O
mice	O	O
.	O	O

The	O	O
extent	O	O
of	O	O
memory	O	O
improvement	O	O
evoked	O	O
by	O	O
DCE	B-Chemical	D010936
was	O	O
23%	O	O
at	O	O
the	O	O
dose	O	O
of	O	O
200	O	O
mg	O	O
/	O	O
kg	O	O
and	O	O
35%	O	O
at	O	O
the	O	O
dose	O	O
of	O	O
400	O	O
mg	O	O
/	O	O
kg	O	O
in	O	O
young	O	O
mice	O	O
using	O	O
elevated	O	O
plus	O	O
maze	O	O
.	O	O

Similarly	O	O
,	O	O
significant	O	O
improvements	O	O
in	O	O
memory	O	O
scores	O	O
were	O	O
observed	O	O
using	O	O
passive	O	O
avoidance	O	O
apparatus	O	O
and	O	O
aged	O	O
mice	O	O
.	O	O

Furthermore	O	O
,	O	O
DCE	B-Chemical	D010936
reversed	O	O
the	O	O
amnesia	B-Disease	D000647
induced	O	O
by	O	O
scopolamine	B-Chemical	D012601
(	O	O
0	O	O
.	O	O

4	O	O
mg	O	O
/	O	O
kg	O	O
,	O	O
i	O	O
.	O	O

p	O	O
.	O	O

)	O	O
and	O	O
diazepam	B-Chemical	D003975
(	O	O
1	O	O
mg	O	O
/	O	O
kg	O	O
,	O	O
i	O	O
.	O	O

p	O	O
.	O	O

)	O	O
.	O	O

Daucus	B-Chemical	D010936
carota	I-Chemical	D010936
extract	I-Chemical	D010936
(	O	O
200	O	O
,	O	O
400	O	O
mg	O	O
/	O	O
kg	O	O
,	O	O
p	O	O
.	O	O

o	O	O
.	O	O

)	O	O
reduced	O	O
significantly	O	O
the	O	O
brain	O	O
acetylcholinesterase	O	O
activity	O	O
and	O	O
cholesterol	B-Chemical	D002784
levels	O	O
in	O	O
young	O	O
and	O	O
aged	O	O
mice	O	O
.	O	O

The	O	O
extent	O	O
of	O	O
inhibition	O	O
of	O	O
brain	O	O
cholinesterase	O	O
activity	O	O
evoked	O	O
by	O	O
DCE	B-Chemical	D010936
at	O	O
the	O	O
dose	O	O
of	O	O
400	O	O
mg	O	O
/	O	O
kg	O	O
was	O	O
22%	O	O
in	O	O
young	O	O
and	O	O
19%	O	O
in	O	O
aged	O	O
mice	O	O
.	O	O

There	O	O
was	O	O
a	O	O
remarkable	O	O
reduction	O	O
in	O	O
total	O	O
cholesterol	B-Chemical	D002784
level	O	O
as	O	O
well	O	O
,	O	O
to	O	O
the	O	O
extent	O	O
of	O	O
23%	O	O
in	O	O
young	O	O
and	O	O
21%	O	O
in	O	O
aged	O	O
animals	O	O
with	O	O
this	O	O
dose	O	O
of	O	O
DCE	B-Chemical	D010936
.	O	O

Therefore	O	O
,	O	O
DCE	B-Chemical	D010936
may	O	O
prove	O	O
to	O	O
be	O	O
a	O	O
useful	O	O
remedy	O	O
for	O	O
the	O	O
management	O	O
of	O	O
cognitive	B-Disease	D003072
dysfunctions	I-Disease	D003072
on	O	O
account	O	O
of	O	O
its	O	O
multifarious	O	O
beneficial	O	O
effects	O	O
such	O	O
as	O	O
,	O	O
memory	O	O
improving	O	O
property	O	O
,	O	O
cholesterol	B-Chemical	D002784
lowering	O	O
property	O	O
and	O	O
anticholinesterase	O	O
activity	O	O
.	O	O

Cauda	B-Disease	D011128
equina	I-Disease	D011128
syndrome	I-Disease	D011128
after	O	O
epidural	O	O
steroid	B-Chemical	D013256
injection	O	O
:	O	O
a	O	O
case	O	O
report	O	O
.	O	O

OBJECTIVE	O	O
:	O	O
Conventional	O	O
treatment	O	O
methods	O	O
of	O	O
lumbusacral	O	O
radiculopathy	B-Disease	D011843
are	O	O
physical	O	O
therapy	O	O
,	O	O
epidural	O	O
steroid	B-Chemical	D013256
injections	O	O
,	O	O
oral	O	O
medications	O	O
,	O	O
and	O	O
spinal	O	O
manipulative	O	O
therapy	O	O
.	O	O

Cauda	B-Disease	D011128
equina	I-Disease	D011128
syndrome	I-Disease	D011128
is	O	O
a	O	O
rare	O	O
complication	O	O
of	O	O
epidural	O	O
anesthesia	O	O
.	O	O

The	O	O
following	O	O
case	O	O
is	O	O
a	O	O
report	O	O
of	O	O
cauda	B-Disease	D011128
equina	I-Disease	D011128
syndrome	I-Disease	D011128
possibly	O	O
caused	O	O
by	O	O
epidural	O	O
injection	O	O
of	O	O
triamcinolone	B-Chemical	D014221
and	O	O
bupivacaine	B-Chemical	D002045
.	O	O

CLINICAL	O	O
FEATURES	O	O
:	O	O
A	O	O
50	O	O
-	O	O
year	O	O
-	O	O
old	O	O
woman	O	O
with	O	O
low	O	O
back	O	O
and	O	O
right	O	O
leg	O	O
pain	O	O
was	O	O
scheduled	O	O
for	O	O
epidural	O	O
steroid	B-Chemical	D013256
injection	O	O
.	O	O

INTERVENTION	O	O
AND	O	O
OUTCOME	O	O
:	O	O
An	O	O
18	O	O
-	O	O
gauge	O	O
Touhy	O	O
needle	O	O
was	O	O
inserted	O	O
until	O	O
loss	O	O
of	O	O
resistance	O	O
occurred	O	O
at	O	O
the	O	O
L4	O	O
-	O	O
5	O	O
level	O	O
.	O	O

Spread	O	O
of	O	O
the	O	O
contrast	O	O
medium	O	O
within	O	O
the	O	O
epidural	O	O
space	O	O
was	O	O
determined	O	O
by	O	O
radiographic	O	O
imaging	O	O
.	O	O

After	O	O
verifying	O	O
the	O	O
epidural	O	O
space	O	O
,	O	O
bupivacaine	B-Chemical	D002045
and	O	O
triamcinolone	B-Chemical	D014221
diacetate	O	O
were	O	O
injected	O	O
.	O	O

After	O	O
the	O	O
injection	O	O
,	O	O
there	O	O
was	O	O
a	O	O
reduction	O	O
in	O	O
radicular	O	O
symptoms	O	O
.	O	O

Three	O	O
hours	O	O
later	O	O
,	O	O
she	O	O
complained	O	O
of	O	O
perineal	O	O
numbness	B-Disease	D006987
and	O	O
lower	B-Disease	D020335
extremity	I-Disease	D020335
weakness	I-Disease	D020335
.	O	O

The	O	O
neurologic	O	O
evaluation	O	O
revealed	O	O
loss	B-Disease	D006987
of	I-Disease	D006987
sensation	I-Disease	D006987
in	O	O
the	O	O
saddle	O	O
area	O	O
and	O	O
medial	O	O
aspect	O	O
of	O	O
her	O	O
right	O	O
leg	O	O
.	O	O

There	O	O
was	O	O
a	O	O
decrease	O	O
in	O	O
the	O	O
perception	O	O
of	O	O
pinprick	O	O
test	O	O
.	O	O

Deep	O	O
-	O	O
tendon	O	O
reflexes	O	O
were	O	O
decreased	O	O
especially	O	O
in	O	O
the	O	O
right	O	O
leg	O	O
.	O	O

She	O	O
was	O	O
unable	O	O
to	O	O
urinate	O	O
.	O	O

The	O	O
patient's	O	O
symptoms	O	O
improved	O	O
slightly	O	O
over	O	O
the	O	O
next	O	O
few	O	O
hours	O	O
.	O	O

She	O	O
had	O	O
a	O	O
gradual	O	O
return	O	O
of	O	O
motor	O	O
function	O	O
and	O	O
ability	O	O
of	O	O
feeling	O	O
Foley	O	O
catheter	O	O
.	O	O

All	O	O
of	O	O
the	O	O
symptoms	O	O
were	O	O
completely	O	O
resolved	O	O
over	O	O
the	O	O
next	O	O
8	O	O
hours	O	O
.	O	O

CONCLUSION	O	O
:	O	O
Complications	O	O
associated	O	O
with	O	O
epidural	O	O
steroid	B-Chemical	D013256
injections	O	O
are	O	O
rare	O	O
.	O	O

Clinical	O	O
examination	O	O
and	O	O
continued	O	O
vigilance	O	O
for	O	O
neurologic	B-Disease	D009422
deterioration	I-Disease	D009422
after	O	O
epidural	O	O
steroid	B-Chemical	D013256
injections	O	O
is	O	O
important	O	O
.	O	O

High	O	O
-	O	O
dose	O	O
testosterone	B-Chemical	D013739
is	O	O
associated	O	O
with	O	O
atherosclerosis	B-Disease	D050197
in	O	O
postmenopausal	O	O
women	O	O
.	O	O

OBJECTIVES	O	O
:	O	O
To	O	O
study	O	O
the	O	O
long	O	O
-	O	O
term	O	O
effects	O	O
of	O	O
androgen	O	O
treatment	O	O
on	O	O
atherosclerosis	B-Disease	D050197
in	O	O
postmenopausal	O	O
women	O	O
.	O	O

METHODS	O	O
:	O	O
In	O	O
a	O	O
population	O	O
-	O	O
based	O	O
study	O	O
in	O	O
513	O	O
naturally	O	O
postmenopausal	O	O
women	O	O
aged	O	O
54	O	O
-	O	O
67	O	O
years	O	O
,	O	O
we	O	O
studied	O	O
the	O	O
association	O	O
between	O	O
self	O	O
-	O	O
reported	O	O
intramuscularly	O	O
administered	O	O
high	O	O
-	O	O
dose	O	O
estrogen	B-Chemical	D004967
-	O	O
testosterone	B-Chemical	D013739
therapy	O	O
(	O	O
estradiol	B-Chemical	C032109
-	I-Chemical	C032109
and	I-Chemical	C032109
testosterone	I-Chemical	C032109
esters	I-Chemical	C032109
)	O	O
and	O	O
aortic	O	O
atherosclerosis	B-Disease	D050197
.	O	O

Aortic	O	O
atherosclerosis	B-Disease	D050197
was	O	O
diagnosed	O	O
by	O	O
radiographic	O	O
detection	O	O
of	O	O
calcified	O	O
deposits	O	O
in	O	O
the	O	O
abdominal	O	O
aorta	O	O
,	O	O
which	O	O
have	O	O
been	O	O
shown	O	O
to	O	O
reflect	O	O
intima	O	O
atherosclerosis	B-Disease	D050197
.	O	O

Hormone	O	O
therapy	O	O
users	O	O
were	O	O
compared	O	O
with	O	O
never	O	O
users	O	O
.	O	O

RESULTS	O	O
:	O	O
Intramuscular	O	O
hormone	O	O
therapy	O	O
use	O	O
for	O	O
1	O	O
year	O	O
or	O	O
longer	O	O
was	O	O
reported	O	O
by	O	O
25	O	O
women	O	O
.	O	O

In	O	O
almost	O	O
half	O	O
of	O	O
these	O	O
women	O	O
severe	O	O
atherosclerosis	B-Disease	D050197
of	O	O
the	O	O
aorta	O	O
was	O	O
present	O	O
(	O	O
n=11	O	O
)	O	O
,	O	O
while	O	O
in	O	O
women	O	O
without	O	O
hormone	O	O
use	O	O
severe	O	O
atherosclerosis	B-Disease	D050197
of	O	O
the	O	O
aorta	O	O
was	O	O
present	O	O
in	O	O
less	O	O
than	O	O
20%	O	O
(	O	O
OR	O	O
3	O	O
.	O	O

1	O	O
;	O	O
95%	O	O
CI	O	O
,	O	O
1	O	O
.	O	O

1	O	O
-	O	O
8	O	O
.	O	O

5	O	O
,	O	O
adjusted	O	O
for	O	O
age	O	O
,	O	O
years	O	O
since	O	O
menopause	O	O
,	O	O
smoking	O	O
,	O	O
and	O	O
body	O	O
mass	O	O
index	O	O
)	O	O
.	O	O

The	O	O
association	O	O
remained	O	O
after	O	O
additional	O	O
adjustment	O	O
for	O	O
diabetes	B-Disease	D003920
,	O	O
cholesterol	B-Chemical	D002784
level	O	O
,	O	O
systolic	O	O
blood	O	O
pressure	O	O
,	O	O
or	O	O
alcohol	B-Chemical	D000431
use	O	O
.	O	O

No	O	O
association	O	O
was	O	O
found	O	O
for	O	O
hormone	O	O
use	O	O
less	O	O
than	O	O
1	O	O
year	O	O
.	O	O

CONCLUSION	O	O
:	O	O
Our	O	O
results	O	O
suggest	O	O
that	O	O
high	O	O
-	O	O
dose	O	O
testosterone	B-Chemical	D013739
therapy	O	O
may	O	O
adversely	O	O
affect	O	O
atherosclerosis	B-Disease	D050197
in	O	O
postmenopausal	O	O
women	O	O
and	O	O
indicate	O	O
that	O	O
androgen	O	O
replacement	O	O
in	O	O
these	O	O
women	O	O
may	O	O
not	O	O
be	O	O
harmless	O	O
.	O	O

Sirolimus	B-Chemical	D020123
-	O	O
associated	O	O
proteinuria	B-Disease	D011507
and	O	O
renal	B-Disease	D007674
dysfunction	I-Disease	D007674
.	O	O

Sirolimus	B-Chemical	D020123
is	O	O
a	O	O
novel	O	O
immunosuppressant	O	O
with	O	O
potent	O	O
antiproliferative	O	O
actions	O	O
through	O	O
its	O	O
ability	O	O
to	O	O
inhibit	O	O
the	O	O
raptor	O	O
-	O	O
containing	O	O
mammalian	O	O
target	O	O
of	O	O
rapamycin	B-Chemical	D020123
protein	O	O
kinase	O	O
.	O	O

Sirolimus	B-Chemical	D020123
represents	O	O
a	O	O
major	O	O
therapeutic	O	O
advance	O	O
in	O	O
the	O	O
prevention	O	O
of	O	O
acute	O	O
renal	O	O
allograft	O	O
rejection	O	O
and	O	O
chronic	O	O
allograft	O	O
nephropathy	B-Disease	D007674
.	O	O

Its	O	O
role	O	O
in	O	O
the	O	O
therapy	O	O
of	O	O
glomerulonephritis	B-Disease	D005921
,	O	O
autoimmunity	B-Disease	D001327
,	O	O
cystic	B-Disease	D052177
renal	I-Disease	D052177
diseases	I-Disease	D052177
and	O	O
renal	B-Disease	D007680
cancer	I-Disease	D007680
is	O	O
under	O	O
investigation	O	O
.	O	O

Because	O	O
sirolimus	B-Chemical	D020123
does	O	O
not	O	O
share	O	O
the	O	O
vasomotor	O	O
renal	O	O
adverse	O	O
effects	O	O
exhibited	O	O
by	O	O
calcineurin	O	O
inhibitors	O	O
,	O	O
it	O	O
has	O	O
been	O	O
designated	O	O
a	O	O
'non	O	O
-	O	O
nephrotoxic	B-Disease	D007674
drug'	O	O
.	O	O

However	O	O
,	O	O
clinical	O	O
reports	O	O
suggest	O	O
that	O	O
,	O	O
under	O	O
some	O	O
circumstances	O	O
,	O	O
sirolimus	B-Chemical	D020123
is	O	O
associated	O	O
with	O	O
proteinuria	B-Disease	D011507
and	O	O
acute	B-Disease	D058186
renal	I-Disease	D058186
dysfunction	I-Disease	D058186
.	O	O

A	O	O
common	O	O
risk	O	O
factor	O	O
appears	O	O
to	O	O
be	O	O
presence	O	O
of	O	O
pre	O	O
-	O	O
existing	O	O
chronic	B-Disease	D051436
renal	I-Disease	D051436
damage	I-Disease	D051436
.	O	O

The	O	O
mechanisms	O	O
of	O	O
sirolimus	B-Chemical	D020123
-	O	O
associated	O	O
proteinuria	B-Disease	D011507
are	O	O
multifactorial	O	O
and	O	O
may	O	O
be	O	O
due	O	O
to	O	O
an	O	O
increase	O	O
in	O	O
glomerular	O	O
capillary	O	O
pressure	O	O
following	O	O
calcineurin	O	O
inhibitor	O	O
withdrawal	O	O
.	O	O

It	O	O
has	O	O
also	O	O
been	O	O
suggested	O	O
that	O	O
sirolimus	B-Chemical	D020123
directly	O	O
causes	O	O
increased	O	O
glomerular	O	O
permeability	O	O
/	O	O
injury	O	O
,	O	O
but	O	O
evidence	O	O
for	O	O
this	O	O
mechanism	O	O
is	O	O
currently	O	O
inconclusive	O	O
.	O	O

The	O	O
acute	B-Disease	D058186
renal	I-Disease	D058186
dysfunction	I-Disease	D058186
associated	O	O
with	O	O
sirolimus	B-Chemical	D020123
(	O	O
such	O	O
as	O	O
in	O	O
delayed	O	O
graft	O	O
function	O	O
)	O	O
may	O	O
be	O	O
due	O	O
to	O	O
suppression	O	O
of	O	O
compensatory	O	O
renal	O	O
cell	O	O
proliferation	O	O
and	O	O
survival	O	O
/	O	O
repair	O	O
processes	O	O
.	O	O

Although	O	O
these	O	O
adverse	O	O
effects	O	O
occur	O	O
in	O	O
some	O	O
patients	O	O
,	O	O
their	O	O
occurrence	O	O
could	O	O
be	O	O
minimised	O	O
by	O	O
knowledge	O	O
of	O	O
the	O	O
molecular	O	O
effects	O	O
of	O	O
sirolimus	B-Chemical	D020123
on	O	O
the	O	O
kidney	O	O
,	O	O
the	O	O
use	O	O
of	O	O
sirolimus	B-Chemical	D020123
in	O	O
appropriate	O	O
patient	O	O
populations	O	O
,	O	O
close	O	O
monitoring	O	O
of	O	O
proteinuria	B-Disease	D011507
and	O	O
renal	O	O
function	O	O
,	O	O
use	O	O
of	O	O
angiotensin	B-Chemical	D000809
-	O	O
converting	O	O
enzyme	O	O
inhibitors	O	O
or	O	O
angiotensin	B-Chemical	D000809
II	O	O
receptor	O	O
blockers	O	O
if	O	O
proteinuria	B-Disease	D011507
occurs	O	O
and	O	O
withdrawal	O	O
if	O	O
needed	O	O
.	O	O

Further	O	O
long	O	O
-	O	O
term	O	O
analysis	O	O
of	O	O
renal	O	O
allograft	O	O
studies	O	O
using	O	O
sirolimus	B-Chemical	D020123
as	O	O
de	O	O
novo	O	O
immunosuppression	O	O
along	O	O
with	O	O
clinical	O	O
and	O	O
laboratory	O	O
studies	O	O
will	O	O
refine	O	O
these	O	O
issues	O	O
in	O	O
the	O	O
future	O	O
.	O	O

Progressive	O	O
myopathy	B-Disease	D009135
with	O	O
up	O	O
-	O	O
regulation	O	O
of	O	O
MHC	O	O
-	O	O
I	O	O
associated	O	O
with	O	O
statin	B-Chemical	D019821
therapy	O	O
.	O	O

Statins	B-Chemical	D019821
can	O	O
cause	O	O
a	O	O
necrotizing	O	O
myopathy	B-Disease	D009135
and	O	O
hyperCKaemia	B-Disease	-1
which	O	O
is	O	O
reversible	O	O
on	O	O
cessation	O	O
of	O	O
the	O	O
drug	O	O
.	O	O

What	O	O
is	O	O
less	O	O
well	O	O
known	O	O
is	O	O
a	O	O
phenomenon	O	O
whereby	O	O
statins	B-Chemical	D019821
may	O	O
induce	O	O
a	O	O
myopathy	B-Disease	D009135
,	O	O
which	O	O
persists	O	O
or	O	O
may	O	O
progress	O	O
after	O	O
stopping	O	O
the	O	O
drug	O	O
.	O	O

We	O	O
investigated	O	O
the	O	O
muscle	O	O
pathology	O	O
in	O	O
8	O	O
such	O	O
cases	O	O
.	O	O

All	O	O
had	O	O
myofibre	O	O
necrosis	B-Disease	D009336
but	O	O
only	O	O
3	O	O
had	O	O
an	O	O
inflammatory	O	O
infiltrate	O	O
.	O	O

In	O	O
all	O	O
cases	O	O
there	O	O
was	O	O
diffuse	O	O
or	O	O
multifocal	O	O
up	O	O
-	O	O
regulation	O	O
of	O	O
MHC	O	O
-	O	O
I	O	O
expression	O	O
even	O	O
in	O	O
non	O	O
-	O	O
necrotic	B-Disease	D009336
fibres	O	O
.	O	O

Progressive	O	O
improvement	O	O
occurred	O	O
in	O	O
7	O	O
cases	O	O
after	O	O
commencement	O	O
of	O	O
prednisolone	B-Chemical	D011239
and	O	O
methotrexate	B-Chemical	D008727
,	O	O
and	O	O
in	O	O
one	O	O
case	O	O
spontaneously	O	O
.	O	O

These	O	O
observations	O	O
suggest	O	O
that	O	O
statins	B-Chemical	D019821
may	O	O
initiate	O	O
an	O	O
immune	O	O
-	O	O
mediated	O	O
myopathy	B-Disease	D009135
that	O	O
persists	O	O
after	O	O
withdrawal	O	O
of	O	O
the	O	O
drug	O	O
and	O	O
responds	O	O
to	O	O
immunosuppressive	O	O
therapy	O	O
.	O	O

The	O	O
mechanism	O	O
of	O	O
this	O	O
myopathy	B-Disease	D009135
is	O	O
uncertain	O	O
but	O	O
may	O	O
involve	O	O
the	O	O
induction	O	O
by	O	O
statins	B-Chemical	D019821
of	O	O
an	O	O
endoplasmic	O	O
reticulum	O	O
stress	O	O
response	O	O
with	O	O
associated	O	O
up	O	O
-	O	O
regulation	O	O
of	O	O
MHC	O	O
-	O	O
I	O	O
expression	O	O
and	O	O
antigen	O	O
presentation	O	O
by	O	O
muscle	O	O
fibres	O	O
.	O	O

Direct	O	O
inhibition	O	O
of	O	O
cardiac	O	O
hyperpolarization	O	O
-	O	O
activated	O	O
cyclic	B-Chemical	D009712
nucleotide	I-Chemical	D009712
-	O	O
gated	O	O
pacemaker	O	O
channels	O	O
by	O	O
clonidine	B-Chemical	D003000
.	O	O

BACKGROUND	O	O
:	O	O
Inhibition	O	O
of	O	O
cardiac	O	O
sympathetic	O	O
tone	O	O
represents	O	O
an	O	O
important	O	O
strategy	O	O
for	O	O
treatment	O	O
of	O	O
cardiovascular	B-Disease	D002318
disease	I-Disease	D002318
,	O	O
including	O	O
arrhythmia	B-Disease	D001145
,	O	O
coronary	B-Disease	D003327
heart	I-Disease	D003327
disease	I-Disease	D003327
,	O	O
and	O	O
chronic	O	O
heart	B-Disease	D006333
failure	I-Disease	D006333
.	O	O

Activation	O	O
of	O	O
presynaptic	O	O
alpha2	O	O
-	O	O
adrenoceptors	O	O
is	O	O
the	O	O
most	O	O
widely	O	O
accepted	O	O
mechanism	O	O
of	O	O
action	O	O
of	O	O
the	O	O
antisympathetic	O	O
drug	O	O
clonidine	B-Chemical	D003000
;	O	O
however	O	O
,	O	O
other	O	O
target	O	O
proteins	O	O
have	O	O
been	O	O
postulated	O	O
to	O	O
contribute	O	O
to	O	O
the	O	O
in	O	O
vivo	O	O
actions	O	O
of	O	O
clonidine	B-Chemical	D003000
.	O	O

METHODS	O	O
AND	O	O
RESULTS	O	O
:	O	O
To	O	O
test	O	O
whether	O	O
clonidine	B-Chemical	D003000
elicits	O	O
pharmacological	O	O
effects	O	O
independent	O	O
of	O	O
alpha2	O	O
-	O	O
adrenoceptors	O	O
,	O	O
we	O	O
have	O	O
generated	O	O
mice	O	O
with	O	O
a	O	O
targeted	O	O
deletion	O	O
of	O	O
all	O	O
3	O	O
alpha2	O	O
-	O	O
adrenoceptor	O	O
subtypes	O	O
(	O	O
alpha2ABC	O	O
-	O	O
/	O	O
-	O	O
)	O	O
.	O	O

Alpha2ABC	O	O
-	O	O
/	O	O
-	O	O
mice	O	O
were	O	O
completely	O	O
unresponsive	O	O
to	O	O
the	O	O
analgesic	O	O
and	O	O
hypnotic	O	O
effects	O	O
of	O	O
clonidine	B-Chemical	D003000
;	O	O
however	O	O
,	O	O
clonidine	B-Chemical	D003000
significantly	O	O
lowered	O	O
heart	O	O
rate	O	O
in	O	O
alpha2ABC	O	O
-	O	O
/	O	O
-	O	O
mice	O	O
by	O	O
up	O	O
to	O	O
150	O	O
bpm	O	O
.	O	O

Clonidine	B-Chemical	D003000
-	O	O
induced	O	O
bradycardia	B-Disease	D001919
in	O	O
conscious	O	O
alpha2ABC	O	O
-	O	O
/	O	O
-	O	O
mice	O	O
was	O	O
32	O	O
.	O	O

3%	O	O
(	O	O
10	O	O
microg	O	O
/	O	O
kg	O	O
)	O	O
and	O	O
26	O	O
.	O	O

6%	O	O
(	O	O
100	O	O
microg	O	O
/	O	O
kg	O	O
)	O	O
of	O	O
the	O	O
effect	O	O
in	O	O
wild	O	O
-	O	O
type	O	O
mice	O	O
.	O	O

A	O	O
similar	O	O
bradycardic	O	O
effect	O	O
of	O	O
clonidine	B-Chemical	D003000
was	O	O
observed	O	O
in	O	O
isolated	O	O
spontaneously	O	O
beating	O	O
right	O	O
atria	O	O
from	O	O
alpha2ABC	O	O
-	O	O
knockout	O	O
and	O	O
wild	O	O
-	O	O
type	O	O
mice	O	O
.	O	O

Clonidine	B-Chemical	D003000
inhibited	O	O
the	O	O
native	O	O
pacemaker	O	O
current	O	O
(	O	O
I	O	O
(	O	O
f	O	O
)	O	O
)	O	O
in	O	O
isolated	O	O
sinoatrial	O	O
node	O	O
pacemaker	O	O
cells	O	O
and	O	O
the	O	O
I	O	O
(	O	O
f	O	O
)	O	O
-	O	O
generating	O	O
hyperpolarization	O	O
-	O	O
activated	O	O
cyclic	B-Chemical	D009712
nucleotide	I-Chemical	D009712
-	O	O
gated	O	O
(	O	O
HCN	O	O
)	O	O
2	O	O
and	O	O
HCN4	O	O
channels	O	O
in	O	O
transfected	O	O
HEK293	O	O
cells	O	O
.	O	O

As	O	O
a	O	O
consequence	O	O
of	O	O
blocking	O	O
I	O	O
(	O	O
f	O	O
)	O	O
,	O	O
clonidine	B-Chemical	D003000
reduced	O	O
the	O	O
slope	O	O
of	O	O
the	O	O
diastolic	O	O
depolarization	O	O
and	O	O
the	O	O
frequency	O	O
of	O	O
pacemaker	O	O
potentials	O	O
in	O	O
sinoatrial	O	O
node	O	O
cells	O	O
from	O	O
wild	O	O
-	O	O
type	O	O
and	O	O
alpha2ABC	O	O
-	O	O
knockout	O	O
mice	O	O
.	O	O

CONCLUSIONS	O	O
:	O	O
Direct	O	O
inhibition	O	O
of	O	O
cardiac	O	O
HCN	O	O
pacemaker	O	O
channels	O	O
contributes	O	O
to	O	O
the	O	O
bradycardic	O	O
effects	O	O
of	O	O
clonidine	B-Chemical	D003000
gene	O	O
-	O	O
targeted	O	O
mice	O	O
in	O	O
vivo	O	O
,	O	O
and	O	O
thus	O	O
,	O	O
clonidine	B-Chemical	D003000
-	O	O
like	O	O
drugs	O	O
represent	O	O
novel	O	O
structures	O	O
for	O	O
future	O	O
HCN	O	O
channel	O	O
inhibitors	O	O
.	O	O

Influence	O	O
of	O	O
smoking	B-Chemical	D012906
on	O	O
developing	O	O
cochlea	O	O
.	O	O

Does	O	O
smoking	B-Chemical	D012906
during	O	O
pregnancy	O	O
affect	O	O
the	O	O
amplitudes	O	O
of	O	O
transient	O	O
evoked	O	O
otoacoustic	O	O
emissions	O	O
in	O	O
newborns?	O	O
OBJECTIVE	O	O
:	O	O
Maternal	O	O
tobacco	O	O
smoking	B-Chemical	D012906
has	O	O
negative	O	O
effects	O	O
on	O	O
fetal	O	O
growth	O	O
.	O	O

The	O	O
influence	O	O
of	O	O
smoking	B-Chemical	D012906
during	O	O
pregnancy	O	O
on	O	O
the	O	O
developing	O	O
cochlea	O	O
has	O	O
not	O	O
been	O	O
estimated	O	O
,	O	O
although	O	O
smoking	B-Chemical	D012906
has	O	O
been	O	O
positively	O	O
associated	O	O
with	O	O
hearing	B-Disease	D034381
loss	I-Disease	D034381
in	O	O
adults	O	O
.	O	O

The	O	O
objective	O	O
of	O	O
this	O	O
study	O	O
was	O	O
to	O	O
determine	O	O
the	O	O
effects	O	O
of	O	O
maternal	O	O
smoking	B-Chemical	D012906
on	O	O
transient	O	O
evoked	O	O
otoacoustic	O	O
emissions	O	O
(	O	O
TEOAEs	O	O
)	O	O
of	O	O
healthy	O	O
neonates	O	O
.	O	O

METHODS	O	O
:	O	O
This	O	O
study	O	O
was	O	O
undertaken	O	O
as	O	O
part	O	O
of	O	O
neonatal	O	O
screening	O	O
for	O	O
hearing	B-Disease	D034381
impairment	I-Disease	D034381
and	O	O
involved	O	O
both	O	O
ears	O	O
of	O	O
200	O	O
newborns	O	O
.	O	O

Newborns	O	O
whose	O	O
mothers	O	O
reported	O	O
smoking	B-Chemical	D012906
during	O	O
pregnancy	O	O
(	O	O
n=200	O	O
ears	O	O
)	O	O
were	O	O
compared	O	O
to	O	O
a	O	O
control	O	O
group	O	O
of	O	O
newborns	O	O
(	O	O
n=200	O	O
ears	O	O
)	O	O
,	O	O
whose	O	O
mothers	O	O
were	O	O
non	O	O
-	O	O
smokers	O	O
.	O	O

Exposure	O	O
to	O	O
tobacco	O	O
was	O	O
characterized	O	O
as	O	O
low	O	O
(	O	O
<5	O	O
cigarettes	O	O
per	O	O
day	O	O
,	O	O
n=88	O	O
ears	O	O
)	O	O
,	O	O
moderate	O	O
(	O	O
5<	O	O
or	O	O
=cigarettes	O	O
per	O	O
day<10	O	O
,	O	O
n=76	O	O
)	O	O
or	O	O
high	O	O
(	O	O
>	O	O
or	O	O
=10	O	O
cigarettes	O	O
per	O	O
day	O	O
,	O	O
n=36	O	O
)	O	O
.	O	O

RESULTS	O	O
:	O	O
In	O	O
exposed	O	O
neonates	O	O
,	O	O
TEOAEs	O	O
mean	O	O
response	O	O
(	O	O
across	O	O
frequency	O	O
)	O	O
and	O	O
mean	O	O
amplitude	O	O
at	O	O
4000Hz	O	O
was	O	O
significantly	O	O
lower	O	O
than	O	O
in	O	O
non	O	O
-	O	O
exposed	O	O
neonates	O	O
.	O	O

Comparisons	O	O
between	O	O
exposed	O	O
newborns'	O	O
subgroups	O	O
revealed	O	O
no	O	O
significant	O	O
differences	O	O
.	O	O

However	O	O
,	O	O
by	O	O
comparing	O	O
each	O	O
subgroup	O	O
to	O	O
control	O	O
group	O	O
,	O	O
we	O	O
found	O	O
statistically	O	O
significant	O	O
decreases	B-Disease	-1
of	I-Disease	-1
TEOAEs	I-Disease	-1
amplitudes	I-Disease	-1
at	O	O
4000Hz	O	O
for	O	O
all	O	O
three	O	O
groups	O	O
.	O	O

Mean	O	O
TEOAEs	O	O
responses	O	O
of	O	O
highly	O	O
exposed	O	O
newborns	O	O
were	O	O
also	O	O
significantly	O	O
lower	O	O
in	O	O
comparison	O	O
to	O	O
our	O	O
control	O	O
group	O	O
.	O	O

CONCLUSION	O	O
:	O	O
In	O	O
utero	O	O
,	O	O
exposure	O	O
to	O	O
tobacco	O	O
smoking	B-Chemical	D012906
seems	O	O
to	O	O
have	O	O
a	O	O
small	O	O
impact	O	O
on	O	O
outer	O	O
hair	O	O
cells	O	O
.	O	O

These	O	O
effects	O	O
seem	O	O
to	O	O
be	O	O
equally	O	O
true	O	O
for	O	O
all	O	O
exposed	O	O
newborns	O	O
,	O	O
regardless	O	O
of	O	O
the	O	O
degree	O	O
of	O	O
exposure	O	O
.	O	O

Further	O	O
studies	O	O
are	O	O
needed	O	O
in	O	O
order	O	O
to	O	O
establish	O	O
a	O	O
potential	O	O
negative	O	O
effect	O	O
of	O	O
maternal	O	O
smoking	B-Chemical	D012906
on	O	O
the	O	O
neonate's	O	O
hearing	O	O
acuity	O	O
.	O	O

Neuroinflammation	B-Disease	D020078
and	O	O
behavioral	B-Disease	D001523
abnormalities	I-Disease	D001523
after	O	O
neonatal	O	O
terbutaline	B-Chemical	D013726
treatment	O	O
in	O	O
rats	O	O
:	O	O
implications	O	O
for	O	O
autism	B-Disease	D001321
.	O	O

Autism	B-Disease	D001321
is	O	O
a	O	O
neurodevelopmental	B-Disease	D002658
disorder	I-Disease	D002658
presenting	O	O
before	O	O
3	O	O
years	O	O
of	O	O
age	O	O
with	O	O
deficits	B-Disease	D003147
in	I-Disease	D003147
communication	I-Disease	D003147
and	I-Disease	D003147
social	I-Disease	D003147
skills	I-Disease	D003147
and	O	O
repetitive	B-Disease	D001523
behaviors	I-Disease	D001523
.	O	O

In	O	O
addition	O	O
to	O	O
genetic	O	O
influences	O	O
,	O	O
recent	O	O
studies	O	O
suggest	O	O
that	O	O
prenatal	O	O
drug	O	O
or	O	O
chemical	O	O
exposures	O	O
are	O	O
risk	O	O
factors	O	O
for	O	O
autism	B-Disease	D001321
.	O	O

Terbutaline	B-Chemical	D013726
,	O	O
a	O	O
beta2	O	O
-	O	O
adrenoceptor	O	O
agonist	O	O
used	O	O
to	O	O
arrest	O	O
preterm	B-Disease	D007752
labor	I-Disease	D007752
,	O	O
has	O	O
been	O	O
associated	O	O
with	O	O
increased	O	O
concordance	O	O
for	O	O
autism	B-Disease	D001321
in	O	O
dizygotic	O	O
twins	O	O
.	O	O

We	O	O
studied	O	O
the	O	O
effects	O	O
of	O	O
terbutaline	B-Chemical	D013726
on	O	O
microglial	O	O
activation	O	O
in	O	O
different	O	O
brain	O	O
regions	O	O
and	O	O
behavioral	O	O
outcomes	O	O
in	O	O
developing	O	O
rats	O	O
.	O	O

Newborn	O	O
rats	O	O
were	O	O
given	O	O
terbutaline	B-Chemical	D013726
(	O	O
10	O	O
mg	O	O
/	O	O
kg	O	O
)	O	O
daily	O	O
on	O	O
postnatal	O	O
days	O	O
(	O	O
PN	O	O
)	O	O
2	O	O
to	O	O
5	O	O
or	O	O
PN	O	O
11	O	O
to	O	O
14	O	O
and	O	O
examined	O	O
24	O	O
h	O	O
after	O	O
the	O	O
last	O	O
dose	O	O
and	O	O
at	O	O
PN	O	O
30	O	O
.	O	O

Immunohistochemical	O	O
studies	O	O
showed	O	O
that	O	O
administration	O	O
of	O	O
terbutaline	B-Chemical	D013726
on	O	O
PN	O	O
2	O	O
to	O	O
5	O	O
produced	O	O
a	O	O
robust	O	O
increase	O	O
in	O	O
microglial	O	O
activation	O	O
on	O	O
PN	O	O
30	O	O
in	O	O
the	O	O
cerebral	O	O
cortex	O	O
,	O	O
as	O	O
well	O	O
as	O	O
in	O	O
cerebellar	O	O
and	O	O
cerebrocortical	O	O
white	O	O
matter	O	O
.	O	O

None	O	O
of	O	O
these	O	O
effects	O	O
occurred	O	O
in	O	O
animals	O	O
given	O	O
terbutaline	B-Chemical	D013726
on	O	O
PN	O	O
11	O	O
to	O	O
14	O	O
.	O	O

In	O	O
behavioral	O	O
tests	O	O
,	O	O
animals	O	O
treated	O	O
with	O	O
terbutaline	B-Chemical	D013726
on	O	O
PN	O	O
2	O	O
to	O	O
5	O	O
showed	O	O
consistent	O	O
patterns	O	O
of	O	O
hyper	O	O
-	O	O
reactivity	O	O
to	O	O
novelty	O	O
and	O	O
aversive	O	O
stimuli	O	O
when	O	O
assessed	O	O
in	O	O
a	O	O
novel	O	O
open	O	O
field	O	O
,	O	O
as	O	O
well	O	O
as	O	O
in	O	O
the	O	O
acoustic	O	O
startle	O	O
response	O	O
test	O	O
.	O	O

Our	O	O
findings	O	O
indicate	O	O
that	O	O
beta2	O	O
-	O	O
adrenoceptor	O	O
overstimulation	O	O
during	O	O
an	O	O
early	O	O
critical	O	O
period	O	O
results	O	O
in	O	O
microglial	O	O
activation	O	O
associated	O	O
with	O	O
innate	O	O
neuroinflammatory	O	O
pathways	O	O
and	O	O
behavioral	B-Disease	D001523
abnormalities	I-Disease	D001523
,	O	O
similar	O	O
to	O	O
those	O	O
described	O	O
in	O	O
autism	B-Disease	D001321
.	O	O

This	O	O
study	O	O
provides	O	O
a	O	O
useful	O	O
animal	O	O
model	O	O
for	O	O
understanding	O	O
the	O	O
neuropathological	O	O
processes	O	O
underlying	O	O
autism	B-Disease	D001321
spectrum	O	O
disorders	O	O
.	O	O

Acute	O	O
myocarditis	B-Disease	D009205
associated	O	O
with	O	O
clozapine	B-Chemical	D003024
.	O	O

OBJECTIVE	O	O
:	O	O
A	O	O
case	O	O
of	O	O
acute	O	O
myocarditis	B-Disease	D009205
associated	O	O
with	O	O
the	O	O
commencement	O	O
of	O	O
clozapine	B-Chemical	D003024
is	O	O
described	O	O
,	O	O
highlighting	O	O
the	O	O
onset	O	O
,	O	O
course	O	O
and	O	O
possible	O	O
contributing	O	O
factors	O	O
.	O	O

There	O	O
is	O	O
an	O	O
urgent	O	O
need	O	O
to	O	O
raise	O	O
awareness	O	O
about	O	O
this	O	O
potentially	O	O
fatal	O	O
complication	O	O
of	O	O
clozapine	B-Chemical	D003024
use	O	O
.	O	O

RESULTS	O	O
:	O	O
A	O	O
20	O	O
-	O	O
year	O	O
-	O	O
old	O	O
male	O	O
with	O	O
schizophrenia	B-Disease	D012559
developed	O	O
a	O	O
sudden	O	O
onset	O	O
of	O	O
myocarditis	B-Disease	D009205
after	O	O
commencement	O	O
of	O	O
clozapine	B-Chemical	D003024
.	O	O

The	O	O
patient	O	O
recovered	O	O
with	O	O
intensive	O	O
medical	O	O
support	O	O
.	O	O

The	O	O
symptoms	O	O
occurred	O	O
around	O	O
2	O	O
weeks	O	O
after	O	O
starting	O	O
clozapine	B-Chemical	D003024
in	O	O
an	O	O
inpatient	O	O
setting	O	O
.	O	O

Possible	O	O
contributing	O	O
factors	O	O
may	O	O
have	O	O
been	O	O
concomitant	O	O
antidepressant	B-Chemical	D000928
use	O	O
and	O	O
unaccustomed	O	O
physical	O	O
activity	O	O
.	O	O

CONCLUSIONS	O	O
:	O	O
Myocarditis	B-Disease	D009205
is	O	O
an	O	O
increasingly	O	O
recognized	O	O
complication	O	O
associated	O	O
with	O	O
the	O	O
use	O	O
of	O	O
clozapine	B-Chemical	D003024
.	O	O

It	O	O
can	O	O
be	O	O
fatal	O	O
if	O	O
not	O	O
recognized	O	O
and	O	O
treated	O	O
early	O	O
.	O	O

Considering	O	O
that	O	O
clozapine	B-Chemical	D003024
remains	O	O
the	O	O
gold	O	O
standard	O	O
in	O	O
treatment	O	O
of	O	O
resistant	O	O
psychosis	B-Disease	D011618
,	O	O
there	O	O
is	O	O
an	O	O
urgent	O	O
need	O	O
to	O	O
raise	O	O
awareness	O	O
among	O	O
medical	O	O
and	O	O
paramedical	O	O
staff	O	O
involved	O	O
in	O	O
the	O	O
care	O	O
of	O	O
these	O	O
patients	O	O
.	O	O

There	O	O
are	O	O
also	O	O
implications	O	O
for	O	O
recommendations	O	O
and	O	O
regulations	O	O
regarding	O	O
the	O	O
use	O	O
of	O	O
clozapine	B-Chemical	D003024
.	O	O

Encephalopathy	B-Disease	D001927
induced	O	O
by	O	O
levetiracetam	B-Chemical	C026098
added	O	O
to	O	O
valproate	B-Chemical	D014635
.	O	O

BACKGROUND	O	O
:	O	O
We	O	O
report	O	O
on	O	O
the	O	O
manifestation	O	O
of	O	O
a	O	O
levetiracetam	B-Chemical	C026098
(	O	O
LEV	B-Chemical	C026098
)	O	O
-	O	O
induced	O	O
encephalopathy	B-Disease	D001927
.	O	O

FINDINGS	O	O
:	O	O
A	O	O
28	O	O
-	O	O
year	O	O
-	O	O
old	O	O
man	O	O
suffering	O	O
from	O	O
idiopathic	B-Disease	C562694
epilepsy	I-Disease	C562694
with	O	O
generalized	O	O
seizures	B-Disease	D012640
was	O	O
treated	O	O
with	O	O
LEV	B-Chemical	C026098
(	O	O
3000	O	O
mg	O	O
)	O	O
added	O	O
to	O	O
valproate	B-Chemical	D014635
(	O	O
VPA	B-Chemical	D014635
)	O	O
(	O	O
2000	O	O
mg	O	O
)	O	O
.	O	O

Frequency	O	O
of	O	O
generalized	O	O
tonic	B-Disease	D004830
-	I-Disease	D004830
clonic	I-Disease	D004830
seizures	I-Disease	D004830
increased	O	O
from	O	O
one	O	O
per	O	O
6	O	O
months	O	O
to	O	O
two	O	O
per	O	O
month	O	O
.	O	O

Neuropsychological	O	O
testing	O	O
showed	O	O
impaired	B-Disease	D008569
word	I-Disease	D008569
fluency	I-Disease	D008569
,	I-Disease	D008569
psychomotor	I-Disease	D008569
speed	I-Disease	D008569
and	I-Disease	D008569
working	I-Disease	D008569
memory	I-Disease	D008569
.	O	O

The	O	O
interictal	O	O
electroencephalogram	O	O
(	O	O
EEG	O	O
)	O	O
showed	O	O
a	O	O
generalized	O	O
slowing	O	O
to	O	O
5	O	O
per	O	O
second	O	O
theta	O	O
rhythms	O	O
with	O	O
bilateral	O	O
generalized	O	O
high	O	O
-	O	O
amplitude	O	O
discharges	O	O
.	O	O

OUTCOME	O	O
:	O	O
Following	O	O
discontinuation	O	O
of	O	O
LEV	B-Chemical	C026098
,	O	O
EEG	O	O
and	O	O
neuropsychological	O	O
findings	O	O
improved	O	O
and	O	O
seizure	B-Disease	D012640
frequency	O	O
decreased	O	O
.	O	O

Norepinephrine	B-Chemical	D009638
signaling	O	O
through	O	O
beta	O	O
-	O	O
adrenergic	O	O
receptors	O	O
is	O	O
critical	O	O
for	O	O
expression	O	O
of	O	O
cocaine	B-Chemical	D003042
-	O	O
induced	O	O
anxiety	B-Disease	D001008
.	O	O

BACKGROUND	O	O
:	O	O
Cocaine	B-Chemical	D003042
is	O	O
a	O	O
widely	O	O
abused	O	O
psychostimulant	O	O
that	O	O
has	O	O
both	O	O
rewarding	O	O
and	O	O
aversive	O	O
properties	O	O
.	O	O

While	O	O
the	O	O
mechanisms	O	O
underlying	O	O
cocaine's	O	O
rewarding	O	O
effects	O	O
have	O	O
been	O	O
studied	O	O
extensively	O	O
,	O	O
less	O	O
attention	O	O
has	O	O
been	O	O
paid	O	O
to	O	O
the	O	O
unpleasant	O	O
behavioral	O	O
states	O	O
induced	O	O
by	O	O
cocaine	B-Chemical	D003042
,	O	O
such	O	O
as	O	O
anxiety	B-Disease	D001008
.	O	O

METHODS	O	O
:	O	O
In	O	O
this	O	O
study	O	O
,	O	O
we	O	O
evaluated	O	O
the	O	O
performance	O	O
of	O	O
dopamine	B-Chemical	D004298
beta	O	O
-	O	O
hydroxylase	O	O
knockout	O	O
(	O	O
Dbh	O	O
-	O	O
/	O	O
-	O	O
)	O	O
mice	O	O
,	O	O
which	O	O
lack	O	O
norepinephrine	B-Chemical	D009638
(	O	O
NE	B-Chemical	D009638
)	O	O
,	O	O
in	O	O
the	O	O
elevated	O	O
plus	O	O
maze	O	O
(	O	O
EPM	O	O
)	O	O
to	O	O
examine	O	O
the	O	O
contribution	O	O
of	O	O
noradrenergic	O	O
signaling	O	O
to	O	O
cocaine	B-Chemical	D003042
-	O	O
induced	O	O
anxiety	B-Disease	D001008
.	O	O

RESULTS	O	O
:	O	O
We	O	O
found	O	O
that	O	O
cocaine	B-Chemical	D003042
dose	O	O
-	O	O
dependently	O	O
increased	O	O
anxiety	B-Disease	D001008
-	O	O
like	O	O
behavior	O	O
in	O	O
control	O	O
(	O	O
Dbh	O	O
+	O	O
/	O	O
-	O	O
)	O	O
mice	O	O
,	O	O
as	O	O
measured	O	O
by	O	O
a	O	O
decrease	O	O
in	O	O
open	O	O
arm	O	O
exploration	O	O
.	O	O

The	O	O
Dbh	O	O
-	O	O
/	O	O
-	O	O
mice	O	O
had	O	O
normal	O	O
baseline	O	O
performance	O	O
in	O	O
the	O	O
EPM	O	O
but	O	O
were	O	O
completely	O	O
resistant	O	O
to	O	O
the	O	O
anxiogenic	O	O
effects	O	O
of	O	O
cocaine	B-Chemical	D003042
.	O	O

Cocaine	B-Chemical	D003042
-	O	O
induced	O	O
anxiety	B-Disease	D001008
was	O	O
also	O	O
attenuated	O	O
in	O	O
Dbh	O	O
+	O	O
/	O	O
-	O	O
mice	O	O
following	O	O
administration	O	O
of	O	O
disulfiram	B-Chemical	D004221
,	O	O
a	O	O
dopamine	B-Chemical	D004298
beta	O	O
-	O	O
hydroxylase	O	O
(	O	O
DBH	O	O
)	O	O
inhibitor	O	O
.	O	O

In	O	O
experiments	O	O
using	O	O
specific	O	O
adrenergic	O	O
antagonists	O	O
,	O	O
we	O	O
found	O	O
that	O	O
pretreatment	O	O
with	O	O
the	O	O
beta	O	O
-	O	O
adrenergic	O	O
receptor	O	O
antagonist	O	O
propranolol	B-Chemical	D011433
blocked	O	O
cocaine	B-Chemical	D003042
-	O	O
induced	O	O
anxiety	B-Disease	D001008
-	O	O
like	O	O
behavior	O	O
in	O	O
Dbh	O	O
+	O	O
/	O	O
-	O	O
and	O	O
wild	O	O
-	O	O
type	O	O
C57BL6	O	O
/	O	O
J	O	O
mice	O	O
,	O	O
while	O	O
the	O	O
alpha	O	O
(	O	O
1	O	O
)	O	O
antagonist	O	O
prazosin	B-Chemical	D011224
and	O	O
the	O	O
alpha	O	O
(	O	O
2	O	O
)	O	O
antagonist	O	O
yohimbine	B-Chemical	D015016
had	O	O
no	O	O
effect	O	O
.	O	O

CONCLUSIONS	O	O
:	O	O
These	O	O
results	O	O
indicate	O	O
that	O	O
noradrenergic	O	O
signaling	O	O
via	O	O
beta	O	O
-	O	O
adrenergic	O	O
receptors	O	O
is	O	O
required	O	O
for	O	O
cocaine	B-Chemical	D003042
-	O	O
induced	O	O
anxiety	B-Disease	D001008
in	O	O
mice	O	O
.	O	O

Clonidine	B-Chemical	D003000
for	O	O
attention	B-Disease	D001289
-	I-Disease	D001289
deficit	I-Disease	D001289
/	I-Disease	D001289
hyperactivity	I-Disease	D001289
disorder	I-Disease	D001289
:	O	O
II	O	O
.	O	O

ECG	O	O
changes	O	O
and	O	O
adverse	O	O
events	O	O
analysis	O	O
.	O	O

OBJECTIVE	O	O
:	O	O
To	O	O
examine	O	O
the	O	O
safety	O	O
and	O	O
tolerability	O	O
of	O	O
clonidine	B-Chemical	D003000
used	O	O
alone	O	O
or	O	O
with	O	O
methylphenidate	B-Chemical	D008774
in	O	O
children	O	O
with	O	O
attention	B-Disease	D001289
-	I-Disease	D001289
deficit	I-Disease	D001289
/	I-Disease	D001289
hyperactivity	I-Disease	D001289
disorder	I-Disease	D001289
(	O	O
ADHD	B-Disease	D001289
)	O	O
.	O	O

METHOD	O	O
:	O	O
In	O	O
a	O	O
16	O	O
-	O	O
week	O	O
multicenter	O	O
,	O	O
double	O	O
-	O	O
blind	O	O
trial	O	O
,	O	O
122	O	O
children	O	O
with	O	O
ADHD	B-Disease	D001289
were	O	O
randomly	O	O
assigned	O	O
to	O	O
clonidine	B-Chemical	D003000
(	O	O
n	O	O
=	O	O
31	O	O
)	O	O
,	O	O
methylphenidate	B-Chemical	D008774
(	O	O
n	O	O
=	O	O
29	O	O
)	O	O
,	O	O
clonidine	B-Chemical	D003000
and	O	O
methylphenidate	B-Chemical	D008774
(	O	O
n	O	O
=	O	O
32	O	O
)	O	O
,	O	O
or	O	O
placebo	O	O
(	O	O
n	O	O
=	O	O
30	O	O
)	O	O
.	O	O

Doses	O	O
were	O	O
flexibly	O	O
titrated	O	O
up	O	O
to	O	O
0	O	O
.	O	O

6	O	O
mg	O	O
/	O	O
day	O	O
for	O	O
clonidine	B-Chemical	D003000
and	O	O
60	O	O
mg	O	O
/	O	O
day	O	O
for	O	O
methylphenidate	B-Chemical	D008774
(	O	O
both	O	O
with	O	O
divided	O	O
dosing	O	O
)	O	O
.	O	O

Groups	O	O
were	O	O
compared	O	O
regarding	O	O
adverse	O	O
events	O	O
and	O	O
changes	O	O
from	O	O
baseline	O	O
to	O	O
week	O	O
16	O	O
in	O	O
electrocardiograms	O	O
and	O	O
vital	O	O
signs	O	O
.	O	O

RESULTS	O	O
:	O	O
There	O	O
were	O	O
more	O	O
incidents	O	O
of	O	O
bradycardia	B-Disease	D001919
in	O	O
subjects	O	O
treated	O	O
with	O	O
clonidine	B-Chemical	D003000
compared	O	O
with	O	O
those	O	O
not	O	O
treated	O	O
with	O	O
clonidine	B-Chemical	D003000
(	O	O
17	O	O
.	O	O

5%	O	O
versus	O	O
3	O	O
.	O	O

4%	O	O
;	O	O
p	O	O
=	O	O
.	O	O

02	O	O
)	O	O
,	O	O
but	O	O
no	O	O
other	O	O
significant	O	O
group	O	O
differences	O	O
regarding	O	O
electrocardiogram	O	O
and	O	O
other	O	O
cardiovascular	O	O
outcomes	O	O
.	O	O

There	O	O
were	O	O
no	O	O
suggestions	O	O
of	O	O
interactions	O	O
between	O	O
clonidine	B-Chemical	D003000
and	O	O
methylphenidate	B-Chemical	D008774
regarding	O	O
cardiovascular	O	O
outcomes	O	O
.	O	O

Moderate	O	O
or	O	O
severe	O	O
adverse	O	O
events	O	O
were	O	O
more	O	O
common	O	O
in	O	O
subjects	O	O
on	O	O
clonidine	B-Chemical	D003000
(	O	O
79	O	O
.	O	O

4%	O	O
versus	O	O
49	O	O
.	O	O

2%	O	O
;	O	O
p	O	O
=	O	O
.	O	O

0006	O	O
)	O	O
but	O	O
not	O	O
associated	O	O
with	O	O
higher	O	O
rates	O	O
of	O	O
early	O	O
study	O	O
withdrawal	O	O
.	O	O

Drowsiness	B-Disease	D006970
was	O	O
common	O	O
on	O	O
clonidine	B-Chemical	D003000
,	O	O
but	O	O
generally	O	O
resolved	O	O
by	O	O
6	O	O
to	O	O
8	O	O
weeks	O	O
.	O	O

CONCLUSIONS	O	O
:	O	O
Clonidine	B-Chemical	D003000
,	O	O
used	O	O
alone	O	O
or	O	O
with	O	O
methylphenidate	B-Chemical	D008774
,	O	O
appears	O	O
safe	O	O
and	O	O
well	O	O
tolerated	O	O
in	O	O
childhood	O	O
ADHD	B-Disease	D001289
.	O	O

Physicians	O	O
prescribing	O	O
clonidine	B-Chemical	D003000
should	O	O
monitor	O	O
for	O	O
bradycardia	B-Disease	D001919
and	O	O
advise	O	O
patients	O	O
about	O	O
the	O	O
high	O	O
likelihood	O	O
of	O	O
initial	O	O
drowsiness	B-Disease	D006970
.	O	O

Thalidomide	B-Chemical	D013792
has	O	O
limited	O	O
single	O	O
-	O	O
agent	O	O
activity	O	O
in	O	O
relapsed	O	O
or	O	O
refractory	O	O
indolent	O	O
non	B-Disease	D008228
-	I-Disease	D008228
Hodgkin	I-Disease	D008228
lymphomas	I-Disease	D008228
:	O	O
a	O	O
phase	O	O
II	O	O
trial	O	O
of	O	O
the	O	O
Cancer	B-Disease	D009369
and	O	O
Leukemia	B-Disease	D007938
Group	O	O
B	O	O
.	O	O

Thalidomide	B-Chemical	D013792
is	O	O
an	O	O
immunomodulatory	O	O
agent	O	O
with	O	O
demonstrated	O	O
activity	O	O
in	O	O
multiple	B-Disease	D009101
myeloma	I-Disease	D009101
,	O	O
mantle	B-Disease	D020522
cell	I-Disease	D020522
lymphoma	I-Disease	D020522
and	O	O
lymphoplasmacytic	B-Disease	D008223
lymphoma	I-Disease	D008223
.	O	O

Its	O	O
activity	O	O
is	O	O
believed	O	O
to	O	O
be	O	O
due	O	O
modulation	O	O
of	O	O
the	O	O
tumour	B-Disease	D009369
milieu	O	O
,	O	O
including	O	O
downregulation	O	O
of	O	O
angiogenesis	O	O
and	O	O
inflammatory	O	O
cytokines	O	O
.	O	O

Between	O	O
July	O	O
2001	O	O
and	O	O
April	O	O
2004	O	O
,	O	O
24	O	O
patients	O	O
with	O	O
relapsed	O	O
/	O	O
refractory	O	O
indolent	O	O
lymphomas	B-Disease	D008223
received	O	O
thalidomide	B-Chemical	D013792
200	O	O
mg	O	O
daily	O	O
with	O	O
escalation	O	O
by	O	O
100	O	O
mg	O	O
daily	O	O
every	O	O
1	O	O
-	O	O
2	O	O
weeks	O	O
as	O	O
tolerated	O	O
,	O	O
up	O	O
to	O	O
a	O	O
maximum	O	O
of	O	O
800	O	O
mg	O	O
daily	O	O
.	O	O

Patients	O	O
had	O	O
received	O	O
a	O	O
median	O	O
of	O	O
2	O	O
(	O	O
range	O	O
,	O	O
1	O	O
-	O	O
4	O	O
)	O	O
prior	O	O
regimens	O	O
.	O	O

Of	O	O
24	O	O
evaluable	O	O
patients	O	O
,	O	O
two	O	O
achieved	O	O
a	O	O
complete	O	O
remission	O	O
and	O	O
one	O	O
achieved	O	O
a	O	O
partial	O	O
remission	O	O
for	O	O
an	O	O
overall	O	O
response	O	O
rate	O	O
of	O	O
12	O	O
.	O	O

5%	O	O
(	O	O
95%	O	O
confidence	O	O
interval	O	O
:	O	O
2	O	O
.	O	O

6	O	O
-	O	O
32	O	O
.	O	O

4%	O	O
)	O	O
.	O	O

Eleven	O	O
patients	O	O
progressed	O	O
during	O	O
therapy	O	O
.	O	O

Grade	O	O
3	O	O
-	O	O
4	O	O
adverse	O	O
effects	O	O
included	O	O
myelosuppression	B-Disease	D001855
,	O	O
fatigue	B-Disease	D005221
,	O	O
somnolence	B-Disease	D006970
/	O	O
depressed	B-Disease	D003866
mood	I-Disease	D003866
,	O	O
neuropathy	B-Disease	D009422
and	O	O
dyspnea	B-Disease	D004417
.	O	O

Of	O	O
concern	O	O
was	O	O
the	O	O
occurrence	O	O
of	O	O
four	O	O
thromboembolic	B-Disease	D013923
events	O	O
.	O	O

Our	O	O
results	O	O
failed	O	O
to	O	O
demonstrate	O	O
an	O	O
important	O	O
response	O	O
rate	O	O
to	O	O
single	O	O
agent	O	O
thalidomide	B-Chemical	D013792
in	O	O
indolent	O	O
lymphomas	B-Disease	D008223
and	O	O
contrast	O	O
with	O	O
the	O	O
higher	O	O
activity	O	O
level	O	O
reported	O	O
with	O	O
the	O	O
second	O	O
generation	O	O
immunomodulatory	O	O
agent	O	O
,	O	O
lenalidomide	B-Chemical	C467567
.	O	O

Intracavernous	O	O
epinephrine	B-Chemical	D004837
:	O	O
a	O	O
minimally	O	O
invasive	O	O
treatment	O	O
for	O	O
priapism	B-Disease	D011317
in	O	O
the	O	O
emergency	O	O
department	O	O
.	O	O

Priapism	B-Disease	D011317
is	O	O
the	O	O
prolonged	O	O
erection	O	O
of	O	O
the	O	O
penis	O	O
in	O	O
the	O	O
absence	O	O
of	O	O
sexual	O	O
arousal	O	O
.	O	O

A	O	O
45	O	O
-	O	O
year	O	O
-	O	O
old	O	O
man	O	O
,	O	O
an	O	O
admitted	O	O
frequent	O	O
cocaine	B-Chemical	D003042
user	O	O
,	O	O
presented	O	O
to	O	O
the	O	O
Emergency	O	O
Department	O	O
(	O	O
ED	O	O
)	O	O
on	O	O
two	O	O
separate	O	O
occasions	O	O
with	O	O
a	O	O
history	O	O
of	O	O
priapism	B-Disease	D011317
after	O	O
cocaine	B-Chemical	D003042
use	O	O
.	O	O

The	O	O
management	O	O
options	O	O
in	O	O
the	O	O
ED	O	O
,	O	O
as	O	O
exemplified	O	O
by	O	O
four	O	O
individual	O	O
case	O	O
reports	O	O
,	O	O
in	O	O
particular	O	O
the	O	O
use	O	O
of	O	O
a	O	O
minimally	O	O
invasive	O	O
method	O	O
of	O	O
intracorporal	O	O
epinephrine	B-Chemical	D004837
instillation	O	O
,	O	O
are	O	O
discussed	O	O
.	O	O

Effect	O	O
of	O	O
green	B-Chemical	D010936
tea	I-Chemical	D010936
and	O	O
vitamin	B-Chemical	D014810
E	I-Chemical	D014810
combination	O	O
in	O	O
isoproterenol	B-Chemical	D007545
induced	O	O
myocardial	B-Disease	D009203
infarction	I-Disease	D009203
in	O	O
rats	O	O
.	O	O

The	O	O
present	O	O
study	O	O
was	O	O
aimed	O	O
to	O	O
investigate	O	O
the	O	O
combined	O	O
effects	O	O
of	O	O
green	B-Chemical	D010936
tea	I-Chemical	D010936
and	O	O
vitamin	B-Chemical	D014810
E	I-Chemical	D014810
on	O	O
heart	O	O
weight	O	O
,	O	O
body	O	O
weight	O	O
,	O	O
serum	O	O
marker	O	O
enzymes	O	O
,	O	O
lipid	O	O
peroxidation	O	O
,	O	O
endogenous	O	O
antioxidants	O	O
and	O	O
membrane	O	O
bound	O	O
ATPases	O	O
in	O	O
isoproterenol	B-Chemical	D007545
(	O	O
ISO	B-Chemical	D007545
)	O	O
-	O	O
induced	O	O
myocardial	B-Disease	D009203
infarction	I-Disease	D009203
in	O	O
rats	O	O
.	O	O

Adult	O	O
male	O	O
albino	O	O
rats	O	O
,	O	O
treated	O	O
with	O	O
ISO	B-Chemical	D007545
(	O	O
200	O	O
mg	O	O
/	O	O
kg	O	O
,	O	O
s	O	O
.	O	O

c	O	O
.	O	O

)	O	O
for	O	O
2	O	O
days	O	O
at	O	O
an	O	O
interval	O	O
of	O	O
24	O	O
h	O	O
caused	O	O
a	O	O
significant	O	O
(	O	O
P<0	O	O
.	O	O

05	O	O
)	O	O
elevation	O	O
of	O	O
heart	O	O
weight	O	O
,	O	O
serum	O	O
marker	O	O
enzymes	O	O
,	O	O
lipid	O	O
peroxidation	O	O
and	O	O
Ca+2	O	O
ATPase	O	O
level	O	O
whereas	O	O
there	O	O
was	O	O
a	O	O
significant	O	O
(	O	O
P<0	O	O
.	O	O

05	O	O
)	O	O
decrease	O	O
in	O	O
body	O	O
weight	O	O
,	O	O
endogenous	O	O
antioxidants	O	O
,	O	O
Na+	O	O
/	O	O
K+	O	O
ATPase	O	O
and	O	O
Mg+2	O	O
ATPase	O	O
levels	O	O
.	O	O

Administration	O	O
of	O	O
green	B-Chemical	D010936
tea	I-Chemical	D010936
(	O	O
100	O	O
mg	O	O
/	O	O
kg	O	O
/	O	O
day	O	O
,	O	O
p	O	O
.	O	O

o	O	O
.	O	O

)	O	O
and	O	O
vitamin	B-Chemical	D014810
E	I-Chemical	D014810
(	O	O
100	O	O
mg	O	O
/	O	O
kg	O	O
/	O	O
day	O	O
,	O	O
p	O	O
.	O	O

o	O	O
.	O	O

)	O	O
together	O	O
for	O	O
30	O	O
consecutive	O	O
days	O	O
and	O	O
challenged	O	O
with	O	O
ISO	B-Chemical	D007545
on	O	O
the	O	O
day	O	O
29th	O	O
and	O	O
30th	O	O
,	O	O
showed	O	O
a	O	O
significant	O	O
(	O	O
P<0	O	O
.	O	O

05	O	O
)	O	O
decrease	O	O
in	O	O
heart	O	O
weight	O	O
,	O	O
serum	O	O
marker	O	O
enzymes	O	O
,	O	O
lipid	O	O
peroxidation	O	O
,	O	O
Ca+2	O	O
ATPase	O	O
and	O	O
a	O	O
significant	O	O
increase	O	O
in	O	O
the	O	O
body	O	O
weight	O	O
,	O	O
endogenous	O	O
antioxidants	O	O
,	O	O
Na+	O	O
/	O	O
K+	O	O
ATPase	O	O
and	O	O
Mg+2	O	O
ATPase	O	O
when	O	O
compared	O	O
with	O	O
ISO	B-Chemical	D007545
treated	O	O
group	O	O
and	O	O
green	B-Chemical	D010936
tea	I-Chemical	D010936
or	O	O
vitamin	B-Chemical	D014810
E	I-Chemical	D014810
alone	O	O
treated	O	O
groups	O	O
.	O	O

These	O	O
findings	O	O
indicate	O	O
the	O	O
synergistic	O	O
protective	O	O
effect	O	O
of	O	O
green	B-Chemical	D010936
tea	I-Chemical	D010936
and	O	O
vitamin	B-Chemical	D014810
E	I-Chemical	D014810
during	O	O
ISO	B-Chemical	D007545
induced	O	O
myocardial	B-Disease	D009203
infarction	I-Disease	D009203
in	O	O
rats	O	O
.	O	O

Development	O	O
of	O	O
ocular	B-Disease	D009157
myasthenia	I-Disease	D009157
during	O	O
pegylated	B-Chemical	C417083
interferon	I-Chemical	C417083
and	O	O
ribavirin	B-Chemical	D012254
treatment	O	O
for	O	O
chronic	B-Disease	D019698
hepatitis	I-Disease	D019698
C	I-Disease	D019698
.	O	O

A	O	O
63	O	O
-	O	O
year	O	O
-	O	O
old	O	O
male	O	O
experienced	O	O
sudden	O	O
diplopia	B-Disease	D004172
after	O	O
9	O	O
weeks	O	O
of	O	O
administration	O	O
of	O	O
pegylated	B-Chemical	C417083
interferon	I-Chemical	C417083
(	O	O
IFN	B-Chemical	C417083
)	O	O
alpha	O	O
-	O	O
2b	O	O
and	O	O
ribavirin	B-Chemical	D012254
for	O	O
chronic	B-Disease	D019698
hepatitis	I-Disease	D019698
C	I-Disease	D019698
(	O	O
CHC	B-Disease	D019698
)	O	O
.	O	O

Ophthalmologic	O	O
examinations	O	O
showed	O	O
ptosis	B-Disease	D001763
on	I-Disease	D001763
the	I-Disease	D001763
right	I-Disease	D001763
upper	I-Disease	D001763
lid	I-Disease	D001763
and	O	O
restricted	B-Disease	D015835
right	I-Disease	D015835
eye	I-Disease	D015835
movement	I-Disease	D015835
without	O	O
any	O	O
other	O	O
neurological	O	O
signs	O	O
.	O	O

A	O	O
brain	O	O
imaging	O	O
study	O	O
and	O	O
repetitive	O	O
nerve	O	O
stimulation	O	O
test	O	O
indicated	O	O
no	O	O
abnormality	O	O
.	O	O

The	O	O
acetylcholine	B-Chemical	D000109
receptor	O	O
antibody	O	O
titer	O	O
and	O	O
response	O	O
to	O	O
acetylcholinesterase	O	O
inhibitors	O	O
were	O	O
negative	O	O
,	O	O
and	O	O
the	O	O
results	O	O
of	O	O
thyroid	O	O
function	O	O
tests	O	O
were	O	O
normal	O	O
.	O	O

The	O	O
patient's	O	O
ophthalmological	O	O
symptoms	O	O
improved	O	O
rapidly	O	O
3	O	O
weeks	O	O
after	O	O
discontinuation	O	O
of	O	O
pegylated	B-Chemical	C417083
IFN	I-Chemical	C417083
alpha	I-Chemical	C417083
-	I-Chemical	C417083
2b	I-Chemical	C417083
and	O	O
ribavirin	B-Chemical	D012254
.	O	O

The	O	O
ocular	B-Disease	D009157
myasthenia	I-Disease	D009157
associated	O	O
with	O	O
combination	O	O
therapy	O	O
of	O	O
pegylated	B-Chemical	C417083
IFN	I-Chemical	C417083
alpha	I-Chemical	C417083
-	I-Chemical	C417083
2b	I-Chemical	C417083
and	O	O
ribavirin	B-Chemical	D012254
for	O	O
CHC	B-Disease	D019698
is	O	O
very	O	O
rarely	O	O
reported	O	O
;	O	O
therefore	O	O
,	O	O
we	O	O
present	O	O
this	O	O
case	O	O
with	O	O
a	O	O
review	O	O
of	O	O
the	O	O
various	O	O
eye	O	O
complications	O	O
of	O	O
IFN	B-Chemical	C417083
therapy	O	O
.	O	O

The	O	O
glycine	B-Chemical	D005998
transporter	O	O
-	O	O
1	O	O
inhibitor	O	O
SSR103800	B-Chemical	-1
displays	O	O
a	O	O
selective	O	O
and	O	O
specific	O	O
antipsychotic	O	O
-	O	O
like	O	O
profile	O	O
in	O	O
normal	O	O
and	O	O
transgenic	O	O
mice	O	O
.	O	O

Schizophrenia	B-Disease	D012559
has	O	O
been	O	O
initially	O	O
associated	O	O
with	O	O
dysfunction	O	O
in	O	O
dopamine	B-Chemical	D004298
neurotransmission	O	O
.	O	O

However	O	O
,	O	O
the	O	O
observation	O	O
that	O	O
antagonists	O	O
of	O	O
the	O	O
glutamate	B-Chemical	D018698
N	B-Chemical	D016202
-	I-Chemical	D016202
methyl	I-Chemical	D016202
-	I-Chemical	D016202
D	I-Chemical	D016202
-	I-Chemical	D016202
aspartate	I-Chemical	D016202
(	O	O
NMDA	B-Chemical	D016202
)	O	O
receptor	O	O
produce	O	O
schizophrenic	B-Disease	D012559
-	O	O
like	O	O
symptoms	O	O
in	O	O
humans	O	O
has	O	O
led	O	O
to	O	O
the	O	O
idea	O	O
of	O	O
a	O	O
dysfunctioning	O	O
of	O	O
the	O	O
glutamatergic	O	O
system	O	O
via	O	O
its	O	O
NMDA	B-Chemical	D016202
receptor	O	O
.	O	O

As	O	O
a	O	O
result	O	O
,	O	O
there	O	O
is	O	O
a	O	O
growing	O	O
interest	O	O
in	O	O
the	O	O
development	O	O
of	O	O
pharmacological	O	O
agents	O	O
with	O	O
potential	O	O
antipsychotic	O	O
properties	O	O
that	O	O
enhance	O	O
the	O	O
activity	O	O
of	O	O
the	O	O
glutamatergic	O	O
system	O	O
via	O	O
a	O	O
modulation	O	O
of	O	O
the	O	O
NMDA	B-Chemical	D016202
receptor	O	O
.	O	O

Among	O	O
them	O	O
are	O	O
glycine	B-Chemical	D005998
transporter	O	O
-	O	O
1	O	O
(	O	O
GlyT1	O	O
)	O	O
inhibitors	O	O
such	O	O
as	O	O
SSR103800	B-Chemical	-1
,	O	O
which	O	O
indirectly	O	O
enhance	O	O
NMDA	B-Chemical	D016202
receptor	O	O
function	O	O
by	O	O
increasing	O	O
the	O	O
glycine	B-Chemical	D005998
(	O	O
a	O	O
co	O	O
-	O	O
agonist	O	O
for	O	O
the	O	O
NMDA	B-Chemical	D016202
receptor	O	O
)	O	O
levels	O	O
in	O	O
the	O	O
synapse	O	O
.	O	O

This	O	O
study	O	O
aimed	O	O
at	O	O
investigating	O	O
the	O	O
potential	O	O
antipsychotic	O	O
-	O	O
like	O	O
properties	O	O
of	O	O
SSR103800	B-Chemical	-1
,	O	O
with	O	O
a	O	O
particular	O	O
focus	O	O
on	O	O
models	O	O
of	O	O
hyperactivity	B-Disease	D006948
,	O	O
involving	O	O
either	O	O
drug	O	O
challenge	O	O
(	O	O
ie	O	O
,	O	O
amphetamine	B-Chemical	D000661
and	O	O
MK	B-Chemical	D016291
-	I-Chemical	D016291
801	I-Chemical	D016291
)	O	O
or	O	O
transgenic	O	O
mice	O	O
(	O	O
ie	O	O
,	O	O
NMDA	B-Chemical	D016202
Nr1	O	O
(	O	O
neo	O	O
-	O	O
/	O	O
-	O	O
)	O	O
and	O	O
DAT	O	O
(	O	O
-	O	O
/	O	O
-	O	O
)	O	O
)	O	O
.	O	O

Results	O	O
showed	O	O
that	O	O
SSR103800	B-Chemical	-1
(	O	O
10	O	O
-	O	O
30	O	O
mg	O	O
/	O	O
kg	O	O
p	O	O
.	O	O

o	O	O
.	O	O

)	O	O
blocked	O	O
hyperactivity	B-Disease	D006948
induced	O	O
by	O	O
the	O	O
non	O	O
-	O	O
competitive	O	O
NMDA	B-Chemical	D016202
receptor	O	O
antagonist	O	O
,	O	O
MK	B-Chemical	D016291
-	I-Chemical	D016291
801	I-Chemical	D016291
and	O	O
partially	O	O
reversed	O	O
spontaneous	O	O
hyperactivity	B-Disease	D006948
of	O	O
NMDA	B-Chemical	D016202
Nr1	O	O
(	O	O
neo	O	O
-	O	O
/	O	O
-	O	O
)	O	O
mice	O	O
.	O	O

In	O	O
contrast	O	O
,	O	O
SSR103800	B-Chemical	-1
failed	O	O
to	O	O
affect	O	O
hyperactivity	B-Disease	D006948
induced	O	O
by	O	O
amphetamine	B-Chemical	D000661
or	O	O
naturally	O	O
observed	O	O
in	O	O
dopamine	B-Chemical	D004298
transporter	O	O
(	O	O
DAT	O	O
(	O	O
-	O	O
/	O	O
-	O	O
)	O	O
)	O	O
knockout	O	O
mice	O	O
(	O	O
10	O	O
-	O	O
30	O	O
mg	O	O
/	O	O
kg	O	O
p	O	O
.	O	O

o	O	O
.	O	O

)	O	O
.	O	O

Importantly	O	O
,	O	O
both	O	O
classical	O	O
(	O	O
haloperidol	B-Chemical	D006220
)	O	O
and	O	O
atypical	O	O
(	O	O
olanzapine	B-Chemical	C076029
,	O	O
clozapine	B-Chemical	D003024
and	O	O
aripiprazole	B-Chemical	C094645
)	O	O
antipsychotics	O	O
were	O	O
effective	O	O
in	O	O
all	O	O
these	O	O
models	O	O
of	O	O
hyperactivity	B-Disease	D006948
.	O	O

However	O	O
,	O	O
unlike	O	O
these	O	O
latter	O	O
,	O	O
SSR103800	B-Chemical	-1
did	O	O
not	O	O
produce	O	O
catalepsy	B-Disease	D002375
(	O	O
retention	O	O
on	O	O
the	O	O
bar	O	O
test	O	O
)	O	O
up	O	O
to	O	O
30	O	O
mg	O	O
/	O	O
kg	O	O
p	O	O
.	O	O

o	O	O
.	O	O

Together	O	O
these	O	O
findings	O	O
show	O	O
that	O	O
the	O	O
GlyT1	O	O
inhibitor	O	O
,	O	O
SSR103800	B-Chemical	-1
,	O	O
produces	O	O
antipsychotic	O	O
-	O	O
like	O	O
effects	O	O
,	O	O
which	O	O
differ	O	O
from	O	O
those	O	O
observed	O	O
with	O	O
compounds	O	O
primarily	O	O
targeting	O	O
the	O	O
dopaminergic	O	O
system	O	O
,	O	O
and	O	O
has	O	O
a	O	O
reduced	O	O
side	O	O
-	O	O
effect	O	O
potential	O	O
as	O	O
compared	O	O
with	O	O
these	O	O
latter	O	O
drugs	O	O
.	O	O

Phenylephrine	B-Chemical	D010656
but	O	O
not	O	O
ephedrine	B-Chemical	D004809
reduces	B-Disease	D002534
frontal	I-Disease	D002534
lobe	I-Disease	D002534
oxygenation	I-Disease	D002534
following	O	O
anesthesia	O	O
-	O	O
induced	O	O
hypotension	B-Disease	D007022
.	O	O

BACKGROUND	O	O
:	O	O
Vasopressor	O	O
agents	O	O
are	O	O
used	O	O
to	O	O
correct	O	O
anesthesia	O	O
-	O	O
induced	O	O
hypotension	B-Disease	D007022
.	O	O

We	O	O
describe	O	O
the	O	O
effect	O	O
of	O	O
phenylephrine	B-Chemical	D010656
and	O	O
ephedrine	B-Chemical	D004809
on	O	O
frontal	O	O
lobe	O	O
oxygenation	O	O
(	O	O
S	O	O
(	O	O
c	O	O
)	O	O
O	O	O
(	O	O
2	O	O
)	O	O
)	O	O
following	O	O
anesthesia	O	O
-	O	O
induced	O	O
hypotension	B-Disease	D007022
.	O	O

METHODS	O	O
:	O	O
Following	O	O
induction	O	O
of	O	O
anesthesia	O	O
by	O	O
fentanyl	B-Chemical	D005283
(	O	O
0	O	O
.	O	O

15	O	O
mg	O	O
kg	O	O
(	O	O
-	O	O
1	O	O
)	O	O
)	O	O
and	O	O
propofol	B-Chemical	D015742
(	O	O
2	O	O
.	O	O

0	O	O
mg	O	O
kg	O	O
(	O	O
-	O	O
1	O	O
)	O	O
)	O	O
,	O	O
13	O	O
patients	O	O
received	O	O
phenylephrine	B-Chemical	D010656
(	O	O
0	O	O
.	O	O

1	O	O
mg	O	O
iv	O	O
)	O	O
and	O	O
12	O	O
patients	O	O
received	O	O
ephedrine	B-Chemical	D004809
(	O	O
10	O	O
mg	O	O
iv	O	O
)	O	O
to	O	O
restore	O	O
mean	O	O
arterial	O	O
pressure	O	O
(	O	O
MAP	O	O
)	O	O
.	O	O

Heart	O	O
rate	O	O
(	O	O
HR	O	O
)	O	O
,	O	O
MAP	O	O
,	O	O
stroke	B-Disease	D020521
volume	O	O
(	O	O
SV	O	O
)	O	O
,	O	O
cardiac	O	O
output	O	O
(	O	O
CO	O	O
)	O	O
,	O	O
and	O	O
frontal	O	O
lobe	O	O
oxygenation	O	O
(	O	O
S	O	O
(	O	O
c	O	O
)	O	O
O	O	O
(	O	O
2	O	O
)	O	O
)	O	O
were	O	O
registered	O	O
.	O	O

RESULTS	O	O
:	O	O
Induction	O	O
of	O	O
anesthesia	O	O
was	O	O
followed	O	O
by	O	O
a	O	O
decrease	O	O
in	O	O
MAP	O	O
,	O	O
HR	O	O
,	O	O
SV	O	O
,	O	O
and	O	O
CO	O	O
concomitant	O	O
with	O	O
an	O	O
elevation	O	O
in	O	O
S	O	O
(	O	O
c	O	O
)	O	O
O	O	O
(	O	O
2	O	O
)	O	O
.	O	O

After	O	O
administration	O	O
of	O	O
phenylephrine	B-Chemical	D010656
,	O	O
MAP	O	O
increased	O	O
(	O	O
51	O	O
+	O	O
/	O	O
-	O	O
12	O	O
to	O	O
81	O	O
+	O	O
/	O	O
-	O	O
13	O	O
mmHg	O	O
;	O	O
P	O	O
<	O	O
0	O	O
.	O	O

001	O	O
;	O	O
mean	O	O
+	O	O
/	O	O
-	O	O
SD	O	O
)	O	O
.	O	O

However	O	O
,	O	O
a	O	O
14%	O	O
(	O	O
from	O	O
70	O	O
+	O	O
/	O	O
-	O	O
8%	O	O
to	O	O
60	O	O
+	O	O
/	O	O
-	O	O
7%	O	O
)	O	O
reduction	O	O
in	O	O
S	O	O
(	O	O
c	O	O
)	O	O
O	O	O
(	O	O
2	O	O
)	O	O
(	O	O
P	O	O
<	O	O
0	O	O
.	O	O

05	O	O
)	O	O
followed	O	O
with	O	O
no	O	O
change	O	O
in	O	O
CO	O	O
(	O	O
3	O	O
.	O	O

7	O	O
+	O	O
/	O	O
-	O	O
1	O	O
.	O	O

1	O	O
to	O	O
3	O	O
.	O	O

4	O	O
+	O	O
/	O	O
-	O	O
0	O	O
.	O	O

9	O	O
l	O	O
min	O	O
(	O	O
-	O	O
1	O	O
)	O	O
)	O	O
.	O	O

The	O	O
administration	O	O
of	O	O
ephedrine	B-Chemical	D004809
led	O	O
to	O	O
a	O	O
similar	O	O
increase	O	O
in	O	O
MAP	O	O
(	O	O
53	O	O
+	O	O
/	O	O
-	O	O
9	O	O
to	O	O
79	O	O
+	O	O
/	O	O
-	O	O
8	O	O
mmHg	O	O
;	O	O
P	O	O
<	O	O
0	O	O
.	O	O

001	O	O
)	O	O
,	O	O
restored	O	O
CO	O	O
(	O	O
3	O	O
.	O	O

2	O	O
+	O	O
/	O	O
-	O	O
1	O	O
.	O	O

2	O	O
to	O	O
5	O	O
.	O	O

0	O	O
+	O	O
/	O	O
-	O	O
1	O	O
.	O	O

3	O	O
l	O	O
min	O	O
(	O	O
-	O	O
1	O	O
)	O	O
)	O	O
,	O	O
and	O	O
preserved	O	O
S	O	O
(	O	O
c	O	O
)	O	O
O	O	O
(	O	O
2	O	O
)	O	O
.	O	O

CONCLUSIONS	O	O
:	O	O
The	O	O
utilization	O	O
of	O	O
phenylephrine	B-Chemical	D010656
to	O	O
correct	O	O
hypotension	B-Disease	D007022
induced	O	O
by	O	O
anesthesia	O	O
has	O	O
a	O	O
negative	O	O
impact	O	O
on	O	O
S	O	O
(	O	O
c	O	O
)	O	O
O	O	O
(	O	O
2	O	O
)	O	O
while	O	O
ephedrine	B-Chemical	D004809
maintains	O	O
frontal	O	O
lobe	O	O
oxygenation	O	O
potentially	O	O
related	O	O
to	O	O
an	O	O
increase	O	O
in	O	O
CO	O	O
.	O	O

A	O	O
novel	O	O
,	O	O
multiple	O	O
symptom	O	O
model	O	O
of	O	O
obsessive	B-Disease	D009771
-	I-Disease	D009771
compulsive	I-Disease	D009771
-	I-Disease	D009771
like	I-Disease	D009771
behaviors	I-Disease	D009771
in	O	O
animals	O	O
.	O	O

BACKGROUND	O	O
:	O	O
Current	O	O
animal	O	O
models	O	O
of	O	O
obsessive	B-Disease	D009771
-	I-Disease	D009771
compulsive	I-Disease	D009771
disorder	I-Disease	D009771
(	O	O
OCD	B-Disease	D009771
)	O	O
typically	O	O
involve	O	O
acute	O	O
,	O	O
drug	O	O
-	O	O
induced	O	O
symptom	O	O
provocation	O	O
or	O	O
a	O	O
genetic	O	O
association	O	O
with	O	O
stereotypies	O	O
or	O	O
anxiety	B-Disease	D001008
.	O	O

None	O	O
of	O	O
these	O	O
current	O	O
models	O	O
demonstrate	O	O
multiple	O	O
OCD	B-Disease	D009771
-	O	O
like	O	O
behaviors	O	O
.	O	O

METHODS	O	O
:	O	O
Neonatal	O	O
rats	O	O
were	O	O
treated	O	O
with	O	O
the	O	O
tricyclic	O	O
antidepressant	B-Chemical	D000928
clomipramine	B-Chemical	D002997
or	O	O
vehicle	O	O
between	O	O
days	O	O
9	O	O
and	O	O
16	O	O
twice	O	O
daily	O	O
and	O	O
behaviorally	O	O
tested	O	O
in	O	O
adulthood	O	O
.	O	O

RESULTS	O	O
:	O	O
Clomipramine	B-Chemical	D002997
exposure	O	O
in	O	O
immature	O	O
rats	O	O
produced	O	O
significant	O	O
behavioral	O	O
and	O	O
biochemical	O	O
changes	O	O
that	O	O
include	O	O
enhanced	O	O
anxiety	B-Disease	D001008
(	O	O
elevated	O	O
plus	O	O
maze	O	O
and	O	O
marble	O	O
burying	O	O
)	O	O
,	O	O
behavioral	B-Disease	-1
inflexibility	I-Disease	-1
(	O	O
perseveration	O	O
in	O	O
the	O	O
spontaneous	O	O
alternation	O	O
task	O	O
and	O	O
impaired	O	O
reversal	O	O
learning	O	O
)	O	O
,	O	O
working	O	O
memory	B-Disease	D008569
impairment	I-Disease	D008569
(	O	O
e	O	O
.	O	O

g	O	O
.	O	O

,	O	O
win	O	O
-	O	O
shift	O	O
paradigm	O	O
)	O	O
,	O	O
hoarding	B-Disease	D060845
,	O	O
and	O	O
corticostriatal	B-Disease	-1
dysfunction	I-Disease	-1
.	O	O

Dopamine	B-Chemical	D004298
D2	O	O
receptors	O	O
were	O	O
elevated	O	O
in	O	O
the	O	O
striatum	O	O
,	O	O
whereas	O	O
serotonin	B-Chemical	D012701
2C	O	O
,	O	O
but	O	O
not	O	O
serotonin	B-Chemical	D012701
1A	O	O
,	O	O
receptors	O	O
were	O	O
elevated	O	O
in	O	O
the	O	O
orbital	O	O
frontal	O	O
cortex	O	O
.	O	O

CONCLUSIONS	O	O
:	O	O
This	O	O
is	O	O
the	O	O
first	O	O
demonstration	O	O
of	O	O
multiple	O	O
symptoms	O	O
consistent	O	O
with	O	O
an	O	O
OCD	B-Disease	D009771
-	O	O
like	O	O
profile	O	O
in	O	O
animals	O	O
.	O	O

Moreover	O	O
,	O	O
these	O	O
behaviors	O	O
are	O	O
accompanied	O	O
by	O	O
biochemical	O	O
changes	O	O
in	O	O
brain	O	O
regions	O	O
previously	O	O
identified	O	O
as	O	O
relevant	O	O
to	O	O
OCD	B-Disease	D009771
.	O	O

This	O	O
novel	O	O
model	O	O
of	O	O
OCD	B-Disease	D009771
demonstrates	O	O
that	O	O
drug	O	O
exposure	O	O
during	O	O
a	O	O
sensitive	O	O
period	O	O
can	O	O
program	O	O
disease	O	O
-	O	O
like	O	O
systems	O	O
permanently	O	O
,	O	O
which	O	O
could	O	O
have	O	O
implications	O	O
for	O	O
current	O	O
and	O	O
future	O	O
therapeutic	O	O
strategies	O	O
for	O	O
this	O	O
and	O	O
other	O	O
psychiatric	B-Disease	D001523
disorders	I-Disease	D001523
.	O	O

Late	O	O
recovery	O	O
of	O	O
renal	O	O
function	O	O
in	O	O
a	O	O
woman	O	O
with	O	O
the	O	O
hemolytic	B-Disease	D006463
uremic	I-Disease	D006463
syndrome	I-Disease	D006463
.	O	O

A	O	O
case	O	O
is	O	O
reported	O	O
of	O	O
the	O	O
hemolytic	B-Disease	D006463
uremic	I-Disease	D006463
syndrome	I-Disease	D006463
(	O	O
HUS	B-Disease	D006463
)	O	O
in	O	O
a	O	O
woman	O	O
taking	O	O
oral	B-Chemical	D003276
contraceptives	I-Chemical	D003276
.	O	O

She	O	O
was	O	O
treated	O	O
with	O	O
heparin	B-Chemical	D006493
,	O	O
dipyridamole	B-Chemical	D004176
and	O	O
hemodialysis	O	O
;	O	O
and	O	O
after	O	O
more	O	O
than	O	O
three	O	O
months	O	O
,	O	O
her	O	O
urinary	O	O
output	O	O
rose	O	O
above	O	O
500	O	O
ml	O	O
;	O	O
and	O	O
six	O	O
months	O	O
after	O	O
the	O	O
onset	O	O
of	O	O
anuria	B-Disease	D001002
,	O	O
dialysis	O	O
treatment	O	O
was	O	O
stopped	O	O
.	O	O

This	O	O
case	O	O
emphasizes	O	O
the	O	O
possibility	O	O
that	O	O
HUS	B-Disease	D006463
in	O	O
adults	O	O
is	O	O
not	O	O
invariably	O	O
irreversible	O	O
and	O	O
that	O	O
,	O	O
despite	O	O
prolonged	O	O
oliguria	B-Disease	D009846
,	O	O
recovery	O	O
of	O	O
renal	O	O
function	O	O
can	O	O
be	O	O
obtained	O	O
.	O	O

Therefore	O	O
,	O	O
in	O	O
adult	O	O
patients	O	O
affected	O	O
by	O	O
HUS	B-Disease	D006463
,	O	O
dialysis	O	O
should	O	O
not	O	O
be	O	O
discontinued	O	O
prematurely	O	O
;	O	O
moreover	O	O
,	O	O
bilateral	O	O
nephrectomy	O	O
,	O	O
for	O	O
treatment	O	O
of	O	O
severe	O	O
hypertension	B-Disease	D006973
and	O	O
microangiopathic	B-Disease	D000743
hemolytic	I-Disease	D000743
anemia	I-Disease	D000743
,	O	O
should	O	O
be	O	O
performed	O	O
with	O	O
caution	O	O
.	O	O

Effects	O	O
of	O	O
acetylsalicylic	B-Chemical	D001241
acid	I-Chemical	D001241
,	O	O
dipyridamole	B-Chemical	D004176
,	O	O
and	O	O
hydrocortisone	B-Chemical	D006854
on	O	O
epinephrine	B-Chemical	D004837
-	O	O
induced	O	O
myocardial	B-Disease	D009202
injury	I-Disease	D009202
in	O	O
dogs	O	O
.	O	O

A	O	O
reproducible	O	O
model	O	O
for	O	O
producing	O	O
diffuse	O	O
myocardial	B-Disease	D009202
injury	I-Disease	D009202
(	O	O
epinephrine	B-Chemical	D004837
infusion	O	O
)	O	O
has	O	O
been	O	O
developed	O	O
to	O	O
study	O	O
the	O	O
cardioprotective	O	O
effects	O	O
of	O	O
agents	O	O
or	O	O
maneuvers	O	O
which	O	O
might	O	O
alter	O	O
the	O	O
evolution	O	O
of	O	O
acute	O	O
myocardial	B-Disease	D009203
infarction	I-Disease	D009203
.	O	O

Infusions	O	O
of	O	O
epinephrine	B-Chemical	D004837
(	O	O
4	O	O
mug	O	O
per	O	O
kilogram	O	O
per	O	O
minute	O	O
for	O	O
6	O	O
hours	O	O
)	O	O
increased	O	O
radiocalcium	B-Chemical	D002132
uptakes	O	O
into	O	O
intact	O	O
myocardium	O	O
and	O	O
each	O	O
of	O	O
its	O	O
subcellular	O	O
components	O	O
with	O	O
the	O	O
mitochondrial	O	O
fraction	O	O
showing	O	O
the	O	O
most	O	O
consistent	O	O
changes	O	O
when	O	O
compared	O	O
to	O	O
saline	O	O
-	O	O
infused	O	O
control	O	O
animals	O	O
(	O	O
4	O	O
,	O	O
957	O	O
vs	O	O
.	O	O

827	O	O
counts	O	O
per	O	O
minute	O	O
per	O	O
gram	O	O
of	O	O
dried	O	O
tissue	O	O
or	O	O
fraction	O	O
)	O	O
.	O	O

Myocardial	O	O
concentrations	O	O
of	O	O
calcium	B-Chemical	D002118
also	O	O
increased	O	O
significantly	O	O
(	O	O
12	O	O
.	O	O

0	O	O
vs	O	O
.	O	O

5	O	O
.	O	O

0	O	O
mg	O	O
.	O	O

per	O	O
100	O	O
Gm	O	O
.	O	O

of	O	O
fat	O	O
-	O	O
free	O	O
dry	O	O
weight	O	O
)	O	O
.	O	O

Infusions	O	O
of	O	O
calcium	B-Chemical	D002118
chloride	O	O
sufficient	O	O
to	O	O
raise	O	O
serum	O	O
calcium	B-Chemical	D002118
concentrations	O	O
2	O	O
mEq	O	O
.	O	O

per	O	O
liter	O	O
failed	O	O
to	O	O
increase	O	O
calcium	B-Chemical	D002118
influx	O	O
into	O	O
the	O	O
myocardial	O	O
cell	O	O
.	O	O

Mitochondrial	O	O
radiocalcium	B-Chemical	D002132
uptakes	O	O
were	O	O
significantly	O	O
decreased	O	O
in	O	O
animals	O	O
pretreated	O	O
with	O	O
acetylsalicylic	B-Chemical	D001241
acid	I-Chemical	D001241
or	O	O
dipyridamole	B-Chemical	D004176
or	O	O
when	O	O
hydrocortisone	B-Chemical	D006854
was	O	O
added	O	O
to	O	O
the	O	O
epinephrine	B-Chemical	D004837
infusion	O	O
(	O	O
2	O	O
,	O	O
682	O	O
,	O	O
2	O	O
,	O	O
803	O	O
,	O	O
and	O	O
3	O	O
,	O	O
424	O	O
counts	O	O
per	O	O
minute	O	O
per	O	O
gram	O	O
of	O	O
dried	O	O
fraction	O	O
,	O	O
respectively	O	O
)	O	O
.	O	O

Myocardial	O	O
calcium	B-Chemical	D002118
concentrations	O	O
also	O	O
were	O	O
decreased	O	O
(	O	O
11	O	O
.	O	O

2	O	O
,	O	O
8	O	O
.	O	O

3	O	O
,	O	O
and	O	O
8	O	O
.	O	O

9	O	O
mg	O	O
.	O	O

per	O	O
100	O	O
Gm	O	O
.	O	O

of	O	O
fat	O	O
-	O	O
free	O	O
dry	O	O
weight	O	O
,	O	O
respectively	O	O
)	O	O
in	O	O
the	O	O
three	O	O
treatment	O	O
groups	O	O
,	O	O
being	O	O
significantly	O	O
decreased	O	O
only	O	O
in	O	O
the	O	O
last	O	O
two	O	O
.	O	O

Evidence	O	O
of	O	O
microscopic	O	O
damage	O	O
was	O	O
graded	O	O
as	O	O
less	O	O
severe	O	O
in	O	O
the	O	O
three	O	O
treatment	O	O
groups	O	O
.	O	O

Acetylsalicylic	B-Chemical	D001241
acid	I-Chemical	D001241
,	O	O
dipyridamole	B-Chemical	D004176
,	O	O
and	O	O
hydrocortisone	B-Chemical	D006854
all	O	O
appear	O	O
to	O	O
have	O	O
cardioprotective	O	O
effects	O	O
when	O	O
tested	O	O
in	O	O
this	O	O
model	O	O
.	O	O

Changes	O	O
in	O	O
depressive	B-Disease	D003866
status	O	O
associated	O	O
with	O	O
topical	O	O
beta	O	O
-	O	O
blockers	O	O
.	O	O

Depression	B-Disease	D003866
and	O	O
sexual	B-Disease	D012735
dysfunction	I-Disease	D012735
have	O	O
been	O	O
related	O	O
to	O	O
side	O	O
effects	O	O
of	O	O
topical	O	O
beta	O	O
-	O	O
blockers	O	O
.	O	O

We	O	O
performed	O	O
a	O	O
preliminary	O	O
study	O	O
in	O	O
order	O	O
to	O	O
determine	O	O
any	O	O
difference	O	O
between	O	O
a	O	O
non	O	O
selective	O	O
beta	O	O
-	O	O
blocker	O	O
(	O	O
timolol	B-Chemical	D013999
)	O	O
and	O	O
a	O	O
selective	O	O
beta	O	O
-	O	O
blocker	O	O
(	O	O
betaxolol	B-Chemical	D015784
)	O	O
regarding	O	O
CNS	O	O
side	O	O
effects	O	O
.	O	O

Eight	O	O
glaucomatous	B-Disease	D005901
patients	O	O
chronically	O	O
treated	O	O
with	O	O
timolol	B-Chemical	D013999
0	O	O
.	O	O

5%	O	O
/	O	O
12h	O	O
,	O	O
suffering	O	O
from	O	O
depression	B-Disease	D003866
diagnosed	O	O
through	O	O
DMS	O	O
-	O	O
III	O	O
-	O	O
R	O	O
criteria	O	O
,	O	O
were	O	O
included	O	O
in	O	O
the	O	O
study	O	O
.	O	O

During	O	O
the	O	O
six	O	O
-	O	O
month	O	O
follow	O	O
up	O	O
,	O	O
depression	B-Disease	D003866
was	O	O
quantified	O	O
through	O	O
the	O	O
Beck	O	O
and	O	O
Zung	O	O
-	O	O
Conde	O	O
scales	O	O
every	O	O
two	O	O
months	O	O
.	O	O

In	O	O
a	O	O
double	O	O
blind	O	O
cross	O	O
-	O	O
over	O	O
study	O	O
with	O	O
control	O	O
group	O	O
,	O	O
the	O	O
patients	O	O
under	O	O
timolol	B-Chemical	D013999
treatment	O	O
presented	O	O
higher	O	O
depression	B-Disease	D003866
values	O	O
measured	O	O
through	O	O
the	O	O
Beck	O	O
and	O	O
the	O	O
Zung	O	O
-	O	O
Conde	O	O
scales	O	O
(	O	O
p	O	O
<	O	O
0	O	O
.	O	O

001	O	O
vs	O	O
control	O	O
)	O	O
.	O	O

These	O	O
results	O	O
suggest	O	O
that	O	O
betaxolol	B-Chemical	D015784
could	O	O
be	O	O
less	O	O
of	O	O
a	O	O
depression	B-Disease	D003866
-	O	O
inducer	O	O
than	O	O
timolol	B-Chemical	D013999
in	O	O
predisposed	O	O
patients	O	O
.	O	O

Long	O	O
-	O	O
term	O	O
follow	O	O
-	O	O
up	O	O
of	O	O
ifosfamide	B-Chemical	D007069
renal	B-Disease	D007674
toxicity	I-Disease	D007674
in	O	O
children	O	O
treated	O	O
for	O	O
malignant	B-Disease	C535700
mesenchymal	I-Disease	C535700
tumors	I-Disease	C535700
:	O	O
an	O	O
International	O	O
Society	O	O
of	O	O
Pediatric	O	O
Oncology	O	O
report	O	O
.	O	O

The	O	O
renal	O	O
function	O	O
of	O	O
74	O	O
children	O	O
with	O	O
malignant	B-Disease	C535700
mesenchymal	I-Disease	C535700
tumors	I-Disease	C535700
in	O	O
complete	O	O
remission	O	O
and	O	O
who	O	O
have	O	O
received	O	O
the	O	O
same	O	O
ifosfamide	B-Chemical	D007069
chemotherapy	O	O
protocol	O	O
(	O	O
International	O	O
Society	O	O
of	O	O
Pediatric	O	O
Oncology	O	O
Malignant	B-Disease	C535700
Mesenchymal	I-Disease	C535700
Tumor	I-Disease	C535700
Study	O	O
84	O	O
[	O	O
SIOP	O	O
MMT	O	O
84	O	O
]	O	O
)	O	O
were	O	O
studied	O	O
1	O	O
year	O	O
after	O	O
the	O	O
completion	O	O
of	O	O
treatment	O	O
.	O	O

Total	O	O
cumulative	O	O
doses	O	O
were	O	O
36	O	O
or	O	O
60	O	O
g	O	O
/	O	O
m2	O	O
of	O	O
ifosfamide	B-Chemical	D007069
(	O	O
six	O	O
or	O	O
10	O	O
cycles	O	O
of	O	O
ifosfamide	B-Chemical	D007069
,	O	O
vincristine	O	O
,	O	O
and	O	O
dactinomycin	O	O
[	O	O
IVA	B-Chemical	C064227
]	O	O
)	O	O
.	O	O

None	O	O
of	O	O
them	O	O
had	O	O
received	O	O
cisplatin	B-Chemical	D002945
chemotherapy	O	O
.	O	O

Ages	O	O
ranged	O	O
from	O	O
4	O	O
months	O	O
to	O	O
17	O	O
years	O	O
;	O	O
58	O	O
patients	O	O
were	O	O
males	O	O
and	O	O
42	O	O
females	O	O
.	O	O

The	O	O
most	O	O
common	O	O
primary	O	O
tumor	B-Disease	D009369
site	O	O
was	O	O
the	O	O
head	O	O
and	O	O
neck	O	O
.	O	O

Renal	O	O
function	O	O
was	O	O
investigated	O	O
by	O	O
measuring	O	O
plasma	O	O
and	O	O
urinary	O	O
electrolytes	O	O
,	O	O
glucosuria	B-Disease	D006030
,	O	O
proteinuria	B-Disease	D011507
,	O	O
aminoaciduria	B-Disease	D000608
,	O	O
urinary	O	O
pH	O	O
,	O	O
osmolarity	O	O
,	O	O
creatinine	B-Chemical	D003404
clearance	O	O
,	O	O
phosphate	B-Chemical	D010710
tubular	O	O
reabsorption	O	O
,	O	O
beta	O	O
2	O	O
microglobulinuria	O	O
,	O	O
and	O	O
lysozymuria	O	O
.	O	O

Fifty	O	O
-	O	O
eight	O	O
patients	O	O
(	O	O
78%	O	O
)	O	O
had	O	O
normal	O	O
renal	O	O
tests	O	O
,	O	O
whereas	O	O
16	O	O
patients	O	O
(	O	O
22%	O	O
)	O	O
had	O	O
renal	B-Disease	D007674
abnormalities	I-Disease	D007674
.	O	O

Two	O	O
subsets	O	O
of	O	O
patients	O	O
were	O	O
identified	O	O
from	O	O
this	O	O
latter	O	O
group	O	O
:	O	O
the	O	O
first	O	O
included	O	O
four	O	O
patients	O	O
(	O	O
5%	O	O
of	O	O
the	O	O
total	O	O
population	O	O
)	O	O
who	O	O
developed	O	O
major	O	O
toxicity	B-Disease	D064420
resulting	O	O
in	O	O
Fanconi's	B-Disease	D005198
syndrome	I-Disease	D005198
(	O	O
TDFS	B-Disease	D005198
)	O	O
;	O	O
and	O	O
the	O	O
second	O	O
group	O	O
included	O	O
five	O	O
patients	O	O
with	O	O
elevated	O	O
beta	O	O
2	O	O
microglobulinuria	O	O
and	O	O
low	O	O
phosphate	B-Chemical	D010710
reabsorption	O	O
.	O	O

The	O	O
remaining	O	O
seven	O	O
patients	O	O
had	O	O
isolated	O	O
beta	O	O
2	O	O
microglobulinuria	O	O
.	O	O

Severe	O	O
toxicity	B-Disease	D064420
was	O	O
correlated	O	O
with	O	O
the	O	O
higher	O	O
cumulative	O	O
dose	O	O
of	O	O
60	O	O
g	O	O
/	O	O
m2	O	O
of	O	O
ifosfamide	B-Chemical	D007069
,	O	O
a	O	O
younger	O	O
age	O	O
(	O	O
less	O	O
than	O	O
2	O	O
1	O	O
/	O	O
2	O	O
years	O	O
old	O	O
)	O	O
,	O	O
and	O	O
a	O	O
predominance	O	O
of	O	O
vesicoprostatic	O	O
tumor	B-Disease	D009369
involvement	O	O
.	O	O

This	O	O
low	O	O
percentage	O	O
(	O	O
5%	O	O
)	O	O
of	O	O
TDFS	B-Disease	D005198
must	O	O
be	O	O
evaluated	O	O
with	O	O
respect	O	O
to	O	O
the	O	O
efficacy	O	O
of	O	O
ifosfamide	B-Chemical	D007069
in	O	O
the	O	O
treatment	O	O
of	O	O
mesenchymal	B-Disease	C535700
tumors	I-Disease	C535700
in	O	O
children	O	O
.	O	O

Evidence	O	O
for	O	O
an	O	O
involvement	O	O
of	O	O
D1	O	O
and	O	O
D2	O	O
dopamine	B-Chemical	D004298
receptors	O	O
in	O	O
mediating	O	O
nicotine	B-Chemical	D009538
-	O	O
induced	O	O
hyperactivity	B-Disease	D006948
in	O	O
rats	O	O
.	O	O

Previous	O	O
studies	O	O
have	O	O
suggested	O	O
that	O	O
repeated	O	O
exposure	O	O
of	O	O
rats	O	O
to	O	O
the	O	O
drug	O	O
or	O	O
to	O	O
the	O	O
experimental	O	O
environment	O	O
is	O	O
necessary	O	O
to	O	O
observe	O	O
nicotine	B-Chemical	D009538
-	O	O
induced	O	O
locomotor	O	O
stimulation	O	O
.	O	O

In	O	O
the	O	O
present	O	O
study	O	O
the	O	O
role	O	O
of	O	O
habituation	O	O
to	O	O
the	O	O
experimental	O	O
environment	O	O
on	O	O
the	O	O
stimulant	O	O
effect	O	O
of	O	O
nicotine	B-Chemical	D009538
in	O	O
rats	O	O
was	O	O
examined	O	O
.	O	O

In	O	O
addition	O	O
,	O	O
the	O	O
role	O	O
of	O	O
dopamine	B-Chemical	D004298
receptors	O	O
in	O	O
mediating	O	O
nicotine	B-Chemical	D009538
-	O	O
induced	O	O
locomotor	O	O
stimulation	O	O
was	O	O
investigated	O	O
by	O	O
examining	O	O
the	O	O
effects	O	O
of	O	O
selective	O	O
D1	O	O
and	O	O
D2	O	O
dopamine	B-Chemical	D004298
receptor	O	O
antagonists	O	O
on	O	O
activity	O	O
induced	O	O
by	O	O
nicotine	B-Chemical	D009538
.	O	O

Locomotor	O	O
activity	O	O
was	O	O
assessed	O	O
in	O	O
male	O	O
Sprague	O	O
-	O	O
Dawley	O	O
rats	O	O
tested	O	O
in	O	O
photocell	O	O
cages	O	O
.	O	O

Nicotine	B-Chemical	D009538
(	O	O
1	O	O
.	O	O

0	O	O
mg	O	O
/	O	O
kg	O	O
)	O	O
caused	O	O
a	O	O
significant	O	O
increase	B-Disease	D006948
in	I-Disease	D006948
locomotor	I-Disease	D006948
activity	I-Disease	D006948
in	O	O
rats	O	O
that	O	O
were	O	O
habituated	O	O
to	O	O
the	O	O
test	O	O
environment	O	O
,	O	O
but	O	O
had	O	O
only	O	O
a	O	O
weak	O	O
and	O	O
delayed	O	O
stimulant	O	O
action	O	O
in	O	O
rats	O	O
that	O	O
were	O	O
unfamiliar	O	O
with	O	O
the	O	O
test	O	O
environment	O	O
.	O	O

The	O	O
stimulant	O	O
action	O	O
of	O	O
nicotine	B-Chemical	D009538
was	O	O
blocked	O	O
by	O	O
the	O	O
central	O	O
nicotinic	O	O
antagonist	O	O
mecamylamine	B-Chemical	D008464
but	O	O
not	O	O
by	O	O
the	O	O
peripheral	O	O
nicotinic	O	O
blocker	O	O
hexamethonium	B-Chemical	D018738
,	O	O
indicating	O	O
that	O	O
the	O	O
response	O	O
is	O	O
probably	O	O
mediated	O	O
by	O	O
central	O	O
nicotinic	O	O
receptors	O	O
.	O	O

Nicotine	B-Chemical	D009538
-	O	O
induced	O	O
hyperactivity	B-Disease	D006948
was	O	O
blocked	O	O
by	O	O
the	O	O
selective	O	O
D1	O	O
antagonist	O	O
SCH	B-Chemical	C534628
23390	I-Chemical	C534628
,	O	O
the	O	O
selective	O	O
D2	O	O
antagonist	O	O
raclopride	B-Chemical	D020891
and	O	O
the	O	O
D1	O	O
/	O	O
D2	O	O
antagonist	O	O
fluphenazine	B-Chemical	D005476
.	O	O

Pretreatment	O	O
with	O	O
the	O	O
D2	O	O
agonist	O	O
PHNO	B-Chemical	-1
enhanced	O	O
nicotine	B-Chemical	D009538
-	O	O
induced	O	O
hyperactivity	B-Disease	D006948
,	O	O
whereas	O	O
the	O	O
D1	O	O
agonist	O	O
SKF	B-Chemical	D015647
38393	I-Chemical	D015647
had	O	O
no	O	O
effect	O	O
.	O	O

The	O	O
results	O	O
indicate	O	O
that	O	O
acute	O	O
nicotine	B-Chemical	D009538
injection	O	O
induces	O	O
a	O	O
pronounced	O	O
hyperactivity	B-Disease	D006948
in	O	O
rats	O	O
habituated	O	O
to	O	O
the	O	O
test	O	O
environment	O	O
.	O	O

The	O	O
effect	O	O
appears	O	O
to	O	O
be	O	O
mediated	O	O
by	O	O
central	O	O
nicotine	B-Chemical	D009538
receptors	O	O
,	O	O
possibly	O	O
located	O	O
on	O	O
dopaminergic	O	O
neurons	O	O
,	O	O
and	O	O
also	O	O
requires	O	O
the	O	O
activation	O	O
of	O	O
both	O	O
D1	O	O
and	O	O
D2	O	O
dopamine	B-Chemical	D004298
receptors	O	O
.	O	O

Neuropsychiatric	O	O
side	O	O
effects	O	O
after	O	O
the	O	O
use	O	O
of	O	O
mefloquine	B-Chemical	D015767
.	O	O

This	O	O
study	O	O
describes	O	O
neuropsychiatric	O	O
side	O	O
effects	O	O
in	O	O
patients	O	O
after	O	O
treatment	O	O
with	O	O
mefloquine	B-Chemical	D015767
.	O	O

Reactions	O	O
consisted	O	O
mainly	O	O
of	O	O
seizures	B-Disease	D012640
,	O	O
acute	O	O
psychoses	B-Disease	D011605
,	O	O
anxiety	B-Disease	D001008
neurosis	I-Disease	D001008
,	O	O
and	O	O
major	O	O
disturbances	B-Disease	D012893
of	I-Disease	D012893
sleep	I-Disease	D012893
-	I-Disease	D012893
wake	I-Disease	D012893
rhythm	I-Disease	D012893
.	O	O

Side	O	O
effects	O	O
occurred	O	O
after	O	O
both	O	O
therapeutic	O	O
and	O	O
prophylactic	O	O
intake	O	O
and	O	O
were	O	O
graded	O	O
from	O	O
moderate	O	O
to	O	O
severe	O	O
.	O	O

In	O	O
a	O	O
risk	O	O
analysis	O	O
of	O	O
neuropsychiatric	O	O
side	O	O
effects	O	O
in	O	O
Germany	O	O
,	O	O
it	O	O
is	O	O
estimated	O	O
that	O	O
one	O	O
of	O	O
8	O	O
,	O	O
000	O	O
mefloquine	B-Chemical	D015767
users	O	O
suffers	O	O
from	O	O
such	O	O
reactions	O	O
.	O	O

The	O	O
incidence	O	O
calculation	O	O
revealed	O	O
that	O	O
one	O	O
of	O	O
215	O	O
therapeutic	O	O
users	O	O
had	O	O
reactions	O	O
,	O	O
compared	O	O
with	O	O
one	O	O
of	O	O
13	O	O
,	O	O
000	O	O
in	O	O
the	O	O
prophylaxis	O	O
group	O	O
,	O	O
making	O	O
the	O	O
risk	O	O
of	O	O
neuropsychiatric	O	O
reactions	O	O
after	O	O
mefloquine	B-Chemical	D015767
treatment	O	O
60	O	O
times	O	O
higher	O	O
than	O	O
after	O	O
prophylaxis	O	O
.	O	O

Therefore	O	O
,	O	O
certain	O	O
limitations	O	O
for	O	O
malaria	B-Disease	D008288
prophylaxis	O	O
and	O	O
treatment	O	O
with	O	O
mefloquine	B-Chemical	D015767
are	O	O
recommended	O	O
.	O	O

Reduction	O	O
in	O	O
injection	O	O
pain	B-Disease	D010146
using	O	O
buffered	O	O
lidocaine	B-Chemical	D008012
as	O	O
a	O	O
local	O	O
anesthetic	O	O
before	O	O
cardiac	O	O
catheterization	O	O
.	O	O

Previous	O	O
reports	O	O
have	O	O
suggested	O	O
that	O	O
pain	B-Disease	D010146
associated	O	O
with	O	O
the	O	O
injection	O	O
of	O	O
lidocaine	B-Chemical	D008012
is	O	O
related	O	O
to	O	O
the	O	O
acidic	O	O
pH	O	O
of	O	O
the	O	O
solution	O	O
.	O	O

To	O	O
determine	O	O
if	O	O
the	O	O
addition	O	O
of	O	O
a	O	O
buffering	O	O
solution	O	O
to	O	O
adjust	O	O
the	O	O
pH	O	O
of	O	O
lidocaine	B-Chemical	D008012
into	O	O
the	O	O
physiologic	O	O
range	O	O
would	O	O
reduce	O	O
pain	B-Disease	D010146
during	O	O
injection	O	O
,	O	O
we	O	O
performed	O	O
a	O	O
blinded	O	O
randomized	O	O
study	O	O
in	O	O
patients	O	O
undergoing	O	O
cardiac	O	O
catheterization	O	O
.	O	O

Twenty	O	O
patients	O	O
were	O	O
asked	O	O
to	O	O
quantify	O	O
the	O	O
severity	O	O
of	O	O
pain	B-Disease	D010146
after	O	O
receiving	O	O
standard	O	O
lidocaine	B-Chemical	D008012
in	O	O
one	O	O
femoral	O	O
area	O	O
and	O	O
buffered	O	O
lidocaine	B-Chemical	D008012
in	O	O
the	O	O
opposite	O	O
femoral	O	O
area	O	O
.	O	O

The	O	O
mean	O	O
pain	B-Disease	D010146
score	O	O
for	O	O
buffered	O	O
lidocaine	B-Chemical	D008012
was	O	O
significantly	O	O
lower	O	O
than	O	O
the	O	O
mean	O	O
score	O	O
for	O	O
standard	O	O
lidocaine	B-Chemical	D008012
(	O	O
2	O	O
.	O	O

7	O	O
+	O	O
/	O	O
-	O	O
1	O	O
.	O	O

9	O	O
vs	O	O
.	O	O

3	O	O
.	O	O

8	O	O
+	O	O
/	O	O
-	O	O
2	O	O
.	O	O

2	O	O
,	O	O
P	O	O
=	O	O
0	O	O
.	O	O

03	O	O
)	O	O
.	O	O

The	O	O
pH	O	O
adjustment	O	O
of	O	O
standard	O	O
lidocaine	B-Chemical	D008012
can	O	O
be	O	O
accomplished	O	O
easily	O	O
in	O	O
the	O	O
catheterization	O	O
laboratory	O	O
before	O	O
injection	O	O
and	O	O
results	O	O
in	O	O
a	O	O
reduction	O	O
of	O	O
the	O	O
pain	B-Disease	D010146
occurring	O	O
during	O	O
the	O	O
infiltration	O	O
of	O	O
tissues	O	O
.	O	O

Randomized	O	O
,	O	O
double	O	O
-	O	O
blind	O	O
trial	O	O
of	O	O
mazindol	B-Chemical	D008454
in	O	O
Duchenne	B-Disease	D020388
dystrophy	I-Disease	D020388
.	O	O

There	O	O
is	O	O
evidence	O	O
that	O	O
growth	O	O
hormone	O	O
may	O	O
be	O	O
related	O	O
to	O	O
the	O	O
progression	O	O
of	O	O
weakness	B-Disease	D018908
in	O	O
Duchenne	B-Disease	D020388
dystrophy	I-Disease	D020388
.	O	O

We	O	O
conducted	O	O
a	O	O
12	O	O
-	O	O
month	O	O
controlled	O	O
trial	O	O
of	O	O
mazindol	B-Chemical	D008454
,	O	O
a	O	O
putative	O	O
growth	O	O
hormone	O	O
secretion	O	O
inhibitor	O	O
,	O	O
in	O	O
83	O	O
boys	O	O
with	O	O
Duchenne	B-Disease	D020388
dystrophy	I-Disease	D020388
.	O	O

Muscle	O	O
strength	O	O
,	O	O
contractures	O	O
,	O	O
functional	O	O
ability	O	O
and	O	O
pulmonary	O	O
function	O	O
were	O	O
tested	O	O
at	O	O
baseline	O	O
,	O	O
and	O	O
6	O	O
and	O	O
12	O	O
months	O	O
after	O	O
treatment	O	O
with	O	O
mazindol	B-Chemical	D008454
(	O	O
3	O	O
mg	O	O
/	O	O
d	O	O
)	O	O
or	O	O
placebo	O	O
.	O	O

The	O	O
study	O	O
was	O	O
designed	O	O
to	O	O
have	O	O
a	O	O
power	O	O
of	O	O
greater	O	O
than	O	O
0	O	O
.	O	O

90	O	O
to	O	O
detect	O	O
a	O	O
slowing	O	O
to	O	O
25%	O	O
of	O	O
the	O	O
expected	O	O
rate	O	O
of	O	O
progression	O	O
of	O	O
weakness	B-Disease	D018908
at	O	O
P	O	O
less	O	O
than	O	O
0	O	O
.	O	O

05	O	O
.	O	O

Mazindol	B-Chemical	D008454
did	O	O
not	O	O
benefit	O	O
strength	O	O
at	O	O
any	O	O
point	O	O
in	O	O
the	O	O
study	O	O
.	O	O

Side	O	O
effects	O	O
attributable	O	O
to	O	O
mazindol	B-Chemical	D008454
included	O	O
decreased	B-Disease	D001068
appetite	I-Disease	D001068
(	O	O
36%	O	O
)	O	O
,	O	O
dry	B-Disease	D014987
mouth	I-Disease	D014987
(	O	O
10%	O	O
)	O	O
,	O	O
behavioral	O	O
change	O	O
(	O	O
22%	O	O
)	O	O
,	O	O
and	O	O
gastrointestinal	B-Disease	D012817
symptoms	I-Disease	D012817
(	O	O
18%	O	O
)	O	O
;	O	O
mazindol	B-Chemical	D008454
dosage	O	O
was	O	O
reduced	O	O
in	O	O
43%	O	O
of	O	O
patients	O	O
.	O	O

The	O	O
effect	O	O
of	O	O
mazindol	B-Chemical	D008454
on	O	O
GH	O	O
secretion	O	O
was	O	O
estimated	O	O
indirectly	O	O
by	O	O
comparing	O	O
the	O	O
postabsorptive	O	O
IGF	O	O
-	O	O
I	O	O
levels	O	O
obtained	O	O
following	O	O
3	O	O
,	O	O
6	O	O
,	O	O
9	O	O
,	O	O
and	O	O
12	O	O
months	O	O
in	O	O
the	O	O
mazindol	B-Chemical	D008454
treated	O	O
to	O	O
those	O	O
in	O	O
the	O	O
placebo	O	O
groups	O	O
.	O	O

Although	O	O
mazindol	B-Chemical	D008454
-	O	O
treated	O	O
patients	O	O
gained	O	O
less	O	O
weight	O	O
and	O	O
height	O	O
than	O	O
placebo	O	O
-	O	O
treated	O	O
patients	O	O
,	O	O
no	O	O
significant	O	O
effect	O	O
on	O	O
IGF	O	O
-	O	O
I	O	O
levels	O	O
was	O	O
observed	O	O
.	O	O

Mazindol	B-Chemical	D008454
doses	O	O
not	O	O
slow	O	O
the	O	O
progression	O	O
of	O	O
weakness	B-Disease	D018908
in	O	O
Duchenne	B-Disease	D020388
dystrophy	I-Disease	D020388
.	O	O

Pentoxifylline	B-Chemical	D010431
(	O	O
Trental	B-Chemical	D010431
)	O	O
does	O	O
not	O	O
inhibit	O	O
dipyridamole	B-Chemical	D004176
-	O	O
induced	O	O
coronary	O	O
hyperemia	B-Disease	D006940
:	O	O
implications	O	O
for	O	O
dipyridamole	B-Chemical	D004176
-	O	O
thallium	B-Chemical	D013793
-	O	O
201	O	O
myocardial	O	O
imaging	O	O
.	O	O

Dipyridamole	B-Chemical	D004176
-	O	O
thallium	B-Chemical	D013793
-	O	O
201	O	O
imaging	O	O
is	O	O
often	O	O
performed	O	O
in	O	O
patients	O	O
unable	O	O
to	O	O
exercise	O	O
because	O	O
of	O	O
peripheral	B-Disease	D016491
vascular	I-Disease	D016491
disease	I-Disease	D016491
.	O	O

Many	O	O
of	O	O
these	O	O
patients	O	O
are	O	O
taking	O	O
pentoxifylline	B-Chemical	D010431
(	O	O
Trental	B-Chemical	D010431
)	O	O
,	O	O
a	O	O
methylxanthine	B-Chemical	C008514
derivative	O	O
which	O	O
may	O	O
improve	O	O
intermittent	B-Disease	D007383
claudication	I-Disease	D007383
.	O	O

Whether	O	O
pentoxifylline	B-Chemical	D010431
inhibits	O	O
dipyridamole	B-Chemical	D004176
-	O	O
induced	O	O
coronary	O	O
hyperemia	B-Disease	D006940
like	O	O
other	O	O
methylxanthines	B-Chemical	C008514
such	O	O
as	O	O
theophylline	B-Chemical	D013806
and	O	O
should	O	O
be	O	O
stopped	O	O
prior	O	O
to	O	O
dipyridamole	B-Chemical	D004176
-	O	O
thallium	B-Chemical	D013793
-	O	O
201	O	O
imaging	O	O
is	O	O
unknown	O	O
.	O	O

Therefore	O	O
,	O	O
we	O	O
studied	O	O
the	O	O
hyperemic	O	O
response	O	O
to	O	O
dipyridamole	B-Chemical	D004176
in	O	O
seven	O	O
open	O	O
-	O	O
chest	O	O
anesthetized	O	O
dogs	O	O
after	O	O
pretreatment	O	O
with	O	O
either	O	O
pentoxifylline	B-Chemical	D010431
(	O	O
0	O	O
,	O	O
7	O	O
.	O	O

5	O	O
,	O	O
or	O	O
15	O	O
mg	O	O
/	O	O
kg	O	O
i	O	O
.	O	O

v	O	O
.	O	O

)	O	O
or	O	O
theophylline	B-Chemical	D013806
(	O	O
3	O	O
mg	O	O
/	O	O
kg	O	O
i	O	O
.	O	O

v	O	O
.	O	O

)	O	O
.	O	O

Baseline	O	O
circumflex	O	O
coronary	O	O
blood	O	O
flows	O	O
did	O	O
not	O	O
differ	O	O
significantly	O	O
among	O	O
treatment	O	O
groups	O	O
.	O	O

Dipyridamole	B-Chemical	D004176
significantly	O	O
increased	O	O
coronary	O	O
blood	O	O
flow	O	O
before	O	O
and	O	O
after	O	O
7	O	O
.	O	O

5	O	O
or	O	O
15	O	O
mm	O	O
/	O	O
kg	O	O
i	O	O
.	O	O

v	O	O
.	O	O

pentoxifylline	B-Chemical	D010431
(	O	O
p	O	O
less	O	O
than	O	O
0	O	O
.	O	O

002	O	O
)	O	O
.	O	O

Neither	O	O
dose	O	O
of	O	O
pentoxifylline	B-Chemical	D010431
significantly	O	O
decreased	O	O
the	O	O
dipyridamole	B-Chemical	D004176
-	O	O
induced	O	O
hyperemia	B-Disease	D006940
,	O	O
while	O	O
peak	O	O
coronary	O	O
blood	O	O
flow	O	O
was	O	O
significantly	O	O
lower	O	O
after	O	O
theophylline	B-Chemical	D013806
(	O	O
p	O	O
less	O	O
than	O	O
0	O	O
.	O	O

01	O	O
)	O	O
.	O	O

We	O	O
conclude	O	O
that	O	O
pentoxyifylline	B-Chemical	D010431
does	O	O
not	O	O
inhibit	O	O
dipyridamole	B-Chemical	D004176
-	O	O
induced	O	O
coronary	O	O
hyperemia	B-Disease	D006940
even	O	O
at	O	O
high	O	O
doses	O	O
.	O	O

Cause	O	O
of	O	O
death	B-Disease	D003643
among	O	O
patients	O	O
with	O	O
Parkinson's	B-Disease	D010300
disease	I-Disease	D010300
:	O	O
a	O	O
rare	O	O
mortality	O	O
due	O	O
to	O	O
cerebral	B-Disease	D002543
haemorrhage	I-Disease	D002543
.	O	O

Causes	O	O
of	O	O
death	B-Disease	D003643
,	O	O
with	O	O
special	O	O
reference	O	O
to	O	O
cerebral	B-Disease	D002543
haemorrhage	I-Disease	D002543
,	O	O
among	O	O
240	O	O
patients	O	O
with	O	O
pathologically	O	O
verified	O	O
Parkinson's	B-Disease	D010300
disease	I-Disease	D010300
were	O	O
investigated	O	O
using	O	O
the	O	O
Annuals	O	O
of	O	O
the	O	O
Pathological	O	O
Autopsy	O	O
Cases	O	O
in	O	O
Japan	O	O
from	O	O
1981	O	O
to	O	O
1985	O	O
.	O	O

The	O	O
leading	O	O
causes	O	O
of	O	O
death	B-Disease	D003643
were	O	O
pneumonia	B-Disease	D011014
and	O	O
bronchitis	B-Disease	D001991
(	O	O
44	O	O
.	O	O

1%	O	O
)	O	O
,	O	O
malignant	O	O
neoplasms	B-Disease	D009369
(	O	O
11	O	O
.	O	O

6%	O	O
)	O	O
,	O	O
heart	B-Disease	D006331
diseases	I-Disease	D006331
(	O	O
4	O	O
.	O	O

1%	O	O
)	O	O
,	O	O
cerebral	B-Disease	D002544
infarction	I-Disease	D002544
(	O	O
3	O	O
.	O	O

7%	O	O
)	O	O
and	O	O
septicaemia	B-Disease	D018805
(	O	O
3	O	O
.	O	O

3%	O	O
)	O	O
.	O	O

Cerebral	B-Disease	D002543
haemorrhage	I-Disease	D002543
was	O	O
the	O	O
11th	O	O
most	O	O
frequent	O	O
cause	O	O
of	O	O
death	B-Disease	D003643
,	O	O
accounting	O	O
for	O	O
only	O	O
0	O	O
.	O	O

8%	O	O
of	O	O
deaths	B-Disease	D003643
among	O	O
the	O	O
patients	O	O
,	O	O
whereas	O	O
it	O	O
was	O	O
the	O	O
5th	O	O
most	O	O
common	O	O
cause	O	O
of	O	O
death	B-Disease	D003643
among	O	O
the	O	O
Japanese	O	O
general	O	O
population	O	O
in	O	O
1985	O	O
.	O	O

The	O	O
low	O	O
incidence	O	O
of	O	O
cerebral	B-Disease	D002543
haemorrhage	I-Disease	D002543
as	O	O
a	O	O
cause	O	O
of	O	O
death	B-Disease	D003643
in	O	O
patients	O	O
with	O	O
Parkinson's	B-Disease	D010300
disease	I-Disease	D010300
may	O	O
reflect	O	O
the	O	O
hypotensive	B-Disease	D007022
effect	O	O
of	O	O
levodopa	B-Chemical	D007980
and	O	O
a	O	O
hypotensive	B-Disease	D007022
mechanism	O	O
due	O	O
to	O	O
reduced	O	O
noradrenaline	B-Chemical	D009638
levels	O	O
in	O	O
the	O	O
parkinsonian	B-Disease	D010300
brain	O	O
.	O	O

Tolerance	O	O
and	O	O
antiviral	O	O
effect	O	O
of	O	O
ribavirin	B-Chemical	D012254
in	O	O
patients	O	O
with	O	O
Argentine	B-Disease	D006478
hemorrhagic	I-Disease	D006478
fever	I-Disease	D006478
.	O	O

Tolerance	O	O
and	O	O
antiviral	O	O
effect	O	O
of	O	O
ribavirin	B-Chemical	D012254
was	O	O
studied	O	O
in	O	O
6	O	O
patients	O	O
with	O	O
Argentine	B-Disease	D006478
hemorrhagic	I-Disease	D006478
fever	I-Disease	D006478
(	O	O
AHF	B-Disease	D006478
)	O	O
of	O	O
more	O	O
than	O	O
8	O	O
days	O	O
of	O	O
evolution	O	O
.	O	O

Administration	O	O
of	O	O
ribavirin	B-Chemical	D012254
resulted	O	O
in	O	O
a	O	O
neutralization	O	O
of	O	O
viremia	B-Disease	D014766
and	O	O
a	O	O
drop	O	O
of	O	O
endogenous	O	O
interferon	O	O
titers	O	O
.	O	O

The	O	O
average	O	O
time	O	O
of	O	O
death	B-Disease	D003643
was	O	O
delayed	O	O
.	O	O

A	O	O
reversible	O	O
anemia	B-Disease	D000740
was	O	O
the	O	O
only	O	O
adverse	O	O
effect	O	O
observed	O	O
.	O	O

From	O	O
these	O	O
results	O	O
,	O	O
we	O	O
conclude	O	O
that	O	O
ribavirin	B-Chemical	D012254
has	O	O
an	O	O
antiviral	O	O
effect	O	O
in	O	O
advanced	O	O
cases	O	O
of	O	O
AHF	B-Disease	D006478
,	O	O
and	O	O
that	O	O
anemia	B-Disease	D000740
,	O	O
the	O	O
only	O	O
secondary	O	O
reaction	O	O
observed	O	O
,	O	O
can	O	O
be	O	O
easily	O	O
managed	O	O
.	O	O

The	O	O
possible	O	O
beneficial	O	O
effect	O	O
of	O	O
ribavirin	B-Chemical	D012254
during	O	O
the	O	O
initial	O	O
days	O	O
of	O	O
AHF	B-Disease	D006478
is	O	O
discussed	O	O
.	O	O

Dipyridamole	B-Chemical	D004176
-	O	O
induced	O	O
myocardial	B-Disease	D017202
ischemia	I-Disease	D017202
.	O	O

Angina	B-Disease	D000787
and	O	O
ischemic	O	O
electrocardiographic	O	O
changes	O	O
occurred	O	O
after	O	O
administration	O	O
of	O	O
oral	O	O
dipyridamole	B-Chemical	D004176
in	O	O
four	O	O
patients	O	O
awaiting	O	O
urgent	O	O
myocardial	O	O
revascularization	O	O
procedures	O	O
.	O	O

To	O	O
our	O	O
knowledge	O	O
,	O	O
this	O	O
has	O	O
not	O	O
previously	O	O
been	O	O
reported	O	O
as	O	O
a	O	O
side	O	O
effect	O	O
of	O	O
preoperative	O	O
dipyridamole	B-Chemical	D004176
therapy	O	O
,	O	O
although	O	O
dipyridamole	B-Chemical	D004176
-	O	O
induced	O	O
myocardial	B-Disease	D017202
ischemia	I-Disease	D017202
has	O	O
been	O	O
demonstrated	O	O
to	O	O
occur	O	O
in	O	O
animals	O	O
and	O	O
humans	O	O
with	O	O
coronary	B-Disease	D003324
artery	I-Disease	D003324
disease	I-Disease	D003324
.	O	O

Epicardial	O	O
coronary	O	O
collateral	O	O
vessels	O	O
were	O	O
demonstrated	O	O
in	O	O
all	O	O
four	O	O
patients	O	O
;	O	O
a	O	O
coronary	O	O
"steal"	O	O
phenomenon	O	O
may	O	O
be	O	O
the	O	O
mechanism	O	O
of	O	O
the	O	O
dipyridamole	B-Chemical	D004176
-	O	O
induced	O	O
ischemia	B-Disease	D007511
observed	O	O
.	O	O

Inhibition	O	O
of	O	O
immunoreactive	O	O
corticotropin	O	O
-	O	O
releasing	O	O
factor	O	O
secretion	O	O
into	O	O
the	O	O
hypophysial	O	O
-	O	O
portal	O	O
circulation	O	O
by	O	O
delayed	O	O
glucocorticoid	O	O
feedback	O	O
.	O	O

Nitroprusside	B-Chemical	D009599
-	O	O
induced	O	O
hypotension	B-Disease	D007022
evokes	O	O
ACTH	O	O
secretion	O	O
which	O	O
is	O	O
primarily	O	O
mediated	O	O
by	O	O
enhanced	O	O
secretion	O	O
of	O	O
immunoreactive	O	O
corticotropin	O	O
-	O	O
releasing	O	O
factor	O	O
(	O	O
irCRF	O	O
)	O	O
into	O	O
the	O	O
hypophysial	O	O
-	O	O
portal	O	O
circulation	O	O
.	O	O

Portal	O	O
plasma	O	O
concentrations	O	O
of	O	O
neither	O	O
arginine	B-Chemical	D001127
vasopressin	I-Chemical	D001127
nor	O	O
oxytocin	B-Chemical	D010121
are	O	O
significantly	O	O
altered	O	O
in	O	O
this	O	O
paradigm	O	O
.	O	O

Application	O	O
of	O	O
a	O	O
delayed	O	O
feedback	O	O
signal	O	O
,	O	O
in	O	O
the	O	O
form	O	O
of	O	O
a	O	O
2	O	O
-	O	O
h	O	O
systemic	O	O
corticosterone	B-Chemical	D003345
infusion	O	O
in	O	O
urethane	B-Chemical	D014520
-	O	O
anesthetized	O	O
rats	O	O
with	O	O
pharmacological	O	O
blockade	O	O
of	O	O
glucocorticoid	O	O
synthesis	O	O
,	O	O
is	O	O
without	O	O
effect	O	O
on	O	O
the	O	O
resting	O	O
secretion	O	O
of	O	O
arginine	B-Chemical	D001127
vasopressin	I-Chemical	D001127
and	O	O
oxytocin	B-Chemical	D010121
at	O	O
any	O	O
corticosterone	B-Chemical	D003345
feedback	O	O
dose	O	O
tested	O	O
.	O	O

Resting	O	O
irCRF	O	O
levels	O	O
are	O	O
suppressed	O	O
only	O	O
at	O	O
the	O	O
highest	O	O
corticosterone	B-Chemical	D003345
infusion	O	O
rate	O	O
,	O	O
which	O	O
resulted	O	O
in	O	O
systemic	O	O
corticosterone	B-Chemical	D003345
levels	O	O
of	O	O
40	O	O
micrograms	O	O
/	O	O
dl	O	O
.	O	O

Suppression	O	O
of	O	O
irCRF	O	O
secretion	O	O
in	O	O
response	O	O
to	O	O
nitroprusside	B-Chemical	D009599
-	O	O
induced	O	O
hypotension	B-Disease	D007022
is	O	O
observed	O	O
and	O	O
occurs	O	O
at	O	O
a	O	O
plasma	O	O
corticosterone	B-Chemical	D003345
level	O	O
between	O	O
8	O	O
-	O	O
12	O	O
micrograms	O	O
/	O	O
dl	O	O
.	O	O

These	O	O
studies	O	O
provide	O	O
further	O	O
evidence	O	O
for	O	O
a	O	O
strong	O	O
central	O	O
component	O	O
of	O	O
the	O	O
delayed	O	O
feedback	O	O
process	O	O
which	O	O
is	O	O
mediated	O	O
by	O	O
modulation	O	O
of	O	O
irCRF	O	O
release	O	O
.	O	O

Noradrenergic	O	O
involvement	O	O
in	O	O
catalepsy	B-Disease	D002375
induced	O	O
by	O	O
delta	B-Chemical	D013759
9	I-Chemical	D013759
-	I-Chemical	D013759
tetrahydrocannabinol	I-Chemical	D013759
.	O	O

In	O	O
order	O	O
to	O	O
elucidate	O	O
the	O	O
role	O	O
of	O	O
the	O	O
catecholaminergic	O	O
system	O	O
in	O	O
the	O	O
cataleptogenic	O	O
effect	O	O
of	O	O
delta	B-Chemical	D013759
9	I-Chemical	D013759
-	I-Chemical	D013759
tetrahydrocannabinol	I-Chemical	D013759
(	O	O
THC	B-Chemical	D013759
)	O	O
,	O	O
the	O	O
effect	O	O
of	O	O
pretreatment	O	O
with	O	O
6	B-Chemical	D016627
-	I-Chemical	D016627
hydroxydopamine	I-Chemical	D016627
(	O	O
6	B-Chemical	D016627
-	I-Chemical	D016627
OHDA	I-Chemical	D016627
)	O	O
or	O	O
with	O	O
desipramine	B-Chemical	D003891
and	O	O
6	B-Chemical	D016627
-	I-Chemical	D016627
OHDA	I-Chemical	D016627
and	O	O
lesions	O	O
of	O	O
the	O	O
locus	O	O
coeruleus	O	O
were	O	O
investigated	O	O
in	O	O
rats	O	O
.	O	O

The	O	O
cataleptogenic	O	O
effect	O	O
of	O	O
THC	B-Chemical	D013759
was	O	O
significantly	O	O
reduced	O	O
in	O	O
rats	O	O
treated	O	O
with	O	O
6	B-Chemical	D016627
-	I-Chemical	D016627
OHDA	I-Chemical	D016627
and	O	O
in	O	O
rats	O	O
with	O	O
lesions	O	O
of	O	O
the	O	O
locus	O	O
coeruleus	O	O
but	O	O
not	O	O
in	O	O
rats	O	O
treated	O	O
with	O	O
desipramine	B-Chemical	D003891
and	O	O
6	B-Chemical	D016627
-	I-Chemical	D016627
OHDA	I-Chemical	D016627
,	O	O
as	O	O
compared	O	O
with	O	O
control	O	O
rats	O	O
.	O	O

On	O	O
the	O	O
contrary	O	O
,	O	O
the	O	O
cataleptogenic	O	O
effect	O	O
of	O	O
haloperidol	B-Chemical	D006220
was	O	O
significantly	O	O
reduced	O	O
in	O	O
rats	O	O
treated	O	O
with	O	O
desipramine	B-Chemical	D003891
and	O	O
6	B-Chemical	D016627
-	I-Chemical	D016627
OHDA	I-Chemical	D016627
but	O	O
not	O	O
in	O	O
rats	O	O
treated	O	O
with	O	O
6	B-Chemical	D016627
-	I-Chemical	D016627
OHDA	I-Chemical	D016627
or	O	O
in	O	O
rats	O	O
with	O	O
lesions	O	O
of	O	O
the	O	O
locus	O	O
coeruleus	O	O
.	O	O

These	O	O
results	O	O
indicate	O	O
that	O	O
noradrenergic	O	O
neurons	O	O
have	O	O
an	O	O
important	O	O
role	O	O
in	O	O
the	O	O
manifestation	O	O
of	O	O
catalepsy	B-Disease	D002375
induced	O	O
by	O	O
THC	B-Chemical	D013759
,	O	O
whereas	O	O
dopaminergic	O	O
neurons	O	O
are	O	O
important	O	O
in	O	O
catalepsy	B-Disease	D002375
induced	O	O
by	O	O
haloperidol	B-Chemical	D006220
.	O	O

Intracranial	O	O
pressure	O	O
increases	O	O
during	O	O
alfentanil	B-Chemical	D015760
-	O	O
induced	O	O
rigidity	B-Disease	D009127
.	O	O

Intracranial	O	O
pressure	O	O
(	O	O
ICP	O	O
)	O	O
was	O	O
measured	O	O
during	O	O
alfentanil	B-Chemical	D015760
-	O	O
induced	O	O
rigidity	B-Disease	D009127
in	O	O
rats	O	O
.	O	O

Ten	O	O
rats	O	O
had	O	O
arterial	O	O
,	O	O
central	O	O
venous	O	O
(	O	O
CVP	O	O
)	O	O
,	O	O
and	O	O
subdural	O	O
cannulae	O	O
inserted	O	O
under	O	O
halothane	B-Chemical	D006221
anesthesia	O	O
.	O	O

The	O	O
animals	O	O
were	O	O
mechanically	O	O
ventilated	O	O
to	O	O
achieve	O	O
normocarbia	O	O
(	O	O
PCO2	O	O
=	O	O
42	O	O
+	O	O
/	O	O
-	O	O
1	O	O
mmHg	O	O
,	O	O
mean	O	O
+	O	O
/	O	O
-	O	O
SE	O	O
)	O	O
.	O	O

Following	O	O
instrumentation	O	O
,	O	O
halothane	B-Chemical	D006221
was	O	O
discontinued	O	O
and	O	O
alfentanil	B-Chemical	D015760
(	O	O
125	O	O
mu	O	O
/	O	O
kg	O	O
)	O	O
administered	O	O
iv	O	O
during	O	O
emergence	O	O
from	O	O
halothane	B-Chemical	D006221
anesthesia	O	O
.	O	O

In	O	O
the	O	O
five	O	O
rats	O	O
that	O	O
developed	O	O
somatic	B-Disease	D009127
rigidity	I-Disease	D009127
,	O	O
ICP	O	O
and	O	O
CVP	O	O
increased	O	O
significantly	O	O
above	O	O
baseline	O	O
(	O	O
delta	O	O
ICP	O	O
7	O	O
.	O	O

5	O	O
+	O	O
/	O	O
-	O	O
1	O	O
.	O	O

0	O	O
mmHg	O	O
,	O	O
delta	O	O
CVP	O	O
5	O	O
.	O	O

9	O	O
+	O	O
/	O	O
-	O	O
1	O	O
.	O	O

3	O	O
mmHg	O	O
)	O	O
.	O	O

These	O	O
variables	O	O
returned	O	O
to	O	O
baseline	O	O
when	O	O
rigidity	B-Disease	D009127
was	O	O
abolished	O	O
with	O	O
metocurine	B-Chemical	C032943
.	O	O

In	O	O
five	O	O
rats	O	O
that	O	O
did	O	O
not	O	O
become	O	O
rigid	O	O
,	O	O
ICP	O	O
and	O	O
CVP	O	O
did	O	O
not	O	O
change	O	O
following	O	O
alfentanil	B-Chemical	D015760
.	O	O

These	O	O
observations	O	O
suggest	O	O
that	O	O
rigidity	B-Disease	D009127
should	O	O
be	O	O
prevented	O	O
when	O	O
alfentanil	B-Chemical	D015760
,	O	O
and	O	O
,	O	O
presumably	O	O
,	O	O
other	O	O
opiates	O	O
,	O	O
are	O	O
used	O	O
in	O	O
the	O	O
anesthetic	O	O
management	O	O
of	O	O
patients	O	O
with	O	O
ICP	O	O
problems	O	O
.	O	O

Adverse	O	O
cardiac	O	O
effects	O	O
during	O	O
induction	O	O
chemotherapy	O	O
treatment	O	O
with	O	O
cis	B-Chemical	D002945
-	I-Chemical	D002945
platin	I-Chemical	D002945
and	O	O
5	B-Chemical	D005472
-	I-Chemical	D005472
fluorouracil	I-Chemical	D005472
.	O	O

Survival	O	O
for	O	O
patients	O	O
with	O	O
advanced	O	O
head	B-Disease	D006258
and	I-Disease	D006258
neck	I-Disease	D006258
carcinoma	I-Disease	D006258
and	O	O
esophageal	B-Disease	D004938
carcinoma	I-Disease	D004938
is	O	O
poor	O	O
with	O	O
radiotherapy	O	O
and	O	O
/	O	O
or	O	O
surgery	O	O
.	O	O

Obviously	O	O
,	O	O
there	O	O
is	O	O
a	O	O
need	O	O
for	O	O
effective	O	O
chemotherapy	O	O
.	O	O

In	O	O
the	O	O
present	O	O
study	O	O
,	O	O
cis	B-Chemical	D002945
-	I-Chemical	D002945
platin	I-Chemical	D002945
(	O	O
80	O	O
-	O	O
120	O	O
mg	O	O
/	O	O
m2BSA	O	O
)	O	O
and	O	O
5	B-Chemical	D005472
-	I-Chemical	D005472
FU	I-Chemical	D005472
(	O	O
1000	O	O
mg	O	O
/	O	O
m2BSA	O	O
daily	O	O
as	O	O
a	O	O
continuous	O	O
infusion	O	O
during	O	O
5	O	O
days	O	O
)	O	O
were	O	O
given	O	O
to	O	O
76	O	O
patients	O	O
before	O	O
radiotherapy	O	O
and	O	O
surgery	O	O
.	O	O

The	O	O
aim	O	O
of	O	O
the	O	O
study	O	O
was	O	O
to	O	O
clarify	O	O
the	O	O
incidence	O	O
and	O	O
severity	O	O
of	O	O
adverse	O	O
cardiac	O	O
effects	O	O
to	O	O
this	O	O
treatment	O	O
.	O	O

Before	O	O
treatment	O	O
all	O	O
patients	O	O
had	O	O
a	O	O
cardiac	O	O
evaluation	O	O
and	O	O
during	O	O
treatment	O	O
serial	O	O
ECG	O	O
recordings	O	O
were	O	O
performed	O	O
.	O	O

In	O	O
the	O	O
pre	O	O
-	O	O
treatment	O	O
evaluation	O	O
,	O	O
signs	O	O
of	O	O
cardiovascular	B-Disease	D002318
disease	I-Disease	D002318
were	O	O
found	O	O
in	O	O
33	O	O
patients	O	O
(	O	O
43%	O	O
)	O	O
.	O	O

During	O	O
treatment	O	O
,	O	O
adverse	O	O
cardiac	O	O
effects	O	O
were	O	O
observed	O	O
in	O	O
14	O	O
patients	O	O
(	O	O
18%	O	O
)	O	O
.	O	O

The	O	O
mean	O	O
age	O	O
of	O	O
these	O	O
patients	O	O
was	O	O
the	O	O
same	O	O
as	O	O
for	O	O
the	O	O
entire	O	O
group	O	O
,	O	O
64	O	O
years	O	O
.	O	O

The	O	O
incidence	O	O
of	O	O
cardiotoxicity	B-Disease	D066126
was	O	O
not	O	O
higher	O	O
in	O	O
patients	O	O
with	O	O
signs	O	O
of	O	O
cardiovascular	B-Disease	D002318
disease	I-Disease	D002318
than	O	O
in	O	O
those	O	O
without	O	O
in	O	O
the	O	O
pre	O	O
-	O	O
treatment	O	O
evaluation	O	O
.	O	O

The	O	O
most	O	O
common	O	O
signs	O	O
of	O	O
cardiotoxicity	B-Disease	D066126
were	O	O
chest	B-Disease	D002637
pain	I-Disease	D002637
,	O	O
ST	O	O
-	O	O
T	O	O
wave	O	O
changes	O	O
and	O	O
atrial	B-Disease	D001281
fibrillation	I-Disease	D001281
.	O	O

This	O	O
was	O	O
followed	O	O
by	O	O
ventricular	B-Disease	D014693
fibrillation	I-Disease	D014693
in	O	O
one	O	O
patient	O	O
and	O	O
sudden	B-Disease	D003645
death	I-Disease	D003645
in	O	O
another	O	O
.	O	O

It	O	O
is	O	O
concluded	O	O
that	O	O
patients	O	O
on	O	O
5	B-Chemical	D005472
-	I-Chemical	D005472
FU	I-Chemical	D005472
treatment	O	O
should	O	O
be	O	O
under	O	O
close	O	O
supervision	O	O
and	O	O
that	O	O
the	O	O
treatment	O	O
should	O	O
be	O	O
discontinued	O	O
if	O	O
chest	B-Disease	D002637
pain	I-Disease	D002637
or	O	O
tachyarrhythmia	B-Disease	D013610
is	O	O
observed	O	O
.	O	O

Verapamil	B-Chemical	D014700
-	O	O
induced	O	O
carbamazepine	B-Chemical	D002220
neurotoxicity	B-Disease	D020258
.	O	O

A	O	O
report	O	O
of	O	O
two	O	O
cases	O	O
.	O	O

Two	O	O
patients	O	O
with	O	O
signs	O	O
of	O	O
carbamazepine	B-Chemical	D002220
neurotoxicity	B-Disease	D020258
after	O	O
combined	O	O
treatment	O	O
with	O	O
verapamil	B-Chemical	D014700
showed	O	O
complete	O	O
recovery	O	O
after	O	O
discontinuation	O	O
of	O	O
the	O	O
calcium	B-Chemical	D002118
entry	O	O
blocker	O	O
.	O	O

Use	O	O
of	O	O
verapamil	B-Chemical	D014700
in	O	O
combination	O	O
with	O	O
carbamazepine	B-Chemical	D002220
should	O	O
either	O	O
be	O	O
avoided	O	O
or	O	O
prescribed	O	O
only	O	O
with	O	O
appropriate	O	O
adjustment	O	O
of	O	O
the	O	O
carbamazepine	B-Chemical	D002220
dose	O	O
(	O	O
usually	O	O
reduction	O	O
of	O	O
the	O	O
carbamazepine	B-Chemical	D002220
dose	O	O
by	O	O
one	O	O
half	O	O
)	O	O
.	O	O

Serial	O	O
studies	O	O
of	O	O
auditory	B-Disease	D006311
neurotoxicity	I-Disease	D006311
in	O	O
patients	O	O
receiving	O	O
deferoxamine	B-Chemical	D003676
therapy	O	O
.	O	O

Visual	O	O
and	O	O
auditory	B-Disease	D006311
neurotoxicity	I-Disease	D006311
was	O	O
previously	O	O
documented	O	O
in	O	O
42	O	O
of	O	O
89	O	O
patients	O	O
with	O	O
transfusion	O	O
-	O	O
dependent	O	O
anemia	B-Disease	D000740
who	O	O
were	O	O
receiving	O	O
iron	B-Chemical	D007501
chelation	O	O
therapy	O	O
with	O	O
daily	O	O
subcutaneous	O	O
deferoxamine	B-Chemical	D003676
.	O	O

Twenty	O	O
-	O	O
two	O	O
patients	O	O
in	O	O
the	O	O
affected	O	O
group	O	O
had	O	O
abnormal	B-Disease	D006316
audiograms	I-Disease	D006316
with	I-Disease	D006316
deficits	I-Disease	D006316
mostly	I-Disease	D006316
in	I-Disease	D006316
the	I-Disease	D006316
high	I-Disease	D006316
frequency	I-Disease	D006316
range	I-Disease	D006316
of	I-Disease	D006316
4	I-Disease	D006316
,	I-Disease	D006316
000	I-Disease	D006316
to	I-Disease	D006316
8	I-Disease	D006316
,	I-Disease	D006316
000	I-Disease	D006316
Hz	I-Disease	D006316
and	O	O
in	O	O
the	O	O
hearing	O	O
threshold	O	O
levels	O	O
of	O	O
30	O	O
to	O	O
100	O	O
decibels	O	O
.	O	O

When	O	O
deferoxamine	B-Chemical	D003676
therapy	O	O
was	O	O
discontinued	O	O
and	O	O
serial	O	O
studies	O	O
were	O	O
performed	O	O
,	O	O
audiograms	O	O
in	O	O
seven	O	O
cases	O	O
reverted	O	O
to	O	O
normal	O	O
or	O	O
near	O	O
normal	O	O
within	O	O
two	O	O
to	O	O
three	O	O
weeks	O	O
,	O	O
and	O	O
nine	O	O
of	O	O
13	O	O
patients	O	O
with	O	O
symptoms	O	O
became	O	O
asymptomatic	O	O
.	O	O

Audiograms	O	O
from	O	O
15	O	O
patients	O	O
remained	O	O
abnormal	O	O
and	O	O
four	O	O
patients	O	O
required	O	O
hearing	O	O
aids	O	O
because	O	O
of	O	O
permanent	B-Disease	D003638
disability	I-Disease	D003638
.	O	O

Since	O	O
18	O	O
of	O	O
the	O	O
22	O	O
patients	O	O
were	O	O
initially	O	O
receiving	O	O
deferoxamine	B-Chemical	D003676
doses	O	O
in	O	O
excess	O	O
of	O	O
the	O	O
commonly	O	O
recommended	O	O
50	O	O
mg	O	O
/	O	O
kg	O	O
per	O	O
dose	O	O
,	O	O
therapy	O	O
was	O	O
restarted	O	O
with	O	O
lower	O	O
doses	O	O
,	O	O
usually	O	O
50	O	O
mg	O	O
/	O	O
kg	O	O
per	O	O
dose	O	O
or	O	O
less	O	O
depending	O	O
on	O	O
the	O	O
degree	O	O
of	O	O
auditory	B-Disease	D006311
abnormality	I-Disease	D006311
,	O	O
and	O	O
with	O	O
the	O	O
exception	O	O
of	O	O
two	O	O
cases	O	O
no	O	O
further	O	O
toxicity	B-Disease	D064420
was	O	O
demonstrated	O	O
.	O	O

Auditory	O	O
deterioration	O	O
and	O	O
improvement	O	O
,	O	O
demonstrated	O	O
serially	O	O
in	O	O
individual	O	O
patients	O	O
receiving	O	O
and	O	O
not	O	O
receiving	O	O
deferoxamine	B-Chemical	D003676
,	O	O
respectively	O	O
,	O	O
provided	O	O
convincing	O	O
evidence	O	O
for	O	O
a	O	O
cause	O	O
-	O	O
and	O	O
-	O	O
effect	O	O
relation	O	O
between	O	O
deferoxamine	B-Chemical	D003676
administration	O	O
and	O	O
ototoxicity	B-Disease	D006311
.	O	O

Based	O	O
on	O	O
these	O	O
data	O	O
,	O	O
a	O	O
plan	O	O
of	O	O
management	O	O
was	O	O
developed	O	O
that	O	O
allows	O	O
effective	O	O
yet	O	O
safe	O	O
administration	O	O
of	O	O
deferoxamine	B-Chemical	D003676
.	O	O

A	O	O
dose	O	O
of	O	O
50	O	O
mg	O	O
/	O	O
kg	O	O
is	O	O
recommended	O	O
in	O	O
those	O	O
without	O	O
audiogram	O	O
abnormalities	O	O
.	O	O

With	O	O
mild	O	O
toxicity	B-Disease	D064420
,	O	O
a	O	O
reduction	O	O
to	O	O
30	O	O
or	O	O
40	O	O
mg	O	O
/	O	O
kg	O	O
per	O	O
dose	O	O
should	O	O
result	O	O
in	O	O
a	O	O
reversal	O	O
of	O	O
the	O	O
abnormal	O	O
results	O	O
to	O	O
normal	O	O
within	O	O
four	O	O
weeks	O	O
.	O	O

Moderate	O	O
abnormalities	O	O
require	O	O
a	O	O
reduction	O	O
of	O	O
deferoxamine	B-Chemical	D003676
to	O	O
25	O	O
mg	O	O
/	O	O
kg	O	O
per	O	O
dose	O	O
with	O	O
careful	O	O
monitoring	O	O
.	O	O

In	O	O
those	O	O
with	O	O
symptoms	O	O
of	O	O
hearing	B-Disease	D034381
loss	I-Disease	D034381
,	O	O
the	O	O
drug	O	O
should	O	O
be	O	O
stopped	O	O
for	O	O
four	O	O
weeks	O	O
,	O	O
and	O	O
when	O	O
the	O	O
audiogram	O	O
is	O	O
stable	O	O
or	O	O
improved	O	O
,	O	O
therapy	O	O
should	O	O
be	O	O
restarted	O	O
at	O	O
10	O	O
to	O	O
25	O	O
mg	O	O
/	O	O
kg	O	O
per	O	O
dose	O	O
.	O	O

Serial	O	O
audiograms	O	O
should	O	O
be	O	O
performed	O	O
every	O	O
six	O	O
months	O	O
in	O	O
those	O	O
without	O	O
problems	O	O
and	O	O
more	O	O
frequently	O	O
in	O	O
young	O	O
patients	O	O
with	O	O
normal	O	O
serum	O	O
ferritin	O	O
values	O	O
and	O	O
in	O	O
those	O	O
with	O	O
auditory	B-Disease	D006311
dysfunction	I-Disease	D006311
.	O	O

Flurbiprofen	B-Chemical	D005480
in	O	O
the	O	O
treatment	O	O
of	O	O
juvenile	B-Disease	D001171
rheumatoid	I-Disease	D001171
arthritis	I-Disease	D001171
.	O	O

Thirty	O	O
-	O	O
four	O	O
patients	O	O
with	O	O
juvenile	B-Disease	D001171
rheumatoid	I-Disease	D001171
arthritis	I-Disease	D001171
,	O	O
who	O	O
were	O	O
treated	O	O
with	O	O
flurbiprofen	B-Chemical	D005480
at	O	O
a	O	O
maximum	O	O
dose	O	O
of	O	O
4	O	O
mg	O	O
/	O	O
kg	O	O
/	O	O
day	O	O
,	O	O
had	O	O
statistically	O	O
significant	O	O
decreases	O	O
from	O	O
baseline	O	O
in	O	O
6	O	O
arthritis	B-Disease	D001168
indices	O	O
after	O	O
12	O	O
weeks	O	O
of	O	O
treatment	O	O
.	O	O

Improvements	O	O
were	O	O
seen	O	O
in	O	O
the	O	O
number	O	O
of	O	O
tender	B-Disease	-1
joints	I-Disease	-1
,	O	O
the	O	O
severity	O	O
of	O	O
swelling	B-Disease	D004487
and	O	O
tenderness	B-Disease	-1
,	O	O
the	O	O
time	O	O
of	O	O
walk	O	O
50	O	O
feet	O	O
,	O	O
the	O	O
duration	O	O
of	O	O
morning	B-Disease	-1
stiffness	I-Disease	-1
and	O	O
the	O	O
circumference	O	O
of	O	O
the	O	O
left	O	O
knee	O	O
.	O	O

The	O	O
most	O	O
frequently	O	O
observed	O	O
side	O	O
effect	O	O
was	O	O
fecal	B-Disease	-1
occult	I-Disease	-1
blood	I-Disease	-1
(	O	O
25%	O	O
of	O	O
patients	O	O
)	O	O
;	O	O
however	O	O
,	O	O
there	O	O
was	O	O
no	O	O
other	O	O
evidence	O	O
of	O	O
gastrointestinal	B-Disease	D006471
(	I-Disease	D006471
GI	I-Disease	D006471
)	I-Disease	D006471
bleeding	I-Disease	D006471
in	O	O
these	O	O
patients	O	O
.	O	O

One	O	O
patient	O	O
was	O	O
prematurely	O	O
discontinued	O	O
from	O	O
the	O	O
study	O	O
for	O	O
severe	O	O
headache	B-Disease	D006261
and	O	O
abdominal	B-Disease	D015746
pain	I-Disease	D015746
.	O	O

Most	O	O
side	O	O
effects	O	O
were	O	O
mild	O	O
and	O	O
related	O	O
to	O	O
the	O	O
GI	O	O
tract	O	O
.	O	O

The	O	O
correlation	O	O
between	O	O
neurotoxic	B-Disease	D020258
esterase	O	O
inhibition	O	O
and	O	O
mipafox	B-Chemical	C005238
-	O	O
induced	O	O
neuropathic	B-Disease	D009422
damage	I-Disease	D009422
in	O	O
rats	O	O
.	O	O

The	O	O
correlation	O	O
between	O	O
neuropathic	B-Disease	D009422
damage	I-Disease	D009422
and	O	O
inhibition	O	O
of	O	O
neurotoxic	B-Disease	D020258
esterase	O	O
or	O	O
neuropathy	B-Disease	D009422
target	O	O
enzyme	O	O
(	O	O
NTE	O	O
)	O	O
was	O	O
examined	O	O
in	O	O
rats	O	O
acutely	O	O
exposed	O	O
to	O	O
Mipafox	B-Chemical	C005238
(	O	O
N	B-Chemical	C005238
,	I-Chemical	C005238
N'	I-Chemical	C005238
-	I-Chemical	C005238
diisopropylphosphorodiamidofluoridate	I-Chemical	C005238
)	O	O
,	O	O
a	O	O
neurotoxic	B-Disease	D020258
organophosphate	B-Chemical	D010755
.	O	O

Brain	O	O
and	O	O
spinal	O	O
cord	O	O
NTE	O	O
activities	O	O
were	O	O
measured	O	O
in	O	O
Long	O	O
-	O	O
Evans	O	O
male	O	O
rats	O	O
1	O	O
hr	O	O
post	O	O
-	O	O
exposure	O	O
to	O	O
various	O	O
dosages	O	O
of	O	O
Mipafox	B-Chemical	C005238
(	O	O
ip	O	O
,	O	O
1	O	O
-	O	O
15	O	O
mg	O	O
/	O	O
kg	O	O
)	O	O
.	O	O

These	O	O
data	O	O
were	O	O
correlated	O	O
with	O	O
histologically	O	O
scored	O	O
cervical	O	O
cord	B-Disease	D013118
damage	I-Disease	D013118
in	O	O
a	O	O
separate	O	O
group	O	O
of	O	O
similarly	O	O
dosed	O	O
rats	O	O
sampled	O	O
14	O	O
-	O	O
21	O	O
days	O	O
post	O	O
-	O	O
exposure	O	O
.	O	O

Those	O	O
dosages	O	O
(	O	O
greater	O	O
than	O	O
or	O	O
equal	O	O
to	O	O
10	O	O
mg	O	O
/	O	O
kg	O	O
)	O	O
that	O	O
inhibited	O	O
mean	O	O
NTE	O	O
activity	O	O
in	O	O
the	O	O
spinal	O	O
cord	O	O
greater	O	O
than	O	O
or	O	O
equal	O	O
to	O	O
73%	O	O
and	O	O
brain	O	O
greater	O	O
than	O	O
or	O	O
equal	O	O
to	O	O
67%	O	O
of	O	O
control	O	O
values	O	O
produced	O	O
severe	O	O
(	O	O
greater	O	O
than	O	O
or	O	O
equal	O	O
to	O	O
3	O	O
)	O	O
cervical	O	O
cord	O	O
pathology	O	O
in	O	O
85%	O	O
of	O	O
the	O	O
rats	O	O
.	O	O

In	O	O
contrast	O	O
,	O	O
dosages	O	O
of	O	O
Mipafox	B-Chemical	C005238
(	O	O
less	O	O
than	O	O
or	O	O
equal	O	O
to	O	O
5	O	O
mg	O	O
/	O	O
kg	O	O
)	O	O
which	O	O
inhibited	O	O
mean	O	O
NTE	O	O
activity	O	O
in	O	O
spinal	O	O
cord	O	O
less	O	O
than	O	O
or	O	O
equal	O	O
to	O	O
61%	O	O
and	O	O
brain	O	O
less	O	O
than	O	O
or	O	O
equal	O	O
to	O	O
60%	O	O
produced	O	O
this	O	O
degree	O	O
of	O	O
cord	B-Disease	D013118
damage	I-Disease	D013118
in	O	O
only	O	O
9%	O	O
of	O	O
the	O	O
animals	O	O
.	O	O

These	O	O
data	O	O
indicate	O	O
that	O	O
a	O	O
critical	O	O
percentage	O	O
of	O	O
NTE	O	O
inhibition	O	O
in	O	O
brain	O	O
and	O	O
spinal	O	O
cord	O	O
sampled	O	O
shortly	O	O
after	O	O
Mipafox	B-Chemical	C005238
exposure	O	O
can	O	O
predict	O	O
neuropathic	B-Disease	D009422
damage	I-Disease	D009422
in	O	O
rats	O	O
several	O	O
weeks	O	O
later	O	O
.	O	O

Cerebral	B-Disease	D002544
infarction	I-Disease	D002544
with	O	O
a	O	O
single	O	O
oral	O	O
dose	O	O
of	O	O
phenylpropanolamine	B-Chemical	D010665
.	O	O

Phenylpropanolamine	B-Chemical	D010665
(	O	O
PPA	B-Chemical	D010665
)	O	O
,	O	O
a	O	O
synthetic	O	O
sympathomimetic	O	O
that	O	O
is	O	O
structurally	O	O
similar	O	O
to	O	O
amphetamine	B-Chemical	D000661
,	O	O
is	O	O
available	O	O
over	O	O
the	O	O
counter	O	O
in	O	O
anorectics	O	O
,	O	O
nasal	O	O
congestants	O	O
,	O	O
and	O	O
cold	O	O
preparations	O	O
.	O	O

Its	O	O
prolonged	O	O
use	O	O
or	O	O
overuse	O	O
has	O	O
been	O	O
associated	O	O
with	O	O
seizures	B-Disease	D012640
,	O	O
intracerebral	B-Disease	D002543
hemorrhage	I-Disease	D002543
,	O	O
neuropsychiatric	B-Disease	D001523
symptoms	I-Disease	D001523
,	O	O
and	O	O
nonhemorrhagic	O	O
cerebral	B-Disease	D002544
infarction	I-Disease	D002544
.	O	O

We	O	O
report	O	O
the	O	O
case	O	O
of	O	O
a	O	O
young	O	O
woman	O	O
who	O	O
suffered	O	O
a	O	O
cerebral	B-Disease	D002544
infarction	I-Disease	D002544
after	O	O
taking	O	O
a	O	O
single	O	O
oral	O	O
dose	O	O
of	O	O
PPA	B-Chemical	D010665
.	O	O

Treatment	O	O
of	O	O
psoriasis	B-Disease	D011565
with	O	O
azathioprine	B-Chemical	D001379
.	O	O

Azathioprine	B-Chemical	D001379
treatment	O	O
benefited	O	O
19	O	O
(	O	O
66%	O	O
)	O	O
out	O	O
of	O	O
29	O	O
patients	O	O
suffering	O	O
from	O	O
severe	O	O
psoriasis	B-Disease	D011565
.	O	O

Haematological	O	O
complications	O	O
were	O	O
not	O	O
troublesome	O	O
and	O	O
results	O	O
of	O	O
biochemical	O	O
liver	O	O
function	O	O
tests	O	O
remained	O	O
normal	O	O
.	O	O

Minimal	O	O
cholestasis	B-Disease	D002779
was	O	O
seen	O	O
in	O	O
two	O	O
cases	O	O
and	O	O
portal	O	O
fibrosis	B-Disease	D005355
of	O	O
a	O	O
reversible	O	O
degree	O	O
in	O	O
eight	O	O
.	O	O

Liver	O	O
biopsies	O	O
should	O	O
be	O	O
undertaken	O	O
at	O	O
regular	O	O
intervals	O	O
if	O	O
azathioprine	B-Chemical	D001379
therapy	O	O
is	O	O
continued	O	O
so	O	O
that	O	O
structural	O	O
liver	B-Disease	D056486
damage	I-Disease	D056486
may	O	O
be	O	O
detected	O	O
at	O	O
an	O	O
early	O	O
and	O	O
reversible	O	O
stage	O	O
.	O	O

Maternal	O	O
lithium	B-Chemical	D008094
and	O	O
neonatal	O	O
Ebstein's	B-Disease	D004437
anomaly	I-Disease	D004437
:	O	O
evaluation	O	O
with	O	O
cross	O	O
-	O	O
sectional	O	O
echocardiography	O	O
.	O	O

Cross	O	O
-	O	O
sectional	O	O
echocardiography	O	O
was	O	O
used	O	O
to	O	O
evaluate	O	O
two	O	O
neonates	O	O
whose	O	O
mothers	O	O
ingested	O	O
lithium	B-Chemical	D008094
during	O	O
pregnancy	O	O
.	O	O

In	O	O
one	O	O
infant	O	O
,	O	O
Ebstein's	B-Disease	D004437
anomaly	I-Disease	D004437
of	O	O
the	O	O
tricuspid	O	O
valve	O	O
was	O	O
identified	O	O
.	O	O

In	O	O
the	O	O
other	O	O
infant	O	O
cross	O	O
-	O	O
sectional	O	O
echocardiography	O	O
provided	O	O
reassurance	O	O
that	O	O
the	O	O
infant	O	O
did	O	O
not	O	O
have	O	O
Ebstein's	B-Disease	D004437
anomaly	I-Disease	D004437
.	O	O

Cross	O	O
-	O	O
sectional	O	O
echocardiographic	O	O
screening	O	O
of	O	O
newborns	O	O
exposed	O	O
to	O	O
lithium	B-Chemical	D008094
during	O	O
gestation	O	O
can	O	O
provide	O	O
highly	O	O
accurate	O	O
,	O	O
noninvasive	O	O
assessment	O	O
of	O	O
the	O	O
presence	O	O
or	O	O
absence	O	O
of	O	O
lithium	B-Chemical	D008094
-	O	O
induced	O	O
cardiac	B-Disease	D006331
malformations	I-Disease	D006331
.	O	O

Effects	O	O
of	O	O
training	O	O
on	O	O
the	O	O
extent	O	O
of	O	O
experimental	O	O
myocardial	B-Disease	D009203
infarction	I-Disease	D009203
in	O	O
aging	O	O
rats	O	O
.	O	O

The	O	O
effects	O	O
of	O	O
exercise	O	O
on	O	O
the	O	O
severity	O	O
of	O	O
isoproterenol	B-Chemical	D007545
-	O	O
induced	O	O
myocardial	B-Disease	D009203
infarction	I-Disease	D009203
were	O	O
studied	O	O
in	O	O
female	O	O
albino	O	O
rats	O	O
of	O	O
20	O	O
,	O	O
40	O	O
,	O	O
60	O	O
and	O	O
80	O	O
weeks	O	O
of	O	O
age	O	O
.	O	O

The	O	O
rats	O	O
were	O	O
trained	O	O
to	O	O
swim	O	O
for	O	O
a	O	O
specific	O	O
duration	O	O
and	O	O
for	O	O
a	O	O
particular	O	O
period	O	O
.	O	O

The	O	O
occurrence	O	O
of	O	O
infarcts	B-Disease	D007238
were	O	O
confirmed	O	O
by	O	O
histological	O	O
methods	O	O
.	O	O

Elevations	O	O
in	O	O
the	O	O
serum	O	O
GOT	O	O
and	O	O
GPT	O	O
were	O	O
maximum	O	O
in	O	O
the	O	O
sedentary	O	O
-	O	O
isoproterenols	B-Chemical	D007545
and	O	O
minimum	O	O
in	O	O
the	O	O
exercise	O	O
-	O	O
controls	O	O
.	O	O

These	O	O
changes	O	O
in	O	O
the	O	O
serum	O	O
transaminases	O	O
were	O	O
associated	O	O
with	O	O
corresponding	O	O
depletions	O	O
in	O	O
the	O	O
cardiac	O	O
GOT	O	O
and	O	O
GPT	O	O
.	O	O

However	O	O
,	O	O
age	O	O
was	O	O
seen	O	O
to	O	O
interfere	O	O
with	O	O
the	O	O
responses	O	O
exhibited	O	O
by	O	O
the	O	O
young	O	O
and	O	O
old	O	O
rats	O	O
.	O	O

Studies	O	O
dealing	O	O
with	O	O
myocardial	B-Disease	D009203
infarction	I-Disease	D009203
are	O	O
more	O	O
informative	O	O
when	O	O
dealt	O	O
with	O	O
age	O	O
.	O	O

Effect	O	O
of	O	O
polyethylene	B-Chemical	D011092
glycol	I-Chemical	D011092
400	I-Chemical	D011092
on	O	O
adriamycin	B-Chemical	D004317
toxicity	B-Disease	D064420
in	O	O
mice	O	O
.	O	O

The	O	O
effect	O	O
of	O	O
a	O	O
widely	O	O
used	O	O
organic	O	O
solvent	O	O
,	O	O
polyethylene	B-Chemical	D011092
glycol	I-Chemical	D011092
400	I-Chemical	D011092
(	O	O
PEG	B-Chemical	D011092
400	I-Chemical	D011092
)	O	O
,	O	O
on	O	O
the	O	O
toxic	O	O
action	O	O
of	O	O
an	O	O
acute	O	O
or	O	O
chronic	O	O
treatment	O	O
with	O	O
adriamycin	B-Chemical	D004317
(	O	O
ADR	B-Chemical	D004317
)	O	O
was	O	O
evaluated	O	O
in	O	O
mice	O	O
.	O	O

PEG	B-Chemical	D011092
400	I-Chemical	D011092
impressively	O	O
decreased	O	O
both	O	O
acute	O	O
high	O	O
-	O	O
dose	O	O
and	O	O
chronic	O	O
low	O	O
-	O	O
dose	O	O
-	O	O
ADR	B-Chemical	D004317
-	O	O
associated	O	O
lethality	O	O
.	O	O

Light	O	O
microscopic	O	O
analysis	O	O
showed	O	O
a	O	O
significant	O	O
protection	O	O
against	O	O
ADR	B-Chemical	D004317
-	O	O
induced	O	O
cardiac	B-Disease	D009202
morphological	I-Disease	D009202
alterations	I-Disease	D009202
.	O	O

Such	O	O
treatment	O	O
did	O	O
not	O	O
diminish	O	O
the	O	O
ADR	B-Chemical	D004317
antitumor	O	O
activity	O	O
in	O	O
L1210	B-Disease	D007939
leukemia	I-Disease	D007939
and	O	O
in	O	O
Ehrlich	B-Disease	D002286
ascites	I-Disease	D002286
tumor	I-Disease	D002286
.	O	O

Intra	O	O
-	O	O
arterial	O	O
BCNU	B-Chemical	D002330
chemotherapy	O	O
for	O	O
treatment	O	O
of	O	O
malignant	B-Disease	D005910
gliomas	I-Disease	D005910
of	O	O
the	O	O
central	O	O
nervous	O	O
system	O	O
.	O	O

Because	O	O
of	O	O
the	O	O
rapid	O	O
systemic	O	O
clearance	O	O
of	O	O
BCNU	B-Chemical	D002330
(	O	O
1	B-Chemical	D002330
,	I-Chemical	D002330
3	I-Chemical	D002330
-	I-Chemical	D002330
bis	I-Chemical	D002330
-	I-Chemical	D002330
(	I-Chemical	D002330
2	I-Chemical	D002330
-	I-Chemical	D002330
chloroethyl	I-Chemical	D002330
)	I-Chemical	D002330
-	I-Chemical	D002330
1	I-Chemical	D002330
-	I-Chemical	D002330
nitrosourea	I-Chemical	D002330
)	O	O
,	O	O
intra	O	O
-	O	O
arterial	O	O
administration	O	O
should	O	O
provide	O	O
a	O	O
substantial	O	O
advantage	O	O
over	O	O
intravenous	O	O
administration	O	O
for	O	O
the	O	O
treatment	O	O
of	O	O
malignant	B-Disease	D005910
gliomas	I-Disease	D005910
.	O	O

Thirty	O	O
-	O	O
six	O	O
patients	O	O
were	O	O
treated	O	O
with	O	O
BCNU	B-Chemical	D002330
every	O	O
6	O	O
to	O	O
8	O	O
weeks	O	O
,	O	O
either	O	O
by	O	O
transfemoral	O	O
catheterization	O	O
of	O	O
the	O	O
internal	O	O
carotid	O	O
or	O	O
vertebral	O	O
artery	O	O
or	O	O
through	O	O
a	O	O
fully	O	O
implantable	O	O
intracarotid	O	O
drug	O	O
delivery	O	O
system	O	O
,	O	O
beginning	O	O
with	O	O
a	O	O
dose	O	O
of	O	O
200	O	O
mg	O	O
/	O	O
sq	O	O
m	O	O
body	O	O
surface	O	O
area	O	O
.	O	O

Twelve	O	O
patients	O	O
with	O	O
Grade	O	O
III	O	O
or	O	O
IV	O	O
astrocytomas	B-Disease	D001254
were	O	O
treated	O	O
after	O	O
partial	O	O
resection	O	O
of	O	O
the	O	O
tumor	B-Disease	D009369
without	O	O
prior	O	O
radiation	O	O
therapy	O	O
.	O	O

After	O	O
two	O	O
to	O	O
seven	O	O
cycles	O	O
of	O	O
chemotherapy	O	O
,	O	O
nine	O	O
patients	O	O
showed	O	O
a	O	O
decrease	O	O
in	O	O
tumor	B-Disease	D009369
size	O	O
and	O	O
surrounding	O	O
edema	B-Disease	D004487
on	O	O
contrast	O	O
-	O	O
enhanced	O	O
computerized	O	O
tomography	O	O
scans	O	O
.	O	O

In	O	O
the	O	O
nine	O	O
responders	O	O
,	O	O
median	O	O
duration	O	O
of	O	O
chemotherapy	O	O
response	O	O
from	O	O
the	O	O
time	O	O
of	O	O
operation	O	O
was	O	O
25	O	O
weeks	O	O
(	O	O
range	O	O
12	O	O
to	O	O
more	O	O
than	O	O
91	O	O
weeks	O	O
)	O	O
.	O	O

The	O	O
median	O	O
duration	O	O
of	O	O
survival	O	O
in	O	O
the	O	O
12	O	O
patients	O	O
was	O	O
54	O	O
weeks	O	O
(	O	O
range	O	O
21	O	O
to	O	O
more	O	O
than	O	O
156	O	O
weeks	O	O
)	O	O
,	O	O
with	O	O
an	O	O
18	O	O
-	O	O
month	O	O
survival	O	O
rate	O	O
of	O	O
42%	O	O
.	O	O

Twenty	O	O
-	O	O
four	O	O
patients	O	O
with	O	O
recurrent	O	O
Grade	O	O
I	O	O
to	O	O
IV	O	O
astrocytomas	B-Disease	D001254
,	O	O
whose	O	O
resection	O	O
and	O	O
irradiation	O	O
therapy	O	O
had	O	O
failed	O	O
,	O	O
received	O	O
two	O	O
to	O	O
eight	O	O
courses	O	O
of	O	O
intra	O	O
-	O	O
arterial	O	O
BCNU	B-Chemical	D002330
therapy	O	O
.	O	O

Seventeen	O	O
of	O	O
these	O	O
had	O	O
a	O	O
response	O	O
or	O	O
were	O	O
stable	O	O
for	O	O
a	O	O
median	O	O
of	O	O
20	O	O
weeks	O	O
(	O	O
range	O	O
6	O	O
to	O	O
more	O	O
than	O	O
66	O	O
weeks	O	O
)	O	O
.	O	O

The	O	O
catheterization	O	O
procedure	O	O
is	O	O
safe	O	O
,	O	O
with	O	O
no	O	O
immediate	O	O
complication	O	O
in	O	O
111	O	O
infusions	O	O
of	O	O
BCNU	B-Chemical	D002330
.	O	O

A	O	O
delayed	O	O
complication	O	O
in	O	O
nine	O	O
patients	O	O
has	O	O
been	O	O
unilateral	O	O
loss	B-Disease	D014786
of	I-Disease	D014786
vision	I-Disease	D014786
secondary	O	O
to	O	O
a	O	O
retinal	B-Disease	D031300
vasculitis	I-Disease	D031300
.	O	O

The	O	O
frequency	O	O
of	O	O
visual	B-Disease	D014786
loss	I-Disease	D014786
decreased	O	O
after	O	O
the	O	O
concentration	O	O
of	O	O
the	O	O
ethanol	B-Chemical	D000431
diluent	O	O
was	O	O
lowered	O	O
.	O	O

Blood	O	O
pressure	O	O
response	O	O
to	O	O
chronic	O	O
low	O	O
-	O	O
dose	O	O
intrarenal	O	O
noradrenaline	B-Chemical	D009638
infusion	O	O
in	O	O
conscious	O	O
rats	O	O
.	O	O

Sodium	B-Chemical	D012965
chloride	I-Chemical	D012965
solution	O	O
(	O	O
0	O	O
.	O	O

9%	O	O
)	O	O
or	O	O
noradrenaline	B-Chemical	D009638
in	O	O
doses	O	O
of	O	O
4	O	O
,	O	O
12	O	O
and	O	O
36	O	O
micrograms	O	O
h	O	O
-	O	O
1	O	O
kg	O	O
-	O	O
1	O	O
was	O	O
infused	O	O
for	O	O
five	O	O
consecutive	O	O
days	O	O
,	O	O
either	O	O
intrarenally	O	O
(	O	O
by	O	O
a	O	O
new	O	O
technique	O	O
)	O	O
or	O	O
intravenously	O	O
into	O	O
rats	O	O
with	O	O
one	O	O
kidney	O	O
removed	O	O
.	O	O

Intrarenal	O	O
infusion	O	O
of	O	O
noradrenaline	B-Chemical	D009638
caused	O	O
hypertension	B-Disease	D006973
at	O	O
doses	O	O
which	O	O
did	O	O
not	O	O
do	O	O
so	O	O
when	O	O
infused	O	O
intravenously	O	O
.	O	O

Intrarenal	O	O
compared	O	O
with	O	O
intravenous	O	O
infusion	O	O
of	O	O
noradrenaline	B-Chemical	D009638
caused	O	O
higher	O	O
plasma	O	O
noradrenaline	B-Chemical	D009638
concentrations	O	O
and	O	O
a	O	O
shift	O	O
of	O	O
the	O	O
plasma	O	O
noradrenaline	B-Chemical	D009638
concentration	O	O
-	O	O
blood	O	O
pressure	O	O
effect	O	O
curve	O	O
towards	O	O
lower	O	O
plasma	O	O
noradrenaline	B-Chemical	D009638
levels	O	O
.	O	O

These	O	O
results	O	O
suggest	O	O
that	O	O
hypertension	B-Disease	D006973
after	O	O
chronic	O	O
intrarenal	O	O
noradrenaline	B-Chemical	D009638
infusion	O	O
is	O	O
produced	O	O
by	O	O
relatively	O	O
higher	O	O
levels	O	O
of	O	O
circulating	O	O
noradrenaline	B-Chemical	D009638
and	O	O
by	O	O
triggering	O	O
of	O	O
an	O	O
additional	O	O
intrarenal	O	O
pressor	O	O
mechanism	O	O
.	O	O

Age	O	O
and	O	O
renal	O	O
clearance	O	O
of	O	O
cimetidine	B-Chemical	D002927
.	O	O

In	O	O
35	O	O
patients	O	O
(	O	O
ages	O	O
20	O	O
to	O	O
86	O	O
yr	O	O
)	O	O
receiving	O	O
cimetidine	B-Chemical	D002927
therapeutically	O	O
two	O	O
serum	O	O
samples	O	O
and	O	O
all	O	O
urine	O	O
formed	O	O
in	O	O
the	O	O
interim	O	O
were	O	O
collected	O	O
for	O	O
analysis	O	O
of	O	O
cimetidine	B-Chemical	D002927
by	O	O
high	O	O
-	O	O
pressure	O	O
liquid	O	O
chromatography	O	O
and	O	O
for	O	O
creatinine	B-Chemical	D003404
.	O	O

Cimetidine	B-Chemical	D002927
clearance	O	O
decreased	O	O
with	O	O
age	O	O
.	O	O

The	O	O
extrapolated	O	O
6	O	O
-	O	O
hr	O	O
serum	O	O
concentration	O	O
of	O	O
cimetidine	B-Chemical	D002927
per	O	O
unit	O	O
dose	O	O
,	O	O
after	O	O
intravenous	O	O
cimetidine	B-Chemical	D002927
,	O	O
increased	O	O
with	O	O
age	O	O
of	O	O
the	O	O
patients	O	O
.	O	O

The	O	O
ratio	O	O
of	O	O
cimetidine	B-Chemical	D002927
clearance	O	O
to	O	O
creatinine	B-Chemical	D003404
clearance	O	O
(	O	O
Rc	O	O
)	O	O
averaged	O	O
4	O	O
.	O	O

8	O	O
+	O	O
/	O	O
-	O	O
2	O	O
.	O	O

0	O	O
,	O	O
indicating	O	O
net	O	O
tubular	O	O
secretion	O	O
for	O	O
cimetidine	B-Chemical	D002927
.	O	O

Rc	O	O
seemed	O	O
to	O	O
be	O	O
independent	O	O
of	O	O
age	O	O
and	O	O
decreased	O	O
with	O	O
increasing	O	O
serum	O	O
concentration	O	O
of	O	O
cimetidine	B-Chemical	D002927
,	O	O
suggesting	O	O
that	O	O
secretion	O	O
of	O	O
cimetidine	B-Chemical	D002927
is	O	O
a	O	O
saturable	O	O
process	O	O
.	O	O

There	O	O
was	O	O
only	O	O
one	O	O
case	O	O
of	O	O
dementia	B-Disease	D003704
possibly	O	O
due	O	O
to	O	O
cimetidine	B-Chemical	D002927
(	O	O
with	O	O
a	O	O
drug	O	O
level	O	O
of	O	O
1	O	O
.	O	O

9	O	O
microgram	O	O
/	O	O
ml	O	O
6	O	O
hr	O	O
after	O	O
a	O	O
dose	O	O
)	O	O
in	O	O
a	O	O
group	O	O
of	O	O
13	O	O
patients	O	O
without	O	O
liver	O	O
or	O	O
kidney	O	O
disease	O	O
who	O	O
had	O	O
cimetidine	B-Chemical	D002927
levels	O	O
above	O	O
1	O	O
.	O	O

25	O	O
microgram	O	O
/	O	O
ml	O	O
.	O	O

Thus	O	O
,	O	O
high	O	O
cimetidine	B-Chemical	D002927
levels	O	O
alone	O	O
do	O	O
not	O	O
always	O	O
induce	O	O
dementia	B-Disease	D003704
.	O	O

Development	O	O
of	O	O
clear	B-Disease	D018262
cell	I-Disease	D018262
adenocarcinoma	I-Disease	D018262
in	O	O
DES	B-Chemical	D004054
-	O	O
exposed	O	O
offspring	O	O
under	O	O
observation	O	O
.	O	O

Two	O	O
cases	O	O
of	O	O
clear	B-Disease	D018262
cell	I-Disease	D018262
adenocarcinoma	I-Disease	D018262
of	O	O
the	O	O
vagina	O	O
detected	O	O
at	O	O
follow	O	O
-	O	O
up	O	O
in	O	O
young	O	O
women	O	O
exposed	O	O
in	O	O
utero	O	O
to	O	O
diethylstilbestrol	B-Chemical	D004054
are	O	O
reported	O	O
.	O	O

One	O	O
patient	O	O
,	O	O
aged	O	O
23	O	O
,	O	O
had	O	O
been	O	O
followed	O	O
for	O	O
2	O	O
years	O	O
before	O	O
carcinoma	B-Disease	D002277
was	O	O
diagnosed	O	O
;	O	O
the	O	O
second	O	O
patient	O	O
,	O	O
aged	O	O
22	O	O
,	O	O
had	O	O
been	O	O
seen	O	O
on	O	O
a	O	O
regular	O	O
basis	O	O
for	O	O
5	O	O
years	O	O
,	O	O
8	O	O
months	O	O
.	O	O

In	O	O
both	O	O
instances	O	O
,	O	O
suspicion	O	O
of	O	O
the	O	O
presence	O	O
of	O	O
carcinoma	B-Disease	D002277
was	O	O
aroused	O	O
by	O	O
the	O	O
palpation	O	O
of	O	O
a	O	O
small	O	O
nodule	O	O
in	O	O
the	O	O
vaginal	O	O
fornix	O	O
.	O	O

Hysterosalpingography	O	O
was	O	O
performed	O	O
on	O	O
both	O	O
patients	O	O
and	O	O
,	O	O
in	O	O
1	O	O
instance	O	O
,	O	O
an	O	O
abnormal	O	O
x	O	O
-	O	O
ray	O	O
film	O	O
was	O	O
reflected	O	O
by	O	O
the	O	O
gross	O	O
appearance	O	O
of	O	O
the	O	O
uterine	O	O
cavity	O	O
found	O	O
in	O	O
the	O	O
surgical	O	O
specimen	O	O
.	O	O

Phenobarbitone	B-Chemical	D010634
-	O	O
induced	O	O
enlargement	B-Disease	D006529
of	I-Disease	D006529
the	I-Disease	D006529
liver	I-Disease	D006529
in	O	O
the	O	O
rat	O	O
:	O	O
its	O	O
relationship	O	O
to	O	O
carbon	B-Chemical	D002251
tetrachloride	I-Chemical	D002251
-	O	O
induced	O	O
cirrhosis	B-Disease	D005355
.	O	O

The	O	O
yield	O	O
of	O	O
severe	O	O
cirrhosis	B-Disease	D005355
of	O	O
the	O	O
liver	O	O
(	O	O
defined	O	O
as	O	O
a	O	O
shrunken	O	O
finely	O	O
nodular	O	O
liver	O	O
with	O	O
micronodular	O	O
histology	O	O
,	O	O
ascites	B-Disease	D001201
greater	O	O
than	O	O
30	O	O
ml	O	O
,	O	O
plasma	O	O
albumin	O	O
less	O	O
than	O	O
2	O	O
.	O	O

2	O	O
g	O	O
/	O	O
dl	O	O
,	O	O
splenomegaly	B-Disease	D013163
2	O	O
-	O	O
3	O	O
times	O	O
normal	O	O
,	O	O
and	O	O
testicular	O	O
atrophy	B-Disease	D001284
approximately	O	O
half	O	O
normal	O	O
weight	O	O
)	O	O
after	O	O
12	O	O
doses	O	O
of	O	O
carbon	B-Chemical	D002251
tetrachloride	I-Chemical	D002251
given	O	O
intragastrically	O	O
in	O	O
the	O	O
phenobarbitone	B-Chemical	D010634
-	O	O
primed	O	O
rat	O	O
was	O	O
increased	O	O
from	O	O
25%	O	O
to	O	O
56%	O	O
by	O	O
giving	O	O
the	O	O
initial	O	O
"calibrating"	O	O
dose	O	O
of	O	O
carbon	B-Chemical	D002251
tetrachloride	I-Chemical	D002251
at	O	O
the	O	O
peak	O	O
of	O	O
the	O	O
phenobarbitone	B-Chemical	D010634
-	O	O
induced	O	O
enlargement	B-Disease	D006529
of	I-Disease	D006529
the	I-Disease	D006529
liver	I-Disease	D006529
.	O	O

At	O	O
this	O	O
point	O	O
it	O	O
was	O	O
assumed	O	O
that	O	O
the	O	O
cytochrome	O	O
P450	O	O
/	O	O
CCl4	B-Chemical	D002251
toxic	O	O
state	O	O
was	O	O
both	O	O
maximal	O	O
and	O	O
stable	O	O
.	O	O

The	O	O
optimal	O	O
rat	O	O
size	O	O
to	O	O
begin	O	O
phenobarbitone	B-Chemical	D010634
was	O	O
determined	O	O
as	O	O
100	O	O
g	O	O
,	O	O
and	O	O
this	O	O
size	O	O
as	O	O
a	O	O
group	O	O
had	O	O
a	O	O
mean	O	O
maximum	O	O
relative	O	O
liver	O	O
weight	O	O
increase	O	O
47%	O	O
greater	O	O
than	O	O
normal	O	O
rats	O	O
of	O	O
the	O	O
same	O	O
body	O	O
weight	O	O
.	O	O

The	O	O
optimal	O	O
time	O	O
for	O	O
the	O	O
initial	O	O
dose	O	O
of	O	O
carbon	B-Chemical	D002251
tetrachloride	I-Chemical	D002251
was	O	O
after	O	O
14	O	O
days	O	O
on	O	O
phenobarbitone	B-Chemical	D010634
.	O	O

Attenuation	O	O
of	O	O
the	O	O
lithium	B-Chemical	D008094
-	O	O
induced	O	O
diabetes	B-Disease	D003919
-	I-Disease	D003919
insipidus	I-Disease	D003919
-	I-Disease	D003919
like	I-Disease	D003919
syndrome	I-Disease	D003919
by	O	O
amiloride	B-Chemical	D000584
in	O	O
rats	O	O
.	O	O

The	O	O
effect	O	O
of	O	O
amiloride	B-Chemical	D000584
on	O	O
lithium	B-Chemical	D008094
-	O	O
induced	O	O
polydipsia	B-Disease	D059606
and	O	O
polyuria	B-Disease	D011141
and	O	O
on	O	O
the	O	O
lithium	B-Chemical	D008094
concentration	O	O
in	O	O
the	O	O
plasma	O	O
,	O	O
brain	O	O
,	O	O
kidney	O	O
,	O	O
thyroid	O	O
and	O	O
red	O	O
blood	O	O
cells	O	O
was	O	O
investigated	O	O
in	O	O
rats	O	O
,	O	O
chronically	O	O
treated	O	O
with	O	O
LiCl	B-Chemical	D018021
.	O	O

Amiloride	B-Chemical	D000584
reduced	O	O
the	O	O
drinking	O	O
and	O	O
urine	O	O
volume	O	O
of	O	O
rats	O	O
in	O	O
an	O	O
acute	O	O
(	O	O
6	O	O
or	O	O
12	O	O
h	O	O
)	O	O
and	O	O
a	O	O
subacute	O	O
(	O	O
3	O	O
days	O	O
)	O	O
experiment	O	O
.	O	O

6	O	O
h	O	O
after	O	O
the	O	O
administration	O	O
of	O	O
amiloride	B-Chemical	D000584
,	O	O
a	O	O
reduction	O	O
was	O	O
observed	O	O
in	O	O
the	O	O
lithium	B-Chemical	D008094
content	O	O
of	O	O
the	O	O
renal	O	O
medulla	O	O
but	O	O
not	O	O
in	O	O
the	O	O
other	O	O
organs	O	O
studied	O	O
.	O	O

At	O	O
12	O	O
h	O	O
,	O	O
all	O	O
the	O	O
tissues	O	O
showed	O	O
a	O	O
slight	O	O
increase	O	O
in	O	O
lithium	B-Chemical	D008094
levels	O	O
.	O	O

After	O	O
3	O	O
days	O	O
of	O	O
combined	O	O
treatment	O	O
,	O	O
a	O	O
marked	O	O
elevation	O	O
in	O	O
plasma	O	O
and	O	O
tissue	O	O
lithium	B-Chemical	D008094
levels	O	O
accompanied	O	O
a	O	O
reduction	O	O
in	O	O
water	O	O
intake	O	O
.	O	O

In	O	O
all	O	O
the	O	O
experiments	O	O
,	O	O
the	O	O
attenuation	O	O
of	O	O
the	O	O
lithium	B-Chemical	D008094
-	O	O
induced	O	O
diabetes	B-Disease	D003919
-	I-Disease	D003919
insipidus	I-Disease	D003919
-	I-Disease	D003919
like	I-Disease	D003919
syndrome	I-Disease	D003919
by	O	O
amiloride	B-Chemical	D000584
was	O	O
accompanied	O	O
by	O	O
a	O	O
reduction	O	O
of	O	O
the	O	O
ratio	O	O
between	O	O
the	O	O
lithium	B-Chemical	D008094
concentration	O	O
in	O	O
the	O	O
renal	O	O
medulla	O	O
and	O	O
its	O	O
levels	O	O
in	O	O
the	O	O
blood	O	O
and	O	O
an	O	O
elevation	O	O
in	O	O
the	O	O
plasma	O	O
potassium	B-Chemical	D011188
level	O	O
.	O	O

It	O	O
is	O	O
concluded	O	O
that	O	O
acute	O	O
amiloride	B-Chemical	D000584
administration	O	O
to	O	O
lithium	B-Chemical	D008094
-	O	O
treated	O	O
patients	O	O
suffering	O	O
from	O	O
polydipsia	B-Disease	D059606
and	O	O
polyuria	B-Disease	D011141
might	O	O
relieve	O	O
these	O	O
patients	O	O
but	O	O
prolonged	O	O
amiloride	B-Chemical	D000584
supplementation	O	O
would	O	O
result	O	O
in	O	O
elevated	O	O
lithium	B-Chemical	D008094
levels	O	O
and	O	O
might	O	O
be	O	O
hazardous	O	O
.	O	O

Safety	O	O
and	O	O
side	O	O
-	O	O
effects	O	O
of	O	O
alprazolam	B-Chemical	D000525
.	O	O

Controlled	O	O
study	O	O
in	O	O
agoraphobia	B-Disease	D000379
with	O	O
panic	B-Disease	D016584
disorder	I-Disease	D016584
.	O	O

BACKGROUND	O	O
:	O	O
The	O	O
widespread	O	O
use	O	O
of	O	O
benzodiazepines	B-Chemical	D001569
has	O	O
led	O	O
to	O	O
increasing	O	O
recognition	O	O
of	O	O
their	O	O
unwanted	O	O
effects	O	O
.	O	O

The	O	O
efficacy	O	O
of	O	O
alprazolam	B-Chemical	D000525
and	O	O
placebo	O	O
in	O	O
panic	B-Disease	D016584
disorder	I-Disease	D016584
with	O	O
agoraphobia	B-Disease	D000379
,	O	O
and	O	O
the	O	O
side	O	O
-	O	O
effect	O	O
and	O	O
adverse	O	O
effect	O	O
profiles	O	O
of	O	O
both	O	O
drug	O	O
groups	O	O
were	O	O
measured	O	O
.	O	O

METHOD	O	O
:	O	O
In	O	O
London	O	O
and	O	O
Toronto	O	O
154	O	O
patients	O	O
who	O	O
met	O	O
DSM	O	O
-	O	O
III	O	O
criteria	O	O
for	O	O
panic	B-Disease	D016584
disorder	I-Disease	D016584
with	O	O
agoraphobia	B-Disease	D000379
were	O	O
randomised	O	O
to	O	O
alprazolam	B-Chemical	D000525
or	O	O
placebo	O	O
.	O	O

Subjects	O	O
in	O	O
each	O	O
drug	O	O
group	O	O
also	O	O
received	O	O
either	O	O
exposure	O	O
or	O	O
relaxation	O	O
.	O	O

Treatment	O	O
was	O	O
from	O	O
weeks	O	O
0	O	O
to	O	O
8	O	O
and	O	O
was	O	O
then	O	O
tapered	O	O
from	O	O
weeks	O	O
8	O	O
to	O	O
16	O	O
.	O	O

RESULTS	O	O
:	O	O
Mean	O	O
alprazolam	B-Chemical	D000525
dose	O	O
was	O	O
5	O	O
mg	O	O
daily	O	O
.	O	O

Compared	O	O
with	O	O
placebo	O	O
subjects	O	O
,	O	O
alprazolam	B-Chemical	D000525
patients	O	O
developed	O	O
more	O	O
adverse	O	O
reactions	O	O
(	O	O
21%	O	O
v	O	O
.	O	O

0%	O	O
)	O	O
of	O	O
depression	B-Disease	D003866
,	O	O
enuresis	B-Disease	D004775
,	O	O
disinhibition	O	O
and	O	O
aggression	B-Disease	D001523
;	O	O
and	O	O
more	O	O
side	O	O
-	O	O
effects	O	O
,	O	O
particularly	O	O
sedation	O	O
,	O	O
irritability	B-Disease	D001523
,	O	O
impaired	B-Disease	D008569
memory	I-Disease	D008569
,	O	O
weight	B-Disease	D015431
loss	I-Disease	D015431
and	O	O
ataxia	B-Disease	D001259
.	O	O

Side	O	O
-	O	O
effects	O	O
tended	O	O
to	O	O
diminish	O	O
during	O	O
treatment	O	O
but	O	O
remained	O	O
significant	O	O
at	O	O
week	O	O
8	O	O
.	O	O

Despite	O	O
this	O	O
,	O	O
the	O	O
drop	O	O
-	O	O
out	O	O
rate	O	O
was	O	O
low	O	O
.	O	O

CONCLUSIONS	O	O
:	O	O
Alprazolam	B-Chemical	D000525
caused	O	O
side	O	O
-	O	O
effects	O	O
and	O	O
adverse	O	O
effects	O	O
during	O	O
treatment	O	O
but	O	O
many	O	O
patients	O	O
were	O	O
willing	O	O
to	O	O
accept	O	O
these	O	O
.	O	O

Dup	B-Chemical	D019808
753	I-Chemical	D019808
prevents	O	O
the	O	O
development	O	O
of	O	O
puromycin	B-Chemical	D011692
aminonucleoside	I-Chemical	D011692
-	O	O
induced	O	O
nephrosis	B-Disease	D009401
.	O	O

The	O	O
appearance	O	O
of	O	O
nephrotic	B-Disease	D009404
syndromes	I-Disease	D009404
such	O	O
as	O	O
proteinuria	B-Disease	D011507
,	O	O
hypoalbuminemia	B-Disease	D034141
,	O	O
hypercholesterolemia	B-Disease	D006937
and	O	O
increase	O	O
in	O	O
blood	B-Chemical	D001806
nitrogen	I-Chemical	D001806
urea	I-Chemical	D001806
,	O	O
induced	O	O
in	O	O
rats	O	O
by	O	O
injection	O	O
of	O	O
puromycin	B-Chemical	D011692
aminonucleoside	I-Chemical	D011692
was	O	O
markedly	O	O
inhibited	O	O
by	O	O
oral	O	O
administration	O	O
of	O	O
Dup	B-Chemical	D019808
753	I-Chemical	D019808
(	O	O
losartan	B-Chemical	D019808
)	O	O
,	O	O
a	O	O
novel	O	O
angiotensin	B-Chemical	D000804
II	I-Chemical	D000804
receptor	O	O
antagonist	O	O
,	O	O
at	O	O
a	O	O
dose	O	O
of	O	O
1	O	O
or	O	O
2	O	O
mg	O	O
/	O	O
kg	O	O
per	O	O
day	O	O
.	O	O

The	O	O
results	O	O
suggest	O	O
a	O	O
possible	O	O
involvement	O	O
of	O	O
the	O	O
renin	O	O
-	O	O
angiotensin	B-Chemical	D000809
system	O	O
in	O	O
the	O	O
development	O	O
of	O	O
puromycin	B-Chemical	D011692
aminonucleoside	I-Chemical	D011692
-	O	O
induced	O	O
nephrosis	B-Disease	D009401
.	O	O

Sodium	B-Chemical	D017693
bicarbonate	I-Chemical	D017693
alleviates	O	O
penile	B-Disease	D004414
pain	I-Disease	D004414
induced	O	O
by	O	O
intracavernous	O	O
injections	O	O
for	O	O
erectile	B-Disease	D007172
dysfunction	I-Disease	D007172
.	O	O

In	O	O
an	O	O
attempt	O	O
to	O	O
determine	O	O
whether	O	O
penile	B-Disease	D004414
pain	I-Disease	D004414
associated	O	O
with	O	O
intracorporeal	O	O
injections	O	O
could	O	O
be	O	O
due	O	O
to	O	O
the	O	O
acidity	O	O
of	O	O
the	O	O
medication	O	O
,	O	O
we	O	O
performed	O	O
a	O	O
randomized	O	O
study	O	O
comparing	O	O
the	O	O
incidence	O	O
of	O	O
penile	B-Disease	D004414
pain	I-Disease	D004414
following	O	O
intracorporeal	O	O
injections	O	O
with	O	O
or	O	O
without	O	O
the	O	O
addition	O	O
of	O	O
sodium	B-Chemical	D017693
bicarbonate	I-Chemical	D017693
to	O	O
the	O	O
intracorporeal	O	O
medications	O	O
.	O	O

A	O	O
total	O	O
of	O	O
38	O	O
consecutive	O	O
patients	O	O
who	O	O
presented	O	O
to	O	O
our	O	O
clinic	O	O
with	O	O
impotence	B-Disease	D007172
received	O	O
0	O	O
.	O	O

2	O	O
ml	O	O
.	O	O

of	O	O
a	O	O
combination	O	O
of	O	O
3	O	O
drugs	O	O
:	O	O
6	O	O
mg	O	O
.	O	O

papaverine	B-Chemical	D010208
,	O	O
100	O	O
micrograms	O	O
.	O	O

phentolamine	B-Chemical	D010646
and	O	O
10	O	O
micrograms	O	O
.	O	O

prostaglandin	B-Chemical	D000527
E1	I-Chemical	D000527
with	O	O
(	O	O
pH	O	O
7	O	O
.	O	O

05	O	O
)	O	O
or	O	O
without	O	O
(	O	O
pH	O	O
4	O	O
.	O	O

17	O	O
)	O	O
the	O	O
addition	O	O
of	O	O
sodium	B-Chemical	D017693
bicarbonate	I-Chemical	D017693
(	O	O
0	O	O
.	O	O

03	O	O
mEq	O	O
.	O	O

)	O	O
.	O	O

Of	O	O
the	O	O
19	O	O
patients	O	O
without	O	O
sodium	B-Chemical	D017693
bicarbonate	I-Chemical	D017693
added	O	O
to	O	O
the	O	O
medication	O	O
11	O	O
(	O	O
58%	O	O
)	O	O
complained	O	O
of	O	O
penile	B-Disease	D004414
pain	I-Disease	D004414
due	O	O
to	O	O
the	O	O
medication	O	O
,	O	O
while	O	O
only	O	O
1	O	O
of	O	O
the	O	O
19	O	O
men	O	O
(	O	O
5%	O	O
)	O	O
who	O	O
received	O	O
sodium	B-Chemical	D017693
bicarbonate	I-Chemical	D017693
complained	O	O
of	O	O
penile	B-Disease	D004414
pain	I-Disease	D004414
.	O	O

From	O	O
these	O	O
data	O	O
we	O	O
conclude	O	O
that	O	O
the	O	O
penile	B-Disease	D004414
pain	I-Disease	D004414
following	O	O
intracorporeal	O	O
injections	O	O
is	O	O
most	O	O
likely	O	O
due	O	O
to	O	O
the	O	O
acidity	O	O
of	O	O
the	O	O
medication	O	O
,	O	O
which	O	O
can	O	O
be	O	O
overcome	O	O
by	O	O
elevating	O	O
the	O	O
pH	O	O
to	O	O
a	O	O
neutral	O	O
level	O	O
.	O	O

Prospective	O	O
study	O	O
of	O	O
the	O	O
long	O	O
-	O	O
term	O	O
effects	O	O
of	O	O
somatostatin	O	O
analog	O	O
(	O	O
octreotide	B-Chemical	D015282
)	O	O
on	O	O
gallbladder	O	O
function	O	O
and	O	O
gallstone	B-Disease	D042882
formation	O	O
in	O	O
Chinese	O	O
acromegalic	B-Disease	D000172
patients	O	O
.	O	O

This	O	O
article	O	O
reports	O	O
the	O	O
changes	O	O
in	O	O
gallbladder	O	O
function	O	O
examined	O	O
by	O	O
ultrasonography	O	O
in	O	O
20	O	O
Chinese	O	O
patients	O	O
with	O	O
active	O	O
acromegaly	B-Disease	D000172
treated	O	O
with	O	O
sc	O	O
injection	O	O
of	O	O
the	O	O
somatostatin	O	O
analog	O	O
octreotide	B-Chemical	D015282
in	O	O
dosages	O	O
of	O	O
300	O	O
-	O	O
1500	O	O
micrograms	O	O
/	O	O
day	O	O
for	O	O
a	O	O
mean	O	O
of	O	O
24	O	O
.	O	O

2	O	O
+	O	O
/	O	O
-	O	O
13	O	O
.	O	O

9	O	O
months	O	O
.	O	O

During	O	O
treatment	O	O
with	O	O
octreotide	B-Chemical	D015282
,	O	O
17	O	O
patients	O	O
developed	O	O
sludge	O	O
,	O	O
10	O	O
had	O	O
gallstones	B-Disease	D042882
,	O	O
and	O	O
1	O	O
developed	O	O
acute	B-Disease	D041881
cholecystitis	I-Disease	D041881
requiring	O	O
surgery	O	O
.	O	O

In	O	O
all	O	O
of	O	O
7	O	O
patients	O	O
examined	O	O
acutely	O	O
,	O	O
gallbladder	O	O
contractility	O	O
was	O	O
inhibited	O	O
after	O	O
a	O	O
single	O	O
100	O	O
-	O	O
micrograms	O	O
injection	O	O
.	O	O

In	O	O
8	O	O
patients	O	O
followed	O	O
for	O	O
24	O	O
weeks	O	O
,	O	O
gallbladder	O	O
contractility	O	O
remained	O	O
depressed	B-Disease	D003866
throughout	O	O
therapy	O	O
.	O	O

After	O	O
withdrawal	O	O
of	O	O
octreotide	B-Chemical	D015282
in	O	O
10	O	O
patients	O	O
without	O	O
gallstones	B-Disease	D042882
,	O	O
8	O	O
patients	O	O
assessed	O	O
had	O	O
return	O	O
of	O	O
normal	O	O
gallbladder	O	O
contractility	O	O
within	O	O
1	O	O
month	O	O
.	O	O

In	O	O
8	O	O
of	O	O
the	O	O
remaining	O	O
10	O	O
patients	O	O
who	O	O
developed	O	O
gallstones	B-Disease	D042882
during	O	O
treatment	O	O
,	O	O
gallbladder	O	O
contractility	O	O
normalized	O	O
in	O	O
5	O	O
patients	O	O
(	O	O
3	O	O
of	O	O
whom	O	O
has	O	O
disappearance	O	O
of	O	O
their	O	O
stones	O	O
within	O	O
3	O	O
weeks	O	O
)	O	O
,	O	O
and	O	O
remained	O	O
depressed	B-Disease	D003866
in	O	O
3	O	O
(	O	O
2	O	O
of	O	O
whom	O	O
had	O	O
stones	O	O
present	O	O
at	O	O
6	O	O
months	O	O
)	O	O
.	O	O

Our	O	O
results	O	O
suggest	O	O
that	O	O
the	O	O
suppression	O	O
of	O	O
gallbladder	O	O
contractility	O	O
is	O	O
the	O	O
cause	O	O
of	O	O
the	O	O
successive	O	O
formation	O	O
of	O	O
bile	O	O
sludge	O	O
,	O	O
gallstones	B-Disease	D042882
,	O	O
and	O	O
cholecystitis	B-Disease	D002764
during	O	O
octreotide	B-Chemical	D015282
therapy	O	O
in	O	O
Chinese	O	O
acromegalic	B-Disease	D000172
patients	O	O
.	O	O

It	O	O
is	O	O
therefore	O	O
very	O	O
important	O	O
to	O	O
follow	O	O
the	O	O
changes	O	O
of	O	O
gallbladder	O	O
function	O	O
during	O	O
long	O	O
-	O	O
term	O	O
octreotide	B-Chemical	D015282
therapy	O	O
of	O	O
acromegalic	B-Disease	D000172
patients	O	O
.	O	O

Improvement	O	O
of	O	O
levodopa	B-Chemical	D007980
-	O	O
induced	O	O
dyskinesia	B-Disease	D004409
by	O	O
propranolol	B-Chemical	D011433
in	O	O
Parkinson's	B-Disease	D010300
disease	I-Disease	D010300
.	O	O

Seven	O	O
patients	O	O
suffering	O	O
from	O	O
Parkinson's	B-Disease	D010300
disease	I-Disease	D010300
(	O	O
PD	B-Disease	D010300
)	O	O
with	O	O
severely	O	O
disabling	O	O
dyskinesia	B-Disease	D004409
received	O	O
low	O	O
-	O	O
dose	O	O
propranolol	B-Chemical	D011433
as	O	O
an	O	O
adjunct	O	O
to	O	O
the	O	O
currently	O	O
used	O	O
medical	O	O
treatment	O	O
.	O	O

There	O	O
was	O	O
a	O	O
significant	O	O
40%	O	O
improvement	O	O
in	O	O
the	O	O
dyskinesia	B-Disease	D004409
score	O	O
without	O	O
increase	O	O
of	O	O
parkinsonian	B-Disease	D010300
motor	B-Disease	D009069
disability	I-Disease	D009069
.	O	O

Ballistic	O	O
and	O	O
choreic	O	O
dyskinesia	B-Disease	D004409
were	O	O
markedly	O	O
ameliorated	O	O
,	O	O
whereas	O	O
dystonia	B-Disease	D004421
was	O	O
not	O	O
.	O	O

This	O	O
study	O	O
suggests	O	O
that	O	O
administration	O	O
of	O	O
low	O	O
doses	O	O
of	O	O
beta	O	O
-	O	O
blockers	O	O
may	O	O
improve	O	O
levodopa	B-Chemical	D007980
-	O	O
induced	O	O
ballistic	O	O
and	O	O
choreic	O	O
dyskinesia	B-Disease	D004409
in	O	O
PD	B-Disease	D010300
.	O	O

Morphological	O	O
features	O	O
of	O	O
encephalopathy	B-Disease	D001927
after	O	O
chronic	O	O
administration	O	O
of	O	O
the	O	O
antiepileptic	O	O
drug	O	O
valproate	B-Chemical	D014635
to	O	O
rats	O	O
.	O	O

A	O	O
transmission	O	O
electron	O	O
microscopic	O	O
study	O	O
of	O	O
capillaries	O	O
in	O	O
the	O	O
cerebellar	O	O
cortex	O	O
.	O	O

Long	O	O
-	O	O
term	O	O
intragastric	O	O
application	O	O
of	O	O
the	O	O
antiepileptic	O	O
drug	O	O
sodium	B-Chemical	D014635
valproate	I-Chemical	D014635
(	O	O
Vupral	O	O
"Polfa"	O	O
)	O	O
at	O	O
the	O	O
effective	O	O
dose	O	O
of	O	O
200	O	O
mg	O	O
/	O	O
kg	O	O
b	O	O
.	O	O

w	O	O
.	O	O

once	O	O
daily	O	O
to	O	O
rats	O	O
for	O	O
1	O	O
,	O	O
3	O	O
,	O	O
6	O	O
,	O	O
9	O	O
and	O	O
12	O	O
months	O	O
revealed	O	O
neurological	B-Disease	D009422
disorders	I-Disease	D009422
indicating	O	O
cerebellum	B-Disease	D002526
damage	I-Disease	D002526
(	O	O
"valproate	O	O
encephalopathy"	O	O
)	O	O
.	O	O

The	O	O
first	O	O
ultrastructural	O	O
changes	O	O
in	O	O
structural	O	O
elements	O	O
of	O	O
the	O	O
blood	O	O
-	O	O
brain	O	O
-	O	O
barrier	O	O
(	O	O
BBB	O	O
)	O	O
in	O	O
the	O	O
cerebellar	O	O
cortex	O	O
were	O	O
detectable	O	O
after	O	O
3	O	O
months	O	O
of	O	O
the	O	O
experiment	O	O
.	O	O

They	O	O
became	O	O
more	O	O
severe	O	O
in	O	O
the	O	O
later	O	O
months	O	O
of	O	O
the	O	O
experiment	O	O
,	O	O
and	O	O
were	O	O
most	O	O
severe	O	O
after	O	O
12	O	O
months	O	O
,	O	O
located	O	O
mainly	O	O
in	O	O
the	O	O
molecular	O	O
layer	O	O
of	O	O
the	O	O
cerebellar	O	O
cortex	O	O
.	O	O

Lesions	O	O
of	O	O
the	O	O
capillary	O	O
included	O	O
necrosis	B-Disease	D009336
of	O	O
endothelial	O	O
cells	O	O
.	O	O

Organelles	O	O
of	O	O
these	O	O
cells	O	O
,	O	O
in	O	O
particular	O	O
the	O	O
mitochondria	O	O
(	O	O
increased	O	O
number	O	O
and	O	O
size	O	O
,	O	O
distinct	O	O
degeneration	O	O
of	O	O
their	O	O
matrix	O	O
and	O	O
cristae	O	O
)	O	O
and	O	O
Golgi	O	O
apparatus	O	O
were	O	O
altered	O	O
.	O	O

Reduced	O	O
size	O	O
of	O	O
capillary	O	O
lumen	O	O
and	O	O
occlusion	O	O
were	O	O
caused	O	O
by	O	O
swollen	O	O
endothelial	O	O
cells	O	O
which	O	O
had	O	O
luminal	B-Chemical	D010634
protrusions	O	O
and	O	O
swollen	O	O
microvilli	O	O
.	O	O

Pressure	O	O
on	O	O
the	O	O
vessel	O	O
wall	O	O
was	O	O
produced	O	O
by	O	O
enlarged	O	O
perivascular	O	O
astrocytic	O	O
processes	O	O
.	O	O

Fragments	O	O
of	O	O
necrotic	B-Disease	D009336
endothelial	O	O
cells	O	O
were	O	O
in	O	O
the	O	O
vascular	O	O
lumens	O	O
and	O	O
in	O	O
these	O	O
there	O	O
was	O	O
loosening	O	O
and	O	O
breaking	O	O
of	O	O
tight	O	O
cellular	O	O
junctions	O	O
.	O	O

Damage	O	O
to	O	O
the	O	O
vascular	O	O
basement	O	O
lamina	O	O
was	O	O
also	O	O
observed	O	O
.	O	O

Damage	O	O
to	O	O
the	O	O
capillary	O	O
was	O	O
accompanied	O	O
by	O	O
marked	O	O
damage	O	O
to	O	O
neuroglial	O	O
cells	O	O
,	O	O
mainly	O	O
to	O	O
perivascular	O	O
processes	O	O
of	O	O
astrocytes	O	O
.	O	O

The	O	O
proliferation	O	O
of	O	O
astrocytes	O	O
(	O	O
Bergmann's	O	O
in	O	O
particular	O	O
)	O	O
and	O	O
occasionally	O	O
of	O	O
oligodendrocytes	O	O
was	O	O
found	O	O
.	O	O

Alterations	O	O
in	O	O
the	O	O
structural	O	O
elements	O	O
of	O	O
the	O	O
BBB	O	O
coexisted	O	O
with	O	O
marked	O	O
lesions	O	O
of	O	O
neurons	O	O
of	O	O
the	O	O
cerebellum	O	O
(	O	O
Purkinje	O	O
cells	O	O
are	O	O
earliest	O	O
)	O	O
.	O	O

In	O	O
electron	O	O
micrographs	O	O
both	O	O
luminal	B-Chemical	D010634
and	O	O
antiluminal	O	O
sides	O	O
of	O	O
the	O	O
BBB	O	O
of	O	O
the	O	O
cerebellar	O	O
cortex	O	O
had	O	O
similar	O	O
lesions	O	O
.	O	O

The	O	O
possible	O	O
influence	O	O
of	O	O
the	O	O
hepatic	B-Disease	D056486
damage	I-Disease	D056486
,	O	O
mainly	O	O
hyperammonemia	B-Disease	D022124
,	O	O
upon	O	O
the	O	O
development	O	O
of	O	O
valproate	B-Chemical	D014635
encephalopathy	B-Disease	D001927
is	O	O
discussed	O	O
.	O	O

Macula	O	O
toxicity	B-Disease	D064420
after	O	O
intravitreal	O	O
amikacin	B-Chemical	D000583
.	O	O

BACKGROUND	O	O
:	O	O
Although	O	O
intravitreal	O	O
aminoglycosides	B-Chemical	D000617
have	O	O
substantially	O	O
improved	O	O
visual	O	O
prognosis	O	O
in	O	O
endophthalmitis	B-Disease	D009877
,	O	O
macular	O	O
infarction	B-Disease	D007238
may	O	O
impair	O	O
full	O	O
visual	O	O
recovery	O	O
.	O	O

METHODS	O	O
:	O	O
We	O	O
present	O	O
a	O	O
case	O	O
of	O	O
presumed	O	O
amikacin	B-Chemical	D000583
retinal	B-Disease	D012164
toxicity	I-Disease	D012164
following	O	O
treatment	O	O
with	O	O
amikacin	B-Chemical	D000583
and	O	O
vancomycin	B-Chemical	D014640
for	O	O
alpha	O	O
-	O	O
haemolytic	O	O
streptococcal	B-Disease	D013290
endophthalmitis	I-Disease	D013290
.	O	O

RESULTS	O	O
:	O	O
Endophthalmitis	B-Disease	D009877
resolved	O	O
with	O	O
improvement	O	O
in	O	O
visual	O	O
acuity	O	O
to	O	O
6	O	O
/	O	O
24	O	O
at	O	O
three	O	O
months	O	O
.	O	O

Fundus	O	O
fluorescein	B-Chemical	D019793
angiography	O	O
confirmed	O	O
macular	O	O
capillary	O	O
closure	O	O
and	O	O
telangiectasis	B-Disease	D013684
.	O	O

CONCLUSIONS	O	O
:	O	O
Currently	O	O
accepted	O	O
intravitreal	O	O
antibiotic	O	O
regimens	O	O
may	O	O
cause	O	O
retinal	B-Disease	D012164
toxicity	I-Disease	D012164
and	O	O
macular	O	O
ischaemia	B-Disease	D007511
.	O	O

Treatment	O	O
strategies	O	O
aimed	O	O
at	O	O
avoiding	O	O
retinal	B-Disease	D012164
toxicity	I-Disease	D012164
are	O	O
discussed	O	O
.	O	O

Iatrogenically	O	O
induced	O	O
intractable	O	O
atrioventricular	B-Disease	D013611
reentrant	I-Disease	D013611
tachycardia	I-Disease	D013611
after	O	O
verapamil	B-Chemical	D014700
and	O	O
catheter	O	O
ablation	O	O
in	O	O
a	O	O
patient	O	O
with	O	O
Wolff	B-Disease	D014927
-	I-Disease	D014927
Parkinson	I-Disease	D014927
-	I-Disease	D014927
White	I-Disease	D014927
syndrome	I-Disease	D014927
and	O	O
idiopathic	B-Disease	D002311
dilated	I-Disease	D002311
cardiomyopathy	I-Disease	D002311
.	O	O

In	O	O
a	O	O
patient	O	O
with	O	O
WPW	B-Disease	D014927
syndrome	I-Disease	D014927
and	O	O
idiopathic	B-Disease	D002311
dilated	I-Disease	D002311
cardiomyopathy	I-Disease	D002311
,	O	O
intractable	O	O
atrioventricular	B-Disease	D013611
reentrant	I-Disease	D013611
tachycardia	I-Disease	D013611
(	O	O
AVRT	B-Disease	D013611
)	O	O
was	O	O
iatrogenically	O	O
induced	O	O
.	O	O

QRS	O	O
without	O	O
preexcitation	O	O
,	O	O
caused	O	O
by	O	O
junctional	O	O
escape	O	O
beats	O	O
after	O	O
verapamil	B-Chemical	D014700
or	O	O
unidirectional	O	O
antegrade	O	O
block	O	O
of	O	O
accessory	O	O
pathway	O	O
after	O	O
catheter	O	O
ablation	O	O
,	O	O
established	O	O
frequent	O	O
AVRT	B-Disease	D013611
attack	O	O
.	O	O

Epidemic	O	O
of	O	O
liver	B-Disease	D008107
disease	I-Disease	D008107
caused	O	O
by	O	O
hydrochlorofluorocarbons	B-Chemical	-1
used	O	O
as	O	O
ozone	B-Chemical	D010126
-	O	O
sparing	O	O
substitutes	O	O
of	O	O
chlorofluorocarbons	B-Chemical	D017402
.	O	O

BACKGROUND	O	O
:	O	O
Hydrochlorofluorocarbons	B-Chemical	-1
(	O	O
HCFCs	B-Chemical	-1
)	O	O
are	O	O
used	O	O
increasingly	O	O
in	O	O
industry	O	O
as	O	O
substitutes	O	O
for	O	O
ozone	B-Chemical	D010126
-	O	O
depleting	O	O
chlorofluorocarbons	B-Chemical	D017402
(	O	O
CFCs	B-Chemical	D017402
)	O	O
.	O	O

Limited	O	O
studies	O	O
in	O	O
animals	O	O
indicate	O	O
potential	O	O
hepatotoxicity	B-Disease	D056486
of	O	O
some	O	O
of	O	O
these	O	O
compounds	O	O
.	O	O

We	O	O
investigated	O	O
an	O	O
epidemic	O	O
of	O	O
liver	B-Disease	D008107
disease	I-Disease	D008107
in	O	O
nine	O	O
industrial	O	O
workers	O	O
who	O	O
had	O	O
had	O	O
repeated	O	O
accidental	O	O
exposure	O	O
to	O	O
a	O	O
mixture	O	O
of	O	O
1	B-Chemical	C067411
,	I-Chemical	C067411
1	I-Chemical	C067411
-	I-Chemical	C067411
dichloro	I-Chemical	C067411
-	I-Chemical	C067411
2	I-Chemical	C067411
,	I-Chemical	C067411
2	I-Chemical	C067411
,	I-Chemical	C067411
2	I-Chemical	C067411
-	I-Chemical	C067411
trifluoroethane	I-Chemical	C067411
(	O	O
HCFC	B-Chemical	C067411
123	I-Chemical	C067411
)	O	O
and	O	O
1	B-Chemical	C072959
-	I-Chemical	C072959
chloro	I-Chemical	C072959
-	I-Chemical	C072959
1	I-Chemical	C072959
,	I-Chemical	C072959
2	I-Chemical	C072959
,	I-Chemical	C072959
2	I-Chemical	C072959
,	I-Chemical	C072959
2	I-Chemical	C072959
-	I-Chemical	C072959
tetrafluoroethane	I-Chemical	C072959
(	O	O
HCFC	B-Chemical	C072959
124	I-Chemical	C072959
)	O	O
.	O	O

All	O	O
nine	O	O
exposed	O	O
workers	O	O
were	O	O
affected	O	O
to	O	O
various	O	O
degrees	O	O
.	O	O

Both	O	O
compounds	O	O
are	O	O
metabolised	O	O
in	O	O
the	O	O
same	O	O
way	O	O
as	O	O
1	B-Chemical	D006221
-	I-Chemical	D006221
bromo	I-Chemical	D006221
-	I-Chemical	D006221
1	I-Chemical	D006221
-	I-Chemical	D006221
chloro	I-Chemical	D006221
-	I-Chemical	D006221
2	I-Chemical	D006221
,	I-Chemical	D006221
2	I-Chemical	D006221
,	I-Chemical	D006221
2	I-Chemical	D006221
-	I-Chemical	D006221
trifluoroethane	I-Chemical	D006221
(	O	O
halothane	B-Chemical	D006221
)	O	O
to	O	O
form	O	O
reactive	O	O
trifluoroacetyl	B-Chemical	D014269
halide	O	O
intermediates	O	O
,	O	O
which	O	O
have	O	O
been	O	O
implicated	O	O
in	O	O
the	O	O
hepatotoxicity	B-Disease	D056486
of	O	O
halothane	B-Chemical	D006221
.	O	O

We	O	O
aimed	O	O
to	O	O
test	O	O
whether	O	O
HCFCs	B-Chemical	-1
123	O	O
and	O	O
124	O	O
can	O	O
result	O	O
in	O	O
serious	O	O
liver	B-Disease	D008107
disease	I-Disease	D008107
.	O	O

METHODS	O	O
:	O	O
For	O	O
one	O	O
severely	O	O
affected	O	O
worker	O	O
liver	O	O
biopsy	O	O
and	O	O
immunohistochemical	O	O
stainings	O	O
for	O	O
the	O	O
presence	O	O
of	O	O
trifluoroacetyl	B-Chemical	D014269
protein	O	O
adducts	O	O
were	O	O
done	O	O
.	O	O

The	O	O
serum	O	O
of	O	O
six	O	O
affected	O	O
workers	O	O
and	O	O
five	O	O
controls	O	O
was	O	O
tested	O	O
for	O	O
autoantibodies	O	O
that	O	O
react	O	O
with	O	O
human	O	O
liver	O	O
cytochrome	O	O
-	O	O
P450	O	O
2E1	O	O
(	O	O
P450	O	O
2E1	O	O
)	O	O
and	O	O
P58	O	O
protein	O	O
disulphide	O	O
isomerase	O	O
isoform	O	O
(	O	O
P58	O	O
)	O	O
.	O	O

FINDINGS	O	O
:	O	O
The	O	O
liver	O	O
biopsy	O	O
sample	O	O
showed	O	O
hepatocellular	O	O
necrosis	B-Disease	D009336
which	O	O
was	O	O
prominent	O	O
in	O	O
perivenular	O	O
zone	O	O
three	O	O
and	O	O
extended	O	O
focally	O	O
from	O	O
portal	O	O
tracts	O	O
to	O	O
portal	O	O
tracts	O	O
and	O	O
centrilobular	O	O
areas	O	O
(	O	O
bridging	O	O
necrosis	B-Disease	D009336
)	O	O
.	O	O

Trifluoroacetyl	B-Chemical	D014269
-	O	O
adducted	O	O
proteins	O	O
were	O	O
detected	O	O
in	O	O
surviving	O	O
hepatocytes	O	O
.	O	O

Autoantibodies	O	O
against	O	O
P450	O	O
2E1	O	O
or	O	O
P58	O	O
,	O	O
previously	O	O
associated	O	O
with	O	O
halothane	B-Chemical	D006221
hepatitis	O	O
,	O	O
were	O	O
detected	O	O
in	O	O
the	O	O
serum	O	O
of	O	O
five	O	O
affected	O	O
workers	O	O
.	O	O

INTERPRETATION	O	O
:	O	O
Repeated	O	O
exposure	O	O
of	O	O
human	O	O
beings	O	O
to	O	O
HCFCs	B-Chemical	-1
123	O	O
and	O	O
124	O	O
can	O	O
result	O	O
in	O	O
serious	O	O
liver	B-Disease	D056486
injury	I-Disease	D056486
in	O	O
a	O	O
large	O	O
proportion	O	O
of	O	O
the	O	O
exposed	O	O
population	O	O
.	O	O

Although	O	O
the	O	O
exact	O	O
mechanism	O	O
of	O	O
hepatotoxicity	B-Disease	D056486
of	O	O
these	O	O
agents	O	O
is	O	O
not	O	O
known	O	O
,	O	O
the	O	O
results	O	O
suggest	O	O
that	O	O
trifluoroacetyl	B-Chemical	D014269
-	O	O
altered	O	O
liver	O	O
proteins	O	O
are	O	O
involved	O	O
.	O	O

In	O	O
view	O	O
of	O	O
the	O	O
potentially	O	O
widespread	O	O
use	O	O
of	O	O
these	O	O
compounds	O	O
,	O	O
there	O	O
is	O	O
an	O	O
urgent	O	O
need	O	O
to	O	O
develop	O	O
safer	O	O
alternatives	O	O
.	O	O

The	O	O
effect	O	O
of	O	O
different	O	O
anaesthetic	O	O
agents	O	O
in	O	O
hearing	B-Disease	D034381
loss	I-Disease	D034381
following	O	O
spinal	O	O
anaesthesia	O	O
.	O	O

The	O	O
cause	O	O
of	O	O
hearing	B-Disease	D034381
loss	I-Disease	D034381
after	O	O
spinal	O	O
anaesthesia	O	O
is	O	O
unknown	O	O
.	O	O

Up	O	O
until	O	O
now	O	O
,	O	O
the	O	O
only	O	O
factor	O	O
studied	O	O
has	O	O
been	O	O
the	O	O
effect	O	O
of	O	O
the	O	O
diameter	O	O
of	O	O
the	O	O
spinal	O	O
needle	O	O
on	O	O
post	O	O
-	O	O
operative	O	O
sensorineural	B-Disease	D006319
hearing	I-Disease	D006319
loss	I-Disease	D006319
.	O	O

The	O	O
aim	O	O
of	O	O
this	O	O
study	O	O
was	O	O
to	O	O
describe	O	O
this	O	O
hearing	B-Disease	D034381
loss	I-Disease	D034381
and	O	O
to	O	O
investigate	O	O
other	O	O
factors	O	O
influencing	O	O
the	O	O
degree	O	O
of	O	O
hearing	B-Disease	D034381
loss	I-Disease	D034381
.	O	O

Two	O	O
groups	O	O
of	O	O
22	O	O
similar	O	O
patients	O	O
were	O	O
studied	O	O
:	O	O
one	O	O
group	O	O
received	O	O
6	O	O
mL	O	O
prilocaine	B-Chemical	D011318
2%	O	O
;	O	O
and	O	O
the	O	O
other	O	O
received	O	O
3	O	O
mL	O	O
bupivacaine	B-Chemical	D002045
0	O	O
.	O	O

5%	O	O
.	O	O

Patients	O	O
given	O	O
prilocaine	B-Chemical	D011318
were	O	O
more	O	O
likely	O	O
to	O	O
develop	O	O
hearing	B-Disease	D034381
loss	I-Disease	D034381
(	O	O
10	O	O
out	O	O
of	O	O
22	O	O
)	O	O
than	O	O
those	O	O
given	O	O
bupivacaine	B-Chemical	D002045
(	O	O
4	O	O
out	O	O
of	O	O
22	O	O
)	O	O
(	O	O
P	O	O
<	O	O
0	O	O
.	O	O

05	O	O
)	O	O
.	O	O

The	O	O
average	O	O
hearing	B-Disease	D034381
loss	I-Disease	D034381
for	O	O
speech	O	O
frequencies	O	O
was	O	O
about	O	O
10	O	O
dB	O	O
after	O	O
prilocaine	B-Chemical	D011318
and	O	O
15	O	O
dB	O	O
after	O	O
bupivacaine	B-Chemical	D002045
.	O	O

None	O	O
of	O	O
the	O	O
patients	O	O
complained	O	O
of	O	O
subjective	O	O
hearing	B-Disease	D034381
loss	I-Disease	D034381
.	O	O

Long	O	O
-	O	O
term	O	O
follow	O	O
-	O	O
up	O	O
of	O	O
the	O	O
patients	O	O
was	O	O
not	O	O
possible	O	O
.	O	O

A	O	O
transient	O	O
neurological	B-Disease	D009461
deficit	I-Disease	D009461
following	O	O
intrathecal	O	O
injection	O	O
of	O	O
1%	O	O
hyperbaric	O	O
bupivacaine	B-Chemical	D002045
for	O	O
unilateral	O	O
spinal	O	O
anaesthesia	O	O
.	O	O

We	O	O
describe	O	O
a	O	O
case	O	O
of	O	O
transient	O	O
neurological	B-Disease	D009461
deficit	I-Disease	D009461
that	O	O
occurred	O	O
after	O	O
unilateral	O	O
spinal	O	O
anaesthesia	O	O
with	O	O
8	O	O
mg	O	O
of	O	O
1%	O	O
hyperbaric	O	O
bupivacaine	B-Chemical	D002045
slowly	O	O
injected	O	O
through	O	O
a	O	O
25	O	O
-	O	O
gauge	O	O
pencil	O	O
-	O	O
point	O	O
spinal	O	O
needle	O	O
.	O	O

The	O	O
surgery	O	O
and	O	O
anaesthesia	O	O
were	O	O
uneventful	O	O
,	O	O
but	O	O
3	O	O
days	O	O
after	O	O
surgery	O	O
,	O	O
the	O	O
patient	O	O
reported	O	O
an	O	O
area	O	O
of	O	O
hypoaesthesia	O	O
over	O	O
L3	O	O
-	O	O
L4	O	O
dermatomes	O	O
of	O	O
the	O	O
leg	O	O
which	O	O
had	O	O
been	O	O
operated	O	O
on	O	O
(	O	O
loss	B-Disease	D012678
of	I-Disease	D012678
pinprick	I-Disease	D012678
sensation	I-Disease	D012678
)	O	O
without	O	O
reduction	O	O
in	O	O
muscular	O	O
strength	O	O
.	O	O

Sensation	O	O
in	O	O
this	O	O
area	O	O
returned	O	O
to	O	O
normal	O	O
over	O	O
the	O	O
following	O	O
2	O	O
weeks	O	O
.	O	O

Prospective	O	O
multicentre	O	O
studies	O	O
with	O	O
a	O	O
large	O	O
population	O	O
and	O	O
a	O	O
long	O	O
follow	O	O
-	O	O
up	O	O
should	O	O
be	O	O
performed	O	O
in	O	O
order	O	O
to	O	O
evaluate	O	O
the	O	O
incidence	O	O
of	O	O
this	O	O
unusual	O	O
side	O	O
effect	O	O
.	O	O

However	O	O
,	O	O
we	O	O
suggest	O	O
that	O	O
a	O	O
low	O	O
solution	O	O
concentration	O	O
should	O	O
be	O	O
preferred	O	O
for	O	O
unilateral	O	O
spinal	O	O
anaesthesia	O	O
with	O	O
a	O	O
hyperbaric	O	O
anaesthetic	O	O
solution	O	O
(	O	O
if	O	O
pencil	O	O
-	O	O
point	O	O
needle	O	O
and	O	O
slow	O	O
injection	O	O
rate	O	O
are	O	O
employed	O	O
)	O	O
,	O	O
in	O	O
order	O	O
to	O	O
minimize	O	O
the	O	O
risk	O	O
of	O	O
a	O	O
localized	O	O
high	O	O
peak	O	O
anaesthetic	O	O
concentration	O	O
,	O	O
which	O	O
might	O	O
lead	O	O
to	O	O
a	O	O
transient	O	O
neurological	B-Disease	D009461
deficit	I-Disease	D009461
.	O	O

Pethidine	B-Chemical	D008614
-	O	O
associated	O	O
seizure	B-Disease	D012640
in	O	O
a	O	O
healthy	O	O
adolescent	O	O
receiving	O	O
pethidine	B-Chemical	D008614
for	O	O
postoperative	B-Disease	D010149
pain	I-Disease	D010149
control	O	O
.	O	O

A	O	O
healthy	O	O
17	O	O
-	O	O
year	O	O
-	O	O
old	O	O
male	O	O
received	O	O
standard	O	O
intermittent	O	O
doses	O	O
of	O	O
pethidine	B-Chemical	D008614
via	O	O
a	O	O
patient	O	O
-	O	O
controlled	O	O
analgesia	O	O
(	O	O
PCA	O	O
)	O	O
pump	O	O
for	O	O
management	O	O
of	O	O
postoperative	B-Disease	D010149
pain	I-Disease	D010149
control	O	O
.	O	O

Twenty	O	O
-	O	O
three	O	O
h	O	O
postoperatively	O	O
he	O	O
developed	O	O
a	O	O
brief	O	O
self	O	O
-	O	O
limited	O	O
seizure	B-Disease	D012640
.	O	O

Both	O	O
plasma	O	O
pethidine	B-Chemical	D008614
and	O	O
norpethidine	B-Chemical	C002752
were	O	O
elevated	O	O
in	O	O
the	O	O
range	O	O
associated	O	O
with	O	O
clinical	O	O
manifestations	O	O
of	O	O
central	O	O
nervous	O	O
system	O	O
excitation	O	O
.	O	O

No	O	O
other	O	O
risk	O	O
factors	O	O
for	O	O
CNS	O	O
toxicity	B-Disease	D064420
were	O	O
identified	O	O
.	O	O

This	O	O
method	O	O
allowed	O	O
frequent	O	O
self	O	O
-	O	O
dosing	O	O
of	O	O
pethidine	B-Chemical	D008614
at	O	O
short	O	O
time	O	O
intervals	O	O
and	O	O
rapid	O	O
accumulation	O	O
of	O	O
pethidine	B-Chemical	D008614
and	O	O
norpethidine	B-Chemical	C002752
.	O	O

The	O	O
routine	O	O
use	O	O
of	O	O
pethidine	B-Chemical	D008614
via	O	O
PCA	O	O
even	O	O
for	O	O
a	O	O
brief	O	O
postoperative	O	O
analgesia	O	O
should	O	O
be	O	O
reconsidered	O	O
.	O	O

Drug	O	O
-	O	O
associated	O	O
acute	O	O
-	O	O
onset	O	O
vanishing	B-Disease	D001649
bile	I-Disease	D001649
duct	I-Disease	D001649
and	O	O
Stevens	B-Disease	D013262
-	I-Disease	D013262
Johnson	I-Disease	D013262
syndromes	I-Disease	D013262
in	O	O
a	O	O
child	O	O
.	O	O

Acute	O	O
vanishing	B-Disease	D001649
bile	I-Disease	D001649
duct	I-Disease	D001649
syndrome	O	O
is	O	O
a	O	O
rare	O	O
but	O	O
established	O	O
cause	O	O
of	O	O
progressive	O	O
cholestasis	B-Disease	D002779
in	O	O
adults	O	O
,	O	O
is	O	O
most	O	O
often	O	O
drug	O	O
or	O	O
toxin	O	O
related	O	O
,	O	O
and	O	O
is	O	O
of	O	O
unknown	O	O
pathogenesis	O	O
.	O	O

It	O	O
has	O	O
not	O	O
been	O	O
reported	O	O
previously	O	O
in	O	O
children	O	O
.	O	O

Stevens	B-Disease	D013262
-	I-Disease	D013262
Johnson	I-Disease	D013262
syndrome	I-Disease	D013262
is	O	O
a	O	O
well	O	O
-	O	O
recognized	O	O
immune	O	O
complex	O	O
-	O	O
mediated	O	O
hypersensitivity	B-Disease	D004342
reaction	O	O
that	O	O
affects	O	O
all	O	O
age	O	O
groups	O	O
,	O	O
is	O	O
drug	O	O
or	O	O
infection	B-Disease	D007239
induced	O	O
,	O	O
and	O	O
has	O	O
classic	O	O
systemic	O	O
,	O	O
mucosal	O	O
,	O	O
and	O	O
dermatologic	O	O
manifestations	O	O
.	O	O

A	O	O
previously	O	O
healthy	O	O
child	O	O
who	O	O
developed	O	O
acute	O	O
,	O	O
severe	O	O
,	O	O
rapidly	O	O
progressive	O	O
vanishing	B-Disease	D001649
bile	I-Disease	D001649
duct	I-Disease	D001649
syndrome	O	O
shortly	O	O
after	O	O
Stevens	B-Disease	D013262
-	I-Disease	D013262
Johnson	I-Disease	D013262
syndrome	I-Disease	D013262
is	O	O
described	O	O
;	O	O
this	O	O
was	O	O
temporally	O	O
associated	O	O
with	O	O
ibuprofen	B-Chemical	D007052
use	O	O
.	O	O

Despite	O	O
therapy	O	O
with	O	O
ursodeoxycholic	B-Chemical	D014580
acid	I-Chemical	D014580
,	O	O
prednisone	B-Chemical	D011241
,	O	O
and	O	O
then	O	O
tacrolimus	B-Chemical	D016559
,	O	O
her	O	O
cholestatic	B-Disease	D002779
disease	I-Disease	D002779
was	O	O
unrelenting	O	O
,	O	O
with	O	O
cirrhosis	B-Disease	D005355
shown	O	O
by	O	O
biopsy	O	O
6	O	O
months	O	O
after	O	O
presentation	O	O
.	O	O

This	O	O
case	O	O
documents	O	O
acute	O	O
drug	O	O
-	O	O
related	O	O
vanishing	B-Disease	D001649
bile	I-Disease	D001649
duct	I-Disease	D001649
syndrome	O	O
in	O	O
the	O	O
pediatric	O	O
age	O	O
group	O	O
and	O	O
suggests	O	O
shared	O	O
immune	O	O
mechanisms	O	O
in	O	O
the	O	O
pathogenesis	O	O
of	O	O
both	O	O
Stevens	B-Disease	D013262
-	I-Disease	D013262
Johnson	I-Disease	D013262
syndrome	I-Disease	D013262
and	O	O
vanishing	B-Disease	D001649
bile	I-Disease	D001649
duct	I-Disease	D001649
syndrome	O	O
.	O	O

High	O	O
incidence	O	O
of	O	O
primary	B-Disease	D006976
pulmonary	I-Disease	D006976
hypertension	I-Disease	D006976
associated	O	O
with	O	O
appetite	B-Chemical	D001067
suppressants	I-Chemical	D001067
in	O	O
Belgium	O	O
.	O	O

Primary	B-Disease	D006976
pulmonary	I-Disease	D006976
hypertension	I-Disease	D006976
is	O	O
a	O	O
rare	O	O
,	O	O
progressive	O	O
and	O	O
incurable	O	O
disease	O	O
,	O	O
which	O	O
has	O	O
been	O	O
associated	O	O
with	O	O
the	O	O
intake	O	O
of	O	O
appetite	B-Chemical	D001067
suppressant	I-Chemical	D001067
drugs	O	O
.	O	O

The	O	O
importance	O	O
of	O	O
this	O	O
association	O	O
was	O	O
evaluated	O	O
in	O	O
Belgium	O	O
while	O	O
this	O	O
country	O	O
still	O	O
had	O	O
no	O	O
restriction	O	O
on	O	O
the	O	O
prescription	O	O
of	O	O
appetite	B-Chemical	D001067
suppressants	I-Chemical	D001067
.	O	O

Thirty	O	O
-	O	O
five	O	O
patients	O	O
with	O	O
primary	B-Disease	D006976
pulmonary	I-Disease	D006976
hypertension	I-Disease	D006976
and	O	O
85	O	O
matched	O	O
controls	O	O
were	O	O
recruited	O	O
over	O	O
32	O	O
months	O	O
(	O	O
1992	O	O
-	O	O
1994	O	O
)	O	O
in	O	O
Belgium	O	O
.	O	O

Exposure	O	O
to	O	O
appetite	B-Chemical	D001067
-	I-Chemical	D001067
suppressants	I-Chemical	D001067
was	O	O
assessed	O	O
on	O	O
the	O	O
basis	O	O
of	O	O
hospital	O	O
records	O	O
and	O	O
standardized	O	O
interview	O	O
.	O	O

Twenty	O	O
-	O	O
three	O	O
of	O	O
the	O	O
patients	O	O
had	O	O
previously	O	O
taken	O	O
appetite	B-Chemical	D001067
suppressants	I-Chemical	D001067
,	O	O
mainly	O	O
fenfluramines	B-Chemical	D005277
,	O	O
as	O	O
compared	O	O
with	O	O
only	O	O
5	O	O
of	O	O
the	O	O
controls	O	O
(	O	O
66	O	O
versus	O	O
6%	O	O
,	O	O
p<0	O	O
.	O	O

0001	O	O
)	O	O
.	O	O

Five	O	O
patients	O	O
died	O	O
before	O	O
the	O	O
interview	O	O
,	O	O
all	O	O
of	O	O
them	O	O
had	O	O
taken	O	O
appetite	B-Chemical	D001067
suppressants	I-Chemical	D001067
.	O	O

In	O	O
8	O	O
patients	O	O
the	O	O
diagnosis	O	O
of	O	O
primary	B-Disease	D006976
pulmonary	I-Disease	D006976
hypertension	I-Disease	D006976
was	O	O
uncertain	O	O
,	O	O
5	O	O
of	O	O
them	O	O
had	O	O
taken	O	O
appetite	B-Chemical	D001067
suppressants	I-Chemical	D001067
.	O	O

The	O	O
patients	O	O
who	O	O
had	O	O
been	O	O
exposed	O	O
to	O	O
appetite	B-Chemical	D001067
suppressants	I-Chemical	D001067
tended	O	O
to	O	O
be	O	O
on	O	O
average	O	O
more	O	O
severely	O	O
ill	O	O
,	O	O
and	O	O
to	O	O
have	O	O
a	O	O
shorter	O	O
median	O	O
delay	O	O
between	O	O
onset	O	O
of	O	O
symptoms	O	O
and	O	O
diagnosis	O	O
.	O	O

A	O	O
policy	O	O
of	O	O
unrestricted	O	O
prescription	O	O
of	O	O
appetite	B-Chemical	D001067
suppressants	I-Chemical	D001067
may	O	O
lead	O	O
to	O	O
a	O	O
high	O	O
incidence	O	O
of	O	O
associated	O	O
primary	B-Disease	D006976
pulmonary	I-Disease	D006976
hypertension	I-Disease	D006976
.	O	O

Intake	O	O
of	O	O
appetite	B-Chemical	D001067
suppressants	I-Chemical	D001067
may	O	O
accelerate	O	O
the	O	O
progression	O	O
of	O	O
the	O	O
disease	O	O
.	O	O

Choreoathetoid	B-Disease	D002819
movements	I-Disease	D002819
associated	O	O
with	O	O
rapid	O	O
adjustment	O	O
to	O	O
methadone	B-Chemical	D008691
.	O	O

Choreatiform	O	O
hyperkinesias	O	O
are	O	O
known	O	O
to	O	O
be	O	O
occasional	O	O
movement	B-Disease	D020820
abnormalities	I-Disease	D020820
during	O	O
intoxications	O	O
with	O	O
cocaine	B-Chemical	D003042
but	O	O
not	O	O
opiates	O	O
.	O	O

This	O	O
is	O	O
a	O	O
case	O	O
report	O	O
of	O	O
euphoria	O	O
and	O	O
choreoathetoid	B-Disease	D002819
movements	I-Disease	D002819
both	O	O
transiently	O	O
induced	O	O
by	O	O
rapid	O	O
adjustment	O	O
to	O	O
the	O	O
selective	O	O
mu	O	O
-	O	O
opioid	O	O
receptor	O	O
agonist	O	O
methadone	B-Chemical	D008691
in	O	O
an	O	O
inpatient	O	O
previously	O	O
abusing	O	O
heroine	B-Chemical	D003932
and	O	O
cocaine	B-Chemical	D003042
.	O	O

In	O	O
addition	O	O
,	O	O
minor	O	O
EEG	O	O
abnormalities	O	O
occurred	O	O
.	O	O

Possible	O	O
underlying	O	O
neurobiological	O	O
phenomena	O	O
are	O	O
discussed	O	O
.	O	O

Cocaine	B-Chemical	D003042
-	O	O
induced	O	O
mood	B-Disease	D019964
disorder	I-Disease	D019964
:	O	O
prevalence	O	O
rates	O	O
and	O	O
psychiatric	B-Disease	D001523
symptoms	O	O
in	O	O
an	O	O
outpatient	O	O
cocaine	B-Chemical	D003042
-	O	O
dependent	O	O
sample	O	O
.	O	O

This	O	O
paper	O	O
attempts	O	O
to	O	O
examine	O	O
and	O	O
compare	O	O
prevalence	O	O
rates	O	O
and	O	O
symptom	O	O
patterns	O	O
of	O	O
DSM	O	O
substance	O	O
-	O	O
induced	O	O
and	O	O
other	O	O
mood	B-Disease	D019964
disorders	I-Disease	D019964
.	O	O

243	O	O
cocaine	B-Chemical	D003042
-	O	O
dependent	O	O
outpatients	O	O
with	O	O
cocaine	B-Chemical	D003042
-	O	O
induced	O	O
mood	B-Disease	D019964
disorder	I-Disease	D019964
(	O	O
CIMD	B-Disease	D019970
)	O	O
,	O	O
other	O	O
mood	B-Disease	D019964
disorders	I-Disease	D019964
,	O	O
or	O	O
no	O	O
mood	B-Disease	D019964
disorder	I-Disease	D019964
were	O	O
compared	O	O
on	O	O
measures	O	O
of	O	O
psychiatric	B-Disease	D001523
symptoms	O	O
.	O	O

The	O	O
prevalence	O	O
rate	O	O
for	O	O
CIMD	B-Disease	D019970
was	O	O
12%	O	O
at	O	O
baseline	O	O
.	O	O

Introduction	O	O
of	O	O
the	O	O
DSM	O	O
-	O	O
IV	O	O
diagnosis	O	O
of	O	O
CIMD	B-Disease	D019970
did	O	O
not	O	O
substantially	O	O
affect	O	O
rates	O	O
of	O	O
the	O	O
other	O	O
depressive	B-Disease	D003866
disorders	I-Disease	D003866
.	O	O

Patients	O	O
with	O	O
CIMD	B-Disease	D019970
had	O	O
symptom	O	O
severity	O	O
levels	O	O
between	O	O
those	O	O
of	O	O
patients	O	O
with	O	O
and	O	O
without	O	O
a	O	O
mood	B-Disease	D019964
disorder	I-Disease	D019964
.	O	O

These	O	O
findings	O	O
suggest	O	O
some	O	O
validity	O	O
for	O	O
the	O	O
new	O	O
DSM	O	O
-	O	O
IV	O	O
diagnosis	O	O
of	O	O
CIMD	B-Disease	D019970
,	O	O
but	O	O
also	O	O
suggest	O	O
that	O	O
it	O	O
requires	O	O
further	O	O
specification	O	O
and	O	O
replication	O	O
.	O	O

Hemolysis	B-Disease	D006461
of	O	O
human	O	O
erythrocytes	O	O
induced	O	O
by	O	O
tamoxifen	B-Chemical	D013629
is	O	O
related	O	O
to	O	O
disruption	O	O
of	O	O
membrane	O	O
structure	O	O
.	O	O

Tamoxifen	B-Chemical	D013629
(	O	O
TAM	B-Chemical	D013629
)	O	O
,	O	O
the	O	O
antiestrogenic	O	O
drug	O	O
most	O	O
widely	O	O
prescribed	O	O
in	O	O
the	O	O
chemotherapy	O	O
of	O	O
breast	B-Disease	D001943
cancer	I-Disease	D001943
,	O	O
induces	O	O
changes	O	O
in	O	O
normal	O	O
discoid	O	O
shape	O	O
of	O	O
erythrocytes	O	O
and	O	O
hemolytic	B-Disease	D000743
anemia	I-Disease	D000743
.	O	O

This	O	O
work	O	O
evaluates	O	O
the	O	O
effects	O	O
of	O	O
TAM	B-Chemical	D013629
on	O	O
isolated	O	O
human	O	O
erythrocytes	O	O
,	O	O
attempting	O	O
to	O	O
identify	O	O
the	O	O
underlying	O	O
mechanisms	O	O
on	O	O
TAM	B-Chemical	D013629
-	O	O
induced	O	O
hemolytic	B-Disease	D000743
anemia	I-Disease	D000743
and	O	O
the	O	O
involvement	O	O
of	O	O
biomembranes	O	O
in	O	O
its	O	O
cytostatic	O	O
action	O	O
mechanisms	O	O
.	O	O

TAM	B-Chemical	D013629
induces	O	O
hemolysis	B-Disease	D006461
of	O	O
erythrocytes	O	O
as	O	O
a	O	O
function	O	O
of	O	O
concentration	O	O
.	O	O

The	O	O
extension	O	O
of	O	O
hemolysis	B-Disease	D006461
is	O	O
variable	O	O
with	O	O
erythrocyte	O	O
samples	O	O
,	O	O
but	O	O
12	O	O
.	O	O

5	O	O
microM	O	O
TAM	B-Chemical	D013629
induces	O	O
total	O	O
hemolysis	B-Disease	D006461
of	O	O
all	O	O
tested	O	O
suspensions	O	O
.	O	O

Despite	O	O
inducing	O	O
extensive	O	O
erythrocyte	O	O
lysis	O	O
,	O	O
TAM	B-Chemical	D013629
does	O	O
not	O	O
shift	O	O
the	O	O
osmotic	O	O
fragility	O	O
curves	O	O
of	O	O
erythrocytes	O	O
.	O	O

The	O	O
hemolytic	B-Disease	D006461
effect	O	O
of	O	O
TAM	B-Chemical	D013629
is	O	O
prevented	O	O
by	O	O
low	O	O
concentrations	O	O
of	O	O
alpha	B-Chemical	D024502
-	I-Chemical	D024502
tocopherol	I-Chemical	D024502
(	O	O
alpha	B-Chemical	D024502
-	I-Chemical	D024502
T	I-Chemical	D024502
)	O	O
and	O	O
alpha	B-Chemical	D024502
-	I-Chemical	D024502
tocopherol	I-Chemical	D024502
acetate	O	O
(	O	O
alpha	B-Chemical	D024502
-	I-Chemical	D024502
TAc	I-Chemical	D024502
)	O	O
(	O	O
inactivated	O	O
functional	O	O
hydroxyl	B-Chemical	D017665
)	O	O
indicating	O	O
that	O	O
TAM	B-Chemical	D013629
-	O	O
induced	O	O
hemolysis	B-Disease	D006461
is	O	O
not	O	O
related	O	O
to	O	O
oxidative	O	O
membrane	O	O
damage	O	O
.	O	O

This	O	O
was	O	O
further	O	O
evidenced	O	O
by	O	O
absence	O	O
of	O	O
oxygen	B-Chemical	D010100
consumption	O	O
and	O	O
hemoglobin	O	O
oxidation	O	O
both	O	O
determined	O	O
in	O	O
parallel	O	O
with	O	O
TAM	B-Chemical	D013629
-	O	O
induced	O	O
hemolysis	B-Disease	D006461
.	O	O

Furthermore	O	O
,	O	O
it	O	O
was	O	O
observed	O	O
that	O	O
TAM	B-Chemical	D013629
inhibits	O	O
the	O	O
peroxidation	O	O
of	O	O
human	O	O
erythrocytes	O	O
induced	O	O
by	O	O
AAPH	B-Chemical	C046728
,	O	O
thus	O	O
ruling	O	O
out	O	O
TAM	B-Chemical	D013629
-	O	O
induced	O	O
cell	O	O
oxidative	O	O
stress	O	O
.	O	O

Hemolysis	B-Disease	D006461
caused	O	O
by	O	O
TAM	B-Chemical	D013629
was	O	O
not	O	O
preceded	O	O
by	O	O
the	O	O
leakage	O	O
of	O	O
K	B-Chemical	D011188
(	O	O
+	O	O
)	O	O
from	O	O
the	O	O
cells	O	O
,	O	O
also	O	O
excluding	O	O
a	O	O
colloid	O	O
-	O	O
osmotic	O	O
type	O	O
mechanism	O	O
of	O	O
hemolysis	B-Disease	D006461
,	O	O
according	O	O
to	O	O
the	O	O
effects	O	O
on	O	O
osmotic	O	O
fragility	O	O
curves	O	O
.	O	O

However	O	O
,	O	O
TAM	B-Chemical	D013629
induces	O	O
release	O	O
of	O	O
peripheral	O	O
proteins	O	O
of	O	O
membrane	O	O
-	O	O
cytoskeleton	O	O
and	O	O
cytosol	O	O
proteins	O	O
essentially	O	O
bound	O	O
to	O	O
band	O	O
3	O	O
.	O	O

Either	O	O
alpha	B-Chemical	D024502
-	I-Chemical	D024502
T	I-Chemical	D024502
or	O	O
alpha	B-Chemical	D024502
-	I-Chemical	D024502
TAc	I-Chemical	D024502
increases	O	O
membrane	O	O
packing	O	O
and	O	O
prevents	O	O
TAM	B-Chemical	D013629
partition	O	O
into	O	O
model	O	O
membranes	O	O
.	O	O

These	O	O
effects	O	O
suggest	O	O
that	O	O
the	O	O
protection	O	O
from	O	O
hemolysis	B-Disease	D006461
by	O	O
tocopherols	B-Chemical	D024505
is	O	O
related	O	O
to	O	O
a	O	O
decreased	O	O
TAM	B-Chemical	D013629
incorporation	O	O
in	O	O
condensed	O	O
membranes	O	O
and	O	O
the	O	O
structural	O	O
damage	O	O
of	O	O
the	O	O
erythrocyte	O	O
membrane	O	O
is	O	O
consequently	O	O
avoided	O	O
.	O	O

Therefore	O	O
,	O	O
TAM	B-Chemical	D013629
-	O	O
induced	O	O
hemolysis	B-Disease	D006461
results	O	O
from	O	O
a	O	O
structural	O	O
perturbation	O	O
of	O	O
red	O	O
cell	O	O
membrane	O	O
,	O	O
leading	O	O
to	O	O
changes	O	O
in	O	O
the	O	O
framework	O	O
of	O	O
the	O	O
erythrocyte	O	O
membrane	O	O
and	O	O
its	O	O
cytoskeleton	O	O
caused	O	O
by	O	O
its	O	O
high	O	O
partition	O	O
in	O	O
the	O	O
membrane	O	O
.	O	O

These	O	O
defects	O	O
explain	O	O
the	O	O
abnormal	O	O
erythrocyte	O	O
shape	O	O
and	O	O
decreased	O	O
mechanical	O	O
stability	O	O
promoted	O	O
by	O	O
TAM	B-Chemical	D013629
,	O	O
resulting	O	O
in	O	O
hemolytic	B-Disease	D000743
anemia	I-Disease	D000743
.	O	O

Additionally	O	O
,	O	O
since	O	O
membrane	O	O
leakage	O	O
is	O	O
a	O	O
final	O	O
stage	O	O
of	O	O
cytotoxicity	O	O
,	O	O
the	O	O
disruption	O	O
of	O	O
the	O	O
structural	O	O
characteristics	O	O
of	O	O
biomembranes	O	O
by	O	O
TAM	B-Chemical	D013629
may	O	O
contribute	O	O
to	O	O
the	O	O
multiple	O	O
mechanisms	O	O
of	O	O
its	O	O
anticancer	O	O
action	O	O
.	O	O

Changes	O	O
of	O	O
sodium	B-Chemical	D012964
and	O	O
ATP	B-Chemical	D000255
affinities	O	O
of	O	O
the	O	O
cardiac	O	O
(	O	O
Na	B-Chemical	D012964
,	O	O
K	B-Chemical	D011188
)	O	O
-	O	O
ATPase	O	O
during	O	O
and	O	O
after	O	O
nitric	B-Chemical	D009569
oxide	I-Chemical	D009569
deficient	O	O
hypertension	B-Disease	D006973
.	O	O

In	O	O
the	O	O
cardiovascular	O	O
system	O	O
,	O	O
NO	B-Chemical	D009569
is	O	O
involved	O	O
in	O	O
the	O	O
regulation	O	O
of	O	O
a	O	O
variety	O	O
of	O	O
functions	O	O
.	O	O

Inhibition	O	O
of	O	O
NO	B-Chemical	D009569
synthesis	O	O
induces	O	O
sustained	O	O
hypertension	B-Disease	D006973
.	O	O

In	O	O
several	O	O
models	O	O
of	O	O
hypertension	B-Disease	D006973
,	O	O
elevation	O	O
of	O	O
intracellular	O	O
sodium	B-Chemical	D012964
level	O	O
was	O	O
documented	O	O
in	O	O
cardiac	O	O
tissue	O	O
.	O	O

To	O	O
assess	O	O
the	O	O
molecular	O	O
basis	O	O
of	O	O
disturbances	O	O
in	O	O
transmembraneous	O	O
transport	O	O
of	O	O
Na+	O	O
,	O	O
we	O	O
studied	O	O
the	O	O
response	O	O
of	O	O
cardiac	O	O
(	O	O
Na	B-Chemical	D012964
,	O	O
K	B-Chemical	D011188
)	O	O
-	O	O
ATPase	O	O
to	O	O
NO	B-Chemical	D009569
-	O	O
deficient	O	O
hypertension	B-Disease	D006973
induced	O	O
in	O	O
rats	O	O
by	O	O
NO	B-Chemical	D009569
-	O	O
synthase	O	O
inhibition	O	O
with	O	O
40	O	O
mg	O	O
/	O	O
kg	O	O
/	O	O
day	O	O
N	B-Chemical	D019331
(	I-Chemical	D019331
G	I-Chemical	D019331
)	I-Chemical	D019331
-	I-Chemical	D019331
nitro	I-Chemical	D019331
-	I-Chemical	D019331
L	I-Chemical	D019331
-	I-Chemical	D019331
arginine	I-Chemical	D019331
methyl	I-Chemical	D019331
ester	I-Chemical	D019331
(	O	O
L	B-Chemical	D019331
-	I-Chemical	D019331
NAME	I-Chemical	D019331
)	O	O
for	O	O
4	O	O
four	O	O
weeks	O	O
.	O	O

After	O	O
4	O	O
-	O	O
week	O	O
administration	O	O
of	O	O
L	B-Chemical	D019331
-	I-Chemical	D019331
NAME	I-Chemical	D019331
,	O	O
the	O	O
systolic	O	O
blood	O	O
pressure	O	O
(	O	O
SBP	O	O
)	O	O
increased	O	O
by	O	O
36%	O	O
.	O	O

Two	O	O
weeks	O	O
after	O	O
terminating	O	O
the	O	O
treatment	O	O
,	O	O
the	O	O
SBP	O	O
recovered	O	O
to	O	O
control	O	O
value	O	O
.	O	O

When	O	O
activating	O	O
the	O	O
(	O	O
Na	B-Chemical	D012964
,	O	O
K	B-Chemical	D011188
)	O	O
-	O	O
ATPase	O	O
with	O	O
its	O	O
substrate	O	O
ATP	B-Chemical	D000255
,	O	O
no	O	O
changes	O	O
in	O	O
Km	O	O
and	O	O
Vmax	O	O
values	O	O
were	O	O
observed	O	O
in	O	O
NO	B-Chemical	D009569
-	O	O
deficient	O	O
rats	O	O
.	O	O

During	O	O
activation	O	O
with	O	O
Na+	O	O
,	O	O
the	O	O
Vmax	O	O
remained	O	O
unchanged	O	O
,	O	O
however	O	O
the	O	O
K	B-Chemical	D011188
(	O	O
Na	B-Chemical	D012964
)	O	O
increased	O	O
by	O	O
50%	O	O
,	O	O
indicating	O	O
a	O	O
profound	O	O
decrease	O	O
in	O	O
the	O	O
affinity	O	O
of	O	O
the	O	O
Na+	O	O
-	O	O
binding	O	O
site	O	O
in	O	O
NO	B-Chemical	D009569
-	O	O
deficient	O	O
rats	O	O
.	O	O

After	O	O
recovery	O	O
from	O	O
hypertension	B-Disease	D006973
,	O	O
the	O	O
activity	O	O
of	O	O
(	O	O
Na	B-Chemical	D012964
,	O	O
K	B-Chemical	D011188
)	O	O
-	O	O
ATPase	O	O
increased	O	O
,	O	O
due	O	O
to	O	O
higher	O	O
affinity	O	O
of	O	O
the	O	O
ATP	B-Chemical	D000255
-	O	O
binding	O	O
site	O	O
,	O	O
as	O	O
revealed	O	O
from	O	O
the	O	O
lowered	O	O
Km	O	O
value	O	O
for	O	O
ATP	B-Chemical	D000255
.	O	O

The	O	O
K	B-Chemical	D011188
(	O	O
Na	B-Chemical	D012964
)	O	O
value	O	O
for	O	O
Na+	O	O
returned	O	O
to	O	O
control	O	O
value	O	O
.	O	O

Inhibition	O	O
of	O	O
NO	B-Chemical	D009569
-	O	O
synthase	O	O
induced	O	O
a	O	O
reversible	O	O
hypertension	B-Disease	D006973
accompanied	O	O
by	O	O
depressed	B-Disease	D003866
Na+	O	O
-	O	O
extrusion	O	O
from	O	O
cardiac	O	O
cells	O	O
as	O	O
a	O	O
consequence	O	O
of	O	O
deteriorated	O	O
Na+	O	O
-	O	O
binding	O	O
properties	O	O
of	O	O
the	O	O
(	O	O
Na	B-Chemical	D012964
,	O	O
K	B-Chemical	D011188
)	O	O
-	O	O
ATPase	O	O
.	O	O

After	O	O
recovery	O	O
of	O	O
blood	O	O
pressure	O	O
to	O	O
control	O	O
values	O	O
,	O	O
the	O	O
extrusion	O	O
of	O	O
Na+	O	O
from	O	O
cardiac	O	O
cells	O	O
was	O	O
normalized	O	O
,	O	O
as	O	O
revealed	O	O
by	O	O
restoration	O	O
of	O	O
the	O	O
(	O	O
Na	B-Chemical	D012964
,	O	O
K	B-Chemical	D011188
)	O	O
-	O	O
ATPase	O	O
activity	O	O
.	O	O

Effects	O	O
of	O	O
long	O	O
-	O	O
term	O	O
pretreatment	O	O
with	O	O
isoproterenol	B-Chemical	D007545
on	O	O
bromocriptine	B-Chemical	D001971
-	O	O
induced	O	O
tachycardia	B-Disease	D013610
in	O	O
conscious	O	O
rats	O	O
.	O	O

It	O	O
has	O	O
been	O	O
shown	O	O
that	O	O
bromocriptine	B-Chemical	D001971
-	O	O
induced	O	O
tachycardia	B-Disease	D013610
,	O	O
which	O	O
persisted	O	O
after	O	O
adrenalectomy	O	O
,	O	O
is	O	O
(	O	O
i	O	O
)	O	O
mediated	O	O
by	O	O
central	O	O
dopamine	B-Chemical	D004298
D2	O	O
receptor	O	O
activation	O	O
and	O	O
(	O	O
ii	O	O
)	O	O
reduced	O	O
by	O	O
5	O	O
-	O	O
day	O	O
isoproterenol	B-Chemical	D007545
pretreatment	O	O
,	O	O
supporting	O	O
therefore	O	O
the	O	O
hypothesis	O	O
that	O	O
this	O	O
effect	O	O
is	O	O
dependent	O	O
on	O	O
sympathetic	O	O
outflow	O	O
to	O	O
the	O	O
heart	O	O
.	O	O

This	O	O
study	O	O
was	O	O
conducted	O	O
to	O	O
examine	O	O
whether	O	O
prolonged	O	O
pretreatment	O	O
with	O	O
isoproterenol	B-Chemical	D007545
could	O	O
abolish	O	O
bromocriptine	B-Chemical	D001971
-	O	O
induced	O	O
tachycardia	B-Disease	D013610
in	O	O
conscious	O	O
rats	O	O
.	O	O

Isoproterenol	B-Chemical	D007545
pretreatment	O	O
for	O	O
15	O	O
days	O	O
caused	O	O
cardiac	B-Disease	D006332
hypertrophy	I-Disease	D006332
without	O	O
affecting	O	O
baseline	O	O
blood	O	O
pressure	O	O
and	O	O
heart	O	O
rate	O	O
.	O	O

In	O	O
control	O	O
rats	O	O
,	O	O
intravenous	O	O
bromocriptine	B-Chemical	D001971
(	O	O
150	O	O
microg	O	O
/	O	O
kg	O	O
)	O	O
induced	O	O
significant	O	O
hypotension	B-Disease	D007022
and	O	O
tachycardia	B-Disease	D013610
.	O	O

Bromocriptine	B-Chemical	D001971
-	O	O
induced	O	O
hypotension	B-Disease	D007022
was	O	O
unaffected	O	O
by	O	O
isoproterenol	B-Chemical	D007545
pretreatment	O	O
,	O	O
while	O	O
tachycardia	B-Disease	D013610
was	O	O
reversed	O	O
to	O	O
significant	O	O
bradycardia	B-Disease	D001919
,	O	O
an	O	O
effect	O	O
that	O	O
was	O	O
partly	O	O
reduced	O	O
by	O	O
i	O	O
.	O	O

v	O	O
.	O	O

domperidone	B-Chemical	D004294
(	O	O
0	O	O
.	O	O

5	O	O
mg	O	O
/	O	O
kg	O	O
)	O	O
.	O	O

Neither	O	O
cardiac	O	O
vagal	O	O
nor	O	O
sympathetic	O	O
tone	O	O
was	O	O
altered	O	O
by	O	O
isoproterenol	B-Chemical	D007545
pretreatment	O	O
.	O	O

In	O	O
isolated	O	O
perfused	O	O
heart	O	O
preparations	O	O
from	O	O
isoproterenol	B-Chemical	D007545
-	O	O
pretreated	O	O
rats	O	O
,	O	O
the	O	O
isoproterenol	B-Chemical	D007545
-	O	O
induced	O	O
maximal	O	O
increase	O	O
in	O	O
left	O	O
ventricular	O	O
systolic	O	O
pressure	O	O
was	O	O
significantly	O	O
reduced	O	O
,	O	O
compared	O	O
with	O	O
saline	O	O
-	O	O
pretreated	O	O
rats	O	O
(	O	O
the	O	O
EC50	O	O
of	O	O
the	O	O
isoproterenol	B-Chemical	D007545
-	O	O
induced	O	O
increase	O	O
in	O	O
left	O	O
ventricular	O	O
systolic	O	O
pressure	O	O
was	O	O
enhanced	O	O
approximately	O	O
22	O	O
-	O	O
fold	O	O
)	O	O
.	O	O

These	O	O
results	O	O
show	O	O
that	O	O
15	O	O
-	O	O
day	O	O
isoproterenol	B-Chemical	D007545
pretreatment	O	O
not	O	O
only	O	O
abolished	O	O
but	O	O
reversed	O	O
bromocriptine	B-Chemical	D001971
-	O	O
induced	O	O
tachycardia	B-Disease	D013610
to	O	O
bradycardia	B-Disease	D001919
,	O	O
an	O	O
effect	O	O
that	O	O
is	O	O
mainly	O	O
related	O	O
to	O	O
further	O	O
cardiac	O	O
beta	O	O
-	O	O
adrenoceptor	O	O
desensitization	O	O
rather	O	O
than	O	O
to	O	O
impairment	O	O
of	O	O
autonomic	O	O
regulation	O	O
of	O	O
the	O	O
heart	O	O
.	O	O

They	O	O
suggest	O	O
that	O	O
,	O	O
in	O	O
normal	O	O
conscious	O	O
rats	O	O
,	O	O
the	O	O
central	O	O
tachycardia	B-Disease	D013610
of	O	O
bromocriptine	B-Chemical	D001971
appears	O	O
to	O	O
predominate	O	O
and	O	O
to	O	O
mask	O	O
the	O	O
bradycardia	B-Disease	D001919
of	O	O
this	O	O
agonist	O	O
at	O	O
peripheral	O	O
dopamine	B-Chemical	D004298
D2	O	O
receptors	O	O
.	O	O

A	O	O
developmental	O	O
analysis	O	O
of	O	O
clonidine's	O	O
effects	O	O
on	O	O
cardiac	O	O
rate	O	O
and	O	O
ultrasound	O	O
production	O	O
in	O	O
infant	O	O
rats	O	O
.	O	O

Under	O	O
controlled	O	O
conditions	O	O
,	O	O
infant	O	O
rats	O	O
emit	O	O
ultrasonic	O	O
vocalizations	O	O
during	O	O
extreme	O	O
cold	O	O
exposure	O	O
and	O	O
after	O	O
administration	O	O
of	O	O
the	O	O
alpha	O	O
(	O	O
2	O	O
)	O	O
adrenoceptor	O	O
agonist	O	O
,	O	O
clonidine	B-Chemical	D003000
.	O	O

Previous	O	O
investigations	O	O
have	O	O
determined	O	O
that	O	O
,	O	O
in	O	O
response	O	O
to	O	O
clonidine	B-Chemical	D003000
,	O	O
ultrasound	O	O
production	O	O
increases	O	O
through	O	O
the	O	O
2nd	O	O
-	O	O
week	O	O
postpartum	O	O
and	O	O
decreases	O	O
thereafter	O	O
.	O	O

Given	O	O
that	O	O
sympathetic	O	O
neural	O	O
dominance	O	O
exhibits	O	O
a	O	O
similar	O	O
developmental	O	O
pattern	O	O
,	O	O
and	O	O
given	O	O
that	O	O
clonidine	B-Chemical	D003000
induces	O	O
sympathetic	O	O
withdrawal	O	O
and	O	O
bradycardia	B-Disease	D001919
,	O	O
we	O	O
hypothesized	O	O
that	O	O
clonidine's	O	O
developmental	O	O
effects	O	O
on	O	O
cardiac	O	O
rate	O	O
and	O	O
ultrasound	O	O
production	O	O
would	O	O
mirror	O	O
each	O	O
other	O	O
.	O	O

Therefore	O	O
,	O	O
in	O	O
the	O	O
present	O	O
experiment	O	O
,	O	O
the	O	O
effects	O	O
of	O	O
clonidine	B-Chemical	D003000
administration	O	O
(	O	O
0	O	O
.	O	O

5	O	O
mg	O	O
/	O	O
kg	O	O
)	O	O
on	O	O
cardiac	O	O
rate	O	O
and	O	O
ultrasound	O	O
production	O	O
were	O	O
examined	O	O
in	O	O
2	O	O
-	O	O
,	O	O
8	O	O
-	O	O
,	O	O
15	O	O
-	O	O
,	O	O
and	O	O
20	O	O
-	O	O
day	O	O
-	O	O
old	O	O
rats	O	O
.	O	O

Age	O	O
-	O	O
related	O	O
changes	O	O
in	O	O
ultrasound	O	O
production	O	O
corresponded	O	O
with	O	O
changes	O	O
in	O	O
cardiovascular	O	O
variables	O	O
,	O	O
including	O	O
baseline	O	O
cardiac	O	O
rate	O	O
and	O	O
clonidine	B-Chemical	D003000
-	O	O
induced	O	O
bradycardia	B-Disease	D001919
.	O	O

This	O	O
experiment	O	O
is	O	O
discussed	O	O
with	O	O
regard	O	O
to	O	O
the	O	O
hypothesis	O	O
that	O	O
ultrasound	O	O
production	O	O
is	O	O
the	O	O
acoustic	O	O
by	O	O
-	O	O
product	O	O
of	O	O
a	O	O
physiological	O	O
maneuver	O	O
that	O	O
compensates	O	O
for	O	O
clonidine's	O	O
detrimental	O	O
effects	O	O
on	O	O
cardiovascular	O	O
function	O	O
.	O	O

Differential	O	O
effects	O	O
of	O	O
systemically	O	O
administered	O	O
ketamine	B-Chemical	D007649
and	O	O
lidocaine	B-Chemical	D008012
on	O	O
dynamic	O	O
and	O	O
static	O	O
hyperalgesia	B-Disease	D006930
induced	O	O
by	O	O
intradermal	O	O
capsaicin	B-Chemical	D002211
in	O	O
humans	O	O
.	O	O

We	O	O
have	O	O
examined	O	O
the	O	O
effect	O	O
of	O	O
systemic	O	O
administration	O	O
of	O	O
ketamine	B-Chemical	D007649
and	O	O
lidocaine	B-Chemical	D008012
on	O	O
brush	O	O
-	O	O
evoked	O	O
(	O	O
dynamic	O	O
)	O	O
pain	B-Disease	D010146
and	O	O
punctate	O	O
-	O	O
evoked	O	O
(	O	O
static	O	O
)	O	O
hyperalgesia	B-Disease	D006930
induced	O	O
by	O	O
capsaicin	B-Chemical	D002211
.	O	O

In	O	O
a	O	O
randomized	O	O
,	O	O
double	O	O
-	O	O
blind	O	O
,	O	O
placebo	O	O
-	O	O
controlled	O	O
,	O	O
crossover	O	O
study	O	O
,	O	O
we	O	O
studied	O	O
12	O	O
volunteers	O	O
in	O	O
three	O	O
experiments	O	O
.	O	O

Capsaicin	B-Chemical	D002211
100	O	O
micrograms	O	O
was	O	O
injected	O	O
intradermally	O	O
on	O	O
the	O	O
volar	O	O
forearm	O	O
followed	O	O
by	O	O
an	O	O
i	O	O
.	O	O

v	O	O
.	O	O

infusion	O	O
of	O	O
ketamine	B-Chemical	D007649
(	O	O
bolus	O	O
0	O	O
.	O	O

1	O	O
mg	O	O
kg	O	O
-	O	O
1	O	O
over	O	O
10	O	O
min	O	O
followed	O	O
by	O	O
infusion	O	O
of	O	O
7	O	O
micrograms	O	O
kg	O	O
-	O	O
1	O	O
min	O	O
-	O	O
1	O	O
)	O	O
,	O	O
lidocaine	B-Chemical	D008012
5	O	O
mg	O	O
kg	O	O
-	O	O
1	O	O
or	O	O
saline	O	O
for	O	O
50	O	O
min	O	O
.	O	O

Infusion	O	O
started	O	O
15	O	O
min	O	O
after	O	O
injection	O	O
of	O	O
capsaicin	B-Chemical	D002211
.	O	O

The	O	O
following	O	O
were	O	O
measured	O	O
:	O	O
spontaneous	O	O
pain	B-Disease	D010146
,	O	O
pain	B-Disease	D010146
evoked	O	O
by	O	O
punctate	O	O
and	O	O
brush	O	O
stimuli	O	O
(	O	O
VAS	O	O
)	O	O
,	O	O
and	O	O
areas	O	O
of	O	O
brush	O	O
-	O	O
evoked	O	O
and	O	O
punctate	O	O
-	O	O
evoked	O	O
hyperalgesia	B-Disease	D006930
.	O	O

Ketamine	B-Chemical	D007649
reduced	O	O
both	O	O
the	O	O
area	O	O
of	O	O
brush	O	O
-	O	O
evoked	O	O
and	O	O
punctate	O	O
-	O	O
evoked	O	O
hyperalgesia	B-Disease	D006930
significantly	O	O
and	O	O
it	O	O
tended	O	O
to	O	O
reduce	O	O
brush	O	O
-	O	O
evoked	O	O
pain	B-Disease	D010146
.	O	O

Lidocaine	B-Chemical	D008012
reduced	O	O
the	O	O
area	O	O
of	O	O
punctate	O	O
-	O	O
evoked	O	O
hyperalgesia	B-Disease	D006930
significantly	O	O
.	O	O

It	O	O
tended	O	O
to	O	O
reduce	O	O
VAS	O	O
scores	O	O
of	O	O
spontaneous	O	O
pain	B-Disease	D010146
but	O	O
had	O	O
no	O	O
effect	O	O
on	O	O
evoked	O	O
pain	B-Disease	D010146
.	O	O

The	O	O
differential	O	O
effects	O	O
of	O	O
ketamine	B-Chemical	D007649
and	O	O
lidocaine	B-Chemical	D008012
on	O	O
static	O	O
and	O	O
dynamic	O	O
hyperalgesia	B-Disease	D006930
suggest	O	O
that	O	O
the	O	O
two	O	O
types	O	O
of	O	O
hyperalgesia	B-Disease	D006930
are	O	O
mediated	O	O
by	O	O
separate	O	O
mechanisms	O	O
and	O	O
have	O	O
a	O	O
distinct	O	O
pharmacology	O	O
.	O	O

Cyclosporine	B-Chemical	D016572
and	O	O
tacrolimus	B-Chemical	D016559
-	O	O
associated	O	O
thrombotic	B-Disease	D057049
microangiopathy	I-Disease	D057049
.	O	O

The	O	O
development	O	O
of	O	O
thrombotic	B-Disease	D057049
microangiopathy	I-Disease	D057049
(	O	O
TMA	B-Disease	D057049
)	O	O
associated	O	O
with	O	O
the	O	O
use	O	O
of	O	O
cyclosporine	B-Chemical	D016572
has	O	O
been	O	O
well	O	O
documented	O	O
.	O	O

Treatments	O	O
have	O	O
included	O	O
discontinuation	O	O
or	O	O
reduction	O	O
of	O	O
cyclosporine	B-Chemical	D016572
dose	O	O
with	O	O
or	O	O
without	O	O
concurrent	O	O
plasma	O	O
exchange	O	O
,	O	O
plasma	O	O
infusion	O	O
,	O	O
anticoagulation	O	O
,	O	O
and	O	O
intravenous	O	O
immunoglobulin	O	O
G	O	O
infusion	O	O
.	O	O

However	O	O
,	O	O
for	O	O
recipients	O	O
of	O	O
organ	O	O
transplantation	O	O
,	O	O
removing	O	O
the	O	O
inciting	O	O
agent	O	O
is	O	O
not	O	O
without	O	O
the	O	O
attendant	O	O
risk	O	O
of	O	O
precipitating	O	O
acute	O	O
rejection	O	O
and	O	O
graft	O	O
loss	O	O
.	O	O

The	O	O
last	O	O
decade	O	O
has	O	O
seen	O	O
the	O	O
emergence	O	O
of	O	O
tacrolimus	B-Chemical	D016559
as	O	O
a	O	O
potent	O	O
immunosuppressive	O	O
agent	O	O
with	O	O
mechanisms	O	O
of	O	O
action	O	O
virtually	O	O
identical	O	O
to	O	O
those	O	O
of	O	O
cyclosporine	B-Chemical	D016572
.	O	O

As	O	O
a	O	O
result	O	O
,	O	O
switching	O	O
to	O	O
tacrolimus	B-Chemical	D016559
has	O	O
been	O	O
reported	O	O
to	O	O
be	O	O
a	O	O
viable	O	O
therapeutic	O	O
option	O	O
in	O	O
the	O	O
setting	O	O
of	O	O
cyclosporine	B-Chemical	D016572
-	O	O
induced	O	O
TMA	B-Disease	D057049
.	O	O

With	O	O
the	O	O
more	O	O
widespread	O	O
application	O	O
of	O	O
tacrolimus	B-Chemical	D016559
in	O	O
organ	O	O
transplantation	O	O
,	O	O
tacrolimus	B-Chemical	D016559
-	O	O
associated	O	O
TMA	B-Disease	D057049
has	O	O
also	O	O
been	O	O
recognized	O	O
.	O	O

However	O	O
,	O	O
literature	O	O
regarding	O	O
the	O	O
incidence	O	O
of	O	O
the	O	O
recurrence	O	O
of	O	O
TMA	B-Disease	D057049
in	O	O
patients	O	O
exposed	O	O
sequentially	O	O
to	O	O
cyclosporine	B-Chemical	D016572
and	O	O
tacrolimus	B-Chemical	D016559
is	O	O
limited	O	O
.	O	O

We	O	O
report	O	O
a	O	O
case	O	O
of	O	O
a	O	O
living	O	O
donor	O	O
renal	O	O
transplant	O	O
recipient	O	O
who	O	O
developed	O	O
cyclosporine	B-Chemical	D016572
-	O	O
induced	O	O
TMA	B-Disease	D057049
that	O	O
responded	O	O
to	O	O
the	O	O
withdrawal	O	O
of	O	O
cyclosporine	B-Chemical	D016572
in	O	O
conjunction	O	O
with	O	O
plasmapheresis	O	O
and	O	O
fresh	O	O
frozen	O	O
plasma	O	O
replacement	O	O
therapy	O	O
.	O	O

Introduction	O	O
of	O	O
tacrolimus	B-Chemical	D016559
as	O	O
an	O	O
alternative	O	O
immunosuppressive	O	O
agent	O	O
resulted	O	O
in	O	O
the	O	O
recurrence	O	O
of	O	O
TMA	B-Disease	D057049
and	O	O
the	O	O
subsequent	O	O
loss	O	O
of	O	O
the	O	O
renal	O	O
allograft	O	O
.	O	O

Patients	O	O
who	O	O
are	O	O
switched	O	O
from	O	O
cyclosporine	B-Chemical	D016572
to	O	O
tacrolimus	B-Chemical	D016559
or	O	O
vice	O	O
versa	O	O
should	O	O
be	O	O
closely	O	O
monitored	O	O
for	O	O
the	O	O
signs	O	O
and	O	O
symptoms	O	O
of	O	O
recurrent	O	O
TMA	B-Disease	D057049
.	O	O

Repeated	O	O
transient	O	O
anuria	B-Disease	D001002
following	O	O
losartan	B-Chemical	D019808
administration	O	O
in	O	O
a	O	O
patient	O	O
with	O	O
a	O	O
solitary	O	O
kidney	O	O
.	O	O

We	O	O
report	O	O
the	O	O
case	O	O
of	O	O
a	O	O
70	O	O
-	O	O
year	O	O
-	O	O
old	O	O
hypertensive	B-Disease	D006973
man	O	O
with	O	O
a	O	O
solitary	O	O
kidney	O	O
and	O	O
chronic	B-Disease	D051436
renal	I-Disease	D051436
insufficiency	I-Disease	D051436
who	O	O
developed	O	O
two	O	O
episodes	O	O
of	O	O
transient	O	O
anuria	B-Disease	D001002
after	O	O
losartan	B-Chemical	D019808
administration	O	O
.	O	O

He	O	O
was	O	O
hospitalized	O	O
for	O	O
a	O	O
myocardial	B-Disease	D009203
infarction	I-Disease	D009203
with	O	O
pulmonary	B-Disease	D011654
edema	I-Disease	D011654
,	O	O
treated	O	O
with	O	O
high	O	O
-	O	O
dose	O	O
diuretics	O	O
.	O	O

Due	O	O
to	O	O
severe	O	O
systolic	B-Disease	D006331
dysfunction	I-Disease	D006331
losartan	B-Chemical	D019808
was	O	O
prescribed	O	O
.	O	O

Surprisingly	O	O
,	O	O
the	O	O
first	O	O
dose	O	O
of	O	O
50	O	O
mg	O	O
of	O	O
losartan	B-Chemical	D019808
resulted	O	O
in	O	O
a	O	O
sudden	O	O
anuria	B-Disease	D001002
,	O	O
which	O	O
lasted	O	O
eight	O	O
hours	O	O
despite	O	O
high	O	O
-	O	O
dose	O	O
furosemide	B-Chemical	D005665
and	O	O
amine	B-Chemical	D000588
infusion	O	O
.	O	O

One	O	O
week	O	O
later	O	O
,	O	O
by	O	O
mistake	O	O
,	O	O
losartan	B-Chemical	D019808
was	O	O
prescribed	O	O
again	O	O
and	O	O
after	O	O
the	O	O
second	O	O
dose	O	O
of	O	O
50	O	O
mg	O	O
,	O	O
the	O	O
patient	O	O
developed	O	O
a	O	O
second	O	O
episode	O	O
of	O	O
transient	O	O
anuria	B-Disease	D001002
lasting	O	O
10	O	O
hours	O	O
.	O	O

During	O	O
these	O	O
two	O	O
episodes	O	O
,	O	O
his	O	O
blood	O	O
pressure	O	O
diminished	O	O
but	O	O
no	O	O
severe	O	O
hypotension	B-Disease	D007022
was	O	O
noted	O	O
.	O	O

Ultimately	O	O
,	O	O
an	O	O
arteriography	O	O
showed	O	O
a	O	O
70	O	O
-	O	O
80%	O	O
renal	B-Disease	D012078
artery	I-Disease	D012078
stenosis	I-Disease	D012078
.	O	O

In	O	O
this	O	O
patient	O	O
,	O	O
renal	B-Disease	D012078
artery	I-Disease	D012078
stenosis	I-Disease	D012078
combined	O	O
with	O	O
heart	B-Disease	D006333
failure	I-Disease	D006333
and	O	O
diuretic	O	O
therapy	O	O
certainly	O	O
resulted	O	O
in	O	O
a	O	O
strong	O	O
activation	O	O
of	O	O
the	O	O
renin	O	O
-	O	O
angiotensin	B-Chemical	D000809
system	O	O
(	O	O
RAS	O	O
)	O	O
.	O	O

Under	O	O
such	O	O
conditions	O	O
,	O	O
angiotensin	B-Chemical	D000809
II	O	O
receptor	O	O
blockade	O	O
by	O	O
losartan	B-Chemical	D019808
probably	O	O
induced	O	O
a	O	O
critical	O	O
fall	O	O
in	O	O
glomerular	O	O
filtration	O	O
pressure	O	O
.	O	O

This	O	O
case	O	O
report	O	O
highlights	O	O
the	O	O
fact	O	O
that	O	O
the	O	O
angiotensin	B-Chemical	D000809
II	O	O
receptor	O	O
antagonist	O	O
losartan	B-Chemical	D019808
can	O	O
cause	O	O
serious	O	O
unexpected	O	O
complications	O	O
in	O	O
patients	O	O
with	O	O
renovascular	B-Disease	D014652
disease	I-Disease	D014652
and	O	O
should	O	O
be	O	O
used	O	O
with	O	O
extreme	O	O
caution	O	O
in	O	O
this	O	O
setting	O	O
.	O	O

In	O	O
vivo	O	O
protection	O	O
of	O	O
dna	O	O
damage	O	O
associated	O	O
apoptotic	O	O
and	O	O
necrotic	B-Disease	D009336
cell	O	O
deaths	O	O
during	O	O
acetaminophen	B-Chemical	D000082
-	O	O
induced	O	O
nephrotoxicity	B-Disease	D007674
,	O	O
amiodarone	B-Chemical	D000638
-	O	O
induced	O	O
lung	B-Disease	D008171
toxicity	I-Disease	D008171
and	O	O
doxorubicin	B-Chemical	D004317
-	O	O
induced	O	O
cardiotoxicity	B-Disease	D066126
by	O	O
a	O	O
novel	O	O
IH636	B-Chemical	C511402
grape	I-Chemical	C511402
seed	I-Chemical	C511402
proanthocyanidin	I-Chemical	C511402
extract	I-Chemical	C511402
.	O	O

Grape	B-Chemical	C511402
seed	I-Chemical	C511402
extract	I-Chemical	C511402
,	O	O
primarily	O	O
a	O	O
mixture	O	O
of	O	O
proanthocyanidins	B-Chemical	D044945
,	O	O
has	O	O
been	O	O
shown	O	O
to	O	O
modulate	O	O
a	O	O
wide	O	O
-	O	O
range	O	O
of	O	O
biological	O	O
,	O	O
pharmacological	O	O
and	O	O
toxicological	O	O
effects	O	O
which	O	O
are	O	O
mainly	O	O
cytoprotective	O	O
.	O	O

This	O	O
study	O	O
assessed	O	O
the	O	O
ability	O	O
of	O	O
IH636	B-Chemical	C511402
grape	I-Chemical	C511402
seed	I-Chemical	C511402
proanthocyanidin	I-Chemical	C511402
extract	I-Chemical	C511402
(	O	O
GSPE	B-Chemical	C511402
)	O	O
to	O	O
prevent	O	O
acetaminophen	B-Chemical	D000082
(	O	O
AAP	B-Chemical	D000082
)	O	O
-	O	O
induced	O	O
nephrotoxicity	B-Disease	D007674
,	O	O
amiodarone	B-Chemical	D000638
(	O	O
AMI	B-Chemical	D000638
)	O	O
-	O	O
induced	O	O
lung	B-Disease	D008171
toxicity	I-Disease	D008171
,	O	O
and	O	O
doxorubicin	B-Chemical	D004317
(	O	O
DOX	B-Chemical	D004317
)	O	O
-	O	O
induced	O	O
cardiotoxicity	B-Disease	D066126
in	O	O
mice	O	O
.	O	O

Experimental	O	O
design	O	O
consisted	O	O
of	O	O
four	O	O
groups	O	O
:	O	O
control	O	O
(	O	O
vehicle	O	O
alone	O	O
)	O	O
,	O	O
GSPE	B-Chemical	C511402
alone	O	O
,	O	O
drug	O	O
alone	O	O
and	O	O
GSPE+drug	O	O
.	O	O

For	O	O
the	O	O
cytoprotection	O	O
study	O	O
,	O	O
animals	O	O
were	O	O
orally	O	O
gavaged	O	O
100	O	O
mg	O	O
/	O	O
Kg	O	O
GSPE	B-Chemical	C511402
for	O	O
7	O	O
-	O	O
10	O	O
days	O	O
followed	O	O
by	O	O
i	O	O
.	O	O

p	O	O
.	O	O

injections	O	O
of	O	O
organ	O	O
specific	O	O
three	O	O
drugs	O	O
(	O	O
AAP	B-Chemical	D000082
:	O	O
500	O	O
mg	O	O
/	O	O
Kg	O	O
for	O	O
24	O	O
h	O	O
;	O	O
AMI	B-Chemical	D000638
:	O	O
50	O	O
mg	O	O
/	O	O
Kg	O	O
/	O	O
day	O	O
for	O	O
four	O	O
days	O	O
;	O	O
DOX	B-Chemical	D004317
:	O	O
20	O	O
mg	O	O
/	O	O
Kg	O	O
for	O	O
48	O	O
h	O	O
)	O	O
.	O	O

Parameters	O	O
of	O	O
study	O	O
included	O	O
analysis	O	O
of	O	O
serum	O	O
chemistry	O	O
(	O	O
ALT	O	O
,	O	O
BUN	O	O
and	O	O
CPK	O	O
)	O	O
,	O	O
and	O	O
orderly	O	O
fragmentation	O	O
of	O	O
genomic	O	O
DNA	O	O
(	O	O
both	O	O
endonuclease	O	O
-	O	O
dependent	O	O
and	O	O
independent	O	O
)	O	O
in	O	O
addition	O	O
to	O	O
microscopic	O	O
evaluation	O	O
of	O	O
damage	O	O
and	O	O
/	O	O
or	O	O
protection	O	O
in	O	O
corresponding	O	O
PAS	O	O
stained	O	O
tissues	O	O
.	O	O

Results	O	O
indicate	O	O
that	O	O
GSPE	B-Chemical	C511402
preexposure	O	O
prior	O	O
to	O	O
AAP	B-Chemical	D000082
,	O	O
AMI	B-Chemical	D000638
and	O	O
DOX	B-Chemical	D004317
,	O	O
provided	O	O
near	O	O
complete	O	O
protection	O	O
in	O	O
terms	O	O
of	O	O
serum	O	O
chemistry	O	O
changes	O	O
(	O	O
ALT	O	O
,	O	O
BUN	O	O
and	O	O
CPK	O	O
)	O	O
,	O	O
and	O	O
significantly	O	O
reduced	O	O
DNA	O	O
fragmentation	O	O
.	O	O

Histopathological	O	O
examination	O	O
of	O	O
kidney	O	O
,	O	O
heart	O	O
and	O	O
lung	O	O
sections	O	O
revealed	O	O
moderate	O	O
to	O	O
massive	O	O
tissue	B-Disease	D017695
damage	I-Disease	D017695
with	O	O
a	O	O
variety	O	O
of	O	O
morphological	O	O
aberrations	O	O
by	O	O
all	O	O
the	O	O
three	O	O
drugs	O	O
in	O	O
the	O	O
absence	O	O
of	O	O
GSPE	B-Chemical	C511402
preexposure	O	O
than	O	O
in	O	O
its	O	O
presence	O	O
.	O	O

GSPE+drug	O	O
exposed	O	O
tissues	O	O
exhibited	O	O
minor	O	O
residual	O	O
damage	O	O
or	O	O
near	O	O
total	O	O
recovery	O	O
.	O	O

Additionally	O	O
,	O	O
histopathological	O	O
alterations	O	O
mirrored	O	O
both	O	O
serum	O	O
chemistry	O	O
changes	O	O
and	O	O
the	O	O
pattern	O	O
of	O	O
DNA	O	O
fragmentation	O	O
.	O	O

Interestingly	O	O
,	O	O
all	O	O
the	O	O
drugs	O	O
,	O	O
such	O	O
as	O	O
,	O	O
AAP	B-Chemical	D000082
,	O	O
AMI	B-Chemical	D000638
and	O	O
DOX	B-Chemical	D004317
induced	O	O
apoptotic	O	O
death	O	O
in	O	O
addition	O	O
to	O	O
necrosis	B-Disease	D009336
in	O	O
the	O	O
respective	O	O
organs	O	O
which	O	O
was	O	O
very	O	O
effectively	O	O
blocked	O	O
by	O	O
GSPE	B-Chemical	C511402
.	O	O

Since	O	O
AAP	B-Chemical	D000082
,	O	O
AMI	B-Chemical	D000638
and	O	O
DOX	B-Chemical	D004317
undergo	O	O
biotransformation	O	O
and	O	O
are	O	O
known	O	O
to	O	O
produce	O	O
damaging	O	O
radicals	O	O
in	O	O
vivo	O	O
,	O	O
the	O	O
protection	O	O
by	O	O
GSPE	B-Chemical	C511402
may	O	O
be	O	O
linked	O	O
to	O	O
both	O	O
inhibition	O	O
of	O	O
metabolism	O	O
and	O	O
/	O	O
or	O	O
detoxification	O	O
of	O	O
cytotoxic	O	O
radicals	O	O
.	O	O

In	O	O
addition	O	O
,	O	O
its'	O	O
presumed	O	O
contribution	O	O
to	O	O
DNA	O	O
repair	O	O
may	O	O
be	O	O
another	O	O
important	O	O
attribute	O	O
,	O	O
which	O	O
played	O	O
a	O	O
role	O	O
in	O	O
the	O	O
chemoprevention	O	O
process	O	O
.	O	O

Additionally	O	O
,	O	O
this	O	O
may	O	O
have	O	O
been	O	O
the	O	O
first	O	O
report	O	O
on	O	O
AMI	B-Chemical	D000638
-	O	O
induced	O	O
apoptotic	O	O
death	O	O
in	O	O
the	O	O
lung	O	O
tissue	O	O
.	O	O

Taken	O	O
together	O	O
,	O	O
these	O	O
events	O	O
undoubtedly	O	O
establish	O	O
GSPE's	O	O
abundant	O	O
bioavailability	O	O
,	O	O
and	O	O
the	O	O
power	O	O
to	O	O
defend	O	O
multiple	O	O
target	O	O
organs	O	O
from	O	O
toxic	O	O
assaults	O	O
induced	O	O
by	O	O
structurally	O	O
diverse	O	O
and	O	O
functionally	O	O
different	O	O
entities	O	O
in	O	O
vivo	O	O
.	O	O

Palpebral	B-Disease	D004409
twitching	I-Disease	D004409
in	O	O
a	O	O
depressed	B-Disease	D003866
adolescent	O	O
on	O	O
citalopram	B-Chemical	D015283
.	O	O

Current	O	O
estimates	O	O
suggest	O	O
that	O	O
between	O	O
0	O	O
.	O	O

4%	O	O
and	O	O
8	O	O
.	O	O

3%	O	O
of	O	O
children	O	O
and	O	O
adolescents	O	O
are	O	O
affected	O	O
by	O	O
major	B-Disease	D003865
depression	I-Disease	D003865
.	O	O

We	O	O
report	O	O
a	O	O
favorable	O	O
response	O	O
to	O	O
treatment	O	O
with	O	O
citalopram	B-Chemical	D015283
by	O	O
a	O	O
15	O	O
-	O	O
year	O	O
-	O	O
old	O	O
boy	O	O
with	O	O
major	B-Disease	D003865
depression	I-Disease	D003865
who	O	O
exhibited	O	O
palpebral	B-Disease	D004409
twitching	I-Disease	D004409
during	O	O
his	O	O
first	O	O
2	O	O
weeks	O	O
of	O	O
treatment	O	O
.	O	O

This	O	O
may	O	O
have	O	O
been	O	O
a	O	O
side	O	O
effect	O	O
of	O	O
citalopram	B-Chemical	D015283
as	O	O
it	O	O
remitted	O	O
with	O	O
redistribution	O	O
of	O	O
doses	O	O
.	O	O

Metamizol	B-Chemical	D004177
potentiates	O	O
morphine	B-Chemical	D009020
antinociception	O	O
but	O	O
not	O	O
constipation	B-Disease	D003248
after	O	O
chronic	O	O
treatment	O	O
.	O	O

This	O	O
work	O	O
evaluates	O	O
the	O	O
antinociceptive	O	O
and	O	O
constipating	B-Disease	D003248
effects	O	O
of	O	O
the	O	O
combination	O	O
of	O	O
3	O	O
.	O	O

2	O	O
mg	O	O
/	O	O
kg	O	O
s	O	O
.	O	O

c	O	O
.	O	O

morphine	B-Chemical	D009020
with	O	O
177	O	O
.	O	O

8	O	O
mg	O	O
/	O	O
kg	O	O
s	O	O
.	O	O

c	O	O
.	O	O

metamizol	B-Chemical	D004177
in	O	O
acutely	O	O
and	O	O
chronically	O	O
treated	O	O
(	O	O
once	O	O
a	O	O
day	O	O
for	O	O
12	O	O
days	O	O
)	O	O
rats	O	O
.	O	O

On	O	O
the	O	O
13th	O	O
day	O	O
,	O	O
antinociceptive	O	O
effects	O	O
were	O	O
assessed	O	O
using	O	O
a	O	O
model	O	O
of	O	O
inflammatory	O	O
nociception	O	O
,	O	O
pain	B-Disease	D010146
-	O	O
induced	O	O
functional	O	O
impairment	O	O
model	O	O
,	O	O
and	O	O
the	O	O
charcoal	B-Chemical	D002606
meal	O	O
test	O	O
was	O	O
used	O	O
to	O	O
evaluate	O	O
the	O	O
intestinal	O	O
transit	O	O
.	O	O

Simultaneous	O	O
administration	O	O
of	O	O
morphine	B-Chemical	D009020
with	O	O
metamizol	B-Chemical	D004177
resulted	O	O
in	O	O
a	O	O
markedly	O	O
antinociceptive	O	O
potentiation	O	O
and	O	O
an	O	O
increasing	O	O
of	O	O
the	O	O
duration	O	O
of	O	O
action	O	O
after	O	O
a	O	O
single	O	O
(	O	O
298+	O	O
/	O	O
-	O	O
7	O	O
vs	O	O
.	O	O

139+	O	O
/	O	O
-	O	O
36	O	O
units	O	O
area	O	O
(	O	O
ua	O	O
)	O	O
;	O	O
P<0	O	O
.	O	O

001	O	O
)	O	O
and	O	O
repeated	O	O
administration	O	O
(	O	O
280+	O	O
/	O	O
-	O	O
17	O	O
vs	O	O
.	O	O

131+	O	O
/	O	O
-	O	O
22	O	O
ua	O	O
;	O	O
P<0	O	O
.	O	O

001	O	O
)	O	O
.	O	O

Antinociceptive	O	O
effect	O	O
of	O	O
morphine	B-Chemical	D009020
was	O	O
reduced	O	O
in	O	O
chronically	O	O
treated	O	O
rats	O	O
(	O	O
39+	O	O
/	O	O
-	O	O
10	O	O
vs	O	O
.	O	O

18+	O	O
/	O	O
-	O	O
5	O	O
au	O	O
)	O	O
while	O	O
the	O	O
combination	O	O
-	O	O
induced	O	O
antinociception	O	O
was	O	O
remained	O	O
similar	O	O
as	O	O
an	O	O
acute	O	O
treatment	O	O
(	O	O
298+	O	O
/	O	O
-	O	O
7	O	O
vs	O	O
.	O	O

280+	O	O
/	O	O
-	O	O
17	O	O
au	O	O
)	O	O
.	O	O

Acute	O	O
antinociceptive	O	O
effects	O	O
of	O	O
the	O	O
combination	O	O
were	O	O
partially	O	O
prevented	O	O
by	O	O
3	O	O
.	O	O

2	O	O
mg	O	O
/	O	O
kg	O	O
naloxone	B-Chemical	D009270
s	O	O
.	O	O

c	O	O
.	O	O

(	O	O
P<0	O	O
.	O	O

05	O	O
)	O	O
,	O	O
suggesting	O	O
the	O	O
partial	O	O
involvement	O	O
of	O	O
the	O	O
opioidergic	O	O
system	O	O
in	O	O
the	O	O
synergism	O	O
observed	O	O
.	O	O

In	O	O
independent	O	O
groups	O	O
,	O	O
morphine	B-Chemical	D009020
inhibited	O	O
the	O	O
intestinal	O	O
transit	O	O
in	O	O
48+	O	O
/	O	O
-	O	O
4%	O	O
and	O	O
38+	O	O
/	O	O
-	O	O
4%	O	O
after	O	O
acute	O	O
and	O	O
chronic	O	O
treatment	O	O
,	O	O
respectively	O	O
,	O	O
suggesting	O	O
that	O	O
tolerance	O	O
did	O	O
not	O	O
develop	O	O
to	O	O
the	O	O
constipating	B-Disease	D003248
effects	O	O
.	O	O

The	O	O
combination	O	O
inhibited	O	O
intestinal	O	O
transit	O	O
similar	O	O
to	O	O
that	O	O
produced	O	O
by	O	O
morphine	B-Chemical	D009020
regardless	O	O
of	O	O
the	O	O
time	O	O
of	O	O
treatment	O	O
,	O	O
suggesting	O	O
that	O	O
metamizol	B-Chemical	D004177
did	O	O
not	O	O
potentiate	O	O
morphine	B-Chemical	D009020
-	O	O
induced	O	O
constipation	B-Disease	D003248
.	O	O

These	O	O
findings	O	O
show	O	O
a	O	O
significant	O	O
interaction	O	O
between	O	O
morphine	B-Chemical	D009020
and	O	O
metamizol	B-Chemical	D004177
in	O	O
chronically	O	O
treated	O	O
rats	O	O
,	O	O
suggesting	O	O
that	O	O
this	O	O
combination	O	O
could	O	O
be	O	O
useful	O	O
for	O	O
the	O	O
treatment	O	O
of	O	O
chronic	B-Disease	D059350
pain	I-Disease	D059350
.	O	O

Ifosfamide	B-Chemical	D007069
encephalopathy	B-Disease	D001927
presenting	O	O
with	O	O
asterixis	B-Disease	D020820
.	O	O

CNS	O	O
toxic	O	O
effects	O	O
of	O	O
the	O	O
antineoplastic	O	O
agent	O	O
ifosfamide	B-Chemical	D007069
(	O	O
IFX	B-Chemical	D007069
)	O	O
are	O	O
frequent	O	O
and	O	O
include	O	O
a	O	O
variety	O	O
of	O	O
neurological	O	O
symptoms	O	O
that	O	O
can	O	O
limit	O	O
drug	O	O
use	O	O
.	O	O

We	O	O
report	O	O
a	O	O
case	O	O
of	O	O
a	O	O
51	O	O
-	O	O
year	O	O
-	O	O
old	O	O
man	O	O
who	O	O
developed	O	O
severe	O	O
,	O	O
disabling	O	O
negative	O	O
myoclonus	B-Disease	D009207
of	O	O
the	O	O
upper	O	O
and	O	O
lower	O	O
extremities	O	O
after	O	O
the	O	O
infusion	O	O
of	O	O
ifosfamide	B-Chemical	D007069
for	O	O
plasmacytoma	B-Disease	D010954
.	O	O

He	O	O
was	O	O
awake	O	O
,	O	O
revealed	O	O
no	O	O
changes	O	O
of	O	O
mental	O	O
status	O	O
and	O	O
at	O	O
rest	O	O
there	O	O
were	O	O
no	O	O
further	O	O
motor	O	O
symptoms	O	O
.	O	O

Cranial	O	O
magnetic	O	O
resonance	O	O
imaging	O	O
and	O	O
extensive	O	O
laboratory	O	O
studies	O	O
failed	O	O
to	O	O
reveal	O	O
structural	B-Disease	D001927
lesions	I-Disease	D001927
of	I-Disease	D001927
the	I-Disease	D001927
brain	I-Disease	D001927
and	O	O
metabolic	B-Disease	D008659
abnormalities	I-Disease	D008659
.	O	O

An	O	O
electroencephalogram	O	O
showed	O	O
continuous	O	O
,	O	O
generalized	O	O
irregular	O	O
slowing	O	O
with	O	O
admixed	O	O
periodic	O	O
triphasic	O	O
waves	O	O
indicating	O	O
symptomatic	O	O
encephalopathy	B-Disease	D001927
.	O	O

The	O	O
administration	O	O
of	O	O
ifosfamide	B-Chemical	D007069
was	O	O
discontinued	O	O
and	O	O
within	O	O
12	O	O
h	O	O
the	O	O
asterixis	B-Disease	D020820
resolved	O	O
completely	O	O
.	O	O

In	O	O
the	O	O
patient	O	O
described	O	O
,	O	O
the	O	O
presence	O	O
of	O	O
asterixis	B-Disease	D020820
during	O	O
infusion	O	O
of	O	O
ifosfamide	B-Chemical	D007069
,	O	O
normal	O	O
laboratory	O	O
findings	O	O
and	O	O
imaging	O	O
studies	O	O
and	O	O
the	O	O
resolution	O	O
of	O	O
symptoms	O	O
following	O	O
the	O	O
discontinuation	O	O
of	O	O
the	O	O
drug	O	O
suggest	O	O
that	O	O
negative	O	O
myoclonus	B-Disease	D009207
is	O	O
associated	O	O
with	O	O
the	O	O
use	O	O
of	O	O
IFX	B-Chemical	D007069
.	O	O

Sub	O	O
-	O	O
chronic	O	O
low	O	O
dose	O	O
gamma	B-Chemical	D020888
-	I-Chemical	D020888
vinyl	I-Chemical	D020888
GABA	I-Chemical	D020888
(	O	O
vigabatrin	B-Chemical	D020888
)	O	O
inhibits	O	O
cocaine	B-Chemical	D003042
-	O	O
induced	O	O
increases	O	O
in	O	O
nucleus	O	O
accumbens	O	O
dopamine	B-Chemical	D004298
.	O	O

RATIONALE	O	O
:	O	O
gamma	B-Chemical	D020888
-	I-Chemical	D020888
Vinyl	I-Chemical	D020888
GABA	I-Chemical	D020888
(	O	O
GVG	B-Chemical	D020888
)	O	O
irreversibly	O	O
inhibits	O	O
GABA	B-Chemical	D005680
-	O	O
transaminase	O	O
.	O	O

This	O	O
non	O	O
-	O	O
receptor	O	O
mediated	O	O
inhibition	O	O
requires	O	O
de	O	O
novo	O	O
synthesis	O	O
for	O	O
restoration	O	O
of	O	O
functional	O	O
GABA	B-Chemical	D005680
catabolism	O	O
.	O	O

OBJECTIVES	O	O
:	O	O
Given	O	O
its	O	O
preclinical	O	O
success	O	O
for	O	O
treating	O	O
substance	B-Disease	D019966
abuse	I-Disease	D019966
and	O	O
the	O	O
increased	O	O
risk	O	O
of	O	O
visual	B-Disease	D005128
field	I-Disease	D005128
defects	I-Disease	D005128
(	O	O
VFD	B-Disease	D005128
)	O	O
associated	O	O
with	O	O
cumulative	O	O
lifetime	O	O
exposure	O	O
,	O	O
we	O	O
explored	O	O
the	O	O
effects	O	O
of	O	O
sub	O	O
-	O	O
chronic	O	O
low	O	O
dose	O	O
GVG	B-Chemical	D020888
on	O	O
cocaine	B-Chemical	D003042
-	O	O
induced	O	O
increases	O	O
in	O	O
nucleus	O	O
accumbens	O	O
(	O	O
NAcc	O	O
)	O	O
dopamine	B-Chemical	D004298
(	O	O
DA	B-Chemical	D004298
)	O	O
.	O	O

METHODS	O	O
:	O	O
Using	O	O
in	O	O
vivo	O	O
microdialysis	O	O
,	O	O
we	O	O
compared	O	O
acute	O	O
exposure	O	O
(	O	O
450	O	O
mg	O	O
/	O	O
kg	O	O
)	O	O
to	O	O
an	O	O
identical	O	O
sub	O	O
-	O	O
chronic	O	O
exposure	O	O
(	O	O
150	O	O
mg	O	O
/	O	O
kg	O	O
per	O	O
day	O	O
for	O	O
3	O	O
days	O	O
)	O	O
,	O	O
followed	O	O
by	O	O
1	O	O
-	O	O
or	O	O
3	O	O
-	O	O
day	O	O
washout	O	O
.	O	O

Finally	O	O
,	O	O
we	O	O
examined	O	O
the	O	O
low	O	O
dose	O	O
of	O	O
150	O	O
mg	O	O
/	O	O
kg	O	O
(	O	O
50	O	O
mg	O	O
/	O	O
kg	O	O
per	O	O
day	O	O
)	O	O
using	O	O
a	O	O
similar	O	O
washout	O	O
period	O	O
.	O	O

RESULTS	O	O
:	O	O
Sub	O	O
-	O	O
chronic	O	O
GVG	B-Chemical	D020888
exposure	O	O
inhibited	O	O
the	O	O
effect	O	O
of	O	O
cocaine	B-Chemical	D003042
for	O	O
3	O	O
days	O	O
,	O	O
which	O	O
exceeded	O	O
in	O	O
magnitude	O	O
and	O	O
duration	O	O
the	O	O
identical	O	O
acute	O	O
dose	O	O
.	O	O

CONCLUSIONS	O	O
:	O	O
Sub	O	O
-	O	O
chronic	O	O
low	O	O
dose	O	O
GVG	B-Chemical	D020888
potentiates	O	O
and	O	O
extends	O	O
the	O	O
inhibition	O	O
of	O	O
cocaine	B-Chemical	D003042
-	O	O
induced	O	O
increases	O	O
in	O	O
dopamine	B-Chemical	D004298
,	O	O
effectively	O	O
reducing	O	O
cumulative	O	O
exposures	O	O
and	O	O
the	O	O
risk	O	O
for	O	O
VFDS	O	O
.	O	O

Amount	O	O
of	O	O
bleeding	B-Disease	D006470
and	O	O
hematoma	B-Disease	D006406
size	O	O
in	O	O
the	O	O
collagenase	O	O
-	O	O
induced	O	O
intracerebral	B-Disease	D002543
hemorrhage	I-Disease	D002543
rat	O	O
model	O	O
.	O	O

The	O	O
aggravated	O	O
risk	O	O
on	O	O
intracerebral	B-Disease	D002543
hemorrhage	I-Disease	D002543
(	O	O
ICH	B-Disease	D002543
)	O	O
with	O	O
drugs	O	O
used	O	O
for	O	O
stroke	B-Disease	D020521
patients	O	O
should	O	O
be	O	O
estimated	O	O
carefully	O	O
.	O	O

We	O	O
therefore	O	O
established	O	O
sensitive	O	O
quantification	O	O
methods	O	O
and	O	O
provided	O	O
a	O	O
rat	O	O
ICH	B-Disease	D002543
model	O	O
for	O	O
detection	O	O
of	O	O
ICH	B-Disease	D002543
deterioration	O	O
.	O	O

In	O	O
ICH	B-Disease	D002543
intrastriatally	O	O
induced	O	O
by	O	O
0	O	O
.	O	O

014	O	O
-	O	O
unit	O	O
,	O	O
0	O	O
.	O	O

070	O	O
-	O	O
unit	O	O
,	O	O
and	O	O
0	O	O
.	O	O

350	O	O
-	O	O
unit	O	O
collagenase	O	O
,	O	O
the	O	O
amount	O	O
of	O	O
bleeding	B-Disease	D006470
was	O	O
measured	O	O
using	O	O
a	O	O
hemoglobin	O	O
assay	O	O
developed	O	O
in	O	O
the	O	O
present	O	O
study	O	O
and	O	O
was	O	O
compared	O	O
with	O	O
the	O	O
morphologically	O	O
determined	O	O
hematoma	B-Disease	D006406
volume	O	O
.	O	O

The	O	O
blood	O	O
amounts	O	O
and	O	O
hematoma	B-Disease	D006406
volumes	O	O
were	O	O
significantly	O	O
correlated	O	O
,	O	O
and	O	O
the	O	O
hematoma	B-Disease	D006406
induced	O	O
by	O	O
0	O	O
.	O	O

014	O	O
-	O	O
unit	O	O
collagenase	O	O
was	O	O
adequate	O	O
to	O	O
detect	O	O
ICH	B-Disease	D002543
deterioration	O	O
.	O	O

In	O	O
ICH	B-Disease	D002543
induction	O	O
using	O	O
0	O	O
.	O	O

014	O	O
-	O	O
unit	O	O
collagenase	O	O
,	O	O
heparin	B-Chemical	D006493
enhanced	O	O
the	O	O
hematoma	B-Disease	D006406
volume	O	O
3	O	O
.	O	O

4	O	O
-	O	O
fold	O	O
over	O	O
that	O	O
seen	O	O
in	O	O
control	O	O
ICH	B-Disease	D002543
animals	O	O
and	O	O
the	O	O
bleeding	B-Disease	D006470
7	O	O
.	O	O

6	O	O
-	O	O
fold	O	O
.	O	O

Data	O	O
suggest	O	O
that	O	O
this	O	O
sensitive	O	O
hemoglobin	O	O
assay	O	O
is	O	O
useful	O	O
for	O	O
ICH	B-Disease	D002543
detection	O	O
,	O	O
and	O	O
that	O	O
a	O	O
model	O	O
with	O	O
a	O	O
small	O	O
ICH	B-Disease	D002543
induced	O	O
with	O	O
a	O	O
low	O	O
-	O	O
dose	O	O
collagenase	O	O
should	O	O
be	O	O
used	O	O
for	O	O
evaluation	O	O
of	O	O
drugs	O	O
that	O	O
may	O	O
affect	O	O
ICH	B-Disease	D002543
.	O	O

Estradiol	B-Chemical	D004958
reduces	O	O
seizure	B-Disease	D012640
-	O	O
induced	O	O
hippocampal	B-Disease	D001930
injury	I-Disease	D001930
in	O	O
ovariectomized	O	O
female	O	O
but	O	O
not	O	O
in	O	O
male	O	O
rats	O	O
.	O	O

Estrogens	O	O
protect	O	O
ovariectomized	O	O
rats	O	O
from	O	O
hippocampal	B-Disease	D001930
injury	I-Disease	D001930
induced	O	O
by	O	O
kainic	B-Chemical	D007608
acid	I-Chemical	D007608
-	O	O
induced	O	O
status	B-Disease	D013226
epilepticus	I-Disease	D013226
(	O	O
SE	B-Disease	D013226
)	O	O
.	O	O

We	O	O
compared	O	O
the	O	O
effects	O	O
of	O	O
17beta	B-Chemical	D004958
-	I-Chemical	D004958
estradiol	I-Chemical	D004958
in	O	O
adult	O	O
male	O	O
and	O	O
ovariectomized	O	O
female	O	O
rats	O	O
subjected	O	O
to	O	O
lithium	B-Chemical	D008094
-	O	O
pilocarpine	B-Chemical	D010862
-	O	O
induced	O	O
SE	B-Disease	D013226
.	O	O

Rats	O	O
received	O	O
subcutaneous	O	O
injections	O	O
of	O	O
17beta	B-Chemical	D004958
-	I-Chemical	D004958
estradiol	I-Chemical	D004958
(	O	O
2	O	O
microg	O	O
/	O	O
rat	O	O
)	O	O
or	O	O
oil	O	O
once	O	O
daily	O	O
for	O	O
four	O	O
consecutive	O	O
days	O	O
.	O	O

SE	B-Disease	D013226
was	O	O
induced	O	O
20	O	O
h	O	O
following	O	O
the	O	O
second	O	O
injection	O	O
and	O	O
terminated	O	O
3	O	O
h	O	O
later	O	O
.	O	O

The	O	O
extent	O	O
of	O	O
silver	B-Chemical	D012834
-	O	O
stained	O	O
CA3	O	O
and	O	O
CA1	O	O
hippocampal	O	O
neurons	O	O
was	O	O
evaluated	O	O
2	O	O
days	O	O
after	O	O
SE	B-Disease	D013226
.	O	O

17beta	B-Chemical	D004958
-	I-Chemical	D004958
Estradiol	I-Chemical	D004958
did	O	O
not	O	O
alter	O	O
the	O	O
onset	O	O
of	O	O
first	O	O
clonus	O	O
in	O	O
ovariectomized	O	O
rats	O	O
but	O	O
accelerated	O	O
it	O	O
in	O	O
males	O	O
.	O	O

17beta	B-Chemical	D004958
-	I-Chemical	D004958
Estradiol	I-Chemical	D004958
reduced	O	O
the	O	O
argyrophilic	O	O
neurons	O	O
in	O	O
the	O	O
CA1	O	O
and	O	O
CA3	O	O
-	O	O
C	O	O
sectors	O	O
of	O	O
ovariectomized	O	O
rats	O	O
.	O	O

In	O	O
males	O	O
,	O	O
estradiol	B-Chemical	D004958
increased	O	O
the	O	O
total	O	O
damage	O	O
score	O	O
.	O	O

These	O	O
findings	O	O
suggest	O	O
that	O	O
the	O	O
effects	O	O
of	O	O
estradiol	B-Chemical	D004958
on	O	O
seizure	B-Disease	D012640
threshold	O	O
and	O	O
damage	O	O
may	O	O
be	O	O
altered	O	O
by	O	O
sex	O	O
-	O	O
related	O	O
differences	O	O
in	O	O
the	O	O
hormonal	O	O
environment	O	O
.	O	O

Delirium	B-Disease	D003693
during	O	O
clozapine	B-Chemical	D003024
treatment	O	O
:	O	O
incidence	O	O
and	O	O
associated	O	O
risk	O	O
factors	O	O
.	O	O

BACKGROUND	O	O
:	O	O
Incidence	O	O
and	O	O
risk	O	O
factors	O	O
for	O	O
delirium	B-Disease	D003693
during	O	O
clozapine	B-Chemical	D003024
treatment	O	O
require	O	O
further	O	O
clarification	O	O
.	O	O

METHODS	O	O
:	O	O
We	O	O
used	O	O
computerized	O	O
pharmacy	O	O
records	O	O
to	O	O
identify	O	O
all	O	O
adult	O	O
psychiatric	B-Disease	D001523
inpatients	O	O
treated	O	O
with	O	O
clozapine	B-Chemical	D003024
(	O	O
1995	O	O
-	O	O
96	O	O
)	O	O
,	O	O
reviewed	O	O
their	O	O
medical	O	O
records	O	O
to	O	O
score	O	O
incidence	O	O
and	O	O
severity	O	O
of	O	O
delirium	B-Disease	D003693
,	O	O
and	O	O
tested	O	O
associations	O	O
with	O	O
potential	O	O
risk	O	O
factors	O	O
.	O	O

RESULTS	O	O
:	O	O
Subjects	O	O
(	O	O
n	O	O
=	O	O
139	O	O
)	O	O
were	O	O
72	O	O
women	O	O
and	O	O
67	O	O
men	O	O
,	O	O
aged	O	O
40	O	O
.	O	O

8	O	O
+	O	O
/	O	O
-	O	O
12	O	O
.	O	O

1	O	O
years	O	O
,	O	O
hospitalized	O	O
for	O	O
24	O	O
.	O	O

9	O	O
+	O	O
/	O	O
-	O	O
23	O	O
.	O	O

3	O	O
days	O	O
,	O	O
and	O	O
given	O	O
clozapine	B-Chemical	D003024
,	O	O
gradually	O	O
increased	O	O
to	O	O
an	O	O
average	O	O
daily	O	O
dose	O	O
of	O	O
282	O	O
+	O	O
/	O	O
-	O	O
203	O	O
mg	O	O
(	O	O
3	O	O
.	O	O

45	O	O
+	O	O
/	O	O
-	O	O
2	O	O
.	O	O

45	O	O
mg	O	O
/	O	O
kg	O	O
)	O	O
for	O	O
18	O	O
.	O	O

9	O	O
+	O	O
/	O	O
-	O	O
16	O	O
.	O	O

4	O	O
days	O	O
.	O	O

Delirium	B-Disease	D003693
was	O	O
diagnosed	O	O
in	O	O
14	O	O
(	O	O
10	O	O
.	O	O

1	O	O
%	O	O
incidence	O	O
,	O	O
or	O	O
1	O	O
.	O	O

48	O	O
cases	O	O
/	O	O
person	O	O
-	O	O
years	O	O
of	O	O
exposure	O	O
)	O	O
;	O	O
71	O	O
.	O	O

4	O	O
%	O	O
of	O	O
cases	O	O
were	O	O
moderate	O	O
or	O	O
severe	O	O
.	O	O

Associated	O	O
factors	O	O
were	O	O
co	O	O
-	O	O
treatment	O	O
with	O	O
other	O	O
centrally	O	O
antimuscarinic	O	O
agents	O	O
,	O	O
poor	O	O
clinical	O	O
outcome	O	O
,	O	O
older	O	O
age	O	O
,	O	O
and	O	O
longer	O	O
hospitalization	O	O
(	O	O
by	O	O
17	O	O
.	O	O

5	O	O
days	O	O
,	O	O
increasing	O	O
cost	O	O
)	O	O
;	O	O
sex	O	O
,	O	O
diagnosis	O	O
or	O	O
medical	O	O
co	O	O
-	O	O
morbidity	O	O
,	O	O
and	O	O
daily	O	O
clozapine	B-Chemical	D003024
dose	O	O
,	O	O
which	O	O
fell	O	O
with	O	O
age	O	O
,	O	O
were	O	O
unrelated	O	O
.	O	O

CONCLUSIONS	O	O
:	O	O
Delirium	B-Disease	D003693
was	O	O
found	O	O
in	O	O
10	O	O
%	O	O
of	O	O
clozapine	B-Chemical	D003024
-	O	O
treated	O	O
inpatients	O	O
,	O	O
particularly	O	O
in	O	O
older	O	O
patients	O	O
exposed	O	O
to	O	O
other	O	O
central	O	O
anticholinergics	O	O
.	O	O

Delirium	B-Disease	D003693
was	O	O
inconsistently	O	O
recognized	O	O
clinically	O	O
in	O	O
milder	O	O
cases	O	O
and	O	O
was	O	O
associated	O	O
with	O	O
increased	O	O
length	O	O
-	O	O
of	O	O
-	O	O
stay	O	O
and	O	O
higher	O	O
costs	O	O
,	O	O
and	O	O
inferior	O	O
clinical	O	O
outcome	O	O
.	O	O

Ketoconazole	B-Chemical	D007654
-	O	O
induced	O	O
neurologic	B-Disease	D009422
sequelae	I-Disease	D009422
.	O	O

A	O	O
77	O	O
-	O	O
y	O	O
-	O	O
old	O	O
patient	O	O
developed	O	O
weakness	B-Disease	D018908
of	I-Disease	D018908
extremities	I-Disease	D018908
,	O	O
legs	B-Disease	D010243
paralysis	I-Disease	D010243
,	O	O
dysarthria	B-Disease	D004401
and	O	O
tremor	B-Disease	D014202
1	O	O
h	O	O
after	O	O
ingestion	O	O
of	O	O
200	O	O
mg	O	O
ketoconazole	B-Chemical	D007654
for	O	O
the	O	O
first	O	O
time	O	O
in	O	O
his	O	O
life	O	O
.	O	O

All	O	O
complaints	O	O
faded	O	O
away	O	O
within	O	O
24	O	O
h	O	O
.	O	O

Few	O	O
days	O	O
later	O	O
,	O	O
the	O	O
patient	O	O
used	O	O
another	O	O
200	O	O
mg	O	O
ketoconazole	B-Chemical	D007654
tablet	O	O
,	O	O
and	O	O
within	O	O
an	O	O
hour	O	O
experienced	O	O
a	O	O
similar	O	O
clinical	O	O
picture	O	O
,	O	O
which	O	O
resolved	O	O
again	O	O
spontaneously	O	O
within	O	O
hours	O	O
.	O	O

Laboratory	O	O
evaluations	O	O
,	O	O
including	O	O
head	O	O
CT	O	O
scan	O	O
,	O	O
were	O	O
normal	O	O
.	O	O

This	O	O
case	O	O
illustrates	O	O
the	O	O
need	O	O
for	O	O
close	O	O
vigilance	O	O
in	O	O
adverse	B-Disease	D064420
drug	I-Disease	D064420
reactions	I-Disease	D064420
,	O	O
particularly	O	O
in	O	O
the	O	O
elderly	O	O
.	O	O

Noxious	O	O
chemical	O	O
stimulation	O	O
of	O	O
rat	O	O
facial	O	O
mucosa	O	O
increases	O	O
intracranial	O	O
blood	O	O
flow	O	O
through	O	O
a	O	O
trigemino	O	O
-	O	O
parasympathetic	O	O
reflex	O	O
-	O	O
-	O	O
an	O	O
experimental	O	O
model	O	O
for	O	O
vascular	B-Disease	D002561
dysfunctions	I-Disease	D002561
in	O	O
cluster	B-Disease	D003027
headache	I-Disease	D003027
.	O	O

Cluster	B-Disease	D003027
headache	I-Disease	D003027
is	O	O
characterized	O	O
by	O	O
typical	O	O
autonomic	O	O
dysfunctions	O	O
including	O	O
facial	O	O
and	O	O
intracranial	B-Disease	D002561
vascular	I-Disease	D002561
disturbances	I-Disease	D002561
.	O	O

Both	O	O
the	O	O
trigeminal	O	O
and	O	O
the	O	O
cranial	O	O
parasympathetic	O	O
systems	O	O
may	O	O
be	O	O
involved	O	O
in	O	O
mediating	O	O
these	O	O
dysfunctions	O	O
.	O	O

An	O	O
experimental	O	O
model	O	O
was	O	O
developed	O	O
in	O	O
the	O	O
rat	O	O
to	O	O
measure	O	O
changes	O	O
in	O	O
lacrimation	O	O
and	O	O
intracranial	O	O
blood	O	O
flow	O	O
following	O	O
noxious	O	O
chemical	O	O
stimulation	O	O
of	O	O
facial	O	O
mucosa	O	O
.	O	O

Blood	O	O
flow	O	O
was	O	O
monitored	O	O
in	O	O
arteries	O	O
of	O	O
the	O	O
exposed	O	O
cranial	O	O
dura	O	O
mater	O	O
and	O	O
the	O	O
parietal	O	O
cortex	O	O
using	O	O
laser	O	O
Doppler	O	O
flowmetry	O	O
.	O	O

Capsaicin	B-Chemical	D002211
(	O	O
0	O	O
.	O	O

01	O	O
-	O	O
1	O	O
mm	O	O
)	O	O
applied	O	O
to	O	O
oral	O	O
or	O	O
nasal	O	O
mucosa	O	O
induced	O	O
increases	B-Disease	D006940
in	I-Disease	D006940
dural	I-Disease	D006940
and	I-Disease	D006940
cortical	I-Disease	D006940
blood	I-Disease	D006940
flow	I-Disease	D006940
and	O	O
provoked	O	O
lacrimation	O	O
.	O	O

These	O	O
responses	O	O
were	O	O
blocked	O	O
by	O	O
systemic	O	O
pre	O	O
-	O	O
administration	O	O
of	O	O
hexamethonium	B-Chemical	D018738
chloride	I-Chemical	D018738
(	O	O
20	O	O
mg	O	O
/	O	O
kg	O	O
)	O	O
.	O	O

The	O	O
evoked	O	O
increases	B-Disease	D006940
in	I-Disease	D006940
dural	I-Disease	D006940
blood	I-Disease	D006940
flow	I-Disease	D006940
were	O	O
also	O	O
abolished	O	O
by	O	O
topical	O	O
pre	O	O
-	O	O
administration	O	O
of	O	O
atropine	B-Chemical	D001285
(	O	O
1	O	O
mm	O	O
)	O	O
and	O	O
[	O	O
Lys1	O	O
,	O	O
Pro2	O	O
,	O	O
5	O	O
,	O	O
Arg3	O	O
,	O	O
4	O	O
,	O	O
Tyr6	O	O
]	O	O
-	O	O
VIP	O	O
(	O	O
0	O	O
.	O	O

1	O	O
mm	O	O
)	O	O
,	O	O
a	O	O
vasoactive	O	O
intestinal	O	O
polypeptide	O	O
(	O	O
VIP	O	O
)	O	O
antagonist	O	O
,	O	O
onto	O	O
the	O	O
exposed	O	O
dura	O	O
mater	O	O
.	O	O

We	O	O
conclude	O	O
that	O	O
noxious	O	O
stimulation	O	O
of	O	O
facial	O	O
mucosa	O	O
increases	O	O
intracranial	O	O
blood	O	O
flow	O	O
and	O	O
lacrimation	O	O
via	O	O
a	O	O
trigemino	O	O
-	O	O
parasympathetic	O	O
reflex	O	O
.	O	O

The	O	O
blood	O	O
flow	O	O
responses	O	O
seem	O	O
to	O	O
be	O	O
mediated	O	O
by	O	O
the	O	O
release	O	O
of	O	O
acetylcholine	B-Chemical	D000109
and	O	O
VIP	O	O
within	O	O
the	O	O
meninges	O	O
.	O	O

Similar	O	O
mechanisms	O	O
may	O	O
be	O	O
involved	O	O
in	O	O
the	O	O
pathogenesis	O	O
of	O	O
cluster	B-Disease	D003027
headache	I-Disease	D003027
.	O	O

Recurrent	O	O
excitation	O	O
in	O	O
the	O	O
dentate	O	O
gyrus	O	O
of	O	O
a	O	O
murine	O	O
model	O	O
of	O	O
temporal	B-Disease	D004833
lobe	I-Disease	D004833
epilepsy	I-Disease	D004833
.	O	O

Similar	O	O
to	O	O
rats	O	O
,	O	O
systemic	O	O
pilocarpine	B-Chemical	D010862
injection	O	O
causes	O	O
status	B-Disease	D013226
epilepticus	I-Disease	D013226
(	O	O
SE	B-Disease	D013226
)	O	O
and	O	O
the	O	O
eventual	O	O
development	O	O
of	O	O
spontaneous	O	O
seizures	B-Disease	D012640
and	O	O
mossy	O	O
fiber	O	O
sprouting	O	O
in	O	O
C57BL	O	O
/	O	O
6	O	O
and	O	O
CD1	O	O
mice	O	O
,	O	O
but	O	O
the	O	O
physiological	O	O
correlates	O	O
of	O	O
these	O	O
events	O	O
have	O	O
not	O	O
been	O	O
identified	O	O
in	O	O
mice	O	O
.	O	O

Population	O	O
responses	O	O
in	O	O
granule	O	O
cells	O	O
of	O	O
the	O	O
dentate	O	O
gyrus	O	O
were	O	O
examined	O	O
in	O	O
transverse	O	O
slices	O	O
of	O	O
the	O	O
ventral	O	O
hippocampus	O	O
from	O	O
pilocarpine	B-Chemical	D010862
-	O	O
treated	O	O
and	O	O
untreated	O	O
mice	O	O
.	O	O

In	O	O
Mg	B-Chemical	D008274
(	O	O
2+	O	O
)	O	O
-	O	O
free	O	O
bathing	O	O
medium	O	O
containing	O	O
bicuculline	B-Chemical	D001640
,	O	O
conditions	O	O
designed	O	O
to	O	O
increase	O	O
excitability	O	O
in	O	O
the	O	O
slices	O	O
,	O	O
electrical	O	O
stimulation	O	O
of	O	O
the	O	O
hilus	O	O
resulted	O	O
in	O	O
a	O	O
single	O	O
population	O	O
spike	O	O
in	O	O
granule	O	O
cells	O	O
from	O	O
control	O	O
mice	O	O
and	O	O
pilocarpine	B-Chemical	D010862
-	O	O
treated	O	O
mice	O	O
that	O	O
did	O	O
not	O	O
experience	O	O
SE	B-Disease	D013226
.	O	O

In	O	O
SE	B-Disease	D013226
survivors	O	O
,	O	O
similar	O	O
stimulation	O	O
resulted	O	O
in	O	O
a	O	O
population	O	O
spike	O	O
followed	O	O
,	O	O
at	O	O
a	O	O
variable	O	O
latency	O	O
,	O	O
by	O	O
negative	O	O
DC	O	O
shifts	O	O
and	O	O
repetitive	O	O
afterdischarges	O	O
of	O	O
3	O	O
-	O	O
60	O	O
s	O	O
duration	O	O
,	O	O
which	O	O
were	O	O
blocked	O	O
by	O	O
ionotropic	O	O
glutamate	B-Chemical	D018698
receptor	O	O
antagonists	O	O
.	O	O

Focal	O	O
glutamate	B-Chemical	D018698
photostimulation	O	O
of	O	O
the	O	O
granule	O	O
cell	O	O
layer	O	O
at	O	O
sites	O	O
distant	O	O
from	O	O
the	O	O
recording	O	O
pipette	O	O
resulted	O	O
in	O	O
population	O	O
responses	O	O
of	O	O
1	O	O
-	O	O
30	O	O
s	O	O
duration	O	O
in	O	O
slices	O	O
from	O	O
SE	B-Disease	D013226
survivors	O	O
but	O	O
not	O	O
other	O	O
groups	O	O
.	O	O

These	O	O
data	O	O
support	O	O
the	O	O
hypothesis	O	O
that	O	O
SE	B-Disease	D013226
-	O	O
induced	O	O
mossy	O	O
fiber	O	O
sprouting	O	O
and	O	O
synaptic	O	O
reorganization	O	O
are	O	O
relevant	O	O
characteristics	O	O
of	O	O
seizure	B-Disease	D012640
development	O	O
in	O	O
these	O	O
murine	O	O
strains	O	O
,	O	O
resembling	O	O
rat	O	O
models	O	O
of	O	O
human	O	O
temporal	B-Disease	D004833
lobe	I-Disease	D004833
epilepsy	I-Disease	D004833
.	O	O

The	O	O
alpha3	O	O
and	O	O
beta4	O	O
nicotinic	O	O
acetylcholine	B-Chemical	D000109
receptor	O	O
subunits	O	O
are	O	O
necessary	O	O
for	O	O
nicotine	B-Chemical	D009538
-	O	O
induced	O	O
seizures	B-Disease	D012640
and	O	O
hypolocomotion	B-Disease	D006948
in	O	O
mice	O	O
.	O	O

Binding	O	O
of	O	O
nicotine	B-Chemical	D009538
to	O	O
nicotinic	O	O
acetylcholine	B-Chemical	D000109
receptors	O	O
(	O	O
nAChRs	O	O
)	O	O
elicits	O	O
a	O	O
series	O	O
of	O	O
dose	O	O
-	O	O
dependent	O	O
behaviors	O	O
that	O	O
go	O	O
from	O	O
altered	O	O
exploration	O	O
,	O	O
sedation	O	O
,	O	O
and	O	O
tremors	B-Disease	D014202
,	O	O
to	O	O
seizures	B-Disease	D012640
and	O	O
death	B-Disease	D003643
.	O	O

nAChRs	O	O
are	O	O
pentameric	O	O
ion	O	O
channels	O	O
usually	O	O
composed	O	O
of	O	O
alpha	O	O
and	O	O
beta	O	O
subunits	O	O
.	O	O

A	O	O
gene	O	O
cluster	O	O
comprises	O	O
the	O	O
alpha3	O	O
,	O	O
alpha5	O	O
and	O	O
beta4	O	O
subunits	O	O
,	O	O
which	O	O
coassemble	O	O
to	O	O
form	O	O
functional	O	O
receptors	O	O
.	O	O

We	O	O
examined	O	O
the	O	O
role	O	O
of	O	O
the	O	O
beta4	O	O
subunits	O	O
in	O	O
nicotine	B-Chemical	D009538
-	O	O
induced	O	O
seizures	B-Disease	D012640
and	O	O
hypolocomotion	B-Disease	D006948
in	O	O
beta4	O	O
homozygous	O	O
null	O	O
(	O	O
beta4	O	O
-	O	O
/	O	O
-	O	O
)	O	O
and	O	O
alpha3	O	O
heterozygous	O	O
(	O	O
+	O	O
/	O	O
-	O	O
)	O	O
mice	O	O
.	O	O

beta4	O	O
-	O	O
/	O	O
-	O	O
mice	O	O
were	O	O
less	O	O
sensitive	O	O
to	O	O
the	O	O
effects	O	O
of	O	O
nicotine	B-Chemical	D009538
both	O	O
at	O	O
low	O	O
doses	O	O
,	O	O
measured	O	O
as	O	O
decreased	O	O
exploration	O	O
in	O	O
an	O	O
open	O	O
field	O	O
,	O	O
and	O	O
at	O	O
high	O	O
doses	O	O
,	O	O
measured	O	O
as	O	O
sensitivity	O	O
to	O	O
nicotine	B-Chemical	D009538
-	O	O
induced	O	O
seizures	B-Disease	D012640
.	O	O

Using	O	O
in	O	O
situ	O	O
hybridization	O	O
probes	O	O
for	O	O
the	O	O
alpha3	O	O
and	O	O
alpha5	O	O
subunits	O	O
,	O	O
we	O	O
showed	O	O
that	O	O
alpha5	O	O
mRNA	O	O
levels	O	O
are	O	O
unchanged	O	O
,	O	O
whereas	O	O
alpha3	O	O
mRNA	O	O
levels	O	O
are	O	O
selectively	O	O
decreased	O	O
in	O	O
the	O	O
mitral	O	O
cell	O	O
layer	O	O
of	O	O
the	O	O
olfactory	O	O
bulb	O	O
,	O	O
and	O	O
the	O	O
inferior	O	O
and	O	O
the	O	O
superior	O	O
colliculus	O	O
of	O	O
beta4	O	O
-	O	O
/	O	O
-	O	O
brains	O	O
.	O	O

alpha3	O	O
+	O	O
/	O	O
-	O	O
mice	O	O
were	O	O
partially	O	O
resistant	O	O
to	O	O
nicotine	B-Chemical	D009538
-	O	O
induced	O	O
seizures	B-Disease	D012640
when	O	O
compared	O	O
to	O	O
wild	O	O
-	O	O
type	O	O
littermates	O	O
.	O	O

mRNA	O	O
levels	O	O
for	O	O
the	O	O
alpha5	O	O
and	O	O
the	O	O
beta4	O	O
subunits	O	O
were	O	O
unchanged	O	O
in	O	O
alpha3	O	O
+	O	O
/	O	O
-	O	O
brains	O	O
.	O	O

Together	O	O
,	O	O
these	O	O
results	O	O
suggest	O	O
that	O	O
the	O	O
beta4	O	O
and	O	O
the	O	O
alpha3	O	O
subunits	O	O
are	O	O
mediators	O	O
of	O	O
nicotine	B-Chemical	D009538
-	O	O
induced	O	O
seizures	B-Disease	D012640
and	O	O
hypolocomotion	B-Disease	D006948
.	O	O

Recurrent	O	O
acute	O	O
interstitial	B-Disease	D009395
nephritis	I-Disease	D009395
induced	O	O
by	O	O
azithromycin	B-Chemical	D017963
.	O	O

A	O	O
14	O	O
-	O	O
year	O	O
-	O	O
old	O	O
girl	O	O
is	O	O
reported	O	O
with	O	O
recurrent	O	O
,	O	O
azithromycin	B-Chemical	D017963
-	O	O
induced	O	O
,	O	O
acute	O	O
interstitial	B-Disease	D009395
nephritis	I-Disease	D009395
.	O	O

The	O	O
second	O	O
episode	O	O
was	O	O
more	O	O
severe	O	O
than	O	O
the	O	O
first	O	O
;	O	O
and	O	O
although	O	O
both	O	O
were	O	O
treated	O	O
with	O	O
intensive	O	O
corticosteroid	O	O
therapy	O	O
,	O	O
renal	O	O
function	O	O
remained	O	O
impaired	O	O
.	O	O

Although	O	O
most	O	O
cases	O	O
of	O	O
antibiotic	O	O
induced	O	O
acute	O	O
interstitial	B-Disease	D009395
nephritis	I-Disease	D009395
are	O	O
benign	O	O
and	O	O
self	O	O
-	O	O
limited	O	O
,	O	O
some	O	O
patients	O	O
are	O	O
at	O	O
risk	O	O
for	O	O
permanent	O	O
renal	B-Disease	D007674
injury	I-Disease	D007674
.	O	O

Valproate	B-Chemical	D014635
-	O	O
induced	O	O
encephalopathy	B-Disease	D001927
.	O	O

Valproate	B-Chemical	D014635
-	O	O
induced	O	O
encephalopathy	B-Disease	D001927
is	O	O
a	O	O
rare	O	O
syndrome	O	O
that	O	O
may	O	O
manifest	O	O
in	O	O
otherwise	O	O
normal	O	O
epileptic	B-Disease	D004827
individuals	O	O
.	O	O

It	O	O
may	O	O
even	O	O
present	O	O
in	O	O
patients	O	O
who	O	O
have	O	O
tolerated	O	O
this	O	O
medicine	O	O
well	O	O
in	O	O
the	O	O
past	O	O
.	O	O

It	O	O
is	O	O
usually	O	O
but	O	O
not	O	O
necessarily	O	O
associated	O	O
with	O	O
hyperammonemia	B-Disease	D022124
.	O	O

The	O	O
EEG	O	O
shows	O	O
characteristic	O	O
triphasic	O	O
waves	O	O
in	O	O
most	O	O
patients	O	O
with	O	O
this	O	O
complication	O	O
.	O	O

A	O	O
case	O	O
of	O	O
valproate	B-Chemical	D014635
-	O	O
induced	O	O
encephalopathy	B-Disease	D001927
is	O	O
presented	O	O
.	O	O

The	O	O
problems	O	O
in	O	O
diagnosing	O	O
this	O	O
condition	O	O
are	O	O
subsequently	O	O
discussed	O	O
.	O	O

Nitro	B-Chemical	D019331
-	I-Chemical	D019331
L	I-Chemical	D019331
-	I-Chemical	D019331
arginine	I-Chemical	D019331
methyl	I-Chemical	D019331
ester	I-Chemical	D019331
:	O	O
a	O	O
potential	O	O
protector	O	O
against	O	O
gentamicin	B-Chemical	D005839
ototoxicity	B-Disease	D006311
.	O	O

The	O	O
nitric	B-Chemical	D009569
oxide	I-Chemical	D009569
(	O	O
NO	B-Chemical	D009569
)	O	O
inhibitor	O	O
nitro	B-Chemical	D019331
-	I-Chemical	D019331
L	I-Chemical	D019331
-	I-Chemical	D019331
arginine	I-Chemical	D019331
methyl	I-Chemical	D019331
ester	I-Chemical	D019331
(	O	O
L	B-Chemical	D019331
-	I-Chemical	D019331
NAME	I-Chemical	D019331
)	O	O
may	O	O
act	O	O
as	O	O
an	O	O
otoprotectant	O	O
against	O	O
high	B-Disease	D006316
-	I-Disease	D006316
frequency	I-Disease	D006316
hearing	I-Disease	D006316
loss	I-Disease	D006316
caused	O	O
by	O	O
gentamicin	B-Chemical	D005839
,	O	O
but	O	O
further	O	O
studies	O	O
are	O	O
needed	O	O
to	O	O
confirm	O	O
this	O	O
.	O	O

Aminoglycoside	B-Chemical	D000617
antibiotics	O	O
are	O	O
still	O	O
widely	O	O
used	O	O
by	O	O
virtue	O	O
of	O	O
their	O	O
efficacy	O	O
and	O	O
low	O	O
cost	O	O
.	O	O

Their	O	O
ototoxicity	B-Disease	D006311
is	O	O
a	O	O
serious	O	O
health	O	O
problem	O	O
and	O	O
,	O	O
as	O	O
their	O	O
ototoxic	B-Disease	D006311
mechanism	O	O
involves	O	O
the	O	O
production	O	O
of	O	O
NO	B-Chemical	D009569
,	O	O
we	O	O
need	O	O
to	O	O
assess	O	O
the	O	O
use	O	O
of	O	O
NO	B-Chemical	D009569
inhibitors	O	O
for	O	O
the	O	O
prevention	O	O
of	O	O
aminoglycoside	B-Chemical	D000617
-	O	O
induced	O	O
sensorineural	B-Disease	D006319
hearing	I-Disease	D006319
loss	I-Disease	D006319
.	O	O

In	O	O
this	O	O
experimental	O	O
study	O	O
we	O	O
used	O	O
30	O	O
Sprague	O	O
-	O	O
Dawley	O	O
rats	O	O
,	O	O
27	O	O
of	O	O
which	O	O
had	O	O
gentamicin	B-Chemical	D005839
instilled	O	O
into	O	O
the	O	O
middle	O	O
ear	O	O
.	O	O

The	O	O
otoprotectant	O	O
L	B-Chemical	D019331
-	I-Chemical	D019331
NAME	I-Chemical	D019331
was	O	O
administered	O	O
topically	O	O
to	O	O
12	O	O
/	O	O
27	O	O
animals	O	O
.	O	O

Its	O	O
effect	O	O
was	O	O
determined	O	O
in	O	O
terms	O	O
of	O	O
attenuation	O	O
of	O	O
hearing	B-Disease	D034381
loss	I-Disease	D034381
,	O	O
measured	O	O
by	O	O
shifts	O	O
in	O	O
the	O	O
auditory	O	O
brainstem	O	O
response	O	O
threshold	O	O
.	O	O

L	B-Chemical	D019331
-	I-Chemical	D019331
NAME	I-Chemical	D019331
reduced	O	O
gentamicin	B-Chemical	D005839
-	O	O
induced	O	O
hearing	B-Disease	D034381
loss	I-Disease	D034381
in	O	O
the	O	O
high	O	O
-	O	O
frequency	O	O
range	O	O
,	O	O
but	O	O
gave	O	O
no	O	O
protection	O	O
in	O	O
the	O	O
middle	O	O
or	O	O
low	O	O
frequencies	O	O
.	O	O

Cerebral	B-Disease	D020293
vasculitis	I-Disease	D020293
following	O	O
oral	O	O
methylphenidate	B-Chemical	D008774
intake	O	O
in	O	O
an	O	O
adult	O	O
:	O	O
a	O	O
case	O	O
report	O	O
.	O	O

Methylphenidate	B-Chemical	D008774
is	O	O
structurally	O	O
and	O	O
functionally	O	O
similar	O	O
to	O	O
amphetamine	B-Chemical	D000661
.	O	O

Cerebral	B-Disease	D020293
vasculitis	I-Disease	D020293
associated	O	O
with	O	O
amphetamine	B-Chemical	D000661
abuse	O	O
is	O	O
well	O	O
documented	O	O
,	O	O
and	O	O
in	O	O
rare	O	O
cases	O	O
ischaemic	B-Disease	D002544
stroke	I-Disease	D002544
has	O	O
been	O	O
reported	O	O
after	O	O
methylphenidate	B-Chemical	D008774
intake	O	O
in	O	O
children	O	O
.	O	O

We	O	O
report	O	O
the	O	O
case	O	O
of	O	O
a	O	O
63	O	O
-	O	O
year	O	O
-	O	O
old	O	O
female	O	O
who	O	O
was	O	O
treated	O	O
with	O	O
methylphenidate	B-Chemical	D008774
due	O	O
to	O	O
hyperactivity	B-Disease	D006948
and	O	O
suffered	O	O
from	O	O
multiple	O	O
ischaemic	B-Disease	D002544
strokes	I-Disease	D002544
.	O	O

We	O	O
consider	O	O
drug	O	O
-	O	O
induced	O	O
cerebral	B-Disease	D020293
vasculitis	I-Disease	D020293
as	O	O
the	O	O
most	O	O
likely	O	O
cause	O	O
of	O	O
recurrent	O	O
ischaemic	B-Disease	D002544
strokes	I-Disease	D002544
in	O	O
the	O	O
absence	O	O
of	O	O
any	O	O
pathological	O	O
findings	O	O
during	O	O
the	O	O
diagnostic	O	O
work	O	O
-	O	O
up	O	O
.	O	O

We	O	O
conclude	O	O
that	O	O
methylphenidate	B-Chemical	D008774
mediated	O	O
vasculitis	B-Disease	D014657
should	O	O
be	O	O
considered	O	O
in	O	O
patients	O	O
with	O	O
neurological	O	O
symptoms	O	O
and	O	O
a	O	O
history	O	O
of	O	O
methylphenidate	B-Chemical	D008774
therapy	O	O
.	O	O

This	O	O
potential	O	O
side	O	O
-	O	O
effect	O	O
,	O	O
though	O	O
very	O	O
rare	O	O
,	O	O
represents	O	O
one	O	O
more	O	O
reason	O	O
to	O	O
be	O	O
very	O	O
restrictive	O	O
in	O	O
the	O	O
use	O	O
of	O	O
methylphenidate	B-Chemical	D008774
.	O	O

Cerebral	B-Disease	D002543
haemorrhage	I-Disease	D002543
induced	O	O
by	O	O
warfarin	B-Chemical	D014859
-	O	O
the	O	O
influence	O	O
of	O	O
drug	O	O
-	O	O
drug	O	O
interactions	O	O
.	O	O

PURPOSE	O	O
:	O	O
To	O	O
evaluate	O	O
the	O	O
frequency	O	O
,	O	O
severity	O	O
and	O	O
preventability	O	O
of	O	O
warfarin	B-Chemical	D014859
-	O	O
induced	O	O
cerebral	B-Disease	D002543
haemorrhages	I-Disease	D002543
due	O	O
to	O	O
warfarin	B-Chemical	D014859
and	O	O
warfarin	B-Chemical	D014859
-	O	O
drug	O	O
interactions	O	O
in	O	O
patients	O	O
living	O	O
in	O	O
the	O	O
county	O	O
of	O	O
Osterg	O	O
tland	O	O
,	O	O
Sweden	O	O
.	O	O

METHODS	O	O
:	O	O
All	O	O
patients	O	O
with	O	O
a	O	O
diagnosed	O	O
cerebral	B-Disease	D002543
haemorrhage	I-Disease	D002543
at	O	O
three	O	O
hospitals	O	O
during	O	O
the	O	O
period	O	O
2000	O	O
-	O	O
2002	O	O
were	O	O
identified	O	O
.	O	O

Medical	O	O
records	O	O
were	O	O
studied	O	O
retrospectively	O	O
to	O	O
evaluate	O	O
whether	O	O
warfarin	B-Chemical	D014859
and	O	O
warfarin	B-Chemical	D014859
-	O	O
drug	O	O
interactions	O	O
could	O	O
have	O	O
caused	O	O
the	O	O
cerebral	B-Disease	D002543
haemorrhage	I-Disease	D002543
.	O	O

The	O	O
proportion	O	O
of	O	O
possibly	O	O
avoidable	O	O
cases	O	O
due	O	O
to	O	O
drug	O	O
interactions	O	O
was	O	O
estimated	O	O
.	O	O

RESULTS	O	O
:	O	O
Among	O	O
593	O	O
patients	O	O
with	O	O
cerebral	B-Disease	D002543
haemorrhage	I-Disease	D002543
,	O	O
59	O	O
(	O	O
10%	O	O
)	O	O
were	O	O
assessed	O	O
as	O	O
related	O	O
to	O	O
warfarin	B-Chemical	D014859
treatment	O	O
.	O	O

This	O	O
imply	O	O
an	O	O
incidence	O	O
of	O	O
1	O	O
.	O	O

7	O	O
/	O	O
100	O	O
,	O	O
000	O	O
treatment	O	O
years	O	O
.	O	O

Of	O	O
the	O	O
59	O	O
cases	O	O
,	O	O
26	O	O
(	O	O
44%	O	O
)	O	O
had	O	O
a	O	O
fatal	O	O
outcome	O	O
,	O	O
compared	O	O
to	O	O
136	O	O
(	O	O
25%	O	O
)	O	O
among	O	O
the	O	O
non	O	O
-	O	O
warfarin	B-Chemical	D014859
patients	O	O
(	O	O
p	O	O
<	O	O
0	O	O
.	O	O

01	O	O
)	O	O
.	O	O

A	O	O
warfarin	B-Chemical	D014859
-	O	O
drug	O	O
interaction	O	O
could	O	O
have	O	O
contributed	O	O
to	O	O
the	O	O
haemorrhage	B-Disease	D006470
in	O	O
24	O	O
(	O	O
41%	O	O
)	O	O
of	O	O
the	O	O
warfarin	B-Chemical	D014859
patients	O	O
and	O	O
in	O	O
7	O	O
of	O	O
these	O	O
(	O	O
12%	O	O
)	O	O
the	O	O
bleeding	B-Disease	D006470
complication	O	O
was	O	O
considered	O	O
being	O	O
possible	O	O
to	O	O
avoid	O	O
.	O	O

CONCLUSIONS	O	O
:	O	O
Warfarin	B-Chemical	D014859
-	O	O
induced	O	O
cerebral	B-Disease	D002543
haemorrhages	I-Disease	D002543
are	O	O
a	O	O
major	O	O
clinical	O	O
problem	O	O
with	O	O
a	O	O
high	O	O
fatality	O	O
rate	O	O
.	O	O

Almost	O	O
half	O	O
of	O	O
the	O	O
cases	O	O
was	O	O
related	O	O
to	O	O
a	O	O
warfarin	B-Chemical	D014859
-	O	O
drug	O	O
interaction	O	O
.	O	O

A	O	O
significant	O	O
proportion	O	O
of	O	O
warfarin	B-Chemical	D014859
-	O	O
related	O	O
cerebral	B-Disease	D002543
haemorrhages	I-Disease	D002543
might	O	O
have	O	O
been	O	O
prevented	O	O
if	O	O
greater	O	O
caution	O	O
had	O	O
been	O	O
taken	O	O
when	O	O
prescribing	O	O
drugs	O	O
known	O	O
to	O	O
interact	O	O
with	O	O
warfarin	B-Chemical	D014859
.	O	O

Side	O	O
effects	O	O
of	O	O
postoperative	O	O
administration	O	O
of	O	O
methylprednisolone	B-Chemical	D008775
and	O	O
gentamicin	B-Chemical	D005839
into	O	O
the	O	O
posterior	O	O
sub	O	O
-	O	O
Tenon's	O	O
space	O	O
.	O	O

PURPOSE	O	O
:	O	O
To	O	O
assess	O	O
the	O	O
incidence	O	O
of	O	O
postoperative	O	O
emetic	O	O
side	O	O
effects	O	O
after	O	O
the	O	O
administration	O	O
of	O	O
methylprednisolone	B-Chemical	D008775
and	O	O
gentamicin	B-Chemical	D005839
into	O	O
the	O	O
posterior	O	O
sub	O	O
-	O	O
Tenon's	O	O
space	O	O
at	O	O
the	O	O
end	O	O
of	O	O
routine	O	O
cataract	B-Disease	D002386
surgery	O	O
.	O	O

SETTING	O	O
:	O	O
St	O	O
.	O	O

Luke's	O	O
Hospital	O	O
,	O	O
Gwardamangia	O	O
,	O	O
Malta	O	O
.	O	O

METHODS	O	O
:	O	O
A	O	O
double	O	O
-	O	O
blind	O	O
double	O	O
-	O	O
armed	O	O
prospective	O	O
study	O	O
comprised	O	O
40	O	O
patients	O	O
who	O	O
had	O	O
uneventful	O	O
sutureless	O	O
phacoemulsification	O	O
under	O	O
sub	O	O
-	O	O
Tenon's	O	O
local	O	O
infiltration	O	O
of	O	O
3	O	O
mL	O	O
of	O	O
plain	O	O
lignocaine	B-Chemical	D008012
.	O	O

At	O	O
the	O	O
end	O	O
of	O	O
the	O	O
procedure	O	O
,	O	O
Group	O	O
A	O	O
(	O	O
n	O	O
=	O	O
20	O	O
)	O	O
had	O	O
20	O	O
mg	O	O
/	O	O
0	O	O
.	O	O

5	O	O
mL	O	O
of	O	O
methylprednisolone	B-Chemical	D008775
and	O	O
10	O	O
mg	O	O
/	O	O
0	O	O
.	O	O

5	O	O
mL	O	O
of	O	O
gentamicin	B-Chemical	D005839
injected	O	O
into	O	O
the	O	O
posterior	O	O
sub	O	O
-	O	O
Tenon's	O	O
space	O	O
and	O	O
Group	O	O
B	O	O
(	O	O
n	O	O
=	O	O
20	O	O
)	O	O
had	O	O
the	O	O
same	O	O
combination	O	O
injected	O	O
into	O	O
the	O	O
anterior	O	O
sub	O	O
-	O	O
Tenon's	O	O
space	O	O
.	O	O

Postoperatively	O	O
,	O	O
all	O	O
patients	O	O
were	O	O
assessed	O	O
for	O	O
symptoms	O	O
of	O	O
nausea	B-Disease	D020250
,	I-Disease	D020250
vomiting	I-Disease	D020250
,	O	O
and	O	O
headache	B-Disease	D006261
.	O	O

A	O	O
chi	O	O
-	O	O
square	O	O
test	O	O
was	O	O
used	O	O
to	O	O
assess	O	O
the	O	O
statistical	O	O
significance	O	O
of	O	O
results	O	O
.	O	O

RESULTS	O	O
:	O	O
Sixty	O	O
percent	O	O
in	O	O
Group	O	O
A	O	O
developed	O	O
postoperative	B-Disease	D020250
emetic	I-Disease	D020250
symptoms	I-Disease	D020250
,	O	O
headache	B-Disease	D006261
,	O	O
or	O	O
both	O	O
;	O	O
1	O	O
patient	O	O
in	O	O
Group	O	O
B	O	O
developed	O	O
symptoms	O	O
.	O	O

CONCLUSIONS	O	O
:	O	O
The	O	O
administration	O	O
of	O	O
methylprednisolone	B-Chemical	D008775
and	O	O
gentamicin	B-Chemical	D005839
in	O	O
the	O	O
posterior	O	O
sub	O	O
-	O	O
Tenon's	O	O
space	O	O
was	O	O
related	O	O
to	O	O
a	O	O
high	O	O
incidence	O	O
of	O	O
side	O	O
effects	O	O
including	O	O
nausea	B-Disease	D020250
,	I-Disease	D020250
vomiting	I-Disease	D020250
,	O	O
and	O	O
headache	B-Disease	D006261
.	O	O

All	O	O
adverse	O	O
effects	O	O
were	O	O
self	O	O
-	O	O
limiting	O	O
.	O	O

Cardiac	O	O
Angiography	O	O
in	O	O
Renally	O	O
Impaired	O	O
Patients	O	O
(	O	O
CARE	O	O
)	O	O
study	O	O
:	O	O
a	O	O
randomized	O	O
double	O	O
-	O	O
blind	O	O
trial	O	O
of	O	O
contrast	O	O
-	O	O
induced	O	O
nephropathy	B-Disease	D007674
in	O	O
patients	O	O
with	O	O
chronic	B-Disease	D051436
kidney	I-Disease	D051436
disease	I-Disease	D051436
.	O	O

BACKGROUND	O	O
:	O	O
No	O	O
direct	O	O
comparisons	O	O
exist	O	O
of	O	O
the	O	O
renal	O	O
tolerability	O	O
of	O	O
the	O	O
low	O	O
-	O	O
osmolality	O	O
contrast	B-Chemical	D003287
medium	I-Chemical	D003287
iopamidol	B-Chemical	D007479
with	O	O
that	O	O
of	O	O
the	O	O
iso	O	O
-	O	O
osmolality	O	O
contrast	B-Chemical	D003287
medium	I-Chemical	D003287
iodixanol	B-Chemical	C044834
in	O	O
high	O	O
-	O	O
risk	O	O
patients	O	O
.	O	O

METHODS	O	O
AND	O	O
RESULTS	O	O
:	O	O
The	O	O
present	O	O
study	O	O
is	O	O
a	O	O
multicenter	O	O
,	O	O
randomized	O	O
,	O	O
double	O	O
-	O	O
blind	O	O
comparison	O	O
of	O	O
iopamidol	B-Chemical	D007479
and	O	O
iodixanol	B-Chemical	C044834
in	O	O
patients	O	O
with	O	O
chronic	B-Disease	D051436
kidney	I-Disease	D051436
disease	I-Disease	D051436
(	O	O
estimated	O	O
glomerular	O	O
filtration	O	O
rate	O	O
,	O	O
20	O	O
to	O	O
59	O	O
mL	O	O
/	O	O
min	O	O
)	O	O
who	O	O
underwent	O	O
cardiac	O	O
angiography	O	O
or	O	O
percutaneous	O	O
coronary	O	O
interventions	O	O
.	O	O

Serum	O	O
creatinine	B-Chemical	D003404
(	O	O
SCr	O	O
)	O	O
levels	O	O
and	O	O
estimated	O	O
glomerular	O	O
filtration	O	O
rate	O	O
were	O	O
assessed	O	O
at	O	O
baseline	O	O
and	O	O
2	O	O
to	O	O
5	O	O
days	O	O
after	O	O
receiving	O	O
medications	O	O
.	O	O

The	O	O
primary	O	O
outcome	O	O
was	O	O
a	O	O
postdose	O	O
SCr	O	O
increase	O	O
>	O	O
or	O	O
=	O	O
0	O	O
.	O	O

5	O	O
mg	O	O
/	O	O
dL	O	O
(	O	O
44	O	O
.	O	O

2	O	O
micromol	O	O
/	O	O
L	O	O
)	O	O
over	O	O
baseline	O	O
.	O	O

Secondary	O	O
outcomes	O	O
were	O	O
a	O	O
postdose	O	O
SCr	O	O
increase	O	O
>	O	O
or	O	O
=	O	O
25%	O	O
,	O	O
a	O	O
postdose	O	O
estimated	O	O
glomerular	O	O
filtration	O	O
rate	O	O
decrease	O	O
of	O	O
>	O	O
or	O	O
=	O	O
25%	O	O
,	O	O
and	O	O
the	O	O
mean	O	O
peak	O	O
change	O	O
in	O	O
SCr	O	O
.	O	O

In	O	O
414	O	O
patients	O	O
,	O	O
contrast	O	O
volume	O	O
,	O	O
presence	O	O
of	O	O
diabetes	B-Disease	D003920
mellitus	I-Disease	D003920
,	O	O
use	O	O
of	O	O
N	B-Chemical	D000111
-	I-Chemical	D000111
acetylcysteine	I-Chemical	D000111
,	O	O
mean	O	O
baseline	O	O
SCr	O	O
,	O	O
and	O	O
estimated	O	O
glomerular	O	O
filtration	O	O
rate	O	O
were	O	O
comparable	O	O
in	O	O
the	O	O
2	O	O
groups	O	O
.	O	O

SCr	O	O
increases	O	O
>	O	O
or	O	O
=	O	O
0	O	O
.	O	O

5	O	O
mg	O	O
/	O	O
dL	O	O
occurred	O	O
in	O	O
4	O	O
.	O	O

4%	O	O
(	O	O
9	O	O
of	O	O
204	O	O
patients	O	O
)	O	O
after	O	O
iopamidol	B-Chemical	D007479
and	O	O
6	O	O
.	O	O

7%	O	O
(	O	O
14	O	O
of	O	O
210	O	O
patients	O	O
)	O	O
after	O	O
iodixanol	B-Chemical	C044834
(	O	O
P=0	O	O
.	O	O

39	O	O
)	O	O
,	O	O
whereas	O	O
rates	O	O
of	O	O
SCr	O	O
increases	O	O
>	O	O
or	O	O
=	O	O
25%	O	O
were	O	O
9	O	O
.	O	O

8%	O	O
and	O	O
12	O	O
.	O	O

4%	O	O
,	O	O
respectively	O	O
(	O	O
P=0	O	O
.	O	O

44	O	O
)	O	O
.	O	O

In	O	O
patients	O	O
with	O	O
diabetes	B-Disease	D003920
,	O	O
SCr	O	O
increases	O	O
>	O	O
or	O	O
=	O	O
0	O	O
.	O	O

5	O	O
mg	O	O
/	O	O
dL	O	O
were	O	O
5	O	O
.	O	O

1%	O	O
(	O	O
4	O	O
of	O	O
78	O	O
patients	O	O
)	O	O
with	O	O
iopamidol	B-Chemical	D007479
and	O	O
13	O	O
.	O	O

0%	O	O
(	O	O
12	O	O
of	O	O
92	O	O
patients	O	O
)	O	O
with	O	O
iodixanol	B-Chemical	C044834
(	O	O
P=0	O	O
.	O	O

11	O	O
)	O	O
,	O	O
whereas	O	O
SCr	O	O
increases	O	O
>	O	O
or	O	O
=	O	O
25%	O	O
were	O	O
10	O	O
.	O	O

3%	O	O
and	O	O
15	O	O
.	O	O

2%	O	O
,	O	O
respectively	O	O
(	O	O
P=0	O	O
.	O	O

37	O	O
)	O	O
.	O	O

Mean	O	O
post	O	O
-	O	O
SCr	O	O
increases	O	O
were	O	O
significantly	O	O
less	O	O
with	O	O
iopamidol	B-Chemical	D007479
(	O	O
all	O	O
patients	O	O
:	O	O
0	O	O
.	O	O

07	O	O
versus	O	O
0	O	O
.	O	O

12	O	O
mg	O	O
/	O	O
dL	O	O
,	O	O
6	O	O
.	O	O

2	O	O
versus	O	O
10	O	O
.	O	O

6	O	O
micromol	O	O
/	O	O
L	O	O
,	O	O
P=0	O	O
.	O	O

03	O	O
;	O	O
patients	O	O
with	O	O
diabetes	B-Disease	D003920
:	O	O
0	O	O
.	O	O

07	O	O
versus	O	O
0	O	O
.	O	O

16	O	O
mg	O	O
/	O	O
dL	O	O
,	O	O
6	O	O
.	O	O

2	O	O
versus	O	O
14	O	O
.	O	O

1	O	O
micromol	O	O
/	O	O
L	O	O
,	O	O
P=0	O	O
.	O	O

01	O	O
)	O	O
.	O	O

CONCLUSIONS	O	O
:	O	O
The	O	O
rate	O	O
of	O	O
contrast	O	O
-	O	O
induced	O	O
nephropathy	B-Disease	D007674
,	O	O
defined	O	O
by	O	O
multiple	O	O
end	O	O
points	O	O
,	O	O
is	O	O
not	O	O
statistically	O	O
different	O	O
after	O	O
the	O	O
intraarterial	O	O
administration	O	O
of	O	O
iopamidol	B-Chemical	D007479
or	O	O
iodixanol	B-Chemical	C044834
to	O	O
high	O	O
-	O	O
risk	O	O
patients	O	O
,	O	O
with	O	O
or	O	O
without	O	O
diabetes	B-Disease	D003920
mellitus	I-Disease	D003920
.	O	O

Any	O	O
true	O	O
difference	O	O
between	O	O
the	O	O
agents	O	O
is	O	O
small	O	O
and	O	O
not	O	O
likely	O	O
to	O	O
be	O	O
clinically	O	O
significant	O	O
.	O	O

A	O	O
novel	O	O
compound	O	O
,	O	O
maltolyl	B-Chemical	C524754
p	I-Chemical	C524754
-	I-Chemical	C524754
coumarate	I-Chemical	C524754
,	O	O
attenuates	O	O
cognitive	B-Disease	D003072
deficits	I-Disease	D003072
and	O	O
shows	O	O
neuroprotective	O	O
effects	O	O
in	O	O
vitro	O	O
and	O	O
in	O	O
vivo	O	O
dementia	B-Disease	D003704
models	O	O
.	O	O

To	O	O
develop	O	O
a	O	O
novel	O	O
and	O	O
effective	O	O
drug	O	O
that	O	O
could	O	O
enhance	O	O
cognitive	O	O
function	O	O
and	O	O
neuroprotection	O	O
,	O	O
we	O	O
newly	O	O
synthesized	O	O
maltolyl	B-Chemical	C524754
p	I-Chemical	C524754
-	I-Chemical	C524754
coumarate	I-Chemical	C524754
by	O	O
the	O	O
esterification	O	O
of	O	O
maltol	B-Chemical	C008316
and	O	O
p	B-Chemical	C032171
-	I-Chemical	C032171
coumaric	I-Chemical	C032171
acid	I-Chemical	C032171
.	O	O

In	O	O
the	O	O
present	O	O
study	O	O
,	O	O
we	O	O
investigated	O	O
whether	O	O
maltolyl	B-Chemical	C524754
p	I-Chemical	C524754
-	I-Chemical	C524754
coumarate	I-Chemical	C524754
could	O	O
improve	O	O
cognitive	B-Disease	D003072
decline	I-Disease	D003072
in	O	O
scopolamine	B-Chemical	D012601
-	O	O
injected	O	O
rats	O	O
and	O	O
in	O	O
amyloid	B-Chemical	C544092
beta	I-Chemical	C544092
peptide	I-Chemical	C544092
(	I-Chemical	C544092
1	I-Chemical	C544092
-	I-Chemical	C544092
42	I-Chemical	C544092
)	I-Chemical	C544092
-	O	O
infused	O	O
rats	O	O
.	O	O

Maltolyl	B-Chemical	C524754
p	I-Chemical	C524754
-	I-Chemical	C524754
coumarate	I-Chemical	C524754
was	O	O
found	O	O
to	O	O
attenuate	O	O
cognitive	B-Disease	D003072
deficits	I-Disease	D003072
in	O	O
both	O	O
rat	O	O
models	O	O
using	O	O
passive	O	O
avoidance	O	O
test	O	O
and	O	O
to	O	O
reduce	O	O
apoptotic	O	O
cell	O	O
death	O	O
observed	O	O
in	O	O
the	O	O
hippocampus	O	O
of	O	O
the	O	O
amyloid	B-Chemical	C544092
beta	I-Chemical	C544092
peptide	I-Chemical	C544092
(	I-Chemical	C544092
1	I-Chemical	C544092
-	I-Chemical	C544092
42	I-Chemical	C544092
)	I-Chemical	C544092
-	O	O
infused	O	O
rats	O	O
.	O	O

We	O	O
also	O	O
examined	O	O
the	O	O
neuroprotective	O	O
effects	O	O
of	O	O
maltolyl	B-Chemical	C524754
p	I-Chemical	C524754
-	I-Chemical	C524754
coumarate	I-Chemical	C524754
in	O	O
vitro	O	O
using	O	O
SH	O	O
-	O	O
SY5Y	O	O
cells	O	O
.	O	O

Cells	O	O
were	O	O
pretreated	O	O
with	O	O
maltolyl	B-Chemical	C524754
p	I-Chemical	C524754
-	I-Chemical	C524754
coumarate	I-Chemical	C524754
,	O	O
before	O	O
exposed	O	O
to	O	O
amyloid	B-Chemical	C544092
beta	I-Chemical	C544092
peptide	I-Chemical	C544092
(	I-Chemical	C544092
1	I-Chemical	C544092
-	I-Chemical	C544092
42	I-Chemical	C544092
)	I-Chemical	C544092
,	O	O
glutamate	B-Chemical	D018698
or	O	O
H2O2	B-Chemical	D006861
.	O	O

We	O	O
found	O	O
that	O	O
maltolyl	B-Chemical	C524754
p	I-Chemical	C524754
-	I-Chemical	C524754
coumarate	I-Chemical	C524754
significantly	O	O
decreased	O	O
apoptotic	O	O
cell	O	O
death	O	O
and	O	O
reduced	O	O
reactive	O	O
oxygen	O	O
species	O	O
,	O	O
cytochrome	O	O
c	O	O
release	O	O
,	O	O
and	O	O
caspase	O	O
3	O	O
activation	O	O
.	O	O

Taking	O	O
these	O	O
in	O	O
vitro	O	O
and	O	O
in	O	O
vivo	O	O
results	O	O
together	O	O
,	O	O
our	O	O
study	O	O
suggests	O	O
that	O	O
maltolyl	B-Chemical	C524754
p	I-Chemical	C524754
-	I-Chemical	C524754
coumarate	I-Chemical	C524754
is	O	O
a	O	O
potentially	O	O
effective	O	O
candidate	O	O
against	O	O
Alzheimer's	B-Disease	D000544
disease	I-Disease	D000544
that	O	O
is	O	O
characterized	O	O
by	O	O
wide	O	O
spread	O	O
neuronal	B-Disease	D009410
death	I-Disease	D009410
and	O	O
progressive	O	O
decline	B-Disease	D003072
of	I-Disease	D003072
cognitive	I-Disease	D003072
function	I-Disease	D003072
.	O	O

Interaction	O	O
between	O	O
warfarin	B-Chemical	D014859
and	O	O
levofloxacin	B-Chemical	D064704
:	O	O
case	O	O
series	O	O
.	O	O

Warfarin	B-Chemical	D014859
is	O	O
the	O	O
most	O	O
widely	O	O
used	O	O
oral	O	O
anticoagulant	O	O
and	O	O
is	O	O
indicated	O	O
for	O	O
many	O	O
clinical	O	O
conditions	O	O
.	O	O

Levofloxacin	B-Chemical	D064704
,	O	O
a	O	O
fluoroquinolone	B-Chemical	D024841
,	O	O
is	O	O
one	O	O
of	O	O
the	O	O
most	O	O
commonly	O	O
prescribed	O	O
antibiotics	O	O
in	O	O
clinical	O	O
practice	O	O
and	O	O
is	O	O
effective	O	O
against	O	O
Gram	O	O
-	O	O
positive	O	O
,	O	O
Gram	O	O
-	O	O
negative	O	O
,	O	O
and	O	O
atypical	O	O
bacteria	O	O
.	O	O

While	O	O
small	O	O
prospective	O	O
studies	O	O
have	O	O
not	O	O
revealed	O	O
any	O	O
significant	O	O
drug	O	O
-	O	O
drug	O	O
interaction	O	O
between	O	O
warfarin	B-Chemical	D014859
and	O	O
levofloxacin	B-Chemical	D064704
,	O	O
several	O	O
case	O	O
reports	O	O
have	O	O
indicated	O	O
that	O	O
levofloxacin	B-Chemical	D064704
may	O	O
significantly	O	O
potentiate	O	O
the	O	O
anticoagulation	O	O
effect	O	O
of	O	O
warfarin	B-Chemical	D014859
.	O	O

We	O	O
report	O	O
3	O	O
cases	O	O
of	O	O
serious	O	O
bleeding	B-Disease	D006470
complications	O	O
that	O	O
appear	O	O
to	O	O
be	O	O
the	O	O
result	O	O
of	O	O
the	O	O
interaction	O	O
between	O	O
warfarin	B-Chemical	D014859
and	O	O
levofloxacin	B-Chemical	D064704
.	O	O

Physicians	O	O
should	O	O
be	O	O
aware	O	O
of	O	O
this	O	O
potential	O	O
interaction	O	O
and	O	O
use	O	O
caution	O	O
when	O	O
prescribing	O	O
levofloxacin	B-Chemical	D064704
to	O	O
patients	O	O
taking	O	O
warfarin	B-Chemical	D014859
.	O	O

Mutations	O	O
associated	O	O
with	O	O
lamivudine	B-Chemical	D019259
-	O	O
resistance	O	O
in	O	O
therapy	O	O
-	O	O
na	B-Chemical	D012964
ve	O	O
hepatitis	B-Disease	D006509
B	I-Disease	D006509
virus	I-Disease	D006509
(	I-Disease	D006509
HBV	I-Disease	D006509
)	I-Disease	D006509
infected	I-Disease	D006509
patients	O	O
with	O	O
and	O	O
without	O	O
HIV	B-Disease	D015658
co	I-Disease	D015658
-	I-Disease	D015658
infection	I-Disease	D015658
:	O	O
implications	O	O
for	O	O
antiretroviral	O	O
therapy	O	O
in	O	O
HBV	O	O
and	O	O
HIV	O	O
co	O	O
-	O	O
infected	O	O
South	O	O
African	O	O
patients	O	O
.	O	O

This	O	O
was	O	O
an	O	O
exploratory	O	O
study	O	O
to	O	O
investigate	O	O
lamivudine	B-Chemical	D019259
-	O	O
resistant	O	O
hepatitis	B-Disease	D006509
B	I-Disease	D006509
virus	O	O
(	O	O
HBV	O	O
)	O	O
strains	O	O
in	O	O
selected	O	O
lamivudine	B-Chemical	D019259
-	O	O
na	B-Chemical	D012964
ve	O	O
HBV	O	O
carriers	O	O
with	O	O
and	O	O
without	O	O
human	B-Disease	D015658
immunodeficiency	I-Disease	D015658
virus	I-Disease	D015658
(	I-Disease	D015658
HIV	I-Disease	D015658
)	I-Disease	D015658
co	I-Disease	D015658
-	I-Disease	D015658
infection	I-Disease	D015658
in	O	O
South	O	O
African	O	O
patients	O	O
.	O	O

Thirty	O	O
-	O	O
five	O	O
lamivudine	B-Chemical	D019259
-	O	O
na	B-Chemical	D012964
ve	O	O
HBV	B-Disease	D006509
infected	I-Disease	D006509
patients	O	O
with	O	O
or	O	O
without	O	O
HIV	B-Disease	D015658
co	I-Disease	D015658
-	I-Disease	D015658
infection	I-Disease	D015658
were	O	O
studied	O	O
:	O	O
15	O	O
chronic	O	O
HBV	B-Disease	D006509
mono	I-Disease	D006509
-	I-Disease	D006509
infected	I-Disease	D006509
patients	O	O
and	O	O
20	O	O
HBV	O	O
-	O	O
HIV	O	O
co	O	O
-	O	O
infected	O	O
patients	O	O
.	O	O

The	O	O
latter	O	O
group	O	O
was	O	O
further	O	O
sub	O	O
-	O	O
divided	O	O
into	O	O
13	O	O
occult	O	O
HBV	O	O
(	O	O
HBsAg	B-Chemical	D006514
-	O	O
negative	O	O
)	O	O
and	O	O
7	O	O
overt	O	O
HBV	O	O
(	O	O
HBsAg	B-Chemical	D006514
-	O	O
positive	O	O
)	O	O
patients	O	O
.	O	O

HBsAg	B-Chemical	D006514
,	O	O
anti	O	O
-	O	O
HBs	O	O
,	O	O
anti	O	O
-	O	O
HBc	O	O
,	O	O
and	O	O
anti	O	O
-	O	O
HIV	O	O
1	O	O
/	O	O
2	O	O
were	O	O
determined	O	O
as	O	O
part	O	O
of	O	O
routine	O	O
diagnosis	O	O
using	O	O
Axsym	O	O
assays	O	O
(	O	O
Abbott	O	O
Laboratories	O	O
,	O	O
North	O	O
Chicago	O	O
,	O	O
IL	O	O
)	O	O
.	O	O

Serum	O	O
samples	O	O
were	O	O
PCR	O	O
amplified	O	O
with	O	O
HBV	O	O
reverse	O	O
transcriptase	O	O
(	O	O
RT	O	O
)	O	O
primers	O	O
,	O	O
followed	O	O
by	O	O
direct	O	O
sequencing	O	O
across	O	O
the	O	O
tyrosine	B-Chemical	D014443
-	O	O
methionine	B-Chemical	D008715
-	O	O
aspartate	B-Chemical	D001224
-	O	O
aspartate	B-Chemical	D001224
(	O	O
YMDD	O	O
)	O	O
motif	O	O
of	O	O
the	O	O
major	O	O
catalytic	O	O
region	O	O
in	O	O
the	O	O
C	O	O
domain	O	O
of	O	O
the	O	O
HBV	O	O
RT	O	O
enzyme	O	O
.	O	O

HBV	O	O
viral	O	O
load	O	O
was	O	O
performed	O	O
with	O	O
Amplicor	O	O
HBV	O	O
Monitor	O	O
test	O	O
v2	O	O
.	O	O

0	O	O
(	O	O
Roche	O	O
Diagnostics	O	O
,	O	O
Penzberg	O	O
,	O	O
Germany	O	O
)	O	O
.	O	O

HBV	O	O
lamivudine	B-Chemical	D019259
-	O	O
resistant	O	O
strains	O	O
were	O	O
detected	O	O
in	O	O
3	O	O
of	O	O
15	O	O
mono	O	O
-	O	O
infected	O	O
chronic	O	O
hepatitis	B-Disease	D006509
B	I-Disease	D006509
patients	O	O
and	O	O
10	O	O
of	O	O
20	O	O
HBV	O	O
-	O	O
HIV	O	O
co	O	O
-	O	O
infected	O	O
patients	O	O
.	O	O

To	O	O
the	O	O
best	O	O
of	O	O
our	O	O
knowledge	O	O
,	O	O
this	O	O
constitutes	O	O
the	O	O
first	O	O
report	O	O
of	O	O
HBV	O	O
lamivudine	B-Chemical	D019259
-	O	O
resistant	O	O
strains	O	O
in	O	O
therapy	O	O
-	O	O
na	B-Chemical	D012964
ve	O	O
HBV	O	O
-	O	O
HIV	O	O
co	O	O
-	O	O
infected	O	O
patients	O	O
.	O	O

The	O	O
HBV	O	O
viral	O	O
loads	O	O
for	O	O
mono	O	O
-	O	O
infected	O	O
and	O	O
co	O	O
-	O	O
infected	O	O
patients	O	O
ranged	O	O
from	O	O
3	O	O
.	O	O

32	O	O
x	O	O
10	O	O
(	O	O
2	O	O
)	O	O
to	O	O
3	O	O
.	O	O

82	O	O
x	O	O
10	O	O
(	O	O
7	O	O
)	O	O
and	O	O
<200	O	O
to	O	O
4	O	O
.	O	O

40	O	O
x	O	O
10	O	O
(	O	O
3	O	O
)	O	O
copies	O	O
/	O	O
ml	O	O
,	O	O
respectively	O	O
.	O	O

It	O	O
remains	O	O
to	O	O
be	O	O
seen	O	O
whether	O	O
such	O	O
pre	O	O
-	O	O
existing	O	O
antiviral	O	O
mutations	O	O
could	O	O
result	O	O
in	O	O
widespread	O	O
emergence	O	O
of	O	O
HBV	O	O
resistant	O	O
strains	O	O
when	O	O
lamivudine	B-Chemical	D019259
-	O	O
containing	O	O
highly	O	O
active	O	O
antiretroviral	O	O
(	O	O
ARV	O	O
)	O	O
treatment	O	O
(	O	O
HAART	O	O
)	O	O
regimens	O	O
become	O	O
widely	O	O
applied	O	O
in	O	O
South	O	O
Africa	O	O
,	O	O
as	O	O
this	O	O
is	O	O
likely	O	O
to	O	O
have	O	O
potential	O	O
implications	O	O
in	O	O
the	O	O
management	O	O
of	O	O
HBV	O	O
-	O	O
HIV	O	O
co	O	O
-	O	O
infected	O	O
patients	O	O
.	O	O

Sex	O	O
differences	O	O
in	O	O
NMDA	B-Chemical	D016202
antagonist	O	O
enhancement	O	O
of	O	O
morphine	B-Chemical	D009020
antihyperalgesia	O	O
in	O	O
a	O	O
capsaicin	B-Chemical	D002211
model	O	O
of	O	O
persistent	O	O
pain	B-Disease	D010146
:	O	O
comparisons	O	O
to	O	O
two	O	O
models	O	O
of	O	O
acute	B-Disease	D059787
pain	I-Disease	D059787
.	O	O

In	O	O
acute	B-Disease	D059787
pain	I-Disease	D059787
models	O	O
,	O	O
N	B-Chemical	D016202
-	I-Chemical	D016202
methyl	I-Chemical	D016202
-	I-Chemical	D016202
D	I-Chemical	D016202
-	I-Chemical	D016202
aspartate	I-Chemical	D016202
(	O	O
NMDA	B-Chemical	D016202
)	O	O
antagonists	O	O
enhance	O	O
the	O	O
antinociceptive	O	O
effects	O	O
of	O	O
morphine	B-Chemical	D009020
to	O	O
a	O	O
greater	O	O
extent	O	O
in	O	O
males	O	O
than	O	O
females	O	O
.	O	O

The	O	O
purpose	O	O
of	O	O
this	O	O
investigation	O	O
was	O	O
to	O	O
extend	O	O
these	O	O
findings	O	O
to	O	O
a	O	O
persistent	O	O
pain	B-Disease	D010146
model	O	O
which	O	O
could	O	O
be	O	O
distinguished	O	O
from	O	O
acute	B-Disease	D059787
pain	I-Disease	D059787
models	O	O
on	O	O
the	O	O
basis	O	O
of	O	O
the	O	O
nociceptive	O	O
fibers	O	O
activated	O	O
,	O	O
neurochemical	O	O
substrates	O	O
,	O	O
and	O	O
duration	O	O
of	O	O
the	O	O
nociceptive	O	O
stimulus	O	O
.	O	O

To	O	O
this	O	O
end	O	O
,	O	O
persistent	O	O
hyperalgesia	B-Disease	D006930
was	O	O
induced	O	O
by	O	O
administration	O	O
of	O	O
capsaicin	B-Chemical	D002211
in	O	O
the	O	O
tail	O	O
of	O	O
gonadally	O	O
intact	O	O
F344	O	O
rats	O	O
,	O	O
following	O	O
which	O	O
the	O	O
tail	O	O
was	O	O
immersed	O	O
in	O	O
a	O	O
mildly	O	O
noxious	O	O
thermal	O	O
stimulus	O	O
,	O	O
and	O	O
tail	O	O
-	O	O
withdrawal	O	O
latencies	O	O
measured	O	O
.	O	O

For	O	O
comparison	O	O
,	O	O
tests	O	O
were	O	O
conducted	O	O
in	O	O
two	O	O
acute	B-Disease	D059787
pain	I-Disease	D059787
models	O	O
,	O	O
the	O	O
hotplate	O	O
and	O	O
warm	O	O
water	O	O
tail	O	O
-	O	O
withdrawal	O	O
procedures	O	O
.	O	O

In	O	O
males	O	O
,	O	O
the	O	O
non	O	O
-	O	O
competitive	O	O
NMDA	B-Chemical	D016202
antagonist	O	O
dextromethorphan	B-Chemical	D003915
enhanced	O	O
the	O	O
antihyperalgesic	O	O
effect	O	O
of	O	O
low	O	O
to	O	O
moderate	O	O
doses	O	O
of	O	O
morphine	B-Chemical	D009020
in	O	O
a	O	O
dose	O	O
-	O	O
and	O	O
time	O	O
-	O	O
dependent	O	O
manner	O	O
.	O	O

Across	O	O
the	O	O
doses	O	O
and	O	O
pretreatment	O	O
times	O	O
examined	O	O
,	O	O
enhancement	O	O
was	O	O
not	O	O
observed	O	O
in	O	O
females	O	O
.	O	O

Enhancement	O	O
of	O	O
morphine	B-Chemical	D009020
antinociception	O	O
by	O	O
dextromethorphan	B-Chemical	D003915
was	O	O
seen	O	O
in	O	O
both	O	O
males	O	O
and	O	O
females	O	O
in	O	O
the	O	O
acute	B-Disease	D059787
pain	I-Disease	D059787
models	O	O
,	O	O
with	O	O
the	O	O
magnitude	O	O
of	O	O
this	O	O
effect	O	O
being	O	O
greater	O	O
in	O	O
males	O	O
.	O	O

These	O	O
findings	O	O
demonstrate	O	O
a	O	O
sexually	O	O
-	O	O
dimorphic	O	O
interaction	O	O
between	O	O
NMDA	B-Chemical	D016202
antagonists	O	O
and	O	O
morphine	B-Chemical	D009020
in	O	O
a	O	O
persistent	O	O
pain	B-Disease	D010146
model	O	O
that	O	O
can	O	O
be	O	O
distinguished	O	O
from	O	O
those	O	O
observed	O	O
in	O	O
acute	B-Disease	D059787
pain	I-Disease	D059787
models	O	O
.	O	O

Development	O	O
of	O	O
proteinuria	B-Disease	D011507
after	O	O
switch	O	O
to	O	O
sirolimus	B-Chemical	D020123
-	O	O
based	O	O
immunosuppression	O	O
in	O	O
long	O	O
-	O	O
term	O	O
cardiac	O	O
transplant	O	O
patients	O	O
.	O	O

Calcineurin	O	O
-	O	O
inhibitor	O	O
therapy	O	O
can	O	O
lead	O	O
to	O	O
renal	B-Disease	D007674
dysfunction	I-Disease	D007674
in	O	O
heart	O	O
transplantation	O	O
patients	O	O
.	O	O

The	O	O
novel	O	O
immunosuppressive	O	O
(	O	O
IS	O	O
)	O	O
drug	O	O
sirolmus	B-Chemical	D020123
(	O	O
Srl	B-Chemical	D020123
)	O	O
lacks	O	O
nephrotoxic	B-Disease	D007674
effects	O	O
;	O	O
however	O	O
,	O	O
proteinuria	B-Disease	D011507
associated	O	O
with	O	O
Srl	B-Chemical	D020123
has	O	O
been	O	O
reported	O	O
following	O	O
renal	O	O
transplantation	O	O
.	O	O

In	O	O
cardiac	O	O
transplantation	O	O
,	O	O
the	O	O
incidence	O	O
of	O	O
proteinuria	B-Disease	D011507
associated	O	O
with	O	O
Srl	B-Chemical	D020123
is	O	O
unknown	O	O
.	O	O

In	O	O
this	O	O
study	O	O
,	O	O
long	O	O
-	O	O
term	O	O
cardiac	O	O
transplant	O	O
patients	O	O
were	O	O
switched	O	O
from	O	O
cyclosporine	B-Chemical	D016572
to	O	O
Srl	B-Chemical	D020123
-	O	O
based	O	O
IS	O	O
.	O	O

Concomitant	O	O
IS	O	O
consisted	O	O
of	O	O
mycophenolate	B-Chemical	C063008
mofetil	I-Chemical	C063008
+	O	O
/	O	O
-	O	O
steroids	B-Chemical	D013256
.	O	O

Proteinuria	O	O
increased	O	O
significantly	O	O
from	O	O
a	O	O
median	O	O
of	O	O
0	O	O
.	O	O

13	O	O
g	O	O
/	O	O
day	O	O
(	O	O
range	O	O
0	O	O
-	O	O
5	O	O
.	O	O

7	O	O
)	O	O
preswitch	O	O
to	O	O
0	O	O
.	O	O

23	O	O
g	O	O
/	O	O
day	O	O
(	O	O
0	O	O
-	O	O
9	O	O
.	O	O

88	O	O
)	O	O
at	O	O
24	O	O
months	O	O
postswitch	O	O
(	O	O
p	O	O
=	O	O
0	O	O
.	O	O

0024	O	O
)	O	O
.	O	O

Before	O	O
the	O	O
switch	O	O
,	O	O
11	O	O
.	O	O

5%	O	O
of	O	O
patients	O	O
had	O	O
high	O	O
-	O	O
grade	O	O
proteinuria	B-Disease	D011507
(	O	O
>1	O	O
.	O	O

0	O	O
g	O	O
/	O	O
day	O	O
)	O	O
;	O	O
this	O	O
increased	O	O
to	O	O
22	O	O
.	O	O

9%	O	O
postswitch	O	O
(	O	O
p	O	O
=	O	O
0	O	O
.	O	O

006	O	O
)	O	O
.	O	O

ACE	B-Chemical	D000806
inhibitor	I-Chemical	D000806
and	O	O
angiotensin	B-Chemical	D057911
-	I-Chemical	D057911
releasing	I-Chemical	D057911
blocker	I-Chemical	D057911
(	O	O
ARB	B-Chemical	D057911
)	O	O
therapy	O	O
reduced	O	O
proteinuria	B-Disease	D011507
development	O	O
.	O	O

Patients	O	O
without	O	O
proteinuria	B-Disease	D011507
had	O	O
increased	O	O
renal	O	O
function	O	O
(	O	O
median	O	O
42	O	O
.	O	O

5	O	O
vs	O	O
.	O	O

64	O	O
.	O	O

1	O	O
,	O	O
p	O	O
=	O	O
0	O	O
.	O	O

25	O	O
)	O	O
,	O	O
whereas	O	O
patients	O	O
who	O	O
developed	O	O
high	O	O
-	O	O
grade	O	O
proteinuria	B-Disease	D011507
showed	O	O
decreased	O	O
renal	O	O
function	O	O
at	O	O
the	O	O
end	O	O
of	O	O
follow	O	O
-	O	O
up	O	O
(	O	O
median	O	O
39	O	O
.	O	O

6	O	O
vs	O	O
.	O	O

29	O	O
.	O	O

2	O	O
,	O	O
p	O	O
=	O	O
0	O	O
.	O	O

125	O	O
)	O	O
.	O	O

Thus	O	O
,	O	O
proteinuria	B-Disease	D011507
may	O	O
develop	O	O
in	O	O
cardiac	O	O
transplant	O	O
patients	O	O
after	O	O
switch	O	O
to	O	O
Srl	B-Chemical	D020123
,	O	O
which	O	O
may	O	O
have	O	O
an	O	O
adverse	O	O
effect	O	O
on	O	O
renal	O	O
function	O	O
in	O	O
these	O	O
patients	O	O
.	O	O

Srl	B-Chemical	D020123
should	O	O
be	O	O
used	O	O
with	O	O
ACEi	B-Chemical	D000806
/	O	O
ARB	B-Chemical	D057911
therapy	O	O
and	O	O
patients	O	O
monitored	O	O
for	O	O
proteinuria	B-Disease	D011507
and	O	O
increased	O	O
renal	B-Disease	D007674
dysfunction	I-Disease	D007674
.	O	O

Synthesis	O	O
of	O	O
N	B-Chemical	D010642
-	I-Chemical	D010642
pyrimidinyl	I-Chemical	D010642
-	I-Chemical	D010642
2	I-Chemical	D010642
-	I-Chemical	D010642
phenoxyacetamides	I-Chemical	D010642
as	O	O
adenosine	B-Chemical	D000241
A2A	O	O
receptor	O	O
antagonists	O	O
.	O	O

A	O	O
series	O	O
of	O	O
N	B-Chemical	D010642
-	I-Chemical	D010642
pyrimidinyl	I-Chemical	D010642
-	I-Chemical	D010642
2	I-Chemical	D010642
-	I-Chemical	D010642
phenoxyacetamide	I-Chemical	D010642
adenosine	B-Chemical	D000241
A	O	O
(	O	O
2A	O	O
)	O	O
antagonists	O	O
is	O	O
described	O	O
.	O	O

SAR	O	O
studies	O	O
led	O	O
to	O	O
compound	O	O
14	O	O
with	O	O
excellent	O	O
potency	O	O
(	O	O
K	O	O
(	O	O
i	O	O
)	O	O
=	O	O
0	O	O
.	O	O

4	O	O
nM	O	O
)	O	O
,	O	O
selectivity	O	O
(	O	O
A	O	O
(	O	O
1	O	O
)	O	O
/	O	O
A	O	O
(	O	O
2A	O	O
)	O	O
>	O	O
100	O	O
)	O	O
,	O	O
and	O	O
efficacy	O	O
(	O	O
MED	O	O
10	O	O
mg	O	O
/	O	O
kg	O	O
p	O	O
.	O	O

o	O	O
.	O	O

)	O	O
in	O	O
the	O	O
rat	O	O
haloperidol	B-Chemical	D006220
-	O	O
induced	O	O
catalepsy	B-Disease	D002375
model	O	O
for	O	O
Parkinson's	B-Disease	D010300
disease	I-Disease	D010300
.	O	O

Methamphetamine	B-Chemical	D008694
-	O	O
induced	O	O
neurotoxicity	B-Disease	D020258
and	O	O
microglial	O	O
activation	O	O
are	O	O
not	O	O
mediated	O	O
by	O	O
fractalkine	O	O
receptor	O	O
signaling	O	O
.	O	O

Methamphetamine	B-Chemical	D008694
(	O	O
METH	B-Chemical	D008694
)	O	O
damages	O	O
dopamine	B-Chemical	D004298
(	O	O
DA	B-Chemical	D004298
)	O	O
nerve	O	O
endings	O	O
by	O	O
a	O	O
process	O	O
that	O	O
has	O	O
been	O	O
linked	O	O
to	O	O
microglial	O	O
activation	O	O
but	O	O
the	O	O
signaling	O	O
pathways	O	O
that	O	O
mediate	O	O
this	O	O
response	O	O
have	O	O
not	O	O
yet	O	O
been	O	O
delineated	O	O
.	O	O

Cardona	O	O
et	O	O
al	O	O
.	O	O

[	O	O
Nat	O	O
.	O	O

Neurosci	O	O
.	O	O

9	O	O
(	O	O
2006	O	O
)	O	O
,	O	O
917	O	O
]	O	O
recently	O	O
identified	O	O
the	O	O
microglial	O	O
-	O	O
specific	O	O
fractalkine	O	O
receptor	O	O
(	O	O
CX3CR1	O	O
)	O	O
as	O	O
an	O	O
important	O	O
mediator	O	O
of	O	O
MPTP	B-Chemical	D015632
-	O	O
induced	O	O
neurodegeneration	B-Disease	D009422
of	O	O
DA	B-Chemical	D004298
neurons	O	O
.	O	O

Because	O	O
the	O	O
CNS	B-Disease	D009422
damage	I-Disease	D009422
caused	O	O
by	O	O
METH	B-Chemical	D008694
and	O	O
MPTP	B-Chemical	D015632
is	O	O
highly	O	O
selective	O	O
for	O	O
the	O	O
DA	B-Chemical	D004298
neuronal	O	O
system	O	O
in	O	O
mouse	O	O
models	O	O
of	O	O
neurotoxicity	B-Disease	D020258
,	O	O
we	O	O
hypothesized	O	O
that	O	O
the	O	O
CX3CR1	O	O
plays	O	O
a	O	O
role	O	O
in	O	O
METH	B-Chemical	D008694
-	O	O
induced	O	O
neurotoxicity	B-Disease	D020258
and	O	O
microglial	O	O
activation	O	O
.	O	O

Mice	O	O
in	O	O
which	O	O
the	O	O
CX3CR1	O	O
gene	O	O
has	O	O
been	O	O
deleted	O	O
and	O	O
replaced	O	O
with	O	O
a	O	O
cDNA	O	O
encoding	O	O
enhanced	O	O
green	O	O
fluorescent	O	O
protein	O	O
(	O	O
eGFP	O	O
)	O	O
were	O	O
treated	O	O
with	O	O
METH	B-Chemical	D008694
and	O	O
examined	O	O
for	O	O
striatal	O	O
neurotoxicity	B-Disease	D020258
.	O	O

METH	B-Chemical	D008694
depleted	O	O
DA	B-Chemical	D004298
,	O	O
caused	O	O
microglial	O	O
activation	O	O
,	O	O
and	O	O
increased	O	O
body	O	O
temperature	O	O
in	O	O
CX3CR1	O	O
knockout	O	O
mice	O	O
to	O	O
the	O	O
same	O	O
extent	O	O
and	O	O
over	O	O
the	O	O
same	O	O
time	O	O
course	O	O
seen	O	O
in	O	O
wild	O	O
-	O	O
type	O	O
controls	O	O
.	O	O

The	O	O
effects	O	O
of	O	O
METH	B-Chemical	D008694
in	O	O
CX3CR1	O	O
knockout	O	O
mice	O	O
were	O	O
not	O	O
gender	O	O
-	O	O
dependent	O	O
and	O	O
did	O	O
not	O	O
extend	O	O
beyond	O	O
the	O	O
striatum	O	O
.	O	O

Striatal	O	O
microglia	O	O
expressing	O	O
eGFP	O	O
constitutively	O	O
show	O	O
morphological	O	O
changes	O	O
after	O	O
METH	B-Chemical	D008694
that	O	O
are	O	O
characteristic	O	O
of	O	O
activation	O	O
.	O	O

This	O	O
response	O	O
was	O	O
restricted	O	O
to	O	O
the	O	O
striatum	O	O
and	O	O
contrasted	O	O
sharply	O	O
with	O	O
unresponsive	O	O
eGFP	O	O
-	O	O
microglia	O	O
in	O	O
surrounding	O	O
brain	O	O
areas	O	O
that	O	O
are	O	O
not	O	O
damaged	O	O
by	O	O
METH	B-Chemical	D008694
.	O	O

We	O	O
conclude	O	O
from	O	O
these	O	O
studies	O	O
that	O	O
CX3CR1	O	O
signaling	O	O
does	O	O
not	O	O
modulate	O	O
METH	B-Chemical	D008694
neurotoxicity	B-Disease	D020258
or	O	O
microglial	O	O
activation	O	O
.	O	O

Furthermore	O	O
,	O	O
it	O	O
appears	O	O
that	O	O
striatal	O	O
-	O	O
resident	O	O
microglia	O	O
respond	O	O
to	O	O
METH	B-Chemical	D008694
with	O	O
an	O	O
activation	O	O
cascade	O	O
and	O	O
then	O	O
return	O	O
to	O	O
a	O	O
surveying	O	O
state	O	O
without	O	O
undergoing	O	O
apoptosis	O	O
or	O	O
migration	O	O
.	O	O

Recovery	O	O
of	O	O
tacrolimus	B-Chemical	D016559
-	O	O
associated	O	O
brachial	B-Disease	D020968
neuritis	I-Disease	D020968
after	O	O
conversion	O	O
to	O	O
everolimus	B-Chemical	C107135
in	O	O
a	O	O
pediatric	O	O
renal	O	O
transplant	O	O
recipient	O	O
-	O	O
-	O	O
case	O	O
report	O	O
and	O	O
review	O	O
of	O	O
the	O	O
literature	O	O
.	O	O

TAC	B-Chemical	D016559
has	O	O
been	O	O
shown	O	O
to	O	O
be	O	O
a	O	O
potent	O	O
immunosuppressive	O	O
agent	O	O
for	O	O
solid	O	O
organ	O	O
transplantation	O	O
in	O	O
pediatrics	O	O
.	O	O

Neurotoxicity	B-Disease	D020258
is	O	O
a	O	O
potentially	O	O
serious	O	O
toxic	O	O
effect	O	O
.	O	O

It	O	O
is	O	O
characterized	O	O
by	O	O
encephalopathy	B-Disease	D001927
,	O	O
headaches	B-Disease	D006261
,	O	O
seizures	B-Disease	D012640
,	O	O
or	O	O
neurological	B-Disease	D009461
deficits	I-Disease	D009461
.	O	O

Here	O	O
,	O	O
we	O	O
describe	O	O
an	O	O
eight	O	O
-	O	O
and	O	O
-	O	O
a	O	O
-	O	O
half	O	O
-	O	O
yr	O	O
-	O	O
old	O	O
male	O	O
renal	O	O
transplant	O	O
recipient	O	O
with	O	O
right	O	O
BN	O	O
.	O	O

MRI	O	O
demonstrated	O	O
hyperintense	O	O
T2	O	O
signals	O	O
in	O	O
the	O	O
cervical	O	O
cord	O	O
and	O	O
right	O	O
brachial	O	O
plexus	O	O
roots	O	O
indicative	O	O
of	O	O
both	O	O
myelitis	B-Disease	D009187
and	O	O
right	O	O
brachial	B-Disease	D020968
plexitis	I-Disease	D020968
.	O	O

Symptoms	O	O
persisted	O	O
for	O	O
three	O	O
months	O	O
despite	O	O
TAC	B-Chemical	D016559
dose	O	O
reduction	O	O
,	O	O
administration	O	O
of	O	O
IVIG	O	O
and	O	O
four	O	O
doses	O	O
of	O	O
methylprednisolone	B-Chemical	D008775
pulse	O	O
therapy	O	O
.	O	O

Improvement	O	O
and	O	O
eventually	O	O
full	O	O
recovery	O	O
only	O	O
occurred	O	O
after	O	O
TAC	B-Chemical	D016559
was	O	O
completely	O	O
discontinued	O	O
and	O	O
successfully	O	O
replaced	O	O
by	O	O
everolimus	B-Chemical	C107135
.	O	O

Valvular	B-Disease	D006349
heart	I-Disease	D006349
disease	I-Disease	D006349
in	O	O
patients	O	O
with	O	O
Parkinson's	B-Disease	D010300
disease	I-Disease	D010300
treated	O	O
with	O	O
pergolide	B-Chemical	D010479
.	O	O

Course	O	O
following	O	O
treatment	O	O
modifications	O	O
.	O	O

Valvular	B-Disease	D006349
heart	I-Disease	D006349
abnormalities	I-Disease	D006349
have	O	O
been	O	O
reported	O	O
in	O	O
patients	O	O
with	O	O
Parkinson's	B-Disease	D010300
disease	I-Disease	D010300
(	O	O
PD	B-Disease	D010300
)	O	O
treated	O	O
with	O	O
pergolide	B-Chemical	D010479
.	O	O

However	O	O
,	O	O
the	O	O
incidence	O	O
and	O	O
severity	O	O
of	O	O
these	O	O
abnormalities	O	O
vary	O	O
from	O	O
study	O	O
to	O	O
study	O	O
and	O	O
their	O	O
course	O	O
after	O	O
drug	O	O
withdrawal	O	O
has	O	O
not	O	O
been	O	O
systematically	O	O
assessed	O	O
.	O	O

OBJECTIVES	O	O
:	O	O
To	O	O
estimate	O	O
the	O	O
frequency	O	O
and	O	O
severity	O	O
of	O	O
valvular	B-Disease	D006349
heart	I-Disease	D006349
abnormality	I-Disease	D006349
and	O	O
its	O	O
possible	O	O
reversibility	O	O
after	O	O
drug	O	O
withdrawal	O	O
in	O	O
a	O	O
case	O	O
-	O	O
control	O	O
study	O	O
.	O	O

METHODS	O	O
:	O	O
All	O	O
PD	B-Disease	D010300
patients	O	O
in	O	O
the	O	O
Amiens	O	O
area	O	O
treated	O	O
with	O	O
pergolide	B-Chemical	D010479
were	O	O
invited	O	O
to	O	O
attend	O	O
a	O	O
cardiologic	O	O
assessment	O	O
including	O	O
transthoracic	O	O
echocardiography	O	O
.	O	O

Thirty	O	O
PD	B-Disease	D010300
patients	O	O
participated	O	O
in	O	O
the	O	O
study	O	O
.	O	O

A	O	O
second	O	O
echocardiography	O	O
was	O	O
performed	O	O
(	O	O
median	O	O
interval	O	O
:	O	O
13	O	O
months	O	O
)	O	O
after	O	O
pergolide	B-Chemical	D010479
withdrawal	O	O
(	O	O
n=10	O	O
patients	O	O
)	O	O
.	O	O

Controls	O	O
were	O	O
age	O	O
-	O	O
and	O	O
sex	O	O
-	O	O
matched	O	O
non	O	O
-	O	O
PD	B-Disease	D010300
patients	O	O
referred	O	O
to	O	O
the	O	O
cardiology	O	O
department	O	O
.	O	O

RESULTS	O	O
:	O	O
Compared	O	O
to	O	O
controls	O	O
,	O	O
aortic	B-Disease	D001022
regurgitation	I-Disease	D001022
(	O	O
OR	O	O
:	O	O
3	O	O
.	O	O

1	O	O
;	O	O
95%	O	O
IC	O	O
:	O	O
1	O	O
.	O	O

1	O	O
-	O	O
8	O	O
.	O	O

8	O	O
)	O	O
and	O	O
mitral	B-Disease	D008944
regurgitation	I-Disease	D008944
(	O	O
OR	O	O
:	O	O
10	O	O
.	O	O

7	O	O
;	O	O
95%	O	O
IC	O	O
:	O	O
2	O	O
.	O	O

1	O	O
-	O	O
53	O	O
)	O	O
were	O	O
more	O	O
frequent	O	O
in	O	O
PD	B-Disease	D010300
patients	O	O
(	O	O
tricuspid	O	O
:	O	O
NS	O	O
)	O	O
.	O	O

The	O	O
number	O	O
of	O	O
affected	O	O
valves	O	O
(	O	O
n=2	O	O
.	O	O

4+	O	O
/	O	O
-	O	O
0	O	O
.	O	O

7	O	O
)	O	O
and	O	O
the	O	O
sum	O	O
of	O	O
regurgitation	O	O
grades	O	O
(	O	O
n=2	O	O
.	O	O

8+	O	O
/	O	O
-	O	O
1	O	O
.	O	O

09	O	O
)	O	O
were	O	O
higher	O	O
(	O	O
p=0	O	O
.	O	O

008	O	O
and	O	O
p=0	O	O
.	O	O

006	O	O
,	O	O
respectively	O	O
)	O	O
in	O	O
the	O	O
pergolide	B-Chemical	D010479
group	O	O
.	O	O

Severity	O	O
of	O	O
regurgitation	O	O
was	O	O
not	O	O
correlated	O	O
with	O	O
pergolide	B-Chemical	D010479
cumulative	O	O
dose	O	O
.	O	O

A	O	O
restrictive	O	O
pattern	O	O
of	O	O
valvular	B-Disease	D006349
regurgitation	I-Disease	D006349
,	O	O
suggestive	O	O
of	O	O
the	O	O
role	O	O
of	O	O
pergolide	B-Chemical	D010479
,	O	O
was	O	O
observed	O	O
in	O	O
12	O	O
/	O	O
30	O	O
(	O	O
40%	O	O
)	O	O
patients	O	O
including	O	O
two	O	O
with	O	O
heart	B-Disease	D006333
failure	I-Disease	D006333
.	O	O

Pergolide	B-Chemical	D010479
was	O	O
discontinued	O	O
in	O	O
10	O	O
patients	O	O
with	O	O
valvular	B-Disease	D006349
heart	I-Disease	D006349
disease	I-Disease	D006349
,	O	O
resulting	O	O
in	O	O
a	O	O
lower	O	O
regurgitation	O	O
grade	O	O
(	O	O
p=0	O	O
.	O	O

01	O	O
)	O	O
at	O	O
the	O	O
second	O	O
transthoracic	O	O
echocardiography	O	O
and	O	O
the	O	O
two	O	O
patients	O	O
with	O	O
heart	B-Disease	D006333
failure	I-Disease	D006333
returned	O	O
to	O	O
nearly	O	O
normal	O	O
clinical	O	O
examination	O	O
.	O	O

This	O	O
study	O	O
supports	O	O
the	O	O
high	O	O
frequency	O	O
of	O	O
restrictive	O	O
valve	B-Disease	D006349
regurgitation	I-Disease	D006349
in	O	O
PD	B-Disease	D010300
patients	O	O
treated	O	O
with	O	O
pergolide	B-Chemical	D010479
and	O	O
reveals	O	O
that	O	O
a	O	O
significant	O	O
improvement	O	O
is	O	O
usual	O	O
when	O	O
the	O	O
treatment	O	O
is	O	O
converted	O	O
to	O	O
non	O	O
-	O	O
ergot	O	O
dopamine	B-Chemical	D004298
agonists	O	O
.	O	O

Adverse	O	O
effects	O	O
of	O	O
topical	O	O
papaverine	B-Chemical	D010208
on	O	O
auditory	O	O
nerve	O	O
function	O	O
.	O	O

BACKGROUND	O	O
:	O	O
Papaverine	B-Chemical	D010208
hydrochloride	I-Chemical	D010208
is	O	O
a	O	O
direct	O	O
-	O	O
acting	O	O
vasodilator	O	O
used	O	O
to	O	O
manage	O	O
vasospasm	B-Disease	D020301
during	O	O
various	O	O
neurosurgical	O	O
operations	O	O
.	O	O

Transient	O	O
cranial	B-Disease	D003389
nerve	I-Disease	D003389
dysfunction	I-Disease	D003389
has	O	O
been	O	O
described	O	O
in	O	O
a	O	O
few	O	O
cases	O	O
with	O	O
topical	O	O
papaverine	B-Chemical	D010208
.	O	O

This	O	O
study	O	O
supports	O	O
previous	O	O
reports	O	O
and	O	O
provides	O	O
neurophysiological	O	O
evidence	O	O
of	O	O
an	O	O
adverse	O	O
effect	O	O
on	O	O
the	O	O
auditory	O	O
nerve	O	O
.	O	O

METHODS	O	O
:	O	O
We	O	O
conducted	O	O
a	O	O
retrospective	O	O
review	O	O
of	O	O
70	O	O
consecutive	O	O
microvascular	O	O
decompression	O	O
operations	O	O
and	O	O
studied	O	O
those	O	O
patients	O	O
who	O	O
received	O	O
topical	O	O
papaverine	B-Chemical	D010208
for	O	O
vasospasm	B-Disease	D020301
.	O	O

Topical	O	O
papaverine	B-Chemical	D010208
was	O	O
used	O	O
as	O	O
a	O	O
direct	O	O
therapeutic	O	O
action	O	O
to	O	O
manage	O	O
vasospasm	B-Disease	D020301
in	O	O
a	O	O
total	O	O
of	O	O
11	O	O
patients	O	O
.	O	O

The	O	O
timing	O	O
of	O	O
papaverine	B-Chemical	D010208
application	O	O
and	O	O
ongoing	O	O
operative	O	O
events	O	O
was	O	O
reviewed	O	O
relative	O	O
to	O	O
changes	O	O
in	O	O
neurophysiological	O	O
recordings	O	O
.	O	O

Brainstem	O	O
auditory	O	O
evoked	O	O
potentials	O	O
(	O	O
BAEPs	O	O
)	O	O
were	O	O
routinely	O	O
used	O	O
to	O	O
monitor	O	O
cochlear	O	O
nerve	O	O
function	O	O
during	O	O
these	O	O
operations	O	O
.	O	O

FINDINGS	O	O
:	O	O
A	O	O
temporal	O	O
relationship	O	O
was	O	O
found	O	O
between	O	O
topical	O	O
papaverine	B-Chemical	D010208
and	O	O
BAEP	O	O
changes	O	O
leading	O	O
to	O	O
complete	O	O
waveform	O	O
loss	O	O
.	O	O

The	O	O
average	O	O
temporal	O	O
delay	O	O
between	O	O
papaverine	B-Chemical	D010208
and	O	O
the	O	O
onset	O	O
of	O	O
an	O	O
adverse	O	O
BAEP	O	O
change	O	O
was	O	O
5	O	O
min	O	O
.	O	O

In	O	O
10	O	O
of	O	O
11	O	O
patients	O	O
,	O	O
BAEP	O	O
waves	O	O
II	O	O
/	O	O
III	O	O
-	O	O
V	O	O
completely	O	O
disappeared	O	O
within	O	O
2	O	O
to	O	O
25	O	O
min	O	O
after	O	O
papaverine	B-Chemical	D010208
.	O	O

Eight	O	O
of	O	O
these	O	O
10	O	O
patients	O	O
had	O	O
complete	O	O
loss	O	O
of	O	O
BAEP	O	O
waveforms	O	O
within	O	O
10	O	O
min	O	O
.	O	O

One	O	O
patient	O	O
showed	O	O
no	O	O
recovery	O	O
of	O	O
later	O	O
waves	O	O
and	O	O
a	O	O
delayed	O	O
profound	O	O
sensorineural	B-Disease	D006319
hearing	I-Disease	D006319
loss	I-Disease	D006319
.	O	O

The	O	O
average	O	O
recovery	O	O
time	O	O
of	O	O
BAEP	O	O
waveforms	O	O
to	O	O
pre	O	O
-	O	O
papaverine	B-Chemical	D010208
baseline	O	O
values	O	O
was	O	O
39	O	O
min	O	O
.	O	O

CONCLUSIONS	O	O
:	O	O
Topical	O	O
papaverine	B-Chemical	D010208
for	O	O
the	O	O
treatment	O	O
of	O	O
vasospasm	B-Disease	D020301
was	O	O
associated	O	O
with	O	O
the	O	O
onset	O	O
of	O	O
a	O	O
transient	O	O
disturbance	O	O
in	O	O
neurophysiological	O	O
function	O	O
of	O	O
the	O	O
ascending	O	O
auditory	O	O
brainstem	O	O
pathway	O	O
.	O	O

The	O	O
complete	O	O
disappearance	O	O
of	O	O
BAEP	O	O
waveforms	O	O
with	O	O
a	O	O
consistent	O	O
temporal	O	O
delay	O	O
suggests	O	O
a	O	O
possible	O	O
adverse	B-Disease	D000160
effect	I-Disease	D000160
on	I-Disease	D000160
the	I-Disease	D000160
proximal	I-Disease	D000160
eighth	I-Disease	D000160
nerve	I-Disease	D000160
.	O	O

Recommendations	O	O
to	O	O
avoid	O	O
potential	O	O
cranial	B-Disease	D003389
nerve	I-Disease	D003389
deficits	I-Disease	D003389
from	O	O
papaverine	B-Chemical	D010208
are	O	O
provided	O	O
.	O	O

Massive	O	O
proteinuria	B-Disease	D011507
and	O	O
acute	B-Disease	D058186
renal	I-Disease	D058186
failure	I-Disease	D058186
after	O	O
oral	O	O
bisphosphonate	B-Chemical	D004164
(	O	O
alendronate	B-Chemical	D019386
)	O	O
administration	O	O
in	O	O
a	O	O
patient	O	O
with	O	O
focal	B-Disease	D005923
segmental	I-Disease	D005923
glomerulosclerosis	I-Disease	D005923
.	O	O

A	O	O
61	O	O
-	O	O
year	O	O
-	O	O
old	O	O
Japanese	O	O
man	O	O
with	O	O
nephrotic	B-Disease	D009404
syndrome	I-Disease	D009404
due	O	O
to	O	O
focal	B-Disease	D005923
segmental	I-Disease	D005923
glomerulosclerosis	I-Disease	D005923
was	O	O
initially	O	O
responding	O	O
well	O	O
to	O	O
steroid	B-Chemical	D013256
therapy	O	O
.	O	O

The	O	O
amount	O	O
of	O	O
daily	O	O
urinary	O	O
protein	O	O
decreased	O	O
from	O	O
15	O	O
.	O	O

6	O	O
to	O	O
2	O	O
.	O	O

8	O	O
g	O	O
.	O	O

Within	O	O
14	O	O
days	O	O
of	O	O
the	O	O
oral	O	O
bisphosphonate	B-Chemical	D004164
(	O	O
alendronate	B-Chemical	D019386
sodium	O	O
)	O	O
administration	O	O
,	O	O
the	O	O
amount	O	O
of	O	O
daily	O	O
urinary	O	O
protein	O	O
increased	O	O
rapidly	O	O
up	O	O
to	O	O
12	O	O
.	O	O

8	O	O
g	O	O
with	O	O
acute	B-Disease	D058186
renal	I-Disease	D058186
failure	I-Disease	D058186
.	O	O

After	O	O
discontinuing	O	O
the	O	O
oral	O	O
alendronate	B-Chemical	D019386
,	O	O
the	O	O
patient	O	O
underwent	O	O
six	O	O
cycles	O	O
of	O	O
hemodialysis	O	O
and	O	O
four	O	O
cycles	O	O
of	O	O
LDL	O	O
apheresis	O	O
.	O	O

Urinary	O	O
volume	O	O
and	O	O
serum	O	O
creatinine	B-Chemical	D003404
levels	O	O
recovered	O	O
to	O	O
the	O	O
normal	O	O
range	O	O
,	O	O
with	O	O
urinary	O	O
protein	O	O
disappearing	O	O
completely	O	O
within	O	O
40	O	O
days	O	O
.	O	O

This	O	O
report	O	O
demonstrates	O	O
that	O	O
not	O	O
only	O	O
intravenous	O	O
,	O	O
but	O	O
also	O	O
oral	O	O
bisphosphonates	B-Chemical	D004164
can	O	O
aggravate	O	O
proteinuria	B-Disease	D011507
and	O	O
acute	B-Disease	D058186
renal	I-Disease	D058186
failure	I-Disease	D058186
.	O	O

Serum	O	O
-	O	O
and	O	O
glucocorticoid	O	O
-	O	O
inducible	O	O
kinase	O	O
1	O	O
in	O	O
doxorubicin	B-Chemical	D004317
-	O	O
induced	O	O
nephrotic	B-Disease	D009404
syndrome	I-Disease	D009404
.	O	O

Doxorubicin	B-Chemical	D004317
-	O	O
induced	O	O
nephropathy	B-Disease	D007674
leads	O	O
to	O	O
epithelial	O	O
sodium	B-Chemical	D012964
channel	O	O
(	O	O
ENaC	O	O
)	O	O
-	O	O
dependent	O	O
volume	B-Disease	D016055
retention	I-Disease	D016055
and	O	O
renal	O	O
fibrosis	B-Disease	D005355
.	O	O

The	O	O
aldosterone	B-Chemical	D000450
-	O	O
sensitive	O	O
serum	O	O
-	O	O
and	O	O
glucocorticoid	O	O
-	O	O
inducible	O	O
kinase	O	O
SGK1	O	O
has	O	O
been	O	O
shown	O	O
to	O	O
participate	O	O
in	O	O
the	O	O
stimulation	O	O
of	O	O
ENaC	O	O
and	O	O
to	O	O
mediate	O	O
renal	O	O
fibrosis	B-Disease	D005355
following	O	O
mineralocorticoid	O	O
and	O	O
salt	O	O
excess	O	O
.	O	O

The	O	O
present	O	O
study	O	O
was	O	O
performed	O	O
to	O	O
elucidate	O	O
the	O	O
role	O	O
of	O	O
SGK1	O	O
in	O	O
the	O	O
volume	B-Disease	D016055
retention	I-Disease	D016055
and	O	O
fibrosis	B-Disease	D005355
during	O	O
nephrotic	B-Disease	D009404
syndrome	I-Disease	D009404
.	O	O

To	O	O
this	O	O
end	O	O
,	O	O
doxorubicin	B-Chemical	D004317
(	O	O
15	O	O
mug	O	O
/	O	O
g	O	O
body	O	O
wt	O	O
)	O	O
was	O	O
injected	O	O
intravenously	O	O
into	O	O
gene	O	O
-	O	O
targeted	O	O
mice	O	O
lacking	O	O
SGK1	O	O
(	O	O
sgk1	O	O
(	O	O
-	O	O
/	O	O
-	O	O
)	O	O
)	O	O
and	O	O
their	O	O
wild	O	O
-	O	O
type	O	O
littermates	O	O
(	O	O
sgk1	O	O
(	O	O
+	O	O
/	O	O
+	O	O
)	O	O
)	O	O
.	O	O

Doxorubicin	B-Chemical	D004317
treatment	O	O
resulted	O	O
in	O	O
heavy	O	O
proteinuria	B-Disease	D011507
(	O	O
>100	O	O
mg	O	O
protein	O	O
/	O	O
mg	O	O
crea	O	O
)	O	O
in	O	O
15	O	O
/	O	O
44	O	O
of	O	O
sgk1	O	O
(	O	O
+	O	O
/	O	O
+	O	O
)	O	O
and	O	O
15	O	O
/	O	O
44	O	O
of	O	O
sgk1	O	O
(	O	O
-	O	O
/	O	O
-	O	O
)	O	O
mice	O	O
leading	O	O
to	O	O
severe	O	O
nephrotic	B-Disease	D009404
syndrome	I-Disease	D009404
with	O	O
ascites	B-Disease	D001201
,	O	O
lipidemia	B-Disease	D006949
,	O	O
and	O	O
hypoalbuminemia	B-Disease	D034141
in	O	O
both	O	O
genotypes	O	O
.	O	O

Plasma	O	O
aldosterone	B-Chemical	D000450
levels	O	O
increased	O	O
in	O	O
nephrotic	B-Disease	D009404
mice	O	O
of	O	O
both	O	O
genotypes	O	O
and	O	O
was	O	O
followed	O	O
by	O	O
increased	O	O
SGK1	O	O
protein	O	O
expression	O	O
in	O	O
sgk1	O	O
(	O	O
+	O	O
/	O	O
+	O	O
)	O	O
mice	O	O
.	O	O

Urinary	O	O
sodium	B-Chemical	D012964
excretion	O	O
reached	O	O
signficantly	O	O
lower	O	O
values	O	O
in	O	O
sgk1	O	O
(	O	O
+	O	O
/	O	O
+	O	O
)	O	O
mice	O	O
(	O	O
15	O	O
+	O	O
/	O	O
-	O	O
5	O	O
mumol	O	O
/	O	O
mg	O	O
crea	O	O
)	O	O
than	O	O
in	O	O
sgk1	O	O
(	O	O
-	O	O
/	O	O
-	O	O
)	O	O
mice	O	O
(	O	O
35	O	O
+	O	O
/	O	O
-	O	O
5	O	O
mumol	O	O
/	O	O
mg	O	O
crea	O	O
)	O	O
and	O	O
was	O	O
associated	O	O
with	O	O
a	O	O
significantly	O	O
higher	O	O
body	O	O
weight	B-Disease	D015430
gain	I-Disease	D015430
in	O	O
sgk1	O	O
(	O	O
+	O	O
/	O	O
+	O	O
)	O	O
compared	O	O
with	O	O
sgk1	O	O
(	O	O
-	O	O
/	O	O
-	O	O
)	O	O
mice	O	O
(	O	O
+6	O	O
.	O	O

6	O	O
+	O	O
/	O	O
-	O	O
0	O	O
.	O	O

7	O	O
vs	O	O
.	O	O

+4	O	O
.	O	O

1	O	O
+	O	O
/	O	O
-	O	O
0	O	O
.	O	O

8	O	O
g	O	O
)	O	O
.	O	O

During	O	O
the	O	O
course	O	O
of	O	O
nephrotic	B-Disease	D009404
syndrome	I-Disease	D009404
,	O	O
serum	O	O
urea	B-Chemical	D014508
concentrations	O	O
increased	O	O
significantly	O	O
faster	O	O
in	O	O
sgk1	O	O
(	O	O
-	O	O
/	O	O
-	O	O
)	O	O
mice	O	O
than	O	O
in	O	O
sgk1	O	O
(	O	O
+	O	O
/	O	O
+	O	O
)	O	O
mice	O	O
leading	O	O
to	O	O
uremia	B-Disease	D014511
and	O	O
a	O	O
reduced	O	O
median	O	O
survival	O	O
in	O	O
sgk1	O	O
(	O	O
-	O	O
/	O	O
-	O	O
)	O	O
mice	O	O
(	O	O
29	O	O
vs	O	O
.	O	O

40	O	O
days	O	O
in	O	O
sgk1	O	O
(	O	O
+	O	O
/	O	O
+	O	O
)	O	O
mice	O	O
)	O	O
.	O	O

In	O	O
conclusion	O	O
,	O	O
gene	O	O
-	O	O
targeted	O	O
mice	O	O
lacking	O	O
SGK1	O	O
showed	O	O
blunted	O	O
volume	B-Disease	D016055
retention	I-Disease	D016055
,	O	O
yet	O	O
were	O	O
not	O	O
protected	O	O
against	O	O
renal	O	O
fibrosis	B-Disease	D005355
during	O	O
experimental	O	O
nephrotic	B-Disease	D009404
syndrome	I-Disease	D009404
.	O	O

Severe	O	O
and	O	O
long	O	O
lasting	O	O
cholestasis	B-Disease	D002779
after	O	O
high	O	O
-	O	O
dose	O	O
co	B-Chemical	D015662
-	I-Chemical	D015662
trimoxazole	I-Chemical	D015662
treatment	O	O
for	O	O
Pneumocystis	B-Disease	D011020
pneumonia	I-Disease	D011020
in	O	O
HIV	B-Disease	D015658
-	I-Disease	D015658
infected	I-Disease	D015658
patients	O	O
-	O	O
-	O	O
a	O	O
report	O	O
of	O	O
two	O	O
cases	O	O
.	O	O

Pneumocystis	B-Disease	D011020
pneumonia	I-Disease	D011020
(	O	O
PCP	B-Disease	D011020
)	O	O
,	O	O
a	O	O
common	O	O
opportunistic	B-Disease	D009894
infection	I-Disease	D009894
in	O	O
HIV	B-Disease	D015658
-	I-Disease	D015658
infected	I-Disease	D015658
individuals	O	O
,	O	O
is	O	O
generally	O	O
treated	O	O
with	O	O
high	O	O
doses	O	O
of	O	O
co	B-Chemical	D015662
-	I-Chemical	D015662
trimoxazole	I-Chemical	D015662
.	O	O

However	O	O
,	O	O
treatment	O	O
is	O	O
often	O	O
limited	O	O
by	O	O
adverse	O	O
effects	O	O
.	O	O

Here	O	O
,	O	O
we	O	O
report	O	O
two	O	O
cases	O	O
of	O	O
severely	O	O
immunocompromised	O	O
HIV	B-Disease	D015658
-	I-Disease	D015658
infected	I-Disease	D015658
patients	O	O
who	O	O
developed	O	O
severe	O	O
intrahepatic	B-Disease	D002780
cholestasis	I-Disease	D002780
,	O	O
and	O	O
in	O	O
one	O	O
patient	O	O
lesions	O	O
mimicking	O	O
liver	B-Disease	D008100
abscess	I-Disease	D008100
formation	O	O
on	O	O
radiologic	O	O
exams	O	O
,	O	O
during	O	O
co	B-Chemical	D015662
-	I-Chemical	D015662
trimoxazole	I-Chemical	D015662
treatment	O	O
for	O	O
PCP	B-Disease	D011020
.	O	O

Whereas	O	O
patient	O	O
1	O	O
showed	O	O
lesions	O	O
of	O	O
up	O	O
to	O	O
1	O	O
cm	O	O
readily	O	O
detectable	O	O
on	O	O
magnetic	O	O
resonance	O	O
imaging	O	O
under	O	O
prolonged	O	O
co	B-Chemical	D015662
-	I-Chemical	D015662
trimoxazole	I-Chemical	D015662
treatment	O	O
,	O	O
therapy	O	O
of	O	O
patient	O	O
2	O	O
was	O	O
switched	O	O
early	O	O
.	O	O

Clinically	O	O
significant	O	O
proteinuria	B-Disease	D011507
following	O	O
the	O	O
administration	O	O
of	O	O
sirolimus	B-Chemical	D020123
to	O	O
renal	O	O
transplant	O	O
recipients	O	O
.	O	O

BACKGROUND	O	O
:	O	O
Sirolimus	B-Chemical	D020123
is	O	O
the	O	O
latest	O	O
immunosuppressive	O	O
agent	O	O
used	O	O
to	O	O
prevent	O	O
rejection	O	O
,	O	O
and	O	O
may	O	O
have	O	O
less	O	O
nephrotoxicity	B-Disease	D007674
than	O	O
calcineurin	O	O
inhibitor	O	O
(	O	O
CNI	O	O
)	O	O
-	O	O
based	O	O
regimens	O	O
.	O	O

To	O	O
date	O	O
there	O	O
has	O	O
been	O	O
little	O	O
documentation	O	O
of	O	O
clinically	O	O
significant	O	O
proteinuria	B-Disease	D011507
linked	O	O
with	O	O
the	O	O
use	O	O
of	O	O
sirolimus	B-Chemical	D020123
.	O	O

We	O	O
have	O	O
encountered	O	O
several	O	O
patients	O	O
who	O	O
developed	O	O
substantial	O	O
proteinuria	B-Disease	D011507
associated	O	O
with	O	O
sirolimus	B-Chemical	D020123
use	O	O
.	O	O

In	O	O
each	O	O
patient	O	O
,	O	O
the	O	O
close	O	O
temporal	O	O
association	O	O
between	O	O
the	O	O
commencement	O	O
of	O	O
sirolimus	B-Chemical	D020123
therapy	O	O
and	O	O
proteinuria	B-Disease	D011507
implicated	O	O
sirolimus	B-Chemical	D020123
as	O	O
the	O	O
most	O	O
likely	O	O
etiology	O	O
of	O	O
the	O	O
proteinuria	B-Disease	D011507
.	O	O

METHODS	O	O
:	O	O
We	O	O
analyzed	O	O
the	O	O
clinical	O	O
and	O	O
laboratory	O	O
information	O	O
available	O	O
for	O	O
all	O	O
119	O	O
patients	O	O
transplanted	O	O
at	O	O
the	O	O
Washington	O	O
Hospital	O	O
Center	O	O
between	O	O
1999	O	O
-	O	O
2003	O	O
for	O	O
whom	O	O
sirolimus	B-Chemical	D020123
was	O	O
a	O	O
component	O	O
of	O	O
their	O	O
immunosuppressant	O	O
regimen	O	O
.	O	O

In	O	O
these	O	O
patients	O	O
,	O	O
the	O	O
magnitude	O	O
of	O	O
proteinuria	B-Disease	D011507
was	O	O
assessed	O	O
on	O	O
morning	O	O
urine	O	O
samples	O	O
by	O	O
turbidometric	O	O
measurement	O	O
or	O	O
random	O	O
urine	O	O
protein	O	O
:	O	O
creatinine	B-Chemical	D003404
ratios	O	O
,	O	O
an	O	O
estimate	O	O
of	O	O
grams	O	O
of	O	O
proteinuria	B-Disease	D011507
/	O	O
day	O	O
.	O	O

Laboratory	O	O
results	O	O
were	O	O
compared	O	O
between	O	O
prior	O	O
,	O	O
during	O	O
and	O	O
following	O	O
sirolimus	B-Chemical	D020123
use	O	O
.	O	O

RESULTS	O	O
:	O	O
Twenty	O	O
-	O	O
eight	O	O
patients	O	O
(	O	O
24%	O	O
)	O	O
developed	O	O
increased	O	O
proteinuria	B-Disease	D011507
from	O	O
baseline	O	O
during	O	O
their	O	O
post	O	O
-	O	O
transplantation	O	O
course	O	O
.	O	O

In	O	O
21	O	O
patients	O	O
an	O	O
alternative	O	O
cause	O	O
of	O	O
proteinuria	B-Disease	D011507
was	O	O
either	O	O
obvious	O	O
or	O	O
insufficient	O	O
data	O	O
was	O	O
available	O	O
to	O	O
be	O	O
conclusive	O	O
.	O	O

In	O	O
7	O	O
of	O	O
the	O	O
28	O	O
patients	O	O
there	O	O
was	O	O
a	O	O
striking	O	O
temporal	O	O
association	O	O
between	O	O
the	O	O
initiation	O	O
of	O	O
sirolimus	B-Chemical	D020123
and	O	O
the	O	O
development	O	O
of	O	O
nephrotic	B-Disease	D009404
-	O	O
range	O	O
proteinuria	B-Disease	D011507
.	O	O

Proteinuria	B-Disease	D011507
correlated	O	O
most	O	O
strongly	O	O
with	O	O
sirolimus	B-Chemical	D020123
therapy	O	O
when	O	O
compared	O	O
to	O	O
other	O	O
demographic	O	O
and	O	O
clinical	O	O
variables	O	O
.	O	O

In	O	O
most	O	O
patients	O	O
,	O	O
discontinuation	O	O
of	O	O
sirolimus	B-Chemical	D020123
resulted	O	O
in	O	O
a	O	O
decrease	O	O
,	O	O
but	O	O
not	O	O
resolution	O	O
,	O	O
of	O	O
proteinuria	B-Disease	D011507
.	O	O

CONCLUSIONS	O	O
:	O	O
Sirolimus	B-Chemical	D020123
induces	O	O
or	O	O
aggravates	O	O
pre	O	O
-	O	O
existing	O	O
proteinuria	B-Disease	D011507
in	O	O
an	O	O
unpredictable	O	O
subset	O	O
of	O	O
renal	O	O
allograft	O	O
recipients	O	O
.	O	O

Proteinuria	B-Disease	D011507
may	O	O
improve	O	O
,	O	O
but	O	O
does	O	O
not	O	O
resolve	O	O
,	O	O
when	O	O
sirolimus	B-Chemical	D020123
is	O	O
withdrawn	O	O
.	O	O

Comparative	O	O
cognitive	O	O
and	O	O
subjective	O	O
side	O	O
effects	O	O
of	O	O
immediate	O	O
-	O	O
release	O	O
oxycodone	B-Chemical	D010098
in	O	O
healthy	O	O
middle	O	O
-	O	O
aged	O	O
and	O	O
older	O	O
adults	O	O
.	O	O

This	O	O
study	O	O
measured	O	O
the	O	O
objective	O	O
and	O	O
subjective	O	O
neurocognitive	O	O
effects	O	O
of	O	O
a	O	O
single	O	O
10	O	O
-	O	O
mg	O	O
dose	O	O
of	O	O
immediate	O	O
-	O	O
release	O	O
oxycodone	B-Chemical	D010098
in	O	O
healthy	O	O
,	O	O
older	O	O
(	O	O
>	O	O
65	O	O
years	O	O
)	O	O
,	O	O
and	O	O
middle	O	O
-	O	O
aged	O	O
(	O	O
35	O	O
to	O	O
55	O	O
years	O	O
)	O	O
adults	O	O
who	O	O
were	O	O
not	O	O
suffering	O	O
from	O	O
chronic	O	O
or	O	O
significant	O	O
daily	O	O
pain	B-Disease	D010146
.	O	O

Seventy	O	O
-	O	O
one	O	O
participants	O	O
completed	O	O
2	O	O
separate	O	O
study	O	O
days	O	O
and	O	O
were	O	O
blind	O	O
to	O	O
medication	O	O
condition	O	O
(	O	O
placebo	O	O
,	O	O
10	O	O
-	O	O
mg	O	O
oxycodone	B-Chemical	D010098
)	O	O
.	O	O

Plasma	O	O
oxycodone	B-Chemical	D010098
concentration	O	O
peaked	O	O
between	O	O
60	O	O
and	O	O
90	O	O
minutes	O	O
postdose	O	O
(	O	O
P	O	O
<	O	O
.	O	O

01	O	O
)	O	O
and	O	O
pupil	O	O
size	O	O
,	O	O
an	O	O
indication	O	O
of	O	O
physiological	O	O
effects	O	O
of	O	O
the	O	O
medication	O	O
,	O	O
peaked	O	O
at	O	O
approximately	O	O
90	O	O
to	O	O
120	O	O
minutes	O	O
postdose	O	O
(	O	O
P	O	O
<	O	O
.	O	O

01	O	O
)	O	O
.	O	O

Significant	O	O
declines	O	O
in	O	O
simple	O	O
and	O	O
sustained	O	O
attention	O	O
,	O	O
working	O	O
memory	O	O
,	O	O
and	O	O
verbal	O	O
memory	O	O
were	O	O
observed	O	O
at	O	O
1	O	O
hour	O	O
postdose	O	O
compared	O	O
to	O	O
baseline	O	O
for	O	O
both	O	O
age	O	O
groups	O	O
with	O	O
a	O	O
trend	O	O
toward	O	O
return	O	O
to	O	O
baseline	O	O
by	O	O
5	O	O
hours	O	O
postdose	O	O
.	O	O

For	O	O
almost	O	O
all	O	O
cognitive	O	O
measures	O	O
,	O	O
there	O	O
were	O	O
no	O	O
medication	O	O
by	O	O
age	O	O
-	O	O
interaction	O	O
effects	O	O
,	O	O
which	O	O
indicates	O	O
that	O	O
the	O	O
2	O	O
age	O	O
groups	O	O
exhibited	O	O
similar	O	O
responses	O	O
to	O	O
the	O	O
medication	O	O
challenge	O	O
.	O	O

This	O	O
study	O	O
suggests	O	O
that	O	O
for	O	O
healthy	O	O
older	O	O
adults	O	O
who	O	O
are	O	O
not	O	O
suffering	O	O
from	O	O
chronic	B-Disease	D059350
pain	I-Disease	D059350
,	O	O
neurocognitive	O	O
and	O	O
pharmacodynamic	O	O
changes	O	O
in	O	O
response	O	O
to	O	O
a	O	O
10	O	O
-	O	O
mg	O	O
dose	O	O
of	O	O
immediate	O	O
-	O	O
release	O	O
oxycodone	B-Chemical	D010098
are	O	O
similar	O	O
to	O	O
those	O	O
observed	O	O
for	O	O
middle	O	O
-	O	O
aged	O	O
adults	O	O
.	O	O

PERSPECTIVE	O	O
:	O	O
Study	O	O
findings	O	O
indicate	O	O
that	O	O
the	O	O
metabolism	O	O
,	O	O
neurocognitive	O	O
effects	O	O
,	O	O
and	O	O
physical	O	O
side	O	O
effects	O	O
of	O	O
oral	O	O
oxycodone	B-Chemical	D010098
are	O	O
similar	O	O
for	O	O
healthy	O	O
middle	O	O
-	O	O
aged	O	O
and	O	O
older	O	O
adults	O	O
.	O	O

Therefore	O	O
,	O	O
clinicians	O	O
should	O	O
not	O	O
avoid	O	O
prescribing	O	O
oral	O	O
opioids	O	O
to	O	O
older	O	O
adults	O	O
based	O	O
on	O	O
the	O	O
belief	O	O
that	O	O
older	O	O
adults	O	O
are	O	O
at	O	O
higher	O	O
risk	O	O
for	O	O
side	O	O
effects	O	O
than	O	O
younger	O	O
adults	O	O
.	O	O

Normalizing	O	O
effects	O	O
of	O	O
modafinil	B-Chemical	C048833
on	O	O
sleep	O	O
in	O	O
chronic	O	O
cocaine	B-Chemical	D003042
users	O	O
.	O	O

OBJECTIVE	O	O
:	O	O
The	O	O
purpose	O	O
of	O	O
the	O	O
present	O	O
study	O	O
was	O	O
to	O	O
determine	O	O
the	O	O
effect	O	O
of	O	O
morning	O	O
-	O	O
dosed	O	O
modafinil	B-Chemical	C048833
on	O	O
sleep	O	O
and	O	O
daytime	B-Disease	D012893
sleepiness	I-Disease	D012893
in	O	O
chronic	O	O
cocaine	B-Chemical	D003042
users	O	O
.	O	O

METHOD	O	O
:	O	O
Twenty	O	O
cocaine	B-Chemical	D003042
-	O	O
dependent	O	O
participants	O	O
were	O	O
randomly	O	O
assigned	O	O
to	O	O
receive	O	O
modafinil	B-Chemical	C048833
,	O	O
400	O	O
mg	O	O
(	O	O
N=10	O	O
)	O	O
,	O	O
or	O	O
placebo	O	O
(	O	O
N=10	O	O
)	O	O
every	O	O
morning	O	O
at	O	O
7	O	O
:	O	O
30	O	O
a	O	O
.	O	O

m	O	O
.	O	O

for	O	O
16	O	O
days	O	O
in	O	O
an	O	O
inpatient	O	O
,	O	O
double	O	O
-	O	O
blind	O	O
randomized	O	O
trial	O	O
.	O	O

Participants	O	O
underwent	O	O
polysomnographic	O	O
sleep	O	O
recordings	O	O
on	O	O
days	O	O
1	O	O
to	O	O
3	O	O
,	O	O
7	O	O
to	O	O
9	O	O
,	O	O
and	O	O
14	O	O
to	O	O
16	O	O
(	O	O
first	O	O
,	O	O
second	O	O
,	O	O
and	O	O
third	O	O
weeks	O	O
of	O	O
abstinence	O	O
)	O	O
.	O	O

The	O	O
Multiple	O	O
Sleep	O	O
Latency	O	O
Test	O	O
was	O	O
performed	O	O
at	O	O
11	O	O
:	O	O
30	O	O
a	O	O
.	O	O

m	O	O
.	O	O

,	O	O
2	O	O
:	O	O
00	O	O
p	O	O
.	O	O

m	O	O
.	O	O

,	O	O
and	O	O
4	O	O
:	O	O
30	O	O
p	O	O
.	O	O

m	O	O
.	O	O

on	O	O
days	O	O
2	O	O
,	O	O
8	O	O
,	O	O
and	O	O
15	O	O
.	O	O

For	O	O
comparison	O	O
of	O	O
sleep	O	O
architecture	O	O
variables	O	O
,	O	O
12	O	O
healthy	O	O
comparison	O	O
participants	O	O
underwent	O	O
a	O	O
single	O	O
night	O	O
of	O	O
experimental	O	O
polysomnography	O	O
that	O	O
followed	O	O
1	O	O
night	O	O
of	O	O
accommodation	O	O
polysomnography	O	O
.	O	O

RESULTS	O	O
:	O	O
Progressive	O	O
abstinence	O	O
from	O	O
cocaine	B-Chemical	D003042
was	O	O
associated	O	O
with	O	O
worsening	O	O
of	O	O
all	O	O
measured	O	O
polysomnographic	O	O
sleep	O	O
outcomes	O	O
.	O	O

Compared	O	O
with	O	O
placebo	O	O
,	O	O
modafinil	B-Chemical	C048833
decreased	O	O
nighttime	O	O
sleep	O	O
latency	O	O
and	O	O
increased	O	O
slow	O	O
-	O	O
wave	O	O
sleep	O	O
time	O	O
in	O	O
cocaine	B-Chemical	D003042
-	O	O
dependent	O	O
participants	O	O
.	O	O

The	O	O
effect	O	O
of	O	O
modafinil	B-Chemical	C048833
interacted	O	O
with	O	O
the	O	O
abstinence	O	O
week	O	O
and	O	O
was	O	O
associated	O	O
with	O	O
longer	O	O
total	O	O
sleep	O	O
time	O	O
and	O	O
shorter	O	O
REM	O	O
sleep	O	O
latency	O	O
in	O	O
the	O	O
third	O	O
week	O	O
of	O	O
abstinence	O	O
.	O	O

Comparison	O	O
of	O	O
slow	O	O
-	O	O
wave	O	O
sleep	O	O
time	O	O
,	O	O
total	O	O
sleep	O	O
time	O	O
,	O	O
and	O	O
sleep	O	O
latency	O	O
in	O	O
cocaine	B-Chemical	D003042
-	O	O
dependent	O	O
and	O	O
healthy	O	O
participants	O	O
revealed	O	O
a	O	O
normalizing	O	O
effect	O	O
of	O	O
modafinil	B-Chemical	C048833
in	O	O
cocaine	B-Chemical	D003042
-	O	O
dependent	O	O
participants	O	O
.	O	O

Modafinil	B-Chemical	C048833
was	O	O
associated	O	O
with	O	O
increased	O	O
daytime	O	O
sleep	O	O
latency	O	O
,	O	O
as	O	O
measured	O	O
by	O	O
the	O	O
Multiple	O	O
Sleep	O	O
Latency	O	O
Test	O	O
,	O	O
and	O	O
a	O	O
nearly	O	O
significant	O	O
decrease	O	O
in	O	O
subjective	O	O
daytime	B-Disease	D012893
sleepiness	I-Disease	D012893
.	O	O

CONCLUSIONS	O	O
:	O	O
Morning	O	O
-	O	O
dosed	O	O
modafinil	B-Chemical	C048833
promotes	O	O
nocturnal	O	O
sleep	O	O
,	O	O
normalizes	O	O
sleep	O	O
architecture	O	O
,	O	O
and	O	O
decreases	O	O
daytime	B-Disease	D012893
sleepiness	I-Disease	D012893
in	O	O
abstinent	O	O
cocaine	B-Chemical	D003042
users	O	O
.	O	O

These	O	O
effects	O	O
may	O	O
be	O	O
relevant	O	O
in	O	O
the	O	O
treatment	O	O
of	O	O
cocaine	B-Chemical	D003042
dependence	O	O
.	O	O

Efficacy	O	O
and	O	O
safety	O	O
of	O	O
asenapine	B-Chemical	C522667
in	O	O
a	O	O
placebo	O	O
-	O	O
and	O	O
haloperidol	B-Chemical	D006220
-	O	O
controlled	O	O
trial	O	O
in	O	O
patients	O	O
with	O	O
acute	O	O
exacerbation	O	O
of	O	O
schizophrenia	B-Disease	D012559
.	O	O

Asenapine	B-Chemical	C522667
is	O	O
approved	O	O
by	O	O
the	O	O
Food	O	O
and	O	O
Drugs	O	O
Administration	O	O
in	O	O
adults	O	O
for	O	O
acute	O	O
treatment	O	O
of	O	O
schizophrenia	B-Disease	D012559
or	O	O
of	O	O
manic	B-Disease	D001714
or	O	O
mixed	O	O
episodes	O	O
associated	O	O
with	O	O
bipolar	B-Disease	D001714
I	I-Disease	D001714
disorder	I-Disease	D001714
with	O	O
or	O	O
without	O	O
psychotic	B-Disease	D011618
features	O	O
.	O	O

In	O	O
a	O	O
double	O	O
-	O	O
blind	O	O
6	O	O
-	O	O
week	O	O
trial	O	O
,	O	O
458	O	O
patients	O	O
with	O	O
acute	O	O
schizophrenia	B-Disease	D012559
were	O	O
randomly	O	O
assigned	O	O
to	O	O
fixed	O	O
-	O	O
dose	O	O
treatment	O	O
with	O	O
asenapine	B-Chemical	C522667
at	O	O
5	O	O
mg	O	O
twice	O	O
daily	O	O
(	O	O
BID	O	O
)	O	O
,	O	O
asenapine	B-Chemical	C522667
at	O	O
10	O	O
mg	O	O
BID	O	O
,	O	O
placebo	O	O
,	O	O
or	O	O
haloperidol	B-Chemical	D006220
at	O	O
4	O	O
mg	O	O
BID	O	O
(	O	O
to	O	O
verify	O	O
assay	O	O
sensitivity	O	O
)	O	O
.	O	O

With	O	O
last	O	O
observations	O	O
carried	O	O
forward	O	O
(	O	O
LOCF	O	O
)	O	O
,	O	O
mean	O	O
Positive	O	O
and	O	O
Negative	O	O
Syndrome	O	O
Scale	O	O
total	O	O
score	O	O
reductions	O	O
from	O	O
baseline	O	O
to	O	O
endpoint	O	O
were	O	O
significantly	O	O
greater	O	O
with	O	O
asenapine	B-Chemical	C522667
at	O	O
5	O	O
mg	O	O
BID	O	O
(	O	O
-	O	O
16	O	O
.	O	O

2	O	O
)	O	O
and	O	O
haloperidol	B-Chemical	D006220
(	O	O
-	O	O
15	O	O
.	O	O

4	O	O
)	O	O
than	O	O
placebo	O	O
(	O	O
-	O	O
10	O	O
.	O	O

7	O	O
;	O	O
both	O	O
P	O	O
<	O	O
0	O	O
.	O	O

05	O	O
)	O	O
;	O	O
using	O	O
mixed	O	O
model	O	O
for	O	O
repeated	O	O
measures	O	O
(	O	O
MMRM	O	O
)	O	O
,	O	O
changes	O	O
at	O	O
day	O	O
42	O	O
were	O	O
significantly	O	O
greater	O	O
with	O	O
asenapine	B-Chemical	C522667
at	O	O
5	O	O
and	O	O
10	O	O
mg	O	O
BID	O	O
(	O	O
-	O	O
21	O	O
.	O	O

3	O	O
and	O	O
-	O	O
19	O	O
.	O	O

4	O	O
,	O	O
respectively	O	O
)	O	O
and	O	O
haloperidol	B-Chemical	D006220
(	O	O
-	O	O
20	O	O
.	O	O

0	O	O
)	O	O
than	O	O
placebo	O	O
(	O	O
-	O	O
14	O	O
.	O	O

6	O	O
;	O	O
all	O	O
P	O	O
<	O	O
0	O	O
.	O	O

05	O	O
)	O	O
.	O	O

On	O	O
the	O	O
Positive	O	O
and	O	O
Negative	O	O
Syndrome	O	O
Scale	O	O
positive	O	O
subscale	O	O
,	O	O
all	O	O
treatments	O	O
were	O	O
superior	O	O
to	O	O
placebo	O	O
with	O	O
LOCF	O	O
and	O	O
MMRM	O	O
;	O	O
asenapine	B-Chemical	C522667
at	O	O
5	O	O
mg	O	O
BID	O	O
was	O	O
superior	O	O
to	O	O
placebo	O	O
on	O	O
the	O	O
negative	O	O
subscale	O	O
with	O	O
MMRM	O	O
and	O	O
on	O	O
the	O	O
general	O	O
psychopathology	O	O
subscale	O	O
with	O	O
LOCF	O	O
and	O	O
MMRM	O	O
.	O	O

Treatment	O	O
-	O	O
related	O	O
adverse	O	O
events	O	O
(	O	O
AEs	O	O
)	O	O
occurred	O	O
in	O	O
44%	O	O
and	O	O
52%	O	O
,	O	O
57%	O	O
,	O	O
and	O	O
41%	O	O
of	O	O
the	O	O
asenapine	B-Chemical	C522667
at	O	O
5	O	O
and	O	O
10	O	O
mg	O	O
BID	O	O
,	O	O
haloperidol	B-Chemical	D006220
,	O	O
and	O	O
placebo	O	O
groups	O	O
,	O	O
respectively	O	O
.	O	O

Extrapyramidal	B-Disease	D001480
symptoms	I-Disease	D001480
reported	O	O
as	O	O
AEs	O	O
occurred	O	O
in	O	O
15%	O	O
and	O	O
18%	O	O
,	O	O
34%	O	O
,	O	O
and	O	O
10%	O	O
of	O	O
the	O	O
asenapine	B-Chemical	C522667
at	O	O
5	O	O
and	O	O
10	O	O
mg	O	O
BID	O	O
,	O	O
haloperidol	B-Chemical	D006220
,	O	O
and	O	O
placebo	O	O
groups	O	O
,	O	O
respectively	O	O
.	O	O

Across	O	O
all	O	O
groups	O	O
,	O	O
no	O	O
more	O	O
than	O	O
5%	O	O
of	O	O
patients	O	O
had	O	O
clinically	O	O
significant	O	O
weight	O	O
change	O	O
.	O	O

Post	O	O
hoc	O	O
analyses	O	O
indicated	O	O
that	O	O
efficacy	O	O
was	O	O
similar	O	O
with	O	O
asenapine	B-Chemical	C522667
and	O	O
haloperidol	B-Chemical	D006220
;	O	O
greater	O	O
contrasts	O	O
were	O	O
seen	O	O
in	O	O
AEs	O	O
,	O	O
especially	O	O
extrapyramidal	B-Disease	D001480
symptoms	I-Disease	D001480
.	O	O

Permeability	O	O
,	O	O
ultrastructural	O	O
changes	O	O
,	O	O
and	O	O
distribution	O	O
of	O	O
novel	O	O
proteins	O	O
in	O	O
the	O	O
glomerular	O	O
barrier	O	O
in	O	O
early	O	O
puromycin	B-Chemical	D011692
aminonucleoside	I-Chemical	D011692
nephrosis	B-Disease	D009401
.	O	O

BACKGROUND	O	O
/	O	O
AIMS	O	O
:	O	O
It	O	O
is	O	O
still	O	O
unclear	O	O
what	O	O
happens	O	O
in	O	O
the	O	O
glomerulus	O	O
when	O	O
proteinuria	B-Disease	D011507
starts	O	O
.	O	O

Using	O	O
puromycin	B-Chemical	D011692
aminonucleoside	I-Chemical	D011692
nephrosis	B-Disease	D009401
(	O	O
PAN	O	O
)	O	O
rats	O	O
,	O	O
we	O	O
studied	O	O
early	O	O
ultrastructural	O	O
and	O	O
permeability	O	O
changes	O	O
in	O	O
relation	O	O
to	O	O
the	O	O
expression	O	O
of	O	O
the	O	O
podocyte	O	O
-	O	O
associated	O	O
molecules	O	O
nephrin	O	O
,	O	O
a	O	O
-	O	O
actinin	O	O
,	O	O
dendrin	O	O
,	O	O
and	O	O
plekhh2	O	O
,	O	O
the	O	O
last	O	O
two	O	O
of	O	O
which	O	O
were	O	O
only	O	O
recently	O	O
discovered	O	O
in	O	O
podocytes	O	O
.	O	O

METHODS	O	O
:	O	O
Using	O	O
immune	O	O
stainings	O	O
,	O	O
semiquantitative	O	O
measurement	O	O
was	O	O
performed	O	O
under	O	O
the	O	O
electron	O	O
microscope	O	O
.	O	O

Permeability	O	O
was	O	O
assessed	O	O
using	O	O
isolated	O	O
kidney	O	O
perfusion	O	O
with	O	O
tracers	O	O
.	O	O

Possible	O	O
effects	O	O
of	O	O
ACE	O	O
inhibition	O	O
were	O	O
tested	O	O
.	O	O

RESULTS	O	O
:	O	O
By	O	O
day	O	O
2	O	O
,	O	O
some	O	O
patchy	O	O
foot	O	O
process	O	O
effacement	O	O
,	O	O
but	O	O
no	O	O
proteinuria	B-Disease	D011507
,	O	O
appeared	O	O
.	O	O

The	O	O
amount	O	O
of	O	O
nephrin	O	O
was	O	O
reduced	O	O
in	O	O
both	O	O
diseased	O	O
and	O	O
normal	O	O
areas	O	O
.	O	O

The	O	O
other	O	O
proteins	O	O
showed	O	O
few	O	O
changes	O	O
,	O	O
which	O	O
were	O	O
limited	O	O
to	O	O
diseased	O	O
areas	O	O
.	O	O

By	O	O
day	O	O
4	O	O
,	O	O
foot	O	O
process	O	O
effacement	O	O
was	O	O
complete	O	O
and	O	O
proteinuria	B-Disease	D011507
appeared	O	O
in	O	O
parallel	O	O
with	O	O
signs	O	O
of	O	O
size	O	O
barrier	O	O
damage	O	O
.	O	O

Nephrin	O	O
decreased	O	O
further	O	O
,	O	O
while	O	O
dendrin	O	O
and	O	O
plekhh2	O	O
also	O	O
decreased	O	O
but	O	O
a	O	O
-	O	O
actinin	O	O
remained	O	O
unchanged	O	O
.	O	O

ACE	O	O
inhibition	O	O
had	O	O
no	O	O
significant	O	O
protective	O	O
effect	O	O
.	O	O

CONCLUSIONS	O	O
:	O	O
PAN	O	O
glomeruli	O	O
already	O	O
showed	O	O
significant	O	O
pathology	O	O
by	O	O
day	O	O
4	O	O
,	O	O
despite	O	O
relatively	O	O
mild	O	O
proteinuria	B-Disease	D011507
.	O	O

This	O	O
was	O	O
preceded	O	O
by	O	O
altered	O	O
nephrin	O	O
expression	O	O
,	O	O
supporting	O	O
its	O	O
pivotal	O	O
role	O	O
in	O	O
podocyte	O	O
morphology	O	O
.	O	O

The	O	O
novel	O	O
proteins	O	O
dendrin	O	O
and	O	O
plekhh2	O	O
were	O	O
both	O	O
reduced	O	O
,	O	O
suggesting	O	O
roles	O	O
in	O	O
PAN	O	O
,	O	O
whereas	O	O
a	O	O
-	O	O
actinin	O	O
was	O	O
unchanged	O	O
.	O	O

Twin	O	O
preterm	O	O
neonates	O	O
with	O	O
cardiac	B-Disease	D066126
toxicity	I-Disease	D066126
related	O	O
to	O	O
lopinavir	B-Chemical	C558899
/	I-Chemical	C558899
ritonavir	I-Chemical	C558899
therapy	O	O
.	O	O

We	O	O
report	O	O
twin	O	O
neonates	O	O
who	O	O
were	O	O
born	O	O
prematurely	O	O
at	O	O
32	O	O
weeks	O	O
of	O	O
gestation	O	O
to	O	O
a	O	O
mother	O	O
with	O	O
human	B-Disease	D015658
immunodeficiency	I-Disease	D015658
virus	I-Disease	D015658
infection	I-Disease	D015658
.	O	O

One	O	O
of	O	O
the	O	O
twins	O	O
developed	O	O
complete	O	O
heart	B-Disease	D006327
block	I-Disease	D006327
and	O	O
dilated	B-Disease	D002311
cardiomyopathy	I-Disease	D002311
related	O	O
to	O	O
lopinavir	B-Chemical	C558899
/	I-Chemical	C558899
ritonavir	I-Chemical	C558899
therapy	O	O
,	O	O
a	O	O
boosted	O	O
protease	O	O
-	O	O
inhibitor	O	O
agent	O	O
,	O	O
while	O	O
the	O	O
other	O	O
twin	O	O
developed	O	O
mild	O	O
bradycardia	B-Disease	D001919
.	O	O

We	O	O
recommend	O	O
caution	O	O
in	O	O
the	O	O
use	O	O
of	O	O
lopinavir	B-Chemical	C558899
/	I-Chemical	C558899
ritonavir	I-Chemical	C558899
in	O	O
the	O	O
immediate	O	O
neonatal	O	O
period	O	O
.	O	O

Learning	O	O
of	O	O
rats	O	O
under	O	O
amnesia	B-Disease	D000647
caused	O	O
by	O	O
pentobarbital	B-Chemical	D010424
.	O	O

Dissociated	O	O
learning	O	O
of	O	O
rats	O	O
in	O	O
the	O	O
normal	O	O
state	O	O
and	O	O
the	O	O
state	O	O
of	O	O
amnesia	B-Disease	D000647
produced	O	O
by	O	O
pentobarbital	B-Chemical	D010424
(	O	O
15	O	O
mg	O	O
/	O	O
kg	O	O
,	O	O
ip	O	O
)	O	O
was	O	O
carried	O	O
out	O	O
.	O	O

Rats	O	O
were	O	O
trained	O	O
to	O	O
approach	O	O
a	O	O
shelf	O	O
where	O	O
they	O	O
received	O	O
food	O	O
reinforcement	O	O
.	O	O

In	O	O
Group	O	O
1	O	O
the	O	O
rats	O	O
were	O	O
trained	O	O
under	O	O
the	O	O
influence	O	O
of	O	O
pentobarbital	B-Chemical	D010424
to	O	O
run	O	O
to	O	O
the	O	O
same	O	O
shelf	O	O
as	O	O
in	O	O
the	O	O
normal	O	O
state	O	O
.	O	O

In	O	O
Group	O	O
2	O	O
the	O	O
rats	O	O
were	O	O
trained	O	O
to	O	O
approach	O	O
different	O	O
shelves	O	O
in	O	O
different	O	O
drug	O	O
states	O	O
.	O	O

It	O	O
was	O	O
shown	O	O
that	O	O
memory	B-Disease	D008569
dissociation	I-Disease	D008569
occurred	O	O
in	O	O
both	O	O
groups	O	O
.	O	O

Differences	O	O
in	O	O
the	O	O
parameters	O	O
of	O	O
training	O	O
under	O	O
the	O	O
influence	O	O
of	O	O
pentobarbital	B-Chemical	D010424
between	O	O
Groups	O	O
1	O	O
and	O	O
2	O	O
were	O	O
revealed	O	O
.	O	O

These	O	O
findings	O	O
show	O	O
that	O	O
the	O	O
brain	O	O
-	O	O
dissociated	O	O
state	O	O
induced	O	O
by	O	O
pentobarbital	B-Chemical	D010424
is	O	O
formed	O	O
with	O	O
the	O	O
participation	O	O
of	O	O
the	O	O
mechanisms	O	O
of	O	O
information	O	O
perception	O	O
.	O	O

Angiosarcoma	B-Disease	D006394
of	O	O
the	O	O
liver	O	O
associated	O	O
with	O	O
diethylstilbestrol	B-Chemical	D004054
.	O	O

Angiosarcoma	B-Disease	D006394
of	O	O
the	O	O
liver	O	O
occurred	O	O
in	O	O
a	O	O
76	O	O
-	O	O
year	O	O
-	O	O
old	O	O
man	O	O
who	O	O
had	O	O
been	O	O
treated	O	O
for	O	O
a	O	O
well	O	O
-	O	O
differentiated	O	O
adenocarcinoma	O	O
of	O	O
the	O	O
liver	O	O
with	O	O
diethylstilbestrol	B-Chemical	D004054
for	O	O
13	O	O
years	O	O
.	O	O

Angiosarcoma	B-Disease	D006394
was	O	O
also	O	O
present	O	O
within	O	O
pulmonary	O	O
and	O	O
renal	O	O
arteries	O	O
.	O	O

The	O	O
possibility	O	O
that	O	O
the	O	O
intraarterial	B-Disease	D014652
lesions	I-Disease	D014652
might	O	O
represent	O	O
independent	O	O
primary	O	O
tumors	B-Disease	D009369
is	O	O
considered	O	O
.	O	O

Role	O	O
of	O	O
xanthine	B-Chemical	D019820
oxidase	O	O
in	O	O
dexamethasone	B-Chemical	D003907
-	O	O
induced	O	O
hypertension	B-Disease	D006973
in	O	O
rats	O	O
.	O	O

1	O	O
.	O	O

Glucocorticoid	O	O
-	O	O
induced	O	O
hypertension	B-Disease	D006973
(	O	O
GC	O	O
-	O	O
HT	B-Disease	D006973
)	O	O
in	O	O
the	O	O
rat	O	O
is	O	O
associated	O	O
with	O	O
nitric	B-Chemical	D009569
oxide	I-Chemical	D009569
-	O	O
redox	O	O
imbalance	O	O
.	O	O

2	O	O
.	O	O

We	O	O
studied	O	O
the	O	O
role	O	O
of	O	O
xanthine	B-Chemical	D019820
oxidase	O	O
(	O	O
XO	O	O
)	O	O
,	O	O
which	O	O
is	O	O
implicated	O	O
in	O	O
the	O	O
production	O	O
of	O	O
reactive	O	O
oxygen	O	O
species	O	O
,	O	O
in	O	O
dexamethasone	B-Chemical	D003907
-	O	O
induced	O	O
hypertension	B-Disease	D006973
(	O	O
dex	B-Chemical	D003907
-	O	O
HT	B-Disease	D006973
)	O	O
.	O	O

3	O	O
.	O	O

Thirty	O	O
male	O	O
Sprague	O	O
-	O	O
Dawley	O	O
rats	O	O
were	O	O
divided	O	O
randomly	O	O
into	O	O
four	O	O
treatment	O	O
groups	O	O
:	O	O
saline	O	O
,	O	O
dexamethasone	B-Chemical	D003907
(	O	O
dex	B-Chemical	D003907
)	O	O
,	O	O
allopurinol	B-Chemical	D000493
plus	O	O
saline	O	O
,	O	O
and	O	O
allopurinol	B-Chemical	D000493
plus	O	O
dex	B-Chemical	D003907
.	O	O

4	O	O
.	O	O

Systolic	O	O
blood	O	O
pressures	O	O
(	O	O
SBP	O	O
)	O	O
and	O	O
bodyweights	O	O
were	O	O
recorded	O	O
each	O	O
alternate	O	O
day	O	O
.	O	O

Thymus	O	O
weight	O	O
was	O	O
used	O	O
as	O	O
a	O	O
marker	O	O
of	O	O
glucocorticoid	O	O
activity	O	O
,	O	O
and	O	O
serum	O	O
urate	B-Chemical	D014527
to	O	O
assess	O	O
XO	O	O
inhibition	O	O
.	O	O

5	O	O
.	O	O

Dex	B-Chemical	D003907
increased	B-Disease	D006973
SBP	I-Disease	D006973
(	O	O
110	O	O
+	O	O
/	O	O
-	O	O
2	O	O
-	O	O
126	O	O
+	O	O
/	O	O
-	O	O
3	O	O
mmHg	O	O
;	O	O
P	O	O
<	O	O
0	O	O
.	O	O

001	O	O
)	O	O
and	O	O
decreased	B-Disease	D015431
thymus	I-Disease	D015431
(	I-Disease	D015431
P	I-Disease	D015431
<	I-Disease	D015431
0	I-Disease	D015431
.	I-Disease	D015431

001	I-Disease	D015431
)	I-Disease	D015431
and	I-Disease	D015431
bodyweights	I-Disease	D015431
(	O	O
P"	O	O
<	O	O
0	O	O
.	O	O

01	O	O
)	O	O
.	O	O

Allopurinol	B-Chemical	D000493
decreased	O	O
serum	O	O
urate	B-Chemical	D014527
from	O	O
76	O	O
+	O	O
/	O	O
-	O	O
5	O	O
to	O	O
30	O	O
+	O	O
/	O	O
-	O	O
3	O	O
micromol	O	O
/	O	O
L	O	O
(	O	O
P	O	O
<	O	O
0	O	O
.	O	O

001	O	O
)	O	O
in	O	O
saline	O	O
and	O	O
from	O	O
84	O	O
+	O	O
/	O	O
-	O	O
13	O	O
to	O	O
28	O	O
+	O	O
/	O	O
-	O	O
2	O	O
micromol	O	O
/	O	O
L	O	O
in	O	O
dex	B-Chemical	D003907
-	O	O
treated	O	O
(	O	O
P	O	O
<	O	O
0	O	O
.	O	O

01	O	O
)	O	O
groups	O	O
.	O	O

6	O	O
.	O	O

Allopurinol	B-Chemical	D000493
did	O	O
not	O	O
prevent	O	O
dex	B-Chemical	D003907
-	O	O
HT	B-Disease	D006973
.	O	O

This	O	O
,	O	O
together	O	O
with	O	O
our	O	O
previous	O	O
findings	O	O
that	O	O
allopurinol	B-Chemical	D000493
failed	O	O
to	O	O
prevent	O	O
adrenocorticotrophic	O	O
hormone	O	O
induced	O	O
hypertension	B-Disease	D006973
,	O	O
suggests	O	O
that	O	O
XO	O	O
activity	O	O
is	O	O
not	O	O
a	O	O
major	O	O
determinant	O	O
of	O	O
GC	O	O
-	O	O
HT	B-Disease	D006973
in	O	O
the	O	O
rat	O	O
.	O	O

Extrapyramidal	O	O
side	O	O
effects	O	O
with	O	O
risperidone	B-Chemical	D018967
and	O	O
haloperidol	B-Chemical	D006220
at	O	O
comparable	O	O
D2	O	O
receptor	O	O
occupancy	O	O
levels	O	O
.	O	O

Risperidone	B-Chemical	D018967
is	O	O
an	O	O
antipsychotic	O	O
drug	O	O
with	O	O
high	O	O
affinity	O	O
at	O	O
dopamine	B-Chemical	D004298
D2	O	O
and	O	O
serotonin	B-Chemical	D044348
5	I-Chemical	D044348
-	I-Chemical	D044348
HT2	I-Chemical	D044348
receptors	O	O
.	O	O

Previous	O	O
clinical	O	O
studies	O	O
have	O	O
proposed	O	O
that	O	O
risperidone's	O	O
pharmacologic	O	O
profile	O	O
may	O	O
produce	O	O
improved	O	O
efficacy	O	O
for	O	O
negative	O	O
psychotic	B-Disease	D011618
symptoms	I-Disease	D011618
and	O	O
decreased	O	O
propensity	O	O
for	O	O
extrapyramidal	O	O
side	O	O
effects	O	O
;	O	O
features	O	O
shared	O	O
by	O	O
so	O	O
-	O	O
called	O	O
'atypical'	O	O
neuroleptics	O	O
.	O	O

To	O	O
determine	O	O
if	O	O
routine	O	O
risperidone	B-Chemical	D018967
treatment	O	O
is	O	O
associated	O	O
with	O	O
a	O	O
unique	O	O
degree	O	O
of	O	O
D2	O	O
receptor	O	O
occupancy	O	O
and	O	O
pattern	O	O
of	O	O
clinical	O	O
effects	O	O
,	O	O
we	O	O
used	O	O
[	O	O
123I	O	O
]	O	O
IBZM	O	O
SPECT	O	O
to	O	O
determine	O	O
D2	O	O
occupancy	O	O
in	O	O
subjects	O	O
treated	O	O
with	O	O
routine	O	O
clinical	O	O
doses	O	O
of	O	O
risperidone	B-Chemical	D018967
(	O	O
n	O	O
=	O	O
12	O	O
)	O	O
or	O	O
haloperidol	B-Chemical	D006220
(	O	O
n	O	O
=	O	O
7	O	O
)	O	O
.	O	O

Both	O	O
risperidone	B-Chemical	D018967
and	O	O
haloperidol	B-Chemical	D006220
produced	O	O
D2	O	O
occupancy	O	O
levels	O	O
between	O	O
approximately	O	O
60	O	O
and	O	O
90%	O	O
at	O	O
standard	O	O
clinical	O	O
doses	O	O
.	O	O

There	O	O
was	O	O
no	O	O
significant	O	O
difference	O	O
between	O	O
occupancy	O	O
levels	O	O
obtained	O	O
with	O	O
haloperidol	B-Chemical	D006220
or	O	O
risperidone	B-Chemical	D018967
.	O	O

Drug	B-Disease	D010302
-	I-Disease	D010302
induced	I-Disease	D010302
parkinsonism	I-Disease	D010302
was	O	O
observed	O	O
in	O	O
subjects	O	O
treated	O	O
with	O	O
risperidone	B-Chemical	D018967
(	O	O
42%	O	O
)	O	O
and	O	O
haloperidol	B-Chemical	D006220
(	O	O
29%	O	O
)	O	O
and	O	O
was	O	O
observed	O	O
at	O	O
occupancy	O	O
levels	O	O
above	O	O
60%	O	O
.	O	O

Based	O	O
on	O	O
these	O	O
observations	O	O
,	O	O
it	O	O
is	O	O
concluded	O	O
that	O	O
5	O	O
-	O	O
HT2	O	O
blockade	O	O
obtained	O	O
with	O	O
risperidone	B-Chemical	D018967
at	O	O
D2	O	O
occupancy	O	O
rates	O	O
of	O	O
60%	O	O
and	O	O
above	O	O
does	O	O
not	O	O
appear	O	O
to	O	O
protect	O	O
against	O	O
the	O	O
risk	O	O
for	O	O
extrapyramidal	O	O
side	O	O
effects	O	O
.	O	O

Simvastatin	B-Chemical	C492458
-	I-Chemical	C492458
ezetimibe	I-Chemical	C492458
-	O	O
induced	O	O
hepatic	B-Disease	D017093
failure	I-Disease	D017093
necessitating	O	O
liver	O	O
transplantation	O	O
.	O	O

Abstract	O	O
Serum	O	O
aminotransferase	O	O
elevations	O	O
are	O	O
a	O	O
commonly	O	O
known	O	O
adverse	O	O
effect	O	O
of	O	O
3	O	O
-	O	O
hydroxy	O	O
-	O	O
3	O	O
-	O	O
methylglutaryl	O	O
coenzyme	O	O
A	O	O
reductase	O	O
inhibitor	O	O
(	O	O
statin	B-Chemical	D019821
)	O	O
therapy	O	O
.	O	O

However	O	O
,	O	O
hepatotoxic	B-Disease	D056486
events	O	O
have	O	O
not	O	O
been	O	O
widely	O	O
published	O	O
with	O	O
ezetimibe	B-Chemical	C108606
or	O	O
the	O	O
combination	O	O
agent	O	O
simvastatin	B-Chemical	C492458
-	I-Chemical	C492458
ezetimibe	I-Chemical	C492458
.	O	O

We	O	O
describe	O	O
a	O	O
70	O	O
-	O	O
year	O	O
-	O	O
old	O	O
Hispanic	O	O
woman	O	O
who	O	O
developed	O	O
fulminant	B-Disease	D017114
hepatic	I-Disease	D017114
failure	I-Disease	D017114
necessitating	O	O
liver	O	O
transplantation	O	O
10	O	O
weeks	O	O
after	O	O
conversion	O	O
from	O	O
simvastatin	B-Chemical	D019821
40	O	O
mg	O	O
/	O	O
day	O	O
to	O	O
simvastatin	B-Chemical	D019821
10	O	O
mg	O	O
-	O	O
ezetimibe	B-Chemical	C108606
40	O	O
mg	O	O
/	O	O
day	O	O
.	O	O

The	O	O
patient's	O	O
lipid	O	O
panel	O	O
had	O	O
been	O	O
maintained	O	O
with	O	O
simvastatin	B-Chemical	D019821
for	O	O
18	O	O
months	O	O
before	O	O
the	O	O
conversion	O	O
without	O	O
evidence	O	O
of	O	O
hepatotoxicity	B-Disease	D056486
.	O	O

A	O	O
routine	O	O
laboratory	O	O
work	O	O
-	O	O
up	O	O
10	O	O
weeks	O	O
after	O	O
conversion	O	O
revealed	O	O
elevated	O	O
serum	O	O
aminotransferase	O	O
levels	O	O
.	O	O

Simvastatinezetimibe	B-Chemical	C492458
and	O	O
escitalopram	B-Chemical	D015283
(	O	O
which	O	O
she	O	O
was	O	O
taking	O	O
for	O	O
depression	B-Disease	D003866
)	O	O
were	O	O
discontinued	O	O
,	O	O
and	O	O
other	O	O
potential	O	O
causes	O	O
of	O	O
hepatotoxicity	B-Disease	D056486
were	O	O
excluded	O	O
.	O	O

A	O	O
repeat	O	O
work	O	O
-	O	O
up	O	O
revealed	O	O
further	O	O
elevations	O	O
in	O	O
aminotransferase	O	O
levels	O	O
,	O	O
and	O	O
liver	O	O
biopsy	O	O
revealed	O	O
evidence	O	O
of	O	O
moderate	O	O
-	O	O
to	O	O
-	O	O
severe	O	O
drug	B-Disease	D064420
toxicity	I-Disease	D064420
.	O	O

She	O	O
underwent	O	O
liver	O	O
transplantation	O	O
with	O	O
an	O	O
uneventful	O	O
postoperative	O	O
course	O	O
.	O	O

Her	O	O
aminotransferase	O	O
levels	O	O
returned	O	O
to	O	O
normal	O	O
by	O	O
postoperative	O	O
day	O	O
23	O	O
,	O	O
and	O	O
her	O	O
2	O	O
-	O	O
year	O	O
follow	O	O
-	O	O
up	O	O
showed	O	O
no	O	O
adverse	O	O
events	O	O
.	O	O

Ezetimibe	B-Chemical	C108606
undergoes	O	O
extensive	O	O
glucuronidation	O	O
by	O	O
uridine	B-Chemical	D014530
diphosphate	I-Chemical	D014530
glucoronosyltransferases	O	O
(	O	O
UGT	O	O
)	O	O
in	O	O
the	O	O
intestine	O	O
and	O	O
liver	O	O
and	O	O
may	O	O
have	O	O
inhibited	O	O
the	O	O
glucuronidation	O	O
of	O	O
simvastatin	B-Chemical	D019821
hydroxy	O	O
acid	O	O
,	O	O
resulting	O	O
in	O	O
increased	O	O
simvastatin	B-Chemical	D019821
exposure	O	O
and	O	O
subsequent	O	O
hepatotoxicity	B-Disease	D056486
.	O	O

To	O	O
our	O	O
knowledge	O	O
,	O	O
this	O	O
is	O	O
the	O	O
first	O	O
case	O	O
report	O	O
of	O	O
simvastatin	B-Chemical	C492458
-	I-Chemical	C492458
ezetimibe	I-Chemical	C492458
-	O	O
induced	O	O
liver	B-Disease	D017093
failure	I-Disease	D017093
that	O	O
resulted	O	O
in	O	O
liver	O	O
transplantation	O	O
.	O	O

We	O	O
postulate	O	O
that	O	O
the	O	O
mechanism	O	O
of	O	O
the	O	O
simvastatinezetimibe	B-Chemical	C492458
-	O	O
induced	O	O
hepatotoxicity	B-Disease	D056486
is	O	O
the	O	O
increased	O	O
simvastatin	B-Chemical	D019821
exposure	O	O
by	O	O
ezetimibe	B-Chemical	C108606
inhibition	O	O
of	O	O
UGT	O	O
enzymes	O	O
.	O	O

Clinicians	O	O
should	O	O
be	O	O
aware	O	O
of	O	O
potential	O	O
hepatotoxicity	B-Disease	D056486
with	O	O
simvastatin	B-Chemical	C492458
-	I-Chemical	C492458
ezetimibe	I-Chemical	C492458
especially	O	O
in	O	O
elderly	O	O
patients	O	O
and	O	O
should	O	O
carefully	O	O
monitor	O	O
serum	O	O
aminotransferase	O	O
levels	O	O
when	O	O
starting	O	O
therapy	O	O
and	O	O
titrating	O	O
the	O	O
dosage	O	O
.	O	O

Oral	O	O
manifestations	O	O
of	O	O
"meth	O	O
mouth"	O	O
:	O	O
a	O	O
case	O	O
report	O	O
.	O	O

AIM	O	O
:	O	O
The	O	O
aim	O	O
of	O	O
the	O	O
documentation	O	O
of	O	O
this	O	O
clinical	O	O
case	O	O
is	O	O
to	O	O
make	O	O
clinicians	O	O
aware	O	O
of	O	O
"meth	O	O
mouth"	O	O
and	O	O
the	O	O
medical	O	O
risks	O	O
associated	O	O
with	O	O
this	O	O
serious	O	O
condition	O	O
.	O	O

BACKGROUND	O	O
:	O	O
Methamphetamine	B-Chemical	D008694
is	O	O
a	O	O
very	O	O
addictive	O	O
,	O	O
powerful	O	O
stimulant	O	O
that	O	O
increases	O	O
wakefulness	O	O
and	O	O
physical	O	O
activity	O	O
and	O	O
can	O	O
produce	O	O
other	O	O
effects	O	O
such	O	O
as	O	O
cardiac	B-Disease	D001145
dysrhythmias	I-Disease	D001145
,	O	O
hypertension	B-Disease	D006973
,	O	O
hallucinations	B-Disease	D006212
,	O	O
and	O	O
violent	B-Disease	D001523
behavior	I-Disease	D001523
.	O	O

Dental	O	O
patients	O	O
abusing	O	O
methamphetamine	B-Chemical	D008694
can	O	O
present	O	O
with	O	O
poor	O	O
oral	O	O
hygiene	O	O
,	O	O
xerostomia	B-Disease	D014987
,	O	O
rampant	O	O
caries	B-Disease	D003731
(	O	O
"meth	O	O
mouth"	O	O
)	O	O
,	O	O
and	O	O
excessive	O	O
tooth	B-Disease	D057085
wear	I-Disease	D057085
.	O	O

Oral	O	O
rehabilitation	O	O
of	O	O
patients	O	O
using	O	O
methamphetamine	B-Chemical	D008694
can	O	O
be	O	O
challenging	O	O
.	O	O

CASE	O	O
DESCRIPTION	O	O
:	O	O
A	O	O
30	O	O
-	O	O
year	O	O
-	O	O
old	O	O
Caucasian	O	O
woman	O	O
presented	O	O
with	O	O
dental	O	O
pain	B-Disease	D010146
,	O	O
bad	B-Disease	D012120
breath	I-Disease	D012120
,	O	O
and	O	O
self	O	O
-	O	O
reported	O	O
poor	O	O
esthetics	O	O
.	O	O

A	O	O
comprehensive	O	O
examination	O	O
including	O	O
her	O	O
medical	O	O
history	O	O
,	O	O
panoramic	O	O
radiograph	O	O
,	O	O
and	O	O
intraoral	O	O
examination	O	O
revealed	O	O
19	O	O
carious	B-Disease	D003731
lesions	I-Disease	D003731
,	O	O
which	O	O
is	O	O
not	O	O
very	O	O
common	O	O
for	O	O
a	O	O
healthy	O	O
adult	O	O
.	O	O

She	O	O
reported	O	O
her	O	O
use	O	O
of	O	O
methamphetamine	B-Chemical	D008694
for	O	O
five	O	O
years	O	O
and	O	O
had	O	O
not	O	O
experienced	O	O
any	O	O
major	O	O
carious	B-Disease	D003731
episodes	I-Disease	D003731
before	O	O
she	O	O
started	O	O
using	O	O
the	O	O
drug	O	O
.	O	O

SUMMARY	O	O
:	O	O
The	O	O
patient's	O	O
medical	O	O
and	O	O
dental	O	O
histories	O	O
along	O	O
with	O	O
radiographic	O	O
and	O	O
clinical	O	O
findings	O	O
lead	O	O
to	O	O
a	O	O
diagnosis	O	O
of	O	O
"meth	O	O
mouth	O	O
.	O	O

"	O	O
Although	O	O
three	O	O
different	O	O
dental	O	O
treatment	O	O
modalities	O	O
(	O	O
either	O	O
conventional	O	O
or	O	O
implant	O	O
-	O	O
supported	O	O
)	O	O
have	O	O
been	O	O
offered	O	O
to	O	O
the	O	O
patient	O	O
since	O	O
August	O	O
2007	O	O
,	O	O
the	O	O
patient	O	O
has	O	O
yet	O	O
to	O	O
initiate	O	O
any	O	O
treatment	O	O
.	O	O

CLINICAL	O	O
SIGNIFICANCE	O	O
:	O	O
This	O	O
clinical	O	O
case	O	O
showing	O	O
oral	O	O
manifestations	O	O
of	O	O
meth	B-Disease	-1
mouth	I-Disease	-1
was	O	O
presented	O	O
to	O	O
help	O	O
dental	O	O
practitioners	O	O
recognize	O	O
and	O	O
manage	O	O
patients	O	O
who	O	O
may	O	O
be	O	O
abusing	O	O
methamphetamines	B-Chemical	D008694
.	O	O

Dental	O	O
practitioners	O	O
also	O	O
may	O	O
be	O	O
skeptical	O	O
about	O	O
the	O	O
reliability	O	O
of	O	O
appointment	O	O
keeping	O	O
by	O	O
these	O	O
patients	O	O
,	O	O
as	O	O
they	O	O
frequently	O	O
miss	O	O
their	O	O
appointments	O	O
without	O	O
reasonable	O	O
justification	O	O
.	O	O

Thyroxine	B-Chemical	D013974
abuse	O	O
:	O	O
an	O	O
unusual	O	O
case	O	O
of	O	O
thyrotoxicosis	B-Disease	D013971
in	O	O
pregnancy	O	O
.	O	O

Eating	B-Disease	D001068
disorders	I-Disease	D001068
and	O	O
the	O	O
associated	O	O
behavioural	O	O
problems	O	O
and	O	O
drug	B-Disease	D019966
abuse	I-Disease	D019966
are	O	O
uncommon	O	O
in	O	O
pregnancy	O	O
.	O	O

When	O	O
they	O	O
do	O	O
occur	O	O
they	O	O
are	O	O
often	O	O
unrecognized	O	O
because	O	O
of	O	O
denial	O	O
but	O	O
when	O	O
significant	O	O
may	O	O
pose	O	O
a	O	O
risk	O	O
to	O	O
both	O	O
the	O	O
mother	O	O
and	O	O
her	O	O
fetus	O	O
.	O	O

This	O	O
case	O	O
illustrates	O	O
a	O	O
number	O	O
of	O	O
problems	O	O
that	O	O
may	O	O
be	O	O
encountered	O	O
in	O	O
women	O	O
with	O	O
eating	B-Disease	D001068
disorders	I-Disease	D001068
in	O	O
pregnancy	O	O
,	O	O
including	O	O
prolonged	O	O
and	O	O
recurrent	O	O
metabolic	O	O
disturbances	O	O
and	O	O
diuretic	O	O
abuse	O	O
.	O	O

In	O	O
particular	O	O
it	O	O
illustrates	O	O
the	O	O
derangements	O	O
of	O	O
thyroid	O	O
function	O	O
seen	O	O
in	O	O
pregnant	O	O
women	O	O
with	O	O
eating	B-Disease	D001068
disorders	I-Disease	D001068
and	O	O
reminds	O	O
us	O	O
that	O	O
when	O	O
a	O	O
cause	O	O
for	O	O
thyrotoxicosis	B-Disease	D013971
remains	O	O
obscure	O	O
,	O	O
thyroxine	B-Chemical	D013974
abuse	O	O
should	O	O
be	O	O
considered	O	O
and	O	O
explored	O	O
.	O	O

Attenuation	O	O
of	O	O
methamphetamine	B-Chemical	D008694
-	O	O
induced	O	O
nigrostriatal	O	O
dopaminergic	O	O
neurotoxicity	B-Disease	D020258
in	O	O
mice	O	O
by	O	O
lipopolysaccharide	B-Chemical	D008070
pretreatment	O	O
.	O	O

Immunological	O	O
activation	O	O
has	O	O
been	O	O
proposed	O	O
to	O	O
play	O	O
a	O	O
role	O	O
in	O	O
methamphetamine	B-Chemical	D008694
-	O	O
induced	O	O
dopaminergic	B-Disease	D009422
terminal	I-Disease	D009422
damage	I-Disease	D009422
.	O	O

In	O	O
this	O	O
study	O	O
,	O	O
we	O	O
examined	O	O
the	O	O
roles	O	O
of	O	O
lipopolysaccharide	B-Chemical	D008070
,	O	O
a	O	O
pro	O	O
-	O	O
inflammatory	O	O
and	O	O
inflammatory	O	O
factor	O	O
,	O	O
treatment	O	O
in	O	O
modulating	O	O
the	O	O
methamphetamine	B-Chemical	D008694
-	O	O
induced	O	O
nigrostriatal	O	O
dopamine	B-Chemical	D004298
neurotoxicity	B-Disease	D020258
.	O	O

Lipopolysaccharide	B-Chemical	D008070
pretreatment	O	O
did	O	O
not	O	O
affect	O	O
the	O	O
basal	O	O
body	O	O
temperature	O	O
or	O	O
methamphetamine	B-Chemical	D008694
-	O	O
elicited	O	O
hyperthermia	B-Disease	D005334
three	O	O
days	O	O
later	O	O
.	O	O

Such	O	O
systemic	O	O
lipopolysaccharide	B-Chemical	D008070
treatment	O	O
mitigated	O	O
methamphetamine	B-Chemical	D008694
-	O	O
induced	O	O
striatal	O	O
dopamine	B-Chemical	D004298
and	O	O
3	B-Chemical	D015102
,	I-Chemical	D015102
4	I-Chemical	D015102
-	I-Chemical	D015102
dihydroxyphenylacetic	I-Chemical	D015102
acid	I-Chemical	D015102
depletions	O	O
in	O	O
a	O	O
dose	O	O
-	O	O
dependent	O	O
manner	O	O
.	O	O

As	O	O
the	O	O
most	O	O
potent	O	O
dose	O	O
(	O	O
1	O	O
mg	O	O
/	O	O
kg	O	O
)	O	O
of	O	O
lipopolysaccharide	B-Chemical	D008070
was	O	O
administered	O	O
two	O	O
weeks	O	O
,	O	O
one	O	O
day	O	O
before	O	O
or	O	O
after	O	O
the	O	O
methamphetamine	B-Chemical	D008694
dosing	O	O
regimen	O	O
,	O	O
methamphetamine	B-Chemical	D008694
-	O	O
induced	O	O
striatal	O	O
dopamine	B-Chemical	D004298
and	O	O
3	B-Chemical	D015102
,	I-Chemical	D015102
4	I-Chemical	D015102
-	I-Chemical	D015102
dihydroxyphenylacetic	I-Chemical	D015102
acid	I-Chemical	D015102
depletions	O	O
remained	O	O
unaltered	O	O
.	O	O

Moreover	O	O
,	O	O
systemic	O	O
lipopolysaccharide	B-Chemical	D008070
pretreatment	O	O
(	O	O
1	O	O
mg	O	O
/	O	O
kg	O	O
)	O	O
attenuated	O	O
local	O	O
methamphetamine	B-Chemical	D008694
infusion	O	O
-	O	O
produced	O	O
dopamine	B-Chemical	D004298
and	O	O
3	B-Chemical	D015102
,	I-Chemical	D015102
4	I-Chemical	D015102
-	I-Chemical	D015102
dihydroxyphenylacetic	I-Chemical	D015102
acid	I-Chemical	D015102
depletions	O	O
in	O	O
the	O	O
striatum	O	O
,	O	O
indicating	O	O
that	O	O
the	O	O
protective	O	O
effect	O	O
of	O	O
lipopolysaccharide	B-Chemical	D008070
is	O	O
less	O	O
likely	O	O
due	O	O
to	O	O
interrupted	O	O
peripheral	O	O
distribution	O	O
or	O	O
metabolism	O	O
of	O	O
methamphetamine	B-Chemical	D008694
.	O	O

We	O	O
concluded	O	O
a	O	O
critical	O	O
time	O	O
window	O	O
for	O	O
systemic	O	O
lipopolysaccharide	B-Chemical	D008070
pretreatment	O	O
in	O	O
exerting	O	O
effective	O	O
protection	O	O
against	O	O
methamphetamine	B-Chemical	D008694
-	O	O
induced	O	O
nigrostriatal	O	O
dopamine	B-Chemical	D004298
neurotoxicity	B-Disease	D020258
.	O	O

Effect	O	O
of	O	O
converting	O	O
enzyme	O	O
inhibition	O	O
on	O	O
the	O	O
course	O	O
of	O	O
adriamycin	B-Chemical	D004317
-	O	O
induced	O	O
nephropathy	B-Disease	D007674
.	O	O

The	O	O
effect	O	O
of	O	O
the	O	O
converting	O	O
enzyme	O	O
inhibitor	O	O
(	O	O
CEI	O	O
)	O	O
enalapril	B-Chemical	D004656
was	O	O
assessed	O	O
in	O	O
Munich	O	O
-	O	O
Wistar	O	O
rats	O	O
with	O	O
established	O	O
adriamycin	B-Chemical	D004317
nephrosis	B-Disease	D009401
.	O	O

Rats	O	O
were	O	O
given	O	O
a	O	O
single	O	O
dose	O	O
of	O	O
adriamycin	B-Chemical	D004317
and	O	O
one	O	O
month	O	O
later	O	O
divided	O	O
into	O	O
four	O	O
groups	O	O
matched	O	O
for	O	O
albuminuria	B-Disease	D000419
,	O	O
blood	O	O
pressure	O	O
,	O	O
and	O	O
plasma	O	O
albumin	O	O
concentration	O	O
.	O	O

Groups	O	O
1	O	O
and	O	O
3	O	O
remained	O	O
untreated	O	O
while	O	O
groups	O	O
2	O	O
and	O	O
4	O	O
received	O	O
enalapril	B-Chemical	D004656
.	O	O

Groups	O	O
1	O	O
and	O	O
2	O	O
underwent	O	O
micropuncture	O	O
studies	O	O
after	O	O
10	O	O
days	O	O
.	O	O

These	O	O
short	O	O
-	O	O
term	O	O
studies	O	O
showed	O	O
that	O	O
enalapril	B-Chemical	D004656
reduced	O	O
arterial	O	O
blood	O	O
pressure	O	O
(	O	O
101	O	O
+	O	O
/	O	O
-	O	O
2	O	O
vs	O	O
.	O	O

124	O	O
+	O	O
/	O	O
-	O	O
3	O	O
mm	O	O
Hg	O	O
,	O	O
group	O	O
2	O	O
vs	O	O
.	O	O

1	O	O
,	O	O
P	O	O
less	O	O
than	O	O
0	O	O
.	O	O

05	O	O
)	O	O
and	O	O
glomerular	O	O
capillary	O	O
pressure	O	O
(	O	O
54	O	O
+	O	O
/	O	O
-	O	O
1	O	O
vs	O	O
.	O	O

61	O	O
+	O	O
/	O	O
-	O	O
2	O	O
mm	O	O
Hg	O	O
,	O	O
P	O	O
less	O	O
than	O	O
0	O	O
.	O	O

05	O	O
)	O	O
without	O	O
reducing	O	O
albuminuria	B-Disease	D000419
(	O	O
617	O	O
+	O	O
/	O	O
-	O	O
50	O	O
vs	O	O
.	O	O

570	O	O
+	O	O
/	O	O
-	O	O
47	O	O
mg	O	O
/	O	O
day	O	O
)	O	O
or	O	O
GFR	O	O
(	O	O
1	O	O
.	O	O

03	O	O
+	O	O
/	O	O
-	O	O
0	O	O
.	O	O

04	O	O
vs	O	O
.	O	O

1	O	O
.	O	O

04	O	O
+	O	O
/	O	O
-	O	O
0	O	O
.	O	O

11	O	O
ml	O	O
/	O	O
min	O	O
)	O	O
.	O	O

Groups	O	O
3	O	O
and	O	O
4	O	O
were	O	O
studied	O	O
at	O	O
four	O	O
and	O	O
at	O	O
six	O	O
months	O	O
to	O	O
assess	O	O
the	O	O
effect	O	O
of	O	O
enalapril	B-Chemical	D004656
on	O	O
progression	O	O
of	O	O
renal	B-Disease	D007674
injury	I-Disease	D007674
in	O	O
adriamycin	B-Chemical	D004317
nephrosis	B-Disease	D009401
.	O	O

Chronic	O	O
enalapril	B-Chemical	D004656
treatment	O	O
reduced	O	O
blood	O	O
pressure	O	O
without	O	O
reducing	O	O
albuminuria	B-Disease	D000419
in	O	O
group	O	O
4	O	O
.	O	O

Untreated	O	O
group	O	O
3	O	O
rats	O	O
exhibited	O	O
a	O	O
progressive	O	O
reduction	O	O
in	O	O
GFR	O	O
(	O	O
0	O	O
.	O	O

35	O	O
+	O	O
/	O	O
-	O	O
0	O	O
.	O	O

08	O	O
ml	O	O
/	O	O
min	O	O
at	O	O
4	O	O
months	O	O
,	O	O
0	O	O
.	O	O

27	O	O
+	O	O
/	O	O
-	O	O
0	O	O
.	O	O

07	O	O
ml	O	O
/	O	O
min	O	O
at	O	O
6	O	O
months	O	O
)	O	O
.	O	O

Enalapril	B-Chemical	D004656
treatment	O	O
blunted	O	O
but	O	O
did	O	O
not	O	O
prevent	O	O
reduction	O	O
in	O	O
GFR	O	O
in	O	O
group	O	O
4	O	O
(	O	O
0	O	O
.	O	O

86	O	O
+	O	O
/	O	O
-	O	O
0	O	O
.	O	O

15	O	O
ml	O	O
/	O	O
min	O	O
at	O	O
4	O	O
months	O	O
,	O	O
0	O	O
.	O	O

69	O	O
+	O	O
/	O	O
-	O	O
0	O	O
.	O	O

13	O	O
ml	O	O
/	O	O
min	O	O
at	O	O
6	O	O
months	O	O
,	O	O
both	O	O
P	O	O
less	O	O
than	O	O
0	O	O
.	O	O

05	O	O
vs	O	O
.	O	O

group	O	O
3	O	O
)	O	O
.	O	O

Reduction	O	O
in	O	O
GFR	O	O
was	O	O
associated	O	O
with	O	O
the	O	O
development	O	O
of	O	O
glomerular	B-Disease	D007674
sclerosis	I-Disease	D007674
in	O	O
both	O	O
treated	O	O
and	O	O
untreated	O	O
rats	O	O
.	O	O

(	O	O
ABSTRACT	O	O
TRUNCATED	O	O
AT	O	O
250	O	O
WORDS	O	O
)	O	O
Butyrylcholinesterase	O	O
gene	O	O
mutations	O	O
in	O	O
patients	O	O
with	O	O
prolonged	O	O
apnea	B-Disease	D001049
after	O	O
succinylcholine	B-Chemical	D013390
for	O	O
electroconvulsive	O	O
therapy	O	O
.	O	O

BACKGROUND	O	O
:	O	O
patients	O	O
undergoing	O	O
electroconvulsive	O	O
therapy	O	O
(	O	O
ECT	O	O
)	O	O
often	O	O
receive	O	O
succinylcholine	B-Chemical	D013390
as	O	O
part	O	O
of	O	O
the	O	O
anesthetic	O	O
procedure	O	O
.	O	O

The	O	O
duration	O	O
of	O	O
action	O	O
may	O	O
be	O	O
prolonged	O	O
in	O	O
patients	O	O
with	O	O
genetic	O	O
variants	O	O
of	O	O
the	O	O
butyrylcholinesterase	O	O
enzyme	O	O
(	O	O
BChE	O	O
)	O	O
,	O	O
the	O	O
most	O	O
common	O	O
being	O	O
the	O	O
K	O	O
-	O	O
and	O	O
the	O	O
A	O	O
-	O	O
variants	O	O
.	O	O

The	O	O
aim	O	O
of	O	O
the	O	O
study	O	O
was	O	O
to	O	O
assess	O	O
the	O	O
clinical	O	O
significance	O	O
of	O	O
genetic	O	O
variants	O	O
in	O	O
butyrylcholinesterase	O	O
gene	O	O
(	O	O
BCHE	O	O
)	O	O
in	O	O
patients	O	O
with	O	O
a	O	O
suspected	O	O
prolonged	O	O
duration	O	O
of	O	O
action	O	O
of	O	O
succinylcholine	B-Chemical	D013390
after	O	O
ECT	O	O
.	O	O

METHODS	O	O
:	O	O
a	O	O
total	O	O
of	O	O
13	O	O
patients	O	O
were	O	O
referred	O	O
to	O	O
the	O	O
Danish	O	O
Cholinesterase	O	O
Research	O	O
Unit	O	O
after	O	O
ECT	O	O
during	O	O
38	O	O
months	O	O
.	O	O

We	O	O
determined	O	O
the	O	O
BChE	O	O
activity	O	O
and	O	O
the	O	O
BCHE	O	O
genotype	O	O
using	O	O
molecular	O	O
genetic	O	O
methods	O	O
,	O	O
the	O	O
duration	O	O
of	O	O
apnea	B-Disease	D001049
,	O	O
time	O	O
to	O	O
sufficient	O	O
spontaneous	O	O
ventilation	O	O
and	O	O
whether	O	O
neuromuscular	O	O
monitoring	O	O
was	O	O
used	O	O
.	O	O

The	O	O
duration	O	O
of	O	O
apnea	B-Disease	D001049
was	O	O
compared	O	O
with	O	O
published	O	O
data	O	O
on	O	O
normal	O	O
subjects	O	O
.	O	O

RESULTS	O	O
:	O	O
in	O	O
11	O	O
patients	O	O
,	O	O
mutations	O	O
were	O	O
found	O	O
in	O	O
the	O	O
BCHE	O	O
gene	O	O
,	O	O
the	O	O
K	O	O
-	O	O
variant	O	O
being	O	O
the	O	O
most	O	O
frequent	O	O
.	O	O

The	O	O
duration	O	O
of	O	O
apnea	B-Disease	D001049
was	O	O
5	O	O
-	O	O
15	O	O
min	O	O
compared	O	O
with	O	O
3	O	O
-	O	O
5	O	O
.	O	O

3	O	O
min	O	O
from	O	O
the	O	O
literature	O	O
.	O	O

Severe	O	O
distress	O	O
was	O	O
noted	O	O
in	O	O
the	O	O
recovery	O	O
phase	O	O
in	O	O
two	O	O
patients	O	O
.	O	O

Neuromuscular	O	O
monitoring	O	O
was	O	O
used	O	O
in	O	O
two	O	O
patients	O	O
.	O	O

CONCLUSION	O	O
:	O	O
eleven	O	O
of	O	O
13	O	O
patients	O	O
with	O	O
a	O	O
prolonged	O	O
duration	O	O
of	O	O
action	O	O
of	O	O
succinylcholine	B-Chemical	D013390
had	O	O
mutations	O	O
in	O	O
BCHE	O	O
,	O	O
indicating	O	O
that	O	O
this	O	O
is	O	O
the	O	O
possible	O	O
reason	O	O
for	O	O
a	O	O
prolonged	O	O
period	O	O
of	O	O
apnea	B-Disease	D001049
.	O	O

We	O	O
recommend	O	O
objective	O	O
neuromuscular	O	O
monitoring	O	O
during	O	O
the	O	O
first	O	O
ECT	O	O
.	O	O

Ketamine	B-Chemical	D007649
sedation	O	O
for	O	O
the	O	O
reduction	O	O
of	O	O
children's	O	O
fractures	B-Disease	D050723
in	O	O
the	O	O
emergency	O	O
department	O	O
.	O	O

BACKGROUND	O	O
:	O	O
There	O	O
recently	O	O
has	O	O
been	O	O
a	O	O
resurgence	O	O
in	O	O
the	O	O
utilization	O	O
of	O	O
ketamine	B-Chemical	D007649
,	O	O
a	O	O
unique	O	O
anesthetic	O	O
,	O	O
for	O	O
emergency	O	O
-	O	O
department	O	O
procedures	O	O
requiring	O	O
sedation	O	O
.	O	O

The	O	O
purpose	O	O
of	O	O
the	O	O
present	O	O
study	O	O
was	O	O
to	O	O
examine	O	O
the	O	O
safety	O	O
and	O	O
efficacy	O	O
of	O	O
ketamine	B-Chemical	D007649
for	O	O
sedation	O	O
in	O	O
the	O	O
treatment	O	O
of	O	O
children's	O	O
fractures	B-Disease	D050723
in	O	O
the	O	O
emergency	O	O
department	O	O
.	O	O

METHODS	O	O
:	O	O
One	O	O
hundred	O	O
and	O	O
fourteen	O	O
children	O	O
(	O	O
average	O	O
age	O	O
,	O	O
5	O	O
.	O	O

3	O	O
years	O	O
;	O	O
range	O	O
,	O	O
twelve	O	O
months	O	O
to	O	O
ten	O	O
years	O	O
and	O	O
ten	O	O
months	O	O
)	O	O
who	O	O
underwent	O	O
closed	O	O
reduction	O	O
of	O	O
an	O	O
isolated	O	O
fracture	B-Disease	D050723
or	O	O
dislocation	B-Disease	D004204
in	O	O
the	O	O
emergency	O	O
department	O	O
at	O	O
a	O	O
level	O	O
-	O	O
I	O	O
trauma	B-Disease	D014947
center	O	O
were	O	O
prospectively	O	O
evaluated	O	O
.	O	O

Ketamine	B-Chemical	D007649
hydrochloride	O	O
was	O	O
administered	O	O
intravenously	O	O
(	O	O
at	O	O
a	O	O
dose	O	O
of	O	O
two	O	O
milligrams	O	O
per	O	O
kilogram	O	O
of	O	O
body	O	O
weight	O	O
)	O	O
in	O	O
ninety	O	O
-	O	O
nine	O	O
of	O	O
the	O	O
patients	O	O
and	O	O
intramuscularly	O	O
(	O	O
at	O	O
a	O	O
dose	O	O
of	O	O
four	O	O
milligrams	O	O
per	O	O
kilogram	O	O
of	O	O
body	O	O
weight	O	O
)	O	O
in	O	O
the	O	O
other	O	O
fifteen	O	O
.	O	O

A	O	O
board	O	O
-	O	O
certified	O	O
emergency	O	O
physician	O	O
skilled	O	O
in	O	O
airway	O	O
management	O	O
supervised	O	O
administration	O	O
of	O	O
the	O	O
anesthetic	O	O
,	O	O
and	O	O
the	O	O
patients	O	O
were	O	O
monitored	O	O
by	O	O
a	O	O
registered	O	O
nurse	O	O
.	O	O

Any	O	O
pain	B-Disease	D010146
during	O	O
the	O	O
reduction	O	O
was	O	O
rated	O	O
by	O	O
the	O	O
orthopaedic	O	O
surgeon	O	O
treating	O	O
the	O	O
patient	O	O
according	O	O
to	O	O
the	O	O
Children's	O	O
Hospital	O	O
of	O	O
Eastern	O	O
Ontario	O	O
Pain	B-Disease	D010146
Scale	O	O
(	O	O
CHEOPS	O	O
)	O	O
.	O	O

RESULTS	O	O
:	O	O
The	O	O
average	O	O
time	O	O
from	O	O
intravenous	O	O
administration	O	O
of	O	O
ketamine	B-Chemical	D007649
to	O	O
manipulation	O	O
of	O	O
the	O	O
fracture	B-Disease	D050723
or	O	O
dislocation	B-Disease	D004204
was	O	O
one	O	O
minute	O	O
and	O	O
thirty	O	O
-	O	O
six	O	O
seconds	O	O
(	O	O
range	O	O
,	O	O
twenty	O	O
seconds	O	O
to	O	O
five	O	O
minutes	O	O
)	O	O
,	O	O
and	O	O
the	O	O
average	O	O
time	O	O
from	O	O
intramuscular	O	O
administration	O	O
to	O	O
manipulation	O	O
was	O	O
four	O	O
minutes	O	O
and	O	O
forty	O	O
-	O	O
two	O	O
seconds	O	O
(	O	O
range	O	O
,	O	O
sixty	O	O
seconds	O	O
to	O	O
fifteen	O	O
minutes	O	O
)	O	O
.	O	O

The	O	O
average	O	O
score	O	O
according	O	O
to	O	O
the	O	O
Children's	O	O
Hospital	O	O
of	O	O
Eastern	O	O
Ontario	O	O
Pain	B-Disease	D010146
Scale	O	O
was	O	O
6	O	O
.	O	O

4	O	O
points	O	O
(	O	O
range	O	O
,	O	O
5	O	O
to	O	O
10	O	O
points	O	O
)	O	O
,	O	O
reflecting	O	O
minimal	O	O
or	O	O
no	O	O
pain	B-Disease	D010146
during	O	O
fracture	B-Disease	D050723
reduction	O	O
.	O	O

Adequate	O	O
fracture	B-Disease	D050723
reduction	O	O
was	O	O
obtained	O	O
in	O	O
111	O	O
of	O	O
the	O	O
children	O	O
.	O	O

Ninety	O	O
-	O	O
nine	O	O
percent	O	O
(	O	O
sixty	O	O
-	O	O
eight	O	O
)	O	O
of	O	O
the	O	O
sixty	O	O
-	O	O
nine	O	O
parents	O	O
present	O	O
during	O	O
the	O	O
reduction	O	O
were	O	O
pleased	O	O
with	O	O
the	O	O
sedation	O	O
and	O	O
would	O	O
allow	O	O
it	O	O
to	O	O
be	O	O
used	O	O
again	O	O
in	O	O
a	O	O
similar	O	O
situation	O	O
.	O	O

Patency	O	O
of	O	O
the	O	O
airway	O	O
and	O	O
independent	O	O
respiration	O	O
were	O	O
maintained	O	O
in	O	O
all	O	O
of	O	O
the	O	O
patients	O	O
.	O	O

Blood	O	O
pressure	O	O
and	O	O
heart	O	O
rate	O	O
remained	O	O
stable	O	O
.	O	O

Minor	O	O
side	O	O
effects	O	O
included	O	O
nausea	B-Disease	D009325
(	O	O
thirteen	O	O
patients	O	O
)	O	O
,	O	O
emesis	B-Disease	D014839
(	O	O
eight	O	O
of	O	O
the	O	O
thirteen	O	O
patients	O	O
with	O	O
nausea	B-Disease	D009325
)	O	O
,	O	O
clumsiness	B-Disease	D001259
(	O	O
evident	O	O
as	O	O
ataxic	B-Disease	D001259
movements	I-Disease	D001259
in	O	O
ten	O	O
patients	O	O
)	O	O
,	O	O
and	O	O
dysphoric	B-Disease	-1
reaction	I-Disease	-1
(	O	O
one	O	O
patient	O	O
)	O	O
.	O	O

No	O	O
long	O	O
-	O	O
term	O	O
sequelae	O	O
were	O	O
noted	O	O
,	O	O
and	O	O
no	O	O
patients	O	O
had	O	O
hallucinations	B-Disease	D006212
or	O	O
nightmares	O	O
.	O	O

CONCLUSIONS	O	O
:	O	O
Ketamine	B-Chemical	D007649
reliably	O	O
,	O	O
safely	O	O
,	O	O
and	O	O
quickly	O	O
provided	O	O
adequate	O	O
sedation	O	O
to	O	O
effectively	O	O
facilitate	O	O
the	O	O
reduction	O	O
of	O	O
children's	O	O
fractures	B-Disease	D050723
in	O	O
the	O	O
emergency	O	O
department	O	O
at	O	O
our	O	O
institution	O	O
.	O	O

Ketamine	B-Chemical	D007649
should	O	O
only	O	O
be	O	O
used	O	O
in	O	O
an	O	O
environment	O	O
such	O	O
as	O	O
the	O	O
emergency	O	O
department	O	O
,	O	O
where	O	O
proper	O	O
one	O	O
-	O	O
on	O	O
-	O	O
one	O	O
monitoring	O	O
is	O	O
used	O	O
and	O	O
board	O	O
-	O	O
certified	O	O
physicians	O	O
skilled	O	O
in	O	O
airway	O	O
management	O	O
are	O	O
directly	O	O
involved	O	O
in	O	O
the	O	O
care	O	O
of	O	O
the	O	O
patient	O	O
.	O	O

Prophylactic	O	O
use	O	O
of	O	O
lamivudine	B-Chemical	D019259
with	O	O
chronic	O	O
immunosuppressive	O	O
therapy	O	O
for	O	O
rheumatologic	B-Disease	D012216
disorders	I-Disease	D012216
.	O	O

The	O	O
objective	O	O
of	O	O
this	O	O
study	O	O
was	O	O
to	O	O
report	O	O
our	O	O
experience	O	O
concerning	O	O
the	O	O
effectiveness	O	O
of	O	O
the	O	O
prophylactic	O	O
administration	O	O
of	O	O
lamivudine	B-Chemical	D019259
in	O	O
hepatitis	B-Chemical	D006514
B	I-Chemical	D006514
virus	I-Chemical	D006514
surface	I-Chemical	D006514
antigen	I-Chemical	D006514
(	O	O
HBs	B-Chemical	D006514
Ag	I-Chemical	D006514
)	O	O
positive	O	O
patients	O	O
with	O	O
rheumatologic	B-Disease	D012216
disease	I-Disease	D012216
.	O	O

From	O	O
June	O	O
2004	O	O
to	O	O
October	O	O
2006	O	O
,	O	O
11	O	O
HBs	B-Chemical	D006514
Ag	I-Chemical	D006514
positive	O	O
patients	O	O
with	O	O
rheumatologic	B-Disease	D012216
diseases	I-Disease	D012216
,	O	O
who	O	O
were	O	O
on	O	O
both	O	O
immunosuppressive	O	O
and	O	O
prophylactic	O	O
lamivudine	B-Chemical	D019259
therapies	O	O
,	O	O
were	O	O
retrospectively	O	O
assessed	O	O
.	O	O

Liver	O	O
function	O	O
tests	O	O
,	O	O
hepatitis	B-Disease	D006509
B	I-Disease	D006509
virus	O	O
(	O	O
HBV	O	O
)	O	O
serologic	O	O
markers	O	O
,	O	O
and	O	O
HBV	O	O
DNA	O	O
levels	O	O
of	O	O
the	O	O
patients	O	O
during	O	O
follow	O	O
-	O	O
up	O	O
were	O	O
obtained	O	O
from	O	O
hospital	O	O
file	O	O
records	O	O
.	O	O

Eleven	O	O
patients	O	O
(	O	O
six	O	O
male	O	O
)	O	O
with	O	O
median	O	O
age	O	O
47	O	O
years	O	O
(	O	O
range	O	O
27	O	O
-	O	O
73	O	O
)	O	O
,	O	O
median	O	O
disease	O	O
duration	O	O
50	O	O
months	O	O
(	O	O
range	O	O
9	O	O
-	O	O
178	O	O
)	O	O
and	O	O
median	O	O
follow	O	O
-	O	O
up	O	O
period	O	O
of	O	O
patients	O	O
13	O	O
.	O	O

8	O	O
months	O	O
(	O	O
range	O	O
5	O	O
-	O	O
27	O	O
)	O	O
were	O	O
enrolled	O	O
in	O	O
this	O	O
study	O	O
.	O	O

Lamivudine	B-Chemical	D019259
therapy	O	O
was	O	O
started	O	O
3	O	O
-	O	O
7	O	O
days	O	O
prior	O	O
to	O	O
immunosuppressive	O	O
therapy	O	O
in	O	O
all	O	O
patients	O	O
.	O	O

Baseline	O	O
,	O	O
liver	O	O
function	O	O
tests	O	O
were	O	O
elevated	O	O
in	O	O
two	O	O
patients	O	O
(	O	O
fourth	O	O
patient	O	O
:	O	O
ALT	O	O
:	O	O
122	O	O
IU	O	O
/	O	O
l	O	O
,	O	O
AST	O	O
:	O	O
111	O	O
IU	O	O
/	O	O
l	O	O
,	O	O
tenth	O	O
patient	O	O
:	O	O
ALT	O	O
:	O	O
294	O	O
IU	O	O
/	O	O
l	O	O
,	O	O
AST	O	O
:	O	O
274	O	O
IU	O	O
/	O	O
l	O	O
,	O	O
with	O	O
minimal	O	O
changes	O	O
in	O	O
the	O	O
liver	O	O
biopsy	O	O
in	O	O
both	O	O
)	O	O
.	O	O

Shortly	O	O
after	O	O
treatment	O	O
their	O	O
tests	O	O
normalized	O	O
and	O	O
during	O	O
follow	O	O
-	O	O
up	O	O
period	O	O
none	O	O
of	O	O
the	O	O
patients	O	O
had	O	O
abnormal	B-Disease	D056486
liver	I-Disease	D056486
function	I-Disease	D056486
tests	O	O
.	O	O

In	O	O
four	O	O
patients	O	O
HBV	O	O
DNA	O	O
levels	O	O
were	O	O
higher	O	O
than	O	O
normal	O	O
at	O	O
baseline	O	O
.	O	O

Two	O	O
of	O	O
these	O	O
normalized	O	O
and	O	O
the	O	O
others	O	O
increased	O	O
later	O	O
.	O	O

In	O	O
three	O	O
additional	O	O
patients	O	O
,	O	O
HBV	O	O
DNA	O	O
levels	O	O
were	O	O
increased	O	O
during	O	O
follow	O	O
-	O	O
up	O	O
.	O	O

None	O	O
of	O	O
the	O	O
patients	O	O
had	O	O
significant	O	O
clinical	O	O
sings	O	O
of	O	O
HBV	O	O
activation	O	O
.	O	O

Lamivudine	B-Chemical	D019259
was	O	O
well	O	O
tolerated	O	O
and	O	O
was	O	O
continued	O	O
in	O	O
all	O	O
patients	O	O
.	O	O

Prophylactic	O	O
administration	O	O
of	O	O
lamivudine	B-Chemical	D019259
in	O	O
patients	O	O
who	O	O
required	O	O
immunosuppressive	O	O
therapy	O	O
seems	O	O
to	O	O
be	O	O
safe	O	O
,	O	O
well	O	O
tolerated	O	O
and	O	O
effective	O	O
in	O	O
preventing	O	O
HBV	O	O
reactivation	O	O
.	O	O

Safety	O	O
of	O	O
transesophageal	O	O
echocardiography	O	O
in	O	O
adults	O	O
:	O	O
study	O	O
in	O	O
a	O	O
multidisciplinary	O	O
hospital	O	O
.	O	O

BACKGROUND	O	O
:	O	O
TEE	O	O
is	O	O
a	O	O
semi	O	O
-	O	O
invasive	O	O
tool	O	O
broadly	O	O
used	O	O
and	O	O
its	O	O
utilization	O	O
associated	O	O
to	O	O
sedatives	O	O
drugs	O	O
might	O	O
to	O	O
affect	O	O
the	O	O
procedure	O	O
safety	O	O
.	O	O

OBJECTIVE	O	O
:	O	O
to	O	O
analyze	O	O
aspects	O	O
of	O	O
TEE	O	O
safety	O	O
associated	O	O
to	O	O
the	O	O
use	O	O
of	O	O
Midazolan	B-Chemical	D008874
(	O	O
MZ	B-Chemical	D008874
)	O	O
and	O	O
Flumazenil	B-Chemical	D005442
(	O	O
FL	B-Chemical	D005442
)	O	O
and	O	O
the	O	O
influence	O	O
of	O	O
the	O	O
clinical	O	O
variables	O	O
on	O	O
the	O	O
event	O	O
rate	O	O
.	O	O

METHOD	O	O
:	O	O
prospective	O	O
study	O	O
with	O	O
137	O	O
patients	O	O
that	O	O
underwent	O	O
TEE	O	O
with	O	O
MZ	B-Chemical	D008874
associated	O	O
to	O	O
moderate	O	O
sedation	O	O
.	O	O

We	O	O
analyzed	O	O
the	O	O
following	O	O
events	O	O
:	O	O
complications	O	O
related	O	O
with	O	O
the	O	O
topical	O	O
anesthesia	O	O
,	O	O
with	O	O
MZ	B-Chemical	D008874
use	O	O
and	O	O
with	O	O
the	O	O
procedure	O	O
.	O	O

Uni	O	O
-	O	O
and	O	O
multivariate	O	O
analyses	O	O
were	O	O
used	O	O
to	O	O
test	O	O
the	O	O
influence	O	O
of	O	O
the	O	O
clinical	O	O
variables	O	O
:	O	O
age	O	O
,	O	O
sex	O	O
,	O	O
stroke	B-Disease	D020521
,	O	O
myocardiopathy	B-Disease	D009202
(	O	O
MP	B-Disease	D009202
)	O	O
,	O	O
duration	O	O
of	O	O
the	O	O
test	O	O
,	O	O
mitral	B-Disease	D008944
regurgitation	I-Disease	D008944
(	O	O
MR	B-Disease	D008944
)	O	O
and	O	O
the	O	O
MZ	B-Chemical	D008874
dose	O	O
.	O	O

RESULTS	O	O
:	O	O
All	O	O
patients	O	O
(	O	O
65+	O	O
/	O	O
-	O	O
16	O	O
yrs	O	O
;	O	O
58%	O	O
males	O	O
)	O	O
finished	O	O
the	O	O
examination	O	O
.	O	O

The	O	O
mean	O	O
doses	O	O
of	O	O
MZ	B-Chemical	D008874
and	O	O
FL	B-Chemical	D005442
were	O	O
4	O	O
.	O	O

3+	O	O
/	O	O
-	O	O
1	O	O
.	O	O

9	O	O
mg	O	O
and	O	O
0	O	O
.	O	O

28+	O	O
/	O	O
-	O	O
0	O	O
.	O	O

2	O	O
mg	O	O
,	O	O
respectively	O	O
.	O	O

The	O	O
duration	O	O
of	O	O
the	O	O
examination	O	O
and	O	O
the	O	O
mean	O	O
ejection	O	O
fraction	O	O
(	O	O
EF	O	O
)	O	O
were	O	O
16	O	O
.	O	O

4+	O	O
/	O	O
-	O	O
6	O	O
.	O	O

1	O	O
minutes	O	O
and	O	O
60+	O	O
/	O	O
-	O	O
9%	O	O
,	O	O
respectively	O	O
.	O	O

Mild	O	O
hypoxia	B-Disease	D000860
(	O	O
SO2<90%	O	O
)	O	O
was	O	O
the	O	O
most	O	O
common	O	O
event	O	O
(	O	O
11	O	O
patients	O	O
)	O	O
;	O	O
3	O	O
patients	O	O
(	O	O
2%	O	O
)	O	O
presented	O	O
transient	O	O
hypoxia	B-Disease	D000860
due	O	O
to	O	O
upper	O	O
airway	B-Disease	D000402
obstruction	I-Disease	D000402
by	O	O
probe	O	O
introduction	O	O
and	O	O
8	O	O
(	O	O
5	O	O
.	O	O

8%	O	O
)	O	O
due	O	O
to	O	O
hypoxia	B-Disease	D000860
caused	O	O
by	O	O
MZ	B-Chemical	D008874
use	O	O
.	O	O

Transient	O	O
hypotension	B-Disease	D007022
(	O	O
SAP<90mmHg	O	O
)	O	O
occurred	O	O
in	O	O
1	O	O
patient	O	O
(	O	O
0	O	O
.	O	O

7%	O	O
)	O	O
.	O	O

The	O	O
multivariate	O	O
analysis	O	O
showed	O	O
that	O	O
severe	O	O
MR	B-Disease	D008944
,	O	O
MP	B-Disease	D009202
(	O	O
EF<45%	O	O
)	O	O
and	O	O
high	O	O
doses	O	O
of	O	O
MZ	B-Chemical	D008874
(	O	O
>5mg	O	O
)	O	O
were	O	O
associated	O	O
with	O	O
events	O	O
(	O	O
p<0	O	O
.	O	O

001	O	O
)	O	O
.	O	O

The	O	O
EF	O	O
was	O	O
40%	O	O
,	O	O
in	O	O
the	O	O
group	O	O
with	O	O
MP	B-Disease	D009202
and	O	O
44%	O	O
in	O	O
the	O	O
group	O	O
with	O	O
severe	O	O
MR	B-Disease	D008944
and	O	O
it	O	O
can	O	O
be	O	O
a	O	O
factor	O	O
associated	O	O
with	O	O
clinical	O	O
events	O	O
in	O	O
the	O	O
last	O	O
group	O	O
.	O	O

CONCLUSION	O	O
:	O	O
TEE	O	O
with	O	O
sedation	O	O
presents	O	O
a	O	O
low	O	O
rate	O	O
of	O	O
events	O	O
.	O	O

There	O	O
were	O	O
no	O	O
severe	O	O
events	O	O
and	O	O
there	O	O
was	O	O
no	O	O
need	O	O
to	O	O
interrupt	O	O
the	O	O
examinations	O	O
.	O	O

Effects	O	O
of	O	O
calcium	B-Chemical	D002118
channel	O	O
blockers	O	O
on	O	O
bupivacaine	B-Chemical	D002045
-	O	O
induced	O	O
toxicity	B-Disease	D064420
.	O	O

The	O	O
purpose	O	O
of	O	O
this	O	O
study	O	O
was	O	O
to	O	O
investigate	O	O
the	O	O
influence	O	O
of	O	O
calcium	B-Chemical	D002118
channel	O	O
blockers	O	O
on	O	O
bupivacaine	B-Chemical	D002045
-	O	O
induced	O	O
acute	O	O
toxicity	B-Disease	D064420
.	O	O

For	O	O
each	O	O
of	O	O
the	O	O
three	O	O
tested	O	O
calcium	B-Chemical	D002118
channel	O	O
blockers	O	O
(	O	O
diltiazem	B-Chemical	D004110
,	O	O
verapamil	B-Chemical	D014700
and	O	O
bepridil	B-Chemical	D015764
)	O	O
6	O	O
groups	O	O
of	O	O
mice	O	O
were	O	O
treated	O	O
by	O	O
two	O	O
different	O	O
doses	O	O
,	O	O
i	O	O
.	O	O

e	O	O
.	O	O

2	O	O
and	O	O
10	O	O
mg	O	O
/	O	O
kg	O	O
/	O	O
i	O	O
.	O	O

p	O	O
.	O	O

,	O	O
or	O	O
an	O	O
equal	O	O
volume	O	O
of	O	O
saline	O	O
for	O	O
the	O	O
control	O	O
group	O	O
(	O	O
n	O	O
=	O	O
20	O	O
)	O	O
;	O	O
15	O	O
minutes	O	O
later	O	O
,	O	O
all	O	O
the	O	O
animals	O	O
were	O	O
injected	O	O
with	O	O
a	O	O
single	O	O
50	O	O
mg	O	O
/	O	O
kg	O	O
/	O	O
i	O	O
.	O	O

p	O	O
.	O	O

dose	O	O
of	O	O
bupivacaine	B-Chemical	D002045
.	O	O

The	O	O
convulsant	O	O
activity	O	O
,	O	O
the	O	O
time	O	O
of	O	O
latency	O	O
to	O	O
convulse	O	O
and	O	O
the	O	O
mortality	O	O
rate	O	O
were	O	O
assessed	O	O
in	O	O
each	O	O
group	O	O
.	O	O

The	O	O
local	O	O
anesthetic	O	O
-	O	O
induced	O	O
mortality	O	O
was	O	O
significantly	O	O
increased	O	O
by	O	O
the	O	O
three	O	O
different	O	O
calcium	B-Chemical	D002118
channel	O	O
blockers	O	O
.	O	O

The	O	O
convulsant	O	O
activity	O	O
of	O	O
bupivacaine	B-Chemical	D002045
was	O	O
not	O	O
significantly	O	O
modified	O	O
but	O	O
calcium	B-Chemical	D002118
channel	O	O
blockers	O	O
decreased	O	O
the	O	O
time	O	O
of	O	O
latency	O	O
to	O	O
obtain	O	O
bupivacaine	B-Chemical	D002045
-	O	O
induced	O	O
convulsions	B-Disease	D012640
;	O	O
this	O	O
effect	O	O
was	O	O
less	O	O
pronounced	O	O
with	O	O
bepridil	B-Chemical	D015764
.	O	O

Selegiline	B-Chemical	D012642
-	O	O
induced	O	O
postural	B-Disease	D007024
hypotension	I-Disease	D007024
in	O	O
Parkinson's	B-Disease	D010300
disease	I-Disease	D010300
:	O	O
a	O	O
longitudinal	O	O
study	O	O
on	O	O
the	O	O
effects	O	O
of	O	O
drug	O	O
withdrawal	O	O
.	O	O

OBJECTIVES	O	O
:	O	O
The	O	O
United	O	O
Kingdom	O	O
Parkinson's	B-Disease	D010300
Disease	I-Disease	D010300
Research	O	O
Group	O	O
(	O	O
UKPDRG	O	O
)	O	O
trial	O	O
found	O	O
an	O	O
increased	O	O
mortality	O	O
in	O	O
patients	O	O
with	O	O
Parkinson's	B-Disease	D010300
disease	I-Disease	D010300
(	O	O
PD	B-Disease	D010300
)	O	O
randomized	O	O
to	O	O
receive	O	O
10	O	O
mg	O	O
selegiline	B-Chemical	D012642
per	O	O
day	O	O
and	O	O
L	B-Chemical	D007980
-	I-Chemical	D007980
dopa	I-Chemical	D007980
compared	O	O
with	O	O
those	O	O
taking	O	O
L	B-Chemical	D007980
-	I-Chemical	D007980
dopa	I-Chemical	D007980
alone	O	O
.	O	O

Recently	O	O
,	O	O
we	O	O
found	O	O
that	O	O
therapy	O	O
with	O	O
selegiline	B-Chemical	D012642
and	O	O
L	B-Chemical	D007980
-	I-Chemical	D007980
dopa	I-Chemical	D007980
was	O	O
associated	O	O
with	O	O
selective	O	O
systolic	B-Disease	D007024
orthostatic	I-Disease	D007024
hypotension	I-Disease	D007024
which	O	O
was	O	O
abolished	O	O
by	O	O
withdrawal	O	O
of	O	O
selegiline	B-Chemical	D012642
.	O	O

This	O	O
unwanted	O	O
effect	O	O
on	O	O
postural	O	O
blood	O	O
pressure	O	O
was	O	O
not	O	O
the	O	O
result	O	O
of	O	O
underlying	O	O
autonomic	O	O
failure	O	O
.	O	O

The	O	O
aims	O	O
of	O	O
this	O	O
study	O	O
were	O	O
to	O	O
confirm	O	O
our	O	O
previous	O	O
findings	O	O
in	O	O
a	O	O
separate	O	O
cohort	O	O
of	O	O
patients	O	O
and	O	O
to	O	O
determine	O	O
the	O	O
time	O	O
course	O	O
of	O	O
the	O	O
cardiovascular	O	O
consequences	O	O
of	O	O
stopping	O	O
selegiline	B-Chemical	D012642
in	O	O
the	O	O
expectation	O	O
that	O	O
this	O	O
might	O	O
shed	O	O
light	O	O
on	O	O
the	O	O
mechanisms	O	O
by	O	O
which	O	O
the	O	O
drug	O	O
causes	O	O
orthostatic	B-Disease	D007024
hypotension	I-Disease	D007024
.	O	O

METHODS	O	O
:	O	O
The	O	O
cardiovascular	O	O
responses	O	O
to	O	O
standing	O	O
and	O	O
head	O	O
-	O	O
up	O	O
tilt	O	O
were	O	O
studied	O	O
repeatedly	O	O
in	O	O
PD	B-Disease	D010300
patients	O	O
receiving	O	O
selegiline	B-Chemical	D012642
and	O	O
as	O	O
the	O	O
drug	O	O
was	O	O
withdrawn	O	O
.	O	O

RESULTS	O	O
:	O	O
Head	O	O
-	O	O
up	O	O
tilt	O	O
caused	O	O
systolic	B-Disease	D007024
orthostatic	I-Disease	D007024
hypotension	I-Disease	D007024
which	O	O
was	O	O
marked	O	O
in	O	O
six	O	O
of	O	O
20	O	O
PD	B-Disease	D010300
patients	O	O
on	O	O
selegiline	B-Chemical	D012642
,	O	O
one	O	O
of	O	O
whom	O	O
lost	O	O
consciousness	O	O
with	O	O
unrecordable	O	O
blood	O	O
pressures	O	O
.	O	O

A	O	O
lesser	O	O
degree	O	O
of	O	O
orthostatic	B-Disease	D007024
hypotension	I-Disease	D007024
occurred	O	O
with	O	O
standing	O	O
.	O	O

Orthostatic	B-Disease	D007024
hypotension	I-Disease	D007024
was	O	O
ameliorated	O	O
4	O	O
days	O	O
after	O	O
withdrawal	O	O
of	O	O
selegiline	B-Chemical	D012642
and	O	O
totally	O	O
abolished	O	O
7	O	O
days	O	O
after	O	O
discontinuation	O	O
of	O	O
the	O	O
drug	O	O
.	O	O

Stopping	O	O
selegiline	B-Chemical	D012642
also	O	O
significantly	O	O
reduced	B-Disease	D007024
the	I-Disease	D007024
supine	I-Disease	D007024
systolic	I-Disease	D007024
and	I-Disease	D007024
diastolic	I-Disease	D007024
blood	I-Disease	D007024
pressures	I-Disease	D007024
consistent	O	O
with	O	O
a	O	O
previously	O	O
undescribed	O	O
supine	O	O
pressor	O	O
action	O	O
.	O	O

CONCLUSION	O	O
:	O	O
This	O	O
study	O	O
confirms	O	O
our	O	O
previous	O	O
finding	O	O
that	O	O
selegiline	B-Chemical	D012642
in	O	O
combination	O	O
with	O	O
L	B-Chemical	D007980
-	I-Chemical	D007980
dopa	I-Chemical	D007980
is	O	O
associated	O	O
with	O	O
selective	O	O
orthostatic	B-Disease	D007024
hypotension	I-Disease	D007024
.	O	O

The	O	O
possibilities	O	O
that	O	O
these	O	O
cardiovascular	O	O
findings	O	O
might	O	O
be	O	O
the	O	O
result	O	O
of	O	O
non	O	O
-	O	O
selective	O	O
inhibition	O	O
of	O	O
monoamine	O	O
oxidase	O	O
or	O	O
of	O	O
amphetamine	B-Chemical	D000661
and	O	O
metamphetamine	B-Chemical	D008694
are	O	O
discussed	O	O
.	O	O

Explicit	O	O
episodic	O	O
memory	O	O
for	O	O
sensory	O	O
-	O	O
discriminative	O	O
components	O	O
of	O	O
capsaicin	B-Chemical	D002211
-	O	O
induced	O	O
pain	B-Disease	D010146
:	O	O
immediate	O	O
and	O	O
delayed	O	O
ratings	O	O
.	O	O

Pain	B-Disease	D010146
memory	O	O
is	O	O
thought	O	O
to	O	O
affect	O	O
future	O	O
pain	B-Disease	D010146
sensitivity	O	O
and	O	O
thus	O	O
contribute	O	O
to	O	O
clinical	O	O
pain	B-Disease	D010146
conditions	O	O
.	O	O

Systematic	O	O
investigations	O	O
of	O	O
the	O	O
human	O	O
capacity	O	O
to	O	O
remember	O	O
sensory	O	O
features	O	O
of	O	O
experimental	O	O
pain	B-Disease	D010146
are	O	O
sparse	O	O
.	O	O

In	O	O
order	O	O
to	O	O
address	O	O
long	O	O
-	O	O
term	O	O
pain	B-Disease	D010146
memory	O	O
,	O	O
nine	O	O
healthy	O	O
male	O	O
volunteers	O	O
received	O	O
intradermal	O	O
injections	O	O
of	O	O
three	O	O
doses	O	O
of	O	O
capsaicin	B-Chemical	D002211
(	O	O
0	O	O
.	O	O

05	O	O
,	O	O
1	O	O
and	O	O
20	O	O
microg	O	O
,	O	O
separated	O	O
by	O	O
15	O	O
min	O	O
breaks	O	O
)	O	O
,	O	O
each	O	O
given	O	O
three	O	O
times	O	O
in	O	O
a	O	O
balanced	O	O
design	O	O
across	O	O
three	O	O
sessions	O	O
at	O	O
one	O	O
week	O	O
intervals	O	O
.	O	O

Pain	B-Disease	D010146
rating	O	O
was	O	O
performed	O	O
using	O	O
a	O	O
computerized	O	O
visual	O	O
analogue	O	O
scale	O	O
(	O	O
0	O	O
-	O	O
100	O	O
)	O	O
digitized	O	O
at	O	O
1	O	O
/	O	O
s	O	O
,	O	O
either	O	O
immediately	O	O
online	O	O
or	O	O
one	O	O
hour	O	O
or	O	O
one	O	O
day	O	O
after	O	O
injection	O	O
.	O	O

Subjects	O	O
also	O	O
recalled	O	O
their	O	O
pains	B-Disease	D010146
one	O	O
week	O	O
later	O	O
.	O	O

Capsaicin	B-Chemical	D002211
injection	O	O
reliably	O	O
induced	O	O
a	O	O
dose	O	O
-	O	O
dependent	O	O
flare	O	O
(	O	O
p<0	O	O
.	O	O

001	O	O
)	O	O
without	O	O
any	O	O
difference	O	O
within	O	O
or	O	O
across	O	O
sessions	O	O
.	O	O

The	O	O
strong	O	O
burning	O	O
pain	B-Disease	D010146
decayed	O	O
exponentially	O	O
within	O	O
a	O	O
few	O	O
minutes	O	O
.	O	O

Subjects	O	O
were	O	O
able	O	O
to	O	O
reliably	O	O
discriminate	O	O
pain	B-Disease	D010146
magnitude	O	O
and	O	O
duration	O	O
across	O	O
capsaicin	B-Chemical	D002211
doses	O	O
(	O	O
both	O	O
p<0	O	O
.	O	O

001	O	O
)	O	O
,	O	O
regardless	O	O
of	O	O
whether	O	O
first	O	O
-	O	O
time	O	O
ratings	O	O
were	O	O
requested	O	O
immediately	O	O
,	O	O
after	O	O
one	O	O
hour	O	O
or	O	O
after	O	O
one	O	O
day	O	O
.	O	O

Pain	B-Disease	D010146
recall	O	O
after	O	O
one	O	O
week	O	O
was	O	O
similarly	O	O
precise	O	O
(	O	O
magnitude	O	O
:	O	O
p<0	O	O
.	O	O

01	O	O
,	O	O
duration	O	O
:	O	O
p<0	O	O
.	O	O

05	O	O
)	O	O
.	O	O

Correlation	O	O
with	O	O
rating	O	O
recall	O	O
after	O	O
one	O	O
week	O	O
was	O	O
best	O	O
when	O	O
first	O	O
-	O	O
time	O	O
ratings	O	O
were	O	O
requested	O	O
as	O	O
late	O	O
as	O	O
one	O	O
day	O	O
after	O	O
injection	O	O
(	O	O
R	O	O
(	O	O
2	O	O
)	O	O
=0	O	O
.	O	O

79	O	O
)	O	O
indicating	O	O
that	O	O
both	O	O
rating	O	O
retrievals	O	O
utilized	O	O
similar	O	O
memory	O	O
traces	O	O
.	O	O

These	O	O
results	O	O
indicate	O	O
a	O	O
reliable	O	O
memory	O	O
for	O	O
magnitude	O	O
and	O	O
duration	O	O
of	O	O
experimentally	O	O
induced	O	O
pain	B-Disease	D010146
.	O	O

The	O	O
data	O	O
further	O	O
suggest	O	O
that	O	O
the	O	O
consolidation	O	O
of	O	O
this	O	O
memory	O	O
is	O	O
an	O	O
important	O	O
interim	O	O
stage	O	O
,	O	O
and	O	O
may	O	O
take	O	O
up	O	O
to	O	O
one	O	O
day	O	O
.	O	O

Reversibility	O	O
of	O	O
captopril	B-Chemical	D002216
-	O	O
induced	O	O
renal	B-Disease	D051437
insufficiency	I-Disease	D051437
after	O	O
prolonged	O	O
use	O	O
in	O	O
an	O	O
unusual	O	O
case	O	O
of	O	O
renovascular	B-Disease	D006978
hypertension	I-Disease	D006978
.	O	O

We	O	O
report	O	O
a	O	O
case	O	O
of	O	O
severe	O	O
hypertension	B-Disease	D006973
with	O	O
an	O	O
occluded	O	O
renal	O	O
artery	O	O
to	O	O
a	O	O
solitary	O	O
kidney	O	O
,	O	O
who	O	O
developed	O	O
sudden	B-Disease	D058186
deterioration	I-Disease	D058186
of	I-Disease	D058186
renal	I-Disease	D058186
function	I-Disease	D058186
following	O	O
treatment	O	O
with	O	O
captopril	B-Chemical	D002216
.	O	O

His	O	O
renal	O	O
function	O	O
remained	O	O
impaired	O	O
but	O	O
stable	O	O
during	O	O
2	O	O
years'	O	O
treatment	O	O
with	O	O
captopril	B-Chemical	D002216
but	O	O
returned	O	O
to	O	O
pre	O	O
-	O	O
treatment	O	O
levels	O	O
soon	O	O
after	O	O
cessation	O	O
of	O	O
the	O	O
drug	O	O
.	O	O

This	O	O
indicates	O	O
reversibility	O	O
in	O	O
captopril	B-Chemical	D002216
-	O	O
induced	O	O
renal	B-Disease	D051437
failure	I-Disease	D051437
even	O	O
after	O	O
its	O	O
prolonged	O	O
use	O	O
and	O	O
suggests	O	O
that	O	O
no	O	O
organic	O	O
damage	O	O
occurs	O	O
to	O	O
glomerular	O	O
arterioles	O	O
following	O	O
chronic	O	O
ACE	O	O
inhibition	O	O
.	O	O

Liver	B-Disease	D008107
disease	I-Disease	D008107
caused	O	O
by	O	O
propylthiouracil	B-Chemical	D011441
.	O	O

This	O	O
report	O	O
presents	O	O
the	O	O
clinical	O	O
,	O	O
laboratory	O	O
,	O	O
and	O	O
light	O	O
and	O	O
electron	O	O
microscopic	O	O
observations	O	O
on	O	O
a	O	O
patient	O	O
with	O	O
chronic	B-Disease	D006521
active	I-Disease	D006521
(	I-Disease	D006521
aggressive	I-Disease	D006521
)	I-Disease	D006521
hepatitis	I-Disease	D006521
caused	O	O
by	O	O
the	O	O
administration	O	O
of	O	O
propylthiouracil	B-Chemical	D011441
.	O	O

This	O	O
is	O	O
an	O	O
addition	O	O
to	O	O
the	O	O
list	O	O
of	O	O
drugs	O	O
that	O	O
must	O	O
be	O	O
considered	O	O
in	O	O
the	O	O
evaluation	O	O
of	O	O
chronic	O	O
liver	B-Disease	D008107
disease	I-Disease	D008107
.	O	O

Capsaicin	B-Chemical	D002211
-	O	O
induced	O	O
muscle	B-Disease	D063806
pain	I-Disease	D063806
alters	O	O
the	O	O
excitability	O	O
of	O	O
the	O	O
human	O	O
jaw	O	O
-	O	O
stretch	O	O
reflex	O	O
.	O	O

The	O	O
pathophysiology	O	O
of	O	O
painful	O	O
temporomandibular	B-Disease	D013705
disorders	I-Disease	D013705
is	O	O
not	O	O
fully	O	O
understood	O	O
,	O	O
but	O	O
evidence	O	O
suggests	O	O
that	O	O
muscle	B-Disease	D063806
pain	I-Disease	D063806
modulates	O	O
motor	O	O
function	O	O
in	O	O
characteristic	O	O
ways	O	O
.	O	O

This	O	O
study	O	O
tested	O	O
the	O	O
hypothesis	O	O
that	O	O
activation	O	O
of	O	O
nociceptive	B-Disease	D063806
muscle	I-Disease	D063806
afferent	O	O
fibers	O	O
would	O	O
be	O	O
linked	O	O
to	O	O
an	O	O
increased	O	O
excitability	O	O
of	O	O
the	O	O
human	O	O
jaw	O	O
-	O	O
stretch	O	O
reflex	O	O
and	O	O
whether	O	O
this	O	O
process	O	O
would	O	O
be	O	O
sensitive	O	O
to	O	O
length	O	O
and	O	O
velocity	O	O
of	O	O
the	O	O
stretch	O	O
.	O	O

Capsaicin	B-Chemical	D002211
(	O	O
10	O	O
micro	O	O
g	O	O
)	O	O
was	O	O
injected	O	O
into	O	O
the	O	O
masseter	O	O
muscle	O	O
to	O	O
induce	O	O
pain	B-Disease	D010146
in	O	O
11	O	O
healthy	O	O
volunteers	O	O
.	O	O

Short	O	O
-	O	O
latency	O	O
reflex	O	O
responses	O	O
were	O	O
evoked	O	O
in	O	O
the	O	O
masseter	O	O
and	O	O
temporalis	O	O
muscles	O	O
by	O	O
a	O	O
stretch	O	O
device	O	O
with	O	O
different	O	O
velocities	O	O
and	O	O
displacements	O	O
before	O	O
,	O	O
during	O	O
,	O	O
and	O	O
after	O	O
the	O	O
pain	B-Disease	D010146
.	O	O

The	O	O
normalized	O	O
reflex	O	O
amplitude	O	O
increased	O	O
with	O	O
an	O	O
increase	O	O
in	O	O
velocity	O	O
at	O	O
a	O	O
given	O	O
displacement	O	O
,	O	O
but	O	O
remained	O	O
constant	O	O
with	O	O
different	O	O
displacements	O	O
at	O	O
a	O	O
given	O	O
velocity	O	O
.	O	O

The	O	O
normalized	O	O
reflex	O	O
amplitude	O	O
was	O	O
significantly	O	O
higher	O	O
during	O	O
pain	B-Disease	D010146
,	O	O
but	O	O
only	O	O
at	O	O
faster	O	O
stretches	O	O
in	O	O
the	O	O
painful	B-Disease	D063806
muscle	I-Disease	D063806
.	O	O

Increased	O	O
sensitivity	O	O
of	O	O
the	O	O
fusimotor	O	O
system	O	O
during	O	O
acute	O	O
muscle	B-Disease	D063806
pain	I-Disease	D063806
could	O	O
be	O	O
one	O	O
likely	O	O
mechanism	O	O
to	O	O
explain	O	O
the	O	O
findings	O	O
.	O	O

Repetitive	O	O
transcranial	O	O
magnetic	O	O
stimulation	O	O
for	O	O
levodopa	B-Chemical	D007980
-	O	O
induced	O	O
dyskinesias	B-Disease	D004409
in	O	O
Parkinson's	B-Disease	D010300
disease	I-Disease	D010300
.	O	O

In	O	O
a	O	O
placebo	O	O
-	O	O
controlled	O	O
,	O	O
single	O	O
-	O	O
blinded	O	O
,	O	O
crossover	O	O
study	O	O
,	O	O
we	O	O
assessed	O	O
the	O	O
effect	O	O
of	O	O
"real"	O	O
repetitive	O	O
transcranial	O	O
magnetic	O	O
stimulation	O	O
(	O	O
rTMS	O	O
)	O	O
versus	O	O
"sham"	O	O
rTMS	O	O
(	O	O
placebo	O	O
)	O	O
on	O	O
peak	O	O
dose	O	O
dyskinesias	B-Disease	D004409
in	O	O
patients	O	O
with	O	O
Parkinson's	B-Disease	D010300
disease	I-Disease	D010300
(	O	O
PD	B-Disease	D010300
)	O	O
.	O	O

Ten	O	O
patients	O	O
with	O	O
PD	B-Disease	D010300
and	O	O
prominent	O	O
dyskinesias	B-Disease	D004409
had	O	O
rTMS	O	O
(	O	O
1	O	O
,	O	O
800	O	O
pulses	O	O
;	O	O
1	O	O
Hz	O	O
rate	O	O
)	O	O
delivered	O	O
over	O	O
the	O	O
motor	O	O
cortex	O	O
for	O	O
4	O	O
consecutive	O	O
days	O	O
twice	O	O
,	O	O
once	O	O
real	O	O
stimuli	O	O
and	O	O
once	O	O
sham	O	O
stimulation	O	O
were	O	O
used	O	O
;	O	O
evaluations	O	O
were	O	O
done	O	O
at	O	O
the	O	O
baseline	O	O
and	O	O
1	O	O
day	O	O
after	O	O
the	O	O
end	O	O
of	O	O
each	O	O
of	O	O
the	O	O
treatment	O	O
series	O	O
.	O	O

Direct	O	O
comparison	O	O
between	O	O
sham	O	O
and	O	O
real	O	O
rTMS	O	O
effects	O	O
showed	O	O
no	O	O
significant	O	O
difference	O	O
in	O	O
clinician	O	O
-	O	O
assessed	O	O
dyskinesia	B-Disease	D004409
severity	O	O
.	O	O

However	O	O
,	O	O
comparison	O	O
with	O	O
the	O	O
baseline	O	O
showed	O	O
small	O	O
but	O	O
significant	O	O
reduction	O	O
in	O	O
dyskinesia	B-Disease	D004409
severity	O	O
following	O	O
real	O	O
rTMS	O	O
but	O	O
not	O	O
placebo	O	O
.	O	O

The	O	O
major	O	O
effect	O	O
was	O	O
on	O	O
dystonia	B-Disease	D004421
subscore	O	O
.	O	O

Similarly	O	O
,	O	O
in	O	O
patient	O	O
diaries	O	O
,	O	O
although	O	O
both	O	O
treatments	O	O
caused	O	O
reduction	O	O
in	O	O
subjective	O	O
dyskinesia	B-Disease	D004409
scores	O	O
during	O	O
the	O	O
days	O	O
of	O	O
intervention	O	O
,	O	O
the	O	O
effect	O	O
was	O	O
sustained	O	O
for	O	O
3	O	O
days	O	O
after	O	O
the	O	O
intervention	O	O
for	O	O
the	O	O
real	O	O
rTMS	O	O
only	O	O
.	O	O

Following	O	O
rTMS	O	O
,	O	O
no	O	O
side	O	O
effects	O	O
and	O	O
no	O	O
adverse	O	O
effects	O	O
on	O	O
motor	O	O
function	O	O
and	O	O
PD	B-Disease	D010300
symptoms	O	O
were	O	O
noted	O	O
.	O	O

The	O	O
results	O	O
suggest	O	O
the	O	O
existence	O	O
of	O	O
residual	O	O
beneficial	O	O
clinical	O	O
aftereffects	O	O
of	O	O
consecutive	O	O
daily	O	O
applications	O	O
of	O	O
low	O	O
-	O	O
frequency	O	O
rTMS	O	O
on	O	O
dyskinesias	B-Disease	D004409
in	O	O
PD	B-Disease	D010300
.	O	O

The	O	O
effects	O	O
may	O	O
be	O	O
further	O	O
exploited	O	O
for	O	O
potential	O	O
therapeutic	O	O
uses	O	O
.	O	O

Disulfiram	B-Chemical	D004221
-	O	O
like	O	O
syndrome	O	O
after	O	O
hydrogen	B-Chemical	D003484
cyanamide	I-Chemical	D003484
professional	O	O
skin	O	O
exposure	O	O
:	O	O
two	O	O
case	O	O
reports	O	O
in	O	O
France	O	O
.	O	O

Hydrogen	B-Chemical	D003484
cyanamide	I-Chemical	D003484
is	O	O
a	O	O
plant	O	O
growth	O	O
regulator	O	O
used	O	O
in	O	O
agriculture	O	O
to	O	O
induce	O	O
bud	O	O
break	O	O
in	O	O
fruit	O	O
trees	O	O
.	O	O

Contact	O	O
with	O	O
the	O	O
skin	O	O
can	O	O
result	O	O
in	O	O
percutaneous	O	O
absorption	O	O
of	O	O
the	O	O
substance	O	O
that	O	O
inhibits	O	O
aldehyde	B-Chemical	D000079
dehydrogenase	O	O
and	O	O
can	O	O
induce	O	O
acetaldehyde	B-Chemical	D000079
syndrome	O	O
in	O	O
case	O	O
of	O	O
alcohol	B-Chemical	D000431
use	O	O
.	O	O

The	O	O
purpose	O	O
of	O	O
this	O	O
report	O	O
is	O	O
to	O	O
describe	O	O
two	O	O
cases	O	O
of	O	O
a	O	O
disulfiram	B-Chemical	D004221
-	O	O
like	O	O
syndrome	O	O
following	O	O
occupational	O	O
exposure	O	O
to	O	O
hydrogen	B-Chemical	D003484
cyanamide	I-Chemical	D003484
.	O	O

The	O	O
first	O	O
case	O	O
involved	O	O
a	O	O
59	O	O
-	O	O
year	O	O
-	O	O
old	O	O
man	O	O
who	O	O
used	O	O
Dormex	B-Chemical	D003484
,	O	O
which	O	O
contains	O	O
hydrogen	B-Chemical	D003484
cyanamide	I-Chemical	D003484
,	O	O
without	O	O
protection	O	O
after	O	O
consuming	O	O
a	O	O
large	O	O
amount	O	O
of	O	O
alcohol	B-Chemical	D000431
during	O	O
a	O	O
meal	O	O
.	O	O

In	O	O
less	O	O
than	O	O
1	O	O
hour	O	O
after	O	O
the	O	O
ingestion	O	O
of	O	O
alcohol	B-Chemical	D000431
,	O	O
he	O	O
developed	O	O
malaise	O	O
with	O	O
flushing	B-Disease	D005483
of	I-Disease	D005483
the	I-Disease	D005483
face	I-Disease	D005483
,	O	O
tachycardia	B-Disease	D013610
,	O	O
and	O	O
dyspnea	B-Disease	D004417
.	O	O

Manifestations	O	O
regressed	O	O
spontaneously	O	O
under	O	O
surveillance	O	O
in	O	O
the	O	O
hospital	O	O
.	O	O

The	O	O
second	O	O
case	O	O
occurred	O	O
in	O	O
a	O	O
55	O	O
-	O	O
year	O	O
-	O	O
old	O	O
farmer	O	O
following	O	O
cutaneous	O	O
contact	O	O
with	O	O
Dormex	B-Chemical	D003484
.	O	O

Five	O	O
hours	O	O
after	O	O
exposure	O	O
,	O	O
he	O	O
developed	O	O
disulfiram	B-Chemical	D004221
-	O	O
like	O	O
syndrome	O	O
with	O	O
flushing	B-Disease	D005483
,	O	O
tachycardia	B-Disease	D013610
,	O	O
and	O	O
arterial	B-Disease	D007022
hypotension	I-Disease	D007022
after	O	O
consuming	O	O
three	O	O
glasses	O	O
of	O	O
wine	O	O
.	O	O

The	O	O
patient	O	O
recovered	O	O
spontaneously	O	O
in	O	O
3	O	O
hours	O	O
under	O	O
surveillance	O	O
in	O	O
the	O	O
hospital	O	O
.	O	O

These	O	O
cases	O	O
confirm	O	O
the	O	O
necessity	O	O
of	O	O
avoiding	O	O
alcohol	B-Chemical	D000431
consumption	O	O
as	O	O
recommended	O	O
in	O	O
the	O	O
instructions	O	O
for	O	O
use	O	O
of	O	O
Dormex	B-Chemical	D003484
and	O	O
of	O	O
preventing	O	O
cutaneous	O	O
contact	O	O
during	O	O
use	O	O
.	O	O

Repeated	O	O
trimipramine	B-Chemical	D014299
induces	O	O
dopamine	B-Chemical	D004298
D2	O	O
/	O	O
D3	O	O
and	O	O
alpha1	O	O
-	O	O
adrenergic	O	O
up	O	O
-	O	O
regulation	O	O
.	O	O

Trimipramine	B-Chemical	D014299
(	O	O
TRI	B-Chemical	D014299
)	O	O
,	O	O
which	O	O
shows	O	O
a	O	O
clinical	O	O
antidepressant	B-Chemical	D000928
activity	O	O
,	O	O
is	O	O
chemically	O	O
related	O	O
to	O	O
imipramine	B-Chemical	D007099
but	O	O
does	O	O
not	O	O
inhibit	O	O
the	O	O
reuptake	O	O
of	O	O
noradrenaline	B-Chemical	D009638
and	O	O
5	B-Chemical	D012701
-	I-Chemical	D012701
hydroxytryptamine	I-Chemical	D012701
,	O	O
nor	O	O
does	O	O
it	O	O
induce	O	O
beta	O	O
-	O	O
adrenergic	O	O
down	O	O
-	O	O
regulation	O	O
.	O	O

The	O	O
mechanism	O	O
of	O	O
its	O	O
antidepressant	B-Chemical	D000928
activity	O	O
is	O	O
still	O	O
unknown	O	O
.	O	O

The	O	O
aim	O	O
of	O	O
the	O	O
present	O	O
study	O	O
was	O	O
to	O	O
find	O	O
out	O	O
whether	O	O
TRI	B-Chemical	D014299
given	O	O
repeatedly	O	O
was	O	O
able	O	O
to	O	O
induce	O	O
adaptive	O	O
changes	O	O
in	O	O
the	O	O
dopaminergic	O	O
and	O	O
alpha1	O	O
-	O	O
adrenergic	O	O
systems	O	O
,	O	O
demonstrated	O	O
by	O	O
us	O	O
previously	O	O
for	O	O
various	O	O
antidepressants	B-Chemical	D000928
.	O	O

TRI	B-Chemical	D014299
was	O	O
given	O	O
to	O	O
male	O	O
Wistar	O	O
rats	O	O
and	O	O
male	O	O
Albino	O	O
Swiss	O	O
mice	O	O
perorally	O	O
twice	O	O
daily	O	O
for	O	O
14	O	O
days	O	O
.	O	O

In	O	O
the	O	O
acute	O	O
experiment	O	O
TRI	B-Chemical	D014299
(	O	O
given	O	O
i	O	O
.	O	O

p	O	O
.	O	O

)	O	O
does	O	O
not	O	O
antagonize	O	O
the	O	O
reserpine	B-Chemical	D012110
hypothermia	B-Disease	D007035
in	O	O
mice	O	O
and	O	O
does	O	O
not	O	O
potentiate	O	O
the	O	O
5	B-Chemical	D006916
-	I-Chemical	D006916
hydroxytryptophan	I-Chemical	D006916
head	O	O
twitches	O	O
in	O	O
rats	O	O
.	O	O

TRI	B-Chemical	D014299
given	O	O
repeatedly	O	O
to	O	O
rats	O	O
increases	O	O
the	O	O
locomotor	O	O
hyperactivity	B-Disease	D006948
induced	O	O
by	O	O
d	B-Chemical	D003913
-	I-Chemical	D003913
amphetamine	I-Chemical	D003913
,	O	O
quinpirole	B-Chemical	D019257
and	O	O
(	O	O
+	O	O
)	O	O
-	O	O
7	O	O
-	O	O
hydroxy	O	O
-	O	O
dipropyloaminotetralin	O	O
(	O	O
dopamine	B-Chemical	D004298
D2	O	O
and	O	O
D3	O	O
effects	O	O
)	O	O
.	O	O

The	O	O
stereotypies	O	O
induced	O	O
by	O	O
d	B-Chemical	D003913
-	I-Chemical	D003913
amphetamine	I-Chemical	D003913
or	O	O
apomorphine	B-Chemical	D001058
are	O	O
not	O	O
potentiated	O	O
by	O	O
TRI	B-Chemical	D014299
.	O	O

It	O	O
increases	O	O
the	O	O
behaviour	O	O
stimulation	O	O
evoked	O	O
by	O	O
phenylephrine	B-Chemical	D010656
(	O	O
given	O	O
intraventricularly	O	O
)	O	O
in	O	O
rats	O	O
,	O	O
evaluated	O	O
in	O	O
the	O	O
open	O	O
field	O	O
test	O	O
as	O	O
well	O	O
as	O	O
the	O	O
aggressiveness	B-Disease	D010554
evoked	O	O
by	O	O
clonidine	B-Chemical	D003000
in	O	O
mice	O	O
,	O	O
both	O	O
these	O	O
effects	O	O
being	O	O
mediated	O	O
by	O	O
an	O	O
alpha1	O	O
-	O	O
adrenergic	O	O
receptor	O	O
.	O	O

It	O	O
may	O	O
be	O	O
concluded	O	O
that	O	O
,	O	O
like	O	O
other	O	O
tricyclic	O	O
antidepressants	B-Chemical	D000928
studied	O	O
previously	O	O
,	O	O
TRI	B-Chemical	D014299
given	O	O
repeatedly	O	O
increases	O	O
the	O	O
responsiveness	O	O
of	O	O
brain	O	O
dopamine	B-Chemical	D004298
D2	O	O
and	O	O
D3	O	O
(	O	O
locomotor	O	O
activity	O	O
but	O	O
not	O	O
stereotypy	O	O
)	O	O
as	O	O
well	O	O
as	O	O
alpha1	O	O
-	O	O
adrenergic	O	O
receptors	O	O
to	O	O
their	O	O
agonists	O	O
.	O	O

A	O	O
question	O	O
arises	O	O
whether	O	O
the	O	O
reuptake	O	O
inhibition	O	O
is	O	O
of	O	O
any	O	O
importance	O	O
to	O	O
the	O	O
adaptive	O	O
changes	O	O
induced	O	O
by	O	O
repeated	O	O
antidepressants	B-Chemical	D000928
,	O	O
suggested	O	O
to	O	O
be	O	O
responsible	O	O
for	O	O
the	O	O
antidepressant	B-Chemical	D000928
activity	O	O
.	O	O

Ranitidine	B-Chemical	D011899
-	O	O
induced	O	O
acute	O	O
interstitial	B-Disease	D009395
nephritis	I-Disease	D009395
in	O	O
a	O	O
cadaveric	O	O
renal	O	O
allograft	O	O
.	O	O

Ranitidine	B-Chemical	D011899
frequently	O	O
is	O	O
used	O	O
for	O	O
preventing	O	O
peptic	O	O
ulceration	O	O
after	O	O
renal	O	O
transplantation	O	O
.	O	O

This	O	O
drug	O	O
occasionally	O	O
has	O	O
been	O	O
associated	O	O
with	O	O
acute	O	O
interstitial	B-Disease	D009395
nephritis	I-Disease	D009395
in	O	O
native	O	O
kidneys	O	O
.	O	O

There	O	O
are	O	O
no	O	O
similar	O	O
reports	O	O
with	O	O
renal	O	O
transplantation	O	O
.	O	O

We	O	O
report	O	O
a	O	O
case	O	O
of	O	O
ranitidine	B-Chemical	D011899
-	O	O
induced	O	O
acute	O	O
interstitial	B-Disease	D009395
nephritis	I-Disease	D009395
in	O	O
a	O	O
recipient	O	O
of	O	O
a	O	O
cadaveric	O	O
renal	O	O
allograft	O	O
presenting	O	O
with	O	O
acute	O	O
allograft	O	O
dysfunction	O	O
within	O	O
48	O	O
hours	O	O
of	O	O
exposure	O	O
to	O	O
the	O	O
drug	O	O
.	O	O

The	O	O
biopsy	O	O
specimen	O	O
showed	O	O
pathognomonic	O	O
features	O	O
,	O	O
including	O	O
eosinophilic	O	O
infiltration	O	O
of	O	O
the	O	O
interstitial	O	O
compartment	O	O
.	O	O

Allograft	O	O
function	O	O
improved	O	O
rapidly	O	O
and	O	O
returned	O	O
to	O	O
baseline	O	O
after	O	O
stopping	O	O
the	O	O
drug	O	O
.	O	O

Late	O	O
,	O	O
late	O	O
doxorubicin	B-Chemical	D004317
cardiotoxicity	B-Disease	D066126
.	O	O

Cardiac	B-Disease	D066126
toxicity	I-Disease	D066126
is	O	O
a	O	O
major	O	O
complication	O	O
which	O	O
limits	O	O
the	O	O
use	O	O
of	O	O
adriamycin	B-Chemical	D004317
as	O	O
a	O	O
chemotherapeutic	O	O
agent	O	O
.	O	O

Cardiomyopathy	B-Disease	D009202
is	O	O
frequent	O	O
when	O	O
the	O	O
total	O	O
dose	O	O
exceeds	O	O
600	O	O
mg	O	O
/	O	O
m2	O	O
and	O	O
occurs	O	O
within	O	O
one	O	O
to	O	O
six	O	O
months	O	O
after	O	O
cessation	O	O
of	O	O
therapy	O	O
.	O	O

A	O	O
patient	O	O
is	O	O
reported	O	O
who	O	O
developed	O	O
progressive	O	O
cardiomyopathy	B-Disease	D009202
two	O	O
and	O	O
one	O	O
-	O	O
half	O	O
years	O	O
after	O	O
receiving	O	O
580	O	O
mg	O	O
/	O	O
m2	O	O
which	O	O
apparently	O	O
represents	O	O
late	O	O
,	O	O
late	O	O
cardiotoxicity	B-Disease	D066126
.	O	O

Acetazolamide	B-Chemical	D000086
-	O	O
induced	O	O
nephrolithiasis	B-Disease	D053040
:	O	O
implications	O	O
for	O	O
treatment	O	O
of	O	O
neuromuscular	B-Disease	D009468
disorders	I-Disease	D009468
.	O	O

Carbonic	O	O
anhydrase	O	O
inhibitors	O	O
can	O	O
cause	O	O
nephrolithiasis	B-Disease	D053040
.	O	O

We	O	O
studied	O	O
20	O	O
patients	O	O
receiving	O	O
long	O	O
-	O	O
term	O	O
carbonic	O	O
anhydrase	O	O
inhibitor	O	O
treatment	O	O
for	O	O
periodic	O	O
paralysis	B-Disease	D010243
and	O	O
myotonia	B-Disease	D009222
.	O	O

Three	O	O
patients	O	O
on	O	O
acetazolamide	B-Chemical	D000086
(	O	O
15%	O	O
)	O	O
developed	O	O
renal	B-Disease	D007669
calculi	I-Disease	D007669
.	O	O

Extracorporeal	O	O
lithotripsy	O	O
successfully	O	O
removed	O	O
a	O	O
renal	B-Disease	D007669
calculus	I-Disease	D007669
in	O	O
one	O	O
patient	O	O
and	O	O
surgery	O	O
removed	O	O
a	O	O
staghorn	O	O
calculus	B-Disease	D002137
in	O	O
another	O	O
,	O	O
permitting	O	O
continued	O	O
treatment	O	O
.	O	O

Renal	O	O
function	O	O
remained	O	O
normal	O	O
in	O	O
all	O	O
patients	O	O
.	O	O

Nephrolithiasis	B-Disease	D053040
is	O	O
a	O	O
complication	O	O
of	O	O
acetazolamide	B-Chemical	D000086
but	O	O
does	O	O
not	O	O
preclude	O	O
its	O	O
use	O	O
.	O	O

Is	O	O
the	O	O
treatment	O	O
of	O	O
scabies	B-Disease	D012532
hazardous?	O	O
Treatment	O	O
for	O	O
scabies	B-Disease	D012532
is	O	O
usually	O	O
initiated	O	O
by	O	O
general	O	O
practitioners	O	O
;	O	O
most	O	O
consider	O	O
lindane	B-Chemical	D001556
(	O	O
gamma	B-Chemical	D001556
benzene	I-Chemical	D001556
hexachloride	I-Chemical	D001556
)	O	O
the	O	O
treatment	O	O
of	O	O
choice	O	O
.	O	O

Lindane	B-Chemical	D001556
is	O	O
also	O	O
widely	O	O
used	O	O
as	O	O
an	O	O
agricultural	O	O
and	O	O
industrial	O	O
pesticide	O	O
,	O	O
and	O	O
as	O	O
a	O	O
result	O	O
the	O	O
toxic	O	O
profile	O	O
of	O	O
this	O	O
insecticide	O	O
is	O	O
well	O	O
understood	O	O
.	O	O

Evidence	O	O
is	O	O
accumulating	O	O
that	O	O
lindane	B-Chemical	D001556
can	O	O
be	O	O
toxic	B-Disease	D002493
to	I-Disease	D002493
the	I-Disease	D002493
central	I-Disease	D002493
nervous	I-Disease	D002493
system	I-Disease	D002493
and	O	O
may	O	O
be	O	O
associated	O	O
with	O	O
aplastic	B-Disease	D000741
anaemia	I-Disease	D000741
.	O	O

Preparations	O	O
containing	O	O
lindane	B-Chemical	D001556
continue	O	O
to	O	O
be	O	O
sold	O	O
over	O	O
the	O	O
counter	O	O
and	O	O
may	O	O
represent	O	O
a	O	O
hazard	O	O
to	O	O
poorly	O	O
informed	O	O
patients	O	O
.	O	O

This	O	O
literature	O	O
review	O	O
suggests	O	O
that	O	O
general	O	O
practitioners	O	O
should	O	O
prescribe	O	O
scabicides	O	O
with	O	O
increased	O	O
caution	O	O
for	O	O
certain	O	O
at	O	O
-	O	O
risk	O	O
groups	O	O
,	O	O
and	O	O
give	O	O
adequate	O	O
warnings	O	O
regarding	O	O
potential	O	O
toxicity	B-Disease	D064420
.	O	O

Anaesthetists'	O	O
nightmare	O	O
:	O	O
masseter	B-Disease	D014313
spasm	I-Disease	D014313
after	O	O
induction	O	O
in	O	O
an	O	O
undiagnosed	O	O
case	O	O
of	O	O
myotonia	B-Disease	D009224
congenita	I-Disease	D009224
.	O	O

We	O	O
report	O	O
an	O	O
undiagnosed	O	O
case	O	O
of	O	O
myotonia	B-Disease	D009224
congenita	I-Disease	D009224
in	O	O
a	O	O
24	O	O
-	O	O
year	O	O
-	O	O
old	O	O
previously	O	O
healthy	O	O
primigravida	O	O
,	O	O
who	O	O
developed	O	O
life	O	O
threatening	O	O
masseter	B-Disease	D014313
spasm	I-Disease	D014313
following	O	O
a	O	O
standard	O	O
dose	O	O
of	O	O
intravenous	O	O
suxamethonium	B-Chemical	D013390
for	O	O
induction	O	O
of	O	O
anaesthesia	O	O
.	O	O

Neither	O	O
the	O	O
patient	O	O
nor	O	O
the	O	O
anaesthetist	O	O
was	O	O
aware	O	O
of	O	O
the	O	O
diagnosis	O	O
before	O	O
this	O	O
potentially	O	O
lethal	O	O
complication	O	O
occurred	O	O
.	O	O

Toxicity	B-Disease	D064420
in	O	O
rhesus	O	O
monkeys	O	O
following	O	O
administration	O	O
of	O	O
the	O	O
8	B-Chemical	C080436
-	I-Chemical	C080436
aminoquinoline	I-Chemical	C080436
8	B-Chemical	C068820
-	I-Chemical	C068820
[	I-Chemical	C068820
(	I-Chemical	C068820
4	I-Chemical	C068820
-	I-Chemical	C068820
amino	I-Chemical	C068820
-	I-Chemical	C068820
l	I-Chemical	C068820
-	I-Chemical	C068820
methylbutyl	I-Chemical	C068820
)	I-Chemical	C068820
amino	I-Chemical	C068820
]	I-Chemical	C068820
-	I-Chemical	C068820
5	I-Chemical	C068820
-	I-Chemical	C068820
(	I-Chemical	C068820
l	I-Chemical	C068820
-	I-Chemical	C068820
hexyloxy	I-Chemical	C068820
)	I-Chemical	C068820
-	I-Chemical	C068820
6	I-Chemical	C068820
-	I-Chemical	C068820
methoxy	I-Chemical	C068820
-	I-Chemical	C068820
4	I-Chemical	C068820
-	I-Chemical	C068820
methylquinoline	I-Chemical	C068820
(	O	O
WR242511	B-Chemical	C068820
)	O	O
.	O	O

INTRODUCTION	O	O
:	O	O
Many	O	O
substances	O	O
that	O	O
form	O	O
methemoglobin	O	O
(	O	O
MHb	O	O
)	O	O
effectively	O	O
counter	O	O
cyanide	O	O
(	O	O
CN	O	O
)	O	O
toxicity	B-Disease	D064420
.	O	O

Although	O	O
MHb	O	O
formers	O	O
are	O	O
generally	O	O
applied	O	O
as	O	O
treatments	O	O
for	O	O
CN	O	O
poisoning	B-Disease	D011041
,	O	O
it	O	O
has	O	O
been	O	O
proposed	O	O
that	O	O
a	O	O
stable	O	O
,	O	O
long	O	O
-	O	O
acting	O	O
MHb	O	O
former	O	O
could	O	O
serve	O	O
as	O	O
a	O	O
CN	O	O
pretreatment	O	O
.	O	O

Using	O	O
this	O	O
rationale	O	O
,	O	O
the	O	O
8	B-Chemical	C080436
-	I-Chemical	C080436
aminoquinoline	I-Chemical	C080436
WR242511	B-Chemical	C068820
,	O	O
a	O	O
potent	O	O
long	O	O
-	O	O
lasting	O	O
MHb	O	O
former	O	O
in	O	O
rodents	O	O
and	O	O
beagle	O	O
dogs	O	O
,	O	O
was	O	O
studied	O	O
in	O	O
the	O	O
rhesus	O	O
monkey	O	O
for	O	O
advanced	O	O
development	O	O
as	O	O
a	O	O
potential	O	O
CN	O	O
pretreatment	O	O
.	O	O

METHODS	O	O
:	O	O
In	O	O
this	O	O
study	O	O
,	O	O
WR242511	B-Chemical	C068820
was	O	O
administered	O	O
intravenously	O	O
(	O	O
IV	O	O
)	O	O
in	O	O
2	O	O
female	O	O
and	O	O
4	O	O
male	O	O
rhesus	O	O
monkeys	O	O
in	O	O
doses	O	O
of	O	O
3	O	O
.	O	O

5	O	O
and	O	O
/	O	O
or	O	O
7	O	O
.	O	O

0	O	O
mg	O	O
/	O	O
kg	O	O
;	O	O
a	O	O
single	O	O
male	O	O
also	O	O
received	O	O
WR242511	B-Chemical	C068820
orally	O	O
(	O	O
PO	O	O
)	O	O
at	O	O
7	O	O
.	O	O

0	O	O
mg	O	O
/	O	O
kg	O	O
.	O	O

Health	O	O
status	O	O
and	O	O
MHb	O	O
levels	O	O
were	O	O
monitored	O	O
following	O	O
exposure	O	O
.	O	O

RESULTS	O	O
:	O	O
The	O	O
selected	O	O
doses	O	O
of	O	O
WR242511	B-Chemical	C068820
,	O	O
which	O	O
produced	O	O
significant	O	O
methemoglobinemia	B-Disease	D008708
in	O	O
beagle	O	O
dogs	O	O
in	O	O
earlier	O	O
studies	O	O
conducted	O	O
elsewhere	O	O
,	O	O
produced	O	O
very	O	O
little	O	O
MHb	O	O
(	O	O
mean	O	O
<	O	O
2	O	O
.	O	O

0%	O	O
)	O	O
in	O	O
the	O	O
rhesus	O	O
monkey	O	O
.	O	O

Furthermore	O	O
,	O	O
transient	O	O
hemoglobinuria	B-Disease	D006456
was	O	O
noted	O	O
approximately	O	O
60	O	O
minutes	O	O
postinjection	O	O
of	O	O
WR242511	B-Chemical	C068820
(	O	O
3	O	O
.	O	O

5	O	O
or	O	O
7	O	O
.	O	O

0	O	O
mg	O	O
/	O	O
kg	O	O
)	O	O
,	O	O
and	O	O
2	O	O
lethalities	O	O
occurred	O	O
(	O	O
one	O	O
IV	O	O
and	O	O
one	O	O
PO	O	O
)	O	O
following	O	O
the	O	O
7	O	O
.	O	O

0	O	O
mg	O	O
/	O	O
kg	O	O
dose	O	O
.	O	O

Myoglobinuria	B-Disease	D009212
was	O	O
also	O	O
observed	O	O
following	O	O
the	O	O
7	O	O
.	O	O

0	O	O
mg	O	O
/	O	O
kg	O	O
dose	O	O
.	O	O

Histopathology	O	O
analyses	O	O
in	O	O
the	O	O
2	O	O
animals	O	O
that	O	O
died	O	O
revealed	O	O
liver	O	O
and	O	O
kidney	O	O
toxicity	B-Disease	D064420
,	O	O
with	O	O
greater	O	O
severity	O	O
in	O	O
the	O	O
orally	O	O
-	O	O
treated	O	O
animal	O	O
.	O	O

CONCLUSIONS	O	O
:	O	O
These	O	O
data	O	O
demonstrate	O	O
direct	O	O
and	O	O
/	O	O
or	O	O
indirect	O	O
drug	O	O
-	O	O
induced	O	O
toxicity	B-Disease	D064420
.	O	O

It	O	O
is	O	O
concluded	O	O
that	O	O
WR242511	B-Chemical	C068820
should	O	O
not	O	O
be	O	O
pursued	O	O
as	O	O
a	O	O
pretreatment	O	O
for	O	O
CN	O	O
poisoning	B-Disease	D011041
unless	O	O
the	O	O
anti	O	O
-	O	O
CN	O	O
characteristics	O	O
of	O	O
this	O	O
compound	O	O
can	O	O
be	O	O
successfully	O	O
dissociated	O	O
from	O	O
those	O	O
producing	O	O
undesirable	O	O
toxicity	B-Disease	D064420
.	O	O

Neuroplasticity	O	O
of	O	O
the	O	O
adult	O	O
primate	O	O
auditory	O	O
cortex	O	O
following	O	O
cochlear	O	O
hearing	B-Disease	D034381
loss	I-Disease	D034381
.	O	O

Tonotopic	O	O
organization	O	O
is	O	O
an	O	O
essential	O	O
feature	O	O
of	O	O
the	O	O
primary	O	O
auditory	O	O
area	O	O
(	O	O
A1	O	O
)	O	O
of	O	O
primate	O	O
cortex	O	O
.	O	O

In	O	O
A1	O	O
of	O	O
macaque	O	O
monkeys	O	O
,	O	O
low	O	O
frequencies	O	O
are	O	O
represented	O	O
rostrolaterally	O	O
and	O	O
high	O	O
frequencies	O	O
are	O	O
represented	O	O
caudomedially	O	O
.	O	O

The	O	O
purpose	O	O
of	O	O
this	O	O
study	O	O
was	O	O
to	O	O
determine	O	O
if	O	O
changes	O	O
occur	O	O
in	O	O
this	O	O
tonotopic	O	O
organization	O	O
following	O	O
cochlear	O	O
hearing	B-Disease	D034381
loss	I-Disease	D034381
.	O	O

Under	O	O
anesthesia	O	O
,	O	O
the	O	O
superior	O	O
temporal	O	O
gyrus	O	O
of	O	O
adult	O	O
macaque	O	O
monkeys	O	O
was	O	O
exposed	O	O
,	O	O
and	O	O
the	O	O
tonotopic	O	O
organization	O	O
of	O	O
A1	O	O
was	O	O
mapped	O	O
using	O	O
conventional	O	O
microelectrode	O	O
recording	O	O
techniques	O	O
.	O	O

Following	O	O
recovery	O	O
,	O	O
the	O	O
monkeys	O	O
were	O	O
selectively	O	O
deafened	O	O
for	O	O
high	O	O
frequencies	O	O
using	O	O
kanamycin	B-Chemical	D007612
and	O	O
furosemide	B-Chemical	D005665
.	O	O

The	O	O
actual	O	O
frequencies	O	O
deafened	O	O
were	O	O
determined	O	O
by	O	O
the	O	O
loss	O	O
of	O	O
tone	O	O
-	O	O
burst	O	O
elicited	O	O
auditory	O	O
brainstem	O	O
responses	O	O
.	O	O

Three	O	O
months	O	O
after	O	O
deafening	O	O
,	O	O
A1	O	O
was	O	O
remapped	O	O
.	O	O

Postmortem	O	O
cytoarchitectural	O	O
features	O	O
identifying	O	O
A1	O	O
were	O	O
correlated	O	O
with	O	O
the	O	O
electrophysiologic	O	O
data	O	O
.	O	O

The	O	O
results	O	O
indicate	O	O
that	O	O
the	O	O
deprived	O	O
area	O	O
of	O	O
A1	O	O
undergoes	O	O
extensive	O	O
reorganization	O	O
and	O	O
becomes	O	O
responsive	O	O
to	O	O
intact	O	O
cochlear	O	O
frequencies	O	O
.	O	O

The	O	O
region	O	O
of	O	O
cortex	O	O
that	O	O
represents	O	O
the	O	O
low	O	O
frequencies	O	O
was	O	O
not	O	O
obviously	O	O
affected	O	O
by	O	O
the	O	O
cochlear	O	O
hearing	B-Disease	D034381
loss	I-Disease	D034381
.	O	O

The	O	O
site	O	O
of	O	O
common	O	O
side	O	O
effects	O	O
of	O	O
sumatriptan	B-Chemical	D018170
.	O	O

Atypical	B-Disease	D010292
sensations	I-Disease	D010292
following	O	O
the	O	O
use	O	O
of	O	O
subcutaneous	O	O
sumatriptan	B-Chemical	D018170
are	O	O
common	O	O
,	O	O
but	O	O
of	O	O
uncertain	O	O
origin	O	O
.	O	O

They	O	O
are	O	O
almost	O	O
always	O	O
benign	O	O
,	O	O
but	O	O
can	O	O
be	O	O
mistaken	O	O
for	O	O
a	O	O
serious	O	O
adverse	O	O
event	O	O
by	O	O
the	O	O
patient	O	O
.	O	O

Two	O	O
patients	O	O
are	O	O
presented	O	O
with	O	O
tingling	B-Disease	D010292
or	I-Disease	D010292
burning	I-Disease	D010292
sensations	I-Disease	D010292
limited	O	O
to	O	O
areas	O	O
of	O	O
heat	O	O
exposure	O	O
or	O	O
sunburn	B-Disease	D013471
.	O	O

In	O	O
these	O	O
individuals	O	O
,	O	O
side	O	O
effects	O	O
are	O	O
most	O	O
likely	O	O
generated	O	O
superficially	O	O
in	O	O
the	O	O
skin	O	O
.	O	O

Tremor	B-Disease	D014202
side	O	O
effects	O	O
of	O	O
salbutamol	B-Chemical	D000420
,	O	O
quantified	O	O
by	O	O
a	O	O
laser	O	O
pointer	O	O
technique	O	O
.	O	O

OBJECTIVE	O	O
:	O	O
To	O	O
study	O	O
tremor	B-Disease	D014202
side	O	O
effects	O	O
of	O	O
salbutamol	B-Chemical	D000420
an	O	O
easily	O	O
applicable	O	O
,	O	O
quick	O	O
and	O	O
low	O	O
-	O	O
priced	O	O
method	O	O
is	O	O
needed	O	O
.	O	O

A	O	O
new	O	O
method	O	O
using	O	O
a	O	O
commercially	O	O
available	O	O
,	O	O
pen	O	O
-	O	O
shaped	O	O
laser	O	O
pointer	O	O
was	O	O
developed	O	O
.	O	O

Aim	O	O
of	O	O
the	O	O
study	O	O
was	O	O
to	O	O
determine	O	O
sensitivity	O	O
,	O	O
reproducibility	O	O
,	O	O
reference	O	O
values	O	O
and	O	O
the	O	O
agreement	O	O
with	O	O
a	O	O
questionnaire	O	O
.	O	O

METHODS	O	O
:	O	O
Tremor	B-Disease	D014202
was	O	O
measured	O	O
using	O	O
a	O	O
laser	O	O
pointer	O	O
technique	O	O
.	O	O

To	O	O
determine	O	O
sensitivity	O	O
we	O	O
assessed	O	O
tremor	B-Disease	D014202
in	O	O
44	O	O
patients	O	O
with	O	O
obstructive	B-Disease	D008173
lung	I-Disease	D008173
disease	I-Disease	D008173
after	O	O
administration	O	O
of	O	O
cumulative	O	O
doses	O	O
of	O	O
salbutamol	B-Chemical	D000420
.	O	O

Subjects	O	O
were	O	O
asked	O	O
to	O	O
aim	O	O
at	O	O
the	O	O
centre	O	O
of	O	O
a	O	O
target	O	O
,	O	O
subdivided	O	O
in	O	O
concentric	O	O
circles	O	O
,	O	O
from	O	O
5	O	O
m	O	O
distance	O	O
.	O	O

The	O	O
circle	O	O
in	O	O
which	O	O
the	O	O
participant	O	O
succeeded	O	O
to	O	O
aim	O	O
was	O	O
recorded	O	O
in	O	O
millimetres	O	O
radius	O	O
.	O	O

In	O	O
another	O	O
series	O	O
of	O	O
measurements	O	O
,	O	O
reproducibility	O	O
and	O	O
reference	O	O
values	O	O
of	O	O
the	O	O
tremor	B-Disease	D014202
was	O	O
assessed	O	O
in	O	O
65	O	O
healthy	O	O
subjects	O	O
in	O	O
three	O	O
sessions	O	O
,	O	O
at	O	O
9	O	O
a	O	O
.	O	O

m	O	O
.	O	O

,	O	O
4	O	O
p	O	O
.	O	O

m	O	O
.	O	O

and	O	O
9	O	O
a	O	O
.	O	O

m	O	O
.	O	O

,	O	O
respectively	O	O
,	O	O
1	O	O
week	O	O
later	O	O
.	O	O

Postural	O	O
tremor	B-Disease	D014202
was	O	O
measured	O	O
with	O	O
the	O	O
arm	O	O
horizontally	O	O
outstretched	O	O
rest	O	O
tremor	B-Disease	D014202
with	O	O
the	O	O
arm	O	O
supported	O	O
by	O	O
an	O	O
armrest	O	O
and	O	O
finally	O	O
tremor	B-Disease	D014202
was	O	O
measured	O	O
after	O	O
holding	O	O
a	O	O
2	O	O
-	O	O
kg	O	O
weight	O	O
until	O	O
exhaustion	O	O
.	O	O

Inter	O	O
-	O	O
observer	O	O
variability	O	O
was	O	O
measured	O	O
in	O	O
a	O	O
series	O	O
of	O	O
10	O	O
healthy	O	O
subjects	O	O
.	O	O

Tremor	B-Disease	D014202
was	O	O
measured	O	O
simultaneously	O	O
by	O	O
two	O	O
independent	O	O
observers	O	O
.	O	O

RESULTS	O	O
:	O	O
Salbutamol	B-Chemical	D000420
significantly	O	O
increased	O	O
tremor	B-Disease	D014202
severity	O	O
in	O	O
patients	O	O
in	O	O
a	O	O
dose	O	O
-	O	O
dependent	O	O
way	O	O
.	O	O

Within	O	O
healthy	O	O
adults	O	O
no	O	O
age	O	O
-	O	O
dependency	O	O
could	O	O
be	O	O
found	O	O
(	O	O
b	O	O
=	O	O
0	O	O
.	O	O

262	O	O
mm	O	O
/	O	O
year	O	O
;	O	O
P	O	O
=	O	O
0	O	O
.	O	O

72	O	O
)	O	O
.	O	O

There	O	O
was	O	O
no	O	O
agreement	O	O
between	O	O
the	O	O
questionnaire	O	O
and	O	O
tremor	B-Disease	D014202
severity	O	O
(	O	O
r	O	O
=	O	O
0	O	O
.	O	O

093	O	O
;	O	O
P	O	O
=	O	O
0	O	O
.	O	O

53	O	O
)	O	O
.	O	O

Postural	O	O
tremor	B-Disease	D014202
showed	O	O
no	O	O
significant	O	O
difference	O	O
between	O	O
the	O	O
first	O	O
and	O	O
third	O	O
session	O	O
(	O	O
P	O	O
=	O	O
0	O	O
.	O	O

07	O	O
)	O	O
.	O	O

Support	O	O
of	O	O
the	O	O
arm	O	O
decreased	O	O
tremor	B-Disease	D014202
severity	O	O
,	O	O
exhaustion	O	O
increased	O	O
tremor	B-Disease	D014202
severity	O	O
significantly	O	O
.	O	O

A	O	O
good	O	O
agreement	O	O
was	O	O
found	O	O
between	O	O
two	O	O
independent	O	O
observers	O	O
(	O	O
interclass	O	O
correlation	O	O
coefficient	O	O
0	O	O
.	O	O

72	O	O
)	O	O
.	O	O

DISCUSSION	O	O
:	O	O
Quantifying	O	O
tremor	B-Disease	D014202
by	O	O
using	O	O
an	O	O
inexpensive	O	O
laser	O	O
pointer	O	O
is	O	O
,	O	O
with	O	O
the	O	O
exception	O	O
of	O	O
children	O	O
(	O	O
<12	O	O
years	O	O
)	O	O
a	O	O
sensitive	O	O
and	O	O
reproducible	O	O
method	O	O
.	O	O

Increased	O	O
frequency	O	O
of	O	O
venous	B-Disease	D054556
thromboembolism	I-Disease	D054556
with	O	O
the	O	O
combination	O	O
of	O	O
docetaxel	B-Chemical	C067311
and	O	O
thalidomide	B-Chemical	D013792
in	O	O
patients	O	O
with	O	O
metastatic	O	O
androgen	O	O
-	O	O
independent	O	O
prostate	B-Disease	D011471
cancer	I-Disease	D011471
.	O	O

STUDY	O	O
OBJECTIVE	O	O
:	O	O
To	O	O
evaluate	O	O
the	O	O
frequency	O	O
of	O	O
venous	B-Disease	D054556
thromboembolism	I-Disease	D054556
(	O	O
VTE	B-Disease	D054556
)	O	O
in	O	O
patients	O	O
with	O	O
advanced	O	O
androgen	O	O
-	O	O
independent	O	O
prostate	B-Disease	D011471
cancer	I-Disease	D011471
who	O	O
were	O	O
treated	O	O
with	O	O
docetaxel	B-Chemical	C067311
alone	O	O
or	O	O
in	O	O
combination	O	O
with	O	O
thalidomide	B-Chemical	D013792
.	O	O

DESIGN	O	O
:	O	O
Retrospective	O	O
analysis	O	O
of	O	O
a	O	O
randomized	O	O
phase	O	O
II	O	O
trial	O	O
.	O	O

SETTING	O	O
:	O	O
National	O	O
Institutes	O	O
of	O	O
Health	O	O
clinical	O	O
research	O	O
center	O	O
.	O	O

PATIENTS	O	O
:	O	O
Seventy	O	O
men	O	O
,	O	O
aged	O	O
50	O	O
-	O	O
80	O	O
years	O	O
,	O	O
with	O	O
advanced	O	O
androgen	O	O
-	O	O
independent	O	O
prostate	B-Disease	D011471
cancer	I-Disease	D011471
.	O	O

INTERVENTION	O	O
:	O	O
Each	O	O
patient	O	O
received	O	O
either	O	O
intravenous	O	O
docetaxel	B-Chemical	C067311
30	O	O
mg	O	O
/	O	O
m2	O	O
/	O	O
week	O	O
for	O	O
3	O	O
consecutive	O	O
weeks	O	O
,	O	O
followed	O	O
by	O	O
1	O	O
week	O	O
off	O	O
,	O	O
or	O	O
the	O	O
combination	O	O
of	O	O
continuous	O	O
oral	O	O
thalidomide	B-Chemical	D013792
200	O	O
mg	O	O
every	O	O
evening	O	O
plus	O	O
the	O	O
same	O	O
docetaxel	B-Chemical	C067311
regimen	O	O
.	O	O

This	O	O
4	O	O
-	O	O
week	O	O
cycle	O	O
was	O	O
repeated	O	O
until	O	O
there	O	O
was	O	O
evidence	O	O
of	O	O
excessive	O	O
toxicity	B-Disease	D064420
or	O	O
disease	O	O
progression	O	O
.	O	O

MEASUREMENTS	O	O
AND	O	O
MAIN	O	O
RESULTS	O	O
:	O	O
None	O	O
of	O	O
23	O	O
patients	O	O
who	O	O
received	O	O
docetaxel	B-Chemical	C067311
alone	O	O
developed	O	O
VTE	B-Disease	D054556
,	O	O
whereas	O	O
9	O	O
of	O	O
47	O	O
patients	O	O
(	O	O
19%	O	O
)	O	O
who	O	O
received	O	O
docetaxel	B-Chemical	C067311
plus	O	O
thalidomide	B-Chemical	D013792
developed	O	O
VTE	B-Disease	D054556
(	O	O
p=0	O	O
.	O	O

025	O	O
)	O	O
.	O	O

CONCLUSION	O	O
:	O	O
The	O	O
addition	O	O
of	O	O
thalidomide	B-Chemical	D013792
to	O	O
docetaxel	B-Chemical	C067311
in	O	O
the	O	O
treatment	O	O
of	O	O
prostate	B-Disease	D011471
cancer	I-Disease	D011471
significantly	O	O
increases	O	O
the	O	O
frequency	O	O
of	O	O
VTE	B-Disease	D054556
.	O	O

Clinicians	O	O
should	O	O
be	O	O
aware	O	O
of	O	O
this	O	O
potential	O	O
complication	O	O
when	O	O
adding	O	O
thalidomide	B-Chemical	D013792
to	O	O
chemotherapeutic	O	O
regimens	O	O
.	O	O

Sublingual	O	O
absorption	O	O
of	O	O
the	O	O
quaternary	B-Chemical	D000644
ammonium	I-Chemical	D000644
antiarrhythmic	O	O
agent	O	O
,	O	O
UM	B-Chemical	C002616
-	I-Chemical	C002616
272	I-Chemical	C002616
.	O	O

UM	B-Chemical	C002616
-	I-Chemical	C002616
272	I-Chemical	C002616
(	O	O
N	B-Chemical	C002616
,	I-Chemical	C002616
N	I-Chemical	C002616
-	I-Chemical	C002616
dimethylpropranolol	I-Chemical	C002616
)	O	O
,	O	O
a	O	O
quaternary	O	O
antiarrhythmic	O	O
agent	O	O
,	O	O
was	O	O
administered	O	O
sublingually	O	O
to	O	O
dogs	O	O
with	O	O
ouabain	B-Chemical	D010042
-	O	O
induced	O	O
ventricular	B-Disease	D017180
tachycardias	I-Disease	D017180
.	O	O

Both	O	O
anti	O	O
-	O	O
arrhythmic	O	O
efficacy	O	O
and	O	O
bioavailability	O	O
were	O	O
compared	O	O
to	O	O
oral	O	O
drug	O	O
.	O	O

Sublingual	O	O
UM	B-Chemical	C002616
-	I-Chemical	C002616
272	I-Chemical	C002616
converted	O	O
ventricular	B-Disease	D017180
tachycardia	I-Disease	D017180
to	O	O
sinus	O	O
rhythm	O	O
in	O	O
all	O	O
5	O	O
dogs	O	O
.	O	O

The	O	O
area	O	O
under	O	O
the	O	O
plasma	O	O
concentration	O	O
time	O	O
curve	O	O
at	O	O
90	O	O
min	O	O
was	O	O
4	O	O
-	O	O
12	O	O
times	O	O
greater	O	O
than	O	O
for	O	O
oral	O	O
drug	O	O
,	O	O
suggesting	O	O
the	O	O
existence	O	O
of	O	O
an	O	O
absorption	O	O
-	O	O
limiting	O	O
process	O	O
in	O	O
the	O	O
intestine	O	O
,	O	O
and	O	O
providing	O	O
an	O	O
alternate	O	O
form	O	O
of	O	O
administration	O	O
for	O	O
quaternary	O	O
drugs	O	O
.	O	O

Severe	O	O
thrombocytopenia	B-Disease	D013921
and	O	O
haemolytic	B-Disease	D000743
anaemia	I-Disease	D000743
associated	O	O
with	O	O
ciprofloxacin	B-Chemical	D002939
:	O	O
a	O	O
case	O	O
report	O	O
with	O	O
fatal	O	O
outcome	O	O
.	O	O

Haematological	O	O
adverse	O	O
reactions	O	O
associated	O	O
with	O	O
fatal	O	O
outcome	O	O
are	O	O
rare	O	O
during	O	O
treatment	O	O
with	O	O
ciprofloxacin	B-Chemical	D002939
.	O	O

A	O	O
30	O	O
-	O	O
year	O	O
old	O	O
Caucasian	O	O
man	O	O
reported	O	O
with	O	O
abdominal	B-Disease	D015746
pain	I-Disease	D015746
and	O	O
jaundice	B-Disease	D007565
after	O	O
3	O	O
-	O	O
day	O	O
administration	O	O
of	O	O
oral	O	O
ciprofloxacin	B-Chemical	D002939
for	O	O
a	O	O
suspect	O	O
of	O	O
urinary	B-Disease	D014552
tract	I-Disease	D014552
infection	I-Disease	D014552
.	O	O

Clinical	O	O
evaluations	O	O
suggested	O	O
an	O	O
initial	O	O
diagnosis	O	O
of	O	O
severe	O	O
thrombocytopenia	B-Disease	D013921
and	O	O
haemolysis	B-Disease	D006461
.	O	O

The	O	O
patient	O	O
progressively	O	O
developed	O	O
petechiae	B-Disease	D011693
and	O	O
purpura	B-Disease	D011693
on	O	O
thorax	O	O
and	O	O
lower	O	O
limbs	O	O
.	O	O

Despite	O	O
pharmacological	O	O
and	O	O
supportive	O	O
interventions	O	O
,	O	O
laboratory	O	O
parameters	O	O
worsened	O	O
and	O	O
the	O	O
patient	O	O
died	O	O
17	O	O
hours	O	O
after	O	O
admission	O	O
.	O	O

An	O	O
accurate	O	O
autopsy	O	O
revealed	O	O
most	O	O
organs	O	O
with	O	O
diffuse	O	O
petechial	O	O
haemorrhages	B-Disease	D006470
.	O	O

No	O	O
signs	O	O
of	O	O
bone	B-Disease	D001855
marrow	I-Disease	D001855
depression	I-Disease	D001855
were	O	O
found	O	O
.	O	O

No	O	O
thrombi	B-Disease	D013927
or	O	O
signs	O	O
of	O	O
microangiopathies	B-Disease	D014652
were	O	O
observed	O	O
in	O	O
arterial	O	O
vessels	O	O
.	O	O

Blood	O	O
and	O	O
urine	O	O
cultures	O	O
did	O	O
not	O	O
show	O	O
any	O	O
bacterial	O	O
growth	O	O
.	O	O

This	O	O
case	O	O
report	O	O
shows	O	O
that	O	O
ciprofloxacin	B-Chemical	D002939
may	O	O
precipitate	O	O
life	O	O
-	O	O
threatening	O	O
thrombocytopenia	B-Disease	D013921
and	O	O
haemolytic	B-Disease	D000743
anaemia	I-Disease	D000743
,	O	O
even	O	O
in	O	O
the	O	O
early	O	O
phases	O	O
of	O	O
treatment	O	O
and	O	O
without	O	O
apparent	O	O
previous	O	O
exposures	O	O
.	O	O

Simvastatin	B-Chemical	D019821
-	O	O
induced	O	O
bilateral	O	O
leg	O	O
compartment	B-Disease	D003161
syndrome	I-Disease	D003161
and	O	O
myonecrosis	B-Disease	D009135
associated	O	O
with	O	O
hypothyroidism	B-Disease	D007037
.	O	O

A	O	O
54	O	O
-	O	O
year	O	O
-	O	O
old	O	O
hypothyroid	B-Disease	D007037
male	O	O
taking	O	O
thyroxine	B-Chemical	D013974
and	O	O
simvastatin	B-Chemical	D019821
presented	O	O
with	O	O
bilateral	O	O
leg	O	O
compartment	B-Disease	D003161
syndrome	I-Disease	D003161
and	O	O
myonecrosis	B-Disease	D009135
.	O	O

Urgent	O	O
fasciotomies	O	O
were	O	O
performed	O	O
and	O	O
the	O	O
patient	O	O
made	O	O
an	O	O
uneventful	O	O
recovery	O	O
with	O	O
the	O	O
withdrawal	O	O
of	O	O
simvastatin	B-Chemical	D019821
.	O	O

It	O	O
is	O	O
likely	O	O
that	O	O
this	O	O
complication	O	O
will	O	O
be	O	O
seen	O	O
more	O	O
often	O	O
with	O	O
the	O	O
increased	O	O
worldwide	O	O
use	O	O
of	O	O
this	O	O
drug	O	O
and	O	O
its	O	O
approval	O	O
for	O	O
all	O	O
arteriopathic	B-Disease	D014652
patients	O	O
.	O	O

Bile	O	O
duct	O	O
hamartoma	O	O
occurring	O	O
in	O	O
association	O	O
with	O	O
long	O	O
-	O	O
term	O	O
treatment	O	O
with	O	O
danazol	B-Chemical	D003613
.	O	O

We	O	O
report	O	O
a	O	O
case	O	O
of	O	O
bile	O	O
duct	O	O
hamartoma	O	O
which	O	O
developed	O	O
in	O	O
a	O	O
patient	O	O
who	O	O
had	O	O
been	O	O
on	O	O
long	O	O
-	O	O
term	O	O
danazol	B-Chemical	D003613
treatment	O	O
.	O	O

Such	O	O
patients	O	O
should	O	O
be	O	O
under	O	O
close	O	O
follow	O	O
-	O	O
up	O	O
,	O	O
preferably	O	O
with	O	O
periodic	O	O
ultrasound	O	O
examination	O	O
of	O	O
the	O	O
liver	O	O
.	O	O

If	O	O
the	O	O
patient	O	O
develops	O	O
a	O	O
liver	B-Disease	D008107
mass	I-Disease	D008107
,	O	O
because	O	O
of	O	O
non	O	O
-	O	O
specific	O	O
clinical	O	O
features	O	O
and	O	O
imaging	O	O
appearances	O	O
,	O	O
biopsy	O	O
may	O	O
be	O	O
the	O	O
only	O	O
way	O	O
to	O	O
achieve	O	O
a	O	O
definitive	O	O
diagnosis	O	O
.	O	O

Granulomatous	O	O
hepatitis	B-Disease	D056486
due	O	O
to	O	O
combination	B-Chemical	D019980
of	I-Chemical	D019980
amoxicillin	I-Chemical	D019980
and	I-Chemical	D019980
clavulanic	I-Chemical	D019980
acid	I-Chemical	D019980
.	O	O

We	O	O
report	O	O
the	O	O
case	O	O
of	O	O
a	O	O
patient	O	O
with	O	O
amoxicillin	B-Chemical	D019980
-	I-Chemical	D019980
clavulanic	I-Chemical	D019980
acid	I-Chemical	D019980
-	O	O
induced	O	O
hepatitis	B-Disease	D056486
with	O	O
histologic	O	O
multiple	O	O
granulomas	B-Disease	D006099
.	O	O

This	O	O
type	O	O
of	O	O
lesion	O	O
broadens	O	O
the	O	O
spectrum	O	O
of	O	O
liver	B-Disease	D056486
injury	I-Disease	D056486
due	O	O
to	O	O
this	O	O
drug	O	O
combination	O	O
,	O	O
mainly	O	O
represented	O	O
by	O	O
a	O	O
benign	O	O
cholestatic	B-Disease	D002779
syndrome	I-Disease	D002779
.	O	O

The	O	O
association	O	O
of	O	O
granulomas	B-Disease	D006099
and	O	O
eosinophilia	B-Disease	D004802
favor	O	O
an	O	O
immunoallergic	O	O
mechanism	O	O
.	O	O

As	O	O
penicillin	B-Chemical	D010406
derivatives	O	O
and	O	O
amoxicillin	B-Chemical	D000658
alone	O	O
are	O	O
known	O	O
to	O	O
induce	O	O
such	O	O
types	O	O
of	O	O
lesions	O	O
,	O	O
the	O	O
amoxicillin	B-Chemical	D000658
component	O	O
,	O	O
with	O	O
or	O	O
without	O	O
a	O	O
potentiating	O	O
effect	O	O
of	O	O
clavulanic	B-Chemical	D019818
acid	I-Chemical	D019818
,	O	O
might	O	O
have	O	O
a	O	O
major	O	O
role	O	O
.	O	O

Intracranial	B-Disease	D002532
aneurysms	I-Disease	D002532
and	O	O
cocaine	B-Disease	D019970
abuse	I-Disease	D019970
:	O	O
analysis	O	O
of	O	O
prognostic	O	O
indicators	O	O
.	O	O

OBJECTIVE	O	O
:	O	O
The	O	O
outcome	O	O
of	O	O
subarachnoid	B-Disease	D013345
hemorrhage	I-Disease	D013345
associated	O	O
with	O	O
cocaine	B-Disease	D019970
abuse	I-Disease	D019970
is	O	O
reportedly	O	O
poor	O	O
.	O	O

However	O	O
,	O	O
no	O	O
study	O	O
in	O	O
the	O	O
literature	O	O
has	O	O
reported	O	O
the	O	O
use	O	O
of	O	O
a	O	O
statistical	O	O
model	O	O
to	O	O
analyze	O	O
the	O	O
variables	O	O
that	O	O
influence	O	O
outcome	O	O
.	O	O

METHODS	O	O
:	O	O
A	O	O
review	O	O
of	O	O
admissions	O	O
during	O	O
a	O	O
6	O	O
-	O	O
year	O	O
period	O	O
revealed	O	O
14	O	O
patients	O	O
with	O	O
cocaine	B-Chemical	D003042
-	O	O
related	O	O
aneurysms	B-Disease	D000783
.	O	O

This	O	O
group	O	O
was	O	O
compared	O	O
with	O	O
a	O	O
control	O	O
group	O	O
of	O	O
135	O	O
patients	O	O
with	O	O
ruptured	B-Disease	D017542
aneurysms	I-Disease	D017542
and	O	O
no	O	O
history	O	O
of	O	O
cocaine	B-Disease	D019970
abuse	I-Disease	D019970
.	O	O

Age	O	O
at	O	O
presentation	O	O
,	O	O
time	O	O
of	O	O
ictus	O	O
after	O	O
intoxication	O	O
,	O	O
Hunt	O	O
and	O	O
Hess	O	O
grade	O	O
of	O	O
subarachnoid	B-Disease	D013345
hemorrhage	I-Disease	D013345
,	O	O
size	O	O
of	O	O
the	O	O
aneurysm	B-Disease	D000783
,	O	O
location	O	O
of	O	O
the	O	O
aneurysm	B-Disease	D000783
,	O	O
and	O	O
the	O	O
Glasgow	O	O
Outcome	O	O
Scale	O	O
score	O	O
were	O	O
assessed	O	O
and	O	O
compared	O	O
.	O	O

RESULTS	O	O
:	O	O
The	O	O
patients	O	O
in	O	O
the	O	O
study	O	O
group	O	O
were	O	O
significantly	O	O
younger	O	O
than	O	O
the	O	O
patients	O	O
in	O	O
the	O	O
control	O	O
group	O	O
(	O	O
P	O	O
<	O	O
0	O	O
.	O	O

002	O	O
)	O	O
.	O	O

In	O	O
patients	O	O
in	O	O
the	O	O
study	O	O
group	O	O
,	O	O
all	O	O
aneurysms	B-Disease	D000783
were	O	O
located	O	O
in	O	O
the	O	O
anterior	O	O
circulation	O	O
.	O	O

The	O	O
majority	O	O
of	O	O
these	O	O
aneurysms	B-Disease	D000783
were	O	O
smaller	O	O
than	O	O
those	O	O
of	O	O
the	O	O
control	O	O
group	O	O
(	O	O
8	O	O
+	O	O
/	O	O
-	O	O
6	O	O
.	O	O

08	O	O
mm	O	O
versus	O	O
11	O	O
+	O	O
/	O	O
-	O	O
5	O	O
.	O	O

4	O	O
mm	O	O
;	O	O
P	O	O
=	O	O
0	O	O
.	O	O

05	O	O
)	O	O
.	O	O

The	O	O
differences	O	O
in	O	O
mortality	O	O
and	O	O
morbidity	O	O
between	O	O
the	O	O
two	O	O
groups	O	O
were	O	O
not	O	O
significant	O	O
.	O	O

Hunt	O	O
and	O	O
Hess	O	O
grade	O	O
(	O	O
P	O	O
<	O	O
0	O	O
.	O	O

005	O	O
)	O	O
and	O	O
age	O	O
(	O	O
P	O	O
<	O	O
0	O	O
.	O	O

007	O	O
)	O	O
were	O	O
significant	O	O
predictors	O	O
of	O	O
outcome	O	O
for	O	O
the	O	O
patients	O	O
with	O	O
cocaine	B-Chemical	D003042
-	O	O
related	O	O
aneurysms	B-Disease	D000783
.	O	O

CONCLUSION	O	O
:	O	O
Cocaine	B-Chemical	D003042
use	O	O
predisposed	O	O
aneurysmal	B-Disease	D017542
rupture	I-Disease	D017542
at	O	O
a	O	O
significantly	O	O
earlier	O	O
age	O	O
and	O	O
in	O	O
much	O	O
smaller	O	O
aneurysms	B-Disease	D000783
.	O	O

Contrary	O	O
to	O	O
the	O	O
published	O	O
literature	O	O
,	O	O
this	O	O
group	O	O
did	O	O
reasonably	O	O
well	O	O
with	O	O
aggressive	O	O
management	O	O
.	O	O

Anti	O	O
-	O	O
epileptic	B-Disease	D004827
drugs	O	O
-	O	O
induced	O	O
de	O	O
novo	O	O
absence	B-Disease	D004832
seizures	I-Disease	D004832
.	O	O

The	O	O
authors	O	O
present	O	O
three	O	O
patients	O	O
with	O	O
de	O	O
novo	O	O
absence	B-Disease	D004832
epilepsy	I-Disease	D004832
after	O	O
administration	O	O
of	O	O
carbamazepine	B-Chemical	D002220
and	O	O
vigabatrin	B-Chemical	D020888
.	O	O

Despite	O	O
the	O	O
underlying	O	O
diseases	O	O
,	O	O
the	O	O
prognosis	O	O
for	O	O
drug	O	O
-	O	O
induced	O	O
de	O	O
novo	O	O
absence	B-Disease	D004832
seizure	I-Disease	D004832
is	O	O
good	O	O
because	O	O
it	O	O
subsides	O	O
rapidly	O	O
after	O	O
discontinuing	O	O
the	O	O
use	O	O
of	O	O
the	O	O
offending	O	O
drugs	O	O
.	O	O

The	O	O
gamma	B-Chemical	D005680
-	I-Chemical	D005680
aminobutyric	I-Chemical	D005680
acid	I-Chemical	D005680
-	O	O
transmitted	O	O
thalamocortical	O	O
circuitry	O	O
accounts	O	O
for	O	O
a	O	O
major	O	O
part	O	O
of	O	O
the	O	O
underlying	O	O
neurophysiology	O	O
of	O	O
the	O	O
absence	B-Disease	D004832
epilepsy	I-Disease	D004832
.	O	O

Because	O	O
drug	O	O
-	O	O
induced	O	O
de	O	O
novo	O	O
absence	B-Disease	D004832
seizure	I-Disease	D004832
is	O	O
rare	O	O
,	O	O
pro	O	O
-	O	O
absence	O	O
drugs	O	O
can	O	O
only	O	O
be	O	O
considered	O	O
a	O	O
promoting	O	O
factor	O	O
.	O	O

The	O	O
underlying	O	O
epileptogenecity	O	O
of	O	O
the	O	O
patients	O	O
or	O	O
the	O	O
synergistic	O	O
effects	O	O
of	O	O
the	O	O
accompanying	O	O
drugs	O	O
is	O	O
required	O	O
to	O	O
trigger	O	O
the	O	O
de	O	O
novo	O	O
absence	B-Disease	D004832
seizure	I-Disease	D004832
.	O	O

The	O	O
possibility	O	O
of	O	O
drug	O	O
-	O	O
induced	O	O
aggravation	O	O
should	O	O
be	O	O
considered	O	O
whenever	O	O
an	O	O
unexpected	O	O
increase	O	O
in	O	O
seizure	B-Disease	D012640
frequency	O	O
and	O	O
/	O	O
or	O	O
new	O	O
seizure	B-Disease	D012640
types	O	O
appear	O	O
following	O	O
a	O	O
change	O	O
in	O	O
drug	O	O
treatment	O	O
.	O	O

By	O	O
understanding	O	O
the	O	O
underlying	O	O
mechanism	O	O
of	O	O
absence	B-Disease	D004832
epilepsy	I-Disease	D004832
,	O	O
we	O	O
can	O	O
avoid	O	O
the	O	O
inappropriate	O	O
use	O	O
of	O	O
anticonvulsants	O	O
in	O	O
children	O	O
with	O	O
epilepsy	B-Disease	D004827
and	O	O
prevent	O	O
drug	O	O
-	O	O
induced	O	O
absence	B-Disease	D004832
seizures	I-Disease	D004832
.	O	O

Procainamide	B-Chemical	D011342
-	O	O
induced	O	O
polymorphous	O	O
ventricular	B-Disease	D017180
tachycardia	I-Disease	D017180
.	O	O

Seven	O	O
cases	O	O
of	O	O
procainamide	B-Chemical	D011342
-	O	O
induced	O	O
polymorphous	O	O
ventricular	B-Disease	D017180
tachycardia	I-Disease	D017180
are	O	O
presented	O	O
.	O	O

In	O	O
four	O	O
patients	O	O
,	O	O
polymorphous	O	O
ventricular	B-Disease	D017180
tachycardia	I-Disease	D017180
appeared	O	O
after	O	O
intravenous	O	O
administration	O	O
of	O	O
200	O	O
to	O	O
400	O	O
mg	O	O
of	O	O
procainamide	B-Chemical	D011342
for	O	O
the	O	O
treatment	O	O
of	O	O
sustained	O	O
ventricular	B-Disease	D017180
tachycardia	I-Disease	D017180
.	O	O

In	O	O
the	O	O
remaining	O	O
three	O	O
patients	O	O
,	O	O
procainamide	B-Chemical	D011342
was	O	O
administered	O	O
orally	O	O
for	O	O
treatment	O	O
of	O	O
chronic	O	O
premature	B-Disease	D018879
ventricular	I-Disease	D018879
contractions	I-Disease	D018879
or	O	O
atrial	B-Disease	D001282
flutter	I-Disease	D001282
.	O	O

These	O	O
patients	O	O
had	O	O
Q	B-Disease	D008133
-	I-Disease	D008133
T	I-Disease	D008133
prolongation	I-Disease	D008133
and	O	O
recurrent	O	O
syncope	B-Disease	D013575
due	O	O
to	O	O
polymorphous	O	O
ventricular	B-Disease	D017180
tachycardia	I-Disease	D017180
.	O	O

In	O	O
four	O	O
patients	O	O
,	O	O
the	O	O
arrhythmia	B-Disease	D001145
was	O	O
rapidly	O	O
diagnosed	O	O
and	O	O
treated	O	O
with	O	O
disappearance	O	O
of	O	O
further	O	O
episodes	O	O
of	O	O
the	O	O
arrhythmia	B-Disease	D001145
.	O	O

In	O	O
two	O	O
patients	O	O
,	O	O
the	O	O
arrhythmia	B-Disease	D001145
degenerated	O	O
into	O	O
irreversible	O	O
ventricular	B-Disease	D014693
fibrillation	I-Disease	D014693
and	O	O
both	O	O
patients	O	O
died	O	O
.	O	O

In	O	O
the	O	O
seventh	O	O
patient	O	O
,	O	O
a	O	O
permanent	O	O
ventricular	O	O
pacemaker	O	O
was	O	O
inserted	O	O
and	O	O
,	O	O
despite	O	O
continuation	O	O
of	O	O
procainamide	B-Chemical	D011342
therapy	O	O
,	O	O
polymorphous	O	O
ventricular	B-Disease	D017180
tachycardia	I-Disease	D017180
did	O	O
not	O	O
reoccur	O	O
.	O	O

These	O	O
seven	O	O
cases	O	O
demonstrate	O	O
that	O	O
procainamide	B-Chemical	D011342
can	O	O
produce	O	O
an	O	O
acquired	O	O
prolonged	B-Disease	D008133
Q	I-Disease	D008133
-	I-Disease	D008133
T	I-Disease	D008133
syndrome	I-Disease	D008133
with	O	O
polymorphous	O	O
ventricular	B-Disease	D017180
tachycardia	I-Disease	D017180
.	O	O

Role	O	O
of	O	O
activation	O	O
of	O	O
bradykinin	B-Chemical	D001920
B2	O	O
receptors	O	O
in	O	O
disruption	O	O
of	O	O
the	O	O
blood	O	O
-	O	O
brain	O	O
barrier	O	O
during	O	O
acute	O	O
hypertension	B-Disease	D006973
.	O	O

Cellular	O	O
mechanisms	O	O
which	O	O
account	O	O
for	O	O
disruption	O	O
the	O	O
blood	O	O
-	O	O
brain	O	O
barrier	O	O
during	O	O
acute	O	O
hypertension	B-Disease	D006973
are	O	O
not	O	O
clear	O	O
.	O	O

The	O	O
goal	O	O
of	O	O
this	O	O
study	O	O
was	O	O
to	O	O
determine	O	O
the	O	O
role	O	O
of	O	O
synthesis	O	O
/	O	O
release	O	O
of	O	O
bradykinin	B-Chemical	D001920
to	O	O
activate	O	O
B2	O	O
receptors	O	O
in	O	O
disruption	O	O
of	O	O
the	O	O
blood	O	O
-	O	O
brain	O	O
barrier	O	O
during	O	O
acute	O	O
hypertension	B-Disease	D006973
.	O	O

Permeability	O	O
of	O	O
the	O	O
blood	O	O
-	O	O
brain	O	O
barrier	O	O
was	O	O
quantitated	O	O
by	O	O
clearance	O	O
of	O	O
fluorescent	O	O
-	O	O
labeled	O	O
dextran	B-Chemical	D003911
before	O	O
and	O	O
during	O	O
phenylephrine	B-Chemical	D010656
-	O	O
induced	O	O
acute	O	O
hypertension	B-Disease	D006973
in	O	O
rats	O	O
treated	O	O
with	O	O
vehicle	O	O
and	O	O
Hoe	B-Chemical	C065679
-	I-Chemical	C065679
140	I-Chemical	C065679
(	O	O
0	O	O
.	O	O

1	O	O
microM	O	O
)	O	O
.	O	O

Phenylephrine	B-Chemical	D010656
infusion	O	O
increased	O	O
arterial	O	O
pressure	O	O
,	O	O
arteriolar	O	O
diameter	O	O
and	O	O
clearance	O	O
of	O	O
fluorescent	O	O
dextran	B-Chemical	D003911
by	O	O
a	O	O
similar	O	O
magnitude	O	O
in	O	O
both	O	O
groups	O	O
.	O	O

These	O	O
findings	O	O
suggest	O	O
that	O	O
disruption	O	O
of	O	O
the	O	O
blood	O	O
-	O	O
brain	O	O
barrier	O	O
during	O	O
acute	O	O
hypertension	B-Disease	D006973
is	O	O
not	O	O
related	O	O
to	O	O
the	O	O
synthesis	O	O
/	O	O
release	O	O
of	O	O
bradykinin	B-Chemical	D001920
to	O	O
activate	O	O
B2	O	O
receptors	O	O
.	O	O

5	B-Chemical	D001374
-	I-Chemical	D001374
azacytidine	I-Chemical	D001374
potentiates	O	O
initiation	B-Disease	D011230
induced	I-Disease	D011230
by	I-Disease	D011230
carcinogens	I-Disease	D011230
in	O	O
rat	O	O
liver	O	O
.	O	O

To	O	O
test	O	O
the	O	O
validity	O	O
of	O	O
the	O	O
hypothesis	O	O
that	O	O
hypomethylation	O	O
of	O	O
DNA	O	O
plays	O	O
an	O	O
important	O	O
role	O	O
in	O	O
the	O	O
initiation	B-Disease	D011230
of	I-Disease	D011230
carcinogenic	I-Disease	D011230
process	I-Disease	D011230
,	O	O
5	B-Chemical	D001374
-	I-Chemical	D001374
azacytidine	I-Chemical	D001374
(	O	O
5	B-Chemical	D001374
-	I-Chemical	D001374
AzC	I-Chemical	D001374
)	O	O
(	O	O
10	O	O
mg	O	O
/	O	O
kg	O	O
)	O	O
,	O	O
an	O	O
inhibitor	O	O
of	O	O
DNA	O	O
methylation	O	O
,	O	O
was	O	O
given	O	O
to	O	O
rats	O	O
during	O	O
the	O	O
phase	O	O
of	O	O
repair	O	O
synthesis	O	O
induced	O	O
by	O	O
the	O	O
three	O	O
carcinogens	O	O
,	O	O
benzo	B-Chemical	D001564
[	I-Chemical	D001564
a	I-Chemical	D001564
]	I-Chemical	D001564
-	I-Chemical	D001564
pyrene	I-Chemical	D001564
(	O	O
200	O	O
mg	O	O
/	O	O
kg	O	O
)	O	O
,	O	O
N	B-Chemical	D008770
-	I-Chemical	D008770
methyl	I-Chemical	D008770
-	I-Chemical	D008770
N	I-Chemical	D008770
-	I-Chemical	D008770
nitrosourea	I-Chemical	D008770
(	O	O
60	O	O
mg	O	O
/	O	O
kg	O	O
)	O	O
and	O	O
1	B-Chemical	D019813
,	I-Chemical	D019813
2	I-Chemical	D019813
-	I-Chemical	D019813
dimethylhydrazine	I-Chemical	D019813
(	O	O
1	B-Chemical	D019813
,	I-Chemical	D019813
2	I-Chemical	D019813
-	I-Chemical	D019813
DMH	I-Chemical	D019813
)	O	O
(	O	O
100	O	O
mg	O	O
/	O	O
kg	O	O
)	O	O
.	O	O

The	O	O
initiated	O	O
hepatocytes	O	O
in	O	O
the	O	O
liver	O	O
were	O	O
assayed	O	O
as	O	O
the	O	O
gamma	O	O
-	O	O
glutamyltransferase	O	O
(	O	O
gamma	O	O
-	O	O
GT	O	O
)	O	O
positive	O	O
foci	O	O
formed	O	O
following	O	O
a	O	O
2	O	O
-	O	O
week	O	O
selection	O	O
regimen	O	O
consisting	O	O
of	O	O
dietary	O	O
0	O	O
.	O	O

02%	O	O
2	B-Chemical	D015073
-	I-Chemical	D015073
acetylaminofluorene	I-Chemical	D015073
coupled	O	O
with	O	O
a	O	O
necrogenic	O	O
dose	O	O
of	O	O
CCl4	B-Chemical	D002251
.	O	O

The	O	O
results	O	O
obtained	O	O
indicate	O	O
that	O	O
with	O	O
all	O	O
three	O	O
carcinogens	O	O
,	O	O
administration	O	O
of	O	O
5	B-Chemical	D001374
-	I-Chemical	D001374
AzC	I-Chemical	D001374
during	O	O
repair	O	O
synthesis	O	O
increased	O	O
the	O	O
incidence	O	O
of	O	O
initiated	O	O
hepatocytes	O	O
,	O	O
for	O	O
example	O	O
10	O	O
-	O	O
20	O	O
foci	O	O
/	O	O
cm2	O	O
in	O	O
5	B-Chemical	D001374
-	I-Chemical	D001374
AzC	I-Chemical	D001374
and	O	O
carcinogen	O	O
-	O	O
treated	O	O
rats	O	O
compared	O	O
with	O	O
3	O	O
-	O	O
5	O	O
foci	O	O
/	O	O
cm2	O	O
in	O	O
rats	O	O
treated	O	O
with	O	O
carcinogen	O	O
only	O	O
.	O	O

Administration	O	O
of	O	O
[	B-Chemical	C014347
3H	I-Chemical	C014347
]	I-Chemical	C014347
-	I-Chemical	C014347
5	I-Chemical	C014347
-	I-Chemical	C014347
azadeoxycytidine	I-Chemical	C014347
during	O	O
the	O	O
repair	O	O
synthesis	O	O
induced	O	O
by	O	O
1	B-Chemical	D019813
,	I-Chemical	D019813
2	I-Chemical	D019813
-	I-Chemical	D019813
DMH	I-Chemical	D019813
further	O	O
showed	O	O
that	O	O
0	O	O
.	O	O

019	O	O
mol	O	O
%	O	O
of	O	O
cytosine	B-Chemical	D003596
residues	O	O
in	O	O
DNA	O	O
were	O	O
substituted	O	O
by	O	O
the	O	O
analogue	O	O
,	O	O
indicating	O	O
that	O	O
incorporation	O	O
of	O	O
5	B-Chemical	D001374
-	I-Chemical	D001374
AzC	I-Chemical	D001374
occurs	O	O
during	O	O
repair	O	O
synthesis	O	O
.	O	O

In	O	O
the	O	O
absence	O	O
of	O	O
the	O	O
carcinogen	O	O
,	O	O
5	B-Chemical	D001374
-	I-Chemical	D001374
AzC	I-Chemical	D001374
given	O	O
after	O	O
a	O	O
two	O	O
thirds	O	O
partial	O	O
hepatectomy	O	O
,	O	O
when	O	O
its	O	O
incorporation	O	O
should	O	O
be	O	O
maximum	O	O
,	O	O
failed	O	O
to	O	O
induce	O	O
any	O	O
gamma	O	O
-	O	O
GT	O	O
positive	O	O
foci	O	O
.	O	O

The	O	O
results	O	O
suggest	O	O
that	O	O
hypomethylation	O	O
of	O	O
DNA	O	O
per	O	O
se	O	O
may	O	O
not	O	O
be	O	O
sufficient	O	O
for	O	O
initiation	O	O
.	O	O

Perhaps	O	O
two	O	O
events	O	O
might	O	O
be	O	O
necessary	O	O
for	O	O
initiation	O	O
,	O	O
the	O	O
first	O	O
caused	O	O
by	O	O
the	O	O
carcinogen	O	O
and	O	O
a	O	O
second	O	O
involving	O	O
hypomethylation	O	O
of	O	O
DNA	O	O
.	O	O

Withdrawal	O	O
-	O	O
emergent	O	O
rabbit	O	O
syndrome	O	O
during	O	O
dose	O	O
reduction	O	O
of	O	O
risperidone	B-Chemical	D018967
.	O	O

Rabbit	B-Disease	D001480
syndrome	I-Disease	D001480
(	O	O
RS	B-Disease	D001480
)	O	O
is	O	O
a	O	O
rare	O	O
extrapyramidal	O	O
side	O	O
effect	O	O
caused	O	O
by	O	O
prolonged	O	O
neuroleptic	O	O
medication	O	O
.	O	O

Here	O	O
we	O	O
present	O	O
a	O	O
case	O	O
of	O	O
withdrawal	O	O
-	O	O
emergent	O	O
RS	B-Disease	D001480
,	O	O
which	O	O
is	O	O
the	O	O
first	O	O
of	O	O
its	O	O
kind	O	O
to	O	O
be	O	O
reported	O	O
.	O	O

The	O	O
patient	O	O
developed	O	O
RS	B-Disease	D001480
during	O	O
dose	O	O
reduction	O	O
of	O	O
risperidone	B-Chemical	D018967
.	O	O

The	O	O
symptom	O	O
was	O	O
treated	O	O
successfully	O	O
with	O	O
trihexyphenidyl	B-Chemical	D014282
anticholinergic	O	O
therapy	O	O
.	O	O

The	O	O
underlying	O	O
mechanism	O	O
of	O	O
withdrawal	O	O
-	O	O
emergent	O	O
RS	B-Disease	D001480
in	O	O
the	O	O
present	O	O
case	O	O
may	O	O
have	O	O
been	O	O
related	O	O
to	O	O
the	O	O
pharmacological	O	O
profile	O	O
of	O	O
risperidone	B-Chemical	D018967
,	O	O
a	O	O
serotonin	B-Chemical	D012701
-	O	O
dopamine	B-Chemical	D004298
antagonist	O	O
,	O	O
suggesting	O	O
the	O	O
pathophysiologic	O	O
influence	O	O
of	O	O
the	O	O
serotonin	B-Chemical	D012701
system	O	O
in	O	O
the	O	O
development	O	O
of	O	O
RS	B-Disease	D001480
.	O	O

Verapamil	B-Chemical	D014700
withdrawal	O	O
as	O	O
a	O	O
possible	O	O
cause	O	O
of	O	O
myocardial	B-Disease	D009203
infarction	I-Disease	D009203
in	O	O
a	O	O
hypertensive	B-Disease	D006973
woman	O	O
with	O	O
a	O	O
normal	O	O
coronary	O	O
angiogram	O	O
.	O	O

Verapamil	B-Chemical	D014700
is	O	O
an	O	O
effective	O	O
and	O	O
relatively	O	O
-	O	O
safe	O	O
antihypertensive	O	O
drug	O	O
.	O	O

Serious	O	O
adverse	O	O
effects	O	O
are	O	O
uncommon	O	O
and	O	O
mainly	O	O
have	O	O
been	O	O
related	O	O
to	O	O
the	O	O
depression	B-Disease	D003866
of	O	O
cardiac	O	O
contractility	O	O
and	O	O
conduction	O	O
,	O	O
especially	O	O
when	O	O
the	O	O
drug	O	O
is	O	O
combined	O	O
with	O	O
beta	O	O
-	O	O
blocking	O	O
agents	O	O
.	O	O

We	O	O
report	O	O
a	O	O
case	O	O
in	O	O
which	O	O
myocardial	B-Disease	D009203
infarction	I-Disease	D009203
coincided	O	O
with	O	O
the	O	O
introduction	O	O
of	O	O
captopril	B-Chemical	D002216
and	O	O
the	O	O
withdrawal	O	O
of	O	O
verapamil	B-Chemical	D014700
in	O	O
a	O	O
previously	O	O
asymptomatic	O	O
woman	O	O
with	O	O
severe	O	O
hypertension	B-Disease	D006973
.	O	O

Possible	O	O
mechanisms	O	O
that	O	O
involve	O	O
a	O	O
verapamil	B-Chemical	D014700
-	O	O
related	O	O
increase	O	O
in	O	O
platelet	O	O
and	O	O
/	O	O
or	O	O
vascular	O	O
alpha	O	O
2	O	O
-	O	O
adrenoreceptor	O	O
affinity	O	O
for	O	O
catecholamines	B-Chemical	D002395
are	O	O
discussed	O	O
.	O	O

Remission	O	O
induction	O	O
of	O	O
meningeal	B-Disease	D008577
leukemia	I-Disease	D008577
with	O	O
high	O	O
-	O	O
dose	O	O
intravenous	O	O
methotrexate	B-Chemical	D008727
.	O	O

Twenty	O	O
children	O	O
with	O	O
acute	B-Disease	D054198
lymphoblastic	I-Disease	D054198
leukemia	I-Disease	D054198
who	O	O
developed	O	O
meningeal	B-Disease	D002493
disease	I-Disease	D002493
were	O	O
treated	O	O
with	O	O
a	O	O
high	O	O
-	O	O
dose	O	O
intravenous	O	O
methotrexate	B-Chemical	D008727
regimen	O	O
that	O	O
was	O	O
designed	O	O
to	O	O
achieve	O	O
and	O	O
maintain	O	O
CSF	O	O
methotrexate	B-Chemical	D008727
concentrations	O	O
of	O	O
10	O	O
(	O	O
-	O	O
5	O	O
)	O	O
mol	O	O
/	O	O
L	O	O
without	O	O
the	O	O
need	O	O
for	O	O
concomitant	O	O
intrathecal	O	O
dosing	O	O
.	O	O

The	O	O
methotrexate	B-Chemical	D008727
was	O	O
administered	O	O
as	O	O
a	O	O
loading	O	O
dose	O	O
of	O	O
6	O	O
,	O	O
000	O	O
mg	O	O
/	O	O
m2	O	O
for	O	O
a	O	O
period	O	O
of	O	O
one	O	O
hour	O	O
followed	O	O
by	O	O
an	O	O
infusion	O	O
of	O	O
1	O	O
,	O	O
200	O	O
mg	O	O
/	O	O
m2	O	O
/	O	O
h	O	O
for	O	O
23	O	O
hours	O	O
.	O	O

Leucovorin	B-Chemical	D002955
rescue	O	O
was	O	O
initiated	O	O
12	O	O
hours	O	O
after	O	O
the	O	O
end	O	O
of	O	O
the	O	O
infusion	O	O
with	O	O
a	O	O
loading	O	O
dose	O	O
of	O	O
200	O	O
mg	O	O
/	O	O
m2	O	O
followed	O	O
by	O	O
12	O	O
mg	O	O
/	O	O
m2	O	O
every	O	O
three	O	O
hours	O	O
for	O	O
six	O	O
doses	O	O
and	O	O
then	O	O
every	O	O
six	O	O
hours	O	O
until	O	O
the	O	O
plasma	O	O
methotrexate	B-Chemical	D008727
level	O	O
decreased	O	O
to	O	O
less	O	O
than	O	O
1	O	O
X	O	O
10	O	O
(	O	O
-	O	O
7	O	O
)	O	O
mol	O	O
/	O	O
L	O	O
.	O	O

The	O	O
mean	O	O
steady	O	O
-	O	O
state	O	O
plasma	O	O
and	O	O
CSF	O	O
methotrexate	B-Chemical	D008727
concentrations	O	O
achieved	O	O
were	O	O
1	O	O
.	O	O

1	O	O
X	O	O
10	O	O
(	O	O
-	O	O
3	O	O
)	O	O
mol	O	O
/	O	O
L	O	O
and	O	O
3	O	O
.	O	O

6	O	O
X	O	O
10	O	O
(	O	O
-	O	O
5	O	O
)	O	O
mol	O	O
/	O	O
L	O	O
,	O	O
respectively	O	O
.	O	O

All	O	O
20	O	O
patients	O	O
responded	O	O
to	O	O
this	O	O
regimen	O	O
,	O	O
16	O	O
/	O	O
20	O	O
(	O	O
80%	O	O
)	O	O
achieved	O	O
a	O	O
complete	O	O
remission	O	O
,	O	O
and	O	O
20%	O	O
obtained	O	O
a	O	O
partial	O	O
remission	O	O
.	O	O

The	O	O
most	O	O
common	O	O
toxicities	B-Disease	D064420
encountered	O	O
were	O	O
transient	O	O
serum	O	O
transaminase	O	O
and	O	O
bilirubin	B-Chemical	D001663
elevations	O	O
,	O	O
neutropenia	B-Disease	D009503
,	O	O
and	O	O
mucositis	B-Disease	D052016
.	O	O

One	O	O
patient	O	O
had	O	O
focal	O	O
seizures	B-Disease	D012640
and	O	O
transient	B-Disease	D010291
hemiparesis	I-Disease	D010291
but	O	O
recovered	O	O
completely	O	O
.	O	O

High	O	O
-	O	O
dose	O	O
intravenous	O	O
methotrexate	B-Chemical	D008727
is	O	O
an	O	O
effective	O	O
treatment	O	O
for	O	O
the	O	O
induction	O	O
of	O	O
remission	O	O
after	O	O
meningeal	O	O
relapse	O	O
in	O	O
acute	B-Disease	D054198
lymphoblastic	I-Disease	D054198
leukemia	I-Disease	D054198
.	O	O

Hypersensitivity	B-Disease	D004342
to	O	O
carbamazepine	B-Chemical	D002220
presenting	O	O
with	O	O
a	O	O
leukemoid	B-Disease	D007955
reaction	I-Disease	D007955
,	O	O
eosinophilia	B-Disease	D004802
,	O	O
erythroderma	B-Disease	D003873
,	O	O
and	O	O
renal	B-Disease	D051437
failure	I-Disease	D051437
.	O	O

We	O	O
report	O	O
a	O	O
patient	O	O
in	O	O
whom	O	O
hypersensitivity	B-Disease	D004342
to	O	O
carbamazepine	B-Chemical	D002220
presented	O	O
with	O	O
generalized	O	O
erythroderma	B-Disease	D003873
,	O	O
a	O	O
severe	O	O
leukemoid	B-Disease	D007955
reaction	I-Disease	D007955
,	O	O
eosinophilia	B-Disease	D004802
,	O	O
hyponatremia	B-Disease	D007010
,	O	O
and	O	O
renal	B-Disease	D051437
failure	I-Disease	D051437
.	O	O

This	O	O
is	O	O
the	O	O
first	O	O
report	O	O
of	O	O
such	O	O
an	O	O
unusual	O	O
reaction	O	O
to	O	O
carbamazepine	B-Chemical	D002220
.	O	O

The	O	O
interpeduncular	O	O
nucleus	O	O
regulates	O	O
nicotine's	O	O
effects	O	O
on	O	O
free	O	O
-	O	O
field	O	O
activity	O	O
.	O	O

Partial	O	O
lesions	O	O
were	O	O
made	O	O
with	O	O
kainic	B-Chemical	D007608
acid	I-Chemical	D007608
in	O	O
the	O	O
interpeduncular	O	O
nucleus	O	O
of	O	O
the	O	O
ventral	O	O
midbrain	O	O
of	O	O
the	O	O
rat	O	O
.	O	O

Compared	O	O
with	O	O
sham	O	O
-	O	O
operated	O	O
controls	O	O
,	O	O
lesions	O	O
significantly	O	O
(	O	O
p	O	O
<	O	O
0	O	O
.	O	O

25	O	O
)	O	O
blunted	O	O
the	O	O
early	O	O
(	O	O
<60	O	O
min	O	O
)	O	O
free	O	O
-	O	O
field	O	O
locomotor	B-Disease	D009069
hypoactivity	I-Disease	D009069
caused	O	O
by	O	O
nicotine	B-Chemical	D009538
(	O	O
0	O	O
.	O	O

5	O	O
mg	O	O
kg	O	O
(	O	O
-	O	O
1	O	O
)	O	O
,	O	O
i	O	O
.	O	O

m	O	O
.	O	O

)	O	O
,	O	O
enhanced	O	O
the	O	O
later	O	O
(	O	O
60	O	O
-	O	O
120	O	O
min	O	O
)	O	O
nicotine	B-Chemical	D009538
-	O	O
induced	O	O
hyperactivity	B-Disease	D006948
,	O	O
and	O	O
raised	O	O
spontaneous	O	O
nocturnal	O	O
activity	O	O
.	O	O

Lesions	O	O
reduced	O	O
the	O	O
extent	O	O
of	O	O
immunohistological	O	O
staining	O	O
for	O	O
choline	B-Chemical	D002794
acetyltransferase	O	O
in	O	O
the	O	O
interpeduncular	O	O
nucleus	O	O
(	O	O
p	O	O
<0	O	O
.	O	O

025	O	O
)	O	O
,	O	O
but	O	O
not	O	O
for	O	O
tyrosine	B-Chemical	D014443
hydroxylase	O	O
in	O	O
the	O	O
surrounding	O	O
catecholaminergic	O	O
A10	O	O
region	O	O
.	O	O

We	O	O
conclude	O	O
that	O	O
the	O	O
interpeduncular	O	O
nucleus	O	O
mediates	O	O
nicotinic	O	O
depression	B-Disease	D003866
of	O	O
locomotor	O	O
activity	O	O
and	O	O
dampens	O	O
nicotinic	O	O
arousal	O	O
mechanisms	O	O
located	O	O
elsewhere	O	O
in	O	O
the	O	O
brain	O	O
.	O	O

Assessment	O	O
of	O	O
a	O	O
new	O	O
non	O	O
-	O	O
invasive	O	O
index	O	O
of	O	O
cardiac	O	O
performance	O	O
for	O	O
detection	O	O
of	O	O
dobutamine	B-Chemical	D004280
-	O	O
induced	O	O
myocardial	B-Disease	D017202
ischemia	I-Disease	D017202
.	O	O

BACKGROUND	O	O
:	O	O
Electrocardiography	O	O
has	O	O
a	O	O
very	O	O
low	O	O
sensitivity	O	O
in	O	O
detecting	O	O
dobutamine	B-Chemical	D004280
-	O	O
induced	O	O
myocardial	B-Disease	D017202
ischemia	I-Disease	D017202
.	O	O

OBJECTIVES	O	O
:	O	O
To	O	O
assess	O	O
the	O	O
added	O	O
diagnostic	O	O
value	O	O
of	O	O
a	O	O
new	O	O
cardiac	O	O
performance	O	O
index	O	O
(	O	O
dP	O	O
/	O	O
dtejc	O	O
)	O	O
measurement	O	O
,	O	O
based	O	O
on	O	O
brachial	O	O
artery	O	O
flow	O	O
changes	O	O
,	O	O
as	O	O
compared	O	O
to	O	O
standard	O	O
12	O	O
-	O	O
lead	O	O
ECG	O	O
,	O	O
for	O	O
detecting	O	O
dobutamine	B-Chemical	D004280
-	O	O
induced	O	O
myocardial	B-Disease	D017202
ischemia	I-Disease	D017202
,	O	O
using	O	O
Tc99m	B-Chemical	D017256
-	I-Chemical	D017256
Sestamibi	I-Chemical	D017256
single	O	O
-	O	O
photon	O	O
emission	O	O
computed	O	O
tomography	O	O
as	O	O
the	O	O
gold	O	O
standard	O	O
of	O	O
comparison	O	O
to	O	O
assess	O	O
the	O	O
presence	O	O
or	O	O
absence	O	O
of	O	O
ischemia	B-Disease	D007511
.	O	O

METHODS	O	O
:	O	O
The	O	O
study	O	O
group	O	O
comprised	O	O
40	O	O
patients	O	O
undergoing	O	O
Sestamibi	B-Chemical	D017256
-	O	O
SPECT	O	O
/	O	O
dobutamine	B-Chemical	D004280
stress	O	O
test	O	O
.	O	O

Simultaneous	O	O
measurements	O	O
of	O	O
ECG	O	O
and	O	O
brachial	O	O
artery	O	O
dP	O	O
/	O	O
dtejc	O	O
were	O	O
performed	O	O
at	O	O
each	O	O
dobutamine	B-Chemical	D004280
level	O	O
.	O	O

In	O	O
19	O	O
of	O	O
the	O	O
40	O	O
patients	O	O
perfusion	O	O
defects	O	O
compatible	O	O
with	O	O
ischemia	B-Disease	D007511
were	O	O
detected	O	O
on	O	O
SPECT	O	O
.	O	O

The	O	O
increase	O	O
in	O	O
dP	O	O
/	O	O
dtejc	O	O
during	O	O
infusion	O	O
of	O	O
dobutamine	B-Chemical	D004280
in	O	O
this	O	O
group	O	O
was	O	O
severely	O	O
impaired	O	O
as	O	O
compared	O	O
to	O	O
the	O	O
non	O	O
-	O	O
ischemic	O	O
group	O	O
.	O	O

dP	O	O
/	O	O
dtejc	O	O
outcome	O	O
was	O	O
combined	O	O
with	O	O
the	O	O
ECG	O	O
results	O	O
,	O	O
giving	O	O
an	O	O
ECG	O	O
-	O	O
enhanced	O	O
value	O	O
,	O	O
and	O	O
compared	O	O
to	O	O
ECG	O	O
alone	O	O
.	O	O

RESULTS	O	O
:	O	O
The	O	O
sensitivity	O	O
improved	O	O
dramatically	O	O
from	O	O
16%	O	O
to	O	O
79%	O	O
,	O	O
positive	O	O
predictive	O	O
value	O	O
increased	O	O
from	O	O
60%	O	O
to	O	O
68%	O	O
and	O	O
negative	O	O
predictive	O	O
value	O	O
from	O	O
54%	O	O
to	O	O
78%	O	O
,	O	O
and	O	O
specificity	O	O
decreased	O	O
from	O	O
90%	O	O
to	O	O
67%	O	O
.	O	O

CONCLUSIONS	O	O
:	O	O
If	O	O
ECG	O	O
alone	O	O
is	O	O
used	O	O
for	O	O
specificity	O	O
,	O	O
the	O	O
combination	O	O
with	O	O
dP	O	O
/	O	O
dtejc	O	O
improved	O	O
the	O	O
sensitivity	O	O
of	O	O
the	O	O
test	O	O
and	O	O
could	O	O
be	O	O
a	O	O
cost	O	O
-	O	O
savings	O	O
alternative	O	O
to	O	O
cardiac	O	O
imaging	O	O
or	O	O
perfusion	O	O
studies	O	O
to	O	O
detect	O	O
myocardial	B-Disease	D017202
ischemia	I-Disease	D017202
,	O	O
especially	O	O
in	O	O
patients	O	O
unable	O	O
to	O	O
exercise	O	O
.	O	O

Acute	B-Disease	D017114
liver	I-Disease	D017114
failure	I-Disease	D017114
in	O	O
two	O	O
patients	O	O
with	O	O
regular	O	O
alcohol	B-Chemical	D000431
consumption	O	O
ingesting	O	O
paracetamol	B-Chemical	D000082
at	O	O
therapeutic	O	O
dosage	O	O
.	O	O

BACKGROUND	O	O
:	O	O
The	O	O
possible	O	O
role	O	O
of	O	O
alcohol	B-Chemical	D000431
in	O	O
the	O	O
development	O	O
of	O	O
hepatotoxicity	B-Disease	D056486
associated	O	O
with	O	O
therapeutic	O	O
doses	O	O
of	O	O
paracetamol	B-Chemical	D000082
(	O	O
acetaminophen	B-Chemical	D000082
)	O	O
is	O	O
currently	O	O
debated	O	O
.	O	O

CASE	O	O
REPORT	O	O
:	O	O
We	O	O
describe	O	O
2	O	O
patients	O	O
who	O	O
were	O	O
regular	O	O
consumers	O	O
of	O	O
alcohol	B-Chemical	D000431
and	O	O
who	O	O
developed	O	O
liver	B-Disease	D017093
failure	I-Disease	D017093
within	O	O
3	O	O
-	O	O
5	O	O
days	O	O
after	O	O
hospitalization	O	O
and	O	O
stopping	O	O
alcohol	B-Chemical	D000431
consumption	O	O
while	O	O
being	O	O
treated	O	O
with	O	O
4	O	O
g	O	O
paracetamol	B-Chemical	D000082
/	O	O
day	O	O
.	O	O

A	O	O
paracetamol	B-Chemical	D000082
serum	O	O
level	O	O
obtained	O	O
in	O	O
one	O	O
of	O	O
these	O	O
patients	O	O
was	O	O
not	O	O
in	O	O
the	O	O
toxic	O	O
range	O	O
.	O	O

Possible	O	O
risk	O	O
factors	O	O
for	O	O
the	O	O
development	O	O
of	O	O
hepatotoxicity	B-Disease	D056486
in	O	O
patients	O	O
treated	O	O
with	O	O
therapeutic	O	O
doses	O	O
of	O	O
paracetamol	B-Chemical	D000082
are	O	O
discussed	O	O
.	O	O

CONCLUSION	O	O
:	O	O
In	O	O
patients	O	O
with	O	O
risk	O	O
factors	O	O
,	O	O
e	O	O
.	O	O

g	O	O
.	O	O

regular	O	O
consumption	O	O
of	O	O
alcohol	B-Chemical	D000431
,	O	O
liver	B-Disease	D017093
failure	I-Disease	D017093
is	O	O
possible	O	O
when	O	O
therapeutic	O	O
doses	O	O
are	O	O
ingested	O	O
.	O	O

We	O	O
propose	O	O
that	O	O
the	O	O
paracetamol	B-Chemical	D000082
dose	O	O
should	O	O
not	O	O
exceed	O	O
2	O	O
g	O	O
/	O	O
day	O	O
in	O	O
such	O	O
patients	O	O
and	O	O
that	O	O
their	O	O
liver	O	O
function	O	O
should	O	O
be	O	O
monitored	O	O
closely	O	O
while	O	O
being	O	O
treated	O	O
with	O	O
paracetamol	B-Chemical	D000082
.	O	O

Cocaine	B-Chemical	D003042
related	O	O
chest	B-Disease	D002637
pain	I-Disease	D002637
:	O	O
are	O	O
we	O	O
seeing	O	O
the	O	O
tip	O	O
of	O	O
an	O	O
iceberg?	O	O
The	O	O
recreational	O	O
use	O	O
of	O	O
cocaine	B-Chemical	D003042
is	O	O
on	O	O
the	O	O
increase	O	O
.	O	O

The	O	O
emergency	O	O
nurse	O	O
ought	O	O
to	O	O
be	O	O
familiar	O	O
with	O	O
some	O	O
of	O	O
the	O	O
cardiovascular	O	O
consequences	O	O
of	O	O
cocaine	B-Chemical	D003042
use	O	O
.	O	O

In	O	O
particular	O	O
,	O	O
the	O	O
tendency	O	O
of	O	O
cocaine	B-Chemical	D003042
to	O	O
produce	O	O
chest	B-Disease	D002637
pain	I-Disease	D002637
ought	O	O
to	O	O
be	O	O
in	O	O
the	O	O
mind	O	O
of	O	O
the	O	O
emergency	O	O
nurse	O	O
when	O	O
faced	O	O
with	O	O
a	O	O
young	O	O
victim	O	O
of	O	O
chest	B-Disease	D002637
pain	I-Disease	D002637
who	O	O
is	O	O
otherwise	O	O
at	O	O
low	O	O
risk	O	O
.	O	O

The	O	O
mechanism	O	O
of	O	O
chest	B-Disease	D002637
pain	I-Disease	D002637
related	O	O
to	O	O
cocaine	B-Chemical	D003042
use	O	O
is	O	O
discussed	O	O
and	O	O
treatment	O	O
dilemmas	O	O
are	O	O
discussed	O	O
.	O	O

Finally	O	O
,	O	O
moral	O	O
issues	O	O
relating	O	O
to	O	O
the	O	O
testing	O	O
of	O	O
potential	O	O
cocaine	B-Chemical	D003042
users	O	O
will	O	O
be	O	O
addressed	O	O
.	O	O

Severe	O	O
rhabdomyolysis	B-Disease	D012206
and	O	O
acute	B-Disease	D058186
renal	I-Disease	D058186
failure	I-Disease	D058186
secondary	O	O
to	O	O
concomitant	O	O
use	O	O
of	O	O
simvastatin	B-Chemical	D019821
,	O	O
amiodarone	B-Chemical	D000638
,	O	O
and	O	O
atazanavir	B-Chemical	C413408
.	O	O

OBJECTIVE	O	O
:	O	O
To	O	O
report	O	O
a	O	O
case	O	O
of	O	O
a	O	O
severe	O	O
interaction	O	O
between	O	O
simvastatin	B-Chemical	D019821
,	O	O
amiodarone	B-Chemical	D000638
,	O	O
and	O	O
atazanavir	B-Chemical	C413408
resulting	O	O
in	O	O
rhabdomyolysis	B-Disease	D012206
and	O	O
acute	B-Disease	D058186
renal	I-Disease	D058186
failure	I-Disease	D058186
.	O	O

BACKGROUND	O	O
:	O	O
A	O	O
72	O	O
-	O	O
year	O	O
-	O	O
old	O	O
white	O	O
man	O	O
with	O	O
underlying	O	O
human	B-Disease	D015658
immunodeficiency	I-Disease	D015658
virus	I-Disease	D015658
,	O	O
atrial	B-Disease	D001281
fibrillation	I-Disease	D001281
,	O	O
coronary	B-Disease	D003324
artery	I-Disease	D003324
disease	I-Disease	D003324
,	O	O
and	O	O
hyperlipidemia	B-Disease	D006949
presented	O	O
with	O	O
generalized	O	O
pain	B-Disease	D010146
,	O	O
fatigue	B-Disease	D005221
,	O	O
and	O	O
dark	O	O
orange	O	O
urine	O	O
for	O	O
3	O	O
days	O	O
.	O	O

The	O	O
patient	O	O
was	O	O
taking	O	O
80	O	O
mg	O	O
simvastatin	B-Chemical	D019821
at	O	O
bedtime	O	O
(	O	O
initiated	O	O
27	O	O
days	O	O
earlier	O	O
)	O	O
;	O	O
amiodarone	B-Chemical	D000638
at	O	O
a	O	O
dose	O	O
of	O	O
400	O	O
mg	O	O
daily	O	O
for	O	O
7	O	O
days	O	O
,	O	O
then	O	O
200	O	O
mg	O	O
daily	O	O
(	O	O
initiated	O	O
19	O	O
days	O	O
earlier	O	O
)	O	O
;	O	O
and	O	O
400	O	O
mg	O	O
atazanavir	B-Chemical	C413408
daily	O	O
(	O	O
initiated	O	O
at	O	O
least	O	O
2	O	O
years	O	O
previously	O	O
)	O	O
.	O	O

Laboratory	O	O
evaluation	O	O
revealed	O	O
66	O	O
,	O	O
680	O	O
U	O	O
/	O	O
L	O	O
creatine	B-Chemical	D003401
kinase	O	O
,	O	O
93	O	O
mg	O	O
/	O	O
dL	O	O
blood	B-Chemical	D001806
urea	I-Chemical	D001806
nitrogen	I-Chemical	D001806
,	O	O
4	O	O
.	O	O

6	O	O
mg	O	O
/	O	O
dL	O	O
creatinine	B-Chemical	D003404
,	O	O
1579	O	O
U	O	O
/	O	O
L	O	O
aspartate	B-Chemical	D001224
aminotransferase	O	O
,	O	O
and	O	O
738	O	O
U	O	O
/	O	O
L	O	O
alanine	B-Chemical	D000409
aminotransferase	O	O
.	O	O

Simvastatin	B-Chemical	D019821
,	O	O
amiodarone	B-Chemical	D000638
,	O	O
and	O	O
the	O	O
patient's	O	O
human	B-Disease	D015658
immunodeficiency	I-Disease	D015658
virus	I-Disease	D015658
medications	O	O
were	O	O
all	O	O
temporarily	O	O
discontinued	O	O
and	O	O
the	O	O
patient	O	O
was	O	O
given	O	O
forced	O	O
alkaline	O	O
diuresis	O	O
and	O	O
started	O	O
on	O	O
dialysis	O	O
.	O	O

Nine	O	O
days	O	O
later	O	O
the	O	O
patient's	O	O
creatine	B-Chemical	D003401
kinase	O	O
had	O	O
dropped	O	O
to	O	O
1695	O	O
U	O	O
/	O	O
L	O	O
and	O	O
creatinine	B-Chemical	D003404
was	O	O
3	O	O
.	O	O

3	O	O
mg	O	O
/	O	O
dL	O	O
.	O	O

The	O	O
patient	O	O
was	O	O
discharged	O	O
and	O	O
continued	O	O
outpatient	O	O
dialysis	O	O
for	O	O
1	O	O
month	O	O
until	O	O
his	O	O
renal	O	O
function	O	O
recovered	O	O
.	O	O

DISCUSSION	O	O
:	O	O
The	O	O
risk	O	O
of	O	O
rhabdomyolysis	B-Disease	D012206
is	O	O
increased	O	O
in	O	O
the	O	O
presence	O	O
of	O	O
concomitant	O	O
drugs	O	O
that	O	O
inhibit	O	O
simvastatin	B-Chemical	D019821
metabolism	O	O
.	O	O

Simvastatin	B-Chemical	D019821
is	O	O
metabolized	O	O
by	O	O
CYP3A4	O	O
.	O	O

Amiodarone	B-Chemical	D000638
and	O	O
atazanavir	B-Chemical	C413408
are	O	O
recognized	O	O
CYP3A4	O	O
inhibitors	O	O
.	O	O

CONCLUSIONS	O	O
:	O	O
Pharmacokinetic	O	O
differences	O	O
in	O	O
statins	B-Chemical	D019821
are	O	O
an	O	O
important	O	O
consideration	O	O
for	O	O
assessing	O	O
the	O	O
risk	O	O
of	O	O
potential	O	O
drug	O	O
interactions	O	O
.	O	O

In	O	O
patients	O	O
requiring	O	O
the	O	O
concurrent	O	O
use	O	O
of	O	O
statins	B-Chemical	D019821
and	O	O
CYP3A4	O	O
inhibitors	O	O
,	O	O
pravastatin	B-Chemical	D017035
,	O	O
fluvastatin	B-Chemical	C065180
,	O	O
and	O	O
rosuvastatin	B-Chemical	C422923
carry	O	O
the	O	O
lowest	O	O
risk	O	O
of	O	O
drug	O	O
interactions	O	O
;	O	O
atorvastatin	B-Chemical	C065179
carries	O	O
moderate	O	O
risk	O	O
,	O	O
whereas	O	O
simvastatin	B-Chemical	D019821
and	O	O
lovastatin	B-Chemical	D008148
have	O	O
the	O	O
highest	O	O
risk	O	O
and	O	O
should	O	O
be	O	O
avoided	O	O
in	O	O
patients	O	O
taking	O	O
concomitant	O	O
CYP3A4	O	O
inhibitors	O	O
.	O	O

Phase	O	O
II	O	O
trial	O	O
of	O	O
vinorelbine	B-Chemical	C030852
in	O	O
metastatic	O	O
squamous	B-Disease	C562729
cell	I-Disease	C562729
esophageal	I-Disease	C562729
carcinoma	I-Disease	C562729
.	O	O

European	O	O
Organization	O	O
for	O	O
Research	O	O
and	O	O
Treatment	O	O
of	O	O
Cancer	B-Disease	D009369
Gastrointestinal	O	O
Treat	O	O
Cancer	B-Disease	D009369
Cooperative	O	O
Group	O	O
.	O	O

PURPOSE	O	O
:	O	O
To	O	O
evaluate	O	O
the	O	O
response	O	O
rate	O	O
and	O	O
toxic	O	O
effects	O	O
of	O	O
vinorelbine	B-Chemical	C030852
(	O	O
VNB	B-Chemical	C030852
)	O	O
administered	O	O
as	O	O
a	O	O
single	O	O
agent	O	O
in	O	O
metastatic	O	O
squamous	B-Disease	C562729
cell	I-Disease	C562729
esophageal	I-Disease	C562729
carcinoma	I-Disease	C562729
.	O	O

PATIENTS	O	O
AND	O	O
METHODS	O	O
:	O	O
Forty	O	O
-	O	O
six	O	O
eligible	O	O
patients	O	O
with	O	O
measurable	O	O
lesions	O	O
were	O	O
included	O	O
and	O	O
were	O	O
stratified	O	O
according	O	O
to	O	O
previous	O	O
chemotherapy	O	O
.	O	O

Thirty	O	O
patients	O	O
without	O	O
prior	O	O
chemotherapy	O	O
and	O	O
16	O	O
pretreated	O	O
with	O	O
cisplatin	B-Chemical	D002945
-	O	O
based	O	O
chemotherapy	O	O
were	O	O
assessable	O	O
for	O	O
toxicity	B-Disease	D064420
and	O	O
response	O	O
.	O	O

VNB	B-Chemical	C030852
was	O	O
administered	O	O
weekly	O	O
as	O	O
a	O	O
25	O	O
-	O	O
mg	O	O
/	O	O
m2	O	O
short	O	O
intravenous	O	O
(	O	O
i	O	O
.	O	O

v	O	O
.	O	O

)	O	O
infusion	O	O
.	O	O

RESULTS	O	O
:	O	O
Six	O	O
of	O	O
30	O	O
patients	O	O
(	O	O
20%	O	O
)	O	O
without	O	O
prior	O	O
chemotherapy	O	O
achieved	O	O
a	O	O
partial	O	O
response	O	O
(	O	O
PR	O	O
)	O	O
(	O	O
95%	O	O
confidence	O	O
interval	O	O
[	O	O
CI	O	O
]	O	O
,	O	O
8%	O	O
to	O	O
39%	O	O
)	O	O
.	O	O

The	O	O
median	O	O
duration	O	O
of	O	O
response	O	O
was	O	O
21	O	O
weeks	O	O
(	O	O
range	O	O
,	O	O
17	O	O
to	O	O
28	O	O
)	O	O
.	O	O

One	O	O
of	O	O
16	O	O
patients	O	O
(	O	O
6%	O	O
)	O	O
with	O	O
prior	O	O
chemotherapy	O	O
had	O	O
a	O	O
complete	O	O
response	O	O
(	O	O
CR	O	O
)	O	O
of	O	O
31	O	O
weeks'	O	O
duration	O	O
(	O	O
95%	O	O
CI	O	O
,	O	O
0%	O	O
to	O	O
30%	O	O
)	O	O
.	O	O

The	O	O
overall	O	O
response	O	O
rate	O	O
(	O	O
World	O	O
Health	O	O
Organization	O	O
[	O	O
WHO	O	O
]	O	O
criteria	O	O
)	O	O
was	O	O
15%	O	O
(	O	O
CR	O	O
,	O	O
2%	O	O
;	O	O
PR	O	O
13%	O	O
;	O	O
95%	O	O
CI	O	O
,	O	O
6%	O	O
to	O	O
29%	O	O
)	O	O
.	O	O

The	O	O
median	O	O
dose	O	O
-	O	O
intensity	O	O
(	O	O
DI	O	O
)	O	O
was	O	O
20	O	O
mg	O	O
/	O	O
m2	O	O
/	O	O
wk	O	O
.	O	O

VNB	B-Chemical	C030852
was	O	O
well	O	O
tolerated	O	O
and	O	O
zero	O	O
instances	O	O
of	O	O
WHO	O	O
grade	O	O
4	O	O
nonhematologic	O	O
toxicity	B-Disease	D064420
occurred	O	O
.	O	O

At	O	O
least	O	O
one	O	O
episode	O	O
of	O	O
grade	O	O
3	O	O
or	O	O
4	O	O
granulocytopenia	B-Disease	D000380
was	O	O
seen	O	O
in	O	O
59%	O	O
of	O	O
patients	O	O
.	O	O

A	O	O
grade	O	O
2	O	O
or	O	O
3	O	O
infection	B-Disease	D007239
occurred	O	O
in	O	O
16%	O	O
of	O	O
patients	O	O
,	O	O
but	O	O
no	O	O
toxic	O	O
deaths	B-Disease	D003643
occurred	O	O
.	O	O

Other	O	O
side	O	O
effects	O	O
were	O	O
rare	O	O
,	O	O
and	O	O
peripheral	B-Disease	D010523
neurotoxicity	I-Disease	D010523
has	O	O
been	O	O
minor	O	O
(	O	O
26%	O	O
grade	O	O
1	O	O
)	O	O
.	O	O

CONCLUSION	O	O
:	O	O
These	O	O
data	O	O
indicate	O	O
that	O	O
VNB	B-Chemical	C030852
is	O	O
an	O	O
active	O	O
agent	O	O
in	O	O
metastatic	O	O
esophageal	B-Disease	C562729
squamous	I-Disease	C562729
cell	I-Disease	C562729
carcinoma	I-Disease	C562729
.	O	O

Given	O	O
its	O	O
excellent	O	O
tolerance	O	O
profile	O	O
and	O	O
low	O	O
toxicity	B-Disease	D064420
,	O	O
further	O	O
evaluation	O	O
of	O	O
VNB	B-Chemical	C030852
in	O	O
combination	O	O
therapy	O	O
is	O	O
warranted	O	O
.	O	O

Paclitaxel	B-Chemical	D017239
,	O	O
cisplatin	B-Chemical	D002945
,	O	O
and	O	O
gemcitabine	B-Chemical	C056507
combination	O	O
chemotherapy	O	O
within	O	O
a	O	O
multidisciplinary	O	O
therapeutic	O	O
approach	O	O
in	O	O
metastatic	O	O
nonsmall	B-Disease	D002289
cell	I-Disease	D002289
lung	I-Disease	D002289
carcinoma	I-Disease	D002289
.	O	O

BACKGROUND	O	O
:	O	O
Cisplatin	B-Chemical	D002945
-	O	O
based	O	O
chemotherapy	O	O
combinations	O	O
improve	O	O
quality	O	O
of	O	O
life	O	O
and	O	O
survival	O	O
in	O	O
advanced	O	O
nonsmall	B-Disease	D002289
cell	I-Disease	D002289
lung	I-Disease	D002289
carcinoma	I-Disease	D002289
(	O	O
NSCLC	B-Disease	D002289
)	O	O
.	O	O

The	O	O
emergence	O	O
of	O	O
new	O	O
active	O	O
drugs	O	O
might	O	O
translate	O	O
into	O	O
more	O	O
effective	O	O
regimens	O	O
for	O	O
the	O	O
treatment	O	O
of	O	O
this	O	O
disease	O	O
.	O	O

METHODS	O	O
:	O	O
The	O	O
objective	O	O
of	O	O
this	O	O
study	O	O
was	O	O
to	O	O
determine	O	O
the	O	O
feasibility	O	O
,	O	O
response	O	O
rate	O	O
,	O	O
and	O	O
toxicity	B-Disease	D064420
of	O	O
a	O	O
paclitaxel	B-Chemical	D017239
,	O	O
cisplatin	B-Chemical	D002945
,	O	O
and	O	O
gemcitabine	B-Chemical	C056507
combination	O	O
to	O	O
treat	O	O
metastatic	O	O
NSCLC	B-Disease	D002289
.	O	O

Thirty	O	O
-	O	O
five	O	O
consecutive	O	O
chemotherapy	O	O
-	O	O
naive	O	O
patients	O	O
with	O	O
Stage	O	O
IV	O	O
NSCLC	B-Disease	D002289
and	O	O
an	O	O
Eastern	O	O
Cooperative	O	O
Oncology	O	O
Group	O	O
performance	O	O
status	O	O
of	O	O
0	O	O
-	O	O
2	O	O
were	O	O
treated	O	O
with	O	O
a	O	O
combination	O	O
of	O	O
paclitaxel	B-Chemical	D017239
(	O	O
135	O	O
mg	O	O
/	O	O
m	O	O
(	O	O
2	O	O
)	O	O
given	O	O
intravenously	O	O
in	O	O
3	O	O
hours	O	O
)	O	O
on	O	O
Day	O	O
1	O	O
,	O	O
cisplatin	B-Chemical	D002945
(	O	O
120	O	O
mg	O	O
/	O	O
m	O	O
(	O	O
2	O	O
)	O	O
given	O	O
intravenously	O	O
in	O	O
6	O	O
hours	O	O
)	O	O
on	O	O
Day	O	O
1	O	O
,	O	O
and	O	O
gemcitabine	B-Chemical	C056507
(	O	O
800	O	O
mg	O	O
/	O	O
m	O	O
(	O	O
2	O	O
)	O	O
given	O	O
intravenously	O	O
in	O	O
30	O	O
minutes	O	O
)	O	O
on	O	O
Days	O	O
1	O	O
and	O	O
8	O	O
,	O	O
every	O	O
4	O	O
weeks	O	O
.	O	O

Although	O	O
responding	O	O
patients	O	O
were	O	O
scheduled	O	O
to	O	O
receive	O	O
consolidation	O	O
radiotherapy	O	O
and	O	O
24	O	O
patients	O	O
received	O	O
preplanned	O	O
second	O	O
-	O	O
line	O	O
chemotherapy	O	O
after	O	O
disease	O	O
progression	O	O
,	O	O
the	O	O
response	O	O
and	O	O
toxicity	B-Disease	D064420
rates	O	O
reported	O	O
refer	O	O
only	O	O
to	O	O
the	O	O
chemotherapy	O	O
regimen	O	O
given	O	O
.	O	O

RESULTS	O	O
:	O	O
All	O	O
the	O	O
patients	O	O
were	O	O
examined	O	O
for	O	O
toxicity	B-Disease	D064420
;	O	O
34	O	O
were	O	O
examinable	O	O
for	O	O
response	O	O
.	O	O

An	O	O
objective	O	O
response	O	O
was	O	O
observed	O	O
in	O	O
73	O	O
.	O	O

5%	O	O
of	O	O
the	O	O
patients	O	O
(	O	O
95%	O	O
confidence	O	O
interval	O	O
[	O	O
CI	O	O
]	O	O
,	O	O
55	O	O
.	O	O

6	O	O
-	O	O
87	O	O
.	O	O

1%	O	O
)	O	O
,	O	O
including	O	O
4	O	O
complete	O	O
responses	O	O
(	O	O
11	O	O
.	O	O

7%	O	O
)	O	O
.	O	O

According	O	O
to	O	O
intention	O	O
-	O	O
to	O	O
-	O	O
treat	O	O
,	O	O
the	O	O
overall	O	O
response	O	O
rate	O	O
was	O	O
71	O	O
.	O	O

4%	O	O
(	O	O
95%	O	O
CI	O	O
,	O	O
53	O	O
.	O	O

7	O	O
-	O	O
85	O	O
.	O	O

4%	O	O
)	O	O
.	O	O

After	O	O
154	O	O
courses	O	O
of	O	O
therapy	O	O
,	O	O
the	O	O
median	O	O
dose	O	O
intensity	O	O
was	O	O
131	O	O
mg	O	O
/	O	O
m	O	O
(	O	O
2	O	O
)	O	O
for	O	O
paclitaxel	B-Chemical	D017239
(	O	O
97	O	O
.	O	O

3%	O	O
)	O	O
,	O	O
117	O	O
mg	O	O
/	O	O
m	O	O
(	O	O
2	O	O
)	O	O
for	O	O
cisplatin	B-Chemical	D002945
(	O	O
97	O	O
.	O	O

3%	O	O
)	O	O
,	O	O
and	O	O
1378	O	O
mg	O	O
/	O	O
m	O	O
(	O	O
2	O	O
)	O	O
for	O	O
gemcitabine	B-Chemical	C056507
(	O	O
86	O	O
.	O	O

2%	O	O
)	O	O
.	O	O

World	O	O
Health	O	O
Organization	O	O
Grade	O	O
3	O	O
-	O	O
4	O	O
neutropenia	B-Disease	D009503
and	O	O
thrombocytopenia	B-Disease	D013921
occurred	O	O
in	O	O
39	O	O
.	O	O

9%	O	O
and	O	O
11	O	O
.	O	O

4%	O	O
of	O	O
patients	O	O
,	O	O
respectively	O	O
.	O	O

There	O	O
was	O	O
one	O	O
treatment	O	O
-	O	O
related	O	O
death	B-Disease	D003643
.	O	O

Nonhematologic	O	O
toxicities	B-Disease	D064420
were	O	O
mild	O	O
.	O	O

After	O	O
a	O	O
median	O	O
follow	O	O
-	O	O
up	O	O
of	O	O
22	O	O
months	O	O
,	O	O
the	O	O
median	O	O
progression	O	O
free	O	O
survival	O	O
rate	O	O
was	O	O
7	O	O
months	O	O
,	O	O
and	O	O
the	O	O
median	O	O
survival	O	O
time	O	O
was	O	O
16	O	O
months	O	O
.	O	O

CONCLUSIONS	O	O
:	O	O
The	O	O
combination	O	O
of	O	O
paclitaxel	B-Chemical	D017239
,	O	O
cisplatin	B-Chemical	D002945
,	O	O
and	O	O
gemcitabine	B-Chemical	C056507
is	O	O
well	O	O
tolerated	O	O
and	O	O
shows	O	O
high	O	O
activity	O	O
in	O	O
metastatic	O	O
NSCLC	B-Disease	D002289
.	O	O

This	O	O
treatment	O	O
merits	O	O
further	O	O
comparison	O	O
with	O	O
other	O	O
cisplatin	B-Chemical	D002945
-	O	O
based	O	O
regimens	O	O
.	O	O

Evaluation	O	O
of	O	O
adverse	O	O
reactions	O	O
of	O	O
aponidine	B-Chemical	C016986
hydrochloride	I-Chemical	C016986
ophthalmic	O	O
solution	O	O
.	O	O

We	O	O
prospectively	O	O
evaluated	O	O
the	O	O
adverse	O	O
reactions	O	O
of	O	O
apraclonidine	B-Chemical	C016986
in	O	O
20	O	O
normal	O	O
volunteers	O	O
by	O	O
instilling	O	O
a	O	O
single	O	O
drop	O	O
of	O	O
1%	O	O
apraclonidine	B-Chemical	C016986
in	O	O
their	O	O
right	O	O
eyes	O	O
.	O	O

Examinations	O	O
,	O	O
including	O	O
blood	O	O
pressure	O	O
,	O	O
pulse	O	O
rate	O	O
,	O	O
conjunctiva	O	O
and	O	O
cornea	O	O
,	O	O
intraocular	O	O
pressure	O	O
(	O	O
IOP	O	O
)	O	O
,	O	O
pupil	O	O
diameter	O	O
,	O	O
basal	O	O
tear	O	O
secretion	O	O
and	O	O
margin	O	O
reflex	O	O
distance	O	O
of	O	O
both	O	O
upper	O	O
and	O	O
lower	O	O
eyelids	O	O
,	O	O
were	O	O
performed	O	O
prior	O	O
to	O	O
entry	O	O
and	O	O
at	O	O
1	O	O
,	O	O
3	O	O
,	O	O
5	O	O
and	O	O
7	O	O
hours	O	O
after	O	O
instillation	O	O
.	O	O

The	O	O
ocular	B-Disease	D015814
hypotensive	I-Disease	D015814
effects	O	O
were	O	O
statistically	O	O
significant	O	O
for	O	O
apraclonidine	B-Chemical	C016986
-	O	O
treated	O	O
eyes	O	O
throughout	O	O
the	O	O
study	O	O
and	O	O
also	O	O
statistically	O	O
significant	O	O
for	O	O
contralateral	O	O
eyes	O	O
from	O	O
three	O	O
hours	O	O
after	O	O
topical	O	O
administration	O	O
of	O	O
1%	O	O
apraclonidine	B-Chemical	C016986
.	O	O

Decreases	B-Disease	D007022
in	I-Disease	D007022
systolic	I-Disease	D007022
blood	I-Disease	D007022
pressure	I-Disease	D007022
were	O	O
statistically	O	O
,	O	O
but	O	O
not	O	O
clinically	O	O
,	O	O
significant	O	O
.	O	O

No	O	O
significant	O	O
changes	O	O
in	O	O
diastolic	O	O
blood	O	O
pressure	O	O
,	O	O
pulse	O	O
rate	O	O
and	O	O
basal	O	O
tear	O	O
secretion	O	O
were	O	O
noted	O	O
.	O	O

Conjunctival	B-Disease	D003229
blanching	I-Disease	D003229
and	O	O
mydriasis	B-Disease	D015878
were	O	O
commonly	O	O
found	O	O
.	O	O

Upper	O	O
lid	O	O
retraction	O	O
was	O	O
frequently	O	O
noted	O	O
.	O	O

While	O	O
the	O	O
elevations	O	O
of	O	O
the	O	O
upper	O	O
lid	O	O
margin	O	O
in	O	O
most	O	O
subjects	O	O
were	O	O
not	O	O
more	O	O
than	O	O
2	O	O
mm	O	O
and	O	O
did	O	O
not	O	O
cause	O	O
noticeable	O	O
change	O	O
in	O	O
appearance	O	O
,	O	O
one	O	O
subject	O	O
suffered	O	O
from	O	O
mechanical	O	O
entropion	B-Disease	D004774
and	O	O
marked	O	O
corneal	B-Disease	D003316
abrasion	I-Disease	D003316
3	O	O
hours	O	O
after	O	O
instillation	O	O
of	O	O
the	O	O
medication	O	O
.	O	O

This	O	O
may	O	O
well	O	O
be	O	O
a	O	O
particularly	O	O
notable	O	O
finding	O	O
in	O	O
Asian	O	O
people	O	O
.	O	O

Carmofur	B-Chemical	C017367
-	O	O
induced	O	O
organic	B-Disease	D019965
mental	I-Disease	D019965
disorders	I-Disease	D019965
.	O	O

Organic	B-Disease	D019965
mental	I-Disease	D019965
disorder	I-Disease	D019965
was	O	O
observed	O	O
in	O	O
a	O	O
29	O	O
-	O	O
year	O	O
-	O	O
old	O	O
female	O	O
in	O	O
the	O	O
prognostic	O	O
period	O	O
after	O	O
the	O	O
onset	O	O
of	O	O
carmofur	B-Chemical	C017367
-	O	O
induced	O	O
leukoencephalopathy	B-Disease	D056784
.	O	O

Symptoms	O	O
such	O	O
as	O	O
euphoria	O	O
,	O	O
emotional	O	O
lability	O	O
and	O	O
puerile	O	O
attitude	O	O
noted	O	O
in	O	O
the	O	O
patient	O	O
were	O	O
diagnosed	O	O
as	O	O
organic	B-Disease	D010554
personality	I-Disease	D010554
syndrome	I-Disease	D010554
according	O	O
to	O	O
the	O	O
criteria	O	O
defined	O	O
in	O	O
the	O	O
DSM	O	O
-	O	O
III	O	O
-	O	O
R	O	O
.	O	O

It	O	O
is	O	O
referred	O	O
to	O	O
as	O	O
a	O	O
frontal	B-Disease	D001927
lobe	I-Disease	D001927
syndrome	I-Disease	D001927
.	O	O

Brain	O	O
CT	O	O
revealed	O	O
a	O	O
periventricular	O	O
low	O	O
density	O	O
area	O	O
in	O	O
the	O	O
frontal	O	O
white	O	O
matter	O	O
and	O	O
moderate	O	O
dilatation	O	O
of	O	O
the	O	O
lateral	O	O
ventricles	O	O
especially	O	O
at	O	O
the	O	O
bilateral	O	O
anterior	O	O
horns	O	O
.	O	O

Consequently	O	O
,	O	O
carmofur	B-Chemical	C017367
-	O	O
induced	O	O
leukoencephalopathy	B-Disease	D056784
may	O	O
uncommonly	O	O
result	O	O
in	O	O
organic	B-Disease	D010554
personality	I-Disease	D010554
syndrome	I-Disease	D010554
in	O	O
the	O	O
residual	O	O
state	O	O
.	O	O

It	O	O
may	O	O
be	O	O
attributed	O	O
to	O	O
the	O	O
structural	B-Disease	D001927
damage	I-Disease	D001927
to	I-Disease	D001927
the	I-Disease	D001927
frontal	I-Disease	D001927
lobe	I-Disease	D001927
.	O	O

International	O	O
mexiletine	B-Chemical	D008801
and	O	O
placebo	O	O
antiarrhythmic	O	O
coronary	O	O
trial	O	O
:	O	O
I	O	O
.	O	O

Report	O	O
on	O	O
arrhythmia	B-Disease	D001145
and	O	O
other	O	O
findings	O	O
.	O	O

Impact	O	O
Research	O	O
Group	O	O
.	O	O

The	O	O
antiarrhythmic	O	O
effects	O	O
of	O	O
the	O	O
sustained	O	O
release	O	O
form	O	O
of	O	O
mexiletine	B-Chemical	D008801
(	O	O
Mexitil	B-Chemical	D008801
-	I-Chemical	D008801
Perlongets	I-Chemical	D008801
)	O	O
were	O	O
evaluated	O	O
in	O	O
a	O	O
double	O	O
-	O	O
blind	O	O
placebo	O	O
trial	O	O
in	O	O
630	O	O
patients	O	O
with	O	O
recent	O	O
documented	O	O
myocardial	B-Disease	D009203
infarction	I-Disease	D009203
.	O	O

The	O	O
primary	O	O
response	O	O
variable	O	O
was	O	O
based	O	O
on	O	O
central	O	O
reading	O	O
of	O	O
24	O	O
hour	O	O
ambulatory	O	O
electrocardiographic	O	O
recordings	O	O
and	O	O
was	O	O
defined	O	O
as	O	O
the	O	O
occurrence	O	O
of	O	O
30	O	O
or	O	O
more	O	O
single	O	O
premature	O	O
ventricular	O	O
complexes	O	O
in	O	O
any	O	O
two	O	O
consecutive	O	O
30	O	O
minute	O	O
blocks	O	O
or	O	O
one	O	O
or	O	O
more	O	O
runs	O	O
of	O	O
two	O	O
or	O	O
more	O	O
premature	O	O
ventricular	O	O
complexes	O	O
in	O	O
the	O	O
entire	O	O
24	O	O
hour	O	O
electrocardiographic	O	O
recording	O	O
.	O	O

Large	O	O
differences	O	O
,	O	O
regarded	O	O
as	O	O
statistically	O	O
significant	O	O
,	O	O
between	O	O
the	O	O
mexiletine	B-Chemical	D008801
and	O	O
placebo	O	O
groups	O	O
were	O	O
noted	O	O
in	O	O
that	O	O
end	O	O
point	O	O
at	O	O
months	O	O
1	O	O
and	O	O
4	O	O
,	O	O
but	O	O
only	O	O
trends	O	O
were	O	O
observed	O	O
at	O	O
month	O	O
12	O	O
.	O	O

These	O	O
differences	O	O
were	O	O
observed	O	O
even	O	O
though	O	O
the	O	O
serum	O	O
mexiletine	B-Chemical	D008801
levels	O	O
obtained	O	O
in	O	O
this	O	O
study	O	O
were	O	O
generally	O	O
lower	O	O
than	O	O
those	O	O
observed	O	O
in	O	O
studies	O	O
that	O	O
have	O	O
used	O	O
the	O	O
regular	O	O
form	O	O
of	O	O
the	O	O
drug	O	O
.	O	O

There	O	O
were	O	O
more	O	O
deaths	B-Disease	D003643
in	O	O
the	O	O
mexiletine	B-Chemical	D008801
group	O	O
(	O	O
7	O	O
.	O	O

6%	O	O
)	O	O
than	O	O
in	O	O
the	O	O
placebo	O	O
group	O	O
(	O	O
4	O	O
.	O	O

8%	O	O
)	O	O
;	O	O
the	O	O
difference	O	O
was	O	O
not	O	O
statistically	O	O
significant	O	O
.	O	O

The	O	O
incidence	O	O
of	O	O
coronary	O	O
events	O	O
was	O	O
similar	O	O
in	O	O
both	O	O
groups	O	O
.	O	O

Previously	O	O
recognized	O	O
side	O	O
effects	O	O
,	O	O
particularly	O	O
tremor	B-Disease	D014202
and	O	O
gastrointestinal	B-Disease	D012817
problems	I-Disease	D012817
,	O	O
were	O	O
more	O	O
frequent	O	O
in	O	O
the	O	O
mexiletine	B-Chemical	D008801
group	O	O
than	O	O
in	O	O
the	O	O
placebo	O	O
group	O	O
.	O	O

Regional	O	O
localization	O	O
of	O	O
the	O	O
antagonism	O	O
of	O	O
amphetamine	B-Chemical	D000661
-	O	O
induced	O	O
hyperactivity	B-Disease	D006948
by	O	O
intracerebral	O	O
calcitonin	B-Chemical	D002116
injections	O	O
.	O	O

Calcitonin	B-Chemical	D002116
receptors	O	O
are	O	O
found	O	O
in	O	O
the	O	O
brain	O	O
,	O	O
and	O	O
intracerebral	O	O
infusions	O	O
of	O	O
calcitonin	B-Chemical	D002116
can	O	O
produce	O	O
behavioral	O	O
effects	O	O
.	O	O

Among	O	O
these	O	O
behavioral	O	O
effects	O	O
are	O	O
decreases	O	O
in	O	O
food	O	O
intake	O	O
and	O	O
decreases	O	O
in	O	O
amphetamine	B-Chemical	D000661
-	O	O
induced	O	O
locomotor	O	O
activity	O	O
.	O	O

In	O	O
previous	O	O
experiments	O	O
we	O	O
found	O	O
that	O	O
decreases	O	O
in	O	O
food	O	O
intake	O	O
were	O	O
induced	O	O
by	O	O
local	O	O
administration	O	O
of	O	O
calcitonin	B-Chemical	D002116
into	O	O
several	O	O
hypothalamic	O	O
sites	O	O
and	O	O
into	O	O
the	O	O
nucleus	O	O
accumbens	O	O
.	O	O

In	O	O
the	O	O
present	O	O
experiment	O	O
calcitonin	B-Chemical	D002116
decreased	O	O
locomotor	O	O
activity	O	O
when	O	O
locally	O	O
injected	O	O
into	O	O
the	O	O
same	O	O
sites	O	O
where	O	O
it	O	O
decreases	O	O
food	O	O
intake	O	O
.	O	O

The	O	O
areas	O	O
where	O	O
calcitonin	B-Chemical	D002116
is	O	O
most	O	O
effective	O	O
in	O	O
decreasing	O	O
locomotor	O	O
activity	O	O
are	O	O
located	O	O
in	O	O
the	O	O
hypothalamus	O	O
and	O	O
nucleus	O	O
accumbens	O	O
,	O	O
suggesting	O	O
that	O	O
these	O	O
areas	O	O
are	O	O
the	O	O
major	O	O
sites	O	O
of	O	O
action	O	O
of	O	O
calcitonin	B-Chemical	D002116
in	O	O
inhibiting	O	O
amphetamine	B-Chemical	D000661
-	O	O
induced	O	O
locomotor	O	O
activity	O	O
.	O	O

Fatal	O	O
intracranial	B-Disease	D013345
bleeding	I-Disease	D013345
associated	O	O
with	O	O
prehospital	O	O
use	O	O
of	O	O
epinephrine	B-Chemical	D004837
.	O	O

We	O	O
present	O	O
a	O	O
case	O	O
of	O	O
paramedic	O	O
misjudgment	O	O
in	O	O
the	O	O
execution	O	O
of	O	O
a	O	O
protocol	O	O
for	O	O
the	O	O
treatment	O	O
of	O	O
allergic	B-Disease	D004342
reaction	I-Disease	D004342
in	O	O
a	O	O
case	O	O
of	O	O
pulmonary	B-Disease	D011654
edema	I-Disease	D011654
with	O	O
wheezing	B-Disease	D012135
.	O	O

The	O	O
sudden	O	O
onset	O	O
of	O	O
respiratory	B-Disease	D012128
distress	I-Disease	D012128
,	O	O
rash	B-Disease	D005076
,	O	O
and	O	O
a	O	O
history	O	O
of	O	O
a	O	O
new	O	O
medicine	O	O
led	O	O
the	O	O
two	O	O
paramedics	O	O
on	O	O
the	O	O
scene	O	O
to	O	O
administer	O	O
subcutaneous	O	O
epinephrine	B-Chemical	D004837
.	O	O

Subsequently	O	O
,	O	O
acute	O	O
cardiac	B-Disease	D006323
arrest	I-Disease	D006323
and	O	O
fatal	O	O
subarachnoid	B-Disease	D013345
hemorrhage	I-Disease	D013345
occurred	O	O
.	O	O

Epinephrine	B-Chemical	D004837
has	O	O
a	O	O
proven	O	O
role	O	O
in	O	O
cardiac	B-Disease	D006323
arrest	I-Disease	D006323
in	O	O
prehospital	O	O
care	O	O
;	O	O
however	O	O
,	O	O
use	O	O
by	O	O
paramedics	O	O
in	O	O
patients	O	O
with	O	O
suspected	O	O
allergic	B-Disease	D004342
reaction	I-Disease	D004342
and	O	O
severe	O	O
hypertension	B-Disease	D006973
should	O	O
be	O	O
viewed	O	O
with	O	O
caution	O	O
.	O	O

A	O	O
case	O	O
of	O	O
massive	O	O
rhabdomyolysis	B-Disease	D012206
following	O	O
molindone	B-Chemical	D008972
administration	O	O
.	O	O

Rhabdomyolysis	B-Disease	D012206
is	O	O
a	O	O
potentially	O	O
lethal	O	O
syndrome	O	O
that	O	O
psychiatric	B-Disease	D001523
patients	O	O
seem	O	O
predisposed	O	O
to	O	O
develop	O	O
.	O	O

The	O	O
clinical	O	O
signs	O	O
and	O	O
symptoms	O	O
,	O	O
typical	O	O
laboratory	O	O
features	O	O
,	O	O
and	O	O
complications	O	O
of	O	O
rhabdomyolysis	B-Disease	D012206
are	O	O
presented	O	O
.	O	O

The	O	O
case	O	O
of	O	O
a	O	O
schizophrenic	B-Disease	D012559
patient	O	O
is	O	O
reported	O	O
to	O	O
illustrate	O	O
massive	O	O
rhabdomyolysis	B-Disease	D012206
and	O	O
subsequent	O	O
acute	B-Disease	D058186
renal	I-Disease	D058186
failure	I-Disease	D058186
following	O	O
molindone	B-Chemical	D008972
administration	O	O
.	O	O

Physicians	O	O
who	O	O
prescribe	O	O
molindone	B-Chemical	D008972
should	O	O
be	O	O
aware	O	O
of	O	O
this	O	O
reaction	O	O
.	O	O

Cardiovascular	B-Disease	D018376
alterations	I-Disease	D018376
in	O	O
rat	O	O
fetuses	O	O
exposed	O	O
to	O	O
calcium	B-Chemical	D002118
channel	O	O
blockers	O	O
.	O	O

Preclinical	O	O
toxicologic	O	O
investigation	O	O
suggested	O	O
that	O	O
a	O	O
new	O	O
calcium	B-Chemical	D002118
channel	O	O
blocker	O	O
,	O	O
Ro	B-Chemical	D020748
40	I-Chemical	D020748
-	I-Chemical	D020748
5967	I-Chemical	D020748
,	O	O
induced	O	O
cardiovascular	B-Disease	D018376
alterations	I-Disease	D018376
in	O	O
rat	O	O
fetuses	O	O
exposed	O	O
to	O	O
this	O	O
agent	O	O
during	O	O
organogenesis	O	O
.	O	O

The	O	O
present	O	O
study	O	O
was	O	O
designed	O	O
to	O	O
investigate	O	O
the	O	O
hypothesis	O	O
that	O	O
calcium	B-Chemical	D002118
channel	O	O
blockers	O	O
in	O	O
general	O	O
induce	O	O
cardiovascular	B-Disease	D018376
malformations	I-Disease	D018376
indicating	O	O
a	O	O
pharmacologic	O	O
class	O	O
effect	O	O
.	O	O

We	O	O
studied	O	O
three	O	O
calcium	B-Chemical	D002118
channel	O	O
blockers	O	O
of	O	O
different	O	O
structure	O	O
,	O	O
nifedipine	B-Chemical	D009543
,	O	O
diltiazem	B-Chemical	D004110
,	O	O
and	O	O
verapamil	B-Chemical	D014700
,	O	O
along	O	O
with	O	O
the	O	O
new	O	O
agent	O	O
.	O	O

Pregnant	O	O
rats	O	O
were	O	O
administered	O	O
one	O	O
of	O	O
these	O	O
calcium	B-Chemical	D002118
channel	O	O
blockers	O	O
during	O	O
the	O	O
period	O	O
of	O	O
cardiac	O	O
morphogenesis	O	O
and	O	O
the	O	O
offspring	O	O
examined	O	O
on	O	O
day	O	O
20	O	O
of	O	O
gestation	O	O
for	O	O
cardiovascular	B-Disease	D018376
malformations	I-Disease	D018376
.	O	O

A	O	O
low	O	O
incidence	O	O
of	O	O
cardiovascular	B-Disease	D018376
malformations	I-Disease	D018376
was	O	O
observed	O	O
after	O	O
exposure	O	O
to	O	O
each	O	O
of	O	O
the	O	O
four	O	O
calcium	B-Chemical	D002118
channel	O	O
blockers	O	O
,	O	O
but	O	O
this	O	O
incidence	O	O
was	O	O
statistically	O	O
significant	O	O
only	O	O
for	O	O
verapamil	B-Chemical	D014700
and	O	O
nifedipine	B-Chemical	D009543
.	O	O

All	O	O
four	O	O
agents	O	O
were	O	O
associated	O	O
with	O	O
aortic	O	O
arch	O	O
branching	O	O
variants	O	O
,	O	O
although	O	O
significantly	O	O
increased	O	O
only	O	O
for	O	O
Ro	B-Chemical	D020748
40	I-Chemical	D020748
-	I-Chemical	D020748
5967	I-Chemical	D020748
and	O	O
verapamil	B-Chemical	D014700
.	O	O

Differential	O	O
impact	O	O
of	O	O
immune	O	O
escape	O	O
mutations	O	O
G145R	O	O
and	O	O
P120T	O	O
on	O	O
the	O	O
replication	O	O
of	O	O
lamivudine	B-Chemical	D019259
-	O	O
resistant	O	O
hepatitis	B-Chemical	D006513
B	I-Chemical	D006513
virus	I-Chemical	D006513
e	I-Chemical	D006513
antigen	I-Chemical	D006513
-	O	O
positive	O	O
and	O	O
-	O	O
negative	O	O
strains	O	O
.	O	O

Immune	O	O
escape	O	O
variants	O	O
of	O	O
the	O	O
hepatitis	B-Disease	D006509
B	I-Disease	D006509
virus	O	O
(	O	O
HBV	O	O
)	O	O
represent	O	O
an	O	O
emerging	O	O
clinical	O	O
challenge	O	O
,	O	O
because	O	O
they	O	O
can	O	O
be	O	O
associated	O	O
with	O	O
vaccine	O	O
escape	O	O
,	O	O
HBV	O	O
reactivation	O	O
,	O	O
and	O	O
failure	O	O
of	O	O
diagnostic	O	O
tests	O	O
.	O	O

Recent	O	O
data	O	O
suggest	O	O
a	O	O
preferential	O	O
selection	O	O
of	O	O
immune	O	O
escape	O	O
mutants	O	O
in	O	O
distinct	O	O
peripheral	O	O
blood	O	O
leukocyte	O	O
compartments	O	O
of	O	O
infected	O	O
individuals	O	O
.	O	O

We	O	O
therefore	O	O
systematically	O	O
analyzed	O	O
the	O	O
functional	O	O
impact	O	O
of	O	O
the	O	O
most	O	O
prevalent	O	O
immune	O	O
escape	O	O
variants	O	O
,	O	O
the	O	O
sG145R	O	O
and	O	O
sP120T	O	O
mutants	O	O
,	O	O
on	O	O
the	O	O
viral	O	O
replication	O	O
efficacy	O	O
and	O	O
antiviral	O	O
drug	O	O
susceptibility	O	O
of	O	O
common	O	O
treatment	O	O
-	O	O
associated	O	O
mutants	O	O
with	O	O
resistance	O	O
to	O	O
lamivudine	B-Chemical	D019259
(	O	O
LAM	B-Chemical	D019259
)	O	O
and	O	O
/	O	O
or	O	O
HBeAg	B-Chemical	D006513
negativity	O	O
.	O	O

Replication	O	O
-	O	O
competent	O	O
HBV	O	O
strains	O	O
with	O	O
sG145R	O	O
or	O	O
sP120T	O	O
and	O	O
LAM	B-Chemical	D019259
resistance	O	O
(	O	O
rtM204I	O	O
or	O	O
rtL180M	O	O
/	O	O
rtM204V	O	O
)	O	O
were	O	O
generated	O	O
on	O	O
an	O	O
HBeAg	B-Chemical	D006513
-	O	O
positive	O	O
and	O	O
an	O	O
HBeAg	B-Chemical	D006513
-	O	O
negative	O	O
background	O	O
with	O	O
precore	O	O
(	O	O
PC	O	O
)	O	O
and	O	O
basal	O	O
core	O	O
promoter	O	O
(	O	O
BCP	O	O
)	O	O
mutants	O	O
.	O	O

The	O	O
sG145R	O	O
mutation	O	O
strongly	O	O
reduced	O	O
HBsAg	B-Chemical	D006514
levels	O	O
and	O	O
was	O	O
able	O	O
to	O	O
fully	O	O
restore	O	O
the	O	O
impaired	O	O
replication	O	O
of	O	O
LAM	B-Chemical	D019259
-	O	O
resistant	O	O
HBV	O	O
mutants	O	O
to	O	O
the	O	O
levels	O	O
of	O	O
wild	O	O
-	O	O
type	O	O
HBV	O	O
,	O	O
and	O	O
PC	O	O
or	O	O
BCP	O	O
mutations	O	O
further	O	O
enhanced	O	O
viral	O	O
replication	O	O
.	O	O

Although	O	O
the	O	O
sP120T	O	O
substitution	O	O
also	O	O
impaired	O	O
HBsAg	B-Chemical	D006514
secretion	O	O
,	O	O
it	O	O
did	O	O
not	O	O
enhance	O	O
the	O	O
replication	O	O
of	O	O
LAM	B-Chemical	D019259
-	O	O
resistant	O	O
clones	O	O
.	O	O

However	O	O
,	O	O
the	O	O
concomitant	O	O
occurrence	O	O
of	O	O
HBeAg	B-Chemical	D006513
negativity	O	O
(	O	O
PC	O	O
/	O	O
BCP	O	O
)	O	O
,	O	O
sP120T	O	O
,	O	O
and	O	O
LAM	B-Chemical	D019259
resistance	O	O
resulted	O	O
in	O	O
the	O	O
restoration	O	O
of	O	O
replication	O	O
to	O	O
levels	O	O
of	O	O
wild	O	O
-	O	O
type	O	O
HBV	O	O
.	O	O

In	O	O
all	O	O
clones	O	O
with	O	O
combined	O	O
immune	O	O
escape	O	O
and	O	O
LAM	B-Chemical	D019259
resistance	O	O
mutations	O	O
,	O	O
the	O	O
nucleotide	B-Chemical	D009711
analogues	O	O
adefovir	B-Chemical	C053001
and	O	O
tenofovir	B-Chemical	C096918
remained	O	O
effective	O	O
in	O	O
suppressing	O	O
viral	O	O
replication	O	O
in	O	O
vitro	O	O
.	O	O

These	O	O
findings	O	O
reveal	O	O
the	O	O
differential	O	O
impact	O	O
of	O	O
immune	O	O
escape	O	O
variants	O	O
on	O	O
the	O	O
replication	O	O
and	O	O
drug	O	O
susceptibility	O	O
of	O	O
complex	O	O
HBV	O	O
mutants	O	O
,	O	O
supporting	O	O
the	O	O
need	O	O
of	O	O
close	O	O
surveillance	O	O
and	O	O
treatment	O	O
adjustment	O	O
in	O	O
response	O	O
to	O	O
the	O	O
selection	O	O
of	O	O
distinct	O	O
mutational	O	O
patterns	O	O
.	O	O

The	O	O
effects	O	O
of	O	O
sevoflurane	B-Chemical	C009250
on	O	O
lidocaine	B-Chemical	D008012
-	O	O
induced	O	O
convulsions	B-Disease	D012640
.	O	O

The	O	O
influence	O	O
of	O	O
sevoflurane	B-Chemical	C009250
on	O	O
lidocaine	B-Chemical	D008012
-	O	O
induced	O	O
convulsions	B-Disease	D012640
was	O	O
studied	O	O
in	O	O
cats	O	O
.	O	O

The	O	O
convulsive	B-Disease	D012640
threshold	O	O
(	O	O
mean	O	O
+	O	O
/	O	O
-	O	O
SD	O	O
)	O	O
was	O	O
41	O	O
.	O	O

4	O	O
+	O	O
/	O	O
-	O	O
6	O	O
.	O	O

5	O	O
mg	O	O
.	O	O

l	O	O
(	O	O
-	O	O
1	O	O
)	O	O
with	O	O
lidocaine	B-Chemical	D008012
infusion	O	O
(	O	O
6	O	O
mg	O	O
.	O	O

kg	O	O
(	O	O
-	O	O
1	O	O
)	O	O
.	O	O

min	O	O
(	O	O
-	O	O
1	O	O
)	O	O
)	O	O
,	O	O
increasing	O	O
significantly	O	O
to	O	O
66	O	O
.	O	O

6	O	O
+	O	O
/	O	O
-	O	O
10	O	O
.	O	O

9	O	O
mg	O	O
.	O	O

l	O	O
(	O	O
-	O	O
1	O	O
)	O	O
when	O	O
the	O	O
end	O	O
-	O	O
tidal	O	O
concentration	O	O
of	O	O
sevoflurane	B-Chemical	C009250
was	O	O
0	O	O
.	O	O

8%	O	O
.	O	O

However	O	O
,	O	O
the	O	O
threshold	O	O
(	O	O
61	O	O
.	O	O

6	O	O
+	O	O
/	O	O
-	O	O
8	O	O
.	O	O

7	O	O
mg	O	O
.	O	O

l	O	O
(	O	O
-	O	O
1	O	O
)	O	O
)	O	O
during	O	O
1	O	O
.	O	O

6%	O	O
sevoflurane	B-Chemical	C009250
was	O	O
not	O	O
significant	O	O
from	O	O
that	O	O
during	O	O
0	O	O
.	O	O

8%	O	O
sevoflurane	B-Chemical	C009250
,	O	O
indicating	O	O
a	O	O
celling	O	O
effect	O	O
.	O	O

There	O	O
was	O	O
no	O	O
significant	O	O
difference	O	O
in	O	O
the	O	O
convulsive	B-Disease	D012640
threshold	O	O
between	O	O
sevoflurane	B-Chemical	C009250
and	O	O
enflurane	B-Chemical	D004737
.	O	O

The	O	O
rise	O	O
in	O	O
blood	O	O
pressure	O	O
became	O	O
less	O	O
marked	O	O
when	O	O
higher	O	O
concentrations	O	O
of	O	O
sevoflurane	B-Chemical	C009250
or	O	O
enflurane	B-Chemical	D004737
were	O	O
administered	O	O
and	O	O
the	O	O
blood	O	O
pressure	O	O
at	O	O
convulsions	B-Disease	D012640
decreased	O	O
significantly	O	O
in	O	O
1	O	O
.	O	O

6%	O	O
sevoflurane	B-Chemical	C009250
,	O	O
and	O	O
in	O	O
0	O	O
.	O	O

8%	O	O
and	O	O
1	O	O
.	O	O

6%	O	O
enflurane	B-Chemical	D004737
.	O	O

However	O	O
,	O	O
there	O	O
was	O	O
no	O	O
significant	O	O
difference	O	O
in	O	O
the	O	O
lidocaine	B-Chemical	D008012
concentrations	O	O
measured	O	O
when	O	O
the	O	O
systolic	O	O
blood	O	O
pressure	O	O
became	O	O
70	O	O
mmHg	O	O
.	O	O

Apamin	B-Chemical	D001030
,	O	O
a	O	O
selective	O	O
blocker	O	O
of	O	O
calcium	B-Chemical	D002118
-	O	O
dependent	O	O
potassium	B-Chemical	D011188
channels	O	O
,	O	O
was	O	O
administered	O	O
intracerebroventricularly	O	O
in	O	O
rats	O	O
anesthetized	O	O
with	O	O
0	O	O
.	O	O

8%	O	O
sevoflurane	B-Chemical	C009250
to	O	O
investigate	O	O
the	O	O
mechanism	O	O
of	O	O
the	O	O
anticonvulsive	O	O
effects	O	O
.	O	O

Apamin	B-Chemical	D001030
(	O	O
10	O	O
ng	O	O
)	O	O
had	O	O
a	O	O
tendency	O	O
to	O	O
decrease	O	O
the	O	O
convulsive	B-Disease	D012640
threshold	O	O
(	O	O
21	O	O
.	O	O

6	O	O
+	O	O
/	O	O
-	O	O
2	O	O
.	O	O

2	O	O
to	O	O
19	O	O
.	O	O

9	O	O
+	O	O
/	O	O
-	O	O
2	O	O
.	O	O

5	O	O
mg	O	O
.	O	O

l	O	O
(	O	O
-	O	O
1	O	O
)	O	O
)	O	O
but	O	O
this	O	O
was	O	O
not	O	O
statistically	O	O
significant	O	O
.	O	O

It	O	O
is	O	O
suggested	O	O
that	O	O
sevoflurane	B-Chemical	C009250
reduces	O	O
the	O	O
convulsive	B-Disease	D012640
effect	O	O
of	O	O
lidocaine	B-Chemical	D008012
toxicity	B-Disease	D064420
but	O	O
carries	O	O
some	O	O
risk	O	O
due	O	O
to	O	O
circulatory	O	O
depression	B-Disease	D003866
.	O	O

Anti	O	O
-	O	O
oxidant	O	O
effects	O	O
of	O	O
atorvastatin	B-Chemical	C065179
in	O	O
dexamethasone	B-Chemical	D003907
-	O	O
induced	O	O
hypertension	B-Disease	D006973
in	O	O
the	O	O
rat	O	O
.	O	O

1	O	O
.	O	O

Dexamethasone	B-Chemical	D003907
(	O	O
Dex	B-Chemical	D003907
)	O	O
-	O	O
induced	O	O
hypertension	B-Disease	D006973
is	O	O
characterized	O	O
by	O	O
endothelial	O	O
dysfunction	O	O
associated	O	O
with	O	O
nitric	B-Chemical	D009569
oxide	I-Chemical	D009569
(	O	O
NO	B-Chemical	D009569
)	O	O
deficiency	O	O
and	O	O
increased	O	O
superoxide	B-Chemical	D013481
(	O	O
O2	B-Chemical	D013481
-	I-Chemical	D013481
)	O	O
production	O	O
.	O	O

Atorvastatin	B-Chemical	C065179
(	O	O
Ato	B-Chemical	C065179
)	O	O
possesses	O	O
pleiotropic	O	O
properties	O	O
that	O	O
have	O	O
been	O	O
reported	O	O
to	O	O
improve	O	O
endothelial	O	O
function	O	O
through	O	O
increased	O	O
availability	O	O
of	O	O
NO	B-Chemical	D009569
and	O	O
reduced	O	O
O2	B-Chemical	D013481
-	I-Chemical	D013481
production	O	O
in	O	O
various	O	O
forms	O	O
of	O	O
hypertension	B-Disease	D006973
.	O	O

In	O	O
the	O	O
present	O	O
study	O	O
,	O	O
we	O	O
investigated	O	O
whether	O	O
50	O	O
mg	O	O
/	O	O
kg	O	O
per	O	O
day	O	O
,	O	O
p	O	O
.	O	O

o	O	O
.	O	O

,	O	O
Ato	B-Chemical	C065179
could	O	O
prevent	O	O
endothelial	O	O
NO	B-Chemical	D009569
synthase	O	O
(	O	O
eNOS	O	O
)	O	O
downregulation	O	O
and	O	O
the	O	O
increase	O	O
in	O	O
O2	B-Chemical	D013481
-	I-Chemical	D013481
in	O	O
Sprague	O	O
-	O	O
Dawley	O	O
(	O	O
SD	O	O
)	O	O
rats	O	O
,	O	O
thereby	O	O
reducing	O	O
blood	O	O
pressure	O	O
.	O	O

2	O	O
.	O	O

Male	O	O
SD	O	O
rats	O	O
(	O	O
n	O	O
=	O	O
30	O	O
)	O	O
were	O	O
treated	O	O
with	O	O
Ato	B-Chemical	C065179
(	O	O
50	O	O
mg	O	O
/	O	O
kg	O	O
per	O	O
day	O	O
in	O	O
drinking	O	O
water	O	O
)	O	O
or	O	O
tap	O	O
water	O	O
for	O	O
15	O	O
days	O	O
.	O	O

Dexamethasone	B-Chemical	D003907
(	O	O
10	O	O
microg	O	O
/	O	O
kg	O	O
per	O	O
day	O	O
,	O	O
s	O	O
.	O	O

c	O	O
.	O	O

)	O	O
or	O	O
saline	O	O
was	O	O
started	O	O
after	O	O
4	O	O
days	O	O
in	O	O
Ato	B-Chemical	C065179
-	O	O
treated	O	O
and	O	O
non	O	O
-	O	O
treated	O	O
rats	O	O
and	O	O
continued	O	O
for	O	O
11	O	O
-	O	O
13	O	O
days	O	O
.	O	O

Systolic	O	O
blood	O	O
pressure	O	O
(	O	O
SBP	O	O
)	O	O
was	O	O
measured	O	O
on	O	O
alternate	O	O
days	O	O
using	O	O
the	O	O
tail	O	O
-	O	O
cuff	O	O
method	O	O
.	O	O

Endothelial	O	O
function	O	O
was	O	O
assessed	O	O
by	O	O
acetylcholine	B-Chemical	D000109
-	O	O
induced	O	O
vasorelaxation	O	O
and	O	O
phenylephrine	B-Chemical	D010656
-	O	O
induced	O	O
vasoconstriction	O	O
in	O	O
aortic	O	O
segments	O	O
.	O	O

Vascular	O	O
eNOS	O	O
mRNA	O	O
was	O	O
assessed	O	O
by	O	O
semi	O	O
-	O	O
quantitative	O	O
reverse	O	O
transcription	O	O
-	O	O
polymerase	O	O
chain	O	O
reaction	O	O
.	O	O

3	O	O
.	O	O

In	O	O
rats	O	O
treated	O	O
with	O	O
Dex	B-Chemical	D003907
alone	O	O
,	O	O
SBP	O	O
was	O	O
increased	O	O
from	O	O
109	O	O
+	O	O
/	O	O
-	O	O
2	O	O
to	O	O
133	O	O
+	O	O
/	O	O
-	O	O
2	O	O
mmHg	O	O
on	O	O
Days	O	O
4	O	O
and	O	O
Day	O	O
14	O	O
,	O	O
respectively	O	O
(	O	O
P	O	O
<	O	O
0	O	O
.	O	O

001	O	O
)	O	O
.	O	O

In	O	O
the	O	O
Ato	B-Chemical	C065179
+	O	O
Dex	B-Chemical	D003907
group	O	O
,	O	O
SBP	O	O
was	O	O
increased	O	O
from	O	O
113	O	O
+	O	O
/	O	O
-	O	O
2	O	O
to	O	O
119	O	O
+	O	O
/	O	O
-	O	O
2	O	O
mmHg	O	O
on	O	O
Days	O	O
4	O	O
to	O	O
14	O	O
,	O	O
respectively	O	O
(	O	O
P	O	O
<	O	O
0	O	O
.	O	O

001	O	O
)	O	O
,	O	O
but	O	O
was	O	O
significantly	O	O
lower	O	O
than	O	O
SBP	O	O
in	O	O
the	O	O
group	O	O
treated	O	O
with	O	O
Dex	B-Chemical	D003907
alone	O	O
(	O	O
P	O	O
<	O	O
0	O	O
.	O	O

05	O	O
)	O	O
.	O	O

Endothelial	O	O
-	O	O
dependent	O	O
relaxation	O	O
and	O	O
eNOS	O	O
mRNA	O	O
expression	O	O
were	O	O
greater	O	O
in	O	O
the	O	O
Dex	B-Chemical	D003907
+	O	O
Ato	B-Chemical	C065179
group	O	O
than	O	O
in	O	O
the	O	O
Dex	B-Chemical	D003907
only	O	O
group	O	O
(	O	O
P	O	O
<	O	O
0	O	O
.	O	O

05	O	O
and	O	O
P	O	O
<	O	O
0	O	O
.	O	O

0001	O	O
,	O	O
respectively	O	O
)	O	O
.	O	O

Aortic	O	O
superoxide	B-Chemical	D013481
production	O	O
was	O	O
lower	O	O
in	O	O
the	O	O
Dex	B-Chemical	D003907
+	O	O
Ato	B-Chemical	C065179
group	O	O
compared	O	O
with	O	O
the	O	O
group	O	O
treated	O	O
with	O	O
Dex	B-Chemical	D003907
alone	O	O
(	O	O
P	O	O
<	O	O
0	O	O
.	O	O

0001	O	O
)	O	O
.	O	O

4	O	O
.	O	O

Treatment	O	O
with	O	O
Ato	B-Chemical	C065179
improved	O	O
endothelial	O	O
function	O	O
,	O	O
reduced	O	O
superoxide	B-Chemical	D013481
production	O	O
and	O	O
reduced	O	O
SBP	O	O
in	O	O
Dex	B-Chemical	D003907
-	O	O
treated	O	O
SD	O	O
rats	O	O
.	O	O

99mTc	B-Chemical	C067171
-	I-Chemical	C067171
glucarate	I-Chemical	C067171
for	O	O
detection	O	O
of	O	O
isoproterenol	B-Chemical	D007545
-	O	O
induced	O	O
myocardial	B-Disease	D009203
infarction	I-Disease	D009203
in	O	O
rats	O	O
.	O	O

Infarct	B-Disease	D007238
-	O	O
avid	O	O
radiopharmaceuticals	O	O
are	O	O
necessary	O	O
for	O	O
rapid	O	O
and	O	O
timely	O	O
diagnosis	O	O
of	O	O
acute	O	O
myocardial	B-Disease	D009203
infarction	I-Disease	D009203
.	O	O

The	O	O
animal	O	O
model	O	O
used	O	O
to	O	O
produce	O	O
infarction	B-Disease	D007238
implies	O	O
artery	O	O
ligation	O	O
but	O	O
chemical	O	O
induction	O	O
can	O	O
be	O	O
easily	O	O
obtained	O	O
with	O	O
isoproterenol	B-Chemical	D007545
.	O	O

A	O	O
new	O	O
infarct	B-Disease	D007238
-	O	O
avid	O	O
radiopharmaceutical	O	O
based	O	O
on	O	O
glucaric	B-Chemical	D005937
acid	I-Chemical	D005937
was	O	O
prepared	O	O
in	O	O
the	O	O
hospital	O	O
radiopharmacy	O	O
of	O	O
the	O	O
INCMNSZ	O	O
.	O	O

99mTc	B-Chemical	C067171
-	I-Chemical	C067171
glucarate	I-Chemical	C067171
was	O	O
easy	O	O
to	O	O
prepare	O	O
,	O	O
stable	O	O
for	O	O
96	O	O
h	O	O
and	O	O
was	O	O
used	O	O
to	O	O
study	O	O
its	O	O
biodistribution	O	O
in	O	O
rats	O	O
with	O	O
isoproterenol	B-Chemical	D007545
-	O	O
induced	O	O
acute	O	O
myocardial	B-Disease	D009203
infarction	I-Disease	D009203
.	O	O

Histological	O	O
studies	O	O
demonstrated	O	O
that	O	O
the	O	O
rats	O	O
developed	O	O
an	O	O
infarct	B-Disease	D007238
18	O	O
h	O	O
after	O	O
isoproterenol	B-Chemical	D007545
administration	O	O
.	O	O

The	O	O
rat	O	O
biodistribution	O	O
studies	O	O
showed	O	O
a	O	O
rapid	O	O
blood	O	O
clearance	O	O
via	O	O
the	O	O
kidneys	O	O
.	O	O

Thirty	O	O
minutes	O	O
after	O	O
99mTc	B-Chemical	C067171
-	I-Chemical	C067171
glucarate	I-Chemical	C067171
administration	O	O
the	O	O
standardised	O	O
heart	O	O
uptake	O	O
value	O	O
S	O	O
(	O	O
h	O	O
)	O	O
UV	O	O
was	O	O
4	O	O
.	O	O

7	O	O
in	O	O
infarcted	O	O
rat	O	O
heart	O	O
which	O	O
is	O	O
six	O	O
times	O	O
more	O	O
than	O	O
in	O	O
normal	O	O
rats	O	O
.	O	O

ROIs	O	O
drawn	O	O
over	O	O
the	O	O
gamma	O	O
camera	O	O
images	O	O
showed	O	O
a	O	O
ratio	O	O
of	O	O
4	O	O
.	O	O

4	O	O
.	O	O

The	O	O
high	O	O
image	O	O
quality	O	O
suggests	O	O
that	O	O
high	O	O
contrast	O	O
images	O	O
can	O	O
be	O	O
obtained	O	O
in	O	O
humans	O	O
and	O	O
the	O	O
96	O	O
h	O	O
stability	O	O
makes	O	O
it	O	O
an	O	O
ideal	O	O
agent	O	O
to	O	O
detect	O	O
,	O	O
in	O	O
patients	O	O
,	O	O
early	O	O
cardiac	B-Disease	D009203
infarction	I-Disease	D009203
.	O	O

A	O	O
randomized	O	O
,	O	O
placebo	O	O
-	O	O
controlled	O	O
dose	O	O
-	O	O
comparison	O	O
trial	O	O
of	O	O
haloperidol	B-Chemical	D006220
for	O	O
psychosis	B-Disease	D011618
and	O	O
disruptive	B-Disease	D019958
behaviors	I-Disease	D019958
in	O	O
Alzheimer's	B-Disease	D000544
disease	I-Disease	D000544
.	O	O

OBJECTIVE	O	O
:	O	O
The	O	O
goal	O	O
of	O	O
this	O	O
study	O	O
was	O	O
to	O	O
compare	O	O
the	O	O
efficacy	O	O
and	O	O
side	O	O
effects	O	O
of	O	O
two	O	O
doses	O	O
of	O	O
haloperidol	B-Chemical	D006220
and	O	O
placebo	O	O
in	O	O
the	O	O
treatment	O	O
of	O	O
psychosis	B-Disease	D011618
and	O	O
disruptive	B-Disease	D019958
behaviors	I-Disease	D019958
in	O	O
patients	O	O
with	O	O
Alzheimer's	B-Disease	D000544
disease	I-Disease	D000544
.	O	O

METHOD	O	O
:	O	O
In	O	O
a	O	O
6	O	O
-	O	O
week	O	O
random	O	O
-	O	O
assignment	O	O
,	O	O
double	O	O
-	O	O
blind	O	O
,	O	O
placebo	O	O
-	O	O
controlled	O	O
trial	O	O
(	O	O
phase	O	O
A	O	O
)	O	O
,	O	O
haloperidol	B-Chemical	D006220
,	O	O
2	O	O
-	O	O
3	O	O
mg	O	O
/	O	O
day	O	O
(	O	O
standard	O	O
dose	O	O
)	O	O
,	O	O
and	O	O
haloperidol	B-Chemical	D006220
,	O	O
0	O	O
.	O	O

50	O	O
-	O	O
0	O	O
.	O	O

75	O	O
mg	O	O
/	O	O
day	O	O
(	O	O
low	O	O
dose	O	O
)	O	O
,	O	O
were	O	O
compared	O	O
in	O	O
71	O	O
outpatients	O	O
with	O	O
Alzheimer's	B-Disease	D000544
disease	I-Disease	D000544
.	O	O

For	O	O
the	O	O
subsequent	O	O
6	O	O
-	O	O
week	O	O
double	O	O
-	O	O
blind	O	O
crossover	O	O
phase	O	O
(	O	O
phase	O	O
B	O	O
)	O	O
,	O	O
patients	O	O
taking	O	O
standard	O	O
-	O	O
or	O	O
low	O	O
-	O	O
dose	O	O
haloperidol	B-Chemical	D006220
were	O	O
switched	O	O
to	O	O
placebo	O	O
,	O	O
and	O	O
patients	O	O
taking	O	O
placebo	O	O
were	O	O
randomly	O	O
assigned	O	O
to	O	O
standard	O	O
-	O	O
or	O	O
low	O	O
-	O	O
dose	O	O
haloperidol	B-Chemical	D006220
.	O	O

RESULTS	O	O
:	O	O
For	O	O
the	O	O
60	O	O
patients	O	O
who	O	O
completed	O	O
phase	O	O
A	O	O
,	O	O
standard	O	O
-	O	O
dose	O	O
haloperidol	B-Chemical	D006220
was	O	O
efficacious	O	O
and	O	O
superior	O	O
to	O	O
both	O	O
low	O	O
-	O	O
dose	O	O
haloperidol	B-Chemical	D006220
and	O	O
placebo	O	O
for	O	O
scores	O	O
on	O	O
the	O	O
Brief	O	O
Psychiatric	O	O
Rating	O	O
Scale	O	O
psychosis	B-Disease	D011618
factor	O	O
and	O	O
on	O	O
psychomotor	B-Disease	D011595
agitation	I-Disease	D011595
.	O	O

Response	O	O
rates	O	O
according	O	O
to	O	O
three	O	O
sets	O	O
of	O	O
criteria	O	O
were	O	O
greater	O	O
with	O	O
the	O	O
standard	O	O
dose	O	O
(	O	O
55%	O	O
-	O	O
60%	O	O
)	O	O
than	O	O
the	O	O
low	O	O
dose	O	O
(	O	O
25%	O	O
-	O	O
35%	O	O
)	O	O
and	O	O
placebo	O	O
(	O	O
25%	O	O
-	O	O
30%	O	O
)	O	O
.	O	O

The	O	O
advantage	O	O
of	O	O
standard	O	O
dose	O	O
over	O	O
low	O	O
dose	O	O
was	O	O
replicated	O	O
in	O	O
phase	O	O
B	O	O
.	O	O

In	O	O
phase	O	O
A	O	O
,	O	O
extrapyramidal	B-Disease	D001480
signs	I-Disease	D001480
tended	O	O
to	O	O
be	O	O
greater	O	O
with	O	O
the	O	O
standard	O	O
dose	O	O
than	O	O
in	O	O
the	O	O
other	O	O
two	O	O
conditions	O	O
,	O	O
primarily	O	O
because	O	O
of	O	O
a	O	O
subgroup	O	O
(	O	O
20%	O	O
)	O	O
who	O	O
developed	O	O
moderate	O	O
to	O	O
severe	O	O
signs	O	O
.	O	O

Low	O	O
-	O	O
dose	O	O
haloperidol	B-Chemical	D006220
did	O	O
not	O	O
differ	O	O
from	O	O
placebo	O	O
on	O	O
any	O	O
measure	O	O
of	O	O
efficacy	O	O
or	O	O
side	O	O
effects	O	O
.	O	O

CONCLUSIONS	O	O
:	O	O
The	O	O
results	O	O
indicated	O	O
a	O	O
favorable	O	O
therapeutic	O	O
profile	O	O
for	O	O
haloperidol	B-Chemical	D006220
in	O	O
doses	O	O
of	O	O
2	O	O
-	O	O
3	O	O
mg	O	O
/	O	O
day	O	O
,	O	O
although	O	O
a	O	O
subgroup	O	O
developed	O	O
moderate	O	O
to	O	O
severe	O	O
extrapyramidal	B-Disease	D001480
signs	I-Disease	D001480
.	O	O

A	O	O
starting	O	O
dose	O	O
of	O	O
1	O	O
mg	O	O
/	O	O
day	O	O
with	O	O
gradual	O	O
,	O	O
upward	O	O
dose	O	O
titration	O	O
is	O	O
recommended	O	O
.	O	O

The	O	O
narrow	O	O
therapeutic	O	O
window	O	O
observed	O	O
with	O	O
haloperidol	B-Chemical	D006220
may	O	O
also	O	O
apply	O	O
to	O	O
other	O	O
neuroleptics	O	O
used	O	O
in	O	O
Alzheimer's	B-Disease	D000544
disease	I-Disease	D000544
patients	O	O
with	O	O
psychosis	B-Disease	D011618
and	O	O
disruptive	B-Disease	D019958
behaviors	I-Disease	D019958
.	O	O

Individual	O	O
differences	O	O
in	O	O
renal	O	O
ACE	O	O
activity	O	O
in	O	O
healthy	O	O
rats	O	O
predict	O	O
susceptibility	O	O
to	O	O
adriamycin	B-Chemical	D004317
-	O	O
induced	O	O
renal	B-Disease	D007674
damage	I-Disease	D007674
.	O	O

BACKGROUND	O	O
:	O	O
In	O	O
man	O	O
,	O	O
differences	O	O
in	O	O
angiotensin	B-Chemical	D000809
-	O	O
converting	O	O
enzyme	O	O
(	O	O
ACE	O	O
)	O	O
levels	O	O
,	O	O
related	O	O
to	O	O
ACE	O	O
(	O	O
I	O	O
/	O	O
D	O	O
)	O	O
genotype	O	O
,	O	O
are	O	O
associated	O	O
with	O	O
renal	O	O
prognosis	O	O
.	O	O

This	O	O
raises	O	O
the	O	O
hypothesis	O	O
that	O	O
individual	O	O
differences	O	O
in	O	O
renal	O	O
ACE	O	O
activity	O	O
are	O	O
involved	O	O
in	O	O
renal	O	O
susceptibility	O	O
to	O	O
inflicted	O	O
damage	O	O
.	O	O

Therefore	O	O
,	O	O
we	O	O
studied	O	O
the	O	O
predictive	O	O
effect	O	O
of	O	O
renal	O	O
ACE	O	O
activity	O	O
for	O	O
the	O	O
severity	O	O
of	O	O
renal	B-Disease	D007674
damage	I-Disease	D007674
induced	O	O
by	O	O
a	O	O
single	O	O
injection	O	O
of	O	O
adriamycin	B-Chemical	D004317
in	O	O
rats	O	O
.	O	O

METHODS	O	O
:	O	O
Renal	O	O
ACE	O	O
activity	O	O
(	O	O
Hip	B-Chemical	C010980
-	I-Chemical	C010980
His	I-Chemical	C010980
-	I-Chemical	C010980
Leu	I-Chemical	C010980
cleavage	O	O
by	O	O
cortical	O	O
homogenates	O	O
)	O	O
was	O	O
determined	O	O
by	O	O
renal	O	O
biopsy	O	O
in	O	O
27	O	O
adult	O	O
male	O	O
Wistar	O	O
rats	O	O
.	O	O

After	O	O
1	O	O
week	O	O
of	O	O
recovery	O	O
,	O	O
proteinuria	B-Disease	D011507
was	O	O
induced	O	O
by	O	O
adriamycin	B-Chemical	D004317
[	O	O
1	O	O
.	O	O

5	O	O
mg	O	O
/	O	O
kg	O	O
intravenously	O	O
(	O	O
i	O	O
.	O	O

v	O	O
.	O	O

)	O	O
n	O	O
=	O	O
18	O	O
;	O	O
controls	O	O
,	O	O
saline	O	O
i	O	O
.	O	O

v	O	O
.	O	O

n	O	O
=	O	O
9	O	O
]	O	O
.	O	O

Proteinuria	B-Disease	D011507
was	O	O
measured	O	O
every	O	O
2	O	O
weeks	O	O
.	O	O

After	O	O
12	O	O
weeks	O	O
,	O	O
rats	O	O
were	O	O
sacrificed	O	O
and	O	O
their	O	O
kidneys	O	O
harvested	O	O
.	O	O

RESULTS	O	O
:	O	O
As	O	O
anticipated	O	O
,	O	O
adriamycin	B-Chemical	D004317
elicited	O	O
nephrotic	B-Disease	D009404
range	O	O
proteinuria	B-Disease	D011507
,	O	O
renal	B-Disease	D007674
interstitial	I-Disease	D007674
damage	I-Disease	D007674
and	O	O
mild	O	O
focal	B-Disease	D005923
glomerulosclerosis	I-Disease	D005923
.	O	O

Baseline	O	O
renal	O	O
ACE	O	O
positively	O	O
correlated	O	O
with	O	O
the	O	O
relative	O	O
rise	O	O
in	O	O
proteinuria	B-Disease	D011507
after	O	O
adriamycin	B-Chemical	D004317
(	O	O
r	O	O
=	O	O
0	O	O
.	O	O

62	O	O
,	O	O
P<0	O	O
.	O	O

01	O	O
)	O	O
,	O	O
renal	O	O
interstitial	O	O
alpha	O	O
-	O	O
smooth	O	O
muscle	O	O
actin	O	O
(	O	O
r	O	O
=	O	O
0	O	O
.	O	O

49	O	O
,	O	O
P<0	O	O
.	O	O

05	O	O
)	O	O
,	O	O
interstitial	O	O
macrophage	O	O
influx	O	O
(	O	O
r	O	O
=	O	O
0	O	O
.	O	O

56	O	O
,	O	O
P<0	O	O
.	O	O

05	O	O
)	O	O
,	O	O
interstitial	O	O
collagen	O	O
III	O	O
(	O	O
r	O	O
=	O	O
0	O	O
.	O	O

53	O	O
,	O	O
P<0	O	O
.	O	O

05	O	O
)	O	O
,	O	O
glomerular	O	O
alpha	O	O
-	O	O
smooth	O	O
muscle	O	O
actin	O	O
(	O	O
r	O	O
=	O	O
0	O	O
.	O	O

74	O	O
,	O	O
P<0	O	O
.	O	O

01	O	O
)	O	O
and	O	O
glomerular	O	O
desmin	O	O
(	O	O
r	O	O
=	O	O
0	O	O
.	O	O

48	O	O
,	O	O
P<0	O	O
.	O	O

05	O	O
)	O	O
.	O	O

Baseline	O	O
renal	O	O
ACE	O	O
did	O	O
not	O	O
correlate	O	O
with	O	O
focal	B-Disease	D005923
glomerulosclerosis	I-Disease	D005923
(	O	O
r	O	O
=	O	O
0	O	O
.	O	O

22	O	O
,	O	O
NS	O	O
)	O	O
.	O	O

In	O	O
controls	O	O
,	O	O
no	O	O
predictive	O	O
values	O	O
for	O	O
renal	O	O
parameters	O	O
were	O	O
observed	O	O
.	O	O

CONCLUSION	O	O
:	O	O
Individual	O	O
differences	O	O
in	O	O
renal	O	O
ACE	O	O
activity	O	O
predict	O	O
the	O	O
severity	O	O
of	O	O
adriamycin	B-Chemical	D004317
-	O	O
induced	O	O
renal	B-Disease	D007674
damage	I-Disease	D007674
in	O	O
this	O	O
outbred	O	O
rat	O	O
strain	O	O
.	O	O

This	O	O
supports	O	O
the	O	O
assumption	O	O
that	O	O
differences	O	O
in	O	O
renal	O	O
ACE	O	O
activity	O	O
predispose	O	O
to	O	O
a	O	O
less	O	O
favourable	O	O
course	O	O
of	O	O
renal	B-Disease	D007674
damage	I-Disease	D007674
.	O	O

Clinical	O	O
nephrotoxicity	B-Disease	D007674
of	O	O
tobramycin	B-Chemical	D014031
and	O	O
gentamicin	B-Chemical	D005839
.	O	O

A	O	O
prospective	O	O
study	O	O
.	O	O

Nearly	O	O
3	O	O
.	O	O

2	O	O
million	O	O
people	O	O
in	O	O
this	O	O
country	O	O
receive	O	O
aminoglycoside	B-Chemical	D000617
antibiotics	O	O
annually	O	O
.	O	O

Gentamicin	B-Chemical	D005839
sulfate	I-Chemical	D005839
and	O	O
tobramycin	B-Chemical	D014031
sulfate	O	O
continue	O	O
to	O	O
demonstrate	O	O
ototoxicity	B-Disease	D006311
and	O	O
nephrotoxicity	B-Disease	D007674
in	O	O
both	O	O
animal	O	O
and	O	O
clinical	O	O
studies	O	O
.	O	O

In	O	O
this	O	O
study	O	O
,	O	O
62	O	O
patients	O	O
with	O	O
confirmed	O	O
initial	O	O
normal	O	O
renal	O	O
function	O	O
and	O	O
treated	O	O
with	O	O
2	O	O
to	O	O
5	O	O
mg	O	O
/	O	O
kg	O	O
/	O	O
day	O	O
of	O	O
gentamicin	B-Chemical	D005839
sulfate	O	O
or	O	O
tobramycin	B-Chemical	D014031
sulfate	O	O
for	O	O
a	O	O
minimum	O	O
of	O	O
seven	O	O
days	O	O
were	O	O
followed	O	O
up	O	O
prospectively	O	O
for	O	O
the	O	O
development	O	O
of	O	O
aminoglycoside	B-Chemical	D000617
-	O	O
related	O	O
renal	B-Disease	D051437
failure	I-Disease	D051437
,	O	O
defined	O	O
as	O	O
at	O	O
least	O	O
a	O	O
one	O	O
-	O	O
third	O	O
reduction	O	O
in	O	O
renal	O	O
function	O	O
.	O	O

In	O	O
these	O	O
62	O	O
patients	O	O
,	O	O
no	O	O
other	O	O
causes	O	O
for	O	O
renal	B-Disease	D051437
failure	I-Disease	D051437
could	O	O
be	O	O
identified	O	O
.	O	O

Five	O	O
of	O	O
33	O	O
(	O	O
15%	O	O
)	O	O
of	O	O
the	O	O
tobramycin	B-Chemical	D014031
-	O	O
treated	O	O
patients	O	O
and	O	O
16	O	O
of	O	O
29	O	O
(	O	O
55	O	O
.	O	O

2%	O	O
)	O	O
of	O	O
the	O	O
gentamicin	B-Chemical	D005839
-	O	O
treated	O	O
patients	O	O
had	O	O
renal	B-Disease	D051437
failure	I-Disease	D051437
.	O	O

Thus	O	O
,	O	O
gentamicin	B-Chemical	D005839
was	O	O
associated	O	O
with	O	O
renal	B-Disease	D051437
failure	I-Disease	D051437
more	O	O
than	O	O
three	O	O
times	O	O
as	O	O
often	O	O
as	O	O
was	O	O
tobramycin	B-Chemical	D014031
.	O	O

Neuroprotective	O	O
action	O	O
of	O	O
MPEP	B-Chemical	C121465
,	O	O
a	O	O
selective	O	O
mGluR5	O	O
antagonist	O	O
,	O	O
in	O	O
methamphetamine	B-Chemical	D008694
-	O	O
induced	O	O
dopaminergic	O	O
neurotoxicity	B-Disease	D020258
is	O	O
associated	O	O
with	O	O
a	O	O
decrease	O	O
in	O	O
dopamine	B-Chemical	D004298
outflow	O	O
and	O	O
inhibition	O	O
of	O	O
hyperthermia	B-Disease	D005334
in	O	O
rats	O	O
.	O	O

The	O	O
aim	O	O
of	O	O
this	O	O
study	O	O
was	O	O
to	O	O
examine	O	O
the	O	O
role	O	O
of	O	O
metabotropic	O	O
glutamate	B-Chemical	D018698
receptor	O	O
5	O	O
(	O	O
mGluR5	O	O
)	O	O
in	O	O
the	O	O
toxic	O	O
action	O	O
of	O	O
methamphetamine	B-Chemical	D008694
on	O	O
dopaminergic	O	O
neurones	O	O
in	O	O
rats	O	O
.	O	O

Methamphetamine	B-Chemical	D008694
(	O	O
10	O	O
mg	O	O
/	O	O
kg	O	O
sc	O	O
)	O	O
,	O	O
administered	O	O
five	O	O
times	O	O
,	O	O
reduced	O	O
the	O	O
levels	O	O
of	O	O
dopamine	B-Chemical	D004298
and	O	O
its	O	O
metabolites	O	O
in	O	O
striatal	O	O
tissue	O	O
when	O	O
measured	O	O
72	O	O
h	O	O
after	O	O
the	O	O
last	O	O
injection	O	O
.	O	O

A	O	O
selective	O	O
antagonist	O	O
of	O	O
mGluR5	O	O
,	O	O
2	B-Chemical	C121465
-	I-Chemical	C121465
methyl	I-Chemical	C121465
-	I-Chemical	C121465
6	I-Chemical	C121465
-	I-Chemical	C121465
(	I-Chemical	C121465
phenylethynyl	I-Chemical	C121465
)	I-Chemical	C121465
pyridine	I-Chemical	C121465
(	O	O
MPEP	B-Chemical	C121465
;	O	O
5	O	O
mg	O	O
/	O	O
kg	O	O
ip	O	O
)	O	O
,	O	O
when	O	O
administered	O	O
five	O	O
times	O	O
immediately	O	O
before	O	O
each	O	O
methamphetamine	B-Chemical	D008694
injection	O	O
reversed	O	O
the	O	O
above	O	O
-	O	O
mentioned	O	O
methamphetamine	B-Chemical	D008694
effects	O	O
.	O	O

A	O	O
single	O	O
MPEP	B-Chemical	C121465
(	O	O
5	O	O
mg	O	O
/	O	O
kg	O	O
ip	O	O
)	O	O
injection	O	O
reduced	O	O
the	O	O
basal	O	O
extracellular	O	O
dopamine	B-Chemical	D004298
level	O	O
in	O	O
the	O	O
striatum	O	O
,	O	O
as	O	O
well	O	O
as	O	O
dopamine	B-Chemical	D004298
release	O	O
stimulated	O	O
either	O	O
by	O	O
methamphetamine	B-Chemical	D008694
(	O	O
10	O	O
mg	O	O
/	O	O
kg	O	O
sc	O	O
)	O	O
or	O	O
by	O	O
intrastriatally	O	O
administered	O	O
veratridine	B-Chemical	D014701
(	O	O
100	O	O
microM	O	O
)	O	O
.	O	O

Moreover	O	O
,	O	O
it	O	O
transiently	O	O
diminished	O	O
the	O	O
methamphetamine	B-Chemical	D008694
(	O	O
10	O	O
mg	O	O
/	O	O
kg	O	O
sc	O	O
)	O	O
-	O	O
induced	O	O
hyperthermia	B-Disease	D005334
and	O	O
reduced	O	O
basal	O	O
body	O	O
temperature	O	O
.	O	O

MPEP	B-Chemical	C121465
administered	O	O
into	O	O
the	O	O
striatum	O	O
at	O	O
high	O	O
concentrations	O	O
(	O	O
500	O	O
microM	O	O
)	O	O
increased	O	O
extracellular	O	O
dopamine	B-Chemical	D004298
levels	O	O
,	O	O
while	O	O
lower	O	O
concentrations	O	O
(	O	O
50	O	O
-	O	O
100	O	O
microM	O	O
)	O	O
were	O	O
devoid	O	O
of	O	O
any	O	O
effect	O	O
.	O	O

The	O	O
results	O	O
of	O	O
this	O	O
study	O	O
suggest	O	O
that	O	O
the	O	O
blockade	O	O
of	O	O
mGluR5	O	O
by	O	O
MPEP	B-Chemical	C121465
may	O	O
protect	O	O
dopaminergic	O	O
neurones	O	O
against	O	O
methamphetamine	B-Chemical	D008694
-	O	O
induced	O	O
toxicity	B-Disease	D064420
.	O	O

Neuroprotection	O	O
rendered	O	O
by	O	O
MPEP	B-Chemical	C121465
may	O	O
be	O	O
associated	O	O
with	O	O
the	O	O
reduction	O	O
of	O	O
the	O	O
methamphetamine	B-Chemical	D008694
-	O	O
induced	O	O
dopamine	B-Chemical	D004298
efflux	O	O
in	O	O
the	O	O
striatum	O	O
due	O	O
to	O	O
the	O	O
blockade	O	O
of	O	O
extrastriatal	O	O
mGluR5	O	O
,	O	O
and	O	O
with	O	O
a	O	O
decrease	O	O
in	O	O
hyperthermia	B-Disease	D005334
.	O	O

Pharmacokinetics	O	O
of	O	O
desipramine	B-Chemical	D003891
HCl	I-Chemical	D003891
when	O	O
administered	O	O
with	O	O
cinacalcet	B-Chemical	C476217
HCl	I-Chemical	C476217
.	O	O

OBJECTIVE	O	O
:	O	O
In	O	O
vitro	O	O
work	O	O
has	O	O
demonstrated	O	O
that	O	O
cinacalcet	B-Chemical	C476217
is	O	O
a	O	O
strong	O	O
inhibitor	O	O
of	O	O
cytochrome	O	O
P450	O	O
isoenzyme	O	O
(	O	O
CYP	O	O
)	O	O
2D6	O	O
.	O	O

The	O	O
purpose	O	O
of	O	O
this	O	O
study	O	O
was	O	O
to	O	O
evaluate	O	O
the	O	O
effect	O	O
of	O	O
cinacalcet	B-Chemical	C476217
on	O	O
CYP2D6	O	O
activity	O	O
,	O	O
using	O	O
desipramine	B-Chemical	D003891
as	O	O
a	O	O
probe	O	O
substrate	O	O
,	O	O
in	O	O
healthy	O	O
subjects	O	O
.	O	O

METHODS	O	O
:	O	O
Seventeen	O	O
subjects	O	O
who	O	O
were	O	O
genotyped	O	O
as	O	O
CYP2D6	O	O
extensive	O	O
metabolizers	O	O
were	O	O
enrolled	O	O
in	O	O
this	O	O
randomized	O	O
,	O	O
open	O	O
-	O	O
label	O	O
,	O	O
crossover	O	O
study	O	O
to	O	O
receive	O	O
a	O	O
single	O	O
oral	O	O
dose	O	O
of	O	O
desipramine	B-Chemical	D003891
(	O	O
50	O	O
mg	O	O
)	O	O
on	O	O
two	O	O
separate	O	O
occasions	O	O
,	O	O
once	O	O
alone	O	O
and	O	O
once	O	O
after	O	O
multiple	O	O
doses	O	O
of	O	O
cinacalcet	B-Chemical	C476217
(	O	O
90	O	O
mg	O	O
for	O	O
7	O	O
days	O	O
)	O	O
.	O	O

Blood	O	O
samples	O	O
were	O	O
obtained	O	O
predose	O	O
and	O	O
up	O	O
to	O	O
72	O	O
h	O	O
postdose	O	O
.	O	O

RESULTS	O	O
:	O	O
Fourteen	O	O
subjects	O	O
completed	O	O
both	O	O
treatment	O	O
arms	O	O
.	O	O

Relative	O	O
to	O	O
desipramine	B-Chemical	D003891
alone	O	O
,	O	O
mean	O	O
AUC	O	O
and	O	O
C	O	O
(	O	O
max	O	O
)	O	O
of	O	O
desipramine	B-Chemical	D003891
increased	O	O
3	O	O
.	O	O

6	O	O
-	O	O
and	O	O
1	O	O
.	O	O

8	O	O
-	O	O
fold	O	O
when	O	O
coadministered	O	O
with	O	O
cinacalcet	B-Chemical	C476217
.	O	O

The	O	O
t	O	O
(	O	O
1	O	O
/	O	O
2	O	O
,	O	O
z	O	O
)	O	O
of	O	O
desipramine	B-Chemical	D003891
was	O	O
longer	O	O
when	O	O
desipramine	B-Chemical	D003891
was	O	O
coadministered	O	O
with	O	O
cinacalcet	B-Chemical	C476217
(	O	O
21	O	O
.	O	O

0	O	O
versus	O	O
43	O	O
.	O	O

3	O	O
hs	O	O
)	O	O
.	O	O

The	O	O
t	O	O
(	O	O
max	O	O
)	O	O
was	O	O
similar	O	O
between	O	O
the	O	O
regimens	O	O
.	O	O

Fewer	O	O
subjects	O	O
reported	O	O
adverse	O	O
events	O	O
following	O	O
treatment	O	O
with	O	O
desipramine	B-Chemical	D003891
alone	O	O
than	O	O
when	O	O
receiving	O	O
desipramine	B-Chemical	D003891
with	O	O
cinacalcet	B-Chemical	C476217
(	O	O
33	O	O
versus	O	O
86%	O	O
)	O	O
,	O	O
the	O	O
most	O	O
frequent	O	O
of	O	O
which	O	O
(	O	O
nausea	B-Disease	D009325
and	O	O
headache	B-Disease	D006261
)	O	O
have	O	O
been	O	O
reported	O	O
for	O	O
patients	O	O
treated	O	O
with	O	O
either	O	O
desipramine	B-Chemical	D003891
or	O	O
cinacalcet	B-Chemical	C476217
.	O	O

CONCLUSION	O	O
:	O	O
This	O	O
study	O	O
demonstrates	O	O
that	O	O
cinacalcet	B-Chemical	C476217
is	O	O
a	O	O
strong	O	O
inhibitor	O	O
of	O	O
CYP2D6	O	O
.	O	O

These	O	O
data	O	O
suggest	O	O
that	O	O
during	O	O
concomitant	O	O
treatment	O	O
with	O	O
cinacalcet	B-Chemical	C476217
,	O	O
dose	O	O
adjustment	O	O
may	O	O
be	O	O
necessary	O	O
for	O	O
drugs	O	O
that	O	O
demonstrate	O	O
a	O	O
narrow	O	O
therapeutic	O	O
index	O	O
and	O	O
are	O	O
metabolized	O	O
by	O	O
CYP2D6	O	O
.	O	O

Proteomic	O	O
analysis	O	O
of	O	O
striatal	O	O
proteins	O	O
in	O	O
the	O	O
rat	O	O
model	O	O
of	O	O
L	B-Chemical	D007980
-	I-Chemical	D007980
DOPA	I-Chemical	D007980
-	O	O
induced	O	O
dyskinesia	B-Disease	D004409
.	O	O

L	B-Chemical	D007980
-	I-Chemical	D007980
DOPA	I-Chemical	D007980
-	O	O
induced	O	O
dyskinesia	B-Disease	D004409
(	O	O
LID	B-Disease	D004409
)	O	O
is	O	O
among	O	O
the	O	O
motor	O	O
complications	O	O
that	O	O
arise	O	O
in	O	O
Parkinson's	B-Disease	D010300
disease	I-Disease	D010300
(	O	O
PD	B-Disease	D010300
)	O	O
patients	O	O
after	O	O
a	O	O
prolonged	O	O
treatment	O	O
with	O	O
L	B-Chemical	D007980
-	I-Chemical	D007980
DOPA	I-Chemical	D007980
.	O	O

To	O	O
this	O	O
day	O	O
,	O	O
transcriptome	O	O
analysis	O	O
has	O	O
been	O	O
performed	O	O
in	O	O
a	O	O
rat	O	O
model	O	O
of	O	O
LID	B-Disease	D004409
[	O	O
Neurobiol	O	O
.	O	O

Dis	O	O
.	O	O

,	O	O
17	O	O
(	O	O
2004	O	O
)	O	O
,	O	O
219	O	O
]	O	O
but	O	O
information	O	O
regarding	O	O
the	O	O
proteome	O	O
is	O	O
still	O	O
lacking	O	O
.	O	O

In	O	O
the	O	O
present	O	O
study	O	O
,	O	O
we	O	O
investigated	O	O
the	O	O
changes	O	O
occurring	O	O
at	O	O
the	O	O
protein	O	O
level	O	O
in	O	O
striatal	O	O
samples	O	O
obtained	O	O
from	O	O
the	O	O
unilaterally	O	O
6	B-Chemical	D016627
-	I-Chemical	D016627
hydroxydopamine	I-Chemical	D016627
-	O	O
lesion	O	O
rat	O	O
model	O	O
of	O	O
PD	B-Disease	D010300
treated	O	O
with	O	O
saline	O	O
,	O	O
L	B-Chemical	D007980
-	I-Chemical	D007980
DOPA	I-Chemical	D007980
or	O	O
bromocriptine	B-Chemical	D001971
using	O	O
two	O	O
-	O	O
dimensional	O	O
difference	O	O
gel	O	O
electrophoresis	O	O
and	O	O
mass	O	O
spectrometry	O	O
(	O	O
MS	O	O
)	O	O
.	O	O

Rats	O	O
treated	O	O
with	O	O
L	B-Chemical	D007980
-	I-Chemical	D007980
DOPA	I-Chemical	D007980
were	O	O
allocated	O	O
to	O	O
two	O	O
groups	O	O
based	O	O
on	O	O
the	O	O
presence	O	O
or	O	O
absence	O	O
of	O	O
LID	B-Disease	D004409
.	O	O

Among	O	O
the	O	O
2000	O	O
spots	O	O
compared	O	O
for	O	O
statistical	O	O
difference	O	O
,	O	O
67	O	O
spots	O	O
were	O	O
significantly	O	O
changed	O	O
in	O	O
abundance	O	O
and	O	O
identified	O	O
using	O	O
matrix	O	O
-	O	O
assisted	O	O
laser	O	O
desorption	O	O
/	O	O
ionization	O	O
time	O	O
-	O	O
of	O	O
-	O	O
flight	O	O
MS	O	O
,	O	O
atmospheric	O	O
pressure	O	O
matrix	O	O
-	O	O
assisted	O	O
laser	O	O
desorption	O	O
/	O	O
ionization	O	O
and	O	O
HPLC	O	O
coupled	O	O
tandem	O	O
MS	O	O
(	O	O
LC	O	O
/	O	O
MS	O	O
/	O	O
MS	O	O
)	O	O
.	O	O

Out	O	O
of	O	O
these	O	O
67	O	O
proteins	O	O
,	O	O
LID	B-Disease	D004409
significantly	O	O
changed	O	O
the	O	O
expression	O	O
level	O	O
of	O	O
five	O	O
proteins	O	O
:	O	O
alphabeta	O	O
-	O	O
crystalin	O	O
,	O	O
gamma	O	O
-	O	O
enolase	O	O
,	O	O
guanidoacetate	O	O
methyltransferase	O	O
,	O	O
vinculin	O	O
,	O	O
and	O	O
proteasome	O	O
alpha	O	O
-	O	O
2	O	O
subunit	O	O
.	O	O

Complementary	O	O
techniques	O	O
such	O	O
as	O	O
western	O	O
immunoblotting	O	O
and	O	O
immunohistochemistry	O	O
were	O	O
performed	O	O
to	O	O
investigate	O	O
the	O	O
validity	O	O
of	O	O
the	O	O
data	O	O
obtained	O	O
using	O	O
the	O	O
proteomic	O	O
approach	O	O
.	O	O

In	O	O
conclusion	O	O
,	O	O
this	O	O
study	O	O
provides	O	O
new	O	O
insights	O	O
into	O	O
the	O	O
protein	O	O
changes	O	O
occurring	O	O
in	O	O
LID	B-Disease	D004409
.	O	O

Pseudo	O	O
-	O	O
allergic	B-Disease	D004342
reactions	I-Disease	D004342
to	O	O
corticosteroids	B-Chemical	D000305
:	O	O
diagnosis	O	O
and	O	O
alternatives	O	O
.	O	O

Two	O	O
patients	O	O
treated	O	O
with	O	O
parenteral	O	O
paramethasone	B-Chemical	D010248
(	O	O
Triniol	O	O
)	O	O
and	O	O
dexamethasone	B-Chemical	D003907
(	O	O
Sedionbel	O	O
)	O	O
are	O	O
described	O	O
.	O	O

A	O	O
few	O	O
minutes	O	O
after	O	O
administration	O	O
of	O	O
the	O	O
drugs	O	O
,	O	O
they	O	O
presented	O	O
urticaria	B-Disease	D014581
(	O	O
patients	O	O
1	O	O
and	O	O
2	O	O
)	O	O
and	O	O
conjunctivitis	B-Disease	D003231
(	O	O
patient	O	O
1	O	O
)	O	O
.	O	O

The	O	O
purpose	O	O
of	O	O
our	O	O
study	O	O
was	O	O
to	O	O
determine	O	O
the	O	O
cause	O	O
of	O	O
the	O	O
patients'	O	O
reactions	O	O
,	O	O
the	O	O
immunological	O	O
mechanisms	O	O
involved	O	O
and	O	O
whether	O	O
these	O	O
patients	O	O
would	O	O
be	O	O
able	O	O
to	O	O
tolerate	O	O
any	O	O
kind	O	O
of	O	O
corticoid	O	O
.	O	O

Clinical	O	O
examinations	O	O
and	O	O
skin	O	O
,	O	O
oral	O	O
and	O	O
parenteral	O	O
challenges	O	O
with	O	O
different	O	O
corticosteroids	B-Chemical	D000305
and	O	O
ELISA	O	O
tests	O	O
were	O	O
performed	O	O
.	O	O

In	O	O
the	O	O
two	O	O
patients	O	O
,	O	O
skin	O	O
and	O	O
ELISA	O	O
tests	O	O
with	O	O
paramethasone	B-Chemical	D010248
were	O	O
negative	O	O
,	O	O
as	O	O
was	O	O
the	O	O
prick	O	O
test	O	O
with	O	O
each	O	O
of	O	O
its	O	O
excipients	O	O
.	O	O

A	O	O
single	O	O
-	O	O
blind	O	O
parenteral	O	O
challenge	O	O
with	O	O
Triniol	O	O
was	O	O
positive	O	O
in	O	O
both	O	O
patients	O	O
after	O	O
the	O	O
administration	O	O
of	O	O
1	O	O
ml	O	O
of	O	O
the	O	O
drug	O	O
,	O	O
and	O	O
negative	O	O
with	O	O
its	O	O
excipients	O	O
.	O	O

We	O	O
also	O	O
carried	O	O
out	O	O
oral	O	O
and	O	O
parenteral	O	O
challenges	O	O
with	O	O
other	O	O
corticosteroids	B-Chemical	D000305
and	O	O
found	O	O
intolerance	O	O
to	O	O
some	O	O
of	O	O
them	O	O
.	O	O

These	O	O
results	O	O
suggest	O	O
that	O	O
paramethasone	B-Chemical	D010248
caused	O	O
pseudoallergic	O	O
reactions	O	O
in	O	O
our	O	O
patients	O	O
.	O	O

Corticosteroids	O	O
different	O	O
from	O	O
paramethasone	B-Chemical	D010248
also	O	O
produced	O	O
hypersensitivity	B-Disease	D004342
reactions	O	O
in	O	O
these	O	O
patients	O	O
;	O	O
however	O	O
,	O	O
a	O	O
few	O	O
of	O	O
them	O	O
were	O	O
tolerated	O	O
.	O	O

The	O	O
basic	O	O
mechanisms	O	O
of	O	O
those	O	O
reactions	O	O
are	O	O
not	O	O
yet	O	O
fully	O	O
understood	O	O
.	O	O

To	O	O
our	O	O
knowledge	O	O
,	O	O
this	O	O
is	O	O
the	O	O
first	O	O
report	O	O
of	O	O
a	O	O
pseudo	O	O
-	O	O
allergy	B-Disease	D004342
caused	O	O
by	O	O
paramethasone	B-Chemical	D010248
.	O	O

Valproic	B-Chemical	D014635
acid	I-Chemical	D014635
induced	O	O
encephalopathy	B-Disease	D001927
-	O	O
-	O	O
19	O	O
new	O	O
cases	O	O
in	O	O
Germany	O	O
from	O	O
1994	O	O
to	O	O
2003	O	O
-	O	O
-	O	O
a	O	O
side	O	O
effect	O	O
associated	O	O
to	O	O
VPA	B-Chemical	D014635
-	O	O
therapy	O	O
not	O	O
only	O	O
in	O	O
young	O	O
children	O	O
.	O	O

Valproic	B-Chemical	D014635
acid	I-Chemical	D014635
(	O	O
VPA	B-Chemical	D014635
)	O	O
is	O	O
a	O	O
broad	O	O
-	O	O
spectrum	O	O
antiepileptic	O	O
drug	O	O
and	O	O
is	O	O
usually	O	O
well	O	O
-	O	O
tolerated	O	O
.	O	O

Rare	O	O
serious	O	O
complications	O	O
may	O	O
occur	O	O
in	O	O
some	O	O
patients	O	O
,	O	O
including	O	O
haemorrhagic	O	O
pancreatitis	B-Disease	D010195
,	O	O
bone	B-Disease	D001855
marrow	I-Disease	D001855
suppression	I-Disease	D001855
,	O	O
VPA	B-Chemical	D014635
-	O	O
induced	O	O
hepatotoxicity	B-Disease	D056486
and	O	O
VPA	B-Chemical	D014635
-	O	O
induced	O	O
encephalopathy	B-Disease	D001927
.	O	O

The	O	O
typical	O	O
signs	O	O
of	O	O
VPA	B-Chemical	D014635
-	O	O
induced	O	O
encephalopathy	B-Disease	D001927
are	O	O
impaired	B-Disease	D003244
consciousness	I-Disease	D003244
,	O	O
sometimes	O	O
marked	O	O
EEG	O	O
background	O	O
slowing	O	O
,	O	O
increased	O	O
seizure	B-Disease	D012640
frequency	O	O
,	O	O
with	O	O
or	O	O
without	O	O
hyperammonemia	B-Disease	D022124
.	O	O

There	O	O
is	O	O
still	O	O
no	O	O
proof	O	O
of	O	O
causative	O	O
effect	O	O
of	O	O
VPA	B-Chemical	D014635
in	O	O
patients	O	O
with	O	O
encephalopathy	B-Disease	D001927
,	O	O
but	O	O
only	O	O
of	O	O
an	O	O
association	O	O
with	O	O
an	O	O
assumed	O	O
causal	O	O
relation	O	O
.	O	O

We	O	O
report	O	O
19	O	O
patients	O	O
with	O	O
VPA	B-Chemical	D014635
-	O	O
associated	O	O
encephalopathy	B-Disease	D001927
in	O	O
Germany	O	O
from	O	O
the	O	O
years	O	O
1994	O	O
to	O	O
2003	O	O
,	O	O
none	O	O
of	O	O
whom	O	O
had	O	O
been	O	O
published	O	O
previously	O	O
.	O	O

Haemolytic	B-Disease	D006463
-	I-Disease	D006463
uraemic	I-Disease	D006463
syndrome	I-Disease	D006463
after	O	O
treatment	O	O
with	O	O
metronidazole	B-Chemical	D008795
.	O	O

This	O	O
paper	O	O
describes	O	O
the	O	O
clinical	O	O
features	O	O
of	O	O
six	O	O
children	O	O
who	O	O
developed	O	O
the	O	O
haemolytic	B-Disease	D006463
-	I-Disease	D006463
uraemic	I-Disease	D006463
syndrome	I-Disease	D006463
after	O	O
treatment	O	O
with	O	O
metronidazole	B-Chemical	D008795
.	O	O

These	O	O
children	O	O
were	O	O
older	O	O
and	O	O
were	O	O
more	O	O
likely	O	O
to	O	O
have	O	O
undergone	O	O
recent	O	O
bowel	O	O
surgery	O	O
than	O	O
are	O	O
other	O	O
children	O	O
with	O	O
this	O	O
condition	O	O
.	O	O

While	O	O
the	O	O
involvement	O	O
of	O	O
metronidazole	B-Chemical	D008795
in	O	O
the	O	O
aetiology	O	O
of	O	O
the	O	O
haemolytic	B-Disease	D006463
-	I-Disease	D006463
uraemic	I-Disease	D006463
syndrome	I-Disease	D006463
is	O	O
not	O	O
established	O	O
firmly	O	O
,	O	O
the	O	O
action	O	O
of	O	O
this	O	O
drug	O	O
in	O	O
sensitizing	O	O
tissues	O	O
to	O	O
oxidation	O	O
injury	O	O
and	O	O
the	O	O
reported	O	O
evidence	O	O
of	O	O
oxidation	O	O
changes	O	O
in	O	O
the	O	O
haemolytic	B-Disease	D006463
-	I-Disease	D006463
uraemic	I-Disease	D006463
syndrome	I-Disease	D006463
suggest	O	O
a	O	O
possible	O	O
link	O	O
between	O	O
metronidazole	B-Chemical	D008795
treatment	O	O
and	O	O
some	O	O
cases	O	O
of	O	O
the	O	O
haemolytic	B-Disease	D006463
-	I-Disease	D006463
uraemic	I-Disease	D006463
syndrome	I-Disease	D006463
.	O	O

Risk	O	O
factors	O	O
of	O	O
sensorineural	B-Disease	D006319
hearing	I-Disease	D006319
loss	I-Disease	D006319
in	O	O
preterm	O	O
infants	O	O
.	O	O

Among	O	O
547	O	O
preterm	O	O
infants	O	O
of	O	O
<	O	O
or	O	O
=	O	O
34	O	O
weeks	O	O
gestation	O	O
born	O	O
between	O	O
1987	O	O
and	O	O
1991	O	O
,	O	O
8	O	O
children	O	O
(	O	O
1	O	O
.	O	O

46%	O	O
)	O	O
developed	O	O
severe	O	O
progressive	O	O
and	O	O
bilateral	O	O
sensorineural	B-Disease	D006319
hearing	I-Disease	D006319
loss	I-Disease	D006319
.	O	O

Perinatal	O	O
risk	O	O
factors	O	O
of	O	O
infants	O	O
with	O	O
hearing	B-Disease	D034381
loss	I-Disease	D034381
were	O	O
compared	O	O
with	O	O
those	O	O
of	O	O
two	O	O
control	O	O
groups	O	O
matched	O	O
for	O	O
gestation	O	O
and	O	O
birth	O	O
weight	O	O
and	O	O
for	O	O
perinatal	O	O
complications	O	O
.	O	O

Our	O	O
observations	O	O
demonstrated	O	O
an	O	O
association	O	O
of	O	O
hearing	B-Disease	D034381
loss	I-Disease	D034381
with	O	O
a	O	O
higher	O	O
incidence	O	O
of	O	O
perinatal	O	O
complications	O	O
.	O	O

Ototoxicity	B-Disease	D006311
appeared	O	O
closely	O	O
related	O	O
to	O	O
a	O	O
prolonged	O	O
administration	O	O
and	O	O
higher	O	O
total	O	O
dose	O	O
of	O	O
ototoxic	B-Disease	D006311
drugs	O	O
,	O	O
particularly	O	O
aminoglycosides	B-Chemical	D000617
and	O	O
furosemide	B-Chemical	D005665
.	O	O

Finally	O	O
,	O	O
we	O	O
strongly	O	O
recommend	O	O
to	O	O
prospectively	O	O
and	O	O
regularly	O	O
perform	O	O
audiologic	O	O
assessment	O	O
in	O	O
sick	O	O
preterm	O	O
children	O	O
as	O	O
hearing	B-Disease	D034381
loss	I-Disease	D034381
is	O	O
of	O	O
delayed	O	O
onset	O	O
and	O	O
in	O	O
most	O	O
cases	O	O
bilateral	O	O
and	O	O
severe	O	O
.	O	O

Pharmacokinetic	O	O
and	O	O
clinical	O	O
studies	O	O
in	O	O
patients	O	O
with	O	O
cimetidine	B-Chemical	D002927
-	O	O
associated	O	O
mental	O	O
confusion	B-Disease	D003221
.	O	O

15	O	O
cases	O	O
of	O	O
cimetidine	B-Chemical	D002927
-	O	O
associated	O	O
mental	O	O
confusion	B-Disease	D003221
have	O	O
been	O	O
reported	O	O
.	O	O

In	O	O
order	O	O
that	O	O
this	O	O
syndrome	O	O
might	O	O
be	O	O
investigated	O	O
changes	O	O
in	O	O
mental	O	O
status	O	O
(	O	O
M	O	O
.	O	O

S	O	O
.	O	O

)	O	O
were	O	O
correlated	O	O
with	O	O
serum	O	O
concentrations	O	O
and	O	O
renal	O	O
and	O	O
hepatic	O	O
function	O	O
in	O	O
36	O	O
patients	O	O
,	O	O
30	O	O
patients	O	O
had	O	O
no	O	O
M	O	O
.	O	O

S	O	O
.	O	O

change	O	O
on	O	O
cimetidine	B-Chemical	D002927
and	O	O
6	O	O
had	O	O
moderate	O	O
to	O	O
severe	O	O
changes	O	O
.	O	O

These	O	O
6	O	O
patients	O	O
had	O	O
both	O	O
renal	O	O
and	O	O
liver	O	O
dysfunction	O	O
(	O	O
P	O	O
less	O	O
than	O	O
0	O	O
.	O	O

05	O	O
)	O	O
,	O	O
as	O	O
well	O	O
as	O	O
cimetidine	B-Chemical	D002927
trough	O	O
-	O	O
concentrations	O	O
of	O	O
more	O	O
than	O	O
1	O	O
.	O	O

25	O	O
microgram	O	O
/	O	O
ml	O	O
(	O	O
P	O	O
less	O	O
than	O	O
0	O	O
.	O	O

05	O	O
)	O	O
.	O	O

The	O	O
severity	O	O
of	O	O
M	O	O
.	O	O

S	O	O
.	O	O

changes	O	O
increased	O	O
as	O	O
trough	O	O
-	O	O
concentrations	O	O
rose	O	O
,	O	O
5	O	O
patients	O	O
had	O	O
lumbar	O	O
puncture	O	O
.	O	O

The	O	O
cerebrospinal	O	O
fluid	O	O
:	O	O
serum	O	O
ratio	O	O
of	O	O
cimetidine	B-Chemical	D002927
concentrations	O	O
was	O	O
0	O	O
.	O	O

24	O	O
:	O	O
1	O	O
and	O	O
indicates	O	O
that	O	O
cimetidine	B-Chemical	D002927
passes	O	O
the	O	O
blood	O	O
-	O	O
brain	O	O
barrier	O	O
;	O	O
it	O	O
also	O	O
raises	O	O
the	O	O
possibility	O	O
that	O	O
M	O	O
.	O	O

S	O	O
.	O	O

changes	O	O
are	O	O
due	O	O
to	O	O
blockade	O	O
of	O	O
histamine	B-Chemical	D006632
H2	O	O
-	O	O
receptors	O	O
in	O	O
the	O	O
central	O	O
nervous	O	O
system	O	O
.	O	O

Patients	O	O
likely	O	O
to	O	O
have	O	O
both	O	O
raised	O	O
trough	O	O
-	O	O
concentrations	O	O
and	O	O
mental	O	O
confusion	B-Disease	D003221
are	O	O
those	O	O
with	O	O
both	O	O
severe	O	O
renal	O	O
and	O	O
hepatic	O	O
dysfunction	O	O
.	O	O

They	O	O
should	O	O
be	O	O
closely	O	O
observed	O	O
and	O	O
should	O	O
be	O	O
given	O	O
reduced	O	O
doses	O	O
of	O	O
cimetidine	B-Chemical	D002927
.	O	O

Different	O	O
lobular	O	O
distributions	O	O
of	O	O
altered	O	O
hepatocyte	O	O
tight	O	O
junctions	O	O
in	O	O
rat	O	O
models	O	O
of	O	O
intrahepatic	O	O
and	O	O
extrahepatic	B-Disease	D001651
cholestasis	I-Disease	D001651
.	O	O

Hepatocyte	O	O
tight	O	O
junctions	O	O
(	O	O
TJs	O	O
)	O	O
,	O	O
the	O	O
only	O	O
intercellular	O	O
barrier	O	O
between	O	O
the	O	O
sinusoidal	O	O
and	O	O
the	O	O
canalicular	O	O
spaces	O	O
,	O	O
play	O	O
a	O	O
key	O	O
role	O	O
in	O	O
bile	O	O
formation	O	O
.	O	O

Although	O	O
hepatocyte	O	O
TJs	O	O
are	O	O
impaired	O	O
in	O	O
cholestasis	B-Disease	D002779
,	O	O
attempts	O	O
to	O	O
localize	O	O
the	O	O
precise	O	O
site	O	O
of	O	O
hepatocyte	O	O
TJ	O	O
damage	O	O
by	O	O
freeze	O	O
-	O	O
fracture	O	O
electron	O	O
microscopy	O	O
have	O	O
produced	O	O
limited	O	O
information	O	O
.	O	O

Recently	O	O
,	O	O
several	O	O
TJ	O	O
-	O	O
associated	O	O
proteins	O	O
like	O	O
ZO	O	O
-	O	O
1	O	O
and	O	O
7H6	O	O
have	O	O
been	O	O
identified	O	O
and	O	O
characterized	O	O
.	O	O

Immunolocalization	O	O
of	O	O
7H6	O	O
appears	O	O
to	O	O
closely	O	O
correlate	O	O
with	O	O
paracellular	O	O
permeability	O	O
.	O	O

We	O	O
used	O	O
rat	O	O
models	O	O
of	O	O
intrahepatic	B-Disease	D002780
cholestasis	I-Disease	D002780
by	O	O
ethinyl	B-Chemical	D004997
estradiol	I-Chemical	D004997
(	O	O
EE	B-Chemical	D004997
)	O	O
treatment	O	O
and	O	O
extrahepatic	B-Disease	D001651
cholestasis	I-Disease	D001651
by	O	O
bile	O	O
duct	O	O
ligation	O	O
(	O	O
BDL	O	O
)	O	O
to	O	O
precisely	O	O
determine	O	O
the	O	O
site	O	O
of	O	O
TJ	O	O
damage	O	O
.	O	O

Alterations	O	O
in	O	O
hepatocyte	O	O
TJs	O	O
were	O	O
assessed	O	O
by	O	O
double	O	O
-	O	O
immunolabeling	O	O
for	O	O
7H6	O	O
and	O	O
ZO	O	O
-	O	O
1	O	O
using	O	O
a	O	O
confocal	O	O
laser	O	O
scanning	O	O
microscope	O	O
.	O	O

In	O	O
control	O	O
rats	O	O
,	O	O
immunostaining	O	O
for	O	O
7H6	O	O
and	O	O
ZO	O	O
-	O	O
1	O	O
colocalized	O	O
to	O	O
outline	O	O
bile	O	O
canaliculi	O	O
in	O	O
a	O	O
continuous	O	O
fashion	O	O
.	O	O

In	O	O
contrast	O	O
,	O	O
7H6	O	O
and	O	O
ZO	O	O
-	O	O
1	O	O
immunostaining	O	O
was	O	O
more	O	O
discontinuous	O	O
,	O	O
outlining	O	O
the	O	O
bile	O	O
canaliculi	O	O
after	O	O
BDL	O	O
.	O	O

Immunostaining	O	O
for	O	O
7H6	O	O
,	O	O
not	O	O
ZO	O	O
-	O	O
1	O	O
,	O	O
decreased	O	O
and	O	O
predominantly	O	O
appeared	O	O
as	O	O
discrete	O	O
signals	O	O
in	O	O
the	O	O
submembranous	O	O
cytoplasm	O	O
of	O	O
periportal	O	O
hepatocytes	O	O
after	O	O
BDL	O	O
.	O	O

After	O	O
EE	B-Chemical	D004997
treatment	O	O
,	O	O
changes	O	O
in	O	O
immunostaining	O	O
for	O	O
7H6	O	O
and	O	O
ZO	O	O
-	O	O
1	O	O
were	O	O
similar	O	O
to	O	O
those	O	O
seen	O	O
in	O	O
periportal	O	O
hepatocytes	O	O
after	O	O
BDL	O	O
,	O	O
but	O	O
distributed	O	O
more	O	O
diffusely	O	O
throughout	O	O
the	O	O
lobule	O	O
.	O	O

This	O	O
study	O	O
is	O	O
the	O	O
first	O	O
to	O	O
demonstrate	O	O
that	O	O
impairment	O	O
of	O	O
hepatocyte	O	O
TJs	O	O
occurs	O	O
heterogenously	O	O
in	O	O
the	O	O
liver	O	O
lobule	O	O
after	O	O
BDL	O	O
and	O	O
suggests	O	O
that	O	O
BDL	O	O
and	O	O
EE	B-Chemical	D004997
treatments	O	O
produce	O	O
different	O	O
lobular	O	O
distributions	O	O
of	O	O
increased	O	O
paracellular	O	O
permeability	O	O
.	O	O

Long	O	O
term	O	O
audiological	O	O
evaluation	O	O
of	O	O
beta	B-Disease	D017086
-	I-Disease	D017086
thalassemic	I-Disease	D017086
patients	O	O
.	O	O

OBJECTIVE	O	O
:	O	O
The	O	O
objective	O	O
of	O	O
this	O	O
study	O	O
was	O	O
to	O	O
identify	O	O
the	O	O
incidence	O	O
and	O	O
to	O	O
monitor	O	O
the	O	O
progression	O	O
of	O	O
hearing	B-Disease	D034381
loss	I-Disease	D034381
in	O	O
children	O	O
and	O	O
young	O	O
adults	O	O
with	O	O
beta	B-Disease	D017086
-	I-Disease	D017086
thalassemia	I-Disease	D017086
major	O	O
.	O	O

METHODS	O	O
:	O	O
One	O	O
hundred	O	O
and	O	O
four	O	O
(	O	O
104	O	O
)	O	O
patients	O	O
aged	O	O
6	O	O
-	O	O
35	O	O
years	O	O
(	O	O
mean	O	O
17	O	O
,	O	O
2	O	O
years	O	O
)	O	O
participated	O	O
in	O	O
the	O	O
study	O	O
.	O	O

All	O	O
patients	O	O
were	O	O
on	O	O
a	O	O
regular	O	O
transfusion	O	O
-	O	O
chelation	O	O
program	O	O
maintaining	O	O
a	O	O
mean	O	O
hemoglobin	O	O
level	O	O
of	O	O
9	O	O
.	O	O

5	O	O
gr	O	O
/	O	O
dl	O	O
.	O	O

Subjects	O	O
were	O	O
receiving	O	O
desferrioxamine	B-Chemical	D003676
(	O	O
DFO	B-Chemical	D003676
)	O	O
chelation	O	O
treatment	O	O
with	O	O
a	O	O
mean	O	O
daily	O	O
dose	O	O
of	O	O
50	O	O
-	O	O
60	O	O
mg	O	O
/	O	O
kg	O	O
,	O	O
5	O	O
-	O	O
6	O	O
days	O	O
a	O	O
week	O	O
during	O	O
the	O	O
first	O	O
six	O	O
years	O	O
of	O	O
the	O	O
study	O	O
,	O	O
which	O	O
was	O	O
then	O	O
reduced	O	O
to	O	O
40	O	O
-	O	O
50	O	O
mg	O	O
/	O	O
kg	O	O
for	O	O
the	O	O
following	O	O
eight	O	O
years	O	O
.	O	O

Patients	O	O
were	O	O
followed	O	O
for	O	O
8	O	O
-	O	O
14	O	O
years	O	O
.	O	O

RESULTS	O	O
:	O	O
Overall	O	O
,	O	O
21	O	O
out	O	O
of	O	O
104	O	O
patients	O	O
(	O	O
20	O	O
.	O	O

2%	O	O
)	O	O
presented	O	O
with	O	O
high	O	O
frequency	O	O
sensorineural	B-Disease	D006319
hearing	I-Disease	D006319
loss	I-Disease	D006319
(	O	O
SNHL	B-Disease	D006319
)	O	O
,	O	O
either	O	O
unilateral	O	O
or	O	O
bilateral	O	O
.	O	O

No	O	O
ototoxic	B-Disease	D006311
factor	O	O
,	O	O
other	O	O
than	O	O
DFO	B-Chemical	D003676
,	O	O
was	O	O
present	O	O
in	O	O
any	O	O
of	O	O
the	O	O
patients	O	O
.	O	O

Patients	O	O
with	O	O
SNHL	B-Disease	D006319
presented	O	O
with	O	O
relatively	O	O
lower	O	O
serum	O	O
ferritin	O	O
levels	O	O
than	O	O
those	O	O
with	O	O
normal	O	O
hearing	O	O
,	O	O
however	O	O
,	O	O
no	O	O
statistically	O	O
significant	O	O
difference	O	O
was	O	O
observed	O	O
.	O	O

Subjects	O	O
with	O	O
SNHL	B-Disease	D006319
were	O	O
submitted	O	O
to	O	O
DFO	B-Chemical	D003676
reduction	O	O
or	O	O
temporary	O	O
withdrawal	O	O
.	O	O

Following	O	O
intervention	O	O
,	O	O
7	O	O
out	O	O
of	O	O
21	O	O
affected	O	O
patients	O	O
recovered	O	O
,	O	O
10	O	O
remained	O	O
stable	O	O
and	O	O
4	O	O
demonstrated	O	O
aggravation	O	O
.	O	O

CONCLUSION	O	O
:	O	O
The	O	O
findings	O	O
are	O	O
indicative	O	O
of	O	O
DFO's	O	O
contributing	O	O
role	O	O
in	O	O
the	O	O
development	O	O
of	O	O
hearing	B-Disease	D034381
impairment	I-Disease	D034381
.	O	O

Regular	O	O
audiologic	O	O
evaluation	O	O
is	O	O
imperative	O	O
in	O	O
all	O	O
thalassemic	B-Disease	D013789
patients	O	O
so	O	O
that	O	O
early	O	O
changes	O	O
may	O	O
be	O	O
recognized	O	O
and	O	O
treatment	O	O
may	O	O
be	O	O
judiciously	O	O
adjusted	O	O
in	O	O
order	O	O
to	O	O
prevent	O	O
or	O	O
reverse	O	O
hearing	B-Disease	D034381
impairment	I-Disease	D034381
.	O	O

Design	O	O
and	O	O
analysis	O	O
of	O	O
the	O	O
HYPREN	O	O
-	O	O
trial	O	O
:	O	O
safety	O	O
of	O	O
enalapril	B-Chemical	D004656
and	O	O
prazosin	B-Chemical	D011224
in	O	O
the	O	O
initial	O	O
treatment	O	O
phase	O	O
of	O	O
patients	O	O
with	O	O
congestive	B-Disease	D006333
heart	I-Disease	D006333
failure	I-Disease	D006333
.	O	O

Since	O	O
the	O	O
introduction	O	O
of	O	O
angiotensin	B-Chemical	D000806
converting	I-Chemical	D000806
enzyme	I-Chemical	D000806
(	I-Chemical	D000806
ACE	I-Chemical	D000806
)	I-Chemical	D000806
inhibitors	I-Chemical	D000806
into	O	O
the	O	O
adjunctive	O	O
treatment	O	O
of	O	O
patients	O	O
with	O	O
congestive	B-Disease	D006333
heart	I-Disease	D006333
failure	I-Disease	D006333
,	O	O
cases	O	O
of	O	O
severe	O	O
hypotension	B-Disease	D007022
,	O	O
especially	O	O
on	O	O
the	O	O
first	O	O
day	O	O
of	O	O
treatment	O	O
,	O	O
have	O	O
occasionally	O	O
been	O	O
reported	O	O
.	O	O

To	O	O
assess	O	O
the	O	O
safety	O	O
of	O	O
the	O	O
ACE	B-Chemical	D000806
inhibitor	I-Chemical	D000806
enalapril	B-Chemical	D004656
a	O	O
multicenter	O	O
,	O	O
randomized	O	O
,	O	O
prazosin	B-Chemical	D011224
-	O	O
controlled	O	O
trial	O	O
was	O	O
designed	O	O
that	O	O
compared	O	O
the	O	O
incidence	O	O
and	O	O
severity	O	O
of	O	O
symptomatic	O	O
hypotension	B-Disease	D007022
on	O	O
the	O	O
first	O	O
day	O	O
of	O	O
treatment	O	O
.	O	O

Trial	O	O
medication	O	O
was	O	O
2	O	O
.	O	O

5	O	O
mg	O	O
enalapril	B-Chemical	D004656
or	O	O
0	O	O
.	O	O

5	O	O
prazosin	B-Chemical	D011224
.	O	O

Subjects	O	O
were	O	O
1210	O	O
inpatients	O	O
with	O	O
New	O	O
York	O	O
Heart	O	O
Association	O	O
(	O	O
NYHA	O	O
)	O	O
functional	O	O
class	O	O
II	O	O
and	O	O
III	O	O
.	O	O

Patients	O	O
who	O	O
received	O	O
enalapril	B-Chemical	D004656
experienced	O	O
clinically	O	O
and	O	O
statistically	O	O
significantly	O	O
less	O	O
symptomatic	O	O
hypotension	B-Disease	D007022
(	O	O
5	O	O
.	O	O

2%	O	O
)	O	O
than	O	O
the	O	O
patients	O	O
who	O	O
received	O	O
prazosin	B-Chemical	D011224
(	O	O
12	O	O
.	O	O

9%	O	O
)	O	O
.	O	O

All	O	O
patients	O	O
recovered	O	O
.	O	O

It	O	O
was	O	O
concluded	O	O
that	O	O
treatment	O	O
with	O	O
enalapril	B-Chemical	D004656
was	O	O
well	O	O
tolerated	O	O
and	O	O
it	O	O
is	O	O
,	O	O
therefore	O	O
,	O	O
unreasonable	O	O
to	O	O
restrict	O	O
the	O	O
initiation	O	O
of	O	O
treatment	O	O
with	O	O
enalapril	B-Chemical	D004656
to	O	O
inpatients	O	O
.	O	O

Antagonism	O	O
between	O	O
interleukin	O	O
3	O	O
and	O	O
erythropoietin	O	O
in	O	O
mice	O	O
with	O	O
azidothymidine	B-Chemical	D015215
-	O	O
induced	O	O
anemia	B-Disease	D000740
and	O	O
in	O	O
bone	O	O
marrow	O	O
endothelial	O	O
cells	O	O
.	O	O

Azidothymidine	B-Chemical	D015215
(	O	O
AZT	B-Chemical	D015215
)	O	O
-	O	O
induced	O	O
anemia	B-Disease	D000740
in	O	O
mice	O	O
can	O	O
be	O	O
reversed	O	O
by	O	O
the	O	O
administration	O	O
of	O	O
IGF	O	O
-	O	O
IL	O	O
-	O	O
3	O	O
(	O	O
fusion	O	O
protein	O	O
of	O	O
insulin	O	O
-	O	O
like	O	O
growth	O	O
factor	O	O
II	O	O
(	O	O
IGF	O	O
II	O	O
)	O	O
and	O	O
interleukin	O	O
3	O	O
)	O	O
.	O	O

Although	O	O
interleukin	O	O
3	O	O
(	O	O
IL	O	O
-	O	O
3	O	O
)	O	O
and	O	O
erythropoietin	O	O
(	O	O
EPO	O	O
)	O	O
are	O	O
known	O	O
to	O	O
act	O	O
synergistically	O	O
on	O	O
hematopoietic	O	O
cell	O	O
proliferation	O	O
in	O	O
vitro	O	O
,	O	O
injection	O	O
of	O	O
IGF	O	O
-	O	O
IL	O	O
-	O	O
3	O	O
and	O	O
EPO	O	O
in	O	O
AZT	B-Chemical	D015215
-	O	O
treated	O	O
mice	O	O
resulted	O	O
in	O	O
a	O	O
reduction	O	O
of	O	O
red	O	O
cells	O	O
and	O	O
an	O	O
increase	O	O
of	O	O
plasma	O	O
EPO	O	O
levels	O	O
as	O	O
compared	O	O
to	O	O
animals	O	O
treated	O	O
with	O	O
IGF	O	O
-	O	O
IL	O	O
-	O	O
3	O	O
or	O	O
EPO	O	O
alone	O	O
.	O	O

We	O	O
tested	O	O
the	O	O
hypothesis	O	O
that	O	O
the	O	O
antagonistic	O	O
effect	O	O
of	O	O
IL	O	O
-	O	O
3	O	O
and	O	O
EPO	O	O
on	O	O
erythroid	O	O
cells	O	O
may	O	O
be	O	O
mediated	O	O
by	O	O
endothelial	O	O
cells	O	O
.	O	O

Bovine	O	O
liver	O	O
erythroid	O	O
cells	O	O
were	O	O
cultured	O	O
on	O	O
monolayers	O	O
of	O	O
human	O	O
bone	O	O
marrow	O	O
endothelial	O	O
cells	O	O
previously	O	O
treated	O	O
with	O	O
EPO	O	O
and	O	O
IGF	O	O
-	O	O
IL	O	O
-	O	O
3	O	O
.	O	O

There	O	O
was	O	O
a	O	O
significant	O	O
reduction	O	O
of	O	O
thymidine	B-Chemical	D013936
incorporation	O	O
into	O	O
both	O	O
erythroid	O	O
and	O	O
endothelial	O	O
cells	O	O
in	O	O
cultures	O	O
pre	O	O
-	O	O
treated	O	O
with	O	O
IGF	O	O
-	O	O
IL	O	O
-	O	O
3	O	O
and	O	O
EPO	O	O
.	O	O

Endothelial	O	O
cell	O	O
culture	O	O
supernatants	O	O
separated	O	O
by	O	O
ultrafiltration	O	O
and	O	O
ultracentrifugation	O	O
from	O	O
cells	O	O
treated	O	O
with	O	O
EPO	O	O
and	O	O
IL	O	O
-	O	O
3	O	O
significantly	O	O
reduced	O	O
thymidine	B-Chemical	D013936
incorporation	O	O
into	O	O
erythroid	O	O
cells	O	O
as	O	O
compared	O	O
to	O	O
identical	O	O
fractions	O	O
obtained	O	O
from	O	O
the	O	O
media	O	O
of	O	O
cells	O	O
cultured	O	O
with	O	O
EPO	O	O
alone	O	O
.	O	O

These	O	O
results	O	O
suggest	O	O
that	O	O
endothelial	O	O
cells	O	O
treated	O	O
simultaneously	O	O
with	O	O
EPO	O	O
and	O	O
IL	O	O
-	O	O
3	O	O
have	O	O
a	O	O
negative	O	O
effect	O	O
on	O	O
erythroid	O	O
cell	O	O
production	O	O
.	O	O

Interactive	O	O
effects	O	O
of	O	O
variations	O	O
in	O	O
[	O	O
Na	B-Chemical	D012964
]	O	O
o	O	O
and	O	O
[	O	O
Ca	B-Chemical	D002118
]	O	O
o	O	O
on	O	O
rat	O	O
atrial	O	O
spontaneous	O	O
frequency	O	O
.	O	O

The	O	O
effects	O	O
of	O	O
varying	O	O
the	O	O
extracellular	O	O
concentrations	O	O
of	O	O
Na	B-Chemical	D012964
and	O	O
Ca	B-Chemical	D002118
(	O	O
[	O	O
Na	B-Chemical	D012964
]	O	O
o	O	O
and	O	O
[	O	O
Ca	B-Chemical	D002118
]	O	O
o	O	O
)	O	O
on	O	O
both	O	O
,	O	O
the	O	O
spontaneous	O	O
beating	O	O
and	O	O
the	O	O
negative	O	O
chronotropic	O	O
action	O	O
of	O	O
verapamil	B-Chemical	D014700
,	O	O
were	O	O
studied	O	O
in	O	O
the	O	O
isolated	O	O
rat	O	O
atria	O	O
.	O	O

Basal	O	O
frequency	O	O
(	O	O
BF	O	O
)	O	O
evaluated	O	O
by	O	O
surface	O	O
electrogram	O	O
was	O	O
223	O	O
+	O	O
/	O	O
-	O	O
4	O	O
beats	O	O
/	O	O
min	O	O
.	O	O

in	O	O
control	O	O
Krebs	O	O
-	O	O
Ringer	O	O
containing	O	O
137	O	O
mM	O	O
Na	B-Chemical	D012964
and	O	O
1	O	O
.	O	O

35	O	O
mM	O	O
Ca	B-Chemical	D002118
(	O	O
N	O	O
)	O	O
.	O	O

It	O	O
decreased	O	O
by	O	O
16	O	O
+	O	O
/	O	O
-	O	O
3%	O	O
by	O	O
lowering	O	O
[	O	O
Na	B-Chemical	D012964
]	O	O
o	O	O
to	O	O
78	O	O
mM	O	O
(	O	O
LNa	O	O
)	O	O
,	O	O
23	O	O
+	O	O
/	O	O
-	O	O
2%	O	O
by	O	O
lowering	O	O
simultaneously	O	O
[	O	O
Na	B-Chemical	D012964
]	O	O
o	O	O
to	O	O
78	O	O
mM	O	O
and	O	O
[	O	O
Ca	B-Chemical	D002118
]	O	O
o	O	O
to	O	O
0	O	O
.	O	O

675	O	O
mM	O	O
(	O	O
LNa+LCa	O	O
)	O	O
and	O	O
31	O	O
+	O	O
/	O	O
-	O	O
5%	O	O
by	O	O
lowering	O	O
[	O	O
Na	B-Chemical	D012964
]	O	O
o	O	O
to	O	O
78	O	O
mM	O	O
plus	O	O
increasing	O	O
[	O	O
Ca	B-Chemical	D002118
]	O	O
o	O	O
to	O	O
3	O	O
.	O	O

6	O	O
mM	O	O
(	O	O
LNa+HCa	O	O
)	O	O
.	O	O

At	O	O
normal	O	O
[	O	O
Na	B-Chemical	D012964
]	O	O
o	O	O
,	O	O
decrease	O	O
(	O	O
0	O	O
.	O	O

675	O	O
mM	O	O
)	O	O
or	O	O
increase	O	O
(	O	O
3	O	O
.	O	O

6	O	O
mM	O	O
)	O	O
of	O	O
[	O	O
Ca	B-Chemical	D002118
]	O	O
o	O	O
did	O	O
not	O	O
modify	O	O
BF	O	O
;	O	O
a	O	O
reduction	O	O
of	O	O
ten	O	O
times	O	O
(	O	O
0	O	O
.	O	O

135	O	O
mM	O	O
of	O	O
normal	O	O
[	O	O
Ca	B-Chemical	D002118
]	O	O
o	O	O
was	O	O
effective	O	O
to	O	O
reduce	O	O
BF	O	O
by	O	O
40	O	O
+	O	O
/	O	O
-	O	O
13%	O	O
.	O	O

All	O	O
negative	O	O
chronotropic	O	O
effects	O	O
were	O	O
BF	O	O
-	O	O
dependent	O	O
.	O	O

Dose	O	O
-	O	O
dependent	O	O
bradycardia	B-Disease	D001919
induced	O	O
by	O	O
verapamil	B-Chemical	D014700
was	O	O
potentiated	O	O
by	O	O
LNa	O	O
,	O	O
LCa	O	O
,	O	O
and	O	O
HCa	O	O
.	O	O

Independent	O	O
but	O	O
not	O	O
additive	O	O
effects	O	O
of	O	O
Na	B-Chemical	D012964
and	O	O
Ca	B-Chemical	D002118
are	O	O
shown	O	O
by	O	O
decreases	O	O
in	O	O
the	O	O
values	O	O
of	O	O
[	O	O
verapamil	B-Chemical	D014700
]	O	O
o	O	O
needed	O	O
to	O	O
reduce	O	O
BF	O	O
by	O	O
30%	O	O
(	O	O
IC30	O	O
)	O	O
with	O	O
the	O	O
following	O	O
order	O	O
of	O	O
inhibitory	O	O
potency	O	O
:	O	O
LNa	O	O
>	O	O
LCa	O	O
>	O	O
HCa	O	O
>	O	O
N	O	O
,	O	O
resulting	O	O
LNa+HCa	O	O
similar	O	O
to	O	O
LNa	O	O
.	O	O

The	O	O
[	O	O
verapamil	B-Chemical	D014700
]	O	O
o	O	O
that	O	O
arrested	O	O
atrial	O	O
beating	O	O
(	O	O
AC	O	O
)	O	O
was	O	O
also	O	O
potentiated	O	O
with	O	O
the	O	O
order	O	O
LNa	O	O
=	O	O
LNa+LCa	O	O
=	O	O
LNa+HCa	O	O
=	O	O
LCa	O	O
>	O	O
HCa	O	O
=	O	O
N	O	O
.	O	O

The	O	O
results	O	O
indicate	O	O
that	O	O
rat	O	O
atrial	O	O
spontaneous	O	O
beating	O	O
is	O	O
more	O	O
dependent	O	O
on	O	O
[	O	O
Na	B-Chemical	D012964
]	O	O
o	O	O
than	O	O
on	O	O
[	O	O
Ca	B-Chemical	D002118
]	O	O
o	O	O
in	O	O
a	O	O
range	O	O
of	O	O
+	O	O
/	O	O
-	O	O
50%	O	O
of	O	O
their	O	O
normal	O	O
concentration	O	O
.	O	O

Also	O	O
the	O	O
enhancement	O	O
of	O	O
verapamil	B-Chemical	D014700
effects	O	O
on	O	O
atrial	O	O
beating	O	O
was	O	O
more	O	O
pronounced	O	O
at	O	O
LNa	O	O
than	O	O
at	O	O
LCa	O	O
.	O	O

(	O	O
ABSTRACT	O	O
TRUNCATED	O	O
AT	O	O
250	O	O
WORDS	O	O
)	O	O
Sodium	B-Chemical	D012964
status	O	O
influences	O	O
chronic	O	O
amphotericin	B-Chemical	D000666
B	I-Chemical	D000666
nephrotoxicity	B-Disease	D007674
in	O	O
rats	O	O
.	O	O

The	O	O
nephrotoxic	B-Disease	D007674
potential	O	O
of	O	O
amphotericin	B-Chemical	D000666
B	I-Chemical	D000666
(	O	O
5	O	O
mg	O	O
/	O	O
kg	O	O
per	O	O
day	O	O
intraperitoneally	O	O
for	O	O
3	O	O
weeks	O	O
)	O	O
has	O	O
been	O	O
investigated	O	O
in	O	O
salt	O	O
-	O	O
depleted	O	O
,	O	O
normal	O	O
-	O	O
salt	O	O
,	O	O
and	O	O
salt	O	O
-	O	O
loaded	O	O
rats	O	O
.	O	O

In	O	O
salt	O	O
-	O	O
depleted	O	O
rats	O	O
,	O	O
amphotericin	B-Chemical	D000666
B	I-Chemical	D000666
decreased	O	O
creatinine	B-Chemical	D003404
clearance	O	O
linearly	O	O
with	O	O
time	O	O
,	O	O
with	O	O
an	O	O
85%	O	O
reduction	O	O
by	O	O
week	O	O
3	O	O
.	O	O

In	O	O
contrast	O	O
,	O	O
in	O	O
normal	O	O
-	O	O
salt	O	O
rats	O	O
creatinine	B-Chemical	D003404
clearance	O	O
was	O	O
decreased	O	O
but	O	O
to	O	O
a	O	O
lesser	O	O
extent	O	O
at	O	O
week	O	O
2	O	O
and	O	O
3	O	O
,	O	O
and	O	O
in	O	O
salt	O	O
-	O	O
loaded	O	O
rats	O	O
creatinine	B-Chemical	D003404
clearance	O	O
did	O	O
not	O	O
change	O	O
for	O	O
2	O	O
weeks	O	O
and	O	O
was	O	O
decreased	O	O
by	O	O
43%	O	O
at	O	O
week	O	O
3	O	O
.	O	O

All	O	O
rats	O	O
in	O	O
the	O	O
sodium	B-Chemical	D012964
-	O	O
depleted	O	O
group	O	O
had	O	O
histopathological	O	O
evidence	O	O
of	O	O
patchy	O	O
tubular	O	O
cytoplasmic	O	O
degeneration	O	O
in	O	O
tubules	O	O
that	O	O
was	O	O
not	O	O
observed	O	O
in	O	O
any	O	O
normal	O	O
-	O	O
salt	O	O
or	O	O
salt	O	O
-	O	O
loaded	O	O
rat	O	O
.	O	O

Concentrations	O	O
of	O	O
amphotericin	B-Chemical	D000666
B	I-Chemical	D000666
in	O	O
plasma	O	O
were	O	O
not	O	O
significantly	O	O
different	O	O
among	O	O
the	O	O
three	O	O
groups	O	O
at	O	O
any	O	O
time	O	O
during	O	O
the	O	O
study	O	O
.	O	O

However	O	O
,	O	O
at	O	O
the	O	O
end	O	O
of	O	O
3	O	O
weeks	O	O
,	O	O
amphotericin	B-Chemical	D000666
B	I-Chemical	D000666
levels	O	O
in	O	O
the	O	O
kidneys	O	O
and	O	O
liver	O	O
were	O	O
significantly	O	O
higher	O	O
in	O	O
salt	O	O
-	O	O
depleted	O	O
and	O	O
normal	O	O
-	O	O
salt	O	O
rats	O	O
than	O	O
those	O	O
in	O	O
salt	O	O
-	O	O
loaded	O	O
rats	O	O
,	O	O
with	O	O
plasma	O	O
/	O	O
kidney	O	O
ratios	O	O
of	O	O
21	O	O
,	O	O
14	O	O
,	O	O
and	O	O
8	O	O
in	O	O
salt	O	O
-	O	O
depleted	O	O
,	O	O
normal	O	O
-	O	O
salt	O	O
,	O	O
and	O	O
salt	O	O
-	O	O
loaded	O	O
rats	O	O
,	O	O
respectively	O	O
.	O	O

In	O	O
conclusion	O	O
,	O	O
reductions	O	O
in	O	O
creatinine	B-Chemical	D003404
clearance	O	O
and	O	O
renal	O	O
amphotericin	B-Chemical	D000666
B	I-Chemical	D000666
accumulation	O	O
after	O	O
chronic	O	O
amphotericin	B-Chemical	D000666
B	I-Chemical	D000666
administration	O	O
were	O	O
enhanced	O	O
by	O	O
salt	O	O
depletion	O	O
and	O	O
attenuated	O	O
by	O	O
sodium	B-Chemical	D012964
loading	O	O
in	O	O
rats	O	O
.	O	O

Reversible	O	O
inferior	B-Disease	D001927
colliculus	I-Disease	D001927
lesion	I-Disease	D001927
in	O	O
metronidazole	B-Chemical	D008795
-	O	O
induced	O	O
encephalopathy	B-Disease	D001927
:	O	O
magnetic	O	O
resonance	O	O
findings	O	O
on	O	O
diffusion	O	O
-	O	O
weighted	O	O
and	O	O
fluid	O	O
attenuated	O	O
inversion	O	O
recovery	O	O
imaging	O	O
.	O	O

OBJECTIVE	O	O
:	O	O
This	O	O
is	O	O
to	O	O
present	O	O
reversible	O	O
inferior	B-Disease	D001927
colliculus	I-Disease	D001927
lesions	I-Disease	D001927
in	O	O
metronidazole	B-Chemical	D008795
-	O	O
induced	O	O
encephalopathy	B-Disease	D001927
,	O	O
to	O	O
focus	O	O
on	O	O
the	O	O
diffusion	O	O
-	O	O
weighted	O	O
imaging	O	O
(	O	O
DWI	O	O
)	O	O
and	O	O
fluid	O	O
attenuated	O	O
inversion	O	O
recovery	O	O
(	O	O
FLAIR	O	O
)	O	O
imaging	O	O
.	O	O

MATERIALS	O	O
AND	O	O
METHODS	O	O
:	O	O
From	O	O
November	O	O
2005	O	O
to	O	O
September	O	O
2007	O	O
,	O	O
8	O	O
patients	O	O
(	O	O
5	O	O
men	O	O
and	O	O
3	O	O
women	O	O
)	O	O
were	O	O
diagnosed	O	O
as	O	O
having	O	O
metronidazole	B-Chemical	D008795
-	O	O
induced	O	O
encephalopathy	B-Disease	D001927
(	O	O
age	O	O
range	O	O
;	O	O
43	O	O
-	O	O
78	O	O
years	O	O
)	O	O
.	O	O

They	O	O
had	O	O
been	O	O
taking	O	O
metronidazole	B-Chemical	D008795
(	O	O
total	O	O
dosage	O	O
,	O	O
45	O	O
-	O	O
120	O	O
g	O	O
;	O	O
duration	O	O
,	O	O
30	O	O
days	O	O
to	O	O
2	O	O
months	O	O
)	O	O
to	O	O
treat	O	O
the	O	O
infection	B-Disease	D007239
in	O	O
various	O	O
organs	O	O
.	O	O

Initial	O	O
brain	O	O
magnetic	O	O
resonance	O	O
imaging	O	O
(	O	O
MRI	O	O
)	O	O
were	O	O
obtained	O	O
after	O	O
the	O	O
hospitalization	O	O
,	O	O
including	O	O
DWI	O	O
(	O	O
8	O	O
/	O	O
8	O	O
)	O	O
,	O	O
apparent	O	O
diffusion	O	O
coefficient	O	O
(	O	O
ADC	O	O
)	O	O
map	O	O
(	O	O
4	O	O
/	O	O
8	O	O
)	O	O
,	O	O
FLAIR	O	O
(	O	O
7	O	O
/	O	O
8	O	O
)	O	O
,	O	O
and	O	O
T2	O	O
-	O	O
weighted	O	O
image	O	O
(	O	O
8	O	O
/	O	O
8	O	O
)	O	O
.	O	O

Follow	O	O
-	O	O
up	O	O
MRIs	O	O
were	O	O
performed	O	O
on	O	O
5	O	O
patients	O	O
from	O	O
third	O	O
to	O	O
14th	O	O
days	O	O
after	O	O
discontinuation	O	O
of	O	O
metronidazole	B-Chemical	D008795
administration	O	O
.	O	O

Findings	O	O
of	O	O
initial	O	O
and	O	O
follow	O	O
-	O	O
up	O	O
MRIs	O	O
were	O	O
retrospectively	O	O
evaluated	O	O
by	O	O
2	O	O
neuroradiologists	O	O
by	O	O
consensus	O	O
,	O	O
to	O	O
analyze	O	O
the	O	O
presence	O	O
of	O	O
abnormal	O	O
signal	O	O
intensities	O	O
,	O	O
their	O	O
locations	O	O
,	O	O
and	O	O
signal	O	O
changes	O	O
on	O	O
follow	O	O
-	O	O
up	O	O
images	O	O
.	O	O

RESULTS	O	O
:	O	O
Initial	O	O
MRIs	O	O
showed	O	O
abnormal	O	O
high	O	O
signal	O	O
intensities	O	O
on	O	O
DWI	O	O
and	O	O
FLAIR	O	O
(	O	O
or	O	O
T2	O	O
-	O	O
weighted	O	O
image	O	O
)	O	O
at	O	O
the	O	O
dentate	O	O
nucleus	O	O
(	O	O
8	O	O
/	O	O
8	O	O
)	O	O
,	O	O
inferior	O	O
colliculus	O	O
(	O	O
6	O	O
/	O	O
8	O	O
)	O	O
,	O	O
corpus	O	O
callosum	O	O
(	O	O
2	O	O
/	O	O
8	O	O
)	O	O
,	O	O
pons	O	O
(	O	O
2	O	O
/	O	O
8	O	O
)	O	O
,	O	O
medulla	O	O
(	O	O
1	O	O
/	O	O
8	O	O
)	O	O
,	O	O
and	O	O
bilateral	O	O
cerebral	O	O
white	O	O
matter	O	O
(	O	O
1	O	O
/	O	O
8	O	O
)	O	O
.	O	O

High	O	O
-	O	O
signal	O	O
intensity	O	O
lesions	O	O
on	O	O
DWI	O	O
tended	O	O
to	O	O
show	O	O
low	O	O
signal	O	O
intensity	O	O
on	O	O
ADC	O	O
map	O	O
(	O	O
3	O	O
/	O	O
4	O	O
)	O	O
,	O	O
but	O	O
in	O	O
one	O	O
patient	O	O
,	O	O
high	O	O
signal	O	O
intensity	O	O
was	O	O
shown	O	O
at	O	O
bilateral	O	O
dentate	O	O
nuclei	O	O
on	O	O
not	O	O
only	O	O
DWI	O	O
but	O	O
also	O	O
ADC	O	O
map	O	O
.	O	O

All	O	O
the	O	O
lesions	O	O
in	O	O
dentate	O	O
,	O	O
inferior	O	O
colliculus	O	O
,	O	O
pons	O	O
,	O	O
and	O	O
medullas	O	O
had	O	O
been	O	O
resolved	O	O
completely	O	O
on	O	O
follow	O	O
-	O	O
up	O	O
MRIs	O	O
in	O	O
5	O	O
patients	O	O
,	O	O
but	O	O
in	O	O
1	O	O
patient	O	O
of	O	O
them	O	O
,	O	O
corpus	O	O
callosal	B-Disease	D001927
lesion	I-Disease	D001927
persisted	O	O
.	O	O

CONCLUSIONS	O	O
:	O	O
Reversible	O	O
inferior	B-Disease	D001927
colliculus	I-Disease	D001927
lesions	I-Disease	D001927
could	O	O
be	O	O
considered	O	O
as	O	O
the	O	O
characteristic	O	O
for	O	O
metronidazole	B-Chemical	D008795
-	O	O
induced	O	O
encephalopathy	B-Disease	D001927
,	O	O
next	O	O
to	O	O
the	O	O
dentate	O	O
nucleus	O	O
involvement	O	O
.	O	O

Comparison	O	O
of	O	O
the	O	O
respiratory	O	O
effects	O	O
of	O	O
i	O	O
.	O	O

v	O	O
.	O	O

infusions	O	O
of	O	O
morphine	B-Chemical	D009020
and	O	O
regional	O	O
analgesia	O	O
by	O	O
extradural	O	O
block	O	O
.	O	O

The	O	O
incidence	O	O
of	O	O
postoperative	O	O
respiratory	O	O
apnoea	B-Disease	D001049
was	O	O
compared	O	O
between	O	O
five	O	O
patients	O	O
receiving	O	O
a	O	O
continuous	O	O
i	O	O
.	O	O

v	O	O
.	O	O

infusion	O	O
of	O	O
morphine	B-Chemical	D009020
(	O	O
mean	O	O
73	O	O
.	O	O

6	O	O
mg	O	O
)	O	O
and	O	O
five	O	O
patients	O	O
receiving	O	O
a	O	O
continuous	O	O
extradural	O	O
infusion	O	O
of	O	O
0	O	O
.	O	O

25%	O	O
bupivacaine	B-Chemical	D002045
(	O	O
mean	O	O
192	O	O
mg	O	O
)	O	O
in	O	O
the	O	O
24	O	O
-	O	O
h	O	O
period	O	O
following	O	O
upper	O	O
abdominal	O	O
surgery	O	O
.	O	O

Monitoring	O	O
consisted	O	O
of	O	O
airflow	O	O
detection	O	O
by	O	O
a	O	O
carbon	B-Chemical	D002245
dioxide	I-Chemical	D002245
analyser	O	O
,	O	O
chest	O	O
wall	O	O
movement	O	O
detected	O	O
by	O	O
pneumatic	O	O
capsules	O	O
,	O	O
and	O	O
continuous	O	O
electrocardiograph	O	O
recorded	O	O
with	O	O
a	O	O
Holter	O	O
ambulatory	O	O
monitor	O	O
.	O	O

Both	O	O
obstructive	O	O
(	O	O
P	O	O
less	O	O
than	O	O
0	O	O
.	O	O

05	O	O
)	O	O
and	O	O
central	O	O
apnoea	B-Disease	D001049
(	O	O
P	O	O
less	O	O
than	O	O
0	O	O
.	O	O

05	O	O
)	O	O
occurred	O	O
more	O	O
frequently	O	O
in	O	O
patients	O	O
who	O	O
had	O	O
a	O	O
morphine	B-Chemical	D009020
infusion	O	O
.	O	O

There	O	O
was	O	O
also	O	O
a	O	O
higher	O	O
incidence	O	O
of	O	O
tachyarrhythmias	B-Disease	D013610
(	O	O
P	O	O
less	O	O
than	O	O
0	O	O
.	O	O

05	O	O
)	O	O
and	O	O
ventricular	B-Disease	D018879
ectopic	I-Disease	D018879
beats	I-Disease	D018879
(	O	O
P	O	O
less	O	O
than	O	O
0	O	O
.	O	O

05	O	O
)	O	O
in	O	O
the	O	O
morphine	B-Chemical	D009020
infusion	O	O
group	O	O
.	O	O

Magnetic	O	O
resonance	O	O
volumetry	O	O
of	O	O
the	O	O
cerebellum	O	O
in	O	O
epileptic	B-Disease	D004827
patients	O	O
after	O	O
phenytoin	B-Chemical	D010672
overdosages	B-Disease	D062787
.	O	O

The	O	O
aim	O	O
of	O	O
this	O	O
study	O	O
was	O	O
to	O	O
evaluate	O	O
the	O	O
relationship	O	O
between	O	O
phenytoin	B-Chemical	D010672
medication	O	O
and	O	O
cerebellar	B-Disease	D002526
atrophy	I-Disease	D002526
in	O	O
patients	O	O
who	O	O
had	O	O
experienced	O	O
clinical	O	O
intoxication	O	O
.	O	O

Five	O	O
females	O	O
and	O	O
6	O	O
males	O	O
,	O	O
21	O	O
-	O	O
59	O	O
years	O	O
of	O	O
age	O	O
,	O	O
were	O	O
examined	O	O
with	O	O
a	O	O
1	O	O
.	O	O

5	O	O
-	O	O
T	O	O
whole	O	O
-	O	O
body	O	O
system	O	O
using	O	O
a	O	O
circular	O	O
polarized	O	O
head	O	O
coil	O	O
.	O	O

Conventional	O	O
spin	O	O
echo	O	O
images	O	O
were	O	O
acquired	O	O
in	O	O
the	O	O
sagittal	O	O
and	O	O
transverse	O	O
orientation	O	O
.	O	O

In	O	O
addition	O	O
,	O	O
we	O	O
performed	O	O
a	O	O
high	O	O
-	O	O
resolution	O	O
3D	O	O
gradient	O	O
echo	O	O
,	O	O
T1	O	O
-	O	O
weighted	O	O
sequences	O	O
at	O	O
a	O	O
1	O	O
-	O	O
mm	O	O
slice	O	O
thickness	O	O
.	O	O

The	O	O
images	O	O
were	O	O
subsequently	O	O
processed	O	O
to	O	O
obtain	O	O
volumetric	O	O
data	O	O
for	O	O
the	O	O
cerebellum	O	O
.	O	O

Cerebellar	O	O
volume	O	O
for	O	O
the	O	O
patient	O	O
group	O	O
ranged	O	O
between	O	O
67	O	O
.	O	O

66	O	O
and	O	O
131	O	O
.	O	O

08	O	O
ml	O	O
(	O	O
mean	O	O
108	O	O
.	O	O

9	O	O
ml	O	O
)	O	O
.	O	O

In	O	O
addition	O	O
3D	O	O
gradient	O	O
echo	O	O
data	O	O
sets	O	O
from	O	O
10	O	O
healthy	O	O
male	O	O
and	O	O
10	O	O
healthy	O	O
female	O	O
age	O	O
-	O	O
matched	O	O
volunteers	O	O
were	O	O
used	O	O
to	O	O
compare	O	O
cerebellar	O	O
volumes	O	O
.	O	O

Using	O	O
linear	O	O
regression	O	O
we	O	O
found	O	O
that	O	O
no	O	O
correlation	O	O
exists	O	O
between	O	O
seizure	B-Disease	D012640
duration	O	O
,	O	O
elevation	O	O
of	O	O
phenytoin	B-Chemical	D010672
serum	O	O
levels	O	O
and	O	O
cerebellar	O	O
volume	O	O
.	O	O

However	O	O
,	O	O
multiple	O	O
regression	O	O
for	O	O
the	O	O
daily	O	O
dosage	O	O
,	O	O
duration	O	O
of	O	O
phenytoin	B-Chemical	D010672
treatment	O	O
and	O	O
cerebellar	O	O
volume	O	O
revealed	O	O
a	O	O
correlation	O	O
of	O	O
these	O	O
parameters	O	O
.	O	O

We	O	O
conclude	O	O
that	O	O
phenytoin	B-Chemical	D010672
overdosage	B-Disease	D062787
does	O	O
not	O	O
necessarily	O	O
result	O	O
in	O	O
cerebellar	B-Disease	D002526
atrophy	I-Disease	D002526
and	O	O
it	O	O
is	O	O
unlikely	O	O
that	O	O
phenytoin	B-Chemical	D010672
medication	O	O
was	O	O
the	O	O
only	O	O
cause	O	O
of	O	O
cerebellar	B-Disease	D002526
atrophy	I-Disease	D002526
in	O	O
the	O	O
remaining	O	O
patients	O	O
.	O	O

Quantitative	O	O
morphometric	O	O
studies	O	O
of	O	O
the	O	O
cerebellum	O	O
provide	O	O
valuable	O	O
insights	O	O
into	O	O
the	O	O
pathogenesis	O	O
of	O	O
cerebellar	B-Disease	D002526
disorders	I-Disease	D002526
.	O	O

Evaluation	O	O
of	O	O
cardiac	O	O
troponin	O	O
I	O	O
and	O	O
T	O	O
levels	O	O
as	O	O
markers	O	O
of	O	O
myocardial	B-Disease	D009202
damage	I-Disease	D009202
in	O	O
doxorubicin	B-Chemical	D004317
-	O	O
induced	O	O
cardiomyopathy	B-Disease	D009202
rats	O	O
,	O	O
and	O	O
their	O	O
relationship	O	O
with	O	O
echocardiographic	O	O
and	O	O
histological	O	O
findings	O	O
.	O	O

BACKGROUND	O	O
:	O	O
Cardiac	O	O
troponins	O	O
I	O	O
(	O	O
cTnI	O	O
)	O	O
and	O	O
T	O	O
(	O	O
cTnT	O	O
)	O	O
have	O	O
been	O	O
shown	O	O
to	O	O
be	O	O
highly	O	O
sensitive	O	O
and	O	O
specific	O	O
markers	O	O
of	O	O
myocardial	B-Disease	D009202
cell	I-Disease	D009202
injury	I-Disease	D009202
.	O	O

We	O	O
investigated	O	O
the	O	O
diagnostic	O	O
value	O	O
of	O	O
cTnI	O	O
and	O	O
cTnT	O	O
for	O	O
the	O	O
diagnosis	O	O
of	O	O
myocardial	B-Disease	D009202
damage	I-Disease	D009202
in	O	O
a	O	O
rat	O	O
model	O	O
of	O	O
doxorubicin	B-Chemical	D004317
(	O	O
DOX	B-Chemical	D004317
)	O	O
-	O	O
induced	O	O
cardiomyopathy	B-Disease	D009202
,	O	O
and	O	O
we	O	O
examined	O	O
the	O	O
relationship	O	O
between	O	O
serial	O	O
cTnI	O	O
and	O	O
cTnT	O	O
with	O	O
the	O	O
development	O	O
of	O	O
cardiac	B-Disease	D006331
disorders	I-Disease	D006331
monitored	O	O
by	O	O
echocardiography	O	O
and	O	O
histological	O	O
examinations	O	O
in	O	O
this	O	O
model	O	O
.	O	O

METHODS	O	O
:	O	O
Thirty	O	O
-	O	O
five	O	O
Wistar	O	O
rats	O	O
were	O	O
given	O	O
1	O	O
.	O	O

5	O	O
mg	O	O
/	O	O
kg	O	O
DOX	B-Chemical	D004317
,	O	O
i	O	O
.	O	O

v	O	O
.	O	O

,	O	O
weekly	O	O
for	O	O
up	O	O
to	O	O
8	O	O
weeks	O	O
for	O	O
a	O	O
total	O	O
cumulative	O	O
dose	O	O
of	O	O
12	O	O
mg	O	O
/	O	O
kg	O	O
BW	O	O
.	O	O

Ten	O	O
rats	O	O
received	O	O
saline	O	O
as	O	O
a	O	O
control	O	O
group	O	O
.	O	O

cTnI	O	O
was	O	O
measured	O	O
with	O	O
Access	O	O
(	O	O
R	O	O
)	O	O
(	O	O
ng	O	O
/	O	O
ml	O	O
)	O	O
and	O	O
a	O	O
research	O	O
immunoassay	O	O
(	O	O
pg	O	O
/	O	O
ml	O	O
)	O	O
,	O	O
and	O	O
compared	O	O
with	O	O
cTnT	O	O
,	O	O
CK	O	O
-	O	O
MB	O	O
mass	O	O
and	O	O
CK	O	O
.	O	O

By	O	O
using	O	O
transthoracic	O	O
echocardiography	O	O
,	O	O
anterior	O	O
and	O	O
posterior	O	O
wall	O	O
thickness	O	O
,	O	O
LV	O	O
diameters	O	O
and	O	O
LV	O	O
fractional	O	O
shortening	O	O
(	O	O
FS	O	O
)	O	O
were	O	O
measured	O	O
in	O	O
all	O	O
rats	O	O
before	O	O
DOX	B-Chemical	D004317
or	O	O
saline	O	O
,	O	O
and	O	O
at	O	O
weeks	O	O
6	O	O
and	O	O
9	O	O
after	O	O
treatment	O	O
in	O	O
all	O	O
surviving	O	O
rats	O	O
.	O	O

Histology	O	O
was	O	O
performed	O	O
in	O	O
DOX	B-Chemical	D004317
-	O	O
rats	O	O
at	O	O
6	O	O
and	O	O
9	O	O
weeks	O	O
after	O	O
the	O	O
last	O	O
DOX	B-Chemical	D004317
dose	O	O
and	O	O
in	O	O
all	O	O
controls	O	O
.	O	O

RESULTS	O	O
:	O	O
Eighteen	O	O
of	O	O
the	O	O
DOX	B-Chemical	D004317
rats	O	O
died	O	O
prematurely	O	O
of	O	O
general	O	O
toxicity	B-Disease	D064420
during	O	O
the	O	O
9	O	O
-	O	O
week	O	O
period	O	O
.	O	O

End	O	O
-	O	O
diastolic	O	O
(	O	O
ED	O	O
)	O	O
and	O	O
end	O	O
-	O	O
systolic	O	O
(	O	O
ES	O	O
)	O	O
LV	O	O
diameters	O	O
/	O	O
BW	O	O
significantly	O	O
increased	O	O
,	O	O
whereas	O	O
LV	O	O
FS	O	O
was	O	O
decreased	O	O
after	O	O
9	O	O
weeks	O	O
in	O	O
the	O	O
DOX	B-Chemical	D004317
group	O	O
(	O	O
p<0	O	O
.	O	O

001	O	O
)	O	O
.	O	O

These	O	O
parameters	O	O
remained	O	O
unchanged	O	O
in	O	O
controls	O	O
.	O	O

Histological	O	O
evaluation	O	O
of	O	O
hearts	O	O
from	O	O
all	O	O
rats	O	O
given	O	O
DOX	B-Chemical	D004317
revealed	O	O
significant	O	O
slight	O	O
degrees	O	O
of	O	O
perivascular	O	O
and	O	O
interstitial	O	O
fibrosis	B-Disease	D005355
.	O	O

In	O	O
7	O	O
of	O	O
the	O	O
18	O	O
rats	O	O
,	O	O
degeneration	O	O
and	O	O
myocyte	O	O
vacuolisation	O	O
were	O	O
found	O	O
.	O	O

Only	O	O
five	O	O
of	O	O
the	O	O
controls	O	O
exhibited	O	O
evidence	O	O
of	O	O
very	O	O
slight	O	O
perivascular	O	O
fibrosis	B-Disease	D005355
.	O	O

A	O	O
significant	O	O
rise	O	O
in	O	O
cTnT	O	O
was	O	O
found	O	O
in	O	O
DOX	B-Chemical	D004317
rats	O	O
after	O	O
cumulative	O	O
doses	O	O
of	O	O
7	O	O
.	O	O

5	O	O
and	O	O
12	O	O
mg	O	O
/	O	O
kg	O	O
in	O	O
comparison	O	O
with	O	O
baseline	O	O
(	O	O
p<0	O	O
.	O	O

05	O	O
)	O	O
.	O	O

cTnT	O	O
found	O	O
in	O	O
rats	O	O
after	O	O
12	O	O
mg	O	O
/	O	O
kg	O	O
were	O	O
significantly	O	O
greater	O	O
than	O	O
that	O	O
found	O	O
after	O	O
7	O	O
.	O	O

5	O	O
mg	O	O
/	O	O
kg	O	O
DOX	B-Chemical	D004317
.	O	O

Maximal	O	O
cTnI	O	O
(	O	O
pg	O	O
/	O	O
ml	O	O
)	O	O
and	O	O
cTnT	O	O
levels	O	O
were	O	O
significantly	O	O
increased	O	O
in	O	O
DOX	B-Chemical	D004317
rats	O	O
compared	O	O
with	O	O
controls	O	O
(	O	O
p=0	O	O
.	O	O

006	O	O
,	O	O
0	O	O
.	O	O

007	O	O
)	O	O
.	O	O

cTnI	O	O
(	O	O
ng	O	O
/	O	O
ml	O	O
)	O	O
,	O	O
CK	O	O
-	O	O
MB	O	O
mass	O	O
and	O	O
CK	O	O
remained	O	O
unchanged	O	O
in	O	O
DOX	B-Chemical	D004317
rats	O	O
compared	O	O
with	O	O
controls	O	O
.	O	O

All	O	O
markers	O	O
remained	O	O
stable	O	O
in	O	O
controls	O	O
.	O	O

Analysis	O	O
of	O	O
data	O	O
revealed	O	O
a	O	O
significant	O	O
correlation	O	O
between	O	O
maximal	O	O
cTnT	O	O
and	O	O
ED	O	O
and	O	O
ES	O	O
LV	O	O
diameters	O	O
/	O	O
BW	O	O
(	O	O
r=0	O	O
.	O	O

81	O	O
and	O	O
0	O	O
.	O	O

65	O	O
;	O	O
p<0	O	O
.	O	O

0001	O	O
)	O	O
.	O	O

A	O	O
significant	O	O
relationship	O	O
was	O	O
observed	O	O
between	O	O
maximal	O	O
cTnT	O	O
and	O	O
the	O	O
extent	O	O
of	O	O
myocardial	O	O
morphological	O	O
changes	O	O
,	O	O
and	O	O
between	O	O
LV	O	O
diameters	O	O
/	O	O
BW	O	O
and	O	O
histological	O	O
findings	O	O
.	O	O

CONCLUSIONS	O	O
:	O	O
Among	O	O
markers	O	O
of	O	O
ischemic	B-Disease	D017202
injury	I-Disease	D017202
after	O	O
DOX	B-Chemical	D004317
in	O	O
rats	O	O
,	O	O
cTnT	O	O
showed	O	O
the	O	O
greatest	O	O
ability	O	O
to	O	O
detect	O	O
myocardial	B-Disease	D009202
damage	I-Disease	D009202
assessed	O	O
by	O	O
echocardiographic	O	O
detection	O	O
and	O	O
histological	O	O
changes	O	O
.	O	O

Although	O	O
there	O	O
was	O	O
a	O	O
discrepancy	O	O
between	O	O
the	O	O
amount	O	O
of	O	O
cTnI	O	O
and	O	O
cTnT	O	O
after	O	O
DOX	B-Chemical	D004317
,	O	O
probably	O	O
due	O	O
to	O	O
heterogeneity	O	O
in	O	O
cross	O	O
-	O	O
reactivities	O	O
of	O	O
mAbs	O	O
to	O	O
various	O	O
cTnI	O	O
and	O	O
cTnT	O	O
forms	O	O
,	O	O
it	O	O
is	O	O
likely	O	O
that	O	O
cTnT	O	O
in	O	O
rats	O	O
after	O	O
DOX	B-Chemical	D004317
indicates	O	O
cell	O	O
damage	O	O
determined	O	O
by	O	O
the	O	O
magnitude	O	O
of	O	O
injury	O	O
induced	O	O
and	O	O
that	O	O
cTnT	O	O
should	O	O
be	O	O
a	O	O
useful	O	O
marker	O	O
for	O	O
the	O	O
prediction	O	O
of	O	O
experimentally	O	O
induced	O	O
cardiotoxicity	B-Disease	D066126
and	O	O
possibly	O	O
for	O	O
cardioprotective	O	O
experiments	O	O
.	O	O

Calcineurin	O	O
-	O	O
inhibitor	O	O
induced	O	O
pain	B-Disease	D010146
syndrome	O	O
(	O	O
CIPS	B-Disease	-1
)	O	O
:	O	O
a	O	O
severe	O	O
disabling	O	O
complication	O	O
after	O	O
organ	O	O
transplantation	O	O
.	O	O

Bone	O	O
pain	B-Disease	D010146
after	O	O
transplantation	O	O
is	O	O
a	O	O
frequent	O	O
complication	O	O
that	O	O
can	O	O
be	O	O
caused	O	O
by	O	O
several	O	O
diseases	O	O
.	O	O

Treatment	O	O
strategies	O	O
depend	O	O
on	O	O
the	O	O
correct	O	O
diagnosis	O	O
of	O	O
the	O	O
pain	B-Disease	D010146
.	O	O

Nine	O	O
patients	O	O
with	O	O
severe	O	O
pain	B-Disease	D010146
in	O	O
their	O	O
feet	O	O
,	O	O
which	O	O
was	O	O
registered	O	O
after	O	O
transplantation	O	O
,	O	O
were	O	O
investigated	O	O
.	O	O

Bone	O	O
scans	O	O
showed	O	O
an	O	O
increased	O	O
tracer	O	O
uptake	O	O
of	O	O
the	O	O
foot	O	O
bones	O	O
.	O	O

Magnetic	O	O
resonance	O	O
imaging	O	O
demonstrated	O	O
bone	O	O
marrow	O	O
oedema	O	O
in	O	O
the	O	O
painful	O	O
bones	O	O
.	O	O

Pain	B-Disease	D010146
was	O	O
not	O	O
explained	O	O
by	O	O
other	O	O
diseases	O	O
causing	O	O
foot	O	O
pain	B-Disease	D010146
,	O	O
like	O	O
reflex	B-Disease	D012019
sympathetic	I-Disease	D012019
dystrophy	I-Disease	D012019
,	O	O
polyneuropathy	B-Disease	D011115
,	O	O
Morton's	B-Disease	D009437
neuralgia	I-Disease	D009437
,	O	O
gout	B-Disease	D006073
,	O	O
osteoporosis	B-Disease	D010024
,	O	O
avascular	B-Disease	D010020
necrosis	I-Disease	D010020
,	O	O
intermittent	B-Disease	D007383
claudication	I-Disease	D007383
,	O	O
orthopaedic	O	O
foot	B-Disease	D005530
deformities	I-Disease	D005530
,	O	O
stress	B-Disease	D015775
fractures	I-Disease	D015775
,	O	O
and	O	O
hyperparathyroidism	B-Disease	D006961
.	O	O

The	O	O
reduction	O	O
of	O	O
cyclosporine	B-Chemical	D016572
-	O	O
or	O	O
tacrolimus	B-Chemical	D016559
trough	O	O
levels	O	O
and	O	O
the	O	O
administration	O	O
of	O	O
calcium	B-Chemical	D002118
channel	O	O
blockers	O	O
led	O	O
to	O	O
relief	O	O
of	O	O
pain	B-Disease	D010146
.	O	O

The	O	O
Calcineurin	O	O
-	O	O
inhibitor	O	O
Induced	O	O
Pain	B-Disease	D010146
Syndrome	O	O
(	O	O
CIPS	B-Disease	-1
)	O	O
is	O	O
a	O	O
rare	O	O
but	O	O
severe	O	O
side	O	O
effect	O	O
of	O	O
cyclosporine	B-Chemical	D016572
or	O	O
tacrolimus	B-Chemical	D016559
and	O	O
is	O	O
accurately	O	O
diagnosed	O	O
by	O	O
its	O	O
typical	O	O
presentation	O	O
,	O	O
magnetic	O	O
resonance	O	O
imaging	O	O
and	O	O
bone	O	O
scans	O	O
.	O	O

Incorrect	O	O
diagnosis	O	O
of	O	O
the	O	O
syndrome	O	O
will	O	O
lead	O	O
to	O	O
a	O	O
significant	O	O
reduction	O	O
of	O	O
life	O	O
quality	O	O
in	O	O
patients	O	O
suffering	O	O
from	O	O
CIPS	B-Disease	-1
.	O	O

The	O	O
haemodynamic	O	O
effects	O	O
of	O	O
propofol	B-Chemical	D015742
in	O	O
combination	O	O
with	O	O
ephedrine	B-Chemical	D004809
in	O	O
elderly	O	O
patients	O	O
(	O	O
ASA	O	O
groups	O	O
3	O	O
and	O	O
4	O	O
)	O	O
.	O	O

The	O	O
marked	O	O
vasodilator	O	O
and	O	O
negative	O	O
inotropic	O	O
effects	O	O
of	O	O
propofol	B-Chemical	D015742
are	O	O
disadvantages	O	O
in	O	O
frail	O	O
elderly	O	O
patients	O	O
.	O	O

We	O	O
investigated	O	O
the	O	O
safety	O	O
and	O	O
efficacy	O	O
of	O	O
adding	O	O
different	O	O
doses	O	O
of	O	O
ephedrine	B-Chemical	D004809
to	O	O
propofol	B-Chemical	D015742
in	O	O
order	O	O
to	O	O
obtund	O	O
the	O	O
hypotensive	B-Disease	D007022
response	O	O
.	O	O

The	O	O
haemodynamic	O	O
effects	O	O
of	O	O
adding	O	O
15	O	O
,	O	O
20	O	O
or	O	O
25	O	O
mg	O	O
of	O	O
ephedrine	B-Chemical	D004809
to	O	O
200	O	O
mg	O	O
of	O	O
propofol	B-Chemical	D015742
were	O	O
compared	O	O
to	O	O
control	O	O
in	O	O
40	O	O
ASA	O	O
3	O	O
/	O	O
4	O	O
patients	O	O
over	O	O
60	O	O
years	O	O
presenting	O	O
for	O	O
genito	O	O
-	O	O
urinary	O	O
surgery	O	O
.	O	O

The	O	O
addition	O	O
of	O	O
ephedrine	B-Chemical	D004809
to	O	O
propofol	B-Chemical	D015742
appears	O	O
to	O	O
be	O	O
an	O	O
effective	O	O
method	O	O
of	O	O
obtunding	O	O
the	O	O
hypotensive	B-Disease	D007022
response	O	O
to	O	O
propofol	B-Chemical	D015742
at	O	O
all	O	O
doses	O	O
used	O	O
in	O	O
this	O	O
study	O	O
.	O	O

However	O	O
,	O	O
marked	O	O
tachycardia	B-Disease	D013610
associated	O	O
with	O	O
the	O	O
use	O	O
of	O	O
ephedrine	B-Chemical	D004809
in	O	O
combination	O	O
with	O	O
propofol	B-Chemical	D015742
occurred	O	O
in	O	O
the	O	O
majority	O	O
of	O	O
patients	O	O
,	O	O
occasionally	O	O
reaching	O	O
high	O	O
levels	O	O
in	O	O
individual	O	O
patients	O	O
.	O	O

Due	O	O
to	O	O
the	O	O
risk	O	O
of	O	O
this	O	O
tachycardia	B-Disease	D013610
inducing	O	O
myocardial	B-Disease	D017202
ischemia	I-Disease	D017202
,	O	O
we	O	O
would	O	O
not	O	O
recommend	O	O
the	O	O
use	O	O
in	O	O
elderly	O	O
patients	O	O
of	O	O
any	O	O
of	O	O
the	O	O
ephedrine	B-Chemical	D004809
/	O	O
propofol	B-Chemical	D015742
/	O	O
mixtures	O	O
studied	O	O
.	O	O

Neurotoxicity	B-Disease	D020258
of	O	O
halogenated	B-Chemical	D006912
hydroxyquinolines	I-Chemical	D006912
:	O	O
clinical	O	O
analysis	O	O
of	O	O
cases	O	O
reported	O	O
outside	O	O
Japan	O	O
.	O	O

An	O	O
analysis	O	O
is	O	O
presented	O	O
of	O	O
220	O	O
cases	O	O
of	O	O
possible	O	O
neurotoxic	B-Disease	D020258
reactions	O	O
to	O	O
halogenated	B-Chemical	D006912
hydroxyquinolines	I-Chemical	D006912
reported	O	O
from	O	O
outside	O	O
Japan	O	O
.	O	O

In	O	O
80	O	O
cases	O	O
insufficient	O	O
information	O	O
was	O	O
available	O	O
for	O	O
adequate	O	O
comment	O	O
and	O	O
in	O	O
29	O	O
a	O	O
relationship	O	O
to	O	O
the	O	O
administration	O	O
of	O	O
clioquinol	B-Chemical	D007464
could	O	O
be	O	O
excluded	O	O
.	O	O

Of	O	O
the	O	O
remainder	O	O
,	O	O
a	O	O
relationship	O	O
to	O	O
clioquinol	B-Chemical	D007464
was	O	O
considered	O	O
probable	O	O
in	O	O
42	O	O
and	O	O
possible	O	O
in	O	O
69	O	O
cases	O	O
.	O	O

In	O	O
six	O	O
of	O	O
the	O	O
probable	O	O
cases	O	O
the	O	O
neurological	B-Disease	D009422
disturbance	I-Disease	D009422
consisted	O	O
of	O	O
an	O	O
acute	O	O
reversible	O	O
encephalopathy	B-Disease	D001927
usually	O	O
related	O	O
to	O	O
the	O	O
ingestion	O	O
of	O	O
a	O	O
high	O	O
dose	O	O
of	O	O
clioquinol	B-Chemical	D007464
over	O	O
a	O	O
short	O	O
period	O	O
.	O	O

The	O	O
most	O	O
common	O	O
manifestation	O	O
,	O	O
observed	O	O
in	O	O
15	O	O
further	O	O
cases	O	O
,	O	O
was	O	O
isolated	O	O
optic	B-Disease	D009896
atrophy	I-Disease	D009896
.	O	O

This	O	O
was	O	O
most	O	O
frequently	O	O
found	O	O
in	O	O
children	O	O
,	O	O
many	O	O
of	O	O
whom	O	O
had	O	O
received	O	O
clioquinol	B-Chemical	D007464
as	O	O
treatment	O	O
for	O	O
acrodermatitis	B-Disease	C538178
enteropathica	I-Disease	C538178
.	O	O

In	O	O
the	O	O
remaining	O	O
cases	O	O
,	O	O
a	O	O
combination	O	O
of	O	O
myelopathy	B-Disease	D013118
,	O	O
visual	B-Disease	D014786
disturbance	I-Disease	D014786
,	O	O
and	O	O
peripheral	B-Disease	D010523
neuropathy	I-Disease	D010523
was	O	O
the	O	O
most	O	O
common	O	O
manifestation	O	O
.	O	O

Isolated	O	O
myelopathy	B-Disease	D013118
or	O	O
peripheral	B-Disease	D010523
neuropathy	I-Disease	D010523
,	O	O
or	O	O
these	O	O
manifestations	O	O
occurring	O	O
together	O	O
,	O	O
were	O	O
infrequent	O	O
.	O	O

The	O	O
onset	O	O
of	O	O
all	O	O
manifestations	O	O
(	O	O
except	O	O
toxic	O	O
encephalopathy	B-Disease	D001927
)	O	O
was	O	O
usually	O	O
subacute	O	O
,	O	O
with	O	O
subsequent	O	O
partial	O	O
recovery	O	O
.	O	O

Older	O	O
subjects	O	O
tended	O	O
to	O	O
display	O	O
more	O	O
side	O	O
effects	O	O
.	O	O

The	O	O
full	O	O
syndrome	O	O
of	O	O
subacute	O	O
myelo	O	O
-	O	O
optic	O	O
neuropathy	O	O
was	O	O
more	O	O
frequent	O	O
in	O	O
women	O	O
,	O	O
but	O	O
they	O	O
tended	O	O
to	O	O
have	O	O
taken	O	O
greater	O	O
quantities	O	O
of	O	O
the	O	O
drug	O	O
.	O	O

Epileptic	B-Disease	D004827
seizures	I-Disease	D004827
following	O	O
cortical	O	O
application	O	O
of	O	O
fibrin	O	O
sealants	O	O
containing	O	O
tranexamic	B-Chemical	D014148
acid	I-Chemical	D014148
in	O	O
rats	O	O
.	O	O

BACKGROUND	O	O
:	O	O
Fibrin	O	O
sealants	O	O
(	O	O
FS	O	O
)	O	O
derived	O	O
from	O	O
human	O	O
plasma	O	O
are	O	O
frequently	O	O
used	O	O
in	O	O
neurosurgery	O	O
.	O	O

In	O	O
order	O	O
to	O	O
increase	O	O
clot	O	O
stability	O	O
,	O	O
FS	O	O
typically	O	O
contain	O	O
aprotinin	O	O
,	O	O
a	O	O
natural	O	O
fibrinolysis	O	O
inhibitor	O	O
.	O	O

Recently	O	O
,	O	O
synthetic	O	O
fibrinolysis	O	O
inhibitors	O	O
such	O	O
as	O	O
tranexamic	B-Chemical	D014148
acid	I-Chemical	D014148
(	O	O
tAMCA	B-Chemical	D014148
)	O	O
have	O	O
been	O	O
considered	O	O
as	O	O
substitutes	O	O
for	O	O
aprotinin	O	O
.	O	O

However	O	O
,	O	O
tAMCA	B-Chemical	D014148
has	O	O
been	O	O
shown	O	O
to	O	O
cause	O	O
epileptic	B-Disease	D004827
seizures	I-Disease	D004827
.	O	O

We	O	O
wanted	O	O
to	O	O
study	O	O
whether	O	O
tAMCA	B-Chemical	D014148
retains	O	O
its	O	O
convulsive	B-Disease	D012640
action	O	O
if	O	O
incorporated	O	O
into	O	O
a	O	O
FS	O	O
.	O	O

METHOD	O	O
:	O	O
FS	O	O
containing	O	O
aprotinin	O	O
or	O	O
different	O	O
concentrations	O	O
of	O	O
tAMCA	B-Chemical	D014148
(	O	O
0	O	O
.	O	O

5	O	O
-	O	O
47	O	O
.	O	O

5	O	O
mg	O	O
/	O	O
ml	O	O
)	O	O
were	O	O
applied	O	O
to	O	O
the	O	O
pial	O	O
surface	O	O
of	O	O
the	O	O
cortex	O	O
of	O	O
anaesthetized	O	O
rats	O	O
.	O	O

The	O	O
response	O	O
of	O	O
the	O	O
animals	O	O
was	O	O
evaluated	O	O
using	O	O
electroencephalography	O	O
and	O	O
by	O	O
monitoring	O	O
the	O	O
clinical	O	O
behaviour	O	O
during	O	O
and	O	O
after	O	O
recovery	O	O
from	O	O
anaesthesia	O	O
.	O	O

FINDINGS	O	O
:	O	O
FS	O	O
containing	O	O
tAMCA	B-Chemical	D014148
caused	O	O
paroxysmal	O	O
brain	O	O
activity	O	O
which	O	O
was	O	O
associated	O	O
with	O	O
distinct	O	O
convulsive	B-Disease	D012640
behaviours	O	O
.	O	O

The	O	O
degree	O	O
of	O	O
these	O	O
seizures	B-Disease	D012640
increased	O	O
with	O	O
increasing	O	O
concentration	O	O
of	O	O
tAMCA	B-Chemical	D014148
.	O	O

Thus	O	O
,	O	O
FS	O	O
containing	O	O
47	O	O
.	O	O

5	O	O
mg	O	O
/	O	O
ml	O	O
tAMCA	B-Chemical	D014148
evoked	O	O
generalized	B-Disease	D012640
seizures	I-Disease	D012640
in	O	O
all	O	O
tested	O	O
rats	O	O
(	O	O
n=6	O	O
)	O	O
while	O	O
the	O	O
lowest	O	O
concentration	O	O
of	O	O
tAMCA	B-Chemical	D014148
(	O	O
0	O	O
.	O	O

5	O	O
mg	O	O
/	O	O
ml	O	O
)	O	O
only	O	O
evoked	O	O
brief	O	O
episodes	O	O
of	O	O
jerk	O	O
-	O	O
correlated	O	O
convulsive	B-Disease	D012640
potentials	O	O
in	O	O
1	O	O
of	O	O
6	O	O
rats	O	O
.	O	O

In	O	O
contrast	O	O
,	O	O
FS	O	O
containing	O	O
aprotinin	O	O
did	O	O
not	O	O
evoke	O	O
any	O	O
paroxysmal	O	O
activity	O	O
.	O	O

INTERPRETATION	O	O
:	O	O
Tranexamic	B-Chemical	D014148
acid	I-Chemical	D014148
retains	O	O
its	O	O
convulsive	B-Disease	D012640
action	O	O
within	O	O
FS	O	O
.	O	O

Thus	O	O
,	O	O
use	O	O
of	O	O
FS	O	O
containing	O	O
tAMCA	B-Chemical	D014148
for	O	O
surgery	O	O
within	O	O
or	O	O
close	O	O
to	O	O
the	O	O
CNS	O	O
may	O	O
pose	O	O
a	O	O
substantial	O	O
risk	O	O
to	O	O
the	O	O
patient	O	O
.	O	O

A	O	O
diet	O	O
promoting	O	O
sugar	B-Disease	D019966
dependency	I-Disease	D019966
causes	O	O
behavioral	B-Disease	D006948
cross	I-Disease	D006948
-	I-Disease	D006948
sensitization	I-Disease	D006948
to	O	O
a	O	O
low	O	O
dose	O	O
of	O	O
amphetamine	B-Chemical	D000661
.	O	O

Previous	O	O
research	O	O
in	O	O
this	O	O
laboratory	O	O
has	O	O
shown	O	O
that	O	O
a	O	O
diet	O	O
of	O	O
intermittent	O	O
excessive	O	O
sugar	O	O
consumption	O	O
produces	O	O
a	O	O
state	O	O
with	O	O
neurochemical	O	O
and	O	O
behavioral	O	O
similarities	O	O
to	O	O
drug	B-Disease	D019966
dependency	I-Disease	D019966
.	O	O

The	O	O
present	O	O
study	O	O
examined	O	O
whether	O	O
female	O	O
rats	O	O
on	O	O
various	O	O
regimens	O	O
of	O	O
sugar	O	O
access	O	O
would	O	O
show	O	O
behavioral	B-Disease	D006948
cross	I-Disease	D006948
-	I-Disease	D006948
sensitization	I-Disease	D006948
to	O	O
a	O	O
low	O	O
dose	O	O
of	O	O
amphetamine	B-Chemical	D000661
.	O	O

After	O	O
a	O	O
30	O	O
-	O	O
min	O	O
baseline	O	O
measure	O	O
of	O	O
locomotor	O	O
activity	O	O
(	O	O
day	O	O
0	O	O
)	O	O
,	O	O
animals	O	O
were	O	O
maintained	O	O
on	O	O
a	O	O
cyclic	O	O
diet	O	O
of	O	O
12	O	O
-	O	O
h	O	O
deprivation	O	O
followed	O	O
by	O	O
12	O	O
-	O	O
h	O	O
access	O	O
to	O	O
10%	O	O
sucrose	B-Chemical	D013395
solution	O	O
and	O	O
chow	O	O
pellets	O	O
(	O	O
12	O	O
h	O	O
access	O	O
starting	O	O
4	O	O
h	O	O
after	O	O
onset	O	O
of	O	O
the	O	O
dark	O	O
period	O	O
)	O	O
for	O	O
21	O	O
days	O	O
.	O	O

Locomotor	O	O
activity	O	O
was	O	O
measured	O	O
again	O	O
for	O	O
30	O	O
min	O	O
at	O	O
the	O	O
beginning	O	O
of	O	O
days	O	O
1	O	O
and	O	O
21	O	O
of	O	O
sugar	O	O
access	O	O
.	O	O

Beginning	O	O
on	O	O
day	O	O
22	O	O
,	O	O
all	O	O
rats	O	O
were	O	O
maintained	O	O
on	O	O
ad	O	O
libitum	O	O
chow	O	O
.	O	O

Nine	O	O
days	O	O
later	O	O
locomotor	O	O
activity	O	O
was	O	O
measured	O	O
in	O	O
response	O	O
to	O	O
a	O	O
single	O	O
low	O	O
dose	O	O
of	O	O
amphetamine	B-Chemical	D000661
(	O	O
0	O	O
.	O	O

5	O	O
mg	O	O
/	O	O
kg	O	O
)	O	O
.	O	O

The	O	O
animals	O	O
that	O	O
had	O	O
experienced	O	O
cyclic	O	O
sucrose	B-Chemical	D013395
and	O	O
chow	O	O
were	O	O
hyperactive	B-Disease	D006948
in	O	O
response	O	O
to	O	O
amphetamine	B-Chemical	D000661
compared	O	O
with	O	O
four	O	O
control	O	O
groups	O	O
(	O	O
ad	O	O
libitum	O	O
10%	O	O
sucrose	B-Chemical	D013395
and	O	O
chow	O	O
followed	O	O
by	O	O
amphetamine	B-Chemical	D000661
injection	O	O
,	O	O
cyclic	O	O
chow	O	O
followed	O	O
by	O	O
amphetamine	B-Chemical	D000661
injection	O	O
,	O	O
ad	O	O
libitum	O	O
chow	O	O
with	O	O
amphetamine	B-Chemical	D000661
,	O	O
or	O	O
cyclic	O	O
10%	O	O
sucrose	B-Chemical	D013395
and	O	O
chow	O	O
with	O	O
a	O	O
saline	O	O
injection	O	O
)	O	O
.	O	O

These	O	O
results	O	O
suggest	O	O
that	O	O
a	O	O
diet	O	O
comprised	O	O
of	O	O
alternating	O	O
deprivation	O	O
and	O	O
access	O	O
to	O	O
a	O	O
sugar	O	O
solution	O	O
and	O	O
chow	O	O
produces	O	O
bingeing	O	O
on	O	O
sugar	O	O
that	O	O
leads	O	O
to	O	O
a	O	O
long	O	O
lasting	O	O
state	O	O
of	O	O
increased	O	O
sensitivity	O	O
to	O	O
amphetamine	B-Chemical	D000661
,	O	O
possibly	O	O
due	O	O
to	O	O
a	O	O
lasting	O	O
alteration	O	O
in	O	O
the	O	O
dopamine	B-Chemical	D004298
system	O	O
.	O	O

D	B-Chemical	D010396
-	I-Chemical	D010396
penicillamine	I-Chemical	D010396
-	O	O
induced	O	O
angiopathy	B-Disease	D001018
in	O	O
rats	O	O
.	O	O

The	O	O
effect	O	O
of	O	O
high	O	O
dose	O	O
D	B-Chemical	D010396
-	I-Chemical	D010396
penicillamine	I-Chemical	D010396
treatment	O	O
on	O	O
aortic	O	O
permeability	O	O
to	O	O
albumin	O	O
and	O	O
on	O	O
the	O	O
ultrastructure	O	O
of	O	O
the	O	O
vessel	O	O
.	O	O

Male	O	O
Sprague	O	O
-	O	O
Dawley	O	O
rats	O	O
were	O	O
treated	O	O
with	O	O
D	B-Chemical	D010396
-	I-Chemical	D010396
penicillamine	I-Chemical	D010396
(	O	O
D	B-Chemical	D010396
-	I-Chemical	D010396
pen	I-Chemical	D010396
)	O	O
500	O	O
mg	O	O
/	O	O
kg	O	O
/	O	O
day	O	O
for	O	O
10	O	O
or	O	O
42	O	O
days	O	O
.	O	O

Pair	O	O
fed	O	O
rats	O	O
served	O	O
as	O	O
controls	O	O
.	O	O

Changes	O	O
in	O	O
aortic	O	O
morphology	O	O
were	O	O
examined	O	O
by	O	O
light	O	O
-	O	O
and	O	O
transmission	O	O
-	O	O
electron	O	O
microscopy	O	O
(	O	O
TEM	O	O
)	O	O
.	O	O

In	O	O
addition	O	O
,	O	O
the	O	O
endothelial	O	O
permeability	O	O
and	O	O
the	O	O
penetration	O	O
through	O	O
the	O	O
aortic	O	O
wall	O	O
of	O	O
albumin	O	O
were	O	O
studied	O	O
10	O	O
minutes	O	O
,	O	O
24	O	O
and	O	O
48	O	O
hours	O	O
after	O	O
i	O	O
.	O	O

v	O	O
.	O	O

injection	O	O
of	O	O
human	O	O
serum	O	O
131I	O	O
-	O	O
albumin	O	O
(	O	O
131I	O	O
-	O	O
HSA	O	O
)	O	O
.	O	O

TEM	O	O
revealed	O	O
extensive	O	O
elastolysis	O	O
in	O	O
the	O	O
arterial	O	O
wall	O	O
of	O	O
D	B-Chemical	D010396
-	I-Chemical	D010396
pen	I-Chemical	D010396
-	O	O
treated	O	O
rats	O	O
,	O	O
consistent	O	O
with	O	O
an	O	O
inhibitory	O	O
effect	O	O
on	O	O
crosslink	O	O
formation	O	O
.	O	O

In	O	O
experimental	O	O
animals	O	O
excess	O	O
deposition	O	O
of	O	O
collagen	O	O
and	O	O
glycoaminoglycans	O	O
was	O	O
observed	O	O
in	O	O
the	O	O
subendothelial	O	O
and	O	O
medial	O	O
layer	O	O
of	O	O
the	O	O
aortic	O	O
wall	O	O
,	O	O
together	O	O
with	O	O
prominent	O	O
basal	O	O
membrane	O	O
substance	O	O
around	O	O
aortic	O	O
smooth	O	O
muscle	O	O
cells	O	O
.	O	O

The	O	O
aorta	O	O
/	O	O
serum	O	O
-	O	O
ratio	O	O
and	O	O
the	O	O
radioactive	O	O
build	O	O
-	O	O
up	O	O
24	O	O
and	O	O
48	O	O
hours	O	O
after	O	O
injection	O	O
of	O	O
131I	O	O
-	O	O
HSA	O	O
was	O	O
reduced	O	O
in	O	O
animals	O	O
treated	O	O
with	O	O
D	B-Chemical	D010396
-	I-Chemical	D010396
pen	I-Chemical	D010396
for	O	O
42	O	O
days	O	O
,	O	O
indicating	O	O
an	O	O
impeded	O	O
transmural	O	O
transport	O	O
of	O	O
tracer	O	O
which	O	O
may	O	O
be	O	O
caused	O	O
by	O	O
a	O	O
steric	O	O
exclusion	O	O
effect	O	O
of	O	O
abundant	O	O
hyaluronate	B-Chemical	D006820
.	O	O

The	O	O
endothelial	O	O
ultrastructure	O	O
was	O	O
unaffected	O	O
by	O	O
D	B-Chemical	D010396
-	I-Chemical	D010396
pen	I-Chemical	D010396
,	O	O
and	O	O
no	O	O
differences	O	O
in	O	O
aortic	O	O
131I	O	O
-	O	O
HSA	O	O
radioactivity	O	O
or	O	O
aorta	O	O
/	O	O
serum	O	O
-	O	O
ratio	O	O
were	O	O
recorded	O	O
between	O	O
experimental	O	O
and	O	O
control	O	O
groups	O	O
10	O	O
minutes	O	O
after	O	O
tracer	O	O
injection	O	O
,	O	O
indicating	O	O
that	O	O
the	O	O
permeability	O	O
of	O	O
the	O	O
endothelial	O	O
barrier	O	O
to	O	O
albumin	O	O
remained	O	O
unaffected	O	O
by	O	O
D	B-Chemical	D010396
-	I-Chemical	D010396
pen	I-Chemical	D010396
treatment	O	O
.	O	O

These	O	O
observations	O	O
support	O	O
the	O	O
hypothesis	O	O
that	O	O
treatment	O	O
with	O	O
high	O	O
doses	O	O
of	O	O
D	B-Chemical	D010396
-	I-Chemical	D010396
pen	I-Chemical	D010396
may	O	O
induce	O	O
a	O	O
fibroproliferative	O	O
response	O	O
in	O	O
rat	O	O
aorta	O	O
,	O	O
possibly	O	O
by	O	O
an	O	O
inhibitory	O	O
effect	O	O
on	O	O
the	O	O
cross	O	O
-	O	O
linking	O	O
of	O	O
collagen	O	O
and	O	O
elastin	O	O
.	O	O

Brain	O	O
natriuretic	O	O
peptide	O	O
is	O	O
a	O	O
predictor	O	O
of	O	O
anthracycline	B-Chemical	D018943
-	O	O
induced	O	O
cardiotoxicity	B-Disease	D066126
.	O	O

Anthracyclines	B-Chemical	D018943
are	O	O
effective	O	O
antineoplastic	O	O
drugs	O	O
,	O	O
but	O	O
they	O	O
frequently	O	O
cause	O	O
dose	O	O
-	O	O
related	O	O
cardiotoxicity	B-Disease	D066126
.	O	O

The	O	O
cardiotoxicity	B-Disease	D066126
of	O	O
conventional	O	O
anthracycline	B-Chemical	D018943
therapy	O	O
highlights	O	O
a	O	O
need	O	O
to	O	O
search	O	O
for	O	O
methods	O	O
that	O	O
are	O	O
highly	O	O
sensitive	O	O
and	O	O
capable	O	O
of	O	O
predicting	O	O
cardiac	B-Disease	D006331
dysfunction	I-Disease	D006331
.	O	O

We	O	O
measured	O	O
the	O	O
plasma	O	O
level	O	O
of	O	O
brain	O	O
natriuretic	O	O
peptide	O	O
(	O	O
BNP	O	O
)	O	O
to	O	O
determine	O	O
whether	O	O
BNP	O	O
might	O	O
serve	O	O
as	O	O
a	O	O
simple	O	O
diagnostic	O	O
indicator	O	O
of	O	O
anthracycline	B-Chemical	D018943
-	O	O
induced	O	O
cardiotoxicity	B-Disease	D066126
in	O	O
patients	O	O
with	O	O
acute	B-Disease	D015470
leukemia	I-Disease	D015470
treated	O	O
with	O	O
a	O	O
daunorubicin	B-Chemical	D003630
(	O	O
DNR	B-Chemical	D003630
)	O	O
-	O	O
containing	O	O
regimen	O	O
.	O	O

Thirteen	O	O
patients	O	O
with	O	O
acute	B-Disease	D015470
leukemia	I-Disease	D015470
were	O	O
treated	O	O
with	O	O
a	O	O
DNR	B-Chemical	D003630
-	O	O
containing	O	O
regimen	O	O
.	O	O

Cardiac	O	O
functions	O	O
were	O	O
evaluated	O	O
with	O	O
radionuclide	O	O
angiography	O	O
before	O	O
chemotherapies	O	O
.	O	O

The	O	O
plasma	O	O
levels	O	O
of	O	O
atrial	O	O
natriuretic	O	O
peptide	O	O
(	O	O
ANP	O	O
)	O	O
and	O	O
BNP	O	O
were	O	O
measured	O	O
at	O	O
the	O	O
time	O	O
of	O	O
radionuclide	O	O
angiography	O	O
.	O	O

Three	O	O
patients	O	O
developed	O	O
congestive	B-Disease	D006333
heart	I-Disease	D006333
failure	I-Disease	D006333
after	O	O
the	O	O
completion	O	O
of	O	O
chemotherapy	O	O
.	O	O

Five	O	O
patients	O	O
were	O	O
diagnosed	O	O
as	O	O
having	O	O
subclinical	O	O
heart	B-Disease	D006333
failure	I-Disease	D006333
after	O	O
the	O	O
completion	O	O
of	O	O
chemotherapy	O	O
.	O	O

The	O	O
plasma	O	O
levels	O	O
of	O	O
BNP	O	O
in	O	O
all	O	O
the	O	O
patients	O	O
with	O	O
clinical	O	O
and	O	O
subclinical	O	O
heart	B-Disease	D006333
failure	I-Disease	D006333
increased	O	O
above	O	O
the	O	O
normal	O	O
limit	O	O
(	O	O
40	O	O
pg	O	O
/	O	O
ml	O	O
)	O	O
before	O	O
the	O	O
detection	O	O
of	O	O
clinical	O	O
or	O	O
subclinical	O	O
heart	B-Disease	D006333
failure	I-Disease	D006333
by	O	O
radionuclide	O	O
angiography	O	O
.	O	O

On	O	O
the	O	O
other	O	O
hand	O	O
,	O	O
BNP	O	O
did	O	O
not	O	O
increase	O	O
in	O	O
the	O	O
patients	O	O
without	O	O
heart	B-Disease	D006333
failure	I-Disease	D006333
given	O	O
DNR	B-Chemical	D003630
,	O	O
even	O	O
at	O	O
more	O	O
than	O	O
700	O	O
mg	O	O
/	O	O
m	O	O
(	O	O
2	O	O
)	O	O
.	O	O

The	O	O
plasma	O	O
level	O	O
of	O	O
ANP	O	O
did	O	O
not	O	O
always	O	O
increase	O	O
in	O	O
all	O	O
the	O	O
patients	O	O
with	O	O
clinical	O	O
and	O	O
subclinical	O	O
heart	B-Disease	D006333
failure	I-Disease	D006333
.	O	O

These	O	O
preliminary	O	O
results	O	O
suggest	O	O
that	O	O
BNP	O	O
may	O	O
be	O	O
useful	O	O
as	O	O
an	O	O
early	O	O
and	O	O
sensitive	O	O
indicator	O	O
of	O	O
anthracycline	B-Chemical	D018943
-	O	O
induced	O	O
cardiotoxicity	B-Disease	D066126
.	O	O

Antibacterial	O	O
medication	O	O
use	O	O
during	O	O
pregnancy	O	O
and	O	O
risk	O	O
of	O	O
birth	B-Disease	D000014
defects	I-Disease	D000014
:	O	O
National	O	O
Birth	B-Disease	D000014
Defects	I-Disease	D000014
Prevention	O	O
Study	O	O
.	O	O

OBJECTIVE	O	O
:	O	O
To	O	O
estimate	O	O
the	O	O
association	O	O
between	O	O
antibacterial	O	O
medications	O	O
and	O	O
selected	O	O
birth	B-Disease	D000014
defects	I-Disease	D000014
.	O	O

DESIGN	O	O
,	O	O
SETTING	O	O
,	O	O
AND	O	O
PARTICIPANTS	O	O
:	O	O
Population	O	O
-	O	O
based	O	O
,	O	O
multisite	O	O
,	O	O
case	O	O
-	O	O
control	O	O
study	O	O
of	O	O
women	O	O
who	O	O
had	O	O
pregnancies	O	O
affected	O	O
by	O	O
1	O	O
of	O	O
more	O	O
than	O	O
30	O	O
eligible	O	O
major	O	O
birth	B-Disease	D000014
defects	I-Disease	D000014
identified	O	O
via	O	O
birth	B-Disease	D000014
defect	I-Disease	D000014
surveillance	O	O
programs	O	O
in	O	O
10	O	O
states	O	O
(	O	O
n	O	O
=	O	O
13	O	O
155	O	O
)	O	O
and	O	O
control	O	O
women	O	O
randomly	O	O
selected	O	O
from	O	O
the	O	O
same	O	O
geographical	O	O
regions	O	O
(	O	O
n	O	O
=	O	O
4941	O	O
)	O	O
.	O	O

MAIN	O	O
EXPOSURE	O	O
:	O	O
Reported	O	O
maternal	O	O
use	O	O
of	O	O
antibacterials	O	O
(	O	O
1	O	O
month	O	O
before	O	O
pregnancy	O	O
through	O	O
the	O	O
end	O	O
of	O	O
the	O	O
first	O	O
trimester	O	O
)	O	O
.	O	O

MAIN	O	O
OUTCOME	O	O
MEASURE	O	O
:	O	O
Odds	O	O
ratios	O	O
(	O	O
ORs	O	O
)	O	O
measuring	O	O
the	O	O
association	O	O
between	O	O
antibacterial	O	O
use	O	O
and	O	O
selected	O	O
birth	B-Disease	D000014
defects	I-Disease	D000014
adjusted	O	O
for	O	O
potential	O	O
confounders	O	O
.	O	O

RESULTS	O	O
:	O	O
The	O	O
reported	O	O
use	O	O
of	O	O
antibacterials	O	O
increased	O	O
during	O	O
pregnancy	O	O
,	O	O
peaking	O	O
during	O	O
the	O	O
third	O	O
month	O	O
.	O	O

Sulfonamides	B-Chemical	D013449
were	O	O
associated	O	O
with	O	O
anencephaly	B-Disease	D000757
(	O	O
adjusted	O	O
OR	O	O
[	O	O
AOR	O	O
]	O	O
=	O	O
3	O	O
.	O	O

4	O	O
;	O	O
95%	O	O
confidence	O	O
interval	O	O
[	O	O
CI	O	O
]	O	O
,	O	O
1	O	O
.	O	O

3	O	O
-	O	O
8	O	O
.	O	O

8	O	O
)	O	O
,	O	O
hypoplastic	B-Disease	D018636
left	I-Disease	D018636
heart	I-Disease	D018636
syndrome	I-Disease	D018636
(	O	O
AOR	O	O
=	O	O
3	O	O
.	O	O

2	O	O
;	O	O
95%	O	O
CI	O	O
,	O	O
1	O	O
.	O	O

3	O	O
-	O	O
7	O	O
.	O	O

6	O	O
)	O	O
,	O	O
coarctation	B-Disease	D001017
of	I-Disease	D001017
the	I-Disease	D001017
aorta	I-Disease	D001017
(	O	O
AOR	O	O
=	O	O
2	O	O
.	O	O

7	O	O
;	O	O
95%	O	O
CI	O	O
,	O	O
1	O	O
.	O	O

3	O	O
-	O	O
5	O	O
.	O	O

6	O	O
)	O	O
,	O	O
choanal	B-Disease	D002754
atresia	I-Disease	D002754
(	O	O
AOR	O	O
=	O	O
8	O	O
.	O	O

0	O	O
;	O	O
95%	O	O
CI	O	O
,	O	O
2	O	O
.	O	O

7	O	O
-	O	O
23	O	O
.	O	O

5	O	O
)	O	O
,	O	O
transverse	B-Disease	D017880
limb	I-Disease	D017880
deficiency	I-Disease	D017880
(	O	O
AOR	O	O
=	O	O
2	O	O
.	O	O

5	O	O
;	O	O
95%	O	O
CI	O	O
,	O	O
1	O	O
.	O	O

0	O	O
-	O	O
5	O	O
.	O	O

9	O	O
)	O	O
,	O	O
and	O	O
diaphragmatic	B-Disease	D006548
hernia	I-Disease	D006548
(	O	O
AOR	O	O
=	O	O
2	O	O
.	O	O

4	O	O
;	O	O
95%	O	O
CI	O	O
,	O	O
1	O	O
.	O	O

1	O	O
-	O	O
5	O	O
.	O	O

4	O	O
)	O	O
.	O	O

Nitrofurantoins	B-Chemical	D009582
were	O	O
associated	O	O
with	O	O
anophthalmia	B-Disease	D000853
or	O	O
microphthalmos	B-Disease	D008850
(	O	O
AOR	O	O
=	O	O
3	O	O
.	O	O

7	O	O
;	O	O
95%	O	O
CI	O	O
,	O	O
1	O	O
.	O	O

1	O	O
-	O	O
12	O	O
.	O	O

2	O	O
)	O	O
,	O	O
hypoplastic	B-Disease	D018636
left	I-Disease	D018636
heart	I-Disease	D018636
syndrome	I-Disease	D018636
(	O	O
AOR	O	O
=	O	O
4	O	O
.	O	O

2	O	O
;	O	O
95%	O	O
CI	O	O
,	O	O
1	O	O
.	O	O

9	O	O
-	O	O
9	O	O
.	O	O

1	O	O
)	O	O
,	O	O
atrial	B-Disease	D006344
septal	I-Disease	D006344
defects	I-Disease	D006344
(	O	O
AOR	O	O
=	O	O
1	O	O
.	O	O

9	O	O
;	O	O
95%	O	O
CI	O	O
,	O	O
1	O	O
.	O	O

1	O	O
-	O	O
3	O	O
.	O	O

4	O	O
)	O	O
,	O	O
and	O	O
cleft	B-Disease	D002971
lip	I-Disease	D002971
with	O	O
cleft	B-Disease	D002972
palate	I-Disease	D002972
(	O	O
AOR	O	O
=	O	O
2	O	O
.	O	O

1	O	O
;	O	O
95%	O	O
CI	O	O
,	O	O
1	O	O
.	O	O

2	O	O
-	O	O
3	O	O
.	O	O

9	O	O
)	O	O
.	O	O

Other	O	O
antibacterial	O	O
agents	O	O
that	O	O
showed	O	O
associations	O	O
included	O	O
erythromycins	B-Chemical	D004917
(	O	O
2	O	O
defects	O	O
)	O	O
,	O	O
penicillins	B-Chemical	D010406
(	O	O
1	O	O
defect	O	O
)	O	O
,	O	O
cephalosporins	B-Chemical	D002511
(	O	O
1	O	O
defect	O	O
)	O	O
,	O	O
and	O	O
quinolones	B-Chemical	D015363
(	O	O
1	O	O
defect	O	O
)	O	O
.	O	O

CONCLUSIONS	O	O
:	O	O
Reassuringly	O	O
,	O	O
penicillins	B-Chemical	D010406
,	O	O
erythromycins	B-Chemical	D004917
,	O	O
and	O	O
cephalosporins	B-Chemical	D002511
,	O	O
although	O	O
used	O	O
commonly	O	O
by	O	O
pregnant	O	O
women	O	O
,	O	O
were	O	O
not	O	O
associated	O	O
with	O	O
many	O	O
birth	B-Disease	D000014
defects	I-Disease	D000014
.	O	O

Sulfonamides	B-Chemical	D013449
and	O	O
nitrofurantoins	B-Chemical	D009582
were	O	O
associated	O	O
with	O	O
several	O	O
birth	B-Disease	D000014
defects	I-Disease	D000014
,	O	O
indicating	O	O
a	O	O
need	O	O
for	O	O
additional	O	O
scrutiny	O	O
.	O	O

Incidence	O	O
of	O	O
neoplasms	B-Disease	D009369
in	O	O
patients	O	O
with	O	O
rheumatoid	B-Disease	D001172
arthritis	I-Disease	D001172
exposed	O	O
to	O	O
different	O	O
treatment	O	O
regimens	O	O
.	O	O

Immunosuppressive	O	O
drugs	O	O
have	O	O
been	O	O
used	O	O
during	O	O
the	O	O
last	O	O
30	O	O
years	O	O
in	O	O
treatment	O	O
of	O	O
patients	O	O
with	O	O
severe	O	O
rheumatoid	B-Disease	D001172
arthritis	I-Disease	D001172
.	O	O

The	O	O
drugs	O	O
commonly	O	O
used	O	O
are	O	O
cyclophosphamide	B-Chemical	D003520
and	O	O
chlorambucil	B-Chemical	D002699
(	O	O
alkylating	B-Chemical	D000477
agents	I-Chemical	D000477
)	O	O
,	O	O
azathioprine	B-Chemical	D001379
(	O	O
purine	B-Chemical	D011687
analogue	O	O
)	O	O
,	O	O
and	O	O
methotrexate	B-Chemical	D008727
(	O	O
folic	B-Chemical	D005492
acid	I-Chemical	D005492
analogue	O	O
)	O	O
.	O	O

There	O	O
is	O	O
evidence	O	O
that	O	O
all	O	O
four	O	O
immunosuppressive	O	O
drugs	O	O
can	O	O
reduce	O	O
synovitis	B-Disease	D013585
,	O	O
but	O	O
disease	O	O
activity	O	O
almost	O	O
always	O	O
recurs	O	O
after	O	O
therapy	O	O
is	O	O
stopped	O	O
.	O	O

Since	O	O
adverse	O	O
reactions	O	O
are	O	O
frequent	O	O
,	O	O
less	O	O
than	O	O
50	O	O
percent	O	O
of	O	O
patients	O	O
are	O	O
able	O	O
to	O	O
continue	O	O
a	O	O
particular	O	O
drug	O	O
for	O	O
more	O	O
than	O	O
one	O	O
year	O	O
.	O	O

Since	O	O
it	O	O
takes	O	O
three	O	O
to	O	O
12	O	O
months	O	O
to	O	O
achieve	O	O
maximal	O	O
effects	O	O
,	O	O
those	O	O
patients	O	O
who	O	O
are	O	O
unable	O	O
to	O	O
continue	O	O
the	O	O
drug	O	O
receive	O	O
little	O	O
benefit	O	O
from	O	O
it	O	O
.	O	O

Patients	O	O
treated	O	O
with	O	O
alkylating	B-Chemical	D000477
agents	I-Chemical	D000477
have	O	O
an	O	O
increased	O	O
risk	O	O
of	O	O
development	O	O
of	O	O
acute	B-Disease	D015470
nonlymphocytic	I-Disease	D015470
leukemia	I-Disease	D015470
,	O	O
and	O	O
both	O	O
alkylating	B-Chemical	D000477
agents	I-Chemical	D000477
and	O	O
azathioprine	B-Chemical	D001379
are	O	O
associated	O	O
with	O	O
the	O	O
development	O	O
of	O	O
non	B-Disease	D008228
-	I-Disease	D008228
Hodgkin's	I-Disease	D008228
lymphoma	I-Disease	D008228
.	O	O

Cyclophosphamide	B-Chemical	D003520
therapy	O	O
increases	O	O
the	O	O
risk	O	O
of	O	O
carcinoma	O	O
of	O	O
the	O	O
bladder	O	O
.	O	O

There	O	O
have	O	O
been	O	O
several	O	O
long	O	O
-	O	O
term	O	O
studies	O	O
of	O	O
patients	O	O
with	O	O
rheumatoid	B-Disease	D001172
arthritis	I-Disease	D001172
treated	O	O
with	O	O
azathioprine	B-Chemical	D001379
and	O	O
cyclophosphamide	B-Chemical	D003520
and	O	O
the	O	O
incidence	O	O
of	O	O
most	O	O
of	O	O
the	O	O
common	O	O
cancers	B-Disease	D009369
is	O	O
not	O	O
increased	O	O
.	O	O

Data	O	O
on	O	O
the	O	O
possible	O	O
increased	O	O
risk	O	O
of	O	O
malignancy	B-Disease	D009369
in	O	O
rheumatoid	B-Disease	D001172
arthritis	I-Disease	D001172
are	O	O
still	O	O
being	O	O
collected	O	O
,	O	O
and	O	O
until	O	O
further	O	O
information	O	O
is	O	O
available	O	O
,	O	O
the	O	O
use	O	O
of	O	O
immunosuppressive	O	O
drugs	O	O
,	O	O
particularly	O	O
alkylating	B-Chemical	D000477
agents	I-Chemical	D000477
,	O	O
in	O	O
the	O	O
treatment	O	O
of	O	O
rheumatoid	B-Disease	D001172
arthritis	I-Disease	D001172
should	O	O
be	O	O
reserved	O	O
for	O	O
patients	O	O
with	O	O
severe	O	O
progressive	O	O
disease	O	O
or	O	O
life	O	O
-	O	O
threatening	O	O
complications	O	O
.	O	O

Patterns	O	O
of	O	O
hepatic	B-Disease	D056486
injury	I-Disease	D056486
induced	O	O
by	O	O
methyldopa	B-Chemical	D008750
.	O	O

Twelve	O	O
patients	O	O
with	O	O
liver	B-Disease	D008107
disease	I-Disease	D008107
related	O	O
to	O	O
methyldopa	B-Chemical	D008750
were	O	O
seen	O	O
between	O	O
1967	O	O
and	O	O
1977	O	O
.	O	O

Illness	O	O
occurred	O	O
within	O	O
1	O	O
-	O	O
-	O	O
9	O	O
weeks	O	O
of	O	O
commencement	O	O
of	O	O
therapy	O	O
in	O	O
9	O	O
patients	O	O
,	O	O
the	O	O
remaining	O	O
3	O	O
patients	O	O
having	O	O
received	O	O
the	O	O
drug	O	O
for	O	O
13	O	O
months	O	O
,	O	O
15	O	O
months	O	O
and	O	O
7	O	O
years	O	O
before	O	O
experiencing	O	O
symptoms	O	O
.	O	O

Jaundice	B-Disease	D007565
with	O	O
tender	O	O
hepatomegaly	B-Disease	D006529
,	O	O
usually	O	O
preceded	O	O
by	O	O
symptoms	O	O
of	O	O
malaise	O	O
,	O	O
anorexia	B-Disease	D000855
,	O	O
nausea	B-Disease	D009325
and	O	O
vomiting	B-Disease	D014839
,	O	O
and	O	O
associated	O	O
with	O	O
upper	O	O
abdominal	B-Disease	D015746
pain	I-Disease	D015746
,	O	O
was	O	O
an	O	O
invariable	O	O
finding	O	O
in	O	O
all	O	O
patients	O	O
.	O	O

Biochemical	O	O
liver	O	O
function	O	O
tests	O	O
indicated	O	O
hepatocellular	O	O
necrosis	B-Disease	D009336
and	O	O
correlated	O	O
with	O	O
histopathological	O	O
evidence	O	O
of	O	O
hepatic	B-Disease	D056486
injury	I-Disease	D056486
,	O	O
the	O	O
spectrum	O	O
of	O	O
which	O	O
ranged	O	O
from	O	O
fatty	B-Disease	D005234
change	I-Disease	D005234
and	O	O
focal	O	O
hepatocellular	O	O
necrosis	B-Disease	D009336
to	O	O
massive	B-Disease	D047508
hepatic	I-Disease	D047508
necrosis	I-Disease	D047508
.	O	O

Most	O	O
patients	O	O
showed	O	O
moderate	O	O
to	O	O
severe	O	O
acute	B-Disease	D017114
hepatitis	I-Disease	D017114
or	O	O
chronic	B-Disease	D006521
active	I-Disease	D006521
hepatitis	I-Disease	D006521
with	O	O
associated	O	O
cholestasis	B-Disease	D002779
.	O	O

The	O	O
drug	O	O
was	O	O
withdrawn	O	O
on	O	O
presentation	O	O
to	O	O
hospital	O	O
in	O	O
11	O	O
patients	O	O
,	O	O
with	O	O
rapid	O	O
clinical	O	O
improvement	O	O
in	O	O
9	O	O
.	O	O

One	O	O
patient	O	O
died	O	O
,	O	O
having	O	O
presented	O	O
in	O	O
hepatic	B-Disease	D017093
failure	I-Disease	D017093
,	O	O
and	O	O
another	O	O
,	O	O
who	O	O
had	O	O
been	O	O
taking	O	O
methyldopa	B-Chemical	D008750
for	O	O
7	O	O
years	O	O
,	O	O
showed	O	O
slower	O	O
clinical	O	O
and	O	O
biochemical	O	O
resolution	O	O
over	O	O
a	O	O
period	O	O
of	O	O
several	O	O
months	O	O
.	O	O

The	O	O
remaining	O	O
patient	O	O
in	O	O
the	O	O
series	O	O
developed	O	O
fulminant	B-Disease	D017114
hepatitis	I-Disease	D017114
when	O	O
the	O	O
drug	O	O
was	O	O
accidentally	O	O
recommenced	O	O
1	O	O
year	O	O
after	O	O
a	O	O
prior	O	O
episode	O	O
of	O	O
methyldopa	B-Chemical	D008750
-	O	O
induced	O	O
hepatitis	B-Disease	D056486
.	O	O

In	O	O
this	O	O
latter	O	O
patient	O	O
,	O	O
and	O	O
in	O	O
2	O	O
others	O	O
,	O	O
the	O	O
causal	O	O
relationship	O	O
between	O	O
methyldopa	B-Chemical	D008750
and	O	O
hepatic	B-Disease	D008107
dysfunction	I-Disease	D008107
was	O	O
proved	O	O
with	O	O
the	O	O
recurrence	O	O
of	O	O
hepatitis	B-Disease	D056486
within	O	O
2	O	O
weeks	O	O
of	O	O
re	O	O
-	O	O
exposure	O	O
to	O	O
the	O	O
drug	O	O
.	O	O

A	O	O
phase	O	O
I	O	O
/	O	O
II	O	O
study	O	O
of	O	O
paclitaxel	B-Chemical	D017239
plus	O	O
cisplatin	B-Chemical	D002945
as	O	O
first	O	O
-	O	O
line	O	O
therapy	O	O
for	O	O
head	B-Disease	D006258
and	I-Disease	D006258
neck	I-Disease	D006258
cancers	I-Disease	D006258
:	O	O
preliminary	O	O
results	O	O
.	O	O

Improved	O	O
outcomes	O	O
among	O	O
patients	O	O
with	O	O
head	B-Disease	D006258
and	I-Disease	D006258
neck	I-Disease	D006258
carcinomas	I-Disease	D006258
require	O	O
investigations	O	O
of	O	O
new	O	O
drugs	O	O
for	O	O
induction	O	O
therapy	O	O
.	O	O

Preliminary	O	O
results	O	O
of	O	O
an	O	O
Eastern	O	O
Cooperative	O	O
Oncology	O	O
Group	O	O
study	O	O
of	O	O
single	O	O
-	O	O
agent	O	O
paclitaxel	B-Chemical	D017239
(	O	O
Taxol	B-Chemical	D017239
;	O	O
Bristol	O	O
-	O	O
Myers	O	O
Squibb	O	O
Company	O	O
,	O	O
Princeton	O	O
,	O	O
NJ	O	O
)	O	O
reported	O	O
a	O	O
37%	O	O
response	O	O
rate	O	O
in	O	O
patients	O	O
with	O	O
head	B-Disease	D006258
and	I-Disease	D006258
neck	I-Disease	D006258
cancer	I-Disease	D006258
,	O	O
and	O	O
the	O	O
paclitaxel	B-Chemical	D017239
/	O	O
cisplatin	B-Chemical	D002945
combination	O	O
has	O	O
been	O	O
used	O	O
successfully	O	O
and	O	O
has	O	O
significantly	O	O
improved	O	O
median	O	O
response	O	O
duration	O	O
in	O	O
ovarian	B-Disease	D010051
cancer	I-Disease	D010051
patients	O	O
.	O	O

We	O	O
initiated	O	O
a	O	O
phase	O	O
I	O	O
/	O	O
II	O	O
trial	O	O
to	O	O
determine	O	O
the	O	O
response	O	O
and	O	O
toxicity	B-Disease	D064420
of	O	O
escalating	O	O
paclitaxel	B-Chemical	D017239
doses	O	O
combined	O	O
with	O	O
fixed	O	O
-	O	O
dose	O	O
cisplatin	B-Chemical	D002945
with	O	O
granulocyte	O	O
colony	O	O
-	O	O
stimulating	O	O
factor	O	O
support	O	O
in	O	O
patients	O	O
with	O	O
untreated	O	O
locally	O	O
advanced	O	O
inoperable	O	O
head	B-Disease	D006258
and	I-Disease	D006258
neck	I-Disease	D006258
carcinoma	I-Disease	D006258
.	O	O

To	O	O
date	O	O
,	O	O
23	O	O
men	O	O
with	O	O
a	O	O
median	O	O
age	O	O
of	O	O
50	O	O
years	O	O
and	O	O
good	O	O
performance	O	O
status	O	O
have	O	O
entered	O	O
the	O	O
trial	O	O
.	O	O

Primary	O	O
tumor	B-Disease	D009369
sites	O	O
were	O	O
oropharynx	O	O
,	O	O
10	O	O
patients	O	O
;	O	O
hypopharynx	O	O
,	O	O
four	O	O
;	O	O
larynx	O	O
,	O	O
two	O	O
;	O	O
oral	O	O
cavity	O	O
,	O	O
three	O	O
;	O	O
unknown	O	O
primary	O	O
,	O	O
two	O	O
;	O	O
and	O	O
nasal	O	O
cavity	O	O
and	O	O
parotid	O	O
gland	O	O
,	O	O
one	O	O
each	O	O
.	O	O

Of	O	O
20	O	O
patients	O	O
evaluable	O	O
for	O	O
toxicity	B-Disease	D064420
,	O	O
four	O	O
had	O	O
stage	O	O
III	O	O
and	O	O
16	O	O
had	O	O
stage	O	O
IV	O	O
disease	O	O
.	O	O

Treatment	O	O
,	O	O
given	O	O
every	O	O
21	O	O
days	O	O
for	O	O
a	O	O
maximum	O	O
of	O	O
three	O	O
cycles	O	O
,	O	O
consisted	O	O
of	O	O
paclitaxel	B-Chemical	D017239
by	O	O
3	O	O
-	O	O
hour	O	O
infusion	O	O
followed	O	O
the	O	O
next	O	O
day	O	O
by	O	O
a	O	O
fixed	O	O
dose	O	O
of	O	O
cisplatin	B-Chemical	D002945
(	O	O
75	O	O
mg	O	O
/	O	O
m2	O	O
)	O	O
.	O	O

The	O	O
dose	O	O
levels	O	O
incorporate	O	O
escalating	O	O
paclitaxel	B-Chemical	D017239
doses	O	O
,	O	O
and	O	O
intrapatient	O	O
escalations	O	O
within	O	O
a	O	O
given	O	O
dose	O	O
level	O	O
are	O	O
permitted	O	O
if	O	O
toxicity	B-Disease	D064420
permits	O	O
.	O	O

At	O	O
the	O	O
time	O	O
of	O	O
this	O	O
writing	O	O
,	O	O
dose	O	O
level	O	O
4	O	O
(	O	O
260	O	O
,	O	O
270	O	O
,	O	O
and	O	O
280	O	O
mg	O	O
/	O	O
m2	O	O
)	O	O
is	O	O
being	O	O
evaluated	O	O
;	O	O
three	O	O
patients	O	O
from	O	O
this	O	O
level	O	O
are	O	O
evaluable	O	O
.	O	O

With	O	O
paclitaxel	B-Chemical	D017239
doses	O	O
of	O	O
200	O	O
mg	O	O
/	O	O
m2	O	O
and	O	O
higher	O	O
,	O	O
granulocyte	O	O
colony	O	O
-	O	O
stimulating	O	O
factor	O	O
5	O	O
micrograms	O	O
/	O	O
kg	O	O
/	O	O
d	O	O
is	O	O
given	O	O
(	O	O
days	O	O
4	O	O
through	O	O
12	O	O
)	O	O
.	O	O

Of	O	O
18	O	O
patients	O	O
evaluable	O	O
for	O	O
response	O	O
,	O	O
seven	O	O
(	O	O
39%	O	O
)	O	O
achieved	O	O
a	O	O
complete	O	O
response	O	O
and	O	O
six	O	O
(	O	O
33%	O	O
)	O	O
achieved	O	O
a	O	O
partial	O	O
response	O	O
.	O	O

Three	O	O
patients	O	O
had	O	O
no	O	O
change	O	O
and	O	O
disease	O	O
progressed	O	O
in	O	O
two	O	O
.	O	O

The	O	O
overall	O	O
response	O	O
rate	O	O
is	O	O
72%	O	O
.	O	O

Eleven	O	O
responding	O	O
patients	O	O
had	O	O
subsequent	O	O
surgery	O	O
/	O	O
radiotherapy	O	O
or	O	O
radical	O	O
radiotherapy	O	O
.	O	O

Two	O	O
pathologic	O	O
complete	O	O
responses	O	O
were	O	O
observed	O	O
in	O	O
patients	O	O
who	O	O
had	O	O
achieved	O	O
clinical	O	O
complete	O	O
responses	O	O
.	O	O

Alopecia	B-Disease	D000505
,	O	O
paresthesias	B-Disease	D010292
,	O	O
and	O	O
arthralgias	B-Disease	D018771
/	O	O
myalgias	B-Disease	D063806
have	O	O
occurred	O	O
frequently	O	O
,	O	O
but	O	O
with	O	O
one	O	O
exception	O	O
(	O	O
a	O	O
grade	O	O
3	O	O
myalgia	B-Disease	D063806
)	O	O
they	O	O
have	O	O
been	O	O
grade	O	O
1	O	O
or	O	O
2	O	O
.	O	O

No	O	O
dose	O	O
-	O	O
limiting	O	O
hematologic	O	O
toxicity	B-Disease	D064420
has	O	O
been	O	O
seen	O	O
.	O	O

Paclitaxel	B-Chemical	D017239
/	O	O
cisplatin	B-Chemical	D002945
is	O	O
an	O	O
effective	O	O
first	O	O
-	O	O
line	O	O
regimen	O	O
for	O	O
locoregionally	O	O
advanced	O	O
head	B-Disease	D006258
and	I-Disease	D006258
neck	I-Disease	D006258
cancer	I-Disease	D006258
and	O	O
continued	O	O
study	O	O
is	O	O
warranted	O	O
.	O	O

Results	O	O
thus	O	O
far	O	O
suggest	O	O
no	O	O
dose	O	O
-	O	O
response	O	O
effect	O	O
for	O	O
paclitaxel	B-Chemical	D017239
doses	O	O
above	O	O
200	O	O
mg	O	O
/	O	O
m2	O	O
.	O	O

A	O	O
phase	O	O
I	O	O
study	O	O
of	O	O
4'	B-Chemical	C027260
-	I-Chemical	C027260
0	I-Chemical	C027260
-	I-Chemical	C027260
tetrahydropyranyladriamycin	I-Chemical	C027260
.	O	O

Clinical	O	O
pharmacology	O	O
and	O	O
pharmacokinetics	O	O
.	O	O

A	O	O
Phase	O	O
I	O	O
study	O	O
of	O	O
intravenous	O	O
(	O	O
IV	O	O
)	O	O
bolus	O	O
4'	B-Chemical	C027260
-	I-Chemical	C027260
0	I-Chemical	C027260
-	I-Chemical	C027260
tetrahydropyranyladriamycin	I-Chemical	C027260
(	O	O
Pirarubicin	B-Chemical	C027260
)	O	O
was	O	O
done	O	O
in	O	O
55	O	O
patients	O	O
in	O	O
good	O	O
performance	O	O
status	O	O
with	O	O
refractory	O	O
tumors	B-Disease	D009369
.	O	O

Twenty	O	O
-	O	O
six	O	O
had	O	O
minimal	O	O
prior	O	O
therapy	O	O
(	O	O
good	O	O
risk	O	O
)	O	O
,	O	O
23	O	O
had	O	O
extensive	O	O
prior	O	O
therapy	O	O
(	O	O
poor	O	O
risk	O	O
)	O	O
,	O	O
and	O	O
six	O	O
had	O	O
renal	O	O
and	O	O
/	O	O
or	O	O
hepatic	B-Disease	D008107
dysfunction	I-Disease	D008107
.	O	O

A	O	O
total	O	O
of	O	O
167	O	O
courses	O	O
at	O	O
doses	O	O
of	O	O
15	O	O
to	O	O
70	O	O
mg	O	O
/	O	O
m2	O	O
were	O	O
evaluable	O	O
.	O	O

Maximum	O	O
tolerated	O	O
dose	O	O
in	O	O
good	O	O
-	O	O
risk	O	O
patients	O	O
was	O	O
70	O	O
mg	O	O
/	O	O
m2	O	O
,	O	O
and	O	O
in	O	O
poor	O	O
-	O	O
risk	O	O
patients	O	O
,	O	O
60	O	O
mg	O	O
/	O	O
m2	O	O
.	O	O

The	O	O
dose	O	O
-	O	O
limiting	O	O
toxic	O	O
effect	O	O
was	O	O
transient	O	O
noncumulative	O	O
granulocytopenia	B-Disease	D000380
.	O	O

Granulocyte	O	O
nadir	O	O
was	O	O
on	O	O
day	O	O
14	O	O
(	O	O
range	O	O
,	O	O
4	O	O
-	O	O
22	O	O
)	O	O
.	O	O

Less	O	O
frequent	O	O
toxic	O	O
effects	O	O
included	O	O
thrombocytopenia	B-Disease	D013921
,	O	O
anemia	B-Disease	D000740
,	O	O
nausea	B-Disease	D009325
,	O	O
mild	O	O
alopecia	B-Disease	D000505
,	O	O
phlebitis	B-Disease	D010689
,	O	O
and	O	O
mucositis	B-Disease	D052016
.	O	O

Myelosuppression	B-Disease	D001855
was	O	O
more	O	O
in	O	O
patients	O	O
with	O	O
hepatic	B-Disease	D008107
dysfunction	I-Disease	D008107
.	O	O

Pharmacokinetic	O	O
analyses	O	O
in	O	O
21	O	O
patients	O	O
revealed	O	O
Pirarubicin	B-Chemical	C027260
plasma	O	O
T	O	O
1	O	O
/	O	O
2	O	O
alpha	O	O
(	O	O
+	O	O
/	O	O
-	O	O
SE	O	O
)	O	O
of	O	O
2	O	O
.	O	O

5	O	O
+	O	O
/	O	O
-	O	O
0	O	O
.	O	O

85	O	O
minutes	O	O
,	O	O
T	O	O
beta	O	O
1	O	O
/	O	O
2	O	O
of	O	O
25	O	O
.	O	O

6	O	O
+	O	O
/	O	O
-	O	O
6	O	O
.	O	O

5	O	O
minutes	O	O
,	O	O
and	O	O
T	O	O
1	O	O
/	O	O
2	O	O
gamma	O	O
of	O	O
23	O	O
.	O	O

6	O	O
+	O	O
/	O	O
-	O	O
7	O	O
.	O	O

6	O	O
hours	O	O
.	O	O

The	O	O
area	O	O
under	O	O
the	O	O
curve	O	O
was	O	O
537	O	O
+	O	O
/	O	O
-	O	O
149	O	O
ng	O	O
/	O	O
ml	O	O
x	O	O
hours	O	O
,	O	O
volume	O	O
of	O	O
distribution	O	O
(	O	O
Vd	O	O
)	O	O
3504	O	O
+	O	O
/	O	O
-	O	O
644	O	O
l	O	O
/	O	O
m2	O	O
,	O	O
and	O	O
total	O	O
clearance	O	O
(	O	O
ClT	O	O
)	O	O
was	O	O
204	O	O
+	O	O
39	O	O
.	O	O

3	O	O
l	O	O
/	O	O
hour	O	O
/	O	O
m2	O	O
.	O	O

Adriamycinol	B-Chemical	C010013
,	O	O
doxorubicin	B-Chemical	D004317
,	O	O
adriamycinone	B-Chemical	C010012
,	O	O
and	O	O
tetrahydropyranyladriamycinol	B-Chemical	C027260
were	O	O
the	O	O
metabolites	O	O
detected	O	O
in	O	O
plasma	O	O
and	O	O
the	O	O
amount	O	O
of	O	O
doxorubicin	B-Chemical	D004317
was	O	O
less	O	O
than	O	O
or	O	O
equal	O	O
to	O	O
10%	O	O
of	O	O
the	O	O
total	O	O
metabolites	O	O
.	O	O

Urinary	O	O
excretion	O	O
of	O	O
Pirarubicin	B-Chemical	C027260
in	O	O
the	O	O
first	O	O
24	O	O
hours	O	O
was	O	O
less	O	O
than	O	O
or	O	O
equal	O	O
to	O	O
10%	O	O
.	O	O

Activity	O	O
was	O	O
noted	O	O
in	O	O
mesothelioma	B-Disease	D008654
,	O	O
leiomyosarcoma	B-Disease	D007890
,	O	O
and	O	O
basal	B-Disease	D002280
cell	I-Disease	D002280
carcinoma	I-Disease	D002280
.	O	O

The	O	O
recommended	O	O
starting	O	O
dose	O	O
for	O	O
Phase	O	O
II	O	O
trials	O	O
is	O	O
60	O	O
mg	O	O
/	O	O
m2	O	O
IV	O	O
bolus	O	O
every	O	O
3	O	O
weeks	O	O
.	O	O

Differential	O	O
effects	O	O
of	O	O
gamma	B-Chemical	D001556
-	I-Chemical	D001556
hexachlorocyclohexane	I-Chemical	D001556
(	O	O
lindane	B-Chemical	D001556
)	O	O
on	O	O
pharmacologically	O	O
-	O	O
induced	O	O
seizures	B-Disease	D012640
.	O	O

Gamma	B-Chemical	D001556
-	I-Chemical	D001556
hexachlorocyclohexane	I-Chemical	D001556
(	O	O
gamma	B-Chemical	D001556
-	I-Chemical	D001556
HCH	I-Chemical	D001556
)	O	O
,	O	O
the	O	O
active	O	O
ingredient	O	O
of	O	O
the	O	O
insecticide	O	O
lindane	B-Chemical	D001556
,	O	O
has	O	O
been	O	O
shown	O	O
to	O	O
decrease	O	O
seizure	B-Disease	D012640
threshold	O	O
to	O	O
pentylenetrazol	O	O
(	O	O
PTZ	B-Chemical	D010433
)	O	O
3	O	O
h	O	O
after	O	O
exposure	O	O
to	O	O
gamma	B-Chemical	D001556
-	I-Chemical	D001556
HCH	I-Chemical	D001556
and	O	O
conversely	O	O
increase	O	O
threshold	O	O
to	O	O
PTZ	B-Chemical	D010433
-	O	O
induced	O	O
seizures	B-Disease	D012640
24	O	O
h	O	O
after	O	O
exposure	O	O
to	O	O
gamma	B-Chemical	D001556
-	I-Chemical	D001556
HCH	I-Chemical	D001556
(	O	O
Vohland	O	O
et	O	O
al	O	O
.	O	O

1981	O	O
)	O	O
.	O	O

In	O	O
this	O	O
study	O	O
,	O	O
the	O	O
severity	O	O
of	O	O
response	O	O
to	O	O
other	O	O
seizure	B-Disease	D012640
-	O	O
inducing	O	O
agents	O	O
was	O	O
tested	O	O
in	O	O
mice	O	O
1	O	O
and	O	O
24	O	O
h	O	O
after	O	O
intraperitoneal	O	O
administration	O	O
of	O	O
80	O	O
mg	O	O
/	O	O
kg	O	O
gamma	B-Chemical	D001556
-	I-Chemical	D001556
HCH	I-Chemical	D001556
.	O	O

One	O	O
hour	O	O
after	O	O
the	O	O
administration	O	O
of	O	O
gamma	B-Chemical	D001556
-	I-Chemical	D001556
HCH	I-Chemical	D001556
,	O	O
the	O	O
activity	O	O
of	O	O
seizure	B-Disease	D012640
-	O	O
inducing	O	O
agents	O	O
was	O	O
increased	O	O
,	O	O
regardless	O	O
of	O	O
their	O	O
mechanism	O	O
,	O	O
while	O	O
24	O	O
h	O	O
after	O	O
gamma	B-Chemical	D001556
-	I-Chemical	D001556
HCH	I-Chemical	D001556
a	O	O
differential	O	O
response	O	O
was	O	O
observed	O	O
.	O	O

Seizure	B-Disease	D012640
activity	O	O
due	O	O
to	O	O
PTZ	B-Chemical	D010433
and	O	O
picrotoxin	B-Chemical	D010852
(	O	O
PTX	B-Chemical	D010852
)	O	O
was	O	O
significantly	O	O
decreased	O	O
;	O	O
however	O	O
,	O	O
seizure	B-Disease	D012640
activity	O	O
due	O	O
to	O	O
3	B-Chemical	D015097
-	I-Chemical	D015097
mercaptopropionic	I-Chemical	D015097
acid	I-Chemical	D015097
(	O	O
MPA	B-Chemical	D015097
)	O	O
,	O	O
bicuculline	B-Chemical	D001640
(	O	O
BCC	B-Chemical	D001640
)	O	O
,	O	O
methyl	B-Chemical	C034818
6	I-Chemical	C034818
,	I-Chemical	C034818
7	I-Chemical	C034818
-	I-Chemical	C034818
dimethoxy	I-Chemical	C034818
-	I-Chemical	C034818
4	I-Chemical	C034818
-	I-Chemical	C034818
ethyl	I-Chemical	C034818
-	I-Chemical	C034818
B	I-Chemical	C034818
-	I-Chemical	C034818
carboline	I-Chemical	C034818
-	I-Chemical	C034818
3	I-Chemical	C034818
-	I-Chemical	C034818
carboxylate	I-Chemical	C034818
(	O	O
DMCM	B-Chemical	C034818
)	O	O
,	O	O
or	O	O
strychnine	B-Chemical	D013331
(	O	O
STR	B-Chemical	D013331
)	O	O
was	O	O
not	O	O
different	O	O
from	O	O
control	O	O
.	O	O

In	O	O
vitro	O	O
,	O	O
gamma	B-Chemical	D001556
-	I-Chemical	D001556
HCH	I-Chemical	D001556
,	O	O
pentylenetetrazol	B-Chemical	D010433
and	O	O
picrotoxin	B-Chemical	D010852
were	O	O
shown	O	O
to	O	O
inhibit	O	O
3H	B-Chemical	C046308
-	I-Chemical	C046308
TBOB	I-Chemical	C046308
binding	O	O
in	O	O
mouse	O	O
whole	O	O
brain	O	O
,	O	O
with	O	O
IC50	O	O
values	O	O
of	O	O
4	O	O
.	O	O

6	O	O
,	O	O
404	O	O
and	O	O
9	O	O
.	O	O

4	O	O
microM	O	O
,	O	O
respectively	O	O
.	O	O

MPA	B-Chemical	D015097
,	O	O
BCC	B-Chemical	D001640
,	O	O
DMCM	B-Chemical	C034818
,	O	O
and	O	O
STR	B-Chemical	D013331
showed	O	O
no	O	O
inhibition	O	O
of	O	O
3H	B-Chemical	C046308
-	I-Chemical	C046308
TBOB	I-Chemical	C046308
(	O	O
t	B-Chemical	C046308
-	I-Chemical	C046308
butyl	I-Chemical	C046308
bicyclo	I-Chemical	C046308
-	I-Chemical	C046308
orthobenzoate	I-Chemical	C046308
)	O	O
binding	O	O
at	O	O
concentrations	O	O
of	O	O
100	O	O
micron	O	O
.	O	O

The	O	O
pharmacological	O	O
challenge	O	O
data	O	O
suggest	O	O
that	O	O
tolerance	O	O
may	O	O
occur	O	O
to	O	O
seizure	B-Disease	D012640
activity	O	O
induced	O	O
by	O	O
PTZ	B-Chemical	D010433
and	O	O
PTX	B-Chemical	D010852
24	O	O
h	O	O
after	O	O
gamma	B-Chemical	D001556
-	I-Chemical	D001556
HCH	I-Chemical	D001556
,	O	O
since	O	O
the	O	O
response	O	O
to	O	O
only	O	O
these	O	O
two	O	O
seizure	B-Disease	D012640
-	O	O
inducing	O	O
agents	O	O
is	O	O
decreased	O	O
.	O	O

The	O	O
in	O	O
vitro	O	O
data	O	O
suggest	O	O
that	O	O
the	O	O
site	O	O
responsible	O	O
for	O	O
the	O	O
decrease	O	O
in	O	O
seizure	B-Disease	D012640
activity	O	O
24	O	O
h	O	O
after	O	O
gamma	B-Chemical	D001556
-	I-Chemical	D001556
HCH	I-Chemical	D001556
may	O	O
be	O	O
the	O	O
GABA	B-Chemical	D005680
-	O	O
A	O	O
receptor	O	O
-	O	O
linked	O	O
chloride	O	O
channel	O	O
.	O	O

Severe	O	O
ocular	O	O
and	O	O
orbital	O	O
toxicity	B-Disease	D064420
after	O	O
intracarotid	O	O
injection	O	O
of	O	O
carboplatin	B-Chemical	D016190
for	O	O
recurrent	O	O
glioblastomas	B-Disease	D005909
.	O	O

BACKGROUND	O	O
:	O	O
Glioblastoma	B-Disease	D005909
is	O	O
a	O	O
malignant	B-Disease	D009369
tumor	I-Disease	D009369
that	O	O
occurs	O	O
in	O	O
the	O	O
cerebrum	O	O
during	O	O
adulthood	O	O
.	O	O

With	O	O
current	O	O
treatment	O	O
regimens	O	O
including	O	O
combined	O	O
surgery	O	O
,	O	O
radiation	O	O
and	O	O
chemotherapy	O	O
,	O	O
the	O	O
average	O	O
life	O	O
expectancy	O	O
of	O	O
the	O	O
patients	O	O
is	O	O
limited	O	O
to	O	O
approximately	O	O
1	O	O
year	O	O
.	O	O

Therefore	O	O
,	O	O
patients	O	O
with	O	O
glioblastoma	B-Disease	D005909
sometimes	O	O
have	O	O
intracarotid	O	O
injection	O	O
of	O	O
carcinostatics	O	O
added	O	O
to	O	O
the	O	O
treatment	O	O
regimen	O	O
.	O	O

Generally	O	O
,	O	O
carboplatin	B-Chemical	D016190
is	O	O
said	O	O
to	O	O
have	O	O
milder	O	O
side	O	O
effects	O	O
than	O	O
cisplatin	B-Chemical	D002945
,	O	O
whose	O	O
ocular	O	O
and	O	O
orbital	O	O
toxicity	B-Disease	D064420
are	O	O
well	O	O
known	O	O
.	O	O

However	O	O
,	O	O
we	O	O
experienced	O	O
a	O	O
case	O	O
of	O	O
severe	O	O
ocular	O	O
and	O	O
orbital	O	O
toxicity	B-Disease	D064420
after	O	O
intracarotid	O	O
injection	O	O
of	O	O
carboplatin	B-Chemical	D016190
,	O	O
which	O	O
is	O	O
infrequently	O	O
reported	O	O
.	O	O

CASE	O	O
:	O	O
A	O	O
58	O	O
-	O	O
year	O	O
-	O	O
old	O	O
man	O	O
received	O	O
an	O	O
intracarotid	O	O
injection	O	O
of	O	O
carboplatin	B-Chemical	D016190
for	O	O
recurrent	O	O
glioblastomas	B-Disease	D005909
in	O	O
his	O	O
left	O	O
temporal	O	O
lobe	O	O
.	O	O

He	O	O
complained	O	O
of	O	O
pain	O	O
and	O	O
visual	O	O
disturbance	O	O
in	O	O
the	O	O
ipsilateral	O	O
eye	O	O
30	O	O
h	O	O
after	O	O
the	O	O
injection	O	O
.	O	O

Various	O	O
ocular	O	O
symptoms	O	O
and	O	O
findings	O	O
caused	O	O
by	O	O
carboplatin	B-Chemical	D016190
toxicity	B-Disease	D064420
were	O	O
seen	O	O
.	O	O

RESULTS	O	O
:	O	O
He	O	O
was	O	O
treated	O	O
with	O	O
intravenous	O	O
administration	O	O
of	O	O
corticosteroids	O	O
and	O	O
glycerin	B-Chemical	D005990
for	O	O
6	O	O
days	O	O
after	O	O
the	O	O
injection	O	O
.	O	O

Although	O	O
the	O	O
intraocular	O	O
pressure	O	O
elevation	O	O
caused	O	O
by	O	O
secondary	O	O
acute	O	O
angle	O	O
-	O	O
closure	O	O
glaucoma	B-Disease	D005901
decreased	O	O
and	O	O
ocular	B-Disease	D058447
pain	I-Disease	D058447
diminished	O	O
,	O	O
inexorable	O	O
papilledema	B-Disease	D010211
and	O	O
exudative	O	O
retinal	B-Disease	D012163
detachment	I-Disease	D012163
continued	O	O
for	O	O
3	O	O
weeks	O	O
.	O	O

Finally	O	O
,	O	O
6	O	O
weeks	O	O
later	O	O
,	O	O
diffuse	O	O
chorioretinal	B-Disease	C566236
atrophy	I-Disease	C566236
with	O	O
optic	B-Disease	D009896
atrophy	I-Disease	D009896
occurred	O	O
and	O	O
the	O	O
vision	O	O
in	O	O
his	O	O
left	O	O
eye	O	O
was	O	O
lost	O	O
.	O	O

CONCLUSION	O	O
:	O	O
When	O	O
performing	O	O
intracarotid	O	O
injection	O	O
of	O	O
carboplatin	B-Chemical	D016190
,	O	O
we	O	O
must	O	O
be	O	O
aware	O	O
of	O	O
its	O	O
potentially	O	O
blinding	O	O
ocular	B-Disease	D005128
toxicity	I-Disease	D005128
.	O	O

It	O	O
is	O	O
recommended	O	O
that	O	O
further	O	O
studies	O	O
and	O	O
investigations	O	O
are	O	O
undertaken	O	O
in	O	O
the	O	O
effort	O	O
to	O	O
minimize	O	O
such	O	O
severe	O	O
side	O	O
effects	O	O
.	O	O

Phase	O	O
II	O	O
study	O	O
of	O	O
the	O	O
amsacrine	B-Chemical	D000677
analogue	O	O
CI	B-Chemical	C042315
-	I-Chemical	C042315
921	I-Chemical	C042315
(	O	O
NSC	B-Chemical	C042315
343499	I-Chemical	C042315
)	O	O
in	O	O
non	B-Disease	D002289
-	I-Disease	D002289
small	I-Disease	D002289
cell	I-Disease	D002289
lung	I-Disease	D002289
cancer	I-Disease	D002289
.	O	O

CI	B-Chemical	C042315
-	I-Chemical	C042315
921	I-Chemical	C042315
(	O	O
NSC	B-Chemical	C042315
343499	I-Chemical	C042315
;	O	O
9	B-Chemical	C042315
-	I-Chemical	C042315
[	I-Chemical	C042315
[	I-Chemical	C042315
2	I-Chemical	C042315
-	I-Chemical	C042315
methoxy	I-Chemical	C042315
-	I-Chemical	C042315
4	I-Chemical	C042315
-	I-Chemical	C042315
[	I-Chemical	C042315
(	I-Chemical	C042315
methylsulphonyl	I-Chemical	C042315
)	I-Chemical	C042315
amino	I-Chemical	C042315
]	I-Chemical	C042315
phenyl	I-Chemical	C042315
]	I-Chemical	C042315
amino	I-Chemical	C042315
]	I-Chemical	C042315
-	I-Chemical	C042315
N	I-Chemical	C042315
,	I-Chemical	C042315
5	I-Chemical	C042315
-	I-Chemical	C042315
dimethyl	I-Chemical	C042315
-	I-Chemical	C042315
4	I-Chemical	C042315
-	I-Chemical	C042315
acridinecarboxamide	I-Chemical	C042315
)	O	O
is	O	O
a	O	O
topoisomerase	O	O
II	O	O
poison	O	O
with	O	O
high	O	O
experimental	O	O
antitumour	O	O
activity	O	O
.	O	O

It	O	O
was	O	O
administered	O	O
by	O	O
15	O	O
min	O	O
infusion	O	O
to	O	O
16	O	O
evaluable	O	O
patients	O	O
with	O	O
non	B-Disease	D002289
-	I-Disease	D002289
small	I-Disease	D002289
cell	I-Disease	D002289
lung	I-Disease	D002289
cancer	I-Disease	D002289
(	O	O
NSCLC	B-Disease	D002289
)	O	O
(	O	O
7	O	O
with	O	O
no	O	O
prior	O	O
treatment	O	O
,	O	O
9	O	O
patients	O	O
in	O	O
relapse	O	O
following	O	O
surgery	O	O
/	O	O
radiotherapy	O	O
)	O	O
at	O	O
a	O	O
dose	O	O
(	O	O
648	O	O
mg	O	O
/	O	O
m2	O	O
divided	O	O
over	O	O
3	O	O
days	O	O
,	O	O
repeated	O	O
every	O	O
3	O	O
weeks	O	O
)	O	O
determined	O	O
by	O	O
phase	O	O
I	O	O
trial	O	O
.	O	O

Patients	O	O
had	O	O
a	O	O
median	O	O
performance	O	O
status	O	O
of	O	O
1	O	O
(	O	O
WHO	O	O
)	O	O
,	O	O
and	O	O
median	O	O
age	O	O
of	O	O
61	O	O
years	O	O
.	O	O

The	O	O
histology	O	O
comprised	O	O
squamous	B-Disease	D002294
carcinoma	I-Disease	D002294
(	O	O
11	O	O
)	O	O
,	O	O
adenocarcinoma	B-Disease	D000230
(	O	O
1	O	O
)	O	O
,	O	O
mixed	O	O
histology	O	O
(	O	O
2	O	O
)	O	O
,	O	O
bronchio	B-Disease	D002282
-	I-Disease	D002282
alveolar	I-Disease	D002282
carcinoma	I-Disease	D002282
(	O	O
1	O	O
)	O	O
and	O	O
large	O	O
cell	O	O
undifferentiated	B-Disease	D002277
carcinoma	I-Disease	D002277
(	O	O
1	O	O
)	O	O
.	O	O

Neutropenia	B-Disease	D009503
grade	O	O
greater	O	O
than	O	O
or	O	O
equal	O	O
to	O	O
3	O	O
was	O	O
seen	O	O
in	O	O
15	O	O
patients	O	O
,	O	O
infections	B-Disease	D007239
with	O	O
recovery	O	O
in	O	O
3	O	O
,	O	O
and	O	O
grand	O	O
mal	O	O
seizures	B-Disease	D012640
in	O	O
1	O	O
patient	O	O
.	O	O

Grade	O	O
less	O	O
than	O	O
or	O	O
equal	O	O
to	O	O
2	O	O
nausea	B-Disease	D009325
and	O	O
vomiting	B-Disease	D014839
occurred	O	O
in	O	O
66%	O	O
courses	O	O
and	O	O
phlebitis	B-Disease	D010689
in	O	O
the	O	O
infusion	O	O
arm	O	O
in	O	O
37%	O	O
.	O	O

1	O	O
patient	O	O
with	O	O
squamous	B-Disease	D002294
cell	I-Disease	D002294
carcinoma	I-Disease	D002294
achieved	O	O
a	O	O
partial	O	O
response	O	O
lasting	O	O
5	O	O
months	O	O
.	O	O

Further	O	O
testing	O	O
in	O	O
this	O	O
and	O	O
other	O	O
tumour	B-Disease	D009369
types	O	O
using	O	O
multiple	O	O
daily	O	O
schedules	O	O
is	O	O
warranted	O	O
.	O	O

Alpha	B-Chemical	D008063
-	I-Chemical	D008063
lipoic	I-Chemical	D008063
acid	I-Chemical	D008063
prevents	O	O
mitochondrial	B-Disease	D028361
damage	I-Disease	D028361
and	O	O
neurotoxicity	B-Disease	D020258
in	O	O
experimental	O	O
chemotherapy	O	O
neuropathy	B-Disease	D009422
.	O	O

The	O	O
study	O	O
investigates	O	O
if	O	O
alpha	B-Chemical	D008063
-	I-Chemical	D008063
lipoic	I-Chemical	D008063
acid	I-Chemical	D008063
is	O	O
neuroprotective	O	O
against	O	O
chemotherapy	O	O
induced	O	O
neurotoxicity	B-Disease	D020258
,	O	O
if	O	O
mitochondrial	B-Disease	D028361
damage	I-Disease	D028361
plays	O	O
a	O	O
critical	O	O
role	O	O
in	O	O
toxic	B-Disease	D009410
neurodegenerative	I-Disease	D009410
cascade	I-Disease	D009410
,	O	O
and	O	O
if	O	O
neuroprotective	O	O
effects	O	O
of	O	O
alpha	B-Chemical	D008063
-	I-Chemical	D008063
lipoic	I-Chemical	D008063
acid	I-Chemical	D008063
depend	O	O
on	O	O
mitochondria	O	O
protection	O	O
.	O	O

We	O	O
used	O	O
an	O	O
in	O	O
vitro	O	O
model	O	O
of	O	O
chemotherapy	O	O
induced	O	O
peripheral	B-Disease	D010523
neuropathy	I-Disease	D010523
that	O	O
closely	O	O
mimic	O	O
the	O	O
in	O	O
vivo	O	O
condition	O	O
by	O	O
exposing	O	O
primary	O	O
cultures	O	O
of	O	O
dorsal	O	O
root	O	O
ganglion	O	O
(	O	O
DRG	O	O
)	O	O
sensory	O	O
neurons	O	O
to	O	O
paclitaxel	B-Chemical	D017239
and	O	O
cisplatin	B-Chemical	D002945
,	O	O
two	O	O
widely	O	O
used	O	O
and	O	O
highly	O	O
effective	O	O
chemotherapeutic	O	O
drugs	O	O
.	O	O

This	O	O
approach	O	O
allowed	O	O
investigating	O	O
the	O	O
efficacy	O	O
of	O	O
alpha	B-Chemical	D008063
-	I-Chemical	D008063
lipoic	I-Chemical	D008063
acid	I-Chemical	D008063
in	O	O
preventing	O	O
axonal	B-Disease	D001480
damage	I-Disease	D001480
and	O	O
apoptosis	O	O
and	O	O
the	O	O
function	O	O
and	O	O
ultrastructural	O	O
morphology	O	O
of	O	O
mitochondria	O	O
after	O	O
exposure	O	O
to	O	O
toxic	O	O
agents	O	O
and	O	O
alpha	B-Chemical	D008063
-	I-Chemical	D008063
lipoic	I-Chemical	D008063
acid	I-Chemical	D008063
.	O	O

Our	O	O
results	O	O
demonstrate	O	O
that	O	O
both	O	O
cisplatin	B-Chemical	D002945
and	O	O
paclitaxel	B-Chemical	D017239
cause	O	O
early	O	O
mitochondrial	B-Disease	D028361
impairment	I-Disease	D028361
with	O	O
loss	O	O
of	O	O
membrane	O	O
potential	O	O
and	O	O
induction	O	O
of	O	O
autophagic	O	O
vacuoles	O	O
in	O	O
neurons	O	O
.	O	O

Alpha	B-Chemical	D008063
-	I-Chemical	D008063
lipoic	I-Chemical	D008063
acid	I-Chemical	D008063
exerts	O	O
neuroprotective	O	O
effects	O	O
against	O	O
chemotherapy	O	O
induced	O	O
neurotoxicity	B-Disease	D020258
in	O	O
sensory	O	O
neurons	O	O
:	O	O
it	O	O
rescues	O	O
the	O	O
mitochondrial	B-Disease	D028361
toxicity	I-Disease	D028361
and	O	O
induces	O	O
the	O	O
expression	O	O
of	O	O
frataxin	O	O
,	O	O
an	O	O
essential	O	O
mitochondrial	O	O
protein	O	O
with	O	O
anti	O	O
-	O	O
oxidant	O	O
and	O	O
chaperone	O	O
properties	O	O
.	O	O

In	O	O
conclusion	O	O
mitochondrial	B-Disease	D028361
toxicity	I-Disease	D028361
is	O	O
an	O	O
early	O	O
common	O	O
event	O	O
both	O	O
in	O	O
paclitaxel	B-Chemical	D017239
and	O	O
cisplatin	B-Chemical	D002945
induced	O	O
neurotoxicity	B-Disease	D020258
.	O	O

Alpha	B-Chemical	D008063
-	I-Chemical	D008063
lipoic	I-Chemical	D008063
acid	I-Chemical	D008063
protects	O	O
sensory	O	O
neurons	O	O
through	O	O
its	O	O
anti	O	O
-	O	O
oxidant	O	O
and	O	O
mitochondrial	O	O
regulatory	O	O
functions	O	O
,	O	O
possibly	O	O
inducing	O	O
the	O	O
expression	O	O
of	O	O
frataxin	O	O
.	O	O

These	O	O
findings	O	O
suggest	O	O
that	O	O
alpha	B-Chemical	D008063
-	I-Chemical	D008063
lipoic	I-Chemical	D008063
acid	I-Chemical	D008063
might	O	O
reduce	O	O
the	O	O
risk	O	O
of	O	O
developing	O	O
peripheral	B-Disease	D010523
nerve	I-Disease	D010523
toxicity	I-Disease	D010523
in	O	O
patients	O	O
undergoing	O	O
chemotherapy	O	O
and	O	O
encourage	O	O
further	O	O
confirmatory	O	O
clinical	O	O
trials	O	O
.	O	O

Optimising	O	O
stroke	B-Disease	D020521
prevention	O	O
in	O	O
non	O	O
-	O	O
valvular	O	O
atrial	B-Disease	D001281
fibrillation	I-Disease	D001281
.	O	O

Atrial	B-Disease	D001281
fibrillation	I-Disease	D001281
is	O	O
associated	O	O
with	O	O
substantial	O	O
morbidity	O	O
and	O	O
mortality	O	O
.	O	O

Pooled	O	O
data	O	O
from	O	O
trials	O	O
comparing	O	O
antithrombotic	O	O
treatment	O	O
with	O	O
placebo	O	O
have	O	O
shown	O	O
that	O	O
warfarin	B-Chemical	D014859
reduces	O	O
the	O	O
risk	O	O
of	O	O
stroke	B-Disease	D020521
by	O	O
62%	O	O
,	O	O
and	O	O
that	O	O
aspirin	B-Chemical	D001241
alone	O	O
reduces	O	O
the	O	O
risk	O	O
by	O	O
22%	O	O
.	O	O

Overall	O	O
,	O	O
in	O	O
high	O	O
-	O	O
risk	O	O
patients	O	O
,	O	O
warfarin	B-Chemical	D014859
is	O	O
superior	O	O
to	O	O
aspirin	B-Chemical	D001241
in	O	O
preventing	O	O
strokes	B-Disease	D020521
,	O	O
with	O	O
a	O	O
relative	O	O
risk	O	O
reduction	O	O
of	O	O
36%	O	O
.	O	O

Ximelagatran	B-Chemical	C426686
,	O	O
an	O	O
oral	O	O
direct	O	O
thrombin	O	O
inhibitor	O	O
,	O	O
was	O	O
found	O	O
to	O	O
be	O	O
as	O	O
efficient	O	O
as	O	O
vitamin	B-Chemical	D014812
K	I-Chemical	D014812
antagonist	O	O
drugs	O	O
in	O	O
the	O	O
prevention	O	O
of	O	O
embolic	B-Disease	D004617
events	I-Disease	D004617
,	O	O
but	O	O
has	O	O
been	O	O
recently	O	O
withdrawn	O	O
because	O	O
of	O	O
abnormal	B-Disease	D056486
liver	I-Disease	D056486
function	I-Disease	D056486
tests	O	O
.	O	O

The	O	O
ACTIVE	O	O
-	O	O
W	O	O
(	O	O
Atrial	B-Disease	D001281
Fibrillation	I-Disease	D001281
Clopidogrel	B-Chemical	C055162
Trial	O	O
with	O	O
Irbesartan	B-Chemical	C081309
for	O	O
Prevention	O	O
of	O	O
Vascular	O	O
Events	O	O
)	O	O
study	O	O
has	O	O
demonstrated	O	O
that	O	O
warfarin	B-Chemical	D014859
is	O	O
superior	O	O
to	O	O
platelet	O	O
therapy	O	O
(	O	O
clopidogrel	B-Chemical	C055162
plus	O	O
aspirin	B-Chemical	D001241
)	O	O
in	O	O
the	O	O
prevention	O	O
af	O	O
embolic	B-Disease	D004617
events	I-Disease	D004617
.	O	O

Idraparinux	B-Chemical	C479958
,	O	O
a	O	O
Factor	O	O
Xa	O	O
inhibitor	O	O
,	O	O
is	O	O
being	O	O
evaluated	O	O
in	O	O
patients	O	O
with	O	O
atrial	B-Disease	D001281
fibrillation	I-Disease	D001281
.	O	O

Angiotensin	B-Chemical	D000809
-	O	O
converting	O	O
enzyme	O	O
inhibitors	O	O
and	O	O
angiotensin	B-Chemical	D000804
II	I-Chemical	D000804
receptor	O	O
-	O	O
blocking	O	O
drugs	O	O
hold	O	O
promise	O	O
in	O	O
atrial	B-Disease	D001281
fibrillation	I-Disease	D001281
through	O	O
cardiac	B-Disease	D020257
remodelling	I-Disease	D020257
.	O	O

Preliminary	O	O
studies	O	O
suggest	O	O
that	O	O
statins	B-Chemical	D019821
could	O	O
interfere	O	O
with	O	O
the	O	O
risk	O	O
of	O	O
recurrence	O	O
after	O	O
electrical	O	O
cardioversion	O	O
.	O	O

Finally	O	O
,	O	O
percutaneous	O	O
methods	O	O
for	O	O
the	O	O
exclusion	O	O
of	O	O
left	O	O
atrial	O	O
appendage	O	O
are	O	O
under	O	O
investigation	O	O
in	O	O
high	O	O
-	O	O
risk	O	O
patients	O	O
.	O	O

Interaction	O	O
of	O	O
cyclosporin	B-Chemical	D016572
A	I-Chemical	D016572
with	O	O
antineoplastic	O	O
agents	O	O
.	O	O

A	O	O
synergistic	O	O
effect	O	O
of	O	O
etoposide	B-Chemical	D005047
and	O	O
cyclosporin	B-Chemical	D016572
A	I-Chemical	D016572
was	O	O
observed	O	O
in	O	O
a	O	O
patient	O	O
with	O	O
acute	B-Disease	D054218
T	I-Disease	D054218
-	I-Disease	D054218
lymphocytic	I-Disease	D054218
leukemia	I-Disease	D054218
in	O	O
relapse	O	O
.	O	O

The	O	O
concomitant	O	O
administration	O	O
of	O	O
etoposide	B-Chemical	D005047
and	O	O
cyclosporin	B-Chemical	D016572
A	I-Chemical	D016572
resulted	O	O
in	O	O
eradication	O	O
of	O	O
hitherto	O	O
refractory	O	O
leukemic	B-Disease	D017254
infiltration	I-Disease	D017254
of	O	O
bone	O	O
marrow	O	O
.	O	O

Severe	O	O
side	O	O
effects	O	O
in	O	O
terms	O	O
of	O	O
mental	O	O
confusion	B-Disease	D003221
and	O	O
progressive	O	O
hyperbilirubinemia	B-Disease	D006932
,	O	O
however	O	O
,	O	O
point	O	O
to	O	O
an	O	O
enhancement	O	O
not	O	O
only	O	O
of	O	O
antineoplastic	O	O
effects	O	O
but	O	O
also	O	O
of	O	O
toxicity	B-Disease	D064420
in	O	O
normal	O	O
tissues	O	O
.	O	O

This	O	O
report	O	O
demonstrates	O	O
for	O	O
the	O	O
first	O	O
time	O	O
that	O	O
the	O	O
pharmacodynamic	O	O
properties	O	O
of	O	O
cyclosporin	B-Chemical	D016572
A	I-Chemical	D016572
may	O	O
not	O	O
be	O	O
confined	O	O
strictly	O	O
to	O	O
suppression	O	O
of	O	O
normal	O	O
T	O	O
-	O	O
cell	O	O
functions	O	O
.	O	O

The	O	O
hematologic	O	O
effects	O	O
of	O	O
cefonicid	B-Chemical	D015790
and	O	O
cefazedone	B-Chemical	C021341
in	O	O
the	O	O
dog	O	O
:	O	O
a	O	O
potential	O	O
model	O	O
of	O	O
cephalosporin	B-Chemical	D002511
hematotoxicity	B-Disease	D006402
in	O	O
man	O	O
.	O	O

Cephalosporin	B-Chemical	D002511
antibiotics	O	O
cause	O	O
a	O	O
variety	O	O
of	O	O
hematologic	B-Disease	D006402
disturbances	I-Disease	D006402
in	O	O
man	O	O
,	O	O
the	O	O
pathogeneses	O	O
and	O	O
hematopathology	O	O
of	O	O
which	O	O
remain	O	O
poorly	O	O
characterized	O	O
.	O	O

There	O	O
is	O	O
a	O	O
need	O	O
for	O	O
a	O	O
well	O	O
-	O	O
defined	O	O
animal	O	O
model	O	O
in	O	O
which	O	O
these	O	O
blood	B-Disease	D006402
dyscrasias	I-Disease	D006402
can	O	O
be	O	O
studied	O	O
.	O	O

In	O	O
four	O	O
subacute	O	O
toxicity	B-Disease	D064420
studies	O	O
,	O	O
the	O	O
intravenous	O	O
administration	O	O
of	O	O
cefonicid	B-Chemical	D015790
or	O	O
cefazedone	B-Chemical	C021341
to	O	O
beagle	O	O
dogs	O	O
caused	O	O
a	O	O
dose	O	O
-	O	O
dependent	O	O
incidence	O	O
of	O	O
anemia	B-Disease	D000740
,	O	O
neutropenia	B-Disease	D009503
,	O	O
and	O	O
thrombocytopenia	B-Disease	D013921
after	O	O
1	O	O
-	O	O
3	O	O
months	O	O
of	O	O
treatment	O	O
.	O	O

A	O	O
nonregenerative	O	O
anemia	B-Disease	D000740
was	O	O
the	O	O
most	O	O
compromising	O	O
of	O	O
the	O	O
cytopenias	B-Disease	D006402
and	O	O
occurred	O	O
in	O	O
approximately	O	O
50%	O	O
of	O	O
dogs	O	O
receiving	O	O
400	O	O
-	O	O
500	O	O
mg	O	O
/	O	O
kg	O	O
cefonicid	B-Chemical	D015790
or	O	O
540	O	O
-	O	O
840	O	O
mg	O	O
/	O	O
kg	O	O
cefazedone	B-Chemical	C021341
.	O	O

All	O	O
three	O	O
cytopenias	B-Disease	D006402
were	O	O
completely	O	O
reversible	O	O
following	O	O
cessation	O	O
of	O	O
treatment	O	O
;	O	O
the	O	O
time	O	O
required	O	O
for	O	O
recovery	O	O
of	O	O
the	O	O
erythron	O	O
(	O	O
approximately	O	O
1	O	O
month	O	O
)	O	O
was	O	O
considerably	O	O
longer	O	O
than	O	O
that	O	O
of	O	O
the	O	O
granulocytes	O	O
and	O	O
platelets	O	O
(	O	O
hours	O	O
to	O	O
a	O	O
few	O	O
days	O	O
)	O	O
.	O	O

Upon	O	O
rechallenge	O	O
with	O	O
either	O	O
cephalosporin	B-Chemical	D002511
,	O	O
the	O	O
hematologic	B-Disease	D006402
syndrome	I-Disease	D006402
was	O	O
reproduced	O	O
in	O	O
most	O	O
dogs	O	O
tested	O	O
;	O	O
cefonicid	B-Chemical	D015790
(	O	O
but	O	O
not	O	O
cefazedone	B-Chemical	C021341
)	O	O
-	O	O
treated	O	O
dogs	O	O
showed	O	O
a	O	O
substantially	O	O
reduced	O	O
induction	O	O
period	O	O
(	O	O
15	O	O
+	O	O
/	O	O
-	O	O
5	O	O
days	O	O
)	O	O
compared	O	O
to	O	O
that	O	O
of	O	O
the	O	O
first	O	O
exposure	O	O
to	O	O
the	O	O
drug	O	O
(	O	O
61	O	O
+	O	O
/	O	O
-	O	O
24	O	O
days	O	O
)	O	O
.	O	O

This	O	O
observation	O	O
,	O	O
along	O	O
with	O	O
the	O	O
rapid	O	O
rate	O	O
of	O	O
decline	O	O
in	O	O
red	O	O
cell	O	O
mass	O	O
parameters	O	O
of	O	O
affected	O	O
dogs	O	O
,	O	O
suggests	O	O
that	O	O
a	O	O
hemolytic	B-Disease	D006461
component	O	O
complicated	O	O
the	O	O
red	O	O
cell	O	O
production	O	O
problem	O	O
and	O	O
that	O	O
multiple	O	O
toxicologic	O	O
mechanisms	O	O
contributed	O	O
to	O	O
the	O	O
cytopenia	B-Disease	D006402
.	O	O

We	O	O
conclude	O	O
that	O	O
the	O	O
administration	O	O
of	O	O
high	O	O
doses	O	O
of	O	O
cefonicid	B-Chemical	D015790
or	O	O
cefazedone	B-Chemical	C021341
to	O	O
dogs	O	O
can	O	O
induce	O	O
hematotoxicity	B-Disease	D006402
similar	O	O
to	O	O
the	O	O
cephalosporin	B-Chemical	D002511
-	O	O
induced	O	O
blood	B-Disease	D006402
dyscrasias	I-Disease	D006402
described	O	O
in	O	O
man	O	O
and	O	O
thus	O	O
provides	O	O
a	O	O
useful	O	O
model	O	O
for	O	O
studying	O	O
the	O	O
mechanisms	O	O
of	O	O
these	O	O
disorders	O	O
.	O	O

A	O	O
pyridoxine	B-Chemical	D011736
-	O	O
dependent	O	O
behavioral	B-Disease	D002653
disorder	I-Disease	D002653
unmasked	O	O
by	O	O
isoniazid	B-Chemical	D007538
.	O	O

A	O	O
3	O	O
-	O	O
year	O	O
-	O	O
old	O	O
girl	O	O
had	O	O
behavioral	B-Disease	D002653
deterioration	I-Disease	D002653
,	O	O
with	O	O
hyperkinesis	B-Disease	D006948
,	O	O
irritability	B-Disease	D001523
,	O	O
and	O	O
sleeping	B-Disease	D012893
difficulties	I-Disease	D012893
after	O	O
the	O	O
therapeutic	O	O
administration	O	O
of	O	O
isoniazid	B-Chemical	D007538
.	O	O

The	O	O
administration	O	O
of	O	O
pharmacologic	O	O
doses	O	O
of	O	O
pyridoxine	B-Chemical	D011736
hydrochloride	O	O
led	O	O
to	O	O
a	O	O
disappearance	O	O
of	O	O
symptoms	O	O
.	O	O

After	O	O
discontinuing	O	O
isoniazid	B-Chemical	D007538
therapy	O	O
a	O	O
similar	O	O
pattern	O	O
of	O	O
behavior	O	O
was	O	O
noted	O	O
that	O	O
was	O	O
controlled	O	O
by	O	O
pyridoxine	B-Chemical	D011736
.	O	O

A	O	O
placebo	O	O
had	O	O
no	O	O
effect	O	O
,	O	O
but	O	O
niacinamide	B-Chemical	D009536
was	O	O
as	O	O
effective	O	O
as	O	O
pyridoxine	B-Chemical	D011736
.	O	O

Periodic	O	O
withdrawal	O	O
of	O	O
pyridoxine	B-Chemical	D011736
was	O	O
associated	O	O
with	O	O
return	O	O
of	O	O
the	O	O
hyperkinesis	B-Disease	D006948
.	O	O

The	O	O
level	O	O
of	O	O
pyridoxal	B-Chemical	D011730
in	O	O
the	O	O
blood	O	O
was	O	O
normal	O	O
during	O	O
the	O	O
periods	O	O
of	O	O
relapse	O	O
.	O	O

Metabolic	O	O
studies	O	O
suggested	O	O
a	O	O
block	O	O
in	O	O
the	O	O
kynurenine	B-Chemical	D007737
pathway	O	O
of	O	O
tryptophan	B-Chemical	D014364
metabolism	O	O
.	O	O

The	O	O
patient	O	O
has	O	O
been	O	O
followed	O	O
for	O	O
six	O	O
years	O	O
and	O	O
has	O	O
required	O	O
pharmacologic	O	O
doses	O	O
of	O	O
pyridoxine	B-Chemical	D011736
to	O	O
control	O	O
her	O	O
behavior	O	O
.	O	O

A	O	O
selective	O	O
dopamine	B-Chemical	D004298
D4	O	O
receptor	O	O
antagonist	O	O
,	O	O
NRA0160	B-Chemical	C121249
:	O	O
a	O	O
preclinical	O	O
neuropharmacological	O	O
profile	O	O
.	O	O

NRA0160	B-Chemical	C121249
,	O	O
5	B-Chemical	C121249
-	I-Chemical	C121249
[	I-Chemical	C121249
2	I-Chemical	C121249
-	I-Chemical	C121249
(	I-Chemical	C121249
4	I-Chemical	C121249
-	I-Chemical	C121249
(	I-Chemical	C121249
3	I-Chemical	C121249
-	I-Chemical	C121249
fluorobenzylidene	I-Chemical	C121249
)	I-Chemical	C121249
piperidin	I-Chemical	C121249
-	I-Chemical	C121249
1	I-Chemical	C121249
-	I-Chemical	C121249
yl	I-Chemical	C121249
)	I-Chemical	C121249
ethyl	I-Chemical	C121249
]	I-Chemical	C121249
-	I-Chemical	C121249
4	I-Chemical	C121249
-	I-Chemical	C121249
(	I-Chemical	C121249
4	I-Chemical	C121249
-	I-Chemical	C121249
fluorophenyl	I-Chemical	C121249
)	I-Chemical	C121249
thiazole	I-Chemical	C121249
-	I-Chemical	C121249
2	I-Chemical	C121249
-	I-Chemical	C121249
carboxamide	I-Chemical	C121249
,	O	O
has	O	O
a	O	O
high	O	O
affinity	O	O
for	O	O
human	O	O
cloned	O	O
dopamine	B-Chemical	D004298
D4	O	O
.	O	O

2	O	O
,	O	O
D4	O	O
.	O	O

4	O	O
and	O	O
D4	O	O
.	O	O

7	O	O
receptors	O	O
,	O	O
with	O	O
Ki	O	O
values	O	O
of	O	O
0	O	O
.	O	O

5	O	O
,	O	O
0	O	O
.	O	O

9	O	O
and	O	O
2	O	O
.	O	O

7	O	O
nM	O	O
,	O	O
respectively	O	O
.	O	O

NRA0160	B-Chemical	C121249
is	O	O
over	O	O
20	O	O
,	O	O
000fold	O	O
more	O	O
potent	O	O
at	O	O
the	O	O
dopamine	B-Chemical	D004298
D4	O	O
.	O	O

2	O	O
receptor	O	O
compared	O	O
with	O	O
the	O	O
human	O	O
cloned	O	O
dopamine	B-Chemical	D004298
D2L	O	O
receptor	O	O
.	O	O

NRA0160	B-Chemical	C121249
has	O	O
negligible	O	O
affinity	O	O
for	O	O
the	O	O
human	O	O
cloned	O	O
dopamine	B-Chemical	D004298
D3	O	O
receptor	O	O
(	O	O
Ki=39	O	O
nM	O	O
)	O	O
,	O	O
rat	O	O
serotonin	B-Chemical	D012701
(	O	O
5	B-Chemical	D012701
-	I-Chemical	D012701
HT	I-Chemical	D012701
)	O	O
2A	O	O
receptors	O	O
(	O	O
Ki=180	O	O
nM	O	O
)	O	O
and	O	O
rat	O	O
alpha1	O	O
adrenoceptor	O	O
(	O	O
Ki=237	O	O
nM	O	O
)	O	O
.	O	O

NRA0160	B-Chemical	C121249
and	O	O
clozapine	B-Chemical	D003024
antagonized	O	O
locomotor	O	O
hyperactivity	B-Disease	D006948
induced	O	O
by	O	O
methamphetamine	B-Chemical	D008694
(	O	O
MAP	B-Chemical	D008694
)	O	O
in	O	O
mice	O	O
.	O	O

NRA0160	B-Chemical	C121249
and	O	O
clozapine	B-Chemical	D003024
antagonized	O	O
MAP	B-Chemical	D008694
-	O	O
induced	O	O
stereotyped	O	O
behavior	O	O
in	O	O
mice	O	O
,	O	O
although	O	O
their	O	O
effects	O	O
did	O	O
not	O	O
exceed	O	O
50%	O	O
inhibition	O	O
,	O	O
even	O	O
at	O	O
the	O	O
highest	O	O
dose	O	O
given	O	O
.	O	O

NRA0160	B-Chemical	C121249
and	O	O
clozapine	B-Chemical	D003024
significantly	O	O
induced	O	O
catalepsy	B-Disease	D002375
in	O	O
rats	O	O
,	O	O
although	O	O
their	O	O
effects	O	O
did	O	O
not	O	O
exceed	O	O
50%	O	O
induction	O	O
even	O	O
at	O	O
the	O	O
highest	O	O
dose	O	O
given	O	O
.	O	O

NRA0160	B-Chemical	C121249
and	O	O
clozapine	B-Chemical	D003024
significantly	O	O
reversed	O	O
the	O	O
disruption	O	O
of	O	O
prepulse	O	O
inhibition	O	O
(	O	O
PPI	O	O
)	O	O
in	O	O
rats	O	O
produced	O	O
by	O	O
apomorphine	B-Chemical	D001058
.	O	O

NRA0160	B-Chemical	C121249
and	O	O
clozapine	B-Chemical	D003024
significantly	O	O
shortened	O	O
the	O	O
phencyclidine	B-Chemical	D010622
(	O	O
PCP	B-Chemical	D010622
)	O	O
-	O	O
induced	O	O
prolonged	O	O
swimming	O	O
latency	O	O
in	O	O
rats	O	O
in	O	O
a	O	O
water	O	O
maze	O	O
task	O	O
.	O	O

These	O	O
findings	O	O
suggest	O	O
that	O	O
NRA0160	B-Chemical	C121249
may	O	O
have	O	O
unique	O	O
antipsychotic	O	O
activities	O	O
without	O	O
the	O	O
liability	O	O
of	O	O
motor	O	O
side	O	O
effects	O	O
typical	O	O
of	O	O
classical	O	O
antipsychotics	O	O
.	O	O

Prolonged	O	O
cholestasis	B-Disease	D002779
after	O	O
troleandomycin	B-Chemical	D014217
-	O	O
induced	O	O
acute	O	O
hepatitis	B-Disease	D056486
.	O	O

We	O	O
report	O	O
the	O	O
case	O	O
of	O	O
a	O	O
patient	O	O
in	O	O
whom	O	O
troleandomycin	B-Chemical	D014217
-	O	O
induced	O	O
hepatitis	B-Disease	D056486
was	O	O
followed	O	O
by	O	O
prolonged	O	O
anicteric	O	O
cholestasis	B-Disease	D002779
.	O	O

Jaundice	B-Disease	D007565
occurred	O	O
after	O	O
administration	O	O
of	O	O
troleandomycin	B-Chemical	D014217
for	O	O
7	O	O
days	O	O
and	O	O
was	O	O
associated	O	O
with	O	O
hypereosinophilia	B-Disease	D004802
.	O	O

Jaundice	B-Disease	D007565
disappeared	O	O
within	O	O
3	O	O
months	O	O
but	O	O
was	O	O
followed	O	O
by	O	O
prolonged	O	O
anicteric	O	O
cholestasis	B-Disease	D002779
marked	O	O
by	O	O
pruritus	B-Disease	D011537
and	O	O
high	O	O
levels	O	O
of	O	O
alkaline	O	O
phosphatase	O	O
and	O	O
gammaglutamyltransferase	O	O
activities	O	O
.	O	O

Finally	O	O
,	O	O
pruritus	B-Disease	D011537
disappeared	O	O
within	O	O
19	O	O
months	O	O
,	O	O
and	O	O
liver	O	O
tests	O	O
returned	O	O
to	O	O
normal	O	O
27	O	O
months	O	O
after	O	O
the	O	O
onset	O	O
of	O	O
hepatitis	B-Disease	D056486
.	O	O

This	O	O
observation	O	O
demonstrates	O	O
that	O	O
prolonged	O	O
cholestasis	B-Disease	D002779
can	O	O
follow	O	O
troleandomycin	B-Chemical	D014217
-	O	O
induced	O	O
acute	O	O
hepatitis	B-Disease	D056486
.	O	O

HMG	O	O
CoA	O	O
reductase	O	O
inhibitors	O	O
.	O	O

Current	O	O
clinical	O	O
experience	O	O
.	O	O

Lovastatin	B-Chemical	D008148
and	O	O
simvastatin	B-Chemical	D019821
are	O	O
the	O	O
2	O	O
best	O	O
-	O	O
known	O	O
members	O	O
of	O	O
the	O	O
class	O	O
of	O	O
hypolipidaemic	O	O
agents	O	O
known	O	O
as	O	O
HMG	O	O
CoA	O	O
reductase	O	O
inhibitors	O	O
.	O	O

Clinical	O	O
experience	O	O
with	O	O
lovastatin	B-Chemical	D008148
includes	O	O
over	O	O
5000	O	O
patients	O	O
,	O	O
700	O	O
of	O	O
whom	O	O
have	O	O
been	O	O
treated	O	O
for	O	O
2	O	O
years	O	O
or	O	O
more	O	O
,	O	O
and	O	O
experience	O	O
with	O	O
simvastatin	B-Chemical	D019821
includes	O	O
over	O	O
3500	O	O
patients	O	O
,	O	O
of	O	O
whom	O	O
350	O	O
have	O	O
been	O	O
treated	O	O
for	O	O
18	O	O
months	O	O
or	O	O
more	O	O
.	O	O

Lovastatin	B-Chemical	D008148
has	O	O
been	O	O
marketed	O	O
in	O	O
the	O	O
United	O	O
States	O	O
for	O	O
over	O	O
6	O	O
months	O	O
.	O	O

Both	O	O
agents	O	O
show	O	O
substantial	O	O
clinical	O	O
efficacy	O	O
,	O	O
with	O	O
reductions	O	O
in	O	O
total	O	O
cholesterol	B-Chemical	D002784
of	O	O
over	O	O
30%	O	O
and	O	O
in	O	O
LDL	O	O
-	O	O
cholesterol	B-Chemical	D002784
of	O	O
40%	O	O
in	O	O
clinical	O	O
studies	O	O
.	O	O

Modest	O	O
increases	O	O
in	O	O
HDL	O	O
-	O	O
cholesterol	B-Chemical	D002784
levels	O	O
of	O	O
about	O	O
10%	O	O
are	O	O
also	O	O
reported	O	O
.	O	O

Clinical	O	O
tolerability	O	O
of	O	O
both	O	O
agents	O	O
has	O	O
been	O	O
good	O	O
,	O	O
with	O	O
fewer	O	O
than	O	O
3%	O	O
of	O	O
patients	O	O
withdrawn	O	O
from	O	O
treatment	O	O
because	O	O
of	O	O
clinical	O	O
adverse	O	O
experiences	O	O
.	O	O

Ophthalmological	O	O
examinations	O	O
in	O	O
over	O	O
1100	O	O
patients	O	O
treated	O	O
with	O	O
one	O	O
or	O	O
the	O	O
other	O	O
agent	O	O
have	O	O
revealed	O	O
no	O	O
evidence	O	O
of	O	O
significant	O	O
short	O	O
term	O	O
(	O	O
up	O	O
to	O	O
2	O	O
years	O	O
)	O	O
cataractogenic	O	O
potential	O	O
.	O	O

One	O	O
to	O	O
2%	O	O
of	O	O
patients	O	O
have	O	O
elevations	O	O
of	O	O
serum	O	O
transaminases	O	O
to	O	O
greater	O	O
than	O	O
3	O	O
times	O	O
the	O	O
upper	O	O
limit	O	O
of	O	O
normal	O	O
.	O	O

These	O	O
episodes	O	O
are	O	O
asymptomatic	O	O
and	O	O
reversible	O	O
when	O	O
therapy	O	O
is	O	O
discontinued	O	O
.	O	O

Minor	O	O
elevations	O	O
of	O	O
creatine	B-Chemical	D003401
kinase	O	O
levels	O	O
are	O	O
reported	O	O
in	O	O
about	O	O
5%	O	O
of	O	O
patients	O	O
.	O	O

Myopathy	B-Disease	D009135
,	O	O
associated	O	O
in	O	O
some	O	O
cases	O	O
with	O	O
myoglobinuria	B-Disease	D009212
,	O	O
and	O	O
in	O	O
2	O	O
cases	O	O
with	O	O
transient	O	O
renal	B-Disease	D051437
failure	I-Disease	D051437
,	O	O
has	O	O
been	O	O
rarely	O	O
reported	O	O
with	O	O
lovastatin	B-Chemical	D008148
,	O	O
especially	O	O
in	O	O
patients	O	O
concomitantly	O	O
treated	O	O
with	O	O
cyclosporin	B-Chemical	D016572
,	O	O
gemfibrozil	B-Chemical	D015248
or	O	O
niacin	B-Chemical	D009525
.	O	O

Lovastatin	B-Chemical	D008148
and	O	O
simvastatin	B-Chemical	D019821
are	O	O
both	O	O
effective	O	O
and	O	O
well	O	O
-	O	O
tolerated	O	O
agents	O	O
for	O	O
lowering	O	O
elevated	O	O
levels	O	O
of	O	O
serum	O	O
cholesterol	B-Chemical	D002784
.	O	O

As	O	O
wider	O	O
use	O	O
confirms	O	O
their	O	O
safety	O	O
profile	O	O
,	O	O
they	O	O
will	O	O
gain	O	O
increasing	O	O
importance	O	O
in	O	O
the	O	O
therapeutic	O	O
approach	O	O
to	O	O
hypercholesterolaemia	B-Disease	D006937
and	O	O
its	O	O
consequences	O	O
.	O	O

Sulfasalazine	B-Chemical	D012460
-	O	O
induced	O	O
lupus	B-Disease	D008180
erythematosus	I-Disease	D008180
.	O	O

Pneumonitis	B-Disease	D011014
,	O	O
bilateral	O	O
pleural	B-Disease	D010996
effusions	I-Disease	D010996
,	O	O
echocardiographic	O	O
evidence	O	O
of	O	O
cardiac	B-Disease	D002305
tamponade	I-Disease	D002305
,	O	O
and	O	O
positive	O	O
autoantibodies	O	O
developed	O	O
in	O	O
a	O	O
43	O	O
-	O	O
year	O	O
-	O	O
old	O	O
man	O	O
,	O	O
who	O	O
was	O	O
receiving	O	O
long	O	O
-	O	O
term	O	O
sulfasalazine	B-Chemical	D012460
therapy	O	O
for	O	O
chronic	O	O
ulcerative	B-Disease	D003093
colitis	I-Disease	D003093
.	O	O

After	O	O
cessation	O	O
of	O	O
the	O	O
sulfasalazine	B-Chemical	D012460
and	O	O
completion	O	O
of	O	O
a	O	O
six	O	O
-	O	O
week	O	O
course	O	O
of	O	O
corticosteroids	O	O
,	O	O
these	O	O
problems	O	O
resolved	O	O
over	O	O
a	O	O
period	O	O
of	O	O
four	O	O
to	O	O
six	O	O
months	O	O
.	O	O

It	O	O
is	O	O
suggested	O	O
that	O	O
the	O	O
patient	O	O
had	O	O
sulfasalazine	B-Chemical	D012460
-	O	O
induced	O	O
lupus	B-Disease	D008180
,	O	O
which	O	O
manifested	O	O
with	O	O
serositis	B-Disease	D012700
and	O	O
pulmonary	O	O
parenchymal	O	O
involvement	O	O
in	O	O
the	O	O
absence	O	O
of	O	O
joint	O	O
symptoms	O	O
.	O	O

Physicians	O	O
who	O	O
use	O	O
sulfasalazine	B-Chemical	D012460
to	O	O
treat	O	O
patients	O	O
with	O	O
inflammatory	B-Disease	D015212
bowel	I-Disease	D015212
disease	I-Disease	D015212
should	O	O
be	O	O
aware	O	O
of	O	O
the	O	O
signs	O	O
of	O	O
sulfasalazine	B-Chemical	D012460
-	O	O
induced	O	O
lupus	B-Disease	D008180
syndrome	O	O
.	O	O

Optimization	O	O
of	O	O
levodopa	B-Chemical	D007980
therapy	O	O
.	O	O

While	O	O
there	O	O
is	O	O
no	O	O
single	O	O
correct	O	O
starting	O	O
dose	O	O
for	O	O
levodopa	B-Chemical	D007980
therapy	O	O
,	O	O
many	O	O
individuals	O	O
can	O	O
be	O	O
started	O	O
on	O	O
either	O	O
the	O	O
25	O	O
/	O	O
100	O	O
or	O	O
controlled	O	O
-	O	O
release	O	O
formula	O	O
,	O	O
following	O	O
the	O	O
general	O	O
rule	O	O
not	O	O
to	O	O
attempt	O	O
to	O	O
titrate	O	O
carbidopa	B-Chemical	D002230
-	O	O
levodopa	B-Chemical	D007980
to	O	O
the	O	O
point	O	O
of	O	O
"normality	O	O
,	O	O
"	O	O
which	O	O
can	O	O
lead	O	O
to	O	O
toxicity	B-Disease	D064420
.	O	O

The	O	O
physician	O	O
should	O	O
also	O	O
determine	O	O
the	O	O
proper	O	O
use	O	O
of	O	O
any	O	O
adjunctive	O	O
medications	O	O
;	O	O
such	O	O
combined	O	O
therapy	O	O
has	O	O
become	O	O
the	O	O
standard	O	O
approach	O	O
to	O	O
treatment	O	O
.	O	O

Following	O	O
the	O	O
initial	O	O
period	O	O
of	O	O
therapy	O	O
,	O	O
emerging	O	O
difficulties	O	O
require	O	O
a	O	O
reassessment	O	O
of	O	O
therapeutic	O	O
approaches	O	O
,	O	O
such	O	O
as	O	O
dosage	O	O
adjustment	O	O
or	O	O
introduction	O	O
of	O	O
a	O	O
dopamine	B-Chemical	D004298
agonist	O	O
.	O	O

Other	O	O
possible	O	O
adverse	O	O
effects	O	O
-	O	O
-	O	O
such	O	O
as	O	O
gastrointestinal	B-Disease	D005767
disorders	I-Disease	D005767
,	O	O
orthostatic	B-Disease	D007024
hypotension	I-Disease	D007024
,	O	O
levodopa	B-Chemical	D007980
-	O	O
induced	O	O
psychosis	B-Disease	D011618
,	O	O
sleep	B-Disease	D012893
disturbances	I-Disease	D012893
or	O	O
parasomnias	B-Disease	D020447
,	O	O
or	O	O
drug	O	O
interactions	O	O
-	O	O
-	O	O
also	O	O
require	O	O
carefully	O	O
monitored	O	O
individual	O	O
treatment	O	O
.	O	O

Nonpharmacologic	O	O
concerns	O	O
can	O	O
help	O	O
the	O	O
Parkinson's	B-Disease	D010300
disease	I-Disease	D010300
patient	O	O
achieve	O	O
and	O	O
maintain	O	O
optimal	O	O
functioning	O	O
,	O	O
including	O	O
daily	O	O
exercise	O	O
,	O	O
physical	O	O
therapy	O	O
,	O	O
and	O	O
involvement	O	O
with	O	O
support	O	O
groups	O	O
.	O	O

Alpha	O	O
and	O	O
beta	O	O
coma	B-Disease	D003128
in	O	O
drug	O	O
intoxication	O	O
uncomplicated	O	O
by	O	O
cerebral	B-Disease	D002534
hypoxia	I-Disease	D002534
.	O	O

Four	O	O
patients	O	O
who	O	O
were	O	O
rendered	O	O
comatose	B-Disease	D003128
or	O	O
stuporous	B-Disease	D053608
by	O	O
drug	O	O
intoxication	O	O
,	O	O
but	O	O
who	O	O
were	O	O
not	O	O
hypoxic	O	O
,	O	O
are	O	O
described	O	O
.	O	O

Three	O	O
patients	O	O
received	O	O
high	O	O
doses	O	O
of	O	O
chlormethiazole	B-Chemical	D002719
for	O	O
alcohol	B-Chemical	D000431
withdrawal	B-Disease	D013375
symptoms	I-Disease	D013375
,	O	O
and	O	O
one	O	O
took	O	O
a	O	O
suicidal	O	O
overdose	B-Disease	D062787
of	O	O
nitrazepam	B-Chemical	D009567
.	O	O

The	O	O
patient	O	O
with	O	O
nitrazepam	B-Chemical	D009567
overdose	B-Disease	D062787
and	O	O
two	O	O
of	O	O
those	O	O
with	O	O
chlormethiazole	B-Chemical	D002719
intoxication	O	O
conformed	O	O
to	O	O
the	O	O
criteria	O	O
of	O	O
'alpha	O	O
coma'	O	O
,	O	O
showing	O	O
non	O	O
-	O	O
reactive	O	O
generalized	O	O
or	O	O
frontally	O	O
predominant	O	O
alpha	O	O
activity	O	O
in	O	O
the	O	O
EEG	O	O
.	O	O

The	O	O
fourth	O	O
patient	O	O
who	O	O
was	O	O
unconscious	O	O
after	O	O
chlormethiazole	B-Chemical	D002719
administration	O	O
exhibite	O	O
generalized	O	O
non	O	O
-	O	O
reactive	O	O
activity	O	O
in	O	O
the	O	O
slow	O	O
beta	O	O
range	O	O
.	O	O

All	O	O
four	O	O
recovered	O	O
completely	O	O
without	O	O
neurological	B-Disease	D009422
sequelae	I-Disease	D009422
following	O	O
the	O	O
withdrawal	O	O
of	O	O
the	O	O
offending	O	O
agents	O	O
.	O	O

The	O	O
similarities	O	O
between	O	O
the	O	O
effects	O	O
of	O	O
structural	O	O
lesions	O	O
and	O	O
pharmacological	O	O
depression	B-Disease	D003866
of	O	O
the	O	O
brain	O	O
stem	O	O
reticular	O	O
formation	O	O
are	O	O
discussed	O	O
.	O	O

It	O	O
is	O	O
suggested	O	O
that	O	O
in	O	O
both	O	O
situations	O	O
disturbed	O	O
reticulo	O	O
-	O	O
thalamic	O	O
interactions	O	O
are	O	O
important	O	O
in	O	O
the	O	O
pathogenesis	O	O
of	O	O
alpha	O	O
coma	B-Disease	D003128
.	O	O

It	O	O
is	O	O
concluded	O	O
that	O	O
when	O	O
this	O	O
electroencephalographic	O	O
and	O	O
behavioural	O	O
picture	O	O
is	O	O
seen	O	O
in	O	O
drug	O	O
intoxication	O	O
,	O	O
in	O	O
the	O	O
absence	O	O
of	O	O
significant	O	O
hypoxaemia	B-Disease	D000860
,	O	O
a	O	O
favourable	O	O
outcome	O	O
may	O	O
be	O	O
anticipated	O	O
.	O	O

Omitting	O	O
fentanyl	B-Chemical	D005283
reduces	O	O
nausea	B-Disease	D009325
and	O	O
vomiting	B-Disease	D014839
,	O	O
without	O	O
increasing	O	O
pain	B-Disease	D010146
,	O	O
after	O	O
sevoflurane	B-Chemical	C009250
for	O	O
day	O	O
surgery	O	O
.	O	O

BACKGROUND	O	O
AND	O	O
OBJECTIVE	O	O
:	O	O
Despite	O	O
advantages	O	O
of	O	O
induction	O	O
and	O	O
maintenance	O	O
of	O	O
anaesthesia	O	O
with	O	O
sevoflurane	B-Chemical	C009250
,	O	O
postoperative	B-Disease	D020250
nausea	I-Disease	D020250
and	I-Disease	D020250
vomiting	I-Disease	D020250
occurs	O	O
frequently	O	O
.	O	O

Fentanyl	B-Chemical	D005283
is	O	O
a	O	O
commonly	O	O
used	O	O
supplement	O	O
that	O	O
may	O	O
contribute	O	O
to	O	O
this	O	O
,	O	O
although	O	O
it	O	O
may	O	O
also	O	O
improve	O	O
analgesia	O	O
.	O	O

METHODS	O	O
:	O	O
This	O	O
double	O	O
-	O	O
blind	O	O
study	O	O
examined	O	O
the	O	O
incidence	O	O
and	O	O
severity	O	O
of	O	O
postoperative	B-Disease	D020250
nausea	I-Disease	D020250
and	I-Disease	D020250
vomiting	I-Disease	D020250
and	O	O
pain	B-Disease	D010146
in	O	O
the	O	O
first	O	O
24	O	O
h	O	O
after	O	O
sevoflurane	B-Chemical	C009250
anaesthesia	O	O
in	O	O
216	O	O
adult	O	O
day	O	O
surgery	O	O
patients	O	O
.	O	O

Patients	O	O
were	O	O
randomly	O	O
allocated	O	O
to	O	O
either	O	O
receive	O	O
or	O	O
not	O	O
receive	O	O
1	O	O
1	O	O
fentanyl	B-Chemical	D005283
,	O	O
while	O	O
a	O	O
third	O	O
group	O	O
received	O	O
dexamethasone	B-Chemical	D003907
in	O	O
addition	O	O
to	O	O
fentanyl	B-Chemical	D005283
.	O	O

RESULTS	O	O
:	O	O
Omission	O	O
of	O	O
fentanyl	B-Chemical	D005283
did	O	O
not	O	O
reduce	O	O
the	O	O
overall	O	O
incidence	O	O
of	O	O
postoperative	B-Disease	D020250
nausea	I-Disease	D020250
and	I-Disease	D020250
vomiting	I-Disease	D020250
,	O	O
but	O	O
did	O	O
reduce	O	O
the	O	O
incidence	O	O
of	O	O
vomiting	B-Disease	D014839
and	O	O
/	O	O
or	O	O
moderate	O	O
to	O	O
severe	O	O
nausea	B-Disease	D009325
prior	O	O
to	O	O
discharge	O	O
from	O	O
20%	O	O
and	O	O
17%	O	O
with	O	O
fentanyl	B-Chemical	D005283
and	O	O
fentanyl	B-Chemical	D005283
-	O	O
dexamethasone	B-Chemical	D003907
,	O	O
respectively	O	O
,	O	O
to	O	O
5%	O	O
(	O	O
P	O	O
=	O	O
0	O	O
.	O	O

013	O	O
)	O	O
.	O	O

Antiemetic	O	O
requirements	O	O
were	O	O
reduced	O	O
from	O	O
24%	O	O
and	O	O
31%	O	O
to	O	O
7%	O	O
(	O	O
P	O	O
=	O	O
0	O	O
.	O	O

0012	O	O
)	O	O
.	O	O

Dexamethasone	B-Chemical	D003907
had	O	O
no	O	O
significant	O	O
effect	O	O
on	O	O
the	O	O
incidence	O	O
or	O	O
severity	O	O
of	O	O
postoperative	B-Disease	D020250
nausea	I-Disease	D020250
and	I-Disease	D020250
vomiting	I-Disease	D020250
.	O	O

Combining	O	O
the	O	O
two	O	O
fentanyl	B-Chemical	D005283
groups	O	O
revealed	O	O
further	O	O
significant	O	O
benefits	O	O
from	O	O
the	O	O
avoidance	O	O
of	O	O
opioids	O	O
,	O	O
reducing	O	O
postoperative	B-Disease	D020250
nausea	I-Disease	D020250
and	I-Disease	D020250
vomiting	I-Disease	D020250
and	O	O
nausea	B-Disease	D009325
prior	O	O
to	O	O
discharge	O	O
from	O	O
35%	O	O
and	O	O
33%	O	O
to	O	O
22%	O	O
and	O	O
19%	O	O
(	O	O
P	O	O
=	O	O
0	O	O
.	O	O

049	O	O
and	O	O
P	O	O
=	O	O
0	O	O
.	O	O

035	O	O
)	O	O
,	O	O
respectively	O	O
,	O	O
while	O	O
nausea	B-Disease	D009325
in	O	O
the	O	O
first	O	O
24	O	O
h	O	O
was	O	O
decreased	O	O
from	O	O
42%	O	O
to	O	O
27%	O	O
(	O	O
P	O	O
=	O	O
0	O	O
.	O	O

034	O	O
)	O	O
.	O	O

Pain	B-Disease	D010146
severity	O	O
and	O	O
analgesic	O	O
requirements	O	O
were	O	O
unaffected	O	O
by	O	O
the	O	O
omission	O	O
of	O	O
fentanyl	B-Chemical	D005283
.	O	O

Fentanyl	B-Chemical	D005283
did	O	O
reduce	O	O
minor	O	O
intraoperative	O	O
movement	O	O
but	O	O
had	O	O
no	O	O
sevoflurane	B-Chemical	C009250
-	O	O
sparing	O	O
effect	O	O
and	O	O
increased	O	O
respiratory	B-Disease	D012131
depression	I-Disease	D012131
,	O	O
hypotension	B-Disease	D007022
and	O	O
bradycardia	B-Disease	D001919
.	O	O

CONCLUSION	O	O
:	O	O
As	O	O
fentanyl	B-Chemical	D005283
exacerbated	O	O
postoperative	B-Disease	D020250
nausea	I-Disease	D020250
and	I-Disease	D020250
vomiting	I-Disease	D020250
without	O	O
an	O	O
improvement	O	O
in	O	O
postoperative	B-Disease	D010149
pain	I-Disease	D010149
and	O	O
also	O	O
had	O	O
adverse	O	O
cardiorespiratory	O	O
effects	O	O
,	O	O
it	O	O
appears	O	O
to	O	O
be	O	O
an	O	O
unnecessary	O	O
and	O	O
possibly	O	O
detrimental	O	O
supplement	O	O
to	O	O
sevoflurane	B-Chemical	C009250
in	O	O
day	O	O
surgery	O	O
.	O	O

Renal	B-Disease	D005198
Fanconi	I-Disease	D005198
syndrome	I-Disease	D005198
and	O	O
myopathy	B-Disease	D009135
after	O	O
liver	O	O
transplantation	O	O
:	O	O
drug	O	O
-	O	O
related	O	O
mitochondrial	O	O
cytopathy?	O	O
Advances	O	O
in	O	O
the	O	O
field	O	O
of	O	O
transplantation	O	O
provide	O	O
a	O	O
better	O	O
quality	O	O
of	O	O
life	O	O
and	O	O
allow	O	O
more	O	O
favorable	O	O
conditions	O	O
for	O	O
growth	O	O
and	O	O
development	O	O
in	O	O
children	O	O
.	O	O

However	O	O
,	O	O
combinations	O	O
of	O	O
different	O	O
therapeutic	O	O
regimens	O	O
require	O	O
consideration	O	O
of	O	O
potential	O	O
adverse	O	O
reactions	O	O
.	O	O

We	O	O
describe	O	O
a	O	O
15	O	O
-	O	O
yr	O	O
-	O	O
old	O	O
girl	O	O
who	O	O
had	O	O
orthotopic	O	O
liver	O	O
transplantation	O	O
because	O	O
of	O	O
Wilson's	B-Disease	D006527
disease	I-Disease	D006527
.	O	O

Tacrolimus	B-Chemical	D016559
,	O	O
MMF	B-Chemical	-1
,	O	O
and	O	O
steroids	B-Chemical	D013256
were	O	O
given	O	O
as	O	O
immunosuppressant	O	O
.	O	O

Lamivudine	B-Chemical	D019259
was	O	O
added	O	O
because	O	O
of	O	O
de	O	O
nova	O	O
hepatitis	B-Disease	D006509
B	I-Disease	D006509
infection	I-Disease	D006509
during	O	O
her	O	O
follow	O	O
-	O	O
up	O	O
.	O	O

Three	O	O
yr	O	O
after	O	O
transplantation	O	O
she	O	O
developed	O	O
renal	B-Disease	D005198
Fanconi	I-Disease	D005198
syndrome	I-Disease	D005198
with	O	O
severe	O	O
metabolic	B-Disease	D000138
acidosis	I-Disease	D000138
,	O	O
hypophosphatemia	B-Disease	D017674
,	O	O
glycosuria	B-Disease	D006029
,	O	O
and	O	O
aminoaciduria	B-Disease	D000608
.	O	O

Although	O	O
tacrolimus	B-Chemical	D016559
was	O	O
suspected	O	O
to	O	O
be	O	O
the	O	O
cause	O	O
of	O	O
late	O	O
post	O	O
-	O	O
transplant	O	O
renal	O	O
acidosis	B-Disease	D000138
and	O	O
was	O	O
replaced	O	O
by	O	O
sirolimus	B-Chemical	D020123
,	O	O
acidosis	B-Disease	D000138
,	O	O
and	O	O
electrolyte	O	O
imbalance	O	O
got	O	O
worse	O	O
.	O	O

Proximal	O	O
muscle	B-Disease	D018908
weakness	I-Disease	D018908
has	O	O
developed	O	O
during	O	O
her	O	O
follow	O	O
-	O	O
up	O	O
.	O	O

Fanconi	B-Disease	D005198
syndrome	I-Disease	D005198
,	O	O
as	O	O
well	O	O
as	O	O
myopathy	B-Disease	D009135
,	O	O
is	O	O
well	O	O
recognized	O	O
in	O	O
patients	O	O
with	O	O
mitochondrial	B-Disease	D028361
disorders	I-Disease	D028361
and	O	O
caused	O	O
by	O	O
depletion	O	O
of	O	O
mtDNA	O	O
.	O	O

We	O	O
suggest	O	O
that	O	O
our	O	O
patient's	O	O
tubular	B-Disease	D005198
dysfunction	I-Disease	D005198
and	O	O
myopathy	B-Disease	D009135
may	O	O
have	O	O
resulted	O	O
from	O	O
mitochondrial	B-Disease	D028361
dysfunction	I-Disease	D028361
which	O	O
is	O	O
triggered	O	O
by	O	O
tacrolimus	B-Chemical	D016559
and	O	O
augmented	O	O
by	O	O
lamivudine	B-Chemical	D019259
.	O	O

Antipsychotic	O	O
-	O	O
like	O	O
profile	O	O
of	O	O
thioperamide	B-Chemical	C052075
,	O	O
a	O	O
selective	O	O
H3	O	O
-	O	O
receptor	O	O
antagonist	O	O
in	O	O
mice	O	O
.	O	O

Experimental	O	O
and	O	O
clinical	O	O
evidence	O	O
points	O	O
to	O	O
a	O	O
role	O	O
of	O	O
central	O	O
histaminergic	O	O
system	O	O
in	O	O
the	O	O
pathogenesis	O	O
of	O	O
schizophrenia	B-Disease	D012559
.	O	O

The	O	O
present	O	O
study	O	O
was	O	O
designed	O	O
to	O	O
study	O	O
the	O	O
effect	O	O
of	O	O
histamine	B-Chemical	D006632
H	O	O
(	O	O
3	O	O
)	O	O
-	O	O
receptor	O	O
ligands	O	O
on	O	O
neuroleptic	O	O
-	O	O
induced	O	O
catalepsy	B-Disease	D002375
,	O	O
apomorphine	B-Chemical	D001058
-	O	O
induced	O	O
climbing	O	O
behavior	O	O
and	O	O
amphetamine	B-Chemical	D000661
-	O	O
induced	O	O
locomotor	O	O
activities	O	O
in	O	O
mice	O	O
.	O	O

Catalepsy	B-Disease	D002375
was	O	O
induced	O	O
by	O	O
haloperidol	B-Chemical	D006220
(	O	O
2	O	O
mg	O	O
/	O	O
kg	O	O
p	O	O
.	O	O

o	O	O
.	O	O

)	O	O
,	O	O
while	O	O
apomorphine	B-Chemical	D001058
(	O	O
1	O	O
.	O	O

5	O	O
mg	O	O
/	O	O
kg	O	O
s	O	O
.	O	O

c	O	O
.	O	O

)	O	O
and	O	O
amphetamine	B-Chemical	D000661
(	O	O
2	O	O
mg	O	O
/	O	O
kg	O	O
s	O	O
.	O	O

c	O	O
.	O	O

)	O	O
were	O	O
used	O	O
for	O	O
studying	O	O
climbing	O	O
behavior	O	O
and	O	O
locomotor	O	O
activities	O	O
,	O	O
respectively	O	O
.	O	O

(	B-Chemical	C069357
R	I-Chemical	C069357
)	I-Chemical	C069357
-	I-Chemical	C069357
alpha	I-Chemical	C069357
-	I-Chemical	C069357
methylhistamine	I-Chemical	C069357
(	O	O
RAMH	B-Chemical	C069357
)	O	O
(	O	O
5	O	O
microg	O	O
i	O	O
.	O	O

c	O	O
.	O	O

v	O	O
.	O	O

)	O	O
and	O	O
thioperamide	B-Chemical	C052075
(	O	O
THP	B-Chemical	C052075
)	O	O
(	O	O
15	O	O
mg	O	O
/	O	O
kg	O	O
i	O	O
.	O	O

p	O	O
.	O	O

)	O	O
,	O	O
per	O	O
se	O	O
did	O	O
not	O	O
cause	O	O
catalepsy	B-Disease	D002375
.	O	O

Administration	O	O
of	O	O
THP	B-Chemical	C052075
(	O	O
3	O	O
.	O	O

75	O	O
,	O	O
7	O	O
.	O	O

5	O	O
and	O	O
15	O	O
mg	O	O
/	O	O
kg	O	O
i	O	O
.	O	O

p	O	O
.	O	O

)	O	O
1	O	O
h	O	O
prior	O	O
to	O	O
haloperidol	B-Chemical	D006220
resulted	O	O
in	O	O
a	O	O
dose	O	O
-	O	O
dependent	O	O
increase	O	O
in	O	O
the	O	O
catalepsy	B-Disease	D002375
times	O	O
(	O	O
P	O	O
<	O	O
0	O	O
.	O	O

05	O	O
)	O	O
.	O	O

However	O	O
,	O	O
pretreatment	O	O
with	O	O
RAMH	B-Chemical	C069357
significantly	O	O
reversed	O	O
such	O	O
an	O	O
effect	O	O
of	O	O
THP	B-Chemical	C052075
(	O	O
15	O	O
mg	O	O
/	O	O
kg	O	O
i	O	O
.	O	O

p	O	O
.	O	O

)	O	O
.	O	O

RAMH	B-Chemical	C069357
per	O	O
se	O	O
showed	O	O
significant	O	O
reduction	O	O
in	O	O
locomotor	O	O
time	O	O
,	O	O
distance	O	O
traveled	O	O
and	O	O
average	O	O
speed	O	O
but	O	O
THP	B-Chemical	C052075
(	O	O
15	O	O
mg	O	O
/	O	O
kg	O	O
i	O	O
.	O	O

p	O	O
.	O	O

)	O	O
per	O	O
se	O	O
had	O	O
no	O	O
effect	O	O
on	O	O
these	O	O
parameters	O	O
.	O	O

On	O	O
amphetamine	B-Chemical	D000661
-	O	O
induced	O	O
hyperactivity	B-Disease	D006948
,	O	O
THP	B-Chemical	C052075
(	O	O
3	O	O
.	O	O

75	O	O
and	O	O
7	O	O
.	O	O

5	O	O
mg	O	O
/	O	O
kg	O	O
i	O	O
.	O	O

p	O	O
.	O	O

)	O	O
reduced	O	O
locomotor	O	O
time	O	O
,	O	O
distance	O	O
traveled	O	O
and	O	O
average	O	O
speed	O	O
(	O	O
P	O	O
<	O	O
0	O	O
.	O	O

05	O	O
)	O	O
.	O	O

Pretreatment	O	O
with	O	O
RAMH	B-Chemical	C069357
(	O	O
5	O	O
microg	O	O
i	O	O
.	O	O

c	O	O
.	O	O

v	O	O
.	O	O

)	O	O
could	O	O
partially	O	O
reverse	O	O
such	O	O
effects	O	O
of	O	O
THP	B-Chemical	C052075
(	O	O
3	O	O
.	O	O

75	O	O
mg	O	O
/	O	O
kg	O	O
i	O	O
.	O	O

p	O	O
.	O	O

)	O	O
.	O	O

Climbing	O	O
behavior	O	O
induced	O	O
by	O	O
apomorphine	B-Chemical	D001058
was	O	O
reduced	O	O
in	O	O
animals	O	O
treated	O	O
with	O	O
THP	B-Chemical	C052075
.	O	O

Such	O	O
an	O	O
effect	O	O
was	O	O
,	O	O
however	O	O
,	O	O
reversed	O	O
in	O	O
presence	O	O
of	O	O
RAMH	B-Chemical	C069357
.	O	O

THP	B-Chemical	C052075
exhibited	O	O
an	O	O
antipsychotic	O	O
-	O	O
like	O	O
profile	O	O
by	O	O
potentiating	O	O
haloperidol	B-Chemical	D006220
-	O	O
induced	O	O
catalepsy	B-Disease	D002375
,	O	O
reducing	O	O
amphetamine	B-Chemical	D000661
-	O	O
induced	O	O
hyperactivity	B-Disease	D006948
and	O	O
reducing	O	O
apomorphine	B-Chemical	D001058
-	O	O
induced	O	O
climbing	O	O
in	O	O
mice	O	O
.	O	O

Such	O	O
effects	O	O
of	O	O
THP	B-Chemical	C052075
were	O	O
reversed	O	O
by	O	O
RAMH	B-Chemical	C069357
indicating	O	O
the	O	O
involvement	O	O
of	O	O
histamine	B-Chemical	D006632
H	O	O
(	O	O
3	O	O
)	O	O
-	O	O
receptors	O	O
.	O	O

Findings	O	O
suggest	O	O
a	O	O
potential	O	O
for	O	O
H	O	O
(	O	O
3	O	O
)	O	O
-	O	O
receptor	O	O
antagonists	O	O
in	O	O
improving	O	O
the	O	O
refractory	O	O
cases	O	O
of	O	O
schizophrenia	B-Disease	D012559
.	O	O

Transient	O	O
platypnea	B-Disease	-1
-	I-Disease	-1
orthodeoxia	I-Disease	-1
-	I-Disease	-1
like	I-Disease	-1
syndrome	I-Disease	-1
induced	O	O
by	O	O
propafenone	B-Chemical	D011405
overdose	B-Disease	D062787
in	O	O
a	O	O
young	O	O
woman	O	O
with	O	O
Ebstein's	B-Disease	D004437
anomaly	I-Disease	D004437
.	O	O

In	O	O
this	O	O
report	O	O
we	O	O
describe	O	O
the	O	O
case	O	O
of	O	O
a	O	O
37	O	O
-	O	O
year	O	O
-	O	O
old	O	O
white	O	O
woman	O	O
with	O	O
Ebstein's	B-Disease	D004437
anomaly	I-Disease	D004437
,	O	O
who	O	O
developed	O	O
a	O	O
rare	O	O
syndrome	O	O
called	O	O
platypnea	B-Disease	-1
-	I-Disease	-1
orthodeoxia	I-Disease	-1
,	O	O
characterized	O	O
by	O	O
massive	O	O
right	O	O
-	O	O
to	O	O
-	O	O
left	O	O
interatrial	O	O
shunting	O	O
with	O	O
transient	O	O
profound	O	O
hypoxia	B-Disease	D000860
and	O	O
cyanosis	B-Disease	D003490
.	O	O

This	O	O
shunt	O	O
of	O	O
blood	O	O
via	O	O
a	O	O
patent	B-Disease	D054092
foramen	I-Disease	D054092
ovale	I-Disease	D054092
occurred	O	O
in	O	O
the	O	O
presence	O	O
of	O	O
a	O	O
normal	O	O
pulmonary	O	O
artery	O	O
pressure	O	O
,	O	O
and	O	O
was	O	O
probably	O	O
precipitated	O	O
by	O	O
a	O	O
propafenone	B-Chemical	D011405
overdose	B-Disease	D062787
.	O	O

This	O	O
drug	O	O
caused	O	O
biventricular	B-Disease	D018754
dysfunction	I-Disease	D018754
,	O	O
due	O	O
to	O	O
its	O	O
negative	O	O
inotropic	O	O
effect	O	O
,	O	O
and	O	O
hypotension	B-Disease	D007022
,	O	O
due	O	O
to	O	O
its	O	O
peripheral	O	O
vasodilatory	O	O
effect	O	O
.	O	O

These	O	O
effects	O	O
gave	O	O
rise	O	O
to	O	O
an	O	O
increase	O	O
in	O	O
the	O	O
right	O	O
atrial	O	O
pressure	O	O
and	O	O
a	O	O
decrease	O	O
in	O	O
the	O	O
left	O	O
one	O	O
with	O	O
a	O	O
consequent	O	O
stretching	O	O
of	O	O
the	O	O
foramen	O	O
ovale	O	O
and	O	O
the	O	O
creation	O	O
of	O	O
massive	O	O
right	O	O
-	O	O
to	O	O
-	O	O
left	O	O
shunting	O	O
.	O	O

In	O	O
our	O	O
case	O	O
this	O	O
interatrial	O	O
shunt	O	O
was	O	O
very	O	O
accurately	O	O
detected	O	O
at	O	O
bubble	O	O
contrast	O	O
echocardiography	O	O
.	O	O

A	O	O
Phase	O	O
II	O	O
trial	O	O
of	O	O
cisplatin	B-Chemical	D002945
plus	O	O
WR	B-Chemical	D004999
-	I-Chemical	D004999
2721	I-Chemical	D004999
(	O	O
amifostine	B-Chemical	D004999
)	O	O
for	O	O
metastatic	O	O
breast	B-Disease	D001943
carcinoma	I-Disease	D001943
:	O	O
an	O	O
Eastern	O	O
Cooperative	O	O
Oncology	O	O
Group	O	O
Study	O	O
(	O	O
E8188	O	O
)	O	O
.	O	O

BACKGROUND	O	O
:	O	O
Cisplatin	B-Chemical	D002945
has	O	O
minimal	O	O
antitumor	O	O
activity	O	O
when	O	O
used	O	O
as	O	O
second	O	O
-	O	O
or	O	O
third	O	O
-	O	O
line	O	O
treatment	O	O
of	O	O
metastatic	O	O
breast	B-Disease	D001943
carcinoma	I-Disease	D001943
.	O	O

Older	O	O
reports	O	O
suggest	O	O
an	O	O
objective	O	O
response	O	O
rate	O	O
of	O	O
8%	O	O
when	O	O
60	O	O
-	O	O
120	O	O
mg	O	O
/	O	O
m2	O	O
of	O	O
cisplatin	B-Chemical	D002945
is	O	O
administered	O	O
every	O	O
3	O	O
-	O	O
4	O	O
weeks	O	O
.	O	O

Although	O	O
a	O	O
dose	O	O
-	O	O
response	O	O
effect	O	O
has	O	O
been	O	O
observed	O	O
with	O	O
cisplatin	B-Chemical	D002945
,	O	O
the	O	O
dose	O	O
-	O	O
limiting	O	O
toxicities	B-Disease	D064420
associated	O	O
with	O	O
cisplatin	B-Chemical	D002945
(	O	O
e	O	O
.	O	O

g	O	O
.	O	O

,	O	O
nephrotoxicity	B-Disease	D007674
,	O	O
ototoxicity	B-Disease	D006311
,	O	O
and	O	O
neurotoxicity	B-Disease	D020258
)	O	O
have	O	O
limited	O	O
its	O	O
use	O	O
as	O	O
a	O	O
treatment	O	O
for	O	O
breast	B-Disease	D001943
carcinoma	I-Disease	D001943
.	O	O

WR	B-Chemical	D004999
-	I-Chemical	D004999
2721	I-Chemical	D004999
or	O	O
amifostine	B-Chemical	D004999
initially	O	O
was	O	O
developed	O	O
to	O	O
protect	O	O
military	O	O
personnel	O	O
in	O	O
the	O	O
event	O	O
of	O	O
nuclear	O	O
war	O	O
.	O	O

Amifostine	B-Chemical	D004999
subsequently	O	O
was	O	O
shown	O	O
to	O	O
protect	O	O
normal	O	O
tissues	O	O
from	O	O
the	O	O
toxic	O	O
effects	O	O
of	O	O
alkylating	B-Chemical	D000477
agents	I-Chemical	D000477
and	O	O
cisplatin	B-Chemical	D002945
without	O	O
decreasing	O	O
the	O	O
antitumor	O	O
effect	O	O
of	O	O
the	O	O
chemotherapy	O	O
.	O	O

Early	O	O
trials	O	O
of	O	O
cisplatin	B-Chemical	D002945
and	O	O
amifostine	B-Chemical	D004999
also	O	O
suggested	O	O
that	O	O
the	O	O
incidence	O	O
and	O	O
severity	O	O
of	O	O
cisplatin	B-Chemical	D002945
-	O	O
induced	O	O
nephrotoxicity	B-Disease	D007674
,	O	O
ototoxicity	B-Disease	D006311
,	O	O
and	O	O
neuropathy	B-Disease	D009422
were	O	O
reduced	O	O
.	O	O

METHODS	O	O
:	O	O
A	O	O
Phase	O	O
II	O	O
study	O	O
of	O	O
the	O	O
combination	O	O
of	O	O
cisplatin	B-Chemical	D002945
plus	O	O
amifostine	B-Chemical	D004999
was	O	O
conducted	O	O
in	O	O
patients	O	O
with	O	O
progressive	O	O
metastatic	O	O
breast	B-Disease	D001943
carcinoma	I-Disease	D001943
who	O	O
had	O	O
received	O	O
one	O	O
,	O	O
but	O	O
not	O	O
more	O	O
than	O	O
one	O	O
,	O	O
chemotherapy	O	O
regimen	O	O
for	O	O
metastatic	O	O
disease	O	O
.	O	O

Patients	O	O
received	O	O
amifostine	B-Chemical	D004999
,	O	O
910	O	O
mg	O	O
/	O	O
m2	O	O
intravenously	O	O
over	O	O
15	O	O
minutes	O	O
.	O	O

After	O	O
completion	O	O
of	O	O
the	O	O
amifostine	B-Chemical	D004999
infusion	O	O
,	O	O
cisplatin	B-Chemical	D002945
120	O	O
mg	O	O
/	O	O
m2	O	O
was	O	O
administered	O	O
over	O	O
30	O	O
minutes	O	O
.	O	O

Intravenous	O	O
hydration	O	O
and	O	O
mannitol	B-Chemical	D008353
was	O	O
administered	O	O
before	O	O
and	O	O
after	O	O
cisplatin	B-Chemical	D002945
.	O	O

Treatment	O	O
was	O	O
administered	O	O
every	O	O
3	O	O
weeks	O	O
until	O	O
disease	O	O
progression	O	O
.	O	O

RESULTS	O	O
:	O	O
Forty	O	O
-	O	O
four	O	O
patients	O	O
were	O	O
enrolled	O	O
in	O	O
the	O	O
study	O	O
of	O	O
which	O	O
7	O	O
(	O	O
16%	O	O
)	O	O
were	O	O
ineligible	O	O
.	O	O

A	O	O
median	O	O
of	O	O
2	O	O
cycles	O	O
of	O	O
therapy	O	O
was	O	O
administered	O	O
to	O	O
the	O	O
37	O	O
eligible	O	O
patients	O	O
.	O	O

Six	O	O
partial	O	O
responses	O	O
were	O	O
observed	O	O
for	O	O
an	O	O
overall	O	O
response	O	O
rate	O	O
of	O	O
16%	O	O
.	O	O

Most	O	O
patients	O	O
(	O	O
57%	O	O
)	O	O
stopped	O	O
treatment	O	O
because	O	O
of	O	O
disease	O	O
progression	O	O
.	O	O

Neurologic	B-Disease	D020258
toxicity	I-Disease	D020258
was	O	O
reported	O	O
in	O	O
52%	O	O
of	O	O
patients	O	O
.	O	O

Seven	O	O
different	O	O
life	O	O
-	O	O
threatening	O	O
toxicities	B-Disease	D064420
were	O	O
observed	O	O
in	O	O
patients	O	O
while	O	O
receiving	O	O
treatment	O	O
.	O	O

CONCLUSIONS	O	O
:	O	O
The	O	O
combination	O	O
of	O	O
cisplatin	B-Chemical	D002945
and	O	O
amifostine	B-Chemical	D004999
in	O	O
this	O	O
study	O	O
resulted	O	O
in	O	O
an	O	O
overall	O	O
response	O	O
rate	O	O
of	O	O
16%	O	O
.	O	O

Neither	O	O
a	O	O
tumor	B-Disease	D009369
-	O	O
protective	O	O
effect	O	O
nor	O	O
reduced	O	O
toxicity	B-Disease	D064420
to	O	O
normal	O	O
tissues	O	O
was	O	O
observed	O	O
with	O	O
the	O	O
addition	O	O
of	O	O
amifostine	B-Chemical	D004999
to	O	O
cisplatin	B-Chemical	D002945
in	O	O
this	O	O
trial	O	O
.	O	O

Warfarin	B-Chemical	D014859
-	O	O
induced	O	O
iliopsoas	O	O
hemorrhage	B-Disease	D006470
with	O	O
subsequent	O	O
femoral	B-Disease	D020428
nerve	I-Disease	D020428
palsy	I-Disease	D020428
.	O	O

We	O	O
present	O	O
the	O	O
case	O	O
of	O	O
a	O	O
28	O	O
-	O	O
year	O	O
-	O	O
old	O	O
man	O	O
on	O	O
chronic	O	O
warfarin	B-Chemical	D014859
therapy	O	O
who	O	O
sustained	O	O
a	O	O
minor	O	O
muscle	B-Disease	D009135
tear	I-Disease	D009135
and	O	O
developed	O	O
increasing	O	O
pain	B-Disease	D010146
and	O	O
a	O	O
flexure	O	O
contracture	B-Disease	D003286
of	O	O
the	O	O
right	O	O
hip	O	O
.	O	O

Surgical	O	O
exploration	O	O
revealed	O	O
an	O	O
iliopsoas	O	O
hematoma	B-Disease	D006406
and	O	O
femoral	O	O
nerve	B-Disease	D009408
entrapment	I-Disease	D009408
,	O	O
resulting	O	O
in	O	O
a	O	O
femoral	B-Disease	D020428
nerve	I-Disease	D020428
palsy	I-Disease	D020428
and	O	O
partial	B-Disease	D009135
loss	I-Disease	D009135
of	I-Disease	D009135
quadriceps	I-Disease	D009135
functions	I-Disease	D009135
.	O	O

Anticoagulant	O	O
-	O	O
induced	O	O
femoral	B-Disease	D020428
nerve	I-Disease	D020428
palsy	I-Disease	D020428
represents	O	O
the	O	O
most	O	O
common	O	O
form	O	O
of	O	O
warfarin	B-Chemical	D014859
-	O	O
induced	O	O
peripheral	B-Disease	D010523
neuropathy	I-Disease	D010523
;	O	O
it	O	O
is	O	O
characterized	O	O
by	O	O
severe	O	O
pain	B-Disease	D010146
in	O	O
the	O	O
inguinal	O	O
region	O	O
,	O	O
varying	O	O
degrees	O	O
of	O	O
motor	B-Disease	D015417
and	I-Disease	D015417
sensory	I-Disease	D015417
impairment	I-Disease	D015417
,	O	O
and	O	O
flexure	O	O
contracture	B-Disease	D003286
of	O	O
the	O	O
involved	O	O
extremity	O	O
.	O	O

Myasthenia	B-Disease	D009157
gravis	I-Disease	D009157
caused	O	O
by	O	O
penicillamine	B-Chemical	D010396
and	O	O
chloroquine	B-Chemical	D002738
therapy	O	O
for	O	O
rheumatoid	B-Disease	D001172
arthritis	I-Disease	D001172
.	O	O

We	O	O
have	O	O
described	O	O
a	O	O
unique	O	O
patient	O	O
who	O	O
had	O	O
reversible	O	O
and	O	O
dose	O	O
-	O	O
related	O	O
myasthenia	B-Disease	D009157
gravis	I-Disease	D009157
after	O	O
penicillamine	B-Chemical	D010396
and	O	O
chloroquine	B-Chemical	D002738
therapy	O	O
for	O	O
rheumatoid	B-Disease	D001172
arthritis	I-Disease	D001172
.	O	O

Although	O	O
acetylcholine	B-Chemical	D000109
receptor	O	O
antibodies	O	O
were	O	O
not	O	O
detectable	O	O
,	O	O
the	O	O
time	O	O
course	O	O
was	O	O
consistent	O	O
with	O	O
an	O	O
autoimmune	O	O
process	O	O
.	O	O

Nephrotoxicity	B-Disease	D007674
of	O	O
combined	O	O
cephalothin	B-Chemical	D002512
-	O	O
gentamicin	B-Chemical	D005839
regimen	O	O
.	O	O

Two	O	O
patients	O	O
developed	O	O
acute	B-Disease	D007683
tubular	I-Disease	D007683
necrosis	I-Disease	D007683
,	O	O
characterized	O	O
clinically	O	O
by	O	O
acute	O	O
oliguric	O	O
renal	O	O
failure	O	O
,	O	O
while	O	O
they	O	O
were	O	O
receiving	O	O
a	O	O
combination	O	O
of	O	O
cephalothin	B-Chemical	D002512
sodium	O	O
and	O	O
gentamicin	B-Chemical	D005839
sulfate	O	O
therapy	O	O
.	O	O

Patients	O	O
who	O	O
are	O	O
given	O	O
this	O	O
drug	O	O
regimen	O	O
should	O	O
be	O	O
observed	O	O
very	O	O
carefully	O	O
for	O	O
early	O	O
signs	O	O
of	O	O
nephrotoxicity	B-Disease	D007674
.	O	O

High	O	O
doses	O	O
of	O	O
this	O	O
antibiotic	O	O
combination	O	O
should	O	O
be	O	O
avoided	O	O
especially	O	O
in	O	O
elderly	O	O
patients	O	O
.	O	O

Patients	O	O
with	O	O
renal	B-Disease	D051437
insufficiency	I-Disease	D051437
should	O	O
not	O	O
be	O	O
given	O	O
this	O	O
regimen	O	O
.	O	O

Components	O	O
of	O	O
lemon	O	O
essential	O	O
oil	O	O
attenuate	O	O
dementia	B-Disease	D003704
induced	O	O
by	O	O
scopolamine	B-Chemical	D012601
.	O	O

The	O	O
anti	O	O
-	O	O
dementia	B-Disease	D003704
effects	O	O
of	O	O
s	B-Chemical	C008281
-	I-Chemical	C008281
limonene	I-Chemical	C008281
and	O	O
s	B-Chemical	C032208
-	I-Chemical	C032208
perillyl	I-Chemical	C032208
alcohol	I-Chemical	C032208
were	O	O
observed	O	O
using	O	O
the	O	O
passive	O	O
avoidance	O	O
test	O	O
(	O	O
PA	O	O
)	O	O
and	O	O
the	O	O
open	O	O
field	O	O
habituation	O	O
test	O	O
(	O	O
OFH	O	O
)	O	O
.	O	O

These	O	O
lemon	O	O
essential	O	O
oils	O	O
showed	O	O
strong	O	O
ability	O	O
to	O	O
improve	O	O
memory	B-Disease	D008569
impaired	I-Disease	D008569
by	O	O
scopolamine	B-Chemical	D012601
;	O	O
however	O	O
,	O	O
s	B-Chemical	C032208
-	I-Chemical	C032208
perillyl	I-Chemical	C032208
alcohol	I-Chemical	C032208
relieved	O	O
the	O	O
deficit	B-Disease	D008569
of	I-Disease	D008569
associative	I-Disease	D008569
memory	I-Disease	D008569
in	O	O
PA	O	O
only	O	O
,	O	O
and	O	O
did	O	O
not	O	O
improve	O	O
non	O	O
-	O	O
associative	O	O
memory	O	O
significantly	O	O
in	O	O
OFH	O	O
.	O	O

Analysis	O	O
of	O	O
neurotransmitter	O	O
concentration	O	O
in	O	O
some	O	O
brain	O	O
regions	O	O
on	O	O
the	O	O
test	O	O
day	O	O
showed	O	O
that	O	O
dopamine	B-Chemical	D004298
concentration	O	O
of	O	O
the	O	O
vehicle	O	O
/	O	O
scopolamine	B-Chemical	D012601
group	O	O
was	O	O
significantly	O	O
lower	O	O
than	O	O
that	O	O
of	O	O
the	O	O
vehicle	O	O
/	O	O
vehicle	O	O
group	O	O
,	O	O
but	O	O
this	O	O
phenomenon	O	O
was	O	O
reversed	O	O
when	O	O
s	B-Chemical	C008281
-	I-Chemical	C008281
limonene	I-Chemical	C008281
or	O	O
s	B-Chemical	C032208
-	I-Chemical	C032208
perillyl	I-Chemical	C032208
alcohol	I-Chemical	C032208
were	O	O
administered	O	O
before	O	O
the	O	O
injection	O	O
of	O	O
scopolamine	B-Chemical	D012601
.	O	O

Simultaneously	O	O
,	O	O
we	O	O
found	O	O
that	O	O
these	O	O
two	O	O
lemon	O	O
essential	O	O
oil	O	O
components	O	O
could	O	O
inhibit	O	O
acetylcholinesterase	O	O
activity	O	O
in	O	O
vitro	O	O
using	O	O
the	O	O
Ellman	O	O
method	O	O
.	O	O

The	O	O
selective	O	O
5	O	O
-	O	O
HT6	O	O
receptor	O	O
antagonist	O	O
Ro4368554	B-Chemical	C507242
restores	O	O
memory	O	O
performance	O	O
in	O	O
cholinergic	O	O
and	O	O
serotonergic	O	O
models	O	O
of	O	O
memory	B-Disease	D008569
deficiency	I-Disease	D008569
in	O	O
the	O	O
rat	O	O
.	O	O

Antagonists	O	O
at	O	O
serotonin	B-Chemical	D012701
type	O	O
6	O	O
(	O	O
5	B-Chemical	D012701
-	I-Chemical	D012701
HT	I-Chemical	D012701
(	O	O
6	O	O
)	O	O
)	O	O
receptors	O	O
show	O	O
activity	O	O
in	O	O
models	O	O
of	O	O
learning	O	O
and	O	O
memory	O	O
.	O	O

Although	O	O
the	O	O
underlying	O	O
mechanism	O	O
(	O	O
s	O	O
)	O	O
are	O	O
not	O	O
well	O	O
understood	O	O
,	O	O
these	O	O
effects	O	O
may	O	O
involve	O	O
an	O	O
increase	O	O
in	O	O
acetylcholine	B-Chemical	D000109
(	O	O
ACh	B-Chemical	D000109
)	O	O
levels	O	O
.	O	O

The	O	O
present	O	O
study	O	O
sought	O	O
to	O	O
characterize	O	O
the	O	O
cognitive	O	O
-	O	O
enhancing	O	O
effects	O	O
of	O	O
the	O	O
5	B-Chemical	D012701
-	I-Chemical	D012701
HT	I-Chemical	D012701
(	O	O
6	O	O
)	O	O
antagonist	O	O
Ro4368554	B-Chemical	C507242
(	O	O
3	B-Chemical	C507242
-	I-Chemical	C507242
benzenesulfonyl	I-Chemical	C507242
-	I-Chemical	C507242
7	I-Chemical	C507242
-	I-Chemical	C507242
(	I-Chemical	C507242
4	I-Chemical	C507242
-	I-Chemical	C507242
methyl	I-Chemical	C507242
-	I-Chemical	C507242
piperazin	I-Chemical	C507242
-	I-Chemical	C507242
1	I-Chemical	C507242
-	I-Chemical	C507242
yl	I-Chemical	C507242
)	I-Chemical	C507242
1H	I-Chemical	C507242
-	I-Chemical	C507242
indole	I-Chemical	C507242
)	O	O
in	O	O
a	O	O
rat	O	O
object	O	O
recognition	O	O
task	O	O
employing	O	O
a	O	O
cholinergic	O	O
(	O	O
scopolamine	B-Chemical	D012601
pretreatment	O	O
)	O	O
and	O	O
a	O	O
serotonergic	O	O
-	O	O
(	O	O
tryptophan	B-Chemical	D014364
(	O	O
TRP	B-Chemical	D014364
)	O	O
depletion	O	O
)	O	O
deficient	O	O
model	O	O
,	O	O
and	O	O
compared	O	O
its	O	O
pattern	O	O
of	O	O
action	O	O
with	O	O
that	O	O
of	O	O
the	O	O
acetylcholinesterase	O	O
inhibitor	O	O
metrifonate	B-Chemical	D014236
.	O	O

Initial	O	O
testing	O	O
in	O	O
a	O	O
time	O	O
-	O	O
dependent	O	O
forgetting	O	O
task	O	O
employing	O	O
a	O	O
24	O	O
-	O	O
h	O	O
delay	O	O
between	O	O
training	O	O
and	O	O
testing	O	O
showed	O	O
that	O	O
metrifonate	B-Chemical	D014236
improved	O	O
object	O	O
recognition	O	O
(	O	O
at	O	O
10	O	O
and	O	O
30	O	O
mg	O	O
/	O	O
kg	O	O
,	O	O
p	O	O
.	O	O

o	O	O
.	O	O

)	O	O
,	O	O
whereas	O	O
Ro4368554	B-Chemical	C507242
was	O	O
inactive	O	O
.	O	O

Both	O	O
,	O	O
Ro4368554	B-Chemical	C507242
(	O	O
3	O	O
and	O	O
10	O	O
mg	O	O
/	O	O
kg	O	O
,	O	O
intraperitoneally	O	O
(	O	O
i	O	O
.	O	O

p	O	O
.	O	O

)	O	O
)	O	O
and	O	O
metrifonate	B-Chemical	D014236
(	O	O
10	O	O
mg	O	O
/	O	O
kg	O	O
,	O	O
p	O	O
.	O	O

o	O	O
.	O	O

,	O	O
respectively	O	O
)	O	O
reversed	O	O
memory	B-Disease	D008569
deficits	I-Disease	D008569
induced	O	O
by	O	O
scopolamine	B-Chemical	D012601
and	O	O
TRP	B-Chemical	D014364
depletion	O	O
(	O	O
10	O	O
mg	O	O
/	O	O
kg	O	O
,	O	O
i	O	O
.	O	O

p	O	O
.	O	O

,	O	O
and	O	O
3	O	O
mg	O	O
/	O	O
kg	O	O
,	O	O
p	O	O
.	O	O

o	O	O
.	O	O

,	O	O
respectively	O	O
)	O	O
.	O	O

In	O	O
conclusion	O	O
,	O	O
although	O	O
Ro4368554	B-Chemical	C507242
did	O	O
not	O	O
improve	O	O
a	O	O
time	O	O
-	O	O
related	O	O
retention	O	O
deficit	O	O
,	O	O
it	O	O
reversed	O	O
a	O	O
cholinergic	O	O
and	O	O
a	O	O
serotonergic	O	O
memory	B-Disease	D008569
deficit	I-Disease	D008569
,	O	O
suggesting	O	O
that	O	O
both	O	O
mechanisms	O	O
may	O	O
be	O	O
involved	O	O
in	O	O
the	O	O
facilitation	O	O
of	O	O
object	O	O
memory	O	O
by	O	O
Ro4368554	B-Chemical	C507242
and	O	O
,	O	O
possibly	O	O
,	O	O
other	O	O
5	B-Chemical	D012701
-	I-Chemical	D012701
HT	I-Chemical	D012701
(	O	O
6	O	O
)	O	O
receptor	O	O
antagonists	O	O
.	O	O

Lone	O	O
atrial	B-Disease	D001281
fibrillation	I-Disease	D001281
associated	O	O
with	O	O
creatine	B-Chemical	D003401
monohydrate	O	O
supplementation	O	O
.	O	O

Atrial	B-Disease	D001281
fibrillation	I-Disease	D001281
in	O	O
young	O	O
patients	O	O
without	O	O
structural	O	O
heart	B-Disease	D006331
disease	I-Disease	D006331
is	O	O
rare	O	O
.	O	O

Therefore	O	O
,	O	O
when	O	O
the	O	O
arrhythmia	B-Disease	D001145
is	O	O
present	O	O
in	O	O
this	O	O
population	O	O
,	O	O
reversible	O	O
causes	O	O
must	O	O
be	O	O
identified	O	O
and	O	O
resolved	O	O
.	O	O

Thyroid	B-Disease	D013959
disorders	I-Disease	D013959
,	O	O
illicit	O	O
drug	O	O
or	O	O
stimulant	O	O
use	O	O
,	O	O
and	O	O
acute	B-Disease	D000435
alcohol	I-Disease	D000435
intoxication	I-Disease	D000435
are	O	O
among	O	O
these	O	O
causes	O	O
.	O	O

We	O	O
report	O	O
the	O	O
case	O	O
of	O	O
a	O	O
30	O	O
-	O	O
year	O	O
-	O	O
old	O	O
Caucasian	O	O
man	O	O
who	O	O
came	O	O
to	O	O
the	O	O
emergency	O	O
department	O	O
in	O	O
atrial	B-Disease	D001281
fibrillation	I-Disease	D001281
with	O	O
rapid	O	O
ventricular	O	O
response	O	O
.	O	O

His	O	O
medical	O	O
history	O	O
was	O	O
unremarkable	O	O
,	O	O
except	O	O
for	O	O
minor	O	O
fractures	B-Disease	D050723
of	O	O
the	O	O
fingers	O	O
and	O	O
foot	O	O
.	O	O

Thyroid	O	O
-	O	O
stimulating	O	O
hormone	O	O
,	O	O
magnesium	B-Chemical	D008274
,	O	O
and	O	O
potassium	B-Chemical	D011188
levels	O	O
were	O	O
within	O	O
normal	O	O
limits	O	O
,	O	O
urine	O	O
drug	O	O
screen	O	O
was	O	O
negative	O	O
,	O	O
and	O	O
alcohol	B-Chemical	D000431
use	O	O
was	O	O
denied	O	O
.	O	O

However	O	O
,	O	O
when	O	O
the	O	O
patient	O	O
was	O	O
questioned	O	O
about	O	O
use	O	O
of	O	O
herbal	O	O
products	O	O
and	O	O
supplements	O	O
,	O	O
the	O	O
use	O	O
of	O	O
creatine	B-Chemical	D003401
monohydrate	O	O
was	O	O
revealed	O	O
.	O	O

The	O	O
patient	O	O
was	O	O
admitted	O	O
to	O	O
the	O	O
hospital	O	O
,	O	O
anticoagulated	O	O
with	O	O
unfractionated	O	O
heparin	B-Chemical	D006493
,	O	O
and	O	O
given	O	O
intravenous	O	O
diltiazem	B-Chemical	D004110
for	O	O
rate	O	O
control	O	O
and	O	O
intravenous	O	O
amiodarone	B-Chemical	D000638
for	O	O
rate	O	O
and	O	O
rhythm	O	O
control	O	O
.	O	O

When	O	O
discharged	O	O
less	O	O
than	O	O
24	O	O
hours	O	O
later	O	O
,	O	O
he	O	O
was	O	O
receiving	O	O
metoprolol	B-Chemical	D008790
and	O	O
aspirin	B-Chemical	D001241
,	O	O
with	O	O
follow	O	O
-	O	O
up	O	O
plans	O	O
for	O	O
echocardiography	O	O
and	O	O
nuclear	O	O
imaging	O	O
to	O	O
assess	O	O
perfusion	O	O
.	O	O

Exogenous	O	O
creatine	B-Chemical	D003401
is	O	O
used	O	O
by	O	O
athletes	O	O
to	O	O
theoretically	O	O
improve	O	O
exercise	O	O
performance	O	O
.	O	O

Vegetarians	O	O
may	O	O
also	O	O
take	O	O
creatine	B-Chemical	D003401
to	O	O
replace	O	O
what	O	O
they	O	O
are	O	O
not	O	O
consuming	O	O
from	O	O
meat	O	O
,	O	O
fish	O	O
,	O	O
and	O	O
other	O	O
animal	O	O
products	O	O
.	O	O

Previous	O	O
anecdotal	O	O
reports	O	O
have	O	O
linked	O	O
creatine	B-Chemical	D003401
to	O	O
the	O	O
development	O	O
of	O	O
arrhythmia	B-Disease	D001145
.	O	O

Clinicians	O	O
must	O	O
be	O	O
diligent	O	O
when	O	O
interviewing	O	O
patients	O	O
about	O	O
their	O	O
drug	O	O
therapy	O	O
histories	O	O
and	O	O
include	O	O
questions	O	O
about	O	O
their	O	O
use	O	O
of	O	O
herbal	O	O
products	O	O
and	O	O
dietary	O	O
supplements	O	O
.	O	O

In	O	O
addition	O	O
,	O	O
it	O	O
is	O	O
important	O	O
to	O	O
report	O	O
adverse	O	O
effects	O	O
associated	O	O
with	O	O
frequently	O	O
consumed	O	O
supplements	O	O
and	O	O
herbal	O	O
products	O	O
to	O	O
the	O	O
Food	O	O
and	O	O
Drug	O	O
Administration	O	O
and	O	O
in	O	O
the	O	O
literature	O	O
.	O	O

Comparison	O	O
of	O	O
developmental	O	O
toxicity	B-Disease	D064420
of	O	O
selective	O	O
and	O	O
non	O	O
-	O	O
selective	O	O
cyclooxygenase	O	O
-	O	O
2	O	O
inhibitors	O	O
in	O	O
CRL	O	O
:	O	O
(	O	O
WI	O	O
)	O	O
WUBR	O	O
Wistar	O	O
rats	O	O
-	O	O
-	O	O
DFU	B-Chemical	C106876
and	O	O
piroxicam	B-Chemical	D010894
study	O	O
.	O	O

BACKGROUND	O	O
:	O	O
Cyclooxygenase	O	O
(	O	O
COX	O	O
)	O	O
inhibitors	O	O
are	O	O
one	O	O
of	O	O
the	O	O
most	O	O
often	O	O
ingested	O	O
drugs	O	O
during	O	O
pregnancy	O	O
.	O	O

Unlike	O	O
general	O	O
toxicity	B-Disease	D064420
data	O	O
,	O	O
their	O	O
prenatal	O	O
toxic	O	O
effects	O	O
were	O	O
not	O	O
extensively	O	O
studied	O	O
before	O	O
.	O	O

The	O	O
aim	O	O
of	O	O
the	O	O
experiment	O	O
was	O	O
to	O	O
evaluate	O	O
the	O	O
developmental	O	O
toxicity	B-Disease	D064420
of	O	O
the	O	O
non	O	O
-	O	O
selective	O	O
(	O	O
piroxicam	B-Chemical	D010894
)	O	O
and	O	O
selective	O	O
(	O	O
DFU	B-Chemical	C106876
;	O	O
5	B-Chemical	C106876
,	I-Chemical	C106876
5	I-Chemical	C106876
-	I-Chemical	C106876
dimethyl	I-Chemical	C106876
-	I-Chemical	C106876
3	I-Chemical	C106876
-	I-Chemical	C106876
(	I-Chemical	C106876
3	I-Chemical	C106876
-	I-Chemical	C106876
fluorophenyl	I-Chemical	C106876
)	I-Chemical	C106876
-	I-Chemical	C106876
4	I-Chemical	C106876
-	I-Chemical	C106876
(	I-Chemical	C106876
4	I-Chemical	C106876
-	I-Chemical	C106876
methylsulphonyl	I-Chemical	C106876
)	I-Chemical	C106876
phenyl	I-Chemical	C106876
-	I-Chemical	C106876
2	I-Chemical	C106876
(	I-Chemical	C106876
5H	I-Chemical	C106876
)	I-Chemical	C106876
-	I-Chemical	C106876
furanon	I-Chemical	C106876
)	O	O
COX	O	O
-	O	O
2	O	O
inhibitors	O	O
.	O	O

METHODS	O	O
:	O	O
Drugs	O	O
were	O	O
separately	O	O
,	O	O
orally	O	O
once	O	O
daily	O	O
dosed	O	O
to	O	O
pregnant	O	O
rats	O	O
from	O	O
day	O	O
8	O	O
to	O	O
21	O	O
(	O	O
GD1=plug	O	O
day	O	O
)	O	O
.	O	O

Doses	O	O
were	O	O
set	O	O
at	O	O
0	O	O
.	O	O

3	O	O
,	O	O
3	O	O
.	O	O

0	O	O
and	O	O
30	O	O
.	O	O

0mg	O	O
/	O	O
kg	O	O
for	O	O
piroxicam	B-Chemical	D010894
and	O	O
0	O	O
.	O	O

2	O	O
,	O	O
2	O	O
.	O	O

0	O	O
and	O	O
20	O	O
.	O	O

0mg	O	O
/	O	O
kg	O	O
for	O	O
DFU	B-Chemical	C106876
.	O	O

Fetuses	O	O
were	O	O
delivered	O	O
on	O	O
GD	O	O
21	O	O
and	O	O
routinely	O	O
examined	O	O
.	O	O

Comprehensive	O	O
clinical	O	O
and	O	O
developmental	O	O
measurements	O	O
were	O	O
done	O	O
.	O	O

The	O	O
pooled	O	O
statistical	O	O
analysis	O	O
for	O	O
ventricular	O	O
septal	O	O
(	O	O
VSD	O	O
)	O	O
and	O	O
midline	O	O
(	O	O
MD	O	O
)	O	O
defects	O	O
was	O	O
performed	O	O
for	O	O
rat	O	O
fetuses	O	O
exposed	O	O
to	O	O
piroxicam	B-Chemical	D010894
,	O	O
selective	O	O
and	O	O
non	O	O
-	O	O
selective	O	O
COX	O	O
-	O	O
2	O	O
inhibitor	O	O
based	O	O
on	O	O
present	O	O
and	O	O
historic	O	O
data	O	O
.	O	O

RESULTS	O	O
:	O	O
Maternal	O	O
toxicity	B-Disease	D064420
,	O	O
intrauterine	B-Disease	D005317
growth	I-Disease	D005317
retardation	I-Disease	D005317
,	O	O
and	O	O
increase	B-Disease	D009139
of	I-Disease	D009139
external	I-Disease	D009139
and	I-Disease	D009139
skeletal	I-Disease	D009139
variations	I-Disease	D009139
were	O	O
found	O	O
in	O	O
rats	O	O
treated	O	O
with	O	O
the	O	O
highest	O	O
dose	O	O
of	O	O
piroxicam	B-Chemical	D010894
.	O	O

Decrease	O	O
of	O	O
fetal	O	O
length	O	O
was	O	O
the	O	O
only	O	O
signs	O	O
of	O	O
the	O	O
DFU	B-Chemical	C106876
developmental	O	O
toxicity	B-Disease	D064420
observed	O	O
in	O	O
pups	O	O
exposed	O	O
to	O	O
the	O	O
highest	O	O
compound	O	O
dose	O	O
.	O	O

Lack	O	O
of	O	O
teratogenicity	O	O
was	O	O
found	O	O
in	O	O
piroxicam	B-Chemical	D010894
and	O	O
DFU	B-Chemical	C106876
-	O	O
exposed	O	O
groups	O	O
.	O	O

Prenatal	O	O
exposure	O	O
to	O	O
non	O	O
-	O	O
selective	O	O
COX	O	O
inhibitors	O	O
increases	O	O
the	O	O
risk	O	O
of	O	O
VSD	O	O
and	O	O
MD	O	O
when	O	O
compared	O	O
to	O	O
historic	O	O
control	O	O
but	O	O
not	O	O
with	O	O
selective	O	O
COX	O	O
-	O	O
2	O	O
inhibitors	O	O
.	O	O

CONCLUSION	O	O
:	O	O
Both	O	O
selective	O	O
and	O	O
non	O	O
-	O	O
selective	O	O
COX	O	O
-	O	O
2	O	O
inhibitors	O	O
were	O	O
toxic	O	O
for	O	O
rats	O	O
fetuses	O	O
when	O	O
administered	O	O
in	O	O
the	O	O
highest	O	O
dose	O	O
.	O	O

Unlike	O	O
DFU	B-Chemical	C106876
,	O	O
piroxicam	B-Chemical	D010894
was	O	O
also	O	O
highly	O	O
toxic	O	O
to	O	O
the	O	O
dams	O	O
.	O	O

Prenatal	O	O
exposure	O	O
to	O	O
selective	O	O
COX	O	O
-	O	O
2	O	O
inhibitors	O	O
does	O	O
not	O	O
increase	O	O
the	O	O
risk	O	O
of	O	O
ventricular	O	O
septal	O	O
and	O	O
midline	O	O
defects	O	O
in	O	O
rat	O	O
when	O	O
compared	O	O
to	O	O
non	O	O
-	O	O
selective	O	O
drugs	O	O
and	O	O
historic	O	O
control	O	O
.	O	O

Protective	O	O
efficacy	O	O
of	O	O
neuroactive	O	O
steroids	B-Chemical	D013256
against	O	O
cocaine	B-Chemical	D003042
kindled	O	O
-	O	O
seizures	B-Disease	D012640
in	O	O
mice	O	O
.	O	O

Neuroactive	O	O
steroids	B-Chemical	D013256
demonstrate	O	O
pharmacological	O	O
actions	O	O
that	O	O
have	O	O
relevance	O	O
for	O	O
a	O	O
host	O	O
of	O	O
neurological	O	O
and	O	O
psychiatric	O	O
disorders	O	O
.	O	O

They	O	O
offer	O	O
protection	O	O
against	O	O
seizures	B-Disease	D012640
in	O	O
a	O	O
range	O	O
of	O	O
models	O	O
and	O	O
seem	O	O
to	O	O
inhibit	O	O
certain	O	O
stages	O	O
of	O	O
drug	B-Disease	D019966
dependence	I-Disease	D019966
in	O	O
preclinical	O	O
assessments	O	O
.	O	O

The	O	O
present	O	O
study	O	O
was	O	O
designed	O	O
to	O	O
evaluate	O	O
two	O	O
endogenous	O	O
and	O	O
one	O	O
synthetic	O	O
neuroactive	O	O
steroid	B-Chemical	D013256
that	O	O
positively	O	O
modulate	O	O
the	O	O
gamma	B-Chemical	D005680
-	I-Chemical	D005680
aminobutyric	I-Chemical	D005680
acid	I-Chemical	D005680
(	O	O
GABA	B-Chemical	D005680
(	O	O
A	O	O
)	O	O
)	O	O
receptor	O	O
against	O	O
the	O	O
increase	O	O
in	O	O
sensitivity	O	O
to	O	O
the	O	O
convulsant	O	O
effects	O	O
of	O	O
cocaine	B-Chemical	D003042
engendered	O	O
by	O	O
repeated	O	O
cocaine	B-Chemical	D003042
administration	O	O
(	O	O
seizure	B-Disease	D012640
kindling	O	O
)	O	O
.	O	O

Allopregnanolone	B-Chemical	D011280
(	O	O
3alpha	B-Chemical	D011280
-	I-Chemical	D011280
hydroxy	I-Chemical	D011280
-	I-Chemical	D011280
5alpha	I-Chemical	D011280
-	I-Chemical	D011280
pregnan	I-Chemical	D011280
-	I-Chemical	D011280
20	I-Chemical	D011280
-	I-Chemical	D011280
one	I-Chemical	D011280
)	O	O
,	O	O
pregnanolone	B-Chemical	D011280
(	O	O
3alpha	B-Chemical	D011280
-	I-Chemical	D011280
hydroxy	I-Chemical	D011280
-	I-Chemical	D011280
5beta	I-Chemical	D011280
-	I-Chemical	D011280
pregnan	I-Chemical	D011280
-	I-Chemical	D011280
20	I-Chemical	D011280
-	I-Chemical	D011280
one	I-Chemical	D011280
)	O	O
and	O	O
ganaxolone	B-Chemical	C105051
(	O	O
a	O	O
synthetic	O	O
derivative	O	O
of	O	O
allopregnanolone	B-Chemical	D011280
3alpha	B-Chemical	C105051
-	I-Chemical	C105051
hydroxy	I-Chemical	C105051
-	I-Chemical	C105051
3beta	I-Chemical	C105051
-	I-Chemical	C105051
methyl	I-Chemical	C105051
-	I-Chemical	C105051
5alpha	I-Chemical	C105051
-	I-Chemical	C105051
pregnan	I-Chemical	C105051
-	I-Chemical	C105051
20	I-Chemical	C105051
-	I-Chemical	C105051
one	I-Chemical	C105051
)	O	O
were	O	O
tested	O	O
for	O	O
their	O	O
ability	O	O
to	O	O
suppress	O	O
the	O	O
expression	O	O
(	O	O
anticonvulsant	O	O
effect	O	O
)	O	O
and	O	O
development	O	O
(	O	O
antiepileptogenic	O	O
effect	O	O
)	O	O
of	O	O
cocaine	B-Chemical	D003042
-	O	O
kindled	O	O
seizures	B-Disease	D012640
in	O	O
male	O	O
,	O	O
Swiss	O	O
-	O	O
Webster	O	O
mice	O	O
.	O	O

Kindled	O	O
seizures	B-Disease	D012640
were	O	O
induced	O	O
by	O	O
daily	O	O
administration	O	O
of	O	O
60	O	O
mg	O	O
/	O	O
kg	O	O
cocaine	B-Chemical	D003042
for	O	O
5	O	O
days	O	O
.	O	O

All	O	O
of	O	O
these	O	O
positive	O	O
GABA	B-Chemical	D005680
(	O	O
A	O	O
)	O	O
modulators	O	O
suppressed	O	O
the	O	O
expression	O	O
of	O	O
kindled	O	O
seizures	B-Disease	D012640
,	O	O
whereas	O	O
only	O	O
allopregnanolone	B-Chemical	D011280
and	O	O
ganaxolone	B-Chemical	C105051
inhibited	O	O
the	O	O
development	O	O
of	O	O
kindling	O	O
.	O	O

Allopregnanolone	B-Chemical	D011280
and	O	O
pregnanolone	B-Chemical	D011280
,	O	O
but	O	O
not	O	O
ganaxolone	B-Chemical	C105051
,	O	O
also	O	O
reduced	O	O
cumulative	O	O
lethality	O	O
associated	O	O
with	O	O
kindling	O	O
.	O	O

These	O	O
findings	O	O
demonstrate	O	O
that	O	O
some	O	O
neuroactive	O	O
steroids	B-Chemical	D013256
attenuate	O	O
convulsant	O	O
and	O	O
sensitizing	O	O
properties	O	O
of	O	O
cocaine	B-Chemical	D003042
and	O	O
add	O	O
to	O	O
a	O	O
growing	O	O
literature	O	O
on	O	O
their	O	O
potential	O	O
use	O	O
in	O	O
the	O	O
modulation	O	O
of	O	O
effects	O	O
of	O	O
drugs	O	O
of	O	O
abuse	O	O
.	O	O

Kidney	O	O
function	O	O
and	O	O
morphology	O	O
after	O	O
short	O	O
-	O	O
term	O	O
combination	O	O
therapy	O	O
with	O	O
cyclosporine	B-Chemical	D016572
A	I-Chemical	D016572
,	O	O
tacrolimus	B-Chemical	D016559
and	O	O
sirolimus	B-Chemical	D020123
in	O	O
the	O	O
rat	O	O
.	O	O

BACKGROUND	O	O
:	O	O
Sirolimus	B-Chemical	D020123
(	O	O
SRL	B-Chemical	D020123
)	O	O
may	O	O
supplement	O	O
calcineurin	O	O
inhibitors	O	O
in	O	O
clinical	O	O
organ	O	O
transplantation	O	O
.	O	O

These	O	O
are	O	O
nephrotoxic	B-Disease	D007674
,	O	O
but	O	O
SRL	B-Chemical	D020123
seems	O	O
to	O	O
act	O	O
differently	O	O
displaying	O	O
only	O	O
minor	O	O
nephrotoxic	B-Disease	D007674
effects	O	O
,	O	O
although	O	O
this	O	O
question	O	O
is	O	O
still	O	O
open	O	O
.	O	O

In	O	O
a	O	O
number	O	O
of	O	O
treatment	O	O
protocols	O	O
where	O	O
SRL	B-Chemical	D020123
was	O	O
combined	O	O
with	O	O
a	O	O
calcineurin	O	O
inhibitor	O	O
indications	O	O
of	O	O
a	O	O
synergistic	O	O
nephrotoxic	B-Disease	D007674
effect	O	O
were	O	O
described	O	O
.	O	O

The	O	O
aim	O	O
of	O	O
this	O	O
study	O	O
was	O	O
to	O	O
examine	O	O
further	O	O
the	O	O
renal	O	O
function	O	O
,	O	O
including	O	O
morphological	O	O
analysis	O	O
of	O	O
the	O	O
kidneys	O	O
of	O	O
male	O	O
Sprague	O	O
-	O	O
Dawley	O	O
rats	O	O
treated	O	O
with	O	O
either	O	O
cyclosporine	B-Chemical	D016572
A	I-Chemical	D016572
(	O	O
CsA	B-Chemical	D016572
)	O	O
,	O	O
tacrolimus	B-Chemical	D016559
(	O	O
FK506	B-Chemical	D016559
)	O	O
or	O	O
SRL	B-Chemical	D020123
as	O	O
monotherapies	O	O
or	O	O
in	O	O
different	O	O
combinations	O	O
.	O	O

METHODS	O	O
:	O	O
For	O	O
a	O	O
period	O	O
of	O	O
2	O	O
weeks	O	O
,	O	O
CsA	B-Chemical	D016572
15	O	O
mg	O	O
/	O	O
kg	O	O
/	O	O
day	O	O
(	O	O
given	O	O
orally	O	O
)	O	O
,	O	O
FK506	B-Chemical	D016559
3	O	O
.	O	O

0	O	O
mg	O	O
/	O	O
kg	O	O
/	O	O
day	O	O
(	O	O
given	O	O
orally	O	O
)	O	O
or	O	O
SRL	B-Chemical	D020123
0	O	O
.	O	O

4	O	O
mg	O	O
/	O	O
kg	O	O
/	O	O
day	O	O
(	O	O
given	O	O
intraperitoneally	O	O
)	O	O
was	O	O
administered	O	O
once	O	O
a	O	O
day	O	O
as	O	O
these	O	O
doses	O	O
have	O	O
earlier	O	O
been	O	O
found	O	O
to	O	O
achieve	O	O
a	O	O
significant	O	O
immunosuppressive	O	O
effect	O	O
in	O	O
Sprague	O	O
-	O	O
Dawley	O	O
rats	O	O
.	O	O

In	O	O
the	O	O
'conscious	O	O
catheterized	O	O
rat'	O	O
model	O	O
,	O	O
the	O	O
glomerular	O	O
filtration	O	O
rate	O	O
(	O	O
GFR	O	O
)	O	O
was	O	O
measured	O	O
as	O	O
the	O	O
clearance	O	O
of	O	O
Cr	O	O
(	O	O
EDTA	O	O
)	O	O
.	O	O

The	O	O
morphological	O	O
analysis	O	O
of	O	O
the	O	O
kidneys	O	O
included	O	O
a	O	O
semi	O	O
-	O	O
quantitative	O	O
scoring	O	O
system	O	O
analysing	O	O
the	O	O
degree	O	O
of	O	O
striped	O	O
fibrosis	B-Disease	D005355
,	O	O
subcapsular	O	O
fibrosis	B-Disease	D005355
and	O	O
the	O	O
number	O	O
of	O	O
basophilic	O	O
tubules	O	O
,	O	O
plus	O	O
an	O	O
additional	O	O
stereological	O	O
analysis	O	O
of	O	O
the	O	O
total	O	O
grade	O	O
of	O	O
fibrosis	B-Disease	D005355
in	O	O
the	O	O
cortex	O	O
stained	O	O
with	O	O
Sirius	O	O
Red	O	O
.	O	O

RESULTS	O	O
:	O	O
CsA	B-Chemical	D016572
,	O	O
FK506	B-Chemical	D016559
and	O	O
SRL	B-Chemical	D020123
all	O	O
significantly	O	O
decreased	O	O
the	O	O
GFR	O	O
.	O	O

A	O	O
further	O	O
deterioration	O	O
was	O	O
seen	O	O
when	O	O
CsA	B-Chemical	D016572
was	O	O
combined	O	O
with	O	O
either	O	O
FK506	B-Chemical	D016559
or	O	O
SRL	B-Chemical	D020123
,	O	O
whereas	O	O
the	O	O
GFR	O	O
remained	O	O
unchanged	O	O
in	O	O
the	O	O
group	O	O
treated	O	O
with	O	O
FK506	B-Chemical	D016559
plus	O	O
SRL	B-Chemical	D020123
when	O	O
compared	O	O
with	O	O
treatment	O	O
with	O	O
any	O	O
of	O	O
the	O	O
single	O	O
substances	O	O
.	O	O

The	O	O
morphological	O	O
changes	O	O
presented	O	O
a	O	O
similar	O	O
pattern	O	O
.	O	O

The	O	O
semi	O	O
-	O	O
quantitative	O	O
scoring	O	O
was	O	O
significantly	O	O
worst	O	O
in	O	O
the	O	O
group	O	O
treated	O	O
with	O	O
CsA	B-Chemical	D016572
plus	O	O
SRL	B-Chemical	D020123
(	O	O
P<0	O	O
.	O	O

001	O	O
compared	O	O
with	O	O
controls	O	O
)	O	O
and	O	O
the	O	O
analysis	O	O
of	O	O
the	O	O
total	O	O
grade	O	O
of	O	O
fibrosis	B-Disease	D005355
also	O	O
showed	O	O
the	O	O
highest	O	O
proportion	O	O
in	O	O
the	O	O
same	O	O
group	O	O
and	O	O
was	O	O
significantly	O	O
different	O	O
from	O	O
controls	O	O
(	O	O
P<0	O	O
.	O	O

02	O	O
)	O	O
.	O	O

The	O	O
FK506	B-Chemical	D016559
plus	O	O
SRL	B-Chemical	D020123
combination	O	O
showed	O	O
only	O	O
a	O	O
marginally	O	O
higher	O	O
degree	O	O
of	O	O
fibrosis	B-Disease	D005355
as	O	O
compared	O	O
with	O	O
controls	O	O
(	O	O
P=0	O	O
.	O	O

05	O	O
)	O	O
.	O	O

CONCLUSION	O	O
:	O	O
This	O	O
rat	O	O
study	O	O
demonstrated	O	O
a	O	O
synergistic	O	O
nephrotoxic	B-Disease	D007674
effect	O	O
of	O	O
CsA	B-Chemical	D016572
plus	O	O
SRL	B-Chemical	D020123
,	O	O
whereas	O	O
FK506	B-Chemical	D016559
plus	O	O
SRL	B-Chemical	D020123
was	O	O
better	O	O
tolerated	O	O
.	O	O

Effect	O	O
of	O	O
fucoidan	B-Chemical	C007789
treatment	O	O
on	O	O
collagenase	O	O
-	O	O
induced	O	O
intracerebral	B-Disease	D002543
hemorrhage	I-Disease	D002543
in	O	O
rats	O	O
.	O	O

Inflammatory	O	O
cells	O	O
are	O	O
postulated	O	O
to	O	O
mediate	O	O
some	O	O
of	O	O
the	O	O
brain	B-Disease	D001925
damage	I-Disease	D001925
following	O	O
ischemic	B-Disease	D002544
stroke	I-Disease	D002544
.	O	O

Intracerebral	B-Disease	D002543
hemorrhage	I-Disease	D002543
is	O	O
associated	O	O
with	O	O
more	O	O
inflammation	B-Disease	D007249
than	O	O
ischemic	B-Disease	D002544
stroke	I-Disease	D002544
.	O	O

We	O	O
tested	O	O
the	O	O
sulfated	O	O
polysaccharide	O	O
fucoidan	B-Chemical	C007789
,	O	O
which	O	O
has	O	O
been	O	O
reported	O	O
to	O	O
reduce	O	O
inflammatory	O	O
brain	B-Disease	D001925
damage	I-Disease	D001925
,	O	O
in	O	O
a	O	O
rat	O	O
model	O	O
of	O	O
intracerebral	B-Disease	D002543
hemorrhage	I-Disease	D002543
induced	O	O
by	O	O
injection	O	O
of	O	O
bacterial	O	O
collagenase	O	O
into	O	O
the	O	O
caudate	O	O
nucleus	O	O
.	O	O

Rats	O	O
were	O	O
treated	O	O
with	O	O
seven	O	O
day	O	O
intravenous	O	O
infusion	O	O
of	O	O
fucoidan	B-Chemical	C007789
(	O	O
30	O	O
micrograms	O	O
h	O	O
-	O	O
1	O	O
)	O	O
or	O	O
vehicle	O	O
.	O	O

The	O	O
hematoma	B-Disease	D006406
was	O	O
assessed	O	O
in	O	O
vivo	O	O
by	O	O
magnetic	O	O
resonance	O	O
imaging	O	O
.	O	O

Motor	O	O
behavior	O	O
,	O	O
passive	O	O
avoidance	O	O
,	O	O
and	O	O
skilled	O	O
forelimb	O	O
function	O	O
were	O	O
tested	O	O
repeatedly	O	O
for	O	O
six	O	O
weeks	O	O
.	O	O

Fucoidan	B-Chemical	C007789
-	O	O
treated	O	O
rats	O	O
exhibited	O	O
evidence	O	O
of	O	O
impaired	B-Disease	D020141
blood	I-Disease	D020141
clotting	I-Disease	D020141
and	O	O
hemodilution	B-Disease	D020141
,	O	O
had	O	O
larger	O	O
hematomas	B-Disease	D006406
,	O	O
and	O	O
tended	O	O
to	O	O
have	O	O
less	O	O
inflammation	B-Disease	D007249
in	O	O
the	O	O
vicinity	O	O
of	O	O
the	O	O
hematoma	B-Disease	D006406
after	O	O
three	O	O
days	O	O
.	O	O

They	O	O
showed	O	O
significantly	O	O
more	O	O
rapid	O	O
improvement	O	O
of	O	O
motor	O	O
function	O	O
in	O	O
the	O	O
first	O	O
week	O	O
following	O	O
hemorrhage	B-Disease	D006470
and	O	O
better	O	O
memory	O	O
retention	O	O
in	O	O
the	O	O
passive	O	O
avoidance	O	O
test	O	O
.	O	O

Acute	O	O
white	B-Disease	D001929
matter	I-Disease	D001929
edema	I-Disease	D001929
and	O	O
eventual	O	O
neuronal	B-Disease	D009410
loss	I-Disease	D009410
in	O	O
the	O	O
striatum	O	O
adjacent	O	O
to	O	O
the	O	O
hematoma	B-Disease	D006406
did	O	O
not	O	O
differ	O	O
between	O	O
the	O	O
two	O	O
groups	O	O
.	O	O

Investigation	O	O
of	O	O
more	O	O
specific	O	O
anti	O	O
-	O	O
inflammatory	O	O
agents	O	O
and	O	O
hemodiluting	O	O
agents	O	O
are	O	O
warranted	O	O
in	O	O
intracerebral	B-Disease	D002543
hemorrhage	I-Disease	D002543
.	O	O

Paracetamol	B-Chemical	D000082
-	O	O
associated	O	O
coma	B-Disease	D003128
,	O	O
metabolic	B-Disease	D000138
acidosis	I-Disease	D000138
,	O	O
renal	O	O
and	O	O
hepatic	O	O
failure	O	O
.	O	O

A	O	O
case	O	O
of	O	O
metabolic	B-Disease	D000138
acidosis	I-Disease	D000138
,	O	O
acute	O	O
renal	O	O
failure	O	O
and	O	O
hepatic	O	O
failure	O	O
following	O	O
paracetamol	B-Chemical	D000082
ingestion	O	O
is	O	O
presented	O	O
.	O	O

The	O	O
diagnostic	O	O
difficulty	O	O
at	O	O
presentation	O	O
is	O	O
highlighted	O	O
.	O	O

Continuous	O	O
arteriovenous	O	O
haemofiltration	O	O
proved	O	O
a	O	O
valuable	O	O
means	O	O
of	O	O
maintaining	O	O
fluid	O	O
and	O	O
electrolyte	O	O
balance	O	O
.	O	O

The	O	O
patient	O	O
recovered	O	O
.	O	O

Hepatic	O	O
reactions	O	O
associated	O	O
with	O	O
ketoconazole	B-Chemical	D007654
in	O	O
the	O	O
United	O	O
Kingdom	O	O
.	O	O

Ketoconazole	B-Chemical	D007654
was	O	O
introduced	O	O
in	O	O
the	O	O
United	O	O
Kingdom	O	O
in	O	O
1981	O	O
.	O	O

By	O	O
November	O	O
1984	O	O
the	O	O
Committee	O	O
on	O	O
Safety	O	O
of	O	O
Medicines	O	O
had	O	O
received	O	O
82	O	O
reports	O	O
of	O	O
possible	O	O
hepatotoxicity	B-Disease	D056486
associated	O	O
with	O	O
the	O	O
drug	O	O
,	O	O
including	O	O
five	O	O
deaths	B-Disease	D003643
.	O	O

An	O	O
analysis	O	O
of	O	O
the	O	O
75	O	O
cases	O	O
that	O	O
had	O	O
been	O	O
adequately	O	O
followed	O	O
up	O	O
suggested	O	O
that	O	O
16	O	O
,	O	O
including	O	O
three	O	O
deaths	B-Disease	D003643
,	O	O
were	O	O
probably	O	O
related	O	O
to	O	O
treatment	O	O
with	O	O
the	O	O
drug	O	O
.	O	O

Of	O	O
the	O	O
remainder	O	O
,	O	O
48	O	O
were	O	O
possibly	O	O
related	O	O
to	O	O
treatment	O	O
,	O	O
five	O	O
were	O	O
unlikely	O	O
to	O	O
be	O	O
so	O	O
,	O	O
and	O	O
six	O	O
were	O	O
unclassifiable	O	O
.	O	O

The	O	O
mean	O	O
age	O	O
of	O	O
patients	O	O
in	O	O
the	O	O
16	O	O
probable	O	O
cases	O	O
was	O	O
57	O	O
.	O	O

9	O	O
,	O	O
with	O	O
hepatotoxicity	B-Disease	D056486
being	O	O
more	O	O
common	O	O
in	O	O
women	O	O
.	O	O

The	O	O
average	O	O
duration	O	O
of	O	O
treatment	O	O
before	O	O
the	O	O
onset	O	O
of	O	O
jaundice	B-Disease	D007565
was	O	O
61	O	O
days	O	O
.	O	O

None	O	O
of	O	O
these	O	O
well	O	O
validated	O	O
cases	O	O
occurred	O	O
within	O	O
the	O	O
first	O	O
10	O	O
days	O	O
after	O	O
treatment	O	O
.	O	O

The	O	O
results	O	O
of	O	O
serum	O	O
liver	O	O
function	O	O
tests	O	O
suggested	O	O
hepatocellular	B-Disease	D056486
injury	I-Disease	D056486
in	O	O
10	O	O
(	O	O
63%	O	O
)	O	O
;	O	O
the	O	O
rest	O	O
showed	O	O
a	O	O
mixed	O	O
pattern	O	O
.	O	O

In	O	O
contrast	O	O
,	O	O
the	O	O
results	O	O
of	O	O
histological	O	O
examination	O	O
of	O	O
the	O	O
liver	O	O
often	O	O
showed	O	O
evidence	O	O
of	O	O
cholestasis	B-Disease	D002779
.	O	O

The	O	O
characteristics	O	O
of	O	O
the	O	O
48	O	O
patients	O	O
in	O	O
the	O	O
possible	O	O
cases	O	O
were	O	O
similar	O	O
.	O	O

Allergic	O	O
manifestations	O	O
such	O	O
as	O	O
rash	B-Disease	D005076
and	O	O
eosinophilia	B-Disease	D004802
were	O	O
rare	O	O
.	O	O

Hepatitis	B-Disease	D056486
was	O	O
usually	O	O
reversible	O	O
when	O	O
treatment	O	O
was	O	O
stopped	O	O
,	O	O
with	O	O
the	O	O
results	O	O
of	O	O
liver	O	O
function	O	O
tests	O	O
returning	O	O
to	O	O
normal	O	O
after	O	O
an	O	O
average	O	O
of	O	O
3	O	O
.	O	O

1	O	O
months	O	O
.	O	O

In	O	O
two	O	O
of	O	O
the	O	O
three	O	O
deaths	B-Disease	D003643
probably	O	O
associated	O	O
with	O	O
ketoconazole	B-Chemical	D007654
treatment	O	O
the	O	O
drug	O	O
had	O	O
been	O	O
continued	O	O
after	O	O
the	O	O
onset	O	O
of	O	O
jaundice	B-Disease	D007565
and	O	O
other	O	O
symptoms	O	O
of	O	O
hepatitis	B-Disease	D056486
.	O	O

Clinical	O	O
and	O	O
biochemical	O	O
monitoring	O	O
at	O	O
regular	O	O
intervals	O	O
for	O	O
evidence	O	O
of	O	O
hepatitis	B-Disease	D056486
is	O	O
advised	O	O
during	O	O
long	O	O
term	O	O
treatment	O	O
with	O	O
ketoconazole	B-Chemical	D007654
to	O	O
prevent	O	O
possible	O	O
serious	O	O
hepatic	B-Disease	D056486
injury	I-Disease	D056486
.	O	O

Combined	O	O
effects	O	O
of	O	O
prolonged	O	O
prostaglandin	B-Chemical	D000527
E1	I-Chemical	D000527
-	O	O
induced	O	O
hypotension	B-Disease	D007022
and	O	O
haemodilution	B-Disease	D020141
on	O	O
human	O	O
hepatic	O	O
function	O	O
.	O	O

Combined	O	O
effects	O	O
of	O	O
prolonged	O	O
prostaglandin	B-Chemical	D000527
E1	I-Chemical	D000527
(	O	O
PGE1	B-Chemical	D000527
)	O	O
-	O	O
induced	O	O
hypotension	B-Disease	D007022
and	O	O
haemodilution	B-Disease	D020141
on	O	O
hepatic	O	O
function	O	O
were	O	O
studied	O	O
in	O	O
30	O	O
patients	O	O
undergoing	O	O
hip	O	O
surgery	O	O
.	O	O

The	O	O
patients	O	O
were	O	O
randomly	O	O
allocated	O	O
to	O	O
one	O	O
of	O	O
three	O	O
groups	O	O
;	O	O
those	O	O
in	O	O
group	O	O
A	O	O
(	O	O
n	O	O
=	O	O
10	O	O
)	O	O
were	O	O
subjected	O	O
to	O	O
controlled	O	O
hypotension	B-Disease	D007022
alone	O	O
,	O	O
those	O	O
in	O	O
group	O	O
B	O	O
(	O	O
n	O	O
=	O	O
10	O	O
)	O	O
to	O	O
haemodilution	B-Disease	D020141
alone	O	O
and	O	O
those	O	O
in	O	O
group	O	O
C	O	O
(	O	O
n	O	O
=	O	O
10	O	O
)	O	O
to	O	O
both	O	O
controlled	O	O
hypotension	B-Disease	D007022
and	O	O
haemodilution	B-Disease	D020141
.	O	O

Haemodilution	B-Disease	D020141
in	O	O
groups	O	O
B	O	O
and	O	O
C	O	O
was	O	O
produced	O	O
by	O	O
withdrawing	O	O
approximately	O	O
1000	O	O
mL	O	O
of	O	O
blood	O	O
and	O	O
replacing	O	O
it	O	O
with	O	O
the	O	O
same	O	O
amount	O	O
of	O	O
dextran	B-Chemical	D003911
solution	O	O
,	O	O
and	O	O
final	O	O
haematocrit	O	O
values	O	O
were	O	O
21	O	O
or	O	O
22%	O	O
.	O	O

Controlled	O	O
hypotension	B-Disease	D007022
in	O	O
groups	O	O
A	O	O
and	O	O
C	O	O
was	O	O
induced	O	O
with	O	O
PGE1	B-Chemical	D000527
to	O	O
maintain	O	O
mean	O	O
arterial	O	O
blood	O	O
pressure	O	O
at	O	O
55	O	O
mmHg	O	O
for	O	O
180	O	O
min	O	O
.	O	O

Measurements	O	O
included	O	O
arterial	O	O
ketone	O	O
body	O	O
ratio	O	O
(	O	O
AKBR	O	O
,	O	O
aceto	B-Chemical	C016635
-	I-Chemical	C016635
acetate	I-Chemical	C016635
/	O	O
3	B-Chemical	D020155
-	I-Chemical	D020155
hydroxybutyrate	I-Chemical	D020155
)	O	O
and	O	O
clinical	O	O
hepatic	O	O
function	O	O
parameters	O	O
.	O	O

AKBR	O	O
and	O	O
biological	O	O
hepatic	O	O
function	O	O
tests	O	O
showed	O	O
no	O	O
change	O	O
throughout	O	O
the	O	O
time	O	O
course	O	O
in	O	O
groups	O	O
A	O	O
and	O	O
B	O	O
.	O	O

In	O	O
group	O	O
C	O	O
,	O	O
AKBR	O	O
showed	O	O
a	O	O
significant	O	O
decrease	O	O
at	O	O
120	O	O
min	O	O
(	O	O
-	O	O
40%	O	O
)	O	O
and	O	O
at	O	O
180	O	O
min	O	O
(	O	O
-	O	O
49%	O	O
)	O	O
after	O	O
the	O	O
start	O	O
of	O	O
hypotension	B-Disease	D007022
and	O	O
at	O	O
60	O	O
min	O	O
(	O	O
-	O	O
32%	O	O
)	O	O
after	O	O
recovery	O	O
of	O	O
normotension	O	O
,	O	O
and	O	O
SGOT	O	O
,	O	O
SGPT	O	O
,	O	O
LDH	O	O
and	O	O
total	O	O
bilirubin	B-Chemical	D001663
showed	O	O
significant	O	O
increases	O	O
after	O	O
operation	O	O
.	O	O

The	O	O
results	O	O
suggest	O	O
that	O	O
a	O	O
prolonged	O	O
combination	O	O
of	O	O
more	O	O
than	O	O
120	O	O
min	O	O
of	O	O
PGE1	B-Chemical	D000527
-	O	O
induced	O	O
hypotension	B-Disease	D007022
and	O	O
moderate	O	O
haemodilution	B-Disease	D020141
would	O	O
cause	O	O
impairment	B-Disease	D008107
of	I-Disease	D008107
hepatic	I-Disease	D008107
function	I-Disease	D008107
.	O	O

Levodopa	B-Chemical	D007980
-	O	O
induced	O	O
dyskinesias	B-Disease	D004409
in	O	O
patients	O	O
with	O	O
Parkinson's	B-Disease	D010300
disease	I-Disease	D010300
:	O	O
filling	O	O
the	O	O
bench	O	O
-	O	O
to	O	O
-	O	O
bedside	O	O
gap	O	O
.	O	O

Levodopa	B-Chemical	D007980
is	O	O
the	O	O
most	O	O
effective	O	O
drug	O	O
for	O	O
the	O	O
treatment	O	O
of	O	O
Parkinson's	B-Disease	D010300
disease	I-Disease	D010300
.	O	O

However	O	O
,	O	O
the	O	O
long	O	O
-	O	O
term	O	O
use	O	O
of	O	O
this	O	O
dopamine	B-Chemical	D004298
precursor	O	O
is	O	O
complicated	O	O
by	O	O
highly	O	O
disabling	O	O
fluctuations	O	O
and	O	O
dyskinesias	B-Disease	D004409
.	O	O

Although	O	O
preclinical	O	O
and	O	O
clinical	O	O
findings	O	O
suggest	O	O
pulsatile	O	O
stimulation	O	O
of	O	O
striatal	O	O
postsynaptic	O	O
receptors	O	O
as	O	O
a	O	O
key	O	O
mechanism	O	O
underlying	O	O
levodopa	B-Chemical	D007980
-	O	O
induced	O	O
dyskinesias	B-Disease	D004409
,	O	O
their	O	O
pathogenesis	O	O
is	O	O
still	O	O
unclear	O	O
.	O	O

In	O	O
recent	O	O
years	O	O
,	O	O
evidence	O	O
from	O	O
animal	O	O
models	O	O
of	O	O
Parkinson's	B-Disease	D010300
disease	I-Disease	D010300
has	O	O
provided	O	O
important	O	O
information	O	O
to	O	O
understand	O	O
the	O	O
effect	O	O
of	O	O
specific	O	O
receptor	O	O
and	O	O
post	O	O
-	O	O
receptor	O	O
molecular	O	O
mechanisms	O	O
underlying	O	O
the	O	O
development	O	O
of	O	O
dyskinetic	B-Disease	D004409
movements	I-Disease	D004409
.	O	O

Recent	O	O
preclinical	O	O
and	O	O
clinical	O	O
data	O	O
from	O	O
promising	O	O
lines	O	O
of	O	O
research	O	O
focus	O	O
on	O	O
the	O	O
differential	O	O
role	O	O
of	O	O
presynaptic	O	O
versus	O	O
postsynaptic	O	O
mechanisms	O	O
,	O	O
dopamine	B-Chemical	D004298
receptor	O	O
subtypes	O	O
,	O	O
ionotropic	O	O
and	O	O
metabotropic	O	O
glutamate	B-Chemical	D018698
receptors	O	O
,	O	O
and	O	O
non	O	O
-	O	O
dopaminergic	O	O
neurotransmitter	O	O
systems	O	O
in	O	O
the	O	O
pathophysiology	O	O
of	O	O
levodopa	B-Chemical	D007980
-	O	O
induced	O	O
dyskinesias	B-Disease	D004409
.	O	O

Prevention	O	O
of	O	O
seizures	B-Disease	D012640
and	O	O
reorganization	O	O
of	O	O
hippocampal	O	O
functions	O	O
by	O	O
transplantation	O	O
of	O	O
bone	O	O
marrow	O	O
cells	O	O
in	O	O
the	O	O
acute	O	O
phase	O	O
of	O	O
experimental	O	O
epilepsy	B-Disease	D004827
.	O	O

In	O	O
this	O	O
study	O	O
,	O	O
we	O	O
investigated	O	O
the	O	O
therapeutic	O	O
potential	O	O
of	O	O
bone	O	O
marrow	O	O
mononuclear	O	O
cells	O	O
(	O	O
BMCs	O	O
)	O	O
in	O	O
a	O	O
model	O	O
of	O	O
epilepsy	B-Disease	D004827
induced	O	O
by	O	O
pilocarpine	B-Chemical	D010862
in	O	O
rats	O	O
.	O	O

BMCs	O	O
obtained	O	O
from	O	O
green	O	O
fluorescent	O	O
protein	O	O
(	O	O
GFP	O	O
)	O	O
transgenic	O	O
mice	O	O
or	O	O
rats	O	O
were	O	O
transplanted	O	O
intravenously	O	O
after	O	O
induction	O	O
of	O	O
status	B-Disease	D013226
epilepticus	I-Disease	D013226
(	O	O
SE	B-Disease	D013226
)	O	O
.	O	O

Spontaneous	B-Disease	-1
recurrent	I-Disease	-1
seizures	I-Disease	-1
(	O	O
SRS	B-Disease	-1
)	O	O
were	O	O
monitored	O	O
using	O	O
Racine's	O	O
seizure	B-Disease	D012640
severity	O	O
scale	O	O
.	O	O

All	O	O
of	O	O
the	O	O
rats	O	O
in	O	O
the	O	O
saline	O	O
-	O	O
treated	O	O
epileptic	B-Disease	D004827
control	O	O
group	O	O
developed	O	O
SRS	B-Disease	-1
,	O	O
whereas	O	O
none	O	O
of	O	O
the	O	O
BMC	O	O
-	O	O
treated	O	O
epileptic	B-Disease	D004827
animals	O	O
had	O	O
seizures	B-Disease	D012640
in	O	O
the	O	O
short	O	O
term	O	O
(	O	O
15	O	O
days	O	O
after	O	O
transplantation	O	O
)	O	O
,	O	O
regardless	O	O
of	O	O
the	O	O
BMC	O	O
source	O	O
.	O	O

Over	O	O
the	O	O
long	O	O
-	O	O
term	O	O
chronic	O	O
phase	O	O
(	O	O
120	O	O
days	O	O
after	O	O
transplantation	O	O
)	O	O
,	O	O
only	O	O
25%	O	O
of	O	O
BMC	O	O
-	O	O
treated	O	O
epileptic	B-Disease	D004827
animals	O	O
had	O	O
seizures	B-Disease	D012640
,	O	O
but	O	O
with	O	O
a	O	O
lower	O	O
frequency	O	O
and	O	O
duration	O	O
compared	O	O
to	O	O
the	O	O
epileptic	B-Disease	D004827
control	O	O
group	O	O
.	O	O

The	O	O
density	O	O
of	O	O
hippocampal	O	O
neurons	O	O
in	O	O
the	O	O
brains	O	O
of	O	O
animals	O	O
treated	O	O
with	O	O
BMCs	O	O
was	O	O
markedly	O	O
preserved	O	O
.	O	O

At	O	O
hippocampal	O	O
Schaeffer	O	O
collateral	O	O
-	O	O
CA1	O	O
synapses	O	O
,	O	O
long	O	O
-	O	O
term	O	O
potentiation	O	O
was	O	O
preserved	O	O
in	O	O
BMC	O	O
-	O	O
transplanted	O	O
rats	O	O
compared	O	O
to	O	O
epileptic	B-Disease	D004827
controls	O	O
.	O	O

The	O	O
donor	O	O
-	O	O
derived	O	O
GFP	O	O
(	O	O
+	O	O
)	O	O
cells	O	O
were	O	O
rarely	O	O
found	O	O
in	O	O
the	O	O
brains	O	O
of	O	O
transplanted	O	O
epileptic	B-Disease	D004827
rats	O	O
.	O	O

In	O	O
conclusion	O	O
,	O	O
treatment	O	O
with	O	O
BMCs	O	O
can	O	O
prevent	O	O
the	O	O
development	O	O
of	O	O
chronic	O	O
seizures	B-Disease	D012640
,	O	O
reduce	O	O
neuronal	B-Disease	D009410
loss	I-Disease	D009410
,	O	O
and	O	O
influence	O	O
the	O	O
reorganization	O	O
of	O	O
the	O	O
hippocampal	O	O
neuronal	O	O
network	O	O
.	O	O

Cardioprotective	O	O
effect	O	O
of	O	O
salvianolic	B-Chemical	C066201
acid	I-Chemical	C066201
A	I-Chemical	C066201
on	O	O
isoproterenol	B-Chemical	D007545
-	O	O
induced	O	O
myocardial	B-Disease	D009203
infarction	I-Disease	D009203
in	O	O
rats	O	O
.	O	O

The	O	O
present	O	O
study	O	O
was	O	O
designed	O	O
to	O	O
evaluate	O	O
the	O	O
cardioprotective	O	O
potential	O	O
of	O	O
salvianolic	B-Chemical	C066201
acid	I-Chemical	C066201
A	I-Chemical	C066201
on	O	O
isoproterenol	B-Chemical	D007545
-	O	O
induced	O	O
myocardial	B-Disease	D009203
infarction	I-Disease	D009203
in	O	O
rats	O	O
.	O	O

Hemodynamic	O	O
parameters	O	O
and	O	O
lead	O	O
II	O	O
electrocardiograph	O	O
were	O	O
monitored	O	O
and	O	O
recorded	O	O
continuously	O	O
.	O	O

Cardiac	O	O
marker	O	O
enzymes	O	O
and	O	O
antioxidative	O	O
parameters	O	O
in	O	O
serum	O	O
and	O	O
heart	O	O
tissues	O	O
were	O	O
measured	O	O
.	O	O

Assay	O	O
for	O	O
mitochondrial	O	O
respiratory	O	O
function	O	O
and	O	O
histopathological	O	O
examination	O	O
of	O	O
heart	O	O
tissues	O	O
were	O	O
performed	O	O
.	O	O

Isoproterenol	B-Chemical	D007545
-	O	O
treated	O	O
rats	O	O
showed	O	O
significant	O	O
increases	O	O
in	O	O
the	O	O
levels	O	O
of	O	O
lactate	B-Chemical	D019344
dehydrogenase	O	O
,	O	O
aspartate	B-Chemical	D001224
transaminase	O	O
,	O	O
creatine	B-Chemical	D003401
kinase	O	O
and	O	O
malondialdehyde	B-Chemical	D008315
and	O	O
significant	O	O
decreases	O	O
in	O	O
the	O	O
activities	O	O
of	O	O
superoxide	B-Chemical	D013481
dismutase	O	O
,	O	O
catalase	O	O
and	O	O
glutathione	B-Chemical	D005978
peroxidase	O	O
in	O	O
serum	O	O
and	O	O
heart	O	O
.	O	O

These	O	O
rats	O	O
also	O	O
showed	O	O
declines	O	O
in	O	O
left	O	O
ventricular	O	O
systolic	O	O
pressure	O	O
,	O	O
maximum	O	O
and	O	O
minimum	O	O
rate	O	O
of	O	O
developed	O	O
left	O	O
ventricular	O	O
pressure	O	O
,	O	O
and	O	O
elevation	O	O
of	O	O
left	O	O
ventricular	O	O
end	O	O
-	O	O
diastolic	O	O
pressure	O	O
and	O	O
ST	O	O
-	O	O
segment	O	O
.	O	O

In	O	O
addition	O	O
,	O	O
mitochondrial	O	O
respiratory	B-Disease	D012131
dysfunction	I-Disease	D012131
characterized	O	O
by	O	O
decreased	O	O
respiratory	O	O
control	O	O
ratio	O	O
and	O	O
ADP	B-Chemical	D000244
/	O	O
O	O	O
was	O	O
observed	O	O
in	O	O
isoproterenol	B-Chemical	D007545
-	O	O
treated	O	O
rats	O	O
.	O	O

Administration	O	O
of	O	O
salvianolic	B-Chemical	C066201
acid	I-Chemical	C066201
A	I-Chemical	C066201
for	O	O
a	O	O
period	O	O
of	O	O
8	O	O
days	O	O
significantly	O	O
attenuated	O	O
isoproterenol	B-Chemical	D007545
-	O	O
induced	O	O
cardiac	B-Disease	D006331
dysfunction	I-Disease	D006331
and	O	O
myocardial	B-Disease	D009202
injury	I-Disease	D009202
and	O	O
improved	O	O
mitochondrial	O	O
respiratory	O	O
function	O	O
.	O	O

The	O	O
protective	O	O
role	O	O
of	O	O
salvianolic	B-Chemical	C066201
acid	I-Chemical	C066201
A	I-Chemical	C066201
against	O	O
isoproterenol	B-Chemical	D007545
-	O	O
induced	O	O
myocardial	B-Disease	D009202
damage	I-Disease	D009202
was	O	O
further	O	O
confirmed	O	O
by	O	O
histopathological	O	O
examination	O	O
.	O	O

The	O	O
results	O	O
of	O	O
our	O	O
study	O	O
suggest	O	O
that	O	O
salvianolic	B-Chemical	C066201
acid	I-Chemical	C066201
A	I-Chemical	C066201
possessing	O	O
antioxidant	O	O
activity	O	O
has	O	O
a	O	O
significant	O	O
protective	O	O
effect	O	O
against	O	O
isoproterenol	B-Chemical	D007545
-	O	O
induced	O	O
myocardial	B-Disease	D009203
infarction	I-Disease	D009203
.	O	O

Acute	O	O
effects	O	O
of	O	O
N	B-Chemical	C108761
-	I-Chemical	C108761
(	I-Chemical	C108761
2	I-Chemical	C108761
-	I-Chemical	C108761
propylpentanoyl	I-Chemical	C108761
)	I-Chemical	C108761
urea	I-Chemical	C108761
on	O	O
hippocampal	O	O
amino	B-Chemical	D000596
acid	I-Chemical	D000596
neurotransmitters	O	O
in	O	O
pilocarpine	B-Chemical	D010862
-	O	O
induced	O	O
seizure	B-Disease	D012640
in	O	O
rats	O	O
.	O	O

The	O	O
present	O	O
study	O	O
aimed	O	O
to	O	O
investigate	O	O
the	O	O
anticonvulsant	O	O
activity	O	O
as	O	O
well	O	O
as	O	O
the	O	O
effects	O	O
on	O	O
the	O	O
level	O	O
of	O	O
hippocampal	O	O
amino	B-Chemical	D000596
acid	I-Chemical	D000596
neurotransmitters	O	O
(	O	O
glutamate	B-Chemical	D018698
,	O	O
aspartate	B-Chemical	D001224
,	O	O
glycine	B-Chemical	D005998
and	O	O
GABA	B-Chemical	D005680
)	O	O
of	O	O
N	B-Chemical	C108761
-	I-Chemical	C108761
(	I-Chemical	C108761
2	I-Chemical	C108761
-	I-Chemical	C108761
propylpentanoyl	I-Chemical	C108761
)	I-Chemical	C108761
urea	I-Chemical	C108761
(	O	O
VPU	B-Chemical	C108761
)	O	O
in	O	O
comparison	O	O
to	O	O
its	O	O
parent	O	O
compound	O	O
,	O	O
valproic	B-Chemical	D014635
acid	I-Chemical	D014635
(	O	O
VPA	B-Chemical	D014635
)	O	O
.	O	O

VPU	B-Chemical	C108761
was	O	O
more	O	O
potent	O	O
than	O	O
VPA	B-Chemical	D014635
,	O	O
exhibiting	O	O
the	O	O
median	O	O
effective	O	O
dose	O	O
(	O	O
ED	O	O
(	O	O
50	O	O
)	O	O
)	O	O
of	O	O
49	O	O
mg	O	O
/	O	O
kg	O	O
in	O	O
protecting	O	O
rats	O	O
against	O	O
pilocarpine	B-Chemical	D010862
-	O	O
induced	O	O
seizure	B-Disease	D012640
whereas	O	O
the	O	O
corresponding	O	O
value	O	O
for	O	O
VPA	B-Chemical	D014635
was	O	O
322	O	O
mg	O	O
/	O	O
kg	O	O
.	O	O

In	O	O
vivo	O	O
microdialysis	O	O
demonstrated	O	O
that	O	O
an	O	O
intraperitoneal	O	O
administration	O	O
of	O	O
pilocarpine	B-Chemical	D010862
induced	O	O
a	O	O
pronounced	O	O
increment	O	O
of	O	O
hippocampal	O	O
glutamate	B-Chemical	D018698
and	O	O
aspartate	B-Chemical	D001224
whereas	O	O
no	O	O
significant	O	O
change	O	O
was	O	O
observed	O	O
on	O	O
the	O	O
level	O	O
of	O	O
glycine	B-Chemical	D005998
and	O	O
GABA	B-Chemical	D005680
.	O	O

Pretreatment	O	O
with	O	O
either	O	O
VPU	B-Chemical	C108761
(	O	O
50	O	O
and	O	O
100	O	O
mg	O	O
/	O	O
kg	O	O
)	O	O
or	O	O
VPA	B-Chemical	D014635
(	O	O
300	O	O
and	O	O
600	O	O
mg	O	O
/	O	O
kg	O	O
)	O	O
completely	O	O
abolished	O	O
pilocarpine	B-Chemical	D010862
-	O	O
evoked	O	O
increases	O	O
in	O	O
extracellular	O	O
glutamate	B-Chemical	D018698
and	O	O
aspartate	B-Chemical	D001224
.	O	O

In	O	O
addition	O	O
,	O	O
a	O	O
statistically	O	O
significant	O	O
reduction	O	O
was	O	O
also	O	O
observed	O	O
on	O	O
the	O	O
level	O	O
of	O	O
GABA	B-Chemical	D005680
and	O	O
glycine	B-Chemical	D005998
but	O	O
less	O	O
than	O	O
a	O	O
drastic	O	O
reduction	O	O
of	O	O
glutamate	B-Chemical	D018698
and	O	O
aspartate	B-Chemical	D001224
level	O	O
.	O	O

Based	O	O
on	O	O
the	O	O
finding	O	O
that	O	O
VPU	B-Chemical	C108761
and	O	O
VPA	B-Chemical	D014635
could	O	O
protect	O	O
the	O	O
animals	O	O
against	O	O
pilocarpine	B-Chemical	D010862
-	O	O
induced	O	O
seizure	B-Disease	D012640
it	O	O
is	O	O
suggested	O	O
that	O	O
the	O	O
reduction	O	O
of	O	O
inhibitory	O	O
amino	B-Chemical	D000596
acid	I-Chemical	D000596
neurotransmitters	O	O
was	O	O
comparatively	O	O
minor	O	O
and	O	O
offset	O	O
by	O	O
a	O	O
pronounced	O	O
reduction	O	O
of	O	O
glutamate	B-Chemical	D018698
and	O	O
aspartate	B-Chemical	D001224
.	O	O

Therefore	O	O
,	O	O
like	O	O
VPA	B-Chemical	D014635
,	O	O
the	O	O
finding	O	O
that	O	O
VPU	B-Chemical	C108761
could	O	O
drastically	O	O
reduce	O	O
pilocarpine	B-Chemical	D010862
-	O	O
induced	O	O
increases	O	O
in	O	O
glutamate	B-Chemical	D018698
and	O	O
aspartate	B-Chemical	D001224
should	O	O
account	O	O
,	O	O
at	O	O
least	O	O
partly	O	O
,	O	O
for	O	O
its	O	O
anticonvulsant	O	O
activity	O	O
observed	O	O
in	O	O
pilocarpine	B-Chemical	D010862
-	O	O
induced	O	O
seizure	B-Disease	D012640
in	O	O
experimental	O	O
animals	O	O
.	O	O

Some	O	O
other	O	O
mechanism	O	O
than	O	O
those	O	O
being	O	O
reported	O	O
herein	O	O
should	O	O
be	O	O
further	O	O
investigated	O	O
.	O	O

Acute	O	O
hepatitis	B-Disease	D056486
attack	O	O
after	O	O
exposure	O	O
to	O	O
telithromycin	B-Chemical	C106791
.	O	O

INTRODUCTION	O	O
:	O	O
Antibiotic	O	O
-	O	O
associated	O	O
hepatotoxicity	B-Disease	D056486
is	O	O
rare	O	O
.	O	O

With	O	O
widespread	O	O
use	O	O
of	O	O
antimicrobial	O	O
agents	O	O
,	O	O
however	O	O
,	O	O
hepatic	B-Disease	D056486
injury	I-Disease	D056486
occurs	O	O
frequently	O	O
,	O	O
and	O	O
among	O	O
adverse	B-Disease	D064420
drug	I-Disease	D064420
reactions	I-Disease	D064420
,	O	O
idiosyncratic	O	O
reactions	O	O
are	O	O
the	O	O
most	O	O
serious	O	O
.	O	O

CASE	O	O
SUMMARY	O	O
:	O	O
A	O	O
25	O	O
-	O	O
year	O	O
-	O	O
old	O	O
male	O	O
patient	O	O
,	O	O
with	O	O
a	O	O
height	O	O
of	O	O
175	O	O
cm	O	O
and	O	O
weight	O	O
of	O	O
72	O	O
kg	O	O
presented	O	O
to	O	O
Marmara	O	O
University	O	O
Hospital	O	O
Emergency	O	O
Department	O	O
,	O	O
Istanbul	O	O
,	O	O
Turkey	O	O
,	O	O
with	O	O
5	O	O
days'	O	O
history	O	O
of	O	O
jaundice	B-Disease	D007565
,	O	O
malaise	O	O
,	O	O
nausea	B-Disease	D009325
,	O	O
and	O	O
vomiting	B-Disease	D014839
.	O	O

He	O	O
had	O	O
been	O	O
prescribed	O	O
telithromycin	B-Chemical	C106791
400	O	O
mg	O	O
/	O	O
d	O	O
PO	O	O
to	O	O
treat	O	O
an	O	O
upper	B-Disease	D012141
respiratory	I-Disease	D012141
tract	I-Disease	D012141
infection	I-Disease	D012141
7	O	O
days	O	O
prior	O	O
.	O	O

Admission	O	O
laboratory	O	O
tests	O	O
were	O	O
as	O	O
follows	O	O
:	O	O
alanine	B-Chemical	D000409
aminotransferase	O	O
,	O	O
67	O	O
U	O	O
/	O	O
L	O	O
(	O	O
reference	O	O
range	O	O
,	O	O
10	O	O
-	O	O
37	O	O
U	O	O
/	O	O
L	O	O
)	O	O
;	O	O
aspartate	B-Chemical	D001224
aminotransferase	O	O
,	O	O
98	O	O
U	O	O
/	O	O
L	O	O
(	O	O
10	O	O
-	O	O
40	O	O
U	O	O
/	O	O
L	O	O
)	O	O
;	O	O
alkaline	O	O
phosphatase	O	O
,	O	O
513	O	O
U	O	O
/	O	O
L	O	O
(	O	O
0	O	O
-	O	O
270	O	O
U	O	O
/	O	O
L	O	O
)	O	O
;	O	O
gamma	O	O
-	O	O
glutamyltransferase	O	O
,	O	O
32	O	O
U	O	O
/	O	O
L	O	O
(	O	O
7	O	O
-	O	O
49	O	O
U	O	O
/	O	O
L	O	O
)	O	O
;	O	O
amylase	O	O
,	O	O
46	O	O
U	O	O
/	O	O
L	O	O
(	O	O
0	O	O
-	O	O
220	O	O
U	O	O
/	O	O
L	O	O
)	O	O
;	O	O
total	O	O
bilirubin	B-Chemical	D001663
,	O	O
20	O	O
.	O	O

1	O	O
mg	O	O
/	O	O
dL	O	O
(	O	O
0	O	O
.	O	O

2	O	O
-	O	O
1	O	O
.	O	O

0	O	O
mg	O	O
/	O	O
dL	O	O
)	O	O
;	O	O
direct	O	O
bilirubin	B-Chemical	D001663
,	O	O
14	O	O
.	O	O

8	O	O
mg	O	O
/	O	O
dL	O	O
(	O	O
0	O	O
-	O	O
0	O	O
.	O	O

3	O	O
mg	O	O
/	O	O
dL	O	O
)	O	O
;	O	O
and	O	O
albumin	O	O
,	O	O
4	O	O
.	O	O

7	O	O
mg	O	O
/	O	O
dL	O	O
(	O	O
3	O	O
.	O	O

5	O	O
-	O	O
5	O	O
.	O	O

4	O	O
mg	O	O
/	O	O
dL	O	O
)	O	O
.	O	O

No	O	O
toxin	O	O
,	O	O
alcohol	B-Chemical	D000431
,	O	O
or	O	O
other	O	O
drugs	O	O
were	O	O
reported	O	O
.	O	O

The	O	O
patient	O	O
had	O	O
suffered	O	O
a	O	O
previous	O	O
episode	O	O
of	O	O
"acute	O	O
hepatitis	B-Disease	D056486
of	O	O
unknown	O	O
origin	O	O
,	O	O
"	O	O
that	O	O
occurred	O	O
after	O	O
telithromycin	B-Chemical	C106791
usage	O	O
.	O	O

Both	O	O
incidents	O	O
occurred	O	O
within	O	O
a	O	O
year	O	O
.	O	O

DISCUSSION	O	O
:	O	O
Telithromycin	B-Chemical	C106791
is	O	O
the	O	O
first	O	O
of	O	O
the	O	O
ketolide	O	O
antibacterials	O	O
to	O	O
receive	O	O
US	O	O
Food	O	O
and	O	O
Drug	O	O
Administration	O	O
approval	O	O
for	O	O
clinical	O	O
use	O	O
.	O	O

It	O	O
has	O	O
been	O	O
associated	O	O
with	O	O
infrequent	O	O
and	O	O
usually	O	O
reversible	O	O
severe	O	O
hepatic	B-Disease	D008107
dysfunction	I-Disease	D008107
.	O	O

Based	O	O
on	O	O
a	O	O
score	O	O
of	O	O
8	O	O
on	O	O
the	O	O
Naranjo	O	O
adverse	B-Disease	D064420
drug	I-Disease	D064420
reaction	I-Disease	D064420
probability	O	O
scale	O	O
,	O	O
telithromycin	B-Chemical	C106791
was	O	O
the	O	O
probable	O	O
cause	O	O
of	O	O
acute	O	O
hepatitis	B-Disease	D056486
in	O	O
this	O	O
patient	O	O
,	O	O
and	O	O
pathological	O	O
findings	O	O
suggested	O	O
drug	O	O
-	O	O
induced	O	O
toxic	B-Disease	D056486
hepatitis	I-Disease	D056486
.	O	O

Recurrence	O	O
of	O	O
hepatitis	B-Disease	D056486
attack	O	O
might	O	O
have	O	O
been	O	O
avoided	O	O
if	O	O
the	O	O
initial	O	O
incident	O	O
had	O	O
been	O	O
communicated	O	O
to	O	O
the	O	O
attending	O	O
physician	O	O
who	O	O
prescribed	O	O
telithromycin	B-Chemical	C106791
the	O	O
second	O	O
time	O	O
.	O	O

CONCLUSION	O	O
:	O	O
Here	O	O
we	O	O
report	O	O
a	O	O
case	O	O
of	O	O
acute	O	O
hepatitis	B-Disease	D056486
probably	O	O
associated	O	O
with	O	O
the	O	O
administration	O	O
of	O	O
telithromycin	B-Chemical	C106791
.	O	O

Spironolactone	B-Chemical	D013148
-	O	O
induced	O	O
renal	B-Disease	D051437
insufficiency	I-Disease	D051437
and	O	O
hyperkalemia	B-Disease	D006947
in	O	O
patients	O	O
with	O	O
heart	B-Disease	D006333
failure	I-Disease	D006333
.	O	O

BACKGROUND	O	O
:	O	O
A	O	O
previous	O	O
randomized	O	O
controlled	O	O
trial	O	O
evaluating	O	O
the	O	O
use	O	O
of	O	O
spironolactone	B-Chemical	D013148
in	O	O
heart	B-Disease	D006333
failure	I-Disease	D006333
patients	O	O
reported	O	O
a	O	O
low	O	O
risk	O	O
of	O	O
hyperkalemia	B-Disease	D006947
(	O	O
2%	O	O
)	O	O
and	O	O
renal	B-Disease	D051437
insufficiency	I-Disease	D051437
(	O	O
0%	O	O
)	O	O
.	O	O

Because	O	O
treatments	O	O
for	O	O
heart	B-Disease	D006333
failure	I-Disease	D006333
have	O	O
changed	O	O
since	O	O
the	O	O
benefits	O	O
of	O	O
spironolactone	B-Chemical	D013148
were	O	O
reported	O	O
,	O	O
the	O	O
prevalence	O	O
of	O	O
these	O	O
complications	O	O
may	O	O
differ	O	O
in	O	O
current	O	O
clinical	O	O
practice	O	O
.	O	O

We	O	O
therefore	O	O
sought	O	O
to	O	O
determine	O	O
the	O	O
prevalence	O	O
and	O	O
clinical	O	O
associations	O	O
of	O	O
hyperkalemia	B-Disease	D006947
and	O	O
renal	B-Disease	D051437
insufficiency	I-Disease	D051437
in	O	O
heart	B-Disease	D006333
failure	I-Disease	D006333
patients	O	O
treated	O	O
with	O	O
spironolactone	B-Chemical	D013148
.	O	O

METHODS	O	O
:	O	O
We	O	O
performed	O	O
a	O	O
case	O	O
control	O	O
study	O	O
of	O	O
heart	B-Disease	D006333
failure	I-Disease	D006333
patients	O	O
treated	O	O
with	O	O
spironolactone	B-Chemical	D013148
in	O	O
our	O	O
clinical	O	O
practice	O	O
.	O	O

Cases	O	O
were	O	O
patients	O	O
who	O	O
developed	O	O
hyperkalemia	B-Disease	D006947
(	O	O
K	B-Chemical	D011188
(	O	O
+	O	O
)	O	O
>5	O	O
.	O	O

0	O	O
mEq	O	O
/	O	O
L	O	O
)	O	O
or	O	O
renal	B-Disease	D051437
insufficiency	I-Disease	D051437
(	O	O
Cr	B-Chemical	D002857
>or=2	O	O
.	O	O

5	O	O
mg	O	O
/	O	O
dL	O	O
)	O	O
,	O	O
and	O	O
they	O	O
were	O	O
compared	O	O
to	O	O
2	O	O
randomly	O	O
selected	O	O
controls	O	O
per	O	O
case	O	O
.	O	O

Clinical	O	O
characteristics	O	O
,	O	O
medications	O	O
,	O	O
and	O	O
serum	O	O
chemistries	O	O
at	O	O
baseline	O	O
and	O	O
follow	O	O
-	O	O
up	O	O
time	O	O
periods	O	O
were	O	O
compared	O	O
.	O	O

RESULTS	O	O
:	O	O
Sixty	O	O
-	O	O
seven	O	O
of	O	O
926	O	O
patients	O	O
(	O	O
7	O	O
.	O	O

2%	O	O
)	O	O
required	O	O
discontinuation	O	O
of	O	O
spironolactone	B-Chemical	D013148
due	O	O
to	O	O
hyperkalemia	B-Disease	D006947
(	O	O
n	O	O
=	O	O
33	O	O
)	O	O
or	O	O
renal	B-Disease	D051437
failure	I-Disease	D051437
(	O	O
n	O	O
=	O	O
34	O	O
)	O	O
.	O	O

Patients	O	O
who	O	O
developed	O	O
hyperkalemia	B-Disease	D006947
were	O	O
older	O	O
and	O	O
more	O	O
likely	O	O
to	O	O
have	O	O
diabetes	B-Disease	D003920
,	O	O
had	O	O
higher	O	O
baseline	O	O
serum	O	O
potassium	B-Chemical	D011188
levels	O	O
and	O	O
lower	O	O
baseline	O	O
potassium	B-Chemical	D011188
supplement	O	O
doses	O	O
,	O	O
and	O	O
were	O	O
more	O	O
likely	O	O
to	O	O
be	O	O
treated	O	O
with	O	O
beta	O	O
-	O	O
blockers	O	O
than	O	O
controls	O	O
(	O	O
n	O	O
=	O	O
134	O	O
)	O	O
.	O	O

Patients	O	O
who	O	O
developed	O	O
renal	B-Disease	D051437
insufficiency	I-Disease	D051437
had	O	O
lower	O	O
baseline	O	O
body	O	O
weight	O	O
and	O	O
higher	O	O
baseline	O	O
serum	O	O
creatinine	B-Chemical	D003404
,	O	O
required	O	O
higher	O	O
doses	O	O
of	O	O
loop	O	O
diuretics	O	O
,	O	O
and	O	O
were	O	O
more	O	O
likely	O	O
to	O	O
be	O	O
treated	O	O
with	O	O
thiazide	B-Chemical	D049971
diuretics	O	O
than	O	O
controls	O	O
.	O	O

CONCLUSIONS	O	O
:	O	O
Spironolactone	B-Chemical	D013148
-	O	O
induced	O	O
hyperkalemia	B-Disease	D006947
and	O	O
renal	B-Disease	D051437
insufficiency	I-Disease	D051437
are	O	O
more	O	O
common	O	O
in	O	O
our	O	O
clinical	O	O
experience	O	O
than	O	O
reported	O	O
previously	O	O
.	O	O

This	O	O
difference	O	O
is	O	O
explained	O	O
by	O	O
patient	O	O
comorbidities	O	O
and	O	O
more	O	O
frequent	O	O
use	O	O
of	O	O
beta	O	O
-	O	O
blockers	O	O
.	O	O

End	B-Disease	D007676
-	I-Disease	D007676
stage	I-Disease	D007676
renal	I-Disease	D007676
disease	I-Disease	D007676
(	O	O
ESRD	B-Disease	D007676
)	O	O
after	O	O
orthotopic	O	O
liver	O	O
transplantation	O	O
(	O	O
OLTX	O	O
)	O	O
using	O	O
calcineurin	O	O
-	O	O
based	O	O
immunotherapy	O	O
:	O	O
risk	O	O
of	O	O
development	O	O
and	O	O
treatment	O	O
.	O	O

BACKGROUND	O	O
:	O	O
The	O	O
calcineurin	O	O
inhibitors	O	O
cyclosporine	B-Chemical	D016572
and	O	O
tacrolimus	B-Chemical	D016559
are	O	O
both	O	O
known	O	O
to	O	O
be	O	O
nephrotoxic	B-Disease	D007674
.	O	O

Their	O	O
use	O	O
in	O	O
orthotopic	O	O
liver	O	O
transplantation	O	O
(	O	O
OLTX	O	O
)	O	O
has	O	O
dramatically	O	O
improved	O	O
success	O	O
rates	O	O
.	O	O

Recently	O	O
,	O	O
however	O	O
,	O	O
we	O	O
have	O	O
had	O	O
an	O	O
increase	O	O
of	O	O
patients	O	O
who	O	O
are	O	O
presenting	O	O
after	O	O
OLTX	O	O
with	O	O
end	B-Disease	D007676
-	I-Disease	D007676
stage	I-Disease	D007676
renal	I-Disease	D007676
disease	I-Disease	D007676
(	O	O
ESRD	B-Disease	D007676
)	O	O
.	O	O

This	O	O
retrospective	O	O
study	O	O
examines	O	O
the	O	O
incidence	O	O
and	O	O
treatment	O	O
of	O	O
ESRD	B-Disease	D007676
and	O	O
chronic	B-Disease	D007676
renal	I-Disease	D007676
failure	I-Disease	D007676
(	O	O
CRF	B-Disease	D007676
)	O	O
in	O	O
OLTX	O	O
patients	O	O
.	O	O

METHODS	O	O
:	O	O
Patients	O	O
receiving	O	O
an	O	O
OLTX	O	O
only	O	O
from	O	O
June	O	O
1985	O	O
through	O	O
December	O	O
of	O	O
1994	O	O
who	O	O
survived	O	O
6	O	O
months	O	O
postoperatively	O	O
were	O	O
studied	O	O
(	O	O
n=834	O	O
)	O	O
.	O	O

Our	O	O
prospectively	O	O
collected	O	O
database	O	O
was	O	O
the	O	O
source	O	O
of	O	O
information	O	O
.	O	O

Patients	O	O
were	O	O
divided	O	O
into	O	O
three	O	O
groups	O	O
:	O	O
Controls	O	O
,	O	O
no	O	O
CRF	B-Disease	D007676
or	O	O
ESRD	B-Disease	D007676
,	O	O
n=748	O	O
;	O	O
CRF	B-Disease	D007676
,	O	O
sustained	O	O
serum	O	O
creatinine	B-Chemical	D003404
>2	O	O
.	O	O

5	O	O
mg	O	O
/	O	O
dl	O	O
,	O	O
n=41	O	O
;	O	O
and	O	O
ESRD	B-Disease	D007676
,	O	O
n=45	O	O
.	O	O

Groups	O	O
were	O	O
compared	O	O
for	O	O
preoperative	O	O
laboratory	O	O
variables	O	O
,	O	O
diagnosis	O	O
,	O	O
postoperative	O	O
variables	O	O
,	O	O
survival	O	O
,	O	O
type	O	O
of	O	O
ESRD	B-Disease	D007676
therapy	O	O
,	O	O
and	O	O
survival	O	O
from	O	O
onset	O	O
of	O	O
ESRD	B-Disease	D007676
.	O	O

RESULTS	O	O
:	O	O
At	O	O
13	O	O
years	O	O
after	O	O
OLTX	O	O
,	O	O
the	O	O
incidence	O	O
of	O	O
severe	O	O
renal	B-Disease	D007674
dysfunction	I-Disease	D007674
was	O	O
18	O	O
.	O	O

1%	O	O
(	O	O
CRF	B-Disease	D007676
8	O	O
.	O	O

6%	O	O
and	O	O
ESRD	B-Disease	D007676
9	O	O
.	O	O

5%	O	O
)	O	O
.	O	O

Compared	O	O
with	O	O
control	O	O
patients	O	O
,	O	O
CRF	B-Disease	D007676
and	O	O
ESRD	B-Disease	D007676
patients	O	O
had	O	O
higher	O	O
preoperative	O	O
serum	O	O
creatinine	B-Chemical	D003404
levels	O	O
,	O	O
a	O	O
greater	O	O
percentage	O	O
of	O	O
patients	O	O
with	O	O
hepatorenal	B-Disease	D006530
syndrome	I-Disease	D006530
,	O	O
higher	O	O
percentage	O	O
requirement	O	O
for	O	O
dialysis	O	O
in	O	O
the	O	O
first	O	O
3	O	O
months	O	O
postoperatively	O	O
,	O	O
and	O	O
a	O	O
higher	O	O
1	O	O
-	O	O
year	O	O
serum	O	O
creatinine	B-Chemical	D003404
.	O	O

Multivariate	O	O
stepwise	O	O
logistic	O	O
regression	O	O
analysis	O	O
using	O	O
preoperative	O	O
and	O	O
postoperative	O	O
variables	O	O
identified	O	O
that	O	O
an	O	O
increase	O	O
of	O	O
serum	O	O
creatinine	B-Chemical	D003404
compared	O	O
with	O	O
average	O	O
at	O	O
1	O	O
year	O	O
,	O	O
3	O	O
months	O	O
,	O	O
and	O	O
4	O	O
weeks	O	O
postoperatively	O	O
were	O	O
independent	O	O
risk	O	O
factors	O	O
for	O	O
the	O	O
development	O	O
of	O	O
CRF	B-Disease	D007676
or	O	O
ESRD	B-Disease	D007676
with	O	O
odds	O	O
ratios	O	O
of	O	O
2	O	O
.	O	O

6	O	O
,	O	O
2	O	O
.	O	O

2	O	O
,	O	O
and	O	O
1	O	O
.	O	O

6	O	O
,	O	O
respectively	O	O
.	O	O

Overall	O	O
survival	O	O
from	O	O
the	O	O
time	O	O
of	O	O
OLTX	O	O
was	O	O
not	O	O
significantly	O	O
different	O	O
among	O	O
groups	O	O
,	O	O
but	O	O
by	O	O
year	O	O
13	O	O
,	O	O
the	O	O
survival	O	O
of	O	O
the	O	O
patients	O	O
who	O	O
had	O	O
ESRD	B-Disease	D007676
was	O	O
only	O	O
28	O	O
.	O	O

2%	O	O
compared	O	O
with	O	O
54	O	O
.	O	O

6%	O	O
in	O	O
the	O	O
control	O	O
group	O	O
.	O	O

Patients	O	O
developing	O	O
ESRD	B-Disease	D007676
had	O	O
a	O	O
6	O	O
-	O	O
year	O	O
survival	O	O
after	O	O
onset	O	O
of	O	O
ESRD	B-Disease	D007676
of	O	O
27%	O	O
for	O	O
the	O	O
patients	O	O
receiving	O	O
hemodialysis	O	O
versus	O	O
71	O	O
.	O	O

4%	O	O
for	O	O
the	O	O
patients	O	O
developing	O	O
ESRD	B-Disease	D007676
who	O	O
subsequently	O	O
received	O	O
kidney	O	O
transplants	O	O
.	O	O

CONCLUSIONS	O	O
:	O	O
Patients	O	O
who	O	O
are	O	O
more	O	O
than	O	O
10	O	O
years	O	O
post	O	O
-	O	O
OLTX	O	O
have	O	O
CRF	B-Disease	D007676
and	O	O
ESRD	B-Disease	D007676
at	O	O
a	O	O
high	O	O
rate	O	O
.	O	O

The	O	O
development	O	O
of	O	O
ESRD	B-Disease	D007676
decreases	O	O
survival	O	O
,	O	O
particularly	O	O
in	O	O
those	O	O
patients	O	O
treated	O	O
with	O	O
dialysis	O	O
only	O	O
.	O	O

Patients	O	O
who	O	O
develop	O	O
ESRD	B-Disease	D007676
have	O	O
a	O	O
higher	O	O
preoperative	O	O
and	O	O
1	O	O
-	O	O
year	O	O
serum	O	O
creatinine	B-Chemical	D003404
and	O	O
are	O	O
more	O	O
likely	O	O
to	O	O
have	O	O
hepatorenal	B-Disease	D006530
syndrome	I-Disease	D006530
.	O	O

However	O	O
,	O	O
an	O	O
increase	O	O
of	O	O
serum	O	O
creatinine	B-Chemical	D003404
at	O	O
various	O	O
times	O	O
postoperatively	O	O
is	O	O
more	O	O
predictive	O	O
of	O	O
the	O	O
development	O	O
of	O	O
CRF	B-Disease	D007676
or	O	O
ESRD	B-Disease	D007676
.	O	O

New	O	O
strategies	O	O
for	O	O
long	O	O
-	O	O
term	O	O
immunosuppression	O	O
may	O	O
be	O	O
needed	O	O
to	O	O
decrease	O	O
this	O	O
complication	O	O
.	O	O

Effect	O	O
of	O	O
intravenous	O	O
nimodipine	B-Chemical	D009553
on	O	O
blood	O	O
pressure	O	O
and	O	O
outcome	O	O
after	O	O
acute	B-Disease	D020521
stroke	I-Disease	D020521
.	O	O

BACKGROUND	O	O
AND	O	O
PURPOSE	O	O
:	O	O
The	O	O
Intravenous	O	O
Nimodipine	B-Chemical	D009553
West	O	O
European	O	O
Stroke	B-Disease	D020521
Trial	O	O
(	O	O
INWEST	O	O
)	O	O
found	O	O
a	O	O
correlation	O	O
between	O	O
nimodipine	B-Chemical	D009553
-	O	O
induced	O	O
reduction	B-Disease	D007022
in	I-Disease	D007022
blood	I-Disease	D007022
pressure	I-Disease	D007022
(	O	O
BP	O	O
)	O	O
and	O	O
an	O	O
unfavorable	O	O
outcome	O	O
in	O	O
acute	B-Disease	D020521
stroke	I-Disease	D020521
.	O	O

We	O	O
sought	O	O
to	O	O
confirm	O	O
this	O	O
correlation	O	O
with	O	O
and	O	O
without	O	O
adjustment	O	O
for	O	O
prognostic	O	O
variables	O	O
and	O	O
to	O	O
investigate	O	O
outcome	O	O
in	O	O
subgroups	O	O
with	O	O
increasing	O	O
levels	O	O
of	O	O
BP	B-Disease	D007022
reduction	I-Disease	D007022
.	O	O

METHODS	O	O
:	O	O
Patients	O	O
with	O	O
a	O	O
clinical	O	O
diagnosis	O	O
of	O	O
ischemic	B-Disease	D002544
stroke	I-Disease	D002544
(	O	O
within	O	O
24	O	O
hours	O	O
)	O	O
were	O	O
consecutively	O	O
allocated	O	O
to	O	O
receive	O	O
placebo	O	O
(	O	O
n=100	O	O
)	O	O
,	O	O
1	O	O
mg	O	O
/	O	O
h	O	O
(	O	O
low	O	O
-	O	O
dose	O	O
)	O	O
nimodipine	B-Chemical	D009553
(	O	O
n=101	O	O
)	O	O
,	O	O
or	O	O
2	O	O
mg	O	O
/	O	O
h	O	O
(	O	O
high	O	O
-	O	O
dose	O	O
)	O	O
nimodipine	B-Chemical	D009553
(	O	O
n=94	O	O
)	O	O
.	O	O

The	O	O
correlation	O	O
between	O	O
average	O	O
BP	O	O
change	O	O
during	O	O
the	O	O
first	O	O
2	O	O
days	O	O
and	O	O
the	O	O
outcome	O	O
at	O	O
day	O	O
21	O	O
was	O	O
analyzed	O	O
.	O	O

RESULTS	O	O
:	O	O
Two	O	O
hundred	O	O
sixty	O	O
-	O	O
five	O	O
patients	O	O
were	O	O
included	O	O
in	O	O
this	O	O
analysis	O	O
(	O	O
n=92	O	O
,	O	O
93	O	O
,	O	O
and	O	O
80	O	O
for	O	O
placebo	O	O
,	O	O
low	O	O
dose	O	O
,	O	O
and	O	O
high	O	O
dose	O	O
,	O	O
respectively	O	O
)	O	O
.	O	O

Nimodipine	B-Chemical	D009553
treatment	O	O
resulted	O	O
in	O	O
a	O	O
statistically	O	O
significant	O	O
reduction	B-Disease	D007022
in	I-Disease	D007022
systolic	I-Disease	D007022
BP	I-Disease	D007022
(	O	O
SBP	O	O
)	O	O
and	O	O
diastolic	O	O
BP	O	O
(	O	O
DBP	O	O
)	O	O
from	O	O
baseline	O	O
compared	O	O
with	O	O
placebo	O	O
during	O	O
the	O	O
first	O	O
few	O	O
days	O	O
.	O	O

In	O	O
multivariate	O	O
analysis	O	O
,	O	O
a	O	O
significant	O	O
correlation	O	O
between	O	O
DBP	B-Disease	D007022
reduction	I-Disease	D007022
and	O	O
worsening	O	O
of	O	O
the	O	O
neurological	O	O
score	O	O
was	O	O
found	O	O
for	O	O
the	O	O
high	O	O
-	O	O
dose	O	O
group	O	O
(	O	O
beta=0	O	O
.	O	O

49	O	O
,	O	O
P=0	O	O
.	O	O

048	O	O
)	O	O
.	O	O

Patients	O	O
with	O	O
a	O	O
DBP	B-Disease	D007022
reduction	I-Disease	D007022
of	O	O
>	O	O
or	O	O
=20%	O	O
in	O	O
the	O	O
high	O	O
-	O	O
dose	O	O
group	O	O
had	O	O
a	O	O
significantly	O	O
increased	O	O
adjusted	O	O
OR	O	O
for	O	O
the	O	O
compound	O	O
outcome	O	O
variable	O	O
death	B-Disease	D003643
or	O	O
dependency	O	O
(	O	O
Barthel	O	O
Index	O	O
<60	O	O
)	O	O
(	O	O
n	O	O
/	O	O
N=25	O	O
/	O	O
26	O	O
,	O	O
OR	O	O
10	O	O
.	O	O

16	O	O
,	O	O
95%	O	O
CI	O	O
1	O	O
.	O	O

02	O	O
to	O	O
101	O	O
.	O	O

74	O	O
)	O	O
and	O	O
death	B-Disease	D003643
alone	O	O
(	O	O
n	O	O
/	O	O
N=9	O	O
/	O	O
26	O	O
,	O	O
OR	O	O
4	O	O
.	O	O

336	O	O
,	O	O
95%	O	O
CI	O	O
1	O	O
.	O	O

131	O	O
16	O	O
.	O	O

619	O	O
)	O	O
compared	O	O
with	O	O
all	O	O
placebo	O	O
patients	O	O
(	O	O
n	O	O
/	O	O
N=62	O	O
/	O	O
92	O	O
and	O	O
14	O	O
/	O	O
92	O	O
,	O	O
respectively	O	O
)	O	O
.	O	O

There	O	O
was	O	O
no	O	O
correlation	O	O
between	O	O
SBP	O	O
change	O	O
and	O	O
outcome	O	O
.	O	O

CONCLUSIONS	O	O
:	O	O
DBP	O	O
,	O	O
but	O	O
not	O	O
SBP	O	O
,	O	O
reduction	O	O
was	O	O
associated	O	O
with	O	O
neurological	O	O
worsening	O	O
after	O	O
the	O	O
intravenous	O	O
administration	O	O
of	O	O
high	O	O
-	O	O
dose	O	O
nimodipine	B-Chemical	D009553
after	O	O
acute	B-Disease	D020521
stroke	I-Disease	D020521
.	O	O

For	O	O
low	O	O
-	O	O
dose	O	O
nimodipine	B-Chemical	D009553
,	O	O
the	O	O
results	O	O
were	O	O
not	O	O
conclusive	O	O
.	O	O

These	O	O
results	O	O
do	O	O
not	O	O
confirm	O	O
or	O	O
exclude	O	O
a	O	O
neuroprotective	O	O
property	O	O
of	O	O
nimodipine	B-Chemical	D009553
.	O	O

Transient	B-Disease	D009422
neurologic	I-Disease	D009422
symptoms	I-Disease	D009422
after	O	O
spinal	O	O
anesthesia	O	O
:	O	O
a	O	O
lower	O	O
incidence	O	O
with	O	O
prilocaine	B-Chemical	D011318
and	O	O
bupivacaine	B-Chemical	D002045
than	O	O
with	O	O
lidocaine	B-Chemical	D008012
.	O	O

BACKGROUND	O	O
:	O	O
Recent	O	O
evidence	O	O
suggests	O	O
that	O	O
transient	B-Disease	D009422
neurologic	I-Disease	D009422
symptoms	I-Disease	D009422
(	O	O
TNSs	B-Disease	D009422
)	O	O
frequently	O	O
follow	O	O
lidocaine	B-Chemical	D008012
spinal	O	O
anesthesia	O	O
but	O	O
are	O	O
infrequent	O	O
with	O	O
bupivacaine	B-Chemical	D002045
.	O	O

However	O	O
,	O	O
identification	O	O
of	O	O
a	O	O
short	O	O
-	O	O
acting	O	O
local	O	O
anesthetic	O	O
to	O	O
substitute	O	O
for	O	O
lidocaine	B-Chemical	D008012
for	O	O
brief	O	O
surgical	O	O
procedures	O	O
remains	O	O
an	O	O
important	O	O
goal	O	O
.	O	O

Prilocaine	B-Chemical	D011318
is	O	O
an	O	O
amide	O	O
local	O	O
anesthetic	O	O
with	O	O
a	O	O
duration	O	O
of	O	O
action	O	O
similar	O	O
to	O	O
that	O	O
of	O	O
lidocaine	B-Chemical	D008012
.	O	O

Accordingly	O	O
,	O	O
the	O	O
present	O	O
,	O	O
prospective	O	O
double	O	O
-	O	O
blind	O	O
study	O	O
compares	O	O
prilocaine	B-Chemical	D011318
with	O	O
lidocaine	B-Chemical	D008012
and	O	O
bupivacaine	B-Chemical	D002045
with	O	O
respect	O	O
to	O	O
duration	O	O
of	O	O
action	O	O
and	O	O
relative	O	O
risk	O	O
of	O	O
TNSs	B-Disease	D009422
.	O	O

METHODS	O	O
:	O	O
Ninety	O	O
patients	O	O
classified	O	O
as	O	O
American	O	O
Society	O	O
of	O	O
Anesthesiologists	O	O
physical	O	O
status	O	O
I	O	O
or	O	O
II	O	O
who	O	O
were	O	O
scheduled	O	O
for	O	O
short	O	O
gynecologic	O	O
procedures	O	O
under	O	O
spinal	O	O
anesthesia	O	O
were	O	O
randomly	O	O
allocated	O	O
to	O	O
receive	O	O
2	O	O
.	O	O

5	O	O
ml	O	O
2%	O	O
lidocaine	B-Chemical	D008012
in	O	O
7	O	O
.	O	O

5%	O	O
glucose	B-Chemical	D005947
,	O	O
2%	O	O
prilocaine	B-Chemical	D011318
in	O	O
7	O	O
.	O	O

5%	O	O
glucose	B-Chemical	D005947
,	O	O
or	O	O
0	O	O
.	O	O

5%	O	O
bupivacaine	B-Chemical	D002045
in	O	O
7	O	O
.	O	O

5%	O	O
glucose	B-Chemical	D005947
.	O	O

All	O	O
solutions	O	O
were	O	O
provided	O	O
in	O	O
blinded	O	O
vials	O	O
by	O	O
the	O	O
hospital	O	O
pharmacy	O	O
.	O	O

Details	O	O
of	O	O
spinal	O	O
puncture	O	O
,	O	O
extension	O	O
and	O	O
regression	O	O
of	O	O
spinal	O	O
block	O	O
,	O	O
and	O	O
the	O	O
times	O	O
to	O	O
reach	O	O
discharge	O	O
criteria	O	O
were	O	O
noted	O	O
.	O	O

In	O	O
the	O	O
evening	O	O
of	O	O
postoperative	O	O
day	O	O
1	O	O
,	O	O
patients	O	O
were	O	O
evaluated	O	O
for	O	O
TNSs	B-Disease	D009422
by	O	O
a	O	O
physician	O	O
unaware	O	O
of	O	O
the	O	O
drug	O	O
administered	O	O
and	O	O
the	O	O
details	O	O
of	O	O
the	O	O
anesthetic	O	O
procedure	O	O
.	O	O

RESULTS	O	O
:	O	O
Nine	O	O
of	O	O
30	O	O
patients	O	O
receiving	O	O
lidocaine	B-Chemical	D008012
experienced	O	O
TNSs	B-Disease	D009422
,	O	O
1	O	O
of	O	O
30	O	O
patients	O	O
receiving	O	O
prilocaine	B-Chemical	D011318
(	O	O
P	O	O
=	O	O
0	O	O
.	O	O

03	O	O
)	O	O
had	O	O
them	O	O
,	O	O
and	O	O
none	O	O
of	O	O
30	O	O
patients	O	O
receiving	O	O
bupivacaine	B-Chemical	D002045
had	O	O
TNSs	B-Disease	D009422
.	O	O

Times	O	O
to	O	O
ambulate	O	O
and	O	O
to	O	O
void	O	O
were	O	O
similar	O	O
after	O	O
lidocaine	B-Chemical	D008012
and	O	O
prilocaine	B-Chemical	D011318
(	O	O
150	O	O
vs	O	O
.	O	O

165	O	O
min	O	O
and	O	O
238	O	O
vs	O	O
.	O	O

253	O	O
min	O	O
,	O	O
respectively	O	O
)	O	O
but	O	O
prolonged	O	O
after	O	O
bupivacaine	B-Chemical	D002045
(	O	O
200	O	O
and	O	O
299	O	O
min	O	O
,	O	O
respectively	O	O
;	O	O
P	O	O
<	O	O
0	O	O
.	O	O

05	O	O
)	O	O
.	O	O

CONCLUSIONS	O	O
:	O	O
Prilocaine	B-Chemical	D011318
may	O	O
be	O	O
preferable	O	O
to	O	O
lidocaine	B-Chemical	D008012
for	O	O
short	O	O
surgical	O	O
procedures	O	O
because	O	O
it	O	O
has	O	O
a	O	O
similar	O	O
duration	O	O
of	O	O
action	O	O
but	O	O
a	O	O
lower	O	O
incidence	O	O
of	O	O
TNSs	B-Disease	D009422
.	O	O

The	O	O
role	O	O
of	O	O
nicotine	B-Chemical	D009538
in	O	O
smoking	O	O
-	O	O
related	O	O
cardiovascular	B-Disease	D002318
disease	I-Disease	D002318
.	O	O

Nicotine	B-Chemical	D009538
activates	O	O
the	O	O
sympathetic	O	O
nervous	O	O
system	O	O
and	O	O
in	O	O
this	O	O
way	O	O
could	O	O
contribute	O	O
to	O	O
cardiovascular	B-Disease	D002318
disease	I-Disease	D002318
.	O	O

Animal	O	O
studies	O	O
and	O	O
mechanistic	O	O
studies	O	O
indicate	O	O
that	O	O
nicotine	B-Chemical	D009538
could	O	O
play	O	O
a	O	O
role	O	O
in	O	O
accelerating	O	O
atherosclerosis	B-Disease	D050197
,	O	O
but	O	O
evidence	O	O
among	O	O
humans	O	O
is	O	O
too	O	O
inadequate	O	O
to	O	O
be	O	O
definitive	O	O
about	O	O
such	O	O
an	O	O
effect	O	O
.	O	O

Almost	O	O
certainly	O	O
,	O	O
nicotine	B-Chemical	D009538
via	O	O
its	O	O
hemodynamic	O	O
effects	O	O
contributes	O	O
to	O	O
acute	O	O
cardiovascular	O	O
events	O	O
,	O	O
although	O	O
current	O	O
evidence	O	O
suggests	O	O
that	O	O
the	O	O
effects	O	O
of	O	O
nicotine	B-Chemical	D009538
are	O	O
much	O	O
less	O	O
important	O	O
than	O	O
are	O	O
the	O	O
prothrombotic	O	O
effects	O	O
of	O	O
cigarette	O	O
smoking	O	O
or	O	O
the	O	O
effects	O	O
of	O	O
carbon	B-Chemical	D002248
monoxide	I-Chemical	D002248
.	O	O

Nicotine	B-Chemical	D009538
does	O	O
not	O	O
appear	O	O
to	O	O
enhance	O	O
thrombosis	B-Disease	D013927
among	O	O
humans	O	O
.	O	O

Clinical	O	O
studies	O	O
of	O	O
pipe	O	O
smokers	O	O
and	O	O
people	O	O
using	O	O
transdermal	O	O
nicotine	B-Chemical	D009538
support	O	O
the	O	O
idea	O	O
that	O	O
toxins	O	O
other	O	O
than	O	O
nicotine	B-Chemical	D009538
are	O	O
the	O	O
most	O	O
important	O	O
causes	O	O
of	O	O
acute	O	O
cardiovascular	O	O
events	O	O
.	O	O

Finally	O	O
,	O	O
the	O	O
dose	O	O
response	O	O
for	O	O
cardiovascular	O	O
events	O	O
of	O	O
nicotine	B-Chemical	D009538
appears	O	O
to	O	O
be	O	O
flat	O	O
,	O	O
suggesting	O	O
that	O	O
if	O	O
nicotine	B-Chemical	D009538
is	O	O
involved	O	O
,	O	O
adverse	O	O
effects	O	O
might	O	O
be	O	O
seen	O	O
with	O	O
relatively	O	O
low	O	O
-	O	O
level	O	O
cigarette	O	O
exposures	O	O
.	O	O

Seizure	B-Disease	D012640
resulting	O	O
from	O	O
a	O	O
venlafaxine	B-Chemical	C047426
overdose	B-Disease	D062787
.	O	O

OBJECTIVE	O	O
:	O	O
To	O	O
report	O	O
a	O	O
case	O	O
of	O	O
venlafaxine	B-Chemical	C047426
overdose	B-Disease	D062787
.	O	O

CASE	O	O
SUMMARY	O	O
:	O	O
A	O	O
40	O	O
-	O	O
year	O	O
-	O	O
old	O	O
woman	O	O
with	O	O
major	B-Disease	D003865
depression	I-Disease	D003865
took	O	O
an	O	O
overdose	B-Disease	D062787
of	O	O
venlafaxine	B-Chemical	C047426
in	O	O
an	O	O
apparent	O	O
suicide	O	O
attempt	O	O
.	O	O

After	O	O
the	O	O
ingestion	O	O
of	O	O
26	O	O
venlafaxine	B-Chemical	C047426
50	O	O
-	O	O
mg	O	O
tablets	O	O
,	O	O
the	O	O
patient	O	O
experienced	O	O
a	O	O
witnessed	O	O
generalized	O	O
seizure	B-Disease	D012640
.	O	O

She	O	O
was	O	O
admitted	O	O
to	O	O
the	O	O
medical	O	O
intensive	O	O
care	O	O
unit	O	O
,	O	O
venlafaxine	B-Chemical	C047426
was	O	O
discontinued	O	O
,	O	O
and	O	O
no	O	O
further	O	O
sequelae	O	O
were	O	O
seen	O	O
.	O	O

DISCUSSION	O	O
:	O	O
To	O	O
our	O	O
knowledge	O	O
,	O	O
this	O	O
is	O	O
the	O	O
first	O	O
reported	O	O
case	O	O
of	O	O
venlafaxine	B-Chemical	C047426
overdose	B-Disease	D062787
that	O	O
resulted	O	O
in	O	O
a	O	O
generalized	O	O
seizure	B-Disease	D012640
.	O	O

Based	O	O
on	O	O
nonoverdose	O	O
pharmacokinetics	O	O
and	O	O
pharmacodynamics	O	O
of	O	O
venlafaxine	B-Chemical	C047426
and	O	O
the	O	O
potential	O	O
risks	O	O
of	O	O
available	O	O
interventions	O	O
,	O	O
no	O	O
emergent	O	O
therapy	O	O
was	O	O
instituted	O	O
.	O	O

CONCLUSIONS	O	O
:	O	O
The	O	O
venlafaxine	B-Chemical	C047426
overdose	B-Disease	D062787
in	O	O
our	O	O
patient	O	O
resulted	O	O
in	O	O
a	O	O
single	O	O
episode	O	O
of	O	O
generalized	O	O
seizure	B-Disease	D012640
but	O	O
elicited	O	O
no	O	O
further	O	O
sequelae	O	O
.	O	O

Effect	O	O
of	O	O
nifedipine	B-Chemical	D009543
on	O	O
renal	O	O
function	O	O
in	O	O
liver	O	O
transplant	O	O
recipients	O	O
receiving	O	O
tacrolimus	B-Chemical	D016559
.	O	O

The	O	O
effect	O	O
of	O	O
nifedipine	B-Chemical	D009543
on	O	O
renal	O	O
function	O	O
in	O	O
liver	O	O
transplant	O	O
recipients	O	O
who	O	O
were	O	O
receiving	O	O
tacrolimus	B-Chemical	D016559
was	O	O
evaluated	O	O
between	O	O
January	O	O
1992	O	O
and	O	O
January	O	O
1996	O	O
.	O	O

Two	O	O
groups	O	O
of	O	O
patients	O	O
receiving	O	O
tacrolimus	B-Chemical	D016559
were	O	O
compared	O	O
over	O	O
a	O	O
period	O	O
of	O	O
1	O	O
year	O	O
,	O	O
one	O	O
group	O	O
comprising	O	O
hypertensive	B-Disease	D006973
patients	O	O
who	O	O
were	O	O
receiving	O	O
nifedipine	B-Chemical	D009543
,	O	O
and	O	O
the	O	O
other	O	O
comprising	O	O
nonhypertensive	O	O
patients	O	O
not	O	O
receiving	O	O
nifedipine	B-Chemical	D009543
.	O	O

The	O	O
time	O	O
from	O	O
transplant	O	O
to	O	O
baseline	O	O
was	O	O
similar	O	O
in	O	O
all	O	O
patients	O	O
.	O	O

Nifedipine	B-Chemical	D009543
significantly	O	O
improved	O	O
kidney	O	O
function	O	O
as	O	O
indicated	O	O
by	O	O
a	O	O
significant	O	O
lowering	O	O
of	O	O
serum	O	O
creatinine	B-Chemical	D003404
levels	O	O
at	O	O
6	O	O
and	O	O
12	O	O
months	O	O
.	O	O

The	O	O
observed	O	O
positive	O	O
impact	O	O
of	O	O
nifedipine	B-Chemical	D009543
on	O	O
reducing	O	O
the	O	O
nephrotoxicity	B-Disease	D007674
associated	O	O
with	O	O
tacrolimus	B-Chemical	D016559
in	O	O
liver	O	O
transplant	O	O
recipients	O	O
should	O	O
be	O	O
an	O	O
important	O	O
factor	O	O
in	O	O
selecting	O	O
an	O	O
agent	O	O
to	O	O
treat	O	O
hypertension	B-Disease	D006973
in	O	O
this	O	O
population	O	O
.	O	O

Sinus	B-Disease	D054138
arrest	I-Disease	D054138
associated	O	O
with	O	O
continuous	O	O
-	O	O
infusion	O	O
cimetidine	B-Chemical	D002927
.	O	O

The	O	O
administration	O	O
of	O	O
intermittent	O	O
intravenous	O	O
infusions	O	O
of	O	O
cimetidine	B-Chemical	D002927
is	O	O
infrequently	O	O
associated	O	O
with	O	O
the	O	O
development	O	O
of	O	O
bradyarrhythmias	B-Disease	D001919
.	O	O

A	O	O
40	O	O
-	O	O
year	O	O
-	O	O
old	O	O
man	O	O
with	O	O
leukemia	B-Disease	D007938
and	O	O
no	O	O
history	O	O
of	O	O
cardiac	B-Disease	D006331
disease	I-Disease	D006331
developed	O	O
recurrent	O	O
,	O	O
brief	O	O
episodes	O	O
of	O	O
apparent	O	O
sinus	B-Disease	D054138
arrest	I-Disease	D054138
while	O	O
receiving	O	O
continuous	O	O
-	O	O
infusion	O	O
cimetidine	B-Chemical	D002927
50	O	O
mg	O	O
/	O	O
hour	O	O
.	O	O

The	O	O
arrhythmias	B-Disease	D001145
were	O	O
temporally	O	O
related	O	O
to	O	O
cimetidine	B-Chemical	D002927
administration	O	O
,	O	O
disappeared	O	O
after	O	O
dechallenge	O	O
,	O	O
and	O	O
did	O	O
not	O	O
recur	O	O
during	O	O
ranitidine	B-Chemical	D011899
treatment	O	O
.	O	O

This	O	O
is	O	O
the	O	O
first	O	O
reported	O	O
case	O	O
of	O	O
sinus	B-Disease	D054138
arrest	I-Disease	D054138
associated	O	O
with	O	O
continuous	O	O
-	O	O
infusion	O	O
cimetidine	B-Chemical	D002927
.	O	O

Composition	O	O
of	O	O
gall	B-Disease	D042882
bladder	I-Disease	D042882
stones	I-Disease	D042882
associated	O	O
with	O	O
octreotide	B-Chemical	D015282
:	O	O
response	O	O
to	O	O
oral	O	O
ursodeoxycholic	B-Chemical	D014580
acid	I-Chemical	D014580
.	O	O

Octreotide	B-Chemical	D015282
,	O	O
an	O	O
effective	O	O
treatment	O	O
for	O	O
acromegaly	B-Disease	D000172
,	O	O
induces	O	O
gall	B-Disease	D042882
bladder	I-Disease	D042882
stones	I-Disease	D042882
in	O	O
13	O	O
-	O	O
60%	O	O
of	O	O
patients	O	O
.	O	O

Because	O	O
knowledge	O	O
of	O	O
stone	O	O
composition	O	O
is	O	O
essential	O	O
for	O	O
studies	O	O
of	O	O
their	O	O
pathogenesis	O	O
,	O	O
treatment	O	O
,	O	O
and	O	O
prevention	O	O
,	O	O
this	O	O
was	O	O
investigated	O	O
by	O	O
direct	O	O
and	O	O
indirect	O	O
methods	O	O
in	O	O
14	O	O
octreotide	B-Chemical	D015282
treated	O	O
acromegalic	B-Disease	D000172
patients	O	O
with	O	O
gall	B-Disease	D042882
stones	I-Disease	D042882
.	O	O

Chemical	O	O
analysis	O	O
of	O	O
gall	B-Disease	D042882
stones	I-Disease	D042882
retrieved	O	O
at	O	O
cholecystectomy	O	O
from	O	O
two	O	O
patients	O	O
,	O	O
showed	O	O
that	O	O
they	O	O
contained	O	O
71%	O	O
and	O	O
87%	O	O
cholesterol	B-Chemical	D002784
by	O	O
weight	O	O
.	O	O

In	O	O
the	O	O
remaining	O	O
12	O	O
patients	O	O
,	O	O
localised	O	O
computed	O	O
tomography	O	O
of	O	O
the	O	O
gall	O	O
bladder	O	O
showed	O	O
that	O	O
eight	O	O
had	O	O
stones	O	O
with	O	O
maximum	O	O
attenuation	O	O
scores	O	O
of	O	O
<	O	O
100	O	O
Hounsfield	O	O
units	O	O
(	O	O
values	O	O
of	O	O
<	O	O
100	O	O
HU	O	O
predict	O	O
cholesterol	B-Chemical	D002784
rich	O	O
,	O	O
dissolvable	O	O
stones	O	O
)	O	O
.	O	O

Gall	O	O
bladder	O	O
bile	O	O
was	O	O
obtained	O	O
by	O	O
ultrasound	O	O
guided	O	O
,	O	O
fine	O	O
needle	O	O
puncture	O	O
from	O	O
six	O	O
patients	O	O
.	O	O

All	O	O
six	O	O
patients	O	O
had	O	O
supersaturated	O	O
bile	O	O
(	O	O
mean	O	O
(	O	O
SEM	O	O
)	O	O
cholesterol	B-Chemical	D002784
saturation	O	O
index	O	O
of	O	O
1	O	O
.	O	O

19	O	O
(	O	O
0	O	O
.	O	O

08	O	O
)	O	O
(	O	O
range	O	O
1	O	O
.	O	O

01	O	O
-	O	O
1	O	O
.	O	O

53	O	O
)	O	O
)	O	O
and	O	O
all	O	O
had	O	O
abnormally	O	O
rapid	O	O
cholesterol	B-Chemical	D002784
microcrystal	O	O
nucleation	O	O
times	O	O
(	O	O
<	O	O
4	O	O
days	O	O
(	O	O
range	O	O
1	O	O
-	O	O
4	O	O
)	O	O
)	O	O
,	O	O
whilst	O	O
in	O	O
four	O	O
,	O	O
the	O	O
bile	O	O
contained	O	O
cholesterol	B-Chemical	D002784
microcrystals	O	O
immediately	O	O
after	O	O
sampling	O	O
.	O	O

Of	O	O
the	O	O
12	O	O
patients	O	O
considered	O	O
for	O	O
oral	O	O
ursodeoxycholic	B-Chemical	D014580
acid	I-Chemical	D014580
(	O	O
UDCA	B-Chemical	D014580
)	O	O
treatment	O	O
,	O	O
two	O	O
had	O	O
a	O	O
blocked	O	O
cystic	O	O
duct	O	O
and	O	O
were	O	O
not	O	O
started	O	O
on	O	O
UDCA	B-Chemical	D014580
while	O	O
one	O	O
was	O	O
lost	O	O
to	O	O
follow	O	O
up	O	O
.	O	O

After	O	O
one	O	O
year	O	O
of	O	O
treatment	O	O
,	O	O
five	O	O
of	O	O
the	O	O
remaining	O	O
nine	O	O
patients	O	O
showed	O	O
either	O	O
partial	O	O
(	O	O
n	O	O
=	O	O
3	O	O
)	O	O
or	O	O
complete	O	O
(	O	O
n	O	O
=	O	O
2	O	O
)	O	O
gall	B-Disease	D042882
stone	I-Disease	D042882
dissolution	O	O
,	O	O
suggesting	O	O
that	O	O
their	O	O
stones	O	O
were	O	O
cholesterol	B-Chemical	D002784
rich	O	O
.	O	O

This	O	O
corresponds	O	O
,	O	O
by	O	O
actuarial	O	O
(	O	O
life	O	O
table	O	O
)	O	O
analysis	O	O
,	O	O
to	O	O
a	O	O
combined	O	O
gall	B-Disease	D042882
stone	I-Disease	D042882
dissolution	O	O
rate	O	O
of	O	O
58	O	O
.	O	O

3	O	O
(	O	O
15	O	O
.	O	O

9%	O	O
)	O	O
.	O	O

In	O	O
conclusion	O	O
,	O	O
octreotide	B-Chemical	D015282
induced	O	O
gall	B-Disease	D042882
stones	I-Disease	D042882
are	O	O
generally	O	O
small	O	O
,	O	O
multiple	O	O
,	O	O
and	O	O
cholesterol	B-Chemical	D002784
rich	O	O
although	O	O
,	O	O
in	O	O
common	O	O
with	O	O
spontaneous	O	O
gall	B-Disease	D042882
stone	I-Disease	D042882
disease	O	O
,	O	O
at	O	O
presentation	O	O
some	O	O
patients	O	O
will	O	O
have	O	O
a	O	O
blocked	O	O
cystic	O	O
duct	O	O
and	O	O
some	O	O
gall	B-Disease	D042882
stones	I-Disease	D042882
containing	O	O
calcium	B-Chemical	D002118
.	O	O

Cardiovascular	B-Disease	D002318
complications	I-Disease	D002318
associated	O	O
with	O	O
terbutaline	B-Chemical	D013726
treatment	O	O
for	O	O
preterm	B-Disease	D007752
labor	I-Disease	D007752
.	O	O

Severe	O	O
cardiovascular	B-Disease	D002318
complications	I-Disease	D002318
occurred	O	O
in	O	O
eight	O	O
of	O	O
160	O	O
patients	O	O
treated	O	O
with	O	O
terbutaline	B-Chemical	D013726
for	O	O
preterm	B-Disease	D007752
labor	I-Disease	D007752
.	O	O

Associated	O	O
corticosteroid	O	O
therapy	O	O
and	O	O
twin	O	O
gestations	O	O
appear	O	O
to	O	O
be	O	O
predisposing	O	O
factors	O	O
.	O	O

Potential	O	O
mechanisms	O	O
of	O	O
the	O	O
pathophysiology	O	O
are	O	O
briefly	O	O
discussed	O	O
.	O	O

Neurologic	O	O
effects	O	O
of	O	O
subarachnoid	O	O
administration	O	O
of	O	O
2	B-Chemical	C004616
-	I-Chemical	C004616
chloroprocaine	I-Chemical	C004616
-	I-Chemical	C004616
CE	I-Chemical	C004616
,	O	O
bupivacaine	B-Chemical	D002045
,	O	O
and	O	O
low	O	O
pH	O	O
normal	O	O
saline	O	O
in	O	O
dogs	O	O
.	O	O

The	O	O
purpose	O	O
of	O	O
this	O	O
study	O	O
was	O	O
to	O	O
evaluate	O	O
the	O	O
neurologic	O	O
consequences	O	O
of	O	O
deliberate	O	O
subarachnoid	O	O
injection	O	O
of	O	O
large	O	O
volumes	O	O
of	O	O
2	B-Chemical	C004616
-	I-Chemical	C004616
chloroprocaine	I-Chemical	C004616
-	I-Chemical	C004616
CE	I-Chemical	C004616
in	O	O
experimental	O	O
animals	O	O
.	O	O

The	O	O
possible	O	O
role	O	O
of	O	O
low	O	O
pH	O	O
as	O	O
well	O	O
as	O	O
total	O	O
volume	O	O
as	O	O
potential	O	O
factors	O	O
in	O	O
causing	O	O
neurotoxicity	B-Disease	D020258
was	O	O
evaluated	O	O
.	O	O

The	O	O
65	O	O
dogs	O	O
in	O	O
the	O	O
study	O	O
received	O	O
injections	O	O
in	O	O
the	O	O
subarachnoid	O	O
space	O	O
as	O	O
follows	O	O
:	O	O
6	O	O
to	O	O
8	O	O
ml	O	O
of	O	O
bupivacaine	B-Chemical	D002045
(	O	O
N	O	O
=	O	O
15	O	O
)	O	O
,	O	O
2	B-Chemical	C004616
-	I-Chemical	C004616
chloroprocaine	I-Chemical	C004616
-	I-Chemical	C004616
CE	I-Chemical	C004616
(	O	O
N	O	O
=	O	O
20	O	O
)	O	O
,	O	O
low	O	O
pH	O	O
normal	O	O
saline	O	O
(	O	O
pH	O	O
3	O	O
.	O	O

0	O	O
)	O	O
(	O	O
N	O	O
=	O	O
20	O	O
)	O	O
,	O	O
or	O	O
normal	O	O
saline	O	O
(	O	O
N	O	O
=	O	O
10	O	O
)	O	O
.	O	O

Of	O	O
the	O	O
20	O	O
animals	O	O
that	O	O
received	O	O
subarachnoid	O	O
injection	O	O
of	O	O
2	B-Chemical	C004616
-	I-Chemical	C004616
chloroprocaine	I-Chemical	C004616
-	I-Chemical	C004616
CE	I-Chemical	C004616
seven	O	O
(	O	O
35%	O	O
)	O	O
developed	O	O
hind	O	O
-	O	O
limb	O	O
paralysis	B-Disease	D010243
.	O	O

None	O	O
of	O	O
the	O	O
animals	O	O
that	O	O
received	O	O
bupivacaine	B-Chemical	D002045
,	O	O
normal	O	O
saline	O	O
,	O	O
or	O	O
normal	O	O
saline	O	O
titrated	O	O
to	O	O
a	O	O
pH	O	O
3	O	O
.	O	O

0	O	O
developed	O	O
hind	O	O
-	O	O
limb	O	O
paralysis	B-Disease	D010243
.	O	O

Of	O	O
the	O	O
15	O	O
spinal	O	O
cords	O	O
of	O	O
the	O	O
animals	O	O
that	O	O
received	O	O
2	B-Chemical	C004616
-	I-Chemical	C004616
chloroprocaine	I-Chemical	C004616
-	I-Chemical	C004616
CE	I-Chemical	C004616
,	O	O
13	O	O
showed	O	O
subpial	B-Disease	D013118
necrosis	I-Disease	D013118
;	O	O
the	O	O
nerve	O	O
roots	O	O
and	O	O
subarachnoid	O	O
vessels	O	O
were	O	O
normal	O	O
.	O	O

The	O	O
spinal	O	O
cords	O	O
of	O	O
the	O	O
animals	O	O
that	O	O
received	O	O
bupivacaine	B-Chemical	D002045
,	O	O
low	O	O
pH	O	O
normal	O	O
saline	O	O
(	O	O
pH	O	O
3	O	O
.	O	O

0	O	O
)	O	O
,	O	O
or	O	O
normal	O	O
saline	O	O
did	O	O
not	O	O
show	O	O
abnormal	O	O
findings	O	O
.	O	O

Early	O	O
adjuvant	O	O
adriamycin	B-Chemical	D004317
in	O	O
superficial	O	O
bladder	O	O
carcinoma	O	O
.	O	O

A	O	O
multicenter	O	O
study	O	O
was	O	O
performed	O	O
in	O	O
110	O	O
patients	O	O
with	O	O
superficial	O	O
transitional	O	O
cell	O	O
carcinoma	O	O
of	O	O
the	O	O
bladder	O	O
.	O	O

Adriamycin	B-Chemical	D004317
(	O	O
50	O	O
mg	O	O
/	O	O
50	O	O
ml	O	O
)	O	O
was	O	O
administered	O	O
intravesically	O	O
within	O	O
24	O	O
h	O	O
after	O	O
transurethral	O	O
resection	O	O
of	O	O
TA	O	O
-	O	O
T1	O	O
(	O	O
O	O	O
-	O	O
A	O	O
)	O	O
bladder	B-Disease	D001749
tumors	I-Disease	D001749
.	O	O

Instillation	O	O
was	O	O
repeated	O	O
twice	O	O
during	O	O
the	O	O
first	O	O
week	O	O
,	O	O
then	O	O
weekly	O	O
during	O	O
the	O	O
first	O	O
month	O	O
and	O	O
afterwards	O	O
monthly	O	O
for	O	O
1	O	O
year	O	O
.	O	O

The	O	O
tolerance	O	O
was	O	O
evaluated	O	O
in	O	O
these	O	O
110	O	O
patients	O	O
,	O	O
and	O	O
29	O	O
patients	O	O
presented	O	O
with	O	O
local	O	O
side	O	O
-	O	O
effects	O	O
.	O	O

In	O	O
24	O	O
of	O	O
these	O	O
patients	O	O
chemical	O	O
cystitis	B-Disease	D003556
was	O	O
severe	O	O
enough	O	O
for	O	O
them	O	O
to	O	O
drop	O	O
out	O	O
of	O	O
the	O	O
study	O	O
.	O	O

No	O	O
systemic	O	O
side	O	O
-	O	O
effects	O	O
were	O	O
observed	O	O
.	O	O

Recurrence	O	O
was	O	O
studied	O	O
in	O	O
82	O	O
evaluable	O	O
patients	O	O
after	O	O
1	O	O
year	O	O
of	O	O
follow	O	O
-	O	O
up	O	O
and	O	O
in	O	O
72	O	O
patients	O	O
followed	O	O
for	O	O
2	O	O
-	O	O
3	O	O
years	O	O
(	O	O
mean	O	O
32	O	O
months	O	O
)	O	O
.	O	O

Of	O	O
the	O	O
82	O	O
patients	O	O
studied	O	O
after	O	O
1	O	O
year	O	O
,	O	O
23	O	O
had	O	O
primary	O	O
and	O	O
59	O	O
recurrent	O	O
disease	O	O
.	O	O

Of	O	O
the	O	O
82	O	O
evaluable	O	O
patients	O	O
,	O	O
50	O	O
did	O	O
not	O	O
show	O	O
any	O	O
recurrence	O	O
after	O	O
1	O	O
year	O	O
(	O	O
61%	O	O
)	O	O
,	O	O
while	O	O
32	O	O
presented	O	O
with	O	O
one	O	O
or	O	O
more	O	O
recurrences	O	O
(	O	O
39%	O	O
)	O	O
.	O	O

Of	O	O
these	O	O
recurrences	O	O
,	O	O
27	O	O
were	O	O
T1	O	O
tumors	B-Disease	D009369
while	O	O
five	O	O
progressed	O	O
to	O	O
more	O	O
highly	O	O
invasive	O	O
lesions	O	O
.	O	O

In	O	O
patients	O	O
that	O	O
were	O	O
free	O	O
of	O	O
recurrence	O	O
during	O	O
the	O	O
first	O	O
year	O	O
,	O	O
80%	O	O
remained	O	O
tumor	B-Disease	D009369
-	O	O
free	O	O
during	O	O
the	O	O
2	O	O
-	O	O
to	O	O
3	O	O
-	O	O
year	O	O
follow	O	O
-	O	O
up	O	O
period	O	O
.	O	O

Of	O	O
the	O	O
patients	O	O
developing	O	O
one	O	O
or	O	O
more	O	O
recurrences	O	O
during	O	O
the	O	O
first	O	O
year	O	O
,	O	O
only	O	O
50%	O	O
presented	O	O
with	O	O
further	O	O
recurrence	O	O
once	O	O
the	O	O
instillations	O	O
were	O	O
stopped	O	O
.	O	O

The	O	O
beneficial	O	O
effect	O	O
of	O	O
Adriamycin	B-Chemical	D004317
appears	O	O
obvious	O	O
and	O	O
might	O	O
be	O	O
related	O	O
to	O	O
the	O	O
drug	O	O
itself	O	O
,	O	O
the	O	O
early	O	O
and	O	O
repeated	O	O
instillations	O	O
after	O	O
TUR	O	O
,	O	O
or	O	O
both	O	O
.	O	O

Hyperkalemia	B-Disease	D006947
associated	O	O
with	O	O
sulindac	B-Chemical	D013467
therapy	O	O
.	O	O

Hyperkalemia	B-Disease	D006947
has	O	O
recently	O	O
been	O	O
recognized	O	O
as	O	O
a	O	O
complication	O	O
of	O	O
nonsteroidal	O	O
antiinflammatory	O	O
agents	O	O
(	O	O
NSAID	O	O
)	O	O
such	O	O
as	O	O
indomethacin	B-Chemical	D007213
.	O	O

Several	O	O
recent	O	O
studies	O	O
have	O	O
stressed	O	O
the	O	O
renal	O	O
sparing	O	O
features	O	O
of	O	O
sulindac	B-Chemical	D013467
,	O	O
owing	O	O
to	O	O
its	O	O
lack	O	O
of	O	O
interference	O	O
with	O	O
renal	O	O
prostacyclin	B-Chemical	D011464
synthesis	O	O
.	O	O

We	O	O
describe	O	O
4	O	O
patients	O	O
in	O	O
whom	O	O
hyperkalemia	B-Disease	D006947
ranging	O	O
from	O	O
6	O	O
.	O	O

1	O	O
to	O	O
6	O	O
.	O	O

9	O	O
mEq	O	O
/	O	O
l	O	O
developed	O	O
within	O	O
3	O	O
to	O	O
8	O	O
days	O	O
of	O	O
sulindac	B-Chemical	D013467
administration	O	O
.	O	O

In	O	O
all	O	O
of	O	O
them	O	O
normal	O	O
serum	O	O
potassium	B-Chemical	D011188
levels	O	O
reached	O	O
within	O	O
2	O	O
to	O	O
4	O	O
days	O	O
of	O	O
stopping	O	O
sulindac	B-Chemical	D013467
.	O	O

As	O	O
no	O	O
other	O	O
medications	O	O
known	O	O
to	O	O
effect	O	O
serum	O	O
potassium	B-Chemical	D011188
had	O	O
been	O	O
given	O	O
concomitantly	O	O
,	O	O
this	O	O
course	O	O
of	O	O
events	O	O
is	O	O
suggestive	O	O
of	O	O
a	O	O
cause	O	O
-	O	O
and	O	O
-	O	O
effect	O	O
relationship	O	O
between	O	O
sulindac	B-Chemical	D013467
and	O	O
hyperkalemia	B-Disease	D006947
.	O	O

These	O	O
observations	O	O
indicate	O	O
that	O	O
initial	O	O
hopes	O	O
that	O	O
sulindac	B-Chemical	D013467
may	O	O
not	O	O
be	O	O
associated	O	O
with	O	O
the	O	O
adverse	O	O
renal	O	O
effects	O	O
of	O	O
other	O	O
NSAID	O	O
are	O	O
probably	O	O
not	O	O
justified	O	O
.	O	O

Ventricular	B-Disease	D014693
tachyarrhythmias	I-Disease	D014693
during	O	O
cesarean	O	O
section	O	O
after	O	O
ritodrine	B-Chemical	D012312
therapy	O	O
:	O	O
interaction	O	O
with	O	O
anesthetics	O	O
.	O	O

This	O	O
case	O	O
illustrates	O	O
that	O	O
patients	O	O
receiving	O	O
ritodrine	B-Chemical	D012312
for	O	O
preterm	B-Disease	D007752
labor	I-Disease	D007752
may	O	O
risk	O	O
interactions	O	O
between	O	O
the	O	O
residual	O	O
betamimetic	O	O
effects	O	O
of	O	O
ritodrine	B-Chemical	D012312
and	O	O
the	O	O
effects	O	O
of	O	O
anesthetics	O	O
during	O	O
cesarean	O	O
section	O	O
.	O	O

Such	O	O
interactions	O	O
may	O	O
result	O	O
in	O	O
serious	O	O
cardiovascular	B-Disease	D002318
complications	I-Disease	D002318
even	O	O
after	O	O
cessation	O	O
of	O	O
an	O	O
infusion	O	O
of	O	O
ritodrine	B-Chemical	D012312
.	O	O

Preoperative	O	O
assessment	O	O
should	O	O
focus	O	O
on	O	O
cardiovascular	O	O
status	O	O
and	O	O
serum	O	O
potassium	B-Chemical	D011188
level	O	O
.	O	O

Delaying	O	O
induction	O	O
of	O	O
anesthesia	O	O
should	O	O
be	O	O
considered	O	O
whenever	O	O
possible	O	O
.	O	O

Careful	O	O
fluid	O	O
administration	O	O
and	O	O
cautious	O	O
use	O	O
of	O	O
titrated	O	O
doses	O	O
of	O	O
ephedrine	B-Chemical	D004809
are	O	O
advised	O	O
.	O	O

After	O	O
delivery	O	O
of	O	O
the	O	O
infant	O	O
,	O	O
there	O	O
should	O	O
be	O	O
no	O	O
contraindication	O	O
to	O	O
the	O	O
use	O	O
of	O	O
an	O	O
alpha	O	O
-	O	O
adrenergic	O	O
vasopressor	O	O
such	O	O
as	O	O
phenylephrine	B-Chemical	D010656
to	O	O
treat	O	O
hypotensive	B-Disease	D007022
patients	O	O
with	O	O
tachycardia	B-Disease	D013610
.	O	O

Immunohistochemical	O	O
,	O	O
electron	O	O
microscopic	O	O
and	O	O
morphometric	O	O
studies	O	O
of	O	O
estrogen	B-Chemical	D004967
-	O	O
induced	O	O
rat	O	O
prolactinomas	B-Disease	D015175
after	O	O
bromocriptine	B-Chemical	D001971
treatment	O	O
.	O	O

To	O	O
clarify	O	O
the	O	O
effects	O	O
of	O	O
bromocriptine	B-Chemical	D001971
on	O	O
prolactinoma	B-Disease	D015175
cells	O	O
in	O	O
vivo	O	O
,	O	O
immunohistochemical	O	O
,	O	O
ultrastructural	O	O
and	O	O
morphometrical	O	O
analyses	O	O
were	O	O
applied	O	O
to	O	O
estrogen	B-Chemical	D004967
-	O	O
induced	O	O
rat	O	O
prolactinoma	B-Disease	D015175
cells	O	O
1	O	O
h	O	O
and	O	O
6	O	O
h	O	O
after	O	O
injection	O	O
of	O	O
bromocriptine	B-Chemical	D001971
(	O	O
3	O	O
mg	O	O
/	O	O
kg	O	O
of	O	O
body	O	O
weight	O	O
)	O	O
.	O	O

One	O	O
h	O	O
after	O	O
treatment	O	O
,	O	O
serum	O	O
prolactin	O	O
levels	O	O
decreased	O	O
markedly	O	O
.	O	O

Electron	O	O
microscopy	O	O
disclosed	O	O
many	O	O
secretory	O	O
granules	O	O
,	O	O
slightly	O	O
distorted	O	O
rough	O	O
endoplasmic	O	O
reticulum	O	O
,	O	O
and	O	O
partially	O	O
dilated	O	O
Golgi	O	O
cisternae	O	O
in	O	O
the	O	O
prolactinoma	B-Disease	D015175
cells	O	O
.	O	O

Morphometric	O	O
analysis	O	O
revealed	O	O
that	O	O
the	O	O
volume	O	O
density	O	O
of	O	O
secretory	O	O
granules	O	O
increased	O	O
,	O	O
while	O	O
the	O	O
volume	O	O
density	O	O
of	O	O
cytoplasmic	O	O
microtubules	O	O
decreased	O	O
.	O	O

These	O	O
findings	O	O
suggest	O	O
that	O	O
lowered	O	O
serum	O	O
prolactin	O	O
levels	O	O
in	O	O
the	O	O
early	O	O
phase	O	O
of	O	O
bromocriptine	B-Chemical	D001971
treatment	O	O
may	O	O
result	O	O
from	O	O
an	O	O
impaired	O	O
secretion	O	O
of	O	O
prolactin	O	O
due	O	O
to	O	O
decreasing	O	O
numbers	O	O
of	O	O
cytoplasmic	O	O
microtubules	O	O
.	O	O

At	O	O
6	O	O
h	O	O
after	O	O
injection	O	O
,	O	O
serum	O	O
prolactin	O	O
levels	O	O
were	O	O
still	O	O
considerably	O	O
lower	O	O
than	O	O
in	O	O
controls	O	O
.	O	O

The	O	O
prolactinoma	B-Disease	D015175
cells	O	O
at	O	O
this	O	O
time	O	O
were	O	O
well	O	O
granulated	O	O
,	O	O
with	O	O
vesiculated	O	O
rough	O	O
endoplasmic	O	O
reticulum	O	O
and	O	O
markedly	O	O
dilated	O	O
Golgi	O	O
cisternae	O	O
.	O	O

Electron	O	O
microscopical	O	O
immunohistochemistry	O	O
revealed	O	O
positive	O	O
reaction	O	O
products	O	O
noted	O	O
on	O	O
the	O	O
secretory	O	O
granules	O	O
,	O	O
Golgi	O	O
cisternae	O	O
,	O	O
and	O	O
endoplasmic	O	O
reticulum	O	O
of	O	O
the	O	O
untreated	O	O
rat	O	O
prolactinoma	B-Disease	D015175
cells	O	O
.	O	O

However	O	O
,	O	O
only	O	O
secretory	O	O
granules	O	O
showed	O	O
the	O	O
positive	O	O
reaction	O	O
products	O	O
for	O	O
prolactin	O	O
6	O	O
h	O	O
after	O	O
bromocriptine	B-Chemical	D001971
treatment	O	O
of	O	O
the	O	O
adenoma	B-Disease	D000236
cells	O	O
.	O	O

An	O	O
increase	O	O
in	O	O
the	O	O
volume	O	O
density	O	O
of	O	O
secretory	O	O
granules	O	O
and	O	O
a	O	O
decrease	O	O
in	O	O
the	O	O
volume	O	O
densities	O	O
of	O	O
rough	O	O
endoplasmic	O	O
reticulum	O	O
and	O	O
microtubules	O	O
was	O	O
determined	O	O
by	O	O
morphometric	O	O
analysis	O	O
,	O	O
suggesting	O	O
that	O	O
bromocriptine	B-Chemical	D001971
inhibits	O	O
protein	O	O
synthesis	O	O
as	O	O
well	O	O
as	O	O
bringing	O	O
about	O	O
a	O	O
disturbance	O	O
of	O	O
the	O	O
prolactin	O	O
secretion	O	O
.	O	O

On	O	O
two	O	O
paradoxical	O	O
side	O	O
-	O	O
effects	O	O
of	O	O
prednisolone	B-Chemical	D011239
in	O	O
rats	O	O
,	O	O
ribosomal	O	O
RNA	O	O
biosyntheses	O	O
,	O	O
and	O	O
a	O	O
mechanism	O	O
of	O	O
action	O	O
.	O	O

Liver	B-Disease	D006529
enlargement	I-Disease	D006529
and	O	O
muscle	B-Disease	D009133
wastage	I-Disease	D009133
occurred	O	O
in	O	O
Wistar	O	O
rats	O	O
following	O	O
the	O	O
subcutaneous	O	O
administration	O	O
of	O	O
prednisolone	B-Chemical	D011239
.	O	O

In	O	O
the	O	O
liver	O	O
both	O	O
the	O	O
content	O	O
of	O	O
RNA	O	O
and	O	O
the	O	O
biosynthesis	O	O
of	O	O
ribosomal	O	O
RNA	O	O
increased	O	O
while	O	O
both	O	O
the	O	O
RNA	O	O
content	O	O
and	O	O
ribosomal	O	O
RNA	O	O
biosynthesis	O	O
were	O	O
reduced	O	O
in	O	O
the	O	O
gastrocnemius	O	O
muscle	O	O
.	O	O

It	O	O
is	O	O
suggested	O	O
that	O	O
the	O	O
drug	O	O
acted	O	O
in	O	O
a	O	O
selective	O	O
and	O	O
tissue	O	O
-	O	O
specific	O	O
manner	O	O
to	O	O
enhance	O	O
ribosomal	O	O
RNA	O	O
synthesis	O	O
in	O	O
the	O	O
liver	O	O
and	O	O
depress	O	O
such	O	O
synthesis	O	O
in	O	O
the	O	O
muscle	O	O
.	O	O

This	O	O
view	O	O
supports	O	O
the	O	O
contention	O	O
that	O	O
the	O	O
liver	O	O
and	O	O
muscle	O	O
are	O	O
independent	O	O
sites	O	O
of	O	O
prednisolone	B-Chemical	D011239
action	O	O
.	O	O

Possible	O	O
intramuscular	O	O
midazolam	B-Chemical	D008874
-	O	O
associated	O	O
cardiorespiratory	B-Disease	D006323
arrest	I-Disease	D006323
and	O	O
death	B-Disease	D003643
.	O	O

Midazolam	B-Chemical	D008874
hydrochloride	I-Chemical	D008874
is	O	O
commonly	O	O
used	O	O
for	O	O
dental	O	O
or	O	O
endoscopic	O	O
procedures	O	O
.	O	O

Although	O	O
generally	O	O
consisted	O	O
safe	O	O
when	O	O
given	O	O
intramuscularly	O	O
,	O	O
intravenous	O	O
administration	O	O
is	O	O
known	O	O
to	O	O
cause	O	O
respiratory	O	O
and	O	O
cardiovascular	O	O
depression	O	O
.	O	O

This	O	O
report	O	O
describes	O	O
the	O	O
first	O	O
published	O	O
case	O	O
of	O	O
cardiorespiratory	B-Disease	D006323
arrest	I-Disease	D006323
and	O	O
death	B-Disease	D003643
associated	O	O
with	O	O
intramuscular	O	O
administration	O	O
of	O	O
midazolam	B-Chemical	D008874
.	O	O

Information	O	O
regarding	O	O
midazolam	B-Chemical	D008874
use	O	O
is	O	O
reviewed	O	O
to	O	O
provide	O	O
recommendation	O	O
for	O	O
safe	O	O
administration	O	O
.	O	O

Serial	O	O
epilepsy	B-Disease	D004827
caused	O	O
by	O	O
levodopa	B-Chemical	C009265
/	I-Chemical	C009265
carbidopa	I-Chemical	C009265
administration	O	O
in	O	O
two	O	O
patients	O	O
on	O	O
hemodialysis	O	O
.	O	O

Two	O	O
patients	O	O
with	O	O
similar	O	O
clinical	O	O
features	O	O
are	O	O
presented	O	O
:	O	O
both	O	O
patients	O	O
had	O	O
chronic	B-Disease	D007676
renal	I-Disease	D007676
failure	I-Disease	D007676
,	O	O
on	O	O
hemodialysis	O	O
for	O	O
many	O	O
years	O	O
but	O	O
recently	O	O
begun	O	O
on	O	O
a	O	O
high	O	O
-	O	O
flux	O	O
dialyzer	O	O
;	O	O
both	O	O
had	O	O
been	O	O
receiving	O	O
a	O	O
carbidopa	B-Chemical	C009265
/	I-Chemical	C009265
levodopa	I-Chemical	C009265
preparation	O	O
;	O	O
and	O	O
both	O	O
had	O	O
the	O	O
onset	O	O
of	O	O
hallucinosis	B-Disease	D001523
and	O	O
recurrent	O	O
seizures	B-Disease	D012640
,	O	O
which	O	O
were	O	O
refractory	O	O
to	O	O
anticonvulsants	O	O
.	O	O

The	O	O
first	O	O
patient	O	O
died	O	O
without	O	O
a	O	O
diagnosis	O	O
;	O	O
the	O	O
second	O	O
patient	O	O
had	O	O
a	O	O
dramatic	O	O
recovery	O	O
following	O	O
the	O	O
administration	O	O
of	O	O
vitamin	B-Chemical	D025101
B6	I-Chemical	D025101
.	O	O

Neither	O	O
patient	O	O
was	O	O
considered	O	O
to	O	O
have	O	O
a	O	O
renal	O	O
state	O	O
sufficiently	O	O
severe	O	O
enough	O	O
to	O	O
explain	O	O
their	O	O
presentation	O	O
.	O	O

Effect	O	O
of	O	O
L	B-Chemical	D005997
-	I-Chemical	D005997
alpha	I-Chemical	D005997
-	I-Chemical	D005997
glyceryl	I-Chemical	D005997
-	I-Chemical	D005997
phosphorylcholine	I-Chemical	D005997
on	O	O
amnesia	B-Disease	D000647
caused	O	O
by	O	O
scopolamine	B-Chemical	D012601
.	O	O

The	O	O
present	O	O
study	O	O
was	O	O
carried	O	O
out	O	O
to	O	O
test	O	O
the	O	O
effects	O	O
of	O	O
L	B-Chemical	D005997
-	I-Chemical	D005997
alpha	I-Chemical	D005997
-	I-Chemical	D005997
glycerylphosphorylcholine	I-Chemical	D005997
(	O	O
L	B-Chemical	D005997
-	I-Chemical	D005997
alpha	I-Chemical	D005997
-	I-Chemical	D005997
GFC	I-Chemical	D005997
)	O	O
on	O	O
memory	B-Disease	D008569
impairment	I-Disease	D008569
induced	O	O
by	O	O
scopolamine	B-Chemical	D012601
in	O	O
man	O	O
.	O	O

Thirty	O	O
-	O	O
two	O	O
healthy	O	O
young	O	O
volunteers	O	O
were	O	O
randomly	O	O
allocated	O	O
to	O	O
four	O	O
different	O	O
groups	O	O
.	O	O

They	O	O
were	O	O
given	O	O
a	O	O
ten	O	O
day	O	O
pretreatment	O	O
with	O	O
either	O	O
L	B-Chemical	D005997
-	I-Chemical	D005997
alpha	I-Chemical	D005997
-	I-Chemical	D005997
GFC	I-Chemical	D005997
or	O	O
placebo	O	O
,	O	O
p	O	O
.	O	O

o	O	O
.	O	O

,	O	O
and	O	O
on	O	O
the	O	O
eleventh	O	O
day	O	O
either	O	O
scopolamine	B-Chemical	D012601
or	O	O
placebo	O	O
,	O	O
i	O	O
.	O	O

m	O	O
.	O	O

Before	O	O
and	O	O
0	O	O
.	O	O

5	O	O
,	O	O
1	O	O
,	O	O
2	O	O
,	O	O
3	O	O
,	O	O
and	O	O
6	O	O
h	O	O
after	O	O
injection	O	O
the	O	O
subjects	O	O
were	O	O
given	O	O
attention	O	O
and	O	O
mnemonic	O	O
tests	O	O
.	O	O

The	O	O
findings	O	O
of	O	O
this	O	O
study	O	O
indicate	O	O
that	O	O
the	O	O
drug	O	O
is	O	O
able	O	O
to	O	O
antagonize	O	O
impairment	B-Disease	D008569
of	I-Disease	D008569
attention	I-Disease	D008569
and	I-Disease	D008569
memory	I-Disease	D008569
induced	O	O
by	O	O
scopolamine	B-Chemical	D012601
.	O	O

Seizures	B-Disease	D012640
induced	O	O
by	O	O
the	O	O
cocaine	B-Chemical	D003042
metabolite	O	O
benzoylecgonine	B-Chemical	C005618
in	O	O
rats	O	O
.	O	O

The	O	O
half	O	O
-	O	O
life	O	O
(	O	O
t1	O	O
/	O	O
2	O	O
)	O	O
of	O	O
cocaine	B-Chemical	D003042
is	O	O
relatively	O	O
short	O	O
,	O	O
but	O	O
some	O	O
of	O	O
the	O	O
consequences	O	O
of	O	O
its	O	O
use	O	O
,	O	O
such	O	O
as	O	O
seizures	B-Disease	D012640
and	O	O
strokes	B-Disease	D020521
,	O	O
can	O	O
occur	O	O
hours	O	O
after	O	O
exposure	O	O
.	O	O

This	O	O
led	O	O
us	O	O
to	O	O
hypothesize	O	O
that	O	O
a	O	O
metabolite	O	O
of	O	O
cocaine	B-Chemical	D003042
may	O	O
be	O	O
responsible	O	O
for	O	O
some	O	O
of	O	O
those	O	O
delayed	O	O
sequelae	O	O
.	O	O

We	O	O
evaluated	O	O
the	O	O
potential	O	O
of	O	O
the	O	O
major	O	O
metabolite	O	O
of	O	O
cocaine	B-Chemical	D003042
,	O	O
benzoylecgonine	B-Chemical	C005618
(	O	O
BE	B-Chemical	C005618
)	O	O
,	O	O
to	O	O
cause	O	O
seizures	B-Disease	D012640
.	O	O

Two	O	O
separate	O	O
equimolar	O	O
doses	O	O
(	O	O
0	O	O
.	O	O

2	O	O
and	O	O
0	O	O
.	O	O

4	O	O
mumol	O	O
)	O	O
of	O	O
either	O	O
cocaine	B-Chemical	D003042
or	O	O
BE	B-Chemical	C005618
were	O	O
injected	O	O
ventricularly	O	O
in	O	O
unanesthetized	O	O
juvenile	O	O
rats	O	O
.	O	O

Treated	O	O
rats	O	O
were	O	O
then	O	O
evaluated	O	O
for	O	O
incidence	O	O
,	O	O
latency	O	O
,	O	O
and	O	O
seizure	B-Disease	D012640
pattern	O	O
or	O	O
for	O	O
locomotor	O	O
activity	O	O
in	O	O
animals	O	O
without	O	O
seizures	B-Disease	D012640
.	O	O

BE	B-Chemical	C005618
-	O	O
Induced	O	O
seizures	B-Disease	D012640
occurred	O	O
more	O	O
frequently	O	O
and	O	O
had	O	O
significantly	O	O
longer	O	O
latencies	O	O
than	O	O
those	O	O
induced	O	O
by	O	O
equimolar	O	O
amounts	O	O
of	O	O
cocaine	B-Chemical	D003042
.	O	O

Whereas	O	O
cocaine	B-Chemical	D003042
-	O	O
induced	O	O
seizures	B-Disease	D012640
were	O	O
best	O	O
characterized	O	O
as	O	O
brief	O	O
,	O	O
generalized	O	O
,	O	O
and	O	O
tonic	O	O
and	O	O
resulted	O	O
in	O	O
death	B-Disease	D003643
,	O	O
those	O	O
induced	O	O
by	O	O
BE	B-Chemical	C005618
were	O	O
prolonged	O	O
,	O	O
often	O	O
multiple	O	O
and	O	O
mixed	O	O
in	O	O
type	O	O
,	O	O
and	O	O
rarely	O	O
resulted	O	O
in	O	O
death	B-Disease	D003643
.	O	O

Electrical	O	O
recordings	O	O
from	O	O
the	O	O
hippocampus	O	O
showed	O	O
a	O	O
rhythmic	O	O
progression	O	O
in	O	O
EEG	O	O
frequency	O	O
and	O	O
voltage	O	O
with	O	O
clinical	O	O
seizure	B-Disease	D012640
expression	O	O
.	O	O

BE	B-Chemical	C005618
-	O	O
Injected	O	O
rats	O	O
that	O	O
did	O	O
not	O	O
have	O	O
seizures	B-Disease	D012640
had	O	O
significantly	O	O
more	O	O
locomotor	O	O
activity	O	O
than	O	O
cocaine	B-Chemical	D003042
-	O	O
injected	O	O
animals	O	O
without	O	O
seizures	B-Disease	D012640
.	O	O

The	O	O
finding	O	O
that	O	O
cocaine	B-Chemical	D003042
-	O	O
and	O	O
BE	B-Chemical	C005618
-	O	O
induced	O	O
seizures	B-Disease	D012640
differ	O	O
in	O	O
several	O	O
respects	O	O
suggests	O	O
more	O	O
than	O	O
one	O	O
mechanism	O	O
for	O	O
cocaine	B-Chemical	D003042
-	O	O
induced	O	O
seizures	B-Disease	D012640
and	O	O
emphasizes	O	O
the	O	O
importance	O	O
of	O	O
a	O	O
cocaine	B-Chemical	D003042
metabolite	O	O
,	O	O
BE	B-Chemical	C005618
.	O	O

Protection	O	O
against	O	O
amphetamine	B-Chemical	D000661
-	O	O
induced	O	O
neurotoxicity	B-Disease	D020258
toward	O	O
striatal	O	O
dopamine	B-Chemical	D004298
neurons	O	O
in	O	O
rodents	O	O
by	O	O
LY274614	B-Chemical	C070935
,	O	O
an	O	O
excitatory	O	O
amino	B-Chemical	D000596
acid	I-Chemical	D000596
antagonist	O	O
.	O	O

LY274614	B-Chemical	C070935
,	O	O
3SR	B-Chemical	C070935
,	I-Chemical	C070935
4aRS	I-Chemical	C070935
,	I-Chemical	C070935
6SR	I-Chemical	C070935
,	I-Chemical	C070935
8aRS	I-Chemical	C070935
-	I-Chemical	C070935
6	I-Chemical	C070935
-	I-Chemical	C070935
[	I-Chemical	C070935
phosphonomethyl	I-Chemical	C070935
]	I-Chemical	C070935
decahydr	I-Chemical	C070935
oisoquinoline	I-Chemical	C070935
-	I-Chemical	C070935
3	I-Chemical	C070935
-	I-Chemical	C070935
carboxylic	I-Chemical	C070935
acid	I-Chemical	C070935
,	O	O
has	O	O
been	O	O
described	O	O
as	O	O
a	O	O
potent	O	O
antagonist	O	O
of	O	O
the	O	O
N	B-Chemical	D016202
-	I-Chemical	D016202
methyl	I-Chemical	D016202
-	I-Chemical	D016202
D	I-Chemical	D016202
-	I-Chemical	D016202
aspartate	I-Chemical	D016202
(	O	O
NMDA	B-Chemical	D016202
)	O	O
subtype	O	O
of	O	O
glutamate	B-Chemical	D018698
receptor	O	O
.	O	O

Here	O	O
its	O	O
ability	O	O
to	O	O
antagonize	O	O
the	O	O
prolonged	O	O
depletion	O	O
of	O	O
dopamine	B-Chemical	D004298
in	O	O
the	O	O
striatum	O	O
by	O	O
amphetamine	B-Chemical	D000661
in	O	O
iprindole	B-Chemical	D007488
-	O	O
treated	O	O
rats	O	O
is	O	O
reported	O	O
.	O	O

A	O	O
single	O	O
18	O	O
.	O	O

4	O	O
mg	O	O
/	O	O
kg	O	O
(	O	O
i	O	O
.	O	O

p	O	O
.	O	O

)	O	O
dose	O	O
of	O	O
(	O	O
+	O	O
/	O	O
-	O	O
)	O	O
-	O	O
amphetamine	B-Chemical	D000661
hemisulfate	O	O
,	O	O
given	O	O
to	O	O
rats	O	O
pretreated	O	O
with	O	O
iprindole	B-Chemical	D007488
,	O	O
resulted	O	O
in	O	O
persistent	O	O
depletion	O	O
of	O	O
dopamine	B-Chemical	D004298
in	O	O
the	O	O
striatum	O	O
1	O	O
week	O	O
later	O	O
.	O	O

This	O	O
prolonged	O	O
depletion	O	O
of	O	O
dopamine	B-Chemical	D004298
in	O	O
the	O	O
striatum	O	O
was	O	O
antagonized	O	O
by	O	O
dizocilpine	B-Chemical	D016291
(	O	O
MK	B-Chemical	D016291
-	I-Chemical	D016291
801	I-Chemical	D016291
,	O	O
a	O	O
non	O	O
-	O	O
competitive	O	O
antagonist	O	O
of	O	O
NMDA	B-Chemical	D016202
receptors	O	O
)	O	O
or	O	O
by	O	O
LY274614	B-Chemical	C070935
(	O	O
a	O	O
competitive	O	O
antagonist	O	O
of	O	O
NMDA	B-Chemical	D016202
receptors	O	O
)	O	O
.	O	O

The	O	O
protective	O	O
effect	O	O
of	O	O
LY274614	B-Chemical	C070935
was	O	O
dose	O	O
-	O	O
dependent	O	O
,	O	O
being	O	O
maximum	O	O
at	O	O
10	O	O
-	O	O
40	O	O
mgkg	O	O
(	O	O
i	O	O
.	O	O

p	O	O
.	O	O

)	O	O
.	O	O

A	O	O
10	O	O
mg	O	O
/	O	O
kg	O	O
dose	O	O
of	O	O
LY274614	B-Chemical	C070935
was	O	O
effective	O	O
in	O	O
antagonizing	O	O
the	O	O
depletion	O	O
of	O	O
dopamine	B-Chemical	D004298
in	O	O
the	O	O
striatum	O	O
,	O	O
when	O	O
given	O	O
as	O	O
long	O	O
as	O	O
8	O	O
hr	O	O
prior	O	O
to	O	O
amphetamine	B-Chemical	D000661
but	O	O
not	O	O
when	O	O
given	O	O
24	O	O
hr	O	O
prior	O	O
to	O	O
amphetamine	B-Chemical	D000661
.	O	O

Depletion	O	O
of	O	O
dopamine	B-Chemical	D004298
in	O	O
the	O	O
striatum	O	O
was	O	O
also	O	O
antagonized	O	O
when	O	O
LY274614	B-Chemical	C070935
was	O	O
given	O	O
after	O	O
the	O	O
injection	O	O
of	O	O
amphetamine	B-Chemical	D000661
;	O	O
LY274614	B-Chemical	C070935
protected	O	O
when	O	O
given	O	O
up	O	O
to	O	O
4	O	O
hr	O	O
after	O	O
but	O	O
not	O	O
when	O	O
given	O	O
8	O	O
or	O	O
24	O	O
hr	O	O
after	O	O
amphetamine	B-Chemical	D000661
.	O	O

The	O	O
prolonged	O	O
depletion	O	O
of	O	O
dopamine	B-Chemical	D004298
in	O	O
the	O	O
striatum	O	O
in	O	O
mice	O	O
,	O	O
given	O	O
multiple	O	O
injections	O	O
of	O	O
methamphetamine	B-Chemical	D008694
,	O	O
was	O	O
also	O	O
antagonized	O	O
dose	O	O
-	O	O
dependently	O	O
and	O	O
completely	O	O
by	O	O
LY274614	B-Chemical	C070935
.	O	O

The	O	O
data	O	O
strengthen	O	O
the	O	O
evidence	O	O
that	O	O
the	O	O
neurotoxic	B-Disease	D020258
effect	O	O
of	O	O
amphetamine	B-Chemical	D000661
and	O	O
related	O	O
compounds	O	O
toward	O	O
nigrostriatal	O	O
dopamine	B-Chemical	D004298
neurons	O	O
involves	O	O
NMDA	B-Chemical	D016202
receptors	O	O
and	O	O
that	O	O
LY274614	B-Chemical	C070935
is	O	O
an	O	O
NMDA	B-Chemical	D016202
receptor	O	O
antagonist	O	O
with	O	O
long	O	O
-	O	O
lasting	O	O
in	O	O
vivo	O	O
effects	O	O
in	O	O
rats	O	O
.	O	O

Neonatal	O	O
pyridoxine	B-Chemical	D011736
responsive	O	O
convulsions	B-Disease	D012640
due	O	O
to	O	O
isoniazid	B-Chemical	D007538
therapy	O	O
.	O	O

A	O	O
17	O	O
-	O	O
day	O	O
-	O	O
old	O	O
infant	O	O
on	O	O
isoniazid	B-Chemical	D007538
therapy	O	O
13	O	O
mg	O	O
/	O	O
kg	O	O
daily	O	O
from	O	O
birth	O	O
because	O	O
of	O	O
maternal	O	O
tuberculosis	B-Disease	D014376
was	O	O
admitted	O	O
after	O	O
4	O	O
days	O	O
of	O	O
clonic	B-Disease	D012640
fits	I-Disease	D012640
.	O	O

No	O	O
underlying	O	O
infective	O	O
or	O	O
biochemical	O	O
cause	O	O
could	O	O
be	O	O
found	O	O
.	O	O

The	O	O
fits	B-Disease	D012640
ceased	O	O
within	O	O
4	O	O
hours	O	O
of	O	O
administering	O	O
intramuscular	O	O
pyridoxine	B-Chemical	D011736
,	O	O
suggesting	O	O
an	O	O
aetiology	O	O
of	O	O
pyridoxine	B-Chemical	D011736
deficiency	O	O
secondary	O	O
to	O	O
isoniazid	B-Chemical	D007538
medication	O	O
.	O	O

Reversal	O	O
by	O	O
phenylephrine	B-Chemical	D010656
of	O	O
the	O	O
beneficial	O	O
effects	O	O
of	O	O
intravenous	O	O
nitroglycerin	B-Chemical	D005996
in	O	O
patients	O	O
with	O	O
acute	B-Disease	D009203
myocardial	I-Disease	D009203
infarction	I-Disease	D009203
.	O	O

Nitroglycerin	B-Chemical	D005996
has	O	O
been	O	O
shown	O	O
to	O	O
reduce	O	O
ST	O	O
-	O	O
segment	O	O
elevation	O	O
during	O	O
acute	B-Disease	D009203
myocardial	I-Disease	D009203
infarction	I-Disease	D009203
,	O	O
an	O	O
effect	O	O
potentiated	O	O
in	O	O
the	O	O
dog	O	O
by	O	O
agents	O	O
that	O	O
reverse	O	O
nitroglycerin	B-Chemical	D005996
-	O	O
induced	O	O
hypotension	B-Disease	D007022
.	O	O

Our	O	O
study	O	O
was	O	O
designed	O	O
to	O	O
determine	O	O
the	O	O
effects	O	O
of	O	O
combined	O	O
nitroglycerin	B-Chemical	D005996
and	O	O
phenylephrine	B-Chemical	D010656
therapy	O	O
.	O	O

Ten	O	O
patients	O	O
with	O	O
acute	O	O
transmural	O	O
myocardial	B-Disease	D009203
infarctions	I-Disease	D009203
received	O	O
intravenous	O	O
nitroglycerin	B-Chemical	D005996
,	O	O
sufficient	O	O
to	O	O
reduce	O	O
mean	O	O
arterial	O	O
pressure	O	O
from	O	O
107	O	O
+	O	O
/	O	O
-	O	O
6	O	O
to	O	O
85	O	O
+	O	O
/	O	O
-	O	O
6	O	O
mm	O	O
Hg	O	O
(	O	O
P	O	O
less	O	O
than	O	O
0	O	O
.	O	O

001	O	O
)	O	O
,	O	O
for	O	O
60	O	O
minutes	O	O
.	O	O

Left	O	O
ventricular	O	O
filling	O	O
pressure	O	O
decreased	O	O
from	O	O
19	O	O
+	O	O
/	O	O
-	O	O
2	O	O
to	O	O
11	O	O
+	O	O
/	O	O
-	O	O
2	O	O
mm	O	O
Hg	O	O
(	O	O
P	O	O
less	O	O
than	O	O
0	O	O
.	O	O

001	O	O
)	O	O
.	O	O

SigmaST	O	O
,	O	O
the	O	O
sum	O	O
of	O	O
ST	O	O
-	O	O
segment	O	O
elevations	O	O
in	O	O
16	O	O
precordial	O	O
leads	O	O
,	O	O
decreased	O	O
(	O	O
P	O	O
less	O	O
than	O	O
0	O	O
.	O	O

02	O	O
)	O	O
with	O	O
intravenous	O	O
nitroglycerin	B-Chemical	D005996
.	O	O

Subsequent	O	O
addition	O	O
of	O	O
phenylephrine	B-Chemical	D010656
infusion	O	O
,	O	O
sufficient	O	O
to	O	O
re	O	O
-	O	O
elevate	O	O
mean	O	O
arterial	O	O
pressure	O	O
to	O	O
106	O	O
+	O	O
/	O	O
-	O	O
4	O	O
mm	O	O
Hg	O	O
(	O	O
P	O	O
less	O	O
than	O	O
0	O	O
.	O	O

001	O	O
)	O	O
for	O	O
30	O	O
minutes	O	O
,	O	O
increased	O	O
left	O	O
ventricular	O	O
filling	O	O
pressure	O	O
to	O	O
17	O	O
+	O	O
/	O	O
-	O	O
2	O	O
mm	O	O
Hg	O	O
(	O	O
P	O	O
less	O	O
than	O	O
0	O	O
.	O	O

05	O	O
)	O	O
and	O	O
also	O	O
significantly	O	O
increased	O	O
sigmaST	O	O
(	O	O
P	O	O
less	O	O
than	O	O
0	O	O
.	O	O

05	O	O
)	O	O
.	O	O

Our	O	O
results	O	O
suggest	O	O
that	O	O
addition	O	O
of	O	O
phenylephrine	B-Chemical	D010656
to	O	O
nitroglycerin	B-Chemical	D005996
is	O	O
not	O	O
beneficial	O	O
in	O	O
the	O	O
treatment	O	O
of	O	O
patients	O	O
with	O	O
acute	B-Disease	D009203
myocardial	I-Disease	D009203
infarction	I-Disease	D009203
.	O	O

Elevation	O	O
of	O	O
ADAM10	O	O
,	O	O
ADAM17	O	O
,	O	O
MMP	O	O
-	O	O
2	O	O
and	O	O
MMP	O	O
-	O	O
9	O	O
expression	O	O
with	O	O
media	O	O
degeneration	O	O
features	O	O
CaCl2	B-Chemical	D002122
-	O	O
induced	O	O
thoracic	B-Disease	D017545
aortic	I-Disease	D017545
aneurysm	I-Disease	D017545
in	O	O
a	O	O
rat	O	O
model	O	O
.	O	O

PURPOSE	O	O
:	O	O
This	O	O
study	O	O
was	O	O
designed	O	O
to	O	O
establish	O	O
a	O	O
rat	O	O
model	O	O
of	O	O
thoracic	B-Disease	D017545
aortic	I-Disease	D017545
aneurysm	I-Disease	D017545
(	O	O
TAA	B-Disease	D017545
)	O	O
by	O	O
calcium	B-Chemical	D002122
chloride	I-Chemical	D002122
(	O	O
CaCl	B-Chemical	D002122
(	I-Chemical	D002122
2	I-Chemical	D002122
)	I-Chemical	D002122
)	O	O
-	O	O
induced	O	O
arterial	B-Disease	D014652
injury	I-Disease	D014652
and	O	O
to	O	O
explore	O	O
the	O	O
potential	O	O
role	O	O
of	O	O
a	O	O
disintegrin	O	O
and	O	O
metalloproteinase	O	O
(	O	O
ADAM	O	O
)	O	O
,	O	O
matrix	O	O
metalloproteinases	O	O
(	O	O
MMPs	O	O
)	O	O
and	O	O
their	O	O
endogenous	O	O
inhibitors	O	O
(	O	O
TIMPs	O	O
)	O	O
in	O	O
TAA	B-Disease	D017545
formation	O	O
.	O	O

METHODS	O	O
:	O	O
Thoracic	O	O
aorta	O	O
of	O	O
male	O	O
Sprague	O	O
-	O	O
Dawley	O	O
rats	O	O
was	O	O
exposed	O	O
to	O	O
0	O	O
.	O	O

5M	O	O
CaCl	B-Chemical	D002122
(	I-Chemical	D002122
2	I-Chemical	D002122
)	I-Chemical	D002122
or	O	O
normal	O	O
saline	O	O
(	O	O
NaCl	B-Chemical	D012965
)	O	O
.	O	O

After	O	O
12weeks	O	O
,	O	O
animals	O	O
were	O	O
euthanized	O	O
,	O	O
and	O	O
CaCl	B-Chemical	D002122
(	I-Chemical	D002122
2	I-Chemical	D002122
)	I-Chemical	D002122
-	O	O
treated	O	O
,	O	O
CaCl	B-Chemical	D002122
(	I-Chemical	D002122
2	I-Chemical	D002122
)	I-Chemical	D002122
-	O	O
untreated	O	O
(	O	O
n=12	O	O
)	O	O
and	O	O
NaCl	B-Chemical	D012965
-	O	O
treated	O	O
aortic	O	O
segments	O	O
(	O	O
n=12	O	O
)	O	O
were	O	O
collected	O	O
for	O	O
histological	O	O
and	O	O
molecular	O	O
assessments	O	O
.	O	O

MMP	O	O
-	O	O
TIMP	O	O
and	O	O
ADAM	O	O
mRNAs	O	O
were	O	O
semi	O	O
-	O	O
quantitatively	O	O
analyzed	O	O
and	O	O
protein	O	O
expressions	O	O
were	O	O
determined	O	O
by	O	O
immunohistochemistry	O	O
.	O	O

RESULTS	O	O
:	O	O
Despite	O	O
similar	O	O
external	O	O
diameters	O	O
among	O	O
CaCl	B-Chemical	D002122
(	I-Chemical	D002122
2	I-Chemical	D002122
)	I-Chemical	D002122
-	O	O
treated	O	O
,	O	O
non	O	O
-	O	O
CaCl	B-Chemical	D002122
(	I-Chemical	D002122
2	I-Chemical	D002122
)	I-Chemical	D002122
-	O	O
treated	O	O
and	O	O
NaCl	B-Chemical	D012965
-	O	O
treated	O	O
segments	O	O
,	O	O
aneurymal	O	O
alteration	O	O
(	O	O
n=6	O	O
,	O	O
50%	O	O
)	O	O
,	O	O
media	O	O
degeneration	O	O
with	O	O
regional	O	O
disruption	O	O
,	O	O
fragmentation	O	O
of	O	O
elastic	O	O
fiber	O	O
,	O	O
and	O	O
increased	O	O
collagen	O	O
deposition	O	O
(	O	O
n=12	O	O
,	O	O
100%	O	O
)	O	O
were	O	O
demonstrated	O	O
in	O	O
CaCl	B-Chemical	D002122
(	I-Chemical	D002122
2	I-Chemical	D002122
)	I-Chemical	D002122
-	O	O
treated	O	O
segments	O	O
.	O	O

MMP	O	O
-	O	O
2	O	O
,	O	O
MMP	O	O
-	O	O
9	O	O
,	O	O
ADAM	O	O
-	O	O
10	O	O
and	O	O
ADAM	O	O
-	O	O
17	O	O
mRNA	O	O
levels	O	O
were	O	O
increased	O	O
in	O	O
CaCl	B-Chemical	D002122
(	I-Chemical	D002122
2	I-Chemical	D002122
)	I-Chemical	D002122
-	O	O
treated	O	O
segments	O	O
(	O	O
all	O	O
p<0	O	O
.	O	O

01	O	O
)	O	O
,	O	O
with	O	O
trends	O	O
of	O	O
elevation	O	O
in	O	O
CaCl	B-Chemical	D002122
(	I-Chemical	D002122
2	I-Chemical	D002122
)	I-Chemical	D002122
-	O	O
untreated	O	O
segments	O	O
,	O	O
as	O	O
compared	O	O
with	O	O
NaCl	B-Chemical	D012965
-	O	O
treated	O	O
segments	O	O
.	O	O

Immunohistochemistry	O	O
displayed	O	O
significantly	O	O
increased	O	O
expressions	O	O
of	O	O
MMP	O	O
-	O	O
2	O	O
,	O	O
MMP	O	O
-	O	O
9	O	O
,	O	O
ADAM	O	O
-	O	O
10	O	O
and	O	O
ADAM	O	O
-	O	O
17	O	O
(	O	O
all	O	O
p<0	O	O
.	O	O

01	O	O
)	O	O
in	O	O
intima	O	O
and	O	O
media	O	O
for	O	O
CaCl	B-Chemical	D002122
(	I-Chemical	D002122
2	I-Chemical	D002122
)	I-Chemical	D002122
-	O	O
treated	O	O
segments	O	O
.	O	O

TIMP	O	O
mRNA	O	O
and	O	O
tissue	O	O
levels	O	O
did	O	O
not	O	O
differ	O	O
obviously	O	O
among	O	O
the	O	O
three	O	O
aortic	O	O
segments	O	O
.	O	O

CONCLUSION	O	O
:	O	O
This	O	O
study	O	O
establishes	O	O
a	O	O
TAA	B-Disease	D017545
model	O	O
by	O	O
periarterial	O	O
CaCl	B-Chemical	D002122
(	I-Chemical	D002122
2	I-Chemical	D002122
)	I-Chemical	D002122
exposure	O	O
in	O	O
rats	O	O
,	O	O
and	O	O
demonstrates	O	O
a	O	O
significant	O	O
elevation	O	O
of	O	O
expression	O	O
of	O	O
MMP	O	O
-	O	O
2	O	O
,	O	O
MMP	O	O
-	O	O
9	O	O
,	O	O
ADAM10	O	O
and	O	O
ADAM17	O	O
in	O	O
the	O	O
pathogenesis	O	O
of	O	O
vascular	O	O
remodeling	O	O
.	O	O

When	O	O
drugs	O	O
disappear	O	O
from	O	O
the	O	O
patient	O	O
:	O	O
elimination	O	O
of	O	O
intravenous	O	O
medication	O	O
by	O	O
hemodiafiltration	O	O
.	O	O

Twenty	O	O
-	O	O
three	O	O
hours	O	O
after	O	O
heart	O	O
transplantation	O	O
,	O	O
life	O	O
-	O	O
threatening	O	O
acute	O	O
right	B-Disease	D006333
heart	I-Disease	D006333
failure	I-Disease	D006333
was	O	O
diagnosed	O	O
in	O	O
a	O	O
patient	O	O
requiring	O	O
continuous	O	O
venovenous	O	O
hemodiafiltration	O	O
(	O	O
CVVHDF	O	O
)	O	O
.	O	O

Increasing	O	O
doses	O	O
of	O	O
catecholamines	B-Chemical	D002395
,	O	O
sedatives	O	O
,	O	O
and	O	O
muscle	O	O
relaxants	O	O
administered	O	O
through	O	O
a	O	O
central	O	O
venous	O	O
catheter	O	O
were	O	O
ineffective	O	O
.	O	O

However	O	O
,	O	O
a	O	O
bolus	O	O
of	O	O
epinephrine	B-Chemical	D004837
injected	O	O
through	O	O
an	O	O
alternative	O	O
catheter	O	O
provoked	O	O
a	O	O
hypertensive	B-Disease	D006973
crisis	O	O
.	O	O

Thus	O	O
,	O	O
interference	O	O
with	O	O
the	O	O
central	O	O
venous	O	O
infusion	O	O
by	O	O
the	O	O
dialysis	O	O
catheter	O	O
was	O	O
suspected	O	O
.	O	O

The	O	O
catheters	O	O
were	O	O
changed	O	O
,	O	O
and	O	O
hemodynamics	O	O
stabilized	O	O
at	O	O
lower	O	O
catecholamine	B-Chemical	D002395
doses	O	O
.	O	O

When	O	O
the	O	O
effects	O	O
of	O	O
IV	O	O
drugs	O	O
are	O	O
inadequate	O	O
in	O	O
patients	O	O
receiving	O	O
CVVHDF	O	O
,	O	O
interference	O	O
with	O	O
adjacent	O	O
catheters	O	O
resulting	O	O
in	O	O
elimination	O	O
of	O	O
the	O	O
drug	O	O
by	O	O
CVVHDF	O	O
should	O	O
be	O	O
suspected	O	O
.	O	O

Long	O	O
-	O	O
term	O	O
glutamate	B-Chemical	D018698
supplementation	O	O
failed	O	O
to	O	O
protect	O	O
against	O	O
peripheral	B-Disease	D010523
neurotoxicity	I-Disease	D010523
of	O	O
paclitaxel	B-Chemical	D017239
.	O	O

Toxic	O	O
peripheral	B-Disease	D010523
neuropathy	I-Disease	D010523
is	O	O
still	O	O
a	O	O
significant	O	O
limiting	O	O
factor	O	O
for	O	O
chemotherapy	O	O
with	O	O
paclitaxel	B-Chemical	D017239
(	O	O
PAC	B-Chemical	D017239
)	O	O
,	O	O
although	O	O
glutamate	B-Chemical	D018698
and	O	O
its	O	O
closely	O	O
related	O	O
amino	B-Chemical	D000596
acid	I-Chemical	D000596
glutamine	B-Chemical	D018698
were	O	O
claimed	O	O
to	O	O
ameliorate	O	O
PAC	B-Chemical	D017239
neurotoxicity	B-Disease	D020258
.	O	O

This	O	O
pilot	O	O
trial	O	O
aimed	O	O
to	O	O
evaluate	O	O
the	O	O
role	O	O
of	O	O
glutamate	B-Chemical	D018698
supplementation	O	O
for	O	O
preventing	O	O
PAC	B-Chemical	D017239
-	O	O
induced	O	O
peripheral	B-Disease	D010523
neuropathy	I-Disease	D010523
in	O	O
a	O	O
randomized	O	O
,	O	O
placebo	O	O
-	O	O
controlled	O	O
,	O	O
double	O	O
-	O	O
blinded	O	O
clinical	O	O
and	O	O
electro	O	O
-	O	O
diagnostic	O	O
study	O	O
.	O	O

Forty	O	O
-	O	O
three	O	O
ovarian	B-Disease	D010051
cancer	I-Disease	D010051
patients	O	O
were	O	O
available	O	O
for	O	O
analysis	O	O
following	O	O
six	O	O
cycles	O	O
of	O	O
the	O	O
same	O	O
PAC	B-Chemical	D017239
-	O	O
containing	O	O
regimen	O	O
:	O	O
23	O	O
had	O	O
been	O	O
supplemented	O	O
by	O	O
glutamate	B-Chemical	D018698
all	O	O
along	O	O
the	O	O
treatment	O	O
period	O	O
,	O	O
at	O	O
a	O	O
daily	O	O
dose	O	O
of	O	O
three	O	O
times	O	O
500	O	O
mg	O	O
(	O	O
group	O	O
G	O	O
)	O	O
,	O	O
and	O	O
20	O	O
had	O	O
received	O	O
a	O	O
placebo	O	O
(	O	O
group	O	O
P	O	O
)	O	O
.	O	O

Patients	O	O
were	O	O
evaluated	O	O
by	O	O
neurological	O	O
examinations	O	O
,	O	O
questionnaires	O	O
and	O	O
sensory	O	O
-	O	O
motor	O	O
nerve	O	O
conduction	O	O
studies	O	O
.	O	O

There	O	O
was	O	O
no	O	O
significant	O	O
difference	O	O
in	O	O
the	O	O
frequency	O	O
of	O	O
signs	O	O
or	O	O
symptoms	O	O
between	O	O
the	O	O
two	O	O
groups	O	O
although	O	O
neurotoxicity	B-Disease	D020258
symptoms	O	O
presented	O	O
mostly	O	O
with	O	O
lower	O	O
scores	O	O
of	O	O
severity	O	O
in	O	O
group	O	O
G	O	O
.	O	O

However	O	O
,	O	O
this	O	O
difference	O	O
reached	O	O
statistical	O	O
significance	O	O
only	O	O
with	O	O
regard	O	O
to	O	O
reported	O	O
pain	B-Disease	D010146
sensation	O	O
(	O	O
P	O	O
=	O	O
0	O	O
.	O	O

011	O	O
)	O	O
.	O	O

Also	O	O
the	O	O
frequency	O	O
of	O	O
abnormal	O	O
electro	O	O
-	O	O
diagnostic	O	O
findings	O	O
showed	O	O
similarity	O	O
between	O	O
the	O	O
two	O	O
groups	O	O
(	O	O
G	O	O
:	O	O
7	O	O
/	O	O
23	O	O
=	O	O
30	O	O
.	O	O

4%	O	O
;	O	O
P	O	O
:	O	O
6	O	O
/	O	O
20	O	O
=	O	O
30%	O	O
)	O	O
.	O	O

This	O	O
pilot	O	O
study	O	O
leads	O	O
to	O	O
the	O	O
conclusion	O	O
that	O	O
glutamate	B-Chemical	D018698
supplementation	O	O
at	O	O
the	O	O
chosen	O	O
regimen	O	O
fails	O	O
to	O	O
protect	O	O
against	O	O
peripheral	B-Disease	D010523
neurotoxicity	I-Disease	D010523
of	O	O
PAC	B-Chemical	D017239
.	O	O

Attentional	O	O
modulation	O	O
of	O	O
perceived	O	O
pain	B-Disease	D010146
intensity	O	O
in	O	O
capsaicin	B-Chemical	D002211
-	O	O
induced	O	O
secondary	O	O
hyperalgesia	B-Disease	D006930
.	O	O

Perceived	O	O
pain	B-Disease	D010146
intensity	O	O
is	O	O
modulated	O	O
by	O	O
attention	O	O
.	O	O

However	O	O
,	O	O
it	O	O
is	O	O
not	O	O
known	O	O
that	O	O
how	O	O
pain	B-Disease	D010146
intensity	O	O
ratings	O	O
are	O	O
affected	O	O
by	O	O
attention	O	O
in	O	O
capsaicin	B-Chemical	D002211
-	O	O
induced	O	O
secondary	O	O
hyperalgesia	B-Disease	D006930
.	O	O

Here	O	O
we	O	O
show	O	O
that	O	O
perceived	O	O
pain	B-Disease	D010146
intensity	O	O
in	O	O
secondary	O	O
hyperalgesia	B-Disease	D006930
is	O	O
decreased	O	O
when	O	O
attention	O	O
is	O	O
distracted	O	O
away	O	O
from	O	O
the	O	O
painful	O	O
pinprick	O	O
stimulus	O	O
with	O	O
a	O	O
visual	O	O
task	O	O
.	O	O

Furthermore	O	O
,	O	O
it	O	O
was	O	O
found	O	O
that	O	O
the	O	O
magnitude	O	O
of	O	O
attentional	O	O
modulation	O	O
in	O	O
secondary	O	O
hyperalgesia	B-Disease	D006930
is	O	O
very	O	O
similar	O	O
to	O	O
that	O	O
of	O	O
capsaicin	B-Chemical	D002211
-	O	O
untreated	O	O
,	O	O
control	O	O
condition	O	O
.	O	O

Our	O	O
findings	O	O
,	O	O
showing	O	O
no	O	O
interaction	O	O
between	O	O
capsaicin	B-Chemical	D002211
treatment	O	O
and	O	O
attentional	O	O
modulation	O	O
suggest	O	O
that	O	O
capsaicin	B-Chemical	D002211
-	O	O
induced	O	O
secondary	O	O
hyperalgesia	B-Disease	D006930
and	O	O
attention	O	O
might	O	O
affect	O	O
mechanical	O	O
pain	B-Disease	D010146
through	O	O
independent	O	O
mechanisms	O	O
.	O	O

Testosterone	B-Chemical	D013739
-	O	O
dependent	O	O
hypertension	B-Disease	D006973
and	O	O
upregulation	O	O
of	O	O
intrarenal	O	O
angiotensinogen	O	O
in	O	O
Dahl	O	O
salt	B-Chemical	D017673
-	O	O
sensitive	O	O
rats	O	O
.	O	O

Blood	O	O
pressure	O	O
(	O	O
BP	O	O
)	O	O
is	O	O
more	O	O
salt	B-Chemical	D017673
sensitive	O	O
in	O	O
men	O	O
than	O	O
in	O	O
premenopausal	O	O
women	O	O
.	O	O

In	O	O
Dahl	O	O
salt	B-Chemical	D017673
-	O	O
sensitive	O	O
rats	O	O
(	O	O
DS	O	O
)	O	O
,	O	O
high	O	O
-	O	O
salt	B-Chemical	D017673
(	O	O
HS	O	O
)	O	O
diet	O	O
increases	O	O
BP	O	O
more	O	O
in	O	O
males	O	O
than	O	O
females	O	O
.	O	O

In	O	O
contrast	O	O
to	O	O
the	O	O
systemic	O	O
renin	O	O
-	O	O
angiotensin	B-Chemical	D000809
system	O	O
,	O	O
which	O	O
is	O	O
suppressed	O	O
in	O	O
response	O	O
to	O	O
HS	O	O
in	O	O
male	O	O
DS	O	O
,	O	O
intrarenal	O	O
angiotensinogen	O	O
expression	O	O
is	O	O
increased	O	O
,	O	O
and	O	O
intrarenal	O	O
levels	O	O
of	O	O
ANG	O	O
II	O	O
are	O	O
not	O	O
suppressed	O	O
.	O	O

In	O	O
this	O	O
study	O	O
,	O	O
the	O	O
hypothesis	O	O
was	O	O
tested	O	O
that	O	O
there	O	O
is	O	O
a	O	O
sexual	O	O
dimorphism	O	O
in	O	O
HS	O	O
-	O	O
induced	O	O
upregulation	O	O
of	O	O
intrarenal	O	O
angiotensinogen	O	O
mediated	O	O
by	O	O
testosterone	B-Chemical	D013739
that	O	O
also	O	O
causes	O	O
increases	O	O
in	O	O
BP	O	O
and	O	O
renal	B-Disease	D007674
injury	I-Disease	D007674
.	O	O

On	O	O
a	O	O
low	O	O
-	O	O
salt	B-Chemical	D017673
(	O	O
LS	O	O
)	O	O
diet	O	O
,	O	O
male	O	O
DS	O	O
had	O	O
higher	O	O
levels	O	O
of	O	O
intrarenal	O	O
angiotensinogen	O	O
mRNA	O	O
than	O	O
females	O	O
.	O	O

HS	O	O
diet	O	O
for	O	O
4	O	O
wk	O	O
increased	O	O
renal	O	O
cortical	O	O
angiotensinogen	O	O
mRNA	O	O
and	O	O
protein	O	O
only	O	O
in	O	O
male	O	O
DS	O	O
,	O	O
which	O	O
was	O	O
prevented	O	O
by	O	O
castration	O	O
.	O	O

Ovariectomy	O	O
of	O	O
female	O	O
DS	O	O
had	O	O
no	O	O
effect	O	O
on	O	O
intrarenal	O	O
angiotensinogen	O	O
expression	O	O
on	O	O
either	O	O
diet	O	O
.	O	O

Radiotelemetric	O	O
BP	O	O
was	O	O
similar	O	O
between	O	O
males	O	O
and	O	O
castrated	O	O
rats	O	O
on	O	O
LS	O	O
diet	O	O
.	O	O

HS	O	O
diet	O	O
for	O	O
4	O	O
wk	O	O
caused	O	O
a	O	O
progressive	O	O
increase	O	O
in	O	O
BP	O	O
,	O	O
protein	O	O
and	O	O
albumin	O	O
excretion	O	O
,	O	O
and	O	O
glomerular	B-Disease	D007674
sclerosis	I-Disease	D007674
in	O	O
male	O	O
DS	O	O
rats	O	O
,	O	O
which	O	O
were	O	O
attenuated	O	O
by	O	O
castration	O	O
.	O	O

Testosterone	B-Chemical	D013739
replacement	O	O
in	O	O
castrated	O	O
DS	O	O
rats	O	O
increased	O	O
BP	O	O
,	O	O
renal	B-Disease	D007674
injury	I-Disease	D007674
,	O	O
and	O	O
upregulation	O	O
of	O	O
renal	O	O
angiotensinogen	O	O
associated	O	O
with	O	O
HS	O	O
diet	O	O
.	O	O

Testosterone	B-Chemical	D013739
contributes	O	O
to	O	O
the	O	O
development	O	O
of	O	O
hypertension	B-Disease	D006973
and	O	O
renal	B-Disease	D007674
injury	I-Disease	D007674
in	O	O
male	O	O
DS	O	O
rats	O	O
on	O	O
HS	O	O
diet	O	O
possibly	O	O
through	O	O
upregulation	O	O
of	O	O
the	O	O
intrarenal	O	O
renin	O	O
-	O	O
angiotensin	B-Chemical	D000809
system	O	O
.	O	O

Prenatal	O	O
protein	O	O
deprivation	O	O
alters	O	O
dopamine	B-Chemical	D004298
-	O	O
mediated	O	O
behaviors	O	O
and	O	O
dopaminergic	O	O
and	O	O
glutamatergic	O	O
receptor	O	O
binding	O	O
.	O	O

Epidemiological	O	O
evidence	O	O
indicates	O	O
that	O	O
prenatal	O	O
nutritional	O	O
deprivation	O	O
may	O	O
increase	O	O
the	O	O
risk	O	O
of	O	O
schizophrenia	B-Disease	D012559
.	O	O

The	O	O
goal	O	O
of	O	O
these	O	O
studies	O	O
was	O	O
to	O	O
use	O	O
an	O	O
animal	O	O
model	O	O
to	O	O
examine	O	O
the	O	O
effects	O	O
of	O	O
prenatal	O	O
protein	O	O
deprivation	O	O
on	O	O
behaviors	O	O
and	O	O
receptor	O	O
binding	O	O
with	O	O
relevance	O	O
to	O	O
schizophrenia	B-Disease	D012559
.	O	O

We	O	O
report	O	O
that	O	O
prenatally	O	O
protein	O	O
deprived	O	O
(	O	O
PD	O	O
)	O	O
female	O	O
rats	O	O
showed	O	O
an	O	O
increased	O	O
stereotypic	O	O
response	O	O
to	O	O
apomorphine	B-Chemical	D001058
and	O	O
an	O	O
increased	O	O
locomotor	O	O
response	O	O
to	O	O
amphetamine	B-Chemical	D000661
in	O	O
adulthood	O	O
.	O	O

These	O	O
differences	O	O
were	O	O
not	O	O
observed	O	O
during	O	O
puberty	O	O
.	O	O

No	O	O
changes	O	O
in	O	O
haloperidol	B-Chemical	D006220
-	O	O
induced	O	O
catalepsy	B-Disease	D002375
or	O	O
MK	B-Chemical	D016291
-	I-Chemical	D016291
801	I-Chemical	D016291
-	O	O
induced	O	O
locomotion	O	O
were	O	O
seen	O	O
following	O	O
PD	O	O
.	O	O

In	O	O
addition	O	O
,	O	O
PD	O	O
female	O	O
rats	O	O
showed	O	O
increased	O	O
(	O	O
3	O	O
)	O	O
H	B-Chemical	D006859
-	O	O
MK	B-Chemical	D016291
-	I-Chemical	D016291
801	I-Chemical	D016291
binding	O	O
in	O	O
the	O	O
striatum	O	O
and	O	O
hippocampus	O	O
,	O	O
but	O	O
not	O	O
in	O	O
the	O	O
cortex	O	O
.	O	O

PD	O	O
female	O	O
rats	O	O
also	O	O
showed	O	O
increased	O	O
(	O	O
3	O	O
)	O	O
H	B-Chemical	D006859
-	O	O
haloperidol	B-Chemical	D006220
binding	O	O
and	O	O
decreased	O	O
dopamine	B-Chemical	D004298
transporter	O	O
binding	O	O
in	O	O
striatum	O	O
.	O	O

No	O	O
statistically	O	O
significant	O	O
changes	O	O
in	O	O
behavior	O	O
or	O	O
receptor	O	O
binding	O	O
were	O	O
found	O	O
in	O	O
PD	O	O
males	O	O
with	O	O
the	O	O
exception	O	O
of	O	O
increased	O	O
(	O	O
3	O	O
)	O	O
H	B-Chemical	D006859
-	O	O
MK	B-Chemical	D016291
-	I-Chemical	D016291
801	I-Chemical	D016291
binding	O	O
in	O	O
cortex	O	O
.	O	O

This	O	O
animal	O	O
model	O	O
may	O	O
be	O	O
useful	O	O
to	O	O
explore	O	O
the	O	O
mechanisms	O	O
by	O	O
which	O	O
prenatal	O	O
nutritional	B-Disease	D044342
deficiency	I-Disease	D044342
enhances	O	O
risk	O	O
for	O	O
schizophrenia	B-Disease	D012559
in	O	O
humans	O	O
and	O	O
may	O	O
also	O	O
have	O	O
implications	O	O
for	O	O
developmental	O	O
processes	O	O
leading	O	O
to	O	O
differential	O	O
sensitivity	O	O
to	O	O
drugs	O	O
of	O	O
abuse	O	O
.	O	O

mToR	O	O
inhibitors	O	O
-	O	O
induced	O	O
proteinuria	B-Disease	D011507
:	O	O
mechanisms	O	O
,	O	O
significance	O	O
,	O	O
and	O	O
management	O	O
.	O	O

Massive	O	O
urinary	O	O
protein	O	O
excretion	O	O
has	O	O
been	O	O
observed	O	O
after	O	O
conversion	O	O
from	O	O
calcineurin	O	O
inhibitors	O	O
to	O	O
mammalian	O	O
target	O	O
of	O	O
rapamycin	B-Chemical	D020123
(	O	O
mToR	O	O
)	O	O
inhibitors	O	O
,	O	O
especially	O	O
sirolimus	B-Chemical	D020123
,	O	O
in	O	O
renal	O	O
transplant	O	O
recipients	O	O
with	O	O
chronic	B-Disease	D051436
allograft	I-Disease	D051436
nephropathy	I-Disease	D051436
.	O	O

Because	O	O
proteinuria	B-Disease	D011507
is	O	O
a	O	O
major	O	O
predictive	O	O
factor	O	O
of	O	O
poor	O	O
transplantation	O	O
outcome	O	O
,	O	O
many	O	O
studies	O	O
focused	O	O
on	O	O
this	O	O
adverse	O	O
event	O	O
during	O	O
the	O	O
past	O	O
years	O	O
.	O	O

Whether	O	O
proteinuria	B-Disease	D011507
was	O	O
due	O	O
to	O	O
sirolimus	B-Chemical	D020123
or	O	O
only	O	O
a	O	O
consequence	O	O
of	O	O
calcineurin	O	O
inhibitors	O	O
withdrawal	O	O
remained	O	O
unsolved	O	O
until	O	O
high	O	O
range	O	O
proteinuria	B-Disease	D011507
has	O	O
been	O	O
observed	O	O
during	O	O
sirolimus	B-Chemical	D020123
therapy	O	O
in	O	O
islet	O	O
transplantation	O	O
and	O	O
in	O	O
patients	O	O
who	O	O
received	O	O
sirolimus	B-Chemical	D020123
de	O	O
novo	O	O
.	O	O

Podocyte	O	O
injury	O	O
and	O	O
focal	O	O
segmental	O	O
glomerulosclerosis	B-Disease	D005921
have	O	O
been	O	O
related	O	O
to	O	O
mToR	O	O
inhibition	O	O
in	O	O
some	O	O
patients	O	O
,	O	O
but	O	O
the	O	O
pathways	O	O
underlying	O	O
these	O	O
lesions	O	O
remain	O	O
hypothetic	O	O
.	O	O

We	O	O
discuss	O	O
herein	O	O
the	O	O
possible	O	O
mechanisms	O	O
and	O	O
the	O	O
significance	O	O
of	O	O
mToR	O	O
blockade	O	O
-	O	O
induced	O	O
proteinuria	B-Disease	D011507
.	O	O

Hypothalamic	O	O
prolactin	O	O
receptor	O	O
messenger	O	O
ribonucleic	B-Chemical	D012313
acid	I-Chemical	D012313
levels	O	O
,	O	O
prolactin	O	O
signaling	O	O
,	O	O
and	O	O
hyperprolactinemic	B-Disease	D006966
inhibition	O	O
of	O	O
pulsatile	O	O
luteinizing	O	O
hormone	O	O
secretion	O	O
are	O	O
dependent	O	O
on	O	O
estradiol	B-Chemical	D004958
.	O	O

Hyperprolactinemia	B-Disease	D006966
can	O	O
reduce	O	O
fertility	O	O
and	O	O
libido	O	O
.	O	O

Although	O	O
central	O	O
prolactin	O	O
actions	O	O
are	O	O
thought	O	O
to	O	O
contribute	O	O
to	O	O
this	O	O
,	O	O
the	O	O
mechanisms	O	O
are	O	O
poorly	O	O
understood	O	O
.	O	O

We	O	O
first	O	O
tested	O	O
whether	O	O
chronic	O	O
hyperprolactinemia	B-Disease	D006966
inhibited	O	O
two	O	O
neuroendocrine	O	O
parameters	O	O
necessary	O	O
for	O	O
female	O	O
fertility	O	O
:	O	O
pulsatile	O	O
LH	O	O
secretion	O	O
and	O	O
the	O	O
estrogen	B-Chemical	D004967
-	O	O
induced	O	O
LH	O	O
surge	O	O
.	O	O

Chronic	O	O
hyperprolactinemia	B-Disease	D006966
induced	O	O
by	O	O
the	O	O
dopamine	B-Chemical	D004298
antagonist	O	O
sulpiride	B-Chemical	D013469
caused	O	O
a	O	O
40%	O	O
reduction	O	O
LH	O	O
pulse	O	O
frequency	O	O
in	O	O
ovariectomized	O	O
rats	O	O
,	O	O
but	O	O
only	O	O
in	O	O
the	O	O
presence	O	O
of	O	O
chronic	O	O
low	O	O
levels	O	O
of	O	O
estradiol	B-Chemical	D004958
.	O	O

Sulpiride	B-Chemical	D013469
did	O	O
not	O	O
affect	O	O
the	O	O
magnitude	O	O
of	O	O
a	O	O
steroid	B-Chemical	D013256
-	O	O
induced	O	O
LH	O	O
surge	O	O
or	O	O
the	O	O
percentage	O	O
of	O	O
GnRH	O	O
neurons	O	O
activated	O	O
during	O	O
the	O	O
surge	O	O
.	O	O

Estradiol	B-Chemical	D004958
is	O	O
known	O	O
to	O	O
influence	O	O
expression	O	O
of	O	O
the	O	O
long	O	O
form	O	O
of	O	O
prolactin	O	O
receptors	O	O
(	O	O
PRL	O	O
-	O	O
R	O	O
)	O	O
and	O	O
components	O	O
of	O	O
prolactin's	O	O
signaling	O	O
pathway	O	O
.	O	O

To	O	O
test	O	O
the	O	O
hypothesis	O	O
that	O	O
estrogen	B-Chemical	D004967
increases	O	O
PRL	O	O
-	O	O
R	O	O
expression	O	O
and	O	O
sensitivity	O	O
to	O	O
prolactin	O	O
,	O	O
we	O	O
next	O	O
demonstrated	O	O
that	O	O
estradiol	B-Chemical	D004958
greatly	O	O
augments	O	O
prolactin	O	O
-	O	O
induced	O	O
STAT5	O	O
activation	O	O
.	O	O

Lastly	O	O
,	O	O
we	O	O
measured	O	O
PRL	O	O
-	O	O
R	O	O
and	O	O
suppressor	O	O
of	O	O
cytokine	O	O
signaling	O	O
(	O	O
SOCS	O	O
-	O	O
1	O	O
and	O	O
-	O	O
3	O	O
and	O	O
CIS	O	O
,	O	O
which	O	O
reflect	O	O
the	O	O
level	O	O
of	O	O
prolactin	O	O
signaling	O	O
)	O	O
mRNAs	O	O
in	O	O
response	O	O
to	O	O
sulpiride	B-Chemical	D013469
and	O	O
estradiol	B-Chemical	D004958
.	O	O

Sulpiride	B-Chemical	D013469
induced	O	O
only	O	O
SOCS	O	O
-	O	O
1	O	O
in	O	O
the	O	O
medial	O	O
preoptic	O	O
area	O	O
,	O	O
where	O	O
GnRH	O	O
neurons	O	O
are	O	O
regulated	O	O
,	O	O
but	O	O
in	O	O
the	O	O
arcuate	O	O
nucleus	O	O
and	O	O
choroid	O	O
plexus	O	O
,	O	O
PRL	O	O
-	O	O
R	O	O
,	O	O
SOCS	O	O
-	O	O
3	O	O
,	O	O
and	O	O
CIS	O	O
mRNA	O	O
levels	O	O
were	O	O
also	O	O
induced	O	O
.	O	O

Estradiol	B-Chemical	D004958
enhanced	O	O
these	O	O
effects	O	O
on	O	O
SOCS	O	O
-	O	O
3	O	O
and	O	O
CIS	O	O
.	O	O

Interestingly	O	O
,	O	O
estradiol	B-Chemical	D004958
also	O	O
induced	O	O
PRL	O	O
-	O	O
R	O	O
,	O	O
SOCS	O	O
-	O	O
3	O	O
,	O	O
and	O	O
CIS	O	O
mRNA	O	O
levels	O	O
independently	O	O
.	O	O

These	O	O
data	O	O
show	O	O
that	O	O
GnRH	O	O
pulse	O	O
frequency	O	O
is	O	O
inhibited	O	O
by	O	O
chronic	O	O
hyperprolactinemia	B-Disease	D006966
in	O	O
a	O	O
steroid	B-Chemical	D013256
-	O	O
dependent	O	O
manner	O	O
.	O	O

They	O	O
also	O	O
provide	O	O
evidence	O	O
for	O	O
estradiol	B-Chemical	D004958
-	O	O
dependent	O	O
and	O	O
brain	O	O
region	O	O
-	O	O
specific	O	O
regulation	O	O
of	O	O
PRL	O	O
-	O	O
R	O	O
expression	O	O
and	O	O
signaling	O	O
responses	O	O
by	O	O
prolactin	O	O
.	O	O

Estrogen	O	O
prevents	O	O
cholesteryl	B-Chemical	D002788
ester	I-Chemical	D002788
accumulation	O	O
in	O	O
macrophages	O	O
induced	O	O
by	O	O
the	O	O
HIV	O	O
protease	O	O
inhibitor	O	O
ritonavir	B-Chemical	D019438
.	O	O

Individuals	O	O
with	O	O
HIV	O	O
can	O	O
now	O	O
live	O	O
long	O	O
lives	O	O
with	O	O
drug	O	O
therapy	O	O
that	O	O
often	O	O
includes	O	O
protease	O	O
inhibitors	O	O
such	O	O
as	O	O
ritonavir	B-Chemical	D019438
.	O	O

Many	O	O
patients	O	O
,	O	O
however	O	O
,	O	O
develop	O	O
negative	O	O
long	O	O
-	O	O
term	O	O
side	O	O
effects	O	O
such	O	O
as	O	O
premature	B-Disease	D050197
atherosclerosis	I-Disease	D050197
.	O	O

We	O	O
have	O	O
previously	O	O
demonstrated	O	O
that	O	O
ritonavir	B-Chemical	D019438
treatment	O	O
increases	O	O
atherosclerotic	B-Disease	D050197
lesion	I-Disease	D050197
formation	O	O
in	O	O
male	O	O
mice	O	O
to	O	O
a	O	O
greater	O	O
extent	O	O
than	O	O
in	O	O
female	O	O
mice	O	O
.	O	O

Furthermore	O	O
,	O	O
peripheral	O	O
blood	O	O
monocytes	O	O
isolated	O	O
from	O	O
ritonavir	B-Chemical	D019438
-	O	O
treated	O	O
females	O	O
had	O	O
less	O	O
cholesteryl	B-Chemical	D002788
ester	I-Chemical	D002788
accumulation	O	O
.	O	O

In	O	O
the	O	O
present	O	O
study	O	O
,	O	O
we	O	O
have	O	O
investigated	O	O
the	O	O
molecular	O	O
mechanisms	O	O
by	O	O
which	O	O
female	O	O
hormones	O	O
influence	O	O
cholesterol	B-Chemical	D002784
metabolism	O	O
in	O	O
macrophages	O	O
in	O	O
response	O	O
to	O	O
the	O	O
HIV	O	O
protease	O	O
inhibitor	O	O
ritonavir	B-Chemical	D019438
.	O	O

We	O	O
have	O	O
utilized	O	O
the	O	O
human	O	O
monocyte	O	O
cell	O	O
line	O	O
,	O	O
THP	O	O
-	O	O
1	O	O
as	O	O
a	O	O
model	O	O
to	O	O
address	O	O
this	O	O
question	O	O
.	O	O

Briefly	O	O
,	O	O
cells	O	O
were	O	O
differentiated	O	O
for	O	O
72	O	O
h	O	O
with	O	O
100	O	O
nM	O	O
PMA	O	O
to	O	O
obtain	O	O
a	O	O
macrophage	O	O
-	O	O
like	O	O
phenotype	O	O
in	O	O
the	O	O
presence	O	O
or	O	O
absence	O	O
of	O	O
1	O	O
nM	O	O
17beta	B-Chemical	D004958
-	I-Chemical	D004958
estradiol	I-Chemical	D004958
(	O	O
E2	B-Chemical	D004958
)	O	O
,	O	O
100	O	O
nM	O	O
progesterone	B-Chemical	D011374
or	O	O
vehicle	O	O
(	O	O
0	O	O
.	O	O

01%	O	O
ethanol	B-Chemical	D000431
)	O	O
.	O	O

Cells	O	O
were	O	O
then	O	O
treated	O	O
with	O	O
30	O	O
ng	O	O
/	O	O
ml	O	O
ritonavir	B-Chemical	D019438
or	O	O
vehicle	O	O
in	O	O
the	O	O
presence	O	O
of	O	O
aggregated	O	O
LDL	O	O
for	O	O
24	O	O
h	O	O
.	O	O

Cell	O	O
extracts	O	O
were	O	O
harvested	O	O
,	O	O
and	O	O
lipid	O	O
or	O	O
total	O	O
RNA	O	O
was	O	O
isolated	O	O
.	O	O

E2	B-Chemical	D004958
decreased	O	O
the	O	O
accumulation	O	O
of	O	O
cholesteryl	B-Chemical	D002788
esters	I-Chemical	D002788
in	O	O
macrophages	O	O
following	O	O
ritonavir	B-Chemical	D019438
treatment	O	O
.	O	O

Ritonavir	B-Chemical	D019438
increased	O	O
the	O	O
expression	O	O
of	O	O
the	O	O
scavenger	O	O
receptor	O	O
,	O	O
CD36	O	O
mRNA	O	O
,	O	O
responsible	O	O
for	O	O
the	O	O
uptake	O	O
of	O	O
LDL	O	O
.	O	O

Additionally	O	O
,	O	O
ritonavir	B-Chemical	D019438
treatment	O	O
selectively	O	O
increased	O	O
the	O	O
relative	O	O
levels	O	O
of	O	O
PPARgamma	O	O
mRNA	O	O
,	O	O
a	O	O
transcription	O	O
factor	O	O
responsible	O	O
for	O	O
the	O	O
regulation	O	O
of	O	O
CD36	O	O
mRNA	O	O
expression	O	O
.	O	O

Treatment	O	O
with	O	O
E2	B-Chemical	D004958
,	O	O
however	O	O
,	O	O
failed	O	O
to	O	O
prevent	O	O
these	O	O
increases	O	O
at	O	O
the	O	O
mRNA	O	O
level	O	O
.	O	O

E2	B-Chemical	D004958
did	O	O
,	O	O
however	O	O
,	O	O
significantly	O	O
suppress	O	O
CD36	O	O
protein	O	O
levels	O	O
as	O	O
measured	O	O
by	O	O
fluorescent	O	O
immunocytochemistry	O	O
.	O	O

This	O	O
data	O	O
suggests	O	O
that	O	O
E2	B-Chemical	D004958
modifies	O	O
the	O	O
expression	O	O
of	O	O
CD36	O	O
at	O	O
the	O	O
level	O	O
of	O	O
protein	O	O
expression	O	O
in	O	O
monocyte	O	O
-	O	O
derived	O	O
macrophages	O	O
resulting	O	O
in	O	O
reduced	O	O
cholesteryl	B-Chemical	D002788
ester	I-Chemical	D002788
accumulation	O	O
following	O	O
ritonavir	B-Chemical	D019438
treatment	O	O
.	O	O

Upregulation	O	O
of	O	O
brain	O	O
expression	O	O
of	O	O
P	O	O
-	O	O
glycoprotein	O	O
in	O	O
MRP2	O	O
-	O	O
deficient	O	O
TR	O	O
(	O	O
-	O	O
)	O	O
rats	O	O
resembles	O	O
seizure	B-Disease	D012640
-	O	O
induced	O	O
up	O	O
-	O	O
regulation	O	O
of	O	O
this	O	O
drug	O	O
efflux	O	O
transporter	O	O
in	O	O
normal	O	O
rats	O	O
.	O	O

PURPOSE	O	O
:	O	O
The	O	O
multidrug	O	O
resistance	O	O
protein	O	O
2	O	O
(	O	O
MRP2	O	O
)	O	O
is	O	O
a	O	O
drug	O	O
efflux	O	O
transporter	O	O
that	O	O
is	O	O
expressed	O	O
predominantly	O	O
at	O	O
the	O	O
apical	O	O
domain	O	O
of	O	O
hepatocytes	O	O
but	O	O
seems	O	O
also	O	O
to	O	O
be	O	O
expressed	O	O
at	O	O
the	O	O
apical	O	O
membrane	O	O
of	O	O
brain	O	O
capillary	O	O
endothelial	O	O
cells	O	O
that	O	O
form	O	O
the	O	O
blood	O	O
-	O	O
brain	O	O
barrier	O	O
(	O	O
BBB	O	O
)	O	O
.	O	O

MRP2	O	O
is	O	O
absent	O	O
in	O	O
the	O	O
transport	O	O
-	O	O
deficient	O	O
(	O	O
TR	O	O
(	O	O
-	O	O
)	O	O
)	O	O
Wistar	O	O
rat	O	O
mutant	O	O
,	O	O
so	O	O
that	O	O
this	O	O
rat	O	O
strain	O	O
was	O	O
very	O	O
helpful	O	O
in	O	O
defining	O	O
substrates	O	O
of	O	O
MRP2	O	O
by	O	O
comparing	O	O
tissue	O	O
concentrations	O	O
or	O	O
functional	O	O
activities	O	O
of	O	O
compounds	O	O
in	O	O
MRP2	O	O
-	O	O
deficient	O	O
rats	O	O
with	O	O
those	O	O
in	O	O
transport	O	O
-	O	O
competent	O	O
Wistar	O	O
rats	O	O
.	O	O

By	O	O
using	O	O
this	O	O
strategy	O	O
to	O	O
study	O	O
the	O	O
involvement	O	O
of	O	O
MRP2	O	O
in	O	O
brain	O	O
access	O	O
of	O	O
antiepileptic	O	O
drugs	O	O
(	O	O
AEDs	O	O
)	O	O
,	O	O
we	O	O
recently	O	O
reported	O	O
that	O	O
phenytoin	B-Chemical	D010672
is	O	O
a	O	O
substrate	O	O
for	O	O
MRP2	O	O
in	O	O
the	O	O
BBB	O	O
.	O	O

However	O	O
,	O	O
one	O	O
drawback	O	O
of	O	O
such	O	O
studies	O	O
in	O	O
genetically	O	O
deficient	O	O
rats	O	O
is	O	O
the	O	O
fact	O	O
that	O	O
compensatory	O	O
changes	O	O
with	O	O
upregulation	O	O
of	O	O
other	O	O
transporters	O	O
can	O	O
occur	O	O
.	O	O

This	O	O
prompted	O	O
us	O	O
to	O	O
study	O	O
the	O	O
brain	O	O
expression	O	O
of	O	O
P	O	O
-	O	O
glycoprotein	O	O
(	O	O
Pgp	O	O
)	O	O
,	O	O
a	O	O
major	O	O
drug	O	O
efflux	O	O
transporter	O	O
in	O	O
many	O	O
tissues	O	O
,	O	O
including	O	O
the	O	O
BBB	O	O
,	O	O
in	O	O
TR	O	O
(	O	O
-	O	O
)	O	O
rats	O	O
compared	O	O
with	O	O
nonmutant	O	O
(	O	O
wild	O	O
-	O	O
type	O	O
)	O	O
Wistar	O	O
rats	O	O
.	O	O

METHODS	O	O
:	O	O
The	O	O
expression	O	O
of	O	O
MRP2	O	O
and	O	O
Pgp	O	O
in	O	O
brain	O	O
and	O	O
liver	O	O
sections	O	O
of	O	O
TR	O	O
(	O	O
-	O	O
)	O	O
rats	O	O
and	O	O
normal	O	O
Wistar	O	O
rats	O	O
was	O	O
determined	O	O
with	O	O
immunohistochemistry	O	O
,	O	O
by	O	O
using	O	O
a	O	O
novel	O	O
,	O	O
highly	O	O
selective	O	O
monoclonal	O	O
MRP2	O	O
antibody	O	O
and	O	O
the	O	O
monoclonal	O	O
Pgp	O	O
antibody	O	O
C219	O	O
,	O	O
respectively	O	O
.	O	O

RESULTS	O	O
:	O	O
Immunofluorescence	O	O
staining	O	O
with	O	O
the	O	O
MRP2	O	O
antibody	O	O
was	O	O
found	O	O
to	O	O
label	O	O
a	O	O
high	O	O
number	O	O
of	O	O
microvessels	O	O
throughout	O	O
the	O	O
brain	O	O
in	O	O
normal	O	O
Wistar	O	O
rats	O	O
,	O	O
whereas	O	O
such	O	O
labeling	O	O
was	O	O
absent	O	O
in	O	O
TR	O	O
(	O	O
-	O	O
)	O	O
rats	O	O
.	O	O

TR	O	O
(	O	O
-	O	O
)	O	O
rats	O	O
exhibited	O	O
a	O	O
significant	O	O
up	O	O
-	O	O
regulation	O	O
of	O	O
Pgp	O	O
in	O	O
brain	O	O
capillary	O	O
endothelial	O	O
cells	O	O
compared	O	O
with	O	O
wild	O	O
-	O	O
type	O	O
controls	O	O
.	O	O

No	O	O
such	O	O
obvious	O	O
upregulation	O	O
of	O	O
Pgp	O	O
was	O	O
observed	O	O
in	O	O
liver	O	O
sections	O	O
.	O	O

A	O	O
comparable	O	O
overexpression	O	O
of	O	O
Pgp	O	O
in	O	O
the	O	O
BBB	O	O
was	O	O
obtained	O	O
after	O	O
pilocarpine	B-Chemical	D010862
-	O	O
induced	O	O
seizures	B-Disease	D012640
in	O	O
wild	O	O
-	O	O
type	O	O
Wistar	O	O
rats	O	O
.	O	O

Experiments	O	O
with	O	O
systemic	O	O
administration	O	O
of	O	O
the	O	O
Pgp	O	O
substrate	O	O
phenobarbital	B-Chemical	D010634
and	O	O
the	O	O
selective	O	O
Pgp	O	O
inhibitor	O	O
tariquidar	B-Chemical	C402343
in	O	O
TR	O	O
(	O	O
-	O	O
)	O	O
rats	O	O
substantiated	O	O
that	O	O
Pgp	O	O
is	O	O
functional	O	O
and	O	O
compensates	O	O
for	O	O
the	O	O
lack	O	O
of	O	O
MRP2	O	O
in	O	O
the	O	O
BBB	O	O
.	O	O

CONCLUSIONS	O	O
:	O	O
The	O	O
data	O	O
on	O	O
TR	O	O
(	O	O
-	O	O
)	O	O
rats	O	O
indicate	O	O
that	O	O
Pgp	O	O
plays	O	O
an	O	O
important	O	O
role	O	O
in	O	O
the	O	O
compensation	O	O
of	O	O
MRP2	O	O
deficiency	O	O
in	O	O
the	O	O
BBB	O	O
.	O	O

Because	O	O
such	O	O
a	O	O
compensatory	O	O
mechanism	O	O
most	O	O
likely	O	O
occurs	O	O
to	O	O
reduce	O	O
injury	B-Disease	D001927
to	I-Disease	D001927
the	I-Disease	D001927
brain	I-Disease	D001927
from	O	O
cytotoxic	O	O
compounds	O	O
,	O	O
the	O	O
present	O	O
data	O	O
substantiate	O	O
the	O	O
concept	O	O
that	O	O
MRP2	O	O
performs	O	O
a	O	O
protective	O	O
role	O	O
in	O	O
the	O	O
BBB	O	O
.	O	O

Furthermore	O	O
,	O	O
our	O	O
data	O	O
suggest	O	O
that	O	O
TR	O	O
(	O	O
-	O	O
)	O	O
rats	O	O
are	O	O
an	O	O
interesting	O	O
tool	O	O
to	O	O
study	O	O
consequences	O	O
of	O	O
overexpression	O	O
of	O	O
Pgp	O	O
in	O	O
the	O	O
BBB	O	O
on	O	O
access	O	O
of	O	O
drugs	O	O
in	O	O
the	O	O
brain	O	O
,	O	O
without	O	O
the	O	O
need	O	O
of	O	O
inducing	O	O
seizures	B-Disease	D012640
or	O	O
other	O	O
Pgp	O	O
-	O	O
enhancing	O	O
events	O	O
for	O	O
this	O	O
purpose	O	O
.	O	O

Use	O	O
of	O	O
chromosome	O	O
substitution	O	O
strains	O	O
to	O	O
identify	O	O
seizure	B-Disease	D012640
susceptibility	O	O
loci	O	O
in	O	O
mice	O	O
.	O	O

Seizure	B-Disease	D012640
susceptibility	O	O
varies	O	O
among	O	O
inbred	O	O
mouse	O	O
strains	O	O
.	O	O

Chromosome	O	O
substitution	O	O
strains	O	O
(	O	O
CSS	O	O
)	O	O
,	O	O
in	O	O
which	O	O
a	O	O
single	O	O
chromosome	O	O
from	O	O
one	O	O
inbred	O	O
strain	O	O
(	O	O
donor	O	O
)	O	O
has	O	O
been	O	O
transferred	O	O
onto	O	O
a	O	O
second	O	O
strain	O	O
(	O	O
host	O	O
)	O	O
by	O	O
repeated	O	O
backcrossing	O	O
,	O	O
may	O	O
be	O	O
used	O	O
to	O	O
identify	O	O
quantitative	O	O
trait	O	O
loci	O	O
(	O	O
QTLs	O	O
)	O	O
that	O	O
contribute	O	O
to	O	O
seizure	B-Disease	D012640
susceptibility	O	O
.	O	O

QTLs	O	O
for	O	O
susceptibility	O	O
to	O	O
pilocarpine	B-Chemical	D010862
-	O	O
induced	O	O
seizures	B-Disease	D012640
,	O	O
a	O	O
model	O	O
of	O	O
temporal	B-Disease	D004833
lobe	I-Disease	D004833
epilepsy	I-Disease	D004833
,	O	O
have	O	O
not	O	O
been	O	O
reported	O	O
,	O	O
and	O	O
CSS	O	O
have	O	O
not	O	O
previously	O	O
been	O	O
used	O	O
to	O	O
localize	O	O
seizure	B-Disease	D012640
susceptibility	O	O
genes	O	O
.	O	O

We	O	O
report	O	O
QTLs	O	O
identified	O	O
using	O	O
a	O	O
B6	O	O
(	O	O
host	O	O
)	O	O
x	O	O
A	O	O
/	O	O
J	O	O
(	O	O
donor	O	O
)	O	O
CSS	O	O
panel	O	O
to	O	O
localize	O	O
genes	O	O
involved	O	O
in	O	O
susceptibility	O	O
to	O	O
pilocarpine	B-Chemical	D010862
-	O	O
induced	O	O
seizures	B-Disease	D012640
.	O	O

Three	O	O
hundred	O	O
fifty	O	O
-	O	O
five	O	O
adult	O	O
male	O	O
CSS	O	O
mice	O	O
,	O	O
58	O	O
B6	O	O
,	O	O
and	O	O
39	O	O
A	O	O
/	O	O
J	O	O
were	O	O
tested	O	O
for	O	O
susceptibility	O	O
to	O	O
pilocarpine	B-Chemical	D010862
-	O	O
induced	O	O
seizures	B-Disease	D012640
.	O	O

Highest	O	O
stage	O	O
reached	O	O
and	O	O
latency	O	O
to	O	O
each	O	O
stage	O	O
were	O	O
recorded	O	O
for	O	O
all	O	O
mice	O	O
.	O	O

B6	O	O
mice	O	O
were	O	O
resistant	O	O
to	O	O
seizures	B-Disease	D012640
and	O	O
slower	O	O
to	O	O
reach	O	O
stages	O	O
compared	O	O
to	O	O
A	O	O
/	O	O
J	O	O
mice	O	O
.	O	O

The	O	O
CSS	O	O
for	O	O
Chromosomes	O	O
10	O	O
and	O	O
18	O	O
progressed	O	O
to	O	O
the	O	O
most	O	O
severe	O	O
stages	O	O
,	O	O
diverging	O	O
dramatically	O	O
from	O	O
the	O	O
B6	O	O
phenotype	O	O
.	O	O

Latencies	O	O
to	O	O
stages	O	O
were	O	O
also	O	O
significantly	O	O
shorter	O	O
for	O	O
CSS10	O	O
and	O	O
CSS18	O	O
mice	O	O
.	O	O

CSS	O	O
mapping	O	O
suggests	O	O
seizure	B-Disease	D012640
susceptibility	O	O
loci	O	O
on	O	O
mouse	O	O
Chromosomes	O	O
10	O	O
and	O	O
18	O	O
.	O	O

This	O	O
approach	O	O
provides	O	O
a	O	O
framework	O	O
for	O	O
identifying	O	O
potentially	O	O
novel	O	O
homologous	O	O
candidate	O	O
genes	O	O
for	O	O
human	O	O
temporal	B-Disease	D004833
lobe	I-Disease	D004833
epilepsy	I-Disease	D004833
.	O	O

Investigation	O	O
of	O	O
mitochondrial	O	O
involvement	O	O
in	O	O
the	O	O
experimental	O	O
model	O	O
of	O	O
epilepsy	B-Disease	D004827
induced	O	O
by	O	O
pilocarpine	B-Chemical	D010862
.	O	O

Mitochondrial	B-Disease	D028361
abnormalities	I-Disease	D028361
have	O	O
been	O	O
associated	O	O
with	O	O
several	O	O
aspects	O	O
of	O	O
epileptogenesis	O	O
,	O	O
such	O	O
as	O	O
energy	O	O
generation	O	O
,	O	O
control	O	O
of	O	O
cell	O	O
death	B-Disease	D003643
,	O	O
neurotransmitter	O	O
synthesis	O	O
,	O	O
and	O	O
free	O	O
radical	O	O
(	O	O
FR	O	O
)	O	O
production	O	O
.	O	O

Increased	O	O
production	O	O
of	O	O
FRs	O	O
may	O	O
cause	O	O
mtDNA	O	O
damage	O	O
leading	O	O
to	O	O
decreased	O	O
activities	O	O
of	O	O
oxidative	O	O
phosphorylation	O	O
complexes	O	O
containing	O	O
mtDNA	O	O
-	O	O
encoded	O	O
subunits	O	O
.	O	O

In	O	O
this	O	O
study	O	O
,	O	O
we	O	O
investigated	O	O
whether	O	O
increased	O	O
generation	O	O
of	O	O
FR	O	O
during	O	O
status	B-Disease	D013226
epilepticus	I-Disease	D013226
would	O	O
be	O	O
sufficient	O	O
to	O	O
provoke	O	O
abnormalities	O	O
in	O	O
mtDNA	O	O
and	O	O
in	O	O
the	O	O
expression	O	O
and	O	O
activity	O	O
of	O	O
cytochrome	O	O
c	O	O
oxidase	O	O
(	O	O
CCO	O	O
)	O	O
,	O	O
complex	O	O
IV	O	O
of	O	O
the	O	O
respiratory	O	O
chain	O	O
,	O	O
in	O	O
the	O	O
chronic	O	O
phase	O	O
of	O	O
the	O	O
pilocarpine	B-Chemical	D010862
model	O	O
of	O	O
temporal	B-Disease	D004833
lobe	I-Disease	D004833
epilepsy	I-Disease	D004833
.	O	O

DNA	O	O
analysis	O	O
revealed	O	O
low	O	O
amounts	O	O
of	O	O
a	O	O
4	O	O
.	O	O

8	O	O
kb	O	O
mtDNA	O	O
deletion	O	O
but	O	O
with	O	O
no	O	O
differences	O	O
in	O	O
frequency	O	O
or	O	O
quantity	O	O
in	O	O
the	O	O
control	O	O
and	O	O
experimental	O	O
groups	O	O
.	O	O

We	O	O
did	O	O
not	O	O
find	O	O
abnormalities	O	O
in	O	O
the	O	O
expression	O	O
and	O	O
distribution	O	O
of	O	O
an	O	O
mtDNA	O	O
-	O	O
encoded	O	O
subunit	O	O
of	O	O
CCO	O	O
(	O	O
CCO	O	O
-	O	O
I	O	O
)	O	O
or	O	O
a	O	O
relative	O	O
decrease	O	O
in	O	O
CCO	O	O
-	O	O
I	O	O
when	O	O
compared	O	O
with	O	O
nuclear	O	O
-	O	O
encoded	O	O
subunits	O	O
(	O	O
CCO	O	O
-	O	O
IV	O	O
and	O	O
SDH	O	O
-	O	O
fp	O	O
)	O	O
.	O	O

No	O	O
abnormality	O	O
in	O	O
CCO	O	O
activity	O	O
was	O	O
observed	O	O
through	O	O
histochemistry	O	O
.	O	O

Although	O	O
evidences	O	O
of	O	O
mitochondrial	B-Disease	D028361
abnormalities	I-Disease	D028361
were	O	O
found	O	O
in	O	O
previously	O	O
published	O	O
studies	O	O
,	O	O
our	O	O
results	O	O
do	O	O
not	O	O
suggest	O	O
that	O	O
the	O	O
FRs	O	O
,	O	O
generated	O	O
during	O	O
the	O	O
acute	O	O
phase	O	O
,	O	O
determined	O	O
important	O	O
abnormalities	O	O
in	O	O
mtDNA	O	O
,	O	O
in	O	O
expression	O	O
of	O	O
CCO	O	O
-	O	O
I	O	O
,	O	O
and	O	O
in	O	O
CCO	O	O
activity	O	O
.	O	O

Causes	O	O
of	O	O
acute	O	O
thrombotic	B-Disease	D057049
microangiopathy	I-Disease	D057049
in	O	O
patients	O	O
receiving	O	O
kidney	O	O
transplantation	O	O
.	O	O

OBJECTIVES	O	O
:	O	O
Thrombotic	B-Disease	D057049
microangiopathy	I-Disease	D057049
is	O	O
a	O	O
well	O	O
-	O	O
known	O	O
problem	O	O
in	O	O
patients	O	O
following	O	O
renal	O	O
transplantation	O	O
.	O	O

In	O	O
postrenal	O	O
transplantation	O	O
,	O	O
thrombotic	B-Disease	D057049
microangiopathy	I-Disease	D057049
is	O	O
often	O	O
a	O	O
reflection	O	O
of	O	O
hemolytic	B-Disease	D006463
uremic	I-Disease	D006463
syndrome	I-Disease	D006463
.	O	O

We	O	O
aimed	O	O
to	O	O
determine	O	O
the	O	O
causes	O	O
of	O	O
thrombotic	B-Disease	D057049
microangiopathy	I-Disease	D057049
in	O	O
a	O	O
population	O	O
of	O	O
renal	O	O
transplantation	O	O
recipients	O	O
and	O	O
discuss	O	O
the	O	O
literature	O	O
.	O	O

MATERIALS	O	O
AND	O	O
METHODS	O	O
:	O	O
We	O	O
investigated	O	O
the	O	O
causes	O	O
of	O	O
thrombotic	B-Disease	D057049
microangiopathy	I-Disease	D057049
during	O	O
a	O	O
1	O	O
-	O	O
year	O	O
period	O	O
,	O	O
from	O	O
June	O	O
2003	O	O
to	O	O
June	O	O
2004	O	O
,	O	O
at	O	O
the	O	O
King	O	O
Fahad	O	O
National	O	O
Guard	O	O
Hospital	O	O
in	O	O
Riyadh	O	O
,	O	O
Saudi	O	O
Arabia	O	O
,	O	O
by	O	O
reviewing	O	O
the	O	O
slides	O	O
of	O	O
all	O	O
transplant	O	O
biopsies	O	O
(	O	O
n=25	O	O
)	O	O
performed	O	O
during	O	O
this	O	O
interval	O	O
.	O	O

Pre	O	O
-	O	O
and	O	O
posttransplant	O	O
crossmatching	O	O
was	O	O
done	O	O
when	O	O
possible	O	O
.	O	O

RESULTS	O	O
:	O	O
Five	O	O
cases	O	O
of	O	O
thrombotic	B-Disease	D057049
microangiopathy	I-Disease	D057049
were	O	O
found	O	O
.	O	O

Three	O	O
of	O	O
these	O	O
cases	O	O
were	O	O
from	O	O
the	O	O
25	O	O
transplantations	O	O
performed	O	O
at	O	O
King	O	O
Fahad	O	O
National	O	O
Guard	O	O
Hospital	O	O
,	O	O
while	O	O
the	O	O
other	O	O
2	O	O
transplantations	O	O
had	O	O
been	O	O
performed	O	O
abroad	O	O
and	O	O
were	O	O
referred	O	O
to	O	O
us	O	O
for	O	O
follow	O	O
-	O	O
up	O	O
.	O	O

Three	O	O
cases	O	O
were	O	O
related	O	O
to	O	O
cyclosporine	B-Chemical	D016572
,	O	O
and	O	O
1	O	O
case	O	O
was	O	O
secondary	O	O
to	O	O
both	O	O
cyclosporine	B-Chemical	D016572
and	O	O
tacrolimus	B-Chemical	D016559
.	O	O

The	O	O
fifth	O	O
case	O	O
had	O	O
features	O	O
of	O	O
thrombotic	B-Disease	D057049
microangiopathy	I-Disease	D057049
related	O	O
to	O	O
an	O	O
antiphospholipid	B-Disease	D016736
syndrome	I-Disease	D016736
in	O	O
a	O	O
patient	O	O
with	O	O
systemic	B-Disease	D008180
lupus	I-Disease	D008180
erythematosus	I-Disease	D008180
.	O	O

CONCLUSIONS	O	O
:	O	O
In	O	O
the	O	O
literature	O	O
,	O	O
the	O	O
most	O	O
-	O	O
frequent	O	O
cause	O	O
of	O	O
hemolytic	B-Disease	D006463
uremic	I-Disease	D006463
syndrome	I-Disease	D006463
in	O	O
patients	O	O
following	O	O
renal	O	O
transplantation	O	O
is	O	O
recurrence	O	O
of	O	O
the	O	O
hemolytic	B-Disease	D006463
uremic	I-Disease	D006463
syndrome	I-Disease	D006463
.	O	O

Other	O	O
causes	O	O
include	O	O
drug	O	O
-	O	O
related	O	O
(	O	O
cyclosporine	B-Chemical	D016572
,	O	O
tacrolimus	B-Chemical	D016559
)	O	O
toxicity	B-Disease	D064420
,	O	O
procoagulant	O	O
status	O	O
,	O	O
and	O	O
antibody	O	O
-	O	O
mediated	O	O
rejection	O	O
.	O	O

We	O	O
found	O	O
that	O	O
the	O	O
most	O	O
-	O	O
frequent	O	O
cause	O	O
of	O	O
thrombotic	B-Disease	D057049
microangiopathy	I-Disease	D057049
was	O	O
drug	O	O
related	O	O
,	O	O
secondary	O	O
mainly	O	O
to	O	O
cyclosporine	B-Chemical	D016572
.	O	O

In	O	O
the	O	O
current	O	O
study	O	O
,	O	O
the	O	O
frequency	O	O
of	O	O
thrombotic	B-Disease	D057049
microangiopathy	I-Disease	D057049
was	O	O
similar	O	O
to	O	O
the	O	O
percentage	O	O
reported	O	O
in	O	O
the	O	O
literature	O	O
(	O	O
20%	O	O
)	O	O
.	O	O

Severe	O	O
reversible	O	O
left	B-Disease	D018487
ventricular	I-Disease	D018487
systolic	I-Disease	D018487
and	I-Disease	D018487
diastolic	I-Disease	D018487
dysfunction	I-Disease	D018487
due	O	O
to	O	O
accidental	O	O
iatrogenic	O	O
epinephrine	B-Chemical	D004837
overdose	B-Disease	D062787
.	O	O

Catecholamine	B-Chemical	D002395
-	O	O
induced	O	O
cardiomyopathy	B-Disease	D009202
due	O	O
to	O	O
chronic	O	O
excess	O	O
of	O	O
endogenous	O	O
catecholamines	B-Chemical	D002395
has	O	O
been	O	O
recognized	O	O
for	O	O
decades	O	O
as	O	O
a	O	O
clinical	O	O
phenomenon	O	O
.	O	O

In	O	O
contrast	O	O
,	O	O
reports	O	O
of	O	O
myocardial	B-Disease	D009202
dysfunction	I-Disease	D009202
due	O	O
to	O	O
acute	O	O
iatrogenic	O	O
overdose	B-Disease	D062787
are	O	O
rare	O	O
.	O	O

A	O	O
35	O	O
-	O	O
year	O	O
-	O	O
old	O	O
woman	O	O
whose	O	O
cervix	O	O
uteri	O	O
was	O	O
inadvertently	O	O
injected	O	O
with	O	O
8	O	O
mg	O	O
of	O	O
epinephrine	B-Chemical	D004837
developed	O	O
myocardial	B-Disease	D017682
stunning	I-Disease	D017682
that	O	O
was	O	O
characterized	O	O
by	O	O
severe	O	O
hemodynamic	O	O
compromise	O	O
,	O	O
profound	O	O
,	O	O
albeit	O	O
transient	O	O
,	O	O
left	B-Disease	D018487
ventricular	I-Disease	D018487
systolic	I-Disease	D018487
and	I-Disease	D018487
diastolic	I-Disease	D018487
dysfunction	I-Disease	D018487
,	O	O
and	O	O
only	O	O
modestly	O	O
elevated	O	O
biochemical	O	O
markers	O	O
of	O	O
myocardial	B-Disease	D009202
necrosis	I-Disease	D009202
.	O	O

Our	O	O
case	O	O
illustrates	O	O
the	O	O
serious	O	O
consequences	O	O
of	O	O
medical	O	O
errors	O	O
that	O	O
can	O	O
be	O	O
avoided	O	O
through	O	O
improved	O	O
medication	O	O
labeling	O	O
and	O	O
staff	O	O
supervision	O	O
.	O	O

Urinary	B-Disease	D001749
bladder	I-Disease	D001749
cancer	I-Disease	D001749
in	O	O
Wegener's	B-Disease	D014890
granulomatosis	I-Disease	D014890
:	O	O
risks	O	O
and	O	O
relation	O	O
to	O	O
cyclophosphamide	B-Chemical	D003520
.	O	O

OBJECTIVE	O	O
:	O	O
To	O	O
assess	O	O
and	O	O
characterise	O	O
the	O	O
risk	O	O
of	O	O
bladder	B-Disease	D001749
cancer	I-Disease	D001749
,	O	O
and	O	O
its	O	O
relation	O	O
to	O	O
cyclophosphamide	B-Chemical	D003520
,	O	O
in	O	O
patients	O	O
with	O	O
Wegener's	B-Disease	D014890
granulomatosis	I-Disease	D014890
.	O	O

METHODS	O	O
:	O	O
In	O	O
the	O	O
population	O	O
based	O	O
,	O	O
nationwide	O	O
Swedish	O	O
Inpatient	O	O
Register	O	O
a	O	O
cohort	O	O
of	O	O
1065	O	O
patients	O	O
with	O	O
Wegener's	B-Disease	D014890
granulomatosis	I-Disease	D014890
,	O	O
1969	O	O
-	O	O
95	O	O
,	O	O
was	O	O
identified	O	O
.	O	O

Through	O	O
linkage	O	O
with	O	O
the	O	O
Swedish	O	O
Cancer	B-Disease	D009369
Register	O	O
,	O	O
all	O	O
subjects	O	O
in	O	O
this	O	O
cohort	O	O
diagnosed	O	O
with	O	O
bladder	B-Disease	D001749
cancer	I-Disease	D001749
were	O	O
identified	O	O
.	O	O

Nested	O	O
within	O	O
the	O	O
cohort	O	O
,	O	O
a	O	O
matched	O	O
case	O	O
-	O	O
control	O	O
study	O	O
was	O	O
performed	O	O
to	O	O
estimate	O	O
the	O	O
association	O	O
between	O	O
cyclophosphamide	B-Chemical	D003520
and	O	O
bladder	B-Disease	D001749
cancer	I-Disease	D001749
using	O	O
odds	O	O
ratios	O	O
(	O	O
ORs	O	O
)	O	O
as	O	O
relative	O	O
risk	O	O
.	O	O

In	O	O
the	O	O
cohort	O	O
the	O	O
cumulative	O	O
risk	O	O
of	O	O
bladder	B-Disease	D001749
cancer	I-Disease	D001749
after	O	O
Wegener's	B-Disease	D014890
granulomatosis	I-Disease	D014890
,	O	O
and	O	O
the	O	O
relative	O	O
prevalence	O	O
of	O	O
a	O	O
history	O	O
of	O	O
bladder	B-Disease	D001749
cancer	I-Disease	D001749
at	O	O
the	O	O
time	O	O
of	O	O
diagnosis	O	O
of	O	O
Wegener's	B-Disease	D014890
granulomatosis	I-Disease	D014890
,	O	O
were	O	O
also	O	O
estimated	O	O
.	O	O

RESULTS	O	O
:	O	O
The	O	O
median	O	O
cumulative	O	O
doses	O	O
of	O	O
cyclophosphamide	B-Chemical	D003520
among	O	O
cases	O	O
(	O	O
n	O	O
=	O	O
11	O	O
)	O	O
and	O	O
controls	O	O
(	O	O
n	O	O
=	O	O
25	O	O
)	O	O
were	O	O
113	O	O
g	O	O
and	O	O
25	O	O
g	O	O
,	O	O
respectively	O	O
.	O	O

The	O	O
risk	O	O
of	O	O
bladder	B-Disease	D001749
cancer	I-Disease	D001749
doubled	O	O
for	O	O
every	O	O
10	O	O
g	O	O
increment	O	O
in	O	O
cyclophosphamide	B-Chemical	D003520
(	O	O
OR	O	O
=	O	O
2	O	O
.	O	O

0	O	O
,	O	O
95%	O	O
confidence	O	O
interval	O	O
(	O	O
CI	O	O
)	O	O
0	O	O
.	O	O

8	O	O
to	O	O
4	O	O
.	O	O

9	O	O
)	O	O
.	O	O

Treatment	O	O
duration	O	O
longer	O	O
than	O	O
1	O	O
year	O	O
was	O	O
associated	O	O
with	O	O
an	O	O
eightfold	O	O
increased	O	O
risk	O	O
(	O	O
OR	O	O
=	O	O
7	O	O
.	O	O

7	O	O
,	O	O
95%	O	O
CI	O	O
0	O	O
.	O	O

9	O	O
to	O	O
69	O	O
)	O	O
.	O	O

The	O	O
absolute	O	O
risk	O	O
for	O	O
bladder	B-Disease	D001749
cancer	I-Disease	D001749
in	O	O
the	O	O
cohort	O	O
reached	O	O
10%	O	O
16	O	O
years	O	O
after	O	O
diagnosis	O	O
of	O	O
Wegener's	B-Disease	D014890
granulomatosis	I-Disease	D014890
,	O	O
and	O	O
a	O	O
history	O	O
of	O	O
bladder	B-Disease	D001749
cancer	I-Disease	D001749
was	O	O
(	O	O
non	O	O
-	O	O
significantly	O	O
)	O	O
twice	O	O
as	O	O
common	O	O
as	O	O
expected	O	O
at	O	O
the	O	O
time	O	O
of	O	O
diagnosis	O	O
of	O	O
Wegener's	B-Disease	D014890
granulomatosis	I-Disease	D014890
.	O	O

CONCLUSION	O	O
:	O	O
The	O	O
results	O	O
indicate	O	O
a	O	O
dose	O	O
-	O	O
response	O	O
relationship	O	O
between	O	O
cyclophosphamide	B-Chemical	D003520
and	O	O
the	O	O
risk	O	O
of	O	O
bladder	B-Disease	D001749
cancer	I-Disease	D001749
,	O	O
high	O	O
cumulative	O	O
risks	O	O
in	O	O
the	O	O
entire	O	O
cohort	O	O
,	O	O
and	O	O
also	O	O
the	O	O
possibility	O	O
of	O	O
risk	O	O
factors	O	O
operating	O	O
even	O	O
before	O	O
Wegener's	B-Disease	D014890
granulomatosis	I-Disease	D014890
.	O	O

L	B-Chemical	D001120
-	I-Chemical	D001120
arginine	I-Chemical	D001120
transport	O	O
in	O	O
humans	O	O
with	O	O
cortisol	B-Chemical	D006854
-	O	O
induced	O	O
hypertension	B-Disease	D006973
.	O	O

A	O	O
deficient	O	O
L	B-Chemical	D001120
-	I-Chemical	D001120
arginine	I-Chemical	D001120
-	O	O
nitric	B-Chemical	D009569
oxide	I-Chemical	D009569
system	O	O
is	O	O
implicated	O	O
in	O	O
cortisol	B-Chemical	D006854
-	O	O
induced	O	O
hypertension	B-Disease	D006973
.	O	O

We	O	O
investigate	O	O
whether	O	O
abnormalities	O	O
in	O	O
L	B-Chemical	D001120
-	I-Chemical	D001120
arginine	I-Chemical	D001120
uptake	O	O
contribute	O	O
to	O	O
this	O	O
deficiency	O	O
.	O	O

Eight	O	O
healthy	O	O
men	O	O
were	O	O
recruited	O	O
.	O	O

Hydrocortisone	B-Chemical	C021650
acetate	I-Chemical	C021650
(	O	O
50	O	O
mg	O	O
)	O	O
was	O	O
given	O	O
orally	O	O
every	O	O
6	O	O
hours	O	O
for	O	O
24	O	O
hours	O	O
after	O	O
a	O	O
5	O	O
-	O	O
day	O	O
fixed	O	O
-	O	O
salt	O	O
diet	O	O
(	O	O
150	O	O
mmol	O	O
/	O	O
d	O	O
)	O	O
.	O	O

Crossover	O	O
studies	O	O
were	O	O
performed	O	O
2	O	O
weeks	O	O
apart	O	O
.	O	O

Thirty	O	O
milliliters	O	O
of	O	O
blood	O	O
was	O	O
obtained	O	O
for	O	O
isolation	O	O
of	O	O
peripheral	O	O
blood	O	O
mononuclear	O	O
cells	O	O
after	O	O
each	O	O
treatment	O	O
period	O	O
.	O	O

L	B-Chemical	D001120
-	I-Chemical	D001120
arginine	I-Chemical	D001120
uptake	O	O
was	O	O
assessed	O	O
in	O	O
mononuclear	O	O
cells	O	O
incubated	O	O
with	O	O
L	B-Chemical	D001120
-	I-Chemical	D001120
arginine	I-Chemical	D001120
(	O	O
1	O	O
to	O	O
300	O	O
micromol	O	O
/	O	O
L	O	O
)	O	O
,	O	O
incorporating	O	O
100	O	O
nmol	O	O
/	O	O
L	O	O
[	B-Chemical	D001120
3H	I-Chemical	D001120
]	I-Chemical	D001120
-	I-Chemical	D001120
l	I-Chemical	D001120
-	I-Chemical	D001120
arginine	I-Chemical	D001120
for	O	O
a	O	O
period	O	O
of	O	O
5	O	O
minutes	O	O
at	O	O
37	O	O
degrees	O	O
C	O	O
.	O	O

Forearm	O	O
[	B-Chemical	D001120
3H	I-Chemical	D001120
]	I-Chemical	D001120
-	I-Chemical	D001120
L	I-Chemical	D001120
-	I-Chemical	D001120
arginine	I-Chemical	D001120
extraction	O	O
was	O	O
calculated	O	O
after	O	O
infusion	O	O
of	O	O
[	B-Chemical	D001120
3H	I-Chemical	D001120
]	I-Chemical	D001120
-	I-Chemical	D001120
L	I-Chemical	D001120
-	I-Chemical	D001120
arginine	I-Chemical	D001120
into	O	O
the	O	O
brachial	O	O
artery	O	O
at	O	O
a	O	O
rate	O	O
of	O	O
100	O	O
nCi	O	O
/	O	O
min	O	O
for	O	O
80	O	O
minutes	O	O
.	O	O

Deep	O	O
forearm	O	O
venous	O	O
samples	O	O
were	O	O
collected	O	O
for	O	O
determination	O	O
of	O	O
L	B-Chemical	D001120
-	I-Chemical	D001120
arginine	I-Chemical	D001120
extraction	O	O
.	O	O

Plasma	O	O
cortisol	B-Chemical	D006854
concentrations	O	O
were	O	O
significantly	O	O
raised	O	O
during	O	O
the	O	O
active	O	O
phase	O	O
(	O	O
323+	O	O
/	O	O
-	O	O
43	O	O
to	O	O
1082+	O	O
/	O	O
-	O	O
245	O	O
mmol	O	O
/	O	O
L	O	O
,	O	O
P<0	O	O
.	O	O

05	O	O
)	O	O
.	O	O

Systolic	O	O
blood	O	O
pressure	O	O
was	O	O
elevated	O	O
by	O	O
an	O	O
average	O	O
of	O	O
7	O	O
mm	O	O
Hg	O	O
.	O	O

Neither	O	O
L	B-Chemical	D001120
-	I-Chemical	D001120
arginine	I-Chemical	D001120
transport	O	O
into	O	O
mononuclear	O	O
cells	O	O
(	O	O
placebo	O	O
vs	O	O
active	O	O
,	O	O
26	O	O
.	O	O

3+	O	O
/	O	O
-	O	O
3	O	O
.	O	O

6	O	O
vs	O	O
29	O	O
.	O	O

0+	O	O
/	O	O
-	O	O
2	O	O
.	O	O

1	O	O
pmol	O	O
/	O	O
10	O	O
000	O	O
cells	O	O
per	O	O
5	O	O
minutes	O	O
,	O	O
respectively	O	O
,	O	O
at	O	O
an	O	O
l	B-Chemical	D001120
-	I-Chemical	D001120
arginine	I-Chemical	D001120
concentration	O	O
of	O	O
300	O	O
micromol	O	O
/	O	O
L	O	O
)	O	O
nor	O	O
L	B-Chemical	D001120
-	I-Chemical	D001120
arginine	I-Chemical	D001120
extraction	O	O
in	O	O
the	O	O
forearm	O	O
(	O	O
at	O	O
80	O	O
minutes	O	O
,	O	O
placebo	O	O
vs	O	O
active	O	O
,	O	O
1	O	O
868	O	O
904+	O	O
/	O	O
-	O	O
434	O	O
962	O	O
vs	O	O
2	O	O
013	O	O
910+	O	O
/	O	O
-	O	O
770	O	O
619	O	O
disintegrations	O	O
per	O	O
minute	O	O
)	O	O
was	O	O
affected	O	O
by	O	O
cortisol	B-Chemical	D006854
treatment	O	O
;	O	O
ie	O	O
,	O	O
that	O	O
L	B-Chemical	D001120
-	I-Chemical	D001120
arginine	I-Chemical	D001120
uptake	O	O
is	O	O
not	O	O
affected	O	O
by	O	O
short	O	O
-	O	O
term	O	O
cortisol	B-Chemical	D006854
treatment	O	O
.	O	O

We	O	O
conclude	O	O
that	O	O
cortisol	B-Chemical	D006854
-	O	O
induced	O	O
increases	B-Disease	D006973
in	I-Disease	D006973
blood	I-Disease	D006973
pressure	I-Disease	D006973
are	O	O
not	O	O
associated	O	O
with	O	O
abnormalities	O	O
in	O	O
the	O	O
l	B-Chemical	D001120
-	I-Chemical	D001120
arginine	I-Chemical	D001120
transport	O	O
system	O	O
.	O	O

MR	O	O
imaging	O	O
with	O	O
quantitative	O	O
diffusion	O	O
mapping	O	O
of	O	O
tacrolimus	B-Chemical	D016559
-	O	O
induced	O	O
neurotoxicity	B-Disease	D020258
in	O	O
organ	O	O
transplant	O	O
patients	O	O
.	O	O

Our	O	O
objective	O	O
was	O	O
to	O	O
investigate	O	O
brain	O	O
MR	O	O
imaging	O	O
findings	O	O
and	O	O
the	O	O
utility	O	O
of	O	O
diffusion	O	O
-	O	O
weighted	O	O
(	O	O
DW	O	O
)	O	O
imaging	O	O
in	O	O
organ	O	O
transplant	O	O
patients	O	O
who	O	O
developed	O	O
neurologic	O	O
symptoms	O	O
during	O	O
tacrolimus	B-Chemical	D016559
therapy	O	O
.	O	O

Brain	O	O
MR	O	O
studies	O	O
,	O	O
including	O	O
DW	O	O
imaging	O	O
,	O	O
were	O	O
prospectively	O	O
performed	O	O
in	O	O
14	O	O
organ	O	O
transplant	O	O
patients	O	O
receiving	O	O
tacrolimus	B-Chemical	D016559
who	O	O
developed	O	O
neurologic	B-Disease	D009422
complications	I-Disease	D009422
.	O	O

In	O	O
each	O	O
patient	O	O
who	O	O
had	O	O
abnormalities	O	O
on	O	O
the	O	O
initial	O	O
MR	O	O
study	O	O
,	O	O
a	O	O
follow	O	O
-	O	O
up	O	O
MR	O	O
study	O	O
was	O	O
performed	O	O
1	O	O
month	O	O
later	O	O
.	O	O

Apparent	O	O
diffusion	O	O
coefficient	O	O
(	O	O
ADC	O	O
)	O	O
values	O	O
on	O	O
the	O	O
initial	O	O
MR	O	O
study	O	O
were	O	O
correlated	O	O
with	O	O
reversibility	O	O
of	O	O
the	O	O
lesions	O	O
.	O	O

Of	O	O
the	O	O
14	O	O
patients	O	O
,	O	O
5	O	O
(	O	O
35	O	O
.	O	O

7%	O	O
)	O	O
had	O	O
white	B-Disease	D056784
matter	I-Disease	D056784
abnormalities	I-Disease	D056784
,	O	O
1	O	O
(	O	O
7	O	O
.	O	O

1%	O	O
)	O	O
had	O	O
putaminal	B-Disease	D020146
hemorrhage	I-Disease	D020146
,	O	O
and	O	O
8	O	O
(	O	O
57	O	O
.	O	O

1%	O	O
)	O	O
had	O	O
normal	O	O
findings	O	O
on	O	O
initial	O	O
MR	O	O
images	O	O
.	O	O

Among	O	O
the	O	O
5	O	O
patients	O	O
with	O	O
white	B-Disease	D056784
matter	I-Disease	D056784
abnormalities	I-Disease	D056784
,	O	O
4	O	O
patients	O	O
(	O	O
80	O	O
.	O	O

0%	O	O
)	O	O
showed	O	O
higher	O	O
than	O	O
normal	O	O
ADC	O	O
values	O	O
on	O	O
initial	O	O
MR	O	O
images	O	O
,	O	O
and	O	O
all	O	O
showed	O	O
complete	O	O
resolution	O	O
on	O	O
follow	O	O
-	O	O
up	O	O
images	O	O
.	O	O

The	O	O
remaining	O	O
1	O	O
patient	O	O
(	O	O
20	O	O
.	O	O

0%	O	O
)	O	O
showed	O	O
lower	O	O
than	O	O
normal	O	O
ADC	O	O
value	O	O
and	O	O
showed	O	O
incomplete	O	O
resolution	O	O
with	O	O
cortical	B-Disease	D001927
laminar	I-Disease	D001927
necrosis	I-Disease	D001927
.	O	O

Diffusion	O	O
-	O	O
weighted	O	O
imaging	O	O
may	O	O
be	O	O
useful	O	O
in	O	O
predicting	O	O
the	O	O
outcomes	O	O
of	O	O
the	O	O
lesions	O	O
of	O	O
tacrolimus	B-Chemical	D016559
-	O	O
induced	O	O
neurotoxicity	B-Disease	D020258
.	O	O

Octreotide	B-Chemical	D015282
-	O	O
induced	O	O
hypoxemia	B-Disease	D000860
and	O	O
pulmonary	B-Disease	D006976
hypertension	I-Disease	D006976
in	O	O
premature	O	O
neonates	O	O
.	O	O

The	O	O
authors	O	O
report	O	O
2	O	O
cases	O	O
of	O	O
premature	O	O
neonates	O	O
who	O	O
had	O	O
enterocutaneous	O	O
fistula	B-Disease	D005402
complicating	O	O
necrotizing	B-Disease	D020345
enterocolitis	I-Disease	D020345
.	O	O

Pulmonary	B-Disease	D006976
hypertension	I-Disease	D006976
developed	O	O
after	O	O
administration	O	O
of	O	O
a	O	O
somatostatin	O	O
analogue	O	O
,	O	O
octreotide	B-Chemical	D015282
,	O	O
to	O	O
enhance	O	O
resolution	O	O
of	O	O
the	O	O
fistula	B-Disease	D005402
.	O	O

The	O	O
authors	O	O
discuss	O	O
the	O	O
mechanism	O	O
of	O	O
the	O	O
occurrence	O	O
of	O	O
this	O	O
complication	O	O
and	O	O
recommend	O	O
caution	O	O
of	O	O
its	O	O
use	O	O
in	O	O
high	O	O
-	O	O
risk	O	O
premature	O	O
neonates	O	O
.	O	O

Sequential	O	O
observations	O	O
of	O	O
exencephaly	B-Disease	D009436
and	O	O
subsequent	O	O
morphological	O	O
changes	O	O
by	O	O
mouse	O	O
exo	O	O
utero	O	O
development	O	O
system	O	O
:	O	O
analysis	O	O
of	O	O
the	O	O
mechanism	O	O
of	O	O
transformation	O	O
from	O	O
exencephaly	B-Disease	D009436
to	O	O
anencephaly	B-Disease	D000757
.	O	O

Anencephaly	B-Disease	D000757
has	O	O
been	O	O
suggested	O	O
to	O	O
develop	O	O
from	O	O
exencephaly	B-Disease	D009436
;	O	O
however	O	O
,	O	O
there	O	O
is	O	O
little	O	O
direct	O	O
experimental	O	O
evidence	O	O
to	O	O
support	O	O
this	O	O
,	O	O
and	O	O
the	O	O
mechanism	O	O
of	O	O
transformation	O	O
remains	O	O
unclear	O	O
.	O	O

We	O	O
examined	O	O
this	O	O
theory	O	O
using	O	O
the	O	O
exo	O	O
utero	O	O
development	O	O
system	O	O
that	O	O
allows	O	O
direct	O	O
and	O	O
sequential	O	O
observations	O	O
of	O	O
mid	O	O
-	O	O
to	O	O
late	O	O
-	O	O
gestation	O	O
mouse	O	O
embryos	O	O
.	O	O

We	O	O
observed	O	O
the	O	O
exencephaly	B-Disease	D009436
induced	O	O
by	O	O
5	B-Chemical	D001374
-	I-Chemical	D001374
azacytidine	I-Chemical	D001374
at	O	O
embryonic	O	O
day	O	O
13	O	O
.	O	O

5	O	O
(	O	O
E13	O	O
.	O	O

5	O	O
)	O	O
,	O	O
let	O	O
the	O	O
embryos	O	O
develop	O	O
exo	O	O
utero	O	O
until	O	O
E18	O	O
.	O	O

5	O	O
,	O	O
and	O	O
re	O	O
-	O	O
observed	O	O
the	O	O
same	O	O
embryos	O	O
at	O	O
E18	O	O
.	O	O

5	O	O
.	O	O

We	O	O
confirmed	O	O
several	O	O
cases	O	O
of	O	O
transformation	O	O
from	O	O
exencephaly	B-Disease	D009436
to	O	O
anencephaly	B-Disease	D000757
.	O	O

However	O	O
,	O	O
in	O	O
many	O	O
cases	O	O
,	O	O
the	O	O
exencephalic	B-Disease	D009436
brain	O	O
tissue	O	O
was	O	O
preserved	O	O
with	O	O
more	O	O
or	O	O
less	O	O
reduction	O	O
during	O	O
this	O	O
period	O	O
.	O	O

To	O	O
analyze	O	O
the	O	O
transformation	O	O
patterns	O	O
,	O	O
we	O	O
classified	O	O
the	O	O
exencephaly	B-Disease	D009436
by	O	O
size	O	O
and	O	O
shape	O	O
of	O	O
the	O	O
exencephalic	B-Disease	D009436
tissue	O	O
into	O	O
several	O	O
types	O	O
at	O	O
E13	O	O
.	O	O

5	O	O
and	O	O
E18	O	O
.	O	O

5	O	O
.	O	O

It	O	O
was	O	O
found	O	O
that	O	O
the	O	O
transformation	O	O
of	O	O
exencephalic	B-Disease	D009436
tissue	O	O
was	O	O
not	O	O
simply	O	O
size	O	O
-	O	O
dependent	O	O
,	O	O
and	O	O
all	O	O
cases	O	O
of	O	O
anencephaly	B-Disease	D000757
at	O	O
E18	O	O
.	O	O

5	O	O
resulted	O	O
from	O	O
embryos	O	O
with	O	O
a	O	O
large	O	O
amount	O	O
of	O	O
exencephalic	B-Disease	D009436
tissue	O	O
at	O	O
E13	O	O
.	O	O

5	O	O
.	O	O

Microscopic	O	O
observation	O	O
showed	O	O
the	O	O
configuration	O	O
of	O	O
exencephaly	B-Disease	D009436
at	O	O
E13	O	O
.	O	O

5	O	O
,	O	O
frequent	O	O
hemorrhaging	B-Disease	D006470
and	O	O
detachment	O	O
of	O	O
the	O	O
neural	O	O
plate	O	O
from	O	O
surface	O	O
ectoderm	O	O
in	O	O
the	O	O
exencephalic	B-Disease	D009436
head	O	O
at	O	O
E15	O	O
.	O	O

5	O	O
,	O	O
and	O	O
multiple	O	O
modes	O	O
of	O	O
reduction	O	O
in	O	O
the	O	O
exencephalic	B-Disease	D009436
tissue	O	O
at	O	O
E18	O	O
.	O	O

5	O	O
.	O	O

From	O	O
observations	O	O
of	O	O
the	O	O
vasculature	O	O
,	O	O
altered	O	O
distribution	O	O
patterns	O	O
of	O	O
vessels	O	O
were	O	O
identified	O	O
in	O	O
the	O	O
exencephalic	B-Disease	D009436
head	O	O
.	O	O

These	O	O
findings	O	O
suggest	O	O
that	O	O
overgrowth	O	O
of	O	O
the	O	O
exencephalic	B-Disease	D009436
neural	O	O
tissue	O	O
causes	O	O
the	O	O
altered	O	O
distribution	O	O
patterns	O	O
of	O	O
vessels	O	O
,	O	O
subsequent	O	O
peripheral	O	O
circulatory	B-Disease	D012769
failure	I-Disease	D012769
and	O	O
/	O	O
or	O	O
hemorrhaging	B-Disease	D006470
in	O	O
various	O	O
parts	O	O
of	O	O
the	O	O
exencephalic	B-Disease	D009436
head	O	O
,	O	O
leading	O	O
to	O	O
the	O	O
multiple	O	O
modes	O	O
of	O	O
tissue	O	O
reduction	O	O
during	O	O
transformation	O	O
from	O	O
exencephaly	B-Disease	D009436
to	O	O
anencephaly	B-Disease	D000757
.	O	O

Acute	O	O
cocaine	B-Chemical	D003042
-	O	O
induced	O	O
seizures	B-Disease	D012640
:	O	O
differential	O	O
sensitivity	O	O
of	O	O
six	O	O
inbred	O	O
mouse	O	O
strains	O	O
.	O	O

Mature	O	O
male	O	O
and	O	O
female	O	O
mice	O	O
from	O	O
six	O	O
inbred	O	O
stains	O	O
were	O	O
tested	O	O
for	O	O
susceptibility	O	O
to	O	O
behavioral	O	O
seizures	B-Disease	D012640
induced	O	O
by	O	O
a	O	O
single	O	O
injection	O	O
of	O	O
cocaine	B-Chemical	D003042
.	O	O

Cocaine	B-Chemical	D003042
was	O	O
injected	O	O
ip	O	O
over	O	O
a	O	O
range	O	O
of	O	O
doses	O	O
(	O	O
50	O	O
-	O	O
100	O	O
mg	O	O
/	O	O
kg	O	O
)	O	O
and	O	O
behavior	O	O
was	O	O
monitored	O	O
for	O	O
20	O	O
minutes	O	O
.	O	O

Seizure	B-Disease	D012640
end	O	O
points	O	O
included	O	O
latency	O	O
to	O	O
forelimb	O	O
or	O	O
hindlimb	O	O
clonus	O	O
,	O	O
latency	O	O
to	O	O
clonic	O	O
running	O	O
seizure	B-Disease	D012640
and	O	O
latency	O	O
to	O	O
jumping	O	O
bouncing	O	O
seizure	B-Disease	D012640
.	O	O

A	O	O
range	O	O
of	O	O
strain	O	O
specific	O	O
sensitivities	O	O
was	O	O
documented	O	O
with	O	O
A	O	O
/	O	O
J	O	O
and	O	O
SJL	O	O
mice	O	O
being	O	O
most	O	O
sensitive	O	O
and	O	O
C57BL	O	O
/	O	O
6J	O	O
most	O	O
resistant	O	O
.	O	O

DBA	O	O
/	O	O
2J	O	O
,	O	O
BALB	O	O
/	O	O
cByJ	O	O
and	O	O
NZW	O	O
/	O	O
LacJ	O	O
strains	O	O
exhibited	O	O
intermediate	O	O
sensitivity	O	O
.	O	O

EEG	O	O
recordings	O	O
were	O	O
made	O	O
in	O	O
SJL	O	O
,	O	O
A	O	O
/	O	O
J	O	O
and	O	O
C57BL	O	O
/	O	O
6J	O	O
mice	O	O
revealing	O	O
a	O	O
close	O	O
correspondence	O	O
between	O	O
electrical	O	O
activity	O	O
and	O	O
behavior	O	O
.	O	O

Additionally	O	O
,	O	O
levels	O	O
of	O	O
cocaine	B-Chemical	D003042
determined	O	O
in	O	O
hippocampus	O	O
and	O	O
cortex	O	O
were	O	O
not	O	O
different	O	O
between	O	O
sensitive	O	O
and	O	O
resistant	O	O
strains	O	O
.	O	O

Additional	O	O
studies	O	O
of	O	O
these	O	O
murine	O	O
strains	O	O
may	O	O
be	O	O
useful	O	O
for	O	O
investigating	O	O
genetic	O	O
influences	O	O
on	O	O
cocaine	B-Chemical	D003042
-	O	O
induced	O	O
seizures	B-Disease	D012640
.	O	O

Microangiopathic	B-Disease	D000743
hemolytic	I-Disease	D000743
anemia	I-Disease	D000743
complicating	O	O
FK506	B-Chemical	D016559
(	O	O
tacrolimus	B-Chemical	D016559
)	O	O
therapy	O	O
.	O	O

We	O	O
describe	O	O
3	O	O
episodes	O	O
of	O	O
microangiopathic	B-Disease	D000743
hemolytic	I-Disease	D000743
anemia	I-Disease	D000743
(	O	O
MAHA	B-Disease	D000743
)	O	O
in	O	O
2	O	O
solid	O	O
organ	O	O
recipients	O	O
under	O	O
FK506	B-Chemical	D016559
(	O	O
tacrolimus	B-Chemical	D016559
)	O	O
therapy	O	O
.	O	O

In	O	O
both	O	O
cases	O	O
,	O	O
discontinuation	O	O
of	O	O
FK506	B-Chemical	D016559
and	O	O
treatment	O	O
with	O	O
plasma	O	O
exchange	O	O
,	O	O
fresh	O	O
frozen	O	O
plasma	O	O
replacement	O	O
,	O	O
corticosteroids	B-Chemical	D000305
,	O	O
aspirin	B-Chemical	D001241
,	O	O
and	O	O
dipyridamole	B-Chemical	D004176
led	O	O
to	O	O
resolution	O	O
of	O	O
MAHA	B-Disease	D000743
.	O	O

In	O	O
one	O	O
patient	O	O
,	O	O
reintroduction	O	O
of	O	O
FK506	B-Chemical	D016559
led	O	O
to	O	O
rapid	O	O
recurrence	O	O
of	O	O
MAHA	B-Disease	D000743
.	O	O

FK506	B-Chemical	D016559
-	O	O
associated	O	O
MAHA	B-Disease	D000743
is	O	O
probably	O	O
rare	O	O
but	O	O
physicians	O	O
must	O	O
be	O	O
aware	O	O
of	O	O
this	O	O
severe	O	O
complication	O	O
.	O	O

In	O	O
our	O	O
experience	O	O
and	O	O
according	O	O
to	O	O
the	O	O
literature	O	O
,	O	O
FK506	B-Chemical	D016559
does	O	O
not	O	O
seem	O	O
to	O	O
cross	O	O
-	O	O
react	O	O
with	O	O
cyclosporin	B-Chemical	D016572
A	I-Chemical	D016572
(	O	O
CyA	B-Chemical	D016572
)	O	O
,	O	O
an	O	O
immuno	O	O
-	O	O
suppressive	O	O
drug	O	O
already	O	O
known	O	O
to	O	O
induce	O	O
MAHA	B-Disease	D000743
.	O	O

Variant	O	O
ventricular	B-Disease	D017180
tachycardia	I-Disease	D017180
in	O	O
desipramine	B-Chemical	D003891
toxicity	B-Disease	D064420
.	O	O

We	O	O
report	O	O
a	O	O
case	O	O
of	O	O
variant	O	O
ventricular	B-Disease	D017180
tachycardia	I-Disease	D017180
induced	O	O
by	O	O
desipramine	B-Chemical	D003891
toxicity	B-Disease	D064420
.	O	O

Unusual	O	O
features	O	O
of	O	O
the	O	O
arrhythmia	B-Disease	D001145
are	O	O
repetitive	O	O
group	O	O
beating	O	O
,	O	O
progressive	O	O
shortening	O	O
of	O	O
the	O	O
R	O	O
-	O	O
R	O	O
interval	O	O
,	O	O
progressive	O	O
widening	O	O
of	O	O
the	O	O
QRS	O	O
complex	O	O
with	O	O
eventual	O	O
failure	O	O
of	O	O
intraventricular	O	O
conduction	O	O
,	O	O
and	O	O
changes	O	O
in	O	O
direction	O	O
of	O	O
the	O	O
QRS	O	O
axis	O	O
.	O	O

Recognition	O	O
of	O	O
variant	O	O
ventricular	B-Disease	D017180
tachycardia	I-Disease	D017180
is	O	O
important	O	O
because	O	O
therapy	O	O
differs	O	O
from	O	O
that	O	O
of	O	O
classic	O	O
ventricular	B-Disease	D017180
tachycardia	I-Disease	D017180
.	O	O

Desipramine	B-Chemical	D003891
-	O	O
induced	O	O
delirium	B-Disease	D003693
at	O	O
"subtherapeutic"	O	O
concentrations	O	O
:	O	O
a	O	O
case	O	O
report	O	O
.	O	O

An	O	O
elderly	O	O
patient	O	O
treated	O	O
with	O	O
low	O	O
dose	O	O
Desipramine	B-Chemical	D003891
developed	O	O
a	O	O
delirium	B-Disease	D003693
while	O	O
her	O	O
plasma	O	O
level	O	O
was	O	O
in	O	O
the	O	O
"subtherapeutic"	O	O
range	O	O
.	O	O

Delirium	B-Disease	D003693
,	O	O
which	O	O
may	O	O
be	O	O
induced	O	O
by	O	O
tricyclic	O	O
drug	O	O
therapy	O	O
in	O	O
the	O	O
elderly	O	O
,	O	O
can	O	O
be	O	O
caused	O	O
by	O	O
tricyclics	O	O
with	O	O
low	O	O
anticholinergic	O	O
potency	O	O
.	O	O

Therapeutic	O	O
ranges	O	O
for	O	O
antidepressants	B-Chemical	D000928
that	O	O
have	O	O
been	O	O
derived	O	O
from	O	O
general	O	O
adult	O	O
population	O	O
studies	O	O
may	O	O
not	O	O
be	O	O
appropriate	O	O
for	O	O
the	O	O
elderly	O	O
.	O	O

Further	O	O
studies	O	O
of	O	O
specifically	O	O
elderly	O	O
patients	O	O
are	O	O
now	O	O
required	O	O
to	O	O
establish	O	O
safer	O	O
and	O	O
more	O	O
appropriate	O	O
guidelines	O	O
for	O	O
drug	O	O
therapy	O	O
.	O	O

Mouse	O	O
strain	O	O
-	O	O
dependent	O	O
effect	O	O
of	O	O
amantadine	B-Chemical	D000547
on	O	O
motility	O	O
and	O	O
brain	O	O
biogenic	O	O
amines	B-Chemical	D000588
.	O	O

The	O	O
effect	O	O
of	O	O
amantadine	B-Chemical	D000547
hydrochloride	O	O
,	O	O
injected	O	O
i	O	O
.	O	O

p	O	O
.	O	O

in	O	O
6	O	O
increments	O	O
of	O	O
100	O	O
mg	O	O
/	O	O
kg	O	O
each	O	O
over	O	O
30	O	O
hr	O	O
,	O	O
on	O	O
mouse	O	O
motility	O	O
and	O	O
whole	O	O
brain	O	O
content	O	O
of	O	O
selected	O	O
biogenic	O	O
amines	B-Chemical	D000588
and	O	O
major	O	O
metabolites	O	O
was	O	O
studied	O	O
in	O	O
4	O	O
strains	O	O
of	O	O
mice	O	O
.	O	O

These	O	O
were	O	O
the	O	O
albino	O	O
Sprague	O	O
-	O	O
Dawley	O	O
ICR	O	O
and	O	O
BALB	O	O
/	O	O
C	O	O
,	O	O
the	O	O
black	O	O
C57BL	O	O
/	O	O
6	O	O
and	O	O
the	O	O
brown	O	O
CDF	O	O
-	O	O
I	O	O
mouse	O	O
strains	O	O
.	O	O

Amantadine	B-Chemical	D000547
treatment	O	O
produced	O	O
a	O	O
biphasic	O	O
effect	O	O
on	O	O
mouse	O	O
motility	O	O
.	O	O

The	O	O
initial	O	O
dose	O	O
of	O	O
amantadine	B-Chemical	D000547
depressed	B-Disease	D003866
locomotor	O	O
activity	O	O
in	O	O
all	O	O
mouse	O	O
strains	O	O
studied	O	O
with	O	O
the	O	O
BALB	O	O
/	O	O
C	O	O
mice	O	O
being	O	O
the	O	O
most	O	O
sensitive	O	O
.	O	O

Subsequent	O	O
amantadine	B-Chemical	D000547
treatments	O	O
produced	O	O
enhancement	O	O
of	O	O
motility	O	O
from	O	O
corresponding	O	O
control	O	O
in	O	O
all	O	O
mouse	O	O
strains	O	O
with	O	O
the	O	O
BALB	O	O
/	O	O
C	O	O
mice	O	O
being	O	O
the	O	O
least	O	O
sensitive	O	O
.	O	O

The	O	O
locomotor	O	O
activity	O	O
was	O	O
decreased	O	O
from	O	O
corresponding	O	O
controls	O	O
in	O	O
all	O	O
strains	O	O
studied	O	O
,	O	O
except	O	O
for	O	O
the	O	O
ICR	O	O
mice	O	O
,	O	O
during	O	O
an	O	O
overnight	O	O
drug	O	O
-	O	O
free	O	O
period	O	O
following	O	O
the	O	O
fourth	O	O
amantadine	B-Chemical	D000547
treatment	O	O
.	O	O

Readministration	O	O
of	O	O
amantadine	B-Chemical	D000547
,	O	O
after	O	O
a	O	O
drug	O	O
-	O	O
free	O	O
overnight	O	O
period	O	O
,	O	O
increased	O	O
motility	O	O
from	O	O
respective	O	O
saline	O	O
control	O	O
in	O	O
all	O	O
strains	O	O
with	O	O
exception	O	O
of	O	O
the	O	O
BALB	O	O
/	O	O
C	O	O
mice	O	O
where	O	O
suppression	B-Disease	D011596
of	I-Disease	D011596
motility	I-Disease	D011596
occurred	O	O
.	O	O

Treatment	O	O
with	O	O
amantadine	B-Chemical	D000547
did	O	O
not	O	O
alter	O	O
whole	O	O
brain	O	O
dopamine	B-Chemical	D004298
levels	O	O
but	O	O
decreased	O	O
the	O	O
amounts	O	O
of	O	O
3	B-Chemical	D015102
,	I-Chemical	D015102
4	I-Chemical	D015102
-	I-Chemical	D015102
dihydroxyphenylacetic	I-Chemical	D015102
acid	I-Chemical	D015102
in	O	O
the	O	O
BALB	O	O
/	O	O
C	O	O
mice	O	O
compared	O	O
to	O	O
saline	O	O
control	O	O
.	O	O

Conversely	O	O
,	O	O
brain	O	O
normetanephrine	B-Chemical	D009647
concentration	O	O
was	O	O
increased	O	O
from	O	O
saline	O	O
control	O	O
by	O	O
amantadine	B-Chemical	D000547
in	O	O
the	O	O
BALB	O	O
/	O	O
C	O	O
mice	O	O
.	O	O

The	O	O
results	O	O
suggest	O	O
a	O	O
strain	O	O
-	O	O
dependent	O	O
effect	O	O
of	O	O
amantadine	B-Chemical	D000547
on	O	O
motility	O	O
and	O	O
indicate	O	O
a	O	O
differential	O	O
response	O	O
to	O	O
the	O	O
acute	O	O
and	O	O
multiple	O	O
dose	O	O
regimens	O	O
used	O	O
.	O	O

The	O	O
BALB	O	O
/	O	O
C	O	O
mouse	O	O
was	O	O
the	O	O
most	O	O
sensitive	O	O
strain	O	O
and	O	O
could	O	O
serve	O	O
as	O	O
the	O	O
strain	O	O
of	O	O
choice	O	O
for	O	O
evaluating	O	O
the	O	O
side	O	O
effects	O	O
of	O	O
amantadine	B-Chemical	D000547
.	O	O

The	O	O
biochemical	O	O
results	O	O
of	O	O
brain	O	O
biogenic	O	O
amines	B-Chemical	D000588
of	O	O
BALB	O	O
/	O	O
C	O	O
mouse	O	O
strain	O	O
suggest	O	O
a	O	O
probable	O	O
decrease	O	O
of	O	O
catecholamine	B-Chemical	D002395
turnover	O	O
rate	O	O
and	O	O
/	O	O
or	O	O
metabolism	O	O
by	O	O
monoamine	O	O
oxidase	O	O
and	O	O
a	O	O
resulting	O	O
increase	O	O
in	O	O
O	O	O
-	O	O
methylation	O	O
of	O	O
norepinephrine	B-Chemical	D009638
which	O	O
may	O	O
account	O	O
for	O	O
a	O	O
behavioral	B-Disease	D011596
depression	I-Disease	D011596
caused	O	O
by	O	O
amantadine	B-Chemical	D000547
in	O	O
the	O	O
BALB	O	O
/	O	O
C	O	O
mice	O	O
.	O	O

No	O	O
enhancement	O	O
by	O	O
phenobarbital	B-Chemical	D010634
of	O	O
the	O	O
hepatocarcinogenicity	O	O
of	O	O
a	O	O
choline	B-Chemical	D002794
-	O	O
devoid	O	O
diet	O	O
in	O	O
the	O	O
rat	O	O
.	O	O

An	O	O
experiment	O	O
was	O	O
performed	O	O
to	O	O
test	O	O
whether	O	O
inclusion	O	O
of	O	O
phenobarbital	B-Chemical	D010634
in	O	O
a	O	O
choline	B-Chemical	D002794
-	O	O
devoid	O	O
diet	O	O
would	O	O
increase	O	O
the	O	O
hepatocarcinogenicity	O	O
of	O	O
the	O	O
diet	O	O
.	O	O

Groups	O	O
of	O	O
5	O	O
-	O	O
week	O	O
old	O	O
male	O	O
Fischer	O	O
-	O	O
344	O	O
rats	O	O
were	O	O
fed	O	O
for	O	O
7	O	O
-	O	O
25	O	O
months	O	O
semipurified	O	O
choline	B-Chemical	D002794
-	O	O
devoid	O	O
or	O	O
choline	B-Chemical	D002794
-	O	O
supplemented	O	O
diets	O	O
,	O	O
containing	O	O
or	O	O
not	O	O
0	O	O
.	O	O

06%	O	O
phenobarbital	B-Chemical	D010634
.	O	O

No	O	O
hepatic	O	O
preneoplastic	O	O
nodules	O	O
or	O	O
hepatocellular	B-Disease	D006528
carcinomas	I-Disease	D006528
developed	O	O
in	O	O
rats	O	O
fed	O	O
the	O	O
plain	O	O
choline	B-Chemical	D002794
-	O	O
supplemented	O	O
diet	O	O
,	O	O
while	O	O
one	O	O
preneoplastic	O	O
nodule	O	O
and	O	O
one	O	O
hepatocellular	B-Disease	D006528
carcinoma	I-Disease	D006528
developed	O	O
in	O	O
two	O	O
rats	O	O
fed	O	O
the	O	O
same	O	O
diet	O	O
containing	O	O
phenobarbital	B-Chemical	D010634
.	O	O

The	O	O
incidence	O	O
of	O	O
preneoplastic	O	O
nodules	O	O
and	O	O
of	O	O
hepatocellular	B-Disease	D006528
carcinomas	I-Disease	D006528
was	O	O
10%	O	O
and	O	O
37%	O	O
,	O	O
respectively	O	O
,	O	O
in	O	O
rats	O	O
fed	O	O
the	O	O
plain	O	O
choline	B-Chemical	D002794
-	O	O
devoid	O	O
diet	O	O
,	O	O
and	O	O
17%	O	O
and	O	O
30%	O	O
,	O	O
in	O	O
rats	O	O
fed	O	O
the	O	O
phenobarbital	B-Chemical	D010634
-	O	O
containing	O	O
choline	B-Chemical	D002794
-	O	O
devoid	O	O
diet	O	O
.	O	O

The	O	O
results	O	O
evinced	O	O
no	O	O
enhancement	O	O
of	O	O
the	O	O
hepatocarcinogenicity	O	O
of	O	O
the	O	O
choline	B-Chemical	D002794
-	O	O
devoid	O	O
diet	O	O
by	O	O
phenobarbital	B-Chemical	D010634
.	O	O

Sporadic	O	O
neoplastic	O	O
lesions	O	O
were	O	O
observed	O	O
in	O	O
organs	O	O
other	O	O
than	O	O
the	O	O
liver	O	O
of	O	O
some	O	O
of	O	O
the	O	O
animals	O	O
,	O	O
irrespective	O	O
of	O	O
the	O	O
diet	O	O
fed	O	O
.	O	O

Effect	O	O
of	O	O
direct	O	O
intracoronary	O	O
administration	O	O
of	O	O
methylergonovine	B-Chemical	D008755
in	O	O
patients	O	O
with	O	O
and	O	O
without	O	O
variant	B-Disease	D000788
angina	I-Disease	D000788
.	O	O

The	O	O
effects	O	O
of	O	O
intracoronary	O	O
administration	O	O
of	O	O
methylergonovine	B-Chemical	D008755
were	O	O
studied	O	O
in	O	O
21	O	O
patients	O	O
with	O	O
variant	B-Disease	D000788
angina	I-Disease	D000788
and	O	O
22	O	O
patients	O	O
with	O	O
atypical	O	O
chest	B-Disease	D002637
pain	I-Disease	D002637
and	O	O
in	O	O
others	O	O
without	O	O
angina	B-Disease	D000787
pectoris	I-Disease	D000787
(	O	O
control	O	O
group	O	O
)	O	O
.	O	O

Methylergonovine	B-Chemical	D008755
was	O	O
administered	O	O
continuously	O	O
at	O	O
a	O	O
rate	O	O
of	O	O
10	O	O
micrograms	O	O
/	O	O
min	O	O
up	O	O
to	O	O
50	O	O
micrograms	O	O
.	O	O

In	O	O
all	O	O
patients	O	O
with	O	O
variant	B-Disease	D000788
angina	I-Disease	D000788
,	O	O
coronary	B-Disease	D003329
spasm	I-Disease	D003329
was	O	O
provoked	O	O
at	O	O
a	O	O
mean	O	O
dose	O	O
of	O	O
28	O	O
+	O	O
/	O	O
-	O	O
13	O	O
micrograms	O	O
(	O	O
mean	O	O
+	O	O
/	O	O
-	O	O
SD	O	O
)	O	O
.	O	O

In	O	O
the	O	O
control	O	O
group	O	O
neither	O	O
ischemic	O	O
ST	O	O
change	O	O
nor	O	O
localized	O	O
spasm	B-Disease	D013035
occurred	O	O
.	O	O

The	O	O
basal	O	O
tone	O	O
of	O	O
the	O	O
right	O	O
coronary	O	O
artery	O	O
was	O	O
significantly	O	O
lower	O	O
than	O	O
that	O	O
of	O	O
the	O	O
left	O	O
coronary	O	O
artery	O	O
.	O	O

The	O	O
percentage	O	O
of	O	O
vasoconstriction	O	O
of	O	O
the	O	O
right	O	O
coronary	O	O
artery	O	O
was	O	O
significantly	O	O
higher	O	O
than	O	O
that	O	O
of	O	O
the	O	O
left	O	O
coronary	O	O
artery	O	O
.	O	O

These	O	O
results	O	O
suggest	O	O
that	O	O
spasm	B-Disease	D013035
provocation	O	O
tests	O	O
,	O	O
which	O	O
use	O	O
an	O	O
intracoronary	O	O
injection	O	O
of	O	O
a	O	O
relatively	O	O
low	O	O
dose	O	O
of	O	O
methylergonovine	B-Chemical	D008755
,	O	O
have	O	O
a	O	O
high	O	O
sensitivity	O	O
in	O	O
variant	B-Disease	D000788
angina	I-Disease	D000788
and	O	O
the	O	O
vasoreactivity	O	O
of	O	O
the	O	O
right	O	O
coronary	O	O
artery	O	O
may	O	O
be	O	O
greater	O	O
than	O	O
that	O	O
of	O	O
the	O	O
other	O	O
coronary	O	O
arteries	O	O
.	O	O

Dobutamine	B-Chemical	D004280
stress	O	O
echocardiography	O	O
:	O	O
a	O	O
sensitive	O	O
indicator	O	O
of	O	O
diminished	O	O
myocardial	O	O
function	O	O
in	O	O
asymptomatic	O	O
doxorubicin	B-Chemical	D004317
-	O	O
treated	O	O
long	O	O
-	O	O
term	O	O
survivors	O	O
of	O	O
childhood	O	O
cancer	B-Disease	D009369
.	O	O

Doxorubicin	B-Chemical	D004317
is	O	O
an	O	O
effective	O	O
anticancer	O	O
chemotherapeutic	O	O
agent	O	O
known	O	O
to	O	O
cause	O	O
acute	O	O
and	O	O
chronic	O	O
cardiomyopathy	B-Disease	D009202
.	O	O

To	O	O
develop	O	O
a	O	O
more	O	O
sensitive	O	O
echocardiographic	O	O
screening	O	O
test	O	O
for	O	O
cardiac	B-Disease	D006331
damage	I-Disease	D006331
due	O	O
to	O	O
doxorubicin	B-Chemical	D004317
,	O	O
a	O	O
cohort	O	O
study	O	O
was	O	O
performed	O	O
using	O	O
dobutamine	B-Chemical	D004280
infusion	O	O
to	O	O
differentiate	O	O
asymptomatic	O	O
long	O	O
-	O	O
term	O	O
survivors	O	O
of	O	O
childhood	O	O
cancer	B-Disease	D009369
treated	O	O
with	O	O
doxorubicin	B-Chemical	D004317
from	O	O
healthy	O	O
control	O	O
subjects	O	O
.	O	O

Echocardiographic	O	O
data	O	O
from	O	O
the	O	O
experimental	O	O
group	O	O
of	O	O
21	O	O
patients	O	O
(	O	O
mean	O	O
age	O	O
16	O	O
+	O	O
/	O	O
-	O	O
5	O	O
years	O	O
)	O	O
treated	O	O
from	O	O
1	O	O
.	O	O

6	O	O
to	O	O
14	O	O
.	O	O

3	O	O
years	O	O
(	O	O
median	O	O
5	O	O
.	O	O

3	O	O
)	O	O
before	O	O
this	O	O
study	O	O
with	O	O
27	O	O
to	O	O
532	O	O
mg	O	O
/	O	O
m2	O	O
of	O	O
doxorubicin	B-Chemical	D004317
(	O	O
mean	O	O
196	O	O
)	O	O
were	O	O
compared	O	O
with	O	O
echocardiographic	O	O
data	O	O
from	O	O
12	O	O
normal	O	O
age	O	O
-	O	O
matched	O	O
control	O	O
subjects	O	O
.	O	O

Graded	O	O
dobutamine	B-Chemical	D004280
infusions	O	O
of	O	O
0	O	O
.	O	O

5	O	O
,	O	O
2	O	O
.	O	O

5	O	O
,	O	O
5	O	O
and	O	O
10	O	O
micrograms	O	O
/	O	O
kg	O	O
per	O	O
min	O	O
were	O	O
administered	O	O
.	O	O

Echocardiographic	O	O
Doppler	O	O
studies	O	O
were	O	O
performed	O	O
before	O	O
infusion	O	O
and	O	O
after	O	O
15	O	O
min	O	O
of	O	O
infusion	O	O
at	O	O
each	O	O
rate	O	O
.	O	O

Dobutamine	B-Chemical	D004280
infusion	O	O
at	O	O
10	O	O
micrograms	O	O
/	O	O
kg	O	O
per	O	O
min	O	O
was	O	O
discontinued	O	O
after	O	O
six	O	O
studies	O	O
secondary	O	O
to	O	O
a	O	O
50%	O	O
incidence	O	O
rate	O	O
of	O	O
adverse	O	O
symptoms	O	O
.	O	O

The	O	O
most	O	O
important	O	O
findings	O	O
were	O	O
that	O	O
compared	O	O
with	O	O
values	O	O
in	O	O
control	O	O
subjects	O	O
,	O	O
end	O	O
-	O	O
systolic	O	O
left	O	O
ventricular	O	O
posterior	O	O
wall	O	O
dimension	O	O
and	O	O
percent	O	O
of	O	O
left	O	O
ventricular	O	O
posterior	O	O
wall	O	O
thickening	O	O
in	O	O
doxorubicin	B-Chemical	D004317
-	O	O
treated	O	O
patients	O	O
were	O	O
decreased	O	O
at	O	O
baseline	O	O
study	O	O
and	O	O
these	O	O
findings	O	O
were	O	O
more	O	O
clearly	O	O
delineated	O	O
with	O	O
dobutamine	B-Chemical	D004280
stimulation	O	O
.	O	O

End	O	O
-	O	O
systolic	O	O
left	O	O
ventricular	O	O
posterior	O	O
wall	O	O
dimension	O	O
at	O	O
baseline	O	O
for	O	O
the	O	O
doxorubicin	B-Chemical	D004317
-	O	O
treated	O	O
group	O	O
was	O	O
11	O	O
+	O	O
/	O	O
-	O	O
1	O	O
.	O	O

9	O	O
mm	O	O
versus	O	O
13	O	O
.	O	O

1	O	O
+	O	O
/	O	O
-	O	O
1	O	O
.	O	O

5	O	O
mm	O	O
for	O	O
control	O	O
subjects	O	O
(	O	O
p	O	O
less	O	O
than	O	O
0	O	O
.	O	O

01	O	O
)	O	O
.	O	O

End	O	O
-	O	O
systolic	O	O
left	O	O
ventricular	O	O
posterior	O	O
wall	O	O
dimension	O	O
at	O	O
the	O	O
5	O	O
-	O	O
micrograms	O	O
/	O	O
kg	O	O
per	O	O
min	O	O
dobutamine	B-Chemical	D004280
infusion	O	O
for	O	O
the	O	O
doxorubicin	B-Chemical	D004317
-	O	O
treated	O	O
group	O	O
was	O	O
14	O	O
.	O	O

1	O	O
+	O	O
/	O	O
-	O	O
2	O	O
.	O	O

4	O	O
mm	O	O
versus	O	O
19	O	O
.	O	O

3	O	O
+	O	O
/	O	O
-	O	O
2	O	O
.	O	O

6	O	O
mm	O	O
for	O	O
control	O	O
subjects	O	O
(	O	O
p	O	O
less	O	O
than	O	O
0	O	O
.	O	O

01	O	O
)	O	O
.	O	O

(	O	O
ABSTRACT	O	O
TRUNCATED	O	O
AT	O	O
250	O	O
WORDS	O	O
)	O	O
Effects	O	O
of	O	O
aminophylline	B-Chemical	D000628
on	O	O
the	O	O
threshold	O	O
for	O	O
initiating	O	O
ventricular	B-Disease	D014693
fibrillation	I-Disease	D014693
during	O	O
respiratory	B-Disease	D012131
failure	I-Disease	D012131
.	O	O

Cardiac	B-Disease	D001145
arrhythmias	I-Disease	D001145
have	O	O
frequently	O	O
been	O	O
reported	O	O
in	O	O
association	O	O
with	O	O
respiratory	B-Disease	D012131
failure	I-Disease	D012131
.	O	O

The	O	O
possible	O	O
additive	O	O
role	O	O
of	O	O
pharmacologic	O	O
agents	O	O
in	O	O
precipitating	O	O
cardiac	B-Disease	D006331
disturbances	I-Disease	D006331
in	O	O
patients	O	O
with	O	O
respiratory	B-Disease	D012131
failure	I-Disease	D012131
has	O	O
only	O	O
recently	O	O
been	O	O
emphasized	O	O
.	O	O

The	O	O
effects	O	O
of	O	O
aminophylline	B-Chemical	D000628
on	O	O
the	O	O
ventricular	B-Disease	D014693
fibrillation	I-Disease	D014693
threshold	O	O
during	O	O
normal	O	O
acid	O	O
-	O	O
base	O	O
conditions	O	O
and	O	O
during	O	O
respiratory	B-Disease	D012131
failure	I-Disease	D012131
were	O	O
studied	O	O
in	O	O
anesthetized	O	O
open	O	O
chest	O	O
dogs	O	O
.	O	O

The	O	O
ventricular	B-Disease	D014693
fibrillation	I-Disease	D014693
threshold	O	O
was	O	O
measured	O	O
by	O	O
passing	O	O
a	O	O
gated	O	O
train	O	O
of	O	O
12	O	O
constant	O	O
current	O	O
pulses	O	O
through	O	O
the	O	O
ventricular	O	O
myocardium	O	O
during	O	O
the	O	O
vulnerable	O	O
period	O	O
of	O	O
the	O	O
cardiac	O	O
cycle	O	O
.	O	O

During	O	O
the	O	O
infusion	O	O
of	O	O
aminophylline	B-Chemical	D000628
,	O	O
the	O	O
ventricular	B-Disease	D014693
fibrillation	I-Disease	D014693
threshold	O	O
was	O	O
reduced	O	O
by	O	O
30	O	O
to	O	O
40	O	O
percent	O	O
of	O	O
the	O	O
control	O	O
when	O	O
pH	O	O
and	O	O
partial	O	O
pressures	O	O
of	O	O
oxygen	B-Chemical	D010100
(	O	O
PO2	B-Chemical	C093415
)	O	O
and	O	O
carbon	B-Chemical	D002245
dioxide	I-Chemical	D002245
(	O	O
CO2	B-Chemical	D002245
)	O	O
were	O	O
kept	O	O
within	O	O
normal	O	O
limits	O	O
.	O	O

When	O	O
respiratory	B-Disease	D012131
failure	I-Disease	D012131
was	O	O
produced	O	O
by	O	O
hypoventilation	B-Disease	D007040
(	O	O
pH	O	O
7	O	O
.	O	O

05	O	O
to	O	O
7	O	O
.	O	O

25	O	O
;	O	O
PC02	O	O
70	O	O
to	O	O
100	O	O
mm	O	O
Hg	O	O
:	O	O
P02	O	O
20	O	O
to	O	O
40	O	O
mm	O	O
Hg	O	O
)	O	O
,	O	O
infusion	O	O
of	O	O
aminophylline	B-Chemical	D000628
resulted	O	O
in	O	O
an	O	O
even	O	O
greater	O	O
decrease	O	O
in	O	O
ventricular	B-Disease	D014693
fibrillation	I-Disease	D014693
threshold	O	O
to	O	O
60	O	O
percent	O	O
of	O	O
the	O	O
control	O	O
level	O	O
.	O	O

These	O	O
experiments	O	O
suggest	O	O
that	O	O
although	O	O
many	O	O
factors	O	O
may	O	O
contribute	O	O
to	O	O
the	O	O
increased	O	O
incidence	O	O
of	O	O
ventricular	B-Disease	D001145
arrhythmias	I-Disease	D001145
in	O	O
respiratory	B-Disease	D012131
failure	I-Disease	D012131
,	O	O
pharmacologic	O	O
agents	O	O
,	O	O
particularly	O	O
aminophylline	B-Chemical	D000628
,	O	O
may	O	O
play	O	O
a	O	O
significant	O	O
role	O	O
.	O	O

Case	O	O
report	O	O
:	O	O
acute	O	O
unintentional	O	O
carbachol	B-Chemical	D002217
intoxication	O	O
.	O	O

INTRODUCTION	O	O
:	O	O
Intoxications	O	O
with	O	O
carbachol	B-Chemical	D002217
,	O	O
a	O	O
muscarinic	O	O
cholinergic	O	O
receptor	O	O
agonist	O	O
are	O	O
rare	O	O
.	O	O

We	O	O
report	O	O
an	O	O
interesting	O	O
case	O	O
investigating	O	O
a	O	O
(	O	O
near	O	O
)	O	O
fatal	O	O
poisoning	B-Disease	D011041
.	O	O

METHODS	O	O
:	O	O
The	O	O
son	O	O
of	O	O
an	O	O
84	O	O
-	O	O
year	O	O
-	O	O
old	O	O
male	O	O
discovered	O	O
a	O	O
newspaper	O	O
report	O	O
stating	O	O
clinical	O	O
success	O	O
with	O	O
plant	O	O
extracts	O	O
in	O	O
Alzheimer's	B-Disease	D000544
disease	I-Disease	D000544
.	O	O

The	O	O
mode	O	O
of	O	O
action	O	O
was	O	O
said	O	O
to	O	O
be	O	O
comparable	O	O
to	O	O
that	O	O
of	O	O
the	O	O
synthetic	O	O
compound	O	O
'carbamylcholin'	O	O
;	O	O
that	O	O
is	O	O
,	O	O
carbachol	B-Chemical	D002217
.	O	O

He	O	O
bought	O	O
25	O	O
g	O	O
of	O	O
carbachol	B-Chemical	D002217
as	O	O
pure	O	O
substance	O	O
in	O	O
a	O	O
pharmacy	O	O
,	O	O
and	O	O
the	O	O
father	O	O
was	O	O
administered	O	O
400	O	O
to	O	O
500	O	O
mg	O	O
.	O	O

Carbachol	B-Chemical	D002217
concentrations	O	O
in	O	O
serum	O	O
and	O	O
urine	O	O
on	O	O
day	O	O
1	O	O
and	O	O
2	O	O
of	O	O
hospital	O	O
admission	O	O
were	O	O
analysed	O	O
by	O	O
HPLC	O	O
-	O	O
mass	O	O
spectrometry	O	O
.	O	O

RESULTS	O	O
:	O	O
Minutes	O	O
after	O	O
oral	O	O
administration	O	O
,	O	O
the	O	O
patient	O	O
developed	O	O
nausea	B-Disease	D009325
,	O	O
sweating	O	O
and	O	O
hypotension	B-Disease	D007022
,	O	O
and	O	O
finally	O	O
collapsed	O	O
.	O	O

Bradycardia	B-Disease	D001919
,	O	O
cholinergic	O	O
symptoms	O	O
and	O	O
asystole	B-Disease	D006323
occurred	O	O
.	O	O

Initial	O	O
cardiopulmonary	O	O
resuscitation	O	O
and	O	O
immediate	O	O
treatment	O	O
with	O	O
adrenaline	B-Chemical	D004837
(	O	O
epinephrine	B-Chemical	D004837
)	O	O
,	O	O
atropine	B-Chemical	D001285
and	O	O
furosemide	B-Chemical	D005665
was	O	O
successful	O	O
.	O	O

On	O	O
hospital	O	O
admission	O	O
,	O	O
blood	O	O
pressure	O	O
of	O	O
the	O	O
intubated	O	O
,	O	O
bradyarrhythmic	O	O
patient	O	O
was	O	O
100	O	O
/	O	O
65	O	O
mmHg	O	O
.	O	O

Further	O	O
signs	O	O
were	O	O
hyperhidrosis	B-Disease	D006945
,	O	O
hypersalivation	B-Disease	D012798
,	O	O
bronchorrhoea	B-Disease	-1
,	O	O
and	O	O
severe	O	O
miosis	B-Disease	D015877
;	O	O
the	O	O
electrocardiographic	O	O
finding	O	O
was	O	O
atrio	B-Disease	D006327
-	I-Disease	D006327
ventricular	I-Disease	D006327
dissociation	I-Disease	D006327
.	O	O

High	O	O
doses	O	O
of	O	O
atropine	B-Chemical	D001285
(	O	O
up	O	O
to	O	O
50	O	O
mg	O	O
per	O	O
24	O	O
hours	O	O
)	O	O
,	O	O
adrenaline	B-Chemical	D004837
and	O	O
dopamine	B-Chemical	D004298
were	O	O
necessary	O	O
.	O	O

The	O	O
patient	O	O
was	O	O
extubated	O	O
1	O	O
week	O	O
later	O	O
.	O	O

However	O	O
,	O	O
increased	O	O
dyspnoea	B-Disease	D004417
and	O	O
bronchospasm	B-Disease	D001986
necessitated	O	O
reintubation	O	O
.	O	O

Respiratory	B-Disease	D012131
insufficiency	I-Disease	D012131
was	O	O
further	O	O
worsened	O	O
by	O	O
Proteus	B-Disease	D011512
mirabilis	I-Disease	D011512
infection	I-Disease	D011512
and	O	O
severe	O	O
bronchoconstriction	O	O
.	O	O

One	O	O
week	O	O
later	O	O
,	O	O
the	O	O
patient	O	O
was	O	O
again	O	O
extubated	O	O
and	O	O
3	O	O
days	O	O
later	O	O
was	O	O
transferred	O	O
to	O	O
a	O	O
peripheral	O	O
ward	O	O
.	O	O

On	O	O
the	O	O
next	O	O
day	O	O
he	O	O
died	O	O
,	O	O
probably	O	O
as	O	O
a	O	O
result	O	O
of	O	O
heart	B-Disease	D006333
failure	I-Disease	D006333
.	O	O

Serum	O	O
samples	O	O
from	O	O
the	O	O
first	O	O
and	O	O
second	O	O
days	O	O
contained	O	O
3	O	O
.	O	O

6	O	O
and	O	O
1	O	O
.	O	O

9	O	O
mg	O	O
/	O	O
l	O	O
carbachol	B-Chemical	D002217
,	O	O
respectively	O	O
.	O	O

The	O	O
corresponding	O	O
urine	O	O
concentrations	O	O
amounted	O	O
to	O	O
374	O	O
and	O	O
554	O	O
mg	O	O
/	O	O
l	O	O
.	O	O

CONCLUSION	O	O
:	O	O
This	O	O
case	O	O
started	O	O
with	O	O
a	O	O
media	O	O
report	O	O
in	O	O
a	O	O
popular	O	O
newspaper	O	O
,	O	O
initiated	O	O
by	O	O
published	O	O
,	O	O
peer	O	O
-	O	O
reviewed	O	O
research	O	O
on	O	O
herbals	O	O
,	O	O
and	O	O
involved	O	O
human	O	O
failure	O	O
in	O	O
a	O	O
case	O	O
history	O	O
,	O	O
medical	O	O
examination	O	O
and	O	O
clinical	O	O
treatment	O	O
.	O	O

For	O	O
the	O	O
first	O	O
time	O	O
,	O	O
an	O	O
analytical	O	O
method	O	O
for	O	O
the	O	O
determination	O	O
of	O	O
carbachol	B-Chemical	D002217
in	O	O
plasma	O	O
and	O	O
urine	O	O
has	O	O
been	O	O
developed	O	O
.	O	O

The	O	O
analysed	O	O
carbachol	B-Chemical	D002217
concentration	O	O
exceeded	O	O
the	O	O
supposed	O	O
serum	O	O
level	O	O
resulting	O	O
from	O	O
a	O	O
therapeutic	O	O
dose	O	O
by	O	O
a	O	O
factor	O	O
of	O	O
130	O	O
to	O	O
260	O	O
.	O	O

Especially	O	O
in	O	O
old	O	O
patients	O	O
,	O	O
intensivists	O	O
should	O	O
consider	O	O
intoxications	O	O
(	O	O
with	O	O
cholinergics	O	O
)	O	O
as	O	O
a	O	O
cause	O	O
of	O	O
acute	B-Disease	D002318
cardiovascular	I-Disease	D002318
failure	I-Disease	D002318
.	O	O

Crossover	O	O
comparison	O	O
of	O	O
efficacy	O	O
and	O	O
preference	O	O
for	O	O
rizatriptan	B-Chemical	C093622
10	O	O
mg	O	O
versus	O	O
ergotamine	B-Chemical	D004878
/	O	O
caffeine	B-Chemical	D002110
in	O	O
migraine	B-Disease	D008881
.	O	O

Rizatriptan	B-Chemical	C093622
is	O	O
a	O	O
selective	O	O
5	B-Chemical	D012701
-	I-Chemical	D012701
HT	I-Chemical	D012701
(	O	O
1B	O	O
/	O	O
1D	O	O
)	O	O
receptor	O	O
agonist	O	O
with	O	O
rapid	O	O
oral	O	O
absorption	O	O
and	O	O
early	O	O
onset	O	O
of	O	O
action	O	O
in	O	O
the	O	O
acute	O	O
treatment	O	O
of	O	O
migraine	B-Disease	D008881
.	O	O

This	O	O
randomized	O	O
double	O	O
-	O	O
blind	O	O
crossover	O	O
outpatient	O	O
study	O	O
assessed	O	O
the	O	O
preference	O	O
for	O	O
1	O	O
rizatriptan	B-Chemical	C093622
10	O	O
mg	O	O
tablet	O	O
to	O	O
2	O	O
ergotamine	B-Chemical	D004878
1	O	O
mg	O	O
/	O	O
caffeine	B-Chemical	D002110
100	O	O
mg	O	O
tablets	O	O
in	O	O
439	O	O
patients	O	O
treating	O	O
a	O	O
single	O	O
migraine	B-Disease	D008881
attack	O	O
with	O	O
each	O	O
therapy	O	O
.	O	O

Of	O	O
patients	O	O
expressing	O	O
a	O	O
preference	O	O
(	O	O
89	O	O
.	O	O

1%	O	O
)	O	O
,	O	O
more	O	O
than	O	O
twice	O	O
as	O	O
many	O	O
preferred	O	O
rizatriptan	B-Chemical	C093622
to	O	O
ergotamine	B-Chemical	D004878
/	O	O
caffeine	B-Chemical	D002110
(	O	O
69	O	O
.	O	O

9	O	O
vs	O	O
.	O	O

30	O	O
.	O	O

1%	O	O
,	O	O
p	O	O
<	O	O
or	O	O
=	O	O
0	O	O
.	O	O

001	O	O
)	O	O
.	O	O

Faster	O	O
relief	O	O
of	O	O
headache	B-Disease	D006261
was	O	O
the	O	O
most	O	O
important	O	O
reason	O	O
for	O	O
preference	O	O
,	O	O
cited	O	O
by	O	O
67	O	O
.	O	O

3%	O	O
of	O	O
patients	O	O
preferring	O	O
rizatriptan	B-Chemical	C093622
and	O	O
54	O	O
.	O	O

2%	O	O
of	O	O
patients	O	O
who	O	O
preferred	O	O
ergotamine	B-Chemical	D004878
/	O	O
caffeine	B-Chemical	D002110
.	O	O

The	O	O
co	O	O
-	O	O
primary	O	O
endpoint	O	O
of	O	O
being	O	O
pain	B-Disease	D010146
free	O	O
at	O	O
2	O	O
h	O	O
was	O	O
also	O	O
in	O	O
favor	O	O
of	O	O
rizatriptan	B-Chemical	C093622
.	O	O

Forty	O	O
-	O	O
nine	O	O
percent	O	O
of	O	O
patients	O	O
were	O	O
pain	B-Disease	D010146
free	O	O
2	O	O
h	O	O
after	O	O
rizatriptan	B-Chemical	C093622
,	O	O
compared	O	O
with	O	O
24	O	O
.	O	O

3%	O	O
treated	O	O
with	O	O
ergotamine	B-Chemical	D004878
/	O	O
caffeine	B-Chemical	D002110
(	O	O
p	O	O
<	O	O
or	O	O
=	O	O
0	O	O
.	O	O

001	O	O
)	O	O
,	O	O
rizatriptan	B-Chemical	C093622
being	O	O
superior	O	O
within	O	O
1	O	O
h	O	O
of	O	O
treatment	O	O
.	O	O

Headache	B-Disease	D006261
relief	O	O
at	O	O
2	O	O
h	O	O
was	O	O
75	O	O
.	O	O

9%	O	O
for	O	O
rizatriptan	B-Chemical	C093622
and	O	O
47	O	O
.	O	O

3%	O	O
for	O	O
ergotamine	B-Chemical	D004878
/	O	O
caffeine	B-Chemical	D002110
(	O	O
p	O	O
<	O	O
or	O	O
=	O	O
0	O	O
.	O	O

001	O	O
)	O	O
,	O	O
with	O	O
rizatriptan	B-Chemical	C093622
being	O	O
superior	O	O
to	O	O
ergotamine	B-Chemical	D004878
/	O	O
caffeine	B-Chemical	D002110
within	O	O
30	O	O
min	O	O
of	O	O
dosing	O	O
.	O	O

Almost	O	O
36%	O	O
of	O	O
patients	O	O
taking	O	O
rizatriptan	B-Chemical	C093622
were	O	O
pain	B-Disease	D010146
free	O	O
at	O	O
2	O	O
h	O	O
and	O	O
had	O	O
no	O	O
recurrence	O	O
or	O	O
need	O	O
for	O	O
additional	O	O
medication	O	O
within	O	O
24	O	O
h	O	O
,	O	O
compared	O	O
to	O	O
20%	O	O
of	O	O
patients	O	O
on	O	O
ergotamine	B-Chemical	D004878
/	O	O
caffeine	B-Chemical	D002110
(	O	O
p	O	O
<	O	O
or	O	O
=	O	O
0	O	O
.	O	O

001	O	O
)	O	O
.	O	O

Rizatriptan	B-Chemical	C093622
was	O	O
also	O	O
superior	O	O
to	O	O
ergotamine	B-Chemical	D004878
/	O	O
caffeine	B-Chemical	D002110
in	O	O
the	O	O
proportions	O	O
of	O	O
patients	O	O
with	O	O
no	O	O
nausea	B-Disease	D009325
,	O	O
vomiting	B-Disease	D014839
,	O	O
phonophobia	B-Disease	D012001
or	O	O
photophobia	B-Disease	D020795
and	O	O
for	O	O
patients	O	O
with	O	O
normal	O	O
function	O	O
2	O	O
h	O	O
after	O	O
drug	O	O
intake	O	O
(	O	O
p	O	O
<	O	O
or	O	O
=	O	O
0	O	O
.	O	O

001	O	O
)	O	O
.	O	O

More	O	O
patients	O	O
were	O	O
(	O	O
completely	O	O
,	O	O
very	O	O
or	O	O
somewhat	O	O
)	O	O
satisfied	O	O
2	O	O
h	O	O
after	O	O
treatment	O	O
with	O	O
rizatriptan	B-Chemical	C093622
(	O	O
69	O	O
.	O	O

8%	O	O
)	O	O
than	O	O
at	O	O
2	O	O
h	O	O
after	O	O
treatment	O	O
with	O	O
ergotamine	B-Chemical	D004878
/	O	O
caffeine	B-Chemical	D002110
(	O	O
38	O	O
.	O	O

6%	O	O
,	O	O
p	O	O
<	O	O
or	O	O
=	O	O
0	O	O
.	O	O

001	O	O
)	O	O
.	O	O

Recurrence	O	O
rates	O	O
were	O	O
31	O	O
.	O	O

4%	O	O
with	O	O
rizatriptan	B-Chemical	C093622
and	O	O
15	O	O
.	O	O

3%	O	O
with	O	O
ergotamine	B-Chemical	D004878
/	O	O
caffeine	B-Chemical	D002110
.	O	O

Both	O	O
active	O	O
treatments	O	O
were	O	O
well	O	O
tolerated	O	O
.	O	O

The	O	O
most	O	O
common	O	O
adverse	O	O
events	O	O
(	O	O
incidence	O	O
>	O	O
or	O	O
=	O	O
5%	O	O
in	O	O
one	O	O
group	O	O
)	O	O
after	O	O
rizatriptan	B-Chemical	C093622
and	O	O
ergotamine	B-Chemical	D004878
/	O	O
caffeine	B-Chemical	D002110
,	O	O
respectively	O	O
,	O	O
were	O	O
dizziness	B-Disease	D004244
(	O	O
6	O	O
.	O	O

7	O	O
and	O	O
5	O	O
.	O	O

3%	O	O
)	O	O
,	O	O
nausea	B-Disease	D009325
(	O	O
4	O	O
.	O	O

2	O	O
and	O	O
8	O	O
.	O	O

5%	O	O
)	O	O
and	O	O
somnolence	B-Disease	D006970
(	O	O
5	O	O
.	O	O

5	O	O
and	O	O
2	O	O
.	O	O

3%	O	O
)	O	O
.	O	O

Thrombotic	B-Disease	D057049
microangiopathy	I-Disease	D057049
and	O	O
renal	B-Disease	D051437
failure	I-Disease	D051437
associated	O	O
with	O	O
antineoplastic	O	O
chemotherapy	O	O
.	O	O

Five	O	O
patients	O	O
with	O	O
carcinoma	B-Disease	D002277
developed	O	O
thrombotic	B-Disease	D057049
microangiopathy	I-Disease	D057049
(	O	O
characterized	O	O
by	O	O
renal	B-Disease	D051437
insufficiency	I-Disease	D051437
,	O	O
microangiopathic	B-Disease	D000743
hemolytic	I-Disease	D000743
anemia	I-Disease	D000743
,	O	O
and	O	O
usually	O	O
thrombocytopenia	B-Disease	D013921
)	O	O
after	O	O
treatment	O	O
with	O	O
cisplatin	B-Chemical	D002945
,	O	O
bleomycin	B-Chemical	D001761
,	O	O
and	O	O
a	O	O
vinca	B-Chemical	D014748
alkaloid	I-Chemical	D014748
.	O	O

One	O	O
patient	O	O
had	O	O
thrombotic	B-Disease	D011697
thrombocytopenic	I-Disease	D011697
purpura	I-Disease	D011697
,	O	O
three	O	O
the	O	O
hemolytic	B-Disease	D006463
-	I-Disease	D006463
uremic	I-Disease	D006463
syndrome	I-Disease	D006463
,	O	O
and	O	O
one	O	O
an	O	O
apparent	O	O
forme	O	O
fruste	O	O
of	O	O
one	O	O
of	O	O
these	O	O
disorders	O	O
.	O	O

Histologic	O	O
examination	O	O
of	O	O
the	O	O
renal	O	O
tissue	O	O
showed	O	O
evidence	O	O
of	O	O
intravascular	B-Disease	D004211
coagulation	I-Disease	D004211
,	O	O
primarily	O	O
affecting	O	O
the	O	O
small	O	O
arteries	O	O
,	O	O
arterioles	O	O
,	O	O
and	O	O
glomeruli	O	O
.	O	O

Because	O	O
each	O	O
patient	O	O
was	O	O
tumor	B-Disease	D009369
-	O	O
free	O	O
or	O	O
had	O	O
only	O	O
a	O	O
small	O	O
tumor	B-Disease	D009369
at	O	O
the	O	O
onset	O	O
of	O	O
this	O	O
syndrome	O	O
,	O	O
the	O	O
thrombotic	B-Disease	D057049
microangiopathy	I-Disease	D057049
may	O	O
have	O	O
been	O	O
induced	O	O
by	O	O
chemotherapy	O	O
.	O	O

Diagnosis	O	O
of	O	O
this	O	O
potentially	O	O
fatal	O	O
complication	O	O
may	O	O
be	O	O
delayed	O	O
or	O	O
missed	O	O
if	O	O
renal	O	O
tissue	O	O
or	O	O
the	O	O
peripheral	O	O
blood	O	O
smear	O	O
is	O	O
not	O	O
examined	O	O
,	O	O
because	O	O
renal	B-Disease	D051437
failure	I-Disease	D051437
may	O	O
be	O	O
ascribed	O	O
to	O	O
cisplatin	B-Chemical	D002945
nephrotoxicity	B-Disease	D007674
and	O	O
the	O	O
anemia	B-Disease	D000740
and	O	O
thrombocytopenia	B-Disease	D013921
to	O	O
drug	O	O
-	O	O
induced	O	O
bone	B-Disease	D001855
marrow	I-Disease	D001855
suppression	I-Disease	D001855
.	O	O

Salvage	O	O
therapy	O	O
with	O	O
nelarabine	B-Chemical	C104457
,	O	O
etoposide	B-Chemical	D005047
,	O	O
and	O	O
cyclophosphamide	B-Chemical	D003520
in	O	O
relapsed	O	O
/	O	O
refractory	O	O
paediatric	O	O
T	O	O
-	O	O
cell	O	O
lymphoblastic	O	O
leukaemia	O	O
and	O	O
lymphoma	O	O
.	O	O

A	O	O
combination	O	O
of	O	O
5	O	O
d	O	O
of	O	O
nelarabine	B-Chemical	C104457
(	O	O
AraG	B-Chemical	C104457
)	O	O
with	O	O
5	O	O
d	O	O
of	O	O
etoposide	B-Chemical	D005047
(	O	O
VP	B-Chemical	D005047
)	O	O
and	O	O
cyclophosphamide	B-Chemical	D003520
(	O	O
CPM	B-Chemical	D003520
)	O	O
and	O	O
prophylactic	O	O
intrathecal	O	O
chemotherapy	O	O
was	O	O
used	O	O
as	O	O
salvage	O	O
therapy	O	O
in	O	O
seven	O	O
children	O	O
with	O	O
refractory	O	O
or	O	O
relapsed	O	O
T	O	O
-	O	O
cell	O	O
leukaemia	O	O
or	O	O
lymphoma	O	O
.	O	O

The	O	O
most	O	O
common	O	O
side	O	O
effects	O	O
attributable	O	O
to	O	O
the	O	O
AraG	B-Chemical	C104457
included	O	O
Grade	O	O
2	O	O
and	O	O
3	O	O
sensory	O	O
and	O	O
motor	O	O
neuropathy	B-Disease	D009422
and	O	O
musculoskeletal	B-Disease	D059352
pain	I-Disease	D059352
.	O	O

Haematological	B-Disease	D006402
toxicity	I-Disease	D006402
was	O	O
greater	O	O
for	O	O
the	O	O
combination	O	O
than	O	O
AraG	B-Chemical	C104457
alone	O	O
,	O	O
although	O	O
median	O	O
time	O	O
to	O	O
neutrophil	O	O
and	O	O
platelet	O	O
recovery	O	O
was	O	O
consistent	O	O
with	O	O
other	O	O
salvage	O	O
therapies	O	O
.	O	O

All	O	O
patients	O	O
had	O	O
some	O	O
response	O	O
to	O	O
the	O	O
combined	O	O
therapy	O	O
and	O	O
five	O	O
of	O	O
the	O	O
seven	O	O
went	O	O
into	O	O
complete	O	O
remission	O	O
after	O	O
one	O	O
or	O	O
two	O	O
courses	O	O
of	O	O
AraG	B-Chemical	C104457
/	O	O
VP	B-Chemical	D005047
/	O	O
CPM	B-Chemical	D003520
.	O	O

Our	O	O
experience	O	O
supports	O	O
the	O	O
safety	O	O
of	O	O
giving	O	O
AraG	B-Chemical	C104457
as	O	O
salvage	O	O
therapy	O	O
in	O	O
synchrony	O	O
with	O	O
etoposide	B-Chemical	D005047
and	O	O
cyclophosphamide	B-Chemical	D003520
,	O	O
although	O	O
neurological	B-Disease	D009422
toxicity	I-Disease	D009422
must	O	O
be	O	O
closely	O	O
monitored	O	O
.	O	O

The	O	O
3	O	O
-	O	O
week	O	O
sulphasalazine	B-Chemical	D012460
syndrome	O	O
strikes	O	O
again	O	O
.	O	O

A	O	O
34	O	O
-	O	O
year	O	O
-	O	O
old	O	O
lady	O	O
developed	O	O
a	O	O
constellation	O	O
of	O	O
dermatitis	B-Disease	D003872
,	O	O
fever	B-Disease	D005334
,	O	O
lymphadenopathy	B-Disease	D008206
and	O	O
hepatitis	B-Disease	D056486
,	O	O
beginning	O	O
on	O	O
the	O	O
17th	O	O
day	O	O
of	O	O
a	O	O
course	O	O
of	O	O
oral	O	O
sulphasalazine	B-Chemical	D012460
for	O	O
sero	O	O
-	O	O
negative	O	O
rheumatoid	B-Disease	D001172
arthritis	I-Disease	D001172
.	O	O

Cervical	O	O
and	O	O
inguinal	O	O
lymph	O	O
node	O	O
biopsies	O	O
showed	O	O
the	O	O
features	O	O
of	O	O
severe	O	O
necrotising	O	O
lymphadenitis	B-Disease	D008199
,	O	O
associated	O	O
with	O	O
erythrophagocytosis	O	O
and	O	O
prominent	O	O
eosinophilic	O	O
infiltrates	O	O
,	O	O
without	O	O
viral	O	O
inclusion	O	O
bodies	O	O
,	O	O
suggestive	O	O
of	O	O
an	O	O
adverse	B-Disease	D064420
drug	I-Disease	D064420
reaction	I-Disease	D064420
.	O	O

A	O	O
week	O	O
later	O	O
,	O	O
fulminant	O	O
drug	B-Disease	D056486
-	I-Disease	D056486
induced	I-Disease	D056486
hepatitis	I-Disease	D056486
,	O	O
associated	O	O
with	O	O
the	O	O
presence	O	O
of	O	O
anti	O	O
-	O	O
nuclear	O	O
autoantibodies	O	O
(	O	O
but	O	O
not	O	O
with	O	O
other	O	O
markers	O	O
of	O	O
autoimmunity	B-Disease	D001327
)	O	O
,	O	O
and	O	O
accompanied	O	O
by	O	O
multi	B-Disease	D009102
-	I-Disease	D009102
organ	I-Disease	D009102
failure	I-Disease	D009102
and	O	O
sepsis	B-Disease	D018805
,	O	O
supervened	O	O
.	O	O

She	O	O
subsequently	O	O
died	O	O
some	O	O
5	O	O
weeks	O	O
after	O	O
the	O	O
commencement	O	O
of	O	O
her	O	O
drug	O	O
therapy	O	O
.	O	O

Post	O	O
-	O	O
mortem	O	O
examination	O	O
showed	O	O
evidence	O	O
of	O	O
massive	B-Disease	D047508
hepatocellular	I-Disease	D047508
necrosis	I-Disease	D047508
,	O	O
acute	O	O
hypersensitivity	O	O
myocarditis	B-Disease	D009205
,	O	O
focal	O	O
acute	O	O
tubulo	O	O
-	O	O
interstitial	O	O
nephritis	B-Disease	D009393
and	O	O
extensive	O	O
bone	B-Disease	D001855
marrow	I-Disease	D001855
necrosis	I-Disease	D001855
,	O	O
with	O	O
no	O	O
evidence	O	O
of	O	O
malignancy	B-Disease	D009369
.	O	O

It	O	O
is	O	O
thought	O	O
that	O	O
the	O	O
clinico	O	O
-	O	O
pathological	O	O
features	O	O
and	O	O
chronology	O	O
of	O	O
this	O	O
case	O	O
bore	O	O
the	O	O
hallmarks	O	O
of	O	O
the	O	O
so	O	O
-	O	O
called	O	O
"3	O	O
-	O	O
week	O	O
sulphasalazine	B-Chemical	D012460
syndrome"	O	O
,	O	O
a	O	O
rare	O	O
,	O	O
but	O	O
often	O	O
fatal	O	O
,	O	O
immunoallergic	O	O
reaction	O	O
to	O	O
sulphasalazine	B-Chemical	D012460
.	O	O

Bupropion	B-Chemical	D016642
(	O	O
Zyban	B-Chemical	D016642
)	O	O
toxicity	B-Disease	D064420
.	O	O

Bupropion	B-Chemical	D016642
is	O	O
a	O	O
monocyclic	O	O
antidepressant	B-Chemical	D000928
structurally	O	O
related	O	O
to	O	O
amphetamine	B-Chemical	D000661
.	O	O

Zyban	B-Chemical	D016642
,	O	O
a	O	O
sustained	O	O
-	O	O
release	O	O
formulation	O	O
of	O	O
bupropion	B-Chemical	D016642
hydrochloride	I-Chemical	D016642
,	O	O
was	O	O
recently	O	O
released	O	O
in	O	O
Ireland	O	O
,	O	O
as	O	O
a	O	O
smoking	O	O
cessation	O	O
aid	O	O
.	O	O

In	O	O
the	O	O
initial	O	O
6	O	O
months	O	O
since	O	O
it's	O	O
introduction	O	O
,	O	O
12	O	O
overdose	B-Disease	D062787
cases	O	O
have	O	O
been	O	O
reported	O	O
to	O	O
The	O	O
National	O	O
Poisons	O	O
Information	O	O
Centre	O	O
.	O	O

8	O	O
patients	O	O
developed	O	O
symptoms	O	O
of	O	O
toxicity	B-Disease	D064420
.	O	O

Common	O	O
features	O	O
included	O	O
tachycardia	B-Disease	D013610
,	O	O
drowsiness	O	O
,	O	O
hallucinations	B-Disease	D006212
and	O	O
convulsions	B-Disease	D012640
.	O	O

Two	O	O
patients	O	O
developed	O	O
severe	O	O
cardiac	B-Disease	D001145
arrhythmias	I-Disease	D001145
,	O	O
including	O	O
one	O	O
patient	O	O
who	O	O
was	O	O
resuscitated	O	O
following	O	O
a	O	O
cardiac	B-Disease	D006323
arrest	I-Disease	D006323
.	O	O

All	O	O
patients	O	O
recovered	O	O
without	O	O
sequelae	O	O
.	O	O

We	O	O
report	O	O
a	O	O
case	O	O
of	O	O
a	O	O
31	O	O
year	O	O
old	O	O
female	O	O
who	O	O
required	O	O
admission	O	O
to	O	O
the	O	O
Intensive	O	O
Care	O	O
Unit	O	O
for	O	O
ventilation	O	O
and	O	O
full	O	O
supportive	O	O
therapy	O	O
,	O	O
following	O	O
ingestion	O	O
of	O	O
13	O	O
.	O	O

5g	O	O
bupropion	B-Chemical	D016642
.	O	O

Recurrent	O	O
seizures	B-Disease	D012640
were	O	O
treated	O	O
with	O	O
diazepam	B-Chemical	D003975
and	O	O
broad	O	O
complex	O	O
tachycardia	B-Disease	D013610
was	O	O
successfully	O	O
treated	O	O
with	O	O
adenosine	B-Chemical	D000241
.	O	O

Zyban	B-Chemical	D016642
caused	O	O
significant	O	O
neurological	O	O
and	O	O
cardiovascular	O	O
toxicity	B-Disease	D064420
in	O	O
overdose	B-Disease	D062787
.	O	O

The	O	O
potential	O	O
toxic	O	O
effects	O	O
should	O	O
be	O	O
considered	O	O
when	O	O
prescribing	O	O
it	O	O
as	O	O
a	O	O
smoking	O	O
cessation	O	O
aid	O	O
.	O	O

Survey	O	O
of	O	O
complications	O	O
of	O	O
indocyanine	B-Chemical	D007208
green	I-Chemical	D007208
angiography	O	O
in	O	O
Japan	O	O
.	O	O

PURPOSE	O	O
:	O	O
We	O	O
evaluated	O	O
the	O	O
safety	O	O
of	O	O
indocyanine	B-Chemical	D007208
green	I-Chemical	D007208
for	O	O
use	O	O
in	O	O
fundus	O	O
angiography	O	O
.	O	O

METHODS	O	O
:	O	O
We	O	O
sent	O	O
a	O	O
questionnaire	O	O
concerning	O	O
complications	O	O
of	O	O
indocyanine	B-Chemical	D007208
green	I-Chemical	D007208
to	O	O
32	O	O
institutions	O	O
in	O	O
Japan	O	O
,	O	O
which	O	O
were	O	O
selected	O	O
on	O	O
the	O	O
basis	O	O
of	O	O
the	O	O
client	O	O
list	O	O
from	O	O
the	O	O
Topcon	O	O
Company	O	O
,	O	O
which	O	O
manufactures	O	O
the	O	O
indocyanine	B-Chemical	D007208
green	I-Chemical	D007208
fundus	O	O
camera	O	O
.	O	O

RESULTS	O	O
:	O	O
Ophthalmologists	O	O
at	O	O
15	O	O
institutions	O	O
responded	O	O
,	O	O
reporting	O	O
a	O	O
total	O	O
of	O	O
3	O	O
,	O	O
774	O	O
indocyanine	B-Chemical	D007208
green	I-Chemical	D007208
angiograms	O	O
performed	O	O
on	O	O
2	O	O
,	O	O
820	O	O
patients	O	O
between	O	O
June	O	O
1984	O	O
and	O	O
September	O	O
1992	O	O
.	O	O

Before	O	O
angiography	O	O
,	O	O
intradermal	O	O
or	O	O
intravenous	O	O
indocyanine	B-Chemical	D007208
green	I-Chemical	D007208
testing	O	O
,	O	O
or	O	O
both	O	O
was	O	O
performed	O	O
at	O	O
13	O	O
of	O	O
15	O	O
institutions	O	O
.	O	O

For	O	O
three	O	O
patients	O	O
,	O	O
the	O	O
decision	O	O
was	O	O
made	O	O
not	O	O
to	O	O
proceed	O	O
with	O	O
angiography	O	O
after	O	O
positive	O	O
preangiographic	O	O
testing	O	O
.	O	O

The	O	O
dosage	O	O
of	O	O
indocyanine	B-Chemical	D007208
green	I-Chemical	D007208
used	O	O
for	O	O
angiography	O	O
varied	O	O
from	O	O
25	O	O
to	O	O
75	O	O
mg	O	O
,	O	O
depending	O	O
upon	O	O
the	O	O
institution	O	O
.	O	O

There	O	O
were	O	O
13	O	O
cases	O	O
of	O	O
adverse	O	O
reactions	O	O
(	O	O
0	O	O
.	O	O

34%	O	O
)	O	O
,	O	O
ten	O	O
of	O	O
which	O	O
were	O	O
mild	O	O
reactions	O	O
such	O	O
as	O	O
nausea	B-Disease	D009325
,	O	O
exanthema	B-Disease	D005076
,	O	O
urtication	B-Disease	D014581
,	O	O
itchiness	B-Disease	D011537
,	O	O
and	O	O
urgency	O	O
to	O	O
defecate	O	O
,	O	O
and	O	O
did	O	O
not	O	O
require	O	O
treatment	O	O
.	O	O

Also	O	O
recorded	O	O
were	O	O
one	O	O
case	O	O
of	O	O
pain	B-Disease	D010146
of	O	O
the	O	O
vein	O	O
,	O	O
which	O	O
required	O	O
treatment	O	O
,	O	O
and	O	O
two	O	O
cases	O	O
of	O	O
hypotension	B-Disease	D007022
.	O	O

The	O	O
two	O	O
hypotensive	B-Disease	D007022
patients	O	O
required	O	O
treatment	O	O
for	O	O
shock	B-Disease	D012769
.	O	O

CONCLUSIONS	O	O
:	O	O
A	O	O
comparison	O	O
of	O	O
frequency	O	O
of	O	O
adverse	O	O
reactions	O	O
to	O	O
indocyanine	B-Chemical	D007208
green	I-Chemical	D007208
with	O	O
the	O	O
previously	O	O
reported	O	O
frequency	O	O
of	O	O
such	O	O
reactions	O	O
to	O	O
fluorescein	B-Chemical	D019793
sodium	I-Chemical	D019793
indicated	O	O
that	O	O
indocyanine	B-Chemical	D007208
green	I-Chemical	D007208
is	O	O
a	O	O
safe	O	O
as	O	O
fluorescein	B-Chemical	D019793
for	O	O
use	O	O
in	O	O
angiography	O	O
.	O	O

Bradykinin	B-Chemical	D001920
receptors	O	O
antagonists	O	O
and	O	O
nitric	B-Chemical	D009569
oxide	I-Chemical	D009569
synthase	O	O
inhibitors	O	O
in	O	O
vincristine	B-Chemical	D014750
and	O	O
streptozotocin	B-Chemical	D013311
induced	O	O
hyperalgesia	B-Disease	D006930
in	O	O
chemotherapy	O	O
and	O	O
diabetic	B-Disease	D003929
neuropathy	I-Disease	D003929
rat	O	O
model	O	O
.	O	O

PURPOSE	O	O
:	O	O
The	O	O
influence	O	O
of	O	O
an	O	O
irreversible	O	O
inhibitor	O	O
of	O	O
constitutive	O	O
NO	B-Chemical	D009569
synthase	O	O
(	O	O
L	O	O
-	O	O
NOArg	O	O
;	O	O
1	O	O
.	O	O

0	O	O
mg	O	O
/	O	O
kg	O	O
ip	O	O
)	O	O
,	O	O
a	O	O
relatively	O	O
selective	O	O
inhibitor	O	O
of	O	O
inducible	O	O
NO	B-Chemical	D009569
synthase	O	O
(	O	O
L	O	O
-	O	O
NIL	O	O
;	O	O
1	O	O
.	O	O

0	O	O
mg	O	O
/	O	O
kg	O	O
ip	O	O
)	O	O
and	O	O
a	O	O
relatively	O	O
specific	O	O
inhibitor	O	O
of	O	O
neuronal	O	O
NO	B-Chemical	D009569
synthase	O	O
(	O	O
7	O	O
-	O	O
NI	O	O
;	O	O
0	O	O
.	O	O

1	O	O
mg	O	O
/	O	O
kg	O	O
ip	O	O
)	O	O
,	O	O
on	O	O
antihyperalgesic	O	O
action	O	O
of	O	O
selective	O	O
antagonists	O	O
of	O	O
B2	O	O
and	O	O
B1	O	O
receptors	O	O
:	O	O
D	O	O
-	O	O
Arg	O	O
-	O	O
[	O	O
Hyp3	O	O
,	O	O
Thi5	O	O
,	O	O
D	O	O
-	O	O
Tic7	O	O
,	O	O
Oic8	O	O
]	O	O
bradykinin	B-Chemical	D001920
(	O	O
HOE	B-Chemical	C065679
140	I-Chemical	C065679
;	O	O
70	O	O
nmol	O	O
/	O	O
kg	O	O
ip	O	O
)	O	O
or	O	O
des	B-Chemical	C078665
Arg10	I-Chemical	C078665
HOE	I-Chemical	C078665
140	I-Chemical	C078665
(	O	O
70	O	O
nmol	O	O
/	O	O
kg	O	O
ip	O	O
)	O	O
respectively	O	O
,	O	O
in	O	O
model	O	O
of	O	O
diabetic	O	O
(	O	O
streptozotocin	B-Chemical	D013311
-	O	O
induced	O	O
)	O	O
and	O	O
toxic	O	O
(	O	O
vincristine	B-Chemical	D014750
-	O	O
induced	O	O
)	O	O
neuropathy	O	O
was	O	O
investigated	O	O
.	O	O

METHODS	O	O
:	O	O
The	O	O
changes	O	O
in	O	O
pain	B-Disease	D010146
thresholds	O	O
were	O	O
determined	O	O
using	O	O
mechanical	O	O
stimuli	O	O
-	O	O
-	O	O
the	O	O
modification	O	O
of	O	O
the	O	O
classic	O	O
paw	O	O
withdrawal	O	O
test	O	O
described	O	O
by	O	O
Randall	O	O
-	O	O
Selitto	O	O
.	O	O

RESULTS	O	O
:	O	O
The	O	O
results	O	O
of	O	O
this	O	O
paper	O	O
confirm	O	O
that	O	O
inhibition	O	O
of	O	O
bradykinin	B-Chemical	D001920
receptors	O	O
and	O	O
inducible	O	O
NO	B-Chemical	D009569
synthase	O	O
but	O	O
not	O	O
neuronal	O	O
NO	B-Chemical	D009569
synthase	O	O
activity	O	O
reduces	O	O
diabetic	B-Disease	D006930
hyperalgesia	I-Disease	D006930
.	O	O

Pretreatment	O	O
with	O	O
L	O	O
-	O	O
NOArg	O	O
and	O	O
L	O	O
-	O	O
NIL	O	O
but	O	O
not	O	O
7	O	O
-	O	O
NI	O	O
,	O	O
significantly	O	O
increases	O	O
antihyperalgesic	O	O
activity	O	O
both	O	O
HOE	B-Chemical	C065679
140	I-Chemical	C065679
and	O	O
des	B-Chemical	C078665
Arg10	I-Chemical	C078665
HOE	I-Chemical	C078665
140	I-Chemical	C078665
.	O	O

It	O	O
was	O	O
also	O	O
shown	O	O
that	O	O
both	O	O
products	O	O
of	O	O
inducible	O	O
NO	B-Chemical	D009569
synthase	O	O
and	O	O
neuronal	O	O
NO	B-Chemical	D009569
synthase	O	O
activation	O	O
as	O	O
well	O	O
as	O	O
bradykinin	B-Chemical	D001920
are	O	O
involved	O	O
in	O	O
hyperalgesia	B-Disease	D006930
produced	O	O
by	O	O
vincristine	B-Chemical	D014750
.	O	O

Moreover	O	O
,	O	O
L	O	O
-	O	O
NOArg	O	O
and	O	O
7	O	O
-	O	O
NI	O	O
but	O	O
not	O	O
L	O	O
-	O	O
NIL	O	O
intensify	O	O
antihyperalgesic	O	O
activity	O	O
of	O	O
HOE	B-Chemical	C065679
140	I-Chemical	C065679
or	O	O
des	B-Chemical	C078665
-	I-Chemical	C078665
Arg10HOE	I-Chemical	C078665
140	I-Chemical	C078665
in	O	O
toxic	B-Disease	D010523
neuropathy	I-Disease	D010523
.	O	O

CONCLUSIONS	O	O
:	O	O
Results	O	O
of	O	O
these	O	O
studies	O	O
suggest	O	O
that	O	O
B1	O	O
and	O	O
B2	O	O
receptors	O	O
are	O	O
engaged	O	O
in	O	O
transmission	O	O
of	O	O
nociceptive	O	O
stimuli	O	O
in	O	O
both	O	O
diabetic	O	O
and	O	O
toxic	B-Disease	D010523
neuropathy	I-Disease	D010523
.	O	O

In	O	O
streptozotocin	B-Chemical	D013311
-	O	O
induced	O	O
hyperalgesia	B-Disease	D006930
,	O	O
inducible	O	O
NO	B-Chemical	D009569
synthase	O	O
participates	O	O
in	O	O
pronociceptive	O	O
activity	O	O
of	O	O
bradykinin	B-Chemical	D001920
,	O	O
whereas	O	O
in	O	O
vincristine	B-Chemical	D014750
-	O	O
induced	O	O
hyperalgesia	B-Disease	D006930
bradykinin	B-Chemical	D001920
seemed	O	O
to	O	O
activate	O	O
neuronal	O	O
NO	B-Chemical	D009569
synthase	O	O
pathway	O	O
.	O	O

Therefore	O	O
,	O	O
concomitant	O	O
administration	O	O
of	O	O
small	O	O
doses	O	O
of	O	O
bradykinin	B-Chemical	D001920
receptor	O	O
antagonists	O	O
and	O	O
NO	B-Chemical	D009569
synthase	O	O
inhibitors	O	O
can	O	O
be	O	O
effective	O	O
in	O	O
alleviation	O	O
of	O	O
neuropathic	B-Disease	D009437
pain	I-Disease	D009437
,	O	O
even	O	O
in	O	O
hospital	O	O
care	O	O
.	O	O

Cardiac	B-Disease	D066126
toxicity	I-Disease	D066126
observed	O	O
in	O	O
association	O	O
with	O	O
high	O	O
-	O	O
dose	O	O
cyclophosphamide	B-Chemical	D003520
-	O	O
based	O	O
chemotherapy	O	O
for	O	O
metastatic	O	O
breast	B-Disease	D001943
cancer	I-Disease	D001943
.	O	O

INTRODUCTION	O	O
:	O	O
Cyclophosphamide	B-Chemical	D003520
is	O	O
an	O	O
alkylating	O	O
agent	O	O
given	O	O
frequently	O	O
as	O	O
a	O	O
component	O	O
of	O	O
many	O	O
conditioning	O	O
regimens	O	O
.	O	O

In	O	O
high	O	O
doses	O	O
,	O	O
its	O	O
nonhematological	O	O
dose	O	O
-	O	O
limiting	O	O
toxicity	B-Disease	D064420
is	O	O
cardiomyopathy	B-Disease	D009202
.	O	O

STUDY	O	O
DESIGN	O	O
:	O	O
We	O	O
combined	O	O
paclitaxel	B-Chemical	D017239
,	O	O
melphalan	B-Chemical	D008558
and	O	O
high	O	O
-	O	O
dose	O	O
cyclophosphamide	B-Chemical	D003520
,	O	O
thiotepa	B-Chemical	D013852
,	O	O
and	O	O
carboplatin	B-Chemical	D016190
in	O	O
a	O	O
triple	O	O
sequential	O	O
high	O	O
-	O	O
dose	O	O
regimen	O	O
for	O	O
patients	O	O
with	O	O
metastatic	O	O
breast	B-Disease	D001943
cancer	I-Disease	D001943
.	O	O

Analysis	O	O
was	O	O
performed	O	O
on	O	O
61	O	O
women	O	O
with	O	O
chemotherapy	O	O
-	O	O
responsive	O	O
metastatic	O	O
breast	B-Disease	D001943
cancer	I-Disease	D001943
receiving	O	O
96	O	O
-	O	O
h	O	O
infusional	O	O
cyclophosphamide	B-Chemical	D003520
as	O	O
part	O	O
of	O	O
a	O	O
triple	O	O
sequential	O	O
high	O	O
-	O	O
dose	O	O
regimen	O	O
to	O	O
assess	O	O
association	O	O
between	O	O
presence	O	O
of	O	O
peritransplant	O	O
congestive	B-Disease	D006333
heart	I-Disease	D006333
failure	I-Disease	D006333
(	O	O
CHF	B-Disease	D006333
)	O	O
and	O	O
the	O	O
following	O	O
pretreatment	O	O
characteristics	O	O
:	O	O
presence	O	O
of	O	O
electrocardiogram	O	O
(	O	O
EKG	O	O
)	O	O
abnormalities	O	O
,	O	O
age	O	O
,	O	O
hypertension	B-Disease	D006973
,	O	O
prior	O	O
cardiac	O	O
history	O	O
,	O	O
smoking	O	O
,	O	O
diabetes	B-Disease	D003920
mellitus	I-Disease	D003920
,	O	O
prior	O	O
use	O	O
of	O	O
anthracyclines	B-Chemical	D018943
,	O	O
and	O	O
left	O	O
-	O	O
sided	O	O
chest	O	O
irradiation	O	O
.	O	O

RESULTS	O	O
:	O	O
Six	O	O
of	O	O
61	O	O
women	O	O
(	O	O
10%	O	O
)	O	O
developed	O	O
clinically	O	O
reversible	O	O
grade	O	O
3	O	O
CHF	B-Disease	D006333
following	O	O
infusional	O	O
cyclophosphamide	B-Chemical	D003520
with	O	O
a	O	O
median	O	O
percent	O	O
decline	O	O
in	O	O
ejection	O	O
fraction	O	O
of	O	O
31%	O	O
.	O	O

Incidence	O	O
of	O	O
transient	O	O
cyclophosphamide	B-Chemical	D003520
-	O	O
related	O	O
cardiac	B-Disease	D066126
toxicity	I-Disease	D066126
(	O	O
10%	O	O
)	O	O
is	O	O
comparable	O	O
to	O	O
previous	O	O
recorded	O	O
literature	O	O
.	O	O

Older	O	O
age	O	O
was	O	O
significantly	O	O
correlated	O	O
with	O	O
the	O	O
CHF	B-Disease	D006333
development	O	O
;	O	O
with	O	O
median	O	O
ages	O	O
for	O	O
the	O	O
entire	O	O
group	O	O
and	O	O
for	O	O
patients	O	O
developing	O	O
CHF	B-Disease	D006333
of	O	O
45	O	O
and	O	O
59	O	O
,	O	O
respectively	O	O
.	O	O

No	O	O
association	O	O
was	O	O
found	O	O
with	O	O
other	O	O
pretreatment	O	O
characteristics	O	O
.	O	O

CONCLUSIONS	O	O
:	O	O
As	O	O
a	O	O
result	O	O
of	O	O
these	O	O
findings	O	O
,	O	O
oncologists	O	O
should	O	O
carefully	O	O
monitor	O	O
fluid	O	O
balance	O	O
in	O	O
older	O	O
patients	O	O
.	O	O

Routine	O	O
EKG	O	O
monitoring	O	O
during	O	O
infusional	O	O
cyclophosphamide	B-Chemical	D003520
did	O	O
not	O	O
predict	O	O
CHF	B-Disease	D006333
development	O	O
.	O	O

Inappropriate	O	O
use	O	O
of	O	O
carbamazepine	B-Chemical	D002220
and	O	O
vigabatrin	B-Chemical	D020888
in	O	O
typical	O	O
absence	B-Disease	D004832
seizures	I-Disease	D004832
.	O	O

Carbamazepine	B-Chemical	D002220
and	O	O
vigabatrin	B-Chemical	D020888
are	O	O
contraindicated	O	O
in	O	O
typical	O	O
absence	B-Disease	D004832
seizures	I-Disease	D004832
.	O	O

Of	O	O
18	O	O
consecutive	O	O
referrals	O	O
of	O	O
children	O	O
with	O	O
resistant	O	O
typical	O	O
absences	O	O
only	O	O
,	O	O
eight	O	O
were	O	O
erroneously	O	O
treated	O	O
with	O	O
carbamazepine	B-Chemical	D002220
either	O	O
as	O	O
monotherapy	O	O
or	O	O
as	O	O
an	O	O
add	O	O
-	O	O
on	O	O
.	O	O

Vigabatrin	B-Chemical	D020888
was	O	O
also	O	O
used	O	O
in	O	O
the	O	O
treatment	O	O
of	O	O
two	O	O
children	O	O
.	O	O

Frequency	O	O
of	O	O
absences	O	O
increased	O	O
in	O	O
four	O	O
children	O	O
treated	O	O
with	O	O
carbamazepine	B-Chemical	D002220
and	O	O
two	O	O
of	O	O
these	O	O
developed	O	O
myoclonic	B-Disease	D009207
jerks	I-Disease	D009207
,	O	O
which	O	O
resolved	O	O
on	O	O
withdrawal	O	O
of	O	O
carbamazepine	B-Chemical	D002220
.	O	O

Absences	O	O
were	O	O
aggravated	O	O
in	O	O
both	O	O
cases	O	O
where	O	O
vigabatrin	B-Chemical	D020888
was	O	O
added	O	O
on	O	O
to	O	O
concurrent	O	O
treatment	O	O
.	O	O

Optimal	O	O
control	O	O
of	O	O
the	O	O
absences	O	O
was	O	O
achieved	O	O
with	O	O
sodium	B-Chemical	D014635
valproate	I-Chemical	D014635
,	O	O
lamotrigine	B-Chemical	C047781
,	O	O
or	O	O
ethosuximide	B-Chemical	D005013
alone	O	O
or	O	O
in	O	O
combination	O	O
.	O	O

Hemolytic	B-Disease	D000743
anemia	I-Disease	D000743
associated	O	O
with	O	O
the	O	O
use	O	O
of	O	O
omeprazole	B-Chemical	D009853
.	O	O

Omeprazole	B-Chemical	D009853
is	O	O
the	O	O
first	O	O
drug	O	O
designed	O	O
to	O	O
block	O	O
the	O	O
final	O	O
step	O	O
in	O	O
the	O	O
acid	O	O
secretory	O	O
process	O	O
within	O	O
the	O	O
parietal	O	O
cell	O	O
.	O	O

It	O	O
has	O	O
been	O	O
shown	O	O
to	O	O
be	O	O
extremely	O	O
effective	O	O
in	O	O
the	O	O
treatment	O	O
of	O	O
peptic	B-Disease	D010437
ulcer	I-Disease	D010437
disease	I-Disease	D010437
,	O	O
reflux	B-Disease	D005764
esophagitis	I-Disease	D005764
,	O	O
and	O	O
the	O	O
Zollinger	B-Disease	D015043
-	I-Disease	D015043
Ellison	I-Disease	D015043
syndrome	I-Disease	D015043
.	O	O

Although	O	O
clinical	O	O
experience	O	O
with	O	O
omeprazole	B-Chemical	D009853
is	O	O
still	O	O
limited	O	O
,	O	O
many	O	O
controlled	O	O
studies	O	O
have	O	O
established	O	O
the	O	O
short	O	O
-	O	O
term	O	O
safety	O	O
of	O	O
this	O	O
drug	O	O
.	O	O

We	O	O
report	O	O
the	O	O
first	O	O
case	O	O
of	O	O
a	O	O
serious	O	O
short	O	O
-	O	O
term	O	O
adverse	O	O
reaction	O	O
with	O	O
the	O	O
use	O	O
of	O	O
omeprazole	B-Chemical	D009853
:	O	O
hemolytic	B-Disease	D000743
anemia	I-Disease	D000743
.	O	O

The	O	O
patient	O	O
developed	O	O
weakness	O	O
,	O	O
lethargy	B-Disease	D053609
,	O	O
and	O	O
shortness	B-Disease	D004417
of	I-Disease	D004417
breath	I-Disease	D004417
2	O	O
days	O	O
after	O	O
starting	O	O
therapy	O	O
with	O	O
omeprazole	B-Chemical	D009853
.	O	O

Two	O	O
weeks	O	O
after	O	O
the	O	O
initiation	O	O
of	O	O
therapy	O	O
,	O	O
her	O	O
hematocrit	O	O
had	O	O
decreased	O	O
from	O	O
44	O	O
.	O	O

1%	O	O
to	O	O
20	O	O
.	O	O

4%	O	O
,	O	O
and	O	O
she	O	O
had	O	O
a	O	O
positive	O	O
direct	O	O
Coombs	O	O
antiglobulin	O	O
test	O	O
and	O	O
an	O	O
elevated	O	O
indirect	O	O
bilirubin	B-Chemical	D001663
.	O	O

After	O	O
she	O	O
discontinued	O	O
the	O	O
omeprazole	B-Chemical	D009853
,	O	O
her	O	O
hemoglobin	O	O
and	O	O
hematocrit	O	O
gradually	O	O
returned	O	O
to	O	O
normal	O	O
.	O	O

The	O	O
mechanism	O	O
by	O	O
which	O	O
omeprazole	B-Chemical	D009853
caused	O	O
the	O	O
patient's	O	O
hemolytic	B-Disease	D000743
anemia	I-Disease	D000743
is	O	O
uncertain	O	O
,	O	O
but	O	O
physicians	O	O
should	O	O
be	O	O
alerted	O	O
to	O	O
this	O	O
possible	O	O
adverse	O	O
effect	O	O
.	O	O

The	O	O
use	O	O
and	O	O
toxicity	B-Disease	D064420
of	O	O
didanosine	B-Chemical	D016049
(	O	O
ddI	B-Chemical	D016049
)	O	O
in	O	O
HIV	B-Disease	D015658
antibody	I-Disease	D015658
-	I-Disease	D015658
positive	I-Disease	D015658
individuals	O	O
intolerant	O	O
to	O	O
zidovudine	B-Chemical	D015215
(	O	O
AZT	B-Chemical	D015215
)	O	O
One	O	O
hundred	O	O
and	O	O
fifty	O	O
-	O	O
one	O	O
patients	O	O
intolerant	O	O
to	O	O
zidovudine	B-Chemical	D015215
(	O	O
AZT	B-Chemical	D015215
)	O	O
received	O	O
didanosine	B-Chemical	D016049
(	O	O
ddI	B-Chemical	D016049
)	O	O
to	O	O
a	O	O
maximum	O	O
dose	O	O
of	O	O
12	O	O
.	O	O

5	O	O
mg	O	O
/	O	O
kg	O	O
/	O	O
day	O	O
.	O	O

Patient	O	O
response	O	O
was	O	O
assessed	O	O
using	O	O
changes	O	O
in	O	O
CD4+	O	O
lymphocyte	O	O
subset	O	O
count	O	O
,	O	O
HIV	O	O
p24	O	O
antigen	O	O
,	O	O
weight	O	O
,	O	O
and	O	O
quality	O	O
of	O	O
life	O	O
.	O	O

Seventy	O	O
patients	O	O
developed	O	O
major	O	O
opportunistic	B-Disease	D009894
infections	I-Disease	D009894
whilst	O	O
on	O	O
therapy	O	O
;	O	O
this	O	O
was	O	O
the	O	O
first	O	O
AIDS	B-Disease	D000163
diagnosis	O	O
in	O	O
17	O	O
.	O	O

Only	O	O
minor	O	O
changes	O	O
in	O	O
CD4+	O	O
lymphocyte	O	O
subset	O	O
count	O	O
were	O	O
observed	O	O
in	O	O
AIDS	B-Disease	D000163
patients	O	O
,	O	O
although	O	O
a	O	O
more	O	O
significant	O	O
rise	O	O
occurred	O	O
in	O	O
those	O	O
with	O	O
earlier	O	O
stages	O	O
of	O	O
disease	O	O
.	O	O

Of	O	O
those	O	O
positive	O	O
for	O	O
p24	O	O
antigen	O	O
at	O	O
the	O	O
commencement	O	O
of	O	O
the	O	O
study	O	O
67%	O	O
showed	O	O
a	O	O
positive	O	O
response	O	O
,	O	O
and	O	O
this	O	O
was	O	O
most	O	O
likely	O	O
in	O	O
those	O	O
with	O	O
CD4+	O	O
lymphocyte	O	O
subset	O	O
counts	O	O
above	O	O
100	O	O
mm3	O	O
.	O	O

A	O	O
positive	O	O
weight	O	O
response	O	O
was	O	O
seen	O	O
in	O	O
16%	O	O
of	O	O
patients	O	O
.	O	O

Most	O	O
patients	O	O
showed	O	O
improvement	O	O
in	O	O
individual	O	O
parameters	O	O
and	O	O
global	O	O
score	O	O
of	O	O
quality	O	O
of	O	O
life	O	O
.	O	O

Adverse	O	O
reactions	O	O
possibly	O	O
attributable	O	O
to	O	O
didanosine	B-Chemical	D016049
were	O	O
common	O	O
.	O	O

The	O	O
most	O	O
common	O	O
side	O	O
-	O	O
effect	O	O
was	O	O
diarrhoea	B-Disease	D003967
,	O	O
which	O	O
resulted	O	O
in	O	O
cessation	O	O
of	O	O
therapy	O	O
in	O	O
19	O	O
individuals	O	O
.	O	O

Peripheral	B-Disease	D010523
neuropathy	I-Disease	D010523
occurred	O	O
in	O	O
12	O	O
patients	O	O
and	O	O
pancreatitis	B-Disease	D010195
in	O	O
six	O	O
.	O	O

Thirteen	O	O
patients	O	O
developed	O	O
a	O	O
raised	O	O
serum	O	O
amylase	O	O
without	O	O
abdominal	B-Disease	D015746
pain	I-Disease	D015746
.	O	O

Seven	O	O
patients	O	O
developed	O	O
glucose	B-Disease	D018149
tolerance	I-Disease	D018149
curves	I-Disease	D018149
characteristic	O	O
of	O	O
diabetes	B-Disease	D003920
but	O	O
these	O	O
were	O	O
mild	O	O
,	O	O
did	O	O
not	O	O
require	O	O
treatment	O	O
and	O	O
returned	O	O
to	O	O
normal	O	O
on	O	O
ceasing	O	O
didanosine	B-Chemical	D016049
.	O	O

Can	O	O
angiogenesis	O	O
be	O	O
a	O	O
target	O	O
of	O	O
treatment	O	O
for	O	O
ribavirin	B-Chemical	D012254
associated	O	O
hemolytic	O	O
anemia?	O	O
BACKGROUND	O	O
/	O	O
AIMS	O	O
:	O	O
Recently	O	O
ribavirin	B-Chemical	D012254
has	O	O
been	O	O
found	O	O
to	O	O
inhibit	O	O
angiogenesis	O	O
and	O	O
a	O	O
number	O	O
of	O	O
angiogenesis	O	O
inhibitors	O	O
such	O	O
as	O	O
sunitinib	B-Chemical	C473478
and	O	O
sorafenib	B-Chemical	C471405
have	O	O
been	O	O
found	O	O
to	O	O
cause	O	O
acute	O	O
hemolysis	B-Disease	D006461
.	O	O

We	O	O
aimed	O	O
to	O	O
investigate	O	O
whether	O	O
there	O	O
is	O	O
a	O	O
relation	O	O
between	O	O
hemoglobin	O	O
,	O	O
haptoglobin	O	O
and	O	O
angiogenesis	O	O
soluble	O	O
markers	O	O
which	O	O
are	O	O
modifiable	O	O
and	O	O
can	O	O
help	O	O
in	O	O
developing	O	O
strategies	O	O
against	O	O
anemia	B-Disease	D000740
.	O	O

METHODS	O	O
:	O	O
Fourteen	O	O
patients	O	O
chronically	B-Disease	D019698
infected	I-Disease	D019698
with	I-Disease	D019698
hepatitis	I-Disease	D019698
C	I-Disease	D019698
virus	I-Disease	D019698
were	O	O
treated	O	O
by	O	O
pegylated	B-Chemical	C100416
interferon	I-Chemical	C100416
alpha	I-Chemical	C100416
2a	I-Chemical	C100416
and	O	O
ribavirin	B-Chemical	D012254
.	O	O

Serum	O	O
hemoglobin	O	O
,	O	O
haptoglobin	O	O
and	O	O
angiogenesis	O	O
markers	O	O
of	O	O
vascular	O	O
endothelial	O	O
growth	O	O
factor	O	O
and	O	O
angiopoetin	O	O
-	O	O
2	O	O
were	O	O
investigated	O	O
before	O	O
and	O	O
after	O	O
therapy	O	O
.	O	O

RESULTS	O	O
:	O	O
We	O	O
observed	O	O
a	O	O
significant	O	O
decrease	O	O
in	O	O
haptoglobin	O	O
levels	O	O
at	O	O
the	O	O
end	O	O
of	O	O
the	O	O
treatment	O	O
period	O	O
.	O	O

Hemoglobin	O	O
levels	O	O
also	O	O
decreased	O	O
but	O	O
insignificantly	O	O
by	O	O
treatment	O	O
.	O	O

In	O	O
contrast	O	O
with	O	O
the	O	O
literature	O	O
,	O	O
serum	O	O
levels	O	O
of	O	O
angiogenesis	O	O
factors	O	O
did	O	O
not	O	O
change	O	O
significantly	O	O
by	O	O
pegylated	B-Chemical	C417083
interferon	I-Chemical	C417083
and	O	O
ribavirin	B-Chemical	D012254
therapy	O	O
.	O	O

We	O	O
found	O	O
no	O	O
correlation	O	O
of	O	O
angiogenesis	O	O
soluble	O	O
markers	O	O
with	O	O
either	O	O
hemoglobin	O	O
or	O	O
haptoglobin	O	O
.	O	O

CONCLUSION	O	O
:	O	O
This	O	O
is	O	O
the	O	O
first	O	O
study	O	O
in	O	O
the	O	O
literature	O	O
investigating	O	O
a	O	O
link	O	O
between	O	O
angiogenesis	O	O
soluble	O	O
markers	O	O
and	O	O
ribavirin	B-Chemical	D012254
induced	O	O
anemia	B-Disease	D000740
in	O	O
patients	O	O
with	O	O
hepatitis	B-Disease	D019698
C	I-Disease	D019698
and	O	O
we	O	O
could	O	O
not	O	O
find	O	O
any	O	O
relation	O	O
.	O	O

Future	O	O
research	O	O
with	O	O
larger	O	O
number	O	O
of	O	O
patients	O	O
is	O	O
needed	O	O
to	O	O
find	O	O
out	O	O
modifiable	O	O
factors	O	O
that	O	O
will	O	O
improve	O	O
the	O	O
safety	O	O
of	O	O
ribavirin	B-Chemical	D012254
therapy	O	O
.	O	O

Cocaine	B-Chemical	D003042
causes	O	O
memory	O	O
and	O	O
learning	O	O
impairments	O	O
in	O	O
rats	O	O
:	O	O
involvement	O	O
of	O	O
nuclear	O	O
factor	O	O
kappa	O	O
B	O	O
and	O	O
oxidative	O	O
stress	O	O
,	O	O
and	O	O
prevention	O	O
by	O	O
topiramate	B-Chemical	C052342
.	O	O

Different	O	O
mechanisms	O	O
have	O	O
been	O	O
suggested	O	O
for	O	O
cocaine	B-Chemical	D003042
toxicity	B-Disease	D064420
including	O	O
an	O	O
increase	O	O
in	O	O
oxidative	O	O
stress	O	O
but	O	O
the	O	O
association	O	O
between	O	O
oxidative	O	O
status	O	O
in	O	O
the	O	O
brain	O	O
and	O	O
cocaine	B-Chemical	D003042
induced	O	O
-	O	O
behaviour	O	O
is	O	O
poorly	O	O
understood	O	O
.	O	O

Nuclear	O	O
factor	O	O
kappa	O	O
B	O	O
(	O	O
NFkappaB	O	O
)	O	O
is	O	O
a	O	O
sensor	O	O
of	O	O
oxidative	O	O
stress	O	O
and	O	O
participates	O	O
in	O	O
memory	O	O
formation	O	O
that	O	O
could	O	O
be	O	O
involved	O	O
in	O	O
drug	O	O
toxicity	B-Disease	D064420
and	O	O
addiction	O	O
mechanisms	O	O
.	O	O

Therefore	O	O
NFkappaB	O	O
activity	O	O
,	O	O
oxidative	O	O
stress	O	O
,	O	O
neuronal	O	O
nitric	B-Chemical	D009569
oxide	I-Chemical	D009569
synthase	O	O
(	O	O
nNOS	O	O
)	O	O
activity	O	O
,	O	O
spatial	O	O
learning	O	O
and	O	O
memory	O	O
as	O	O
well	O	O
as	O	O
the	O	O
effect	O	O
of	O	O
topiramate	B-Chemical	C052342
,	O	O
a	O	O
previously	O	O
proposed	O	O
therapy	O	O
for	O	O
cocaine	B-Chemical	D003042
addiction	O	O
,	O	O
were	O	O
evaluated	O	O
in	O	O
an	O	O
experimental	O	O
model	O	O
of	O	O
cocaine	B-Chemical	D003042
administration	O	O
in	O	O
rats	O	O
.	O	O

NFkappaB	O	O
activity	O	O
was	O	O
decreased	O	O
in	O	O
the	O	O
frontal	O	O
cortex	O	O
of	O	O
cocaine	B-Chemical	D003042
treated	O	O
rats	O	O
,	O	O
as	O	O
well	O	O
as	O	O
GSH	B-Chemical	D005978
concentration	O	O
and	O	O
glutathione	B-Chemical	D005978
peroxidase	O	O
activity	O	O
in	O	O
the	O	O
hippocampus	O	O
,	O	O
whereas	O	O
nNOS	O	O
activity	O	O
in	O	O
the	O	O
hippocampus	O	O
was	O	O
increased	O	O
.	O	O

Memory	O	O
retrieval	O	O
of	O	O
experiences	O	O
acquired	O	O
prior	O	O
to	O	O
cocaine	B-Chemical	D003042
administration	O	O
was	O	O
impaired	O	O
and	O	O
negatively	O	O
correlated	O	O
with	O	O
NFkappaB	O	O
activity	O	O
in	O	O
the	O	O
frontal	O	O
cortex	O	O
.	O	O

In	O	O
contrast	O	O
,	O	O
learning	O	O
of	O	O
new	O	O
tasks	O	O
was	O	O
enhanced	O	O
and	O	O
correlated	O	O
with	O	O
the	O	O
increase	O	O
of	O	O
nNOS	O	O
activity	O	O
and	O	O
the	O	O
decrease	O	O
of	O	O
glutathione	B-Chemical	D005978
peroxidase	O	O
.	O	O

These	O	O
results	O	O
provide	O	O
evidence	O	O
for	O	O
a	O	O
possible	O	O
mechanistic	O	O
role	O	O
of	O	O
oxidative	O	O
and	O	O
nitrosative	O	O
stress	O	O
and	O	O
NFkappaB	O	O
in	O	O
the	O	O
alterations	O	O
induced	O	O
by	O	O
cocaine	B-Chemical	D003042
.	O	O

Topiramate	B-Chemical	C052342
prevented	O	O
all	O	O
the	O	O
alterations	O	O
observed	O	O
,	O	O
showing	O	O
novel	O	O
neuroprotective	O	O
properties	O	O
.	O	O

Antinociceptive	O	O
and	O	O
antiamnesic	O	O
properties	O	O
of	O	O
the	O	O
presynaptic	O	O
cholinergic	O	O
amplifier	O	O
PG	B-Chemical	C087567
-	I-Chemical	C087567
9	I-Chemical	C087567
.	O	O

The	O	O
antinociceptive	O	O
effect	O	O
of	O	O
3	B-Chemical	C087567
alpha	I-Chemical	C087567
-	I-Chemical	C087567
tropyl	I-Chemical	C087567
2	I-Chemical	C087567
-	I-Chemical	C087567
(	I-Chemical	C087567
p	I-Chemical	C087567
-	I-Chemical	C087567
bromophenyl	I-Chemical	C087567
)	I-Chemical	C087567
propionate	I-Chemical	C087567
[	O	O
(	O	O
+	O	O
/	O	O
-	O	O
)	O	O
-	O	O
PG	B-Chemical	C087567
-	I-Chemical	C087567
9	I-Chemical	C087567
]	O	O
(	O	O
10	O	O
-	O	O
40	O	O
mg	O	O
kg	O	O
-	O	O
1	O	O
s	O	O
.	O	O

c	O	O
.	O	O

;	O	O
30	O	O
-	O	O
60	O	O
mg	O	O
kg	O	O
-	O	O
1	O	O
p	O	O
.	O	O

o	O	O
.	O	O

;	O	O
10	O	O
-	O	O
30	O	O
mg	O	O
kg	O	O
-	O	O
1	O	O
i	O	O
.	O	O

v	O	O
.	O	O

;	O	O
10	O	O
-	O	O
30	O	O
micrograms	O	O
/	O	O
mouse	O	O
i	O	O
.	O	O

c	O	O
.	O	O

v	O	O
.	O	O

)	O	O
was	O	O
examined	O	O
in	O	O
mice	O	O
,	O	O
rats	O	O
and	O	O
guinea	O	O
pigs	O	O
by	O	O
use	O	O
of	O	O
the	O	O
hot	O	O
-	O	O
plate	O	O
,	O	O
abdominal	O	O
-	O	O
constriction	O	O
,	O	O
tail	O	O
-	O	O
flick	O	O
and	O	O
paw	O	O
-	O	O
pressure	O	O
tests	O	O
.	O	O

(	O	O
+	O	O
/	O	O
-	O	O
)	O	O
-	O	O
PG	B-Chemical	C087567
-	I-Chemical	C087567
9	I-Chemical	C087567
antinociception	O	O
peaked	O	O
15	O	O
min	O	O
after	O	O
injection	O	O
and	O	O
then	O	O
slowly	O	O
diminished	O	O
.	O	O

The	O	O
antinociception	O	O
produced	O	O
by	O	O
(	O	O
+	O	O
/	O	O
-	O	O
)	O	O
-	O	O
PG	B-Chemical	C087567
-	I-Chemical	C087567
9	I-Chemical	C087567
was	O	O
prevented	O	O
by	O	O
the	O	O
unselective	O	O
muscarinic	O	O
antagonist	O	O
atropine	B-Chemical	D001285
,	O	O
the	O	O
M1	O	O
-	O	O
selective	O	O
antagonists	O	O
pirenzepine	B-Chemical	D010890
and	O	O
dicyclomine	B-Chemical	D004025
and	O	O
the	O	O
acetylcholine	B-Chemical	D000109
depletor	O	O
hemicholinium	B-Chemical	D006426
-	I-Chemical	D006426
3	I-Chemical	D006426
,	O	O
but	O	O
not	O	O
by	O	O
the	O	O
opioid	O	O
antagonist	O	O
naloxone	B-Chemical	D009270
,	O	O
the	O	O
gamma	B-Chemical	D005680
-	I-Chemical	D005680
aminobutyric	I-Chemical	D005680
acidB	I-Chemical	D005680
antagonist	O	O
3	B-Chemical	C066430
-	I-Chemical	C066430
aminopropyl	I-Chemical	C066430
-	I-Chemical	C066430
diethoxy	I-Chemical	C066430
-	I-Chemical	C066430
methyl	I-Chemical	C066430
-	I-Chemical	C066430
phosphinic	I-Chemical	C066430
acid	I-Chemical	C066430
,	O	O
the	O	O
H3	O	O
agonist	O	O
R	B-Chemical	C069357
-	I-Chemical	C069357
(	I-Chemical	C069357
alpha	I-Chemical	C069357
)	I-Chemical	C069357
-	I-Chemical	C069357
methylhistamine	I-Chemical	C069357
,	O	O
the	O	O
D2	O	O
antagonist	O	O
quinpirole	B-Chemical	D019257
,	O	O
the	O	O
5	B-Chemical	D012701
-	I-Chemical	D012701
hydroxytryptamine4	I-Chemical	D012701
antagonist	O	O
2	B-Chemical	C072790
-	I-Chemical	C072790
methoxy	I-Chemical	C072790
-	I-Chemical	C072790
4	I-Chemical	C072790
-	I-Chemical	C072790
amino	I-Chemical	C072790
-	I-Chemical	C072790
5	I-Chemical	C072790
-	I-Chemical	C072790
chlorobenzoic	I-Chemical	C072790
acid	I-Chemical	C072790
2	I-Chemical	C072790
-	I-Chemical	C072790
(	I-Chemical	C072790
diethylamino	I-Chemical	C072790
)	I-Chemical	C072790
ethyl	I-Chemical	C072790
ester	I-Chemical	C072790
hydrochloride	O	O
,	O	O
the	O	O
5	B-Chemical	D012701
-	I-Chemical	D012701
hydroxytryptamin1A	I-Chemical	D012701
antagonist	O	O
1	B-Chemical	C058895
-	I-Chemical	C058895
(	I-Chemical	C058895
2	I-Chemical	C058895
-	I-Chemical	C058895
methoxyphenyl	I-Chemical	C058895
)	I-Chemical	C058895
-	I-Chemical	C058895
4	I-Chemical	C058895
-	I-Chemical	C058895
[	I-Chemical	C058895
4	I-Chemical	C058895
-	I-Chemical	C058895
(	I-Chemical	C058895
2	I-Chemical	C058895
-	I-Chemical	C058895
phthalimido	I-Chemical	C058895
)	I-Chemical	C058895
butyl	I-Chemical	C058895
]	I-Chemical	C058895
piperazine	I-Chemical	C058895
hydrobromide	O	O
and	O	O
the	O	O
polyamines	O	O
depletor	O	O
reserpine	B-Chemical	D012110
.	O	O

Based	O	O
on	O	O
these	O	O
data	O	O
,	O	O
it	O	O
can	O	O
be	O	O
postulated	O	O
that	O	O
(	O	O
+	O	O
/	O	O
-	O	O
)	O	O
-	O	O
PG	B-Chemical	C087567
-	I-Chemical	C087567
9	I-Chemical	C087567
exerted	O	O
an	O	O
antinociceptive	O	O
effect	O	O
mediated	O	O
by	O	O
a	O	O
central	O	O
potentiation	O	O
of	O	O
cholinergic	O	O
transmission	O	O
.	O	O

(	O	O
+	O	O
/	O	O
-	O	O
)	O	O
-	O	O
PG	B-Chemical	C087567
-	I-Chemical	C087567
9	I-Chemical	C087567
(	O	O
10	O	O
-	O	O
40	O	O
mg	O	O
kg	O	O
-	O	O
1	O	O
i	O	O
.	O	O

p	O	O
.	O	O

)	O	O
was	O	O
able	O	O
to	O	O
prevent	O	O
amnesia	B-Disease	D000647
induced	O	O
by	O	O
scopolamine	B-Chemical	D012601
(	O	O
1	O	O
mg	O	O
kg	O	O
-	O	O
1	O	O
i	O	O
.	O	O

p	O	O
.	O	O

)	O	O
and	O	O
dicyclomine	B-Chemical	D004025
(	O	O
2	O	O
mg	O	O
kg	O	O
-	O	O
1	O	O
i	O	O
.	O	O

p	O	O
.	O	O

)	O	O
in	O	O
the	O	O
mouse	O	O
passive	O	O
-	O	O
avoidance	O	O
test	O	O
.	O	O

Affinity	O	O
profiles	O	O
of	O	O
(	O	O
+	O	O
/	O	O
-	O	O
)	O	O
-	O	O
PG	B-Chemical	C087567
-	I-Chemical	C087567
9	I-Chemical	C087567
for	O	O
muscarinic	O	O
receptor	O	O
subtypes	O	O
,	O	O
determined	O	O
by	O	O
functional	O	O
studies	O	O
(	O	O
rabbit	O	O
vas	O	O
deferens	O	O
for	O	O
M1	O	O
,	O	O
guinea	O	O
pig	O	O
atrium	O	O
for	O	O
M2	O	O
,	O	O
guinea	O	O
pig	O	O
ileum	O	O
for	O	O
M3	O	O
and	O	O
immature	O	O
guinea	O	O
pig	O	O
uterus	O	O
for	O	O
putative	O	O
M4	O	O
)	O	O
,	O	O
have	O	O
shown	O	O
an	O	O
M4	O	O
/	O	O
M1	O	O
selectivity	O	O
ratio	O	O
of	O	O
10	O	O
.	O	O

2	O	O
that	O	O
might	O	O
be	O	O
responsible	O	O
for	O	O
the	O	O
antinociception	O	O
and	O	O
the	O	O
anti	O	O
-	O	O
amnesic	B-Disease	D000647
effect	O	O
induced	O	O
by	O	O
(	O	O
+	O	O
/	O	O
-	O	O
)	O	O
-	O	O
PG	B-Chemical	C087567
-	I-Chemical	C087567
9	I-Chemical	C087567
through	O	O
an	O	O
increase	O	O
in	O	O
acetylcholine	B-Chemical	D000109
extracellular	O	O
levels	O	O
.	O	O

In	O	O
the	O	O
antinociceptive	O	O
and	O	O
antiamnesic	O	O
dose	O	O
range	O	O
,	O	O
(	O	O
+	O	O
/	O	O
-	O	O
)	O	O
-	O	O
PG	B-Chemical	C087567
-	I-Chemical	C087567
9	I-Chemical	C087567
did	O	O
not	O	O
impair	O	O
mouse	O	O
performance	O	O
evaluated	O	O
by	O	O
the	O	O
rota	O	O
-	O	O
rod	O	O
test	O	O
and	O	O
Animex	O	O
apparatus	O	O
.	O	O

Hyperbaric	O	O
oxygen	B-Chemical	D010100
therapy	O	O
for	O	O
control	O	O
of	O	O
intractable	O	O
cyclophosphamide	B-Chemical	D003520
-	O	O
induced	O	O
hemorrhagic	O	O
cystitis	O	O
.	O	O

We	O	O
report	O	O
a	O	O
case	O	O
of	O	O
intractable	O	O
hemorrhagic	O	O
cystitis	O	O
due	O	O
to	O	O
cyclophosphamide	B-Chemical	D003520
therapy	O	O
for	O	O
Wegener's	B-Disease	D014890
granulomatosis	I-Disease	D014890
.	O	O

Conservative	O	O
treatment	O	O
,	O	O
including	O	O
bladder	O	O
irrigation	O	O
with	O	O
physiological	O	O
saline	O	O
and	O	O
instillation	O	O
of	O	O
prostaglandin	B-Chemical	D015237
F2	I-Chemical	D015237
alpha	I-Chemical	D015237
,	O	O
failed	O	O
to	O	O
totally	O	O
control	O	O
hemorrhage	B-Disease	D006470
.	O	O

We	O	O
then	O	O
used	O	O
hyperbaric	O	O
oxygen	B-Chemical	D010100
at	O	O
an	O	O
absolute	O	O
pressure	O	O
of	O	O
2	O	O
atm	O	O
,	O	O
5	O	O
days	O	O
a	O	O
week	O	O
for	O	O
8	O	O
consecutive	O	O
weeks	O	O
.	O	O

The	O	O
bleeding	B-Disease	D006470
ceased	O	O
completely	O	O
by	O	O
the	O	O
end	O	O
of	O	O
treatment	O	O
and	O	O
the	O	O
patient	O	O
remained	O	O
free	O	O
of	O	O
hematuria	B-Disease	D006417
thereafter	O	O
.	O	O

No	O	O
side	O	O
effect	O	O
was	O	O
noted	O	O
during	O	O
the	O	O
course	O	O
of	O	O
therapy	O	O
.	O	O

In	O	O
future	O	O
,	O	O
this	O	O
form	O	O
of	O	O
therapy	O	O
can	O	O
offer	O	O
a	O	O
safe	O	O
alternative	O	O
in	O	O
the	O	O
treatment	O	O
of	O	O
cyclophosphamide	B-Chemical	D003520
-	O	O
induced	O	O
hemorrhagic	O	O
cystitis	O	O
.	O	O

Further	O	O
studies	O	O
on	O	O
effects	O	O
of	O	O
irrigation	O	O
solutions	O	O
on	O	O
rat	O	O
bladders	O	O
.	O	O

Further	O	O
studies	O	O
on	O	O
the	O	O
effects	O	O
of	O	O
certain	O	O
irrigating	O	O
fluids	O	O
on	O	O
the	O	O
rat	O	O
bladder	O	O
for	O	O
18	O	O
hours	O	O
are	O	O
reported	O	O
.	O	O

The	O	O
results	O	O
have	O	O
shown	O	O
that	O	O
the	O	O
degradation	O	O
product	O	O
p	B-Chemical	C004658
-	I-Chemical	C004658
choloroaniline	I-Chemical	C004658
is	O	O
not	O	O
a	O	O
significant	O	O
factor	O	O
in	O	O
chlorhexidine	B-Chemical	C010882
-	I-Chemical	C010882
digluconate	I-Chemical	C010882
associated	O	O
erosive	O	O
cystitis	B-Disease	D003556
.	O	O

A	O	O
high	O	O
percentage	O	O
of	O	O
kanamycin	B-Chemical	D007612
-	O	O
colistin	B-Chemical	D003091
and	O	O
povidone	B-Chemical	D011206
-	I-Chemical	D011206
iodine	I-Chemical	D011206
irrigations	O	O
were	O	O
associated	O	O
with	O	O
erosive	O	O
cystitis	B-Disease	D003556
and	O	O
suggested	O	O
a	O	O
possible	O	O
complication	O	O
with	O	O
human	O	O
usage	O	O
.	O	O

Picloxydine	B-Chemical	C005253
irrigations	O	O
appeared	O	O
to	O	O
have	O	O
a	O	O
lower	O	O
incidence	O	O
of	O	O
erosive	O	O
cystitis	B-Disease	D003556
but	O	O
further	O	O
studies	O	O
would	O	O
have	O	O
to	O	O
be	O	O
performed	O	O
before	O	O
it	O	O
could	O	O
be	O	O
recommended	O	O
for	O	O
use	O	O
in	O	O
urological	O	O
procedures	O	O
.	O	O

Clinical	O	O
experiences	O	O
in	O	O
an	O	O
open	O	O
and	O	O
a	O	O
double	O	O
-	O	O
blind	O	O
trial	O	O
.	O	O

A	O	O
total	O	O
of	O	O
sixty	O	O
patients	O	O
were	O	O
trated	O	O
with	O	O
bromperidol	B-Chemical	C006820
first	O	O
in	O	O
open	O	O
conditions	O	O
(	O	O
20	O	O
patients	O	O
)	O	O
,	O	O
then	O	O
on	O	O
a	O	O
double	O	O
blind	O	O
basis	O	O
(	O	O
40	O	O
patients	O	O
)	O	O
with	O	O
haloperidol	B-Chemical	D006220
as	O	O
the	O	O
reference	O	O
substance	O	O
.	O	O

The	O	O
open	O	O
study	O	O
lasted	O	O
for	O	O
four	O	O
weeks	O	O
;	O	O
the	O	O
drug	O	O
was	O	O
administrated	O	O
in	O	O
the	O	O
form	O	O
of	O	O
1	O	O
mg	O	O
tablets	O	O
.	O	O

The	O	O
daily	O	O
dose	O	O
(	O	O
initial	O	O
dose	O	O
:	O	O
1	O	O
mg	O	O
;	O	O
mean	O	O
dose	O	O
at	O	O
the	O	O
end	O	O
of	O	O
the	O	O
trial	O	O
:	O	O
4	O	O
.	O	O

47	O	O
mg	O	O
)	O	O
was	O	O
always	O	O
administered	O	O
in	O	O
one	O	O
single	O	O
dose	O	O
.	O	O

Nineteen	O	O
patients	O	O
finished	O	O
the	O	O
trial	O	O
,	O	O
and	O	O
in	O	O
18	O	O
cases	O	O
the	O	O
therapeutic	O	O
result	O	O
was	O	O
considered	O	O
very	O	O
good	O	O
to	O	O
good	O	O
.	O	O

These	O	O
results	O	O
were	O	O
confirmed	O	O
by	O	O
statistical	O	O
analysis	O	O
.	O	O

Nine	O	O
patients	O	O
exhibited	O	O
mild	O	O
to	O	O
moderate	O	O
extrapyramidal	B-Disease	D001480
concomitant	I-Disease	D001480
symptoms	I-Disease	D001480
;	O	O
no	O	O
other	O	O
side	O	O
effects	O	O
were	O	O
observed	O	O
.	O	O

The	O	O
results	O	O
of	O	O
detailed	O	O
laboratory	O	O
tests	O	O
and	O	O
evaluations	O	O
of	O	O
various	O	O
quantitative	O	O
and	O	O
qualitative	O	O
tolerability	O	O
parameters	O	O
were	O	O
not	O	O
indicative	O	O
of	O	O
toxic	O	O
effects	O	O
.	O	O

In	O	O
the	O	O
double	O	O
blind	O	O
study	O	O
with	O	O
haloperidol	B-Chemical	D006220
,	O	O
both	O	O
substances	O	O
were	O	O
found	O	O
to	O	O
be	O	O
highly	O	O
effective	O	O
in	O	O
the	O	O
treatment	O	O
of	O	O
psychotic	B-Disease	D019967
syndromes	I-Disease	D019967
belonging	I-Disease	D019967
predominantly	I-Disease	D019967
to	I-Disease	D019967
the	I-Disease	D019967
schizophrenia	I-Disease	D019967
group	I-Disease	D019967
.	O	O

Certain	O	O
clues	O	O
,	O	O
including	O	O
the	O	O
onset	O	O
of	O	O
action	O	O
,	O	O
seem	O	O
to	O	O
be	O	O
indicative	O	O
of	O	O
the	O	O
superiority	O	O
of	O	O
bromperidol	B-Chemical	C006820
.	O	O

No	O	O
differences	O	O
were	O	O
observed	O	O
with	O	O
respect	O	O
to	O	O
side	O	O
effects	O	O
and	O	O
general	O	O
tolerability	O	O
.	O	O

Curcumin	B-Chemical	D003474
ameliorates	O	O
cognitive	B-Disease	D003072
dysfunction	I-Disease	D003072
and	O	O
oxidative	O	O
damage	O	O
in	O	O
phenobarbitone	B-Chemical	D010634
and	O	O
carbamazepine	B-Chemical	D002220
administered	O	O
rats	O	O
.	O	O

The	O	O
antiepileptic	O	O
drugs	O	O
,	O	O
phenobarbitone	B-Chemical	D010634
and	O	O
carbamazepine	B-Chemical	D002220
are	O	O
well	O	O
known	O	O
to	O	O
cause	O	O
cognitive	B-Disease	D003072
impairment	I-Disease	D003072
on	O	O
chronic	O	O
use	O	O
.	O	O

The	O	O
increase	O	O
in	O	O
free	O	O
radical	O	O
generation	O	O
has	O	O
been	O	O
implicated	O	O
as	O	O
one	O	O
of	O	O
the	O	O
important	O	O
mechanisms	O	O
of	O	O
cognitive	B-Disease	D003072
impairment	I-Disease	D003072
by	O	O
antiepileptic	O	O
drugs	O	O
.	O	O

Curcumin	B-Chemical	D003474
has	O	O
shown	O	O
antioxidant	O	O
,	O	O
anti	O	O
-	O	O
inflammatory	O	O
and	O	O
neuro	O	O
-	O	O
protective	O	O
properties	O	O
.	O	O

Therefore	O	O
,	O	O
the	O	O
present	O	O
study	O	O
was	O	O
carried	O	O
out	O	O
to	O	O
investigate	O	O
the	O	O
effect	O	O
of	O	O
chronic	O	O
curcumin	B-Chemical	D003474
administration	O	O
on	O	O
phenobarbitone	B-Chemical	D010634
-	O	O
and	O	O
carbamazepine	B-Chemical	D002220
-	O	O
induced	O	O
cognitive	B-Disease	D003072
impairment	I-Disease	D003072
and	O	O
oxidative	O	O
stress	O	O
in	O	O
rats	O	O
.	O	O

Pharmacokinetic	O	O
interactions	O	O
of	O	O
curcumin	B-Chemical	D003474
with	O	O
phenobarbitone	B-Chemical	D010634
and	O	O
carbamazepine	B-Chemical	D002220
were	O	O
also	O	O
studied	O	O
.	O	O

Vehicle	O	O
/	O	O
drugs	O	O
were	O	O
administered	O	O
daily	O	O
for	O	O
21days	O	O
to	O	O
male	O	O
Wistar	O	O
rats	O	O
.	O	O

Passive	O	O
avoidance	O	O
paradigm	O	O
and	O	O
elevated	O	O
plus	O	O
maze	O	O
test	O	O
were	O	O
used	O	O
to	O	O
assess	O	O
cognitive	O	O
function	O	O
.	O	O

At	O	O
the	O	O
end	O	O
of	O	O
study	O	O
period	O	O
,	O	O
serum	O	O
phenobarbitone	B-Chemical	D010634
and	O	O
carbamazepine	B-Chemical	D002220
,	O	O
whole	O	O
brain	O	O
malondialdehyde	B-Chemical	D008315
and	O	O
reduced	O	O
glutathione	B-Chemical	D005978
levels	O	O
were	O	O
estimated	O	O
.	O	O

The	O	O
administration	O	O
of	O	O
phenobarbitone	B-Chemical	D010634
and	O	O
carbamazepine	B-Chemical	D002220
for	O	O
21days	O	O
caused	O	O
a	O	O
significant	O	O
impairment	B-Disease	D003072
of	I-Disease	D003072
learning	I-Disease	D003072
and	I-Disease	D003072
memory	I-Disease	D003072
as	O	O
well	O	O
as	O	O
an	O	O
increased	O	O
oxidative	O	O
stress	O	O
.	O	O

Concomitant	O	O
curcumin	B-Chemical	D003474
administration	O	O
prevented	O	O
the	O	O
cognitive	B-Disease	D003072
impairment	I-Disease	D003072
and	O	O
decreased	O	O
the	O	O
increased	O	O
oxidative	O	O
stress	O	O
induced	O	O
by	O	O
these	O	O
antiepileptic	O	O
drugs	O	O
.	O	O

Curcumin	B-Chemical	D003474
co	O	O
-	O	O
administration	O	O
did	O	O
not	O	O
cause	O	O
any	O	O
significant	O	O
alteration	O	O
in	O	O
the	O	O
serum	O	O
concentrations	O	O
of	O	O
both	O	O
phenobarbitone	B-Chemical	D010634
as	O	O
well	O	O
as	O	O
carbamazepine	B-Chemical	D002220
.	O	O

These	O	O
results	O	O
show	O	O
that	O	O
curcumin	B-Chemical	D003474
has	O	O
beneficial	O	O
effect	O	O
in	O	O
mitigating	O	O
the	O	O
deterioration	B-Disease	D003072
of	I-Disease	D003072
cognitive	I-Disease	D003072
functions	I-Disease	D003072
and	O	O
oxidative	O	O
damage	O	O
in	O	O
rats	O	O
treated	O	O
with	O	O
phenobarbitone	B-Chemical	D010634
and	O	O
carbamazepine	B-Chemical	D002220
without	O	O
significantly	O	O
altering	O	O
their	O	O
serum	O	O
concentrations	O	O
.	O	O

The	O	O
findings	O	O
suggest	O	O
that	O	O
curcumin	B-Chemical	D003474
can	O	O
be	O	O
considered	O	O
as	O	O
a	O	O
potential	O	O
safe	O	O
and	O	O
effective	O	O
adjuvant	O	O
to	O	O
phenobarbitone	B-Chemical	D010634
and	O	O
carbamazepine	B-Chemical	D002220
therapy	O	O
in	O	O
preventing	O	O
cognitive	B-Disease	D003072
impairment	I-Disease	D003072
associated	O	O
with	O	O
these	O	O
drugs	O	O
.	O	O

Pyrrolidine	B-Chemical	C020972
dithiocarbamate	I-Chemical	C020972
protects	O	O
the	O	O
piriform	O	O
cortex	O	O
in	O	O
the	O	O
pilocarpine	B-Chemical	D010862
status	B-Disease	D013226
epilepticus	I-Disease	D013226
model	O	O
.	O	O

Pyrrolidine	B-Chemical	C020972
dithiocarbamate	I-Chemical	C020972
(	O	O
PDTC	B-Chemical	C020972
)	O	O
has	O	O
a	O	O
dual	O	O
mechanism	O	O
of	O	O
action	O	O
as	O	O
an	O	O
antioxidant	O	O
and	O	O
an	O	O
inhibitor	O	O
of	O	O
the	O	O
transcription	O	O
factor	O	O
kappa	O	O
-	O	O
beta	O	O
.	O	O

Both	O	O
,	O	O
production	O	O
of	O	O
reactive	O	O
oxygen	B-Chemical	D010100
species	O	O
as	O	O
well	O	O
as	O	O
activation	O	O
of	O	O
NF	O	O
-	O	O
kappaB	O	O
have	O	O
been	O	O
implicated	O	O
in	O	O
severe	O	O
neuronal	B-Disease	D009410
damage	I-Disease	D009410
in	O	O
different	O	O
sub	O	O
-	O	O
regions	O	O
of	O	O
the	O	O
hippocampus	O	O
as	O	O
well	O	O
as	O	O
in	O	O
the	O	O
surrounding	O	O
cortices	O	O
.	O	O

The	O	O
effect	O	O
of	O	O
PDTC	B-Chemical	C020972
on	O	O
status	B-Disease	D013226
epilepticus	I-Disease	D013226
-	O	O
associated	O	O
cell	O	O
loss	O	O
in	O	O
the	O	O
hippocampus	O	O
and	O	O
piriform	O	O
cortex	O	O
was	O	O
evaluated	O	O
in	O	O
the	O	O
rat	O	O
fractionated	O	O
pilocarpine	B-Chemical	D010862
model	O	O
.	O	O

Treatment	O	O
with	O	O
150	O	O
mg	O	O
/	O	O
kg	O	O
PDTC	B-Chemical	C020972
before	O	O
and	O	O
following	O	O
status	B-Disease	D013226
epilepticus	I-Disease	D013226
significantly	O	O
increased	O	O
the	O	O
mortality	O	O
rate	O	O
to	O	O
100%	O	O
.	O	O

Administration	O	O
of	O	O
50	O	O
mg	O	O
/	O	O
kg	O	O
PDTC	B-Chemical	C020972
(	O	O
low	O	O
-	O	O
dose	O	O
)	O	O
did	O	O
not	O	O
exert	O	O
major	O	O
effects	O	O
on	O	O
the	O	O
development	O	O
of	O	O
a	O	O
status	B-Disease	D013226
epilepticus	I-Disease	D013226
or	O	O
the	O	O
mortality	O	O
rate	O	O
.	O	O

In	O	O
vehicle	O	O
-	O	O
treated	O	O
rats	O	O
,	O	O
status	B-Disease	D013226
epilepticus	I-Disease	D013226
caused	O	O
pronounced	O	O
neuronal	B-Disease	D009410
damage	I-Disease	D009410
in	O	O
the	O	O
piriform	O	O
cortex	O	O
comprising	O	O
both	O	O
pyramidal	O	O
cells	O	O
and	O	O
interneurons	O	O
.	O	O

Low	O	O
-	O	O
dose	O	O
PDTC	B-Chemical	C020972
treatment	O	O
almost	O	O
completely	O	O
protected	O	O
from	O	O
lesions	O	O
in	O	O
the	O	O
piriform	O	O
cortex	O	O
.	O	O

A	O	O
significant	O	O
decrease	O	O
in	O	O
neuronal	O	O
density	O	O
of	O	O
the	O	O
hippocampal	O	O
hilar	O	O
formation	O	O
was	O	O
identified	O	O
in	O	O
vehicle	O	O
-	O	O
and	O	O
PDTC	B-Chemical	C020972
-	O	O
treated	O	O
rats	O	O
following	O	O
status	B-Disease	D013226
epilepticus	I-Disease	D013226
.	O	O

In	O	O
conclusion	O	O
,	O	O
the	O	O
NF	O	O
-	O	O
kappaB	O	O
inhibitor	O	O
and	O	O
antioxidant	O	O
PDTC	B-Chemical	C020972
protected	O	O
the	O	O
piriform	O	O
cortex	O	O
,	O	O
whereas	O	O
it	O	O
did	O	O
not	O	O
affect	O	O
hilar	O	O
neuronal	B-Disease	D009410
loss	I-Disease	D009410
.	O	O

These	O	O
data	O	O
might	O	O
indicate	O	O
that	O	O
the	O	O
generation	O	O
of	O	O
reactive	O	O
oxygen	B-Chemical	D010100
species	O	O
and	O	O
activation	O	O
of	O	O
NF	O	O
-	O	O
kappaB	O	O
plays	O	O
a	O	O
more	O	O
central	O	O
role	O	O
in	O	O
seizure	B-Disease	D012640
-	O	O
associated	O	O
neuronal	B-Disease	D009410
damage	I-Disease	D009410
in	O	O
the	O	O
temporal	O	O
cortex	O	O
as	O	O
compared	O	O
to	O	O
the	O	O
hippocampal	O	O
hilus	O	O
.	O	O

However	O	O
,	O	O
future	O	O
investigations	O	O
are	O	O
necessary	O	O
to	O	O
exactly	O	O
analyze	O	O
the	O	O
biochemical	O	O
mechanisms	O	O
by	O	O
which	O	O
PDTC	B-Chemical	C020972
exerted	O	O
its	O	O
beneficial	O	O
effects	O	O
in	O	O
the	O	O
piriform	O	O
cortex	O	O
.	O	O

Safety	O	O
profile	O	O
of	O	O
a	O	O
nicotine	B-Chemical	D009538
lozenge	O	O
compared	O	O
with	O	O
that	O	O
of	O	O
nicotine	B-Chemical	D009538
gum	O	O
in	O	O
adult	O	O
smokers	O	O
with	O	O
underlying	O	O
medical	O	O
conditions	O	O
:	O	O
a	O	O
12	O	O
-	O	O
week	O	O
,	O	O
randomized	O	O
,	O	O
open	O	O
-	O	O
label	O	O
study	O	O
.	O	O

BACKGROUND	O	O
:	O	O
Nicotine	B-Chemical	D009538
polacrilex	O	O
lozenges	O	O
deliver	O	O
25%	O	O
to	O	O
27%	O	O
more	O	O
nicotine	B-Chemical	D009538
compared	O	O
with	O	O
equivalent	O	O
doses	O	O
of	O	O
nicotine	B-Chemical	D009538
polacrilex	O	O
gum	O	O
.	O	O

The	O	O
increased	O	O
nicotine	B-Chemical	D009538
exposure	O	O
from	O	O
the	O	O
lozenge	O	O
has	O	O
raised	O	O
questions	O	O
about	O	O
the	O	O
relative	O	O
safety	O	O
of	O	O
the	O	O
lozenge	O	O
and	O	O
gum	O	O
.	O	O

OBJECTIVE	O	O
:	O	O
The	O	O
objective	O	O
of	O	O
this	O	O
study	O	O
was	O	O
to	O	O
compare	O	O
the	O	O
safety	O	O
profiles	O	O
of	O	O
the	O	O
4	O	O
-	O	O
mg	O	O
nicotine	B-Chemical	D009538
lozenge	O	O
and	O	O
4	O	O
-	O	O
mg	O	O
nicotine	B-Chemical	D009538
gum	O	O
in	O	O
smokers	O	O
with	O	O
selected	O	O
label	O	O
-	O	O
restricted	O	O
diseases	O	O
.	O	O

METHODS	O	O
:	O	O
This	O	O
was	O	O
a	O	O
multicenter	O	O
,	O	O
randomized	O	O
,	O	O
open	O	O
-	O	O
label	O	O
study	O	O
in	O	O
adult	O	O
smokers	O	O
with	O	O
heart	B-Disease	D006331
disease	I-Disease	D006331
,	O	O
hypertension	B-Disease	D006973
not	O	O
controlled	O	O
by	O	O
medication	O	O
,	O	O
and	O	O
/	O	O
or	O	O
diabetes	B-Disease	D003920
mellitus	I-Disease	D003920
.	O	O

Patients	O	O
were	O	O
randomized	O	O
in	O	O
a	O	O
1	O	O
:	O	O
1	O	O
ratio	O	O
to	O	O
receive	O	O
the	O	O
4	O	O
-	O	O
mg	O	O
nicotine	B-Chemical	D009538
lozenge	O	O
or	O	O
4	O	O
-	O	O
mg	O	O
nicotine	B-Chemical	D009538
gum	O	O
.	O	O

Safety	O	O
assessments	O	O
were	O	O
made	O	O
at	O	O
baseline	O	O
and	O	O
at	O	O
2	O	O
,	O	O
4	O	O
,	O	O
6	O	O
,	O	O
and	O	O
12	O	O
weeks	O	O
after	O	O
the	O	O
start	O	O
of	O	O
product	O	O
use	O	O
.	O	O

RESULTS	O	O
:	O	O
Nine	O	O
hundred	O	O
one	O	O
patients	O	O
were	O	O
randomized	O	O
to	O	O
treatment	O	O
,	O	O
447	O	O
who	O	O
received	O	O
the	O	O
lozenge	O	O
and	O	O
454	O	O
who	O	O
received	O	O
the	O	O
gum	O	O
(	O	O
safety	O	O
population	O	O
)	O	O
.	O	O

The	O	O
majority	O	O
were	O	O
women	O	O
(	O	O
52	O	O
.	O	O

7%	O	O
)	O	O
.	O	O

Patients'	O	O
mean	O	O
age	O	O
was	O	O
53	O	O
.	O	O

9	O	O
years	O	O
,	O	O
their	O	O
mean	O	O
weight	O	O
was	O	O
193	O	O
.	O	O

9	O	O
pounds	O	O
,	O	O
and	O	O
they	O	O
smoked	O	O
a	O	O
mean	O	O
of	O	O
25	O	O
.	O	O

2	O	O
cigarettes	O	O
per	O	O
day	O	O
at	O	O
baseline	O	O
.	O	O

Five	O	O
hundred	O	O
fifty	O	O
-	O	O
three	O	O
patients	O	O
,	O	O
264	O	O
taking	O	O
the	O	O
lozenge	O	O
and	O	O
289	O	O
taking	O	O
the	O	O
gum	O	O
,	O	O
used	O	O
the	O	O
study	O	O
product	O	O
for	O	O
>	O	O
or	O	O
=4	O	O
days	O	O
per	O	O
week	O	O
during	O	O
the	O	O
first	O	O
2	O	O
weeks	O	O
(	O	O
evaluable	O	O
population	O	O
)	O	O
.	O	O

The	O	O
nicotine	B-Chemical	D009538
lozenge	O	O
and	O	O
nicotine	B-Chemical	D009538
gum	O	O
were	O	O
equally	O	O
well	O	O
tolerated	O	O
,	O	O
despite	O	O
increased	O	O
nicotine	B-Chemical	D009538
exposure	O	O
from	O	O
the	O	O
lozenge	O	O
.	O	O

The	O	O
incidence	O	O
of	O	O
adverse	O	O
events	O	O
in	O	O
the	O	O
2	O	O
groups	O	O
was	O	O
similar	O	O
during	O	O
the	O	O
first	O	O
2	O	O
weeks	O	O
of	O	O
product	O	O
use	O	O
(	O	O
evaluation	O	O
population	O	O
:	O	O
55	O	O
.	O	O

3%	O	O
lozenge	O	O
,	O	O
54	O	O
.	O	O

7%	O	O
gum	O	O
)	O	O
,	O	O
as	O	O
well	O	O
as	O	O
during	O	O
the	O	O
entire	O	O
study	O	O
(	O	O
safety	O	O
population	O	O
:	O	O
63	O	O
.	O	O

8%	O	O
and	O	O
58	O	O
.	O	O

6%	O	O
,	O	O
respectively	O	O
)	O	O
.	O	O

Stratification	O	O
of	O	O
patients	O	O
by	O	O
sex	O	O
,	O	O
age	O	O
,	O	O
extent	O	O
of	O	O
concurrent	O	O
smoking	O	O
,	O	O
extent	O	O
of	O	O
product	O	O
use	O	O
,	O	O
and	O	O
severity	O	O
of	O	O
adverse	O	O
events	O	O
revealed	O	O
no	O	O
clinically	O	O
significant	O	O
differences	O	O
between	O	O
the	O	O
lozenge	O	O
and	O	O
gum	O	O
.	O	O

The	O	O
most	O	O
common	O	O
adverse	O	O
events	O	O
were	O	O
nausea	B-Disease	D009325
(	O	O
17	O	O
.	O	O

2%	O	O
and	O	O
16	O	O
.	O	O

1%	O	O
;	O	O
95%	O	O
CI	O	O
,	O	O
-	O	O
3	O	O
.	O	O

7	O	O
to	O	O
6	O	O
.	O	O

0	O	O
)	O	O
,	O	O
hiccups	B-Disease	D006606
(	O	O
10	O	O
.	O	O

7%	O	O
and	O	O
6	O	O
.	O	O

6%	O	O
;	O	O
95%	O	O
CI	O	O
,	O	O
0	O	O
.	O	O

5	O	O
to	O	O
7	O	O
.	O	O

8	O	O
)	O	O
,	O	O
and	O	O
headache	B-Disease	D006261
(	O	O
8	O	O
.	O	O

7%	O	O
and	O	O
9	O	O
.	O	O

9%	O	O
;	O	O
95%	O	O
Cl	O	O
,	O	O
-	O	O
5	O	O
.	O	O

0	O	O
to	O	O
2	O	O
.	O	O

6	O	O
)	O	O
.	O	O

Serious	O	O
adverse	O	O
events	O	O
were	O	O
reported	O	O
in	O	O
11	O	O
and	O	O
13	O	O
patients	O	O
in	O	O
the	O	O
respective	O	O
groups	O	O
.	O	O

Fewer	O	O
than	O	O
6%	O	O
of	O	O
patients	O	O
in	O	O
either	O	O
group	O	O
were	O	O
considered	O	O
by	O	O
the	O	O
investigator	O	O
to	O	O
have	O	O
a	O	O
worsening	O	O
of	O	O
their	O	O
overall	O	O
disease	O	O
condition	O	O
during	O	O
the	O	O
study	O	O
.	O	O

The	O	O
majority	O	O
of	O	O
patients	O	O
(	O	O
>60%	O	O
)	O	O
experienced	O	O
no	O	O
change	O	O
in	O	O
their	O	O
disease	O	O
status	O	O
from	O	O
baseline	O	O
.	O	O

CONCLUSION	O	O
:	O	O
The	O	O
4	O	O
-	O	O
mg	O	O
nicotine	B-Chemical	D009538
lozenge	O	O
and	O	O
4	O	O
-	O	O
mg	O	O
nicotine	B-Chemical	D009538
gum	O	O
had	O	O
comparable	O	O
safety	O	O
profiles	O	O
in	O	O
these	O	O
patients	O	O
with	O	O
label	O	O
-	O	O
restricted	O	O
medical	O	O
conditions	O	O
.	O	O

Development	O	O
of	O	O
levodopa	B-Chemical	D007980
-	O	O
induced	O	O
dyskinesias	B-Disease	D004409
in	O	O
parkinsonian	B-Disease	D010300
monkeys	O	O
may	O	O
depend	O	O
upon	O	O
rate	O	O
of	O	O
symptom	O	O
onset	O	O
and	O	O
/	O	O
or	O	O
duration	O	O
of	O	O
symptoms	O	O
.	O	O

Levodopa	B-Chemical	D007980
-	O	O
induced	O	O
dyskinesias	B-Disease	D004409
(	O	O
LIDs	B-Disease	D004409
)	O	O
present	O	O
a	O	O
major	O	O
problem	O	O
for	O	O
the	O	O
long	O	O
-	O	O
term	O	O
management	O	O
of	O	O
Parkinson's	B-Disease	D010300
disease	I-Disease	D010300
(	O	O
PD	B-Disease	D010300
)	O	O
patients	O	O
.	O	O

Due	O	O
to	O	O
the	O	O
interdependence	O	O
of	O	O
risk	O	O
factors	O	O
in	O	O
clinical	O	O
populations	O	O
,	O	O
it	O	O
is	O	O
difficult	O	O
to	O	O
independently	O	O
examine	O	O
factors	O	O
that	O	O
may	O	O
influence	O	O
the	O	O
development	O	O
of	O	O
LIDs	B-Disease	D004409
.	O	O

Using	O	O
macaque	O	O
monkeys	O	O
with	O	O
different	O	O
types	O	O
of	O	O
MPTP	B-Chemical	D015632
-	O	O
induced	O	O
parkinsonism	B-Disease	D010302
,	O	O
the	O	O
current	O	O
study	O	O
evaluated	O	O
the	O	O
degree	O	O
to	O	O
which	O	O
rate	O	O
of	O	O
symptom	O	O
progression	O	O
,	O	O
symptom	O	O
severity	O	O
,	O	O
and	O	O
response	O	O
to	O	O
and	O	O
duration	O	O
of	O	O
levodopa	B-Chemical	D007980
therapy	O	O
may	O	O
be	O	O
involved	O	O
in	O	O
the	O	O
development	O	O
of	O	O
LIDs	B-Disease	D004409
.	O	O

Monkeys	O	O
with	O	O
acute	O	O
(	O	O
short	O	O
-	O	O
term	O	O
)	O	O
MPTP	B-Chemical	D015632
exposure	O	O
,	O	O
rapid	O	O
symptom	O	O
onset	O	O
and	O	O
short	O	O
symptom	O	O
duration	O	O
prior	O	O
to	O	O
initiation	O	O
of	O	O
levodopa	B-Chemical	D007980
therapy	O	O
developed	O	O
dyskinesia	B-Disease	D004409
between	O	O
11	O	O
and	O	O
24	O	O
days	O	O
of	O	O
daily	O	O
levodopa	B-Chemical	D007980
administration	O	O
.	O	O

In	O	O
contrast	O	O
,	O	O
monkeys	O	O
with	O	O
long	O	O
-	O	O
term	O	O
MPTP	B-Chemical	D015632
exposure	O	O
,	O	O
slow	O	O
symptom	O	O
progression	O	O
and	O	O
/	O	O
or	O	O
long	O	O
symptom	O	O
duration	O	O
prior	O	O
to	O	O
initiation	O	O
of	O	O
levodopa	B-Chemical	D007980
therapy	O	O
were	O	O
more	O	O
resistant	O	O
to	O	O
developing	O	O
LIDs	B-Disease	D004409
(	O	O
e	O	O
.	O	O

g	O	O
.	O	O

,	O	O
dyskinesia	B-Disease	D004409
developed	O	O
no	O	O
sooner	O	O
than	O	O
146	O	O
days	O	O
of	O	O
chronic	O	O
levodopa	B-Chemical	D007980
administration	O	O
)	O	O
.	O	O

All	O	O
animals	O	O
were	O	O
similarly	O	O
symptomatic	O	O
at	O	O
the	O	O
start	O	O
of	O	O
levodopa	B-Chemical	D007980
treatment	O	O
and	O	O
had	O	O
similar	O	O
therapeutic	O	O
responses	O	O
to	O	O
the	O	O
drug	O	O
.	O	O

These	O	O
data	O	O
suggest	O	O
distinct	O	O
differences	O	O
in	O	O
the	O	O
propensity	O	O
to	O	O
develop	O	O
LIDs	B-Disease	D004409
in	O	O
monkeys	O	O
with	O	O
different	O	O
rates	O	O
of	O	O
symptom	O	O
progression	O	O
or	O	O
symptom	O	O
durations	O	O
prior	O	O
to	O	O
levodopa	B-Chemical	D007980
and	O	O
demonstrate	O	O
the	O	O
value	O	O
of	O	O
these	O	O
models	O	O
for	O	O
further	O	O
studying	O	O
the	O	O
pathophysiology	O	O
of	O	O
LIDs	B-Disease	D004409
.	O	O

Propylthiouracil	B-Chemical	D011441
-	O	O
induced	O	O
perinuclear	O	O
-	O	O
staining	O	O
antineutrophil	O	O
cytoplasmic	O	O
autoantibody	O	O
-	O	O
positive	O	O
vasculitis	B-Disease	D014657
in	O	O
conjunction	O	O
with	O	O
pericarditis	B-Disease	D010493
.	O	O

OBJECTIVE	O	O
:	O	O
To	O	O
describe	O	O
a	O	O
case	O	O
of	O	O
propylthiouracil	B-Chemical	D011441
-	O	O
induced	O	O
vasculitis	B-Disease	D014657
manifesting	O	O
with	O	O
pericarditis	B-Disease	D010493
.	O	O

METHODS	O	O
:	O	O
We	O	O
present	O	O
the	O	O
first	O	O
case	O	O
report	O	O
of	O	O
a	O	O
woman	O	O
with	O	O
hyperthyroidism	B-Disease	D006980
treated	O	O
with	O	O
propylthiouracil	B-Chemical	D011441
in	O	O
whom	O	O
a	O	O
syndrome	O	O
of	O	O
pericarditis	B-Disease	D010493
,	O	O
fever	B-Disease	D005334
,	O	O
and	O	O
glomerulonephritis	B-Disease	D005921
developed	O	O
.	O	O

Serologic	O	O
testing	O	O
and	O	O
immunologic	O	O
studies	O	O
were	O	O
done	O	O
,	O	O
and	O	O
a	O	O
pericardial	O	O
biopsy	O	O
was	O	O
performed	O	O
.	O	O

RESULTS	O	O
:	O	O
A	O	O
25	O	O
-	O	O
year	O	O
-	O	O
old	O	O
woman	O	O
with	O	O
Graves'	B-Disease	D006111
disease	I-Disease	D006111
had	O	O
a	O	O
febrile	B-Disease	D005334
illness	I-Disease	D005334
and	O	O
evidence	O	O
of	O	O
pericarditis	B-Disease	D010493
,	O	O
which	O	O
was	O	O
confirmed	O	O
by	O	O
biopsy	O	O
.	O	O

Serologic	O	O
evaluation	O	O
revealed	O	O
the	O	O
presence	O	O
of	O	O
perinuclear	O	O
-	O	O
staining	O	O
antineutrophil	O	O
cytoplasmic	O	O
autoantibodies	O	O
(	O	O
pANCA	O	O
)	O	O
against	O	O
myeloperoxidase	O	O
(	O	O
MPO	O	O
)	O	O
.	O	O

Propylthiouracil	B-Chemical	D011441
therapy	O	O
was	O	O
withdrawn	O	O
,	O	O
and	O	O
she	O	O
was	O	O
treated	O	O
with	O	O
a	O	O
1	O	O
-	O	O
month	O	O
course	O	O
of	O	O
prednisone	B-Chemical	D011241
,	O	O
which	O	O
alleviated	O	O
her	O	O
symptoms	O	O
.	O	O

A	O	O
literature	O	O
review	O	O
revealed	O	O
no	O	O
prior	O	O
reports	O	O
of	O	O
pericarditis	B-Disease	D010493
in	O	O
anti	O	O
-	O	O
MPO	O	O
pANCA	O	O
-	O	O
positive	O	O
vasculitis	B-Disease	D014657
associated	O	O
with	O	O
propylthio	B-Chemical	D011441
-	I-Chemical	D011441
uracil	I-Chemical	D011441
therapy	O	O
.	O	O

CONCLUSION	O	O
:	O	O
Pericarditis	B-Disease	D010493
may	O	O
be	O	O
the	O	O
initial	O	O
manifestation	O	O
of	O	O
drug	O	O
-	O	O
induced	O	O
vasculitis	B-Disease	D014657
attributable	O	O
to	O	O
propylthio	B-Chemical	D011441
-	I-Chemical	D011441
uracil	I-Chemical	D011441
therapy	O	O
.	O	O

Two	O	O
mouse	O	O
lines	O	O
selected	O	O
for	O	O
differential	O	O
sensitivities	O	O
to	O	O
beta	B-Chemical	C036150
-	I-Chemical	C036150
carboline	I-Chemical	C036150
-	O	O
induced	O	O
seizures	B-Disease	D012640
are	O	O
also	O	O
differentially	O	O
sensitive	O	O
to	O	O
various	O	O
pharmacological	O	O
effects	O	O
of	O	O
other	O	O
GABA	B-Chemical	D005680
(	O	O
A	O	O
)	O	O
receptor	O	O
ligands	O	O
.	O	O

Two	O	O
mouse	O	O
lines	O	O
were	O	O
selectively	O	O
bred	O	O
according	O	O
to	O	O
their	O	O
sensitivity	O	O
(	O	O
BS	O	O
line	O	O
)	O	O
or	O	O
resistance	O	O
(	O	O
BR	O	O
line	O	O
)	O	O
to	O	O
seizures	B-Disease	D012640
induced	O	O
by	O	O
a	O	O
single	O	O
i	O	O
.	O	O

p	O	O
.	O	O

injection	O	O
of	O	O
methyl	B-Chemical	C036150
beta	I-Chemical	C036150
-	I-Chemical	C036150
carboline	I-Chemical	C036150
-	I-Chemical	C036150
3	I-Chemical	C036150
-	I-Chemical	C036150
carboxylate	I-Chemical	C036150
(	O	O
beta	B-Chemical	C036150
-	I-Chemical	C036150
CCM	I-Chemical	C036150
)	O	O
,	O	O
an	O	O
inverse	O	O
agonist	O	O
of	O	O
the	O	O
GABA	B-Chemical	D005680
(	O	O
A	O	O
)	O	O
receptor	O	O
benzodiazepine	B-Chemical	D001569
site	O	O
.	O	O

Our	O	O
aim	O	O
was	O	O
to	O	O
characterize	O	O
both	O	O
lines'	O	O
sensitivities	O	O
to	O	O
various	O	O
physiological	O	O
effects	O	O
of	O	O
other	O	O
ligands	O	O
of	O	O
the	O	O
GABA	B-Chemical	D005680
(	O	O
A	O	O
)	O	O
receptor	O	O
.	O	O

We	O	O
measured	O	O
diazepam	B-Chemical	D003975
-	O	O
induced	O	O
anxiolysis	O	O
with	O	O
the	O	O
elevated	O	O
plus	O	O
-	O	O
maze	O	O
test	O	O
,	O	O
diazepam	B-Chemical	D003975
-	O	O
induced	O	O
sedation	O	O
by	O	O
recording	O	O
the	O	O
vigilance	O	O
states	O	O
,	O	O
and	O	O
picrotoxin	B-Chemical	D010852
-	O	O
and	O	O
pentylenetetrazol	B-Chemical	D010433
-	O	O
induced	O	O
seizures	B-Disease	D012640
after	O	O
i	O	O
.	O	O

p	O	O
.	O	O

injections	O	O
.	O	O

Results	O	O
presented	O	O
here	O	O
show	O	O
that	O	O
the	O	O
differential	O	O
sensitivities	O	O
of	O	O
BS	O	O
and	O	O
BR	O	O
lines	O	O
to	O	O
beta	B-Chemical	C036150
-	I-Chemical	C036150
CCM	I-Chemical	C036150
can	O	O
be	O	O
extended	O	O
to	O	O
diazepam	B-Chemical	D003975
,	O	O
picrotoxin	B-Chemical	D010852
,	O	O
and	O	O
pentylenetetrazol	B-Chemical	D010433
,	O	O
suggesting	O	O
a	O	O
genetic	O	O
selection	O	O
of	O	O
a	O	O
general	O	O
sensitivity	O	O
and	O	O
resistance	O	O
to	O	O
several	O	O
ligands	O	O
of	O	O
the	O	O
GABA	B-Chemical	D005680
(	O	O
A	O	O
)	O	O
receptor	O	O
.	O	O

Analgesic	O	O
effect	O	O
of	O	O
intravenous	O	O
ketamine	B-Chemical	D007649
in	O	O
cancer	B-Disease	D009369
patients	O	O
on	O	O
morphine	B-Chemical	D009020
therapy	O	O
:	O	O
a	O	O
randomized	O	O
,	O	O
controlled	O	O
,	O	O
double	O	O
-	O	O
blind	O	O
,	O	O
crossover	O	O
,	O	O
double	O	O
-	O	O
dose	O	O
study	O	O
.	O	O

Pain	B-Disease	D010146
not	O	O
responsive	O	O
to	O	O
morphine	B-Chemical	D009020
is	O	O
often	O	O
problematic	O	O
.	O	O

Animal	O	O
and	O	O
clinical	O	O
studies	O	O
have	O	O
suggested	O	O
that	O	O
N	B-Chemical	D016202
-	I-Chemical	D016202
methyl	I-Chemical	D016202
-	I-Chemical	D016202
D	I-Chemical	D016202
-	I-Chemical	D016202
aspartate	I-Chemical	D016202
(	O	O
NMDA	B-Chemical	D016202
)	O	O
antagonists	O	O
,	O	O
such	O	O
as	O	O
ketamine	B-Chemical	D007649
,	O	O
may	O	O
be	O	O
effective	O	O
in	O	O
improving	O	O
opioid	O	O
analgesia	O	O
in	O	O
difficult	O	O
pain	B-Disease	D010146
syndromes	O	O
,	O	O
such	O	O
as	O	O
neuropathic	B-Disease	D009437
pain	I-Disease	D009437
.	O	O

A	O	O
slow	O	O
bolus	O	O
of	O	O
subhypnotic	O	O
doses	O	O
of	O	O
ketamine	B-Chemical	D007649
(	O	O
0	O	O
.	O	O

25	O	O
mg	O	O
/	O	O
kg	O	O
or	O	O
0	O	O
.	O	O

50	O	O
mg	O	O
/	O	O
kg	O	O
)	O	O
was	O	O
given	O	O
to	O	O
10	O	O
cancer	B-Disease	D009369
patients	O	O
whose	O	O
pain	B-Disease	D010146
was	O	O
unrelieved	O	O
by	O	O
morphine	B-Chemical	D009020
in	O	O
a	O	O
randomized	O	O
,	O	O
double	O	O
-	O	O
blind	O	O
,	O	O
crossover	O	O
,	O	O
double	O	O
-	O	O
dose	O	O
study	O	O
.	O	O

Pain	B-Disease	D010146
intensity	O	O
on	O	O
a	O	O
0	O	O
to	O	O
10	O	O
numerical	O	O
scale	O	O
;	O	O
nausea	B-Disease	D009325
and	O	O
vomiting	B-Disease	D014839
,	O	O
drowsiness	O	O
,	O	O
confusion	B-Disease	D003221
,	O	O
and	O	O
dry	B-Disease	D014987
mouth	I-Disease	D014987
,	O	O
using	O	O
a	O	O
scale	O	O
from	O	O
0	O	O
to	O	O
3	O	O
(	O	O
not	O	O
at	O	O
all	O	O
,	O	O
slight	O	O
,	O	O
a	O	O
lot	O	O
,	O	O
awful	O	O
)	O	O
;	O	O
Mini	O	O
-	O	O
Mental	O	O
State	O	O
Examination	O	O
(	O	O
MMSE	O	O
)	O	O
(	O	O
0	O	O
-	O	O
30	O	O
)	O	O
;	O	O
and	O	O
arterial	O	O
pressure	O	O
were	O	O
recorded	O	O
before	O	O
administration	O	O
of	O	O
drugs	O	O
(	O	O
T0	O	O
)	O	O
and	O	O
after	O	O
30	O	O
minutes	O	O
(	O	O
T30	O	O
)	O	O
,	O	O
60	O	O
minutes	O	O
(	O	O
T60	O	O
)	O	O
,	O	O
120	O	O
minutes	O	O
(	O	O
T120	O	O
)	O	O
,	O	O
and	O	O
180	O	O
minutes	O	O
(	O	O
T180	O	O
)	O	O
.	O	O

Ketamine	B-Chemical	D007649
,	O	O
but	O	O
not	O	O
saline	O	O
solution	O	O
,	O	O
significantly	O	O
reduced	O	O
the	O	O
pain	B-Disease	D010146
intensity	O	O
in	O	O
almost	O	O
all	O	O
the	O	O
patients	O	O
at	O	O
both	O	O
doses	O	O
.	O	O

This	O	O
effect	O	O
was	O	O
more	O	O
relevant	O	O
in	O	O
patients	O	O
treated	O	O
with	O	O
higher	O	O
doses	O	O
.	O	O

Hallucinations	B-Disease	D006212
occurred	O	O
in	O	O
4	O	O
patients	O	O
,	O	O
and	O	O
an	O	O
unpleasant	O	O
sensation	O	O
(	O	O
"empty	O	O
head"	O	O
)	O	O
was	O	O
also	O	O
reported	O	O
by	O	O
2	O	O
patients	O	O
.	O	O

These	O	O
episodes	O	O
reversed	O	O
after	O	O
the	O	O
administration	O	O
of	O	O
diazepam	B-Chemical	D003975
1	O	O
mg	O	O
intravenously	O	O
.	O	O

Significant	O	O
increases	O	O
in	O	O
drowsiness	O	O
were	O	O
reported	O	O
in	O	O
patients	O	O
treated	O	O
with	O	O
ketamine	B-Chemical	D007649
in	O	O
both	O	O
groups	O	O
and	O	O
were	O	O
more	O	O
marked	O	O
with	O	O
ketamine	B-Chemical	D007649
0	O	O
.	O	O

50	O	O
mg	O	O
/	O	O
kg	O	O
.	O	O

A	O	O
significant	O	O
difference	O	O
in	O	O
MMSE	O	O
was	O	O
observed	O	O
at	O	O
T30	O	O
in	O	O
patients	O	O
who	O	O
received	O	O
0	O	O
.	O	O

50	O	O
mg	O	O
/	O	O
kg	O	O
of	O	O
ketamine	B-Chemical	D007649
.	O	O

Ketamine	B-Chemical	D007649
can	O	O
improve	O	O
morphine	B-Chemical	D009020
analgesia	O	O
in	O	O
difficult	O	O
pain	B-Disease	D010146
syndromes	O	O
,	O	O
such	O	O
as	O	O
neuropathic	B-Disease	D009437
pain	I-Disease	D009437
.	O	O

However	O	O
,	O	O
the	O	O
occurrence	O	O
of	O	O
central	O	O
adverse	O	O
effects	O	O
should	O	O
be	O	O
taken	O	O
into	O	O
account	O	O
,	O	O
especially	O	O
when	O	O
using	O	O
higher	O	O
doses	O	O
.	O	O

This	O	O
observation	O	O
should	O	O
be	O	O
tested	O	O
in	O	O
studies	O	O
of	O	O
prolonged	O	O
ketamine	B-Chemical	D007649
administration	O	O
.	O	O

Endocrine	O	O
screening	O	O
in	O	O
1	O	O
,	O	O
022	O	O
men	O	O
with	O	O
erectile	B-Disease	D007172
dysfunction	I-Disease	D007172
:	O	O
clinical	O	O
significance	O	O
and	O	O
cost	O	O
-	O	O
effective	O	O
strategy	O	O
.	O	O

PURPOSE	O	O
:	O	O
We	O	O
reviewed	O	O
the	O	O
results	O	O
of	O	O
serum	O	O
testosterone	B-Chemical	D013739
and	O	O
prolactin	O	O
determination	O	O
in	O	O
1	O	O
,	O	O
022	O	O
patients	O	O
referred	O	O
because	O	O
of	O	O
erectile	B-Disease	D007172
dysfunction	I-Disease	D007172
and	O	O
compared	O	O
the	O	O
data	O	O
with	O	O
history	O	O
,	O	O
results	O	O
of	O	O
physical	O	O
examination	O	O
,	O	O
other	O	O
etiological	O	O
investigations	O	O
and	O	O
effects	O	O
of	O	O
endocrine	O	O
therapy	O	O
to	O	O
refine	O	O
the	O	O
rules	O	O
of	O	O
cost	O	O
-	O	O
effective	O	O
endocrine	O	O
screening	O	O
and	O	O
to	O	O
pinpoint	O	O
actual	O	O
responsibility	O	O
for	O	O
hormonal	O	O
abnormalities	O	O
.	O	O

MATERIALS	O	O
AND	O	O
METHODS	O	O
:	O	O
Testosterone	B-Chemical	D013739
and	O	O
prolactin	O	O
were	O	O
determined	O	O
by	O	O
radioimmunoassay	O	O
.	O	O

Every	O	O
patient	O	O
was	O	O
screened	O	O
for	O	O
testosterone	B-Chemical	D013739
and	O	O
451	O	O
were	O	O
screened	O	O
for	O	O
prolactin	O	O
on	O	O
the	O	O
basis	O	O
of	O	O
low	B-Disease	D020018
sexual	I-Disease	D020018
desire	I-Disease	D020018
,	O	O
gynecomastia	B-Disease	D006177
or	O	O
testosterone	B-Chemical	D013739
less	O	O
than	O	O
4	O	O
ng	O	O
.	O	O

/	O	O
ml	O	O
.	O	O

Determination	O	O
was	O	O
repeated	O	O
in	O	O
case	O	O
of	O	O
abnormal	O	O
first	O	O
results	O	O
.	O	O

Prolactin	O	O
results	O	O
were	O	O
compared	O	O
with	O	O
those	O	O
of	O	O
a	O	O
previous	O	O
personal	O	O
cohort	O	O
of	O	O
1	O	O
,	O	O
340	O	O
patients	O	O
with	O	O
erectile	B-Disease	D007172
dysfunction	I-Disease	D007172
and	O	O
systematic	O	O
prolactin	O	O
determination	O	O
.	O	O

Main	O	O
clinical	O	O
criteria	O	O
tested	O	O
regarding	O	O
efficiency	O	O
in	O	O
hormone	O	O
determination	O	O
were	O	O
low	B-Disease	D020018
sexual	I-Disease	D020018
desire	I-Disease	D020018
,	O	O
small	O	O
testes	O	O
and	O	O
gynecomastia	B-Disease	D006177
.	O	O

Endocrine	O	O
therapy	O	O
consisted	O	O
of	O	O
testosterone	B-Chemical	D013739
heptylate	O	O
or	O	O
human	O	O
chorionic	O	O
gonadotropin	O	O
for	O	O
hypogonadism	B-Disease	D007006
and	O	O
bromocriptine	B-Chemical	D001971
for	O	O
hyperprolactinemia	B-Disease	D006966
.	O	O

RESULTS	O	O
:	O	O
Testosterone	B-Chemical	D013739
was	O	O
less	O	O
than	O	O
3	O	O
ng	O	O
.	O	O

/	O	O
ml	O	O
.	O	O

in	O	O
107	O	O
patients	O	O
but	O	O
normal	O	O
in	O	O
40%	O	O
at	O	O
repeat	O	O
determination	O	O
.	O	O

The	O	O
prevalence	O	O
of	O	O
repeatedly	O	O
low	O	O
testosterone	B-Chemical	D013739
increased	O	O
with	O	O
age	O	O
(	O	O
4%	O	O
before	O	O
age	O	O
50	O	O
years	O	O
and	O	O
9%	O	O
50	O	O
years	O	O
or	O	O
older	O	O
)	O	O
.	O	O

Two	O	O
pituitary	B-Disease	D010911
tumors	I-Disease	D010911
were	O	O
discovered	O	O
after	O	O
testosterone	B-Chemical	D013739
determination	O	O
.	O	O

Most	O	O
of	O	O
the	O	O
other	O	O
low	O	O
testosterone	B-Chemical	D013739
levels	O	O
seemed	O	O
to	O	O
result	O	O
from	O	O
nonorganic	O	O
hypothalamic	B-Disease	D007027
dysfunction	I-Disease	D007027
because	O	O
of	O	O
normal	O	O
serum	O	O
luteinizing	O	O
hormone	O	O
and	O	O
prolactin	O	O
and	O	O
to	O	O
have	O	O
only	O	O
a	O	O
small	O	O
role	O	O
in	O	O
erectile	B-Disease	D007172
dysfunction	I-Disease	D007172
(	O	O
definite	O	O
improvement	O	O
in	O	O
only	O	O
16	O	O
of	O	O
44	O	O
[	O	O
36%	O	O
]	O	O
after	O	O
androgen	O	O
therapy	O	O
,	O	O
normal	O	O
morning	O	O
or	O	O
nocturnal	O	O
erections	O	O
in	O	O
30%	O	O
and	O	O
definite	O	O
vasculogenic	O	O
contributions	O	O
in	O	O
42%	O	O
)	O	O
.	O	O

Determining	O	O
testosterone	B-Chemical	D013739
only	O	O
in	O	O
cases	O	O
of	O	O
low	B-Disease	D020018
sexual	I-Disease	D020018
desire	I-Disease	D020018
or	O	O
abnormal	O	O
physical	O	O
examination	O	O
would	O	O
have	O	O
missed	O	O
40%	O	O
of	O	O
the	O	O
cases	O	O
with	O	O
low	O	O
testosterone	B-Chemical	D013739
,	O	O
including	O	O
37%	O	O
of	O	O
those	O	O
subsequently	O	O
improved	O	O
by	O	O
androgen	O	O
therapy	O	O
.	O	O

Prolactin	O	O
exceeded	O	O
20	O	O
ng	O	O
.	O	O

/	O	O
ml	O	O
.	O	O

in	O	O
5	O	O
men	O	O
and	O	O
was	O	O
normal	O	O
in	O	O
2	O	O
at	O	O
repeat	O	O
determination	O	O
.	O	O

Only	O	O
1	O	O
prolactinoma	B-Disease	D015175
was	O	O
discovered	O	O
.	O	O

These	O	O
data	O	O
are	O	O
lower	O	O
than	O	O
those	O	O
we	O	O
found	O	O
during	O	O
the	O	O
last	O	O
2	O	O
decades	O	O
(	O	O
overall	O	O
prolactin	O	O
greater	O	O
than	O	O
20	O	O
ng	O	O
.	O	O

/	O	O
ml	O	O
.	O	O

in	O	O
1	O	O
.	O	O

86%	O	O
of	O	O
1	O	O
,	O	O
821	O	O
patients	O	O
,	O	O
prolactinomas	B-Disease	D015175
in	O	O
7	O	O
,	O	O
0	O	O
.	O	O

38%	O	O
)	O	O
.	O	O

Bromocriptine	B-Chemical	D001971
was	O	O
definitely	O	O
effective	O	O
in	O	O
cases	O	O
with	O	O
prolactin	O	O
greater	O	O
than	O	O
35	O	O
ng	O	O
.	O	O

/	O	O
ml	O	O
.	O	O

(	O	O
8	O	O
of	O	O
12	O	O
compared	O	O
to	O	O
only	O	O
9	O	O
of	O	O
22	O	O
cases	O	O
with	O	O
prolactin	O	O
between	O	O
20	O	O
and	O	O
35	O	O
ng	O	O
.	O	O

/	O	O
ml	O	O
.	O	O

)	O	O
.	O	O

Testosterone	B-Chemical	D013739
was	O	O
low	O	O
in	O	O
less	O	O
than	O	O
50%	O	O
of	O	O
cases	O	O
with	O	O
prolactin	O	O
greater	O	O
than	O	O
35	O	O
ng	O	O
.	O	O

/	O	O
ml	O	O
.	O	O

CONCLUSIONS	O	O
:	O	O
Low	O	O
prevalences	O	O
and	O	O
effects	O	O
of	O	O
low	O	O
testosterone	B-Chemical	D013739
and	O	O
high	O	O
prolactin	O	O
in	O	O
erectile	B-Disease	D007172
dysfunction	I-Disease	D007172
cannot	O	O
justify	O	O
their	O	O
routine	O	O
determination	O	O
.	O	O

However	O	O
,	O	O
cost	O	O
-	O	O
effective	O	O
screening	O	O
strategies	O	O
recommended	O	O
so	O	O
far	O	O
missed	O	O
40	O	O
to	O	O
50%	O	O
of	O	O
cases	O	O
improved	O	O
with	O	O
endocrine	O	O
therapy	O	O
and	O	O
the	O	O
pituitary	B-Disease	D010911
tumors	I-Disease	D010911
.	O	O

We	O	O
now	O	O
advocate	O	O
that	O	O
before	O	O
age	O	O
50	O	O
years	O	O
testosterone	B-Chemical	D013739
be	O	O
determined	O	O
only	O	O
in	O	O
cases	O	O
of	O	O
low	B-Disease	D020018
sexual	I-Disease	D020018
desire	I-Disease	D020018
and	O	O
abnormal	O	O
physical	O	O
examination	O	O
but	O	O
that	O	O
it	O	O
be	O	O
measured	O	O
in	O	O
all	O	O
men	O	O
older	O	O
than	O	O
50	O	O
years	O	O
.	O	O

Prolactin	O	O
should	O	O
be	O	O
determined	O	O
only	O	O
in	O	O
cases	O	O
of	O	O
low	B-Disease	D020018
sexual	I-Disease	D020018
desire	I-Disease	D020018
,	O	O
gynecomastia	B-Disease	D006177
and	O	O
/	O	O
or	O	O
testosterone	B-Chemical	D013739
less	O	O
than	O	O
4	O	O
ng	O	O
.	O	O

/	O	O
ml	O	O
.	O	O

Thiopentone	B-Chemical	D013874
pretreatment	O	O
for	O	O
propofol	B-Chemical	D015742
injection	O	O
pain	B-Disease	D010146
in	O	O
ambulatory	O	O
patients	O	O
.	O	O

This	O	O
study	O	O
investigated	O	O
propofol	B-Chemical	D015742
injection	O	O
pain	B-Disease	D010146
in	O	O
patients	O	O
undergoing	O	O
ambulatory	O	O
anaesthesia	O	O
.	O	O

In	O	O
a	O	O
randomized	O	O
,	O	O
double	O	O
-	O	O
blind	O	O
trial	O	O
,	O	O
90	O	O
women	O	O
were	O	O
allocated	O	O
to	O	O
receive	O	O
one	O	O
of	O	O
three	O	O
treatments	O	O
prior	O	O
to	O	O
induction	O	O
of	O	O
anaesthesia	O	O
with	O	O
propofol	B-Chemical	D015742
.	O	O

Patients	O	O
in	O	O
Group	O	O
C	O	O
received	O	O
2	O	O
ml	O	O
normal	O	O
saline	O	O
,	O	O
Group	O	O
L	O	O
,	O	O
2	O	O
ml	O	O
,	O	O
lidocaine	B-Chemical	D008012
2%	O	O
(	O	O
40	O	O
mg	O	O
)	O	O
and	O	O
Group	O	O
T	O	O
,	O	O
2	O	O
ml	O	O
thiopentone	B-Chemical	D013874
2	O	O
.	O	O

5%	O	O
(	O	O
50	O	O
mg	O	O
)	O	O
.	O	O

Venous	O	O
discomfort	O	O
was	O	O
assessed	O	O
with	O	O
a	O	O
visual	O	O
analogue	O	O
scale	O	O
(	O	O
VAS	O	O
)	O	O
5	O	O
-	O	O
15	O	O
sec	O	O
after	O	O
commencing	O	O
propofol	B-Chemical	D015742
administration	O	O
using	O	O
an	O	O
infusion	O	O
pump	O	O
(	O	O
rate	O	O
1000	O	O
micrograms	O	O
.	O	O

kg	O	O
-	O	O
1	O	O
.	O	O

min	O	O
-	O	O
1	O	O
)	O	O
.	O	O

Loss	B-Disease	D014474
of	I-Disease	D014474
consciousness	I-Disease	D014474
occurred	O	O
in	O	O
60	O	O
-	O	O
90	O	O
sec	O	O
.	O	O

Visual	O	O
analogue	O	O
scores	O	O
(	O	O
mean	O	O
+	O	O
/	O	O
-	O	O
SD	O	O
)	O	O
during	O	O
induction	O	O
were	O	O
lower	O	O
in	O	O
Groups	O	O
L	O	O
(	O	O
3	O	O
.	O	O

3	O	O
+	O	O
/	O	O
-	O	O
2	O	O
.	O	O

5	O	O
)	O	O
and	O	O
T	O	O
(	O	O
4	O	O
.	O	O

1	O	O
+	O	O
/	O	O
-	O	O
2	O	O
.	O	O

7	O	O
)	O	O
than	O	O
in	O	O
Group	O	O
C	O	O
(	O	O
5	O	O
.	O	O

6	O	O
+	O	O
/	O	O
-	O	O
2	O	O
.	O	O

3	O	O
)	O	O
;	O	O
P	O	O
=	O	O
0	O	O
.	O	O

0031	O	O
.	O	O

The	O	O
incidence	O	O
of	O	O
venous	O	O
discomfort	O	O
was	O	O
lower	O	O
in	O	O
Group	O	O
L	O	O
(	O	O
76	O	O
.	O	O

6%	O	O
;	O	O
P	O	O
<	O	O
0	O	O
.	O	O

05	O	O
)	O	O
than	O	O
in	O	O
Group	O	O
C	O	O
(	O	O
100%	O	O
)	O	O
but	O	O
not	O	O
different	O	O
from	O	O
Group	O	O
T	O	O
(	O	O
90%	O	O
)	O	O
.	O	O

The	O	O
VAS	O	O
scores	O	O
for	O	O
recall	O	O
of	O	O
pain	B-Disease	D010146
in	O	O
the	O	O
recovery	O	O
room	O	O
were	O	O
correlated	O	O
with	O	O
the	O	O
VAS	O	O
scores	O	O
during	O	O
induction	O	O
(	O	O
r	O	O
=	O	O
0	O	O
.	O	O

7045	O	O
;	O	O
P	O	O
<	O	O
0	O	O
.	O	O

0001	O	O
)	O	O
.	O	O

Recovery	O	O
room	O	O
discharge	O	O
times	O	O
were	O	O
similar	O	O
:	O	O
C	O	O
(	O	O
75	O	O
.	O	O

9	O	O
+	O	O
/	O	O
-	O	O
19	O	O
.	O	O

4	O	O
min	O	O
)	O	O
;	O	O
L	O	O
73	O	O
.	O	O

6	O	O
+	O	O
/	O	O
-	O	O
21	O	O
.	O	O

6	O	O
min	O	O
)	O	O
;	O	O
T	O	O
(	O	O
77	O	O
.	O	O

1	O	O
+	O	O
/	O	O
-	O	O
18	O	O
.	O	O

9	O	O
min	O	O
)	O	O
.	O	O

Assessing	O	O
their	O	O
overall	O	O
satisfaction	O	O
,	O	O
89	O	O
.	O	O

7%	O	O
would	O	O
choose	O	O
propofol	B-Chemical	D015742
anaesthesia	O	O
again	O	O
.	O	O

We	O	O
conclude	O	O
that	O	O
lidocaine	B-Chemical	D008012
reduces	O	O
the	O	O
incidence	O	O
and	O	O
severity	O	O
of	O	O
propofol	B-Chemical	D015742
injection	O	O
pain	B-Disease	D010146
in	O	O
ambulatory	O	O
patients	O	O
whereas	O	O
thiopentone	B-Chemical	D013874
only	O	O
reduces	O	O
its	O	O
severity	O	O
.	O	O

Comparison	O	O
of	O	O
i	O	O
.	O	O

v	O	O
.	O	O

glycopyrrolate	B-Chemical	D006024
and	O	O
atropine	B-Chemical	D001285
in	O	O
the	O	O
prevention	O	O
of	O	O
bradycardia	B-Disease	D001919
and	O	O
arrhythmias	B-Disease	D001145
following	O	O
repeated	O	O
doses	O	O
of	O	O
suxamethonium	B-Chemical	D013390
in	O	O
children	O	O
.	O	O

The	O	O
effectiveness	O	O
of	O	O
administration	O	O
of	O	O
glycopyrrolate	B-Chemical	D006024
5	O	O
and	O	O
10	O	O
micrograms	O	O
kg	O	O
-	O	O
1	O	O
and	O	O
atropine	B-Chemical	D001285
10	O	O
and	O	O
20	O	O
micrograms	O	O
kg	O	O
-	O	O
1	O	O
i	O	O
.	O	O

v	O	O
.	O	O

immediately	O	O
before	O	O
the	O	O
induction	O	O
of	O	O
anaesthesia	O	O
,	O	O
to	O	O
prevent	O	O
arrhythmia	B-Disease	D001145
and	O	O
bradycardia	B-Disease	D001919
following	O	O
repeated	O	O
doses	O	O
of	O	O
suxamethonium	B-Chemical	D013390
in	O	O
children	O	O
,	O	O
was	O	O
studied	O	O
.	O	O

A	O	O
control	O	O
group	O	O
was	O	O
included	O	O
for	O	O
comparison	O	O
with	O	O
the	O	O
lower	O	O
dose	O	O
range	O	O
of	O	O
glycopyrrolate	B-Chemical	D006024
and	O	O
atropine	B-Chemical	D001285
.	O	O

A	O	O
frequency	O	O
of	O	O
bradycardia	B-Disease	D001919
of	O	O
50%	O	O
was	O	O
noted	O	O
in	O	O
the	O	O
control	O	O
group	O	O
,	O	O
but	O	O
this	O	O
was	O	O
not	O	O
significantly	O	O
different	O	O
from	O	O
the	O	O
frequency	O	O
with	O	O
the	O	O
active	O	O
drugs	O	O
.	O	O

Bradycardia	B-Disease	D001919
(	O	O
defined	O	O
as	O	O
a	O	O
decrease	O	O
in	O	O
heart	O	O
rate	O	O
to	O	O
less	O	O
than	O	O
50	O	O
beat	O	O
min	O	O
-	O	O
1	O	O
)	O	O
was	O	O
prevented	O	O
when	O	O
the	O	O
larger	O	O
dose	O	O
of	O	O
either	O	O
active	O	O
drug	O	O
was	O	O
used	O	O
.	O	O

It	O	O
is	O	O
recommended	O	O
that	O	O
either	O	O
glycopyrrolate	B-Chemical	D006024
10	O	O
micrograms	O	O
kg	O	O
-	O	O
1	O	O
or	O	O
atropine	B-Chemical	D001285
20	O	O
micrograms	O	O
kg	O	O
-	O	O
1	O	O
i	O	O
.	O	O

v	O	O
.	O	O

should	O	O
immediately	O	O
precede	O	O
induction	O	O
of	O	O
anaesthesia	O	O
,	O	O
in	O	O
children	O	O
,	O	O
if	O	O
the	O	O
repeated	O	O
administration	O	O
of	O	O
suxamethonium	B-Chemical	D013390
is	O	O
anticipated	O	O
.	O	O

Reduction	O	O
in	O	O
caffeine	B-Chemical	D002110
toxicity	B-Disease	D064420
by	O	O
acetaminophen	B-Chemical	D000082
.	O	O

A	O	O
patient	O	O
who	O	O
allegedly	O	O
consumed	O	O
100	O	O
tablets	O	O
of	O	O
an	O	O
over	O	O
-	O	O
the	O	O
-	O	O
counter	O	O
analgesic	O	O
containing	O	O
sodium	B-Chemical	-1
acetylsalicylate	I-Chemical	-1
,	O	O
caffeine	B-Chemical	D002110
,	O	O
and	O	O
acetaminophen	B-Chemical	D000082
displayed	O	O
no	O	O
significant	O	O
CNS	O	O
stimulation	O	O
despite	O	O
the	O	O
presence	O	O
of	O	O
175	O	O
micrograms	O	O
of	O	O
caffeine	B-Chemical	D002110
per	O	O
mL	O	O
of	O	O
serum	O	O
.	O	O

Because	O	O
salicylates	O	O
have	O	O
been	O	O
reported	O	O
to	O	O
augment	O	O
the	O	O
stimulatory	O	O
effects	O	O
of	O	O
caffeine	B-Chemical	D002110
on	O	O
the	O	O
CNS	O	O
,	O	O
attention	O	O
was	O	O
focused	O	O
on	O	O
the	O	O
possibility	O	O
that	O	O
the	O	O
presence	O	O
of	O	O
acetaminophen	B-Chemical	D000082
(	O	O
52	O	O
micrograms	O	O
/	O	O
mL	O	O
)	O	O
reduced	O	O
the	O	O
CNS	O	O
toxicity	B-Disease	D064420
of	O	O
caffeine	B-Chemical	D002110
.	O	O

Studies	O	O
in	O	O
DBA	O	O
/	O	O
2J	O	O
mice	O	O
showed	O	O
that	O	O
:	O	O
1	O	O
)	O	O
pretreatment	O	O
with	O	O
acetaminophen	B-Chemical	D000082
(	O	O
100	O	O
mg	O	O
/	O	O
kg	O	O
)	O	O
increased	O	O
the	O	O
interval	O	O
between	O	O
the	O	O
administration	O	O
of	O	O
caffeine	B-Chemical	D002110
(	O	O
300	O	O
to	O	O
450	O	O
mg	O	O
/	O	O
kg	O	O
IP	O	O
)	O	O
and	O	O
the	O	O
onset	O	O
of	O	O
fatal	O	O
convulsions	B-Disease	D012640
by	O	O
a	O	O
factor	O	O
of	O	O
about	O	O
two	O	O
;	O	O
and	O	O
2	O	O
)	O	O
pretreatment	O	O
with	O	O
acetaminophen	B-Chemical	D000082
(	O	O
75	O	O
mg	O	O
/	O	O
kg	O	O
)	O	O
reduced	O	O
the	O	O
incidence	O	O
of	O	O
audiogenic	O	O
seizures	B-Disease	D012640
produced	O	O
in	O	O
the	O	O
presence	O	O
of	O	O
caffeine	B-Chemical	D002110
(	O	O
12	O	O
.	O	O

5	O	O
to	O	O
75	O	O
mg	O	O
/	O	O
kg	O	O
IP	O	O
)	O	O
.	O	O

The	O	O
frequency	O	O
of	O	O
sound	O	O
-	O	O
induced	O	O
seizures	B-Disease	D012640
after	O	O
12	O	O
.	O	O

5	O	O
or	O	O
25	O	O
mg	O	O
/	O	O
kg	O	O
caffeine	B-Chemical	D002110
was	O	O
reduced	O	O
from	O	O
50	O	O
to	O	O
5%	O	O
by	O	O
acetaminophen	B-Chemical	D000082
.	O	O

In	O	O
the	O	O
absence	O	O
of	O	O
caffeine	B-Chemical	D002110
,	O	O
acetaminophen	B-Chemical	D000082
(	O	O
up	O	O
to	O	O
300	O	O
mg	O	O
/	O	O
kg	O	O
)	O	O
did	O	O
not	O	O
modify	O	O
the	O	O
seizures	B-Disease	D012640
induced	O	O
by	O	O
maximal	O	O
electroshock	O	O
and	O	O
did	O	O
not	O	O
alter	O	O
the	O	O
convulsant	O	O
dose	O	O
of	O	O
pentylenetetrezol	B-Chemical	D010433
in	O	O
mice	O	O
(	O	O
tests	O	O
performed	O	O
by	O	O
the	O	O
Anticonvulsant	O	O
Screening	O	O
Project	O	O
of	O	O
NINCDS	O	O
)	O	O
.	O	O

Acetaminophen	B-Chemical	D000082
(	O	O
up	O	O
to	O	O
150	O	O
micrograms	O	O
/	O	O
mL	O	O
)	O	O
did	O	O
not	O	O
retard	O	O
the	O	O
incorporation	O	O
of	O	O
radioactive	O	O
adenosine	B-Chemical	D000241
into	O	O
ATP	B-Chemical	D000255
in	O	O
slices	O	O
of	O	O
rat	O	O
cerebral	O	O
cortex	O	O
.	O	O

Thus	O	O
the	O	O
mechanism	O	O
by	O	O
which	O	O
acetaminophen	B-Chemical	D000082
antagonizes	O	O
the	O	O
actions	O	O
of	O	O
caffeine	B-Chemical	D002110
in	O	O
the	O	O
CNS	O	O
remains	O	O
unknown	O	O
.	O	O

Flestolol	B-Chemical	C047847
:	O	O
an	O	O
ultra	O	O
-	O	O
short	O	O
-	O	O
acting	O	O
beta	O	O
-	O	O
adrenergic	O	O
blocking	O	O
agent	O	O
.	O	O

Flestolol	B-Chemical	C047847
(	O	O
ACC	B-Chemical	C047847
-	I-Chemical	C047847
9089	I-Chemical	C047847
)	O	O
is	O	O
a	O	O
nonselective	O	O
,	O	O
competitive	O	O
,	O	O
ultra	O	O
-	O	O
short	O	O
-	O	O
acting	O	O
beta	O	O
-	O	O
adrenergic	O	O
blocking	O	O
agent	O	O
,	O	O
without	O	O
any	O	O
intrinsic	O	O
sympathomimetic	O	O
activity	O	O
.	O	O

Flestolol	B-Chemical	C047847
is	O	O
metabolized	O	O
by	O	O
plasma	O	O
esterases	O	O
and	O	O
has	O	O
an	O	O
elimination	O	O
half	O	O
-	O	O
life	O	O
of	O	O
approximately	O	O
6	O	O
.	O	O

5	O	O
minutes	O	O
.	O	O

This	O	O
agent	O	O
was	O	O
well	O	O
tolerated	O	O
in	O	O
healthy	O	O
volunteers	O	O
at	O	O
doses	O	O
up	O	O
to	O	O
100	O	O
micrograms	O	O
/	O	O
kg	O	O
/	O	O
min	O	O
.	O	O

In	O	O
long	O	O
-	O	O
term	O	O
infusion	O	O
studies	O	O
,	O	O
flestolol	B-Chemical	C047847
was	O	O
well	O	O
tolerated	O	O
at	O	O
the	O	O
effective	O	O
beta	O	O
-	O	O
blocking	O	O
dose	O	O
(	O	O
5	O	O
micrograms	O	O
/	O	O
kg	O	O
/	O	O
min	O	O
)	O	O
for	O	O
up	O	O
to	O	O
seven	O	O
days	O	O
.	O	O

Flestolol	B-Chemical	C047847
blood	O	O
concentrations	O	O
increased	O	O
linearly	O	O
with	O	O
increasing	O	O
dose	O	O
and	O	O
good	O	O
correlation	O	O
exists	O	O
between	O	O
blood	O	O
concentrations	O	O
of	O	O
flestolol	B-Chemical	C047847
and	O	O
beta	O	O
-	O	O
adrenergic	O	O
blockade	O	O
.	O	O

Flestolol	B-Chemical	C047847
produced	O	O
a	O	O
dose	O	O
-	O	O
dependent	O	O
attenuation	O	O
of	O	O
isoproterenol	B-Chemical	D007545
-	O	O
induced	O	O
tachycardia	B-Disease	D013610
.	O	O

Electrophysiologic	O	O
and	O	O
hemodynamic	O	O
effects	O	O
of	O	O
flestolol	B-Chemical	C047847
are	O	O
similar	O	O
to	O	O
those	O	O
of	O	O
other	O	O
beta	O	O
blockers	O	O
.	O	O

In	O	O
contrast	O	O
with	O	O
other	O	O
beta	O	O
blockers	O	O
,	O	O
flestolol	B-Chemical	C047847
-	O	O
induced	O	O
effects	O	O
reverse	O	O
rapidly	O	O
(	O	O
within	O	O
30	O	O
minutes	O	O
)	O	O
following	O	O
discontinuation	O	O
because	O	O
of	O	O
its	O	O
short	O	O
half	O	O
-	O	O
life	O	O
.	O	O

Flestolol	B-Chemical	C047847
effectively	O	O
reduced	O	O
heart	O	O
rate	O	O
in	O	O
patients	O	O
with	O	O
supraventricular	B-Disease	D013617
tachyarrhythmia	I-Disease	D013617
.	O	O

In	O	O
patients	O	O
with	O	O
unstable	B-Disease	D000789
angina	I-Disease	D000789
,	O	O
flestolol	B-Chemical	C047847
infusion	O	O
was	O	O
found	O	O
to	O	O
be	O	O
safe	O	O
and	O	O
effective	O	O
in	O	O
controlling	O	O
chest	B-Disease	D002637
pain	I-Disease	D002637
.	O	O

It	O	O
is	O	O
concluded	O	O
that	O	O
flestolol	B-Chemical	C047847
is	O	O
a	O	O
potent	O	O
,	O	O
well	O	O
-	O	O
tolerated	O	O
,	O	O
ultra	O	O
-	O	O
short	O	O
-	O	O
acting	O	O
beta	O	O
-	O	O
adrenergic	O	O
blocking	O	O
agent	O	O
.	O	O

Use	O	O
of	O	O
flestolol	B-Chemical	C047847
in	O	O
the	O	O
critical	O	O
care	O	O
setting	O	O
is	O	O
currently	O	O
undergoing	O	O
investigation	O	O
.	O	O

Adverse	O	O
effect	O	O
of	O	O
the	O	O
calcium	B-Chemical	D002118
channel	O	O
blocker	O	O
nitrendipine	B-Chemical	D009568
on	O	O
nephrosclerosis	B-Disease	D009400
in	O	O
rats	O	O
with	O	O
renovascular	B-Disease	D006978
hypertension	I-Disease	D006978
.	O	O

The	O	O
effect	O	O
of	O	O
a	O	O
6	O	O
-	O	O
week	O	O
treatment	O	O
with	O	O
the	O	O
calcium	B-Chemical	D002118
channel	O	O
blocker	O	O
nitrendipine	B-Chemical	D009568
or	O	O
the	O	O
angiotensin	B-Chemical	D000809
converting	O	O
enzyme	O	O
inhibitor	O	O
enalapril	B-Chemical	D004656
on	O	O
blood	O	O
pressure	O	O
,	O	O
albuminuria	B-Disease	D000419
,	O	O
renal	O	O
hemodynamics	O	O
,	O	O
and	O	O
morphology	O	O
of	O	O
the	O	O
nonclipped	O	O
kidney	O	O
was	O	O
studied	O	O
in	O	O
rats	O	O
with	O	O
two	O	O
-	O	O
kidney	O	O
,	O	O
one	O	O
clip	O	O
renovascular	B-Disease	D006978
hypertension	I-Disease	D006978
.	O	O

Six	O	O
weeks	O	O
after	O	O
clipping	O	O
of	O	O
one	O	O
renal	O	O
artery	O	O
,	O	O
hypertensive	B-Disease	D006973
rats	O	O
(	O	O
178	O	O
+	O	O
/	O	O
-	O	O
4	O	O
mm	O	O
Hg	O	O
)	O	O
were	O	O
randomly	O	O
assigned	O	O
to	O	O
three	O	O
groups	O	O
:	O	O
untreated	O	O
hypertensive	B-Disease	D006973
controls	O	O
(	O	O
n	O	O
=	O	O
8	O	O
)	O	O
,	O	O
enalapril	B-Chemical	D004656
-	O	O
treated	O	O
(	O	O
n	O	O
=	O	O
8	O	O
)	O	O
,	O	O
or	O	O
nitrendipine	B-Chemical	D009568
-	O	O
treated	O	O
(	O	O
n	O	O
=	O	O
10	O	O
)	O	O
.	O	O

Sham	O	O
-	O	O
operated	O	O
rats	O	O
served	O	O
as	O	O
normotensive	O	O
controls	O	O
(	O	O
128	O	O
+	O	O
/	O	O
-	O	O
3	O	O
mm	O	O
Hg	O	O
,	O	O
n	O	O
=	O	O
8	O	O
)	O	O
.	O	O

After	O	O
6	O	O
weeks	O	O
of	O	O
treatment	O	O
,	O	O
renal	O	O
hemodynamics	O	O
(	O	O
glomerular	O	O
filtration	O	O
rate	O	O
and	O	O
renal	O	O
plasma	O	O
flow	O	O
)	O	O
were	O	O
measured	O	O
in	O	O
the	O	O
anesthetized	O	O
rats	O	O
.	O	O

Renal	O	O
tissue	O	O
was	O	O
obtained	O	O
for	O	O
determination	O	O
of	O	O
glomerular	O	O
size	O	O
and	O	O
sclerosis	O	O
.	O	O

Enalapril	B-Chemical	D004656
but	O	O
not	O	O
nitrendipine	B-Chemical	D009568
reduced	O	O
blood	O	O
pressure	O	O
significantly	O	O
.	O	O

After	O	O
6	O	O
weeks	O	O
of	O	O
therapy	O	O
,	O	O
glomerular	O	O
filtration	O	O
rate	O	O
was	O	O
not	O	O
different	O	O
among	O	O
the	O	O
studied	O	O
groups	O	O
.	O	O

Renal	O	O
plasma	O	O
flow	O	O
increased	O	O
,	O	O
but	O	O
albumin	O	O
excretion	O	O
and	O	O
glomerulosclerosis	B-Disease	D005921
did	O	O
not	O	O
change	O	O
after	O	O
enalapril	B-Chemical	D004656
treatment	O	O
.	O	O

In	O	O
contrast	O	O
,	O	O
in	O	O
the	O	O
nitrendipine	B-Chemical	D009568
-	O	O
treated	O	O
group	O	O
albuminuria	B-Disease	D000419
increased	O	O
from	O	O
12	O	O
.	O	O

8	O	O
+	O	O
/	O	O
-	O	O
2	O	O
progressively	O	O
to	O	O
163	O	O
+	O	O
/	O	O
-	O	O
55	O	O
compared	O	O
with	O	O
19	O	O
.	O	O

2	O	O
+	O	O
/	O	O
-	O	O
9	O	O
mg	O	O
/	O	O
24	O	O
hr	O	O
in	O	O
the	O	O
hypertensive	B-Disease	D006973
controls	O	O
.	O	O

Furthermore	O	O
,	O	O
glomerulosclerosis	B-Disease	D005921
index	O	O
was	O	O
significantly	O	O
increased	O	O
in	O	O
the	O	O
nitrendipine	B-Chemical	D009568
-	O	O
treated	O	O
group	O	O
compared	O	O
with	O	O
the	O	O
hypertensive	B-Disease	D006973
controls	O	O
(	O	O
0	O	O
.	O	O

38	O	O
+	O	O
/	O	O
-	O	O
0	O	O
.	O	O

1	O	O
versus	O	O
0	O	O
.	O	O

13	O	O
+	O	O
/	O	O
-	O	O
0	O	O
.	O	O

04	O	O
)	O	O
.	O	O

In	O	O
addition	O	O
,	O	O
glomerular	O	O
size	O	O
was	O	O
higher	O	O
in	O	O
the	O	O
nitrendipine	B-Chemical	D009568
-	O	O
treated	O	O
group	O	O
(	O	O
14	O	O
.	O	O

9	O	O
+	O	O
/	O	O
-	O	O
0	O	O
.	O	O

17	O	O
10	O	O
(	O	O
-	O	O
3	O	O
)	O	O
mm2	O	O
)	O	O
but	O	O
lower	O	O
in	O	O
the	O	O
enalapril	B-Chemical	D004656
-	O	O
treated	O	O
group	O	O
(	O	O
11	O	O
.	O	O

5	O	O
+	O	O
/	O	O
-	O	O
0	O	O
.	O	O

15	O	O
10	O	O
(	O	O
-	O	O
3	O	O
)	O	O
mm2	O	O
)	O	O
compared	O	O
with	O	O
the	O	O
hypertensive	B-Disease	D006973
controls	O	O
(	O	O
12	O	O
.	O	O

1	O	O
+	O	O
/	O	O
-	O	O
0	O	O
.	O	O

17	O	O
10	O	O
(	O	O
-	O	O
3	O	O
)	O	O
mm2	O	O
)	O	O
.	O	O

(	O	O
ABSTRACT	O	O
TRUNCATED	O	O
AT	O	O
250	O	O
WORDS	O	O
)	O	O
Treatment	O	O
of	O	O
tinnitus	B-Disease	D014012
by	O	O
intratympanic	O	O
instillation	O	O
of	O	O
lignocaine	B-Chemical	D008012
(	O	O
lidocaine	B-Chemical	D008012
)	O	O
2	O	O
per	O	O
cent	O	O
through	O	O
ventilation	O	O
tubes	O	O
.	O	O

Idiopathic	B-Disease	D014012
subjective	I-Disease	D014012
tinnitus	I-Disease	D014012
(	O	O
IST	B-Disease	D014012
)	O	O
is	O	O
one	O	O
of	O	O
the	O	O
most	O	O
obscure	O	O
otological	O	O
pathologies	O	O
.	O	O

This	O	O
paper	O	O
presents	O	O
the	O	O
results	O	O
of	O	O
treating	O	O
IST	B-Disease	D014012
by	O	O
intratympanic	O	O
instillation	O	O
of	O	O
lignocaine	B-Chemical	D008012
(	O	O
lidocaine	B-Chemical	D008012
)	O	O
2	O	O
per	O	O
cent	O	O
through	O	O
a	O	O
grommet	O	O
,	O	O
for	O	O
five	O	O
weekly	O	O
courses	O	O
.	O	O

Fifty	O	O
-	O	O
two	O	O
patients	O	O
suffering	O	O
from	O	O
intractable	O	O
tinnitus	B-Disease	D014012
entered	O	O
this	O	O
therapeutic	O	O
trial	O	O
,	O	O
but	O	O
only	O	O
nine	O	O
finished	O	O
all	O	O
five	O	O
courses	O	O
.	O	O

In	O	O
one	O	O
patient	O	O
,	O	O
the	O	O
tinnitus	B-Disease	D014012
was	O	O
almost	O	O
completely	O	O
abolished	O	O
,	O	O
but	O	O
in	O	O
all	O	O
the	O	O
nine	O	O
patients	O	O
the	O	O
decompensated	O	O
tinnitus	B-Disease	D014012
changed	O	O
to	O	O
a	O	O
compensated	O	O
one	O	O
.	O	O

We	O	O
suggest	O	O
this	O	O
mode	O	O
of	O	O
treatment	O	O
for	O	O
patients	O	O
that	O	O
were	O	O
previously	O	O
treated	O	O
by	O	O
drugs	O	O
,	O	O
acupuncture	O	O
and	O	O
biofeedback	O	O
,	O	O
with	O	O
disappointing	O	O
results	O	O
.	O	O

Patients	O	O
should	O	O
be	O	O
warned	O	O
about	O	O
the	O	O
side	O	O
effects	O	O
of	O	O
vertigo	B-Disease	D014717
and	O	O
vomiting	B-Disease	D014839
,	O	O
which	O	O
subsides	O	O
gradually	O	O
with	O	O
every	O	O
new	O	O
instillation	O	O
,	O	O
and	O	O
that	O	O
the	O	O
tinnitus	B-Disease	D014012
may	O	O
not	O	O
disappear	O	O
but	O	O
will	O	O
be	O	O
alleviated	O	O
,	O	O
enabling	O	O
them	O	O
to	O	O
cope	O	O
more	O	O
easily	O	O
with	O	O
the	O	O
disease	O	O
and	O	O
lead	O	O
a	O	O
more	O	O
normal	O	O
life	O	O
.	O	O

Perhexiline	B-Chemical	C023470
maleate	I-Chemical	C023470
and	O	O
peripheral	B-Disease	D010523
neuropathy	I-Disease	D010523
.	O	O

Peripheral	B-Disease	D010523
neuropathy	I-Disease	D010523
has	O	O
been	O	O
noted	O	O
as	O	O
a	O	O
complication	O	O
of	O	O
therapy	O	O
with	O	O
perhexiline	B-Chemical	C023470
maleate	I-Chemical	C023470
,	O	O
a	O	O
drug	O	O
widely	O	O
used	O	O
in	O	O
France	O	O
(	O	O
and	O	O
in	O	O
clinical	O	O
trials	O	O
in	O	O
the	O	O
United	O	O
States	O	O
)	O	O
for	O	O
the	O	O
prophylactic	O	O
treatment	O	O
of	O	O
angina	B-Disease	D000787
pectoris	I-Disease	D000787
.	O	O

In	O	O
24	O	O
patients	O	O
with	O	O
this	O	O
complication	O	O
,	O	O
the	O	O
marked	O	O
slowing	O	O
of	O	O
motor	O	O
nerve	O	O
conduction	O	O
velocity	O	O
and	O	O
the	O	O
electromyographic	O	O
changes	O	O
imply	O	O
mainly	O	O
a	O	O
demyelinating	B-Disease	D003711
disorder	I-Disease	D003711
.	O	O

Improvement	O	O
was	O	O
noted	O	O
with	O	O
cessation	O	O
of	O	O
therapy	O	O
.	O	O

In	O	O
a	O	O
few	O	O
cases	O	O
the	O	O
presence	O	O
of	O	O
active	O	O
denervation	O	O
signified	O	O
a	O	O
poor	O	O
prognosis	O	O
,	O	O
with	O	O
only	O	O
slight	O	O
improvement	O	O
.	O	O

The	O	O
underlying	O	O
mechanism	O	O
causing	O	O
the	O	O
neuropathy	B-Disease	D009422
is	O	O
not	O	O
yet	O	O
fully	O	O
known	O	O
,	O	O
although	O	O
some	O	O
evidence	O	O
indicates	O	O
that	O	O
it	O	O
may	O	O
be	O	O
a	O	O
lipid	O	O
storage	O	O
process	O	O
.	O	O

Effect	O	O
of	O	O
humoral	O	O
modulators	O	O
of	O	O
morphine	B-Chemical	D009020
-	O	O
induced	O	O
increase	B-Disease	D006948
in	I-Disease	D006948
locomotor	I-Disease	D006948
activity	I-Disease	D006948
of	O	O
mice	O	O
.	O	O

The	O	O
effect	O	O
of	O	O
humoral	O	O
modulators	O	O
on	O	O
the	O	O
morphine	B-Chemical	D009020
-	O	O
induced	O	O
increase	B-Disease	D006948
in	I-Disease	D006948
locomotor	I-Disease	D006948
activity	I-Disease	D006948
of	O	O
mice	O	O
was	O	O
studied	O	O
.	O	O

The	O	O
subcutaneous	O	O
administration	O	O
of	O	O
10	O	O
mg	O	O
/	O	O
kg	O	O
of	O	O
morphine	B-Chemical	D009020
-	O	O
HC1	O	O
produced	O	O
a	O	O
marked	O	O
increase	B-Disease	D006948
in	I-Disease	D006948
locomotor	I-Disease	D006948
activity	I-Disease	D006948
in	O	O
mice	O	O
.	O	O

The	O	O
morphine	B-Chemical	D009020
-	O	O
induced	O	O
hyperactivity	B-Disease	D006948
was	O	O
potentiated	O	O
by	O	O
scopolamine	B-Chemical	D012601
and	O	O
attenuated	O	O
by	O	O
physostigmine	B-Chemical	D010830
.	O	O

In	O	O
contrast	O	O
,	O	O
both	O	O
methscopolamine	B-Chemical	D019832
and	O	O
neostigmine	B-Chemical	D009388
,	O	O
which	O	O
do	O	O
not	O	O
penetrate	O	O
the	O	O
blood	O	O
-	O	O
brain	O	O
barrier	O	O
,	O	O
had	O	O
no	O	O
effect	O	O
on	O	O
the	O	O
hyperactivity	B-Disease	D006948
produced	O	O
by	O	O
morphine	B-Chemical	D009020
.	O	O

Pretreatment	O	O
of	O	O
mice	O	O
with	O	O
alpha	B-Chemical	D019805
-	I-Chemical	D019805
methyltyrosine	I-Chemical	D019805
(	O	O
20	O	O
mg	O	O
/	O	O
kg	O	O
i	O	O
.	O	O

p	O	O
.	O	O

,	O	O
one	O	O
hour	O	O
)	O	O
,	O	O
an	O	O
inhibitor	O	O
of	O	O
tyrosine	B-Chemical	D014443
hydroxylase	O	O
,	O	O
significantly	O	O
decreased	O	O
the	O	O
activity	O	O
-	O	O
increasing	O	O
effects	O	O
of	O	O
morphine	B-Chemical	D009020
.	O	O

On	O	O
the	O	O
other	O	O
hand	O	O
,	O	O
pretreatment	O	O
with	O	O
p	B-Chemical	D010134
-	I-Chemical	D010134
chlorophenylalamine	I-Chemical	D010134
(	O	O
3	O	O
X	O	O
320	O	O
mg	O	O
/	O	O
kg	O	O
i	O	O
.	O	O

p	O	O
.	O	O

,	O	O
24	O	O
hr	O	O
)	O	O
,	O	O
a	O	O
serotonin	B-Chemical	D012701
depletor	O	O
,	O	O
caused	O	O
no	O	O
significant	O	O
change	O	O
in	O	O
the	O	O
hyperactivity	B-Disease	D006948
.	O	O

The	O	O
study	O	O
suggests	O	O
that	O	O
the	O	O
activity	O	O
-	O	O
increasing	O	O
effects	O	O
of	O	O
morphine	B-Chemical	D009020
are	O	O
mediated	O	O
by	O	O
the	O	O
release	O	O
of	O	O
catecholamines	B-Chemical	D002395
from	O	O
adrenergic	O	O
neurons	O	O
in	O	O
the	O	O
brain	O	O
.	O	O

And	O	O
the	O	O
results	O	O
are	O	O
consistent	O	O
with	O	O
the	O	O
hypothesis	O	O
that	O	O
morphine	B-Chemical	D009020
acts	O	O
by	O	O
retarding	O	O
the	O	O
release	O	O
of	O	O
acetylcholine	B-Chemical	D000109
at	O	O
some	O	O
central	O	O
cholinergic	O	O
synapses	O	O
.	O	O

It	O	O
is	O	O
also	O	O
suggested	O	O
from	O	O
collected	O	O
evidence	O	O
that	O	O
the	O	O
activity	O	O
-	O	O
increasing	O	O
effects	O	O
of	O	O
morphine	B-Chemical	D009020
in	O	O
mice	O	O
are	O	O
mediated	O	O
by	O	O
mechanisms	O	O
different	O	O
from	O	O
those	O	O
which	O	O
mediate	O	O
the	O	O
activity	O	O
-	O	O
increasing	O	O
effects	O	O
of	O	O
morphine	B-Chemical	D009020
in	O	O
rats	O	O
.	O	O

Mechanisms	O	O
of	O	O
FK	B-Chemical	D016559
506	I-Chemical	D016559
-	O	O
induced	O	O
hypertension	B-Disease	D006973
in	O	O
the	O	O
rat	O	O
.	O	O

-	O	O
Tacrolimus	B-Chemical	D016559
(	O	O
FK	B-Chemical	D016559
506	I-Chemical	D016559
)	O	O
is	O	O
a	O	O
powerful	O	O
,	O	O
widely	O	O
used	O	O
immunosuppressant	O	O
.	O	O

The	O	O
clinical	O	O
utility	O	O
of	O	O
FK	B-Chemical	D016559
506	I-Chemical	D016559
is	O	O
complicated	O	O
by	O	O
substantial	O	O
hypertension	B-Disease	D006973
and	O	O
nephrotoxicity	B-Disease	D007674
.	O	O

To	O	O
clarify	O	O
the	O	O
mechanisms	O	O
of	O	O
FK	B-Chemical	D016559
506	I-Chemical	D016559
-	O	O
induced	O	O
hypertension	B-Disease	D006973
,	O	O
we	O	O
studied	O	O
the	O	O
chronic	O	O
effects	O	O
of	O	O
FK	B-Chemical	D016559
506	I-Chemical	D016559
on	O	O
the	O	O
synthesis	O	O
of	O	O
endothelin	O	O
-	O	O
1	O	O
(	O	O
ET	O	O
-	O	O
1	O	O
)	O	O
,	O	O
the	O	O
expression	O	O
of	O	O
mRNA	O	O
of	O	O
ET	O	O
-	O	O
1	O	O
and	O	O
endothelin	O	O
-	O	O
converting	O	O
enzyme	O	O
-	O	O
1	O	O
(	O	O
ECE	O	O
-	O	O
1	O	O
)	O	O
,	O	O
the	O	O
endothelial	O	O
nitric	B-Chemical	D009569
oxide	I-Chemical	D009569
synthase	O	O
(	O	O
eNOS	O	O
)	O	O
activity	O	O
,	O	O
and	O	O
the	O	O
expression	O	O
of	O	O
mRNA	O	O
of	O	O
eNOS	O	O
and	O	O
C	O	O
-	O	O
type	O	O
natriuretic	O	O
peptide	O	O
(	O	O
CNP	O	O
)	O	O
in	O	O
rat	O	O
blood	O	O
vessels	O	O
.	O	O

In	O	O
addition	O	O
,	O	O
the	O	O
effect	O	O
of	O	O
the	O	O
specific	O	O
endothelin	O	O
type	O	O
A	O	O
receptor	O	O
antagonist	O	O
FR	B-Chemical	C079574
139317	I-Chemical	C079574
on	O	O
FK	B-Chemical	D016559
506	I-Chemical	D016559
-	O	O
induced	O	O
hypertension	B-Disease	D006973
in	O	O
rats	O	O
was	O	O
studied	O	O
.	O	O

FK	B-Chemical	D016559
506	I-Chemical	D016559
,	O	O
5	O	O
mg	O	O
.	O	O

kg	O	O
-	O	O
1	O	O
.	O	O

d	O	O
-	O	O
1	O	O
given	O	O
for	O	O
4	O	O
weeks	O	O
,	O	O
elevated	O	O
blood	O	O
pressure	O	O
from	O	O
102+	O	O
/	O	O
-	O	O
13	O	O
to	O	O
152+	O	O
/	O	O
-	O	O
15	O	O
mm	O	O
Hg	O	O
and	O	O
increased	O	O
the	O	O
synthesis	O	O
of	O	O
ET	O	O
-	O	O
1	O	O
and	O	O
the	O	O
levels	O	O
of	O	O
ET	O	O
-	O	O
1	O	O
mRNA	O	O
in	O	O
the	O	O
mesenteric	O	O
artery	O	O
(	O	O
240%	O	O
and	O	O
230%	O	O
,	O	O
respectively	O	O
)	O	O
.	O	O

Little	O	O
change	O	O
was	O	O
observed	O	O
in	O	O
the	O	O
expression	O	O
of	O	O
ECE	O	O
-	O	O
1	O	O
mRNA	O	O
and	O	O
CNP	O	O
mRNA	O	O
.	O	O

FK	B-Chemical	D016559
506	I-Chemical	D016559
decreased	O	O
eNOS	O	O
activity	O	O
and	O	O
the	O	O
levels	O	O
of	O	O
eNOS	O	O
mRNA	O	O
in	O	O
the	O	O
aorta	O	O
(	O	O
48%	O	O
and	O	O
55%	O	O
,	O	O
respectively	O	O
)	O	O
.	O	O

The	O	O
administration	O	O
of	O	O
FR	B-Chemical	C079574
139317	I-Chemical	C079574
(	O	O
10	O	O
mg	O	O
.	O	O

kg	O	O
-	O	O
1	O	O
.	O	O

d	O	O
-	O	O
1	O	O
)	O	O
prevented	O	O
FK	B-Chemical	D016559
506	I-Chemical	D016559
-	O	O
induced	O	O
hypertension	B-Disease	D006973
in	O	O
rats	O	O
.	O	O

These	O	O
results	O	O
indicate	O	O
that	O	O
FK	B-Chemical	D016559
506	I-Chemical	D016559
may	O	O
increase	O	O
blood	O	O
pressure	O	O
not	O	O
only	O	O
by	O	O
increasing	O	O
ET	O	O
-	O	O
1	O	O
production	O	O
but	O	O
also	O	O
by	O	O
decreasing	O	O
NO	B-Chemical	D009569
synthesis	O	O
in	O	O
the	O	O
vasculature	O	O
.	O	O

Suxamethonium	B-Chemical	D013390
induced	O	O
prolonged	O	O
apnea	B-Disease	D001049
in	O	O
a	O	O
patient	O	O
receiving	O	O
electroconvulsive	O	O
therapy	O	O
.	O	O

Suxamethonium	B-Chemical	D013390
causes	O	O
prolonged	O	O
apnea	B-Disease	D001049
in	O	O
patients	O	O
in	O	O
whom	O	O
pseudocholinesterase	O	O
enzyme	O	O
gets	O	O
deactivated	O	O
by	O	O
organophosphorus	B-Chemical	D009943
(	I-Chemical	D009943
OP	I-Chemical	D009943
)	I-Chemical	D009943
poisons	I-Chemical	D009943
.	O	O

Here	O	O
,	O	O
we	O	O
present	O	O
a	O	O
similar	O	O
incident	O	O
in	O	O
a	O	O
severely	O	O
depressed	B-Disease	D003866
patient	O	O
who	O	O
received	O	O
electroconvulsive	O	O
therapy	O	O
(	O	O
ECT	O	O
)	O	O
.	O	O

Prolonged	O	O
apnea	B-Disease	D001049
in	O	O
our	O	O
case	O	O
ensued	O	O
because	O	O
the	O	O
information	O	O
about	O	O
suicidal	O	O
attempt	O	O
by	O	O
OP	B-Chemical	D009943
compound	I-Chemical	D009943
was	O	O
concealed	O	O
from	O	O
the	O	O
treating	O	O
team	O	O
.	O	O

The	O	O
effects	O	O
of	O	O
the	O	O
adjunctive	O	O
bupropion	B-Chemical	D016642
on	O	O
male	O	O
sexual	B-Disease	D012735
dysfunction	I-Disease	D012735
induced	O	O
by	O	O
a	O	O
selective	B-Chemical	D017367
serotonin	I-Chemical	D017367
reuptake	I-Chemical	D017367
inhibitor	I-Chemical	D017367
:	O	O
a	O	O
double	O	O
-	O	O
blind	O	O
placebo	O	O
-	O	O
controlled	O	O
and	O	O
randomized	O	O
study	O	O
.	O	O

OBJECTIVE	O	O
:	O	O
To	O	O
determine	O	O
the	O	O
safety	O	O
and	O	O
efficacy	O	O
of	O	O
adjunctive	O	O
bupropion	B-Chemical	D016642
sustained	O	O
-	O	O
release	O	O
(	O	O
SR	O	O
)	O	O
on	O	O
male	O	O
sexual	B-Disease	D012735
dysfunction	I-Disease	D012735
(	O	O
SD	B-Disease	D012735
)	O	O
induced	O	O
by	O	O
a	O	O
selective	B-Chemical	D017367
serotonin	I-Chemical	D017367
reuptake	I-Chemical	D017367
inhibitor	I-Chemical	D017367
(	O	O
SSRI	B-Chemical	D017367
)	O	O
,	O	O
as	O	O
SD	B-Disease	D012735
is	O	O
a	O	O
common	O	O
side	O	O
-	O	O
effect	O	O
of	O	O
SSRIs	B-Chemical	D017367
and	O	O
the	O	O
most	O	O
effective	O	O
treatments	O	O
have	O	O
yet	O	O
to	O	O
be	O	O
determined	O	O
.	O	O

PATIENTS	O	O
AND	O	O
METHODS	O	O
:	O	O
The	O	O
randomized	O	O
sample	O	O
consisted	O	O
of	O	O
234	O	O
euthymic	O	O
men	O	O
who	O	O
were	O	O
receiving	O	O
some	O	O
type	O	O
of	O	O
SSRI	B-Chemical	D017367
.	O	O

The	O	O
men	O	O
were	O	O
randomly	O	O
assigned	O	O
to	O	O
bupropion	B-Chemical	D016642
SR	O	O
(	O	O
150	O	O
mg	O	O
twice	O	O
daily	O	O
,	O	O
117	O	O
)	O	O
or	O	O
placebo	O	O
(	O	O
twice	O	O
daily	O	O
,	O	O
117	O	O
)	O	O
for	O	O
12	O	O
weeks	O	O
.	O	O

Efficacy	O	O
was	O	O
evaluated	O	O
using	O	O
the	O	O
Clinical	O	O
Global	O	O
Impression	O	O
-	O	O
Sexual	O	O
Function	O	O
(	O	O
CGI	O	O
-	O	O
SF	O	O
;	O	O
the	O	O
primary	O	O
outcome	O	O
measure	O	O
)	O	O
,	O	O
the	O	O
International	O	O
Index	O	O
of	O	O
Erectile	O	O
Function	O	O
(	O	O
IIEF	O	O
)	O	O
,	O	O
Arizona	O	O
Sexual	O	O
Experience	O	O
Scale	O	O
(	O	O
ASEX	O	O
)	O	O
,	O	O
and	O	O
Erectile	B-Disease	D007172
Dysfunction	I-Disease	D007172
Inventory	O	O
of	O	O
Treatment	O	O
Satisfaction	O	O
(	O	O
EDITS	O	O
)	O	O
(	O	O
secondary	O	O
outcome	O	O
measures	O	O
)	O	O
.	O	O

Participants	O	O
were	O	O
followed	O	O
biweekly	O	O
during	O	O
study	O	O
period	O	O
.	O	O

RESULTS	O	O
:	O	O
After	O	O
12	O	O
weeks	O	O
of	O	O
treatment	O	O
,	O	O
the	O	O
mean	O	O
(	O	O
sd	O	O
)	O	O
scores	O	O
for	O	O
CGI	O	O
-	O	O
SF	O	O
were	O	O
significantly	O	O
lower	O	O
,	O	O
i	O	O
.	O	O

e	O	O
.	O	O

better	O	O
,	O	O
in	O	O
patients	O	O
on	O	O
bupropion	B-Chemical	D016642
SR	O	O
,	O	O
at	O	O
2	O	O
.	O	O

4	O	O
(	O	O
1	O	O
.	O	O

2	O	O
)	O	O
,	O	O
than	O	O
in	O	O
the	O	O
placebo	O	O
group	O	O
,	O	O
at	O	O
3	O	O
.	O	O

9	O	O
(	O	O
1	O	O
.	O	O

1	O	O
)	O	O
(	O	O
P=	O	O
0	O	O
.	O	O

01	O	O
)	O	O
.	O	O

Men	O	O
who	O	O
received	O	O
bupropion	B-Chemical	D016642
had	O	O
a	O	O
significant	O	O
increase	O	O
in	O	O
the	O	O
total	O	O
IIEF	O	O
score	O	O
(	O	O
54	O	O
.	O	O

4%	O	O
vs	O	O
1	O	O
.	O	O

2%	O	O
;	O	O
P=	O	O
0	O	O
.	O	O

003	O	O
)	O	O
,	O	O
and	O	O
in	O	O
the	O	O
five	O	O
different	O	O
domains	O	O
of	O	O
the	O	O
IIEF	O	O
.	O	O

Total	O	O
ASEX	O	O
scores	O	O
were	O	O
significantly	O	O
lower	O	O
,	O	O
i	O	O
.	O	O

e	O	O
.	O	O

better	O	O
,	O	O
among	O	O
men	O	O
who	O	O
received	O	O
bupropion	B-Chemical	D016642
than	O	O
placebo	O	O
,	O	O
at	O	O
15	O	O
.	O	O

5	O	O
(	O	O
4	O	O
.	O	O

3	O	O
)	O	O
vs	O	O
21	O	O
.	O	O

5	O	O
(	O	O
4	O	O
.	O	O

7	O	O
)	O	O
(	O	O
P=	O	O
0	O	O
.	O	O

002	O	O
)	O	O
.	O	O

The	O	O
EDITS	O	O
scores	O	O
were	O	O
67	O	O
.	O	O

4	O	O
(	O	O
10	O	O
.	O	O

2	O	O
)	O	O
for	O	O
the	O	O
bupropion	B-Chemical	D016642
and	O	O
36	O	O
.	O	O

3	O	O
(	O	O
11	O	O
.	O	O

7	O	O
)	O	O
for	O	O
the	O	O
placebo	O	O
group	O	O
(	O	O
P=	O	O
0	O	O
.	O	O

001	O	O
)	O	O
.	O	O

The	O	O
ASEX	O	O
score	O	O
and	O	O
CGI	O	O
-	O	O
SF	O	O
score	O	O
were	O	O
correlated	O	O
(	O	O
P=	O	O
0	O	O
.	O	O

003	O	O
)	O	O
.	O	O

In	O	O
linear	O	O
regression	O	O
analyses	O	O
the	O	O
CGI	O	O
-	O	O
SF	O	O
score	O	O
was	O	O
not	O	O
affected	O	O
significantly	O	O
by	O	O
the	O	O
duration	O	O
of	O	O
SD	B-Disease	D012735
,	O	O
type	O	O
of	O	O
SSRI	B-Chemical	D017367
used	O	O
and	O	O
age	O	O
.	O	O

CONCLUSIONS	O	O
:	O	O
Bupropion	B-Chemical	D016642
is	O	O
an	O	O
effective	O	O
treatment	O	O
for	O	O
male	O	O
SD	B-Disease	D012735
induced	O	O
by	O	O
SSRIs	B-Chemical	D017367
.	O	O

These	O	O
results	O	O
provide	O	O
empirical	O	O
support	O	O
for	O	O
conducting	O	O
a	O	O
further	O	O
study	O	O
of	O	O
bupropion	B-Chemical	D016642
.	O	O

Lamivudine	B-Chemical	D019259
for	O	O
the	O	O
prevention	O	O
of	O	O
hepatitis	B-Disease	D006509
B	I-Disease	D006509
virus	O	O
reactivation	O	O
in	O	O
hepatitis	B-Chemical	D006514
-	I-Chemical	D006514
B	I-Chemical	D006514
surface	I-Chemical	D006514
antigen	I-Chemical	D006514
(	O	O
HBSAG	B-Chemical	D006514
)	O	O
seropositive	O	O
cancer	B-Disease	D009369
patients	O	O
undergoing	O	O
cytotoxic	O	O
chemotherapy	O	O
.	O	O

Hepatitis	B-Disease	D006509
B	I-Disease	D006509
virus	O	O
(	O	O
HBV	O	O
)	O	O
is	O	O
one	O	O
of	O	O
the	O	O
major	O	O
causes	O	O
of	O	O
chronic	O	O
liver	B-Disease	D008107
disease	I-Disease	D008107
worldwide	O	O
.	O	O

Cancer	B-Disease	D009369
patients	O	O
who	O	O
are	O	O
chronic	O	O
carriers	O	O
of	O	O
HBV	O	O
have	O	O
a	O	O
higher	O	O
hepatic	B-Disease	D008107
complication	I-Disease	D008107
rate	O	O
while	O	O
receiving	O	O
cytotoxic	O	O
chemotherapy	O	O
(	O	O
CT	O	O
)	O	O
and	O	O
this	O	O
has	O	O
mainly	O	O
been	O	O
attributed	O	O
to	O	O
HBV	O	O
reactivation	O	O
.	O	O

In	O	O
this	O	O
study	O	O
,	O	O
cancer	B-Disease	D009369
patients	O	O
who	O	O
have	O	O
solid	O	O
and	O	O
hematological	B-Disease	D019337
malignancies	I-Disease	D019337
with	O	O
chronic	O	O
HBV	B-Disease	D006509
infection	I-Disease	D006509
received	O	O
the	O	O
antiviral	O	O
agent	O	O
lamivudine	B-Chemical	D019259
prior	O	O
and	O	O
during	O	O
CT	O	O
compared	O	O
with	O	O
historical	O	O
control	O	O
group	O	O
who	O	O
did	O	O
not	O	O
receive	O	O
lamivudine	B-Chemical	D019259
.	O	O

The	O	O
objectives	O	O
were	O	O
to	O	O
assess	O	O
the	O	O
efficacy	O	O
of	O	O
lamivudine	B-Chemical	D019259
in	O	O
reducing	O	O
the	O	O
incidence	O	O
of	O	O
HBV	O	O
reactivation	O	O
,	O	O
and	O	O
diminishing	O	O
morbidity	O	O
and	O	O
mortality	O	O
during	O	O
CT	O	O
.	O	O

Two	O	O
groups	O	O
were	O	O
compared	O	O
in	O	O
this	O	O
study	O	O
.	O	O

The	O	O
prophylactic	O	O
lamivudin	B-Chemical	D019259
group	O	O
consisted	O	O
of	O	O
37	O	O
patients	O	O
who	O	O
received	O	O
prophylactic	O	O
lamivudine	B-Chemical	D019259
treatment	O	O
.	O	O

The	O	O
historical	O	O
controls	O	O
consisted	O	O
of	O	O
50	O	O
consecutive	O	O
patients	O	O
who	O	O
underwent	O	O
CT	O	O
without	O	O
prophylactic	O	O
lamivudine	B-Chemical	D019259
.	O	O

They	O	O
were	O	O
followed	O	O
up	O	O
during	O	O
and	O	O
for	O	O
8	O	O
weeks	O	O
after	O	O
CT	O	O
.	O	O

The	O	O
outcomes	O	O
were	O	O
compared	O	O
for	O	O
both	O	O
groups	O	O
.	O	O

Of	O	O
our	O	O
control	O	O
group	O	O
(	O	O
n=	O	O
50	O	O
)	O	O
,	O	O
21	O	O
patients	O	O
(	O	O
42%	O	O
)	O	O
were	O	O
established	O	O
hepatitis	B-Disease	D056486
.	O	O

Twelve	O	O
(	O	O
24%	O	O
)	O	O
of	O	O
them	O	O
were	O	O
evaluated	O	O
as	O	O
severe	O	O
hepatitis	B-Disease	D056486
.	O	O

In	O	O
the	O	O
prophylactic	O	O
lamivudine	B-Chemical	D019259
group	O	O
severe	O	O
hepatitis	B-Disease	D056486
were	O	O
observed	O	O
only	O	O
in	O	O
1	O	O
patient	O	O
(	O	O
2	O	O
.	O	O

7%	O	O
)	O	O
of	O	O
37	O	O
patients	O	O
(	O	O
p	O	O
<	O	O
0	O	O
.	O	O

006	O	O
)	O	O
.	O	O

Comparison	O	O
of	O	O
the	O	O
mean	O	O
ALT	O	O
values	O	O
revealed	O	O
significantly	O	O
higher	O	O
mean	O	O
alanine	B-Chemical	D000409
aminotransferase	O	O
(	O	O
ALT	O	O
)	O	O
values	O	O
in	O	O
the	O	O
control	O	O
group	O	O
than	O	O
the	O	O
prophylactic	O	O
lamivudine	B-Chemical	D019259
group	O	O
;	O	O
154	O	O
:	O	O
64	O	O
(	O	O
p	O	O
<	O	O
0	O	O
.	O	O

32	O	O
)	O	O
.	O	O

Our	O	O
study	O	O
suggests	O	O
that	O	O
prophylactic	O	O
lamivudine	B-Chemical	D019259
significantly	O	O
decreases	O	O
the	O	O
incidence	O	O
of	O	O
HBV	O	O
reactivation	O	O
and	O	O
overall	O	O
morbidity	O	O
in	O	O
cancer	B-Disease	D009369
patients	O	O
during	O	O
and	O	O
after	O	O
immunosuppressive	O	O
therapy	O	O
.	O	O

Further	O	O
studies	O	O
are	O	O
needed	O	O
to	O	O
determine	O	O
the	O	O
most	O	O
appropriate	O	O
nucleoside	B-Chemical	D009705
or	O	O
nucleotide	B-Chemical	D009711
analogue	O	O
for	O	O
antiviral	O	O
prophylaxis	O	O
during	O	O
CT	O	O
and	O	O
the	O	O
optimal	O	O
duration	O	O
of	O	O
administration	O	O
after	O	O
completion	O	O
of	O	O
CT	O	O
.	O	O

Ginsenoside	B-Chemical	C035054
Rg1	I-Chemical	C035054
restores	O	O
the	O	O
impairment	B-Disease	D007859
of	I-Disease	D007859
learning	I-Disease	D007859
induced	O	O
by	O	O
chronic	O	O
morphine	B-Chemical	D009020
administration	O	O
in	O	O
rats	O	O
.	O	O

Rg1	B-Chemical	C035054
,	O	O
as	O	O
a	O	O
ginsenoside	B-Chemical	D036145
extracted	O	O
from	O	O
Panax	O	O
ginseng	O	O
,	O	O
could	O	O
ameliorate	O	O
spatial	O	O
learning	B-Disease	D007859
impairment	I-Disease	D007859
.	O	O

Previous	O	O
studies	O	O
have	O	O
demonstrated	O	O
that	O	O
Rg1	B-Chemical	C035054
might	O	O
be	O	O
a	O	O
useful	O	O
agent	O	O
for	O	O
the	O	O
prevention	O	O
and	O	O
treatment	O	O
of	O	O
the	O	O
adverse	O	O
effects	O	O
of	O	O
morphine	B-Chemical	D009020
.	O	O

The	O	O
aim	O	O
of	O	O
this	O	O
study	O	O
was	O	O
to	O	O
investigate	O	O
the	O	O
effect	O	O
of	O	O
Rg1	B-Chemical	C035054
on	O	O
learning	B-Disease	D007859
impairment	I-Disease	D007859
by	O	O
chronic	O	O
morphine	B-Chemical	D009020
administration	O	O
and	O	O
the	O	O
mechanism	O	O
responsible	O	O
for	O	O
this	O	O
effect	O	O
.	O	O

Male	O	O
rats	O	O
were	O	O
subcutaneously	O	O
injected	O	O
with	O	O
morphine	B-Chemical	D009020
(	O	O
10	O	O
mg	O	O
/	O	O
kg	O	O
)	O	O
twice	O	O
a	O	O
day	O	O
at	O	O
12	O	O
hour	O	O
intervals	O	O
for	O	O
10	O	O
days	O	O
,	O	O
and	O	O
Rg1	B-Chemical	C035054
(	O	O
30	O	O
mg	O	O
/	O	O
kg	O	O
)	O	O
was	O	O
intraperitoneally	O	O
injected	O	O
2	O	O
hours	O	O
after	O	O
the	O	O
second	O	O
injection	O	O
of	O	O
morphine	B-Chemical	D009020
once	O	O
a	O	O
day	O	O
for	O	O
10	O	O
days	O	O
.	O	O

Spatial	O	O
learning	O	O
capacity	O	O
was	O	O
assessed	O	O
in	O	O
the	O	O
Morris	O	O
water	O	O
maze	O	O
.	O	O

The	O	O
results	O	O
showed	O	O
that	O	O
rats	O	O
treated	O	O
with	O	O
Morphine	B-Chemical	D009020
/	O	O
Rg1	B-Chemical	C035054
decreased	O	O
escape	O	O
latency	O	O
and	O	O
increased	O	O
the	O	O
time	O	O
spent	O	O
in	O	O
platform	O	O
quadrant	O	O
and	O	O
entering	O	O
frequency	O	O
.	O	O

By	O	O
implantation	O	O
of	O	O
electrodes	O	O
and	O	O
electrophysiological	O	O
recording	O	O
in	O	O
vivo	O	O
,	O	O
the	O	O
results	O	O
showed	O	O
that	O	O
Rg1	B-Chemical	C035054
restored	O	O
the	O	O
long	O	O
-	O	O
term	O	O
potentiation	O	O
(	O	O
LTP	O	O
)	O	O
impaired	O	O
by	O	O
morphine	B-Chemical	D009020
in	O	O
both	O	O
freely	O	O
moving	O	O
and	O	O
anaesthetised	O	O
rats	O	O
.	O	O

The	O	O
electrophysiological	O	O
recording	O	O
in	O	O
vitro	O	O
showed	O	O
that	O	O
Rg1	B-Chemical	C035054
restored	O	O
the	O	O
LTP	O	O
in	O	O
slices	O	O
from	O	O
the	O	O
rats	O	O
treated	O	O
with	O	O
morphine	B-Chemical	D009020
,	O	O
but	O	O
not	O	O
changed	O	O
LTP	O	O
in	O	O
the	O	O
slices	O	O
from	O	O
normal	O	O
saline	O	O
-	O	O
or	O	O
morphine	B-Chemical	D009020
/	O	O
Rg1	B-Chemical	C035054
-	O	O
treated	O	O
rats	O	O
;	O	O
this	O	O
restoration	O	O
could	O	O
be	O	O
inhibited	O	O
by	O	O
N	B-Chemical	D016202
-	I-Chemical	D016202
methyl	I-Chemical	D016202
-	I-Chemical	D016202
D	I-Chemical	D016202
-	I-Chemical	D016202
aspartate	I-Chemical	D016202
(	O	O
NMDA	B-Chemical	D016202
)	O	O
receptor	O	O
antagonist	O	O
MK801	B-Chemical	D016291
.	O	O

We	O	O
conclude	O	O
that	O	O
Rg1	B-Chemical	C035054
may	O	O
significantly	O	O
improve	O	O
the	O	O
spatial	O	O
learning	O	O
capacity	O	O
impaired	O	O
by	O	O
chonic	O	O
morphine	B-Chemical	D009020
administration	O	O
and	O	O
restore	O	O
the	O	O
morphine	B-Chemical	D009020
-	O	O
inhibited	O	O
LTP	O	O
.	O	O

This	O	O
effect	O	O
is	O	O
NMDA	B-Chemical	D016202
receptor	O	O
dependent	O	O
.	O	O

A	O	O
study	O	O
on	O	O
the	O	O
effect	O	O
of	O	O
the	O	O
duration	O	O
of	O	O
subcutaneous	O	O
heparin	B-Chemical	D006493
injection	O	O
on	O	O
bruising	B-Disease	D003288
and	O	O
pain	B-Disease	D010146
.	O	O

AIM	O	O
:	O	O
This	O	O
study	O	O
was	O	O
carried	O	O
out	O	O
to	O	O
determine	O	O
the	O	O
effect	O	O
of	O	O
injection	O	O
duration	O	O
on	O	O
bruising	B-Disease	D003288
and	O	O
pain	B-Disease	D010146
following	O	O
the	O	O
administration	O	O
of	O	O
the	O	O
subcutaneous	O	O
injection	O	O
of	O	O
heparin	B-Chemical	D006493
.	O	O

BACKGROUND	O	O
:	O	O
Although	O	O
different	O	O
methods	O	O
to	O	O
prevent	O	O
bruising	B-Disease	D003288
and	O	O
pain	B-Disease	D010146
following	O	O
the	O	O
subcutaneous	O	O
injection	O	O
of	O	O
heparin	B-Chemical	D006493
have	O	O
been	O	O
widely	O	O
studied	O	O
and	O	O
described	O	O
,	O	O
the	O	O
effect	O	O
of	O	O
injection	O	O
duration	O	O
on	O	O
the	O	O
occurrence	O	O
of	O	O
bruising	B-Disease	D003288
and	O	O
pain	B-Disease	D010146
is	O	O
little	O	O
documented	O	O
.	O	O

DESIGN	O	O
:	O	O
This	O	O
study	O	O
was	O	O
designed	O	O
as	O	O
within	O	O
-	O	O
subject	O	O
,	O	O
quasi	O	O
-	O	O
experimental	O	O
research	O	O
.	O	O

METHOD	O	O
:	O	O
The	O	O
sample	O	O
for	O	O
the	O	O
study	O	O
consisted	O	O
of	O	O
50	O	O
patients	O	O
to	O	O
whom	O	O
subcutaneous	O	O
heparin	B-Chemical	D006493
was	O	O
administered	O	O
.	O	O

Heparin	B-Chemical	D006493
was	O	O
injected	O	O
over	O	O
10	O	O
seconds	O	O
on	O	O
the	O	O
right	O	O
abdominal	O	O
site	O	O
and	O	O
30	O	O
seconds	O	O
on	O	O
the	O	O
left	O	O
abdominal	O	O
site	O	O
.	O	O

Injections	O	O
areas	O	O
were	O	O
assessed	O	O
for	O	O
the	O	O
presence	O	O
of	O	O
bruising	B-Disease	D003288
at	O	O
48	O	O
and	O	O
72	O	O
hours	O	O
after	O	O
each	O	O
injection	O	O
.	O	O

Dimensions	O	O
of	O	O
the	O	O
bruising	B-Disease	D003288
on	O	O
the	O	O
heparin	B-Chemical	D006493
applied	O	O
areas	O	O
were	O	O
measured	O	O
using	O	O
transparent	O	O
millimetric	O	O
measuring	O	O
paper	O	O
.	O	O

The	O	O
visual	O	O
analog	O	O
scale	O	O
(	O	O
VAS	O	O
)	O	O
was	O	O
used	O	O
to	O	O
measure	O	O
pain	B-Disease	D010146
intensity	O	O
and	O	O
a	O	O
stop	O	O
-	O	O
watch	O	O
was	O	O
used	O	O
to	O	O
time	O	O
the	O	O
pain	B-Disease	D010146
period	O	O
.	O	O

Data	O	O
were	O	O
analysed	O	O
using	O	O
chi	O	O
-	O	O
square	O	O
test	O	O
,	O	O
Mann	O	O
-	O	O
Whitney	O	O
U	O	O
,	O	O
Wilcoxon	O	O
signed	O	O
ranks	O	O
tests	O	O
and	O	O
correlation	O	O
.	O	O

RESULTS	O	O
:	O	O
The	O	O
percentage	O	O
of	O	O
bruising	B-Disease	D003288
occurrence	O	O
was	O	O
64%	O	O
with	O	O
the	O	O
injection	O	O
of	O	O
10	O	O
seconds	O	O
duration	O	O
and	O	O
42%	O	O
in	O	O
the	O	O
30	O	O
-	O	O
second	O	O
injection	O	O
.	O	O

It	O	O
was	O	O
determined	O	O
that	O	O
the	O	O
size	O	O
of	O	O
the	O	O
bruising	B-Disease	D003288
was	O	O
smaller	O	O
in	O	O
the	O	O
30	O	O
-	O	O
second	O	O
injection	O	O
.	O	O

Pain	B-Disease	D010146
intensity	O	O
and	O	O
pain	B-Disease	D010146
period	O	O
were	O	O
statistically	O	O
significantly	O	O
lower	O	O
for	O	O
the	O	O
30	O	O
-	O	O
second	O	O
injection	O	O
than	O	O
for	O	O
the	O	O
10	O	O
-	O	O
second	O	O
injection	O	O
.	O	O

CONCLUSIONS	O	O
:	O	O
It	O	O
was	O	O
determined	O	O
that	O	O
injection	O	O
duration	O	O
had	O	O
an	O	O
effect	O	O
on	O	O
bruising	B-Disease	D003288
and	O	O
pain	B-Disease	D010146
following	O	O
the	O	O
subcutaneous	O	O
administration	O	O
of	O	O
heparin	B-Chemical	D006493
.	O	O

This	O	O
study	O	O
should	O	O
be	O	O
repeated	O	O
on	O	O
a	O	O
larger	O	O
sample	O	O
.	O	O

RELEVANCE	O	O
TO	O	O
CLINICAL	O	O
PRACTICE	O	O
:	O	O
When	O	O
administering	O	O
subcutaneous	O	O
heparin	B-Chemical	D006493
injections	O	O
,	O	O
it	O	O
is	O	O
important	O	O
to	O	O
extend	O	O
the	O	O
duration	O	O
of	O	O
the	O	O
injection	O	O
.	O	O

Acute	O	O
reserpine	B-Chemical	D012110
and	O	O
subchronic	O	O
haloperidol	B-Chemical	D006220
treatments	O	O
change	O	O
synaptosomal	O	O
brain	O	O
glutamate	B-Chemical	D018698
uptake	O	O
and	O	O
elicit	O	O
orofacial	B-Disease	D004409
dyskinesia	I-Disease	D004409
in	O	O
rats	O	O
.	O	O

Reserpine	B-Chemical	D012110
-	O	O
and	O	O
haloperidol	B-Chemical	D006220
-	O	O
induced	O	O
orofacial	B-Disease	D004409
dyskinesia	I-Disease	D004409
are	O	O
putative	O	O
animal	O	O
models	O	O
of	O	O
tardive	B-Disease	D004409
dyskinesia	I-Disease	D004409
(	O	O
TD	B-Disease	D004409
)	O	O
whose	O	O
pathophysiology	O	O
has	O	O
been	O	O
related	O	O
to	O	O
free	O	O
radical	O	O
generation	O	O
and	O	O
oxidative	O	O
stress	O	O
.	O	O

In	O	O
the	O	O
present	O	O
study	O	O
,	O	O
the	O	O
authors	O	O
induced	O	O
orofacial	B-Disease	D004409
dyskinesia	I-Disease	D004409
by	O	O
acute	O	O
reserpine	B-Chemical	D012110
and	O	O
subchronic	O	O
haloperidol	B-Chemical	D006220
administration	O	O
to	O	O
rats	O	O
.	O	O

Reserpine	B-Chemical	D012110
injection	O	O
(	O	O
one	O	O
dose	O	O
of	O	O
1	O	O
mg	O	O
/	O	O
kg	O	O
s	O	O
.	O	O

c	O	O
.	O	O

)	O	O
every	O	O
other	O	O
day	O	O
for	O	O
3	O	O
days	O	O
caused	O	O
a	O	O
significant	O	O
increase	O	O
in	O	O
vacuous	O	O
chewing	O	O
,	O	O
tongue	O	O
protrusion	O	O
and	O	O
duration	O	O
of	O	O
facial	O	O
twitching	O	O
,	O	O
compared	O	O
to	O	O
the	O	O
control	O	O
.	O	O

Haloperidol	B-Chemical	D006220
administration	O	O
(	O	O
one	O	O
dose	O	O
of	O	O
12	O	O
mg	O	O
/	O	O
kg	O	O
once	O	O
a	O	O
week	O	O
s	O	O
.	O	O

c	O	O
.	O	O

)	O	O
for	O	O
4	O	O
weeks	O	O
caused	O	O
an	O	O
increase	O	O
in	O	O
vacuous	O	O
chewing	O	O
,	O	O
tongue	O	O
protrusion	O	O
and	O	O
duration	O	O
of	O	O
facial	O	O
twitching	O	O
observed	O	O
in	O	O
four	O	O
weekly	O	O
evaluations	O	O
.	O	O

After	O	O
the	O	O
treatments	O	O
and	O	O
behavioral	O	O
observation	O	O
,	O	O
glutamate	B-Chemical	D018698
uptake	O	O
by	O	O
segments	O	O
of	O	O
the	O	O
brain	O	O
was	O	O
analyzed	O	O
.	O	O

A	O	O
decreased	O	O
glutamate	B-Chemical	D018698
uptake	O	O
was	O	O
observed	O	O
in	O	O
the	O	O
subcortical	O	O
parts	O	O
of	O	O
animals	O	O
treated	O	O
with	O	O
reserpine	B-Chemical	D012110
and	O	O
haloperidol	B-Chemical	D006220
,	O	O
compared	O	O
to	O	O
the	O	O
control	O	O
.	O	O

Importantly	O	O
,	O	O
a	O	O
decrease	O	O
in	O	O
glutamate	B-Chemical	D018698
uptake	O	O
correlates	O	O
negatively	O	O
with	O	O
an	O	O
increase	O	O
in	O	O
the	O	O
incidence	O	O
of	O	O
orofacial	B-Disease	D004409
diskinesia	I-Disease	D004409
.	O	O

These	O	O
results	O	O
indicate	O	O
that	O	O
early	O	O
changes	O	O
in	O	O
glutamate	B-Chemical	D018698
transport	O	O
may	O	O
be	O	O
related	O	O
to	O	O
the	O	O
development	O	O
of	O	O
vacuous	O	O
chewing	O	O
movements	O	O
in	O	O
rats	O	O
.	O	O

Acute	B-Disease	D011605
psychosis	I-Disease	D011605
due	O	O
to	O	O
treatment	O	O
with	O	O
phenytoin	B-Chemical	D010672
in	O	O
a	O	O
nonepileptic	O	O
patient	O	O
.	O	O

The	O	O
development	O	O
of	O	O
psychosis	B-Disease	D011605
related	O	O
to	O	O
antiepileptic	O	O
drug	O	O
treatment	O	O
is	O	O
usually	O	O
attributed	O	O
to	O	O
the	O	O
interaction	O	O
between	O	O
the	O	O
epileptic	B-Disease	D004827
brain	O	O
substratum	O	O
and	O	O
the	O	O
antiepileptic	O	O
drugs	O	O
.	O	O

The	O	O
case	O	O
of	O	O
a	O	O
nonepileptic	O	O
patient	O	O
who	O	O
developed	O	O
psychosis	B-Disease	D011605
following	O	O
phenytoin	B-Chemical	D010672
treatment	O	O
for	O	O
trigeminal	B-Disease	D014277
neuralgia	I-Disease	D014277
is	O	O
described	O	O
.	O	O

This	O	O
case	O	O
suggests	O	O
that	O	O
the	O	O
psychotic	B-Disease	D011605
symptoms	I-Disease	D011605
that	O	O
occur	O	O
following	O	O
phenytoin	B-Chemical	D010672
treatment	O	O
in	O	O
some	O	O
epileptic	B-Disease	D004827
patients	O	O
may	O	O
be	O	O
the	O	O
direct	O	O
result	O	O
of	O	O
medication	O	O
,	O	O
unrelated	O	O
to	O	O
seizures	B-Disease	D012640
.	O	O

The	O	O
effect	O	O
of	O	O
treatment	O	O
with	O	O
gum	B-Chemical	D006170
Arabic	I-Chemical	D006170
on	O	O
gentamicin	B-Chemical	D005839
nephrotoxicity	B-Disease	D007674
in	O	O
rats	O	O
:	O	O
a	O	O
preliminary	O	O
study	O	O
.	O	O

In	O	O
the	O	O
present	O	O
work	O	O
we	O	O
assessed	O	O
the	O	O
effect	O	O
of	O	O
treatment	O	O
of	O	O
rats	O	O
with	O	O
gum	B-Chemical	D006170
Arabic	I-Chemical	D006170
on	O	O
acute	B-Disease	D058186
renal	I-Disease	D058186
failure	I-Disease	D058186
induced	O	O
by	O	O
gentamicin	B-Chemical	D005839
(	O	O
GM	B-Chemical	D005839
)	O	O
nephrotoxicity	B-Disease	D007674
.	O	O

Rats	O	O
were	O	O
treated	O	O
with	O	O
the	O	O
vehicle	O	O
(	O	O
2	O	O
mL	O	O
/	O	O
kg	O	O
of	O	O
distilled	O	O
water	O	O
and	O	O
5%	O	O
w	O	O
/	O	O
v	O	O
cellulose	O	O
,	O	O
10	O	O
days	O	O
)	O	O
,	O	O
gum	B-Chemical	D006170
Arabic	I-Chemical	D006170
(	O	O
2	O	O
mL	O	O
/	O	O
kg	O	O
of	O	O
a	O	O
10%	O	O
w	O	O
/	O	O
v	O	O
aqueous	O	O
suspension	O	O
of	O	O
gum	B-Chemical	D006170
Arabic	I-Chemical	D006170
powder	O	O
,	O	O
orally	O	O
for	O	O
10	O	O
days	O	O
)	O	O
,	O	O
or	O	O
gum	B-Chemical	D006170
Arabic	I-Chemical	D006170
concomitantly	O	O
with	O	O
GM	B-Chemical	D005839
(	O	O
80mg	O	O
/	O	O
kg	O	O
/	O	O
day	O	O
intramuscularly	O	O
,	O	O
during	O	O
the	O	O
last	O	O
six	O	O
days	O	O
of	O	O
the	O	O
treatment	O	O
period	O	O
)	O	O
.	O	O

Nephrotoxicity	B-Disease	D007674
was	O	O
assessed	O	O
by	O	O
measuring	O	O
the	O	O
concentrations	O	O
of	O	O
creatinine	B-Chemical	D003404
and	O	O
urea	B-Chemical	D014508
in	O	O
the	O	O
plasma	O	O
and	O	O
reduced	O	O
glutathione	B-Chemical	D005978
(	O	O
GSH	B-Chemical	D005978
)	O	O
in	O	O
the	O	O
kidney	O	O
cortex	O	O
,	O	O
and	O	O
by	O	O
light	O	O
microscopic	O	O
examination	O	O
of	O	O
kidney	O	O
sections	O	O
.	O	O

The	O	O
results	O	O
indicated	O	O
that	O	O
concomitant	O	O
treatment	O	O
with	O	O
gum	B-Chemical	D006170
Arabic	I-Chemical	D006170
and	O	O
GM	B-Chemical	D005839
significantly	O	O
increased	O	O
creatinine	B-Chemical	D003404
and	O	O
urea	B-Chemical	D014508
by	O	O
about	O	O
183	O	O
and	O	O
239%	O	O
,	O	O
respectively	O	O
(	O	O
compared	O	O
to	O	O
432	O	O
and	O	O
346%	O	O
,	O	O
respectively	O	O
,	O	O
in	O	O
rats	O	O
treated	O	O
with	O	O
cellulose	O	O
and	O	O
GM	B-Chemical	D005839
)	O	O
,	O	O
and	O	O
decreased	O	O
that	O	O
of	O	O
cortical	O	O
GSH	B-Chemical	D005978
by	O	O
21%	O	O
(	O	O
compared	O	O
to	O	O
27%	O	O
in	O	O
the	O	O
cellulose	O	O
plus	O	O
GM	B-Chemical	D005839
group	O	O
)	O	O
The	O	O
GM	B-Chemical	D005839
-	O	O
induced	O	O
proximal	O	O
tubular	B-Disease	D007683
necrosis	I-Disease	D007683
appeared	O	O
to	O	O
be	O	O
slightly	O	O
less	O	O
severe	O	O
in	O	O
rats	O	O
given	O	O
GM	B-Chemical	D005839
together	O	O
with	O	O
gum	B-Chemical	D006170
Arabic	I-Chemical	D006170
than	O	O
in	O	O
those	O	O
given	O	O
GM	B-Chemical	D005839
and	O	O
cellulose	O	O
.	O	O

It	O	O
could	O	O
be	O	O
inferred	O	O
that	O	O
gum	B-Chemical	D006170
Arabic	I-Chemical	D006170
treatment	O	O
has	O	O
induced	O	O
a	O	O
modest	O	O
amelioration	O	O
of	O	O
some	O	O
of	O	O
the	O	O
histological	O	O
and	O	O
biochemical	O	O
indices	O	O
of	O	O
GM	B-Chemical	D005839
nephrotoxicity	B-Disease	D007674
.	O	O

Further	O	O
work	O	O
is	O	O
warranted	O	O
on	O	O
the	O	O
effect	O	O
of	O	O
the	O	O
treatments	O	O
on	O	O
renal	O	O
functional	O	O
aspects	O	O
in	O	O
models	O	O
of	O	O
chronic	B-Disease	D007676
renal	I-Disease	D007676
failure	I-Disease	D007676
,	O	O
and	O	O
on	O	O
the	O	O
mechanism	O	O
(	O	O
s	O	O
)	O	O
involved	O	O
.	O	O

Visual	B-Disease	D006212
hallucinations	I-Disease	D006212
associated	O	O
with	O	O
zonisamide	B-Chemical	C022189
.	O	O

Zonisamide	B-Chemical	C022189
is	O	O
a	O	O
broad	O	O
-	O	O
spectrum	O	O
antiepileptic	O	O
drug	O	O
used	O	O
to	O	O
treat	O	O
various	O	O
types	O	O
of	O	O
seizures	B-Disease	D012640
.	O	O

Although	O	O
visual	B-Disease	D006212
hallucinations	I-Disease	D006212
have	O	O
not	O	O
been	O	O
reported	O	O
as	O	O
an	O	O
adverse	O	O
effect	O	O
of	O	O
this	O	O
agent	O	O
,	O	O
we	O	O
describe	O	O
three	O	O
patients	O	O
who	O	O
experienced	O	O
complex	O	O
visual	B-Disease	D006212
hallucinations	I-Disease	D006212
and	O	O
altered	O	O
mental	O	O
status	O	O
after	O	O
zonisamide	B-Chemical	C022189
treatment	O	O
was	O	O
begun	O	O
or	O	O
its	O	O
dosage	O	O
increased	O	O
.	O	O

All	O	O
three	O	O
had	O	O
been	O	O
diagnosed	O	O
earlier	O	O
with	O	O
epilepsy	B-Disease	D004827
,	O	O
and	O	O
their	O	O
electroencephalogram	O	O
(	O	O
EEG	O	O
)	O	O
findings	O	O
were	O	O
abnormal	O	O
.	O	O

During	O	O
monitoring	O	O
,	O	O
visual	B-Disease	D006212
hallucinations	I-Disease	D006212
did	O	O
not	O	O
correlate	O	O
with	O	O
EEG	O	O
readings	O	O
,	O	O
nor	O	O
did	O	O
video	O	O
recording	O	O
capture	O	O
any	O	O
of	O	O
the	O	O
described	O	O
events	O	O
.	O	O

None	O	O
of	O	O
the	O	O
patients	O	O
had	O	O
experienced	O	O
visual	B-Disease	D006212
hallucinations	I-Disease	D006212
before	O	O
this	O	O
event	O	O
.	O	O

The	O	O
only	O	O
recent	O	O
change	O	O
in	O	O
their	O	O
treatment	O	O
was	O	O
the	O	O
introduction	O	O
or	O	O
increased	O	O
dosage	O	O
of	O	O
zonisamide	B-Chemical	C022189
.	O	O

With	O	O
either	O	O
discontinuation	O	O
or	O	O
decreased	O	O
dosage	O	O
of	O	O
the	O	O
drug	O	O
the	O	O
symptoms	O	O
disappeared	O	O
and	O	O
did	O	O
not	O	O
recur	O	O
.	O	O

Further	O	O
observations	O	O
and	O	O
reports	O	O
will	O	O
help	O	O
clarify	O	O
this	O	O
adverse	O	O
effect	O	O
.	O	O

Until	O	O
then	O	O
,	O	O
clinicians	O	O
need	O	O
to	O	O
be	O	O
aware	O	O
of	O	O
this	O	O
possible	O	O
complication	O	O
associated	O	O
with	O	O
zonisamide	B-Chemical	C022189
.	O	O

GLEPP1	O	O
receptor	O	O
tyrosine	B-Chemical	D014443
phosphatase	O	O
(	O	O
Ptpro	O	O
)	O	O
in	O	O
rat	O	O
PAN	B-Chemical	D011692
nephrosis	B-Disease	D009401
.	O	O

A	O	O
marker	O	O
of	O	O
acute	O	O
podocyte	O	O
injury	O	O
.	O	O

Glomerular	O	O
epithelial	O	O
protein	O	O
1	O	O
(	O	O
GLEPP1	O	O
)	O	O
is	O	O
a	O	O
podocyte	O	O
receptor	O	O
membrane	O	O
protein	O	O
tyrosine	B-Chemical	D014443
phosphatase	O	O
located	O	O
on	O	O
the	O	O
apical	O	O
cell	O	O
membrane	O	O
of	O	O
visceral	O	O
glomerular	O	O
epithelial	O	O
cell	O	O
and	O	O
foot	O	O
processes	O	O
.	O	O

This	O	O
receptor	O	O
plays	O	O
a	O	O
role	O	O
in	O	O
regulating	O	O
the	O	O
structure	O	O
and	O	O
function	O	O
of	O	O
podocyte	O	O
foot	O	O
process	O	O
.	O	O

To	O	O
better	O	O
understand	O	O
the	O	O
utility	O	O
of	O	O
GLEPP1	O	O
as	O	O
a	O	O
marker	O	O
of	O	O
glomerular	B-Disease	D007674
injury	I-Disease	D007674
,	O	O
the	O	O
amount	O	O
and	O	O
distribution	O	O
of	O	O
GLEPP1	O	O
protein	O	O
and	O	O
mRNA	O	O
were	O	O
examined	O	O
by	O	O
immunohistochemistry	O	O
,	O	O
Western	O	O
blot	O	O
and	O	O
RNase	O	O
protection	O	O
assay	O	O
in	O	O
a	O	O
model	O	O
of	O	O
podocyte	O	O
injury	O	O
in	O	O
the	O	O
rat	O	O
.	O	O

Puromycin	B-Chemical	D011692
aminonucleoside	I-Chemical	D011692
nephrosis	B-Disease	D009401
was	O	O
induced	O	O
by	O	O
single	O	O
intraperitoneal	O	O
injection	O	O
of	O	O
puromycin	B-Chemical	D011692
aminonucleoside	I-Chemical	D011692
(	O	O
PAN	B-Chemical	D011692
,	O	O
20	O	O
mg	O	O
/	O	O
100g	O	O
BW	O	O
)	O	O
.	O	O

Tissues	O	O
were	O	O
analyzed	O	O
at	O	O
0	O	O
,	O	O
5	O	O
,	O	O
7	O	O
,	O	O
11	O	O
,	O	O
21	O	O
,	O	O
45	O	O
,	O	O
80	O	O
and	O	O
126	O	O
days	O	O
after	O	O
PAN	B-Chemical	D011692
injection	O	O
so	O	O
as	O	O
to	O	O
include	O	O
both	O	O
the	O	O
acute	O	O
phase	O	O
of	O	O
proteinuria	B-Disease	D011507
associated	O	O
with	O	O
foot	O	O
process	O	O
effacement	O	O
(	O	O
days	O	O
5	O	O
-	O	O
11	O	O
)	O	O
and	O	O
the	O	O
chronic	O	O
phase	O	O
of	O	O
proteinuria	B-Disease	D011507
associated	O	O
with	O	O
glomerulosclerosis	B-Disease	D005921
(	O	O
days	O	O
45	O	O
-	O	O
126	O	O
)	O	O
.	O	O

At	O	O
day	O	O
5	O	O
,	O	O
GLEPP1	O	O
protein	O	O
and	O	O
mRNA	O	O
were	O	O
reduced	O	O
from	O	O
the	O	O
normal	O	O
range	O	O
(	O	O
265	O	O
.	O	O

2	O	O
+	O	O
/	O	O
-	O	O
79	O	O
.	O	O

6	O	O
x	O	O
10	O	O
(	O	O
6	O	O
)	O	O
moles	O	O
/	O	O
glomerulus	O	O
and	O	O
100%	O	O
)	O	O
to	O	O
15%	O	O
of	O	O
normal	O	O
(	O	O
41	O	O
.	O	O

8	O	O
+	O	O
/	O	O
-	O	O
4	O	O
.	O	O

8	O	O
x	O	O
10	O	O
(	O	O
6	O	O
)	O	O
moles	O	O
/	O	O
glomerulus	O	O
,	O	O
p	O	O
<	O	O
0	O	O
.	O	O

005	O	O
)	O	O
.	O	O

This	O	O
occurred	O	O
in	O	O
association	O	O
with	O	O
an	O	O
increase	O	O
in	O	O
urinary	O	O
protein	O	O
content	O	O
from	O	O
1	O	O
.	O	O

8	O	O
+	O	O
/	O	O
-	O	O
1	O	O
to	O	O
99	O	O
.	O	O

0	O	O
+	O	O
/	O	O
-	O	O
61	O	O
mg	O	O
/	O	O
day	O	O
(	O	O
p	O	O
<	O	O
0	O	O
.	O	O

001	O	O
)	O	O
.	O	O

In	O	O
contrast	O	O
,	O	O
podocalyxin	O	O
did	O	O
not	O	O
change	O	O
significantly	O	O
at	O	O
this	O	O
time	O	O
.	O	O

By	O	O
day	O	O
11	O	O
,	O	O
GLEPP1	O	O
protein	O	O
and	O	O
mRNA	O	O
had	O	O
begun	O	O
to	O	O
return	O	O
towards	O	O
baseline	O	O
.	O	O

By	O	O
day	O	O
45	O	O
-	O	O
126	O	O
,	O	O
at	O	O
a	O	O
time	O	O
when	O	O
glomerular	O	O
scarring	O	O
was	O	O
present	O	O
,	O	O
GLEPP1	O	O
was	O	O
absent	O	O
from	O	O
glomerulosclerotic	O	O
areas	O	O
although	O	O
the	O	O
total	O	O
glomerular	O	O
content	O	O
of	O	O
GLEPP1	O	O
was	O	O
not	O	O
different	O	O
from	O	O
normal	O	O
.	O	O

We	O	O
conclude	O	O
that	O	O
GLEPP1	O	O
expression	O	O
,	O	O
unlike	O	O
podocalyxin	O	O
,	O	O
reflects	O	O
podocyte	O	O
injury	O	O
induced	O	O
by	O	O
PAN	B-Chemical	D011692
.	O	O

GLEPP1	O	O
expression	O	O
may	O	O
be	O	O
a	O	O
useful	O	O
marker	O	O
of	O	O
podocyte	O	O
injury	O	O
.	O	O

Ticlopidine	B-Chemical	D013988
-	O	O
induced	O	O
aplastic	B-Disease	D000741
anemia	I-Disease	D000741
:	O	O
report	O	O
of	O	O
three	O	O
Chinese	O	O
patients	O	O
and	O	O
review	O	O
of	O	O
the	O	O
literature	O	O
.	O	O

In	O	O
this	O	O
study	O	O
,	O	O
three	O	O
Chinese	O	O
patients	O	O
with	O	O
ticlopidine	B-Chemical	D013988
-	O	O
induced	O	O
aplastic	B-Disease	D000741
anemia	I-Disease	D000741
were	O	O
reported	O	O
and	O	O
another	O	O
13	O	O
patients	O	O
in	O	O
the	O	O
English	O	O
literature	O	O
were	O	O
reviewed	O	O
.	O	O

We	O	O
attempted	O	O
to	O	O
find	O	O
underlying	O	O
similarities	O	O
,	O	O
evaluate	O	O
the	O	O
risk	O	O
factors	O	O
,	O	O
and	O	O
identify	O	O
appropriate	O	O
treatment	O	O
for	O	O
this	O	O
complication	O	O
.	O	O

All	O	O
but	O	O
one	O	O
of	O	O
the	O	O
patients	O	O
were	O	O
over	O	O
60	O	O
years	O	O
old	O	O
,	O	O
and	O	O
the	O	O
6	O	O
who	O	O
died	O	O
were	O	O
all	O	O
older	O	O
than	O	O
65	O	O
.	O	O

Therefore	O	O
,	O	O
old	O	O
age	O	O
may	O	O
be	O	O
a	O	O
risk	O	O
factor	O	O
for	O	O
developing	O	O
this	O	O
complication	O	O
.	O	O

Agranulocytosis	B-Disease	D000380
occurred	O	O
3	O	O
-	O	O
20	O	O
weeks	O	O
after	O	O
initiation	O	O
of	O	O
ticlopidine	B-Chemical	D013988
,	O	O
so	O	O
frequent	O	O
examination	O	O
of	O	O
white	O	O
cell	O	O
count	O	O
during	O	O
treatment	O	O
is	O	O
recommended	O	O
.	O	O

There	O	O
seemed	O	O
to	O	O
be	O	O
no	O	O
direct	O	O
correlation	O	O
between	O	O
the	O	O
dose	O	O
or	O	O
duration	O	O
used	O	O
and	O	O
the	O	O
severity	O	O
of	O	O
bone	B-Disease	D001855
marrow	I-Disease	D001855
suppression	I-Disease	D001855
.	O	O

Treatment	O	O
for	O	O
ticlopidine	B-Chemical	D013988
-	O	O
induced	O	O
aplastic	B-Disease	D000741
anemia	I-Disease	D000741
with	O	O
colony	O	O
-	O	O
stimulating	O	O
factors	O	O
seemed	O	O
to	O	O
have	O	O
little	O	O
effect	O	O
.	O	O

The	O	O
fact	O	O
that	O	O
5	O	O
of	O	O
the	O	O
6	O	O
patients	O	O
who	O	O
received	O	O
concurrent	O	O
calcium	B-Chemical	D002118
channel	O	O
blockers	O	O
died	O	O
,	O	O
should	O	O
alert	O	O
clinicians	O	O
to	O	O
be	O	O
more	O	O
cautious	O	O
when	O	O
using	O	O
these	O	O
two	O	O
drugs	O	O
simultaneously	O	O
.	O	O

Facilitation	O	O
of	O	O
memory	O	O
retrieval	O	O
by	O	O
pre	O	O
-	O	O
test	O	O
morphine	B-Chemical	D009020
and	O	O
its	O	O
state	O	O
dependency	O	O
in	O	O
the	O	O
step	O	O
-	O	O
through	O	O
type	O	O
passive	O	O
avoidance	O	O
learning	O	O
test	O	O
in	O	O
mice	O	O
.	O	O

Amnesia	B-Disease	D000647
produced	O	O
by	O	O
scopolamine	B-Chemical	D012601
and	O	O
cycloheximide	B-Chemical	D003513
were	O	O
reversed	O	O
by	O	O
morphine	B-Chemical	D009020
given	O	O
30	O	O
min	O	O
before	O	O
the	O	O
test	O	O
trial	O	O
(	O	O
pre	O	O
-	O	O
test	O	O
)	O	O
,	O	O
and	O	O
pre	O	O
-	O	O
test	O	O
morphine	B-Chemical	D009020
also	O	O
facilitated	O	O
the	O	O
memory	O	O
retrieval	O	O
in	O	O
the	O	O
animals	O	O
administered	O	O
naloxone	B-Chemical	D009270
during	O	O
the	O	O
training	O	O
trial	O	O
.	O	O

Similarly	O	O
,	O	O
pre	O	O
-	O	O
test	O	O
scopolamine	B-Chemical	D012601
partially	O	O
reversed	O	O
the	O	O
scopolamine	B-Chemical	D012601
-	O	O
induced	O	O
amnesia	B-Disease	D000647
,	O	O
but	O	O
not	O	O
significantly	O	O
;	O	O
and	O	O
pre	O	O
-	O	O
test	O	O
cycloheximide	B-Chemical	D003513
failed	O	O
to	O	O
reverse	O	O
the	O	O
cycloheximide	B-Chemical	D003513
-	O	O
induced	O	O
amnesia	B-Disease	D000647
.	O	O

These	O	O
results	O	O
suggest	O	O
that	O	O
the	O	O
facilitation	O	O
of	O	O
memory	O	O
retrieval	O	O
by	O	O
pre	O	O
-	O	O
test	O	O
morphine	B-Chemical	D009020
might	O	O
be	O	O
the	O	O
direct	O	O
action	O	O
of	O	O
morphine	B-Chemical	D009020
rather	O	O
than	O	O
a	O	O
state	O	O
dependent	O	O
effect	O	O
.	O	O

Test	O	O
conditions	O	O
influence	O	O
the	O	O
response	O	O
to	O	O
a	O	O
drug	O	O
challenge	O	O
in	O	O
rodents	O	O
.	O	O

These	O	O
studies	O	O
were	O	O
conducted	O	O
to	O	O
examine	O	O
the	O	O
differential	O	O
response	O	O
to	O	O
a	O	O
drug	O	O
challenge	O	O
under	O	O
varied	O	O
experimental	O	O
test	O	O
conditions	O	O
routinely	O	O
employed	O	O
to	O	O
study	O	O
drug	O	O
-	O	O
induced	O	O
behavioral	O	O
and	O	O
neurophysiological	O	O
responses	O	O
in	O	O
rodents	O	O
.	O	O

Apomorphine	B-Chemical	D001058
,	O	O
a	O	O
nonselective	O	O
dopamine	B-Chemical	D018491
agonist	I-Chemical	D018491
,	O	O
was	O	O
selected	O	O
due	O	O
to	O	O
its	O	O
biphasic	O	O
behavioral	O	O
effects	O	O
,	O	O
its	O	O
ability	O	O
to	O	O
induce	O	O
hypothermia	B-Disease	D007035
,	O	O
and	O	O
to	O	O
produce	O	O
distinct	O	O
changes	O	O
to	O	O
dopamine	B-Chemical	D004298
turnover	O	O
in	O	O
the	O	O
rodent	O	O
brain	O	O
.	O	O

From	O	O
such	O	O
experiments	O	O
there	O	O
is	O	O
evidence	O	O
that	O	O
characterization	O	O
and	O	O
detection	O	O
of	O	O
apomorphine	B-Chemical	D001058
-	O	O
induced	O	O
activity	O	O
in	O	O
rodents	O	O
critically	O	O
depends	O	O
upon	O	O
the	O	O
test	O	O
conditions	O	O
employed	O	O
.	O	O

In	O	O
rats	O	O
,	O	O
detection	O	O
of	O	O
apomorphine	B-Chemical	D001058
-	O	O
induced	O	O
hyperactivity	B-Disease	D006948
was	O	O
facilitated	O	O
by	O	O
a	O	O
period	O	O
of	O	O
acclimatization	O	O
to	O	O
the	O	O
test	O	O
conditions	O	O
.	O	O

Moreover	O	O
,	O	O
test	O	O
conditions	O	O
can	O	O
impact	O	O
upon	O	O
other	O	O
physiological	O	O
responses	O	O
to	O	O
apomorphine	B-Chemical	D001058
such	O	O
as	O	O
drug	O	O
-	O	O
induced	O	O
hypothermia	B-Disease	D007035
.	O	O

In	O	O
mice	O	O
,	O	O
apomorphine	B-Chemical	D001058
produced	O	O
qualitatively	O	O
different	O	O
responses	O	O
under	O	O
novel	O	O
conditions	O	O
when	O	O
compared	O	O
to	O	O
those	O	O
behaviors	O	O
elicited	O	O
in	O	O
the	O	O
home	O	O
test	O	O
cage	O	O
.	O	O

Drug	O	O
-	O	O
induced	O	O
gross	O	O
activity	O	O
counts	O	O
were	O	O
increased	O	O
in	O	O
the	O	O
novel	O	O
exploratory	O	O
box	O	O
only	O	O
,	O	O
while	O	O
measures	O	O
of	O	O
stereotypic	O	O
behavior	O	O
were	O	O
similar	O	O
in	O	O
both	O	O
.	O	O

By	O	O
contrast	O	O
,	O	O
apomorphine	B-Chemical	D001058
-	O	O
induced	O	O
locomotion	O	O
was	O	O
more	O	O
prominent	O	O
in	O	O
the	O	O
novel	O	O
exploratory	O	O
box	O	O
.	O	O

Dopamine	B-Chemical	D004298
turnover	O	O
ratios	O	O
(	O	O
DOPAC	B-Chemical	D015102
:	O	O
DA	B-Chemical	D018491
and	O	O
HVA	B-Chemical	D006719
:	O	O
DA	B-Chemical	D018491
)	O	O
were	O	O
found	O	O
to	O	O
be	O	O
lower	O	O
in	O	O
those	O	O
animals	O	O
exposed	O	O
to	O	O
the	O	O
exploratory	O	O
box	O	O
when	O	O
compared	O	O
to	O	O
their	O	O
home	O	O
cage	O	O
counterparts	O	O
.	O	O

However	O	O
,	O	O
apomorphine	B-Chemical	D001058
-	O	O
induced	O	O
reductions	O	O
in	O	O
striatal	O	O
dopamine	B-Chemical	D004298
turnover	O	O
were	O	O
detected	O	O
in	O	O
both	O	O
novel	O	O
and	O	O
home	O	O
cage	O	O
environments	O	O
.	O	O

The	O	O
implications	O	O
of	O	O
these	O	O
findings	O	O
are	O	O
discussed	O	O
with	O	O
particular	O	O
emphasis	O	O
upon	O	O
conducting	O	O
psychopharmacological	O	O
challenge	O	O
tests	O	O
in	O	O
rodents	O	O
.	O	O

